"Rank","NCT Number","Title","Acronym","Status","Study Results","Conditions","Interventions","Outcome Measures","Sponsor/Collaborators","Gender","Age","Phases","Enrollment","Funded Bys","Study Type","Study Designs","Other IDs","Start Date","Primary Completion Date","Completion Date","First Posted","Results First Posted","Last Update Posted","Locations","Study Documents","URL"
1,"NCT04722068","Regeneron 1331 Kinetics Sub-Study HoFH",,"Completed","No Results Available","Hypercholesterolemia, Familial","Other: Kinetics test","Fractional catabolic rate (FCR) pools/day|Production rate (PR) of lipoproteins mg/kg/day","University of Pennsylvania|Regeneron Pharmaceuticals","All","18 Years and older   (Adult, Older Adult)","Not Applicable","4","Other|Industry","Interventional","Allocation: N/A|Intervention Model: Single Group Assignment|Masking: None (Open Label)|Primary Purpose: Other","1331-Kin","October 7, 2016","November 30, 2016","January 1, 2021","January 25, 2021",,"May 17, 2021","University of Pennsylvania, Philadelphia, Pennsylvania, United States|Department of Vascular Medicine Amsterdam UMC, Amsterdam, AZ, Netherlands",,"https://ClinicalTrials.gov/show/NCT04722068"
2,"NCT05133531","Ravulizumab-Controlled Study to Evaluate the Efficacy and Safety of Pozelimab and Cemdisiran Combination Therapy in Adult Patients With Paroxysmal Nocturnal Hemoglobinuria Who Are Complement Inhibitor Treatment-Naive or Have Not Recently Received Complement Inhibitor Therapy","ACCESS-1","Recruiting","No Results Available","Paroxysmal Nocturnal Hemoglobinuria","Drug: Ravulizumab|Drug: Pozelimab|Drug: Cemdisiran","Proportion of patients with adequate control of hemolysis|Proportion of patients with transfusion avoidance|Proportion of patients with breakthrough hemolysis|Proportion of patients with hemoglobin stabilization|Proportion of patients with normalization of LDH|Percent change in LDH|Change in fatigue as measured by the FACIT-Fatigue Scale|Change in physical function (PF) scores on the European Organisation for Research and Treatment of Cancer Quality of Life Questionnaire (EORTC-QLQ-C30)|Change in global health status (GHS)/QoL scale score on the EORTC-QLC-C30|Rate of RBC transfusion per protocol algorithm from day 1 through week 24|Number of units of RBC transfusion per protocol algorithm from day 1 through week 24|Time to first LDH ≤1.5 × ULN|Time to first LDH ≤1.0 × ULN|Percentage of days with LDH ≤1.5 × ULN|Change in hemoglobin levels|Incidence and severity of treatment emergent serious adverse events (SAEs)|Incidence and severity of treatment-emergent adverse events (TEAEs) of special interest|Incidence and severity of TEAE leading to treatment discontinuation|Change in total CH50|Percent change in total CH50|Concentration of total C5 in plasma|Concentrations of total pozelimab in serum|Concentrations of total cemdisiran in plasma|Concentrations of total ravulizumab in serum|Incidence of treatment emergent anti-drug antibodies (ADAs) to pozelimab|Incidence of treatment emergent ADAs to cemdisiran","Regeneron Pharmaceuticals","All","18 Years and older   (Adult, Older Adult)","Phase 3","124","Industry","Interventional","Allocation: Randomized|Intervention Model: Parallel Assignment|Masking: None (Open Label)|Primary Purpose: Treatment","R3918-PNH-2021|2020-004486-40","July 31, 2022","May 18, 2026","July 16, 2027","November 24, 2021",,"December 27, 2021","Regeneron Study Site, Whittier, California, United States",,"https://ClinicalTrials.gov/show/NCT05133531"
3,"NCT05102136","Study to Evaluate the Safety, Tolerability, Pharmacokinetics, and Pharmacodynamics of REGN9933 in Adult Healthy Volunteers",,"Recruiting","No Results Available","Healthy Volunteers","Drug: REGN9933|Drug: Placebo","Incidence and severity of treatment emergent adverse events (TEAE)|Change from baseline in activated partial thromboplastin time (aPTT)|Change from baseline in prothrombin time (PT)|Concentration of REGN9933 in serum|Change from baseline in total Factor XI (FXI) concentrations|The incidence of antidrug antibodies (ADAs) to REGN9933 over time","Regeneron Pharmaceuticals","All","18 Years to 55 Years   (Adult)","Phase 1","72","Industry","Interventional","Allocation: Randomized|Intervention Model: Parallel Assignment|Masking: Quadruple (Participant, Care Provider, Investigator, Outcomes Assessor)|Primary Purpose: Treatment","R9933-HV-2107|2021-002568-34","October 27, 2021","November 30, 2022","November 30, 2022","November 1, 2021",,"November 11, 2021","Regeneron Study Site, Edegem, Antwerp, Belgium",,"https://ClinicalTrials.gov/show/NCT05102136"
4,"NCT04888507","Pozelimab and Cemdisiran Combination Therapy in Adult Participants With Paroxysmal Nocturnal Hemoglobinuria Who Switch From Eculizumab Therapy",,"Recruiting","No Results Available","Paroxysmal Nocturnal Hemoglobinuria","Drug: Pozelimab|Drug: Cemdisiran","Incidence and severity of treatment emergent adverse events (TEAEs)|Percent change in LDH from pre-treatment to end-of-treatment period|Percent change in LDH from pre-treatment|Proportion of participants who are transfusion-free|Rate of RBCs transfused|Number of units of RBCs transfused|Proportion of participants with breakthrough hemolysis|Proportion of participants with adequate control of their LDH|Proportion of participants with normalization of their LDH|Area under the curve (AUC) of LDH over time|AUC of LDH over time|Proportion of participants with hemoglobin stabilization|Change in hemoglobin levels|Change in fatigue as measured by Functional Assessment of Chronic Illness Therapy-Fatigue (FACIT-Fatigue) scale|Change in health related quality of life (HRQoL) as measured by the global health status subscale of the European Organization for Research and Treatment of Cancer (EORTC)- Quality of Life Cancer Patients Questionnaire (QLQ) - 30 Scale|Change in physical function (PF) scores on the EORTC QLQ-C30|Change in total CH50|Concentrations of total pozelimab and eculizumab in serum|Concentrations of total cemdisiran in plasma|Change from baseline in concentration of total C5|Incidence of pozelimab anti-drug antibody (ADA) responses over time|Incidence of cemdisiran anti-drug antibody (ADA) responses over time|Incidence and severity of TEAEs for participants who receive dose intensification|Incidence and severity of TEAEs in participants treated with pozelimab and cemdisiran combination therapy|Change of LDH|Percent change of LDH|Proportion of participants with normalization of LDH|Change in fatigue as measured by FACIT-Fatigue scale|Change in GHS/QoL on the EORTC QLQ-C30|Change in PF scores on the EORTC QLQ-C30|Change in CH50|Concentrations of total C5|Concentrations of cemdisiran in plasma","Regeneron Pharmaceuticals","All","18 Years and older   (Adult, Older Adult)","Phase 2","12","Industry","Interventional","Allocation: N/A|Intervention Model: Single Group Assignment|Masking: None (Open Label)|Primary Purpose: Treatment","R3918-PNH-20105|2020-005006-25","July 8, 2021","September 29, 2022","October 11, 2024","May 17, 2021",,"November 15, 2021","Regeneron Study Site, Leeds, United Kingdom",,"https://ClinicalTrials.gov/show/NCT04888507"
5,"NCT05181683","COVID-19 Study Assessing the Safety and Tolerability of Co-Formulated Anti-Spike (S) SARS-CoV-2 Monoclonal Antibodies (Casirivimab+Imdevimab) in Adult Volunteers",,"Active, not recruiting","No Results Available","Healthy|Chronic Stable Illness","Drug: Casirivimab+Imdevimab","Targeted grade ≥3 treatment-emergent adverse events (TEAEs)|Grade ≥3 injection-site reactions (ISRs)|Grade ≥2 infusion-related reactions (IRRs)|Grade ≥2 hypersensitivity reactions|Serious adverse events (SAEs)|Concentrations of casirivimab and imdevimab in serum over time|Incidence and titer of anti-drug antibodies (ADA) to casirivimab and imdevimab|Incidence of neutralizing antibodies (NAb) to casirivimab and imdevimab","Regeneron Pharmaceuticals","All","18 Years to 65 Years   (Adult, Older Adult)","Phase 1","45","Industry","Interventional","Allocation: Randomized|Intervention Model: Parallel Assignment|Masking: None (Open Label)|Primary Purpose: Treatment","R10933-10987-COV-2179","January 7, 2022","May 11, 2022","May 11, 2022","January 6, 2022",,"March 7, 2022","Regeneron Study Site, Miami, Florida, United States|Regeneron StudySite, Winter Park, Florida, United States",,"https://ClinicalTrials.gov/show/NCT05181683"
6,"NCT05070858","A Study to Examine the Efficacy and Safety of Pozelimab and Cemdisiran Combination Therapy in Adult Patients With Symptomatic Generalized Myasthenia Gravis",,"Recruiting","No Results Available","Generalized Myasthenia Gravis","Drug: Pozelimab (REGN3918) + Cemdisiran|Drug: Cemdisiran|Other: Placebo","Change in Myasthenia Gravis-Activities of Daily Living (MG-ADL) total score|Change from baseline in Quantitative Myasthenia Gravis (QMG) score|Proportion of patients responding on the MG-ADL|Proportion of patients responding on the QMG|Proportion of patients with consistent response on the MG-ADL|Proportion of patients with minimal symptom expression (MSE)|Change from baseline in the Myasthenia Gravis Composite (MGC) total score|Change from baseline in Myasthenia Gravis Quality of Life (MG QOL15r) total score|Proportion of patients with improvement point thresholds on MG-ADL|Proportion of patients with improvement point thresholds on QMG|Incidence and severity of treatment-related adverse events (TEAEs) in patients treated with pozelimab + cemdisiran or placebo|Incidence and severity of serious adverse events (SAEs) in patients treated with pozelimab + cemdisiran or placebo|Incidence and severity of adverse events of special interest (AESIs) in patients treated with pozelimab + cemdisiran or placebo|Concentrations of total pozelimab in serum|Concentrations of cemdisiran and its metabolites in plasma|Incidence of treatment-emergent anti-drug antibodies (ADAs) to pozelimab over time|Incidence of treatment-emergent ADAs to cemdisiran over time|Change in CH50 over time|Percent change in CH50 over time","Regeneron Pharmaceuticals","All","18 Years and older   (Adult, Older Adult)","Phase 3","210","Industry","Interventional","Allocation: Randomized|Intervention Model: Parallel Assignment|Masking: Quadruple (Participant, Care Provider, Investigator, Outcomes Assessor)|Primary Purpose: Treatment","R3918-MG-2018|2020-003272-41","December 14, 2021","August 14, 2024","May 1, 2027","October 7, 2021",,"March 2, 2022","Regeneron Research Site, Naples, Florida, United States",,"https://ClinicalTrials.gov/show/NCT05070858"
7,"NCT04940364","A Study to Examine the Safety, Tolerability and Biological Effects of Single Doses of Subcutaneously and Intravenously Administered Pozelimab as Monotherapy and in Combination With Single Doses of Subcutaneously Administered Cemdisiran in Adult Japanese Healthy Volunteers",,"Recruiting","No Results Available","Healthy","Drug: Pozelimab|Drug: Cemdisiran","Concentrations of pozelimab in serum over time|Concentrations of cemdisiran in plasma over time.|The incidence and severity of treatment-emergent adverse events (TEAE) in subjects administered pozelimab with/without cemdisiran|Concentrations of total C5 in plasma over time|Change from baseline in CH50 over time|Incidence of treatment-emergent anti-drug antibodies (ADA) to pozelimab|Incidence of treatment-emergent ADA to cemdisiran","Regeneron Pharmaceuticals","All","18 Years to 65 Years   (Adult, Older Adult)","Phase 1","36","Industry","Interventional","Allocation: Non-Randomized|Intervention Model: Parallel Assignment|Masking: None (Open Label)|Primary Purpose: Treatment","R3918-HV-20117|2021-001794-23","August 4, 2021","July 20, 2022","July 20, 2022","June 25, 2021",,"February 3, 2022","Regeneron Research Site, London, United Kingdom",,"https://ClinicalTrials.gov/show/NCT04940364"
8,"NCT05131204","Efficacy and Safety of the Combination of Pozelimab and Cemdisiran Versus Continued Eculizumab or Ravulizumab Treatment in Adult Patients With Paroxysmal Nocturnal Hemoglobinuria","ACCESS 2","Recruiting","No Results Available","Paroxysmal Nocturnal Hemoglobinuria","Drug: Cemdisiran|Drug: Eculizumab|Drug: Pozelimab|Drug: Ravulizumab","Percent change in lactate dehydrogenase (LDH)|Proportion of patients with transfusion avoidance|Proportion of patients with breakthrough hemolysis|Proportion of patients with hemoglobin stabilization|Proportion of patients with adequate control of LDH|Proportion of patients with normalization of LDH|Change in fatigue as measured by the Functional Assessment of Chronic Illness Therapy-Fatigue (FACIT-Fatigue) Scale|Change in Physical Function (PF) score on the European organization for research and treatment of cancer quality-of-Life questionnaire Core 30 Items (EORTC-QLQ-C30)|Change in global health status (GHS)/QoL scale score on the EORTC-QLQ-C30|Rate of RBCs transfused per protocol algorithm|Number of units of RBCs transfused per protocol algorithm|Change in hemoglobin levels|Incidence and severity of treatment emergent serious adverse events (SAEs)|Incidence and severity of treatment-emergent adverse events (TEAEs) of special interest|Incidence and severity TEAEs leading to treatment discontinuation|Change in total CH50|Percent change in total CH50|Concentration of total C5 in plasma|Concentrations of total pozelimab in serum|Concentrations of total cemdisiran in plasma|Concentrations of total eculizumab in serum|Concentrations of total ravulizumab in plasma|Incidence of treatment emergent anti-drug antibodies (ADAs) to pozelimab|Incidence of treatment emergent ADAs to cemdisiran","Regeneron Pharmaceuticals","All","18 Years and older   (Adult, Older Adult)","Phase 3","140","Industry","Interventional","Allocation: Randomized|Intervention Model: Parallel Assignment|Masking: None (Open Label)|Primary Purpose: Treatment","R3918-PNH-2022|2020-002761-33","March 31, 2022","June 24, 2025","September 18, 2026","November 23, 2021",,"February 14, 2022","Regeneron Research Facility, Whittier, California, United States",,"https://ClinicalTrials.gov/show/NCT05131204"
9,"NCT04616105","Study of the Safety, Tolerability, and Pharmacokinetics of REGN6490 in Healthy Japanese Adult Volunteers",,"Terminated","No Results Available","Healthy Volunteer","Drug: REGN6490|Drug: Placebo","Incidence and severity of Treatment-Emergent Adverse Events (TEAEs)|Serum Concentration of REGN6490 over time|Incidence of Treatment-Emergent REGN6490 Anti-Drug Antibodies (ADAs)","Regeneron Pharmaceuticals","All","20 Years to 60 Years   (Adult)","Phase 1","19","Industry","Interventional","Allocation: Randomized|Intervention Model: Sequential Assignment|Masking: Quadruple (Participant, Care Provider, Investigator, Outcomes Assessor)|Primary Purpose: Treatment","R6490-HV-1993","November 18, 2020","May 28, 2021","May 28, 2021","November 4, 2020",,"November 11, 2021","Regeneron Study Site, Glendale, California, United States",,"https://ClinicalTrials.gov/show/NCT04616105"
10,"NCT04616079","Ascending Dose Study of the Safety and Tolerability of REGN6490 in Healthy Volunteers",,"Terminated","No Results Available","Healthy Volunteer","Drug: REGN6490|Drug: Placebo","Incidence and severity of Treatment-Emergent Adverse Events (TEAEs)|Serum Concentration of REGN6490 over time|Incidence of Treatment-Emergent REGN6490 Anti-Drug Antibodies (ADAs)","Regeneron Pharmaceuticals","All","18 Years to 55 Years   (Adult)","Phase 1","57","Industry","Interventional","Allocation: Randomized|Intervention Model: Sequential Assignment|Masking: Quadruple (Participant, Care Provider, Investigator, Outcomes Assessor)|Primary Purpose: Treatment","R6490-HV-1946|2020-003261-19","November 19, 2020","June 1, 2021","June 1, 2021","November 4, 2020",,"November 11, 2021","Regeneron Study Site, Ghent, Belgium",,"https://ClinicalTrials.gov/show/NCT04616079"
11,"NCT04506645","Study to Assess the Safety, Tolerability, and Pharmacokinetics of REGN5381 (an NPR1 Agonist) in Adult Humans",,"Recruiting","No Results Available","Healthy","Drug: REGN5381|Other: Placebo","Incidence of Treatment-Emergent Adverse Events|Change from baseline in Systolic Blood Pressure (SBP)|Change from baseline in Diastolic Blood Pressure (DBP)|Change from baseline in Mean Arterial Pressure (MAP)|Change from baseline in Pulse Pressure (PP)|Change from baseline in Heart Rate (HR)|Change from baseline in Stroke Volume (SV)|Maximum change from baseline in SBP across the first 24 hours postdose|Maximum change from baseline in DBP across the first 24 hours postdose|Maximum change from baseline in MAP across the first 24 hours postdose|Maximum change from baseline in PP across the first 24 hours postdose|Maximum change from baseline in HR across the first 24 hours postdose|Maximum change from baseline in SV across the first 24 hours postdose|Change from baseline in the 24-hour mean SBP measured from 0 to 24 hours, 24 to 48 hours, and 48 to 72 hours postdose|Change from baseline in the 24-hour mean DBP measured from 0 to 24 hours, 24 to 48 hours, and 48 to 72 hours postdose|Change from baseline in the 24-hour mean MAP measured from 0 to 24 hours, 24 to 48 hours, and 48 to 72 hours postdose|Change from baseline in the 24-hour mean PP measured from 0 to 24 hours, 24 to 48 hours, and 48 to 72 hours postdose|Change from baseline in the 24-hour mean HR measured from 0 to 24 hours, 24 to 48 hours, and 48 to 72 hours postdose|Concentrations of REGN5381 over time|Number of subjects who develop anti-drug antibodies (ADA) and titers|Percentage of subjects who develop anti-drug antibodies (ADA) and titers","Regeneron Pharmaceuticals","All","18 Years to 55 Years   (Adult)","Phase 1","112","Industry","Interventional","Allocation: Randomized|Intervention Model: Sequential Assignment|Masking: Quadruple (Participant, Care Provider, Investigator, Outcomes Assessor)|Primary Purpose: Treatment","R5381-HV-1987|2020-000940-75","September 1, 2020","July 8, 2022","July 8, 2022","August 10, 2020",,"November 9, 2021","Regeneron Study Site, Leuven, Belgium",,"https://ClinicalTrials.gov/show/NCT04506645"
12,"NCT04491838","Study of a Single Subcutaneous Dose of Pozelimab Produced From Two Different Manufacturing Processes in Healthy Adult Participants",,"Completed","No Results Available","Healthy Volunteer","Drug: Pozelimab","Assess the time of the last positive concentration (AUClast) pharmacokinetic (PK) profile of pozelimab in Process A|Assess the time of the last positive concentration (AUClast) PK profile of pozelimab in Process B|Assess peak concentration (Cmax) PK profile of pozelimabin in Process A|Assess peak concentration (Cmax) PK profile of pozelimab in Process B|Incidence of treatment emergent adverse events (TEAEs)|Incidence of anti-drug antibodies (ADA) to pozelimab over time","Regeneron Pharmaceuticals","All","18 Years to 55 Years   (Adult)","Phase 1","40","Industry","Interventional","Allocation: Randomized|Intervention Model: Parallel Assignment|Masking: None (Open Label)|Primary Purpose: Treatment","R3918-HV-2014|2020-002365-33","August 3, 2020","March 5, 2021","March 5, 2021","July 29, 2020",,"March 23, 2021","Regeneron Study Site, Antwerpen, Belgium",,"https://ClinicalTrials.gov/show/NCT04491838"
13,"NCT04601844","Safety, Tolerability, Pharmacokinetics, and Pharmacodynamics of Pozelimab in Combination With Cemdisiran in Healthy Adult Volunteers",,"Completed","No Results Available","Healthy","Drug: Pozelimab|Drug: Cemdisiran","Incidence and severity of treatment emergent adverse events (TEAEs)|Concentrations of pozelimab in serum over time|Concentrations of cemdisiran in plasma over time|Concentrations of total C5 over time|Change from baseline in total complement hemolytic activity assay (CH50) over time|Incidence of treatment-emergent anti-drug antibodies (ADA) to pozelimab|Incidence of treatment-emergent anti-drug antibodies (ADA) to cemdisiran","Regeneron Pharmaceuticals|Alnylam Pharmaceuticals","All","18 Years to 55 Years   (Adult)","Phase 1","19","Industry","Interventional","Allocation: Non-Randomized|Intervention Model: Parallel Assignment|Masking: None (Open Label)|Primary Purpose: Treatment","R3918-HV-1982|2020-000300-11","November 16, 2020","July 23, 2021","July 23, 2021","October 26, 2020",,"November 12, 2021","Regeneron Research Site, Antwerp, Belgium",,"https://ClinicalTrials.gov/show/NCT04601844"
14,"NCT04173442","Post-authorization Safety Study in North America to Monitor Pregnancy and Infant Outcomes Following Administration of Dupilumab During Planned or Unexpected Pregnancy",,"Recruiting","No Results Available","Atopic Dermatitis (AD)|Asthma","Drug: dupilumab","Rate of major structural defects|Incidence of spontaneous abortion or miscarriage|Incidence of stillbirth|Incidence of elective termination/abortion|Incidence of premature delivery|Incidence of small for gestational age|Incidence of a pattern of 3 or more minor structural defects|Postnatal growth deficiency|Incidence of postnatal serious or opportunistic infections in live born children|Incidence of hospitalizations in live born children","Regeneron Pharmaceuticals|Sanofi","Female","18 Years and older   (Adult, Older Adult)",,"300","Industry","Observational","Observational Model: Cohort|Time Perspective: Prospective","R668-AD-1639","October 24, 2018","July 9, 2026","July 9, 2026","November 22, 2019",,"August 4, 2021","Regeneron Research Site, La Jolla, California, United States",,"https://ClinicalTrials.gov/show/NCT04173442"
15,"NCT04863014","Efficacy and Safety of Evinacumab in Adult Patients With Severe Hypertriglyceridemia for the Prevention of Recurrent Acute Pancreatitis",,"Recruiting","No Results Available","Hypertriglyceridemia","Drug: evinacumab|Other: Placebo","Proportion of patients with at least 1 positively adjudicated acute pancreatitis (AP) episode|Percent change in ApoC3|Percent change in fasting triglycerides (TGs)|Percent change in total cholesterol (TC)|Percent change in non-high-density lipoprotein cholesterol (non-HDL-C)|Percent change in ApoB48|Percent change in ApoB100 levels|Percent change in nuclear magnetic resonance (NMR)-determined particle size and number|Number of independently adjudicated episodes of AP per patient","Regeneron Pharmaceuticals","All","18 Years to 80 Years   (Adult, Older Adult)","Phase 2","120","Industry","Interventional","Allocation: Randomized|Intervention Model: Parallel Assignment|Masking: Quadruple (Participant, Care Provider, Investigator, Outcomes Assessor)|Primary Purpose: Treatment","R1500-HTG-20118|2021-000437-13","July 12, 2021","October 22, 2024","October 22, 2024","April 28, 2021",,"July 21, 2021","Regeneron Research Site, Boca Raton, Florida, United States|Regeneron Research Site, San Antonio, Texas, United States",,"https://ClinicalTrials.gov/show/NCT04863014"
16,"NCT04811716","Pozelimab and Cemdisiran Combination Treatment in Adult Participants With Paroxysmal Nocturnal Hemoglobinuria Who Have Received Pozelimab Monotherapy",,"Enrolling by invitation","No Results Available","Paroxysmal Nocturnal Hemoglobinuria","Drug: Pozelimab|Drug: Cemdisiran","Incidence and severity of treatment emergent adverse events (TEAEs)|Percent change of LDH from pre-treatment to end-of-treatment period|Proportion of participants with adequate control of their LDH|Proportion of participants with normalization of their LDH|Area under the curve (AUC) of LDH over time|AUC of LDH over time|Proportion of participants with breakthrough hemolysis|Proportion of participants with hemoglobin stabilization|Change in hemoglobin levels|Proportion of participants who are transfusion-free|Rate of RBCs transfused|Number of units of RBCs transfused|Change in CH50|Change in fatigue as measured by Functional Assessment of Chronic Illness Therapy-Fatigue (FACIT-Fatigue) scale|Mean change in global health status/quality of life scale (GHS/QoL) on the European Organization for Research and Treatment of Cancer: Quality-of-Life Questionnaire core 30 items (EORTC QLQ-C30)|Mean change in physical function (PF) scores on the EORTC QLQ-C30|Concentrations of total pozelimab in serum|Concentrations of cemdisiran in plasma|Change from baseline in concentration of total C5|Incidence of pozelimab anti-drug antibody (ADA) responses over time|Incidence of cemdisiran anti-drug antibody (ADA) responses over time|Incidence and severity of TEAEs for participants who received treatment intensification|Change of LDH|Percent change of LDH|Proportion of participants with normalization of LDH|Percent change in CH50|Change in GHS/QoL on the EORTC QLQ-C30|Change in PF scores on the EORTC QLQ-C30|Incidence and severity of TEAEs|Concentrations of total C5","Regeneron Pharmaceuticals","All","18 Years and older   (Adult, Older Adult)","Phase 2","24","Industry","Interventional","Allocation: Randomized|Intervention Model: Parallel Assignment|Masking: None (Open Label)|Primary Purpose: Treatment","R3918-PNH-2092|2020-005005-17","July 28, 2021","January 28, 2024","January 28, 2024","March 23, 2021",,"August 3, 2021","Regeneron Research Site, Budapest, Nagyvárad Tér 1, Hungary|Regeneron Research Site, Seoul, Seoul Teugbyeolsi, Korea, Republic of",,"https://ClinicalTrials.gov/show/NCT04811716"
17,"NCT03936335","An Observational Retrospective Cohort Study Being Conducted in Women With Atopic Dermatitis (AD)",,"Recruiting","No Results Available","Adverse Pregnancy Outcomes|Atopic Dermatitis","Drug: dupilumab","Incidence of major congenital malformations|Incidence of spontaneous abortion or miscarriage|Incidence of stillbirth|Incidence of small for gestational age","Regeneron Pharmaceuticals|Sanofi","Female","18 Years to 49 Years   (Adult)",,"3930","Industry","Observational","Observational Model: Cohort|Time Perspective: Retrospective","R668-AD-1760","September 30, 2019","July 21, 2027","July 21, 2027","May 3, 2019",,"February 21, 2022","Regeneron Research Site, Boston, Massachusetts, United States",,"https://ClinicalTrials.gov/show/NCT03936335"
18,"NCT04417894","A Study to Evaluate the Efficacy and Safety of Dupilumab in Adult and Adolescent Patients With Moderate-to-Severe Atopic Hand and Foot Dermatitis (Liberty-AD-HAFT)",,"Recruiting","No Results Available","Moderate to Severe Atopic Hand and Foot Dermatitis","Drug: dupilumab|Drug: Placebo","Proportion of patients achieving an Investigator Global Assessment (IGA) (hand and foot) score of 0 or 1|Proportion of patients with improvement (reduction) of weekly average of daily hand and foot peak Pruritus Numerical Rating Scale (NRS) ≥4|Proportion of patients with improvement (reduction) of weekly average of daily hand and foot peak Pruritus NRS ≥3|Percent change in weekly average of daily hand and foot peak Pruritus NRS|Percent change in Modified Total Lesion Sign Score (mTLSS) for hand/foot lesions|Percent change in weekly average of daily hand and foot peak Pain NRS|Percent change in weekly average of daily Sleep NRS|Change in percent surface area of hand and foot involvement with AD|Proportion of patients with improvement (reduction) of weekly average of daily hand and foot peak Pruritus NRS ≥4|Percent change in Hand Eczema Severity Index (HECSI) score|Proportion of patients with HECSI-75|Proportion of patients with HECSI-50|Proportion of patients with HECSI-90|Change in Quality of Life in Hand Eczema Questionnaire (QOLHEQ)|Change in Work Productivity and Impairment (WPAI) + Classroom Impairment Questionnaire (CIQ)|Incidence of treatment-emergent adverse events (TEAEs)|Trough concentration of functional dupilumab in serum|Incidence of treatment-emergent anti-drug antibody (ADA) and titer","Regeneron Pharmaceuticals|Sanofi","All","12 Years and older   (Child, Adult, Older Adult)","Phase 3","130","Industry","Interventional","Allocation: Randomized|Intervention Model: Parallel Assignment|Masking: Quadruple (Participant, Care Provider, Investigator, Outcomes Assessor)|Primary Purpose: Treatment","R668-AD-1924|2019-003088-22","April 14, 2021","November 17, 2022","May 25, 2023","June 5, 2020",,"May 20, 2021","Regeneron Study Site, Rockville, Maryland, United States|Regeneron Study Site, Saint Joseph, Missouri, United States",,"https://ClinicalTrials.gov/show/NCT04417894"
19,"NCT03838731","Study in Cat-Allergic Patients With Asthma to Evaluate the Efficacy of a Single Dose of REGN1908-1909 to Reduce Bronchoconstriction Upon Cat Allergen Challenge",,"Completed","Has Results","Cat Allergy|Mild Asthma","Drug: REGN1908-1909|Drug: Placebo","Time to Early Asthmatic Response (EAR) Upon Controlled Cat Allergen Challenge in an Environmental Exposure Unit (EEU) on Day 8|Time to EAR Upon Controlled Cat Allergen Challenge in an EEU on Days 29, 57, and 85|Percent Change in Normalized Area Under the Curve (AUC) of Forced Expiratory Volume in 1 Second (FEV1) Induced by a Controlled Cat Allergen Challenge Over Exposure Interval From Baseline to Controlled Cat Allergen Challenge on Days 8, 29, 57, and 85|Change in Normalized Area Under the Curve (AUC) of Forced Expiratory Volume in 1 Second (FEV1) Induced by a Controlled Cat Allergen Challenge Over Exposure Interval From Baseline to Controlled Cat Allergen Challenge on Days 8, 29, 57, and 85|Change From Baseline in the Normalized AUC of Patient-Assessed Nasal Symptoms Induced by a Controlled Cat Allergen Challenge Over the Exposure Interval to the Controlled Cat Allergen Challenge on Days 8, 29, 57, and 85|Change From Baseline in the Normalized AUC in Patient-Assessed Ocular Symptoms Induced by a Controlled Cat Allergen Challenge Over the Exposure Interval to the Controlled Cat Allergen Challenge on Days 8, 29, 57, and 85|Mean Change From Baseline in Cat Allergen Quantity as Experienced by Participants During Exposure on Days 8, 29, 57, and 85|Percent Change in Cat Allergen Quantity as Experienced by Participants During Exposure on Days 8, 29, 57, and 85|Number of Non-Serious and Serious Treatment-Emergent Adverse Events (TEAEs) Through End of Study","Regeneron Pharmaceuticals","All","18 Years to 65 Years   (Adult, Older Adult)","Phase 2","56","Industry","Interventional","Allocation: Randomized|Intervention Model: Parallel Assignment|Masking: Quadruple (Participant, Care Provider, Investigator, Outcomes Assessor)|Primary Purpose: Treatment","R1908-1909-ALG-1703|2018-002477-22","February 12, 2019","December 21, 2019","April 6, 2020","February 12, 2019","July 1, 2021","July 1, 2021","Regeneron Research Site, Strasbourg, France","""Study Protocol"", https://ClinicalTrials.gov/ProvidedDocs/31/NCT03838731/Prot_000.pdf|""Statistical Analysis Plan"", https://ClinicalTrials.gov/ProvidedDocs/31/NCT03838731/SAP_001.pdf","https://ClinicalTrials.gov/show/NCT03838731"
20,"NCT03645746","Safety, Tolerability, and Pharmacokinetics of REGN5069 in Healthy Volunteers",,"Completed","No Results Available","Healthy Volunteer","Drug: REGN5069|Drug: Placebo","Incidence and severity of treatment-emergent adverse events (TEAEs)|Incidence of laboratory abnormalities|Incidence of vital signs abnormalties|Incidence of standard 12-lead electrocardiogram (ECG) abnormalties|Concentration of REGN5069 in serum over time|Incidence of anti-drug antibody (ADA)","Regeneron Pharmaceuticals","All","18 Years to 55 Years   (Adult)","Phase 1","56","Industry","Interventional","Allocation: Randomized|Intervention Model: Sequential Assignment|Masking: Quadruple (Participant, Care Provider, Investigator, Outcomes Assessor)|Primary Purpose: Basic Science","R5069-HV-1810|2018-000651-41","August 23, 2018","September 30, 2019","September 30, 2019","August 24, 2018",,"November 26, 2019","Regeneron Research Facility, Gent, Belgium",,"https://ClinicalTrials.gov/show/NCT03645746"
21,"NCT03767738","Study to Evaluate an Aflibercept (EYLEA®) Prefilled Syringe",,"Completed","Has Results","Chorioretinal Vascular Disease","Drug: Intravitreal Aflibercept Injection (IAI)","Number of Aflibercept Injections Successfully Administered Utilizing the Prefilled Syringe (PFS)|Incidence of Ocular Treatment-Emergent Adverse Events (TEAEs) of Study Eye Through Day 29|Incidence of Ocular Serious TEAEs of Study Eye Through Day 29","Regeneron Pharmaceuticals","All","18 Years and older   (Adult, Older Adult)","Phase 4","65","Industry","Interventional","Allocation: N/A|Intervention Model: Single Group Assignment|Masking: None (Open Label)|Primary Purpose: Treatment","VGFTe-OD-1881","December 19, 2018","August 19, 2020","August 19, 2020","December 7, 2018","September 16, 2021","September 16, 2021","Regeneron Study Site, Houston, Texas, United States|Regeneron Study Site, The Woodlands, Texas, United States","""Study Protocol"", https://ClinicalTrials.gov/ProvidedDocs/38/NCT03767738/Prot_000.pdf|""Statistical Analysis Plan"", https://ClinicalTrials.gov/ProvidedDocs/38/NCT03767738/SAP_001.pdf","https://ClinicalTrials.gov/show/NCT03767738"
22,"NCT03746704","Study of ImmunoPet Imaging of PD-L1 in Tumors Using 89Zr-DFO-REGN3504 in Adult Participants With Advanced PD-L1 Positive Malignancies",,"Terminated","No Results Available","Advanced PD-L1 Positive Malignancies","Drug: 89Zr˗DFO˗REGN3504","Incidence and severity of treatment-emergent adverse events (TEAEs)|Standardized uptake value (SUV) of 89Zr˗DFO˗REGN3504 in the blood pool|Clinical dosimetry based on the equivalent dose of radiation|Clinical dosimetry based on the effective dose of radiation|SUVs across the tumor region of interest (ROIs)|Maximal SUVs (SUVmax) within tumor ROIs|Pharmacokinetics (PK) of 89Zr˗DFO˗REGN3504; plasma tracer activity concentration of area under the curve (AUC0-7)|Change in SUV of 89Zr˗DFO˗REGN3504 in the blood pool|Change in SUVs across the tumor ROIs|Change in SUVmax within the tumor ROIs|Biodistribution of 89Zr˗DFO˗REGN3504","Regeneron Pharmaceuticals","All","18 Years and older   (Adult, Older Adult)","Phase 1","2","Industry","Interventional","Allocation: N/A|Intervention Model: Sequential Assignment|Masking: None (Open Label)|Primary Purpose: Basic Science","R3504-ONC-1701","September 4, 2019","July 8, 2021","July 8, 2021","November 20, 2018",,"February 23, 2022","Regeneron Study Site, New York, New York, United States|Regeneron Study Site, New York, New York, United States",,"https://ClinicalTrials.gov/show/NCT03746704"
23,"NCT03051347","Asthma and Atopic Dermatitis Validation of PROMIS Pediatric Instruments",,"Completed","No Results Available","Atopic Dermatitis|Ichthyosis|Psoriasis","Other: Itch Questionnaire and Interview|Other: Stigma Questionnaire and Interview|Other: Cognitive Interview and PROMIS Itch Questionnaire","Analysis and Coding of Itch & Stigma questionnaire Responses|Validation of PROMIS Pediatric Instruments","Northwestern University|Regeneron Pharmaceuticals","All","up to 17 Years   (Child)","Not Applicable","943","Other|Industry","Interventional","Allocation: Non-Randomized|Intervention Model: Single Group Assignment|Masking: None (Open Label)|Primary Purpose: Other","ASP11022015","September 2016","February 9, 2020","June 30, 2020","February 13, 2017",,"October 9, 2020","Department of Dermatology, Northwestern University Feinberg School of Medicine and Lurie Children's Hospital, Chicago, Illinois, United States",,"https://ClinicalTrials.gov/show/NCT03051347"
24,"NCT03530514","A Study to Examine the Safety, Tolerability and Biological Effects of REGN4461 in Healthy Volunteers",,"Completed","No Results Available","Healthy Volunteers","Drug: REGN4461|Drug: Placebo","Number of treatment-emergent adverse events (TEAEs)|Concentrations of REGN4461 in serum over time|Percent change from baseline to week 12 in body weight in overweight or obese participants|Absolute change from baseline to week 12 in body weight in overweight or obese participants|Change from baseline in caloric intake in response to standardized meals in overweight or obese participants|Change in lipid-regulating protein levels over time after single doses of REGN4461|Change in lipid-regulating protein levels over time after repeated doses of REGN4461|Incidence of anti-drug antibodies to REGN4461 over time after single doses of REGN4461|Incidence of anti-drug antibodies to REGN4461 over time after repeated doses of REGN4461|Pharmacokinetic (PK) parameter: Area under curve (AUC) computed from time zero to the time of the last positive concentration (AUClast)|PK parameter: AUC computed across a dosing interval with length τ (AUCo-τ)|PK parameter: peak concentration (Cmax)|PK parameter: time to Cmax (tmax)|PK parameter: clearance (CL)|PK parameter: trough concentration (Ctrough)","Regeneron Pharmaceuticals","All","18 Years to 65 Years   (Adult, Older Adult)","Phase 1","113","Industry","Interventional","Allocation: Randomized|Intervention Model: Sequential Assignment|Masking: Triple (Participant, Investigator, Outcomes Assessor)|Primary Purpose: Basic Science","R4461-HV-1794|2018-000327-14","April 24, 2018","January 27, 2020","January 27, 2020","May 21, 2018",,"March 9, 2020","Regeneron Investigational Site, Antwerp, Belgium",,"https://ClinicalTrials.gov/show/NCT03530514"
25,"NCT01239017","A Study of the Safety and Efficacy of Subcutaneously Administered REGN475 in Patients With Osteoarthritis of the Knee",,"Withdrawn","No Results Available","Osteoarthritis","Biological: REGN475|Other: Placebo","The incidence of treatment-emergent adverse events (TEAEs) in patients treated with REGN475 or placebo.|Time-integrated change from baseline in walking knee pain using the Numeric Rating Scale (NRS).|Change from baseline in walking knee pain using the Numeric Rating Scale (NRS).|Time-integrated change from baseline in The Western Ontario and McMaster Osteoarthritis Index (WOMAC)|Change from baseline in The Western Ontario and McMaster Osteoarthritis Index (WOMAC)|Patient assessment of response to treatment over time using the Patient Global Impression of Change.|Change from baseline in patient-rated QOL using the Short-Form 12-Item Questionnaire (SF-12).","Regeneron Pharmaceuticals|Sanofi","All","40 Years to 75 Years   (Adult, Older Adult)","Phase 2","0","Industry","Interventional","Allocation: Randomized|Intervention Model: Single Group Assignment|Masking: Quadruple (Participant, Care Provider, Investigator, Outcomes Assessor)|Primary Purpose: Treatment","R475-PN-1004",,,,"November 11, 2010",,"March 18, 2015",,,"https://ClinicalTrials.gov/show/NCT01239017"
26,"NCT01053702","Study of the Safety and Efficacy of REGN475(SAR164877) in Patients With Pain Resulting From Thermal Injury",,"Withdrawn","No Results Available","Thermal Injury Pain","Drug: R475|Drug: Placebo","Change in procedural pain intensity|Cumulative analgesic usage|Weekly Patient-rated Global Impression of Change|Additional quality of life assessments","Regeneron Pharmaceuticals|Sanofi","All","18 Years to 50 Years   (Adult)","Phase 2","0","Industry","Interventional","Allocation: Randomized|Intervention Model: Parallel Assignment|Masking: Quadruple (Participant, Care Provider, Investigator, Outcomes Assessor)|Primary Purpose: Treatment","R475-PN-0909",,,,"January 21, 2010",,"April 19, 2011","Tampa, Florida, United States",,"https://ClinicalTrials.gov/show/NCT01053702"
27,"NCT00609544","Study of the Safety and Effectiveness of Rilonacept (IL-1 Trap) Administered Subcutaneously in Subjects With Non Dialysis-Dependent Chronic Kidney Disease (NDD-CKD) and Anemia",,"Withdrawn","No Results Available","Chronic Kidney Disease|Anemia","Drug: Rilonacept","Change in blood hemoglobin concentration.","Regeneron Pharmaceuticals|Syneos Health","All","18 Years and older   (Adult, Older Adult)","Phase 2","0","Industry|Other","Interventional","Allocation: Randomized|Intervention Model: Parallel Assignment|Masking: Triple (Participant, Care Provider, Investigator)|Primary Purpose: Treatment","IL1T-AN-0704",,,,"February 7, 2008",,"April 19, 2011","Alexander City, Alabama, United States|Muscle Shoals, Alabama, United States|Cerritos, California, United States|Long Beach, California, United States|Los Alampios, California, United States|Thousand Palms, California, United States|Colorado Springs, Colorado, United States|Lauderdale Lakes, Florida, United States|Pembroke Pines, Florida, United States|Tampa, Florida, United States|Blue Ridge, Georgia, United States|Jonesboro, Georgia, United States|Portland, Maine, United States|Queens, New York, United States|Mooresville, North Carolina, United States|Shelby, North Carolina, United States|Allentown, Pennsylvania, United States|Harrisburg, Pennsylvania, United States|Orangeburg, South Carolina, United States|Sumter, South Carolina, United States|Barlett, Tennessee, United States|Clarksville, Tennessee, United States|Collierville, Tennessee, United States|Crossville, Tennessee, United States|Memphis, Tennessee, United States|Ogden, Utah, United States|Falls Church, Virginia, United States",,"https://ClinicalTrials.gov/show/NCT00609544"
28,"NCT00383370","Safety and Tolerability of Intravitreal VEGF Trap Formulations in Subjects With Neovacular AMD",,"Completed","No Results Available","Neovascular Age Related Macular Degeneration","Drug: VEGF Trap|Biological: VEGF Trap","The primary endpoint of the study will be safety and tolerability of the study treatment at Week 12 as assessed by ophthalmic examination and reporting of AEs.","Regeneron Pharmaceuticals","All","50 Years and older   (Adult, Older Adult)","Phase 1","20","Industry","Interventional","Allocation: Randomized|Intervention Model: Parallel Assignment|Masking: Triple (Participant, Investigator, Outcomes Assessor)|Primary Purpose: Treatment","VGFT-OD-0603","October 2006","September 2007","July 2008","October 3, 2006",,"April 21, 2011","Fort Myers, Florida, United States|Wichita, Kansas, United States|Hagerstown, Maryland, United States|Columbia, South Carolina, United States|Austin, Texas, United States|McAllen, Texas, United States",,"https://ClinicalTrials.gov/show/NCT00383370"
29,"NCT00320814","Phase 1 Study of VEGF Trap in Patients With Diabetic Macular Edema",,"Completed","No Results Available","Diabetic Macular Edema","Drug: VEGF Trap-Eye","To assess the ocular and systemic safety and tolerability of a single intravitreal (IVT) injection of VEGF Trap-Eye in patients with diabetic macular edema (DME)|To obtain a preliminary assessment of the effect of a single dose of VEGF Trap-Eye on central retinal thickness (CRT) at the center point as determined by optical coherence tomography (OCT)|To obtain a preliminary assessment of the effect of a single IVT administration of VEGF Trap-Eye on visual acuity","Regeneron Pharmaceuticals","All","18 Years and older   (Adult, Older Adult)","Phase 1","5","Industry","Interventional","Allocation: Non-Randomized|Intervention Model: Single Group Assignment|Masking: None (Open Label)|Primary Purpose: Treatment","VGFT-OD-0512","April 2006","August 2006","August 2007","May 3, 2006",,"June 10, 2011","Baltimore, Maryland, United States|Charlotte, North Carolina, United States",,"https://ClinicalTrials.gov/show/NCT00320814"
30,"NCT04209634","Open-Label Efficacy and Safety Study of Pozelimab in Patients With CD55-Deficient Protein-Losing Enteropathy (CHAPLE Disease)",,"Active, not recruiting","No Results Available","CD55-deficient Protein-losing Enteropathy|CHAPLE","Drug: Pozelimab","Proportion of patients with active disease at baseline achieving both normalization of serum albumin and clinical outcome improvement|Incidence and severity of treatment-emergent adverse events (TEAEs)|Improvement in each patient's most bothersome sign/symptom|Proportion of patients with active disease at baseline who maintain disease control|Proportion of patients with inactive disease on eculizumab at baseline who maintain disease control|The number of bowel movements per day based on a 1-week average|The number of days/week with ≥1 bowel movement of loose/watery stool consistency|Physician assessment of facial edema|Physician assessment of peripheral edema|Change in abdominal symptoms|Health-related quality of life as assessed by the PedsQL™ Generic Core Scales for about my work/studies and school functioning sub-scale|Health-related quality of life as assessed by the PedsQL™ Generic Core Scales for physical functioning sub-scale|Assessment of abdominal ascites|Frequency of albumin infusions|Total albumin absolute value|Total albumin absolute change from baseline|Total albumin percent change|Total albumin time to first normalization|Total protein absolute value|Total protein absolute change from baseline|Total protein percent change|Total protein time to first normalization|Total Ig absolute value|Total Ig absolute change from baseline|Total Ig percent change|Total Ig time to first normalization|Total IgG absolute value|Total IgG absolute change from baseline|Total IgG percent change|Total IgG time to first normalization|Total IgM absolute value|Total IgM absolute change from baseline|Total IgM percent change|Total IgM time to first normalization|Total IgA absolute value|Total IgA absolute change from baseline|Total IgA percent change|Total IgA time to first normalization|Total Vitamin B12 absolute value|Total Vitamin B12 change|Total Vitamin B12 time to first normalization|Total folate absolute value|Total folate change|Total folate time to first normalization|Total iron absolute value|Total iron change|Total iron time to first normalization|Total iron binding capacity absolute value|Total iron binding capacity change|Total iron binding capacity time to first normalization|Total ferritin absolute value|Total ferritin change|Total ferritin time to first normalization|Total magnesium absolute value|Total magnesium change|Total magnesium time to first normalization|Total fasting cholesterol absolute value|Total fasting cholesterol change|Total fasting cholesterol time to first normalization|Total fasting triglycerides absolute value|Total fasting triglycerides change|Total fasting triglycerides time to first normalization|Change in alpha-1 antitrypsin levels in blood|Change in alpha-1 antitrypsin levels in stool|Number of participants use of conmeds|Percentage of days hospitalized|Body weight expressed as z score|Height expressed as z score|Concentrations of total pozelimab in serum|Incidence of treatment-emergent anti-drug antibodies to pozelimab in patients|Change from baseline of total complement activity CH50 assay|Percent change from baseline of total complement activity CH50 assay","Regeneron Pharmaceuticals","All","1 Year and older   (Child, Adult, Older Adult)","Phase 2|Phase 3","10","Industry","Interventional","Allocation: N/A|Intervention Model: Single Group Assignment|Masking: None (Open Label)|Primary Purpose: Treatment","R3918-PLE-1878","January 27, 2020","November 9, 2021","August 17, 2023","December 24, 2019",,"December 21, 2021","Regeneron Research Site, Bethesda, Maryland, United States|Regeneron Research Site, Pathum Wan, Bangkok, Thailand|Regeneron Research Site, Istanbul, Turkey",,"https://ClinicalTrials.gov/show/NCT04209634"
31,"NCT03969849","Study to Assess the Safety, Tolerability, Pharmacokinetic, and Pharmacodynamic Effects of a Single Dose of REGN5713-5714-5715 in Healthy Adult Participants",,"Completed","No Results Available","Healthy Volunteers|Birch Pollen Allergy","Drug: REGN5713-5714-5715|Drug: Matching placebo","Incidence and severity of treatment-emergent adverse events (TEAEs)|The number of participants with abnormal adverse events (AEs)|The number of participants with abnormal vital signs|The number of participants with abnormal 12-lead electrocardiograms (ECGs)|The number or participants with abnormal physical examinations|The number of abnormal laboratory examination|Part B only - The number of participants with abnormal lung function using spirometry - forced vital capacity (FVC) litres (L)|Part B only - The number of participants with abnormal lung function using spirometry - forced expiratory volume in 1 second (FEV1)|Part B only - The number of participants with abnormal lung function using spirometry - FEV1/FVC (%)|Part B only - The number of participants with abnormal lung function using spirometry - peak expiratory flow (PEF) Litre/second (L/s)|Part B only - The number of participants with abnormal lung function using spirometry - forced expiratory flow 25 to 75 (L/s)|Part B only - The number of participants with poorly controlled asthma using asthma control test (ACT)|Total concentration of REGN5713 in serum over time|Total concentration of REGN5714 in serum over time|Total concentration of REGN5715 in serum over time|Immunogenicity as measured by anti-drug antibodies (ADA) to REGN5713|Immunogenicity as measured by ADA to REGN5714|Immunogenicity as measured by ADA to REGN5715|Change in area under the curve (AUC) for TNSS (0 to 1 hour post-peak TNSS) in response to a nasal allergen challenge (NAC) from the pretreatment baseline TNSS AUC (0 to 1 hour post-peak TNSS) for REGN5713-5714-5715 as compared to placebo|Percent change in AUC for TNSS (0 to 1 hour post-peak TNSS) in response to a NAC from the pretreatment baseline TNSS AUC (0 to 1 hour post-peak TNSS) for REGN5713-5714-5715 as compared to placebo|Change in mean wheal diameters of the skin prick test with serial birch allergen titration from the pretreatment baseline for REGN5713-5714-5715 as compared to placebo|Percent change in mean wheal diameters of the skin prick test with serial birch allergen titration from the pretreatment baseline for REGN5713-5714-5715 as compared to placebo","Regeneron Pharmaceuticals","All","18 Years to 60 Years   (Adult)","Phase 1","96","Industry","Interventional","Allocation: Randomized|Intervention Model: Sequential Assignment|Masking: Quadruple (Participant, Care Provider, Investigator, Outcomes Assessor)|Primary Purpose: Treatment","R5713-5714-5715-HV-1857|2018-004681-34","June 3, 2019","March 27, 2020","March 27, 2020","May 31, 2019",,"April 28, 2020","Regeneron Study Site, Antwerp, Belgium|Regeneron Study Site, Ghent, Belgium|Regeneron Study Site, Leuven, Belgium",,"https://ClinicalTrials.gov/show/NCT03969849"
32,"NCT03515629","REGN2810 (Anti-PD-1 Antibody), Platinum-based Doublet Chemotherapy, and Ipilimumab (Anti-CTLA-4 Antibody) Versus Pembrolizumab Monotherapy in Patients With Lung Cancer",,"Completed","No Results Available","Non-small Cell Lung Cancer","Drug: REGN2810/ipi|Drug: REGN2810/chemo/ipi|Drug: Pembrolizumab","PFS as assessed by a blinded Independent Review Committee (IRC) based on Response Evaluation Criteria in Solid Tumors version 1.1 (RECIST 1.1) assessments|Overall survival (OS)|Objective response rate (ORR)|Incidence of Treatment-emergent adverse events (TEAEs)|Incidence of Dose-limiting toxicities (DLTs)|Incidence of serious adverse events (SAEs)|Incidence of deaths|Incidence of laboratory abnormalities|Overall survival|Quality of life (Core 30 Questionnaire)|Quality of life (Lung Cancer 13 Questionnaire)","Regeneron Pharmaceuticals|Sanofi","All","18 Years and older   (Adult, Older Adult)","Phase 3","5","Industry","Interventional","Allocation: Randomized|Intervention Model: Parallel Assignment|Masking: None (Open Label)|Primary Purpose: Treatment","R2810-ONC-16111|2017-001041-27","June 4, 2018","July 29, 2021","July 29, 2021","May 3, 2018",,"August 13, 2021","Regeneron Research Site, Saint Petersburg, Florida, United States|Regeneron Research Site, Cremona, Italy|Regeneron Research Site, Vilnius, Lithuania",,"https://ClinicalTrials.gov/show/NCT03515629"
33,"NCT02999711","Study of Safety, Tolerability, and Pharmacokinetics of Multiple Ascending Doses of REGN3500 in Adults With Moderate Asthma",,"Completed","No Results Available","Asthma|Moderate Asthma","Drug: REGN3500|Drug: Placebo","Incidence of treatment emergent adverse events (TEAEs) after repeat subcutaneous administration|Severity of TEAEs after repeat subcutaneous administration|The concentration-time profile of REGN3500 after repeat subcutaneous administration|Immunogenicity of REGN3500 assessed by measurement of anti-drug antibodies|Percent change in total from baseline forced expiratory volume (FEV) at day 29|Percent change of the average of the prior 7 days of FEV1 at day 29 compared to average daily FEV1 during the last 14 days of screening|Absolute change from baseline fractional exhaled nitric oxide (FeNO) at day 29|Percent change from baseline FeNO at day 29|Change from baseline in biomarkers at day 29|Percent change from baseline in biomarkers at day 29","Regeneron Pharmaceuticals|Sanofi","All","18 Years to 60 Years   (Adult)","Phase 1","23","Industry","Interventional","Allocation: Randomized|Intervention Model: Parallel Assignment|Masking: Quadruple (Participant, Care Provider, Investigator, Outcomes Assessor)|Primary Purpose: Other","R3500-AS-1619|2016-002979-95","February 3, 2017","August 30, 2018","September 10, 2018","December 21, 2016",,"December 12, 2018","Regeneron Research Site, Belfast, Northern Ireland, United Kingdom|Regeneron Research Site, London, United Kingdom|Regeneron Research Site, Manchester, United Kingdom",,"https://ClinicalTrials.gov/show/NCT02999711"
34,"NCT04982224","Study of REGN5093-M114 (METxMET Antibody-Drug Conjugate) in Adult Patients With Mesenchymal Epithelial Transition Factor (MET) Overexpressing Advanced Cancer",,"Recruiting","No Results Available","Advanced NSCLC","Drug: REGN5093-M114","Dose limiting toxicities (DLTs)|Treatment-emergent adverse events (TEAEs)|Serious adverse events (SAEs)|Deaths|Laboratory abnormalities (grade 3 or higher per Common Terminology Criteria for Adverse Events [CTCAE])|Concentrations of REGN5093-M114 in serum|Total monoclonal antibodies (REGN5093- M114 plus unconjugated antibody) in serum|Concentrations of M24 in plasma|Objective response rate (ORR)|ORR|TEAEs|SAEs|Laboratory abnormalities (grade 3 or higher per CTCAE)|Duration of response (DOR)|Disease control rate (DCR)|Time to tumor response (TTR)|Progression free survival (PFS)|Overall survival (OS)|Immunogenicity as measured by anti-drug antibody (ADA) to REGN5093-M114","Regeneron Pharmaceuticals","All","18 Years and older   (Adult, Older Adult)","Phase 1|Phase 2","83","Industry","Interventional","Allocation: N/A|Intervention Model: Single Group Assignment|Masking: None (Open Label)|Primary Purpose: Treatment","R5093-M114-ONC-1864|2020-005065-14","November 9, 2021","September 30, 2026","September 30, 2026","July 29, 2021",,"January 27, 2022","Regeneron Research Facility, Boston, Massachusetts, United States|Regeneron Research Facility, Detroit, Michigan, United States|Regeneron Research Facility, New York, New York, United States|Regeneron Research Facility, New York, New York, United States|Regeneron Research Facility, Pittsburgh, Pennsylvania, United States",,"https://ClinicalTrials.gov/show/NCT04982224"
35,"NCT04790786","UPMC OPTIMISE-C19 Trial, a COVID-19 Study","OPTIMISE-C19","Recruiting","No Results Available","Covid19","Biological: Lilly Bamlanivimab|Biological: Regeneron Casirivimab + Imdevimab|Biological: Lilly Bamlanivimab + Etesevimab|Biological: Sotrovimab","Alive and Free from Hospitalization|All-location mortality at 90 days|All-location mortality at 28 days|All-cause mortality at 28 days|All-cause mortality at 90 days|Organ-support free days at day 28|SARS-CoV-2 nasopharyngeal viral loads|SARS-CoV-2 plasma viral loads|SARS-CoV-2 antibody titers|SARS-CoV-2 antibody neutralization|SARS-CoV-2 immune responses|Detection of SARS-CoV-2 variants through next-generation sequencing|Duration of SAR-CoV-2 infectivity|Non-culture surrogates for SARS-CoV-2 infectivity","University of Pittsburgh Medical Center|University of Pittsburgh|Berry Consultants","All","12 Years to 120 Years   (Child, Adult, Older Adult)","Phase 3","30000","Other","Interventional","Allocation: Randomized|Intervention Model: Parallel Assignment|Masking: None (Open Label)|Primary Purpose: Other","STUDY21020179","March 10, 2021","February 2023","December 2023","March 10, 2021",,"January 21, 2022","UPMC, Pittsburgh, Pennsylvania, United States",,"https://ClinicalTrials.gov/show/NCT04790786"
36,"NCT02647086","Open Label, Drug-Drug Interaction (DDI) Study of Dupilumab (REGN668/SAR231893) in Patients With Moderate to Severe Atopic Dermatitis (AD)",,"Completed","No Results Available","Atopic Dermatitis","Drug: Dupilumab|Drug: Midazolam|Drug: Omeprazole|Drug: Warfarin|Drug: Caffeine|Drug: Metoprolol","Ratio of Area Under Curve last (AUClast) and maximum concentration (Cmax) for Cytochrome P450 substrates from pre-dupilumab administration at baseline (period 1, day 1)|Ratio of AUClast and Cmax for CYP substrates 4 weeks after initiating a weekly regimen of dupilumab (period 2, day 36)|Incidence of treatment-emergent adverse events (TEAEs) from day of first administration of dupilumab to end of study (day 50 for patients who enroll in the OLE study; day 134 for patients who decline participation in the OLE).","Regeneron Pharmaceuticals|Sanofi","All","18 Years and older   (Adult, Older Adult)","Phase 1","14","Industry","Interventional","Allocation: Non-Randomized|Intervention Model: Single Group Assignment|Masking: None (Open Label)|Primary Purpose: Basic Science","R668-AD-1433","December 2015","July 2016","July 2016","January 6, 2016",,"August 22, 2016","Regeneron Study Site, Little Rock, Arkansas, United States|Regeneron Study Site, Centennial, Colorado, United States|Regeneron Study Site, Minneapolis, Minnesota, United States|Regeneron Study Site, Berlin, New Jersey, United States|Regeneron Study Site, Raleigh, North Carolina, United States",,"https://ClinicalTrials.gov/show/NCT02647086"
37,"NCT04852978","COVID-19 Study to Assess Immunogenicity, Safety, and Tolerability of Moderna mRNA-1273 Vaccine Administered With Casirivimab+Imdevimab in Healthy Adult Volunteers",,"Active, not recruiting","No Results Available","Healthy|Chronic Stable Illness","Drug: casirivimab+imdevimab|Biological: Moderna mRNA-1273 vaccine","50% inhibitory dilution (ID50) titers of vaccine-induced neutralizing antibodies to the SARS-CoV-2 S protein|Absolute values in concentrations of vaccine-induced antibodies to SARS-CoV-2 antigens over time|Change from baseline in concentrations of vaccine-induced antibodies to SARS-CoV-2 antigens over time|Percentage change from baseline in concentrations of vaccine-induced antibodies to SARS-CoV-2 antigens over time|50% inhibitory dilution (ID50) titers of vaccine-induced neutralizing antibodies to SARS-CoV-2 S protein assessed over time after the first dose of Moderna mRNA-1273 vaccine|Proportion of participants with treatment-emergent adverse events (TEAEs) throughout the study|Proportion of participants with treatment-emergent serious adverse events (SAEs) throughout the study|Proportion of participants with infusion-related reactions (grade ≥2) to REGN10933+REGN10987|Proportion of participants with injection site reactions (grade ≥3) to REGN10933+REGN10987 or each dose of Moderna mRNA-1273 vaccine|Proportion of participants with hypersensitivity reactions (grade ≥2) to REGN10933+REGN10987 or each dose of Moderna mRNA-1273 vaccine|Concentrations of REGN10933 in serum over time|Concentrations of REGN10987 in serum over time|Immunogenicity, as measured by anti-drug antibodies (ADA) to REGN10933|Immunogenicity, as measured by ADA to REGN10987|Immunogenicity, as measured by neutralizing antibodies (NAb) to REGN10933|Immunogenicity, as measured by NAb to REGN10987","Regeneron Pharmaceuticals","All","18 Years to 90 Years   (Adult, Older Adult)","Phase 2","295","Industry","Interventional","Allocation: Randomized|Intervention Model: Parallel Assignment|Masking: None (Open Label)|Primary Purpose: Treatment","R10933-10987-COV-2118","April 29, 2021","November 25, 2022","November 25, 2022","April 21, 2021",,"February 8, 2022","Regeneron Research Site, Little Rock, Arkansas, United States|Regeneron Research Site, Rogers, Arkansas, United States|Regeneron Research Site, Hialeah, Florida, United States|Regeneron Research Site, Miami, Florida, United States|Regeneron Research Site, Orlando, Florida, United States|Regeneron Research Site, Dayton, Ohio, United States",,"https://ClinicalTrials.gov/show/NCT04852978"
38,"NCT01782703","Defining the Skin and Blood Biomarkers of Pediatric Atopic Dermatitis",,"Recruiting","No Results Available","Atopic Dermatitis|Eczema",,"Cellular infiltrates|Gene expression|Correlation of biomarkers to quality of life","Northwestern University|Rockefeller University|Icahn School of Medicine at Mount Sinai","All","up to 17 Years   (Child)",,"930","Other","Observational","Observational Model: Case-Control|Time Perspective: Cross-Sectional","2013-15143","January 2013","December 2023","December 2023","February 4, 2013",,"February 26, 2021","Ann & Robert H. Lurie Children's Hospital of Chicago, Chicago, Illinois, United States|Northwestern University, Chicago, Illinois, United States|Northbrook Lurie Children's Outpatient Clinic, Northbrook, Illinois, United States|Icahn School of Medicine at Mount Sinai, New York, New York, United States",,"https://ClinicalTrials.gov/show/NCT01782703"
39,"NCT03580694","Study of REGN4659 in Combination With Cemiplimab in Patients With Advanced or Metastatic Non-Small Cell Lung Cancer (NSCLC)",,"Terminated","No Results Available","Carcinoma, Non-Small-Cell Lung","Drug: REGN4659|Drug: Cemiplimab","Rate of dose limiting toxicities (DLTs) during the dose escalation phase|Rate of treatment emergent adverse events (TEAEs)|Rate of immune-related adverse events (irAEs)|Rate of serious adverse events (SAEs)|Rate of deaths|Laboratory abnormalities (grade 3 or higher per Common Terminology Criteria for Adverse Events [CTCAE])|Objective Response Rate (ORR) based on Response Evaluation Criteria in Solid Tumors (RECIST) 1.1 during the dose expansion phase|REGN4659 and cemiplimab concentrations in serum over time|ORR based on RECIST 1.1 during the dose escalation phase|ORR based on immune-based therapy Response Evaluation Criteria (iRECIST)|Best overall response (BOR)|Duration of response (DOR)|Disease control rate|Progression-free-survival (PFS) based on RECIST 1.1|PFS based on iRECIST|Overall survival (OS)","Regeneron Pharmaceuticals","All","18 Years and older   (Adult, Older Adult)","Phase 1","17","Industry","Interventional","Allocation: Non-Randomized|Intervention Model: Parallel Assignment|Masking: None (Open Label)|Primary Purpose: Treatment","R4659-ONC-1795","June 27, 2018","December 4, 2019","December 4, 2019","July 9, 2018",,"March 13, 2020","Regeneron Investigational Site, Chicago, Illinois, United States|Regeneron Investigational Site, Grand Rapids, Michigan, United States|Regeneron Investigational Site, Charlotte, North Carolina, United States|Regeneron Investigational Site, Oklahoma City, Oklahoma, United States|Regeneron Investigational Site, Nashville, Tennessee, United States|Regeneron Investigational Site, San Antonio, Texas, United States",,"https://ClinicalTrials.gov/show/NCT03580694"
40,"NCT04981717","A Study to Examine the Efficacy and Safety of Anti-Fel d 1 Antibodies Injections in Cat-allergic Adolescent and Adult Patients With Allergic Rhinitis Who Live With a Cat",,"Recruiting","No Results Available","Allergic Rhinitis Due to Cat Allergy","Drug: REGN1908-1909|Drug: Matching Placebo","Daily combined symptom and medication score (CSMS) averaged in patients who receive REGN1908-1909 versus placebo.|Daily total nasal symptom score (TNSS) score averaged over the initial 12 weeks of treatment in patients who receive REGN1908-1909 versus placebo|Daily TNSS averaged over the last 12 weeks of treatment in patients who receive REGN1908-1909 versus placebo|Daily CSMS averaged over the last 12 weeks of treatment in patients who receive REGN1908-1909 versus placebo|Daily total symptom score (TSS) score averaged over the initial 12 weeks of treatment in patients who receive REGN1908-1909 versus placebo|Daily TSS averaged over the last 12 weeks of treatment in patients who receive REGN1908-1909 versus placebo|Percent change from baseline to the week 12 cat skin prick test (SPT) mean wheal diameter in patients who receive REGN1908-1909 versus placebo|Percent change from baseline to the end of treatment cat SPT mean wheal diameter in patients who receive REGN1908-1909 versus placebo|Percent change from baseline to week 12 FEV1 in patients with asthma who receive REGN1908-1909 versus placebo|Percent change from baseline to week 60 FEV1 in patients with asthma who receive REGN1908-1909 versus placebo|Daily total ocular symptom score (TOSS) averaged over the initial 12 weeks of treatment in patients who receive REGN1908-1909 versus placebo|Daily total ocular symptom score (TOSS) averaged over the last 12 weeks of treatment in patients who receive REGN1908-1909 versus placebo|Change from baseline to week 12 FEV1 in patients with asthma who receive REGN1908-1909 versus placebo|Change from baseline to week 60 FEV1 in patients with asthma who receive REGN1908-1909 versus placebo|Change from baseline to week 12 Rhinoconjunctivitis Quality of Life Questionnaire for Ages 12+ (RQLQ[S])+12 in patients who receive REGN1908-1909 versus placebo|Change from baseline to week 60 RQLQ(S)+12 in patients who receive REGN1908-1909 versus placebo|Daily medication score (DMS) averaged in patients who receive REGN1908-1909 versus placebo|DMS averaged in patients who receive REGN1908-1909 versus placebo|Percent change from baseline to week 72 in cat SPT mean wheal diameter in patients who receive REGN1908-1909 versus placebo|Asthma daily symptom (ADS) score, averaged over the initial 12 weeks of the treatment period using Asthma Daytime Symptom Diary (ADSD) and the Asthma Nighttime Symptom Diary (ANSD) in patients with asthma who receive REGN1908-1909 versus placebo|Change from baseline to week 12 in Asthma Control Questionnaire 5 Question Version (ACQ-5) in patients with asthma who receive REGN1908-1909 versus placebo|Change from baseline to week 60 in Asthma Control Questionnaire 5 Question Version (ACQ-5) in patients with asthma who receive REGN1908-1909 versus placebo|Daily frequency of asthma rescue medication use, averaged over the initial 12 weeks, in patients with asthma who receive REGN1908-1909 versus placebo|Daily number of nighttime awakenings averaged over the initial 12 weeks in patients with asthma who receive REGN1908-1909 versus placebo|Incidence of treatment-emergent adverse events (TEAEs) throughout the study|Incidence of adverse event of special interests (AESIs) throughout the study|Incidence of serious TEAEs throughout the study|Total REGN1908 concentration in serum over the study duration|Total REGN1909 concentration in serum over the study duration|Incidence of treatment-emergent anti-drug antibodies (ADAs) to REGN1908 throughout the study|Incidence of treatment-emergent ADAs to REGN1909 throughout the study","Regeneron Pharmaceuticals","All","12 Years and older   (Child, Adult, Older Adult)","Phase 3","630","Industry","Interventional","Allocation: Randomized|Intervention Model: Parallel Assignment|Masking: Quadruple (Participant, Care Provider, Investigator, Outcomes Assessor)|Primary Purpose: Treatment","R1908-1909-ALG-2102|2021-002089-42","July 30, 2021","June 28, 2022","August 17, 2023","July 29, 2021",,"January 10, 2022","Regeneron Study Site, Mission Viejo, California, United States|Regeneron Study Site, Riverside, California, United States|Regeneron Study Site, Rolling Hills Estates, California, United States|Regeneron Study Site, San Diego, California, United States|Regeneron Study Site, San Jose, California, United States|Regeneron Study Site, Colorado Springs, Colorado, United States|Regeneron Study Site, Denver, Colorado, United States|Regeneron Study Site, Atlanta, Georgia, United States|Regeneron Study Site, Meridian, Idaho, United States|Regeneron Study Site, Chicago, Illinois, United States|Regeneron Study Site, Oak Park, Illinois, United States|Regeneron Study Site, Springfield, Illinois, United States|Regeneron Study Site, South Bend, Indiana, United States|Regeneron Study Site, Lexington, Kentucky, United States|Regeneron Study Site, Owensboro, Kentucky, United States|Regeneron Study Site, Baltimore, Maryland, United States|Regeneron Study Site, Chevy Chase, Maryland, United States|Regeneron Study Site, Ypsilanti, Michigan, United States|Regeneron Study Site, Plymouth, Minnesota, United States|Regeneron Study Site, Columbia, Missouri, United States|Regeneron Study Site, Missoula, Montana, United States|Regeneron Study Site, Lincoln, Nebraska, United States|Regeneron Study Site, Papillion, Nebraska, United States|Regeneron Study Site, Belleville, New Jersey, United States|Regeneron Study Site, Ocean City, New Jersey, United States|Regeneron Study Site, Skillman, New Jersey, United States|Regeneron Study Site, Teaneck, New Jersey, United States|Regeneron Study Site, Verona, New Jersey, United States|Regeneron Study Site, Bronx, New York, United States|Regeneron Study Site, Brooklyn, New York, United States|Regeneron Study Site, New York, New York, United States|Regeneron Study Site, Asheville, North Carolina, United States|Regeneron Study Site, Cincinnati, Ohio, United States|Regeneron Study Site, Columbus, Ohio, United States|Regeneron Study Site, Dublin, Ohio, United States|Regeneron Study Site, Oklahoma City, Oklahoma, United States|Regeneron Study Site, Happy Valley, Oregon, United States|Regeneron Study Site, Portland, Oregon, United States|Regeneron Study Site, Pittsburgh, Pennsylvania, United States|Regeneron Study Site, East Providence, Rhode Island, United States|Regeneron Study Site, Warwick, Rhode Island, United States|Regeneron Study Site, Charleston, South Carolina, United States|Regeneron Study Site, Seattle, Washington, United States|Regeneron Study Site, Greenfield, Wisconsin, United States|Regeneron Study Site, Milwaukee, Wisconsin, United States|Regeneron Study Site, Gent, Oost-Vlaanderen, Belgium|Regeneron Study Site, Leuven, Vlaams Brabant, Belgium|Regeneron Study Site, Brussels, Belgium|Regeneron Study Site, Erpent, Belgium|Regeneron Study Site, Liege, Belgium|Regeneron Study Site, Brampton, Ontario, Canada|Regeneron Study Site, Hamilton, Ontario, Canada|Regeneron Study Site, Kingston, Ontario, Canada|Regeneron Study Site, Ottawa, Ontario, Canada|Regeneron Study Site, Stouffville, Ontario, Canada|Regeneron Study Site, Toronto, Ontario, Canada|Regeneron Study Site, Toronto, Ontario, Canada|Regeneron Study Site, Windsor, Ontario, Canada|Regeneron Study Site, Levis, Quebec, Canada|Regeneron Study Site, Trois-Rivieres, Quebec, Canada|Regeneron Study Site, Quebec, Canada|Regeneron Study Site, Strasbourg, Bas-Rhin, France|Regeneron Study Site, Heidelberg, Baden-Wurttemberg, Germany|Regeneron Study Site, Stuttgart, Baden-Wurttemberg, Germany|Regeneron Study Site, Memmingen, Bayern, Germany|Regeneron Study Site, Frankfurt am Main, Hessen, Germany|Regeneron Study Site, Viernheim, Hessen, Germany|Regeneron Study Site, Dusseldorf, Nordrhein-Westfalen, Germany|Regeneron Study Site, Munster, Nordrhein-Westfalen, Germany|Regeneron Study Site, Dresden, Sachsen, Germany|Regeneron Study Site, Dresden, Sachsen, Germany|Regeneron Study Site, Dresden, Sachsen, Germany|Regeneron Study Site, Leipzig, Sachsen, Germany|Regeneron Study Site, Leipzig, Sachsen, Germany|Regeneron Study Site, Berlin, Germany|Regeneron Study Site, Berlin, Germany|Regeneron Study Site, Wroclaw, Dolnoslaskie, Poland|Regeneron Study Site, Wroclaw, Dolnoslaskie, Poland|Regeneron Study Site 1, Lodz, Lodzkie, Poland|Regeneron Study Site 2, Lodz, Lodzkie, Poland|Regeneron Study Site, Lodz, Lodzkie, Poland|Regeneron Study Site, Lodz, Lodzkie, Poland|Regeneron Study Site, Lodz, Lodzkie, Poland|Regeneron Study Site, Lublin, Lubelskie, Poland|Regeneron Study Site, Lublin, Lubelskie, Poland|Regeneron Study Site, Zamosc, Lubelskie, Poland|Regeneron Study Site, Krakow, Malopolskie, Poland|Regeneron Study Site, Tarnow, Malopolskie, Poland|Regeneron Study Site, Krakow, Malopolski, Poland|Regeneron Study Site, Piaseczno, Mazowieckie, Poland|Regeneron Study Site, Siedlce, Mazowieckie, Poland|Regeneron Study Site, Rzeszow, Podkarpackie, Poland|Regeneron Study Site, Bialystok, Podlaskie, Poland|Regeneron Study Site, Gdansk, Pomorskie, Poland|Regeneron Study Site, Kielce, Swietokrzyskie, Poland|Regeneron Study Site, Pila, Wielkopolskie, Poland|Regeneron Study Site, Poznan, Poland",,"https://ClinicalTrials.gov/show/NCT04981717"
41,"NCT04959448","Study Assessing Long-teRm Outcomes of dupiluMAb (DUPIXENT®) Treatment in Adult Patients With Chronic Rhinosinusitis With Nasal Polyposis (CRSwNP)","AROMA","Recruiting","No Results Available","Chronic Rhinosinusitis With Nasal Polyposis","Drug: DUPIXENT®","Baseline Patient Characteristics|Baseline Disease Characteristics|DUPIXENT® Treatment Characteristics|CRSwNP Treatment Characteristics|Incidence and severity of adverse events (AEs)|Participant Assessment: Total symptom score (TSS), including sub-scores (nasal congestion [NC] and loss of smell [LOS])|Physician Assessment: Change in University of Pennsylvania Smell Identification Test (UPSIT) score|Physician Assessment: CT-Lund-Mackay Score|Physician Assessment: Nasal Peak Inspiratory Flow (PNIF)|Physician Assessment: - Forced Expiratory Volume in 1 second (FEV1)|Physician Assessment: Fractional exhaled Nitric Oxide (FeNO)|Participant Assessment: Asthma Control Questionnaire, 6-item (ACQ-6)|Participant Assessment: Mini Asthma Quality of Life Questionnaire (MiniAQLQ)|Participant Assessment: Allergic Rhinitis (AR) using AR Visual Analog Scale (VAS)|Participant Assessment: Mini Rhinoconjunctivitis Quality of Life Questionnaire (MiniRQLQ)|Participant Assessment: Sino-Nasal Outcome Test (SNOT-22)|Participant Assessment: Patient Oriented Eczema Measure (POEM)|Participant Assessment: Work Productivity and Activity Impairment Questionnaire for asthma (WPAI-CRSwNP)|Physician Assessment: Changes of Healthcare Utilization|Participant Assessment: Short Form 12|Participant Assessment: European Quality of Life 5-Dimensions, 5-Level Questionnaire (EQ-5D-5L)|Participant Assessment: Global Impression for Symptom Severity, Treatment Satisfaction (Global Patient Assessment)|Physician Assessment: Global Impression for Disease Severity (Global Physician Assessment)","Regeneron Pharmaceuticals|Sanofi","All","18 Years and older   (Adult, Older Adult)",,"1000","Industry","Observational","Observational Model: Cohort|Time Perspective: Prospective","R668-cSNP-2072|EUPAS41656","August 12, 2021","August 17, 2026","August 17, 2026","July 13, 2021",,"March 2, 2022","Regeneron Study Site, Scottsdale, Arizona, United States|Regeneron Study Site, Roseville, California, United States|Regeneron Study Site, Walnut Creek, California, United States|Regeneron Study Site, Lake Mary, Florida, United States|Regeneron Study Site, Boise, Idaho, United States|Regeneron Study Site, Oak Park, Illinois, United States|Regeneron Study Site, Maplewood, Minnesota, United States|Regeneron Study Site, East Providence, Rhode Island, United States|Regeneron Study Site, Greenville, South Carolina, United States|Regeneron Study Site, Summerville, South Carolina, United States|Regeneron Study Site, San Antonio, Texas, United States|Regeneron Study Site, Norfolk, Virginia, United States|Regeneron Study Site, Richmond, Virginia, United States|Regeneron Study Site, Toronto, Ontario, Canada|Regeneron Study Site, Shinagawa-Ku, Tokyo, Japan",,"https://ClinicalTrials.gov/show/NCT04959448"
42,"NCT05081388","COVID-19 Study to Evaluate Safety, Tolerability, and Efficacy of REGN14256+Imdevimab for the Treatment of COVID-19 Adult and Adolescent Patients Without Risk Factors for Progression to Severe Disease",,"Active, not recruiting","No Results Available","SARS-CoV-2","Drug: REGN14256|Drug: imdevimab|Drug: casirivimab + imdevimab|Drug: Placebo","Treatment emergent adverse events (TEAEs)|Severity of TEAEs|Proportion of patients with injection-site reactions (ISRs)|Severity of ISRs|Proportion of patients with hypersensitivity reactions|Severity of hypersensitivity reactions over time|Time-weighted average (TWA) daily change from baseline in viral load (log10 copies/mL)|Time to COVID-19 symptoms resolution|Proportion of patients with treatment-emergent serious adverse events (SAEs)|TEAEs|Proportion of patients with ISRs|Proportion of patients with treatment-emergent SAEs|Time-weighted average change from baseline in viral load|Change from baseline in viral load|Proportion of patients with viral loads below the limit of detection|Concentrations of REGN14256 in serum over time|Concentrations of imdevimab in serum over time|Incidence and titer of anti-drug antibodies (ADA) to REGN14256 over time|Incidence and titer of ADA to imdevimab over time","Regeneron Pharmaceuticals","All","12 Years to 65 Years   (Child, Adult, Older Adult)","Phase 1|Phase 2","1359","Industry","Interventional","Allocation: Randomized|Intervention Model: Parallel Assignment|Masking: Quadruple (Participant, Care Provider, Investigator, Outcomes Assessor)|Primary Purpose: Treatment","R14256-COV-2149|2021-004760-10","November 8, 2021","July 8, 2022","July 8, 2022","October 18, 2021",,"February 21, 2022","Regeneron Research Site, La Mesa, California, United States|Ark Clinical Research, Long Beach, California, United States|PNS Clinical Research, LLC, Mission Viejo, California, United States|Regeneron Research Site, Fort Pierce, Florida, United States|AGA Clinical Trials, Hialeah, Florida, United States|Regeneron Research Site, Loxahatchee Groves, Florida, United States|Charisma Research and Medical Center, Miami Lakes, Florida, United States|Project 4 Research, Inc., Miami, Florida, United States|Universal Medical and Research Center, LLC, Miami, Florida, United States|Global Medical Trials, Miami, Florida, United States|Bio-Medical Research LLC, Miami, Florida, United States|Triple O Research Institute, P.A., West Palm Beach, Florida, United States|Regeneron Research Site, Winter Park, Florida, United States|IACT Health, Columbus, Georgia, United States|Chicago Clinical Research Institute, Chicago, Illinois, United States|Regeneron Research Site, Ames, Iowa, United States|Regeneron Research Site, Marrero, Louisiana, United States|Olive Branch Family Medical Center, Olive Branch, Mississippi, United States|Forte Family Practice, Las Vegas, Nevada, United States|New York Health and Hospitals / Lincoln, Bronx, New York, United States|NYC H+H / Jacobi Medical Center, Bronx, New York, United States|Regeneron Research Site, Wilmington, North Carolina, United States|Regeneron Research Site, Dayton, Ohio, United States|Carolina Medical Research, Clinton, South Carolina, United States|PharmaTex Research, LLC, Amarillo, Texas, United States|Advanced Diagnostics Clinic, River Oaks Hospital and Clinics, Houston, Texas, United States|Regeneron Research Site, Houston, Texas, United States|Regeneron Research Site, Houston, Texas, United States",,"https://ClinicalTrials.gov/show/NCT05081388"
43,"NCT04709575","Study to Assess the Efficacy of Anti-Bet v 1 Monoclonal Antibodies in Adults to Reduce Symptoms of Seasonal Allergic Rhinitis",,"Completed","No Results Available","Allergic Rhinitis|Conjunctivitis","Drug: REGN5713|Drug: REGN5714|Drug: REGN5715|Drug: Placebo","Combined symptom and medication score (CSMS) in participants who receive a single dose of REGN5713-5714-5715 versus placebo|Total symptom score (TSS), averaged over the duration of the birch pollen season, in participants who receive a single dose of REGN5713-5714-5715 versus placebo|Total nasal symptom score (TNSS), averaged over the duration of the birch pollen season, in participants who receive a single dose of REGN5713-5714-5715 versus placebo|Total ocular symptom score (TOSS), averaged over the duration of the birch pollen season, in participants who receive a single dose of REGN5713-5714-5715 versus placebo|Daily medication score (DMS), averaged over the duration of the birch pollen season, in participants who receive a single dose of REGN5713-5714-5715 versus placebo|Incidence of Treatment-Emergent Adverse Events (TEAEs) throughout the study|Incidence of Serious TEAEs throughout the study|Change from baseline to the end of study in birch SPT mean wheal diameter in participants who receive a single dose of REGN5713-5714-5715 versus placebo|Percent change from baseline to the end of study in birch SPT mean wheal diameter in participants who receive a single dose of REGN5713-5714-5715 versus placebo|Serum concentration of REGN5713 over the study duration|Serum concentration of REGN5714 over the study duration|Serum concentration of REGN5715 over the study duration|Incidence of treatment emergent anti-drug antibodies to REGN5713 throughout the study|Incidence of treatment emergent anti-drug antibodies to REGN5714 throughout the study|Incidence of treatment emergent anti-drug antibodies to REGN5715 throughout the study|Number of ""Well Days""","Regeneron Pharmaceuticals","All","18 Years and older   (Adult, Older Adult)","Phase 3","353","Industry","Interventional","Allocation: Randomized|Intervention Model: Parallel Assignment|Masking: Quadruple (Participant, Care Provider, Investigator, Outcomes Assessor)|Primary Purpose: Treatment","R5713-5714-5715-ALG-2001|2020-004094-52","January 14, 2021","August 24, 2021","August 24, 2021","January 14, 2021",,"November 9, 2021","Regeneron Study Site, Bangor, Maine, United States|Regeneron Study Site, Baltimore, Maryland, United States|Regeneron Study Site, Plymouth, Minnesota, United States|Regeneron Study Site, Columbia, Missouri, United States|Regeneron Study Site, Saint Louis, Missouri, United States|Regeneron Study Site, Missoula, Montana, United States|Regeneron Study Site, Verona, New Jersey, United States|Regeneron Study Site, Great Neck, New York, United States|Regeneron Study Site, Cincinnati, Ohio, United States|Regeneron Study Site, Toledo, Ohio, United States|Regeneron Study Site, Portland, Oregon, United States|Regeneron Study Site, Pittsburgh, Pennsylvania, United States|Regeneron Study Site, Lincoln, Rhode Island, United States|Regeneron Study Site, Greenfield, Wisconsin, United States|Regeneron Study Site, Gent, Oost-Vlaanderen, Belgium|Regeneron Study Site, Leuven, Vlaams Brabant, Belgium|Regeneron Study Site, Kingston, Ontario, Canada|Regeneron Study Site, London, Ontario, Canada|Regeneron Study Site, Ottawa, Ontario, Canada|Regeneron Study Site, Toronto, Ontario, Canada|Regeneron Study Site, Toronto, Ontario, Canada|Regeneron Study Site, Toronto, Ontario, Canada|Regeneron Study Site, Trois-Rivieres, Quebec, Canada|Regeneron Study Site, Quebec, Canada|Regeneron Study Site, Hvidovre, Capital, Denmark|Regeneron Study Site, Hellerup, Copenhagen Surroundings, Denmark|Regeneron Study Site, Vejle, South Jutland, Denmark|Regeneron Study Site, Heidelberg, Baden-Wurttemberg, Germany|Regeneron Study Site, Stuttgart, Baden-Wurttemberg, Germany|Regeneron Study Site, Dreieich, Hessen, Germany|Regeneron Study Site, Wiesbaden, Hessen, Germany|Regeneron Study Site, Duisburg, Nordrhein-Westfalen, Germany|Regeneron Study Site, Dusseldorf, North Rhine-Westphalia, Germany|Regeneron Study Site, Dresden, Sachsen, Germany|Regeneron Study Site, Berlin, Germany|Regeneron Study Site, Berlin, Germany|Regeneron Study Site, Hamburg, Germany",,"https://ClinicalTrials.gov/show/NCT04709575"
44,"NCT04666441","COVID-19 Study Assessing the Virologic Efficacy of REGN10933+REGN10987 Across Different Dose Regimens in Adult Outpatients With SARS-CoV-2 Infection",,"Completed","No Results Available","COVID-19","Drug: REGN10933+REGN10987 combination therapy|Drug: Placebo","Time-weighted average daily change from baseline in viral load (log10 copies/mL), as measured by reverse transcription quantitative polymerase chain reaction (RT-qPCR) in nasopharyngeal (NP) swab samples|Time-weighted average daily change from baseline in viral load (log10 copies/mL)|Time-weighted average daily change from baseline in viral load (log10 copies/mL) in patients with high viral load at baseline|Proportion of patients with high viral load|Proportion of patients with viral loads below the limit of detection|Proportion of patients with viral loads below the lower limit of quantification|Change from baseline in viral load (log10 copies/mL) as measured by RT-qPCR in NP samples|Proportion of patients with treatment-emergent serious adverse events (SAEs)|Proportion of patients with infusion-related reactions (grade ≥2)|Proportion of patients with injection-site reactions (grade ≥3)|Proportion of patients with hypersensitivity reactions (grade ≥2)|Concentrations of REGN10933 in serum|Concentrations of REGN10987 in serum|Immunogenicity as measured by anti-drug antibodies (ADAs) to REGN10933|Immunogenicity as measured by neutralizing anti-drug antibody (NAb) to REGN10933|Immunogenicity as measured by anti-drug antibodies (ADAs) to REGN10987|Immunogenicity as measured by neutralizing anti-drug antibody (NAb) to REGN10987","Regeneron Pharmaceuticals","All","18 Years and older   (Adult, Older Adult)","Phase 2","1164","Industry","Interventional","Allocation: Randomized|Intervention Model: Parallel Assignment|Masking: Quadruple (Participant, Care Provider, Investigator, Outcomes Assessor)|Primary Purpose: Treatment","R10933-10987-COV-20145","December 15, 2020","March 4, 2021","September 21, 2021","December 14, 2020",,"October 8, 2021","Regeneron Study Site, Mesa, Arizona, United States|Regeneron Study Site, Tucson, Arizona, United States|Regeneron Study Site, Canoga Park, California, United States|Regeneron Study Site, Long Beach, California, United States|Regeneron Study Site, Los Angeles, California, United States|Regeneron Study Site, Rolling Hills Estates, California, United States|Regeneron Study Site, San Francisco, California, United States|Regeneron Study Site, Santa Monica, California, United States|Regeneron Study Site, Stanford, California, United States|Regeneron Study Site, Colorado Springs, Colorado, United States|Regeneron Study Site, Washington, District of Columbia, United States|Regeneron Study Site, DeLand, Florida, United States|Regeneron Study Site, Fort Pierce, Florida, United States|Regeneron Study Site, Hialeah, Florida, United States|Regeneron Study Site, Hialeah, Florida, United States|Regeneron Study Site, Maitland, Florida, United States|Regeneron Study Site, Miami, Florida, United States|Regeneron Study Site, Miami, Florida, United States|Regeneron Study Site, Saint Petersburg, Florida, United States|Regeneron Study Site, Tampa, Florida, United States|Regeneron Study Site, West Palm Beach, Florida, United States|Regeneron Study Site, Winter Haven, Florida, United States|Regeneron Study Site, Winter Park, Florida, United States|Regeneron Study Site, Atlanta, Georgia, United States|Regeneron Study Site, Columbus, Georgia, United States|Regeneron Study Site, Downers Grove, Illinois, United States|Regeneron Study Site, Ames, Iowa, United States|Regeneron Study Site, Iowa City, Iowa, United States|Regeneron Study Site, Lake Charles, Louisiana, United States|Regeneron Study Site, Marrero, Louisiana, United States|Regeneron Study Site, Shreveport, Louisiana, United States|Regeneron Study Site, Baltimore, Maryland, United States|Regeneron Study Site, Las Vegas, Nevada, United States|Regeneron Study Site, Teaneck, New Jersey, United States|Regeneron Study Site, Bronx, New York, United States|Regeneron Study Site, New York, New York, United States|Regeneron Study Site, Charlotte, North Carolina, United States|Regeneron Study Site, Durham, North Carolina, United States|Regeneron Study Site, Wilmington, North Carolina, United States|Regeneron Study Site, Columbus, Ohio, United States|Regeneron Study Site, Dayton, Ohio, United States|Regeneron Study Site, Dayton, Ohio, United States|Regeneron Study Site, Philadelphia, Pennsylvania, United States|Regeneron Study Site, Charleston, South Carolina, United States|Regeneron Study Site, Clinton, South Carolina, United States|Regeneron Study Site, Amarillo, Texas, United States|Regeneron Study Site, Corpus Christi, Texas, United States|Regeneron Study Site, Houston, Texas, United States|Regeneron Study Site, Houston, Texas, United States|Regeneron Study Site, Houston, Texas, United States|Regeneron Study Site, Houston, Texas, United States|Regeneron Study Site, Pearland, Texas, United States|Regeneron Study Site, Red Oak, Texas, United States|Regeneron Study Site, San Antonio, Texas, United States|Regeneron Study Site, Splendora, Texas, United States|Regeneron Study Site, Tyler, Texas, United States|Regeneron Study Site, Falls Church, Virginia, United States",,"https://ClinicalTrials.gov/show/NCT04666441"
45,"NCT05074433","A Study to Evaluate Efficacy and Safety of Casirivimab+Imdevimab (Monoclonal Antibodies) for Prevention of COVID-19 in Immunocompromised Adolescents and Adults",,"Active, not recruiting","No Results Available","Immunocompromised","Drug: casirivimab+imdevimab|Drug: Placebo","Cumulative incidence of symptomatic (broad term), RT-PCR-confirmed SARS-CoV-2 infection cases|Proportion of participants with grade ≥3 treatment-emergent adverse events (TEAEs)|Proportion of participants with TEAEs leading to study drug discontinuation|Proportion of participants with treatment-emergent serious adverse events (SAEs)|Incidence of adverse events of special interest (AESIs)|Concentration of each mAb over time|Incidence and titer of anti-drug antibodies (ADA) over time|Incidence of neutralizing antibodies (NAb) to each mAb over time","Regeneron Pharmaceuticals","All","12 Years and older   (Child, Adult, Older Adult)","Phase 3","66","Industry","Interventional","Allocation: Randomized|Intervention Model: Sequential Assignment|Masking: Triple (Participant, Care Provider, Investigator)|Primary Purpose: Prevention","R10933-10987-COV-2176|2021-005222-14","October 25, 2021","May 25, 2022","May 25, 2022","October 12, 2021",,"February 23, 2022","Central Alabama Research, Birmingham, Alabama, United States|Baptist Health Center for Clinical Research, Little Rock, Arkansas, United States|Regeneron Study Site, Long Beach, California, United States|Regeneron Study Site, Los Angeles, California, United States|Cedars-Sinai Medical Center, Los Angeles, California, United States|Stanford University, Palo Alto, California, United States|University of California, Sacramento, California, United States|Regeneron Study Site, Stanford, California, United States|James R Berenson MD Inc., West Hollywood, California, United States|University Of Colorado, Aurora, Colorado, United States|Regeneron Study Site, North Haven, Connecticut, United States|Georgetown University, Washington, District of Columbia, United States|Arthritis and Rheumatic Disease Specialties, Aventura, Florida, United States|Innovative Research of West Florida, Inc., Clearwater, Florida, United States|Midway Immunology and Research Center, Fort Pierce, Florida, United States|Elixia COVID-19, Hollywood, Florida, United States|AppleMed Research Group, LLC, Miami, Florida, United States|De La Cruz Research Center, LLC, Miami, Florida, United States|University of South Florida, Tampa, Florida, United States|Florida Medical Clinic, LLC, Zephyrhills, Florida, United States|Regeneron Study Site, Atlanta, Georgia, United States|Regeneron Study Site, Marietta, Georgia, United States|Great Lakes Clinical Trials - Ravenswood, Chicago, Illinois, United States|University of Iowa, Iowa City, Iowa, United States|Tulane University, New Orleans, Louisiana, United States|Institute of Human Virology, Baltimore, Maryland, United States|Johns Hopkins Hospital, Baltimore, Maryland, United States|Laboratory of Clinical Immunology and Microbiology, NIAID, Bethesda, Maryland, United States|Tufts Medical Center, Boston, Massachusetts, United States|Regeneron Study Site, Boston, Massachusetts, United States|Beth Israel Deaconess Medical Center, Boston, Massachusetts, United States|University of Michigan, Ann Arbor, Michigan, United States|Spectrum Health, Grand Rapids, Michigan, United States|Mayo Clinic, Rochester, Minnesota, United States|University of Nebraska Medical Center, Omaha, Nebraska, United States|Jersey Shore University Medical Center, Neptune, New Jersey, United States|Holy Name, Teaneck, New Jersey, United States|Montefiore Medical Center, Bronx, New York, United States|Maimonides Cancer Center, Brooklyn, New York, United States|Icahn School of Medicine at Mount Sinai, New York, New York, United States|Regeneron Study Site, New York, New York, United States|Memorial Sloan Kettering Cancer Center, New York, New York, United States|Regeneron Study Site 2, New York, New York, United States|Regeneron Study Site, Rochester, New York, United States|Regeneron Study Site, Syracuse, New York, United States|SUNY Upstate Medical University, Syracuse, New York, United States|Burke Primary Care, Morganton, North Carolina, United States|Gabrail Cancer Center Research, Canton, Ohio, United States|Regeneron Study Site, Cleveland, Ohio, United States|Miami Valley Hospital, Dayton, Ohio, United States|Altoona Center for Clinical Research, Duncansville, Pennsylvania, United States|Penn Prevention Clinical Research Site, Philadelphia, Pennsylvania, United States|Temple University, Philadelphia, Pennsylvania, United States|Regeneron Study Site, Providence, Rhode Island, United States|West Tennessee Research Institute, Jackson, Tennessee, United States|PharmaTex Research, LLC, Amarillo, Texas, United States|Central Texas Clinical Research, Austin, Texas, United States|Therapeutic Concepts, PA, Houston, Texas, United States|Houston Methodist Hospital, Houston, Texas, United States|MD Anderson Cancer Center, Houston, Texas, United States|Synergy Group Medical,LLC, Houston, Texas, United States|Regeneron Study Site, Richmond, Virginia, United States|Fred Hutchinson Cancer Research Center, Seattle, Washington, United States|Regeneron Study Site, Seattle, Washington, United States|Swedish Medical Center- First Hill, Seattle, Washington, United States|University of Wisconsin - Madison, Madison, Wisconsin, United States|Regeneron Study Site, Cuauhtemoc, Distrito Federal, Mexico",,"https://ClinicalTrials.gov/show/NCT05074433"
46,"NCT04646005","Cemiplimab and ISA101b Vaccine in Adult Participants With Recurrent/Metastatic Human Papillomavirus (HPV)16 Cervical Cancer Who Have Experienced Disease Progression After First Line Chemotherapy",,"Recruiting","No Results Available","Cervical Cancer","Drug: Cemiplimab|Biological: ISA101b","Objective response rate (ORR)|Incidence and severity of treatment emergent adverse events (TEAEs)|Incidence and severity of adverse events of special interest (AESIs)|Incidence and severity of serious adverse events (SAEs)|Incidence and severity of ≥ grade 3 laboratory abnormalities|Duration of response (DOR)|Progression free survival (PFS)|Overall survival (OS)","Regeneron Pharmaceuticals|ISA Pharmaceuticals B.V.","Female","18 Years and older   (Adult, Older Adult)","Phase 2","105","Industry","Interventional","Allocation: N/A|Intervention Model: Single Group Assignment|Masking: None (Open Label)|Primary Purpose: Treatment","R2810-ONC-ISA-1981|2020-001239-29","June 28, 2021","October 22, 2024","October 22, 2024","November 27, 2020",,"January 18, 2022","Regeneron Research Site, Tucson, Arizona, United States|Regeneron Research Site, Tucson, Arizona, United States|Regeneron Research Site, Orange, California, United States|Regeneron Research Site, New Haven, Connecticut, United States|Regeneron Research Site, Lake Success, New York, United States|Regeneron Research Site, Houston, Texas, United States|Regeneron Research Site, Gent, East Flanders, Belgium|Regeneron Research Site, Leuven, Vlaams Brabant, Belgium|Regeneron Research Site, Brussels, Belgium|Regeneron Research Site, Santo Cristo, Rio De Janeiro, Brazil|Regeneron Research Site, Porto Alegre, Rio Grande Do Sul, Brazil|Regeneron Research Site, Itajai, Santa Catarina, Brazil|Regeneron Research Site, Barretos, Sao Paulo, Brazil|Regeneron Research Site, Rio de Janeiro, Brazil|Regeneron Research Site, Meldola, Emilia-Romagna, Italy|Regeneron Research Site, Roma, Lazio, Italy|Regeneron Research Site, Milan, Italy|Regeneron Research Site, Seoul, Korea, Republic of|Regeneron Research Site, Seoul, Korea, Republic of|Regeneron Research Site, Seoul, Korea, Republic of|Regeneron Research Site, Seoul, Korea, Republic of|Regeneron Research Site, Maastricht, Limburg, Netherlands|Regeneron Research Site, Leiden, South Holland, Netherlands|Regeneron Research Site, Groningen, Netherlands|Regeneron Research Site, Nijmegen, Netherlands|Regeneron Research Site, Ivanovo, Ivanovo Region, Russian Federation|Regeneron Research Site, Krasnodar, Krasnodar Region, Russian Federation|Regeneron Research Site, Vsevolozhskiy District, Leningrad Oblast, Russian Federation|Regeneron Research Site, Saint-Petersburg, Saint-Petersburg Region, Russian Federation|Regeneron Research Site, Girona, Catalonia, Spain|Regeneron Research Site, Barcelona, Spain",,"https://ClinicalTrials.gov/show/NCT04646005"
47,"NCT04626635","REGN7075 in Combination With Cemiplimab in Adult Participants With Advanced Solid Tumors","COMBINE-EGFR-1","Recruiting","No Results Available","Advanced Solid Tumors","Drug: REGN7075|Drug: cemiplimab","The incidence of dose-limiting toxicities (DLTs) during the DLT period|Incidence and severity of treatment emergent adverse events (TEAEs)|Incidence and severity of adverse events of special interest (AESIs)|Incidence and severity of serious adverse events (SAEs)|Incidence and severity of grade ≥3 laboratory abnormalities|Objective Response Rate (ORR)|Drug concentrations of REGN7075 in serum|Drug concentrations of cemiplimab|ORR|Progression free survival (PFS)|Duration of Response (DOR)|Disease control rate (DCR)|Complete response (CR) rate|Overall survival (OS)|Incidence of anti-drug antibodies (ADA) to REGN7075|Incidence of ADA to cemiplimab|The incidence and severity of TEAEs|The incidence and severity of AESIs|The incidence and severity of SAEs|The incidence and severity of grade ≥3 laboratory abnormalities","Regeneron Pharmaceuticals","All","18 Years and older   (Adult, Older Adult)","Phase 1|Phase 2","402","Industry","Interventional","Allocation: Non-Randomized|Intervention Model: Sequential Assignment|Masking: None (Open Label)|Primary Purpose: Treatment","R7075-ONC-2009","December 21, 2020","April 3, 2025","April 3, 2025","November 12, 2020",,"December 22, 2021","Regeneron Research Site, Boston, Massachusetts, United States|Regeneron Research Site, Grand Rapids, Michigan, United States|Regeneron Research Site, New Brunswick, New Jersey, United States|Regeneron Research Site, New York, New York, United States|Regeneron Research Site, Columbus, Ohio, United States|Regeneron Research Site, Philadelphia, Pennsylvania, United States|Regeneron Research Site, Nashville, Tennessee, United States",,"https://ClinicalTrials.gov/show/NCT04626635"
48,"NCT04590326","Study of REGN5668 Administered in Combination With Cemiplimab or REGN4018 in Adult Women With Recurrent Ovarian Cancer.",,"Recruiting","No Results Available","Ovarian Cancer|Fallopian Tube Cancer|Primary Peritoneal Cancer","Drug: REGN5668|Drug: Cemiplimab|Drug: REGN4018","Incidence of dose limiting toxicities (DLT)|Incidence of DLTs|Incidence of treatment-emergent adverse events (TEAEs)|Incidence of serious adverse events (SAEs)|Incidence of deaths|Incidence of laboratory abnormalities (Grade 3 or higher per National Cancer Institute Common Terminology Criteria for Adverse Events [NCI-CTCAE] version 5.0 [v5.0])|Concentrations of REGN5668 in serum when dosed alone and in combinations with cemiplimab or REGN4018|ORR defined by RECIST 1.1 (Eisenhauer, 2009) in combination with cemiplimab or REGN4018 (separately by cohort and combination)|Concentration of REGN4018 in serum over time|Concentration of cemiplimab in serum over time|ORR based on iRECIST|BOR based on RECIST 1.1 and iRECIST|DOR based on RECIST 1.1 and iRECIST|DCR based on RECIST 1.1 and iRECIST|PFS based on RECIST 1.1 and iRECIST|CA-125 change from baseline after treatment with REGN5668 in combinations with cemiplimab or REGN4018 (separately by cohort and combination)|Presence or absence of anti-drug antibodies against REGN5668|Presence or absence of anti-drug antibodies against REGN4018|Presence or absence of anti-drug antibodies against cemiplimab","Regeneron Pharmaceuticals","Female","18 Years and older   (Adult, Older Adult)","Phase 1|Phase 2","290","Industry","Interventional","Allocation: Non-Randomized|Intervention Model: Sequential Assignment|Masking: None (Open Label)|Primary Purpose: Treatment","R5668-ONC-1938|2020-000063-23","December 9, 2020","February 11, 2026","February 11, 2026","October 19, 2020",,"July 29, 2021","Regeneron Research Site, San Francisco, California, United States|Regeneron Research Site, Tampa, Florida, United States|Regeneron Research Site, Chicago, Illinois, United States|Regeneron Research Site, Boston, Massachusetts, United States|Regeneron Research Site, Boston, Massachusetts, United States|Regeneron Research Site, Detroit, Michigan, United States|Regeneron Research Site, New York, New York, United States|Regeneron Research Site, Columbus, Ohio, United States|Regeneron Research Site, Providence, Rhode Island, United States|Regeneron Research Site, Salt Lake City, Utah, United States|Regeneron Research Site, Seattle, Washington, United States",,"https://ClinicalTrials.gov/show/NCT04590326"
49,"NCT04515524","Extension Study to Evaluate the Long-Term Outcomes of Pediatric Patients Who Received Treatment for Retinopathy of Prematurity in the VGFTe-ROP-1920 Study (Acronym: Butterfleye Next)",,"Enrolling by invitation","No Results Available","Retinopathy of Prematurity","Other: Non-Interventional","Binocular best-corrected visual acuity (BCVA)|Proportion of Patients with Adverse Events|Proportion of Patients with Serious Adverse Events|Proportion of patients developing unfavorable ocular structural outcome|BCVA in each eye|Refractive spherical equivalent in each eye|Neurodevelopmental outcomes using BSID-III|Neurodevelopmental outcomes using WPPSI-IV|Neurodevelopmental outcomes using VABS-II|Proportion of patients with recurrence of ROP|Proportion of patients requiring treatment for ROP","Regeneron Pharmaceuticals","All","11 Months to 5 Years   (Child)",,"112","Industry","Observational","Observational Model: Cohort|Time Perspective: Prospective","VGFTe-ROP-2036|2020-005875-10","February 5, 2021","December 2, 2026","December 2, 2026","August 17, 2020",,"January 5, 2022","Regeneron Study Site, La Jolla, California, United States|Regeneron Study Site, Loma Linda, California, United States|Regeneron Study Site, San Francisco, California, United States|Regeneron Study Site, New York, New York, United States|Regeneron Study Site, New York, New York, United States|Regeneron Study Site, Cleveland, Ohio, United States|Regeneron Study Site, Providence, Rhode Island, United States|Regeneron Study Site, San Antonio, Texas, United States|Regeneron Study Site, Morgantown, West Virginia, United States|Regeneron Study Site, Pathum wan, Bangkok, Thailand|Regeneron Study Site, Ratchathewi, Bangkok, Thailand|Regeneron Study Site, Hat Yai, Songkla, Thailand|Regeneron Study Site, Chiang Mai, Thailand|Regeneron Study Site, Khon Kaen, Thailand",,"https://ClinicalTrials.gov/show/NCT04515524"
50,"NCT04519437","Study Assessing the Safety, Tolerability, Pharmacokinetics, and Immunogenicity of Repeated Subcutaneous Doses of Anti-Spike (S) SARS-CoV-2 Monoclonal Antibodies (REGN10933+REGN10987) in Adult Volunteers as Related to COVID-19",,"Completed","No Results Available","Healthy|Chronic Stable Illness","Drug: REGN10933+REGN10987|Drug: Placebo","Incidence of adverse event of special interests (AESIs) that occur within 4 days of study drug administration|Concentrations of REGN10933 in serum over time|Concentrations of REGN10987 in serum over time|Proportion of participants with treatment-emergent adverse events (TEAEs)|Severity of TEAEs|Proportion of participants who achieve or exceed target concentration in serum of REGN10933|Proportion of participants who achieve or exceed target concentration in serum of REGN10987|Immunogenicity as measured by anti-drug antibodies (ADA) to REGN10933|Immunogenicity as measured by anti-drug antibodies (ADA) to REGN10987","Regeneron Pharmaceuticals","All","18 Years to 90 Years   (Adult, Older Adult)","Phase 1","974","Industry","Interventional","Allocation: Randomized|Intervention Model: Parallel Assignment|Masking: Quadruple (Participant, Care Provider, Investigator, Outcomes Assessor)|Primary Purpose: Treatment","R10933-10987-HV-2093","July 26, 2020","November 22, 2021","November 22, 2021","August 19, 2020",,"January 26, 2022","Regeneron Study Site, Tempe, Arizona, United States|Regeneron Study Site, Rogers, Arkansas, United States|Regeneron Study Site, Sacramento, California, United States|Regeneron Study Site, Miami, Florida, United States|Regeneron Study Site, Lincoln, Nebraska, United States|Regeneron Study Site, Dayton, Ohio, United States|Regeneron Study Site, Austin, Texas, United States",,"https://ClinicalTrials.gov/show/NCT04519437"
51,"NCT04452318","COVID-19 Study Assessing the Efficacy and Safety of Anti-Spike SARS CoV-2 Monoclonal Antibodies for Prevention of SARS CoV-2 Infection Asymptomatic in Healthy Adults and Adolescents Who Are Household Contacts to an Individual With a Positive SARS-CoV-2 RT-PCR Assay",,"Completed","No Results Available","Healthy Participants","Drug: REGN10933 + REGN10987|Drug: Placebo","Proportion of participants who have a symptomatic RT-qPCR confirmed SARS-CoV-2 infection (broad-term) during the EAP|Proportion of participants with treatment-emergent adverse events (TEAEs) and severity of TEAEs|Proportion of participants who subsequently develop signs and symptoms (broad-term) within 14 days of a positive RT-qPCR at baseline or during the EAP|Proportion of participants with a viral load >4 (log10 copies/mL) in Nasopharyngeal (NP) swab samples during the EAP|Number of weeks of symptomatic RT-qPCR confirmed SARS-CoV-2 infection (broad term) during the EAP|Number of weeks of high viral load >4 (log10 copies/mL) in NP swab samples during the EAP|Number of weeks of RT-qPCR confirmed SARS-CoV-2 infection (regardless of symptoms) during the EAP|Proportion of participants who have a RT-qPCR confirmed SARS-CoV-2 infection (regardless of symptoms) during the EAP|Proportion of participants in placebo group with a RT-qPCR confirmed SARS-CoV-2 infection during the EAP with an index case participating in study R10933-10987-COV-2067 (NCT04425629)|Proportion of participants who have a symptomatic RT-qPCR confirmed SARS-CoV-2 infection (CDC definition) during the EAP|Number of weeks of symptomatic RT-qPCR-confirmed SARS-CoV-2 infection (CDC definition) during the EAP|Proportion of participants who have a symptomatic RT-qPCR confirmed SARS-CoV-2 infection (strict-term) during the EAP|Number of weeks of symptomatic RT-qPCR confirmed SARS-CoV-2 infection (strict-term) during the EAP|Proportion of participants who have a RT-qPCR confirmed SARS-CoV-2 infections at each week in the EAP|Proportion of participants who have a symptomatic RT-qPCR confirmed SARS-CoV-2 infection (broad-term) at each week in the EAP|Time-weighted average of viral load (log10 copies/mL) from the first positive SARS CoV-2 RT-qPCR in NP swab samples (that has an onset during the EAP) until the third weekly visit after the first positive test during the EAP|Time-weighted average of viral load (log10 copies/mL) from the first positive SARS-CoV-2 RT-qPCR in NP swab samples (that has an onset during the EAP) until the second weekly visit after the first positive test during the EAP|Maximum SARS-CoV-2 RT-qPCR viral load (log10 copies/mL) in NP swab samples among individuals with ≥1 RT-qPCR positive that has an onset during the EAP|SARS-CoV-2 RT-qPCR viral load (log10 copies/mL) in NP swab samples corresponding to the onset of first positive RT-qPCR during the EAP|Area under the curve (AUC) in viral load (log10 copies/mL) from the first positive SARS-CoV-2 RT-qPCR NP swab samples detected during the EAP until the first confirmed negative test|Number of medically attended visits in emergency rooms or urgent care centers related to a RT-qPCR confirmed SARS-CoV-2 infection that has an onset during the EAP|Proportion of participants with at least 1 COVID-19-related hospitalization or emergency room visit associated with a positive RT-qPCR during the EAP or all-cause death|Proportion of participants requiring medically attended visits in emergency rooms or urgent care centers related to a RT-qPCR confirmed SARS CoV-2 infection that has an onset during the EAP|Proportion of participants hospitalized related to a RT-qPCR confirmed SARS-CoV-2 infection that has an onset during the EAP|Number of days of hospital and intensive care unit (ICU) stay in participants hospitalized for a RT-qPCR confirmed SARS-CoV-2 infection that has an onset during the EAP|Number of days missed for daily responsibilities (where applicable) due to a RT-qPCR confirmed SARS-CoV-2 infection that has an onset during the EAP|Proportion of participants in the placebo group with a RT-qPCR confirmed SARS-CoV-2 infection during the EAP with at least 1 household member participating either in study R10933-10987-COV-2067 (NCT04425629) or in cohort B|Proportion of subjects who have a symptomatic RT-qPCR confirmed SARS-CoV-2 infection (broad-term) during the EAP|Proportion of baseline seropositive subjects (based on central lab test) with TEAEs and severity of TEAEs|Incidence of symptomatic SARS-CoV-2 infection in seronegative and seropositive participants (based on central lab test) in both the EAP and follow-up periods|Severity of symptomatic SARS-CoV-2 infection in seronegative and seropositive participants (based on central lab test) in both the EAP and follow-up periods|Concentrations of REGN10933 in serum over time and selected PK parameters in seronegative and seropositive participants (based on central lab test)|Concentrations of REGN10987 in serum over time and selected PK parameters in seronegative and seropositive participants (based on central lab test)|Immunogenicity as measured by anti-drug antibodies (ADA) to REGN10933 over time in seronegative and seropositive participants (based on central lab test)|Immunogenicity as measured by neutralizing anti-drug antibodies (NAbs) to REGN10933 over time in seronegative and seropositive participants (based on central lab test)|Immunogenicity as measured by anti-drug antibodies (ADA) to REGN10987 over time in seronegative and seropositive participants (based on central lab test)|Immunogenicity as measured by neutralizing anti-drug antibodies (NAbs) to REGN10987 over time in seronegative and seropositive participants (based on central lab test)|Number of weeks of symptomatic SARS-CoV-2 infection (broad-term) within 14 days of a positive RT-qPCR at baseline or during the EAP|Proportion of participants who subsequently develop signs and symptoms (CDC definition) within 14 days of a positive RT-qPCR at baseline or during the EAP|Proportion of participants who subsequently develop signs and symptoms (strict-term) within 14 days of a positive RT-qPCR at baseline or during the EAP|Number of weeks of symptomatic SARS-CoV-2 infection (CDC definition) within 14 days of a positive RT-qPCR at baseline or during the EAP|Number of weeks of symptomatic SARS CoV-2 infection (strict-term) within 14 days of a postive RT-qPCR at baseline or during the EAP|Change in viral load (log10 copies/mL) from baseline to day 8 visit in NP swab samples|Change in viral load (log10 copies/mL) from baseline to day 15 visit in NP swab samples|Time-weighted average change from baseline in viral load (log10 copies/mL) in NP swab samples until the day 22 visit|Area under the curve (AUC) in viral load (log10 copies/mL) in NP swab samples from baseline to the first confirmed negative test|Maximum SARS-CoV-2 RT-qPCR viral load (log10 copies/mL) in NP swab samples during the EAP|Number of medically attended visits in emergency rooms or urgent care centers related to RT-qPCR confirmed SARS-CoV-2 infection that has an onset at baseline or during the EAP|Proportion of participants requiring medically attended visits in emergency rooms or urgent care centers related to a RT-qPCR confirmed SARS CoV-2 infection that has an onset at baseline or during the EAP|Proportion of participants hospitalized related to a RT-qPCR confirmed SARS-CoV-2 infection that has an onset at baseline or during the EAP|Number of days of hospital and intensive care unit (ICU) stay in participants hospitalized for a RT-qPCR confirmed SARS-CoV-2 infection that has an onset at baseline or during the EAP|Number of days missed for daily responsibilities (where applicable) due to a RT-qPCR confirmed SARS-CoV-2 infection that has an onset at baseline or during the EAP|Proportion of participants with at least one COVID-19 related hospitalization or emergency room visit associated with a positive RT-qPCR at baseline or during the EAP, or all-cause death|Proportion of participants with TEAEs and severity of TEAEs|Incidence of symptomatic SARS-CoV-2 infection in both the EAP and follow-up periods|Severity of symptomatic SARS-CoV-2 infection in both the EAP and follow-up periods","Regeneron Pharmaceuticals","All","Child, Adult, Older Adult","Phase 3","3303","Industry","Interventional","Allocation: Randomized|Intervention Model: Parallel Assignment|Masking: Quadruple (Participant, Care Provider, Investigator, Outcomes Assessor)|Primary Purpose: Treatment","R10933-10987-COV-2069|2020-003654-71","July 13, 2020","October 4, 2021","October 4, 2021","June 30, 2020",,"October 7, 2021","Regeneron Study Site, Mesa, Arizona, United States|Regeneron Study Site, Tucson, Arizona, United States|Regeneron Study Site, Tucson, Arizona, United States|Regeneron Study Site, La Mesa, California, United States|Regeneron Study Site, La Palma, California, United States|Regeneron Study Site, Long Beach, California, United States|Regeneron Study Site, Los Angeles, California, United States|Regeneron Study Site, Los Angeles, California, United States|Regeneron Study Site, Los Angeles, California, United States|Regeneron Study Site, Montclair, California, United States|Regeneron Study Site, Northridge, California, United States|Regeneron Study Site, Oxnard, California, United States|Regeneron Study Site, Sacramento, California, United States|Regeneron Study Site, Sacramento, California, United States|Regeneron Study Site, San Diego, California, United States|Regeneron Study Site, San Francisco, California, United States|Regeneron Study Site, Stanford, California, United States|Regeneron Study Site, Torrance, California, United States|Regeneron Study Site, Torrance, California, United States|Regeneron Study Site, Aurora, Colorado, United States|Regeneron Study Site, Colorado Springs, Colorado, United States|Regeneron Study Site, Washington, District of Columbia, United States|Regeneron Study Site, Boca Raton, Florida, United States|Regeneron Study Site, Clearwater, Florida, United States|Regeneron Study Site, DeLand, Florida, United States|Regeneron Study Site, Fort Pierce, Florida, United States|Regeneron Study Site, Hialeah, Florida, United States|Regeneron Study Site, Jacksonville, Florida, United States|Regeneron Study Site, Lakeland, Florida, United States|Regeneron Study Site, Loxahatchee Groves, Florida, United States|Regeneron Study Site, Maitland, Florida, United States|Regeneron Study Site, Miami, Florida, United States|Regeneron Study Site, Miami, Florida, United States|Regeneron Study Site, Miami, Florida, United States|Regeneron Study Site, Miami, Florida, United States|Regeneron Study Site, Miami, Florida, United States|Regeneron Study Site, Miami, Florida, United States|Regeneron Study Site, Miami, Florida, United States|Regeneron Study Site, Orlando, Florida, United States|Regeneron Study Site, Sarasota, Florida, United States|Regeneron Study Site, Tampa, Florida, United States|Regeneron Study Site, West Palm Beach, Florida, United States|Regeneron Study Site, Winter Park, Florida, United States|Regeneron Study Site, Atlanta, Georgia, United States|Regeneron Study Site, Atlanta, Georgia, United States|Regeneron Study Site, Columbus, Georgia, United States|Regeneron Study Site, Decatur, Georgia, United States|Regeneron Study Site, Eatonton, Georgia, United States|Regeneron Study Site, Marietta, Georgia, United States|Regeneron Study Site, Sandy Springs, Georgia, United States|Regeneron Study Site, Chicago, Illinois, United States|Regeneron Study Site 2, Chicago, Illinois, United States|Regeneron Study Site 3, Chicago, Illinois, United States|Regeneron Study Site, Chicago, Illinois, United States|Regeneron Study Site 1, Downers Grove, Illinois, United States|Regeneron Study Site 2, Downers Grove, Illinois, United States|Regeneron Study Site, Ames, Iowa, United States|Regeneron Study Site, Lake Charles, Louisiana, United States|Regeneron Study Site, Marrero, Louisiana, United States|Regeneron Study Site, Metairie, Louisiana, United States|Regeneron Study Site, New Orleans, Louisiana, United States|Regeneron Study Site, Baltimore, Maryland, United States|Regeneron Study Site, Boston, Massachusetts, United States|Regeneron Study Site, Boston, Massachusetts, United States|Regeneron Study Site, Boston, Massachusetts, United States|Regeneron Study Site, Boston, Massachusetts, United States|Regeneron Study Site, Boston, Massachusetts, United States|Regeneron Study Site, Detroit, Michigan, United States|Regeneron Study Site, Royal Oak, Michigan, United States|Regeneron Study Site, Minneapolis, Minnesota, United States|Regeneron Study Site, Gulfport, Mississippi, United States|Regeneron Study Site, Jackson, Mississippi, United States|Regeneron Study Site, Hazelwood, Missouri, United States|Regeneron Study Site, Saint Louis, Missouri, United States|Regeneron Study Site, Las Vegas, Nevada, United States|Regeneron Study Site, Las Vegas, Nevada, United States|Regeneron Study Site, Morristown, New Jersey, United States|Regeneron Study Site, Newark, New Jersey, United States|Regeneron Study Site, Summit, New Jersey, United States|Regeneron Study Site, Teaneck, New Jersey, United States|Regeneron Study Site 1, Bronx, New York, United States|Regeneron Study Site 2, Bronx, New York, United States|Regeneron Study Site, Bronx, New York, United States|Regeneron Study Site, Buffalo, New York, United States|Regeneron Study Site, New York, New York, United States|Regeneron Study Site, New York, New York, United States|Regeneron Study Site, New York, New York, United States|Regeneron Study Site, New York, New York, United States|Regeneron Study Site, New York, New York, United States|Regeneron Study Site, New York, New York, United States|Regeneron Study Site, Chapel Hill, North Carolina, United States|Regeneron Study Site, Charlotte, North Carolina, United States|Regeneron Study Site, Fayetteville, North Carolina, United States|Regeneron Study Site, Raleigh, North Carolina, United States|Regeneron Study Site, Wilmington, North Carolina, United States|Regeneron Study Site, Winston-Salem, North Carolina, United States|Regeneron Study Site, Cincinnati, Ohio, United States|Regeneron Study Site, Columbus, Ohio, United States|Regeneron Study Site, Columbus, Ohio, United States|Regeneron Study Site, Dayton, Ohio, United States|Regeneron Study Site, Danville, Pennsylvania, United States|Regeneron Study Site, Philadelphia, Pennsylvania, United States|Regeneron Study Site, Philadelphia, Pennsylvania, United States|Regeneron Study Site, Wilkes-Barre, Pennsylvania, United States|Regeneron Study Site, Providence, Rhode Island, United States|Regeneron Study Site, Charleston, South Carolina, United States|Regeneron Study Site, Charleston, South Carolina, United States|Regeneron Study Site, Clinton, South Carolina, United States|Regeneron Study Site, Gaffney, South Carolina, United States|Regeneron Study Site, Sioux Falls, South Dakota, United States|Regeneron Study Site, Chattanooga, Tennessee, United States|Regeneron Study Site, Knoxville, Tennessee, United States|Regeneron Study Site, Memphis, Tennessee, United States|Regeneron Study Site, Nashville, Tennessee, United States|Regeneron Study Site, Bellaire, Texas, United States|Regeneron Study Site, Corpus Christi, Texas, United States|Regeneron Study Site, Dallas, Texas, United States|Regeneron Study Site, Houston, Texas, United States|Regeneron Study Site, Houston, Texas, United States|Regeneron Study Site, Houston, Texas, United States|Regeneron Study Site, Houston, Texas, United States|Regeneron Study Site, Houston, Texas, United States|Regeneron Study Site, Pearland, Texas, United States|Regeneron Study Site, Red Oak, Texas, United States|Regeneron Study Site, San Antonio, Texas, United States|Regeneron Study Site, Tyler, Texas, United States|Regeneron Study Site, Charlottesville, Virginia, United States|Regeneron Study Site, Richmond, Virginia, United States|Regeneron Study Site, Everett, Washington, United States|Regeneron Study Site, Seattle, Washington, United States|Regeneron Study Site, Yakima, Washington, United States|Regeneron Study Site, Madison, Wisconsin, United States|Regeneron Study Site, Chisinau, Moldova, Republic of|Regeneron Study Site, Bucharest, Romania","""Informed Consent Form"", https://ClinicalTrials.gov/ProvidedDocs/18/NCT04452318/ICF_000.pdf","https://ClinicalTrials.gov/show/NCT04452318"
52,"NCT04442269","A Study to Evaluate the Efficacy and Safety of Dupilumab in Participants With Allergic Bronchopulmonary Aspergillosis (ABPA) (LIBERTY ABPA AIRED)",,"Recruiting","No Results Available","Allergic Bronchopulmonary Aspergillosis","Drug: dupilumab|Drug: Placebo","Annualized rate of severe respiratory exacerbations|Change in pre-bronchodilator Forced expiratory volume in 1 second (FEV1) compared to placebo|Change from baseline in pre-bronchodilator FEV1 compared to placebo|Annualized rate of ABPA-related exacerbations compared to placebo|Annualized rate of severe respiratory exacerbations requiring either hospitalization or observation for >24 hours in an ED/urgent care facility compared to compared to placebo|Change from baseline in Asthma Control Questionnaire (ACQ)-5 compared to placebo|Change from baseline in St. George's Respiratory Questionnaire (SGRQ) total score compared to placebo|Percentage of participants achieving a reduction in the SGRQ score of 4 points or greater from baseline compared to placebo|Percent change from baseline in total IgE in serum compared to placebo|Percent change from baseline in A fumigatus-specific IgE in serum compared to placebo|Percent and absolute change from baseline in fractional exhaled nitric oxide (FeNO) compared to placebo|Incidence of treatment-emergent adverse events (TEAEs)|Incidence of treatment-emergent anti-drug antibody (ADA) responses and titer|Concentrations of functional dupilumab in serum by treatment regimen","Regeneron Pharmaceuticals|Sanofi","All","12 Years and older   (Child, Adult, Older Adult)","Phase 3","170","Industry","Interventional","Allocation: Randomized|Intervention Model: Parallel Assignment|Masking: Quadruple (Participant, Care Provider, Investigator, Outcomes Assessor)|Primary Purpose: Treatment","R668-ABPA-1923|2019-002619-24","September 15, 2020","September 26, 2023","December 21, 2023","June 22, 2020",,"February 7, 2022","Regeneron Study Site, Birmingham, Alabama, United States|Regeneron Study Site, Scottsdale, Arizona, United States|Regeneron Study Site, Bakersfield, California, United States|Regeneron Study Site, La Jolla, California, United States|Regeneron Study Site, Los Angeles, California, United States|Regeneron Study Site, Riverside, California, United States|Regeneron Study Site, Stockton, California, United States|Regeneron Study Site, Walnut Creek, California, United States|Regeneron Study Site, Boise, Idaho, United States|Regeneron Study Site, Iowa City, Iowa, United States|Regeneron Study Site, Fort Mitchell, Kentucky, United States|Regeneron Study Site, Minneapolis, Minnesota, United States|Regeneron Study Site, Brick, New Jersey, United States|Regeneron Study Site, Bronx, New York, United States|Regeneron Study Site, New York, New York, United States|Regeneron Study Site, Syracuse, New York, United States|Regeneron Study Site, Mooresville, North Carolina, United States|Regeneron Study Site, DuBois, Pennsylvania, United States|Regeneron Study Site, Cudahy, Wisconsin, United States|Regeneron Study Site, Haskovo, Bulgaria|Regeneron Study Site, Razgrad, Bulgaria|Regeneron Study Site, Smolyan, Bulgaria|Regeneron Study Site, Sofia, Bulgaria|Regeneron Study Site, Vancouver, British Columbia, Canada|Regeneron Study Site, Ottawa, Ontario, Canada|Regeneron Study Site, Montreal, Quebec, Canada|Regeneron Study Site, Quebec City, Quebec, Canada|Regeneron Study Site, Brest, France|Regeneron Study Site, Grenoble, France|Regeneron Study Site, Le Mans, France|Regeneron Study Site, Lyon, France|Regeneron Study Site, Marseille, France|Regeneron Study Site, Montpellier, France|Regeneron Study Site, Paris, France|Regeneron Study Site, Pessac, France|Regeneron Study Site, Reims Cedex, France|Regeneron Study Site, Rennes, France|Regeneron Study Site, Suresnes, France|Regeneron Study Site, Tours, France|Regeneron Study Site, Leipzig, Saxony, Germany|Regeneron Study Site, Berlin, Germany|Regeneron Study Site, Berlin, Germany|Regeneron Study Site, Frankfurt am Main, Germany|Regeneron Study Site, Hannover, Germany|Regeneron Study Site, Koln, Germany|Regeneron Study Site, Schleswig, Germany|Regeneron Study Site, Budapest, Hungary|Regeneron Study Site, Debrecen, Hungary|Regeneron Study Site, Fukuyama, Japan|Regeneron Study Site, Kanagawa, Japan|Regeneron Study Site, Nagoya, Japan|Regeneron Study Site, Naka-gun, Japan|Regeneron Study Site, Sakai, Japan|Regeneron Study Site, Yanagawa, Japan|Regeneron Study Site, Yokohama, Japan|Regeneron Study Site, Arnhem, Netherlands|Regeneron Study Site, Breda, Netherlands|Regeneron Study Site, Eindhoven, Netherlands|Regeneron Study Site, Zutphen, Netherlands|Regeneron Study Site, Bialystok, Poland|Regeneron Study Site, Gdansk, Poland|Regeneron Study Site, Lublin, Poland|Regeneron Study Site, Oradea, Bihor, Romania|Regeneron Study Site, Bragadiru, Romania|Regeneron Study Site, Brasov, Romania|Regeneron Study Site, Bucharest, Romania|Regeneron Study Site, Bucharest, Romania|Regeneron Study Site, Iași, Romania|Regeneron Study Site, London, England, United Kingdom|Regeneron Study Site, Wythenshawe, England, United Kingdom",,"https://ClinicalTrials.gov/show/NCT04442269"
53,"NCT04429503","Study of a High-Dose Aflibercept in Participants With Diabetic Eye Disease","PHOTON","Active, not recruiting","No Results Available","Diabetic Macular Edema|Type 1 Diabetes Mellitus|Type 2 Diabetes Mellitus","Drug: aflibercept|Drug: High-dose aflibercept","Change from baseline in best corrected visual acuity (BCVA)|Proportion of participants without retinal fluid at the foveal center|Proportion of participants with a ≥2 step improvement in Diabetic Retinopathy Severity Scale (DRSS)|Change from baseline in best corrected visual acuity (BCVA) (region-specific analysis)|Proportion of participants gaining ≥15 letters|Proportion of participants with BCVA ≥69 letters|Proportion of participants without fluid at foveal center|Change from baseline in central retinal thickness (CRT)|Proportion of participants without leakage on fluorescein angiography (FA)|Change from baseline in National Eye Institute Visual Function Questionnaire (NEI-VFQ) total score|Systemic exposure to aflibercept as assessed by plasma concentrations|Assessment of immunogenicity to aflibercept by measuring the incidence of treatment-emergent anti-drug antibodies (ADA) response|Safety assessed by adverse events (AEs)|Safety assessed by serious adverse events (SAEs)","Regeneron Pharmaceuticals|Bayer","All","18 Years and older   (Adult, Older Adult)","Phase 2|Phase 3","660","Industry","Interventional","Allocation: Randomized|Intervention Model: Parallel Assignment|Masking: Quadruple (Participant, Care Provider, Investigator, Outcomes Assessor)|Primary Purpose: Treatment","VGFTe-HD-DME-1934|2019-003643-30","June 29, 2020","May 30, 2022","June 9, 2023","June 12, 2020",,"September 2, 2021","Regeneron Study Site, Phoenix, Arizona, United States|Regeneron Study Site, Arcadia, California, United States|Regeneron Study Site, Beverly Hills, California, United States|Regeneron Study Site, Campbell, California, United States|Regeneron Study Site, Encino, California, United States|Regeneron Study Site, Fullerton, California, United States|Regeneron Study Site, Huntington Beach, California, United States|Regeneron Study Site, Long Beach, California, United States|Regeneron Study Site, Palo Alto, California, United States|Regeneron Study Site, Pasadena, California, United States|Regeneron Study Site, Poway, California, United States|Regeneron Study Site, Rancho Cordova, California, United States|Regeneron Study Site, Riverside, California, United States|Regeneron Study Site, Torrance, California, United States|Regeneron Study Site, Colorado Springs, Colorado, United States|Regeneron Study Site, Durango, Colorado, United States|Regeneron Study Site, Lakewood, Colorado, United States|Regeneron Study Site, Waterford, Connecticut, United States|Regeneron Study Site, Clearwater, Florida, United States|Regeneron Study Site, Fort Lauderdale, Florida, United States|Regeneron Study Site, Fort Myers, Florida, United States|Regeneron Study Site, Jacksonville, Florida, United States|Regeneron Study Site, Lakeland, Florida, United States|Regeneron Study Site, Largo, Florida, United States|Regeneron Study Site, Melbourne, Florida, United States|Regeneron Study Site, Miami, Florida, United States|Regeneron Study Site, Orlando, Florida, United States|Regeneron Study Site, Pinellas Park, Florida, United States|Regeneron Study Site, Plantation, Florida, United States|Regeneron Study Site, Saint Petersburg, Florida, United States|Regeneron Study Site, Stuart, Florida, United States|Regeneron Study Site, Winter Haven, Florida, United States|Regeneron Study Site, Augusta, Georgia, United States|Regeneron Study Site 1, Marietta, Georgia, United States|Regeneron Study Site 2, Marietta, Georgia, United States|Regeneron Study Site, 'Aiea, Hawaii, United States|Regeneron Study Site, Oak Forest, Illinois, United States|Regeneron Study Site, Springfield, Illinois, United States|Regeneron Study Site, Springfield, Illinois, United States|Regeneron Study Site, Carmel, Indiana, United States|Regeneron Study Site, Shawnee Mission, Kansas, United States|Regeneron Study Site, Baltimore, Maryland, United States|Regeneron Study Site, Hagerstown, Maryland, United States|Regeneron Study Site, Boston, Massachusetts, United States|Regeneron Study Site, Royal Oak, Michigan, United States|Regeneron Study Site, Southaven, Mississippi, United States|Regeneron Study Site, Henderson, Nevada, United States|Regeneron Study Site, Bloomfield, New Jersey, United States|Regeneron Study Site, Edison, New Jersey, United States|Regeneron Study Site, Teaneck, New Jersey, United States|Regeneron Study Site, Great Neck, New York, United States|Regeneron Study Site, Liverpool, New York, United States|Regeneron Study Site, New York, New York, United States|Regeneron Study Site, Oceanside, New York, United States|Regeneron Study Site, Shirley, New York, United States|Regeneron Study Site, Asheville, North Carolina, United States|Regeneron Study Site, Charlotte, North Carolina, United States|Regeneron Study Site, Beachwood, Ohio, United States|Regeneron Study Site, Cincinnati, Ohio, United States|Regeneron Study Site, Cincinnati, Ohio, United States|Regeneron Study Site, Cleveland, Ohio, United States|Regeneron Study Site, Dublin, Ohio, United States|Regeneron Study Site, Edmond, Oklahoma, United States|Regeneron Study Site, Tulsa, Oklahoma, United States|Regeneron Study Site, Portland, Oregon, United States|Regeneron Study Site, Bethlehem, Pennsylvania, United States|Regeneron Study Site, Kingston, Pennsylvania, United States|Regeneron Study Site, Monroeville, Pennsylvania, United States|Regeneron Study Site, Beaufort, South Carolina, United States|Regeneron Study Site, Ladson, South Carolina, United States|Regeneron Study Site, West Columbia, South Carolina, United States|Regeneron Study Site, Rapid City, South Dakota, United States|Regeneron Study Site, Germantown, Tennessee, United States|Regeneron Study Site, Knoxville, Tennessee, United States|Regeneron Study Site, Nashville, Tennessee, United States|Regeneron Study Site, Abilene, Texas, United States|Regeneron Study Site, Bellaire, Texas, United States|Regeneron Study Site 2, San Antonio, Texas, United States|Regeneron Study Site, The Woodlands, Texas, United States|Regeneron Study Site, Willow Park, Texas, United States|Regeneron Study Site 1, Salt Lake City, Utah, United States|Regeneron Study Site, Fairfax, Virginia, United States|Regeneron Study Site, Norfolk, Virginia, United States|Regeneron Study Site, Morgantown, West Virginia, United States|Regeneron Study Site, Calgary, Alberta, Canada|Regeneron Study Site, Mississauga, Ontario, Canada|Regeneron Study Site, North York, Ontario, Canada|Regeneron Study Site, Sherbrooke, Quebec, Canada|Regeneron Study Site, Pardubice, Czechia|Regeneron Study Site, Prague 5, Czechia|Regeneron Study Site, Praha 10, Czechia|Regeneron Study Site, Praha 2, Czechia|Regeneron Study Site, Neubrandenburg, Mecklenburg-Westfalen, Germany|Regeneron Study Site, Gottingen, Nordrhein-Westfalen, Germany|Regeneron Study Site, Munster, Nordrhein-Westfalen, Germany|Regeneron Study Site 1, Pecs, Baranya, Hungary|Regeneron Study Site, Szombathely, Vas, Hungary|Regeneron Study Site, Zalaegerszeg, Zala Megye, Hungary|Regeneron Study Site, Budapest, Hungary|Regeneron Study Site, Budapest, Hungary|Regeneron Study Site, Budapest, Hungary|Regeneron Study Site, Budapest, Hungary|Regeneron Study Site, Debrecen, Hungary|Regeneron Study Site, Szeged, Hungary|Regeneron Study Site, Nagakute, Aichi, Japan|Regeneron Study Site, Nagoya, Aichi, Japan|Regeneron Study Site, Nagoya, Aichi, Japan|Regeneron Study Site, Yoshida-Gun, Fukui, Japan|Regeneron Study Site, Kurume, Fukuoka, Japan|Regeneron Study Site, Koriyama, Fukushima, Japan|Regeneron Study Site, Hakodate, Hokkaido, Japan|Regeneron Study Site, Kobe, Hyogo, Japan|Regeneron Study Site, Mito, Ibaraki, Japan|Regeneron Study Site, Toride, Ibaraki, Japan|Regeneron Study Site, Tsuchiura-shi, Ibaraki, Japan|Regeneron Study Site, Kita-gun, Kagawa, Japan|Regeneron Study Site, Kawasaki, Kanagawa, Japan|Regeneron Study Site, Matsumoto, Nagano, Japan|Regeneron Study Site, Nagasaki City, Nagasaki, Japan|Regeneron Study Site, Kashihara, Nara, Japan|Regeneron Study Site, Hirakata, Osaka, Japan|Regeneron Study Site, Tokorozawa, Saitama, Japan|Regeneron Study Site, Susono, Shizuoka, Japan|Regeneron Study Site, Chiyoda-ku, Tokyo, Japan|Regeneron Study Site, Hachioji, Tokyo, Japan|Regeneron Study Site, Itabashi-ku, Tokyo, Japan|Regeneron Study Site, Meguro-ku, Tokyo, Japan|Regeneron Study Site, Shimotsuke-shi, Totigi, Japan|Regeneron Study Site, Ube, Yamaguchi, Japan|Regeneron Study Site, Fukuoka, Japan|Regeneron Study Site, Fukuoka, Japan|Regeneron Study Site, Kagoshima, Japan|Regeneron Study Site, Osaka, Japan|Regeneron Study Site, Saitama, Japan|Regeneron Study Site, Tokushima, Japan|Regeneron Study Site, Arecibo, Puerto Rico|Regeneron Study Site, Sunderland, Tyne And Wear, United Kingdom|Regeneron Study Site, London, United Kingdom",,"https://ClinicalTrials.gov/show/NCT04429503"
54,"NCT04425629","Safety, Tolerability, and Efficacy of Anti-Spike (S) SARS-CoV-2 Monoclonal Antibodies for the Treatment of Ambulatory Adult and Pediatric Patients With COVID-19",,"Active, not recruiting","No Results Available","COVID-19","Drug: casirivimab+imdevimab combination therapy","Proportion of patients with treatment-emergent serious adverse events (SAEs)|Proportion of patients with infusion-related reactions|Proportion of patients with hypersensitivity reactions|Time-weighted average change from baseline in viral load (log10 copies/mL), as measured by quantitative reverse transcription quantitative polymerase chain reaction (RT-qPCR) in nasopharyngeal (NP) swab samples|Proportion of patients with at least one (≥1) COVID-19-related hospitalization or all-cause death|Concentration of REGN10933 in serum over time|Concentration of REGN10987 in serum over time|Time-weighted average change from baseline in viral load (log10 copies/mL), as measured by RT-qPCR in saliva samples|Time-weighted average change from baseline in viral load (log10 copies/mL), as measured by RT-qPCR in nasal swab samples|Time to negative RT-qPCR in all tested samples with no subsequent positive RT-qPCR in any tested samples|Time to negative RT-qPCR in nasopharyngeal swabs with no subsequent positive RT-qPCR|Change from baseline in viral load at each visit, as measured by RT-qPCR in nasopharyngeal swabs|Change from baseline in viral load at each visit, as measured by RT-qPCR in saliva samples|Change from baseline in viral load at each visit, as measured by RT-qPCR in nasal swabs|Correlation of RT-qPCR results over time between different sample types (NP, nasal, and saliva)|Concordance of RT-qPCR results over time between different sample types (NP, nasal, and saliva)|Time-weighted average change from baseline in viral load (log10 copies/mL) from day 1 to post-baseline study days|Proportion of participants with ≥1 COVID-19-related medically-attended visit|Proportion of participants with ≥2 COVID-19-related medically-attended visit|Total number of COVID-19-related medically-attended visits|Proportion of participants admitted to a hospital due to COVID-19|Proportion of participants with ≥1 outpatient or telemedicine visit due to COVID-19|Assessment of pharmacokinetic (PK) parameter: maximum serum concentration observed (Cmax) of REGN10933|Assessment of PK parameter: maximum serum concentration observed (Cmax) of REGN10987|Assessment of PK parameter: Cmax-to-dose ratio (Cmax/dose) of REGN10933|Assessment of PK parameter: Cmax-to-dose ratio (Cmax/dose) of REGN10987|Assessment of PK parameter: Time to Cmax (tmax) for REGN10933|Assessment of PK parameter: Time to Cmax (tmax) for REGN10987|Assessment of PK parameter: Area Under the Curve (AUC) computed from time zero to the time of the last positive concentration (AUClast) for REGN10933|Assessment of PK parameter: AUC computed from time zero to the time of the last positive concentration (AUClast) for REGN10987|Immunogenicity as measured by anti-drug (ADA) to REGN10933|Immunogenicity as measured by ADA to REGN10987|Immunogenicity as measured by neutralizing antibodies (NAbs) to REGN10933|Immunogenicity as measured by NAbs to REGN10987|Proportion of participants with high viral load at each visit|Proportion of participants with viral loads below the limit of detection at each visit|Proportion of participants with viral loads below the lower limit of quantitation at each visit|Proportion of participants admitted to an intensive care unit (ICU) due to COVID-19|Proportion of participants requiring mechanical ventilation due to COVID-19|Number of days of hospitalization due to COVID-19|Proportion of participants with all-cause mortality|Time to first onset of symptoms consistent with COVID-19 (asymptomatic cohort only)|Duration of symptoms consistent with COVID-19|Proportion of participants with ≥1 COVID-19-related hospitalization or all-cause death|Time to COVID-19 symptoms resolution|Proportion of participants with ≥1 COVID-19-related hospitalization, emergency room visit, or all-cause death|Proportion of patients with (≥1) COVID-19-related medically-attended visit or all-cause death|Proportion of participants with ≥1 COVID-19-related medically-attended visit by type of visit|Cumulative incidence of patients with ≥1 COVID-19-related hospitalization or all-cause death|Cumulative incidence of patients with ≥1 COVID-19-related hospitalization, emergency room visit, or all-cause death|Cumulative incidence of patients with ≥1 COVID-19-related medically-attended visit or all-cause death|Proportion of participants requiring supplemental oxygen due to COVID-19|Time to all-cause death|All-cause death","Regeneron Pharmaceuticals","All","Child, Adult, Older Adult","Phase 3","10078","Industry","Interventional","Allocation: N/A|Intervention Model: Single Group Assignment|Masking: None (Open Label)|Primary Purpose: Treatment","R10933-10987-COV-2067|2020-003690-21","June 16, 2020","January 21, 2022","June 9, 2022","June 11, 2020",,"February 11, 2022","Regeneron Study Site, Mesa, Arizona, United States|Regeneron Study Site, Tucson, Arizona, United States|Regeneron Study Site, Tucson, Arizona, United States|Regeneron Study Site, Canoga Park, California, United States|Regeneron Study Site, La Mesa, California, United States|Regeneron Study Site, La Palma, California, United States|Regeneron Study Site 1, Long Beach, California, United States|Regeneron Study Site 2, Long Beach, California, United States|Regeneron Study Site 3, Long Beach, California, United States|Regeneron Study Site, Los Angeles, California, United States|Regeneron Study Site, Montclair, California, United States|Regeneron Study Site, Rolling Hills Estates, California, United States|Regeneron Study Site, Sacramento, California, United States|Regeneron Study Site, San Francisco, California, United States|Regeneron Study Site, Santa Monica, California, United States|Regeneron Study Site, Stanford, California, United States|Regeneron Study Site, Aurora, Colorado, United States|Regeneron Study Site, Colorado Springs, Colorado, United States|Regeneron Study Site, Washington, District of Columbia, United States|Regeneron Study Site, Boca Raton, Florida, United States|Regeneron Study Site, DeLand, Florida, United States|Regeneron Study Site, Fort Pierce, Florida, United States|Regeneron Study Site, Hialeah, Florida, United States|Regeneron Study Site, Loxahatchee Groves, Florida, United States|Regeneron Study Site, Maitland, Florida, United States|Regeneron Study Site, Miami, Florida, United States|Regeneron Study Site 1, Miami, Florida, United States|Regeneron Study Site 2, Miami, Florida, United States|Regeneron Study Site, Miami, Florida, United States|Regeneron Study Site, Miami, Florida, United States|Regeneron Study Site, Miami, Florida, United States|Regeneron Study Site, Saint Petersburg, Florida, United States|Regeneron Study Site, Sarasota, Florida, United States|Regeneron Study Site, Tampa, Florida, United States|Regeneron Study Site, West Palm Beach, Florida, United States|Regeneron Study Site, Winter Haven, Florida, United States|Regeneron Study Site, Winter Park, Florida, United States|Regeneron Study Site, Atlanta, Georgia, United States|Regeneron Study Site, Atlanta, Georgia, United States|Regeneron Study Site, Augusta, Georgia, United States|Regeneron Study Site, Columbus, Georgia, United States|Regeneron Study Site, Marietta, Georgia, United States|Regeneron Study Site, Chicago, Illinois, United States|Regeneron Study Site 1, Downers Grove, Illinois, United States|Regeneron Study Site 2, Downers Grove, Illinois, United States|Regeneron Study Site, Downers Grove, Illinois, United States|Regeneron Study Site, Ames, Iowa, United States|Regeneron Study Site, Iowa City, Iowa, United States|Regeneron Study Site, Lake Charles, Louisiana, United States|Regeneron Study Site, Marrero, Louisiana, United States|Regeneron Study Site, New Orleans, Louisiana, United States|Regeneron Study Site, Shreveport, Louisiana, United States|Regeneron Study Site, Baltimore, Maryland, United States|Regeneron Study Site, Royal Oak, Michigan, United States|Regeneron Study Site, Jackson, Mississippi, United States|Regeneron Study Site, Las Vegas, Nevada, United States|Regeneron Study Site, Ridgewood, New Jersey, United States|Regeneron Study Site, Teaneck, New Jersey, United States|Regeneron Study Site, Santa Fe, New Mexico, United States|Regeneron Study Site, Bronx, New York, United States|Regeneron Study Site, Bronx, New York, United States|Regeneron Study Site, Jamaica, New York, United States|Regeneron Study Site, New York, New York, United States|Regeneron Study Site, New York, New York, United States|Regeneron Study Site, New York, New York, United States|Regeneron Study Site, New York, New York, United States|Regeneron Study Site, New York, New York, United States|Regeneron Study Site, New York, New York, United States|Regeneron Study Site, Charlotte, North Carolina, United States|Regeneron Study Site, Durham, North Carolina, United States|Regeneron Study Site, Wilmington, North Carolina, United States|Regeneron Study Site, Columbus, Ohio, United States|Regeneron Study Site, Dayton, Ohio, United States|Regeneron Study Site, Dayton, Ohio, United States|Regeneron Study Site, Philadelphia, Pennsylvania, United States|Regeneron Study Site, Providence, Rhode Island, United States|Regeneron Study Site, Charleston, South Carolina, United States|Regeneron Study Site, Clinton, South Carolina, United States|Regeneron Study Site, Sioux Falls, South Dakota, United States|Regeneron Study Site 2, Memphis, Tennessee, United States|Regeneron Study Site, Memphis, Tennessee, United States|Regeneron Study Site, Amarillo, Texas, United States|Regeneron Study Site, Corpus Christi, Texas, United States|Regeneron Study Site, Dallas, Texas, United States|Regeneron Study Site, Dallas, Texas, United States|Regeneron Study Site, Houston, Texas, United States|Regeneron Study Site, Houston, Texas, United States|Regeneron Study Site, Houston, Texas, United States|Regeneron Study Site, Houston, Texas, United States|Regeneron Study Site, Houston, Texas, United States|Regeneron Study Site, Houston, Texas, United States|Regeneron Study Site, Pearland, Texas, United States|Regeneron Study Site, Red Oak, Texas, United States|Regeneron Study Site, San Antonio, Texas, United States|Regeneron Study Site, San Antonio, Texas, United States|Regeneron Study Site, San Antonio, Texas, United States|Regeneron Study Site, Tyler, Texas, United States|Regeneron Study Site, Falls Church, Virginia, United States|Regeneron Study Site, Everett, Washington, United States|Regeneron Study Site, Seattle, Washington, United States|Regeneron Study Site, Seattle, Washington, United States|Regeneron Study Site, Madison, Wisconsin, United States|Regeneron Study Site, Guadalajara, Jalisco, Mexico|Regeneron Study Site, Guadalajara, Jalisco, Mexico|Regeneron Study Site, Zapopan, Jalisco, Mexico|Regeneron Study Site, Monterrey, Nuevo Leon, Mexico|Regeneron Study Site, Monterrey, Nuevo León, Mexico|Regeneron Study Site, Merida, Yucatan, Mexico|Regeneron Study Site, Chihuahua, Mexico|Regeneron Study Site, Ciudad de Mexico, Mexico|Regeneron Study Site, Durango, Mexico|Regeneron Study Site, Mérida, Mexico|Regeneron Study Site, Veracruz, Mexico|Regeneron Study Site, Bucuresti, Romania",,"https://ClinicalTrials.gov/show/NCT04425629"
55,"NCT04426695","Safety, Tolerability, and Efficacy of Anti-Spike (S) SARS-CoV-2 Monoclonal Antibodies for Hospitalized Adult Patients With COVID-19",,"Completed","No Results Available","COVID-19","Drug: REGN10933+REGN10987 combination therapy|Drug: Placebo","Time-weighted average change from baseline in viral load as measured by quantitative reverse transcription polymerase chain reaction (RT-qPCR) in nasopharyngeal (NP) swab samples|Proportion of patients who died or required mechanical ventilation|Incidence of patients who died or required mechanical ventilation|Proportion of patients with treatment-emergent Serious Adverse Events (SAEs)|Proportion of patients with infusion-related reactions|Proportion of patients with hypersensitivity reactions|Proportion of patients who required mechanical ventilation|Proportion of patients who died|Proportion of patients who were discharged|Proportion of patients who died or were readmitted to hospital over time|Cumulative incidence of death over time|Cumulative incidence of mechanical ventilation over time|Cumulative incidence of death or mechanical ventilation over time|Time to discharge|Time-weighted average change from baseline in viral load as measured by RT-qPCR in NP swab samples|Change from baseline in viral load as measured by RT-qPCR in NP swabs|Percent change from baseline in viral load as measured by RT-qPCR in NP swabs|Time to sustained negative RT-qPCR in NP swab samples|Serum concentration of REGN10933 over time|Serum concentration of REGN10987 over time|Assessment of pharmacokinetic (PK) parameter: maximum serum concentration observed (Cmax) of REGN10933|Assessment of PK parameter: maximum serum concentration observed (Cmax) of REGN10987|Assessment of PK parameter: Cmax-to-dose ratio (Cmax/dose) for REGN10933|Assessment of PK parameter: Cmax-to-dose ratio (Cmax/dose) for REGN10987|Assessment of PK parameter: Time to Cmax (tmax) for REGN10933|Assessment of PK parameter: Time to Cmax (tmax) for REGN10987|Assessment of PK parameter: Area Under the Curve (AUC) computed from time zero to the time of the last positive concentration (AUClast) for REGN10933|Assessment of PK parameter: AUC computed from time zero to the time of the last positive concentration (AUClast) for REGN10987|Assessment of PK parameter: AUC from time zero extrapolated to infinity (AUCinf) for REGN10933|Assessment of PK parameter: AUC from time zero extrapolated to infinity (AUCinf) for REGN10987|Assessment of PK parameter: AUCinf-to-dose ratio (AUCinf/dose) of REGN10933|Assessment of PK parameter: AUCinf-to-dose ratio (AUCinf/dose) of REGN10987|Assessment of PK parameter: Observed terminal half-life [t1/2] for REGN10933|Assessment of PK parameter: Observed terminal half-life [t1/2] of REGN10987|Assessment of PK parameter: Clearance (CL) for REGN10933|Assessment of PK parameter: Clearance (CL) of REGN10987|Assessment of PK parameter: Volume of distribution at steady state (Vss) of REGN10933|Assessment of PK parameter: Volume of distribution at steady state (Vss) of REGN10987|Assessment of PK parameter: Mean residence time (MRT) of REGN10933|Assessment of PK parameter: Mean residence time (MRT) of REGN10987|Incidence of anti-drug antibodies (ADA) to REGN10933|Incidence of anti-drug antibodies (ADA) to REGN10987|Incidence of neutralizing antibodies (NAbs) to REGN10933|Incidence of neutralizing antibodies (NAbs) to REGN10987","Regeneron Pharmaceuticals","All","18 Years and older   (Adult, Older Adult)","Phase 1|Phase 2","2252","Industry","Interventional","Allocation: Randomized|Intervention Model: Parallel Assignment|Masking: Quadruple (Participant, Care Provider, Investigator, Outcomes Assessor)|Primary Purpose: Treatment","R10933-10987-COV-2066|2020-002537-15","June 11, 2020","May 7, 2021","October 22, 2021","June 11, 2020",,"December 1, 2021","Regeneron Study Site, Birmingham, Alabama, United States|Regeneron Study Site, Chandler, Arizona, United States|Regeneron Study Site, Phoenix, Arizona, United States|Regeneron Study Site 1, Tucson, Arizona, United States|Regeneron Study Site, Long Beach, California, United States|Regeneron Study Site, Mission Hills, California, United States|Regeneron Study Site, Sacramento, California, United States|Regeneron Study Site, Santa Monica, California, United States|Regeneron Study Site, Stanford, California, United States|Regeneron Study Site, Aurora, Colorado, United States|Regeneron Study Site, Boca Raton, Florida, United States|Regeneron Study Site, Fort Pierce, Florida, United States|Regeneron Study Site, Gainesville, Florida, United States|Regeneron Study Site, Orlando, Florida, United States|Regeneron Study Site, Pensacola, Florida, United States|Regeneron Study Site, Sarasota, Florida, United States|Regeneron Study Site, Tampa, Florida, United States|Regeneron Study Site, Atlanta, Georgia, United States|Regeneron Study Site, Atlanta, Georgia, United States|Regeneron Study Site, Augusta, Georgia, United States|Regeneron Study Site, Marietta, Georgia, United States|Regeneron Study Site, Chicago, Illinois, United States|Regeneron Study Site, Chicago, Illinois, United States|Regeneron Study Site, Glenview, Illinois, United States|Regeneron Study Site, Urbana, Illinois, United States|Regeneron Study Site, Indianapolis, Indiana, United States|Regeneron Study Site, Iowa City, Iowa, United States|Regeneron Study Site, Louisville, Kentucky, United States|Regeneron Study Site, Louisville, Kentucky, United States|Regeneron Study Site, New Orleans, Louisiana, United States|Regeneron Study Site, New Orleans, Louisiana, United States|Regeneron Study Site, Baltimore, Maryland, United States|Regeneron Study Site, Boston, Massachusetts, United States|Regeneron Study Site, Boston, Massachusetts, United States|Regeneron Study Site, Boston, Massachusetts, United States|Regeneron Study Site, Grand Rapids, Michigan, United States|Regeneron Study Site, Royal Oak, Michigan, United States|Regeneron Study Site, Rochester, Minnesota, United States|Regeneron Study Site, Chesterfield, Missouri, United States|Regeneron Study Site, Saint Louis, Missouri, United States|Regeneron Study Site, Saint Louis, Missouri, United States|Regeneron Study Site, Omaha, Nebraska, United States|Regeneron Study Site, Las Vegas, Nevada, United States|Regeneron Study Site, Englewood, New Jersey, United States|Regeneron Study Site, Hackensack, New Jersey, United States|Regeneron Study Site, Morristown, New Jersey, United States|Regeneron Study Site, Neptune, New Jersey, United States|Regeneron Study Site, Pennington, New Jersey, United States|Regeneron Study Site, Summit, New Jersey, United States|Regeneron Study Site, Teaneck, New Jersey, United States|Regeneron Study Site, Albuquerque, New Mexico, United States|Regeneron Study Site, Bronx, New York, United States|Regeneron Study Site, Bronx, New York, United States|Regeneron Study Site, Brooklyn, New York, United States|Regeneron Study Site, Buffalo, New York, United States|Regeneron Study Site 1, Buffalo, New York, United States|Regeneron Study Site 2, Buffalo, New York, United States|Regeneron Study Site, Jamaica, New York, United States|Regeneron Study Site, New York, New York, United States|Regeneron Study Site, New York, New York, United States|Regeneron Study Site, New York, New York, United States|Regeneron Study Site, New York, New York, United States|Regeneron Study Site, New York, New York, United States|Regeneron Study Site, New York, New York, United States|Regeneron Study Site, Rochester, New York, United States|Regeneron Study Site, Syracuse, New York, United States|Regeneron Study Site, West Islip, New York, United States|Regeneron Study Site, White Plains, New York, United States|Regeneron Study Site, Chapel Hill, North Carolina, United States|Regeneron Study Site, Greensboro, North Carolina, United States|Regeneron Study Site, Columbus, Ohio, United States|Regeneron Study Site, Columbus, Ohio, United States|Regeneron Study Site, Dayton, Ohio, United States|Regeneron Study Site, Portland, Oregon, United States|Regeneron Study Site, Portland, Oregon, United States|Regeneron Study Site, Philadelphia, Pennsylvania, United States|Regeneron Study Site, Providence, Rhode Island, United States|Regeneron Study Site, Providence, Rhode Island, United States|Regeneron Study Site, Sioux Falls, South Dakota, United States|Regeneron Study Site 1, Amarillo, Texas, United States|Regeneron Study Site 2, Amarillo, Texas, United States|Regeneron Study Site, Dallas, Texas, United States|Regeneron Study Site, Dallas, Texas, United States|Regeneron Study Site, Dallas, Texas, United States|Regeneron Study Site, Houston, Texas, United States|Regeneron Study Site, Houston, Texas, United States|Regeneron Study Site, Houston, Texas, United States|Regeneron Study Site, Lubbock, Texas, United States|Regeneron Study Site, Sugar Land, Texas, United States|Regeneron Study Site, Tyler, Texas, United States|Regeneron Study Site, Murray, Utah, United States|Regeneron Study Site, Salt Lake City, Utah, United States|Regeneron Study Site, Richmond, Virginia, United States|Regeneron Study Site, Everett, Washington, United States|Regeneron Study Site 1, Seattle, Washington, United States|Regeneron Study Site, Madison, Wisconsin, United States|Regeneron Study Site, Salvador, Bahia, Brazil|Regeneron Study Site, Fortaleza, Ceara, Brazil|Regeneron Study Site, Curitiba, Paraná, Brazil|Regeneron Study Site, Porto Alegre, Rio Grande Do Sul, Brazil|Regeneron Study Site, Passo Fundo, RS, Brazil|Regeneron Study Site, Chapeco, Santa Catarina, Brazil|Regeneron Study Site, Criciuma, Santa Catarina, Brazil|Regeneron Study Site, Botucatu, Sao Paolo, Brazil|Regeneron Study Site, Campinas, Sao Paolo, Brazil|Regeneron Study Site, São Paulo, Brazil|Regeneron Study Site, São Paulo, Brazil|Regeneron Study Site, São Paulo, Brazil|Regeneron Study Site 1, Las Condes, Santiago De Chile, Chile|Regeneron Study Site 2, Las Condes, Santiago De Chile, Chile|Regeneron Study Site, Vitacura, Santiago De Chile, Chile|Regeneron Study Site, Santiago de Chile, Chile|Regeneron Study Site, Guadalajara, Jalisco, Mexico|Regeneron Study Site, Monterrey, Nuevo Leon, Mexico|Regeneron Study Site, Culiacán, Sinaloa, Mexico|Regeneron Study Site, Culiacan, Mexico|Regeneron Study Site, Monterrey, Mexico|Regeneron Study Site 1, Mérida, Mexico|Regeneron Study Site 2, Mérida, Mexico|Regeneron Study Site, Veracruz, Mexico|Regeneron Study Site, Zapopan, Mexico|Regeneron Study Site, Chisinau, Moldova, Republic of|Regeneron Study Site, Bucuresti, Romania",,"https://ClinicalTrials.gov/show/NCT04426695"
56,"NCT04394351","Study to Investigate the Efficacy and Safety of Dupilumab in Pediatric Patients With Active Eosinophilic Esophagitis (EoE)","EoE KIDS","Active, not recruiting","No Results Available","Eosinophilic Esophagitis (EoE)","Drug: Dupilumab|Drug: Matching Placebo","Proportion of patients achieving peak esophageal intraepithelial eosinophil count ≤6 eos/hpf (400×)|Proportion of patients achieving peak esophageal intraepithelial eosinophil count of <15 eos/hpf|Percent change in peak esophageal intraepithelial eosinophil count (eos/hpf)|Absolute change in mean eosinophilic esophagitis (EoE) Histology Scoring System (EoE-HSS)|Absolute change in Eosinophilic Esophagitis-Endoscopic Reference (EoE EREFS)|Change in the type 2 inflammation transcriptional signature|Change in the proportion of days with 1 or more EoE signs as measured by the Pediatric EoE Sign/Symptom Questionnaire- caregiver version (PESQ-C)|Number of sign-free days during the 14-day period preceding week 16 as measured by the PESQ-C|Change in the proportion of total segments within a day with 1 or more EoE signs as measured by PESQ-C|Change in the proportion of days with 1 or more EoE symptoms as measured by the Pediatric EoE Sign/Symptom Questionnaire-patient version (PESQ-P)|Number of symptom-free days during the 14-day period preceding week 16 as measured by the PESQ-P (patient version)|Change in the proportion of total segments within a day with 1 or more EoE symptoms as measured by PESQ-P|Change in total score as measured by the PEESSv2.0-caregiver version questionnaire|Normalized Enrichment Scores (NES) for the relative change in the EoE diagnostic panel (EDP) transcriptome signature|NES for the relative change in the type 2 inflammation transcriptome signature|Incidence of treatment-emergent adverse events (TEAEs)|Incidence of treatment-emergent serious adverse events (SAEs)|Incidence of treatment-emergent adverse events of special interest (AESIs)|Incidence of TEAEs leading to permanent discontinuation of study treatment|Incidence of treatment-emergent Anti-drug antibody (ADA) responses and titer|Change in the proportion of days with 1 or more EoE signs as measured by the PESQ-C|Number of sign-free days during the 14-day period preceding week 52 as measured by the PESQ-C|Change in the proportion of days with 1 or more EoE symptoms as measured by PESQ-P|Number of symptom-free days during the 14-day period preceding week 52 as measured by the PESQ-P (patient version)|NES for the relative change in the EDP transcriptome signature|Incidence of TEAEs|Incidence of treatment-emergent SAEs|Incidence of treatment-emergent AESIs|Incidence of treatment-emergent ADA responses and titer|Concentration of functional dupilumab in serum","Regeneron Pharmaceuticals|Sanofi","All","1 Year to 11 Years   (Child)","Phase 3","102","Industry","Interventional","Allocation: Randomized|Intervention Model: Parallel Assignment|Masking: Quadruple (Participant, Care Provider, Investigator, Outcomes Assessor)|Primary Purpose: Treatment","R668-EE-1877|2019-003078-24","September 1, 2020","April 27, 2022","April 7, 2023","May 19, 2020",,"March 2, 2022","Regeneron Study Site, Phoenix, Arizona, United States|Regeneron Study Site, Little Rock, Arkansas, United States|Regeneron Study Site, Los Angeles, California, United States|Regeneron Study Site, San Francisco, California, United States|Regeneron Study Site, Aurora, Colorado, United States|Regeneron Study Site, Saint Petersburg, Florida, United States|Regeneron Study Site, Atlanta, Georgia, United States|Regeneron Study Site, Atlanta, Georgia, United States|Regeneron Study Site, Chicago, Illinois, United States|Regeneron Study Site, Indianapolis, Indiana, United States|Regeneron Study Site, Iowa City, Iowa, United States|Regeneron Study Site, Boston, Massachusetts, United States|Regeneron Study Site, Boston, Massachusetts, United States|Regeneron Study Site, Boston, Massachusetts, United States|Regeneron Study Site, Lincoln, Nebraska, United States|Regeneron Study Site, New York, New York, United States|Regeneron Study Site, New York, New York, United States|Regeneron Study Site, New York, New York, United States|Regeneron Study Site, Chapel Hill, North Carolina, United States|Regeneron Study Site, Cincinnati, Ohio, United States|Regeneron Study Site, Cleveland, Ohio, United States|Regeneron Study Site, Philadelphia, Pennsylvania, United States|Regeneron Study Site, Dallas, Texas, United States|Regeneron Study Site, Fort Worth, Texas, United States|Regeneron Study Site, Houston, Texas, United States|Regeneron Study Site, Milwaukee, Wisconsin, United States|Regeneron Study Site, London, Ontario, Canada",,"https://ClinicalTrials.gov/show/NCT04394351"
57,"NCT04409080","REGN7257 in Adult Patients With Severe Aplastic Anemia That Is Refractory to or Relapsed on Immunosuppressive Therapy",,"Recruiting","No Results Available","Severe Aplastic Anemia (SAA)","Drug: REGN7257","Incidence of adverse events (AEs)|Incidence of serious adverse events (SAEs)|Incidence and severity of treatment-emergent adverse events (TEAEs) up|Overall response rate (ORR)|ORR|Complete response (CR)|Partial response (PR)|Time to best response|Time to first response|Proportion of patients who maintain any clinical response|Platelet transfusions per month over time|Red blood cell transfusions per month over time|Changes in lymphocyte cell counts|Changes in neutrophil cell counts|Changes in hemoglobin cell counts|Changes in reticulocyte cell counts|Changes in platelet cell counts|Changes in the whole blood immune cell subsets (T cells)|Changes in the whole blood immune cell subsets (B cells)|Changes in the whole blood immune cell subsets (NK cells)|Drug concentrations in serum over time|Incidence of treatment-emergent anti-drug antibody (ADA) over time","Regeneron Pharmaceuticals","All","18 Years and older   (Adult, Older Adult)","Phase 1|Phase 2","48","Industry","Interventional","Allocation: N/A|Intervention Model: Sequential Assignment|Masking: None (Open Label)|Primary Purpose: Treatment","R7257-RAA-1947|2020-002031-29","January 13, 2021","August 8, 2024","August 8, 2024","June 1, 2020",,"October 25, 2021","Regeneron Research Site, Cleveland, Ohio, United States|Regeneron Research Site, Paris, Ile-de-France, France|Regeneron Research Site, Incheon, Gyeonggi, Korea, Republic of|Regeneron Research Site, Seoul, Seoul Capital Area, Korea, Republic of|Regeneron Research Site, Seoul, Seoul Capital Area, Korea, Republic of|Regeneron Research Site, Seoul, Seoul Capital Area, Korea, Republic of|Regeneron Research Site, Seoul, Seoul Capital Area, Korea, Republic of|Regeneron Research Site, London, United Kingdom",,"https://ClinicalTrials.gov/show/NCT04409080"
58,"NCT04315298","Evaluation of the Efficacy and Safety of Sarilumab in Hospitalized Patients With COVID-19",,"Completed","Has Results","COVID-19","Drug: Sarilumab|Drug: Placebo","Percent Change From Baseline in CRP Levels at Day 4 in Participants With Serum IL-6 Level Greater Than the ULN (Phase 2)|Percentage of Participants With at Least a 1-point Improvement in Clinical Status From Baseline to Day 22 Using the 7-point Ordinal Scale in Participants With Critical COVID-19 Receiving Mechanical Ventilation at Baseline (Phase 3 Cohort 1)|Percentage of Participants With at Least 1-point Improvement in Clinical Status Using the 7-point Ordinal Scale in Participants With COVID-19 Receiving Mechanical Ventilation at Baseline (Phase 3 Cohort 2)|Time to Improvement (2 Points) in Clinical Status Assessment in Severe or Critical Patients With Serum IL-6 Levels Greater Than the Upper Limit of Normal (Phase 2)|Time to Improvement (2 Points) in Clinical Status Assessment in Severe or Critical Patients With All Serum IL-6 Levels (Phase 2)|Time to Resolution of Fever for at Least 48 Hours Without Antipyretics or Until Discharge, Whichever is Sooner, in Patients With Documented Fever at Baseline (Phase 2)|Time to Resolution of Fever for at Least 48 Hours Without Antipyretics by Clinical Severity (Phase 2)|Time to Resolution of Fever for at Least 48 Hours Without Antipyretics or Until Discharge, Whichever is Sooner, by Baseline IL-6 Levels (Phase 2)|Time to Improvement in Oxygenation for at Least 48 Hours (Phase 2)|Time to Improvement in Oxygenation for at Least 48 Hours by Baseline IL-6 Levels (Phase 2)|Time to Resolution of Fever and Improvement in Oxygenation for at Least 48 Hours (Phase 2)|Percentage of Participants in Each Clinical Status Category Using the 7-point Ordinal Scale up to Day 29 (Phase 2)|Time to Discharge or to a National Early Warning Score 2 (NEWS2) of ≤2 and Maintained for 24 Hours (Phase 2)|Change From Baseline in NEWS2 Scoring System (Phase 2)|Number of Days With Fever (Phase 2)|Percentage of Participants Alive, Off Oxygen (Phase 2)|Number of Days of Resting Respiratory Rate >24 Breaths/Min (Phase 2)|Number of Days With Hypoxemia (Phase 2)|Number of Days of Supplemental Oxygen Use (Phase 2)|Time to Saturation ≥94% on Room Air (Phase 2)|Number of Ventilator Free Days (Phase 2)|Number of Participants Who Initiated Mechanical Ventilation After Baseline (Phase 2)|Number of Days in an Intensive Care Unit (ICU) in Participants Who Were Not in ICU at Baseline (Phase 2)|Number of Days of Hospitalization Among Survivors (Phase 2)|Number of Deaths Due to Any Cause|Percentage of Participants With at Least 1-point Improvement in Clinical Status Using the 7-point Ordinal Scale in Participants With Critical COVID-19 (Phase 3 Cohort 1: Critical ITT)|Percentage of Participants Who Recover (Phase 3 Cohort 1: Critical on Mechanical Ventilation at Baseline)|Percentage of Participants Who Recover (Phase 3 Cohort 1: Critical ITT)|Percentage of Participants Who Die (Phase 3 Cohort 1: Critical on Mechanical Ventilation at Baseline)|Percentage of Participants Who Die (Phase 3 Cohort 1: Critical ITT)|Percentage of Participants Alive Not Receiving Mechanical Ventilation or ECMO at Day 22 (Phase 3 Cohort 1: Critical on Mechanical Ventilation at Baseline)|Percentage of Participants With at Least a 2-point Improvement in Clinical Status From Baseline to Day 22 Using the 7-point Ordinal Scale (Phase 3 Cohort 1: Critical on Mechanical Ventilation at Baseline)|Percentage of Participants Alive Not Receiving Mechanical Ventilation or ECMO at Day 22 (Phase 3 Cohort 1: Critical ITT)|Percentage of Participants With at Least a 2-point Improvement in Clinical Status From Baseline to Day 22 Using the 7-point Ordinal Scale (Phase 3 Cohort 1: Critical ITT)|Time to at Least 1-point Improvement in Clinical Status Assessment on the 7-point Ordinal Scale (Phase 3 Cohort 1: Critical on Mechanical Ventilation at Baseline)|Time to at Least 1-point Improvement in Clinical Status Assessment on the 7-point Ordinal Scale (Phase 3 Cohort 1: Critical ITT)|Time to at Least 1-point Improvement in Clinical Status Assessment on the 7-point Ordinal Scale (Phase 3 Cohort 2)|Time to at Least 2-point Improvement in Clinical Status Assessment on the 7-point Ordinal Scale (Phase 3 Cohort 1)|Time to at Least 2-point Improvement in Clinical Status Assessment on the 7-point Ordinal Scale (Phase 3 Cohort 1: Critical ITT)|Percentage of Participants Receiving Mechanical Ventilation or ECMO at Day 22 (Phase 3 Cohort 1: Critical on Mechanical Ventilation at Baseline)|Percentage of Participants Receiving Mechanical Ventilation or ECMO at Day 22 (Phase 3 Cohort 1: Critical ITT)|Percentage of Patients Discharged and Alive (Phase 3 Cohort 1)|Percentage of Participants Discharged and Alive at Day 22 (Phase 3 Cohort 1: Critical ITT)|Time to Recovery (Phase 3 Cohort 1: Critical on Mechanical Ventilation at Baseline)|Time to Recovery (Phase 3 Cohort 1: Critical ITT)|Time to Recovery (Phase 3 Cohort 2)|Time to Death (Phase 3 Cohort 1: Critical on Mechanical Ventilation at Baseline)|Time to Death (Phase 3 Cohort 1: Critical ITT)|Time to Death (Phase 3 Cohort 2)|Number of Ventilator-Free Days (Phase 3 Cohort 1: Critical on Mechanical Ventilation at Baseline)|Number of Ventilator-Free Days (Phase 3 Cohort 1: Critical ITT)|Number of Days of Hospitalization Among Survivors (Phase 3 Cohort 1)|Number of Days of Hospitalization Among Survivors (Phase 3 Cohort 1: Critical ITT)|Number of Participants With Any Serious Adverse Event|Number of Participants With Grade 4 Neutropenia (ANC <500/mm3)|Number of Participants With Severe or Life-threatening Bacterial, Invasive Fungal, or Opportunistic Infection|Number of Participants With Grade 4 Neutropenia and Concurrent Invasive Infection|Number of Participants With Grade >=2 Infusion Related Reactions|Number of Participants With Grade >=2 Hypersensitivity Reactions|Number of Participants With Gastrointestinal Perforation|Mean Observed Leukocyte Values Across Study Days (Phase 2)|Mean Observed Leukocyte Values Across Study Days (Phase 3)|Mean Observed Hemoglobin Values Across Study Days (Phase 2)|Mean Observed Hemoglobin Values Across Study Days (Phase 3)|Mean Observed Platelet Count Across Study Days (Phase 2)|Mean Observed Platelet Count Across Study Days (Phase 3)|Mean Observed Total Bilirubin Values Across Study Days (Phase 2)|Mean Observed Total Bilirubin Across Study Days (Phase 3)|Mean Observed Aspartate Aminotransferase Values Across Study Days (Phase 2)|Mean Observed Aspartate Aminotransferase Values Across Study Days (Phase 3)|Mean Observed Alanine Aminotransferase Values Across Study Days (Phase 2)|Mean Observed Alanine Aminotransferase Values Across Study Days (Phase 3)|Mean Observed Creatinine Values Across Study Days (Phase 2)|Mean Observed Creatinine Values Across Study Days (Phase 3)","Regeneron Pharmaceuticals|Sanofi","All","18 Years and older   (Adult, Older Adult)","Phase 2|Phase 3","1912","Industry","Interventional","Allocation: Randomized|Intervention Model: Parallel Assignment|Masking: Quadruple (Participant, Care Provider, Investigator, Outcomes Assessor)|Primary Purpose: Treatment","6R88-COV-2040","March 18, 2020","July 24, 2020","September 2, 2020","March 19, 2020","September 23, 2021","September 23, 2021","Regeneron Study Site, Los Angeles, California, United States|Regeneron Study Site, Sacramento, California, United States|Regeneron Study Site, Santa Monica, California, United States|Regeneron Study Site, Aurora, Colorado, United States|Regeneron Study Site, Denver, Colorado, United States|Regeneron Study Site, New Haven, Connecticut, United States|Regeneron Study Site, Washington, District of Columbia, United States|Regeneron Study Site, Gainesville, Florida, United States|Regeneron Study Site, Orlando, Florida, United States|Regeneron Study Site, Tampa, Florida, United States|Regeneron Study Site, Atlanta, Georgia, United States|Regeneron Study Site, Decatur, Georgia, United States|Regeneron Study Site, Marietta, Georgia, United States|Regeneron Study Site, Chicago, Illinois, United States|Regeneron Study Site, Chicago, Illinois, United States|Regeneron Study Site, New Orleans, Louisiana, United States|Regeneron Study Site, Boston, Massachusetts, United States|Regeneron Study Site, Boston, Massachusetts, United States|Regeneron Study Site, Boston, Massachusetts, United States|Regeneron Study Site, Ann Arbor, Michigan, United States|Regeneron Study Site, Rochester, Minnesota, United States|Regeneron Study Site, Edison, New Jersey, United States|Regeneron Study Site, Hackensack, New Jersey, United States|Regeneron Study Site, Livingston, New Jersey, United States|Regeneron Study Site, Morristown, New Jersey, United States|Regeneron Study Site, Neptune, New Jersey, United States|Regeneron Study Site, Newark, New Jersey, United States|Regeneron Study Site, Teaneck, New Jersey, United States|Regeneron Study Site, Bronx, New York, United States|Regeneron Study Site 1, Bronx, New York, United States|Regeneron Study Site 2, Bronx, New York, United States|Regeneron Study Site, Bronx, New York, United States|Regeneron Study Site, Brooklyn, New York, United States|Regeneron Study Site, Buffalo, New York, United States|Regeneron Study Site, Elmhurst, New York, United States|Regeneron Study Site 1, Manhasset, New York, United States|Regeneron Study Site 2, Manhasset, New York, United States|Regeneron Study Site, New York, New York, United States|Regeneron Study Site, New York, New York, United States|Regeneron Study Site 1, New York, New York, United States|Regeneron Study Site 2, New York, New York, United States|Regeneron Study Site, New York, New York, United States|Regeneron Study Site, New York, New York, United States|Regeneron Study Site, New York, New York, United States|Regeneron Study Site, New York, New York, United States|Regeneron Study Site, New York, New York, United States|Regeneron Study Site, Stony Brook, New York, United States|Regeneron Study Site, Valhalla, New York, United States|Regeneron Study Site, Tulsa, Oklahoma, United States|Regeneron Study Site, Portland, Oregon, United States|Regeneron Study Site, Portland, Oregon, United States|Regeneron Study Site, Danville, Pennsylvania, United States|Regeneron Study Site, Philadelphia, Pennsylvania, United States|Regeneron Study Site, Scranton, Pennsylvania, United States|Regeneron Study Site, Wilkes-Barre, Pennsylvania, United States|Regeneron Study Site, Dallas, Texas, United States|Regeneron Study Site, Dallas, Texas, United States|Regeneron Study Site, Murray, Utah, United States|Regeneron Study Site, Falls Church, Virginia, United States|Regeneron Study Site, Richmond, Virginia, United States|Regeneron Study Site, Everett, Washington, United States|Regeneron Study Site, Renton, Washington, United States","""Study Protocol"", https://ClinicalTrials.gov/ProvidedDocs/98/NCT04315298/Prot_001.pdf|""Statistical Analysis Plan"", https://ClinicalTrials.gov/ProvidedDocs/98/NCT04315298/SAP_002.pdf|""Informed Consent Form"", https://ClinicalTrials.gov/ProvidedDocs/98/NCT04315298/ICF_000.pdf","https://ClinicalTrials.gov/show/NCT04315298"
59,"NCT04465487","Study of REGN6569 and Cemiplimab in Adult Patients With Advanced Solid Tumor Malignancies",,"Recruiting","No Results Available","Squamous Cell Carcinoma of Head and Neck","Drug: REGN6569|Drug: Cemiplimab","Incidence of dose-limited toxicities (DLTs)|Incidence and severity of treatment emergent adverse events(TEAEs)|Incidence and severity of adverse events of special interest (AESIs)|Incidence and severity of serious adverse events (SAEs)|Incidence and severity of grade ≥3 laboratory abnormalities|Objective response rate (ORR)|Percentage change in glucocorticoid-induced tumor necrosis factor receptor-Related(GITR)+ Treg density|ORR|Disease control rate (DCR)|Duration of Response (DOR)|Progression-free Survival (PFS)|Overall survival (OS)|Drug concentrations of REGN6569 in serum|Drug concentrations of cemiplimab in serum|Immunogenicity as measured by anti-drug antibodies (ADA) to REGN6569|Immunogenicity as measured by anti-drug antibodies (ADA) to cemiplimab","Regeneron Pharmaceuticals","All","18 Years and older   (Adult, Older Adult)","Phase 1","85","Industry","Interventional","Allocation: N/A|Intervention Model: Sequential Assignment|Masking: None (Open Label)|Primary Purpose: Treatment","R6569-ONC-1933|2020-000075-20","October 5, 2020","June 8, 2026","June 8, 2026","July 10, 2020",,"November 16, 2021","Regeneron Research Facility, Los Angeles, California, United States|Regeneron Research Facility, Tampa, Florida, United States|Regeneron Research Facility, Ann Arbor, Michigan, United States|Regeneron Research Facility, Grand Rapids, Michigan, United States|Regeneron Research Facility, Barcelona, Spain|Regeneron Research Facility, Barcelona, Spain|Regeneron Research Facility, Madrid, Spain|Regeneron Research Facility, Madrid, Spain|Regeneron Research Facility, Madrid, Spain|Regeneron Research Facility, Madrid, Spain",,"https://ClinicalTrials.gov/show/NCT04465487"
60,"NCT04287608","Observational Study of Conjunctivitis in the Setting of DUPIXENT® Treatment for Atopic Dermatitis",,"Recruiting","No Results Available","Conjunctivitis|Atopic Dermatitis","Drug: dupilumab","Baseline Ophthalmologist Diagnosis|Proportion of patients in each category of ophthalmologist diagnoses|Proportion of patients with symptoms|Proportion of patients with morphological features|Proportion of conjunctivitis events by severity|Duration of conjunctivitis event(s) in patients whose conjunctivitis resolved|Proportion of patients with conjunctivitis event resolution|Proportion of patients who discontinued DUPIXENT® due to conjunctivitis events|Ophthalmologists assessment of treatment effectiveness, overall and by clinical phenotype based on a 5-point scale.|Change in eosinophil counts and other cells identified by impression cytology from the conjunctival tissue","Regeneron Pharmaceuticals|Sanofi","All","18 Years to 65 Years   (Adult, Older Adult)",,"75","Industry","Observational","Observational Model: Case-Control|Time Perspective: Prospective","R668-AD-1884","March 10, 2021","December 13, 2022","December 13, 2022","February 27, 2020",,"November 19, 2021","Regeneron Study Site, Irvine, California, United States|Regeneron Study Site, Palo Alto, California, United States|Regeneron Study Site, Pasadena, California, United States|Regeneron Study Site, Miami, Florida, United States|Regeneron Study Site, New Orleans, Louisiana, United States|Regeneron Study Site, Baltimore, Maryland, United States|Regeneron Study Site, Boston, Massachusetts, United States|Regeneron Study Site, Great Neck, New York, United States|Regeneron Study Site, New York, New York, United States|Regeneron Study Site, Portland, Oregon, United States|Regeneron Study Site, Philadelphia, Pennsylvania, United States|Regeneron Study Site, Pittsburgh, Pennsylvania, United States|Regeneron Study Site, Memphis, Tennessee, United States|Regeneron Study Site, Dallas, Texas, United States|Regeneron Study Site, Houston, Texas, United States",,"https://ClinicalTrials.gov/show/NCT04287608"
61,"NCT04206553","A Study to Evaluate the Efficacy and Safety of Dupilumab in Adult Patients With Bullous Pemphigoid","LIBERTY-BP","Recruiting","No Results Available","Bullous Pemphigoid","Drug: dupilumab|Drug: Matching Placebo|Drug: Oral corticosteroids (OCS)","Proportion of patients achieving sustained remission|Total cumulative dose of oral corticosteroids (OCS)|Percent change in weekly average of daily peak pruritus numerical rating score (NRS)|Proportion of patients with improvement (reduction) of weekly average of daily peak pruritus NRS ≥4|Percent change in Bullous Pemphigoid Disease Area Index Activity Score (BPDAI) activity score","Regeneron Pharmaceuticals|Sanofi","All","18 Years to 90 Years   (Adult, Older Adult)","Phase 2|Phase 3","98","Industry","Interventional","Allocation: Randomized|Intervention Model: Parallel Assignment|Masking: Quadruple (Participant, Care Provider, Investigator, Outcomes Assessor)|Primary Purpose: Treatment","R668-BP-1902|2019-003520-20","October 28, 2020","February 27, 2023","September 15, 2023","December 20, 2019",,"October 20, 2021","Regeneron Study Site, Scottsdale, Arizona, United States|Regeneron Study Site, Farmington, Connecticut, United States|Regeneron Study Site, Miami, Florida, United States|Regeneron Study Site, Macon, Georgia, United States|Regeneron Study Site, Rockville, Maryland, United States|Regeneron Study Site, Boston, Massachusetts, United States|Regeneron Study Site, Portland, Oregon, United States|Regeneron Study Site, Philadelphia, Pennsylvania, United States|Regeneron Study Site, Pittsburgh, Pennsylvania, United States|Regeneron Study Site, Murray, Utah, United States|Regeneron Study Site, Kogarah, New South Wales, Australia|Regeneron Study Site, Box Hill, Victoria, Australia|Regeneron Study Site, Parkville, Victoria, Australia|Regeneron Study Site, East Melbourne, Australia|Regeneron Study Site, Bobigny, France|Regeneron Study Site, Bordeaux, France|Regeneron Study Site, Chambray Les Tours, France|Regeneron Study Site, Le Mans Cedex 9, France|Regeneron Study Site, Nice, France|Regeneron Study Site, Rouen Cedex, France|Regeneron Study Site, Toulouse, France|Regeneron Study Site, Muenster, North Rhine-Westphal, Germany|Regeneron Study Site, Dresden, Saxony, Germany|Regeneron Study Site, Luebeck, Schleswig-Holstein, Germany|Regeneron Study Site, Berlin, Germany|Regeneron Study Site, Berlin, Germany|Regeneron Study Site, Buxtehude, Germany|Regeneron Study Site, Erlangen, Germany|Regeneron Study Site, Freiburg, Germany|Regeneron Study Site, Munich, Germany|Regeneron Study Site, Munich, Germany|Regeneron Study Site, Stuttgart, Germany|Regeneron Study Site, Osaka, Japan|Regeneron Study Site, Sapporo, Japan|Regeneron Study Site, Tokyo, Japan",,"https://ClinicalTrials.gov/show/NCT04206553"
62,"NCT04203797","A Study to Evaluate the Effect of Dupilumab on Exercise Capacity in Adult Patients With Asthma",,"Recruiting","No Results Available","Asthma","Drug: dupilumab|Drug: Matching placebo","Change in constant work rate exercise endurance time|Change in average number of steps walked per day|Change in total energy expenditure|Change in the mean duration of moderate-to-vigorous physical activity|Change in pre- and post-exercise Forced Expiratory Volume in One Second (FEV1)","Regeneron Pharmaceuticals","All","18 Years to 55 Years   (Adult)","Phase 4","140","Industry","Interventional","Allocation: Randomized|Intervention Model: Parallel Assignment|Masking: Quadruple (Participant, Care Provider, Investigator, Outcomes Assessor)|Primary Purpose: Treatment","R668-AS-1903|2019-002742-20","July 16, 2020","April 11, 2022","April 25, 2022","December 18, 2019",,"August 27, 2021","Regeneron Study Site, Rolling Hills Estates, California, United States|Regeneron Study Site, Westminster, California, United States|Regeneron Study Site, Iowa City, Iowa, United States|Regeneron Study Site, Kansas City, Kansas, United States|Regeneron Study Site, North Dartmouth, Massachusetts, United States|Regeneron Study Site, Ann Arbor, Michigan, United States|Regeneron Study Site, Charlotte, North Carolina, United States|Regeneron Study Site, Cleveland, Ohio, United States|Regeneron Study Site, Philadelphia, Pennsylvania, United States|Regeneron Study Site, Hendersonville, Tennessee, United States|Regeneron Study Site, Houston, Texas, United States|Regeneron Study Site, Dijon, Bourgogne, France|Regeneron Study Site, Reims, Marne, France|Regeneron Study Site, Strasbourg, France|Regeneron Study Site, Aschaffenburg, Bavaria, Germany|Regeneron Study Site, Frankfurt am Main, Hessen, Germany|Regeneron Study Site, Frankfurt am Main, Hessen, Germany|Regeneron Study Site, Hannover, Lower Saxony, Germany|Regeneron Study Site, Koblenz, Rheinland-Pfalz, Germany|Regeneron Study Site, Mainz, Rheinland-Pfalz, Germany|Regeneron Study Site, Grosshansdorf, Schleswig-Holstein, Germany|Regeneron Study Site, Berlin, Germany|Regeneron Study Site, Lubin, Dolnoslaskie, Poland|Regeneron Study Site, Bialystok, Poland|Regeneron Study Site, Wroclaw, Poland|Regeneron Study Site, Barcelona, Spain|Regeneron Study Site, Madrid, Spain",,"https://ClinicalTrials.gov/show/NCT04203797"
63,"NCT04233918","Evaluate the Efficacy and Safety of Evinacumab in Pediatric Patients With Homozygous Familial Hypercholesterolemia",,"Active, not recruiting","No Results Available","Homozygous Familial Hypercholesterolemia","Drug: Evinacumab","PK parameter: Maximum serum concentration observed (Cmax)|PK parameter: Area under the concentration-time curve (AUC)|PK parameter: Observed terminal half-life linear (t1/2)|Percent change in calculated low-density lipoprotein cholesterol (LDL-C) from baseline to week 24|Incidence of treatment-emergent adverse events (TEAE) and other safety variables over time|Percent change in Apoliprotein (Apo) B from baseline to week 24|Percent change in non-high-density lipoprotein cholesterol (non-HDL-C) from baseline to week 24|Percent change in total cholesterol (TC) from baseline to week 24|Proportion of patients with ≥50% reduction in calculated LDL-C at week 24|Percent change in calculated LDL-C from baseline to week 24 in patients who have negative/negative and null/null mutations|Percent change in lipoprotein a [Lp(a)] from baseline to week 24|Absolute change in LDL-C at week 24|Concentrations of total evinacumab over time|PK parameter: Cmax steady state(Cmax.ss)|PK parameter: Concentration of drug over time (the area under the concentration verses time curve over the dosing interval [AUCtau.ss[)|PK parameter: Ctrough.ss|Incidence and titer of treatment-emergent anti-drug antibodies (ADA) over time","Regeneron Pharmaceuticals","All","5 Years to 11 Years   (Child)","Phase 3","20","Industry","Interventional","Allocation: N/A|Intervention Model: Single Group Assignment|Masking: None (Open Label)|Primary Purpose: Treatment","R1500-CL-17100|2019-001931-30","June 29, 2020","January 31, 2022","May 22, 2023","January 18, 2020",,"February 14, 2022","Regeneron Research Site, Wilmington, Delaware, United States|Regeneron Research Site, Boca Raton, Florida, United States|Regeneron Research Site, Kansas City, Kansas, United States|Regeneron Research Center, Boston, Massachusetts, United States|Regeneron Research Center, Philadelphia, Pennsylvania, United States|Regeneron Research Center, Salt Lake City, Utah, United States|Regeneron Research Center, Westmead, New South Wales, Australia|Regeneron Research Site, Vienna, Austria|Regeneron Research Site, Amsterdam, Netherlands|Regeneron Research Center, Taipei, Taiwan|Regeneron Research Site, Kyiv, Ukraine",,"https://ClinicalTrials.gov/show/NCT04233918"
64,"NCT04162470","REGN3918 in Patients With Paroxysmal Nocturnal Hemoglobinuria (PNH) to Evaluate Its Long Term Safety, Efficacy and Tolerability.",,"Active, not recruiting","No Results Available","Paroxysmal Nocturnal Hemoglobinuria","Drug: REGN3918","Incidence and severity of treatment-emergent adverse events (TEAEs)|Proportion of patients achieving lactate dehydrogenase (LDH) less than or equal to 1.5ULN|Proportion of patients with breakthrough hemolysis|Rate/number of units of transfusion|Proportions of patients who are transfusion-free (with red blood cell [RBCs])|Proportions of patients achieving adequate control of their intravascular hemolysis|Proportions of patients achieving normalization of their intravascular hemolysis|Changes in LDH from baseline of the Open-label extension (OLE) study|Percent changes in LDH from baseline of the OLE study|Changes in RBC hemoglobin levels from baseline of the OLE study|Changes in free hemoglobin levels from baseline of the OLE study|Concentrations of REGN3918 in serum|Incidence of treatment-emergent anti-drug antibodies (ADA) to REGN3918","Regeneron Pharmaceuticals","All","18 Years and older   (Adult, Older Adult)","Phase 3","24","Industry","Interventional","Allocation: N/A|Intervention Model: Single Group Assignment|Masking: None (Open Label)|Primary Purpose: Treatment","R3918-PNH-1868|2019-000130-20","December 3, 2019","June 29, 2022","June 29, 2022","November 14, 2019",,"February 17, 2022","Regeneron Study Site, Sha Tin, Hong Kong|Regeneron Study Site, Budapest, Hungary|Regeneron Study Site, Busan, Korea, Republic of|Regeneron Study Site, Seoul, Korea, Republic of|Regeneron Study Site, Seoul, Korea, Republic of|Regeneron Study Site, Seoul, Korea, Republic of|Regeneron Study Site, Seoul, Korea, Republic of|Regeneron Study Site, Seoul, Korea, Republic of|Regeneron Study Site, Miri, Sarawak, Malaysia|Regeneron Study Site, Sibu, Sarawak, Malaysia|Regeneron Study Site, Kuala Terengganu, Terengganu, Malaysia|Regeneron Study Site, Taipei City, Taiwan|Regeneron Study Site, Taoyuan City, Taiwan|Regeneron Study Site, Leeds, United Kingdom",,"https://ClinicalTrials.gov/show/NCT04162470"
65,"NCT04154943","Study of Cemiplimab in Patients With Type of Skin Cancer Stage II to IV Cutaneous Squamous Cell Carcinoma",,"Active, not recruiting","No Results Available","Cutaneous Squamous Cell Carcinoma","Drug: Cemiplimab","Pathologic complete response (pCR) rate assessed by independent central pathology review|Major pathologic response (mPR) rate assessed by independent central pathology review|pCR rate assessed by local pathology review|mPR rate assessed by local pathology review|Objective response rate (ORR) prior to surgery, according to investigator assessment using RECIST 1.1|Event free survival (EFS)|Disease free survival (DFS)|Overall survival (OS)|Incidence of adverse events (AEs)|Incidence of serious adverse events (SAEs)|Incidence of deaths|Incidence of laboratory abnormalities|Change in surgical plan in the screening period versus actual surgery after neoadjuvant cemiplimab|Change in post-surgical management plan in the screening period versus actual post-surgical management","Regeneron Pharmaceuticals|Sanofi","All","18 Years and older   (Adult, Older Adult)","Phase 2","80","Industry","Interventional","Allocation: N/A|Intervention Model: Single Group Assignment|Masking: None (Open Label)|Primary Purpose: Treatment","R2810-ONC-1901|2019-003007-35","March 20, 2020","December 1, 2021","September 5, 2025","November 7, 2019",,"February 3, 2022","Regeneron Study Site, Palo Alto, California, United States|Regeneron Study Site, Washington, District of Columbia, United States|Regeneron Study Site, Miami, Florida, United States|Regeneron Study Site, Tampa, Florida, United States|Regeneron Study Site, Baltimore, Maryland, United States|Regeneron Study Site, Boston, Massachusetts, United States|Regeneron Study Site, Boston, Massachusetts, United States|Regeneron Study Site, Ann Arbor, Michigan, United States|Regeneron Study Site, Omaha, Nebraska, United States|Regeneron Study Site, New York, New York, United States|Regeneron Study Site, Charlotte, North Carolina, United States|Regeneron Study Site, Durham, North Carolina, United States|Regeneron Study Site, Cleveland, Ohio, United States|Regeneron Study Site, Dallas, Texas, United States|Regeneron Study Site, Houston, Texas, United States|Regeneron Study Site, St Leonards, New South Wales, Australia|Regeneron Study Site, Herston, Queensland, Australia|Regeneron Study Site, Melbourne, Victoria, Australia|Regeneron Study Site, Dresden, Germany|Regeneron Study Site, Essen, Germany|Regeneron Study Site, Kiel, Germany|Regeneron Study Site, Tübingen, Germany",,"https://ClinicalTrials.gov/show/NCT04154943"
66,"NCT04126317","Safety, Tolerability, and Efficacy of Aflibercept in Patients With Neovascular Age-Related Macular Degeneration","CANDELA","Completed","No Results Available","Neovascular (Wet) Age-Related Macular Degeneration","Drug: aflibercept|Drug: High-dose aflibercept","Incidence of treatment-emergent adverse events|Incidence of serious adverse events (SAEs)|Proportion of patients without retinal fluid in the center subfield","Regeneron Pharmaceuticals|Bayer","All","50 Years and older   (Adult, Older Adult)","Phase 2","106","Industry","Interventional","Allocation: Randomized|Intervention Model: Parallel Assignment|Masking: Single (Participant)|Primary Purpose: Treatment","VGFTe (HD)-AMD-1905","November 4, 2019","May 14, 2021","November 30, 2021","October 15, 2019",,"December 9, 2021","Regeneron Study Site, Phoenix, Arizona, United States|Regeneron Study Site, Sun City, Arizona, United States|Regeneron Study Site, Encino, California, United States|Regeneron Study Site, Fullerton, California, United States|Regeneron Study Site, Mountain View, California, United States|Regeneron Study Site, Palm Desert, California, United States|Regeneron Study Site, Sacramento, California, United States|Regeneron Study Site, Santa Ana, California, United States|Regeneron Study Site, Colorado Springs, Colorado, United States|Regeneron Study Site, Golden, Colorado, United States|Regeneron Study Site, Waterford, Connecticut, United States|Regeneron Study Site, Fort Lauderdale, Florida, United States|Regeneron Study Site, Fort Myers, Florida, United States|Regeneron Study Site, Lakeland, Florida, United States|Regeneron Study Site, Largo, Florida, United States|Regeneron Study Site, Melbourne, Florida, United States|Regeneron Study Site, Tallahassee, Florida, United States|Regeneron Study Site, Winter Haven, Florida, United States|Regeneron Study Site, Augusta, Georgia, United States|Regeneron Study Site, Marietta, Georgia, United States|Regeneron Study Site, Oak Forest, Illinois, United States|Regeneron Study Site, Hagerstown, Maryland, United States|Regeneron Study Site, Royal Oak, Michigan, United States|Regeneron Study Site, Bloomfield, New Jersey, United States|Regeneron Study Site, Teaneck, New Jersey, United States|Regeneron Study Site, Albuquerque, New Mexico, United States|Regeneron Study Site, Great Neck, New York, United States|Regeneron Study Site, Asheville, North Carolina, United States|Regeneron Study Site, Charlotte, North Carolina, United States|Regeneron Study Site, Columbus, Ohio, United States|Regeneron Study Site, Edmond, Oklahoma, United States|Regeneron Study Site, Portland, Oregon, United States|Regeneron Study Site, Kingston, Pennsylvania, United States|Regeneron Study Site, Ladson, South Carolina, United States|Regeneron Study Site, West Columbia, South Carolina, United States|Regeneron Study Site, Rapid City, South Dakota, United States|Regeneron Study Site, Abilene, Texas, United States|Regeneron Study Site, Arlington, Texas, United States|Regeneron Study Site, Austin, Texas, United States|Regeneron Study Site, Houston, Texas, United States|Regeneron Study Site, The Woodlands, Texas, United States|Regeneron Study Site, Salt Lake City, Utah, United States|Regeneron Study Site, Fairfax, Virginia, United States|Regeneron Study Site, Spokane, Washington, United States|Regeneron Study Site, Morgantown, West Virginia, United States|Regeneron Study Site, Arecibo, Puerto Rico",,"https://ClinicalTrials.gov/show/NCT04126317"
67,"NCT04101721","Study to Assess the Efficacy, Safety, and Tolerability of Intravitreal Aflibercept Compared to Laser Photocoagulation in Patients With Retinopathy of Prematurity","BUTTERFLEYE","Active, not recruiting","No Results Available","Retinopathy of Prematurity","Drug: aflibercept|Procedure: laser photocoagulation","Proportion of patients with absence of active retinopathy of prematurity (ROP) and of unfavorable structural outcomes|Proportion of patients requiring intervention with a second treatment modality|Proportion of patients with recurrence of ROP|Proportion of patients with ocular treatment-emergent adverse events (TEAEs) and serious adverse events (SAEs)|Proportion of patients with systematic TEAEs and SAEs","Regeneron Pharmaceuticals","All","Child, Adult, Older Adult","Phase 3","127","Industry","Interventional","Allocation: Randomized|Intervention Model: Parallel Assignment|Masking: None (Open Label)|Primary Purpose: Treatment","VGFTe-ROP-1920|2019-001764-29","October 30, 2019","September 15, 2022","September 15, 2022","September 24, 2019",,"December 21, 2021","Regeneron Study Site, Phoenix, Arizona, United States|Regeneron Study Site, La Jolla, California, United States|Regeneron Study Site, Loma Linda, California, United States|Regeneron Study Site, Orange, California, United States|Regeneron Study Site, Palo Alto, California, United States|Regeneron Study Site, San Diego, California, United States|Regeneron Study Site, San Francisco, California, United States|Regeneron Study Site, Gainesville, Florida, United States|Regeneron Study Site, Augusta, Georgia, United States|Regeneron Study Site, Chicago, Illinois, United States|Regeneron Study Site, Boston, Massachusetts, United States|Regeneron Study Site, Ann Arbor, Michigan, United States|Regeneron Study Site, Royal Oak, Michigan, United States|Regeneron Study Site, Bronx, New York, United States|Regeneron Study Site, Brooklyn, New York, United States|Regeneron Study Site, Brooklyn, New York, United States|Regeneron Study Site, Buffalo, New York, United States|Regeneron Study Site, New York, New York, United States|Regeneron Study Site, New York, New York, United States|Regeneron Study Site, Valhalla, New York, United States|Regeneron Study Site, Cleveland, Ohio, United States|Regeneron Study Site, Oklahoma City, Oklahoma, United States|Regeneron Study Site, Providence, Rhode Island, United States|Regeneron Study Site, Austin, Texas, United States|Regeneron Study Site, San Antonio, Texas, United States|Regeneron Study Site, San Antonio, Texas, United States|Regeneron Study Site, Morgantown, West Virginia, United States|Regeneron Study Site, Sofia, Bulgaria|Regeneron Study Site, Sofia, Bulgaria|Regeneron Study Site, Varna, Bulgaria|Regeneron Study Site, Medellin, Antioquia, Colombia|Regeneron Study Site, Floridablanca, Santander, Colombia|Regeneron Study Site, Ostrava-Poruba, Czechia|Regeneron Study Site, Debrecen, Hungary|Regeneron Study Site, Cheonan, Korea, Republic of|Regeneron Study Site, Iași, Romania|Regeneron Study Site, Saint-Petersburg, Sankt-Peterburg, Russian Federation|Regeneron Study Site, Moscow, Russian Federation|Regeneron Study Site, Moscow, Russian Federation|Regeneron Study Site, Bratislava, Slovakia|Regeneron Study Site, Kaohsiung, Taiwan|Regeneron Study Site, Pathum Wan, Bangkok, Thailand|Regeneron Study Site, Ratchathewi, Bangkok, Thailand|Regeneron Study Site, Chiangmai, Chiang Mai, Thailand|Regeneron Study Site, Hat Yai, Songkhla, Thailand|Regeneron Study Site, Khon Kaen, Thailand|Regeneron Study Site, Adana, Turkey|Regeneron Study Site, Ankara, Turkey|Regeneron Study Site, Ankara, Turkey|Regeneron Study Site, Eskisehir, Turkey|Regeneron Study Site, Ho Chi Minh, Vietnam|Regeneron Study Site, Hue, Vietnam",,"https://ClinicalTrials.gov/show/NCT04101721"
68,"NCT04159415","Study of REGN4461, a Leptin Receptor Agonist Antibody, in Patients With Generalized Lipodystrophy",,"Recruiting","No Results Available","Generalized Lipodystrophy","Drug: Placebo|Drug: Low-Dose REGN4461|Drug: High-dose REGN4461","Absolute change from baseline hemoglobin A1c (HbA1c)|Absolute change from baseline fasting glucose|Absolute change from baseline weighted mean glucose (WMG)|Percent change from baseline fasting triglycerides (TG)|Absolute change in composite endpoint comprising absolute change in either HbA1c or percent change in fasting TG|Absolute change in HbA1c from baseline|Percent change in fasting TG from baseline over time|Absolute change from baseline in fasting glucose|Percent change from baseline in fasting TG|Absolute change from baseline in HbA1c over time|Absolute change from baseline in WMG over time|Change from baseline in glucose area under the concentration-time curve (AUC0-4) during a mixed meal tolerance test (MMTT)|Change from baseline in glucose AUC0-4 during a MMTT|Change from baseline in glucose infusion rate per kilogram body mass during hyperinsulinemia-euglycemic clamp (clamp study)|Change from baseline in glucose clearance rate (kITT) during insulin-tolerance test (ITT)|Incidence and severity of treatment-emergent adverse events (TEAEs)|Concentrations of total REGN4461 in serum over time|Incidence of anti-drug antibodies (ADA) to REGN4461 over time|Incidence of abnormal weight change|Incidence of vital sign abnormalities|Incidence of 12-lead electrocardiogram (ECG) abnormalities|Incidence of physical examination abnormalities|Incidence of laboratory abnormalities|Concentrations of total soluble leptin receptor (sLEPR) in serum over time","Regeneron Pharmaceuticals","All","12 Years and older   (Child, Adult, Older Adult)","Phase 2","26","Industry","Interventional","Allocation: Randomized|Intervention Model: Sequential Assignment|Masking: Quadruple (Participant, Care Provider, Investigator, Outcomes Assessor)|Primary Purpose: Treatment","R4461-GLD-1875|2019-000614-11","January 7, 2020","March 24, 2022","June 14, 2023","November 12, 2019",,"August 12, 2021","Regeneron Research Site, Bethesda, Maryland, United States|Regeneron Research Site, Ann Arbor, Michigan, United States|Regeneron Research Site, Dallas, Texas, United States|Regeneron Research Site, Piura, Peru|Regeneron Research Site, Moscow, Russian Federation|Regeneron Research Site, Ankara, Turkey|Regeneron Research Site, Diyarbakir, Turkey|Regeneron Research Site, Izmir, Turkey",,"https://ClinicalTrials.gov/show/NCT04159415"
69,"NCT04083534","First In Human (FIH) Study of REGN5459 in Adult Patients With Relapsed or Refractory Multiple Myeloma (MM)",,"Active, not recruiting","No Results Available","Relapsed Multiple Myeloma|Refractory Multiple Myeloma","Drug: REGN5459","Incidence of dose-limiting toxicities (DLTs) from the first dose through the end of the DLT observation period|Incidence and severity of treatment-emergent adverse events (TEAEs) during REGN5459 treatment period|Incidence and severity of adverse events of special interest (AESI) with REGN5459 treatment period|Objective response rate (ORR) as measured using the International Myeloma Working Group (IMWG) criteria|Concentrations of REGN5459 in the serum over time|Incidence over time of anti-drug antibodies (ADAs) to REGN5459|Duration of response (DOR) using the IMWG criteria|Progression-free survival (PFS) as measured using the IMWG criteria|Rate of minimal residual disease (MRD) negative status using the IMWG criteria|Overall survival (OS)|Patient-reported Quality of Life (QOL) per European Organization for Research and Treatment of Cancer Quality of Life Questionnaire-Core 30 (EORTC QLQ-C30)|Patient-reported QOL per EORTC Quality of Life Questionnaire-Multiple Myeloma module 20 (EORTC QLQ-MY20)|Patient-reported QOL per EuroQoL-5 Dimension-3 Level Scale (EQ-5D-3L)|Change in patient-reported global health status/QOL per EORTC QLQ-C30|Time to definitive deterioration in patient-reported global health status/QOL per EORTC QLQ-C30|Change in patient-reported general health status per EQ-5D-3L|ORR as measured using the IMWG criteria|Incidence and severity of TEAEs during REGN5459 treatment period|Incidence and severity of AESI during REGN5459 treatment period","Regeneron Pharmaceuticals","All","18 Years and older   (Adult, Older Adult)","Phase 1|Phase 2","43","Industry","Interventional","Allocation: N/A|Intervention Model: Sequential Assignment|Masking: None (Open Label)|Primary Purpose: Treatment","R5459-ONC-1888|2019-001108-39","September 26, 2019","August 22, 2023","August 22, 2023","September 10, 2019",,"January 5, 2022","Regeneron Study Site, Indianapolis, Indiana, United States|Regeneron Study Site, Ann Arbor, Michigan, United States|Regeneron Study Site, Rochester, Minnesota, United States|Regeneron Study Site, New York, New York, United States|Regeneron Study Site, Dallas, Texas, United States|Regeneron Study Site, Houston, Texas, United States|Regeneron Study Site, Milwaukee, Wisconsin, United States",,"https://ClinicalTrials.gov/show/NCT04083534"
70,"NCT03956550","A Study to Examine the Efficacy and Safety of REGN5069 in Patients With Pain Due to Osteoarthritis of the Knee",,"Terminated","Has Results","Osteoarthritis of the Knee|Pain","Drug: REGN5069|Drug: Matching Placebo","Change From Baseline to Week 12 in the Western Ontario and McMaster Universities Osteoarthritis Index (WOMAC) Pain Subscale Score|Change From Baseline to Week 12 in WOMAC Total Score|Change From Baseline to Week 12 in WOMAC Physical Function Subscale Score|Change From Baseline to Week 12 in Patient Global Assessment (PGA) Score|Change From Baseline to Week 12 in WOMAC Stiffness Subscale Score|Percentage of Participants With ≥30% Improvement in WOMAC Pain Subscale Score|Number of Non-Serious and Serious Treatment-Emergent Adverse Events (TEAEs) Through End of Study|Number of Imaging Abnormalities Consistent With Adjudicated Arthropathies Through End of Study|Number of Participants With Presence of Anti-REGN5049 Antibody Development Through End of Study","Regeneron Pharmaceuticals","All","40 Years and older   (Adult, Older Adult)","Phase 2","259","Industry","Interventional","Allocation: Randomized|Intervention Model: Parallel Assignment|Masking: Quadruple (Participant, Care Provider, Investigator, Outcomes Assessor)|Primary Purpose: Treatment","R5069-OA-1849","May 21, 2019","May 1, 2020","October 29, 2020","May 20, 2019","July 1, 2021","July 1, 2021","Regeneron Study Site, DeLand, Florida, United States|Regeneron Study Site, Jupiter, Florida, United States|Regeneron Study Site, Miami, Florida, United States|Regeneron Study Site, Charleston, South Carolina, United States|Regeneron Study Site, Tbilisi, Georgia|Regeneron Study Site, Chisinau, Moldova, Republic of|Regeneron Study Site, Zgierz, Lodzkie, Poland|Regeneron Study Site, Lublin, Lubelskie, Poland|Regeneron Study Site, Zamosc, Lubelskie, Poland|Regeneron Study Site, Warsaw, Mazowieckie, Poland|Regeneron Study Site, Bialystok, Podlaskie, Poland|Regeneron Study Site, Kyiv, Ukraine","""Study Protocol"", https://ClinicalTrials.gov/ProvidedDocs/50/NCT03956550/Prot_000.pdf|""Statistical Analysis Plan"", https://ClinicalTrials.gov/ProvidedDocs/50/NCT03956550/SAP_001.pdf","https://ClinicalTrials.gov/show/NCT03956550"
71,"NCT03946748","Study to Evaluate the Efficacy and Safety of REGN3918 in Patients With Paroxysmal Nocturnal Hemoglobinuria (PNH)",,"Completed","No Results Available","Paroxysmal Nocturnal Hemoglobinuria (PNH)","Drug: REGN3918","Proportion of patients achieving adequate control of their intravascular hemolysis|Proportion of patients achieving transfusion avoidance|Rate of breakthrough hemolysis|Proportion of patients achieving normalization of their intravascular hemolysis|Time to first LDH ≤ 1.5 x ULN|Percentage of days with LDH ≤ 1.5 x ULN|Change in LDH levels|Percent change in LDH levels|Rate of transfusion with RBCs|Number of units of transfusion with RBCs|Change in RBC hemoglobin levels|Change in free hemoglobin levels|Change in total complement hemolytic activity assay (CH50)|Percent change in CH50|Changes in scores of patient-reported outcomes as measured by FACIT-Fatigue|Changes in scores of patient-reported outcomes as measured by European Organization for Research and Treatment of Cancer [EORTC]- Quality of life questionnaire-core 30 (QLQ-30)|Changes in scores of patient-reported outcomes as measured by EQ-5D-3L|Incidence and severity of treatment-emergent adverse events (TEAEs)|Safety measured by number of patients who experience abnormal laboratory values|Safety measured by number of patients who experience abnormal vital signs|Concentrations of total REGN3918 in serum|Incidence of treatment-emergent anti-drug antibodies to REGN3918","Regeneron Pharmaceuticals","All","18 Years and older   (Adult, Older Adult)","Phase 2","24","Industry","Interventional","Allocation: N/A|Intervention Model: Sequential Assignment|Masking: None (Open Label)|Primary Purpose: Treatment","R3918-PNH-1852|2018-002734-20","May 16, 2019","June 9, 2021","June 10, 2021","May 13, 2019",,"July 14, 2021","Regeneron Study Site, Sha Tin, Hong Kong|Regeneron Study Site, Budapest, Hungary|Regeneron Study Site, Kaposvár, Hungary|Regeneron Study Site, Seoul, Korea, Republic of|Regeneron Study Site, Seoul, Korea, Republic of|Regeneron Study Site, Seoul, Korea, Republic of|Regeneron Study Site, Seoul, Korea, Republic of|Regeneron Study Site, Seoul, Korea, Republic of|Regeneron Study Site, Kota Bharu, Kelantan, Malaysia|Regeneron Study Site, Sibu, Sarawak, Malaysia|Regeneron Study Site, Kuala Terengganu, Terengganu, Malaysia|Regeneron Study Site, Airdrie, Lanarkshire, United Kingdom",,"https://ClinicalTrials.gov/show/NCT03946748"
72,"NCT04077099","REGN5093 in Patients With MET-Altered Advanced Non-Small Cell Lung Cancer",,"Recruiting","No Results Available","NSCLC","Drug: REGN5093","Number of patients with Dose Limiting Toxicities|Incidence and severity of treatment-emergent adverse events|Incidence and severity of adverse events of special interest (AESIs)|Incidence and severity of serious adverse events (SAEs)|Incidence and severity of grade ≥3 laboratory abnormalities|REGN5093 concentrations in serum over time|Objective response rate (ORR) per RECIST 1.1|ORR per RECIST 1.1|Incidence and severity of TEAEs|Incidence and severity of AESIs|Incidence and severity of SAEs|REGN5093 Pharmacokinetics (PK)|Duration of response (DOR) per RECIST 1.1.|Disease control rate (DCR) per RECIST 1.1.|Progression free survival (PFS) per RECIST 1.1.|Overall survival (OS)|Immunogenicity as measured by Anti-drug antibodies (ADA) to REGN5093","Regeneron Pharmaceuticals","All","18 Years and older   (Adult, Older Adult)","Phase 1|Phase 2","111","Industry","Interventional","Allocation: N/A|Intervention Model: Single Group Assignment|Masking: None (Open Label)|Primary Purpose: Treatment","R5093-ONC-1863|2019-001908-38","January 7, 2020","October 20, 2024","October 20, 2024","September 4, 2019",,"October 29, 2021","Regeneron Research Facility, Birmingham, Alabama, United States|Regeneron Research Facility, Orange, California, United States|Regeneron Research Facility, Washington, District of Columbia, United States|Regeneron Research Facility, Tampa, Florida, United States|Regeneron Research Facility, Lexington, Kentucky, United States|Regeneron Research Facility, Boston, Massachusetts, United States|Regeneron Research Facility, Detroit, Michigan, United States|Regeneron Research Facility, Saint Louis, Missouri, United States|Regeneron Research Facility, New York, New York, United States|Regeneron Research Facility, New York, New York, United States|Regeneron Research Facility, New York, New York, United States|Regeneron Research Facility, Durham, North Carolina, United States|Regeneron Research Facility, Oklahoma City, Oklahoma, United States|Regeneron Research Facility, Philadelphia, Pennsylvania, United States|Regeneron Research Facility, Pittsburgh, Pennsylvania, United States|Regeneron Research Facility, Dallas, Texas, United States|Regeneron Research Facility, Houston, Texas, United States|Regeneron Research Facility, Bordeaux Cedex 9, France|Regeneron Research Facility, Dijon Cedex, France|Regeneron Research Facility, Grenoble, France|Regeneron Research Facility, Montpellier, France|Regeneron Research Facility, Rennes Cedex 9, France|Regeneron Research Facility, Gyeonggi do, Gyeonggi, Korea, Republic of|Regeneron Research Facility, Suwon, Gyeonggi, Korea, Republic of|Regeneron Research Facility, Seoul, Korea, Republic of|Regeneron Research Facility, Seoul, Korea, Republic of|Regeneron Research Facility, Seoul, Korea, Republic of|Regeneron Research Facility, Seoul, Korea, Republic of|Regeneron Research Facility, Seoul, Korea, Republic of",,"https://ClinicalTrials.gov/show/NCT04077099"
73,"NCT03888105","Assess the Anti-Tumor Activity and Safety of Odronextamab in Patients With Relapsed or Refractory B-cell Non-Hodgkin Lymphoma","ELM-2","Recruiting","No Results Available","B-cell Non-Hodgkin Lymphoma (NHL)","Drug: Odronextamab","ORR (FL grade 1-3a/MZL)|ORR (DLBCL/MCL/Other B-NHL)|ORR (FL/MZL)|CR rate (FL grade 1-3a/MZL)|CR rate (DLBCL/MCL/Other B-NHL)|PFS|OS|DOR|DCR (FL grade 1-3a/MZL)|DCR (DLBCL/MCL/Other B-NHL)|Incidence and severity of treatment emergent adverse events (TEAEs)|Pharmacokinetics: Concentration of odronextamab|Immunogenicity: Anti-odronextamab antibodies|Changes in scores of patient-reported outcomes as measured by EORTC QLQ-C30|Changes in scores of patient-reported outcomes as measured by FACT-Lym|Changes in scores of patient-reported outcomes as measured by EQ-5D-3L","Regeneron Pharmaceuticals","All","18 Years and older   (Adult, Older Adult)","Phase 2","512","Industry","Interventional","Allocation: Non-Randomized|Intervention Model: Parallel Assignment|Masking: None (Open Label)|Primary Purpose: Treatment","R1979-ONC-1625|2017-002139-41","November 13, 2019","January 31, 2025","December 15, 2028","March 25, 2019",,"February 4, 2022","Regeneron Study Site, Chicago, Illinois, United States|Regeneron Study Site, Iowa City, Iowa, United States|Regeneron Study Site, Louisville, Kentucky, United States|Regeneron Study Site, Boston, Massachusetts, United States|Regeneron Study Site, Boston, Massachusetts, United States|Regeneron Study Site, Ann Arbor, Michigan, United States|Regeneron Study Site, Rochester, Minnesota, United States|Regeneron Study Site, Saint Louis, Missouri, United States|Regeneron Study Site, Hackensack, New Jersey, United States|Regeneron Study Site, Morristown, New Jersey, United States|Regeneron Study Site, New York, New York, United States|Regeneron Study Site, Stony Brook, New York, United States|Regeneron Study Site, Winston-Salem, North Carolina, United States|Regeneron Study Site, Cleveland, Ohio, United States|Regeneron Study Site, Oklahoma City, Oklahoma, United States|Regeneron Study Site, Dallas, Texas, United States|Regeneron Study Site, Fort Sam Houston, Texas, United States|Regeneron Study Site, East Albury, Australia|Regeneron Study Site, East Melbourne, Australia|Regeneron Study Site, Frankston, Australia|Regeneron Study Site, Geelong, Australia|Regeneron Study Site, Heidelberg, Australia|Regeneron Study Site, Murdoch, Australia|Regeneron Study Site, Perth, Australia|Regeneron Study Site, Tweed Heads, Australia|Regeneron Study Site, Edmonton, Alberta, Canada|Regeneron Study Site, Halifax, Nova Scotia, Canada|Regeneron Study Site, Beijing, Beijing, China|Regeneron Study Site, Zhengzhou City, Henan, China|Regeneron Study Site, Chengdu, Sichuan, China|Regeneron Study Site, Qiaokou District, Wuhan Hubei Province, China|Regeneron Study Site, Hangzhou, Zhejiang, China|Regeneron Study Site, Shangcheng District Hangzhou, Zhejiang, China|Regeneron Study Site, Beijing City Beijing, China|Regeneron Study Site, Beijing City, Beijing, China|Regeneron Study Site, Chaoyang District Changchun, China|Regeneron Study Site, Gusu District Suzhou, China|Regeneron Study Site, HeXi District Tianjin City, China|Regeneron Study Site, Nangang District Harbin Heilongjiang, China|Regeneron Study Site, Shapingba District Chongqing, China|Regeneron Study Site, Tianjin City Tianjin, China|Regeneron Study Site, Wuhan Hubei Province, China|Regeneron Study Site, Xuhui District Shanghai, China|Regeneron Study Site, Yanta District Xi'an Shanxi, China|Regeneron Study Site, Caen, France|Regeneron Study Site, Créteil, France|Regeneron Study Site, Lille, France|Regeneron Study Site, Nantes, France|Regeneron Study Site, Paris, France|Regeneron Study Site, Pessac, France|Regeneron Study Site, Pierre Bénite, France|Regeneron Study Site, Poitiers, France|Regeneron Study Site, Chemnitz, Germany|Regeneron Study Site, Halle, Germany|Regeneron Study Site, Mutlangen, Germany|Regeneron Study Site, Villingen-Schwenningen, Germany|Regeneron Study Site, Wurzburg, Germany|Regeneron Study Site, Bologna, Italy|Regeneron Study Site, Firenze, Italy|Regeneron Study Site, Livorno, Italy|Regeneron Study Site, Milano, Italy|Regeneron Study Site, Milano, Italy|Regeneron Study Site, Novara, Italy|Regeneron Study Site, Perugia, Italy|Regeneron Study Site, Ravenna, Italy|Regeneron Study Site, Reggio Emilia, Italy|Regeneron Study Site, San Giovanni Rotondo, Italy|Regeneron Study Site, Terni, Italy|Regeneron Study Site, Varese, Italy|Regeneron Study Site, Venice, Italy|Regeneron Study Site, Busan, Korea, Republic of|Regeneron Study Site, Daegu-si, Korea, Republic of|Regeneron Study Site, Goyang-si, Korea, Republic of|Regeneron Study Site, Seoul, Korea, Republic of|Regeneron Study Site, Seoul, Korea, Republic of|Regeneron Study Site, Seoul, Korea, Republic of|Regeneron Study Site, Seoul, Korea, Republic of|Regeneron Study Site, Seoul, Korea, Republic of|Regeneron Study Site, Seoul, Korea, Republic of|Regeneron Study Site, Ulsan, Korea, Republic of|Regeneron Study Site, Gdańsk, Poland|Regeneron Study Site, Gdynia, Poland|Regeneron Study Site, Krakow, Poland|Regeneron Study Site, Lodz, Poland|Regeneron Study Site, Warszawa, Poland|Regeneron Study Site, Warszawa, Poland|Regeneron Study Site, Wrocław, Poland|Regeneron Study Site, Singapore, Singapore|Regeneron Study Site, Singapore, Singapore|Regeneron Study Site, Singapore, Singapore|Regeneron Study Site, Singapore, Singapore|Regeneron Study Site, Barcelona, Spain|Regeneron Study Site, Barcelona, Spain|Regeneron Study Site, Barcelona, Spain|Regeneron Study Site, Donostia, Spain|Regeneron Study Site, Madrid, Spain|Regeneron Study Site, Madrid, Spain|Regeneron Study Site, Madrid, Spain|Regeneron Study Site, Madrid, Spain|Regeneron Study Site, Madrid, Spain|Regeneron Study Site, Marbella, Spain|Regeneron Study Site, Palma de Mallorca, Spain|Regeneron Study Site, Palma, Spain|Regeneron Study Site, Salamanca, Spain|Regeneron Study Site, Valencia, Spain|Regeneron Study Site, Kaohsiung, Taiwan|Regeneron Study Site, New Taipei City, Taiwan|Regeneron Study Site, Taichung City, Taiwan|Regeneron Study Site, Tainan City, Taiwan|Regeneron Study Site, Tainan, Taiwan|Regeneron Study Site, Taipei City, Taiwan|Regeneron Study Site, Taipei City, Taiwan|Regeneron Study Site, Taipei City, Taiwan|Regeneron Study Site, Taipei City, Taiwan|Regeneron Study Site, Taoyuan, Taiwan|Regeneron Study Site, Cardiff, United Kingdom|Regeneron Study Site, Edinburgh, United Kingdom|Regeneron Study Site, London, United Kingdom|Regeneron Study Site, Plymouth, United Kingdom|Regeneron Study Site, Sutton, United Kingdom|Regeneron Study Site, Truro, United Kingdom",,"https://ClinicalTrials.gov/show/NCT03888105"
74,"NCT03949673","Study to Evaluate Arthroplasty Specimens for Osteoarthritis of the Knee and Hip",,"Terminated","No Results Available","Osteoarthritis, Knee|Osteoarthritis, Hip","Drug: Fasinumab|Drug: Naproxen|Drug: Diclofenac|Drug: Celecoxib|Drug: Placebo","Number of patients with histological findings not characteristic of advanced osteoarthritis","Regeneron Pharmaceuticals|Teva Pharmaceutical Industries, Ltd.","All","18 Years and older   (Adult, Older Adult)","Phase 2","23","Industry","Interventional","Allocation: N/A|Intervention Model: Single Group Assignment|Masking: None (Open Label)|Primary Purpose: Diagnostic","R475-OA-1816|2018-001618-13","April 8, 2019","August 25, 2020","August 25, 2020","May 14, 2019",,"August 27, 2021","Regeneron Research Site, Phoenix, Arizona, United States|Regeneron Research Site, Littleton, Colorado, United States|Regeneron Research Site, Jacksonville, Florida, United States|Regeneron Research Site, Chicago, Illinois, United States|Regeneron Research Site, Brooklyn, New York, United States|Regeneron Research Site, New York, New York, United States|Regeneron Recruting SIte, Bialystok, Poland|Regeneron Research Site, Reading, Berkshire, United Kingdom|Regeneron Research Site, Glasgow, Lanarkshire, United Kingdom|Regeneron Research Site, Romford, London City, United Kingdom|Regeneron Research Site, Northwood, Middlesex, United Kingdom|Regeneron Research Site, Hexham, Northumberland, United Kingdom|Regeneron Research Site, Yaxley, Peterborough, United Kingdom|Regeneron Research Site, Kenilworth, Warwickshire, United Kingdom|Regeneron Research Site, Liverpool, United Kingdom",,"https://ClinicalTrials.gov/show/NCT03949673"
75,"NCT00943072","Vascular Endothelial Growth Factor (VEGF) Trap-Eye: Investigation of Efficacy and Safety in Central Retinal Vein Occlusion (CRVO)",,"Completed","Has Results","Macular Edema Secondary to Central Retinal Vein Occlusion","Biological: VEGF Trap-Eye 2.0mg|Drug: Sham","Percentage of Participants Who Gained at Least 15 Letters in BCVA at Week 24 as Measured by ETDRS Letter Score|Change From Baseline in BCVA as Measured by ETDRS Letter Score at Week 24 - Last Observation Carried Forward (LOCF)|Change From Baseline in Central Retinal Thickness (CRT) at Week 24 - LOCF|Percentage of Participants Progressing to Any of the Following: Anterior Segment Neovascularization, New Vessels of the Disc (NVD) or New Vessels Elsewhere (NVE) During the First 24 Weeks|Change From Baseline in the NEI VFQ-25 in Total Score at Week 24 (LOCF)","Regeneron Pharmaceuticals|Bayer","All","18 Years and older   (Adult, Older Adult)","Phase 3","189","Industry","Interventional","Allocation: Randomized|Intervention Model: Parallel Assignment|Masking: Quadruple (Participant, Care Provider, Investigator, Outcomes Assessor)|Primary Purpose: Treatment","VGFT-OD-0819","July 2009","October 2010","April 2012","July 21, 2009","May 27, 2013","May 27, 2013","Phoenix, Arizona, United States|Phoenix, Arizona, United States|Tucson, Arizona, United States|Arcadia, California, United States|Beverly Hills, California, United States|La Jolla, California, United States|Mountain View, California, United States|Oakland, California, United States|Sacramento, California, United States|Torrance, California, United States|New London, Connecticut, United States|Altamonte Springs, Florida, United States|Fort Lauderdale, Florida, United States|Fort Myers, Florida, United States|Fort Myers, Florida, United States|Miami, Florida, United States|Palm Beach Gardens, Florida, United States|Winter Haven, Florida, United States|Augusta, Georgia, United States|Chicago, Illinois, United States|Wichita, Kansas, United States|Baltimore, Maryland, United States|Hagerstown, Maryland, United States|Towson, Maryland, United States|Boston, Massachusetts, United States|Grand Rapids, Michigan, United States|Jackson, Michigan, United States|Lincoln, Nebraska, United States|Las Vegas, Nevada, United States|Northfield, New Jersey, United States|Toms River, New Jersey, United States|Rochester, New York, United States|Winston-Salem, North Carolina, United States|Cleveland, Ohio, United States|Oklahoma City, Oklahoma, United States|Portland, Oregon, United States|Salem, Oregon, United States|Kingston, Pennsylvania, United States|Pittsburgh, Pennsylvania, United States|West Columbia, South Carolina, United States|Rapid City, South Dakota, United States|Nashville, Tennessee, United States|Abilene, Texas, United States|Ft Worth, Texas, United States|Houston, Texas, United States|San Antonio, Texas, United States|Vancouver, British Columbia, Canada|Victoria, British Columbia, Canada|Halifax, Nova Scotia, Canada|London, Ontario, Canada|Mississauga, Ontario, Canada|Toronto, Ontario, Canada|Medellin, Antioquia, Colombia|Bogota, Colombia|Hyderabad, A.p., India|Bangalore, Karnataka, India|Kolkata, West Bengal, India|Kfar-Saba, Israel|Petah Tikva, Israel|Rehovot, Israel|Tel Aviv, Israel",,"https://ClinicalTrials.gov/show/NCT00943072"
76,"NCT03969004","Study of Adjuvant Cemiplimab Versus Placebo After Surgery and Radiation Therapy in Patients With High Risk Cutaneous Squamous Cell Carcinoma",,"Recruiting","No Results Available","Cutaneous Squamous Cell Carcinoma","Drug: Cemiplimab|Drug: Placebo","DFS defined as time from randomization to the first documented disease recurrence (local, regional and/or distant); or death due to any cause.|Overall survival (OS), defined as time from randomization to the date of death. A patient who has not died will be censored on the last known date as alive.|FFLRR defined as time from randomization to the date of first locoregional recurrence (LRR). Patients who died without a preceding LRR will be censored on the date of death.|Freedom from distant recurrence (FFDR), defined as time from randomization to the date of first distant recurrence (DR). Patients who died without a preceding DR will be censored on the date of death.|Cumulative occurrence of second primary cutaneous squamous cell carcinoma tumor (SPTs) for each patient from randomization to occurrence of first primary endpoint event or end of study.|Incidence and severity of treatment-emergent adverse events (TEAE)|Incidence of deaths|Incidence of laboratory abnormalities|Cemiplimab concentrations in serum|Anti-drug antibodies (ADA) in serum","Regeneron Pharmaceuticals|Sanofi","All","18 Years and older   (Adult, Older Adult)","Phase 3","412","Industry","Interventional","Allocation: Randomized|Intervention Model: Parallel Assignment|Masking: Quadruple (Participant, Care Provider, Investigator, Outcomes Assessor)|Primary Purpose: Treatment","R2810-ONC-1788|2019-000566-38","June 4, 2019","December 19, 2025","February 28, 2027","May 31, 2019",,"February 11, 2022","Regeneron Research Facility, Gilbert, Arizona, United States|Regeneron Study Site, Tucson, Arizona, United States|Regeneron Research Site, Los Angeles, California, United States|Regeneron Research Site, Los Angeles, California, United States|Regeneron Research Site, San Francisco, California, United States|Regeneron Research Site, Washington, District of Columbia, United States|Regeneron Research Site, Miami, Florida, United States|Regeneron Research Site, Tampa, Florida, United States|Regeneron Study Site, Atlanta, Georgia, United States|Regeneron Study Site, Chicago, Illinois, United States|Regeneron Study Site, Louisville, Kentucky, United States|Regeneron Study Site, Baltimore, Maryland, United States|Regeneron Research Site, Boston, Massachusetts, United States|Regeneron Research Site, Boston, Massachusetts, United States|Regeneron Research Site, Columbia, Missouri, United States|Regeneron Research Site, Saint Louis, Missouri, United States|Regeneron Research Site, Omaha, Nebraska, United States|Regeneron Research Site, Basking Ridge, New Jersey, United States|Regeneron Research Site, Middletown, New Jersey, United States|Regeneron Research Site, Montvale, New Jersey, United States|Regeneron Study Site, New Brunswick, New Jersey, United States|Regeneron Research Site, Commack, New York, United States|Regeneron Research Site, Harrison, New York, United States|Regeneron Research Site, New York, New York, United States|Regeneron Research Site, New York, New York, United States|Regeneron Research Site, New York, New York, United States|Regeneron Research Site, Uniondale, New York, United States|Regeneron Research Site, Cincinnati, Ohio, United States|Regeneron Research Site, Gahanna, Ohio, United States|Regeneron Research Site, Hershey, Pennsylvania, United States|Regeneron Research Site, Philadelphia, Pennsylvania, United States|Regeneron Research Site, Nashville, Tennessee, United States|Regeneron Research Site, Dallas, Texas, United States|Regeneron Research Facility, Dallas, Texas, United States|Regeneron Research Site, Charlottesville, Virginia, United States|Regeneron Research Site, Albury, New South Wales, Australia|Regeneron Study Site, Coffs Harbour, New South Wales, Australia|Regeneron Research Site, Gosford, New South Wales, Australia|Regeneron Research Site, Kogarah, New South Wales, Australia|Regeneron Research Site, Liverpool, New South Wales, Australia|Regeneron Research Site, St Leonards, New South Wales, Australia|Regeneron Research Sites, Wagga Wagga, New South Wales, Australia|Regeneron Research Facility, Waratah, New South Wales, Australia|Regeneron Research Site, Westmead, New South Wales, Australia|Regeneron Research Site, Wollongong, New South Wales, Australia|Regeneron Research Site, Bundaberg, Queensland, Australia|Regeneron Research Facility, Herston, Queensland, Australia|Regeneron Research Site, Southport, Queensland, Australia|Regeneron Research Site, Tugun, Queensland, Australia|Regeneron Research Site, Urraween, Queensland, Australia|Regeneron Research Site, Woolloongabba, Queensland, Australia|Regeneron Research Site, Kurralta Park, South Australia, Australia|Regeneron Research Facility, Hobart, Tasmania, Australia|Regeneron Research Site, Bendigo, Victoria, Australia|Regeneron Research Site, Fitzroy, Victoria, Australia|Regeneron Research Site, Heidelberg, Victoria, Australia|Regeneron Research Site, Nedlands, Western Australia, Australia|Regeneron Study Site, Adelaide, Australia|Regeneron Research Site, Melbourne, Australia|Regeneron Research Site, Townsville, Australia|Regeneron Research Site, Leuven, Vlaams-Brabant, Belgium|Regeneron Research Site, Bruxelles, Belgium|Regeneron Research Site, Ipatinga, Minas Gerais, Brazil|Regeneron Study Site, Barretos, Porte Alegre, Brazil|Regeneron Study Site, Santo Cristo, Rio De Janiero, Brazil|Regeneron Research Site, Passo Fundo, Rio Grande Do Sul, Brazil|Regeneron Research Site, Centro, Santa Catarina, Brazil|Regeneron Research Site, Itajai, Santa Catarina, Brazil|Regeneron Research Site, Lajes, Santa Catarina, Brazil|Regeneron Study Site, Mogi das Cruzes, Sao Paulo, Brazil|Regeneron Study Site, Ribeirao Preto, Sao Paulo, Brazil|Regeneron Research Site, Florianopolis, Brazil|Regeneron Research Site, Sao Paulo, Brazil|Regeneron Research Site, Toronto, Ontario, Canada|Regeneron Research Site, Dijon, Dijon Cedex, France|Regeneron Research Site, Bordeaux, France|Regeneron Research Site, Boulogne Billancourt, France|Regeneron Study Site, Grenoble Cedex 09, France|Regeneron Research Site, La Tronche, France|Regeneron Research Site, Lille, France|Regeneron Research Site, Nantes, France|Regeneron Research Site, Nice, France|Regeneron Research Site, Paris Cedex 10, France|Regeneron Research Site, Pierre Benite Cedex, France|Regeneron Research Site, Rouen cedex, France|Regeneron Research Site, Villejuif Cedex, France|Regeneron Research Site, Heidelberg, Baden-Württemberg, Germany|Regeneron Research Site, Mainz, Rheinland-Pfalz, Germany|Regeneron Research Site, Buxtehude, Germany|Regeneron Research Site, Dresden, Germany|Regeneron Research Site, Essen, Germany|Regeneron Research Site, Heilbronn, Germany|Regeneron Research Site, Kiel, Germany|Regeneron Research Site, Koeln, Germany|Regeneron Research Site, Muenchen, Germany|Regeneron Research Site, Tuebingen, Germany|Regeneron Research Site, Athens, Attiki, Greece|Regeneron Research Site, Dublin, Leinster, Ireland|Regeneron Research Site, Cork, Ireland|Regeneron Research Site, Bergamo, Italy|Regeneron Research Site, Bologna, Italy|Regeneron Research Site, Brescia, Italy|Regeneron Research Site, Firenze, Italy|Regeneron Research Site, L'Aquila, Italy|Regeneron Research Site, Milan, Italy|Regeneron Research Facility, Napoli, Italy|Regeneron Study Site, Rome, Italy|Regeneron Study Site, Torino, Italy|Regeneron Research Site, Sapporo, Hokkaido, Japan|Regeneron Research Site, Nagaizumi-Cho, Sizuoka, Japan|Regeneron Research Site, Chuo-ku, Tokyo, Japan|Regeneron Research Site, Niigata, Japan|Regeneron Research Site, Osaka, Japan|Regeneron Study Site, Auckland, New Zealand|Regeneron Research Site, Palmerston North, New Zealand|Regeneron Study Site, Gliwice, Poland|Regeneron Study Site, Krakow, Poland|Regeneron Study Site, Poznan, Poland|Regeneron Study Site, Warsaw, Poland|Regeneron Research Site, Warszawa, Poland|Regeneron Research Site, Sochi, Krasnodar Krai, Russian Federation|Regeneron Research Site, Pyatigorsk, Stavropol Region, Russian Federation|Regeneron Study Site, Magnitogorsk, Russian Federation|Regeneron Study Site, Moscow, Russian Federation|Regeneron Research Site, Omsk, Russian Federation|Regeneron Research Site, Rostov-Na-Donu, Russian Federation|Regeneron Study Site, Saint Petersburg, Russian Federation|Regeneron Research Facility, Barcelona, Cataluna, Spain|Regeneron Research Site, Alcorcon, Madrid, Spain|Regeneron Research Facility, Torrejon de Ardoz, Madrid, Spain|Regeneron Research Site, Badalona, Spain|Regeneron Research Facility, Barcelona, Spain|Regeneron Research Site, Madrid, Spain|Regeneron Research Site, Madrid, Spain|Regeneron Research Site, Salamanca, Spain|Regeneron Research Site, Sevilla, Spain|Regeneron Research Site, Valencia, Spain|Regeneron Research Site, Valencia, Spain|Regeneron Study Site, Plymouth, Devon, United Kingdom|Regeneron Research Site, Edinburgh, Scotland, United Kingdom|Regeneron Research Site, Bristol, Somerset, United Kingdom|Regeneron Research Site, Manchester, United Kingdom",,"https://ClinicalTrials.gov/show/NCT03969004"
77,"NCT03889912","Pre-Operative Cemiplimab Administered Intralesionally for Patients With Recurrent Cutaneous Squamous Cell Carcinoma",,"Completed","No Results Available","Cutaneous Squamous Cell Carcinoma","Drug: Cemiplimab","Incidence, nature, and severity of dose limiting toxicities (DLTs) (if any) graded according to the National Cancer Institute-Common Terminology Criteria for Adverse Events (NCI CTCAE) v5|Incidence, nature, and severity of treatment-emergent adverse events (TEAEs) graded according to the National Cancer Institute-Common Terminology Criteria for Adverse Events (NCI CTCAE) v5|Incidence and severity of TEAEs graded according to the NCI CTCAE v5|The incidence and severity of injection site reactions (ISRs)|Objective response rate (ORR)|Pathologic complete response rate|Major pathologic response rate|Cemiplimab concentration in serum over time|Incidence of anti-drug antibody (ADA) titers for cemiplimab|Selection of the recommended dose of cemiplimab for further study based on clinical and pharmacokinetic (PK) observations","Regeneron Pharmaceuticals|Sanofi","All","18 Years and older   (Adult, Older Adult)","Phase 1","17","Industry","Interventional","Allocation: N/A|Intervention Model: Single Group Assignment|Masking: None (Open Label)|Primary Purpose: Treatment","R2810-ONC-1787","April 11, 2019","July 12, 2021","July 12, 2021","March 26, 2019",,"July 16, 2021","Regeneron Research Facility, Delray Beach, Florida, United States|Regeneron Research Facility, Tampa, Florida, United States|Regeneron Research Facility, Atlanta, Georgia, United States|Regeneron Research Facility, Louisville, Kentucky, United States|Regeneron Research Facility, New York, New York, United States|Regeneron Research Facility, Victor, New York, United States|Regeneron Research Facility, Durham, North Carolina, United States|Regeneron Research Facility, Houston, Texas, United States",,"https://ClinicalTrials.gov/show/NCT03889912"
78,"NCT03738423","Efficacy, Safety, and Pharmacokinetic Profiles of REGN3500 Administered to Adult Patients With Moderate-to-Severe Atopic Dermatitis",,"Completed","No Results Available","Atopic Dermatitis","Drug: REGN3500|Drug: REGN3500-Matching Placebo","Percent change in Eczema Area and Severity Index (EASI) score|Proportion of participants achieving EASI-50, (≥50% improvement from baseline)|Proportion of participants achieving EASI-75 (≥75% improvement from baseline)|Proportion of participants achieving EASI-90 (≥90% improvement from baseline)|Absolute change in EASI scores|Proportion of participants with both an Investigator's Global Assessment (IGA) score of 0 or 1 (on a 5-point scale) and a reduction from baseline of ≥2 points at week 16|Absolute change in weekly average of daily peak Pruritus Numerical Rating Scale (NRS)|Percent change in weekly average of daily peak NRS|Proportion of participants with improvement (reduction) of weekly average of daily peak Pruritus NRS ≥4|Time to onset of effect on pruritus|Percent change in SCORing Atopic Dermatitis (SCORAD)|Change in percent body surface area (BSA) of AD involvement|Serum REGN3500 concentration|Anti-REGN3500 antibody|Incidence of treatment-emergent adverse events (TEAEs)|Incidence of treatment-emergent serious adverse events (SAEs)|Incidence of treatment-emergent adverse events of special interest (AESIs)|Incidence of TEAEs|Incidence of SAEs|Incidence of AESIs","Regeneron Pharmaceuticals|Sanofi","All","18 Years to 75 Years   (Adult, Older Adult)","Phase 2","129","Industry","Interventional","Allocation: Randomized|Intervention Model: Parallel Assignment|Masking: Quadruple (Participant, Care Provider, Investigator, Outcomes Assessor)|Primary Purpose: Treatment","R3500-AD-1805|2018-001544-64","November 13, 2018","March 13, 2020","July 24, 2020","November 13, 2018",,"March 22, 2021","Regeneron Study Site, Birmingham, Alabama, United States|Regeneron Study Site, Phoenix, Arizona, United States|Regeneron Study Site, Scottsdale, Arizona, United States|Regeneron Study Site, Tucson, Arizona, United States|Regeneron Study Site, Little Rock, Arkansas, United States|Regeneron Study Site, Fountain Valley, California, United States|Regeneron Study Site, Fremont, California, United States|Regeneron Study Site, Oceanside, California, United States|Regeneron Study Site, Sacramento, California, United States|Regeneron Study Site, Santa Monica, California, United States|Regeneron Study Site, Jacksonville, Florida, United States|Regeneron Study Site, Macon, Georgia, United States|Regeneron Study Site, Skokie, Illinois, United States|Regeneron Study Site, Evansville, Indiana, United States|Regeneron Study Site, Overland Park, Kansas, United States|Regeneron Study Site, Louisville, Kentucky, United States|Regeneron Study Site, Louisville, Kentucky, United States|Regeneron Study Site, Louisville, Kentucky, United States|Regeneron Study Site, Saint Joseph, Michigan, United States|Regeneron Study Site, Minneapolis, Minnesota, United States|Regeneron Study Site, Las Vegas, Nevada, United States|Regeneron Study Site, Lebanon, New Hampshire, United States|Regeneron Study Site, New York, New York, United States|Regeneron Study Site, Wilmington, North Carolina, United States|Regeneron Study Site, Cincinnati, Ohio, United States|Regeneron Study Site, Norman, Oklahoma, United States|Regeneron Study Site, North Charleston, South Carolina, United States|Regeneron Study Site, San Antonio, Texas, United States|Regeneron Study Site, San Antonio, Texas, United States|Regeneron Study Site, San Antonio, Texas, United States|Regeneron Study Site, Norfolk, Virginia, United States|Regeneron Study Site, Kogarah, Australia|Regeneron Study Site, Melbourne, Australia|Regeneron Study Site, Calgary, Alberta, Canada|Regeneron Study Site, Hamilton, Ontario, Canada|Regeneron Study Site, Hamilton, Ontario, Canada|Regeneron Study Site, Toronto, Ontario, Canada|Regeneron Study Site, Windsor, Ontario, Canada|Regeneron Study Site, Verdun, Quebec, Canada|Regeneron Study Site, Brno, Czechia|Regeneron Study Site, Nachod, Czechia|Regeneron Study Site, Ostrava, Czechia|Regeneron Study Site, Praha, Czechia|Regeneron Study Site, Bad Bentheim, Germany|Regeneron Study Site, Berlin, Germany|Regeneron Study Site, Berlin, Germany|Regeneron Study Site, Frankfurt, Germany|Regeneron Study Site, Hamburg, Germany|Regeneron Study Site, Hanau, Germany|Regeneron Study Site, Ibbenburen, Germany|Regeneron Study Site, Leipzig, Germany|Regeneron Study Site, Lubeck, Germany|Regeneron Study Site, Munchen, Germany|Regeneron Study Site, Munster, Germany|Regeneron Study Site, Tubingen, Germany|Regeneron Study Site, Tuebingen, Germany|Regeneron Study Site, Witten, Germany|Regeneron Study Site, Oroshaza, Bekes, Hungary|Regeneron Study Site, Debrecen, Hajdu-Bihar, Hungary|Regeneron Study Site, Budapest, Hungary|Regeneron Study Site, Chuo, Japan|Regeneron Study Site, Hiroshima, Japan|Regeneron Study Site, Kanagawa, Japan|Regeneron Study Site, Kyoto, Japan|Regeneron Study Site, Kyoto, Japan|Regeneron Study Site, Shizuoka, Japan|Regeneron Study Site, Shizuoka, Japan|Regeneron Study Site, Wakayama, Japan|Regeneron Study Site, Yamanashi, Japan|Regeneron Study Site, Bucheon-Si, Korea, Republic of|Regeneron Study Site, Busan, Korea, Republic of|Regeneron Study Site, Gyeonggi-do, Korea, Republic of|Regeneron Study Site, Incheon, Korea, Republic of|Regeneron Study Site, Incheon, Korea, Republic of|Regeneron Study Site, Seoul, Korea, Republic of|Regeneron Study Site, Seoul, Korea, Republic of|Regeneron Study Site, Seoul, Korea, Republic of|Regeneron Study Site, Seoul, Korea, Republic of|Regeneron Study Site, Krakow, Poland|Regeneron Study Site, Lodz, Poland|Regeneron Study Site, Szczecin, Poland|Regeneron Study Site, Warszawa, Poland|Regeneron Study Site, Warszawa, Poland|Regeneron Study Site, Wroclaw, Poland|Regeneron Study Site, Wroclaw, Poland|Regeneron Study Site, Barakaldo, Spain|Regeneron Study Site, Cordoba, Spain|Regeneron Study Site, Madrid, Spain|Regeneron Study Site, Santiago de Compostela, Spain|Regeneron Study Site, Sheffield, United Kingdom",,"https://ClinicalTrials.gov/show/NCT03738423"
79,"NCT03691974","Study to Evaluate the Effects of Fasinumab on Peripheral Nerve Function in Patients With Pain Due to Osteoarthritis of the Hip or Knee",,"Completed","No Results Available","Osteoarthritis, Knee|Osteoarthritis, Hip","Drug: Fasinumab|Other: Placebo","Change in peroneal motor nerve conduction velocity|Change in peroneal motor nerve action potential amplitude|Change in sural sensory nerve conduction velocity|Change in sural sensory nerve action potential amplitude|Change in ulnar sensory nerve conduction velocity|Change in ulnar sensory nerve action potential amplitude|Change in Western Ontario and McMaster Universities Osteoarthritis Index (WOMAC) pain subscale score|Change in WOMAC physical function subscale score|Incidence of Adjudicated arthropathy (AA)|Incidence of Destructive arthropathy (DA)|Incidence of treatment-emergent adverse event (TEAEs)|Incidence of Sympathetic Nervous System (SNS) dysfunction|Incidence of peripheral sensory Adverse Events (AEs) that require a neurology consultation|Incidence of all-cause joint replacement (JR) surgeries|Incidence of all-cause JR surgeries|Incidence of JRs at telephone survey","Regeneron Pharmaceuticals|Teva Pharmaceutical Industries, Ltd.","All","18 Years and older   (Adult, Older Adult)","Phase 2","180","Industry","Interventional","Allocation: Randomized|Intervention Model: Parallel Assignment|Masking: Quadruple (Participant, Care Provider, Investigator, Outcomes Assessor)|Primary Purpose: Treatment","R475-OA-1758|2017-004921-33","October 15, 2018","January 30, 2020","January 7, 2021","October 2, 2018",,"December 8, 2021","Regeneron Study Site, Glendale, Arizona, United States|Regeneron Study Site, Glendale, Arizona, United States|Regeneron Study Site, Phoenix, Arizona, United States|Regeneron Study Site, Tucson, Arizona, United States|Regeneron Study Site, Anaheim, California, United States|Regeneron Study Site, Clearwater, Florida, United States|Regeneron Study Site, Jacksonville, Florida, United States|Regeneron Study Site, Miami, Florida, United States|Regeneron Study Site, Ocoee, Florida, United States|Regeneron Study Site, Orlando, Florida, United States|Regeneron Study Site, Woodstock, Georgia, United States|Regeneron Study Site, Chicago, Illinois, United States|Regeneron Study Site, Chicago, Illinois, United States|Regeneron Study Site, Caro, Michigan, United States|Regeneron Study Site, Hartsdale, New York, United States|Regeneron Study Site, Cincinnati, Ohio, United States|Regeneron Study Site, Columbus, Ohio, United States|Regeneron Study Site, Bellaire, Texas, United States|Regeneron Study Site, Houston, Texas, United States|Regeneron Study Site, Houston, Texas, United States|Regeneron Study Site, San Antonio, Texas, United States|Regeneron Study Site, Wroclaw, Dolnoslaskie, Poland|Regeneron Study Site, Lodz, Lodzkie, Poland|Regeneron Study Site, Warszawa, Mazowieckie, Poland|Regeneron Study Site, Gdansk, Pomorskie, Poland|Regeneron Study Site, Gdynia, Pomorskie, Poland|Regeneron Study Site, Czestochowa, Slaskie, Poland|Regeneron Study Site, Katowice, Slaskie, Poland|Regeneron Study Site, Poznan, Wielkopolskie, Poland|Regeneron Study Site, Lodz, Poland|Regeneron Study Site, London, Greater London, United Kingdom|Regeneron Study Site, Chorley, United Kingdom|Regeneron Study Site, Corby, United Kingdom|Regeneron Study Site, Edgbaston, United Kingdom|Regeneron Study Site, Glasgow, United Kingdom|Regeneron Study Site, Hardwick, United Kingdom|Regeneron Study Site, Hexham, United Kingdom|Regeneron Study Site, Kenilworth, United Kingdom|Regulatory Study Site, London, United Kingdom|Regeneron Study Site, London, United Kingdom|Regeneron Study Site, London, United Kingdom|Regeneron Study Site, Manchester, United Kingdom|Regeneron Study Site, Northwood, United Kingdom|Regeneron Study Site, Peterborough, United Kingdom|Regeneron Study Site, Reading, United Kingdom|Regeneron Study Site, Shipley, United Kingdom|Regeneron Study Site, Waterloo, United Kingdom",,"https://ClinicalTrials.gov/show/NCT03691974"
80,"NCT03736967","Efficacy and Safety of REGN3500 Monotherapy and Combination of REGN3500 Plus Dupilumab in Adult Patients With Moderate-to-Severe Atopic Dermatitis",,"Terminated","Has Results","Atopic Dermatitis","Drug: REGN3500|Drug: Dupilumab|Drug: REGN3500 + Dupilumab Combo|Drug: Placebo","Percent Change From Baseline in Eczema Area and Severity Index (EASI) Score Based on Observed Values Set to Missing After Rescue Treatment at Week 16|Percent Change From Baseline in Eczema Area and Severity Index (EASI) Score Based on All Observed Values Regardless of Rescue Treatment at Week 16|Percentage of Participants Who Achieved Eczema Area and Severity Index-50 (EASI-50) (Greater Than or Equal to [≥] 50 Percent [%] Improvement From Baseline) Based on Observed Values Set to Missing After Rescue Treatment at Week 16|Percentage of Participants Who Achieved Eczema Area and Severity Index-50 (EASI-50) (≥50% Improvement From Baseline) Based on All Observed Values Regardless of Rescue Treatment at Week 16|Percentage of Participants Who Achieved Eczema Area and Severity Index-75 (EASI-75) (≥75% Improvement From Baseline) Based on Observed Values Set to Missing After Rescue Treatment at Week 16|Percentage of Participants Who Achieved Eczema Area and Severity Index-75 (EASI-75) (≥75% Improvement From Baseline) Based on All Observed Values Regardless of Rescue Treatment at Week 16|Percentage of Participants Who Achieved Eczema Area and Severity Index-90 (EASI-90) (≥90% Improvement From Baseline) Based on Observed Values Set to Missing After Rescue Treatment at Week 16|Percentage of Participants Who Achieved Eczema Area and Severity Index-90 (EASI-90) (≥90% Improvement From Baseline) Based on All Observed Values Regardless of Rescue Treatment at Week 16|Absolute Change From Baseline in Eczema Area and Severity Index (EASI) Score Based on Observed Values Set to Missing After Rescue Treatment at Week 16|Absolute Change From Baseline in Eczema Area and Severity Index (EASI) Score Based on All Observed Values Regardless of Rescue Treatment at Week 16|Percentage of Participants With Both Investigator Global Assessment (IGA) Score 0 or 1 (on the 0 to 5 IGA Scale) and a Reduction From Baseline of ≥2 Points Based on Observed Values Set to Missing After Rescue Treatment at Week 16|Percentage of Participants With Both IGA Score 0 or 1 (on the 0 to 5 IGA Scale) and a Reduction From Baseline of ≥2 Points Based on All Observed Values Regardless of Rescue Treatment at Week 16|Absolute Change From Baseline in Weekly Average of Daily Peak Pruritus Numerical Rating Scale (NRS) Score Based on Observed Values Set to Missing After Rescue Treatment at Week 16|Absolute Change From Baseline in Weekly Average of Daily Peak Pruritus NRS Score Based on All Observed Values Regardless of Rescue Treatment at Week 16|Percent Change From Baseline in in Weekly Average of Daily Peak Pruritus NRS Score Based on Observed Values Set to Missing After Rescue Treatment at Week 16|Percent Change From Baseline in in Weekly Average of Daily Peak Pruritus NRS Score Based on All Observed Values Regardless of Rescue Treatment at Week 16|Percentage of Participants With Improvement (Reduction From Baseline) in Weekly Average of Peak Daily Pruritus NRS ≥4 Based on Observed Values Set to Missing After Rescue Treatment at Week 16|Percentage of Participants With Improvement (Reduction From Baseline) in Weekly Average of Peak Daily Pruritus NRS ≥4 Based on All Observed Values Regardless of Rescue Treatment at Week 16|Time to Onset of Effect on Pruritus (≥4-point Reduction of Weekly Average of Daily Peak Pruritus NRS From Baseline)|Percent Change From Baseline in SCORing Atopic Dermatitis (SCORAD) at Week 16|Absolute Change From Baseline in Percent Body Surface Area (BSA) of Atopic Dermatitis (AD) Involvement at Week 16|Number of Participants With Treatment-Emergent Adverse Events (TEAEs), Serious TEAEs and Adverse Events of Special Interest (AESIs) From Baseline up to Week 16|Number of Participants With Treatment-Emergent Adverse Events (TEAEs), Serious TEAEs and Adverse Events of Special Interest (AESIs) From Baseline up to Week 36|Number of Participants With Positive Treatment-Emergent Anti-drug Antibodies (ADA) to REGN3500 and Dupilumab|Serum Concentration of Functional REGN3500|Serum Concentration of Functional Dupilumab","Regeneron Pharmaceuticals|Sanofi","All","18 Years to 75 Years   (Adult, Older Adult)","Phase 2","206","Industry","Interventional","Allocation: Randomized|Intervention Model: Parallel Assignment|Masking: Quadruple (Participant, Care Provider, Investigator, Outcomes Assessor)|Primary Purpose: Treatment","R3500-AD-1798|2018-001543-30","November 12, 2018","March 13, 2020","July 28, 2020","November 9, 2018","November 1, 2021","November 1, 2021","Regeneron Research Site, Phoenix, Arizona, United States|Regeneron Research Site, Fountain Valley, California, United States|Regeneron Research Site, Long Beach, California, United States|Regeneron Research Site, Los Angeles, California, United States|Regeneron Research Site, Los Angeles, California, United States|Regeneron Research Site, Sacramento, California, United States|Regeneron Research Site, Davie, Florida, United States|Regeneron Research Site, Sandy Springs, Georgia, United States|Regeneron Research Site, Rockville, Maryland, United States|Regeneron Research Site, Bay City, Michigan, United States|Regeneron Research Site, Saint Joseph, Michigan, United States|Regeneron Research Site, Troy, Michigan, United States|Regeneron Research Site, Bronx, New York, United States|Regeneron Research Site, Forest Hills, New York, United States|Regeneron Research Site, New York, New York, United States|Regeneron Research Site, New York, New York, United States|Regeneron Research Site, High Point, North Carolina, United States|Regeneron Research Site, Norman, Oklahoma, United States|Regeneron Research Site, Portland, Oregon, United States|Regeneron Research Site, Pittsburgh, Pennsylvania, United States|Regeneron Research Site, Arlington, Texas, United States|Regeneron Research Site, Richmond, Virginia, United States|Regeneron Research Site, Anderlecht, Belgium|Regeneron Research Site, Antwerp, Belgium|Regeneron Research Site, Brussels, Belgium|Regeneron Research Site, Brussels, Belgium|Regeneron Research Site, Liege, Belgium|Regeneron Research Site, Loverval, Belgium|Regeneron Research Site, Brno, Czechia|Regeneron Research Site, Pardubice, Czechia|Regeneron Research Site, Praha 1, Czechia|Regeneron Research Site, Praha, Czechia|Regeneron Research Site, Bad Bentheim, Germany|Regeneron Research Site, Berlin, Germany|Regeneron Research Site, Halle/Saale, Germany|Regeneron Research Site, Hamburg, Germany|Regeneron Research Site, Hamburg, Germany|Regeneron Research Site, Hanau, Germany|Regeneron Research Site, Leipzig, Germany|Regeneron Research Site, Lubeck, Germany|Regeneron Research Site, Mahlow, Germany|Regeneron Research Site, Munchen, Germany|Regeneron Research Site, Munster, Germany|Regeneron Research Site, Quedlinburg, Germany|Regeneron Research Site, Tuebingen, Germany|Regeneron Research Site, Witten, Germany|Regeneron Research Site, Gyeonggi-do, Korea, Republic of|Regeneron Research Site, Gyeonggi-do, Korea, Republic of|Regeneron Research Site, Gyeonggi-do, Korea, Republic of|Regeneron Research Site, Gyeonggi-do, Korea, Republic of|Regeneron Research Site, Gyeonggi-do, Korea, Republic of|Regeneron Research Site, Incheon, Korea, Republic of|Regeneron Research Site, Incheon, Korea, Republic of|Regeneron Research Site, Incheon, Korea, Republic of|Regeneron Research Site, Seoul, Korea, Republic of|Regeneron Research Site, Seoul, Korea, Republic of|Regeneron Research Site, Seoul, Korea, Republic of|Regeneron Research Site, Seoul, Korea, Republic of|Regeneron Research Site, Bydgoszcz, Poland|Regeneron Research Site, Bydgoszcz, Poland|Regeneron Research Site, Iwonicz Zdroj, Poland|Regeneron Research Site, Krakow, Poland|Regeneron Research Site, Lodz, Poland|Regeneron Research Site, Wroclaw, Poland|Regeneron Research Site, Barakaldo, Spain|Regeneron Research Site, Santiago de Compostela, Spain","""Study Protocol"", https://ClinicalTrials.gov/ProvidedDocs/67/NCT03736967/Prot_000.pdf|""Statistical Analysis Plan"", https://ClinicalTrials.gov/ProvidedDocs/67/NCT03736967/SAP_001.pdf","https://ClinicalTrials.gov/show/NCT03736967"
81,"NCT03633617","Study to Determine the Efficacy and Safety of Dupilumab in Adult and Adolescent Patients With Eosinophilic Esophagitis (EoE)",,"Active, not recruiting","No Results Available","Eosinophilic Esophagitis","Drug: Dupilumab|Drug: Placebo","Proportion of patients achieving peak esophageal intraepithelial eosinophil count of ≤6 eosinophils per high-power field (eos/hpf)|Absolute change in Dysphagia Symptom Questionnaire (DSQ) score|Absolute change in EoE endoscopic reference score (EREFS)|Absolute change in EREFS|Percent change in peak esophageal intraepithelial eosinophil count (eos/hpf)|Absolute change in EoE Grade Score from the EoE Histology Scoring System (EoEHSS)|Absolute change in EoEHSS|Absolute change in EoE Stage Score from the EoEHSS|Proportion of patients achieving peak esophageal intraepithelial eosinophil count of ≤15 eos/hpf|Proportion of patients achieving peak esophageal intraepithelial eosinophil count of ≤1 eos/hpf|Percent change in DSQ|Normalized Enrichment Scores (NES) for the relative change in the EoE diagnostic panel (EDP) transcriptome signature|NES for the relative change in the EDP transcriptome signature|NES for the relative change in the type 2 inflammation transcriptome signature|Absolute change in health-related Quality of Life (QOL) as measured by EoE Impact Questionnaire (EoE-IQ)|Absolute change in health-related QOL as measured by EoE-IQ|Absolute change in severity and/or frequency of EoE symptoms other than dysphagia|Portion of patients with use of rescue medications or procedures during the placebo-controlled treatment period|Absolute change in esophageal distensibility plateau measured by functional lumen imagining|Concentration of functional dupilumab in serum|Incidence of treatment-emergent anti-drug antibody (ADA) responses and titer","Regeneron Pharmaceuticals|Sanofi","All","12 Years and older   (Child, Adult, Older Adult)","Phase 3","321","Industry","Interventional","Allocation: Randomized|Intervention Model: Parallel Assignment|Masking: Quadruple (Participant, Care Provider, Investigator, Outcomes Assessor)|Primary Purpose: Treatment","R668-EE-1774|2018-000844-25","September 24, 2018","September 9, 2021","July 1, 2022","August 16, 2018",,"December 17, 2021","Regeneron Study Site, Phoenix, Arizona, United States|Regeneron Study Site, Scottsdale, Arizona, United States|Regeneron Study Site, Little Rock, Arkansas, United States|Regeneron Study Site, La Jolla, California, United States|Regeneron Study Site, Los Angeles, California, United States|Regeneron Study Site, Mountain View, California, United States|Regeneron Study Site, Orange, California, United States|Regeneron Study Site, Rolling Hills Estates, California, United States|Regeneron Study Site, San Diego, California, United States|Regeneron Study Site, Aurora, Colorado, United States|Regeneron Study Site, Aurora, Colorado, United States|Regeneron Study Site, Colorado Springs, Colorado, United States|Regeneron Study Site, Lone Tree, Colorado, United States|Regeneron Study Site, Bristol, Connecticut, United States|Regeneron Study Site, Miami, Florida, United States|Regeneron Study Site, Saint Petersburg, Florida, United States|Regeneron Study Site, Boise, Idaho, United States|Regeneron Study Site, Idaho Falls, Idaho, United States|Regeneron Study Site #1, Chicago, Illinois, United States|Regeneron Study Site #2, Chicago, Illinois, United States|Regeneron Study Site, Park Ridge, Illinois, United States|Regeneron Study Site, Urbana, Illinois, United States|Regeneron Study Site, Indianapolis, Indiana, United States|Regeneron Study Site, Clive, Iowa, United States|Regeneron Study Site, Iowa City, Iowa, United States|Regeneron Study Site, Topeka, Kansas, United States|Regeneron Study Site, Hagerstown, Maryland, United States|Regeneron Study Site, Boston, Massachusetts, United States|Regeneron Study Site, Worcester, Massachusetts, United States|Regeneron Study Site, Ann Arbor, Michigan, United States|Regeneron Study Site, Chesterfield, Michigan, United States|Regeneron Study Site, Plymouth, Minnesota, United States|Regeneron Study Site, Rochester, Minnesota, United States|Regeneron Study Site, Lincoln, Nebraska, United States|Regeneron Study Site, Omaha, Nebraska, United States|Regeneron Study Site, Bronx, New York, United States|Regeneron Study Site, Great Neck, New York, United States|Regeneron Study Site, Great Neck, New York, United States|Regeneron Study Site, New York, New York, United States|Regeneron Study Site, New York, New York, United States|Regeneron Study Site, New York, New York, United States|Regeneron Study Site, Chapel Hill, North Carolina, United States|Regeneron Study Site, Cincinnati, Ohio, United States|Regeneron Study Site, Dublin, Ohio, United States|Regeneron Study Site, Englewood, Ohio, United States|Regeneron Study Site, Mentor, Ohio, United States|Regeneron Study Site, Hershey, Pennsylvania, United States|Regeneron Study Site, Philadelphia, Pennsylvania, United States|Regeneron Study Site, Charleston, South Carolina, United States|Regeneron Study Site, Greenville, South Carolina, United States|Regeneron Study Site, Johnson City, Tennessee, United States|Regeneron Study Site, Memphis, Tennessee, United States|Regeneron Study Site, Dallas, Texas, United States|Regeneron Study Site, Fort Worth, Texas, United States|Regeneron Study Site, Garland, Texas, United States|Regeneron Study Site, Houston, Texas, United States|Regeneron Study Site, San Antonio, Texas, United States|Regeneron Study Site, Salt Lake City, Utah, United States|Regeneron Study Site, Charlottesville, Virginia, United States|Regeneron Study Site, Roanoke, Virginia, United States|Regeneron Study Site, Seattle, Washington, United States|Regeneron Study Site, Milwaukee, Wisconsin, United States|Regeneron Study Site, Camperdown, New South Wales, Australia|Regeneron Study Site, Woolloongabba, Queensland, Australia|Regeneron Study Site, Elizabeth Vale, South Australia, Australia|Regeneron Study Site, Melbourne, Victoria, Australia|Regeneron Study Site, Bruges, Belgium|Regeneron Study Site, Edegem, Belgium|Regeneron Study Site, Leuven, Belgium|Regeneron Study Site, London, Ontario, Canada|Regeneron Study Site, Ottawa, Ontario, Canada|Regeneron Study Site, Montreal, Quebec, Canada|Regeneron Study Site, Hamilton, Canada|Regeneron Study Site, Ottawa, Canada|Regeneron Study Site, Pessac, France|Regeneron Study Site, Toulouse, France|Regeneron Study Site, Hannover, Germany|Regeneron Study Site, Magdeburg, Germany|Regeneron Study Site, Munich, Germany|Regeneron Study Site, Genoa, Italy|Regeneron Study Site, Milano, Italy|Regeneron Study Site, Naples, Italy|Regeneron Study Site, Pisa, Italy|Regeneron Study Site, Rome, Italy|Regeneron Study Site, Rome, Italy|Regeneron Study Site, Rozzano, Italy|Regeneron Study Site, Amsterdam, Netherlands|Regeneron Study Site, Maastricht, Netherlands|Regeneron Study Site, Nijmegen, Netherlands|Regeneron Study Site, Tomelloso, Ciudad Real, Spain|Regeneron Study Site, Barcelona, Spain|Regeneron Study Site, Madrid, Spain|Regeneron Study Site, Stockholm, Sweden|Regeneron Study Site, Zurich, Switzerland|Regeneron Study Site, London, Whitechapel, United Kingdom|Regeneron Study Site, Barnsley, Yorkshire, United Kingdom",,"https://ClinicalTrials.gov/show/NCT03633617"
82,"NCT03694197","Long Term Safety Study of PRALUENT",,"Terminated","Has Results","Heterozygous Familial Hypercholesterolemia|Non-familial Hypercholesterolemia","Drug: Praluent","Number of Participants With Adverse Events (AE) After First Administration of Study Drug Through the Last Dose of Study Drug Plus 2 Weeks|Calculated Low-density Lipoprotein Cholesterol (LDL-C) Values From Baseline Over Time|Percent Change in LDL-C From Baseline Over Time|Total Cholesterol (Total-C) Values From Baseline Over Time|Percent Change From Baseline in Total-C Over Time|Lipoprotein a (Lp(a)) Values From Baseline Over Time|Percent Change From Baseline in Lp(a) Over Time|Non-high-density Lipoprotein Cholesterol (Non-HDL-C) Values From Baseline Over Time|Percent Change From Baseline in Non-HDL-C Over Time|High-density Lipoprotein Cholesterol (HDL-C) Values From Baseline Over Time|Percent Change From Baseline in HDL-C Over Time|Fasting Triglycerides (TGs) Values From Baseline Over Time|Percent Change From Baseline in Fasting TGs Over Time|Apolipoprotein B (Apo B) Values From Baseline Over Time|Percent Change From Baseline in Apo B Over Time|Apolipoprotein-A1 (Apo A1) Values From Baseline Over Time|Percent Change From Baseline in Apo A1 Over Time|Gonadal Hormone (Follicle Stimulating Hormone [FSH] and Luteinizing Hormone [LH]) Values for Female Participants From Baseline Over Time|Change From Baseline in Gonadal Hormones (FSH and LH) for Female Participants Over Time|Gonadal (FSH and LH) Hormone Values for Male Participants From Baseline Over Time|Change From Baseline in Gonadal Hormones (FSH and LH) for Male Participants Over Time|Gonadotropin (Estradiol) Values for Female Participants From Baseline Over Time|Change From Baseline in Gonadotropins (Estradiol) for Female Participants Over Time|Gonadotropin (Testosterone) Values for Male Participants From Baseline Over Time|Change From Baseline in Gonadotropins (Testosterone) for Male Participants Over Time|Alanine Aminotransferase Values From Baseline Over Time|Change From Baseline in Alanine Aminotransferase Over Time|Aspartate Aminotransferase Values From Baseline Over Time|Change From Baseline in Aspartate Aminotransferase Over Time|Alkaline Phosphatase Values From Baseline Over Time|Change From Baseline in Alkaline Phosphatase Over Time|Total Bilirubin Values From Baseline Over Time|Change From Baseline in Total Bilirubin Over Time","Regeneron Pharmaceuticals|Sanofi","All","40 Years to 85 Years   (Adult, Older Adult)","Phase 4","1389","Industry","Interventional","Allocation: N/A|Intervention Model: Single Group Assignment|Masking: None (Open Label)|Primary Purpose: Treatment","R727-CL-1609|2018-002810-11","September 28, 2018","April 8, 2020","April 8, 2020","October 3, 2018","June 15, 2021","June 15, 2021","Regeneron Research Site, Auburn, Alabama, United States|Regeneron Research Site, Mobile, Alabama, United States|Regeneron Research Site, Beverly Hills, California, United States|Regeneron Research Site, Los Gatos, California, United States|Regeneron Research Site, North Hollywood, California, United States|Regeneron Research Site, Port Hueneme, California, United States|Regeneron Research Site, Aurora, Colorado, United States|Regeneron Research Site, Colorado Springs, Colorado, United States|Regeneron Research Site, Lake Worth, Florida, United States|Regeneron Research Site, Miami Springs, Florida, United States|Regeneron Research Site, Champaign, Illinois, United States|Regeneron Research Site, Evansville, Indiana, United States|Regeneron Research Site, Indianapolis, Indiana, United States|Regeneron Research Site, Ames, Iowa, United States|Regeneron Research Site, Iowa City, Iowa, United States|Regeneron Research Site, Waterloo, Iowa, United States|Regeneron Research Site, Newton, Kansas, United States|Regeneron Research Site, Louisville, Kentucky, United States|Regeneron Research Site, Bangor, Maine, United States|Regeneron Research Site, Baltimore, Maryland, United States|Regeneron Research Site, Oxon Hill, Maryland, United States|Regeneron Research Site, Olive Branch, Mississippi, United States|Regeneron Research Site, Washington, Missouri, United States|Regeneron Research Site, Buffalo, New York, United States|Regeneron Research Site, New Hyde Park, New York, United States|Regeneron Research Site, Cary, North Carolina, United States|Regeneron Research Site, Charlotte, North Carolina, United States|Regeneron Research Site, Charlotte, North Carolina, United States|Regeneron Research Site, Greensboro, North Carolina, United States|Regeneron Research Site, Hickory, North Carolina, United States|Regeneron Research Site, Raleigh, North Carolina, United States|Regeneron Research Site, Rocky Mount, North Carolina, United States|Regeneron Research Site, Salisbury, North Carolina, United States|Regeneron Research Site, Statesville, North Carolina, United States|Regeneron Research Site, Wilmington, North Carolina, United States|Regeneron Research Site, Winston-Salem, North Carolina, United States|Regeneron Research Site, Cincinnati, Ohio, United States|Regeneron Research Site, Cleveland, Ohio, United States|Regeneron Research Site, Dayton, Ohio, United States|Regeneron Research Site, Charleston, South Carolina, United States|Regeneron Research Site, Summerville, South Carolina, United States|Regeneron Research Site, Rapid City, South Dakota, United States|Regeneron Research Site, Bristol, Tennessee, United States|Regeneron Research Site 2, Knoxville, Tennessee, United States|Regeneron Research Site 3, Knoxville, Tennessee, United States|Regeneron Research Site, Knoxville, Tennessee, United States|Regeneron Research Site, Powell, Tennessee, United States|Regeneron Research Site, Dallas, Texas, United States|Regeneron Research Site, Houston, Texas, United States|Regeneron Research Site, Schertz, Texas, United States|Regeneron Research Site, Shavano Park, Texas, United States|Regeneron Research Site, Shavano Park, Texas, United States|Regeneron Research Site, Falls Church, Virginia, United States|Regeneron Research Site, Winchester, Virginia, United States|Regeneron Research Site, Tacoma, Washington, United States|Regeneron Research Site, Walla Walla, Washington, United States|Regeneron Research Site, Manitowoc, Wisconsin, United States|Regeneron Research Site, Pleven, Bulgaria|Regeneron Research Site, Plovdiv, Bulgaria|Regeneron Research Site, Sofia, Bulgaria|Regeneron Research Site, Sofia, Bulgaria|Regeneron Research Site #2, Sofia, Bulgaria|Regeneron Research Site, Stara Zagora, Bulgaria|Regeneron Research Site, Varna, Bulgaria|Regeneron Research Site, Tallinn, Harjumaa, Estonia|Regeneron Research Site, Paide, Estonia|Regeneron Research Site #2, Tallinn, Estonia|Regeneron Research Site, Tallinn, Estonia|Regeneron Research Site, Tartu, Estonia|Regeneron Research Site, Ekaterinburg, Russian Federation|Regeneron Research Site, Ivanovo, Russian Federation|Regeneron Research Site, Kirov, Russian Federation|Regeneron Research Site, Moscow, Russian Federation|Regeneron Research Site, Moscow, Russian Federation|Regeneron Research Site, Moscow, Russian Federation|Regeneron Research Site, Novosibirsk, Russian Federation|Regeneron Research Site, Rostov-na-Donu, Russian Federation|Regeneron Research Site, Saint Petersburg, Russian Federation|Regeneron Research Site, Saint-Petersburg, Russian Federation|Regeneron Research Site, Saint-Petersburg, Russian Federation|Regeneron Research Site, Saratov, Russian Federation|Regeneron Research Site #2, St. Petersburg, Russian Federation|Regeneron Research Site, St. Petersburg, Russian Federation|Regeneron Research Site, St. Petersburg, Russian Federation|Regeneron Research Site, St. Petersburg, Russian Federation|Regeneron Research Site, St. Petersburg, Russian Federation|Regeneron Research Site, Sverdlovskaya, Russian Federation|Regeneron Research Site, Tyumen, Russian Federation|Regeneron Research Site 1, Yaroslavl, Russian Federation|Regeneron Research Site 2, Yaroslavl, Russian Federation|Regeneron Research Site, Kuilsrivier, Cape Town, South Africa|Regeneron Research Site, Parow, Cape Town, South Africa|Regeneron Research Site, Port Elizabeth, Eastern Cape, South Africa|Regeneron Research Site, Halfway House, Gauteng, South Africa|Regeneron Research Site, Pretoria West, Gauteng, South Africa|Regeneron Research Site, Pretoria, Gauteng, South Africa|Regeneron Research Site, Pretoria, Gauteng, South Africa|Regeneron Research Site, Pretoria, Gauteng, South Africa|Regeneron Research Site, Kempton Park, Johannesburg, South Africa|Regeneron Research Site, Soweto, Johannesburg, South Africa|Regeneron Research Site, Cape Town, Western Cape, South Africa|Regeneron Research Site, Cape Town, Western Cape, South Africa|Regeneron Research Site, George, Western Cape, South Africa|Regeneron Research Site, Paarl, Western Cape, South Africa|Regeneron Research Site, Somerset West, Western Cape, South Africa|Regeneron Research Site, Worcester, Western Cape, South Africa|Regeneron Research Site, Bloemfontein, South Africa|Regeneron Research Site, Claremont, South Africa|Regeneron Research Site, Johannesburg, South Africa|Regeneron Research Site #2, Kharkiv, Ukraine|Regeneron Research Site, Kharkov, Ukraine|Regeneron Research Site, Kiev, Ukraine|Regeneron Research Site, Kyiv, Ukraine|Regeneron Research Site, Kyiv, Ukraine|Regeneron Research Site, Kyiv, Ukraine|Regeneron Research Site, Kyiv, Ukraine|Regeneron Research Site, Kyiv, Ukraine|Regeneron Research Site #2, Kyiv, Ukraine|Regeneron Research Site, Kyiv, Ukraine|Regeneron Research Site, Lviv, Ukraine|Regeneron Research Site, Uzhorod, Ukraine|Regeneron Research Site, Vinnitsa, Ukraine|Regeneron Research Site, Vinnitsya, Ukraine|Regeneron Research Site, Vinnytsya, Ukraine","""Study Protocol"", https://ClinicalTrials.gov/ProvidedDocs/97/NCT03694197/Prot_000.pdf|""Statistical Analysis Plan"", https://ClinicalTrials.gov/ProvidedDocs/97/NCT03694197/SAP_001.pdf","https://ClinicalTrials.gov/show/NCT03694197"
83,"NCT03793608","Study to Evaluate Dupilumab Monotherapy in Pediatric Patients With Peanut Allergy",,"Completed","No Results Available","Peanut Allergy","Drug: Dupilumab","Proportion of patients treated with dupilumab that pass a Double-blind, placebo-controlled food challenge (DBPCFC) with low-dose (cumulative) peanut protein|Change in the cumulative tolerated dose (log transformed) of peanut protein during a DBPCFC|Proportion of patients treated with dupilumab that pass a DBPCFC with low-dose (cumulative) peanut protein|Proportion of patients treated with dupilumab that pass a DBPCFC with mid-dose (cumulative) peanut protein|Proportion of patients treated with dupilumab that pass a DBPCFC with high-dose (cumulative) peanut protein|Percent change in peanut-specific Immunoglobulin E (sIgE)|Change in titrated SPT as measured by the average wheal size AUC after peanut allergen stimulation at different concentrations|Proportion of patients with Grade II or above allergic reactions during the DBPCFC|Proportion of patients using epinephrine as a rescue medication during the DBPCFC","Regeneron Pharmaceuticals|Sanofi","All","6 Years to 17 Years   (Child)","Phase 2","25","Industry","Interventional","Allocation: N/A|Intervention Model: Single Group Assignment|Masking: None (Open Label)|Primary Purpose: Treatment","R668-ALG-1702|2018-003133-15","March 12, 2019","February 19, 2021","May 12, 2021","January 4, 2019",,"August 23, 2021","Regeneron Investigational Site, Mountain View, California, United States|Regeneron Investigational Site, Tampa, Florida, United States|Regeneron Investigational Site, Indianapolis, Indiana, United States|Regeneron Investigational Site, Ypsilanti, Michigan, United States|Regeneron Investigational Site, Bronx, New York, United States|Regeneron Investigational Site, Great Neck, New York, United States|Regeneron Investigational Site, Hamilton, Ontario, Canada|Regeneron Investigational Site, Toronto, Ontario, Canada|Regeneron Investigational Site, Montreal, Quebec, Canada",,"https://ClinicalTrials.gov/show/NCT03793608"
84,"NCT03564340","Study of REGN4018 Administered Alone or in Combination With Cemiplimab in Adult Patients With Recurrent Ovarian Cancer",,"Recruiting","No Results Available","Recurrent Ovarian Cancer|Recurrent Fallopian Tube Cancer|Recurrent Primary Peritoneal Cancer","Drug: REGN4018|Drug: cemiplimab","Number of participants with Dose-limiting toxicity (DLTs) for REGN4018 monotherapy|Number of participants with DLTs for REGN4018 with cemiplimab|Number of participants with Treatment-emergent adverse event (TEAE)s (including immune-related adverse events (irAEs)) for REGN4018 monotherapy|Number of participants with TEAEs (including irAEs) for REGN4018 with cemiplimab|Number of participants with serious adverse events (SAEs) for REGN4018 monotherapy|Number of participants with SAEs for REGN4018 with cemiplimab|Number of deaths for REGN4018 monotherapy|Number of deaths for REGN4018 with cemiplimab|Number of participants with laboratory abnormalities (grade 3 or higher per Common Terminology Criteria for Adverse Events [CTCAE]) for REGN4018 monotherapy|Number of participants with laboratory abnormalities (grade 3 or higher per CTCAE) for REGN4018 with cemiplimab|Concentration of REGN4018 in serum over time for REGN4018 monotherapy|Concentration of REGN4018 in serum over time for REGN4018 with cemiplimab|Objective response rate (ORR) defined by Response Evaluation Criteria in Solid Tumors (RECIST 1.1) (Eisenhauer 2009) for REGN4018 monotherapy|ORR defined by RECIST 1.1 for REGN4018 with cemiplimab|ORR based on RECIST 1.1 (Eisenhauer 2009) for REGN4018 monotherapy|ORR based on RECIST 1.1 for REGN4018 with cemiplimab|Number of participants with TEAEs (including irAEs) for REGN4018 monotherapy|Number of participants with SAEs for REGN4018 monotherapy|Number of participants with laboratory abnormalities (grade 3 or higher per CTCAE) for REGN4018 monotherapy|Change from baseline in quality of life (QoL) as measured by the European Organisation for Research and Treatment of Cancer (EORTC) Quality of Life Questionnaire (QLQ)-C30 GHS/QoL score for REGN4018 monotherapy|Change from baseline in quality of life (QoL) as measured by the European Organisation for Research and Treatment of Cancer (EORTC) Quality of Life Questionnaire (QLQ)-C30 GHS/QoL score for REGN4018 with cemiplimab|Change from baseline in physical functioning as measured by the EORTC QLQ-C30 physical functioning score for REGN4018 monotherapy|Change from baseline in physical functioning as measured by the EORTC QLQ-C30 physical functioning score for REGN4018 with cemiplimab|Change from baseline in abdominal symptoms as measured by the Measure of Ovarian Symptoms and Treatment (MOST)-Abdominal index score for REGN4018 monotherapy|Change from baseline in abdominal symptoms as measured by the Measure of Ovarian Symptoms and Treatment (MOST)-Abdominal index score for REGN4018 with cemiplimab|Time to deterioration in GHS/QoL for REGN4018 monotherapy|Time to deterioration in GHS/QoL for REGN4018 with cemiplimab|Time to deterioration in physical functioning for REGN4018 monotherapy|Time to deterioration in physical functioning for REGN4018 with cemiplimab|Time to deterioration in abdominal symptoms for REGN4018 monotherapy|Time to deterioration in abdominal symptoms for REGN4018 with cemiplimab|Change from baseline in QoL as measured by EQ-5D for REGN4018 monotherapy|Change from baseline in QoL as measured by EQ-5D for REGN4018 with cemiplimab|ORR based on iRECIST (Seymour 2017) for REGN4018 monotherapy|ORR based on iRECIST for REGN4018 with cemiplimab|Best overall response (BOR) based on RECIST 1.1 for REGN4018 monotherapy|BOR based on iRECIST for REGN4018 monotherapy|BOR based on RECIST 1.1 for REGN4018 with cemiplimab|BOR based on iRECIST for REGN4018 with cemiplimab|Duration of response (DOR) based on RECIST 1.1 for REGN4018 monotherapy|DOR based on iRECIST for REGN4018 monotherapy|DOR based on RECIST 1.1 for REGN4018 with cemiplimab|DOR based on iRECIST for REGN4018 with cemiplimab|Disease control rate based on RECIST 1.1 for REGN4018 monotherapy|Disease control rate based on iRECIST for REGN4018 monotherapy|Disease control rate based on RECIST 1.1 for REGN4018 with cemiplimab|Disease control rate based on iRECIST for REGN4018 with cemiplimab|Complete response (CR) rate based on RECIST 1.1 for REGN4018 monotherapy|CR rate based on iRECIST 1.1 for REGN4018 monotherapy|CR rate based on RECIST 1.1 for REGN4018 with cemiplimab|CR rate based on iRECIST 1.1 for REGN4018 with cemiplimab|Progression-free survival (PFS) based on RECIST 1.1 for REGN4018 monotherapy|PFS based on iRECIST for REGN4018 monotherapy|PFS based on RECIST 1.1 for REGN4018 with cemiplimab|PFS based on iRECIST for REGN4018 with cemiplimab|Cancer antigen-125 (CA-125) response for REGN4018 monotherapy|CA-125 response for REGN4018 with cemiplimab|Presence or absence of anti-drug antibodies against REGN4018|Presence or absence of anti-drug antibodies against cemiplimab","Regeneron Pharmaceuticals","Female","18 Years and older   (Adult, Older Adult)","Phase 1|Phase 2","554","Industry","Interventional","Allocation: Non-Randomized|Intervention Model: Parallel Assignment|Masking: None (Open Label)|Primary Purpose: Treatment","R4018-ONC-1721|2019-003298-24","May 21, 2018","July 24, 2024","July 24, 2024","June 20, 2018",,"February 23, 2022","Regeneron Study Site, Boston, Massachusetts, United States|Regeneron Study Site, Boston, Massachusetts, United States|Regeneron Study Site, Buffalo, New York, United States|Regeneron Study Site, New York, New York, United States|Regeneron Study Site, New York, New York, United States|Regeneron Study Site, Columbus, Ohio, United States|Regeneron Study Site, Oklahoma City, Oklahoma, United States|Regeneron Study Site, Nashville, Tennessee, United States|Regeneron Research Site, Leuven, Belgium",,"https://ClinicalTrials.gov/show/NCT03564340"
85,"NCT03682770","Study in Pediatric Subjects With Peanut Allergy to Evaluate Efficacy and Safety of Dupilumab as Adjunct to AR101 (Peanut Oral Immunotherapy)",,"Completed","No Results Available","Peanut Allergy","Drug: Dupilumab|Drug: Placebo matching dupilumab|Drug: AR101","Proportion of participants treated with dupilumab plus AR101 vs placebo plus AR101 who ""pass"" a post up-dosing double-blind, placebo-controlled food challenge (DBPCFC) with 2044 mg (cumulative) peanut protein|Change in the cumulative tolerated dose (log transformed) of peanut protein during a DBPCFC in participants treated with dupilumab plus AR101 vs placebo plus AR101|Proportion of participants treated with dupilumab plus AR101 vs placebo plus AR101 who reach the protocol defined dose of AR101|Time from randomization to the first time when participants reach the protocol defined dose of AR101|Proportion of participants (continuously) treated with dupilumab plus AR101 vs placebo plus AR101 who ""pass"" a post maintenance DBPCFC with 2044 mg (cumulative) peanut protein|Change in the cumulative tolerated dose (log transformed) of peanut protein during a DBPCFC in participants (continuously) treated with dupilumab plus AR101 vs placebo plus AR101|Proportion of participants (previously) treated with dupilumab plus AR101 (and re-randomized to placebo plus AR101) vs placebo plus AR101 who ""pass"" a post maintenance DBPCFC with 2044 mg (cumulative) peanut protein|Change in the cumulative tolerated dose (log transformed) of peanut protein during a DBPCFC in participants (previously) treated with dupilumab plus AR101 (and re-randomized to placebo plus AR101) vs placebo plus AR101|Percent change in peanut-specific Immunoglobulin E (IgE) in participants treated with dupilumab plus AR101 vs participants treated placebo plus AR101|Percent change in peanut-specific IgE in participants (continuously) treated with dupilumab plus AR101 vs participants treated placebo plus AR101|Proportion of participants experiencing allergic symptoms by treatment group measured by the daily symptom e-diary|Mean severity score for each symptom by treatment group measured by the daily symptom e-diary|Maximum severity score for each symptom by treatment group measured by the daily symptom e-diary|Difference in mean/median duration of symptoms by treatment group measured by the daily symptom e-diary","Regeneron Pharmaceuticals|Sanofi|Aimmune Therapeutics, Inc.","All","6 Years to 17 Years   (Child)","Phase 2","149","Industry","Interventional","Allocation: Randomized|Intervention Model: Parallel Assignment|Masking: Quadruple (Participant, Care Provider, Investigator, Outcomes Assessor)|Primary Purpose: Treatment","R668-ALG-16114","October 3, 2018","October 16, 2020","July 23, 2021","September 25, 2018",,"November 1, 2021","Regeneron Investigational Site, Birmingham, Alabama, United States|Regeneron Investigational Site, Tucson, Arizona, United States|Regeneron Investigational Site, Little Rock, Arkansas, United States|Regeneron Investigational Site, Los Angeles, California, United States|Regeneron Investigational Site, Los Angeles, California, United States|Regeneron Investigational Site, Mission Viejo, California, United States|Regeneron Investigational Site, Mountain View, California, United States|Regeneron Investigational Site, Rolling Hills Estates, California, United States|Regeneron Investigational Site, Denver, Colorado, United States|Regeneron Investigational Site, Washington, District of Columbia, United States|Regeneron Investigational Site, Tampa, Florida, United States|Regeneron Investigational Site, Atlanta, Georgia, United States|Regeneron Investigational Site, Marietta, Georgia, United States|Regeneron Investigational Site, Chicago, Illinois, United States|Regeneron Investigational Site, Baltimore, Maryland, United States|Regeneron Investigational Site, Boston, Massachusetts, United States|Regeneron Investigational Site, Ann Arbor, Michigan, United States|Regeneron Investigational Site, Ypsilanti, Michigan, United States|Regeneron Investigational Site, Minneapolis, Minnesota, United States|Regeneron Investigational Site, Ocean Township, New Jersey, United States|Regeneron Investigational Site, Great Neck, New York, United States|Regeneron Investigational Site, New York, New York, United States|Regeneron Investigational Site, Chapel Hill, North Carolina, United States|Regeneron Investigational Site, Philadelphia, Pennsylvania, United States|Regeneron Investigational Site, Seattle, Washington, United States",,"https://ClinicalTrials.gov/show/NCT03682770"
86,"NCT03558997","Dupilumab As An Adjunct For Subcutaneous Grass Immunotherapy",,"Completed","Has Results","Allergic Rhinitis","Drug: Dupilumab|Drug: Timothy Grass SCIT|Drug: Placebo matching dupilumab|Drug: Placebo matching SCIT","Percent Change From Baseline in Total Nasal Symptom Score (TNSS) Area Under Curve (AUC) (0-1 Hour (hr) Post Peak TNSS) in Response to Post Nasal Allergen Challenge (NAC) at Week 17|Change From Baseline in Total Nasal Symptom Score (TNSS) Area Under Curve (AUC) Post Nasal Allergen Challenge (NAC) Over the First Hour After the Challenge (0-1 Hour (hr) Post Peak TNSS) at Week 17 in SCIT vs. Dupilumab + SCIT|Change From Baseline in Total Nasal Symptom Score (TNSS) Area Under Curve (AUC) Post Nasal Allergen Challenge (NAC) Over the First Hour After the Challenge (0-1 Hour (hr) Post Peak TNSS) at Week 17 in Placebo vs. Dupilumab|Percent Change From Baseline in Total Nasal Symptom Score (TNSS) Area Under Curve (AUC) Post Nasal Allergen Challenge (NAC) Over the First Hour of the Challenge (0-1 Hour (hr) Post Peak TNSS) at Week 17|Change From Baseline in TNSS Area Under Curve (AUC) Post Nasal Allergen Challenge (NAC) Over the First Hour of the Challenge (0-1 Hour (hr) Post Peak TNSS) at Week 17|Percent Change From Baseline in TNSS Area Under Curve (AUC) Post Nasal Allergen Challenge (NAC) Over the First Hour of the Challenge (0-1 Hour (hr) Post Peak TNSS) at Week 17|Change From Baseline in Serum Timothy Grass Specific Immunoglobulin G4 (sIgG4) to Week 17|Percent Change From Baseline in Serum Timothy Grass Specific Immunoglobulin G4 (sIgG4) to Week 17|Change From Baseline in Serum Timothy Grass Specific Immunoglobulin E (sIgE) to Week 17|Percent Change From Baseline in Serum Timothy Grass Specific Immunoglobulin E (sIgE) to Week 17|Change From Baseline in Log-Transformed Value of Serum Timothy Grass Specific Immunoglobulin G4 (sIgG4) to Serum Timothy Grass Specific Immunoglobulin E (sIgE) Ratio to Week 17|Number of Participants With Treatment-Emergent Adverse Events (TEAEs) and Serious TEAEs","Regeneron Pharmaceuticals|Sanofi","All","18 Years to 55 Years   (Adult)","Phase 2","103","Industry","Interventional","Allocation: Randomized|Intervention Model: Parallel Assignment|Masking: Triple (Participant, Investigator, Outcomes Assessor)|Primary Purpose: Treatment","R668-ALG-16115","June 7, 2018","May 14, 2019","June 13, 2019","June 15, 2018","May 28, 2020","May 28, 2020","Regeneron Investigational Site, Los Angeles, California, United States|Regeneron Investigational Site, Mountain View, California, United States|Regeneron Investigational Site, Walnut Creek, California, United States|Regeneron Investigational Site, Baltimore, Maryland, United States|Regeneron Investigational Site, Andover, Massachusetts, United States|Regeneron Investigational Site, North Dartmouth, Massachusetts, United States|Regeneron Investigational Site, Saint Louis, Missouri, United States|Regeneron Investigational Site, Bellevue, Nebraska, United States|Regeneron Investigational Site, Portland, Oregon, United States|Regeneron Investigational Site, East Providence, Rhode Island, United States|Regeneron Investigational Site, Seattle, Washington, United States|Regeneron Investigational Site, Madison, Wisconsin, United States|Regeneron Investigational Site, Kingston, Ontario, Canada|Regeneron Investigational Site, Mississauga, Ontario, Canada|Regeneron Investigational Site, Ottawa, Ontario, Canada|Regeneron Investigational Site, Toronto, Ontario, Canada|Regeneron Investigational Site, Québec, Quebec, Canada","""Study Protocol"", https://ClinicalTrials.gov/ProvidedDocs/97/NCT03558997/Prot_000.pdf|""Statistical Analysis Plan"", https://ClinicalTrials.gov/ProvidedDocs/97/NCT03558997/SAP_001.pdf","https://ClinicalTrials.gov/show/NCT03558997"
87,"NCT03430063","A Study of REGN2810 and Ipilimumab in Patients With Lung Cancer",,"Completed","No Results Available","Advanced Non-Small Cell Lung Carcinoma","Drug: SDREGN2810|Drug: SDREGN2810/ipi|Drug: HDREGN2810","ORR|ORR in all patients|Overall survival (OS) in patients whose tumors express PD-L1 in <50% of tumor cells|OS in all patients|Progression free survival (PFS) in patients whose tumors express PD-L1 in <50% of tumor cells|PFS in all patients|Incidences of treatment emergent adverse events (TEAEs) as assessed by the National Cancer Institute Common Terminology Criteria for Adverse Events (NCI-CTCAE) grading system|Incidences of serious adverse events (SAEs) as assessed by the NCI-CTCAE grading system|Incidences of deaths|Incidences of laboratory abnormalities as assessed by the NCI-CTCAE grading system","Regeneron Pharmaceuticals|Sanofi","All","18 Years and older   (Adult, Older Adult)","Phase 2","28","Industry","Interventional","Allocation: Randomized|Intervention Model: Parallel Assignment|Masking: None (Open Label)|Primary Purpose: Treatment","R2810-ONC-1763|2017-003684-35","May 29, 2018","October 27, 2021","October 27, 2021","February 12, 2018",,"November 17, 2021","Regeneron Research Site, Phoenix, Arizona, United States|Regeneron Research Site, Los Angeles, California, United States|Regeneron Research Site, Whittier, California, United States|Regeneron Research Site, Scarborough, Maine, United States|Regeneron Research Site, Canton, Ohio, United States|Regeneron Research Site, Massillon, Ohio, United States|Regeneron Research Site, Herstal, Belgium|Regeneron Research Site, Yvoir, Belgium|Regeneron Research Site, Poitiers, France|Regeneron Research Site, Rennes, France|Regeneron Research Site, Saint-Mandé, France|Regeneron Research Site, Gauting, Germany|Regeneron Research Site, Incheon, Korea, Republic of|Regeneron Research Site, Jeongnam, Korea, Republic of|Regeneron Research Site, Seongnam, Korea, Republic of|Regeneron Research Site, Seoul, Korea, Republic of|Regeneron Research Site, Seoul, Korea, Republic of|Regeneron Research Site, Seoul, Korea, Republic of|Regeneron Research Site, Suwon, Korea, Republic of|Regeneron Research Site, Gdynia, Poland|Regeneron Research Site, Grudziądz, Poland|Regeneron Research Site, Otwock, Poland|Regeneron Research Site, Badalona, Spain|Regeneron Research Site, Barcelona, Spain|Regeneron Research Site, Madrid, Spain|Regeneron Research Site, Málaga, Spain|Regeneron Research Site, Zaragoza, Spain|Regeneron Research Site, Taipei, Taiwan|Regeneron Research Site, London, United Kingdom|Regeneron Research Site, Manchester, United Kingdom|Regeneron Research Site, Plymouth, United Kingdom",,"https://ClinicalTrials.gov/show/NCT03430063"
88,"NCT03491904","To Assess the Patients' Ability to Self-Administer Fasinumab","FACT DEVICE","Completed","No Results Available","Osteoarthritis, Knee|Osteoarthritis, Hip","Drug: Fasinumab AI|Drug: Fasinumab PFS","Percentage of device-associated product technical failure (PTF) for the AI based on the total number of fasinumab injections administered by patients/caregivers in an unsupervised setting|Proportion of successful fasinumab injections administered by patients or their caregivers using an AI in an unsupervised setting (per patient report)|Number of AI associated product technical complaint (PTCs)|Number of validated AI associated PTFs|Number of patients with an AI associated PTC|Number of AI use-related errors|Patient satisfaction with the AI as assessed using the Self-Injection Assessment Questionnaire (SIAQ)|Number of participants who experience Adjudicated arthropathy (AA)|Number of participants who experience Destructive arthropathy (DA)|Number of participants who experience treatment-emergent adverse events (TEAEs)|Number of participants who experience sympathetic nervous system dysfunction|Number of participants who experience peripheral sensory adverse events (AEs) that require a neurology or other specialty consultation|Number of participants who experience all-cause Joint replacement (JR)s|Number of participants who experienced JR at the telephone survey|Maximum observed drug concentration (Cmax)|Area under the curve from the time of dosing to the end of dosing interval (AUC)|Geometric mean ratio of Cmax and AUC for the AI device (CI) of the geometric mean ratio|Geometric mean ratio of Cmax and AUC for the PFS device (CI) of the geometric mean ratio|Incidence of anti-drug antibody (ADA)","Regeneron Pharmaceuticals|Teva Pharmaceutical Industries, Ltd.","All","18 Years and older   (Adult, Older Adult)","Phase 1","100","Industry","Interventional","Allocation: Randomized|Intervention Model: Parallel Assignment|Masking: None (Open Label)|Primary Purpose: Treatment","R475-PN-1602","January 23, 2019","January 15, 2020","December 15, 2020","April 9, 2018",,"March 3, 2021","Regeneron Research Facility, Gilbert, Arizona, United States|Regeneron Research Facility, Glendale, Arizona, United States|Regeneron Research Facility, Los Angeles, California, United States|Regeneron Research Facility, Wheat Ridge, Colorado, United States|Regeneron Research Facility, Ocala, Florida, United States|Regeneron Research Facility, Orlando, Florida, United States|Regeneron Research Facility, Pinellas Park, Florida, United States|Regeneron Research Facility, Port Orange, Florida, United States|Regeneron Research Facility, Atlanta, Georgia, United States|Regeneron Research Facility, West Des Moines, Iowa, United States|Regeneron Research Facility, Wichita, Kansas, United States|Regeneron Research Facility, Lexington, Kentucky, United States|Regeneron Research Facility, Lexington, Kentucky, United States|Regeneron Research Facility, Jamaica, New York, United States|Regeneron Research Facility, Statesville, North Carolina, United States|Regeneron Research Facility, Wilmington, North Carolina, United States|Regeneron Research Facility, Oklahoma City, Oklahoma, United States|Regeneron Research Facility, Bristol, Tennessee, United States|Regeneron Research Facility, Knoxville, Tennessee, United States|Regeneron Research Facility, Dallas, Texas, United States|Regeneron Research Facility, Houston, Texas, United States|Regeneron Research Facility, Houston, Texas, United States|Regeneron Research Facility, Houston, Texas, United States",,"https://ClinicalTrials.gov/show/NCT03491904"
89,"NCT05157997","Transplantation of Deceased Donors With COVID-19 Into COVID-19 Negative Recipients Utilizing Casirivimab and Imdevimab Antibody Cocktail",,"Not yet recruiting","No Results Available","COVID-19|Organ Transplant","Drug: Casirivimab and Imdevimab Antibody Cocktail","Monitoring for SARS-CoV-2 infection|30-day admission rate to hospital post-transplant due to COVID-19|Patient and graft survival at 30 days, 6 months and 1 year|Adverse effects of casirivimab with imdevimab (REGEN-COV) antibody cocktail|Stored serum will be evaluated when feasible for SARS-CoV-2 RNA","Northwell Health|Regeneron Pharmaceuticals","All","18 Years and older   (Adult, Older Adult)","Phase 1","14","Other|Industry","Interventional","Allocation: N/A|Intervention Model: Single Group Assignment|Masking: None (Open Label)|Primary Purpose: Prevention","21-1223","January 2022","January 2024","January 2025","December 15, 2021",,"December 15, 2021","Northwell Health Organ Transplant Center, Manhasset, New York, United States",,"https://ClinicalTrials.gov/show/NCT05157997"
90,"NCT03409614","Combinations of Cemiplimab (Anti-PD-1 Antibody) and Platinum-based Doublet Chemotherapy in Patients With Lung Cancer",,"Active, not recruiting","No Results Available","Non-small Cell Lung Cancer","Drug: REGN2810|Drug: REGN2810/chemo/ipi|Other: Chemotherapy|Drug: Placebo","Overall survival|Progression-free survival|Objective response rate|Duration of Response (DOR)|Best overall response (BOR)|Incidence of Treatment-emergent adverse events (TEAEs)|Incidence of Dose-limiting toxicities (DLTs)|Incidence of serious adverse events (SAEs)|Incidence of deaths|Incidence of laboratory abnormalities|Overall survival rate|Quality of life as measured by EORTC QLQ-C30|Quality of life as measured by EORTC QLQ-LC13","Regeneron Pharmaceuticals|Sanofi","All","18 Years and older   (Adult, Older Adult)","Phase 3","790","Industry","Interventional","Allocation: Randomized|Intervention Model: Parallel Assignment|Masking: Quadruple (Participant, Care Provider, Investigator, Outcomes Assessor)|Primary Purpose: Treatment","R2810-ONC-16113|2017-001311-36","March 6, 2018","May 1, 2023","May 1, 2023","January 24, 2018",,"February 17, 2022","Regeneron Research Site, Rancho Mirage, California, United States|Regeneron Research Site, Riverside, California, United States|Regeneron Research Site, Whittier, California, United States|Regeneron Research Site, Orange City, Florida, United States|Regeneron Research Site, Saint Petersburg, Florida, United States|Regeneron Research Site, Wichita, Kansas, United States|Regeneron Research Site, Farmington, New Mexico, United States|Regeneron Research Site, Gettysburg, Pennsylvania, United States|Regeneron Research Site, Wien, Austria|Regeneron Research Site, Baoding, China|Regeneron research Site, Beijing, China|Regeneron Research Site, Changsha, China|Regeneron Reserach Site, Fujian, China|Regeneron Research Site, Guangzhou, China|Regeneron Research Site, Guangzhou, China|Regeneron Research Site, Hangzhou Shi, China|Regeneron Reserach Site, Hangzhou, China|Regeneron Research Site, Hangzhou, China|Regeneron Research Site, Hangzhou, China|Regeneron Research Site, Hefei Shi, China|Regeneron Research Site, Jinan, China|Regeneron Research Site, Linyi City, China|Regeneron Research Site, Nanjing Shi, China|Regeneron Research Site, Shanghai, China|Regeneron Research Site, Shanghai, China|Regeneron Research Site, Shenyang, China|Regeneron Research Site, Xiangyang Shi, China|Regeneron Research Site, Xinjiang, China|Regeneron Research Site, Zhengzhou City, China|Regeneron Research Site, Zhengzhou, China|Regeneron Research Site, Horovice, Czechia|Regeneron Research Site, Novy Jicin, Czechia|Regeneron Research Site, Ostrava-Poruba, Czechia|Regeneron Research Site, Bayonne, France|Regeneron Research Site, Creteil, France|Regeneron Research Site, Le Mans, France|Regeneron Research Site, Lille, France|Regeneron Research Site, Lyon, France|Regeneron Research Site, Mont-de-Marsan, France|Regeneron Research Site, Saint Herblain Cedex, France|Regeneron Research Site, Saint-Mandé, France|Regeneron Research Site, Strasbourg, France|Regeneron Research Site, Batumi, Georgia|Regeneron Research Site, Tbilisi, Georgia|Regeneron Research Site, Tbilisi, Georgia|Regeneron Research Site #1, Tbilisi, Georgia|Regeneron Research Site #2, Tbilisi, Georgia|Regeneron Research Site, Tbilisi, Georgia|Regeneron Research Site, Thessaloniki, Macedonia, Greece|Regeneron Research Site, Athens, Greece|Regeneron Research Site, Kifisia, Greece|Regeneron Research Site, Larissa, Greece|Regeneron Research Site, Pylaia, Greece|Regeneron Research Site, Thessaloniki, Greece|Regeneron Research Site, Dublin, Ireland|Regeneron Research Site, Limerick, Ireland|Regeneron Research Site, Cremona, Italy|Regeneron Research Site, Meldola, Italy|Regeneron Research Site, Milano, Italy|Regeneron Research Site, Monserrato, Italy|Regeneron Research Site, Piacenza, Italy|Regeneron Research Site, Saronno, Italy|Regeneron Research Site, Terni, Italy|Regeneron Research Site, Treviglio, Italy|Regeneron Research Site, Cheongju-si, Korea, Republic of|Regeneron Research Site, Incheon, Korea, Republic of|Regeneron Research Site, Jeonju, Korea, Republic of|Regeneron Research Site, Seongnam-si, Korea, Republic of|Regeneron Research Site, Seongnam-si, Korea, Republic of|Regeneron Research Site, Seoul, Korea, Republic of|Regeneron Research Site, Seoul, Korea, Republic of|Regeneron Research Site, Seoul, Korea, Republic of|Regeneron Research Site, Suwon-si, Korea, Republic of|Regeneron Research Site, Klaipeda, Lithuania|Regeneron Research Site, Vilnius, Lithuania|Regeneron Research Site, Kuala Lumpur, Wilayah Persekutuan, Malaysia|Regeneron Research Site, Johor Bahru, Malaysia|Regeneron Research Site, Kota Kinabalu, Malaysia|Regeneron Research Site, Kuala Lumpur, Malaysia|Regeneron Research Site, Kuala Lumpur, Malaysia|Regeneron Research Site, Kuantan, Malaysia|Regeneron Research Site, Penang, Malaysia|Regeneron Research Site, Pulau Pinang, Malaysia|Regeneron Research Site, Tanjung Bungah, Malaysia|Regeneron Research Site, Krakow, Malopolskie, Poland|Regeneron Research Site, Gdynia, Pomorskie, Poland|Regeneron Research Site, Lublin, Poland|Regeneron Research Site, Olsztyn, Poland|Regeneron Research Site, Otwock, Poland|Regeneron Research Site, Poznan, Poland|Regeneron Research Site, Rzeszow, Poland|Regeneron Research Site, Torun, Poland|Regeneron Research Site, Wodzisław Śląski, Poland|Regeneron Research Site, Łódź, Poland|Regeneron Research Site, Bucuresti, Romania|Regeneron Research Site, Cluj Napoca, Romania|Regeneron Research Site, Craiova, Romania|Regeneron Research Site, Craiova, Romania|Regeneron Research Site, Craiova, Romania|Regeneron Research Site, Iasi, Romania|Regeneron Research Site, Iasi, Romania|Regeneron Research Site, Timisoara, Romania|Regeneron Research Site, Ufa, Republic Bashkortost, Russian Federation|Regeneron Research Site, Arkhangel'sk, Russian Federation|Regeneron Research Site, Belgorod, Russian Federation|Regeneron Research Site, Chelyabinsk, Russian Federation|Regeneron Research Site, Ekaterinburg, Russian Federation|Regeneron Research Site, Kaluga, Russian Federation|Regeneron Research Site, Kazan, Russian Federation|Regeneron Research Site, Kursk, Russian Federation|Regeneron Research Site, Moscow region, Russian Federation|Regeneron Research Site, Moscow, Russian Federation|Regeneron Research Site, Moscow, Russian Federation|Regeneron Research Site, Omsk, Russian Federation|Regeneron Research Site, Pushkin, Russian Federation|Regeneron Research Site, Pyatigorsk, Russian Federation|Regeneron Research Site, Saint Petersburg, Russian Federation|Regeneron Research Site, Saint Petersburg, Russian Federation|Regeneron Research Site, Saint Petersburg, Russian Federation|Regeneron Research Site, Samara, Russian Federation|Regeneron Research Site, Saransk, Russian Federation|Regeneron Research Site, Sochi, Russian Federation|Regeneron Research Site, Tomsk, Russian Federation|Regeneron Research Site, Tomsk, Russian Federation|Regeneron Research Site, Banka, Slovakia|Regeneron Research Site, Ratchathewi, Bangkok, Thailand|Regeneron Research Site, Muang, Chiang Rai, Thailand|Regeneron Research Site, A. Mueang, Lampang, Thailand|Regeneron Research Site, Muang, Phitsanulok, Thailand|Regeneron Research Site, Hat Yai, Songkhla, Thailand|Regeneron Research Site, Muang, Thailand|Regeneron Research Site 1, Ratchathewi, Thailand|Regeneron Research Site, Udonthani, Thailand|Regeneron Research Site, Adana, Turkey|Regeneron Research Site, Ankara, Turkey|Regeneron Research Site, Istanbul, Turkey|Regeneron Research Site, Istanbul, Turkey|Regeneron Research Site, Dnipro, Ukraine|Regeneron Research Site, Kharkiv, Ukraine|Regeneron Research Site, Kiev, Ukraine|Regeneron Research Site, Kirovohrad, Ukraine|Regeneron Research Site, Uzhgorod, Ukraine|Regeneron Research Site, Vinnytsia, Ukraine",,"https://ClinicalTrials.gov/show/NCT03409614"
91,"NCT03399786","Efficacy and Safety of Evinacumab in Patients With Homozygous Familial Hypercholesterolemia",,"Completed","Has Results","Homozygous Familial Hypercholesterolemia","Drug: evinacumab|Drug: Placebo","Percent Change in Calculated Low-Density Lipoprotein Cholesterol (LDL-C) From Baseline to Week 24 (Intent-to-Treat [ITT] Estimand)|Percent Change in Apolipoprotein B (Apo B) From Baseline to Week 24 (ITT Estimand)|Percent Change in Non-High-Density Lipoprotein Cholesterol (Non-HDL-C) From Baseline to Week 24 (ITT Estimand)|Percent Change in Total Cholesterol (TC) From Baseline to Week 24 (ITT Estimand)|Percentage of Participants With ≥30% Reduction in Calculated Low-Density Lipoprotein Cholesterol (LDL-C) at Week 24 (ITT Estimand)|Percentage of Participants With ≥50% Reduction in Calculated Low-Density Lipoprotein Cholesterol (LDL-C) at Week 24 (ITT Estimand)|Absolute Change in Calculated Low-Density Lipoprotein Cholesterol (LDL-C) From Baseline to Week 24 (ITT Estimand)|Percentage of Participants Who Met United States (US) Apheresis Eligibility Criteria at Week 24 (ITT Estimand)|Percentage of Participants With Low-Density Lipoprotein Cholesterol (LDL-C) <100 Milligrams Per Deciliter (mg/dL) (2.59 Millimoles Per Liter [mmol/L]) at Week 24 (ITT Estimand)|Percentage of Participants Who Met European Union (EU) Apheresis Eligibility Criteria at Week 24 (ITT Estimand)|Percentage of Participants With Calculated Low-Density Lipoprotein Cholesterol (LDL-C) <70 mg/dL (1.81 mmol/L) at Week 24 (ITT Estimand)|Percent Change in Fasting Triglycerides (TG) From Baseline to Week 24 (ITT Estimand)|Percent Change in Lipoprotein A (Lp[a]) From Baseline to Week 24 (ITT Estimand)|Absolute Change in Apolipoprotein B (Apo B) From Baseline to Week 24 (ITT Estimand)|Absolute Change in Non-High-Density Lipoprotein Cholesterol (Non-HDL-C) From Baseline to Week 24 (ITT Estimand)|Absolute Change in Total Cholesterol (TC) From Baseline to Week 24 (ITT Estimand)|Percent Change in Apolipoprotein CIII (Apo CIII) From Baseline to Week 24 (ITT Estimand)","Regeneron Pharmaceuticals","All","12 Years and older   (Child, Adult, Older Adult)","Phase 3","65","Industry","Interventional","Allocation: Randomized|Intervention Model: Parallel Assignment|Masking: Quadruple (Participant, Care Provider, Investigator, Outcomes Assessor)|Primary Purpose: Treatment","R1500-CL-1629|2017-001388-19","January 18, 2018","June 10, 2019","March 17, 2020","January 16, 2018","May 18, 2021","May 18, 2021","Regeneron Research Site, Boca Raton, Florida, United States|Regeneron Research Site, Boston, Massachusetts, United States|Regeneron Research Site, New York, New York, United States|Regeneron Research Site, Cincinnati, Ohio, United States|Regeneron Research Site, Portland, Oregon, United States|Regeneron Research Site, Dallas, Texas, United States|Regeneron Research Site, Camperdown, New South Wales, Australia|Regeneron Research Site, Perth, Western Australia, Australia|Regeneron Research Site, Innsbruck, Austria|Regeneron Research Site, Chicoutimi, Quebec, Canada|Regeneron Research Site, Québec, Quebec, Canada|Regeneron Research Site, Paris, Cedex, France|Regeneron Research Site, Marseille, France|Regeneron Research Site, Ioánnina, Ioannina, Greece|Regeneron Research Site, Athens, Greece|Regeneron Research Site # 2, Napoli, Italy|Regeneron Research Site, Kurume, Fukuoka, Japan|Regeneron Research Site, Nishinomiya, Hyogo, Japan|Regeneron Research Site, Kanazawa, Ishikawa, Japan|Regeneron Research Site #3, Suita, Osaka, Japan|Regeneron Research Site, Suita, Osaka, Japan|Regeneron Research Site, Osaka, Japan|Regeneron Research Site, Amsterdam, Netherlands|Regeneron Research Site, Rotterdam, Netherlands|Regeneron Research Site, Parktown, Johannesburg, South Africa|Regeneron Research Site, Ivano-Frankivs'k, Ukraine|Regeneron Research Site, Kharkiv, Ukraine|Regeneron Research Site #2, Kharkiv, Ukraine|Regeneron Research Site #2, Kyiv, Ukraine|Regeneron Research Site, Kyiv, Ukraine","""Study Protocol"", https://ClinicalTrials.gov/ProvidedDocs/86/NCT03399786/Prot_000.pdf|""Statistical Analysis Plan"", https://ClinicalTrials.gov/ProvidedDocs/86/NCT03399786/SAP_001.pdf","https://ClinicalTrials.gov/show/NCT03399786"
92,"NCT03452228","Safety and Efficacy Following Repeat-Dose of Evinacumab (Anti-ANGPTL3) in Patients With Severe Hypertriglyceridemia (sHTG) at Risk for Acute Pancreatitis",,"Completed","No Results Available","Severe Hypertriglyceridemia (sHTG)","Drug: evinacumab|Drug: Placebo","Percent lowering of TG levels from baseline following 12 weeks of repeated IV doses of evinacumab|Percent TG lowering from baseline following 2 to 24 weeks of repeated IV doses of evinacumab|Changes in patient reported abdominal and GI daily symptom questionnaire|Changes in patient reported daily dietary habits and impact questionnaire|Degree of pancreatic injury/inflammation through 18F-2-Fluoro-2-Deoxy-D glucose positron emission tomography (18F-FDG-PET) imaging at baseline as assessed by 18F-FDG standardized uptake values SUVmax and SUVmean|Change from baseline to degree of pancreatic injury/inflammation through 18F-FDG-PET imaging following 12 weeks of treatment with evinacumab as assessed by 18F-FDG standardized uptake values SUVmax and SUVmean|Degree of pancreatic injury/inflammation through Diffusion Weighted-Magnetic Resonance Imaging (DW-MRI) at baseline as assessed by ADC|Change from baseline to degree of pancreatic injury/inflammation through DW-MRI following 12 weeks of treatment with evinacumab as assessed by ADC|Change from baseline to degree of pancreatic injury/inflammation through DW-MRI following 24 weeks of treatment with evinacumab as assessed by ADC|Total evinacumab concentration in serum|Total ANGPTL3 concentrations|Incidence of anti-drug antibody (ADA)|Incidence of Treatment-emergent adverse events (TEAEs)|Incidence of serious adverse events (SAEs)|Incidence of laboratory abnormalities","Regeneron Pharmaceuticals","All","18 Years to 75 Years   (Adult, Older Adult)","Phase 2","52","Industry","Interventional","Allocation: Randomized|Intervention Model: Parallel Assignment|Masking: Quadruple (Participant, Care Provider, Investigator, Outcomes Assessor)|Primary Purpose: Treatment","R1500-HTG-1522|2016-003307-62","June 7, 2018","December 17, 2019","July 23, 2020","March 2, 2018",,"December 24, 2020","Regeneron Research Facility, Boca Raton, Florida, United States|Regeneron Research Facility, Atlanta, Georgia, United States|Regeneron Research Facility, Kansas City, Kansas, United States|Regeneron Research Facility, New York, New York, United States|Regeneron Research Facility, Philadelphia, Pennsylvania, United States|Regeneron Research Facility, Pittsburgh, Pennsylvania, United States|Regeneron Research Facility, Dallas, Texas, United States|Regeneron Research Facility, Houston, Texas, United States|Regeneron Research Facility, Milwaukee, Wisconsin, United States|Regeneron Research Facility, Chicoutimi, Quebec, Canada|Regeneron Research Facility, Québec, Quebec, Canada|Regeneron Research Facility, Napoli, Campania, Italy|Regeneron Research Facility, Rome, Italy|Regeneron Research Facility, Birmingham, United Kingdom|Regeneron Research Facility, London, United Kingdom|Regeneron Research Facility, London, United Kingdom|Regeneron Research Facility, Manchester, United Kingdom",,"https://ClinicalTrials.gov/show/NCT03452228"
93,"NCT03345914","Study to Investigate the Efficacy and Safety of Dupilumab Administered With Topical Corticosteroids (TCS) in Participants ≥6 to <12 Years With Severe Atopic Dermatitis (AD)",,"Completed","Has Results","Dermatitis, Atopic","Drug: Dupilumab|Drug: Matching Placebo|Other: Background Treatment: Topical Corticosteroids|Other: Background Treatment: Moisturizers","Percentage of Participants With Investigator's Global Assessment (IGA) 0 or 1 at Week 16|Percentage of Participants With Eczema Area and Severity Index -75 (EASI-75) (≥ 75 Percent (%) Improvement From Baseline) at Week 16|Percent Change From Baseline in Eczema Area and Severity Index (EASI) Score at Week 16|Percent Change From Baseline in Weekly Average of Daily Worst Itch Score at Week 16|Percentage of Participants With Improvement (Reduction From Baseline) of Weekly Average of Daily Worst Itch Score ≥3 Points at Week 16|Percentage of Participants With Improvement (Reduction From Baseline) of Weekly Average of Daily Worst Itch Score ≥4 Points at Week 16|Percentage of Participants Achieving Eczema Area and Severity Index - 50 (EASI-50) (≥ 50% Improvement From Baseline) at Week 16|Percentage of Participants Achieving Eczema Area and Severity Index - 90 (EASI - 90) (≥ 90% Improvement From Baseline) at Week 16|Time to Achieve ≥ 4 Point Reduction of Weekly Average of Daily Worst Itch Score From Baseline During the 16-week Treatment Period|Time to Achieve ≥ 3 Point Reduction of Weekly Average of Daily Worst Itch Score From Baseline During the 16-week Treatment Period|Change From Baseline in Percent Body Surface Area (BSA) Affected by Atopic Dermatitis (AD) at Week 16|Percent Change From Baseline in SCORing Atopic Dermatitis (SCORAD) at Week 16|Change From Baseline in Children's Dermatology Life Quality Index (CDLQI) at Week 16|Change From Baseline in Patient Oriented Eczema Measure (POEM) at Week 16|Change From Baseline in Weekly Average of Daily Worst Itch Score at Week 16|Change From Baseline in Dermatitis Family Index (DFI) at Week 16|Change From Baseline in Patient Reported Outcomes Measurements Information Systems (PROMIS) Pediatric Anxiety Short Form Scale Total Score at Week 16|Change From Baseline in Patient Reported Outcomes Measurements Information Systems (PROMIS) Pediatric Depressive Symptoms Short Form Scale Score at Week 16|Percentage of Participants Having at Least One Skin Infection Treatment Emergent Adverse Event (TEAE) (Excluding Herpetic Infections) Through Week 16|Percentage of Participants Having at Least One Serious Treatment Emergent Adverse Event (TEAE) Through Week 16|Proportion of Topical Corticosteroid (TCS) Medication-free Days From Baseline to Week 16|Mean Weekly Dose of Topical Corticosteroid (TCS) in Grams for Low or Medium Potency TCS From Baseline to Week 16","Regeneron Pharmaceuticals|Sanofi","All","6 Years to 11 Years   (Child)","Phase 3","367","Industry","Interventional","Allocation: Randomized|Intervention Model: Parallel Assignment|Masking: Quadruple (Participant, Care Provider, Investigator, Outcomes Assessor)|Primary Purpose: Treatment","R668-AD-1652|2016-004997-16","November 17, 2017","June 20, 2019","September 10, 2019","November 17, 2017","August 13, 2020","August 13, 2020","Regeneron Research Site, Birmingham, Alabama, United States|Regeneron Research Site, Gilbert, Arizona, United States|Regeneron Research Site, Bakersfield, California, United States|Regeneron Research Site, Long Beach, California, United States|Regeneron Research Site, Mission Viejo, California, United States|Regeneron Research Site, Rolling Hills Estates, California, United States|Regeneron Research Site, San Diego, California, United States|Regeneron Research Site, Denver, Colorado, United States|Regeneron Research Site, Coral Gables, Florida, United States|Regeneron Research Site, Tampa, Florida, United States|Regeneron Research Site, Tampa, Florida, United States|Regeneron Research Site, Macon, Georgia, United States|Regeneron Research Site, Sandy Springs, Georgia, United States|Regeneron Research Site, Chicago, Illinois, United States|Regeneron Research Site, Normal, Illinois, United States|Regeneron Research Site, Rockville, Maryland, United States|Regeneron Research Site, Ypsilanti, Michigan, United States|Regeneron Research Site, Minneapolis, Minnesota, United States|Regeneron Research Site, Saint Louis, Missouri, United States|Regeneron Research Site, Forest Hills, New York, United States|Regeneron Research Site, New York, New York, United States|Regeneron Research Site, Rochester, New York, United States|Regeneron Research Site, Gahanna, Ohio, United States|Regeneron Research Site, Portland, Oregon, United States|Regeneron Research Site, Philadelphia, Pennsylvania, United States|Regeneron Research Site, Charleston, South Carolina, United States|Regeneron Research Site, North Charleston, South Carolina, United States|Regeneron Research Site, Bellaire, Texas, United States|Regeneron Research Site, San Antonio, Texas, United States|Regeneron Research Site, Norfolk, Virginia, United States|Regeneron Research Site, Seattle, Washington, United States|Regeneron Research Site, Calgary, Alberta, Canada|Regeneron Research Site, Markham, Ontario, Canada|Regeneron Research Site, Peterborough, Ontario, Canada|Regeneron Research Site, Montréal, Quebec, Canada|Regeneron Research Site, Kutná Hora, Czechia|Regeneron Research Site, Ústí Nad Labem, Czechia|Regeneron Research Site, Muenchen, Bavaria, Germany|Regeneron Research Site, Osnabruck, Lower Saxony, Germany|Regeneron Research Site, Munster, Nordrhein-Westfalen, Germany|Regeneron Research Site, Dresden, Sachsen, Germany|Regeneron Research Site, Gera, Thuringen, Germany|Regeneron Research Site, Bad Bentheim, Germany|Regeneron Research Site, Hamburg, Germany|Regeneron Research Site, Wroclaw, Dolnoslaskie, Poland|Regeneron Research Site, Krakow, Malopolska, Poland|Regeneron Research Site, Białystok, Poland|Regeneron Research Site, Bydgoszcz, Poland|Regeneron Research Site, Gdańsk, Poland|Regeneron Research Site, Katowice, Poland|Regeneron Research Site, Katowice, Poland|Regeneron Research Site, Katowice, Poland|Regeneron Research Site, Warszawa, Poland|Regeneron Research Site, Warszawa, Poland|Regeneron Research Site, Warszawa, Poland|Regeneron Research Site, Łódź, Poland|Regeneron Research Site, Świętokrzyskie, Poland|Regeneron Research Site, London, United Kingdom|Regeneron Research Site, Manchester, United Kingdom|Regeneron Research Site, Newcastle Upon Tyne, United Kingdom|Regeneron Research Site, Sheffield, United Kingdom","""Study Protocol"", https://ClinicalTrials.gov/ProvidedDocs/14/NCT03345914/Prot_000.pdf|""Statistical Analysis Plan"", https://ClinicalTrials.gov/ProvidedDocs/14/NCT03345914/SAP_001.pdf","https://ClinicalTrials.gov/show/NCT03345914"
94,"NCT03428646","Study of Patients Receiving DUPIXENT® for Atopic Dermatitis (AD)","PROSE","Recruiting","No Results Available","Dermatitis, Atopic","Drug: Dupilumab","Registry Assessment: Baseline Characteristics|Registry Assessment: Baseline Characteristic|Registry (Physician) Assessment: Body Surface Area Affected (BSA) by Atopic Dermatitis|Registry (Physician) Assessment: Eczema Area and Severity Index (EASI)|Registry (Physician) Assessment: Overall Disease Severity scale|Registry (Participant) Assessment: Patient Oriented Eczema Measure|Registry (Participant) Assessment: Pruritus Numerical Rating Scales (NRS)|Registry (Participant) Assessment: Skin Pain or Soreness NRS|Registry (Participant) Assessment: Skin Feeling Hot NRS|Registry (Participant) Assessment: Skin Sensitivity NRS|Registry (Participant) Assessment: Sleep Disturbance NRS|Registry (Participant) Assessment: Global Assessment of Atopic Dermatitis scale|Registry (Participant) Assessment: Dermatology Life Quality Index (DLQI)|Registry (Participant) Assessment: Children's Dermatology Life Quality Index (CDLQI)|Registry (Participant) Assessment: Work Productivity and Activity Impairment Questionnaire for AD (WPAI-AD)|Registry (Participant) Assessment: Health Care Resource Utilization Questionnaire|Registry (Participant) Assessment: Dermatitis Family Impact Questionnaire|Registry (Participant) Assessment: Missed School Days|Registry (Participant) Assessment: Juniper Asthma Control Questionnaire (ACQ-5)|Registry (Participant) Assessment: Allergic Rhinitis Visual Analog Scale (AR-VAS)|Registry (Participant) Assessment: Changes in Concurrent Conditions|Registry (Participant) Assessment: Overall Health State","Regeneron Pharmaceuticals|Sanofi","All","12 Years and older   (Child, Adult, Older Adult)",,"1000","Industry","Observational","Observational Model: Case-Only|Time Perspective: Prospective","R668-AD-1762","April 6, 2018","November 13, 2025","November 13, 2025","February 9, 2018",,"September 8, 2021","Regeneron Investigational Site, Birmingham, Alabama, United States|Regeneron Investigational Site, Gilbert, Arizona, United States|Regeneron Investigational Site, Fountain Valley, California, United States|Regeneron Investigational Site, Laguna Hills, California, United States|Regeneron Investigational Site, Loma Linda, California, United States|Regeneron Investigational Site, Los Angeles, California, United States|Regeneron Investigational Site, Los Angeles, California, United States|Regeneron Investigational Site, Manhattan Beach, California, United States|Regeneron Investigational Site, Newport Beach, California, United States|Regeneron Investigational Site, Oceanside, California, United States|Regeneron Investigational Site, Redondo Beach, California, United States|Regeneron Investigational Site, Riverside, California, United States|Regeneron Investigational Site, Roseville, California, United States|Regeneron Investigational Site, San Diego, California, United States|Regeneron Investigational Site, Santa Monica, California, United States|Regeneron Investigational Site, Thousand Oaks, California, United States|Regeneron Investigational Site, New Haven, Connecticut, United States|Regeneron Investigational Site, Coral Gables, Florida, United States|Regeneron Investigational Site, Margate, Florida, United States|Regeneron Investigational Site, West Palm Beach, Florida, United States|Regeneron Investigational Site, Atlanta, Georgia, United States|Regeneron Investigational Site, Macon, Georgia, United States|Regeneron Investigational Site, Marietta, Georgia, United States|Regeneron Investigational Site, Marietta, Georgia, United States|Regeneron Investigational Site, Sandy Springs, Georgia, United States|Regeneron Investigational Site, Champaign, Illinois, United States|Regeneron Investigational Site, Chicago, Illinois, United States|Regeneron Investigational Site, La Grange Park, Illinois, United States|Regeneron Investigational Site, Skokie, Illinois, United States|Regeneron Investigational Site, Springfield, Illinois, United States|Regeneron Investigational Site, Fort Wayne, Indiana, United States|Regeneron Investigational Site, Plainfield, Indiana, United States|Regeneron Investigational Site, Overland Park, Kansas, United States|Regeneron Investigational Site, Corbin, Kentucky, United States|Regeneron Investigational Site, Louisville, Kentucky, United States|Regeneron Investigational Site, Rockville, Maryland, United States|Regeneron Investigational Site, Towson, Maryland, United States|Regeneron Investigational Site, Upper Marlboro, Maryland, United States|Regeneron Investigational Site, White Marsh, Maryland, United States|Regeneron Investigational Site, Quincy, Massachusetts, United States|Regeneron Investigational Site, Ann Arbor, Michigan, United States|Regeneron Investigational Site, Bay City, Michigan, United States|Regeneron Investigational Site, Troy, Michigan, United States|Regeneron Investigational Site, Warren, Michigan, United States|Regeneron Investigational Site, Columbia, Missouri, United States|Regeneron Investigational Site, Kirksville, Missouri, United States|Regeneron Investigational Site, Saint Louis, Missouri, United States|Regeneron Investigational Site, Lincoln, Nebraska, United States|Regeneron Investigational Site, Henderson, Nevada, United States|Regeneron Investigational Site, Las Vegas, Nevada, United States|Regeneron Investigational Site, Brick, New Jersey, United States|Regeneron Investigational Site, East Windsor, New Jersey, United States|Regeneron Investigational Site, Edison, New Jersey, United States|Regeneron Investigational Site, Piscataway, New Jersey, United States|Regeneron Investigational Site, Bronx, New York, United States|Regeneron Investigational Site, Elmhurst, New York, United States|Regeneron Investigational Site, Forest Hills, New York, United States|Regeneron Investigational Site, Garden City, New York, United States|Regeneron Investigational Site, Kew Gardens, New York, United States|Regeneron Investigational Site, Lake Success, New York, United States|Regeneron Investigational Site, Manhasset, New York, United States|Regeneron Investigational Site, Mineola, New York, United States|Regeneron Investigational Site, Mount Vernon, New York, United States|Regeneron Investigational Site, New York, New York, United States|Regeneron Investigational Site, New York, New York, United States|Regeneron Investigational Site, New York, New York, United States|Regeneron Investigational Site, New York, New York, United States|Regeneron Investigational Site, Troy, New York, United States|Regeneron Investigational Site, Concord, North Carolina, United States|Regeneron Investigational Site, Akron, Ohio, United States|Regeneron Investigational Site, Athens, Ohio, United States|Regeneron Investigational Site, Bexley, Ohio, United States|Regeneron Investigational Site, Marion, Ohio, United States|Regeneron Investigational Site, Mason, Ohio, United States|Regeneron Investigational Site, Tulsa, Oklahoma, United States|Regeneron Investigational Site, Portland, Oregon, United States|Regeneron Investigational Site, Blue Bell, Pennsylvania, United States|Regeneron Investigational Site, Philadelphia, Pennsylvania, United States|Regeneron Investigational Site, Philadelphia, Pennsylvania, United States|Regeneron Investigational Site, Sellersville, Pennsylvania, United States|Regeneron Investigational Site, Yardley, Pennsylvania, United States|Regeneron Investigational Site, Charleston, South Carolina, United States|Regeneron Investigational Site, North Charleston, South Carolina, United States|Regeneron Investigational Site, Bellaire, Texas, United States|Regeneron Investigational Site, Dallas, Texas, United States|Regeneron Investigational Site, Grapevine, Texas, United States|Regeneron Investigational Site, San Antonio, Texas, United States|Regeneron Investigational Site, Sugar Land, Texas, United States|Regeneron Investigational Site, Sugar Land, Texas, United States|Regeneron Investigational Site, Arlington, Virginia, United States|Regeneron Investigational Site, Norfolk, Virginia, United States|Regeneron Investigational Site, Bellevue, Washington, United States|Regeneron Investigational Site, Milwaukee, Wisconsin, United States|Regeneron Investigational Site, Hamilton, Ontario, Canada|Regeneron Investigational Site, Markham, Ontario, Canada|Regeneron Investigational Site, Ottawa, Ontario, Canada|Regeneron Investigational Site, Peterborough, Ontario, Canada|Regeneron Investigational Site, Toronto, Ontario, Canada|Regeneron Investigational Site, Quebec, Canada",,"https://ClinicalTrials.gov/show/NCT03428646"
95,"NCT03285646","Evaluate the Efficacy and Safety of Fasinumab in Patients With Moderate-to-Severe Chronic Low Back Pain and Osteoarthritis of the Hip or Knee","FACT CLBP 1","Terminated","Has Results","Chronic Low Back Pain|Osteoarthritis","Drug: Fasinumab|Drug: Placebo","Change From Baseline to Week 16 in the Average Daily Low Back Pain Intensity (LBPI) Numeric Rating Scale (NRS) Score|Change From Baseline to Week 16 in the Roland Morris Disability Questionnaire (RMDQ) Total Score|Change From Baseline to Week 16 in Patient Global Assessment (PGA) of Low Back Pain (LBP) Score|Number of Participants Achieving ≥30% Reduction From Baseline to Week 16 in Average Daily LBPI NRS Score|Change From Baseline to Week 16 in the Brief Pain Inventory-Short Form (BPI-sf) Pain Interference Score|Number of Adjudicated Arthropathy (AA) Events|Number of Adjudicated Arthropathy (AA) Events Meeting Destructive Arthropathy (DA) Criteria|Number of Treatment-Emergent Adverse Events (TEAEs)|Number of Sympathetic Nervous System (SNS) Dysfunction Events|Number of Peripheral Sensory Adverse Events (AEs) That Require a Neurology Consultation|Number of All-Cause Joint Replacement (JR) Surgery Events|Number of Joint Replacement (JR) Surgery Events Reported at Telephone Survey After Last Dose of Study Drug|Number of Participants With at Least One Positive Anti-Drug Antibody (ADA) Assay|Serum Concentration of Functional Fasinumab Over Time","Regeneron Pharmaceuticals|Teva Pharmaceutical Industries, Ltd.","All","18 Years and older   (Adult, Older Adult)","Phase 3","63","Industry","Interventional","Allocation: Randomized|Intervention Model: Parallel Assignment|Masking: Quadruple (Participant, Care Provider, Investigator, Outcomes Assessor)|Primary Purpose: Treatment","R475-PN-1612|2017-001943-12","October 30, 2017","May 5, 2018","May 2, 2019","September 18, 2017","June 30, 2021","June 30, 2021","Regeneron Research Site, Phoenix, Arizona, United States|Regeneron Research Site, Tucson, Arizona, United States|Regeneron Research Site, Tucson, Arizona, United States|Regeneron Research Site, Anaheim, California, United States|Regeneron Research Site, Anaheim, California, United States|Regeneron Research Site, La Mesa, California, United States|Regeneron Research Site, North Hollywood, California, United States|Regeneron Research Site, San Diego, California, United States|Regeneron Research Site, San Marcos, California, United States|Regeneron Research Site, Santa Ana, California, United States|Regeneron Research Site, Spring Valley, California, United States|Regeneron Research Site, Whittier, California, United States|Regeneron Research Site, Stamford, Connecticut, United States|Regeneron Research Site, Waterbury, Connecticut, United States|Regeneron Research Site, Clearwater, Florida, United States|Regeneron Research Site, Hialeah, Florida, United States|Regeneron Research Site, Jacksonville, Florida, United States|Regeneron Research Site, Lauderdale Lakes, Florida, United States|Regeneron Research Site, Miami, Florida, United States|Regeneron Research Site, Ocoee, Florida, United States|Regeneron Research Site, Orlando, Florida, United States|Regeneron Research Site, Orlando, Florida, United States|Regeneron Research Site, Port Orange, Florida, United States|Regeneron Research Site, Sarasota, Florida, United States|Regeneron Research Site, Atlanta, Georgia, United States|Regeneron Research Site, Columbus, Georgia, United States|Regeneron Research Site #1, Marietta, Georgia, United States|Regeneron Research Site #2, Marietta, Georgia, United States|Regeneron Research Site, Newnan, Georgia, United States|Regeneron Research Site, Idaho Falls, Idaho, United States|Regeneron Research Site, Chicago, Illinois, United States|Regeneron Research Site, Chicago, Illinois, United States|Regeneron Research Site, Valparaiso, Indiana, United States|Regeneron Research Site, West Des Moines, Iowa, United States|Regeneron Research Site, Edgewood, Kentucky, United States|Regeneron Research Site, New Orleans, Louisiana, United States|Regeneron Research Site, Bay City, Michigan, United States|Regeneron Research Site, Saint Louis, Missouri, United States|Regeneron Research Site, Lincoln, Nebraska, United States|Regeneron Research Site, Las Vegas, Nevada, United States|Regeneron Research Site, Berlin, New Jersey, United States|Regeneron Research Site, Albuquerque, New Mexico, United States|Regeneron Research Site, Hartsdale, New York, United States|Regeneron Research Site, New York, New York, United States|Regeneron Research Site, High Point, North Carolina, United States|Regeneron Research Site, Fargo, North Dakota, United States|Regeneron Research Site, Beavercreek, Ohio, United States|Regeneron Research Site, Oklahoma City, Oklahoma, United States|Regeneron Research Site, Duncansville, Pennsylvania, United States|Regeneron Research Site, Rapid City, South Dakota, United States|Regeneron Research Site #1, Memphis, Tennessee, United States|Regeneron Research Site #2, Memphis, Tennessee, United States|Regeneron Research Site, Houston, Texas, United States|Regeneron Research Site, Katy, Texas, United States|Regeneron Research Site, Plano, Texas, United States|Regeneron Research Site, Kenosha, Wisconsin, United States","""Study Protocol"", https://ClinicalTrials.gov/ProvidedDocs/46/NCT03285646/Prot_002.pdf|""Statistical Analysis Plan"", https://ClinicalTrials.gov/ProvidedDocs/46/NCT03285646/SAP_003.pdf","https://ClinicalTrials.gov/show/NCT03285646"
96,"NCT03346434","Safety, Pharmacokinetics and Efficacy of Dupilumab in Patients ≥6 Months to <6 Years With Moderate-to-Severe Atopic Dermatitis (Liberty AD PRESCHOOL)","Liberty AD","Completed","No Results Available","Dermatitis, Atopic","Drug: Dupilumab|Drug: Matching placebo","Part A: Concentration of total dupilumab in serum over time and pharmacokinetic (PK) parameters|Part A: Incidence of Treatment-Emergent Adverse Events (TEAEs)|Part B: Proportion of participants with an Investigator Global Assessment (IGA) score of 0 to 1|Part B: For European Medicines Agency (EMA) only: Proportion of participants with Eczema Area and Severity Index (EASI) -75 (≥75% improvement from baseline)|Part B: For EMA only: Proportion of participants with an IGA score of either 0 or 1|Part A: Incidence of Serious Adverse Events (SAEs)|Part A: Incidence of severe TEAEs|Part A: Percent change in EASI score|Part A: Percent change in SCORing Atopic Dermatitis (SCORAD) score|Part A: Proportion of participants with an IGA score of either 0 or 1|Part A: Determine immunogenicity titer|Part B: Not applicable for EMA: Proportion of participants with EASI-75 (≥75% improvement from baseline)|Part B: Percent change in EASI score|Part B: Percent change in weekly average of daily worst scratch/itch numeric rating score (NRS)|Part B: Proportion of participants with EASI-50 (≥50% improvement from baseline)|Part B: Proportion of participants with EASI-90 (≥90% improvement from baseline)|Part B: Change in percent Body Surface Area (BSA) affected by AD|Part B: Percent change in SCORAD|Part B: Change in weekly average of daily worst scratch/itch NRS score|Part B: Proportion of participants with improvement (reduction) of weekly average of daily worst scratch/itch NRS score ≥4|Part B: Proportion of participants with improvement (reduction) of weekly average of daily worst scratch/itch NRS score ≥3|Part B: Change in skin pain NRS|Part B: Change in sleep quality NRS|Part B: Change in health-related quality of life, as measured by Childrens' Dermatology Life Quality Index (CDLQI) (participants ≥4 years of age) and Infants' Dermatology Quality of Life Index (IDQOL) (participants <4 years of age)|Part B: Change in Dermatitis Family Index (DFI)|Part B: Change in Patient Oriented Eczema Measure (POEM)|Part B: Topical treatment for AD - proportion of topical corticosteroids (TCS) medication-free days|Part B: Mean weekly dose of low potency TCS|Part B: Mean of caregiver missed workdays|Part B: Incidence of skin infection TEAEs|Part B: Incidence of SAEs through week 16","Regeneron Pharmaceuticals|Sanofi","All","6 Months to 5 Years   (Child)","Phase 2|Phase 3","162","Industry","Interventional","Allocation: Non-Randomized|Intervention Model: Single Group Assignment|Masking: None (Open Label)|Primary Purpose: Treatment","R668-AD-1539|2016-000955-28","November 30, 2017","July 8, 2021","July 8, 2021","November 17, 2017",,"September 29, 2021","Regeneron Investigational Site, Birmingham, Alabama, United States|Regeneron Investigational Site, Gilbert, Arizona, United States|Regeneron Investigational Site, Long Beach, California, United States|Regeneron Investigational site, Los Angeles, California, United States|Regeneron Investigational Site, Palo Alto, California, United States|Regeneron Investigational Site, Rolling Hills Estates, California, United States|Regeneron Investigational Site, San Diego, California, United States|Regeneron Investigational Site, Washington, District of Columbia, United States|Regeneron Investigational Site, Coral Gables, Florida, United States|Regeneron Investigational Site, Tampa, Florida, United States|Regeneron Investigational Site, Columbus, Georgia, United States|Regeneron Investigational Site, Macon, Georgia, United States|Regeneron Investigational Site, Sandy Springs, Georgia, United States|Regeneron Investigational Site, Chicago, Illinois, United States|Regeneron Investigational Site, Rockville, Maryland, United States|Regeneron Investigational Site, Boston, Massachusetts, United States|Regeneron Investigational Site, Ann Arbor, Michigan, United States|Regeneron Investigational Site, Ypsilanti, Michigan, United States|Regeneron Investigational Site, Saint Louis, Missouri, United States|Regeneron Investigational Site, Lincoln, Nebraska, United States|Regeneron Investigational Site, Hackensack, New Jersey, United States|Regeneron Investigational Site, Forest Hills, New York, United States|Regeneron Investigational Site, New York, New York, United States|Regeneron Investigational Site, Rochester, New York, United States|Regeneron Investigational Site, Portland, Oregon, United States|Regeneron Investigational Site, Philadelphia, Pennsylvania, United States|Regeneron Investigational Site, Charleston, South Carolina, United States|Regeneron Investigational Site, North Charleston, South Carolina, United States|Regeneron Investigational Site, Austin, Texas, United States|Regeneron Investigational Site, San Antonio, Texas, United States|Regeneron Investigational Site, Norfolk, Virginia, United States|Regeneron Investigational Site, Seattle, Washington, United States|Regeneron Investigational Site, Milwaukee, Wisconsin, United States|Regeneron Investigational Site, Osnabrück, Lower Saxony, Germany|Regeneron Investigational site, Muenster, North Rhine-Westphal, Germany|Regeneron Investigational Site, Dresden, Sachsen, Germany|Regeneron Investigational site, Frankfurt/ Main, Germany|Regeneron Investigational Site, Kiel, Germany|Regeneron Investigational Site, Muenchen, Germany|Regeneron Investigational site, Muenchen, Germany|Regeneron Investigational Site, Bialystok, Poland|Regeneron Investigational Site, Katowice, Poland|Regeneron Investigational Site, Krakow, Poland|Regeneron Investigational Site, Ostrowiec Swietokrzyski, Poland|Regeneron Investigational Site, Warszawa, Poland|Regeneron Investigational Site, Warszawa, Poland|Regeneron Investigational Site, Manchester, Lancashire, United Kingdom|Regeneron Investigational Site, Sheffield, South Yorkshire, United Kingdom",,"https://ClinicalTrials.gov/show/NCT03346434"
97,"NCT03156621","Study in Participants With Homozygous Familial Hypercholesterolemia (HoFH)","ODYSSEY HoFH","Completed","Has Results","Homozygous Familial Hypercholesterolemia","Drug: Alirocumab|Drug: Placebo","Percent Change in Low-density Lipoprotein Cholesterol (LDL-C) From Baseline to Week 12 (Intent-to-Treat [ITT] Estimand)|Percent Change in Apolipoprotein (Apo) B From Baseline to Week 12 (ITT Estimand)|Percent Change in Non-high-density Lipoprotein Cholesterol (Non-HDL-C) From Baseline to Week 12|Percent Change in Total Cholesterol (TC) From Baseline to Week 12|Percentage of Participants With ≥15% Reduction in LDL-C at Week 12|Percentage of Participants With ≥30% Reduction in LDL-C at Week 12|Percent Change in Lipoprotein(a) [Lp(a)] From Baseline to Week 12|Percentage of Participants With ≥50% Reduction in LDL-C at Week 12|Percent Change in HDL-C From Baseline to Week 12 - ITT Analysis|Percent Change in Fasting Triglycerides (TG) From Baseline to Week 12|Percent Change in Apo A-1 From Baseline to Week 12 -- ITT Analysis|Percent Change in LDL-C From Baseline to Week 12 (On-treatment Estimand)|Percent Change in Apo B From Baseline to Week 12 (On-treatment Estimand)|Percent Change in Non-HDL-C From Baseline to Week 12 (On-treatment Estimand)|Percent Change in TC From Baseline to Week 12 (On-treatment Estimand)|Percent Change in Lp(a) From Baseline to Week 12 (On-treatment Estimand)|Percent Change in HDL-C From Baseline to Week 12 (On-treatment Estimand)|Percent Change in Fasting TG From Baseline to Week 12 (On-treatment Estimand)|Percent Change in Apo A-1 From Baseline to Week 12 (On-treatment Estimand)|Percentage of Participants With ≥15% Reduction, ≥30% Reduction, and ≥50% Reduction in LDL-C at Week 12 (On-treatment Estimand)|Absolute Change in the Ratio of Apo B/Apo A-1 From Baseline to Week 12 (ITT Estimand)|Number of Participants With Anti-Drug Antibodies (ADA) to REGN727 Over Time|Number of Participants With Adverse Events (AEs)","Regeneron Pharmaceuticals|Sanofi","All","18 Years and older   (Adult, Older Adult)","Phase 3","69","Industry","Interventional","Allocation: Randomized|Intervention Model: Parallel Assignment|Masking: Triple (Participant, Investigator, Outcomes Assessor)|Primary Purpose: Treatment","R727-CL-1628|2017-000351-95","October 3, 2017","September 27, 2019","February 13, 2020","May 17, 2017","June 29, 2021","June 29, 2021","Regeneron Research Site, Boca Raton, Florida, United States|Regeneron Research Site, New York, New York, United States|Regeneron Research Site, Cincinnati, Ohio, United States|Regeneron Study Site, Dallas, Texas, United States|Regeneron Research Site, Innsbruck, Tirol, Austria|Regeneron Research Site, Chicoutimi, Quebec, Canada|Regeneron Research Site, Québec, Quebec, Canada|Regeneron Research Site, Praha, Czechia|Regeneron Research Site, Marseille, France|Regeneron Research Site, Paris, France|Regeneron Research Site, Berlin, Germany|Regeneron Research Site, Athens, Greece|Regeneron Research Site, Ioánnina, Greece|Regeneron Research Site, Napoli, Italy|Regeneron Research Site, Roma, Italy|Regeneron Research Site, Nishinomiya, Hyogo, Japan|Regeneron Research Site, Kanazawa, Ishikawa, Japan|Regeneron Research Site, Suita, Osaka, Japan|Regeneron Research Site, Parktown, Johannesburg, South Africa|Regeneron Research Site, Cape Town, Western Cape, South Africa|Regeneron Study Site, Taipei, Taiwan|Regeneron Research Site, Besevler, Ankara, Turkey|Regeneron Research Site, İzmir, Bornova, Turkey|Regeneron Research Site, Ivano-Frankivs'k, Ukraine|Regeneron Research Site, Kharkiv, Ukraine|Regeneron Research Site, Kharkiv, Ukraine|Regeneron Research Site, Kyiv, Ukraine|Regeneron Research Site, Kyiv, Ukraine","""Study Protocol"", https://ClinicalTrials.gov/ProvidedDocs/21/NCT03156621/Prot_000.pdf|""Statistical Analysis Plan"", https://ClinicalTrials.gov/ProvidedDocs/21/NCT03156621/SAP_001.pdf","https://ClinicalTrials.gov/show/NCT03156621"
98,"NCT02957682","Evaluating Effect of the Study Drug Praluent (Alirocumab) on Neurocognitive Function When Compared to Placebo",,"Completed","Has Results","Hypercholesterolemia","Drug: Praluent (Alirocumab)|Drug: Placebo","Change From Baseline in Cambridge Neuropsychological Test Automated Battery (CANTAB) Cognitive Domain Spatial Working Memory (SWM) Strategy Z-Score at Week 96|Change From Baseline in CANTAB Cognitive Domain SWM Strategy Raw Score at Week 96|Percent Change From Baseline in Calculated Low-density Lipoprotein Cholesterol (LDL-C) at Week 12, 24, 48, 72, and 96|Percent Change From Baseline in Apolipoprotein (Apo) B at Week 12, 24, 48, 72, and 96|Percent Change From Baseline in Non-High-Density Lipoprotein Cholesterol (Non-HDL-C) at Week 12, 24, 48, 72, and 96|Percent Change From Baseline in Total Cholesterol (Total-C) at Week 12, 24, 48, 72, and 96|Percent Change From Baseline in Lipoprotein a [Lp(a)] at Week 12, 24, 48, 72, and 96|Percent Change From Baseline in High-Density Lipoprotein Cholesterol (HDL-C) at Week 12, 24, 48, 72, and 96|Percent Change From Baseline in Triglycerides (TG) at Week 12, 24, 48, 72, and 96|Percent Change From Baseline in Apolipoprotein (Apo) A-1 at Week 12, 24, 48, 72, and 96|Percentage of Participants Who Reached Low Density Lipoprotein Cholesterol (LDL-C) Level Less Than (<) 70 mg/dL (1.81 Millimoles Per Liter [mmol/L]) at Week 12, 24, 48, 72, and 96|Percentage of Participants Who Reached Low Density Lipoprotein Cholesterol (LDL-C) Level Less Than (<) 50 mg/dL (1.29 mmol/L) at Week 12, 24, 48, 72, and 96|Number of Participants With Treatment-Emergent Adverse Events (TEAEs) and Serious TEAEs","Regeneron Pharmaceuticals|Sanofi","All","40 Years to 85 Years   (Adult, Older Adult)","Phase 4","2176","Industry","Interventional","Allocation: Randomized|Intervention Model: Parallel Assignment|Masking: Quadruple (Participant, Care Provider, Investigator, Outcomes Assessor)|Primary Purpose: Treatment","R727-CL-1532|2016-003189-16","November 2, 2016","March 5, 2020","March 5, 2020","November 8, 2016","May 7, 2021","May 7, 2021","Regeneron Study Site, Auburn, Alabama, United States|Regeneron Study Site, Birmingham, Alabama, United States|Regeneron Study Site, Mobile, Alabama, United States|Regeneron Study Site, Beverly Hills, California, United States|Regeneron Study Site, Los Gatos, California, United States|Regeneron Study Site, North Hollywood, California, United States|Regeneron Study Site, Port Hueneme, California, United States|Regeneron Study Site, Westminster, California, United States|Regeneron Study Site 1, Aurora, Colorado, United States|Regeneron Study Site 2, Aurora, Colorado, United States|Regeneron Study Site, Colorado Springs, Colorado, United States|Regeneron Study Site, Lake Worth, Florida, United States|Regeneron Study Site, Lake Worth, Florida, United States|Regeneron Study Site, Miami Springs, Florida, United States|Regeneron Study Site, Covington, Georgia, United States|Regeneron Study Site, Champaign, Illinois, United States|Regeneron Study Site, Chicago, Illinois, United States|Regeneron Study Site, Chicago, Illinois, United States|Regeneron Study Site, Rock Island, Illinois, United States|Regeneron Study Site, Evansville, Indiana, United States|Regeneron Study Site, Indianapolis, Indiana, United States|Regeneron Study Site, Ames, Iowa, United States|Regeneron Study Site, Iowa City, Iowa, United States|Regeneron Study Site, Waterloo, Iowa, United States|Regeneron Study Site, Hutchinson, Kansas, United States|Regeneron Study Site, Newton, Kansas, United States|Regeneron Study Site, Overland Park, Kansas, United States|Regeneron Study Site, Louisville, Kentucky, United States|Regeneron Study Site, Bangor, Maine, United States|Regeneron Study Site, Baltimore, Maryland, United States|Regeneron Study Site, Oxon Hill, Maryland, United States|Regeneron Study Site, Minneapolis, Minnesota, United States|Regeneron Study Site, Olive Branch, Mississippi, United States|Regeneron Study Site, Washington, Missouri, United States|Regeneron Study Site, Buffalo, New York, United States|Regeneron Study Site, New Hyde Park, New York, United States|Regeneron Study Site, Cary, North Carolina, United States|Regeneron Study Site, Charlotte, North Carolina, United States|Regeneron Study Site, Charlotte, North Carolina, United States|Regeneron Study Site, Greensboro, North Carolina, United States|Regeneron Study Site, Hickory, North Carolina, United States|Regeneron Study Site, High Point, North Carolina, United States|Regeneron Study Site, Raleigh, North Carolina, United States|Regeneron Study Site, Rocky Mount, North Carolina, United States|Regeneron Study Site, Salisbury, North Carolina, United States|Regeneron Study Site, Statesville, North Carolina, United States|Regeneron Study Site, Wilmington, North Carolina, United States|Regeneron Study Site, Winston-Salem, North Carolina, United States|Regeneron Study Site, Cincinnati, Ohio, United States|Regeneron Study Site, Cleveland, Ohio, United States|Regeneron Study Site, Dayton, Ohio, United States|Regeneron Study Site, Duncansville, Pennsylvania, United States|Regeneron Study Site, Charleston, South Carolina, United States|Regeneron Study Site, Greenville, South Carolina, United States|Regeneron Study Site, Summerville, South Carolina, United States|Regeneron Study Site, Rapid City, South Dakota, United States|Regeneron Study Site, Bristol, Tennessee, United States|Regeneron Study Site, Knoxville, Tennessee, United States|Regeneron Study Site, Knoxville, Tennessee, United States|Regeneron Study Site, Knoxville, Tennessee, United States|Regeneron Study Site, Powell, Tennessee, United States|Regeneron Study Site, Dallas, Texas, United States|Regeneron Study Site, Houston, Texas, United States|Regeneron Study Site, Houston, Texas, United States|Regeneron Study Site, Schertz, Texas, United States|Regeneron Study Site, Shavano Park, Texas, United States|Regeneron Study Site, Falls Church, Virginia, United States|Regeneron Study Site, Winchester, Virginia, United States|Regeneron Study Site, Burien, Washington, United States|Regeneron Study Site, Everett, Washington, United States|Regeneron Study Site, Tacoma, Washington, United States|Regeneron Study Site, Walla Walla, Washington, United States|Regeneron Study Site, Manitowoc, Wisconsin, United States|Regeneron Study Site, Pleven, Bulgaria|Regeneron Study Site, Plovdiv, Bulgaria|Regeneron Study Site, Plovdiv, Bulgaria|Regeneron Study Site, Sofia, Bulgaria|Regeneron Study Site, Sofia, Bulgaria|Regeneron Study Site, Sofia, Bulgaria|Regeneron Study Site, Stara Zagora, Bulgaria|Regeneron Study Site 1, Varna, Bulgaria|Regeneron Study Site 2, Varna, Bulgaria|Regeneron Study Site, Osorno, Chile|Regeneron Study Site, San Miguel, Chile|Regeneron Study Site, Santiago, Chile|Regeneron Study Site, Santiago, Chile|Regeneron Study Site, Santiago, Chile|Regeneron Study Site, Santiago, Chile|Regeneron Study Site, Temuco, Chile|Regeneron Study Site, Temuco, Chile|Regeneron Study Site, Viña del Mar, Chile|Regeneron Study Site, Paide, Estonia|Regeneron Study Site, Tallinn, Estonia|Regeneron Study Site, Tallinn, Estonia|Regeneron Study Site 1, Tallinn, Estonia|Regeneron Study Site 2, Tallinn, Estonia|Regeneron Study Site, Tallinn, Estonia|Regeneron Study Site, Tallinn, Estonia|Regeneron Study Site, Tartu, Estonia|Regeneron Study Site, Nishinomiya, Hogo, Japan|Regeneron Study Site, Kahoku-gun, Ishikawa, Japan|Regeneron Study Site, Kawasaki, Kanagawa, Japan|Regeneron Study Site, Yokohama, Kanagawa, Japan|Regeneron Study Site, Uji-shi, Kyoto, Japan|Regeneron Study Site, Nakagami-gun, Okinawa, Japan|Regeneron Study Site, Iruma-gun, Saitama, Japan|Regeneron Study Site, Bunkyō-Ku, Tokyo, Japan|Regeneron Study Site, Chuo Ku, Tokyo, Japan|Regeneron Study Site, Hachiōji, Tokyo, Japan|Regeneron Study Site, Itabashi-ku, Tokyo, Japan|Regeneron Study Site, Shinagawa-Ku, Tokyo, Japan|Regeneron Study Site, Aguascalientes, Mexico|Regeneron Study Site, Cuernavaca, Mexico|Regeneron Study Site, Culiacán, Mexico|Regeneron Study Site, Distrito Federal, Mexico|Regeneron Study Site, Durango, Mexico|Regeneron Study Site, Guadalajara, Mexico|Regeneron Study Site, Guadalajara, Mexico|Regeneron Study Site, Guadalajara, Mexico|Regeneron Study Site, Merida, Mexico|Regeneron Study Site, Mexico City, Mexico|Regeneron Study Site, Mexico City, Mexico|Regeneron Study Site, Mexico City, Mexico|Regeneron Study Site 1, Monterrey, Mexico|Regeneron Study Site 2, Monterrey, Mexico|Regeneron Study Site, Monterrey, Mexico|Regeneron Study Site, Pachuca, Mexico|Regeneron Study Site, Querétaro, Mexico|Regeneron Study Site, San Juan Del Río, Mexico|Regeneron Study Site, Torreon, Mexico|Regeneron Study Site, Ivanovo, Russian Federation|Regeneron Study Site, Kirov, Russian Federation|Regeneron Study Site, Moscow, Russian Federation|Regeneron Study Site, Moscow, Russian Federation|Regeneron Study Site, Moscow, Russian Federation|Regeneron Study Site, Novosibirsk, Russian Federation|Regeneron Study Site, Rostov-on-Don, Russian Federation|Regeneron Study Site, Saint Petersburg, Russian Federation|Regeneron Study Site, Saint Petersburg, Russian Federation|Regeneron Study Site, Saint Petersburg, Russian Federation|Regeneron Study Site, Saint Petersburg, Russian Federation|Regeneron Study Site, Saint Petersburg, Russian Federation|Regeneron Study Site, Saint Petersburg, Russian Federation|Regeneron Study Site, Saint Petersburg, Russian Federation|Regeneron Study Site, Saint Petersburg, Russian Federation|Regeneron Study Site, Saratov, Russian Federation|Regeneron Study Site, Tyumen', Russian Federation|Regeneron Study Site, Yaroslavl, Russian Federation|Regeneron Study Site, Yaroslavl, Russian Federation|Regeneron Study Site 1, Yaroslavl, Russian Federation|Regeneron Study Site 2, Yaroslavl, Russian Federation|Regeneron Study Site, Kuils River, Cape Town, South Africa|Regeneron Study Site, Port Elizabeth, Eastern Cape, South Africa|Regeneron Study Site, Halfway House, Gauteng, South Africa|Regeneron Study Site, Pretoria West, Gauteng, South Africa|Regeneron Study Site, Pretoria, Gauteng, South Africa|Regeneron Study Site, Pretoria, Gauteng, South Africa|Regeneron Study Site, Kempton Park, Johannesburg, South Africa|Regeneron Study Site, Soweto, Johannesburg, South Africa|Regeneron Study Site, Soweto, Johannesburg, South Africa|Regeneron Study Site, Middelburg, Mpumalanga, South Africa|Regeneron Study Site, Cape Town, Western Cape, South Africa|Regeneron Study Site, Cape Town, Western Cape, South Africa|Regeneron Study Site, Paarl, Western Cape, South Africa|Regeneron Study Site, Somerset West, Western Cape, South Africa|Regeneron Study Site, Worcester, Western Cape, South Africa|Regeneron Study Site 1, Bloemfontein, South Africa|Regeneron Study Site 2, Bloemfontein, South Africa|Regeneron Study Site, Claremont, South Africa|Regeneron Study Site, Úzhgorod, Transcarpathian Region, Ukraine|Regeneron Study Site, Kharkiv, Ukraine|Regeneron Study Site, Kharkiv, Ukraine|Regeneron Study Site, Kharkov, Ukraine|Regeneron Study Site 1, Kiev, Ukraine|Regeneron Study Site 2, Kiev, Ukraine|Regeneron Study Site, Kyiv, Ukraine|Regeneron Study Site 1, Kyiv, Ukraine|Regeneron Study Site 2, Kyiv, Ukraine|Regeneron Study Site, Kyiv, Ukraine|Regeneron Study Site 1, Kyiv, Ukraine|Regeneron Study Site 2, Kyiv, Ukraine|Regeneron Study Site 1, Kyiv, Ukraine|Regeneron Study Site 2, Kyiv, Ukraine|Regeneron Study Site, Kyiv, Ukraine|Regeneron Study Site, Kyiv, Ukraine|Regeneron Study Site, L'viv, Ukraine|Regeneron Study Site 1, Vinnitsa, Ukraine|Regeneron Study Site 2, Vinnitsa, Ukraine|Regeneron Study Site, Vinnitsa, Ukraine","""Study Protocol"", https://ClinicalTrials.gov/ProvidedDocs/82/NCT02957682/Prot_000.pdf|""Statistical Analysis Plan"", https://ClinicalTrials.gov/ProvidedDocs/82/NCT02957682/SAP_001.pdf","https://ClinicalTrials.gov/show/NCT02957682"
99,"NCT03054428","Efficacy and Safety of Dupilumab in Participants ≥12 to <18 Years of Age, With Moderate-to-severe Atopic Dermatitis",,"Completed","Has Results","Moderate-to-Severe Atopic Dermatitis|Dermatitis, Dermatitis Atopic|Eczema, Skin Diseases, Skin|Diseases Genetic, Genetic|Diseases Inborn, Skin|Disease, Eczematous Skin|Hypersensitivity, Immediate|Hypersensitivity, Immune System Diseases|Dermatitis, Atopic","Drug: Dupilumab|Drug: Placebo","Percentage of Participants With Investigator's Global Assessment (IGA) 0 or 1 (and Reduction From Baseline of ≥2 Points) at Week 16|Percentage of Participants With Eczema Area and Severity Index (EASI)-75 (≥75% Improvement From Baseline) at Week 16|Percent Change From Baseline in EASI Score at Week 16|Percent Change From Baseline in Weekly Average of Daily Peak Pruritus Numerical Rating Scale (NRS) Score at Week 16|Percentage of Participants With Improvement (Reduction ≥3 Points) of Weekly Average of Daily Peak Pruritus NRS From Baseline to Week 16|Percentage of Participants With Improvement (Reduction ≥4 Points) of Weekly Average of Daily Peak Pruritus NRS From Baseline to Week 16|Percentage of Participants With EASI-50 (≥50% Improvement From Baseline) at Week 16|Percentage of Participants With EASI-90 (≥90% Improvement From Baseline) at Week 16|Time to Onset of Effect on Pruritus as Measured by Percentage of Participants With Improvement (Reduction ≥3 Points) of Weekly Average of Daily Peak Pruritus NRS From Baseline|Time to Onset of Effect on Pruritus as Measured by Percentage of Participants With Improvement (Reduction ≥4 Points) of Weekly Average of Daily Peak Pruritus NRS From Baseline|Change From Baseline in Percent Body Surface Area (BSA) at Week 16|Percent Change From Baseline in Scoring Atopic Dermatitis (SCORAD) Score at Week 16|Change From Baseline in Children's Dermatology Life Quality Index (CDLQI) Total Score at Week 16|Change From Baseline in Patient Oriented Eczema Measure (POEM) at Week 16|Change From Baseline in Weekly Average of Daily Peak Pruritus NRS at Week 16|Percent Change From Baseline in Weekly Average of Daily Peak Pruritus NRS at Week 4|Change From Baseline in Total Hospital Anxiety and Depression Scale (HADS) at Week 16|Percentage of Participants With Improvement (Reduction ≥4 Points) of Weekly Average of Daily Peak Pruritus NRS From Baseline at Week 4|Percentage of Participants With Skin-infection Treatment Emergent Adverse Events (TEAEs) (Excluding Herpetic Infections) Through Week 16|Percentage of Participants With Serious TEAEs Through Week 16","Regeneron Pharmaceuticals|Sanofi","All","12 Years to 17 Years   (Child)","Phase 3","251","Industry","Interventional","Allocation: Randomized|Intervention Model: Parallel Assignment|Masking: Quadruple (Participant, Care Provider, Investigator, Outcomes Assessor)|Primary Purpose: Treatment","R668-AD-1526|2015-004458-16","March 21, 2017","April 4, 2018","June 5, 2018","February 15, 2017","July 23, 2019","July 23, 2019","Regeneron Investigational Site, Birmingham, Alabama, United States|Regeneron Investigational Site, Gilbert, Arizona, United States|Regeneron Investigational Site, Bakersfield, California, United States|Regeneron Investigational Site, Long Beach, California, United States|Regeneron Investigational Site, Rolling Hills Estates, California, United States|Regeneron Investigational Site, San Diego, California, United States|Regeneron Investigational Site, Santa Rosa, California, United States|Regeneron Investigational Site, Centennial, Colorado, United States|Regeneron Investigational Site, Denver, Colorado, United States|Regeneron Investigational Site, Washington, District of Columbia, United States|Regeneron Investigational Site, Tampa, Florida, United States|Regeneron Investigational Site, Macon, Georgia, United States|Regeneron Investigational Site, Sandy Springs, Georgia, United States|Regeneron Investigational Site, Chicago, Illinois, United States|Regeneron Investigational Site, Evansville, Indiana, United States|Regeneron Investigational Site, Indianapolis, Indiana, United States|Regeneron Investigational Site, Plainfield, Indiana, United States|Regeneron Investigational Site, Rockville, Maryland, United States|Regeneron Investigational Site, Boston, Massachusetts, United States|Regeneron Investigational Site, Boston, Massachusetts, United States|Regeneron Investigational Site, Plymouth, Minnesota, United States|Regeneron Investigational Site, Saint Louis, Missouri, United States|Regeneron Investigational Site, Forest Hills, New York, United States|Regeneron Investigational Site, New York, New York, United States|Regeneron Investigational Site, Rochester, New York, United States|Regeneron Investigational Site, Chapel Hill, North Carolina, United States|Regeneron Investigational Site, Bexley, Ohio, United States|Regeneron Investigational Site, Tulsa, Oklahoma, United States|Regeneron Investigational Site, Portland, Oregon, United States|Regeneron Investigational Site, Portland, Oregon, United States|Regeneron Investigational Site, Philadelphia, Pennsylvania, United States|Regeneron Investigational Site, Charleston, South Carolina, United States|Regeneron Investigational Site, Bellaire, Texas, United States|Regeneron Investigational Site, San Antonio, Texas, United States|Regeneron Investigational Site, Norfolk, Virginia, United States|Regeneron Investigational Site, Seattle, Washington, United States|Regeneron Investigational Site, Calgary, Alberta, Canada|Regeneron Investigational Site, Surrey, British Columbia, Canada|Regeneron Investigational Site, Surrey, British Columbia, Canada|Regeneron Investigational Site, Winnipeg, Manitoba, Canada|Regeneron Investigational Site, Markham, Ontario, Canada|Regeneron Investigational Site, Ottawa, Ontario, Canada|Regeneron Investigational Site, Peterborough, Ontario, Canada|Regeneron Research Site, Richmond Hill, Ontario, Canada|Regeneron Investigational Site, Windsor, Ontario, Canada","""Study Protocol"", https://ClinicalTrials.gov/ProvidedDocs/28/NCT03054428/Prot_000.pdf|""Statistical Analysis Plan"", https://ClinicalTrials.gov/ProvidedDocs/28/NCT03054428/SAP_001.pdf","https://ClinicalTrials.gov/show/NCT03054428"
100,"NCT03050151","Study of Dupilumab Auto-injector Device When Used by Patients With Atopic Dermatitis",,"Completed","No Results Available","Atopic Disorders|Eczema, Atopic","Drug: Dupilumab|Device: Auto-injector Device|Device: Prefilled syringe","Number of validated AI device-associated product technical failures (PTFs) during the treatment period divided by total number of actual injections|Type of validated AI device-associated PTFs during the treatment period divided by total number of actual injections.|Number of patients with an AI device-associated PTF|Percentage of patients with an AI device-associated PTF|Number of AI device-associated product technical complaints (PTCs) divided by total number of actual injections|Type of AI device-associated PTCs divided by total number of actual injections|Number of patients with an AI device-associated PTC|Percentage of patients with an AI device-associated PTC|Number of AI device-associated failed drug deliveries (defined as patient failure to administer the full dose at a given attempt, excluding PTF) divided by total number of actual injections|Type of AI device-associated failed drug deliveries (defined as patient failure to administer the full dose at a given attempt, excluding PTF) divided by total number of actual injections|Number of patients with an AI device-associated failure to deliver dose|Percentage of patients with an AI device-associated failure to deliver dose|Number of patients with response to patient satisfaction questions with the AI device|Percentage of patients with response to patient satisfaction questions with the AI device","Regeneron Pharmaceuticals|Sanofi","All","12 Years and older   (Child, Adult, Older Adult)","Phase 1","176","Industry","Interventional","Allocation: Randomized|Intervention Model: Parallel Assignment|Masking: None (Open Label)|Primary Purpose: Treatment","R668-AD-1607","February 28, 2017","November 14, 2017","February 12, 2018","February 10, 2017",,"August 1, 2018","Regeneron Investigational Site, Birmingham, Alabama, United States|Regeneron Investigational Site, Birmingham, Alabama, United States|Regeneron Investigational Site, Fort Smith, Arkansas, United States|Regeneron Investigational Site, Long Beach, California, United States|Regeneron Investigational Site, Los Angeles, California, United States|Regeneron Investigational Site, Murrieta, California, United States|Regeneron Investigational Site, Oceanside, California, United States|Regeneron Investigational Site, Orange, California, United States|Regeneron Investigational Site, Rolling Hills Estates, California, United States|Regeneron Investigational Site, Santa Monica, California, United States|Regeneron Investigational Site, Denver, Colorado, United States|Regeneron Investigational Site, Coral Gables, Florida, United States|Regeneron Investigational Site, Tampa, Florida, United States|Regeneron Investigational Site, Normal, Illinois, United States|Regeneron Investigational Site, Skokie, Illinois, United States|Regeneron Investigational Site, Indianapolis, Indiana, United States|Regeneron Investigational Site, Rockville, Maryland, United States|Regeneron Investigational Site, Plymouth, Minnesota, United States|Regeneron Investigational Site, Saint Joseph, Missouri, United States|Regeneron Investigational Site, Berlin, New Jersey, United States|Regeneron Investigational Site, Windsor, New Jersey, United States|Regeneron Investigational Site, Corning, New York, United States|Regeneron Investigational Site, Forest Hills, New York, United States|Regeneron Investigational Site, New York, New York, United States|Regeneron Investigational Site, High Point, North Carolina, United States|Regeneron Investigational Site, Raleigh, North Carolina, United States|Regeneron Investigational Site, Tulsa, Oklahoma, United States|Regeneron Investigational Site, Portland, Oregon, United States|Regeneron Investigational Site, Charleston, South Carolina, United States|Regeneron Investigational Site, Greer, South Carolina, United States|Regeneron Investigational Site, Bellaire, Texas, United States|Regeneron Investigational Site, Fort Worth, Texas, United States|Regeneron Investigational Site, San Antonio, Texas, United States|Regeneron Investigational Site, San Antonio, Texas, United States|Regeneron Investigational Site, Webster, Texas, United States|Regeneron Investigational Site, Norfolk, Virginia, United States|Regeneron Investigational Site, Tacoma, Washington, United States",,"https://ClinicalTrials.gov/show/NCT03050151"
101,"NCT03409744","Evaluate the Long-Term Safety and Efficacy of Evinacumab in Patients With Homozygous Familial Hypercholesterolemia",,"Active, not recruiting","No Results Available","Homozygous Familial Hypercholesterolemia","Drug: evinacumab","Incidence and severity of treatment-emergent adverse events (TEAEs)|Percent change in Low-Density Lipoprotein Cholesterol (LDL-C) over time|Absolute change in LDL-C over time|Percent change in Apolipoprotein B (Apo B) over time|Absolute change in Apo B over time|Percent change in non-High-Density Lipoprotein Cholesterol (HDL-C) over time|Absolute change in non-HDL-C over time|Percent change in Total Cholesterol (TC) over time|Absolute change in TC over time|Percent change in Triglycerides (TGs) over time|Absolute change in TGs over time|Presence of anti-evinacumab antibodies","Regeneron Pharmaceuticals","All","12 Years and older   (Child, Adult, Older Adult)","Phase 3","116","Industry","Interventional","Allocation: N/A|Intervention Model: Single Group Assignment|Masking: None (Open Label)|Primary Purpose: Treatment","R1500-CL-1719|2017-003170-13","March 13, 2018","January 25, 2023","January 25, 2023","January 24, 2018",,"March 4, 2022","Clinical Trial Site, Los Angeles, California, United States|Clinical Trial Site, Boca Raton, Florida, United States|Clinical Trial Site, Boston, Massachusetts, United States|Clinical Trial Site, New York, New York, United States|Clinical Trial Site, Cincinnati, Ohio, United States|Clinical Trial Site, Portland, Oregon, United States|Clinical Trial Site, Philadelphia, Pennsylvania, United States|Clinical Trial Site, Dallas, Texas, United States|Clinical Trial Site, Dallas, Texas, United States|Clinical Trial Site, Camperdown, New South Wales, Australia|Clinical Trial Site, Perth, Western Australia, Australia|Regeneron Study Site, Vienna, Wien, Austria|Regeneron Study Site, Innsbruck, Austria|Clinical Trial Site, Chicoutimi, Quebec, Canada|Clinical Trial Site, Quebec, Canada|Regeneron Study Site, Praha 2, Kateřinská, Czechia|Clinical Trial Site, Paris, Cedex 13, France|Clinical Trial Site, Marseille, Cedex 5, France|Clinical Trial Site, Dijon, Cedex, France|Regeneron Study Site, Kallithea, Athens, Greece|Clinical Trial Site, Ioannina, Greece|Clinical Trial Site, Napoli, Campania, Italy|Clinical Trial Site, Roma, Rome, Italy|Clinical Trial Site, Obu, Aichi, Japan|Regeneron Study Site, Kurume, Fukuoka, Japan|Regeneron Study Site, Nishinomiya, Hyogo, Japan|Regeneron Study Site, Kanazawa, Ishikawa, Japan|Regeneron Study Site, Kita-ku, Osaka, Japan|Regeneron Study Site, Suita, Osaka, Japan|Regeneron Study Site, Suita, Osaka, Japan|Clinical Trial Site, Amsterdam, Netherlands|Regeneron Study Site, Johannesburg, Gauteng, South Africa|Regeneron Study Site, Cape Town, Western Cape, South Africa|Clinical Trial Site, Ivano-Frankivsk, Ukraine|Clinical Trial Site #1, Kharkiv, Ukraine|Clinical Trial Site #2, Kharkiv, Ukraine|Clinical Trial Site, Kyiv, Ukraine|Rgeneron Study Site, Kyiv, Ukraine",,"https://ClinicalTrials.gov/show/NCT03409744"
102,"NCT02718326","Study of the Efficacy and Safety of Intravitreal (IVT) Aflibercept for the Improvement of Moderately Severe to Severe Nonproliferative Diabetic Retinopathy (NPDR)","PANORAMA","Completed","Has Results","Nonproliferative Diabetic Retinopathy","Drug: Intravitreal aflibercept injection [IAI]|Drug: Sham","Percentage of Participants Who Improved by ≥2 Steps From Baseline in the Diabetic Retinopathy Disease Severity Scale (DRSS) Score at Week 24 in the Combined 2Q16 and 2Q8 Groups|Percentage of Participants With a ≥ 2-step Change at Week 52 in Diabetic Retinopathy Severity Scale (DRSS) From Baseline|Percentage of Participants Who Developed a Vision-Threatening Complication Due to Diabetic Retinopathy at Week 52|Percentage of Participants Who Developed Central Involved-Diabetic Macular Edema (CI-DME) at Week 52|Time to Development of Any Neovascular Vision Threatening Complication (PDR/ASNV) Through Week 52|Time to Development of Central Involved-Diabetic Macular Edema (CI-DME) Through Week 52|Percentage of Participants Who Received Panretinal Photocoagulation (PRP), Inclusive of Participants Undergoing Vitrectomy With Endolaser, at Week 52|Area Under the Curve (AUC) for Change From Baseline in Best Corrected Visual Acuity (BCVA) at Week 52","Regeneron Pharmaceuticals","All","18 Years and older   (Adult, Older Adult)","Phase 3","402","Industry","Interventional","Allocation: Randomized|Intervention Model: Parallel Assignment|Masking: Quadruple (Participant, Care Provider, Investigator, Outcomes Assessor)|Primary Purpose: Treatment","VGFTe-OD-1411|2016-002639-14","March 29, 2016","August 6, 2018","July 16, 2019","March 24, 2016","November 21, 2019","July 30, 2020","Regeneron Study Site, Phoenix, Arizona, United States|Regeneron Study Site, Tucson, Arizona, United States|Regeneron Study Site, Arcadia, California, United States|Regeneron Study Site, Beverly Hills, California, United States|Regeneron Study Site, Encino, California, United States|Regeneron Study Site, Fullerton, California, United States|Regeneron Study Site, La Jolla, California, United States|Regeneron Study Site, Mountain View, California, United States|Regeneron Study Site, Oakland, California, United States|Regeneron Study Site, Oceanside, California, United States|Regeneron Study Site, Sacramento, California, United States|Regeneron Study Site, Colorado Springs, Colorado, United States|Regeneron Study Site, Golden, Colorado, United States|Regeneron Study Site, New London, Connecticut, United States|Regeneron Study Site, Altamonte Springs, Florida, United States|Regeneron Study Site, Deerfield Beach, Florida, United States|Regeneron Study Site, Fort Myers, Florida, United States|Regeneron Study Site, Lakeland, Florida, United States|Regeneron Study Site, Largo, Florida, United States|Regeneron Study Site, Melbourne, Florida, United States|Regeneron Study Site, Miami, Florida, United States|Regeneron Study Site, Miami, Florida, United States|Regeneron Study Site, Orlando, Florida, United States|Regeneron Study Site, Plantation, Florida, United States|Regeneron Study Site, Tallahassee, Florida, United States|Regeneron Study Site, Tampa, Florida, United States|Regeneron Study Site, Winter Haven, Florida, United States|Regeneron Study Ssites, Marietta, Georgia, United States|Regeneron study Site, Tucker, Georgia, United States|Regeneron Study Site, Chicago, Illinois, United States|Regeneron Study Site, Oak Forest, Illinois, United States|Regeneron Study Site, Indianapolis, Indiana, United States|Regeneron Study Site, New Albany, Indiana, United States|Regeneron Study Site, Lexington, Kentucky, United States|Regeneron Study Site, Baltimore, Maryland, United States|Regeneron Study Siste, Baltimore, Maryland, United States|Regeneron Study Site, Baltimore, Maryland, United States|Regeneron Study Site, Hagerstown, Maryland, United States|Regeneron Study Site, Boston, Massachusetts, United States|Regeneron Study Site, Henderson, Nevada, United States|Regeneron Study Site, Bloomfield, New Jersey, United States|Regeneron Study Site, Albuquerque, New Mexico, United States|Regeneron Study Site, Asheville, North Carolina, United States|Regeneron Study Site, Charlotte, North Carolina, United States|Regeneron Study Site, Columbus, Ohio, United States|Regeneron Study Site, Oklahoma City, Oklahoma, United States|Regeneron Study Site, Medford, Oregon, United States|Regeneron Study Site, Kingston, Pennsylvania, United States|Regeneron Study Site, Philadelphia, Pennsylvania, United States|Regeneron Study Site, Florence, South Carolina, United States|Regeneron Study Site, Ladson, South Carolina, United States|Regeneron Study Site, West Columbia, South Carolina, United States|Regeneron Study Site, Rapid City, South Dakota, United States|Regeneron Study Site, Chattanooga, Tennessee, United States|Regeneron Study Site, Germantown, Tennessee, United States|Regeneron Study Site, Nashville, Tennessee, United States|Regeneron Study Site, Nashville, Tennessee, United States|Regeneron Study Site, Abilene, Texas, United States|Regeneron Study Site 1, Austin, Texas, United States|Regeneron Study Site 2, Austin, Texas, United States|Regeneron Study Site, Dallas, Texas, United States|Regeneron Study Site, Harlingen, Texas, United States|Regeneron Study Site, Houston, Texas, United States|Regeneron Study Site, San Antonio, Texas, United States|Regeneron Study Site, The Woodlands, Texas, United States|Regeneron Study Site, Willow Park, Texas, United States|Regeneron Study Site, Salt Lake City, Utah, United States|Regeneron Study Site, Burlington, Vermont, United States|Regeneron Study Site, Fairfax, Virginia, United States|Regeneron Study Site, Spokane, Washington, United States|Regeneron Study Site, Morgantown, West Virginia, United States|Regeneron Study Site, Marburg, Hesse, Germany|Regeneron Study Site, Münster, North Rhine-Westphalia, Germany|Regeneron Study Site, Leipzig, Saxony, Germany|Regeneron Study Site, Szeged, Csongrad, Hungary|Regeneron Study Site, Debrecen, Hajdu-Bihar, Hungary|Regeneron Study Site, Budapest, Pest, Hungary|Regeneron Study Site, Budapest, Pest, Hungary|Regeneron Study Site, Zalaegerszeg, Zala, Hungary|Regeneron Study Site, Asahikawa, Hokkaido, Japan|Regeneron Study Site, Amagasaki, Hyogo, Japan|Regeneron Study Site, Matsumoto, Nagano, Japan|Regeneron Study Site, Chiyoda, Tokyo, Japan|Regeneron Study Site, Kagoshima, Japan|Regeneron Study Site, Nagasaki, Japan|Regeneron Study Site, Arecibo, Puerto Rico|Regeneron Study Site, San Juan, Puerto Rico|Regeneron Study Site, Camberley, Surrey, United Kingdom|Regeneron Study Site, London, United Kingdom","""Study Protocol"", https://ClinicalTrials.gov/ProvidedDocs/26/NCT02718326/Prot_000.pdf|""Statistical Analysis Plan"", https://ClinicalTrials.gov/ProvidedDocs/26/NCT02718326/SAP_001.pdf","https://ClinicalTrials.gov/show/NCT02718326"
103,"NCT02651662","Study of Cemiplimab and REGN1979 in Patients With Lymphoma",,"Active, not recruiting","No Results Available","Lymphoma","Drug: cemiplimab|Drug: REGN1979","Incidence of treatment emergent adverse events (TEAEs)|Pharmacokinetics (PK) of cemiplimab when given alone, and of cemiplimab and REGN1979 when given in combination|Antitumor activity (includes response evaluation per Cheson and Lugano criteria)","Regeneron Pharmaceuticals","All","18 Years and older   (Adult, Older Adult)","Phase 1","172","Industry","Interventional","Allocation: Non-Randomized|Intervention Model: Parallel Assignment|Masking: None (Open Label)|Primary Purpose: Treatment","R1979-ONC-1504|2015-001697-17","January 11, 2016","August 19, 2026","August 19, 2026","January 11, 2016",,"September 22, 2021","Regeneron Research Facility, Santa Monica, California, United States|Regeneron Research Facility, Baltimore, Maryland, United States|Regeneron Research Facility, Boston, Massachusetts, United States|Regeneron Research Facility, Grand Rapids, Michigan, United States|Regeneron Research Facility, Lebanon, New Hampshire, United States|Regeneron Research Facility, New York, New York, United States|Regeneron Research Facility, Cleveland, Ohio, United States|Regeneron Research Facility, Cleveland, Ohio, United States|Regeneron Research Facility, Philadelphia, Pennsylvania, United States|Regeneron Research Facility, San Antonio, Texas, United States|Regeneron Research Facility, Heidelberg, Baden-Wurttemberg, Germany|Regeneron Research Facility, Cologne, Germany|Regeneron Research Facility, Frankfurt, Germany|Regeneron Research Facility, Jena, Germany|Regeneron Research Facility, Kiel, Germany|Regeneron Research Facility, Würzburg, Germany|Regeneron Research Facility, Barcelona, Spain|Regeneron Research Facility, Madrid, Spain|Regeneron Research Facility, Madrid, Spain|Regeneron Research Facility, Madrid, Spain|Regeneron Research Facility, Majadahonda, Spain|Regeneron Research Facility, Salamanca, Spain",,"https://ClinicalTrials.gov/show/NCT02651662"
104,"NCT02713204","Anti-angiOpoeitin 2 Plus Anti-vascular eNdothelial Growth Factor as a therapY for Neovascular Age Related Macular Degeneration: Evaluation of a fiXed Combination Intravitreal Injection","ONYX","Completed","Has Results","Neovascular Age-Related Macular Degeneration","Drug: REGN910-3|Drug: Intravitreal Aflibercept Injection (IAI)","Change From Baseline in Best Corrected Visual Acuity (BCVA) Measured by Early Treatment Diabetic Retinopathy Study (ETDRS) Letter Score at Week 12|Change From Baseline in Best Corrected Visual Acuity (BCVA) Measured by Early Treatment Diabetic Retinopathy Study (ETDRS) Letter Score at Week 36|Change From Baseline in Central Sub-field Retinal Thickness (CST) Measured by Spectral Domain Optical Coherence Tomography (SD-OCT) at Week 12|Change From Baseline in Central Sub-field Retinal Thickness (CST) Measured by Spectral Domain Optical Coherence Tomography (SD-OCT) at Week 36|Change From Baseline in Choroidal Neovascularization (CNV) Area at Week 12|Change From Baseline in Choroidal Neovascularization (CNV) Area at Week 36|Change From Baseline in Total Lesion Area at Week 12|Change From Baseline in Total Lesion Area at Week 36","Regeneron Pharmaceuticals","All","50 Years and older   (Adult, Older Adult)","Phase 2","365","Industry","Interventional","Allocation: Randomized|Intervention Model: Parallel Assignment|Masking: Quadruple (Participant, Care Provider, Investigator, Outcomes Assessor)|Primary Purpose: Treatment","R910-3-AMD-1517","March 31, 2016","October 3, 2017","October 3, 2017","March 18, 2016","May 7, 2019","May 7, 2019","Regeneron Investigational Site, Mobile, Alabama, United States|Regeneron Investigational Site 1, Phoenix, Arizona, United States|Regeneron Investigational Site 2, Phoenix, Arizona, United States|Regeneron Investigational Site 3, Phoenix, Arizona, United States|Regeneron Investigational Site 1, Tucson, Arizona, United States|Regeneron Investigational Site 2, Tucson, Arizona, United States|Regeneron Investigational Site, Arcadia, California, United States|Regeneron Investigational Site, Bakersfield, California, United States|Regeneron Investigational Site, Beverly Hills, California, United States|Regeneron Investigational Site, Encino, California, United States|Regeneron Investigational Site 1, Los Angeles, California, United States|Regeneron Investigational Site 2, Los Angeles, California, United States|Regeneron Investigational Site, Mountain View, California, United States|Regeneron Investigational Site, Oceanside, California, United States|Regeneron Investigational Site 1, Palm Desert, California, United States|Regeneron Investigational Site 2, Palm Desert, California, United States|Regeneron Investigational Site, Palo Alto, California, United States|Regeneron Investigational Site, Poway, California, United States|Regeneron Investigational Site, Redlands, California, United States|Regeneron Investigational Site, Sacramento, California, United States|Regeneron Investigational Site, Santa Maria, California, United States|Regeneron Investigational Site, New London, Connecticut, United States|Regeneron Investigational Site, Altamonte Springs, Florida, United States|Regeneron Investigational Site, Fort Lauderdale, Florida, United States|Regeneron Investigational Site, Lakeland, Florida, United States|Regeneron Investigational Site, Largo, Florida, United States|Regeneron Investigational Site, Miami, Florida, United States|Regeneron Investigational Site, Naples, Florida, United States|Regeneron Investigational Site, Palm Beach, Florida, United States|Regeneron Investigational Site, Tallahassee, Florida, United States|Regeneron Investigational Site, Winter Haven, Florida, United States|Regeneron Investigational Site, Augusta, Georgia, United States|Regeneron Investigational Site, Decatur, Georgia, United States|Regeneron Investigational Site, 'Aiea, Hawaii, United States|Regeneron Investigational Site 1, Chicago, Illinois, United States|Regeneron Investigational Site 2, Chicago, Illinois, United States|Regeneron Investigational Site, Lemont, Illinois, United States|Regeneron Investigational Site, Oak Forest, Illinois, United States|Regeneron Investigational Site, Oak Park, Illinois, United States|Regeneron Investigational Site, Urbana, Illinois, United States|Regeneron Investigational Site, New Albany, Indiana, United States|Regeneron Investigational Site, Des Moines, Iowa, United States|Regeneron Investigational Site, Metairie, Louisiana, United States|Regeneron Investigational Site 1, Baltimore, Maryland, United States|Regeneron Investigational Site 2, Baltimore, Maryland, United States|Regeneron Investigational Site, Chevy Chase, Maryland, United States|Regeneron Investigational Site 1, Boston, Massachusetts, United States|Regeneron Investigational Site 2, Boston, Massachusetts, United States|Regeneron Investigational Site, Jackson, Michigan, United States|Regeneron Investigational Site, Minneapolis, Minnesota, United States|Regeneron Investigational Site, Saint Louis, Missouri, United States|Regeneron Investigational Site, Las Vegas, Nevada, United States|Regeneron Investigational Site, Portsmouth, New Hampshire, United States|Regeneron Investigational Site, Edison, New Jersey, United States|Regeneron Investigational Site, Teaneck, New Jersey, United States|Regeneron Investigational Site, Albuquerque, New Mexico, United States|Regeneron Investigational Site, Albany, New York, United States|Regeneron Investigational Site, Bloomfield, New York, United States|Regeneron Investigational Site, Great Neck, New York, United States|Regeneron Investigational Site, Hauppauge, New York, United States|Regeneron Investigational Site, Rochester, New York, United States|Regeneron Investigational Site, Syracuse, New York, United States|Regeneron Investigational Site, Asheville, North Carolina, United States|Regeneron Investigational Site, Charlotte, North Carolina, United States|Regeneron Investigational Site, Durham, North Carolina, United States|Regeneron Investigational Site, Cleveland, Ohio, United States|Regeneron Investigational Site, Dublin, Ohio, United States|Regeneron Investigational Site, Portland, Oregon, United States|Regeneron Investigational Site, Camp Hill, Pennsylvania, United States|Regeneron Investigational Site, Huntingdon, Pennsylvania, United States|Regeneron Investigational Site, Ladson, South Carolina, United States|Regeneron Investigational Site, Rapid City, South Dakota, United States|Regeneron Investigational Site, Germantown, Tennessee, United States|Regeneron Investigational Site, Knoxville, Tennessee, United States|Regeneron Investigational Site, Nashville, Tennessee, United States|Regeneron Investigational Site, Abilene, Texas, United States|Regeneron Investigational Site 1, Austin, Texas, United States|Regeneron Investigational Site 2, Austin, Texas, United States|Regeneron Investigational Site, Dallas, Texas, United States|Regeneron Investigational Site 1, Fort Worth, Texas, United States|Regeneron Investigational Site 2, Fort Worth, Texas, United States|Regeneron Investigational Site, Harlingen, Texas, United States|Regeneron Investigational Site, Houston, Texas, United States|Regeneron Investigational Site, The Woodlands, Texas, United States|Regeneron Investigational Site, Willow Park, Texas, United States|Regeneron Investigational Site, Salt Lake City, Utah, United States|Regeneron Investigational Site, Madison, Wisconsin, United States","""Study Protocol"", https://ClinicalTrials.gov/ProvidedDocs/04/NCT02713204/Prot_000.pdf|""Statistical Analysis Plan"", https://ClinicalTrials.gov/ProvidedDocs/04/NCT02713204/SAP_001.pdf","https://ClinicalTrials.gov/show/NCT02713204"
105,"NCT02612454","Study to Assess the Long-term Safety of Dupilumab Administered in Participants ≥6 Months to <18 Years of Age With Atopic Dermatitis (AD)",,"Enrolling by invitation","No Results Available","Atopic Dermatitis","Drug: Dupilumab","Rate of treatment-emergent adverse events (TEAEs) per participant year from baseline through the last study visit|Number of participants with at least one TEAE per participant year from baseline through the last study visit|OPTIONAL SUB-STUDY: Pharmacokinetic (PK) of dupilumab: Peak concentration (Cmax)|OPTIONAL SUB-STUDY: PK of dupilumab: Trough concentration (Ctrough)|OPTIONAL SUB-STUDY: Incidence of TEAEs during the 12-week PFP treatment period and during entire sub-study|OPTIONAL SUB-STUDY: Incidence of SAEs during the 12-week PFP treatment period and during entire sub-study|Number of treatment-emergent serious adverse events (SAEs) from baseline through the last study visit|Incidence of TEAEs of special interest from baseline through the last study visit|Proportion of participants with an Investigator Global Assessment (IGA) score of 0 or 1 (clear or almost clear) at all in-clinic visits post-baseline|Proportion of participants with Eczema Area and Severity Index (EASI)-75 (≥75% reduction in EASI from baseline of parent study) response at all in-clinic visits post-baseline|Change from baseline in EASI score at all in-clinic visits post-baseline|Percent change from baseline in EASI at all in-clinic visits post-baseline|Change from baseline in Body Surface Area (BSA) affected by AD (BSA) at all in-clinic visits post-baseline|Percent change from baseline in SCORing Atopic Dermatitis (SCORAD) at all in-clinic visits post-baseline|Change from baseline in Children's Dermatology Life Quality Index (CDLQI) for participants ≥4 years of age at all in-clinic visits post-baseline in which the assessments are planned to be performed|Change from baseline in Infants' Dermatology Quality of Life Index (IDQOL) for participants <4 years of age at all in-clinic visits post-baseline in which the assessments are planned to be performed|Proportion of responders (defined as participants with IGA 0 or 1) who maintain IGA 0 or 1 during at least 75% of the subsequent* visits during the treatment period|For responders (defined as participants with IGA 0 or 1), median percentage of subsequent* visits during the treatment period, at which IGA 0 or 1 is maintained|Number of AD flares during the study|Annualize event rate of AD flares during the study|Proportion of participants with at least one flare during the study|Proportion of well-controlled weeks|OPTIONAL SUB-STUDY: Incidence and titer of treatment-emergent anti-drug antibodies (ADA) (PFP Sub-Study)","Regeneron Pharmaceuticals|Sanofi","All","6 Months to 17 Years   (Child)","Phase 3","800","Industry","Interventional","Allocation: Non-Randomized|Intervention Model: Parallel Assignment|Masking: None (Open Label)|Primary Purpose: Treatment","R668-AD-1434|2015-001396-40","October 15, 2015","November 3, 2026","November 3, 2026","November 23, 2015",,"July 2, 2021","Regeneron Investigational Site, Birmingham, Alabama, United States|Regeneron Investigational Site, Gilbert, Arizona, United States|Regeneron Investigational Site, Bakersfield, California, United States|Regeneron Investigational Site, Long Beach, California, United States|Regeneron Investigational Site, Los Angeles, California, United States|Regeneron Investigational site, Mission Viejo, California, United States|Regeneron Investigational Site, Orange, California, United States|Regeneron Investigational Site, Palo Alto, California, United States|Regeneron Investigational Site, Rolling Hills Estates, California, United States|Regeneron Investigational Site, San Diego, California, United States|Regeneron Investigational Site, Centennial, Colorado, United States|Regeneron Investigational Site, Washington, District of Columbia, United States|Regeneron Investigational Site, Coral Gables, Florida, United States|Regeneron Investigational Site, Tampa, Florida, United States|Regeneron Investigational Site, Tampa, Florida, United States|Regeneron Investigational Site, Columbus, Georgia, United States|Regeneron Investigational Site, Macon, Georgia, United States|Regeneron Investigational Site, Sandy Springs, Georgia, United States|Regeneron Investigational Site, Chicago, Illinois, United States|Regeneron Investigational Site, Skokie, Illinois, United States|Regeneron Investigational site, Plainfield, Indiana, United States|Regeneron Investigational Site, Rockville, Maryland, United States|Regeneron Investigational Site, Boston, Massachusetts, United States|Regeneron Investigational Site, Boston, Massachusetts, United States|Regeneron Investigational Site, Ypsilanti, Michigan, United States|Regeneron Investigational Site, Plymouth, Minnesota, United States|Regeneron Investigational Site, Saint Louis, Missouri, United States|Regeneron Investigational Site, Forest Hills, New York, United States|Regeneron Investigational Site, New York, New York, United States|Regeneron Investigational Site, Rochester, New York, United States|Regeneron Investigational Site, Gahanna, Ohio, United States|Regeneron Investigational Site, Portland, Oregon, United States|Regeneron Investigational site, Philadelphia, Pennsylvania, United States|Regeneron Investigational Site, Charleston, South Carolina, United States|Regeneron Investigational Site, North Charleston, South Carolina, United States|Regeneron Investigational Site, Bellaire, Texas, United States|Regeneron Investigational Site, Fort Worth, Texas, United States|Regeneron Investigational Site, San Antonio, Texas, United States|Regeneron Investigational Site, Norfolk, Virginia, United States|Regeneron Investigational Site, Seattle, Washington, United States|Regeneron Investigational Site, Calgary, Alberta, Canada|Regeneron Investigational Site, Surrey, British Columbia, Canada|Regeneron Investigational Site, Winnipeg, Manitoba, Canada|Regeneron Investigational Site, Markham, Ontario, Canada|Regeneron Investigational Site, Ottawa, Ontario, Canada|Regeneron Investigational Site, Peterborough, Ontario, Canada|Regeneron Investigational Site, Waterloo, Ontario, Canada|Regeneron Investigational Site, Windsor, Ontario, Canada|Regeneron Investigational Site, Montreal, Quebec, Canada|Regeneron Investigational Site, Kutna Hora, Czechia|Regeneron Investigational Site, Prague, Czechia|Regeneron Investigational Site, Ústí Nad Labem, Czechia|Regeneron Study Site, Tuebingen, Baden-Wuerttemberg, Germany|Regeneron Investigational Site, Frankfurt, Hessen, Germany|Regeneron Investigational Site, Muenster, North Rhine-Westphal, Germany|Regeneron Investigational Site, Dresden, Sachsen, Germany|Regeneron Investigational Site, Gera, Germany|Regeneron Investigational Site, Hamburg, Germany|Regeneron Study Site, Muenchen, Germany|Regeneron Investigational Site, Munich, Germany|Regeneron Investigational Site, Szolnok, Jasz-Nagykun-Szolnok, Hungary|Regeneron Investigational Site, Kaposvar, Hungary|Regeneron Investigational Site, Miskolc, Hungary|Regeneron Investigational Site, Szeged, Hungary|Regeneron Investigational Site, Wroclaw, Dolnoslaskie, Poland|Regeneron Investigational Site, Wrocław, Dolnoslaskie, Poland|Regeneron Investigational Site, Ostrowiec Świętokrzyski, Kielce, Poland|Regeneron Investigational Site, Krakow, Malopolska, Poland|Regeneron Investigational Site, Kraków, Malopolska, Poland|Regeneron Investigational Site, Katowice, Slaskie, Poland|Regeneron Investigational Site, Białystok, Poland|Regeneron Investigational Site, Bydgoszcz, Poland|Regeneron Investigational Site, Chorzow, Poland|Regeneron Investigational Site, Gdańsk, Poland|Regeneron Investigational Site, Katowice, Poland|Regeneron Investigational Site, Kraków, Poland|Regeneron Investigational Site, Lodz, Poland|Regeneron Investigational Site, Warszawa, Poland|Regeneron Investigational Site, Warszawa, Poland|Regeneron Investigational Site, Warszawa, Poland|Regeneron Investigational Site, Warszawa, Poland|Regeneron Investigational Site, London, Greater London, United Kingdom|Regeneron Investigational Site, Manchester, Lancashire, United Kingdom|Regeneron Investigational Site, Sheffield, South Yorkshire, United Kingdom",,"https://ClinicalTrials.gov/show/NCT02612454"
106,"NCT02683239","Long-Term Safety and Efficacy Study of Fasinumab in Patients With Pain Due to Osteoarthritis (OA) of the Knee or Hip","FACT LTS & OA","Completed","No Results Available","Osteoarthritis of the Knee or Hip","Drug: Fasinumab|Drug: Placebo","Incidence of adverse events (AEs)|Incidence of serious adverse events (SAEs)|Incidence of adverse events of special interest (AESI)|Incidence of laboratory abnormalities|Incidence of anti-fasinumab antibody formation","Regeneron Pharmaceuticals|Teva Pharmaceutical Industries, Ltd.","All","18 Years and older   (Adult, Older Adult)","Phase 3","5331","Industry","Interventional","Allocation: Randomized|Intervention Model: Parallel Assignment|Masking: Quadruple (Participant, Care Provider, Investigator, Outcomes Assessor)|Primary Purpose: Treatment","R475-PN-1523|2015-003783-36","February 17, 2016","December 1, 2020","June 15, 2021","February 17, 2016",,"December 6, 2021","Regeneron Investigational Site, Birmingham, Alabama, United States|Regeneron Investigational Site #1, Chandler, Arizona, United States|Regeneron Investigational Site #2, Chandler, Arizona, United States|Regeneron Investigational Site, Glendale, Arizona, United States|Regeneron Investigational Site, Mesa, Arizona, United States|Regeneron Investigational Site (4 locations), Phoenix, Arizona, United States|Regeneron Investigational Site, Tempe, Arizona, United States|Regeneron Investigational Site (2 locations), Tucson, Arizona, United States|Regeneron Investigational Site, Little Rock, Arkansas, United States|Regeneron Investigational Site, Beverly Hills, California, United States|Regeneron Investigational Site, Carlsbad, California, United States|Regeneron Investigational Site, San Diego, California, United States|Regeneron Investigational Site, San Marcos, California, United States|Regeneron Investigational Site, Vista, California, United States|Regeneron Investigational Site, Aurora, Colorado, United States|Regeneron Investigational Site, Colorado Springs, Colorado, United States|Regeneron Investigational Site, Golden, Colorado, United States|Regeneron Investigational Site, Littleton, Colorado, United States|Regeneron Investigational Site, Clearwater, Florida, United States|Regeneron Investigational Site, Orlando, Florida, United States|Regeneron Investigational Site, Pinellas Park, Florida, United States|Regeneron Investigational Site, Atlanta, Georgia, United States|Regeneron Investigational Site (3 locations), Chicago, Illinois, United States|Regeneron Investigational Site, Evansville, Illinois, United States|Regeneron Investigational Site, Kansas City, Kansas, United States|Regeneron Investigational Site, Frederick, Maryland, United States|Regeneron Investigational Site, Worcester, Massachusetts, United States|Regeneron Investigational Site, Richfield, Minnesota, United States|Regeneron Investigational Site #1, Saint Louis, Missouri, United States|Regeneron Investigational Site #2, Saint Louis, Missouri, United States|Regeneron Investigational Site, Elkhorn, Nebraska, United States|Regeneron Investigational Site, Fremont, Nebraska, United States|Regeneron Investigational Site, Omaha, Nebraska, United States|Regeneron Investigational Site, Las Vegas, Nevada, United States|Regeneron Investigational Site, Jamaica, New York, United States|Regeneron Investigational Site, New York, New York, United States|Regeneron Investigational Site, High Point, North Carolina, United States|Regeneron Investigational Site, Akron, Ohio, United States|Regeneron Investigational Site, Cincinnati, Ohio, United States|Regeneron Investigational Site, Columbus, Ohio, United States|Regeneron Investigational Site, Oklahoma City, Oklahoma, United States|Regeneron Investigational Site, Duncansville, Pennsylvania, United States|Regeneron Investigational Site, Anderson, South Carolina, United States|Regeneron Investigational Site, Greer, South Carolina, United States|Regeneron Investigational Site #1, Dallas, Texas, United States|Regeneron Investigational Site #2, Dallas, Texas, United States|Regeneron Investigational Site, Houston, Texas, United States|Regeneron Investigational Site, Lubbock, Texas, United States|Regeneron Investigational Site, Plano, Texas, United States|Regeneron Investigational Site, San Antonio, Texas, United States|Regeneron Investigational Site, Burgas, Bulgaria|Regeneron Investigational Site #1, Plovdiv, Bulgaria|Regeneron Investigational Site #2, Plovdiv, Bulgaria|Regeneron Investigational Site #3, Plovdiv, Bulgaria|Regeneron Investigational Site #1, Sofia, Bulgaria|Regeneron Investigational Site #2, Sofia, Bulgaria|Regeneron Investigational Site, Stara Zagora, Bulgaria|Regeneron Investigational Site, Santiago, Chile|Regeneron Investigational Site, Bogota, Colombia|Regeneron Investigational Site, Medellin, Colombia|Regeneron Investigational Site, Aalborg, Denmark|Regeneron Investigational Site, Ballerup, Denmark|Regeneron Investigational Site, Vejle, Denmark|Regeneron Investigational Site, Paide, Estonia|Regeneron Investigational Site, Tallinn, Estonia|Regeneron Investigational Site, Leipzig, Sachsen, Germany|Regeneron Investigational Site, Berlin, Germany|Regeneron Investigational Sites, Bochum, Germany|Regeneron Investigational Site, Frankfurt, Germany|Regeneron Investigational Site, Magdeburg, Germany|Regeneron Investigational Site, Central, Hong Kong|Regeneron Investigational Site, Budapest, Hungary|Regeneron Investigational Site, Debrecen, Hungary|Regeneron Investigational Site, Gyula, Hungary|Regeneron Investigational Site, Hatvan, Hungary|Regeneron Investigational Site, Zalaegerszeg, Hungary|Regeneron Investigational Site, Firenze, Italy|Regeneron Investigational Site, Naples, Italy|Regeneron Investigational Site, Alytus, Lithuania|Regeneron Investigational Site, Kaunas, Lithuania|Regeneron Investigational Site, Vilnius, Lithuania|Regeneron Investigational Site, Šiauliai, Lithuania|Regeneron Investigational Site, Mexicali, Baja Californina, Mexico|Regeneron Investigational Site, Cuauhtemoc, Ciudad De Mexico, Mexico|Regeneron Investigational Site, Cuauhtémoc, Ciudad De Mexico, Mexico|Regeneron Investigational Site, Distrito Federal, DF, Mexico|Regeneron Investigational Site, Mexico, Distrito Federal, Mexico|Regeneron Investigational Site, Guadalajara, Jalisco, Mexico|Regeneron Investigational Site, Guadalajara, Jalisco, Mexico|Regeneron Investigational Site, Cuauhtemoc, Mexico City, Mexico|Regeneron Investigational Site, Cuernavaca, Morelos, Mexico|Regeneron Investigational Site, Culiacan, Sinaloa, Mexico|Regeneron Investigational Site, Merida, Yucatan, Mexico|Regeneron Investigational Site, Merida, Yucatan, Mexico|Regeneron Investigational Site, Lima, Peru|Regeneron Investigational Site, Gdańsk, Poland|Regeneron Investigational Site, Gdynia, Poland|Regeneron Investigational Site, Katowice, Poland|Regeneron Investigational Site, Kraków, Poland|Regeneron Investigational Site, Poznań, Poland|Regeneron Investigational Site #1, Warszawa, Poland|Regeneron Investigational Site #2, Warszawa, Poland|Regeneron Investigational Site, Wrocław, Poland|Regeneron Investigational Site, Łódź, Poland|Regeneron Investigational Site #2, Bucharest, Romania|Regeneron Investigational Site #1, Bucharest, Romania|Regeneron Investigational Site, Kazan', Russian Federation|Regeneron Investigational Site, Novosibirsk, Russian Federation|Regeneron Investigational Site, Samara, Russian Federation|Regeneron Investigational Site, Tomsk, Russian Federation|Regeneron Investigational Site #2, Yaroslavl, Russian Federation|Regeneron Investigational Site #1, Yaroslavl, Russian Federation|Regeneron Investigational Site #1, Pretoria, Gauteng, South Africa|Regeneron Investigational Site #2, Pretoria, Gauteng, South Africa|Regeneron Investigational Site, Bloemfontein, South Africa|Regeneron Investigational Site, Cape Town, South Africa|Regeneron Investigational Site, Kempton Park, South Africa|Regeneron Investigational Site, Parow, South Africa|Regeneron Investigational Site, Port Elizabeth, South Africa|Regeneron Investigational Site, Pretoria, South Africa|Regeneron Investigational Site, Roodepoort, South Africa|Regeneron Investigational Site, Somerset West, South Africa|Regeneron Investigational Site, Soweto, South Africa|Regeneron Investigational Site, A Coruna, Spain|Regeneron Investigational Site, Barcelona, Spain|Regeneron Investigational Site, Madrid, Spain|Regeneron Investigational Site, Sevilla, Spain|Regeneron Investigational Site, Malmo, Skane, Sweden|Regeneron Investigational Site, Boras, Sweden|Regeneron Investigational Site, Goteburg, Sweden|Regeneron Investigational Site, Helsingborg, Sweden|Regeneron Investigational Site, Linkoping, Sweden|Regeneron Investigational Site, Lund, Sweden|Regeneron Investigational Site, Uppsala, Sweden|Regeneron Investigational Site, Vällingby, Sweden|Regeneron Investigational Site, Cherkasy, Ukraine|Regeneron Investigational Site #3, Kyiv, Ukraine|Regeneron Investigational Site #1, Kyiv, Ukraine|Regeneron Investigational Site #2, Kyiv, Ukraine|Regeneron Investigational Site, Lviv, Ukraine|Regeneron Investigational Site, Birmingham, United Kingdom|Regeneron Investigational Site, Chorley, United Kingdom|Regeneron Investigational Site, Glasgow, United Kingdom|Regeneron Investigational Site, Hexham, United Kingdom|Regeneron Investigational Site, Liverpool, United Kingdom|Regeneron Investigational Site, Manchester, United Kingdom|Regeneron Investigational Site, Middlesex, United Kingdom|Regeneron Investigational Site, Reading, United Kingdom|Regeneron Investigational Site, Romford, United Kingdom|Regeneron Investigational Site, Sidcup, United Kingdom",,"https://ClinicalTrials.gov/show/NCT02683239"
107,"NCT02325791","Study to Evaluate the Efficacy and Safety of Suptavumab (REGN2222) for the Prevention of Medically Attended RSV (Respiratory Syncytial Virus) Infection in Preterm Infants",,"Completed","Has Results","Respiratory Syncytial Virus Infections","Drug: Suptavumab 30 mg/kg|Drug: Placebo Matched to Suptavumab|Drug: Suptavumab 30 mg/kg- 1 Dose|Drug: Suptavumab 30 mg/kg - 2 Doses","Part A: Serum Concentration of Suptavumab Over Time|Part B: Percentage of Participants With Medically Attended Respiratory Syncytial Virus (RSV) Infection (Hospitalization or Outpatient Visit With Lower Respiratory Tract Infection [LRTI]) Up to Day 150|Part A: Percentage of Participants With Treatment-Emergent Adverse Events (TEAEs)|Part B: Serum Concentration of Suptavumab|Part B: Number of Participants With At Least One Positive Anti-Drug Antibody (ADA) Assay|Part B: Percentage of Participants Hospitalized With Medically Attended RSV Infection or Outpatient Visit Lower Respiratory Tract Infection (LRTI) or Upper Respiratory Tract Infection (URTI) Up to Day 150","Regeneron Pharmaceuticals","All","up to 6 Months   (Child)","Phase 3","1177","Industry","Interventional","Allocation: Randomized|Intervention Model: Parallel Assignment|Masking: Quadruple (Participant, Care Provider, Investigator, Outcomes Assessor)|Primary Purpose: Treatment","R2222-RSV-1332","July 21, 2015","July 5, 2017","September 26, 2017","December 25, 2014","November 6, 2018","November 6, 2018","Regeneron Investigational Site, Birmingham, Alabama, United States|Regeneron Study Site, Mobile, Alabama, United States|Regeneron Study Site, Little Rock, Arkansas, United States|Regeneron Study Site, Anaheim, California, United States|Regeneron Study Site, Bell Gardens, California, United States|Regeneron Study Site, Dinuba, California, United States|Regeneron Study Site, Downey, California, United States|Regeneron Study Site, Huntington Beach, California, United States|Regeneron Study Site, La Puente, California, United States|Regeneron Study Site, Los Angeles, California, United States|Regeneron Study Site, Madera, California, United States|Regeneron Study Site, Palmdale, California, United States|Regeneron Study Site, Ventura, California, United States|Regeneron Study Site, West Covina, California, United States|Regeneron Study Site, Aurora, Colorado, United States|Regeneron Study Site, Thornton, Colorado, United States|Regeneron Study Site, Hartford, Connecticut, United States|Regeneron Study Site, Boynton Beach, Florida, United States|Regeneron Study Site, Gainesville, Florida, United States|Regeneron Study Site, Jacksonville, Florida, United States|Regeneron Study Site, Miami, Florida, United States|Regeneron Study Site, Orlando, Florida, United States|Regeneron Study Site, Pensacola, Florida, United States|Regeneron Study Site, Tampa, Florida, United States|Regeneron Study Site, Winter Park, Florida, United States|Regeneron Study Site, Atlanta, Georgia, United States|Regeneron Study Site, Columbus, Georgia, United States|Regeneron Study Site, Dalton, Georgia, United States|Regeneron Study Site, Meridian, Idaho, United States|Regeneron Study Site, Nampa, Idaho, United States|Regeneron Study Site, Peoria, Illinois, United States|Regeneron Study Site, South Bend, Indiana, United States|Regeneron Study Site, Hutchinson, Kansas, United States|Regeneron Study Site, Topeka, Kansas, United States|Regeneron Study Site, Bardstown, Kentucky, United States|Regeneron Study Site, Louisville, Kentucky, United States|Regeneron Study Site, Metairie, Louisiana, United States|Regeneron Study Site, New Orleans, Louisiana, United States|Regeneron Study Site, Shreveport, Louisiana, United States|Regeneron Study Site, Baltimore, Maryland, United States|Regeneron Study Site, Silver Spring, Maryland, United States|Regeneron Study Site, Fall River, Massachusetts, United States|Regeneron Study Site, Woburn, Massachusetts, United States|Regeneron Study Site, Stevensville, Michigan, United States|Regeneron Study Site, Duluth, Minnesota, United States|Regeneron Study Site, Minneapolis, Minnesota, United States|Regeneron Study Site, Saint Paul, Minnesota, United States|Regeneron Study Site, Jackson, Mississippi, United States|Regeneron Study Site, Bridgeton, Missouri, United States|Regeneron Study Site, Kansas City, Missouri, United States|Regeneron Study Site, Lincoln, Nebraska, United States|Regeneron Study Site, Norfolk, Nebraska, United States|Regeneron Study Site, Omaha, Nebraska, United States|Regeneron Study Site, Reno, Nevada, United States|Regeneron Study Site, Lebanon, New Hampshire, United States|Regeneron Study Site, Neptune, New Jersey, United States|Regeneron Study Site, New Brunswick, New Jersey, United States|Regeneron Study Site, Bronx, New York, United States|Regeneron Study Site, Brooklyn, New York, United States|Regeneron Study Site, Mineola, New York, United States|Regeneron Study Site, New Hyde Park, New York, United States|Regeneron Study Site, New York, New York, United States|Regeneron Study Site, Rochester, New York, United States|Regeneron Study Site, Syracuse, New York, United States|Regeneron Study Site, Boone, North Carolina, United States|Regeneron Study Site, Chapel Hill, North Carolina, United States|Regeneron Study Site, Durham, North Carolina, United States|Regeneron Study Site, Raleigh, North Carolina, United States|Regeneron Study Site, Cincinnati, Ohio, United States|Regeneron Study Site, Cleveland, Ohio, United States|Regeneron Study Site, Columbus, Ohio, United States|Regeneron Study Site, Dayton, Ohio, United States|Regeneron Study Site, Fairfield, Ohio, United States|Regeneron Study Site, Mayfield Heights, Ohio, United States|Regeneron Study Site, Toledo, Ohio, United States|Regeneron Study Site, Youngstown, Ohio, United States|Regeneron Study Site, Oklahoma City, Oklahoma, United States|Regeneron Study Site, Tulsa, Oklahoma, United States|Regeneron Study Site, Gresham, Oregon, United States|Regeneron Study Site, Allentown, Pennsylvania, United States|Regeneron Study Site, Erie, Pennsylvania, United States|Regeneron Study Site, Hermitage, Pennsylvania, United States|Regeneron Study Site, Charleston, South Carolina, United States|Regeneron Study Site, Cheraw, South Carolina, United States|Regeneron Study Site, Greenville, South Carolina, United States|Regeneron Study Site, North Charleston, South Carolina, United States|Regeneron Study Site, Alcoa, Tennessee, United States|Regeneron Study Site, Kingsport, Tennessee, United States|Regeneron Study Site, Nashville, Tennessee, United States|Regeneron Study Site, Austin, Texas, United States|Regeneron Study Site, Fort Sam Houston, Texas, United States|Regeneron Study Site, Houston, Texas, United States|Regeneron Study Site, San Antonio, Texas, United States|Regeneron Study Site, Layton, Utah, United States|Regeneron Study Site, Roy, Utah, United States|Regeneron Study Site, Saint George, Utah, United States|Regeneron Study Site, Syracuse, Utah, United States|Regeneron Study Site, Charlottesville, Virginia, United States|Regeneron Study Site, Midlothian, Virginia, United States|Regeneron Study Site, Richmond, Virginia, United States|Regeneron Study Site, Vienna, Virginia, United States|Regeneron Study Site, Huntington, West Virginia, United States|Regeneron Study Site, Kingwood, West Virginia, United States|Regeneron Study Site, Morgantown, West Virginia, United States|Regeneron Study Site, Madison, Wisconsin, United States|Regeneron Study Site, Marshfield, Wisconsin, United States|Regeneron Study Site, Milwaukee, Wisconsin, United States|Regeneron Study Site, Hobart, Tasmania, Australia|Regeneron Study Site, Sofia, Sofia-Grad, Bulgaria|Regeneron Study Site, Kazanlak, Stara Zagora, Bulgaria|Regeneron Study Site, Blagoevgrad, Bulgaria|Regeneron Study Site, Dobrich, Bulgaria|Regeneron Study Site, Gabrovo, Bulgaria|Regeneron Study Site, Lom, Bulgaria|Regeneron Study Site, Montana, Bulgaria|Regeneron Study Site, Pleven, Bulgaria|Regeneron Study Site, Plovdiv, Bulgaria|Regeneron Study Site, Ruse, Bulgaria|Regeneron Study Site, Silistra, Bulgaria|Regeneron Study Site, Sliven, Bulgaria|Regeneron Study Site, Vidin, Bulgaria|Regeneron Study Site, Calgary, Alberta, Canada|Regeneron Study Site, Halifax, Nova Scotia, Canada|Regeneron Study Site, Ottawa, Ontario, Canada|Regeneron Study Site, La Florida, Santiago, Chile|Regeneron Study Site, Providencia, Santiago, Chile|Regeneron Study Site, Puente Alto, Santiago, Chile|Regeneron Study Site, Recoleta, Santiago, Chile|Regeneron Study Site, San Jose, Santiago, Chile|Regeneron Study Site, San Ramon, Santiago, Chile|Regeneron Study Site, Aalborg, Denmark|Regeneron Study Site, Hjorring, Denmark|Regeneron Study Site, Naestved, Denmark|Regeneron Study Site, Viborg, Denmark|Regeneron Study Site, Oulu, Oulun Iaani, Finland|Regeneron Study Site, Tampere, Oulun Iaani, Finland|Regeneron Study Site, Pori, Finland|Regeneron Study Site, Turku, Finland|Regeneron Study Site, Bochum, Germany|Regeneron Study Site, Bramsche, Germany|Regeneron Study Site, Bretten, Germany|Regeneron Study Site, Frankenthal, Germany|Regeneron Study Site, Freiburg, Germany|Regeneron Study Site, Hamburg, Germany|Regeneron Study Site, Herxheim, Germany|Regeneron Study Site, Leipzig, Germany|Regeneron Study Site, Mainz, Germany|Regeneron Study Site, Mannheim, Germany|Regeneron Study Site, Moenchengladbach, Germany|Regeneron Study Site, Munich, Germany|Regeneron Study Site, Sankt Augustin, Germany|Regeneron Study Site, Wanzleben, Germany|Regeneron Study Site, Szeged, Csongrad, Hungary|Regeneron Study Site, Budapest, Hungary|Regeneron Study Site, Gyula, Hungary|Regeneron Study Site, Nyiregyhaza, Hungary|Regeneron Study Site, Pecs, Hungary|Regeneron Study Site, Veszprem, Hungary|Regeneron Study Site, Utrecht, Netherlands|Regeneron Study Site, Palmerston North, Manawatu-Wanganui, New Zealand|Regeneron Study Site, Auckland, North Island, New Zealand|Regeneron Study Site, Wellington, New Zealand|Regeneron Study Site, Ciudad de Panama, Panama|Regeneron Study Site, San Juan, Puerto Rico|Regeneron Study Site, Johannesburg, Gauteng, South Africa|Regeneron Study Site, Pretoria, Gauteng, South Africa|Regeneron Study Site, Ga-Rankuwa, North - West, South Africa|Regeneron Study Site, Esplugues de Llobregat, Barcelona, Spain|Regeneron Study Site, Granada, Spain|Regeneron Study Site, La Coruna, Spain|Regeneron Study Site, Madrid, Spain|Regeneron Study Site, Malaga, Spain|Regeneron Study Site, Manises, Spain|Regeneron Study Site, Santiago de Compostela, Spain|Regeneron Study Site, Sevilla, Spain|Regeneron Study Site, Goteborg, Sweden|Regeneron Study Site, Uppsala, Sweden|Regeneron Study Site, Ankara, Turkey|Regeneron Study Site, Istanbul, Turkey|Regeneron Study Site, Izmir, Turkey|Regeneron Study Site, Kocaeli, Turkey|Regeneron Study Site, Chernivtsi, Chernivets'ka Oblast', Ukraine|Regeneron Study Site, Dnipropetrovsk, Dnipropetrovs'ka Oblast', Ukraine|Regeneron Study Site, Odessa, Odes'ka Oblast', Ukraine|Regeneron Study Site, Vinnytsia, Vinnyts'ka Oblast', Ukraine|Regeneron Study Site, Kharkiv, Ukraine|Regeneron Study Site, Kyiv, Ukraine|Regeneron Study Site, Poltava, Ukraine|Regeneron Study Site, Sumy, Ukraine|Regeneron Study Site, Ternopil, Ukraine|Regeneron Study Site, Zaporizhzhia, Ukraine|Regeneron Study Site, Coventry, Birmingham, United Kingdom|Regeneron Study Site, Southampton, Hampshire, United Kingdom|Regeneron Study Site, Gillingham, Kent, United Kingdom|Regeneron Study Site, London, London, City Of, United Kingdom|Regeneron Study Site, Oldham, Manchester, United Kingdom|Regeneron Study Site, Stockport, Manchester, United Kingdom|Regeneron Study Site, Belfast, United Kingdom|Regeneron Study Site, Birmingham, United Kingdom|Regeneron Study Site, Glasgow, United Kingdom|Regeneron Study Site, Manchester, United Kingdom|Regeneron Study Site, Poole, United Kingdom|Regeneron Study Site, Reading, United Kingdom|Regeneron Study Site, Sheffield, United Kingdom|Regeneron Study Site, Stockton on Tees, United Kingdom","""Study Protocol"", https://ClinicalTrials.gov/ProvidedDocs/91/NCT02325791/Prot_000.pdf|""Statistical Analysis Plan: Part A"", https://ClinicalTrials.gov/ProvidedDocs/91/NCT02325791/SAP_001.pdf|""Statistical Analysis Plan: Part B"", https://ClinicalTrials.gov/ProvidedDocs/91/NCT02325791/SAP_002.pdf","https://ClinicalTrials.gov/show/NCT02325791"
108,"NCT01949311","Open-label Study of Dupilumab in Patients With Atopic Dermatitis",,"Active, not recruiting","No Results Available","Atopic Dermatitis","Drug: Dupilumab","Number of Treatment Emergent Adverse Events (TEAEs)|OPTIONAL SUB-STUDY: Incidence of Adverse Events of Special Interest (AESIs) through the last study visit after switching to the new dupilumab drug product|Number of Serious Adverse Events (SAEs) of special interest|Number of AESIs|Proportion of patients with Investigator's Global Assessment (IGA) score = 0-1 at each visit|Proportion of patients with Eczema Area and Severity Index (EASI)-75 (≥75% reduction in EASI scores from baseline of the parent study) at each visit|Proportion of patients with low disease activity state (eg, IGA ≤2) at each visit|Change from baseline in EASI score at each visit|Percent change from baseline in EASI score at each visit|Proportion of patients with EASI-50 (≥50% reduction in EASI scores from baseline of the parent study) at each visit|Proportion of patients with EASI-90 (≥90% reduction in EASI scores from baseline of the parent study) at each visit|Change from baseline in Pruritus Numerical Rating Scale (NRS)|Percent change from baseline in Pruritus NRS|Proportion of patients with improvement (reduction) of Pruritus NRS ≥3 from baseline|Proportion of patients with improvement (reduction) of Pruritus NRS ≥4 from baseline|Proportion of patients requiring rescue treatment: Overall|Proportion of patients requiring rescue treatment: Systemic treatment|Proportion of patients requiring rescue treatment: Phototherapy|Number of days on topical medication (per patient-year)|Proportion of patients using topical medications over various periods during the study|Changes from baseline to prespecified time points through the end of the study: Dermatology Life Quality Index (DLQI)|Changes from baseline to prespecified time points through the end of the study: Patient Oriented Eczema Measure (POEM)|Changes from baseline to prespecified time points through the end of the study: EuroQol-5D (EQ-5D)|PK Parameter: Trough concentration (Ctrough)|PK Parameter: Trough concentration at steady state (Ctrough, ss)|PK Parameter: Last positive (quantifiable) concentration (Clast)|PK Parameter: Time of the last positive (quantifiable) concentration (Tlast)|OPTIONAL SUB-STUDY: Ctrough of functional dupilumab in serum before and after switching to the new dupilumab drug product|OPTIONAL SUB-STUDY: Incidence of treatment-emergent anti-drug antibody (ADA) response in patients receiving the new dupilumab drug product","Regeneron Pharmaceuticals|Sanofi","All","18 Years and older   (Adult, Older Adult)","Phase 3","2733","Industry","Interventional","Allocation: N/A|Intervention Model: Single Group Assignment|Masking: None (Open Label)|Primary Purpose: Treatment","R668-AD-1225|2013-001449-15","October 10, 2013","July 12, 2022","July 12, 2022","September 24, 2013",,"June 25, 2021","Regeneron Study Site, Anniston, Alabama, United States|Regeneron Study Site, Birmingham, Alabama, United States|Regeneron Study Site 1, Birmingham, Alabama, United States|Regeneron Study Site 2, Birmingham, Alabama, United States|Regeneron Study Site 2, Phoenix, Arizona, United States|Regeneron Study Site 3, Phoenix, Arizona, United States|Regeneron Study Site 1, Phoenix, Arizona, United States|Regeneron Study Site, Fort Smith, Arkansas, United States|Regeneron Study Site, Rogers, Arkansas, United States|Regeneron Study Site, Bakersfield, California, United States|Regeneron Study Site, Clovis, California, United States|Regeneron Study Site, Costa Mesa, California, United States|Regeneron Study Site, Encinitas, California, United States|Regeneron Study Site, Fremont, California, United States|Regeneron Study Site, Lomita, California, United States|Regeneron Study Site, Long Beach, California, United States|Regeneron Study Site 1, Los Angeles, California, United States|Regeneron Study Site 2, Los Angeles, California, United States|Regeneron Study Site, Los Angeles, California, United States|Regeneron Study Site, Oceanside, California, United States|Regeneron Study Site, Orange, California, United States|Regeneron Study Site, Rolling Hills Estates, California, United States|Regeneron Study Site, San Diego, California, United States|Regeneron Study Site 1, San Diego, California, United States|Regeneron Study Site 2, San Diego, California, United States|Regeneron Study Site, Santa Monica, California, United States|Regeneron Study Site, Centennial, Colorado, United States|Regeneron Study Site, Denver, Colorado, United States|Regeneron Study Site, Denver, Colorado, United States|Regeneron Study Site, Trumbull, Connecticut, United States|Regeneron Study Site, Washington, District of Columbia, United States|Regeneron Study Site, Boca Raton, Florida, United States|Regeneron Study Site, Clearwater, Florida, United States|Regeneron Study Site, Fort Lauderdale, Florida, United States|Regeneron Study Site 1, Jacksonville, Florida, United States|Regeneron Study Site 2, Jacksonville, Florida, United States|Regeneron Study Site, Lake Worth, Florida, United States|Regeneron Study Site, Miami Lakes, Florida, United States|Regeneron Study Site, Miami, Florida, United States|Regeneron Study Site, Miami, Florida, United States|Regeneron Study Site, Orlando, Florida, United States|Regeneron Study Site, Tampa, Florida, United States|Regeneron Study Site, Tampa, Florida, United States|Regeneron Study Site, Tampa, Florida, United States|Regeneron Study Site, West Palm Beach, Florida, United States|Regeneron Study Site, Alpharetta, Georgia, United States|Regeneron Study Site, Atlanta, Georgia, United States|Regeneron Study Site, Columbus, Georgia, United States|Regeneron Study Site, Macon, Georgia, United States|Regeneron Study Site, Newnan, Georgia, United States|Regeneron Study Site, Sandy Springs, Georgia, United States|Regeneron Study Site, Savannah, Georgia, United States|Regeneron Study Site, Chicago, Illinois, United States|Regeneron Study Site, Normal, Illinois, United States|Regeneron Study Site, West Dundee, Illinois, United States|Regeneron Study Site, Indianapolis, Indiana, United States|Regeneron Study Site, Newburgh, Indiana, United States|Regeneron Study Site, Plainfield, Indiana, United States|Regeneron Study Site, Overland Park, Kansas, United States|Regeneron Study Site, New Orleans, Louisiana, United States|Regeneron Study Site, Rockville, Maryland, United States|Regeneron Study Site, Boston, Massachusetts, United States|Regeneron Study Site, Boston, Massachusetts, United States|Regeneron Study Site, Boston, Massachusetts, United States|Regeneron Study Site, Bay City, Michigan, United States|Regeneron Study Site, Farmington Hills, Michigan, United States|Regeneron Study Site, Troy, Michigan, United States|Regeneron Study Site, Edina, Minnesota, United States|Regeneron Study Site, Fridley, Minnesota, United States|Regeneron Study Site, Minneapolis, Minnesota, United States|Regeneron Study Site, Plymouth, Minnesota, United States|Regeneron Study Site, Saint Joseph, Missouri, United States|Regeneron Study Site, Saint Louis, Missouri, United States|Regeneron Study Site, Saint Louis, Missouri, United States|Regeneron Study Site, Henderson, Nevada, United States|Regeneron Study Site, Las Vegas, Nevada, United States|Regeneron Study Site, Portsmouth, New Hampshire, United States|Regeneron Study Site, Berlin, New Jersey, United States|Regeneron Study Site, East Windsor, New Jersey, United States|Regeneron Study Site, Verona, New Jersey, United States|Regeneron Study Site 1, Albuquerque, New Mexico, United States|Regeneron Study Site 2, Albuquerque, New Mexico, United States|Regeneron Study Site, Buffalo, New York, United States|Regeneron Study Site, Corning, New York, United States|Regeneron Study Site, Forest Hills, New York, United States|Regeneron Study Site, New York, New York, United States|Regeneron Study Site, New York, New York, United States|Regeneron Study Site, New York, New York, United States|Regeneron Study Site, New York, New York, United States|Regeneron Study Site, Rochester, New York, United States|Regeneron Study Site, Chapel Hill, North Carolina, United States|Regeneron Study Site, High Point, North Carolina, United States|Regeneron Study Site, Raleigh, North Carolina, United States|Regeneron Study Site, Wilmington, North Carolina, United States|Regeneron Study Site, Winston-Salem, North Carolina, United States|Regeneron Study Site, Cincinnati, Ohio, United States|Regeneron Study Site, Cleveland, Ohio, United States|Regeneron Study Site, Norman, Oklahoma, United States|Regeneron Study Site, Tulsa, Oklahoma, United States|Regeneron Study Site, Medford, Oregon, United States|Regeneron Study Site, Portland, Oregon, United States|Regeneron Study Site, Portland, Oregon, United States|Regeneron Study Site, Bethlehem, Pennsylvania, United States|Regeneron Study Site, Jenkintown, Pennsylvania, United States|Regeneron Study Site, Philadelphia, Pennsylvania, United States|Regeneron Study Site, Pittsburgh, Pennsylvania, United States|Regeneron Study Site, Charleston, South Carolina, United States|Regeneron Study Site, Greer, South Carolina, United States|Regeneron Study Site, Chattanooga, Tennessee, United States|Regeneron Study Site, Nashville, Tennessee, United States|Regeneron Study Site, Arlington, Texas, United States|Regeneron Study Site, Austin, Texas, United States|Regeneron Study Site, Bellaire, Texas, United States|Regeneron Study Site, Dallas, Texas, United States|Regeneron Study Site, Dallas, Texas, United States|Regeneron Study Site, Dallas, Texas, United States|Regeneron Study Site, Houston, Texas, United States|Regeneron Study Site, San Antonio, Texas, United States|Regeneron Study Site 1, San Antonio, Texas, United States|Regeneron Study Site 2, San Antonio, Texas, United States|Regeneron Study Site, San Antonio, Texas, United States|Regeneron Study Site, Waco, Texas, United States|Regeneron Study Site, Webster, Texas, United States|Regeneron Study Site, Salt Lake City, Utah, United States|Regeneron Study Site, South Burlington, Vermont, United States|Regeneron Study Site, Newport News, Virginia, United States|Regeneron Study Site, Norfolk, Virginia, United States|Regeneron Study Site, Richmond, Virginia, United States|Regeneron Study Site, Seattle, Washington, United States|Regeneron Study Site, Phillip, Australian Capital Territory, Australia|Regeneron Study Site, Kogarah, New South Wales, Australia|Regeneron Study Site, Benowa, Queensland, Australia|Regeneron Study Site, Woolloongabba, Queensland, Australia|Regeneron Study Site, Hectorville, South Australia, Australia|Regeneron Study Site, Carlton, Victoria, Australia|Regeneron Study Site, East Melbourne, Victoria, Australia|Regeneron Study Site, Fremantle, Western Australia, Australia|Regeneron Study Site 1, Wien, Austria|Regeneron Study Site 2, Wien, Austria|Regeneron Study Site, Bruxelles, Brussels Capital Region, Belgium|Regeneron Study Site, Loverval, Hainaut, Belgium|Regeneron Study Site, Leuven, Vlaams Brabant, Belgium|Regeneron Study Site, Dupnitsa, Kjustendil, Bulgaria|Regeneron Study Site 1, Sofia, Sofia-Grad, Bulgaria|Regeneron Study Site 2, Sofia, Sofia-Grad, Bulgaria|Regeneron Study Site 1, Calgary, Alberta, Canada|Regeneron Study Site 2, Calgary, Alberta, Canada|Regeneron Study Site 1, Edmonton, Alberta, Canada|Regeneron Study Site 2, Edmonton, Alberta, Canada|Regeneron Study Site 1, Surrey, British Columbia, Canada|Regeneron Study Site 2, Surrey, British Columbia, Canada|Regeneron Study Site 1, Vancouver, British Columbia, Canada|Regeneron Study Site 2, Vancouver, British Columbia, Canada|Regeneron Study Site 3, Vancouver, British Columbia, Canada|Regeneron Study Site 1, Winnipeg, Manitoba, Canada|Regeneron Study Site, Bathurst, New Brunswick, Canada|Regeneron Study Site, St. John's, Newfoundland and Labrador, Canada|Regeneron Study Site, Ajax, Ontario, Canada|Regeneron Study Site 1, Barrie, Ontario, Canada|Regeneron Study Site 2, Barrie, Ontario, Canada|Regeneron Study Site, Etobicoke, Ontario, Canada|Regeneron Study Site 1, Hamilton, Ontario, Canada|Regeneron Study Site 2, Hamilton, Ontario, Canada|Regeneron Study Site, Markham, Ontario, Canada|Regeneron Study Site, Mississauga, Ontario, Canada|Regeneron Study Site, Newmarket, Ontario, Canada|Regeneron Study Site, North Bay, Ontario, Canada|Regeneron Study Site, Oakville, Ontario, Canada|Regeneron Study Site 1, Ottawa, Ontario, Canada|Regeneron Study Site, Peterborough, Ontario, Canada|Regeneron Study Site 1, Richmond Hill, Ontario, Canada|Regeneron Study Site 2, Richmond Hill, Ontario, Canada|Regeneron Study Site, Toronto, Ontario, Canada|Regeneron Study Site, Waterloo, Ontario, Canada|Regeneron Study Site 1, Windsor, Ontario, Canada|Regeneron Study Site 2, Windsor, Ontario, Canada|Regeneron Study Site, Drummondville, Quebec, Canada|Regeneron Study Site, Montreal, Quebec, Canada|Regeneron Study Site 3, Ste-Foy, Quebec, Canada|Regeneron Study Site, Ste-Foy, Canada|Regeneron Study Site, Winnipeg, Canada|Regeneron Study Site, Hong Kong, China|Regeneron Study Site, Hradec Kralove, Czechia|Regeneron Study Site, Kutna Hora, Czechia|Regeneron Study Site, Nachod, Czechia|Regeneron Study Site, Praha 10, Czechia|Regeneron Study Site, Praha 5, Czechia|Regeneron Study Site, Praha 6, Czechia|Regeneron Study Site, Svitavy, Czechia|Regeneron Study Site, Usti nad Labem, Czechia|Regeneron Study Site, Copenhagen, Capital, Denmark|Regeneron Study Site, Hellerup, Capital, Denmark|Regeneron Study Site, Aarhus, Central Jutland, Denmark|Regeneron Study Site, Roskilde, Zeeland, Denmark|Regeneron Study Site 1, Tallinn, Harjumaa, Estonia|Regeneron Study Site 2, Tallinn, Harjumaa, Estonia|Regeneron Study Site 3, Tallinn, Harjumaa, Estonia|Regeneron Study Site 1, Tartu, Tartumaa, Estonia|Regeneron Study Site 2, Tartu, Tartumaa, Estonia|Regeneron Study Site, Helsinki, Etelä-Suomen Iääni, Finland|Regeneron Study Site, Turku, Etelä-Suomen Lääni, Finland|Regeneron Study Site, Tampere, Länsi-Suomen Lääni, Finland|Regeneron Study Site, Nice Cedex 3, Alpes-Maritimes, France|Regeneron Study Site, Marseille, Bouches-du-Rhône, France|Regeneron Study Site, Reims, Marne, France|Regeneron Study Site, Lille, Nord, France|Regeneron Study Site, Pierre Benite, Rhône-Alpes, France|Regeneron Study Site, Lille cedex, France|Regeneron Study Site, Nantes, France|Regeneron Study Site, Paris, Île-de-France, France|Regeneron Study Site, Friedrichshafen, Baden-Württemberg, Germany|Regeneron Study Site, Heidelberg, Baden-Württemberg, Germany|Regeneron Study Site, Langenau, Baden-Württemberg, Germany|Regeneron Study Site, Stuttgart, Baden-Württemberg, Germany|Regeneron Study Site, Tuebingen, Baden-Württemberg, Germany|Regeneron Study Site, Augsburg, Bayern, Germany|Regeneron Study Site, Erlangen, Bayern, Germany|Regeneron Study Site, Munchen, Bayern, Germany|Regeneron Study Site, Munich, Bayern, Germany|Regeneron Study Site, Mahlow, Brandenburg, Germany|Regeneron Study Site 2, Hamburg, Hamburgh, Germany|Regeneron Study Site, Frankfurt/Main, Hessen, Germany|Regeneron Study Site, Schwerin, Mecklenburg-Vorpommern, Germany|Regeneron Study Site, Hannover, Niedersachsen, Germany|Regeneron Study Site 1, Bochum, Nordrhein-Westfalen, Germany|Regeneron Study Site 2, Bochum, Nordrhein-Westfalen, Germany|Regeneron Study Site, Dulmen, Nordrhein-Westfalen, Germany|Regeneron Study Site, Ibbenbüren, Nordrhein-Westfalen, Germany|Regeneron Study Site, Monchengladbach, Nordrhein-Westfalen, Germany|Regeneron Study Site, Muenster, Nordrhein-Westfalen, Germany|Regeneron Study Site, Mainz, Rheinland-Pfalz, Germany|Regeneron Study Site, Selters, Rheinland-Pfalz, Germany|Regeneron Study Site, Halle, Sachsen-Anhalt, Germany|Regeneron Study Site, Magdeburg, Sachsen-Anhalt, Germany|Regeneron Study Site 1, Dresden, Sachsen, Germany|Regeneron Study Site 2, Dresden, Sachsen, Germany|Regeneron Study Site 3, Dresden, Sachsen, Germany|Regeneron Study Site, Leipzig, Sachsen, Germany|Regeneron Study Site 1, Kiel, Schleswig-Holstein, Germany|Regeneron Study Site 2, Kiel, Schleswig-Holstein, Germany|Regeneron Study Site, Lubeck, Schleswig-Holstein, Germany|Regeneron Study Site, Gera, Thüringen, Germany|Regeneron Study Site 1, Berlin, Germany|Regeneron Study Site 2, Berlin, Germany|Regeneron Study Site 3, Berlin, Germany|Regeneron Study Site 4, Berlin, Germany|Regeneron Study Site 5, Berlin, Germany|Regeneron Study Site 6, Berlin, Germany|Regeneron Study Site 7, Berlin, Germany|Regeneron Study Site, Bonn, Germany|Regeneron Study Site, Darmstadt, Germany|Regeneron Study Site 1, Hamburg, Germany|Regeneron Study Site, Münster, Germany|Regeneron Study Site, Osnabrück, Germany|Regeneron Study Site, Sátoraljaújhely, Borsod-Abaúj-Zemplén, Hungary|Regeneron Study Site, Oroshaza, Békés, Hungary|Regeneron Study Site, Szeged, Csongrád, Hungary|Regeneron Study Site, Szolnok, Jász-Nagykun-Szolnok, Hungary|Regeneron Study Site, Kaposvár, Somogy, Hungary|Regeneron Study Site 1, Budapest, Hungary|Regeneron Study Site 2, Budapest, Hungary|Regeneron Study Site 3, Budapest, Hungary|Regeneron Study Site, Veszprem, Hungary|Regeneron Study Site, Dublin, Ireland|Regeneron Study Site, Bologna, Balogna, Italy|Regeneron Study Site, Ancona, Italy|Regeneron Study Site, Chieti, Italy|Regeneron Study Site, Firenze, Italy|Regeneron Study Site, L'Aquila, Italy|Regeneron Study Site, Lucca, Italy|Regeneron Study Site, Messina, Italy|Regeneron Study Site, Milano, Italy|Regeneron Study Site, Novara, Italy|Regeneron Study Site, Pavia, Italy|Regeneron Study Site, Perugia, Italy|Regeneron Study Site, Pisa, Italy|Regeneron Study Site 1, Roma, Italy|Regeneron Study Site 2, Roma, Italy|Regeneron Study Site, Nagakute, Aichi, Japan|Regeneron Study Site, Kurume, Fukuoka, Japan|Regeneron Study Site, Fukuyama, Hiroshima, Japan|Regeneron Study Site, Sapporo, Hokkaido, Japan|Regeneron Study Site 1, Fukuoka, Hukuoka, Japan|Regeneron Study Site 2, Fukuoka, Hukuoka, Japan|Regeneron Study Site, Kitakyushu, Hukuoka, Japan|Regeneron Study Site 1, Amagasaki, Hyôgo, Japan|Regeneron Study Site 2, Amagasaki, Hyôgo, Japan|Regeneron Study Site, Inashiki-gun, Ibaraki, Japan|Regeneron Study Site 1, Yokohama, Kanagawa, Japan|Regeneron Study Site 2, Yokohama, Kanagawa, Japan|Regeneron Study Site 3, Yokohama, Kanagawa, Japan|Regeneron Study Site, Kamimashiki, Kumamoto, Japan|Regeneron Study Site, Habikino, Osaka, Japan|Regeneron Study Site, Neyagawa, Osaka, Japan|Regeneron Study Site, Sakai, Osaka, Japan|Regeneron Study Site, Takatsuki, Osaka, Japan|Regeneron Study Site, Hamamatsu, Shizuoka, Japan|Regeneron Study Site, Yaizu, Shizuoka, Japan|Regeneron Study Site 1, Bunkyo-ku, Tokyo, Japan|Regeneron Study Site 2, Bunkyo-ku, Tokyo, Japan|Regeneron Study Site 1, Chiyoda-ku, Tokyo, Japan|Regeneron Study Site 2, Chiyoda-ku, Tokyo, Japan|Regeneron Study Site, Chuo-ku, Tokyo, Japan|Regeneron Study Site, Koto-ku, Tokyo, Japan|Regeneron Study Site, Nakano-ku, Tokyo, Japan|Regeneron Study Site 1, Nerima, Tokyo, Japan|Regeneron Study Site 2, Nerima, Tokyo, Japan|Regeneron Study Site, Ota-ku, Tokyo, Japan|Regeneron Study Site, Setagaya-ku, Tokyo, Japan|Regeneron Study Site 1, Shibuya-ku, Tokyo, Japan|Regeneron Study Site 2, Shibuya-ku, Tokyo, Japan|Regeneron Study Site 3, Shibuya-ku, Tokyo, Japan|Regeneron Study Site 1, Shinagawa-ku, Tokyo, Japan|Regeneron Study Site 2, Shinagawa-ku, Tokyo, Japan|Regeneron Study Site 1, Shinjuku-ku, Tokyo, Japan|Regeneron Study Site 2, Shinjuku-ku, Tokyo, Japan|Regeneron Study Site 3, Shinjuku-ku, Tokyo, Japan|Regeneron Study Site 4, Shinjuku-ku, Tokyo, Japan|Regeneron Study Site 5, Shinjuku-ku, Tokyo, Japan|Regeneron Study Site 6, Shinjuku-ku, Tokyo, Japan|Regeneron Study Site 1, Suginami, Tokyo, Japan|Regeneron Study Site 2, Suginami, Tokyo, Japan|Regeneron Study Site, Kofu, Yamanashi, Japan|Regeneron Study Site, Chuo, Yamanasi, Japan|Regeneron Study Site 2, Fukuyama, Japan|Regeneron Study Site, Gifu, Japan|Regeneron Study Site 1, Hiroshima, Japan|Regeneron Study Site 2, Hiroshima, Japan|Regeneron Study Site 1, Kyoto, Japan|Regeneron Study Site 2, Kyoto, Japan|Regeneron Study Site 1, Osaka, Japan|Regeneron Study Site 2, Osaka, Japan|Regeneron Study Site, Saitama, Japan|Regeneron Study Site 3, Shinagawa-ku, Japan|Regeneron Study Site, Suginome, Japan|Regeneron Study Site, Wakayama, Japan|Regeneron Study Site 4, Yokohama, Japan|Regeneron Study Site, Busan, Busan Gwang'yeogsi, Korea, Republic of|Regeneron Study Site, Bucheon-Si, Kyonggi-do, Korea, Republic of|Regeneron Study Site, Hwaseong-si, Kyonggi-do, Korea, Republic of|Regeneron Study Site, Suwon, Kyonggi-do, Korea, Republic of|Regeneron Study Site, Uijeongbu-si, Kyonggi-do, Korea, Republic of|Regeneron Study Site 1, Incheon, Korea, Republic of|Regeneron Study Site 2, Incheon, Korea, Republic of|Regeneron Study Site 1, Seoul, Korea, Republic of|Regeneron Study Site 2, Seoul, Korea, Republic of|Regeneron Study Site 3, Seoul, Korea, Republic of|Regeneron Study Site 4, Seoul, Korea, Republic of|Regeneron Study Site 5, Seoul, Korea, Republic of|Regeneron Study Site 6, Seoul, Korea, Republic of|Regeneron Study Site 7, Seoul, Korea, Republic of|Regeneron Study Site 8, Seoul, Korea, Republic of|Regeneron Study Site, Kaunas, Kauno Apskritis, Lithuania|Regeneron Study Site 1, Vilnius, Vilniaus Apskritis, Lithuania|Regeneron Study Site 2, Vilnius, Vilniaus Apskritis, Lithuania|Regeneron Study Site 1, Klaipeda, Lithuania|Regeneron Study Site 2, Klaipeda, Lithuania|Regeneron Study Site, Breda, Noord-Brabant, Netherlands|Regeneron Study Site, Amsterdam, Noord-Holland, Netherlands|Regeneron Study Site, Rotterdam, Zuid-Holland, Netherlands|Regeneron Study Site, Groningen, Netherlands|Regeneron Study Site, Utrecht, Netherlands|Regeneron Study Site, Dunedin, South Island, New Zealand|Regeneron Study Site, Auckland, New Zealand|Regeneron Study Site 1, Wroclaw, Dolnośląskie, Poland|Regeneron Study Site 2, Wroclaw, Dolnośląskie, Poland|Regeneron Study Site 3, Wroclaw, Dolnośląskie, Poland|Regeneron Study Site, Torun, Kujawsko-pomorskie, Poland|Regeneron Study Site 1, Lodz, Lodzkie, Poland|Regeneron Study Site 2, Lodz, Lodzkie, Poland|Regeneron Study Site 3, Lodz, Lodzkie, Poland|Regeneron Study Site, Lublin, Lubelskie, Poland|Regeneron Study Site 1, Krakow, Malopolskie, Poland|Regeneron Study Site 2, Krakow, Malopolskie, Poland|Regeneron Study Site 3, Krakow, Malopolskie, Poland|Regeneron Study Site 1, Warszawa, Mazowieckie, Poland|Regeneron Study Site 2, Warszawa, Mazowieckie, Poland|Regeneron Study Site 3, Warszawa, Mazowieckie, Poland|Regeneron Study Site 4, Warszawa, Mazowieckie, Poland|Regeneron Study Site 5, Warszawa, Mazowieckie, Poland|Regeneron Study Site 6, Warszawa, Mazowieckie, Poland|Regeneron Study Site 7, Warszawa, Mazowieckie, Poland|Regeneron Study Site, Strzelce Opolskie, Opolskie, Poland|Regeneron Study Site, Iwonicz Zdroj, Podkarpackie, Poland|Regeneron Study Site 1, Gdansk, Pomorskie, Poland|Regeneron Study Site 2, Gdansk, Pomorskie, Poland|Regeneron Study Site 1, Poznan, Wielkopolskie, Poland|Regeneron Study Site 2, Poznan, Wielkopolskie, Poland|Regeneron Study Site 3, Poznan, Wielkopolskie, Poland|Regeneron Study Site, Szczecin, Zachodniopomorskie, Poland|Regeneron Study Site, Bialystok, Poland|Regeneron Study Site, Bydgoszcz, Poland|Regeneron Study Site, Chorzow, Poland|Regeneron Study Site, Elblag, Poland|Regeneron Study Site 1, Katowice, Poland|Regeneron Study Site 2, Katowice, Poland|Regeneron Study Site 3, Katowice, Poland|Regeneron Study Site, Ostrowiec Swietokrzyski, Poland|Regeneron Study Site, Skarzysko-Kamienna, Poland|Regeneron Study Site, Zgierz, Poland|Regeneron Study Site, Brasov, Romania|Regeneron Study Site, Moscow, Koskva, Russian Federation|Regeneron Study Site, Ryazan, Ryazanskaya Oblast', Russian Federation|Regeneron Study Site, Saint Petersburg, Sankt-Peterburg, Russian Federation|Regeneron Study Site, Kazan, Tatarstan Respublika, Russian Federation|Regeneron Study Site, Chelyabinsk, Russian Federation|Regeneron Study Site 1, Singapore, Central Singapore, Singapore|Regeneron Study Site 2, Singapore, Central Singapore, Singapore|Regeneron Study Site, Singapore, South West, Singapore|Regeneron Study Site, Kosice, Slovakia|Regeneron Study Site, Svidnik, Slovakia|Regeneron Study Site, Elche, Alicante, Spain|Regeneron Study Site, Badalona, Barcelona, Spain|Regeneron Study Site, Las Palmas de Gran Canaria, Canarias, Spain|Regeneron Study Site 1, Barcelona, Spain|Regeneron Study Site 2, Barcelona, Spain|Regeneron Study Site 3, Barcelona, Spain|Regeneron Study Site 4, Barcelona, Spain|Regeneron Study Site 1, Madrid, Spain|Regeneron Study Site 2, Madrid, Spain|Regeneron Study Site, Sevilla, Spain|Regeneron Study Site, Dundee, Angus, United Kingdom|Regeneron Study Site, Edgbaston, Birmingham, United Kingdom|Regeneron Study Site, Plymouth, Devon, United Kingdom|Regeneron Study Site, Portsmouth, Hampshire, United Kingdom|Regeneron Study Site, Sidcup, Kent, United Kingdom|Regeneron Study Site, Northwood, London, United Kingdom|Regeneron Study Site, Oxford, Oxfordshire, United Kingdom|Regeneron Study Site, Liverpool, United Kingdom|Regeneron Study Site 1, London, United Kingdom|Regeneron Study Site 2, London, United Kingdom|Regeneron Study Site, Manchester, United Kingdom|Regeneron Study Site, Salford, United Kingdom|Regeneron Study Site, Sheffield, United Kingdom",,"https://ClinicalTrials.gov/show/NCT01949311"
109,"NCT00083213","Intravenous VEGF Trap in Treating Patients With Relapsed or Refractory Advanced Solid Tumors or Non-Hodgkin's Lymphoma",,"Completed","No Results Available","Cancer","Biological: ziv-aflibercept",,"Regeneron Pharmaceuticals|National Cancer Institute (NCI)","All","18 Years to 120 Years   (Adult, Older Adult)","Phase 1","25","Industry|NIH","Interventional","Allocation: N/A|Intervention Model: Single Group Assignment|Masking: None (Open Label)|Primary Purpose: Treatment","REGENERON-VGFT-ST-0202|MSKCC-03137|CDR0000360856","January 2004","May 2008",,"May 19, 2004",,"June 3, 2016","Memorial Sloan - Kettering Cancer Center, New York, New York, United States",,"https://ClinicalTrials.gov/show/NCT00083213"
110,"NCT00082823","Intravenous VEGF Trap in Treating Patients With Relapsed or Refractory Advanced Solid Tumors or Non-Hodgkin's Lymphoma",,"Completed","No Results Available","Cancer","Biological: ziv-aflibercept",,"Regeneron Pharmaceuticals|National Cancer Institute (NCI)","All","18 Years to 120 Years   (Adult, Older Adult)","Phase 1","25","Industry|NIH","Interventional","Allocation: N/A|Intervention Model: Single Group Assignment|Masking: None (Open Label)|Primary Purpose: Treatment","REGENERON-VGFT-ST-0304|MSKCC-03138|CDR0000360846","January 2004","May 2008",,"May 19, 2004",,"June 3, 2016","Memorial Sloan - Kettering Cancer Center, New York, New York, United States|Vanderbilt-Ingram Cancer Center, Nashville, Tennessee, United States",,"https://ClinicalTrials.gov/show/NCT00082823"
111,"NCT03836105","CemiplimAb Survivorship Epidemiology","CASE","Recruiting","No Results Available","Cutaneous Squamous Cell Carcinoma|Basal Cell Carcinoma","Drug: cemiplimab","Objective response rate (ORR)|Disease control rate (DCR)|Duration of response (DOR)|Time to response|Progression free survival (PFS)|Overall Survival (OS)|Time to treatment failure (TTTF)|Disease specific death (DSD)|Number of patients with metastatic vs locally advanced cancer summarized every three weeks|Immune related adverse events (irAEs)|Infusion related reactions (IRRs)|Treatment related serious adverse reactions (SARs)","Regeneron Pharmaceuticals","All","18 Years and older   (Adult, Older Adult)",,"500","Industry","Observational","Observational Model: Cohort|Time Perspective: Prospective","R2810-ONC-1806","June 27, 2019","September 11, 2025","September 11, 2025","February 11, 2019",,"January 21, 2022","Regeneron Research Facility, Huntsville, Alabama, United States|Regeneron Research Facility, Little Rock, Arkansas, United States|Regeneron Research Facility, La Jolla, California, United States|Regeneron Research Facility, Los Angeles, California, United States|Regeneron Research Facility, San Francisco, California, United States|Regeneron Research Facility, Stanford, California, United States|Regeneron Research Facility, Aurora, Colorado, United States|Regeneron Research Facility, Englewood, Colorado, United States|Regeneron Research Facility, Manchester, Connecticut, United States|Regeneron Research Facility, Delray Beach, Florida, United States|Regeneron Research Facility, Jacksonville, Florida, United States|Regeneron Research Facility, Largo, Florida, United States|Regeneron Research Facility, Miami, Florida, United States|Regeneron Research Facility, Miami, Florida, United States|Regeneron Research Facility, Tampa, Florida, United States|Regeneron Research Facility, Thomasville, Georgia, United States|Regeneron Research Facility, Chicago, Illinois, United States|Regeneron Research Facility, Evanston, Illinois, United States|Regeneron Research Facility, Richmond, Indiana, United States|Regeneron Research Facility, Shreveport, Louisiana, United States|Regeneron Research Facility, Baltimore, Maryland, United States|Regeneron Research Facility, Boston, Massachusetts, United States|Regeneron Research Facility, Burlington, Massachusetts, United States|Regeneron Research Facility, Ann Arbor, Michigan, United States|Regeneron Research Facility, Lincoln, Nebraska, United States|Regeneron Research Facility, Las Vegas, Nevada, United States|Regeneron Research Facility, Elizabeth, New Jersey, United States|Regeneron Research Facility, Bronx, New York, United States|Regeneron Research Facility, New York, New York, United States|Regeneron Research Facility, New York, New York, United States|Regeneron Research Facility, New York, New York, United States|Regeneron Research Facility, Nyack, New York, United States|Regeneron Research Facility, Port Jefferson Station, New York, United States|Regeneron Research Facility, Charlotte, North Carolina, United States|Regeneron Research Facility, Charlotte, North Carolina, United States|Regeneron Research Facility, Durham, North Carolina, United States|Regeneron Research Facility, Medford, Oregon, United States|Regeneron Research Facility, Portland, Oregon, United States|Regeneron Research Facility, Bethlehem, Pennsylvania, United States|Regeneron Research Facility, Charleston, South Carolina, United States|Regeneron Research Facility, Charleston, South Carolina, United States|Regeneron Research Facility, Knoxville, Tennessee, United States|Regeneron Research Facility, Amarillo, Texas, United States|Regeneron Research Facility, Dallas, Texas, United States|Regeneron Research Facility, Dallas, Texas, United States|Regeneron Research Facility, Houston, Texas, United States|Regeneron Research Facility, The Woodlands, Texas, United States|Regeneron Research Facility, Burlington, Vermont, United States|Regeneron Research Facility, Charlottesville, Virginia, United States|Regeneron Research Facility, Fairfax, Virginia, United States|Regeneron Research Facility, Green Bay, Wisconsin, United States|Regeneron Research Facility, Rio Piedras, Puerto Rico|Regeneron Research Facility, San Juan, Puerto Rico",,"https://ClinicalTrials.gov/show/NCT03836105"
112,"NCT00045266","VEGF Trap in Treating Patients With Solid Tumors or Non-Hodgkin's Lymphoma",,"Completed","No Results Available","Lymphoma|Unspecified Adult Solid Tumor, Protocol Specific","Biological: ziv-aflibercept",,"Regeneron Pharmaceuticals|National Cancer Institute (NCI)","All","25 Years to 120 Years   (Adult, Older Adult)","Phase 1",,"Industry|NIH","Interventional","Masking: None (Open Label)|Primary Purpose: Treatment","REGENERON-VGF-ST-0105|MSKCC-02020|CDR0000256462|NCI-G-02-2101","April 2002","February 2007",,"January 27, 2003",,"June 3, 2016","Memorial Sloan-Kettering Cancer Center, New York, New York, United States",,"https://ClinicalTrials.gov/show/NCT00045266"
113,"NCT00036946","VEGF Trap in Treating Patients With Relapsed or Refractory Solid Tumors or Non-Hodgkin's Lymphoma",,"Completed","No Results Available","Lymphoma|Unspecified Adult Solid Tumor, Protocol Specific","Biological: ziv-aflibercept",,"Regeneron Pharmaceuticals|National Cancer Institute (NCI)","All","25 Years to 120 Years   (Adult, Older Adult)","Phase 1",,"Industry|NIH","Interventional","Primary Purpose: Treatment","REGENERON-VGFT-ST-0103|MSKCC-01131|CDR0000069343|NCI-G02-2065","November 2001","March 2002",,"January 27, 2003",,"June 3, 2016","Memorial Sloan-Kettering Cancer Center, New York, New York, United States",,"https://ClinicalTrials.gov/show/NCT00036946"
114,"NCT00991172","A Study to Evaluate the Safety and Efficacy of Subcutaneously Administered REGN475(SAR164877) in Patients With Sciatic Pain",,"Completed","No Results Available","Sciatica","Drug: REGN475|Drug: Placebo Injection","Sciatic pain between baseline and end of week 4|Additional measures of sciatic pain.","Regeneron Pharmaceuticals|Sanofi","All","18 Years to 65 Years   (Adult, Older Adult)","Phase 2","159","Industry","Interventional","Allocation: Randomized|Intervention Model: Parallel Assignment|Masking: Triple (Participant, Investigator, Outcomes Assessor)|Primary Purpose: Treatment","R475-PN-0908","November 2009","May 2010","May 2010","October 7, 2009",,"December 8, 2011","Regeneron Investigational Site, Birmingham, Alabama, United States|Regeneron Investigational Site, Mobile, Alabama, United States|Regeneron Investigational Site, Peoria, Arizona, United States|Regeneron Investigational Site, Anaheim, California, United States|Regeneron Investigational Site, Beverly Hills, California, United States|Regeneron Investigational Site, National City, California, United States|Regeneron Investigational Site, Santa Ana, California, United States|Regeneron Investigational Site, Milford, Connecticut, United States|Regeneron Investigational Site, Stamford, Connecticut, United States|Regeneron Investigational Site, Clearwater, Florida, United States|Regeneron Investigational Site, Hallandale Beach, Florida, United States|Regeneron Investigational Site, St. Petersburg, Florida, United States|Regeneron Investigational Site, Tampa, Florida, United States|Regeneron Investigational Site, West Palm Beach, Florida, United States|Regeneron Investigational Site, Atlanta, Georgia, United States|Regeneron Investigational Site, Sandy Springs, Georgia, United States|Regeneron Investigational Site, Overland Park, Kansas, United States|Regeneron Investigational Site, Rockville, Maryland, United States|Regeneron Investigational Site, Kansas City, Missouri, United States|Regeneron Investigational Site, Albuquerque, New Mexico, United States|Regeneron Investigational Site, Raleigh, North Carolina, United States|Regeneron Investigational Site, Cincinnati, Ohio, United States|Regeneron Investigational Site, Duncansville, Pennsylvania, United States|Regeneron Investigational Site, Tyrone, Pennsylvania, United States|Regeneron Investigational Site, Warwick, Rhode Island, United States|Regeneron Investigational Site, Greer, South Carolina, United States|Regeneron Investigational Site, Memphis, Tennessee, United States|Regeneron Investigational Site, El Paso, Texas, United States|Regeneron Investigational Site, San Antonio, Texas, United States|Regeneron Invesitgational Site, West Jordan, Utah, United States",,"https://ClinicalTrials.gov/show/NCT00991172"
115,"NCT04992273","COVID-19 Administration of Single-Dose Subcutaneous Anti- Spike(s) SARS-CoV-2 Monoclonal Antibodies Casirivimab and Imdevimab in High-Risk Pediatric Participants Under 12 Years of Age",,"Active, not recruiting","No Results Available","COVID-19","Drug: casirivimab+imdevimab","Concentrations of casirivimab+imdevimab in serum over time.|Number of participants with treatment-emergent adverse events (TEAEs)|Severity of TEAEs|Number of participants with grade ≥3 injection site reactions|Number of participants with grade ≥3 hypersensitivity reactions|Immunogenicity as measured by anti-drug antibodies (ADA) to casirivimab over time|Immunogenicity as measured by ADA to imdevimab over time|Immunogenicity as measured by neutralizing antibodies (NAb) to casirivimab over time|Immunogenicity as measured by NAb to imdevimab over time","Regeneron Pharmaceuticals","All","up to 12 Years   (Child)","Phase 2","28","Industry","Interventional","Allocation: Non-Randomized|Intervention Model: Single Group Assignment|Masking: None (Open Label)|Primary Purpose: Treatment","R10933-10987-COV-2121|2021-004590-30","September 13, 2021","November 17, 2022","November 17, 2022","August 5, 2021",,"February 10, 2022","Advanced Research Center, Inc, Anaheim, California, United States|Batchelor's Children's Research Institute, Miami, Florida, United States|Jacobi Medical Center, Bronx, New York, United States|Stony Brook University Hospital, Stony Brook, New York, United States|SUNY Upstate Medical University, Syracuse, New York, United States|Coastal Pediatric Research, Charleston, South Carolina, United States|Regeneron Research Site, Richmond, Virginia, United States",,"https://ClinicalTrials.gov/show/NCT04992273"
116,"NCT05259709","A Study of ImmunoPet Imaging Using 89Zr-DFO-REGN5054 in Adult Participants With Solid Cancers Treated With Cemiplimab",,"Not yet recruiting","No Results Available","Advanced Solid Tumor|Metastatic Solid Tumor","Drug: 89Zr˗DFO˗REGN5054|Drug: cemiplimab","Incidence and severity of treatment-emergent adverse events (TEAEs)|Incidence and severity of TEAEs|Clinical dosimetry based on tissue radiation absorbed dose calculated from positron emission tomography (PET) image acquisition data|Clinical dosimetry based on tissue radiation effective dose calculated from PET image acquisition data|Concentration of 89Zr-DFO-REGN5054 in serum|Plasma imaging agent activity concentration of area under the curve (AUC0-7)|89Zr-DFO-REGN5054 uptake across cluster of differentiation 8 (CD8)-expressing normal tissues and tumors|Blood pool uptake of 89Zr-DFO-REGN5054 with subsequent calculation of standardized uptake value (SUV) tumor-to-blood ratios|Association of 89Zr˗DFO˗REGN5054 autoradiographic signal intensity distribution with CD8 expression in tumor tissues|Association of 89Zr-DFO-REGN5054 uptake with CD8 expression in tumor tissues|Association of tumor-to-blood ratio of 89Zr-DFO-REGN5054 with CD8 expression in tumor tissues","Regeneron Pharmaceuticals","All","18 Years and older   (Adult, Older Adult)","Phase 1","44","Industry","Interventional","Allocation: Non-Randomized|Intervention Model: Sequential Assignment|Masking: None (Open Label)|Primary Purpose: Treatment","R5054-ONC-1843|2019-001604-38","June 23, 2022","February 10, 2026","February 10, 2026","February 28, 2022",,"February 28, 2022",,,"https://ClinicalTrials.gov/show/NCT05259709"
117,"NCT05203380","Neuropsychologic Assessments of Dupilumab-Treated Adolescent Participants With Moderate-to-Severe Atopic Dermatitis","NEURADAD","Not yet recruiting","No Results Available","Moderate-to-severe Atopic Dermatitis","Drug: dupilumab","Proportion of AD patients with a Conner's CPT-3 d' T-score ≥ 60|Mean change from baseline in Conner's CPT-3 d' T-score|Correlation of values for Conners' Continuous Performance Test 3rd Edition (CPT-3) scores (d' T-score, Commission Errors, Omission Errors, and Reaction Time) with AD disease severity based on Eczema Area and Severity Index (EASI)|Correlation of values for Conners' CPT-3 scores with AD disease severity based on Body Surface Area (BSA)|Correlation of values for Conners' CPT-3 scores with AD disease severity based on Peak Pruritus Numeric Rating Scale (NRS)|Correlation of values for Conners' CPT-3 scores with AD disease severity based on Skin Pain Numeric Rating Scale (SP-NRS)|Correlation of values for Conners' CPT-3 scores with AD disease severity based on Patient-Reported Outcomes Measurement Information System Pediatric Sleep Disturbance Questionnaire (PROMIS Pediatric Sleep Disturbance)|Correlation of values for Conners' CPT-3 scores with AD disease severity based on Children's Dermatology Life Quality Index (CDLQI)|Correlation of values for Conners' CPT-3 scores with AD disease severity based on Hospital Anxiety and Depression Scale (HADS)|Correlation of values for Conners' CPT-3 scores with AD disease severity based on Investigator's Global Assessment (IGA)|Correlation of values for Adult/Adolescent Sensory Profile (AASP) Sensory Sensitivity Score with AD disease severity based on EASI|Correlation of values for AASP Sensory Sensitivity Score with AD disease severity based on BSA|Correlation of values for AASP Sensory Sensitivity Score with AD disease severity based on Peak Pruritus NRS|Correlation of values for AASP Sensory Sensitivity Score with AD disease severity based on SP-NRS|Correlation of values for AASP Sensory Sensitivity Score with AD disease severity based on PROMIS Pediatric Sleep Disturbance Questionnaire|Correlation of values for AASP Sensory Sensitivity Score with AD disease severity based on CDLQI|Correlation of values for AASP Sensory Sensitivity Score with AD disease severity based on HADS|Correlation of values for AASP Sensory Sensitivity Score with AD disease severity based on IGA|Correlation of values for Stroop Interference Score with AD disease severity based on EASI|Correlation of values for SCWT Interference Score with AD disease severity based on BSA|Correlation of values for Stroop Interference Score with AD disease severity based on Peak Pruritus NRS|Correlation of values for Stroop Interference Score with AD disease severity based on SP-NRS|Correlation of values for Stroop Interference Score with AD disease severity based on PROMIS Pediatric Sleep Disturbance Questionnaire|Correlation of values for Stroop Interference Score with AD disease severity based on CDLQI|Correlation of values for Stroop Interference Score with AD disease severity based on HADS|Correlation of values for Stroop Interference Score with AD disease severity based on IGA|Determine the appropriate minimal Conners' CPT-3 d-prime T score|Correlation of change in AD disease severity based on EASI with change in Conners' CPT-3 score|Correlation of change in AD disease severity based on BSA with change in Conners' CPT-3 score|Correlation of change in AD disease severity based on Peak Pruritus NRS with change in Conners' CPT-3 score|Correlation of change in AD disease severity based on SP-NRS with change in Conners' CPT-3 score|Correlation of change in AD disease severity based on PROMIS Pediatric Sleep Disturbance with change in Conners' CPT-3 score|Correlation of change in AD disease severity based on CDLQI with change in Conners' CPT-3 score|Correlation of change in AD disease severity based on HADS with change in Conners' CPT-3 score|Correlation of change in AD disease severity based on IGA with change in Conners' CPT-3 score|Correlation of change in AD disease severity based on EASI with AASP Sensory Sensitivity Summary Score|Correlation of change in AD disease severity based on BSA with AASP Sensory Sensitivity Summary Score|Correlation of change in AD disease severity based on Peak Pruritus NRS with AASP Sensory Sensitivity Summary Score|Correlation of change in AD disease severity based on SP-NRS with AASP Sensory Sensitivity Summary Score|Correlation of change in AD disease severity based on PROMIS Pediatric Sleep Disturbance with AASP Sensory Sensitivity Summary Score|Correlation of change in AD disease severity based on CDLQI with AASP Sensory Sensitivity Summary Score|Correlation of change in AD disease severity based on HADS with AASP Sensory Sensitivity Summary Score|Correlation of change in AD disease severity based on IGA with AASP Sensory Sensitivity Summary Score","Regeneron Pharmaceuticals|Sanofi","All","12 Years to 17 Years   (Child)","Phase 4","82","Industry","Interventional","Allocation: Non-Randomized|Intervention Model: Sequential Assignment|Masking: None (Open Label)|Primary Purpose: Treatment","R668-AD-2024","January 28, 2022","July 15, 2024","August 12, 2024","January 24, 2022",,"January 24, 2022",,,"https://ClinicalTrials.gov/show/NCT05203380"
118,"NCT05137054","REGN5458 (Anti-BCMA x Anti-CD3 Bispecific Antibody) Plus Other Cancer Treatments for Participants With Relapsed/Refractory Multiple Myeloma",,"Not yet recruiting","No Results Available","Multiple Myeloma","Drug: REGN5458|Drug: Daratumumab|Drug: Carfilzomib|Drug: Lenalidomide|Drug: Bortezomib|Drug: Dexamethasone","Incidence of pre-defined safety criteria (dose-limiting toxicities (DLTs)) from the first dose through the end of the DLT observation period|Incidence and severity of treatment-emergent adverse events (TEAEs)|Incidence and severity of serious adverse events (SAEs)|Incidence and severity of adverse events of special interest (AESIs)|Incidence of laboratory abnormalities|Objective response rate (ORR) as measured using the International Myeloma Working Group (IMWG) criteria|Duration of response (DOR) using the IMWG criteria|Progression-free survival (PFS) as measured using the IMWG criteria|Rate of minimal residual disease (MRD) negative status using the IMWG criteria|Concentrations of REGN5458 in the serum over time|Incidence over time of anti-drug antibodies (ADAs) to REGN5458|Overall Survival (OS)","Regeneron Pharmaceuticals","All","18 Years and older   (Adult, Older Adult)","Phase 1","256","Industry","Interventional","Allocation: Non-Randomized|Intervention Model: Sequential Assignment|Masking: None (Open Label)|Primary Purpose: Treatment","R5458-ONC-2012|2020-004638-39","March 28, 2022","October 11, 2024","March 16, 2030","November 30, 2021",,"November 30, 2021",,,"https://ClinicalTrials.gov/show/NCT05137054"
119,"NCT05125016","REGN4336 (a PSMAXCD3 Bispecific Antibody) Administered Alone or in Combination With Cemiplimab in Adult Male Patients With Metastatic Castration-Resistant Prostate Cancer",,"Recruiting","No Results Available","Metastatic Castration-resistant Prostate Cancer","Drug: REGN4336|Drug: Cemiplimab|Other: 18F-DCFPyL","Incidence of dose-limiting toxicities (DLTs)|Incidence and severity of treatment-emergent adverse events (TEAEs)|Incidence and severity of Immune-related Adverse Events (irAEs)|Incidence and severity of SAEs|Incidence and severity of adverse event of special interests (AESIs)|Number of patients with grade ≥3 laboratory abnormalities|REGN4336 concentrations in serum|ORR per modified per modified Prostate Cancer Working Group 3 (PCWG3) criteria|ORR per modified per modified PCWG3 criteria|Incidence and severity of TEAEs|Incidence and severity of Immune-related Adverse Events|Percentage of patients with ≥50% reduction prostate specific antigen (PSA) from baseline, confirmed by a second PSA test ≥4 weeks later|Percentage of patients with ≥90% reduction prostate specific antigen (PSA) from baseline, confirmed by a second PSA test ≥4 weeks later|Anti-drug antibodies (ADA) to REGN4336|ADA to REGN4336 and cemiplimab","Regeneron Pharmaceuticals","Male","18 Years and older   (Adult, Older Adult)","Phase 1|Phase 2","199","Industry","Interventional","Allocation: Non-Randomized|Intervention Model: Parallel Assignment|Masking: None (Open Label)|Primary Purpose: Treatment","R4336-ONC-20104|2021-001104-15","November 30, 2021","August 4, 2026","August 4, 2026","November 18, 2021",,"February 1, 2022","University of Maryland, Greenebaum Comprehensive Cancer Center, Baltimore, Maryland, United States|Thomas Jefferson University, Sidney Kimmel Center, Clinical Research Organization, Philadelphia, Pennsylvania, United States",,"https://ClinicalTrials.gov/show/NCT05125016"
120,"NCT05106387","An Observational Extension Study for Adult Patients Treated in Study R5459-RT-1944 Who Receive A Kidney Transplant",,"Not yet recruiting","No Results Available","Chronic Kidney Disease (CKD)","Other: Noninterventional","Incidence of Adverse Events|Incidence of Serious Adverse Events|Incidence of biopsy-proven kidney allograft rejection|Time to diagnosis of biopsy-proven kidney allograft rejection|Responsiveness to therapy by 12 months of biopsy-proven kidney allograft rejection|Incidence of graft loss|Time to graft loss|Change in estimated glomerular filtration rate (eGFR) over time|Incidence of delayed graft function|Percent Change in anti-HLA alloantibodies|Mean Fluorescence Intensity Change in anti-HLA alloantibodies|Change in Calculated panel-reactive antibody (cPRA) over time|Percent Change in donor-specific anti-HLA alloantibodies|Mean Fluorescence Intensity Change in donor-specific anti-HLA alloantibodies|Incidence of de novo anti-HLA alloantibody development|Serum Concentrations of Ig classes (IgG, IgA, and IgM) over time|Percent change from baseline of circulating serum concentrations of Ig classes|Serum Concentration of R5458|Serum Concentration of R5459","Regeneron Pharmaceuticals","All","18 Years to 70 Years   (Adult, Older Adult)",,"12","Industry","Observational","Observational Model: Cohort|Time Perspective: Prospective","R5459-RT-1956","July 26, 2022","January 28, 2026","January 28, 2026","November 3, 2021",,"February 22, 2022",,,"https://ClinicalTrials.gov/show/NCT05106387"
121,"NCT05092581","COVID-19 Study of Pharmacokinetics, Safety, Tolerability, and Efficacy of Intravenous Anti-Spike(s) SARS-CoV-2 Monoclonal Antibodies (Casirivimab+Imdevimab) for the Treatment of Pediatric Patients Hospitalized Due to COVID-19",,"Active, not recruiting","No Results Available","COVID-19","Drug: casirivimab+imdevimab","Concentrations of casirivimab+imdevimab in serum over time|Proportion of patients with treatment-emergent serious adverse events (SAEs)|Proportion of patients with infusion-related reactions|Proportion of patients with hypersensitivity reactions|Incidence of anti-drug antibodies (ADA) to casirivimab+imdevimab over time|Incidence of neutralizing antibodies (NAb) to casirivimab+imdevimab over time","Regeneron Pharmaceuticals","All","up to 17 Years   (Child)","Phase 1","2","Industry","Interventional","Allocation: N/A|Intervention Model: Single Group Assignment|Masking: None (Open Label)|Primary Purpose: Treatment","R10933-10987-COV-2114|2021-004535-84","December 16, 2021","June 15, 2022","June 15, 2022","October 25, 2021",,"February 21, 2022","State University of New York at Stony Brook, Stony Brook, New York, United States|Le Bonheur Children's Hospital, Memphis, Tennessee, United States",,"https://ClinicalTrials.gov/show/NCT05092581"
122,"NCT05092347","Study for Desensitization of Chronic Kidney Disease Adult Patients in Need of a Kidney Transplant Who Are Highly Sensitized to Human Leukocyte Antigen",,"Not yet recruiting","No Results Available","Chronic Kidney Disease (CKD)","Drug: REGN5459|Drug: REGN5458","Incidence of adverse event(s) of interest (AEI) from the first dose through end of the safety observation period|Incidence and severity of treatment-emergent adverse events (TEAE)s from the first study drug dose up to the end of the study|Proportion of Participants with a clinically meaningful reduction in anti-HLA alloantibodies|Maximum reduction in the peak (immunodominant) MFI of anti-HLA alloantibodies from baseline|Percent change from baseline in the peak (immunodominant) MFI|Percent change from baseline in the sum of MFI of anti-HLA alloantibodies using the SAB assay|Time to first clinically meaningful reduction in anti-HLA alloantibody levels by SAB assay|Time to maximal reduction in anti-HLA alloantibody levels by SAB assay|Maximum reduction in cPRA from baseline|Time to first clinically meaningful reduction in cPRA|Time to maximal reduction in cPRA from baseline|Duration of a reduction in peak anti-HLA alloantibody to MFI <5,000 or by ≥50% by SAB assay|Duration of maximal reduction in anti-HLA alloantibody MFI by SAB assay|Duration of maximal reduction in cPRA by SAB assay|Serum concentration of Immunoglobulin(Ig) classes over time|Percent change from baseline of serum concentration of Ig classes|Concentration of REGN5458 in serum over time|Concentration of REGN5459 in serum over time|Incidence of treatment-emergent REGN5458 anti-drug antibodies (ADA) over time|Incidence of treatment-emergent REGN5459 ADA over time","Regeneron Pharmaceuticals","All","18 Years to 70 Years   (Adult, Older Adult)","Phase 1|Phase 2","60","Industry","Interventional","Allocation: Non-Randomized|Intervention Model: Sequential Assignment|Masking: None (Open Label)|Primary Purpose: Treatment","R5459-RT-1944","March 15, 2022","July 7, 2025","July 7, 2025","October 25, 2021",,"February 22, 2022",,,"https://ClinicalTrials.gov/show/NCT05092347"
123,"NCT05088460","A Study to Examine the Effects of the Leptin Receptor (LEPR) Agonist Antibody REGN4461 in Adult Patients With Familial Partial Lipodystrophy (FPLD)","LEAP","Not yet recruiting","No Results Available","Familial Partial Lipodystrophy|Metabolic Abnormalities","Drug: REGN4461|Drug: Matching Placebo","Percent change in fasting serum triglyceride (TG)|Absolute change in hemoglobin A1c (HbA1c)|Percent change in fasting serum TG|Absolute change in HbA1c|Percent change in fasting serum TG from baseline to week 12 compared to the percent change between week 12 and week 24|Percent change in fasting serum TG after the first 12 weeks of exposure to REGN4461|Change in HbA1c|Change in HbA1c from baseline to week 12 compared to change between week 12 and week 24|Change in fasting glucose|Change in fasting glucose from baseline to week 12 compared to change between week 12 and week 24|Percent change in liver fat magnetic resonance imaging-derived proton density fat fraction (MRI-PDFF) REGN4461|Percent change in liver fat (MRI-PDFF) placebo|Percent change in liver fat (MRI-PDFF) REGN4461 versus placebo|Percent change in liver fat (MRI-PDFF)|Percent change in liver fat (MRI-PDFF) from baseline to week 12 compared to percent change between week 12 and week 24|Change on the daily lipodystrophy hunger questionnaire|Incidence and severity of treatment-emergent adverse events (TEAEs)|Concentrations of REGN4461 in serum over time|Immunogenicity of REGN4461 over time compared to placebo","Regeneron Pharmaceuticals","All","18 Years and older   (Adult, Older Adult)","Phase 2","40","Industry","Interventional","Allocation: Randomized|Intervention Model: Parallel Assignment|Masking: Quadruple (Participant, Care Provider, Investigator, Outcomes Assessor)|Primary Purpose: Treatment","R4461-PLD-20100|2021-000138-33","January 24, 2022","June 1, 2023","December 22, 2023","October 22, 2021",,"January 26, 2022",,,"https://ClinicalTrials.gov/show/NCT05088460"
124,"NCT04614571","T Cell Receptor (TCR) Sequencing and Transcriptional Profiling in Adult Celiac Disease Patients Undergoing Gluten Challenge",,"Recruiting","No Results Available","Celiac Disease","Dietary Supplement: Gluten Powder","Change from Baseline in small intestine TCR repertoire|Change from Baseline in peripheral blood TCR repertoire|Changes from baseline in small intestine and peripheral blood transcriptome|Change from Baseline in Small Intestine Histology Based on Intraepithelial Lymphocytes (IEL) Count per 100 epithelial cells|Change from Baseline in Small Intestine Histology Based on Villous Height (Microns), Crypt Depth (Microns) and Villous Height to Crypt Depth Ratio (Vh:Cd)|Identification and ex vivo functional validation of gluten-specific T cells","Regeneron Pharmaceuticals","All","18 Years to 75 Years   (Adult, Older Adult)","Not Applicable","20","Industry","Interventional","Allocation: N/A|Intervention Model: Single Group Assignment|Masking: None (Open Label)|Primary Purpose: Other","0000-CD-CES-1880","November 2, 2020","May 26, 2022","May 26, 2022","November 4, 2020",,"November 16, 2021","Celiac Research Centre Mass General Hospital, Boston, Massachusetts, United States",,"https://ClinicalTrials.gov/show/NCT04614571"
125,"NCT04577820","Study to Assess the Efficacy and Safety of Garetosmab in Japanese Adult Patients With Fibrodysplasia Ossificans Progressiva (FOP)",,"Withdrawn","No Results Available","Fibrodyplasia Ossificans Progressiva (FOP)|Heterotopic Ossification (HO)","Drug: garetosmab","Incidence and severity of treatment-emergent adverse event (TEAEs)|Number of new HO lesions as assessed by CT|Total volume of new HO lesions as assessed by CT|Number of new HO lesions as assessed by positron emission tomography (PET)|Total lesion activity in new HO lesions as assessed by PET|Percent of patients with new HO lesions as assessed by CT|Percent of patients with new HO lesions as assessed by PET|Percent of patients with investigator-assessed flare-ups|Percent of patients with flare-ups assessed by patient e-diary|Number of new HO lesions as assessed by PET|Change in mean maximum standard uptake volume (SUVmax) of individual active HO site(s) by PET|Percent change in mean maximum standard uptake volume (SUVmax) of individual active HO site(s) by PET|Change in total lesion activity by PET|Percent change in total lesion activity by PET|Change in the total volume of HO lesions as assessed by CT|Percent change in the total volume of HO lesions as assessed by CT|Change in number of HO lesions as assessed by PET|Change in the number of HO lesions detectable by CT|Time-weighted average (standardized area under curve [AUC]) change in daily pain due to FOP, as measured using the daily numeric rating scale (NRS)|Time-weighted average (standardized AUC) change in daily pain due to FOP, as measured using the daily NRS|Total dosage of glucocorticoids use|Incidence and severity of TEAEs|Concentration of total activin A in serum over time|Pharmacokinetic (Pk) Profile - concentrations of garetosmab in serum over time|Immunogenicity as measured by Anti-drug antibodies (ADA) to garetosmab over time|Percent change from baseline in biomarkers of bone formation levels in serum","Regeneron Pharmaceuticals","All","18 Years to 60 Years   (Adult)","Phase 3","0","Industry","Interventional","Allocation: N/A|Intervention Model: Single Group Assignment|Masking: None (Open Label)|Primary Purpose: Treatment","R2477-FOP-1940","October 13, 2021","March 1, 2022","October 8, 2022","October 8, 2020",,"November 1, 2021",,,"https://ClinicalTrials.gov/show/NCT04577820"
126,"NCT04373083","Anti-PD-1 Antibody Treatment With Cemiplimab and Radiotherapy in Early-stage Classical Hodgkin Lymphoma",,"Withdrawn","No Results Available","Hodgkin Lymphoma","Drug: Cemiplimab|Radiation: Involved-site radiotherapy (IS-RT)","Progression-free survival (PFS) at 1 year|PFS at 2 and 3 years|Overall survival (OS) at 1, 2, and 3 years|Incidence of acute toxicities|Rate of patients with long-term fatigue using EORTC-QLQ-FA12|Rate of patients with long-term fatigue using EORTC-QLQ-C30|Quality of life (QoL) using EORTC-QLQ-30|Rate of early discontinuation of study treatment|Frequency of lymphoma treatment administered in addition to study treatment|Types of lymphoma treatment administered in addition to study treatment","Regeneron Pharmaceuticals|Sanofi","All","18 Years to 75 Years   (Adult, Older Adult)","Phase 2","0","Industry","Interventional","Allocation: Randomized|Intervention Model: Parallel Assignment|Masking: None (Open Label)|Primary Purpose: Treatment","R2810-ONC-1615|2017-004265-28","November 15, 2020","December 20, 2022","February 20, 2025","May 4, 2020",,"January 15, 2021",,,"https://ClinicalTrials.gov/show/NCT04373083"
127,"NCT04287621","Registry of Asthma Patients Initiating DUPIXENT®","RAPID","Recruiting","No Results Available","Asthma","Drug: DUPIXENT®","Demography|Baseline Characteristics|Baseline Treatment Characteristics|Incidence of adverse events (AEs)|Physician Assessment: - Spirometry|Physician Assessment: Fractional exhaled Nitric Oxide (FeNO)|Patient Reported Outcome: Asthma Control Questionnaire, 6-item (ACQ-6)|Patient Reported Outcome: Mini Asthma Quality of Life Questionnaire (MiniAQLQ)|Patient Reported Outcome: Global Patient Assessment|Patient Reported Outcome: Physical Activity Limitation Questionnaire (PALQ)|Patient Reported Outcome in patients with allergic rhinitis: Allergic Rhinitis Visual Analog Scale (AR-VAS)|Patient Reported Outcome in patients with allergic rhinitis: Standardized Rhinoconjunctivitis Quality of Life Questionnaire for patients 12 years of age and older (RQLQ[S]+12)|Patient Reported Outcome in patients with chronic (rhino) sinusitis and/or nasal polyps: Sino-Nasal Outcome Test (SNOT-22)|Patient Reported Outcome in patients with atopic dermatitis: Patient Oriented Eczema Measure (POEM)|Patient Reported Outcome: Work Productivity and Activity Impairment Questionnaire for asthma (WPAI-asthma)|Healthcare Utilization: Healthcare Resource Utilization Questionnaire (HCRUQ)","Regeneron Pharmaceuticals|Sanofi","All","12 Years and older   (Child, Adult, Older Adult)",,"1000","Industry","Observational","Observational Model: Cohort|Time Perspective: Prospective","R668-AS-1885|EUPAS41963","March 2, 2020","September 16, 2025","September 16, 2025","February 27, 2020",,"March 2, 2022","Clinical Research Center of Alabama, LLC, Birmingham, Alabama, United States|Arizona Allergy & Immunology Research, Gilbert, Arizona, United States|Medical Research of Arizona, a Division of Allergy, Asthma & Immunology Associates, Ltd., Scottsdale, Arizona, United States|Banner University of Arizona Medical Center, Tucson, Arizona, United States|Stuart Z. Epstein, MD, Beverly Hills, California, United States|Riviera Allergy Medical Center, Redondo Beach, California, United States|Sacramento ENT, Roseville, California, United States|Allergy & Asthma Medical Group and Research, A PC, San Diego, California, United States|Bensch Clinical Research, LLC, Stockton, California, United States|Allianz Research Institute, Inc., Westminster, California, United States|Waterbury Pulmonary Associates, Waterbury, Connecticut, United States|TOPAZ Clinical Research, Inc., Apopka, Florida, United States|Global Research Solutions, Hollywood, Florida, United States|Coral Way Research, LLC, Miami, Florida, United States|Rejuvaline Medical Research, Miami, Florida, United States|Care Research Center, Miami, Florida, United States|Palmetto Professional Research, Miami, Florida, United States|Kratz Allergy & Asthma, Port Richey, Florida, United States|GCP, Global Clinical Professionals, Saint Petersburg, Florida, United States|Allergy & Asthma Diagnostic Treatment Center, Tallahassee, Florida, United States|Emigent Research Center Inc, Tampa, Florida, United States|Georgia Pollens Clinical Research Centers, Inc., Albany, Georgia, United States|Columbus Regional Research Institute, Columbus, Georgia, United States|IACT Health Southeast Lung Associates, Rincon, Georgia, United States|Treasure Valley Medical Research, Boise, Idaho, United States|Northwestern Medical Group Allergy & Immunology Clinic, Chicago, Illinois, United States|NorthShore University Health System, Evanston, Illinois, United States|Asthma and Allergy Center of Chicago, Oak Park, Illinois, United States|Riley Hospital for Children at Indiana University Health, Indianapolis, Indiana, United States|Kansas City Allergy and Asthma Associates, PA, Overland Park, Kansas, United States|Dr. Henry J. Kanarek Allergy, Asthma & Immunology, Overland Park, Kansas, United States|Family Allergy and Asthma, Louisville, Kentucky, United States|Allergy & Asthma Specialists, PSC, Owensboro, Kentucky, United States|Institute for Asthma & Allergy, PC, Chevy Chase, Maryland, United States|Schreiber Allergy, Rockville, Maryland, United States|Virgo-Carter Pediatrics, Silver Spring, Maryland, United States|Registry of Asthma Patients Initiating DUPIXENT® (RAPID) Overview Study Properties Regions Compliance Tasks Forms Roles Submissions Attachments Import Version History Action History Messages Compare Edit Protocol Registration Form R668-AS-1885 Protocol R, White Marsh, Maryland, United States|University of Michigan, Ann Arbor, Michigan, United States|Oakland Medical Research, Troy, Michigan, United States|Allergy and Asthma Center of Minnesota, Maplewood, Minnesota, United States|ENT & Allergy Center of Missouri, Columbia, Missouri, United States|The Clinical Research Center, LLC, Saint Louis, Missouri, United States|Nebraska Medical Research Institute, Inc., Bellevue, Nebraska, United States|Ocean Allergy & Respiratory Research Center, Brick, New Jersey, United States|Montefiore Medical Center, Bronx, New York, United States|New York Allergy and Sinus Centers, Glendale, New York, United States|Northwell Health Division of Allergy & Immunology, Great Neck, New York, United States|RRH Allergy, Immunology & Rheumatology, Rochester, New York, United States|Allergy Partners of Western North Carolina, Asheville, North Carolina, United States|UNC Children's Hospital, Chapel Hill, North Carolina, United States|Javara Inc. and Tryon Medical Partners, PLLC, Charlotte, North Carolina, United States|Clinical Research Solutions, Middleburg Heights, Ohio, United States|Allergy, Asthma and Clinical Research Center, Oklahoma City, Oklahoma, United States|Oklahoma Institute of Allergy and Asthma Clinical Research, LLC, Oklahoma City, Oklahoma, United States|Vital Prospects Clinical Research Institute, PC, Tulsa, Oklahoma, United States|Portland Research, Happy Valley, Oregon, United States|Allergy and Asthma Specialists, P.C., Blue Bell, Pennsylvania, United States|Columbo Asthma, Allergy and Immunology, LLC, Bryn Mawr, Pennsylvania, United States|Asthma, Nasal Disease & Allergy Research Center of New England, East Providence, Rhode Island, United States|National Allergy and Asthma Research, LLC, North Charleston, South Carolina, United States|Medical Research South, LLC, Summerville, South Carolina, United States|Clinical Research Solutions, Jackson, Tennessee, United States|Clinical Research Solutions, Milan, Tennessee, United States|Orion Clinical Research, Austin, Texas, United States|Precision Research Institute, LLC, Houston, Texas, United States|STAAMP Research, LLC, San Antonio, Texas, United States|Element Research Group, San Antonio, Texas, United States|Sugar Land Allergy, Asthma, and Immunology Center, Sugar Land, Texas, United States|Tanner Clinic, Layton, Utah, United States|Suffolk Multispecialty Research David Ramstad & Associates, Suffolk, Virginia, United States|Seattle Allergy & Asthma Research Institute, Seattle, Washington, United States|Gundersen Health System, La Crosse, Wisconsin, United States|Sygehus Lillebaelt - Vejle Sygehus - Lungemedicinsk afdeling, Vejle, Denmark|Instituto Pulmonary Diseases Torre Medica San Lucas, Ponce, Puerto Rico|Rafael H Zaragoza - Urdaz, San Juan, Puerto Rico|Fundacion de Investigacion de Diego, San Juan, Puerto Rico|Fysikalisk Medicin, Lidingö, Stockholms Län [se-01], Sweden|Karolinska Universitetssjukhuset - Astrid Lindgrens barnsjukhus, Solna, Stockholms Län [se-01], Sweden",,"https://ClinicalTrials.gov/show/NCT04287621"
128,"NCT03972657","Study of REGN5678 (Anti-PSMAxCD28) With Cemiplimab (Anti-PD-1) in Patients With Metastatic Castration-resistant Prostate Cancer",,"Recruiting","No Results Available","Metastatic Castration-resistant Prostate Cancer","Drug: REGN5678|Drug: Cemiplimab|Other: 18F-DCFPyL","Incidence and severity of treatment-emergent adverse events (TEAEs)|Incidence and severity of adverse event of special interests (AESIs)|Incidence and severity of serious adverse events (SAEs)|Number of patients with grade ≥3 laboratory abnormalities|Incidence of dose-limiting toxicities (DLTs)|Concentration of REGN5678 in serum over time|Concentration of REGN5678 in combination with cemiplimab in serum over time|Objective response rate (ORR) per modified Prostate Cancer Working Group 3 (PCWG3) criteria|ORR per modified PCWG3 criteria|Incidence and severity of TEAEs|Incidence and severity of AESIs|Incidence and severity of SAEs|ORR based upon prostate specific antigen (PSA) response|Percentage of patients with ≥90% decline of PSA|Percentage of patients who have achieved conversion of circulating tumor cell (CTC) count from baseline of ≥5 cells/7.5mL to <5 cells/7.5mL|Presence or absence of antibodies against REGN5678|Presence or absence of antibodies against cemiplimab","Regeneron Pharmaceuticals","Male","18 Years and older   (Adult, Older Adult)","Phase 1|Phase 2","129","Industry","Interventional","Allocation: Non-Randomized|Intervention Model: Parallel Assignment|Masking: None (Open Label)|Primary Purpose: Treatment","R5678-ONC-1879|2019-000658-71","August 12, 2019","June 28, 2023","July 16, 2024","June 3, 2019",,"February 8, 2022","Sarah Cannon Research Institute at HealthONE, Denver, Colorado, United States|Moffitt Cancer Center, Tampa, Florida, United States|Laura & Isaac Perlmutter Cancer Center at NYU Langone Health, New York, New York, United States|Icahn School of Medicine at Mount Sinai, New York, New York, United States|Columbia University Medical Center, New York, New York, United States|Providence Cancer Institute Franz Clinic, Portland, Oregon, United States|Thomas Jefferson University, Sidney Kimmel Cancer Center, Clinical Research Organization, Philadelphia, Pennsylvania, United States",,"https://ClinicalTrials.gov/show/NCT03972657"
129,"NCT03916627","Neoadjuvant Cemiplimab for the Treatment of Resectable NSCLC, HCC, and HNSCC",,"Recruiting","No Results Available","Non-small Cell Lung Cancer|Hepatocellular Carcinoma|Head and Neck Squamous Cell Carcinoma","Drug: cemiplimab|Drug: Platinum Doublet","Major pathologic response (MPR) at time of surgery for the NSCLC cohorts|Significant tumor necrosis (STN) at time of surgery is the primary endpoint for the HCC cohorts|Major treatment effect (MTE) at time of surgery is the primary endpoint for the HNSCC cohort|Delay to surgery|Event-free survival (EFS)|Disease-free survival (DFS)|Overall response rate (ORR)|Overall survival (OS)|OS rate|Incidence of treatment emergent adverse events (TEAEs)|Incidence of irAEs|Incidence of SAEs|Incidence of deaths|Incidence of laboratory abnormalities|Change in tumor-infiltrating CD8 T-cell density","Regeneron Pharmaceuticals|Sanofi","All","18 Years and older   (Adult, Older Adult)","Phase 2","88","Industry","Interventional","Allocation: Randomized|Intervention Model: Parallel Assignment|Masking: None (Open Label)|Primary Purpose: Treatment","R2810-ONC-1866","July 23, 2019","July 15, 2024","September 3, 2029","April 16, 2019",,"December 8, 2021","Icahn School of Medicine at Mount Sinai, New York, New York, United States",,"https://ClinicalTrials.gov/show/NCT03916627"
130,"NCT03761108","First in Human (FIH) Study of REGN5458 in Patients With Relapsed or Refractory Multiple Myeloma",,"Recruiting","No Results Available","Multiple Myeloma","Drug: REGN5458","Incidence of dose-limiting toxicities (DLTs) from the first dose through the end of the DLT observation period|Incidence and severity of treatment-emergent adverse events (TEAEs)|Incidence and severity of adverse events of special interest (AESIs)|Objective response rate (ORR) as measured using the International Myeloma Working Group (IMWG) criteria|Concentrations of REGN5458 in the serum over time|Incidence over time of anti-drug antibodies (ADAs) to REGN5458|Duration of response (DOR) using the IMWG criteria|Progression-free survival (PFS) as measured using the IMWG criteria|Rate of minimal residual disease (MRD) negative status using the IMWG criteria|Overall survival (OS)|ORR as measured using the IMWG criteria|Effects of REGN5458 on HRQOL and patient-reported symptoms and functioning per European Organization for Research and Treatment of Cancer Quality of Life Questionnaire (EORTC QLQ-C30)|Effects of REGN5458 on HRQOL and patient-reported symptoms and functioning per Quality of Life Questionnaire-Multiple Myeloma module 20 [QLQ-MY20])|Effects of REGN5458 on HRQOL and patient-reported symptoms and functioning per EuroQoL-5 Dimension-3 Level Scale [EQ-5D-3L])|Change in patient-reported global health status/QoL per EORTC QLQ-C30|Time to definitive deterioration in patient-reported global health status/QoL per EORTC QLQ-C30|Effects of REGN5458 on general health status per EQ-5D-3L|Effects of REGN5458 on patient-reported functions and symptoms per EORTC QLQ-C30|Effects of REGN5458 on patient-reported functions and symptoms per QLQ-MY20|Incidence and severity of TEAEs with REGN5458|Incidence and severity of AESIs with REGN5458","Regeneron Pharmaceuticals","All","18 Years and older   (Adult, Older Adult)","Phase 1|Phase 2","292","Industry","Interventional","Allocation: N/A|Intervention Model: Sequential Assignment|Masking: None (Open Label)|Primary Purpose: Treatment","R5458-ONC-1826|2018-003188-78","January 23, 2019","May 1, 2025","May 1, 2025","December 3, 2018",,"March 2, 2022","University of Miami Hospital/Sylvester Comprehensive, Miami, Florida, United States|Moffitt Cancer Center, Tampa, Florida, United States|Winship Cancer Institute of Emory University, Atlanta, Georgia, United States|Indiana University Melvin and Bren Simon Comprehensive Cancer Center, Indianapolis, Indiana, United States|Norton Cancer Institute, Louisville, Kentucky, United States|University of Michigan Health System, Ann Arbor, Michigan, United States|Barbara Ann Karmanos Cancer Institute, Detroit, Michigan, United States|Rutgers Cancer Institute of New Jersey, New Brunswick, New Jersey, United States|The Icahn School of Medicine at Mount Sinai, New York, New York, United States|Columbia University Medical Center, Herbert Irving Pavilion, New York, New York, United States|The Ohio State University, James Cancer Hospital, Columbus, Ohio, United States|University of Texas MD Anderson Clinic, Houston, Texas, United States|Swedish Cancer Institute, Seattle, Washington, United States|Ziekenhuis Netwerk Antwerpen (ZNA)- Stuivenberg, Antwerp, Belgium|Cliniques Universitaires Saint-Luc, Brussels, Belgium|Universitaetsklinikum Essen, Essen, Germany|University Medicine Mainz, Mainz, Germany|Soul National University Hospital, Jongno-gu, Seoul, Korea, Republic of|Seoul St.Mary's Hospital, The Catholic University of Korea, Seocho-gu, Seoul, Korea, Republic of|Severance Hospital, Yonsei University Health System, Seodaemun-gu, Seoul, Korea, Republic of",,"https://ClinicalTrials.gov/show/NCT03761108"
131,"NCT03710941","Safety and Efficacy of REGN2477+REGN1033 in Patients With Sporadic Inclusion Body Myositis",,"Withdrawn","No Results Available","Sporadic Inclusion Body Myositis","Drug: REGN2477+REGN1033|Drug: Matching placebo","Percent change in total lean mass as measured by dual-energy X-ray absorptiometry (DXA)|Change in the Inclusion Body Myositis-Functional Rating Scale (IBM-FRS)|Change in the Sporadic inclusion body myositis (sIBM) Physical Functioning Assessment (sIFA)|Incidence and severity of treatment-emergent adverse events (TEAEs)|Percent change in total and regional body composition (including lean mass and fat mass) as measured by DXA|Absolute change in total and regional body composition (including lean mass and fat mass) as measured by DXA|Change in the 1-repetition maximum (1-RM) chest press strength|Change in hand-grip strength as measured by dynamometry|Change in distance walked in the 6-minute walk test (6MWT)|Change in time to complete the 10-meter walk test (10MWT)|Change in instrumented stair climb power|Change in instrumented, sensor-based sit-to-stand test time|Change in fear of falling as measured via the Falls Efficacy Scale-International (FES-I)|Change in Patient Global Impression of Severity assessments (PGIS/PGIC)|Change in Patient Global Impression of Change Items assessments (PGIS/PGIC)|Change in Clinician Global Impression of Severity assessments (CGIS/CGIC)|Change in Clinician Global Impression of Change Items assessments (CGIS/CGIC)|Change in 36-item Short Form Health Survey (SF-36), including the Physical Function Items (PF-10) and the Vitality Scale of the SF-36|Change in Thigh muscle volume as measured by MRI (sub-study)|Frequency of falls and near-falls as measured by the Hopkins Falls Grading Scale|Pharmacokinetics (PK) profile of REGN2477|Pharmacokinetics (PK) profile of REGN1033|Immunogenicity of REGN2477+REGN1033","Regeneron Pharmaceuticals","All","45 Years to 75 Years   (Adult, Older Adult)","Phase 2","0","Industry","Interventional","Allocation: Randomized|Intervention Model: Parallel Assignment|Masking: Quadruple (Participant, Care Provider, Investigator, Outcomes Assessor)|Primary Purpose: Treatment","R2477-1033-sIBM-1828|2018-002853-31","February 19, 2019","August 27, 2020","November 5, 2020","October 18, 2018",,"April 29, 2019",,,"https://ClinicalTrials.gov/show/NCT03710941"
132,"NCT03690869","REGN2810 in Pediatric Patients With Relapsed, Refractory Solid, or Central Nervous System (CNS) Tumors and Safety and Efficacy of REGN2810 in Combination With Radiotherapy in Pediatric Patients With Newly Diagnosed or Recurrent Glioma",,"Recruiting","No Results Available","Relapsed Solid Tumor|Refractory Solid Tumor|Relapsed Central Nervous System Tumor|Refractory Central Nervous System Tumor|Diffuse Intrinsic Pontine Glioma|High Grade Glioma","Drug: cemiplimab (monotherapy)|Drug: cemiplimab (maintenance)|Radiation: Conventional or hypofractionated|Radiation: Re-irradiation","Incidence and severity of treatment-emergent adverse events (TEAEs)|Incidence and severity of immune-related adverse events (irAEs)|Incidence and severity of adverse events of special interest (AESIs)|Incidence and severity of serious adverse events (SAEs)|Incidence of deaths|Incidence of laboratory abnormalities|Incidence of dose limiting toxicities (DLTs)|PK for REGN2810 estimated Observed terminal half-life (t1/2)|PK for REGN2810 Concentration at end of infusion (Ceoi)|PK for REGN2810 Area under the curve (AUC2w)|Overall survival among newly diagnosed DIPG and recurrent HGG patients|Progression-free survival among newly diagnosed HGG patients|Objective response rate (ORR)|Incidence of anti-drug antibodies (ADA) to REGN2810 given as monotherapy|Incidence of anti-drug antibodies (ADA) to REGN2810 given in combination with radiation","Regeneron Pharmaceuticals|Pacific Pediatric Neuro-Oncology Consortium","All","up to 25 Years   (Child, Adult)","Phase 1|Phase 2","130","Industry|Other","Interventional","Allocation: Randomized|Intervention Model: Parallel Assignment|Masking: None (Open Label)|Primary Purpose: Treatment","R2810-ONC-1690|PNOC 013 (CC#160825)","October 3, 2018","November 20, 2024","November 20, 2024","October 1, 2018",,"February 11, 2022","Children's Hospital Los Angeles (CHLA), Los Angeles, California, United States|Rady Children's Hospital, San Diego, California, United States|UCSF Benioff Children's Hospital, San Francisco, California, United States|Children's National Health System (Children's National Medical Center), Washington, District of Columbia, United States|University of Florida- Neurosurgery, Gainesville, Florida, United States|Ann & Robert H. Lurie Children's Hospital of Chicago, Chicago, Illinois, United States|Johns Hopkins - Pediatric Oncology, Baltimore, Maryland, United States|Massachusetts General Hospital, Boston, Massachusetts, United States|Dana Farber Cancer Institute/ Boston Children's Hospital, Boston, Massachusetts, United States|C. S. Mott/University of Michigan, Ann Arbor, Michigan, United States|Children's Hospitals and Clinics of Minnesota, Minneapolis, Minnesota, United States|University of Minnesota / Masonic Cancer Center, Minneapolis, Minnesota, United States|Washington University School of Medicine, Saint Louis, Missouri, United States|Nationwide Children's Hospital, Columbus, Ohio, United States|Oregon Health & Science University (OHSU) - Doernbecher Children's Hospital, Portland, Oregon, United States|The Children's Hospital of Philadelphia, Philadelphia, Pennsylvania, United States|St. Jude Children's Research Hospital, Memphis, Tennessee, United States|Texas Children's Cancer & Hematology Centers Baylor College of Medicine, Houston, Texas, United States|University of Utah, Salt Lake City, Utah, United States|Seattle Children's Hospital, Seattle, Washington, United States",,"https://ClinicalTrials.gov/show/NCT03690869"
133,"NCT03576690","R3470-3471-3479 (REGN-EB3) Expanded Access Protocol (EAP) for Treatment of Ebola Virus",,"Available","No Results Available","Ebola Virus Disease","Biological: REGN3470-3471-3479",,"Regeneron Pharmaceuticals","All","Child, Adult, Older Adult",,,"Industry","Expanded Access:Individual Patients",,"R3470-3471-3479-EBOV-1846",,,,"July 3, 2018",,"March 5, 2021",,,"https://ClinicalTrials.gov/show/NCT03576690"
134,"NCT03492489","Expanded Access Protocol for Cemiplimab in Metastatic or Locally Advanced Cutaneous Squamous Cell Carcinoma",,"No longer available","No Results Available","Cutaneous Squamous Cell Carcinoma","Drug: cemiplimab",,"Regeneron Pharmaceuticals|Sanofi","All","18 Years and older   (Adult, Older Adult)",,,"Industry","Expanded Access:Intermediate-size Population|Treatment IND/Protocol",,"R2810-ONC-17103",,,,"April 10, 2018",,"August 1, 2019",,,"https://ClinicalTrials.gov/show/NCT03492489"
135,"NCT03304379","Study to Determine the Safety and the Efficacy of Fasinumab Compared to Placebo and Nonsteroidal Anti-inflammatory Drugs (NSAIDs) for Treatment of Adults With Pain From Osteoarthritis of the Knee or Hip","FACT OA2","Completed","No Results Available","Osteoarthritis, Knee|Osteoarthritis, Hip","Drug: Fasinumab|Other: Diclofenac|Other: Celecoxib|Drug: Matching placebo","Change in the Western Ontario and McMaster Universities Osteoarthritis Index (WOMAC) pain subscale scores from baseline to week 24 in patients treated with fasinumab compared to patients treated with placebo.|Change in the WOMAC physical function subscale scores from baseline to week 24 in patients treated with fasinumab compared to patients treated with placebo.|Change from baseline to week 24 in Patient Global Assessment (PGA) in patients treated with fasinumab compared to patients treated with placebo|Percentage of patients treated with fasinumab, compared to patients treated with placebo, who had a response at week 24, with response defined as an improvement by ≥30% in WOMAC pain sub scale score|Change from baseline to week 24 in WOMAC pain subscale scores in patients treated with fasinumab compared to patients treated with NSAIDs (pooled celecoxib and diclofenac arms)|Change from baseline to week 24 in WOMAC physical function subscale scores in patients treated with fasinumab compared to patients treated with NSAIDs (pooled celecoxib and diclofenac arms)|Change from baseline to week 24 in PGA score in patients treated with fasinumab compared to patients treated with NSAIDs (pooled celecoxib and diclofenac arms)|Incidence of adjudicated arthropathy (AA) (as confirmed by independent adjudication)|Incidence of destructive arthropathy (DA) (as confirmed by independent adjudication)|Incidence of Treatment Emergent Adverse Events (TEAEs)|Incidence of sympathetic nervous system dysfunction (as diagnosed after consultation with an appropriate specialist, such as a neurologist and/or cardiologist)|Incidence of peripheral sensory Adverse Events (AEs) that require a neurology consultation|Incidence of all-cause joint replacements (JRs) through week 24|Incidence of all-cause JRs through week 44|Incidence of JR at telephone survey","Regeneron Pharmaceuticals|Teva Pharmaceutical Industries, Ltd.","All","18 Years and older   (Adult, Older Adult)","Phase 3","1650","Industry","Interventional","Allocation: Randomized|Intervention Model: Parallel Assignment|Masking: Triple (Participant, Investigator, Outcomes Assessor)|Primary Purpose: Treatment","R475-OA-1688|2017-001702-15","October 26, 2017","December 13, 2019","November 9, 2020","October 9, 2017",,"December 17, 2020","Pinnacle Research Group, Llc, Anniston, Alabama, United States|Horizon Research Partners, Mobile, Alabama, United States|Clinical Research Advantage, Inc./Warner Family Practice, PC, Chandler, Arizona, United States|Synexus Central Phoenix Medical Clinic, Phoenix, Arizona, United States|Clinical Research Consortium Arizona, Tempe, Arizona, United States|Advance Research Center, Anaheim, California, United States|TriWest Research Associates, LLC, El Cajon, California, United States|Paragon Rx Clinical Research, Inc., Garden Grove, California, United States|Catalina Research Institute, LLC, Montclair, California, United States|Sierra Clinical Research, Roseville, California, United States|UC Davis Center for Musculoskeletal Health, Sacramento, California, United States|Advanced Research Center, Inc, San Diego, California, United States|California Research Foundation, San Diego, California, United States|Paragon Rx Clinical Research, Inc, Santa Ana, California, United States|Encompass Clinical Research, Spring Valley, California, United States|Westlake Medical Research, Thousand Oaks, California, United States|Synexus Clinical Research US, Inc., Vista, California, United States|Mountain View Clinical Research, Denver, Colorado, United States|New England Research Associates, LLC, Bridgeport, Connecticut, United States|CRM of Greater New Haven, LLC, Hamden, Connecticut, United States|Stamford Therapeutics Consortium, Stamford, Connecticut, United States|Avail Clinical Research, LLC, DeLand, Florida, United States|Lakes Research, LLC, Miami Lakes, Florida, United States|AMB Research Center, Inc, Miami, Florida, United States|Allied Biomedical Research Institute, Miami, Florida, United States|Bioclinica Research, Orlando, Florida, United States|Gulf Region Clinical Research institute, Pensacola, Florida, United States|Integral Rheumatology & Immunology Specialists (IRIS), Plantation, Florida, United States|Progressive Medical Research, Port Orange, Florida, United States|Drug Studies America, Marietta, Georgia, United States|Georgia Institute For Clinical Research LLC, Marietta, Georgia, United States|North Georgia Clinical Research, Woodstock, Georgia, United States|Chicago Clinical Research Institute, Inc, Chicago, Illinois, United States|Affinity Clinical Research Institute, Oak Lawn, Illinois, United States|Clinical Research Advantage, Inc., Evansville, Indiana, United States|MediSphere Medical Research Center, LLC, Evansville, Indiana, United States|L-MARC Research Center, Louisville, Kentucky, United States|Tandem Clinical Research, Marrero, Louisiana, United States|Tufts Medical Center, Inc., Boston, Massachusetts, United States|Great Lakes Research Group, Inc., Bay City, Michigan, United States|Onyx Clinical Research, Caro, Michigan, United States|Synexus Clinical Research US, Inc., Richfield, Minnesota, United States|Skyline Medical Center /Radiant Research, Inc., Elkhorn, Nebraska, United States|Meridian Clinical Research Associates, LLC, Omaha, Nebraska, United States|Robert Kaplan, D.O., Las Vegas, Nevada, United States|Amici Clinical Research, LLC, Raritan, New Jersey, United States|Albuquerque Clinical Trials, Inc., Albuquerque, New Mexico, United States|Drug Trial Brooklyn, Brooklyn, New York, United States|Northwell Health, Great Neck, New York, United States|Drug Trials America, Hartsdale, New York, United States|Upstate Clinical Research Associates, LLC, Williamsville, New York, United States|Carolina Research Center, Shelby, North Carolina, United States|PMG Research of Wilmington LLC, Wilmington, North Carolina, United States|The Center For Clinical Research, Winston-Salem, North Carolina, United States|New Horizons Clinical Research, Cincinnati, Ohio, United States|Aventiv Research Inc, Columbus, Ohio, United States|DOC Clinical Research, Dayton, Ohio, United States|Center for Orthopaedics and Sports Medicine, Indiana, Pennsylvania, United States|Radiant Research, Inc., Anderson, South Carolina, United States|Piedmont Comprehensive Pain Management Group, Greenville, South Carolina, United States|Radiant Research, Inc., Greer, South Carolina, United States|Piedmont Research Partners, LLC, Indian Land, South Carolina, United States|Coastal Carolina Research Center at LowCountry Orthopaedics, North Charleston, South Carolina, United States|ACME Research, LLC, Orangeburg, South Carolina, United States|Office of Dr.Ramesh C. Gupta MD, Memphis, Tennessee, United States|West Texas Clinical Research, Lubbock, Texas, United States|Clinical Investigations Of Texas, Plano, Texas, United States|Synexus USA, Plano, Texas, United States|Charlottesville Medical Research Center LLC, Charlottesville, Virginia, United States|Health Research of Hampton Roads, Inc, Newport News, Virginia, United States|Spokane Joint Replacement Center, Spokane, Washington, United States",,"https://ClinicalTrials.gov/show/NCT03304379"
136,"NCT03257267","Study of Cemiplimab in Adults With Cervical Cancer",,"Active, not recruiting","No Results Available","Squamous Cell Carcinoma (SCC)|Recurrent or Metastatic, Platinum-refractory Cervical Cancer","Drug: Cemiplimab|Drug: Investigator Choice (IC) Chemotherapy","Overall survival (OS)|Progression-free survival (PFS)|Objective Response Rate (ORR)|Duration of response (DOR)|Quality of life (QOL)|Incidence of Treatment-Emergent Adverse Events (TEAEs) [Safety and Tolerability]","Regeneron Pharmaceuticals|Sanofi","Female","18 Years and older   (Adult, Older Adult)","Phase 3","608","Industry","Interventional","Allocation: Randomized|Intervention Model: Parallel Assignment|Masking: None (Open Label)|Primary Purpose: Treatment","R2810-ONC-1676|2017-000350-19","September 5, 2017","March 15, 2021","July 9, 2023","August 22, 2017",,"November 19, 2021","Arizona Oncology Associates, Phoenix, Arizona, United States|Arizona Oncology Associates, Tucson, Arizona, United States|University of California Irvine, Orange, California, United States|Ochsner Clinic Foundation, New Orleans, Louisiana, United States|Cancer Research for the Ozarks, Springfield, Missouri, United States|New York Presbyterian Queens, Flushing, New York, United States|Northwell Health, Lake Success, New York, United States|Laura and Issac Perlmutter Cancer Center at NYU Langone, New York, New York, United States|First Health of the Carolinas Outpatient Cancer Center, Pinehurst, North Carolina, United States|Thomas Jefferson University Hospital, Philadelphia, Pennsylvania, United States|Texas Oncology, P.A., Austin, Texas, United States|St. George Hospital, Kogarah, New South Wales, Australia|Northern NSW Health District, The Tweed Hospital, Tweed Heads, New South Wales, Australia|Royal Brisbane & Women's Hospital, Herston, Queensland, Australia|Peter MacCallum Cancer Centre, Melbourne, Victoria, Australia|Sir Charles Gairdner Hospital, Nedlands, Western Australia, Australia|St. John of God Subiaco Hospital, Subiaco, Western Australia, Australia|OLV ziekenhuis Aalst, Medische oncologie- Radiotherapie, Aalst, Belgium|Institut Bordet, Brussels, Belgium|Cliniques universitaires Saint-Luc, Bruxelles, Belgium|UZLeuven Gynaelologic Oncology, Leuven, Belgium|CHC Saint Joseph, Liège, Belgium|CHU Liège, Liège, Belgium|CHU UCL Namur site Sainte Elisabeth, Namur, Belgium|Liga Norte Riograndense Contra o Câncer, Natal, Rio Grande Do Norte, Brazil|Hosptial Sao Lucas da PUC de Porto Alegre, Porto Alegre, Rio Grande Do Sul, Brazil|Irmandade da Santa Casa de Misericórdia de Porto Alegre, Porto Alegre, Rio Grande Do Sul, Brazil|Centro de Novos Tratamentos Itajai, Itajai, Santa Catarina, Brazil|Fundação Pio XII - Hospital de Câncer de Barretos, Barretos, São Paulo, Brazil|Instituto de Pesquisas Clinicas para Estudos Multicentricos - IPCEM, Caxias do Sul, Brazil|Instituto Nacional de Cancer - INCA, Rio de Janeiro, Brazil|Instituto COI de Pesquisa, Rio de Janeiro, Brazil|Tom Baker Cancer Center, Calgary, Alberta, Canada|British Columbia Cancer Agency, Vancouver, British Columbia, Canada|London Health Sciences Centre, London, Ontario, Canada|Princess Margaret Cancer Centre, Toronto, Ontario, Canada|Hospital Maisonneuve-Rosemont, Montreal, Quebec, Canada|Hopital Notre-Dame du Centre Hospitalier de l'Universite de Montreal, Montréal, Quebec, Canada|Jewish General Hospital, Montréal, Quebec, Canada|General Hospital of Athens Alexandra, Athens, Greece|University Hospital of Ioannina, Ioannina, Greece|General Hospital of Patras, Patras, Greece|Euromedica General Clinic, B'Oncology Clinic, Thessaloniki, Greece|Azienda Ospedaliero Universitaria di Bologna, Bologna, Italy|U.O Oncologia Medica P.O Vito Fazzi, Lecce, Italy|Asst Lecco, Lecco, Italy|Irst Irccs, Meldola, Italy|Istituto Europeo di Oncologia, Milano, Italy|AUSL, IRCCS di Reggio Emilia, Reggio Emilia, Italy|Fondazione Policlinico Agostino Gemelli IRCCS di Roma, Roma, Italy|Regina Elena National Cancer Institute, Rome, Italy|Shikoku Cancer Center, Matsuyama, Ehime, Japan|Ehime University Hospital, Toon, Ehime, Japan|Fukui University Hospital, Yoshida-gun, Fukui, Japan|Kurume University Hospital, Kurume, Fukuoka, Japan|Hokkaido University Hospital, Sapporo, Hokkaido, Japan|St. Marianna University School of Medicine Hospital, Kawasaki, Kanagawa, Japan|University of the Ryukyus Hospital, Nakagami-gun, Okinawa, Japan|Saitama Medical University, Saitama, Saitama Prefecture, Japan|National Cancer Center Hospital, Chuo-ku, Tokyo, Japan|The Cancer Institute Hospital of JFCR, Koto-Ku, Tokyo, Japan|Kyorin University Hospital, Mitaka, Tokyo, Japan|Saitama Cancer Center, Saitama, Tokyo, Japan|National Kyushu Cancer Center, Fukuoka, Japan|Kagoshima City Hospital, Kagoshima, Japan|National Cancer Center, Goyang-si, Gyeonggi-do, Korea, Republic of|Keimyung University Dongsan Medical Center, Daegu, Korea, Republic of|Seoul National University Hospital, Seoul, Korea, Republic of|Asan Medical Center, Seoul, Korea, Republic of|Gangnam Severance Hospital, Seoul, Korea, Republic of|Korea University Guro Hospital, Seoul, Korea, Republic of|Bialostockie Centrum Onkologii, Białystok, Poland|Szpitale Pomorskie, Gdynia, Poland|Center and Institute of Oncology Gliwice, Gliwice, Poland|Centrum Onkologii Ziemi Lubelskiej im sw. Jana z Dukli, Lublin, Poland|Greater Poland Cancer Center, Poznań, Poland|Regional Budgetary Institution of Healthcare Ivanovo Regional Oncology Dispensary, Ivanovo, Ivanovo Region, Russian Federation|State Budgetary Healthcare Institution ""Oncology Dispensary"" of Ministry of Healthcare of the Kabardino-Balkarian Republic, Nal'chik, Kabardino-Balkarian, Russian Federation|A. Tsyb Medical Radiological Research Center, Obninsk, Kaluga, Russian Federation|State Budgetary Institution of Healthcare, Clinical Oncology Dispensary #1 of Ministry of Health of Krasnodar Region, Krasnodar, Krasnodar Territory, Russian Federation|State Budgetary Healthcare Institution Leningrad Regional Oncological Dispensary (SBHI ""LROD""), Vsevolozhsk, Leningrad Region, Russian Federation|State Autonomous Healthcare Institution ,Republican Clinical Oncological Dispensary of the Ministry of Healthcare of the Tatarstan Republic, Kazan, Tatarstan, Russian Federation|Budgetary Institution of Healthcare of Omsk region Clinical Oncology Dispensary, Omsk, Russian Federation|State Budgetary Institution of Healthcare ""Orenburg Regional Clinical Oncology Dispensary"", Orenburg, Russian Federation|Saint- Petersburg State Budgetary institution of Healthcare ""City Clinical Oncological Dispensary"", Saint Petersburg, Russian Federation|Hospital Universitario Son Espases, Palma de Mallorca, Illes Balears, Spain|Vall d´Hebron University Hospital, Barcelona, Spain|Hospital Reina Sofia, Cordoba, Spain|Instituto Catalan de Oncologia de Gerona, Girona, Spain|Hospital Ramon y Cajal, Madrid, Spain|Hospital Universitario HM Sanchinarro CIOCC, Madrid, Spain|Hospital Virgen de la Victoria, Malaga, Spain|Fundacion Instituto Valenciano de Oncologia, Valencia, Spain|Hospital Universitario La Fe, Valencia, Spain|Hospital Clinico Universitario Lozano Blesa, Zaragoza, Spain|Taichung Veterans General Hospital, Taichung, Taiwan|MacKay Memorial Hospital, Taipei City, Taiwan|Koo-Foundation Sun Yat-Sen Cancer Center, Taipei, Taiwan|Taipei Veterans General Hospital, Taipei, Taiwan|Velindre Cancer Centre, Cardiff, United Kingdom|NHS Greater Glasgow and Clyde Beatson, West of Scotland Cancer care, Glasgow, United Kingdom|University College Hospital, London, United Kingdom|Royal Marsden NHS Foundation Trust, Chelsea, London, United Kingdom|Nottingham University Hospitals NHS Trust, Nottingham, United Kingdom|Royal Marsden NHS Foundation Trust, Sutton, Sutton, United Kingdom",,"https://ClinicalTrials.gov/show/NCT03257267"
137,"NCT03233139","Safety and Pharmacokinetics of REGN2810 (Cemiplimab) (Anti-PD-1) in Japanese Patients With Advanced Malignancies",,"Recruiting","No Results Available","Advanced Malignancies","Drug: Cemiplimab|Drug: Ipilimumab|Drug: Platinum-doublet chemotherapy","Incidence and severity of treatment-emergent adverse events (TEAEs) in patients treated with cemiplimab|PK of cemiplimab: Cmax|PK of cemiplimab: tmax|PK of cemiplimab: Ctrough|PK of cemiplimab: Area under the drug concentration-time curve in serum AUC3w|PK of cemiplimab: t½ estimated over a 3-week dosing interval|Immunogenicity against cemiplimab|Objective Response Rate (ORR)|Duration of Response (DOR)","Regeneron Pharmaceuticals","All","20 Years and older   (Adult, Older Adult)","Phase 1","117","Industry","Interventional","Allocation: Non-Randomized|Intervention Model: Sequential Assignment|Masking: None (Open Label)|Primary Purpose: Treatment","R2810-ONC-1622","June 21, 2017","May 24, 2026","May 24, 2026","July 28, 2017",,"January 24, 2022","Nagoya Medical Center, Nagoya, Aichi, Japan|Kurume University Hospital, Kurume, Fukuoka, Japan|Kobe City Medical Center General Hospital, Kobe, Hyogo, Japan|Kanazawa University Hospital, Kanazawa, Ishikawa, Japan|Kitasato University Hospital, Sagamihara, Kanagawa, Japan|Kanagawa Cardiovascular and Respiratory Center, Yokohama, Kanagawa, Japan|Kanagawa Cancer Center, Yokohama, Kanagawa, Japan|Sasebo City General Hospital, Sasebo, Nagasaki, Japan|Kurashiki Central Hospital, Kurashiki, Okayama, Japan|Kansai Medical University Hospital, Hirakata, Osaka, Japan|Kinki-Chuo Chest Medical Center, Sakai, Osaka, Japan|Osaka Medical College Hospital, Takatsuki, Osaka, Japan|Saitama Cancer Center, Kita Adachi, Saitama, Japan|National Cancer Center Hospital, Cho-Ku, Tokyo, Japan|Tokyo Medical University Hospital, Shinjuku, Tokyo, Japan|Gunma Prefectural Cancer Center, Gunma, Japan|Hiroshima City Hiroshima Citizens Hospital, Hiroshima, Japan|Nagasaki University Hospital, Nagasaki, Japan|Osaka International Cancer Center, Osaka, Japan|Osaka City University Hospital, Osaka, Japan|Tokushima University Hospital, Tokushima, Japan",,"https://ClinicalTrials.gov/show/NCT03233139"
138,"NCT03198130","An Exploratory Tumor Biopsy-driven Study to Understand the Relationship Between Biomarkers and Clinical Response in Patients With Head and Neck Cancer Receiving REGN2810 (Anti-PD-1)",,"Completed","No Results Available","Recurrent Squamous Cell Carcinoma of Head|Recurrent Squamous Cell Carcinoma of Neck|Metastatic Squamous Cell Carcinoma of Head|Metastatic Squamous Cell Carcinoma Neck","Drug: REGN2810","Correlation between changes in the tumor microenvironment and the change in tumor volume following REGN2810 treatment versus baseline.|Correlation between baseline tumor characteristics and the change in tumor volume following REGN2810 treatment|Number of participants with treatment-related adverse events|Concentrations of REGN2810 in serum|Anti-REGN2810 antibody levels|The overall response rate (ORR) in patients treated with REGN2810|The progression-free survival (PFS) in patients treated with REGN2810","Regeneron Pharmaceuticals|Sanofi","All","18 Years and older   (Adult, Older Adult)","Phase 1","33","Industry","Interventional","Allocation: N/A|Intervention Model: Single Group Assignment|Masking: None (Open Label)|Primary Purpose: Treatment","R2810-ONC-1655|2016-004029-18","July 3, 2017","June 27, 2019","February 21, 2020","June 23, 2017",,"March 19, 2020","Seoul National University, Seoul, Korea, Republic of|Yonsei University College of Medicine, Severence Hospital, Seoul, Korea, Republic of|Samsung Medical Center, Seoul, Korea, Republic of|University Birmingham, Birmingham, United Kingdom|Guy's and St. Thomas' NHS Foundation Trust, London, United Kingdom|Royal Cancer Hospital, London, United Kingdom",,"https://ClinicalTrials.gov/show/NCT03198130"
139,"NCT03188666","A Study to Examine the Safety, Tolerability and Effects on Abnormal Bone Formation of REGN2477 in Patients With Fibrodysplasia Ossificans Progressiva","LUMINA-1","Completed","No Results Available","Fibrodysplasia Ossificans Progressiva","Drug: REGN2477|Drug: Matching placebo","Incidence and severity of treatment-emergent adverse events (TEAEs) through the end of the Period 1|Time-weighted average (standardized AUC) of the percent change in total lesion activity by18F-NaF positron emission tomography (PET) using Baseline-Active HO (AHO)|Percent change in the total volume of HO lesions as assessed by computed tomography (CT) using AHO|Time-weighted average (standardized area under the curve [AUC]) of the percent change in total lesion activity by 18F-NaF PET using Baseline-Active HO Classic Mutation using AHOC|Percent change in the total volume of HO lesions as assessed by CT using AHOC|Number of new HO lesions as assessed by CT|Time-weighted average (standardized AUC) of the change in daily pain due to FOP, as measured using the daily numeric rating scale (NRS) using AHO|Time-weighted average (standardized AUC) of the change from baseline in daily pain due to FOP, as measured using the daily NRS using AHOC|Percent change in 18F-NaF SUVmax of individual active HO site(s) by PET using AHOC|Percent change in 18F-NaF SUVmax of individual active HO site(s) by PET using AHO|Change in number of HO lesions as assessed by 18F-NaF PET using AHOC|Change in number of HO lesions as assessed by 18F-NaF PET using AHO|Change in number of HO lesions as assessed by 18F-NaF PET using Full Analysis Set (FAS)|Change in number of HO lesions detectable by CT using AHOC|Change in number of HO lesions detectable by CT using AHO|Change in number of HO lesions detectable by CT using FAS|Percent change in total lesion activity by 18F-NaF PET versus the same patients between baseline and week 28 using AHO|Percent change in the total volume of HO lesions as assessed by CT versus the same patients between baseline and week 28 using AHO|Change in number of HO lesions by 18F-NaF PET versus the same patients between baseline and week 28 using AHO|Change in number of HO lesions by CT versus the same patients between baseline and week 28 using AHO|Percent change from baseline in total lesion activity by 18F-NaF PET using AHO|Percent change from baseline in the total volume of HO lesions as assessed by CT using AHO|Time-weighted average (standardized AUC) of the change from baseline in daily pain due to FOP, as measured using the daily NRS using FAS|Incidence and severity of TEAEs|Time weighted average (standardized AUC) of the percent change from baseline in biomarkers of bone formation levels in serum over 28 weeks using full analysis set (FAS)|Concentration of total activin A in serum over time|PK profile of REGN2477, assessed as concentrations of REGN2477 in serum over time|Immunogenicity of REGN2477, as determined by the incidence, titer, and clinical impact of treatment-emergent ADA to REGN2477 over time|Total volume of new HO lesions in patients switching from placebo to REGN2477 after the double-blind period as assessed by CT using AHO|Number of new HO lesions in patients switching from placebo to REGN2477 after the double-blind period as assessed by 18F-NaF PET using AHO|Total lesion activity by18F-NaF PET in new HO lesions in patients switching from placebo to REGN2477 after double-blind period using AHO|Percentage of patients switching from placebo to REGN2477 after the double-blind period with new HO lesions as assessed by CT using AHO|Percentage of patients switching from placebo to REGN2477 after the double-blind period with new HO lesions as assessed by 18F-NaF PET using AHO|Number of new HO lesions in patients switching from placebo to REGN2477 after the double-blind period as assessed by CT using AHO|Percentage of patients switching from placebo to REGN2477 after the double-blind period with investigator-assessed flare-ups using AHO|Percent of patients switching from placebo to REGN2477 after the double-blind period with flare-ups assessed by patient e-diary using AHO|Number of new HO lesions in patients who continue REGN2477 after the double-blind period as assessed by CT using AHO|Total volume in new HO lesions as assessed by CT in patients who continue REGN2477 after the double-blind period using AHO|Percent of patients with new HO lesions as assessed by CT in patients who continue REGN2477 after the double-blind period using AHO|Number of new HO lesions as assessed by 18F-NaF PET in patients who continue REGN2477 after the double-blind period using AHO|Total lesion activity in new HO lesions as assessed by 18F-NaF PET in patients who continue REGN2477 after the double-blind period using AHO|Percent of patients with new HO lesions as assessed by 18F-NaF PET in patients who continue REGN2477 after the double-blind period using AHO|Percent change from week 28 in SUVmax to week 56 in patients switching from placebo to REGN2477 after the double-blind period using AHO|Percent change from baseline in SUVmax to week 56 in patients who continue REGN2477 after the double-blind period using AHO|Percent change in total lesion activity from Week 28 to Week 56 as assessed by 18F-NaF PET in patients switching from placebo to REGN2477 after the double-blind period versus the same patients between baseline and week 28 using AHO|Percent change from baseline in total lesion activity in patients who continue REGN2477 after the double-blind period as assessed by 18F-NaF PET using AHO|Percent change in the total volume of HO lesions in patients switching from placebo to REGN2477 after the double-blind period versus the same patients between baseline and week 28 as assessed by CT using AHO|Percent change from baseline in the total volume of HO lesions in patients who continue REGN2477 after the double-blind period as assessed by CT using AHO|Change in number of HO lesions in patients switching from placebo to REGN2477 in double-blind period as assessed by 18F-NaF PET from Week 28 to Week 56 versus the same patients between baseline and week 28 using AHO|Change in number of HO lesions in patients switching from placebo to REGN2477 in double-blind period as assessed by CT scan from Week 28 to Week 56 versus the same patients between baseline and week 28 using AHO","Regeneron Pharmaceuticals","All","18 Years to 60 Years   (Adult)","Phase 2","44","Industry","Interventional","Allocation: Randomized|Intervention Model: Parallel Assignment|Masking: Quadruple (Participant, Care Provider, Investigator, Outcomes Assessor)|Primary Purpose: Treatment","R2477-FOP-1623|2016-005035-33","February 26, 2018","September 16, 2019","September 16, 2021","June 15, 2017",,"October 6, 2021","Mayo Clinic, Rochester, Minnesota, United States|University of Pennsylvania, Philadelphia, Pennsylvania, United States|Vanderbilt University, Nashville, Tennessee, United States|Toronto General Hospital, Toronto, Ontario, Canada|Hopital Cochin, Paris, France|Hopital Lariboisiere,Hospitalier Universitaire Nord, Paris, France|Giannina Gaslini Institute, Genova, Italy|VU University Medical Center, Amsterdam, North Holland, Netherlands|Szpital Wojewodzki Nr 2, Rzeszow, Poland|Hospital Universitario Ramon y Cajal, Madrid, Spain|Royal National Orthopaedic Hospital, Brockley Hill, Stanmore, Middlesex, United Kingdom",,"https://ClinicalTrials.gov/show/NCT03188666"
140,"NCT03175367","Study of Evinacumab (REGN1500) in Participants With Persistent Hypercholesterolemia",,"Completed","No Results Available","Hypercholesterolemia","Drug: Evinacumab|Drug: Matching placebo|Other: Background Lipid Modifying Therapy (LMT)","Percent change in calculated low-density lipoprotein cholesterol (LDL-C) from baseline to week 16 in the intent-to-treat (ITT) population.|Percent change in Apolipoprotein B (ApoB) from baseline to week 16|Percent change in non high-density lipoprotein cholesterol (HDL-C) from baseline to week 16|Percent change in total cholesterol (TC) from baseline to week 16|Proportion of patients with ≥ 30% reduction in calculated LDL-C at week 16|Proportion of patients with ≥ 50% reduction in calculated LDL-C at week 16|Percent change in triglycerides (TGs) from baseline to week 16|Percent change in Lipoprotein(a) [(Lp(a)] from baseline to week 16|Proportion of patients with calculated LDL-C < 100 mg/dL (2.59 mmol/L) at week 16|Proportion of patients with calculated LDL-C < 70 mg/dL (1.81 mmol/L) at week 16|Proportion of patients with calculated LDL-C < 50 mg/dL (1.81 mmol/L) at week 16|Percent change in calculated LDL-C from baseline to week 24|Percent change in calculated ApoB from baseline to week 24|Percent change in calculated non-HDL-C from baseline to week 24|Percent change in calculated TC from baseline to week 24|Percent change in calculated TG from baseline to week 24|Percent change in calculated Lp(a) from baseline to week 24","Regeneron Pharmaceuticals","All","18 Years to 80 Years   (Adult, Older Adult)","Phase 2","272","Industry","Interventional","Allocation: Randomized|Intervention Model: Parallel Assignment|Masking: Triple (Participant, Investigator, Outcomes Assessor)|Primary Purpose: Treatment","R1500-CL-1643|2017-001508-31","November 10, 2017","May 22, 2020","December 14, 2020","June 5, 2017",,"May 25, 2021","Cedars-Sinai Medical Center, Los Angeles, California, United States|Office of Dr. John D Homan MD, Newport Beach, California, United States|Preventive Cardiology Inc, Boca Raton, Florida, United States|Care Research Center Inc, Doral, Florida, United States|Florida Lipid Institute, Winter Park, Florida, United States|St. Vincent Medical Group, Inc, Indianapolis, Indiana, United States|University of Kansas Medical Center, Kansas City, Kansas, United States|EMMC Northeast Cardiology Assocites, Bangor, Maine, United States|University of Maryland School of Medicine, Baltimore, Maryland, United States|Massachusetts General Hospital, Boston, Massachusetts, United States|Heart Health Cardiology, Grand Rapids, Michigan, United States|Minneapolis Heart Institute Foundation, Minneapolis, Minnesota, United States|University of Minnesota, Minneapolis, Minnesota, United States|Washington University School of Medicine, Saint Louis, Missouri, United States|Mt Sinai Ichan Medical Institute, New York, New York, United States|Duke University Medical Center, Durham, North Carolina, United States|Rowan Diagnostic Clinic, Salisbury, North Carolina, United States|Capital Area Research, LLC, Camp Hill, Pennsylvania, United States|The University Of Texas Health Science Center Houston, Houston, Texas, United States|San Antonio Premiere Internal Medicine, San Antonio, Texas, United States|Clear Clinical Research, LLC, Schertz, Texas, United States|PharmaTex Research, Tyler, Texas, United States|Wasatch Clinical Research, Salt Lake City, Utah, United States|Royal Prince Alfred Hospital, Camperdown, New South Wales, Australia|Redcliffe Hospital, Redcliffe, Queensland, Australia|University Hospital Innsbruck - Tyrolean Hospital, Innsbruck, Tyrol, Austria|Medizinische Universitaetsklinik Graz, Graz, Austria|Robarts Research Institute, London, Ontario, Canada|SKDS Research Inc., Newmarket, Ontario, Canada|Centre Etudes Cliniques Econogene-21, Chicoutimi, Quebec, Canada|Clinique des maladies lipidiques de Quebec, Québec, Quebec, Canada|CCR Prague, S.R.O, Praha, Prague 3, Czechia|Univerzita Karlova v Praze 1 Lekarska Fakulta, Karlov, Praha 2, Czechia|University Hospital, Charles University, Hradec Kralove, Czechia|Ikem Institut Klinicke A Experimentalni Mediciny, Prague, Czechia|Sydvestjysk Sygehus, Esbjerg, Denmark|Regionshospitalet Herning, Herning, Denmark|Hopital G Et R Laennec, Nantes, Cedex, France|Houpital Du Bocage, Dijon, France|Edith Wolfson Medical Center, H̱olon, Israel|Galilee Medical Center, Nahariya, Israel|Sheba Mc, Ramat Gan, Israel|Sourasky Medical Center, Cardiovascular Research Center, Tel Aviv, Israel|Azienda Ospedaliero Universitaria Federico II di Napoli, Napoli, Italy|Fondazione Toscana Gabriele Monasterio Per La Ricerca Medica E Di Sanita Pubblica, Pisa, Italy|Ausl Della Romagna-Ospedale Degli Infermi, Rimini, Italy|Dipartimento di Medicina Traslazionale e di Precisione dell'Università degli Studi di, Rome, Italy|Tokyo-Eki Center-building Clinic, Chuo-ku, Japan|Shonan Fujisawa Tokushukai Hospital, Fujisawa-shi, Japan|Minamino Cardiovascular Hospital, Hachioji, Japan|Saitama Medical University Hospital, Iruma-gun, Japan|Istishari Hospital, Amman, Jordan|King Abdullah University Hospital-1, Irbid, Jordan|King Abdullah University Hospital-2, Irbid, Jordan|King Abdullah University Hospital, Irbid, Jordan|VOC Hoorn, Hoorn, Hoorn Noord-Hollan, Netherlands|Admiraal de Ruyter Ziekenhuis, Goes, Zeeland, Netherlands|Academic Medical Center, Amsterdam, Netherlands|Universitair Medisch Centrum Utrech - Locatie AZU, Utrecht, Netherlands|Lipid and Diabetes Research Group, Christchurch, Canterbury, New Zealand|Papamoa Pines Medical Centre, Papamoa, New Zealand|Clinical Horizons NZ Ltd, Tauranga, New Zealand|M3 Helse AS, Oslo, Norway|Halina Serafin NZOZ Centrum Medyczne SERAFIN-MED, Żarów, Dolnoslaskie, Poland|Nzoz Przychodnia Specjalistyczna, Ruda Slaska, Podlaskie, Poland|Wojewodzki Szpital Specjalistyczny, Bytom, Poland|Slaskie Centrum Chorob Serca, III Katedra i Oddzial Kliniczny Kardiologii SUM- Oddzial Chorob Serca i Naczyn, Zabrze, Poland|Federal State Budgetary Institution Research Institute for Complex Issues of Cardiovacsular Disease, Kemerovo, Russian Federation|National Research Center For Preventative Medicine of Federal Agency of High Technology Medical Aid, Moscow, Russian Federation|Federal State Budget Institution Out-patient Clinic 3, Moscow, Russian Federation|NII of Therapy and Preventive Medicine, Novosibirsk, Russian Federation|Municipal Medical and Prophylactic Institution - City Hospital for Emergency Care No.2, Rostov-on-Don, Russian Federation|Limmited Liability Company International Medical Centre SOGAZ, Saint Petersburg, Russian Federation|Federal State Institution of Healthcare Clinical Hospital #122 N.A.L.G Sokolov, Saint Petersburg, Russian Federation|LLC- Institute of Medical Research, Saint Petersburg, Russian Federation|Federal State Budgetary Institution Clinical-Diagnostic Center with Polyclinic, Saint Petersburg, Russian Federation|Samara Regional Clinical Cardiologic Dispensary, Samara, Russian Federation|Cardiology Research Institute, Tomsk, Russian Federation|The Charlotte Maxeke Johannesburg Academic Hospital, Johannesburg, Gauteng, South Africa|Jongaie Research, Pretoria, West Gauteng, South Africa|Dr JM Engelbrecht Trial Site, Cape Town, Western Cape, South Africa|University of Cape Town, Cape Town, South Africa|TREAD Research CC, Parow, South Africa|Hospital Universitario A Coruna, A Coruña, A Coruna, Spain|Hospital Universitario Miguel Servet, Zaragoza, Aragon, Spain|Hospital Universitario de Bellvitge, Barcelona, Spain|Hospital Universitario Reina Sofia, Córdoba, Spain|Hospital Universitario Virgen de las Nieves (HUVN), Granada, Spain|Hospital Universitario Virgen del Rocio, Sevilla, Spain|Karolinska University Hospital, Malmö, Sweden|Akardo MedSite, Stockholm, Sweden|Karolinska Institutet, Stockholm, Sweden|Akademiska sjukhuset, Uppsala, Sweden|Royal Free Hospital-Royal Free London NHS Foundation Trust, London, United Kingdom|Royal Victoria Infirmary - The Newcastle Upon Tyne Hospitals NHS Foundation Trust, Newcastle Upon Tyne, United Kingdom",,"https://ClinicalTrials.gov/show/NCT03175367"
141,"NCT03161093","A Study to Determine the Safety and the Efficacy of Fasinumab Compared to Placebo and Naproxen for Treatment of Adults With Pain From Osteoarthritis of the Knee or Hip","FACT OA1","Completed","No Results Available","Osteoarthritis, Knee|Osteoarthritis, Hip","Drug: Fasinumab|Drug: Naproxen|Drug: Fasinumab-matching placebo|Drug: Naproxen-matching placebo","Change in the WOMAC pain subscale scores from baseline to week 16 in patients treated with fasinumab compared with that of patients treated with placebo|Change in the WOMAC physical function subscale scores from baseline to week 16 in patients treated with fasinumab compared with that of patients treated with placebo|Change in the Patient Global Assessment (PGA) scores from baseline to week 16 in patients treated with fasinumab compared with that of patients treated with placebo|Percentage of patients treated with fasinumab, compared with that of patients treated with placebo, who had a response at week 16, with response defined as an improvement by ≥30% in the WOMAC pain subscale scores|Change in WOMAC pain subscale scores from baseline to week 16 in patients treated with fasinumab, compared with that of patients treated with naproxen|Change in WOMAC physical function subscale scores from baseline to week 16 in patients treated with fasinumab, compared with that of patients treated with naproxen|Change in WOMAC pain subscale scores from baseline to week 44 in patients treated with fasinumab, compared with that of patients treated with placebo|Change in WOMAC physical function subscale scores from baseline to week 44 in patients treated with fasinumab, compared with that of patients treated with placebo|Change in the PGA scores from baseline to week 44 in patients treated with fasinumab compared with that of patients treated with placebo|Change in the PGA scores from baseline to week 16 in patients treated with fasinumab compared with that of patients treated with naproxen|Change in WOMAC pain subscale scores from baseline to week 44 in patients treated with fasinumab, compared with that of patients treated with naproxen|Change in WOMAC physical function subscale scores from baseline to week 44 in patients treated with fasinumab, compared with that of patients treated with naproxen|Percentage of patients treated with fasinumab, compared with that of patients treated with naproxen, who had a response at week 16, with response defined as an improvement by ≥30% in the WOMAC pain subscale scores|Change in WOMAC pain subscale scores from baseline to the average score across weeks 4, 8, 12 and 16, in patients treated with fasinumab compared with that of patients treated with placebo|Change in WOMAC physical function subscale scores from baseline to the average score across weeks 4, 8, 12 and 16, in patients treated with fasinumab compared with that of patients treated with placebo|Change in WOMAC pain subscale scores from baseline to the average score across weeks 36, 40 and 44 in patients treated with fasinumab compared with that of patients treated with placebo|Change in WOMAC physical function subscale scores from baseline to the average score across weeks 36, 40 and 44 in patients treated with fasinumab compared with that of patients treated with placebo|Incidence of Adjudicated Arthropathy (AA) (as confirmed by adjudication)|Incidence of AA (as confirmed by adjudication)|Incidence of Destructive Arthropathy (DA) (as confirmed by adjudication)|Incidence of DA (as confirmed by adjudication)|Incidence of Treatment Emergent Adverse Events (TEAEs)|Incidence of TEAEs|Incidence of sympathetic nervous system dysfunction|Incidence of Peripheral sensory AEs that require a neurology or other specialty consultation|Incidence of all-cause joint replacement (JR)|Incidence of all-cause JR|Incidence of JRs at the telephone survey","Regeneron Pharmaceuticals|Teva Pharmaceutical Industries, Ltd.","All","18 Years and older   (Adult, Older Adult)","Phase 3","3307","Industry","Interventional","Allocation: Randomized|Intervention Model: Parallel Assignment|Masking: Triple (Participant, Investigator, Outcomes Assessor)|Primary Purpose: Treatment","R475-OA-1611|2016-005020-29","August 17, 2017","September 9, 2019","August 27, 2021","May 19, 2017",,"September 14, 2021","Arizona Arthritis & Rheumatology Research, PLLC, Mesa, Arizona, United States|Arizona Research Center, Phoenix, Arizona, United States|Tucson Orthopaedic Research Center, Tucson, Arizona, United States|Baptist Health Center for Clinical Research, Little Rock, Arkansas, United States|Medvin Clinical Research, Covina, California, United States|TriWest Research Associates, LLC, El Cajon, California, United States|BioSolutions Clinical Research, La Mesa, California, United States|Pacific Arthritis Care Center, Los Angeles, California, United States|Artemis Institute for Clinical Research, San Diego, California, United States|Artemis Clinical Research, San Marcos, California, United States|Lynn Institute of Denver, Aurora, Colorado, United States|Lynn Institute of the Rockies, Colorado Springs, Colorado, United States|Panorama Orthopedics & Spine Center, Golden, Colorado, United States|Arthritis and Rheumatic Disease Specialties, Aventura, Florida, United States|Jacksonville Center for Clinical Research, Jacksonville, Florida, United States|Clinical Neuroscience Solutions, Inc., Jacksonville, Florida, United States|Sensible Healthcare, Ocoee, Florida, United States|Clinical Neuroscience Solutions, Inc., Orlando, Florida, United States|Jewett Orthopaedic Clinic, Orlando, Florida, United States|Lovelace Scientific Resources, Venice, Florida, United States|Meridian Clinical Research, Savannah, Georgia, United States|Advanced Clinical Research, Meridian, Idaho, United States|Medex Healthcare Research, Inc., Chicago, Illinois, United States|Northwestern University, Chicago, Illinois, United States|Healthcare Research Network II, LLC, Flossmoor, Illinois, United States|Integrated Clinical Trial Services, Inc., West Des Moines, Iowa, United States|Klein & Associates, MD PA, Cumberland, Maryland, United States|Klein & Associates, MD, PA, Hagerstown, Maryland, United States|The Center for Rheumatology and Bone Research, Wheaton, Maryland, United States|Clinical Pharmacology Study Group, Worcester, Massachusetts, United States|The Center for Pharmaceutical Research, Kansas City, Missouri, United States|Medex Healthcare Research, Inc., Saint Louis, Missouri, United States|Sundance Clinical Research, LLC, Saint Louis, Missouri, United States|Physician Research Collaboration, LLC, Lincoln, Nebraska, United States|Lovelace Scientific Resources, Inc., Albuquerque, New Mexico, United States|United Medical Associates, Binghamton, New York, United States|Regional Clinical Research, Inc., Endwell, New York, United States|Medex Healthcare Research, New York, New York, United States|Buffalo Rheumatology and Medicine, PLLC, Orchard Park, New York, United States|Orchard Park Family Practice, Orchard Park, New York, United States|PMG Research of Raleigh, LLC d/b/a PMG Research of Cary, Cary, North Carolina, United States|DJL Clinical Research, PLLC, Charlotte, North Carolina, United States|Hickory Family Practice Associates, Hickory, North Carolina, United States|Peters Medical Research LLC, High Point, North Carolina, United States|PMG Research of Salisbury, LLC, Salisbury, North Carolina, United States|PMG Research of Winston-Salem, LLC, Winston-Salem, North Carolina, United States|Sterling Research Group, Ltd., Cincinnati, Ohio, United States|Hillcrest Clinical Research, Oklahoma City, Oklahoma, United States|Altoona Center for Clinical Research, Duncansville, Pennsylvania, United States|Low Country Rheumatology, PA, Charleston, South Carolina, United States|PMG Research of Charleston, LLC, Mount Pleasant, South Carolina, United States|Clinical Research Solutions, Franklin, Tennessee, United States|PMG Research of Knoxville, Knoxville, Tennessee, United States|Clinical Neuroscience Solutions, Inc., Memphis, Tennessee, United States|Pioneer Research Solutions, Inc., Cypress, Texas, United States|Southwest Rheumatology Research, LLC, Mesquite, Texas, United States|Center for Arthritis and Rheumatic Diseases, Chesapeake, Virginia, United States|Rheumatology & Pulmonary Clinic, Beckley, West Virginia, United States|CCBR Vejle, Vejle, Denmark|Synexus Clinical Research GmbH, Leipzig, Sachsen, Germany|Synexus Clinical Research GmbH, Berlin, Germany|Synexus Clinical Research GmbH, Bochum, Germany|Synexus Clinical Research GmbH, Frankfurt, Germany|Qualiclinic Kft., Budapest, Hungary|Synexus Magyarorszag Kft, Budapest, Hungary|Synexus Magyarorszag Kft., Debrecen, Hungary|Synexus Magyarorszag Kft., Gyula, Hungary|BKS Research Kft., Hatvan, Hungary|Hevizgyogyfurdo es Szent Andraes ReumaKorhaz, Hévíz, Hungary|Szabolcs-Szatmar-Bereg Megyei Korhazak es Egyetemi Oktato Korhazak Josa Andras Oktatokorhaza Klinikai Kutatasi Osztaly, Nyíregyháza, Hungary|Synexus Magyarorszag Egeszsegugyi Kft., Zalaegerszeg, Hungary|Hospital of Lithuanian University of Health Sciences Kaunas Clinics, Kaunas, Lithuania|Saules Seimos Medicinos Centras, Jsc, Kaunas, Lithuania|Republican Panevezys Hospital, Panevėžys, Lithuania|Center Outpation Clinic, Public Institution, Vilnius, Lithuania|Synexus Polska Sp. z o.o. Oddzial we Wroclawiu, Wrocław, Dolnoslaskie, Poland|Specjalistyczny Osrodek Medycyny Wieku Dojrzalego Sp. z o.o. Jednostka 02 - SOMED - Lodzkie Centrum Osteoporozy, Łódź, Lodzkie, Poland|Krakowskie Centrum Medyczne Sp. z o.o., Kraków, Malopolskie, Poland|MCBK Sc lwona Czajkowska Monika Barney, Grodzisk Mazowiecki, Mazowieckie, Poland|Synexus Polska Sp. z o.o. Oddzial w Warszawie, Warszawa, Mazowieckie, Poland|Specjalistyczny Osrodek Medycyny Wieku Dojrzalego Sp. z o.o., Warszawa, Mazowieckie, Poland|Synexus Polska Sp. z o.o. Oddzial w Gdansku, Gdynia, Pomorskie, Poland|Synexus Polska Sp. z o.o. Oddzial w Gdyni, Gdynia, Pomorskie, Poland|Synexus Polska Sp. z o.o Oddzial w Poznaniu, Poznań, Wielkopolskie, Poland|ClinicMed Daniluk, Nowak Sp.j., Białystok, Poland|Synexus Polska Sp. z o.o. Oddzial w Katowicach, Katowice, Poland|Malopolskie Centrum Kliniczne, Kraków, Poland|CLINMEDICA RESEARCH OMC, Spolka z Ograniczona Odpowiedzialnoscia Spolka Komandytowa, Skierniewice, Poland|Etg Zgierz, Zgierz, Poland|Clinica Medicala Synexus Ltd., Bucharest, Romania|SC Policlinica CCBR SRL, Bucharest, Romania|""SBEIHPE """"Kazan State Medical University"""" of MHSD of Russia"", Kazan, Tatarstan Republic, Russian Federation|""CDCR """"Healthy Joints"""" L.L.C."", Novosibirsk, Russian Federation|City Out-Patient Clinic #109, Saint Petersburg, Russian Federation|Samara Regional Clinical Hospital n.a.V.D.Seredavin, Samara, Russian Federation|""State Autonomous Healthcare Institution of Yaroslavl Oblast """"Clinical Hospital #3"""""", Yaroslavl, Russian Federation|Tread Research-Tygerberg Hospital, Parow, Cape Town, South Africa|Welkom Clinical trial Centre, Welkom, Free State, South Africa|Wits Clinical Research, Johannesburg, Gauteng, South Africa|University of Pretoria, Pretoria, Gauteng, South Africa|Global Clinical Trials, Pretoria, Gauteng, South Africa|Synexus SA Stanza Clinical Research Centre, Pretoria, Gauteng, South Africa|Synexus Watermeyer Clinical Research Centre, Pretoria, Gauteng, South Africa|Roodepoort Medicross Clinical Research Centre, Roodepoort, Gauteng, South Africa|Soweto Clinical Trials Centre (CTC), Soweto, Johannesburg, South Africa|Synapta Clinical Research Center, Durban, Kwa-Zulu Natal, South Africa|Aliwal Shoal Medical Centre, Umkomaas, Kwa-Zulu Natal, South Africa|Enhancing Care, Durban, KwaZulu-Natal, South Africa|Mzansi Ethical Research Centre Middleburg, Middelburg, Mpumalanga, South Africa|Langeberg Medicross Medical Centre, Kraaifontein, Western Cape, South Africa|Paarl Research Centre, Paarl, Western Cape, South Africa|Synexus Helderberg Clinical Trial Centre, Somerset West, Western Cape, South Africa|TASK Applied Science, Cape Town, South Africa|Mzansi Ethical Research Centre Cape Town, Cape Town, South Africa|Newtown Clinical Research, Johannesburg, South Africa|CETA Leganes, Leganés, Madrid, Spain|Complejo Hospitalario Universitario A Coruna, A Coruña, Spain|MeDiNova Investigacion y Desarrollo, Madrid, Spain|Centro De Investigacion Clinica En Enfermedades Cronicas - Cicec, Santiago De Compostela, Spain|Clínica Nuevas Tecnologias en Diabetes y Endocrinologia (NTDE), Sevilla, Spain|Hospital Quiron Salud Infanta Luisa, Sevilla, Spain|""Municipal Establishment """"Cherkasy Regional Hospital of Cherkasy Oblast Council"""""", Cherkasy, Ukraine|Kharkiv City Multispecialty Hospital #18, Kharkiv, Ukraine|Medical center of Private High Educational Institute Institute of General Practice-Family Medicine, Kyiv, Ukraine|""Subsidiary Company """"Medical Research and Practice Center Medbud of the Public Joint Stock """"Holding Company """"Kyivmiskbud"""""", Kyiv, Ukraine|""Kyiv Railway Clinical Hospital No.2 of branch """"Health Center """" of the PJSC """"Ukrainian Railway"""""", Kyiv, Ukraine|Lviv Regional Hospital for veterans of the war and former political prisoners, Lviv, Ukraine|Synexus Thames Valley Clinical Research Centre, Reading, Berkshire, United Kingdom|Synexus Scotland Clinical Research Centre, Glasgow, Lanarkshire, United Kingdom|Synexus Lancashire Clinical Research Centre, Chorley, Lancashire, United Kingdom|MediNova North London Dedicated Research Centre, Mount Vernon Hospital, Northwood, Middlesex, United Kingdom|Synexus North East Clinical Research Centre - Hexham General Hospital, Hexham, Northumberland, United Kingdom|Synexus Midlands Clinical Research Centre, Birmingham, West Midlands, United Kingdom|Synexus Wales Clinical Research Centre, Cardiff, United Kingdom|Synexus Merseyside Clinical Research Centre, Liverpool, United Kingdom|Synexus Manchester Clinical Research Centre-Manchester Science Park, Manchester, United Kingdom|Medinova Research East London Clinical Studies Centre, Romford, United Kingdom|MeDiNova Research Yorkshire Clinical Studies Centre, Shipley, United Kingdom|MediNova South London Dedicated Research Centre, Sidcup, United Kingdom",,"https://ClinicalTrials.gov/show/NCT03161093"
142,"NCT03146416","Study of Evinacumab (REGN1500) in Caucasian and in Japanese Healthy Volunteers",,"Completed","No Results Available","Healthy Volunteers","Drug: Evinacumab|Drug: Placebo","Incidence of Treatment Emergent Adverse Events (TEAEs)|Severity of TEAEs|Pharmacokinetic (PK) parameters of evinacumab for geometric means of maximum (or peak) serum concentration (Cmax)|PK parameters of evinacumab for geometric means of Area under the curve (AUC) computed from time zero to the last measurable concentration (AUClast)|PK parameters of evinacumab for geometric means of AUC computed from time zero to the end of a dosing interval (AUCtau)|Ratio of Japanese versus Caucasian populations for geometric means of Cmax|Ratio of Japanese versus Caucasian populations for geometric means of AUClast|Ratio of Japanese versus Caucasian populations for geometric means of AUCtau|Absolute change from baseline over time in the Pharmacodynamic (PD) variable: Low-density lipoprotein cholesterol (LDL-C)|Absolute change from baseline over time in the PD variable: Total cholesterol|Absolute change from baseline over time in the PD variable: High-density lipoprotein cholesterol (HDL-C)|Absolute change from baseline over time in the PD variable: Triglycerides|Absolute change from baseline over time in the PD variable: non-HDL-C|Absolute change from baseline over time in the PD variable: lipoprotein a [Lp(a)]|Absolute change from baseline over time in the PD variable: apolipoprotein B [ApoB]|Absolute change from baseline over time in the PD variable: apolipoprotein A1 [ApoA1]|Absolute change from baseline over time in the PD variable: apolipoprotein C3 [ApoC3]|Absolute change from baseline over time in the PD variable: high-sensitivity C-reactive protein [hs-CRP]|Absolute change from baseline over time in the PD variable: Total Angiopoietin-like 3 (ANGPTL3)|Percent change from baseline over time in the PD variable: LDL-C|Percent change from baseline over time in the PD variable: Total cholesterol|Percent change from baseline over time in the PD variable: HDL-C|Percent change from baseline over time in the PD variable: Triglycerides|Percent change from baseline over time in the PD variable: non-HDL-C|Percent change from baseline over time in the PD variable: lipoprotein a [Lp(a)]|Percent change from baseline over time in the PD variable: apolipoprotein B [ApoB]|Percent change from baseline over time in the PD variable: apolipoprotein A1 [ApoA1]|Percent change from baseline over time in the PD variable: apolipoprotein C3 [ApoC3]|Percent change from baseline over time in the PD variable: high-sensitivity C-reactive protein [hs-CRP]|Percent change from baseline over time in the PD variable: Total (ANGPTL3)|Presence and titer of anti-evinacumab antibodies","Regeneron Pharmaceuticals","All","18 Years to 55 Years   (Adult)","Phase 1","96","Industry","Interventional","Allocation: Randomized|Intervention Model: Sequential Assignment|Masking: Triple (Participant, Investigator, Outcomes Assessor)|Primary Purpose: Basic Science","R1500-CL-1642","May 16, 2017","June 14, 2018","June 14, 2018","May 10, 2017",,"June 25, 2018","WCCT Global, Inc., Cypress, California, United States",,"https://ClinicalTrials.gov/show/NCT03146416"
143,"NCT03132636","PD-1 in Patients With Advanced Basal Cell Carcinoma Who Experienced Progression of Disease on Hedgehog Pathway Inhibitor Therapy, or Were Intolerant of Prior Hedgehog Pathway Inhibitor Therapy",,"Active, not recruiting","No Results Available","Carcinoma, Basal Cell","Drug: cemiplimab","Objective Response Rate (ORR) for metastatic Basal Cell Carcinoma (BCC)|ORR for unresectable locally advanced BCC|Duration of Response (DOR)|Complete Response (CR) Rate|Progression Free Survival (PFS)|Overall Survival (OS)|Change in scores of patient-reported outcomes in European Organisation for Research and Treatment of Cancer Quality of Life Questionnaire Core 30 (EORTC QLQ-C30)|Change in scores of patient-reported outcomes in Skindex-16|Incidence of treatment emergent adverse events (TEAEs)|Concentration at end of infusion (Ceoi)|Pre-infusion concentration (Ctrough)|Time of end of infusion (teoi)|Anti-cemiplimab antibodies","Regeneron Pharmaceuticals|Sanofi","All","18 Years and older   (Adult, Older Adult)","Phase 2","137","Industry","Interventional","Allocation: Non-Randomized|Intervention Model: Parallel Assignment|Masking: None (Open Label)|Primary Purpose: Treatment","R2810-ONC-1620|2016-003122-16","June 29, 2017","May 20, 2021","November 18, 2022","April 28, 2017",,"June 29, 2021","The University of Arizona Cancer Centre at Dignity Health, Phoenix, Arizona, United States|Mayo Clinic Arizona - Mayo Clinic Hospital, Phoenix, Arizona, United States|UC San Diego Moores Cancer Center, La Jolla, California, United States|Stanford Medicine Outpatient Center - Stanford Dermatology Clinic-Stanford University School of Medicine, Redwood City, California, United States|UCSF Helen Dillion Family Cancer Care Center, San Francisco, California, United States|University of Colorado Hospital, Anschutz Outpatient Pavilion, Denver, Colorado, United States|Mount Sinai Comprehensive Cancer Center, Miami, Florida, United States|H Lee Moffitt Cancer Center and Research Institute, Tampa, Florida, United States|Northwestern Medical Faculty Foundation, Chicago, Illinois, United States|Norton Cancer Institute, Louisville, Kentucky, United States|Massachusetts General Hospital, Boston, Massachusetts, United States|Dana Farber Cancer Institute (DFCI), Boston, Massachusetts, United States|Washington University School of Medicine, Saint Louis, Missouri, United States|Atlantic Health System / Morristown Medical Center, Morristown, New Jersey, United States|Overlook Medical Center, Summit, New Jersey, United States|New York University School Of Medicine, Kaplan Comprehensive Cancer Center, New York, New York, United States|Mount Sinai Hospital, New York, New York, United States|Memorial Sloan Kettering Cancer Center, New York, New York, United States|James Cancer Hospital and Solove Research Institute, Columbus, Ohio, United States|Penn State Hershey Medical Center, Hershey, Pennsylvania, United States|Clinical Research Center of the Carolinas, Charleston, South Carolina, United States|University of Texas MD Anderson Cancer Center, Houston, Texas, United States|Huntsman Cancer Institute, Salt Lake City, Utah, United States|LKH - Universitaetsklinikum Graz, Graz, Steiermark, Austria|Medizinische Universitaet Innsbruck, Universitaetsklinik fuer Dermatologie, Venerologie und Allergologie, Innsbruck, Austria|Cliniques Universitaires Saint-Luc, Bruxelles, Belgium|Universitaire Ziekenhuizen Leuven - Campus Gasthuisberg, Leuven, Belgium|Cross Cancer Institute, Edmonton, Alberta, Canada|Odette Cancer Center-Sunnybrook Health Sciences Centre, Toronto, Ontario, Canada|University Health Network, Toronto, Ontario, Canada|London Regional Cancer Program, London Hsc, Toronto, Ontario, Canada|CHU de Dijon - Hopital du Bocage, Dijon, Cedex, France|Hopital Saint Louis, Paris, Europe, France|Centre Hospitalier Lyon-Sud -Hospices Civils de Lyon Groupement Hospitalier Sud, Pierre Benite Cedex, Paris, France|Centre Hospitalier Universitaire de Bordeaux - Groupe Hospitalier Saint-André - Hôpital Saint-André, Bordeaux, France|Hopital Ambroise Pare, Boulogne Billancourt, France|Centre Hospitalier Universitaire de Grenoble, La Tronche, France|Hopital Huriez - CHRU de Lille, Lille Cedex, France|Centre Leon-Berard (CLB), Lyon, France|CHU Hotel Dieu, Nantes, France|Centre Hospitalier Universitaire de Rouen-Hopital Charles Nicolle, Rouen cedex, France|Institut Claudius Regaud, Toulouse Cedex, France|Institut Gustave Roussy, Villejuif Cedex, France|University Hospital Frankfurt, Frankfurt, Hessen/Germany, Germany|Hauttumorcentrum der Charite (HTCC)-Charite Universitatsmedizin Berlin, Berlin, Germany|Elbekliniken Buxtehude, Buxtehude, Germany|University Hospital Dresden, Dresden, Germany|Universitaetsklinik Essen, Essen, Germany|SRH Wald-Kliniken Gera GmbH, Gera, Germany|Hannover Medical School, Hannover, Germany|NCT Dermatoonkologie, Heidelberg, Germany|University of Kiel, Kiel, Germany|Universitaetsmedizin der Johannes Gutenberg-Universitaet Mainz, Mainz, Germany|Klinik Fur Dermatologie Und Allergollogie, Quedlinburg, Germany|University Hospital Tubingen, Tübingen, Germany|National and Kapodistrian University of Athens - School of Health Sciences - Faculty of Medicine, Athens, Greece|National and Kapodistrian University of Athens - School of Health Sciences, Athens, Greece|Andreas Sygros Hosptial-University of Athen, Athens, Greece|University General Hospital of Ioannina - Dermatology and Venereology Department, Ioánnina, Greece|Policlinico S.Orsola-Malpighi U.O. Dermatologia - University of Bologna, Bologna, Bo, Italy|Azienda Ospedaliera Spedali Civili di Brescia-Universita degli Studi Di Brescia, Brescia, Province Of Brescia, Italy|U.O.Dermatologia Azienda Sanitaria Firenze Universita' Firenze, Firenze, Italy|University L'Aquila, L'Aquila, Italy|Fondazione IRCCS Istituto Nazionale dei Tumori, Milano, Italy|U.O.S.C Di Oncologia Medica E Terapie Innovative, Napoli, Italy|Catholic University of the S.Heart, Roma, Italy|Catalan Institute of Oncology Badalona, Badalona, Spain|Hospital Clinic I Provincialde Barcelona, Barcelona, Spain|Hospital Universitario de Torrejon, Madrid, Spain|Hospital Universitario Virgen Macarena, Sevilla, Spain|University Hospital Zurich Usz, Zürich, Switzerland",,"https://ClinicalTrials.gov/show/NCT03132636"
144,"NCT03115996","Study of the Safety, Tolerability, Pharmacokinetics, and Pharmacodynamics of REGN3918 in Healthy Volunteers",,"Completed","No Results Available","Healthy Volunteers","Drug: REGN3918|Drug: Placebo","Incidence of treatment emergent adverse events (TEAEs)|Severity of TEAEs|Pharmacokinetic profile of REGN3918; single dose IV and SC|Pharmacokinetic profile of REGN3918; single dose IV and repeated SC doses|Pharmacodynamics profile of REGN3918|Pharmacokinetic exploratory analysis|Immunogenicity of REGN3918","Regeneron Pharmaceuticals","All","18 Years to 50 Years   (Adult)","Phase 1","56","Industry","Interventional","Allocation: Randomized|Intervention Model: Parallel Assignment|Masking: Quadruple (Participant, Care Provider, Investigator, Outcomes Assessor)|Primary Purpose: Basic Science","R3918-HV-1659|2016-004208-70","May 10, 2017","August 31, 2018","August 31, 2018","April 14, 2017",,"September 26, 2018","Covance Clinical Research Unit (CRU) Ltd., Leeds, United Kingdom",,"https://ClinicalTrials.gov/show/NCT03115996"
145,"NCT03112577","Study of REGN3500 and Dupilumab in Patients With Asthma",,"Completed","No Results Available","Asthma, Allergic","Drug: REGN3500|Drug: Dupilumab|Drug: Placebo|Drug: Fluticasone propionate","Difference in bronchial allergen challenge (BAC)-induced changes in sputum inflammatory markers in individuals treated with REGN3500, dupilumab and the combination of REGN3500 plus dupilumab or placebo|Incidence of Treatment Emergent Adverse Events (TEAEs)|Severity of TEAEs|Serum concentration-time profile of REGN3500|Serum concentration-time profile of REGN3500: Tmax (time at Cmax)|Serum concentration-time profile of REGN3500: AUClast (area under the curve to the last measurable concentration)|Immunogenicity of REGN3500 and dupilumab|Serum concentration of total IL-33 after single IV dose|Difference in the BAC-induced changes in sputum inflammatory mRNA signature in individual patients treated with fluticasone","Regeneron Pharmaceuticals|Sanofi","All","18 Years to 60 Years   (Adult)","Phase 1","32","Industry","Interventional","Allocation: Randomized|Intervention Model: Parallel Assignment|Masking: Quadruple (Participant, Care Provider, Investigator, Outcomes Assessor)|Primary Purpose: Treatment","R3500-AS-1633|2016-003165-26|SAR440340","June 15, 2017","March 20, 2019","December 9, 2019","April 13, 2017",,"January 18, 2020","WCCT Global, Cypress, California, United States|Celerion, Belfast, United Kingdom|Hammersmith Medicine Research, London, United Kingdom|Respiratory Clinical Trials Ltd, London, United Kingdom|The Medicines Evaluation Unit, Manchester, United Kingdom",,"https://ClinicalTrials.gov/show/NCT03112577"
146,"NCT03088540","Study of REGN 2810 Compared to Platinum-Based Chemotherapies in Participants With Metastatic Non-Small Cell Lung Cancer (NSCLC)",,"Active, not recruiting","No Results Available","Carcinoma，Non-Small-Cell Lung|Lung Carcinomas, Non-Small-Cell|Non-small-cell Lung Carcinoma|Nonsmall Cell Lung Cancer","Drug: Pemetrexed|Drug: Paclitaxel|Drug: Gemcitabine|Drug: Cisplatin|Drug: Carboplatin|Drug: cemiplimab","Overall survival (OS)|Progression-free survival (PFS) as assessed by a blinded Independent review committee (IRC) using RECIST 1.1|Objective response rates (ORR)|Best overall response (BOR)|Compare the duration of response (DOR) of cemiplimab versus platinum based chemotherapies|Change from baseline in quality of life (QoL) scores as assessed by the European Organization for the Research and Treatment of Cancer Quality of Life Questionnaire Core 30 (EORTC QLQ-C30)|Change from baseline in in lung cancer symptom scores as measured by the EORTC Lung Cancer 13 (EORTC QLQ-LC13)|Incidence of Adverse Events (AEs)|Incidence of serious adverse events (SAEs)|Incidence of deaths|Incidence of laboratory abnormalities|Measure concentrations of cemiplimab in serum|Characterize the pharmacokinetics (PK) of cemiplimab","Regeneron Pharmaceuticals|Sanofi","All","18 Years and older   (Adult, Older Adult)","Phase 3","712","Industry","Interventional","Allocation: Randomized|Intervention Model: Crossover Assignment|Masking: None (Open Label)|Primary Purpose: Treatment","R2810-ONC-1624|2016-004407-31","May 29, 2017","November 1, 2022","November 1, 2022","March 23, 2017",,"August 17, 2021","Clinical Study Site, Albury, New South Wales, Australia|Clinical Study Site, Wollongong, New South Wales, Australia|Clinical Study Site, Fitzroy, Australia|Clinical Study Site, Minsk, Belarus|Clinical Study Site, Mogilev, Belarus|Clinical Study Site 1, Porto Alegre, Rio Grande Do Sul, Brazil|Clinical Study Site, Barretos, Brazil|Clinical Study Site, Curitiba, Brazil|Clinical Study Site, Joinville, Brazil|Clinical Study Site, Lajeado, Brazil|Clinical Study Site, Mogi Das Cruzes, Brazil|Clinical Study Site, Passo Fundo, Brazil|Clinical Study Site, Pelotas, Brazil|Clinical Study Site 2, Porto Alegre, Brazil|Clinical Study Site 3, Porto Alegre, Brazil|Clinical Study Site, Recife, Brazil|Clinical Study Site, Rio De Janeiro, Brazil|Clinical Study Site, Salvador, Brazil|Clinical Study Site, Santa Cecília, Brazil|Clinical Study Site #4, Sao Paulo, Brazil|Clinical Study Site, São José Do Rio Preto, Brazil|Clinical Study Site #3, São Paulo, Brazil|Clinical Study Site 1, São Paulo, Brazil|Clinical Study Site 2, São Paulo, Brazil|Clinical Study Site, Dobrich, Bulgaria|Clinical Study Site, Gabrovo, Bulgaria|Clinical Study Site, Recoleta, Chile|Clinical Study Site, Santiago, Chile|Clinical Study Site, Temuco, Chile|Clincial Study Site, Viña Del Mar, Chile|Clinical Study Site, Lanshan, Shandong, China|Clinical Study Site, Guangdong, China|Clinical Study Site, Harbin, China|Clinical Study Site, Linyi, China|Clinical Study Site 1, Shanghai, China|Clinical Study Site 2, Shanghai, China|Clinical Study Site 1, Tianjin, China|Clinical Study Site 2, Tianjin, China|Clinical Study Site, Xuzhou, China|Clinical Study Site, Zhejiang, China|Clinical Study Site, Barranquilla, Colombia|Clinical Study Site, Bogotá, Colombia|Clinical Study Site, Floridablanca, Colombia|Clinical Study Site, Nový Jičín, Czechia|Clinical Study Site, Pelhřimov, Czechia|Clinical Study Site, Prague, Czechia|Clinical Study Site, Praha, Czechia|Clinical Study Site, Batumi, Georgia|Clinical Study Site #6, Tbilisi, Georgia|Clinical Study Site 1, Tbilisi, Georgia|Clinical Study Site 2, Tbilisi, Georgia|Clinical Study Site 3, Tbilisi, Georgia|Clinical Study Site 4, Tbilisi, Georgia|Clinical Study Site 5, Tbilisi, Georgia|Clinical Study Site, Patras, Achaia, Greece|Clinical Study Site, Cholargós, Attiki, Greece|Clinical Study Site 1, Athens, Greece|Clinical Study Site 2, Athens, Greece|Clinical Study Site 3, Athens, Greece|Clinical Study Site, Larissa, Greece|Clinical Study Site, Pylaía, Greece|Clinical Study Site 1, Thessaloníki, Greece|Clinical Study Site 2, Thessaloníki, Greece|Clinical Study Site 3, Thessaloníki, Greece|Clinical Study Site, Gyula, Bekes, Hungary|Clinical Study Site, Tatabánya, Komarom-Esztergom, Hungary|Clinical Study Site, Farkasgyepű, Veszprém, Hungary|Clinical Study Site, Budapest, Hungary|Clinical Study Site, Debrecen, Hungary|Clinical Study Site, Zalaegerszeg, Hungary|Clinical Study Site, Amman, Jordan|Clinical Study Site, Irbid, Jordan|Clinical Study Site, Bsalîm, Lebanon|Clinical Study Site, Mazraat Ech Choûf, Lebanon|Clinical Study Site, Sidon, Lebanon|Clinical Study Site, Kampung Baharu Nilai, Malaysia|Clinical Study Site #1, Kuala Lumpur, Malaysia|Clinical Study Site #2, Kuala Lumpur, Malaysia|Clinical Study Site, Kuching, Malaysia|Clinical Study Site, Pulau Pinang, Malaysia|Clinical Study Site, Tanjong Bungah, Malaysia|Clinical Study Site, Coahuila, Mexico|Clinical Study Site, Cuautitlán, Mexico|Clinical Study Site, Jalisco, Mexico|Clinical Study Site, León de los Aldama, Mexico|Clinical Study Site 1, Monterrey, Mexico|Clinical Study Site 2, Monterrey, Mexico|Clinical Study Site 3, Monterrey, Mexico|Clinical Study Site, Oaxaca, Mexico|Clinical Study Site, San Luis Potosí, Mexico|Clinical Study Site, Bacolod City, Philippines|Clinical Study Site, Batangas, Philippines|Clinical Study Site, Cebu, Philippines|Clinical Study Site, Davao City, Philippines|Clinical Study Site 1, Manila, Philippines|Clinical Study Site 2, Manila, Philippines|Clinical Study Site #1, Quezon City, Philippines|Clinical Study Site #2, Quezon City, Philippines|Clinical Study Site, Taguig, Philippines|Clinical Study Site, Dąbrowa Górnicza, Poland|Clinical Study Site, Gdynia, Poland|Clinical Study Site, Kraków, Poland|Clinical Study Site, Olsztyn, Poland|Clinical Study Site, Poznań, Poland|Clinical Study Site, Prabuty, Poland|Clinical Study Site, Radom, Poland|Clinical Study Site, Rzeszów, Poland|Clinical Study Site, Toruń, Poland|Clinical Study Site, Warszawa, Poland|Clinical Study Site, Wodzisław Śląski, Poland|Clinical Study Site, Łódź, Poland|Clinical Study Site 1, Craiova, Romania|Clinical Study Site 2, Craiova, Romania|Clinical Study Site, Floreşti, Romania|Clinical Study Site, Ploieşti, Romania|Clinical Study Site, Timişoara, Romania|Clinical Study Site, Ufa, Republic Bashkortost, Russian Federation|Clinical Study Site, Pushkin, Saint Petersburg, Russian Federation|Clinical Study Site, Arkhangel'sk, Russian Federation|Clinical Study Site, Belgorod, Russian Federation|Clinical Study Site, Chelyabinsk, Russian Federation|Clinical Study Site, Kaluga, Russian Federation|Clinical Study Site, Kazan, Russian Federation|Clinical Study Site, Kemerovo, Russian Federation|Clinical Study Site, Kislino, Russian Federation|Clinical Study Site, Kursk, Russian Federation|Clinical Study Site 1, Moscow, Russian Federation|Clinical Study Site 2, Moscow, Russian Federation|Clinical Study Site 3, Moscow, Russian Federation|Clinical Study Site, Omsk, Russian Federation|Clinical Study Site, Pyatigorsk, Russian Federation|Clinical Study Site 1, Saint Petersburg, Russian Federation|Clinical Study Site 2, Saint Petersburg, Russian Federation|Clinical Study Site 3, Saint Petersburg, Russian Federation|Clinical Study Site 4, Saint Petersburg, Russian Federation|Clinical Study Site, Samara, Russian Federation|Clinical Study Site, Saransk, Russian Federation|Clinical Study Site, Sochi, Russian Federation|Clinical Study Site 1, Tomsk, Russian Federation|Clinical Study Site 2, Tomsk, Russian Federation|Clinical Study Site, Yekaterinburg, Russian Federation|Clinical Study Site, Manresa, Barcelona, Spain|Clinical Study Site, Barcelona, Spain|Clinical Study Site, Pamplona, Spain|Clinical Study Site, Chang Hua, Taiwan|Clinical Study Site, Hualien City, Taiwan|Clinical Study Site 1, Kaohsiung, Taiwan|Clinical Study Site 2, Kaohsiung, Taiwan|Clinical Study Site 1, New Taipei City, Taiwan|Clinical Study Site 2, New Taipei, Taiwan|Clinical Study Site 1, Taichung, Taiwan|Clinical Study Site 2, Taichung, Taiwan|Clinical Study Site 1, Taipei, Taiwan|Clinical Study Site 2, Taipei, Taiwan|Clinical Study Site 3, Taipei, Taiwan|Clinical Study Site, Lop Buri, Muang, Thailand|Clinical Study Site, Hat Yai, Songkhla, Thailand|Clinical Study Site #1, Bangkok, Thailand|Clinical Study Site #2, Bangkok, Thailand|Clinical Study Site, Chiang Rai, Thailand|Clinical Study Site, Khon Kaen, Thailand|Clinical Study Site, Lampang, Thailand|Clinical Study Site, Phitsanulok, Thailand|Clinical Study Site, Ratchathewi, Thailand|Clinical Study Site, Udon Thani, Thailand|Clinical Study Site 1, Adana, Turkey|Clinical Study Site 2, Adana, Turkey|Clinical Study Site 1, Ankara, Turkey|Clinical Study Site 2, Ankara, Turkey|Clinical Study Site 3, Ankara, Turkey|Clinical Study Site 4, Ankara, Turkey|Clinical Study Site 5, Ankara, Turkey|Clinical Study Site, Edirne, Turkey|Clinical Study Site 1, Istanbul, Turkey|Clinical Study Site 2, Istanbul, Turkey|Clinical Study Site 3, Istanbul, Turkey|Clinical Study Site 4, Istanbul, Turkey|Clinical Study Site 1, İzmir, Turkey|Clinical Study Site 2, İzmir, Turkey|Clinical Study Site 3, İzmir, Turkey|Clinical Study Site, Samsun, Turkey|Clinical Study Site, Dnepropetrovsk, Ukraine|Clinical Study Site, Ivano-Frankivs'k, Ukraine|Clinical Study Site, Kharkiv, Ukraine|Clinical Study Site, Kherson, Ukraine|Clinical Study Site 1, Kiev, Ukraine|Clinical Study Site 2, Kiev, Ukraine|Clinical Study Site, Kirovohrad, Ukraine|Clinical Study Site 1, Kyiv, Ukraine|Clinical Study Site 2, Kyiv, Ukraine|Clinical Study Site, Vinnytsia, Ukraine|Clinical Study Site, Zaporozhye, Ukraine|Clinical Study Site, Úzhgorod, Ukraine",,"https://ClinicalTrials.gov/show/NCT03088540"
147,"NCT03005782","Study of REGN3767 (Anti-LAG-3) With or Without REGN2810 (Anti-PD1) in Advanced Cancers",,"Recruiting","No Results Available","Malignancies","Drug: REGN3767|Drug: cemiplimab","Rate of dose limiting toxicities (Dose Escalation Phase)|Rate of adverse events (Dose Escalation Phase)|Rate of serious adverse events (Dose Escalation Phase)|Occurrence of death (Dose Escalation Phase)|Number of patients with laboratory abnormalities (grade 3 or higher per Common Terminology Criteria for Adverse Events [CTCAE]) (Dose Escalation Phase)|Area under the curve (AUC) computed from time zero to the time of the last concentration [AUCall] (Primary: Dose Escalation Phase; Secondary: Dose Expansion Phase)|AUCall-to-dose ratio [AUCall/Dose] (Primary: Dose Escalation Phase; Secondary: Dose Expansion Phase)|AUC from time zero extrapolated to infinity [AUCinf] (Primary: Dose Escalation Phase; Secondary: Dose Expansion Phase)|AUCinf-to-dose ratio [AUCinf/dose] (Primary: Dose Escalation Phase; Secondary: Dose Expansion Phase)|AUC computed from time zero to the time of the last positive concentration [AUClast] (Primary: Dose Escalation Phase; Secondary: Dose Expansion Phase)|AUClast-to-dose ratio [AUClast/dose] (Primary: Dose Escalation Phase; Secondary: Dose Expansion Phase)|Clearance [CL] (Primary: Dose Escalation Phase; Secondary: Dose Expansion Phase)|Maximum Plasma Concentration [Cmax] (Primary: Dose Escalation Phase; Secondary: Dose Expansion Phase)|Cmax-to-dose ratio [Cmax/dose] (Primary: Dose Escalation Phase; Secondary: Dose Expansion Phase)|Last positive (quantifiable) concentration [Clast] (Primary: Dose Escalation Phase; Secondary: Dose Expansion Phase)|Mean residence time extrapolated to infinity [MRTinf] (Dose Escalation Phase)|Mean residence time when the drug concentration profile is based on values up to and including the last positive concentration [MRTlast] (Primary: Dose Escalation Phase; Secondary: Dose Expansion Phase)|Observed terminal half-life [t1/2] (Primary: Dose Escalation Phase; Secondary: Dose Expansion Phase)|t1/2 beta (Primary: Dose Escalation Phase; Secondary: Dose Expansion Phase)|Time of the last positive (quantifiable) concentration [tlast] (Primary: Dose Escalation Phase; Secondary: Dose Expansion Phase)|Time to Cmax [tmax] (Primary: Dose Escalation Phase; Secondary: Dose Expansion Phase)|Volume of distribution at steady state [Vss] (Primary: Dose Escalation Phase; Secondary: Dose Expansion Phase)|Volume of distribution of the terminal phase [Vz] (Primary: Dose Escalation Phase; Secondary: Dose Expansion Phase)|Objective response rate based on RECIST 1.1 for Solid Tumors (Dose Expansion phase)|Objective response rate by Lugano criteria for Lymphoma (Dose Expansion Phase)|Objective response rate per Response Evaluation Criteria in Solid Tumors (RECIST) 1.1 (solid tumors) (Dose Escalation Phase)|Objective response rate per Lugano criteria (lymphomas) (Dose Escalation Phase)|Best overall response based on RECIST 1.1 criteria (Dose Escalation Phase)|Best overall response based on irRECIST criteria (Dose Escalation Phase)|Best overall response based on Lugano criteria (Dose Escalation Phase)|Duration of response based on RECIST criteria (Dose Escalation Phase)|Duration of response based on irRECIST criteria (Dose Escalation Phase)|Duration of response based on Lugano criteria (Dose Escalation Phase)|Disease control rate based on RECIST criteria (Dose Escalation Phase)|Disease control rate based on irRECIST criteria (Dose Escalation Phase)|Disease control rate based on Lugano criteria (Dose Escalation Phase)|Progression free survival based on RECIST (Dose Escalation Phase)|Progression free survival based on irRECIST (Dose Escalation Phase)|Progression free survival based on Lugano criteria (Dose Escalation Phase)|Incidence of adverse events (Dose Expansion Phase)|Incidence of serious adverse events (Dose Expansion Phase)|Incidence of death (Dose Expansion Phase)|Number of patients with laboratory abnormalities (grade 3 or higher per Common Terminology Criteria for Adverse Events [CTCAE]) (Dose Expansion Phase)|Incidence of anti-drug antibodies (Dose Escalation Phase and Dose Expansion Phase)","Regeneron Pharmaceuticals|Sanofi","All","18 Years and older   (Adult, Older Adult)","Phase 1","669","Industry","Interventional","Allocation: Non-Randomized|Intervention Model: Parallel Assignment|Masking: None (Open Label)|Primary Purpose: Treatment","R3767-ONC-1613|2016-002789-30","November 7, 2016","January 1, 2024","January 1, 2024","December 29, 2016",,"July 26, 2021","California Cancer Associates for Research and Excellence, Encinitas, California, United States|California Cancer Associates For Research And Excellence, Fresno, California, United States|University of California San Diego (UCSD), La Jolla, California, United States|The Angeles Clinic, Los Angeles, California, United States|University of California Davis Health Systems, Sacramento, California, United States|California Pacific Medical Center (CPMC), San Francisco, California, United States|University of Colorado Cancer Center, Aurora, Colorado, United States|Lombardi Comprehensive Cancer Center - MedStar Georgetown University Hospital, Washington, District of Columbia, United States|Miami Cancer Institute, Miami, Florida, United States|Orlando Health, Inc, Orlando, Florida, United States|Winship Cancer Institute at Emory University, Atlanta, Georgia, United States|University of Kansas Clinical Research Center, Fairway, Kansas, United States|Dana Farber Cancer Institute, Jamaica Plain, Massachusetts, United States|Henry Ford Health Hospital, Detroit, Michigan, United States|Cancer and Hematology Centers of Western Michigan, Grand Rapids, Michigan, United States|Washington University in Saint Louis, Saint Louis, Missouri, United States|John Theurer Cancer Center, Hackensack University Medical Center, Hackensack, New Jersey, United States|Rutgers Cancer Institute of New Jersey, New Brunswick, New Jersey, United States|New Mexico Cancer Care Alliance-UNM Cancer Center, Albuquerque, New Mexico, United States|Roswell Park Cancer Institute, Buffalo, New York, United States|Northwell Health-Monter Cancer Center, Lake Success, New York, United States|Laura & Isaac Perlmutter Cancer Center, New York, New York, United States|Columbia University, New York, New York, United States|Memorial Sloan-Kettering Cancer Center, New York, New York, United States|Levine Cancer Institute, Charlotte, North Carolina, United States|University Hospitals Seidman Cancer Center and Case Western Reserve University, Cleveland, Ohio, United States|Stephenson Cancer Center, Oklahoma City, Oklahoma, United States|UPMC- Hillman Cancer Center, Pittsburgh, Pennsylvania, United States|Rhode Island Hospital, Providence, Rhode Island, United States|Hollings Cancer Center - Medical University of South Carolina, Charleston, South Carolina, United States|Sarah Cannon Research Institute, Nashville, Tennessee, United States|The University of Texas MD Anderson Cancer Center, Houston, Texas, United States|South Texas Oncology and Hematology, San Antonio, Texas, United States|Virginia Cancer Care Specialist, PC, Fairfax, Virginia, United States|The University of Western Australia - The Queen Elizabeth II Medical Centre (QEIIMC) - Sir Charles Gairdner Hospital (SCGH), Perth, Western Australia, Australia|Royal Brisbane and Women's Hospital, Brisbane, Australia|Peter Maccallum Cancer Centre (PMCC), Melbourne, Australia|St. Vincents University Hospital, Dublin, Ireland|Seoul National University Hospital, Seoul, Korea, Republic of|Severance Hospital, Yonsei University Health System, Seoul, Korea, Republic of|Asan Medical Center, Seoul, Korea, Republic of|Samsung Medical Center, Seoul, Korea, Republic of|Guy's Hospital, London, Europe, United Kingdom|University Of Oxford - Churchill Hospital, Headington, Oxford, United Kingdom",,"https://ClinicalTrials.gov/show/NCT03005782"
148,"NCT03002376","An Exploratory Tumor Biopsy-driven Study to Understand the Relationship Between Biomarkers and Clinical Response in Melanoma Patients Receiving REGN2810 (Anti-PD-1)",,"Completed","No Results Available","Melanoma","Drug: REGN2810","Correlation between changes in the tumor microenvironment and the change in tumor volume following REGN2810 treatment versus baseline|Correlation between baseline tumor characteristics and the change in tumor volume following treatment in REGN2810|Incidence of Adverse Event (AEs) in patients treated with REGN2810|REGN2810 serum concentrations|Anti-REGN2810 antibody levels|The progression-free survival (PFS) in patients treated with REGN2810|The overall response rate in patients treated with REGN2810","Regeneron Pharmaceuticals|Sanofi","All","18 Years and older   (Adult, Older Adult)","Phase 1","47","Industry","Interventional","Allocation: N/A|Intervention Model: Single Group Assignment|Masking: None (Open Label)|Primary Purpose: Treatment","R2810-ONC-1606|2016-002755-16","April 10, 2017","March 5, 2019","March 19, 2020","December 23, 2016",,"April 20, 2020","Seoul National University Hospital, Seoul, Korea, Republic of|Asan Medical Center, Seoul, Korea, Republic of|Samsung Medical Center, Seoul, Korea, Republic of|Severance Hospital-Yonsei University College of Medicine, Seoul, Korea, Republic of|Radboud University Medical Center, Nijmegen, Netherlands|Military Medical Academy, Belgrade, Serbia|Guy's Hospital and St. Thomas NHS Foundation Trust, London, United Kingdom|Churchill Hospital, Oxford, United Kingdom",,"https://ClinicalTrials.gov/show/NCT03002376"
149,"NCT02958436","A Study of Intravenously or Subcutaneously Administered REGN3500 in Healthy Adult Subjects",,"Completed","No Results Available","Healthy Volunteers","Drug: REGN3500|Drug: Placebo","The incidence and severity of treatment-emergent adverse events in subjects treated with REGN3500|Obtain the pharmacokinetic parameters (Cmax) that describe the serum concentration time profile of REGN3500|Obtain the pharmacokinetic parameters (Tmax) that describe the serum concentration time profile of REGN3500|Obtain the pharmacokinetic parameters (AUClast) that describe the serum concentration time profile of REGN3500","Regeneron Pharmaceuticals|Sanofi","All","18 Years to 65 Years   (Adult, Older Adult)","Phase 1","40","Industry","Interventional","Allocation: Randomized|Intervention Model: Parallel Assignment|Masking: Triple (Participant, Investigator, Outcomes Assessor)|Primary Purpose: Other","R3500-HV-1551|2016-002012-41","August 2016","June 18, 2017","October 3, 2017","November 8, 2016",,"November 8, 2017","Site 1, Ghent, Belgium",,"https://ClinicalTrials.gov/show/NCT02958436"
150,"NCT02943239","Study of Safety, Tolerability, and Pharmacokinetics of REGN2477 Alone and in Combination With REGN1033 in Healthy Postmenopausal Women and Healthy Adult Men",,"Completed","No Results Available","Healthy Volunteers","Drug: REGN1033|Drug: REGN2477|Other: Placebo","Incidence and severity of treatment-emergent adverse events (TEAEs)|Percent change in thigh muscle volume as measured by MRI|Change in thigh muscle volume as measured by MRI|Percent change in total and regional body composition as measured by Dual X-ray absorptiometry (DXA)|Change in total body composition as measured by DXA|Change in regional body composition as measured by DXA|Pharmacokinetic profile of REGN2477 assessed via measurement of concentrations of REGN2477 in serum over time|Pharmacokinetic profile of REGN1033 assessed via measurement of concentrations of REGN1033 in serum overtime|Change in total Activin A levels in blood|Change in total GDF8 levels in blood|Presence or absence of antibodies against REGN2477 and REGN1033","Regeneron Pharmaceuticals","All","35 Years to 70 Years   (Adult, Older Adult)","Phase 1","82","Industry","Interventional","Allocation: Randomized|Intervention Model: Parallel Assignment|Masking: Quadruple (Participant, Care Provider, Investigator, Outcomes Assessor)|Primary Purpose: Basic Science","R2477-1033-HV-1621|2016-002979-95","December 7, 2016","April 30, 2019","April 30, 2019","October 24, 2016",,"June 19, 2019","Auckland, New Zealand|Christchurch, New Zealand",,"https://ClinicalTrials.gov/show/NCT02943239"
151,"NCT02870400","A Study to Examine the Safety and Tolerability of Single Ascending Doses of REGN2477",,"Completed","No Results Available","Healthy Volunteers","Drug: REGN2477|Drug: Placebo","Treatment emergent adverse events (TEAEs) through day 113 in participants treated with REGN2477|Pharmacokinetic profile of REGN2477, assessed via serum concentrations of REGN2477 over time|Immunogenicity of REGN2477, as determined by the presence or absence of Anti-drug antibody (ADA) to REGN2477 over time","Regeneron Pharmaceuticals","Female","18 Years to 65 Years   (Adult, Older Adult)","Phase 1","41","Industry","Interventional","Allocation: Randomized|Intervention Model: Parallel Assignment|Masking: Triple (Participant, Investigator, Outcomes Assessor)|Primary Purpose: Basic Science","R2477-HV-1525","July 2016","January 12, 2017","January 12, 2017","August 17, 2016",,"February 20, 2017","Antwerp, Belgium",,"https://ClinicalTrials.gov/show/NCT02870400"
152,"NCT02828397","Study of the Blood Concentrations of Two Formulations of REGN2222 in Healthy Subjects",,"Completed","No Results Available","Healthy Volunteers","Drug: REGN2222","Serum REGN2222 concentration-time curve (AUC)|Peak REGN2222 concentration (Cmax)|Treatment-emergent adverse events (TEAEs) from baseline to the end of the study|Presence or absence of anti-drug antibody (ADA)","Regeneron Pharmaceuticals","All","18 Years to 60 Years   (Adult)","Phase 1","28","Industry","Interventional","Allocation: Randomized|Intervention Model: Parallel Assignment|Masking: None (Open Label)|Primary Purpose: Basic Science","R2222-HV-1520","April 2016","September 2016","September 2016","July 11, 2016",,"November 4, 2016","Daytona Beach, Florida, United States|Evansville, Indiana, United States",,"https://ClinicalTrials.gov/show/NCT02828397"
153,"NCT02777151","Study of Safety, Tolerability, and Pharmacokinetics of REGN3470-3471-3479 in Healthy Adult Volunteers",,"Completed","No Results Available","Healthy Volunteers","Drug: REGN3470-3471-3479|Drug: Placebo","Incidence and severity of TEAEs through the end of the study visit in subjects treated with REGN3470-3471-3479 in a fixed dose combination|Concentration of REGN3479 in serum over time|Concentration of REGN3471 in serum over time|Concentration of REGN3470 in serum over time|The presence or absence of antibodies against REGN3470 over time|The presence or absence of antibodies against REGN3471 over time|The presence or absence of antibodies against REGN3479 over time","Regeneron Pharmaceuticals|Department of Health and Human Services","All","18 Years to 60 Years   (Adult)","Phase 1","24","Industry|U.S. Fed","Interventional","Allocation: Randomized|Intervention Model: Parallel Assignment|Masking: Triple (Participant, Investigator, Outcomes Assessor)|Primary Purpose: Basic Science","R3470-3471-3479-HV-1528","May 27, 2016","April 26, 2017","April 26, 2017","May 19, 2016",,"February 5, 2018","Evansville, Indiana, United States",,"https://ClinicalTrials.gov/show/NCT02777151"
154,"NCT02760498","Study of REGN2810 in Patients With Advanced Cutaneous Squamous Cell Carcinoma",,"Active, not recruiting","No Results Available","Advanced Cutaneous Squamous Cell Carcinoma","Drug: cemiplimab","Overall Response Rate (ORR)|Investigator Assessments of ORR|Duration of response|PFS (progression-free survival)|Overall Survival|Complete Response (CR) Rate|Change in scores of patient reported outcomes on EORTC QLQ-C30|Incidence of Treatment Emergent Adverse Events (TEAEs)|Cemiplimab PK: Concentration at end-of-infusion (Ceoi) (IV)|Cemiplimab PK: Peak concentrations (Cmax) (SC)|Cemiplimab PK: Pre-infusion concentration (Ctrough)|Cemiplimab PK: Time of end-of-infusion (teoi)|Cemiplimab PK: Time to peak concentration (tmax) (SC)|Cemiplimab PK: Area under the plasma concentration-time curve after the first SC or IV dose|Cemiplimab PK: Absolute bioavailability after SC administration|Anti-cemiplimab antibodies|Immunohistochemistry (IHC) assessment of correlation between PD-L1 status and ORR|IHC assessment of correlation between PD-L1 and DOR|IHC assessment of correlation between PD-L1 and PFS","Regeneron Pharmaceuticals","All","18 Years and older   (Adult, Older Adult)","Phase 2","432","Industry","Interventional","Allocation: Non-Randomized|Intervention Model: Parallel Assignment|Masking: None (Open Label)|Primary Purpose: Treatment","R2810-ONC-1540|2016-000105-36","April 7, 2016","October 19, 2023","October 19, 2023","May 3, 2016",,"January 13, 2022","University of Arizona Cancer Center, Phoenix, Arizona, United States|Mayo Clinic, Phoenix, Arizona, United States|City of Hope Hospital, Duarte, California, United States|University of California, Los Angeles, Los Angeles, California, United States|Stanford University, Redwood City, California, United States|University of California, San Diego, San Diego, California, United States|University of Colorado, Denver, Aurora, Colorado, United States|Mount Sinai Comprehensive Cancer Center, Miami Beach, Florida, United States|H. Lee Moffitt Cancer Center, Tampa, Florida, United States|Northwestern University, Chicago, Illinois, United States|Norton Cancer Institute, Louisville, Kentucky, United States|Massachusetts General Hospital, Boston, Massachusetts, United States|Dana-Farber Cancer Institute, Boston, Massachusetts, United States|Barbara Ann Karmanos Cancer Institute, Detroit, Michigan, United States|St. Louis University, Saint Louis, Missouri, United States|Washington University in St. Louis, Saint Louis, Missouri, United States|Nebraska Methodist Hospital, Omaha, Nebraska, United States|New York University, New York, New York, United States|Memorial Sloan Kettering Cancer Center, New York, New York, United States|University of Rochester Medical Center, Rochester, New York, United States|Cleveland Clinic, Cleveland, Ohio, United States|St. Luke's Hematology Oncology Specialists, Easton, Pennsylvania, United States|Penn State Hershey Medical Center, Hershey, Pennsylvania, United States|Dermatology and Laser Center of Charleston, Charleston, South Carolina, United States|MD Anderson Cancer Center, Houston, Texas, United States|Huntsman Cancer Institute, Salt Lake City, Utah, United States|The Canberra Hospital, Garran, Australian Capital Territory, Australia|Gosford Hospital, Gosford, New South Wales, Australia|Royal North Shore Hospital, St Leonards, New South Wales, Australia|Calvary Mater Newcastle, Waratah, New South Wales, Australia|Royal Brisbane & Women's Hospital, Herston, Queensland, Australia|Princess Alexandra Hospital, Woolloongabba, Queensland, Australia|Adelaide Cancer Centre, Kurralta Park, South Australia, Australia|Peter MacCallum Cancer Centre, Melbourne, Victoria, Australia|Border Medical Oncology, Wodonga, Victoria, Australia|Sir Charles Gairdner Hospital, Nedlands, Western Australia, Australia|Hospital de Clinicas de Porto Alegre, Porto Alegre, Rio Grande Do Sul, Brazil|Liga Paranaense de Combate Ao Cancer - Hospital Erasto Gaertner, Curitiba, Brazil|Fundação São Francisco Xavier-Hospital Márcio Cunha, Ipatinga, Brazil|Animi, Lages, Brazil|Instituto do Cancer do Estado de São Paulo ICESP, Sao Paulo, Brazil|Fundação Antônio Prudente - AC Camargo Câncer Center, São Paulo, Brazil|Hôpital Claude Huriez, Lille, Nord, France|Hopital Avicenne, Bobigny, France|Hôpital Saint-André, Bordeaux, France|CHU Dijon Bourgogne, Dijon, France|CHRU Grenoble, Grenoble, France|Hopitaux de La Timone, Marseille, France|Centre Hospitalier Universitaire de Nantes, Nantes, France|Hopital Cochin, Paris, France|Hôpital Saint Louis, Paris, France|Centre Hospitalier Lyon Sud, Pierre Bénite, France|Institut Gustave Roussy, Villejuif, France|Universitätsklinikum Tübingen, Tübingen, Baden-Württemberg, Germany|LMU Klinikum der Universität München, Munich, Bayern, Germany|Medizinische Hochschule Hannover, Hannover, Niedersachsen, Germany|Universitätsklinikum Essen, Essen, Nordrhein-Westfalen, Germany|Universitätsklinikum Carl Gustav Carus, Dresden, Sachsen, Germany|Universitatsklinikum Schleswig-Holstein, Kiel, Schleswig-Holstein, Germany|Charitè Campus Mitte, Berlin, Germany|SRH Wald-Klinikum Gera, Gera, Germany|Andreas Sygros Hosptial-University of Athen, Athens, Greece|Istituto Nazionale Per Lo Studio E La Cura Dei Tumori Fondazione Giovanni Pascale, Napoli, Campania, Italy|Istituto Oncologico Veneto - I.R.C.C.S., Padova, Veneto, Italy|ASST degli Spedali Civili di Brescia - Spedali Civili di Brescia, Brescia, Italy|Ospedale San Salvatore, L'Aquila, Italy|Istituto Europeo Di Oncologia, Milan, Italy|Fondazione Policlinico Universitario A Gemelli, Roma, Italy|ICO l'Hospitalet - Hospital Duran i Reynals, L'Hospitalet de Llobregat, Barelona, Spain|Hospital Clinic de Barcelona, Barcelona, Cataluna, Spain|Hospital Universitario Vall d'Hebron, Barcelona, Spain|Hospital Universitario Germans Trias i Pujol, Barcelona, Spain|C.H. Regional Reina Sofia - PPDS, Cordoba, Spain|Hospital Universitario Ramon y Cajal, Madrid, Spain|Hospital Universitario Fundacion Jimenez Diaz, Madrid, Spain|Hospital Universitario 12 de Octubre, Madrid, Spain|Hospital Universitario Marques de Valdecilla, Santander, Spain|Fundacion Instituto Valenciano de Oncología, Valencia, Spain",,"https://ClinicalTrials.gov/show/NCT02760498"
155,"NCT02755649","A Study to Assess the Efficacy and Safety of Dupilumab in Participants With Severe Atopic Dermatitis (AD) That Are Not Controlled With Oral Cyclosporine A (CSA) or for Those Who Cannot Take Oral CSA Because it is Not Medically Advisable",,"Completed","Has Results","Atopic Dermatitis","Drug: Dupilumab|Drug: Matching Placebo","Percentage of Participants With Eczema Area and Severity Index (EASI) 75 (≥75% Improvement From Baseline) at Week 16|Percent Change From Baseline in Eczema Area and Severity Index (EASI) Score at Week 16|Percent Change From Baseline in Weekly Average of Peak Pruritus Numerical Rating Scale (NRS) at Week 16|Percent Change From Baseline in SCORing Atopic Dermatitis (SCORAD) Score at Week 16|Percentage of Participants With Improvement (Reduction ≥4 Points) of Weekly Average of Peak Daily Pruritus NRS From Baseline to Week 16|Change From Baseline in Percent Body Surface Area (BSA) Involvement With Atopic Dermatitis (AD) at Week 16|Percentage of Participants With Investigator Global Assessment (IGA) 0 or 1 (on the 0 to 4 IGA Scale) and a Reduction From Baseline of ≥2 Points at Week 16|Change From Baseline in the Dermatology Life Quality Index (DLQI) at Week 16|Change From Baseline in the Patient Oriented Eczema Measure (POEM) at Week 16|Percentage of Participants With Eczema Area and Severity Index (EASI) Score (≥75% Improvement From Baseline) at Week 16 for Participants With Prior CSA Use|Change From Baseline in Mean Weekly Dose of Topical Corticosteroid (TCS) Use During Treatment Period|Change From Baseline in Total Hospital Anxiety and Depression Scale (HADS) Score at Week 16|Percentage of Participants Achieving SCORAD 50 (≥50% Improvement From Baseline) at Week 16|Percent Change From Baseline in the Total Global Individual Signs Score (GISS) at Week 16 (Erythema, Infiltration/ Papulation, Excoriations, Lichenification)|Percent Change From Baseline in Weekly Average of Peak Pruritus Numerical Rating Scale (NRS) Score at Week 2|Percentage of Participants With Skin Infection Treatment Emergent Adverse Events (TEAEs) (Excluding Herpetic Infections) From Baseline Through Treatment Period|Percentage of Participants Having at Least One Serious Treatment Emergent Adverse Event (TEAE) Through Treatment Period|Percentage of Participants Having at Least One Treatment-Emergent Adverse Event (TEAE) Leading to Treatment Discontinuation Through Treatment Period|Percentage of Participants With Treatment-Emergent Adverse Events Through Treatment Period","Regeneron Pharmaceuticals|Sanofi","All","18 Years and older   (Adult, Older Adult)","Phase 3","325","Industry","Interventional","Allocation: Randomized|Intervention Model: Parallel Assignment|Masking: Quadruple (Participant, Care Provider, Investigator, Outcomes Assessor)|Primary Purpose: Treatment","R668-AD-1424","January 31, 2016","January 4, 2017","March 31, 2017","April 29, 2016","August 20, 2020","August 20, 2020","Site 1, Vienna, Austria|Site 2, Vienna, Austria|Brussels, Belgium|Leuven, Belgium|Loverval, Belgium|Site 1, Berlin, Germany|Site 2, Berlin, Germany|Site 3, Berlin, Germany|Site 4, Berlin, Germany|Site 5, Berlin, Germany|Site 6, Berlin, Germany|Site 7, Berlin, Germany|Bochum, Germany|Site 1, Dresden, Germany|Site 2, Dresden, Germany|Site 3, Dresden, Germany|Erlangen, Germany|Frankfurt am Main, Germany|Site 1, Hamburg, Germany|Site 2, Hamburg, Germany|Heidelberg, Germany|Kiel, Germany|Langenau, Germany|Leipzig, Germany|Lubeck, Germany|Magdeburg, Germany|Mahlow, Germany|Mainz, Germany|Muenster, Germany|Site 1, Munchen, Germany|Site 2, Munchen, Germany|Osnabrück, Germany|Selters, Germany|Stuttgart, Germany|Tubingen, Germany|Dublin, Ireland|Amsterdam, Netherlands|Utrecht, Netherlands|Site 1, Bialystok, Poland|Site 1, Bydgoszcz, Poland|Site 2, Bydgoszcz, Poland|Gdansk, Poland|Site 1, Katowice, Poland|Site 2, Katowice, Poland|Site 3, Katowice, Poland|Kielce, Poland|Site 1, Krakow, Poland|Site 2, Krakow, Poland|Site 1, Lodz, Poland|Site 2, Lodz, Poland|Site 3, Lodz, Poland|Lublin, Poland|Szczecin, Poland|Warsaw, Poland|Site 1, Warszawa, Poland|Site 2, Warszawa, Poland|Site 1, Wroclaw, Poland|Site 2, Wroclaw, Poland|Zgierz, Poland|Chelyabinsk, Russian Federation|Kazan, Russian Federation|Moscow, Russian Federation|Ryazan, Russian Federation|Saint Petersburg, Russian Federation|Kosice, Slovakia|Svidnik, Slovakia|Site 1, Barcelona, Spain|Site 2, Barcelona, Spain|Site 1, London, United Kingdom|Site 2, London, United Kingdom|Oxford, United Kingdom|Portsmouth, United Kingdom|Sheffield, United Kingdom",,"https://ClinicalTrials.gov/show/NCT02755649"
156,"NCT02741739","Study of the Blood Concentrations of Two Formulations of REGN1033 in Healthy Subjects",,"Completed","No Results Available","Healthy","Drug: REGN1033","Serum REGN1033 concentration-time curve (AUC)|Peak REGN1033 concentration (Cmax)|Treatment-emergent adverse events (TEAEs) from baseline to the end of the study|Presence or absence of anti-drug antibody (ADA)","Regeneron Pharmaceuticals","All","18 Years to 65 Years   (Adult, Older Adult)","Phase 1","28","Industry","Interventional","Allocation: Randomized|Intervention Model: Parallel Assignment|Masking: None (Open Label)|Primary Purpose: Basic Science","R1033-HV-1503","March 2016","April 2016","May 2016","April 18, 2016",,"October 14, 2016","San Antonio, Texas, United States",,"https://ClinicalTrials.gov/show/NCT02741739"
157,"NCT02712008","Anti-vasculaR Endothelial Growth Factor plUs Anti-angiopoietin 2 in Fixed comBination therapY: Evaluation for the Treatment of Diabetic Macular Edema","RUBY","Completed","Has Results","Diabetic Macular Edema","Drug: REGN910-3|Drug: Intravitreal Aflibercept Injection (IAI)","Change From Baseline in Best Corrected Visual Acuity (BCVA) Measured by Early Treatment Diabetic Retinopathy Study (ETDRS) Letter Score at Week 12|Change From Baseline in Best Corrected Visual Acuity (BCVA) Measured by Early Treatment Diabetic Retinopathy Study (ETDRS) Letter Score at Week 36|Change From Baseline in Central Sub-field Retinal Thickness (CST) Measured by Spectral Domain Optical Coherence Tomography (SD-OCT) at Week 12|Change From Baseline in Central Sub-field Retinal Thickness (CST) Measured by Spectral Domain Optical Coherence Tomography (SD-OCT) at Week 36|Percentage of Participants With a ≥ 2-step Improvement at Week 12 in Diabetic Retinopathy Severity Scale (DRSS) From Baseline|Percentage of Participants With a ≥ 2-step Improvement at Week 36 in Diabetic Retinopathy Severity Scale (DRSS) From Baseline","Regeneron Pharmaceuticals|Bayer","All","18 Years and older   (Adult, Older Adult)","Phase 2","302","Industry","Interventional","Allocation: Randomized|Intervention Model: Parallel Assignment|Masking: Quadruple (Participant, Care Provider, Investigator, Outcomes Assessor)|Primary Purpose: Treatment","R910-3-DME-1518","March 2, 2016","July 10, 2017","July 10, 2017","March 17, 2016","October 3, 2018","October 3, 2018","Mesa, Arizona, United States|Tucson, Arizona, United States|Arcadia, California, United States|Beverly Hills, California, United States|Mountain View, California, United States|Oceanside, California, United States|Palm Desert, California, United States|Colorado Springs, Colorado, United States|New London, Connecticut, United States|Lakeland, Florida, United States|Tampa, Florida, United States|Winter Haven, Florida, United States|Augusta, Georgia, United States|Decatur, Georgia, United States|'Aiea, Hawaii, United States|Chicago, Illinois, United States|New Albany, Indiana, United States|Shawnee Mission, Kansas, United States|Lexington, Kentucky, United States|Portland, Maine, United States|Baltimore, Maryland, United States|Rockville, Maryland, United States|Boston, Massachusetts, United States|Grand Rapids, Michigan, United States|Jackson, Michigan, United States|Minneapolis, Minnesota, United States|Florissant, Missouri, United States|Las Vegas, Nevada, United States|Bloomfield, New Jersey, United States|Edison, New Jersey, United States|Teaneck, New Jersey, United States|Albany, New York, United States|Rochester, New York, United States|Asheville, North Carolina, United States|Charlotte, North Carolina, United States|Kingston, Pennsylvania, United States|Florence, South Carolina, United States|West Columbia, South Carolina, United States|Rapid City, South Dakota, United States|Germantown, Tennessee, United States|Nashville, Tennessee, United States|Abilene, Texas, United States|Austin, Texas, United States|Dallas, Texas, United States|Fort Worth, Texas, United States|Harlingen, Texas, United States|Houston, Texas, United States|San Antonio, Texas, United States|The Woodlands, Texas, United States|Willow Park, Texas, United States|Bellevue, Washington, United States","""Study Protocol"", https://ClinicalTrials.gov/ProvidedDocs/08/NCT02712008/Prot_000.pdf|""Statistical Analysis Plan"", https://ClinicalTrials.gov/ProvidedDocs/08/NCT02712008/SAP_001.pdf","https://ClinicalTrials.gov/show/NCT02712008"
158,"NCT02620020","A Study to Determine the Efficacy and Safety of Fasinumab for the Treatment of Adults With Chronic Low Back Pain",,"Completed","Has Results","Low Back Pain","Drug: Fasinumab|Drug: placebo","Change From Baseline to Week 16 in the Average Daily Low Back Pain Index Numeric Rating Scale (LBPI NRS) Score|Change From Baseline to Weeks 2, 4, 8, and 12 in the Average Low Back Pain Index Numeric Rating Scale Score (LBPI NRS)|Change From Baseline to Week 16 in Roland Morris Disability Questionnaire (RMDQ) Total Score|Change From Baseline to Week 16 in the Patient Global Assessment (PGA) of Low Back Pain (LBP) Score","Regeneron Pharmaceuticals","All","35 Years and older   (Adult, Older Adult)","Phase 2|Phase 3","563","Industry","Interventional","Allocation: Randomized|Intervention Model: Parallel Assignment|Masking: Quadruple (Participant, Care Provider, Investigator, Outcomes Assessor)|Primary Purpose: Treatment","R475-PN-1524|2015-003782-28","January 26, 2016","February 3, 2017","September 13, 2017","December 2, 2015","August 1, 2019","June 16, 2020","Birmingham, Alabama, United States|Chandler, Arizona, United States|Glendale, Arizona, United States|Mesa, Arizona, United States|Phoenix, Arizona, United States|Scottsdale, Arizona, United States|Tucson, Arizona, United States|Little Rock, Arkansas, United States|Beverly Hills, California, United States|Carlsbad, California, United States|Lakewood, California, United States|Long Beach, California, United States|Sacramento, California, United States|San Diego, California, United States|Santa Rosa, California, United States|Vista, California, United States|Aurora, Colorado, United States|Colorado Springs, Colorado, United States|Littleton, Colorado, United States|Washington, District of Columbia, United States|Clearwater, Florida, United States|Fort Myers, Florida, United States|Leesburg, Florida, United States|Miami, Florida, United States|Orlando, Florida, United States|Chicago, Illinois, United States|Evansville, Indiana, United States|Council Bluffs, Iowa, United States|Worcester, Massachusetts, United States|Edina, Minnesota, United States|Kansas City, Missouri, United States|Saint Louis, Missouri, United States|Elkhorn, Nebraska, United States|Henderson, Nevada, United States|Las Vegas, Nevada, United States|Jamaica, New York, United States|New York, New York, United States|Williamsville, New York, United States|Cary, North Carolina, United States|High Point, North Carolina, United States|Raleigh, North Carolina, United States|Salisbury, North Carolina, United States|Wilmington, North Carolina, United States|Akron, Ohio, United States|Cincinnati, Ohio, United States|Columbus, Ohio, United States|Oklahoma City, Oklahoma, United States|Duncansville, Pennsylvania, United States|Anderson, South Carolina, United States|Greer, South Carolina, United States|Bristol, Tennessee, United States|Knoxville, Tennessee, United States|Cypress, Texas, United States|Dallas, Texas, United States|Lubbock, Texas, United States|Plano, Texas, United States|San Antonio, Texas, United States|Salt Lake City, Utah, United States|London, Ontario, Canada|Toronto, Ontario, Canada|Prague, Czechia|Rychnov Nad Kneznou, Czechia|Aalborg, Denmark|Ballerup, Denmark|Tallinn, Estonia|Budapest, Hungary|Gyula, Hungary|Szolnok, Hungary|Bialystok, Poland|Lodz, Poland|Lublin, Poland|Rzeszow, Poland|Warszawa, Poland|Zgierz, Poland","""Study Protocol"", https://ClinicalTrials.gov/ProvidedDocs/20/NCT02620020/Prot_000.pdf|""Statistical Analysis Plan"", https://ClinicalTrials.gov/ProvidedDocs/20/NCT02620020/SAP_001.pdf","https://ClinicalTrials.gov/show/NCT02620020"
159,"NCT02520245","Companion Study for Patients Who Completed Participation in a REGN2810 (Anti-PD-1) Clinical Study",,"Withdrawn","No Results Available","Advanced Malignancies","Drug: REGN2810","Overall survival, from the first dose of study drug administered in the parent REGN2810 clinical study to death or date of last censoring|Safety measured by the number of patients with AEs, AEs leading to discontinuation, SAEs, drug-related AEs, Immune-related adverse events (irAEs), and death as outcome.|Response duration (time from best overall response of partial or complete response, to time to first documented disease progression)|Duration of disease control (time from best overall response of SD as well as PR and CR to time to first do documented disease progression)","Regeneron Pharmaceuticals","All","18 Years and older   (Adult, Older Adult)","Phase 1","0","Industry","Interventional","Allocation: N/A|Intervention Model: Single Group Assignment|Masking: None (Open Label)|Primary Purpose: Treatment","R2810-ONC-1425","August 2015","November 2023","November 2023","August 11, 2015",,"November 6, 2016","City of Hope National Medical Center, Duarte, California, United States|Sarah Cannon Research Institute at HealthONE, Denver, Colorado, United States|Washington University School of Medicine Siteman Cancer Center, St. Louis, Missouri, United States|Laura & Isaac Perlmutter Cancer Center, New York, New York, United States|University Hospitals Case Medical Center, Cleveland, Ohio, United States|Stephenson Cancer Center, Oklahoma City, Oklahoma, United States|Providence Portland Medical Center, Portland, Oregon, United States|Sarah Cannon Research Institute, Nashville, Tennessee, United States|START South Texas Accelerated Research Therapeutics, San Antonio, Texas, United States",,"https://ClinicalTrials.gov/show/NCT02520245"
160,"NCT02516618","Study of Fasinumab (REGN475) in Healthy Japanese and Caucasian Subjects",,"Completed","No Results Available","Healthy Volunteers","Drug: Fasinumab|Drug: Placebo","The primary endpoint in the study is the incidence and severity of treatment emergent adverse events (TEAEs) in participants treated with fasinumab or placebo.|Fasinumab serum concentrations over time|Presence of anti-fasinumab antibodies over time","Regeneron Pharmaceuticals","All","20 Years to 55 Years   (Adult)","Phase 1","72","Industry","Interventional","Allocation: Randomized|Intervention Model: Single Group Assignment|Masking: Quadruple (Participant, Care Provider, Investigator, Outcomes Assessor)|Primary Purpose: Basic Science","R475-PN-1516","July 2015","February 2016","February 2016","August 6, 2015",,"May 12, 2016","Glendale, California, United States",,"https://ClinicalTrials.gov/show/NCT02516618"
161,"NCT02447276","Study of REGN475 in Patients With Pain Due to Osteoarthritis of the Knee or Hip",,"Completed","No Results Available","Osteoarthritis, Knee|Osteoarthritis, Hip","Drug: REGN475|Drug: Placebo","The primary endpoint in the study is the change from baseline to week 16 in the Western Ontario and McMaster Osteoarthritis Index (WOMAC) pain subscale score.|Change from baseline to week 16 in the WOMAC physical function subscale score|Change from baseline to week 16 in the Patient Global Assessment score|Incidence of treatment-emergent adverse events (TEAEs)|Incidence of anti-REGN475 antibody development","Regeneron Pharmaceuticals","All","40 Years to 80 Years   (Adult, Older Adult)","Phase 2|Phase 3","421","Industry","Interventional","Allocation: Randomized|Intervention Model: Parallel Assignment|Masking: Triple (Participant, Investigator, Outcomes Assessor)|Primary Purpose: Treatment","R475-PN-1227","May 2015","March 2016","November 2016","May 18, 2015",,"March 27, 2017","Birmingham, Alabama, United States|Mobile, Alabama, United States|Chandler, Arizona, United States|Phoenix, Arizona, United States|Tuscon, Arizona, United States|Hot Spring, Arkansas, United States|Little Rock, Arkansas, United States|Anaheim, California, United States|Beverly Hills, California, United States|El Cajon, California, United States|Sacramento, California, United States|San Diego, California, United States|Santa Ana, California, United States|Thousand Oaks, California, United States|Upland, California, United States|Walnut Creek, California, United States|Lakewood, Colorado, United States|Clearwater, Florida, United States|Fleming Island, Florida, United States|Jacksonville, Florida, United States|Miami, Florida, United States|Orlando, Florida, United States|Palm Harbor, Florida, United States|Tamarac, Florida, United States|Tampa, Florida, United States|West Palm Beach, Florida, United States|Weston, Florida, United States|Winter Haven, Florida, United States|Decatur, Georgia, United States|Honolulu, Hawaii, United States|Chicago, Illinois, United States|Indianapolis, Indiana, United States|New Orleans, Louisiana, United States|Elkridge, Maryland, United States|Frederick, Maryland, United States|Worcester, Massachusetts, United States|St. Clair Shores, Michigan, United States|Traverse City, Michigan, United States|Hattiesburg, Mississippi, United States|Kansas City, Missouri, United States|St. Louis, Missouri, United States|Omaha, Nebraska, United States|Brooklyn, New York, United States|Hartsdale, New York, United States|New York, New York, United States|Plainview, New York, United States|Rochester, New York, United States|Charlotte, North Carolina, United States|High Point, North Carolina, United States|Raleigh, North Carolina, United States|Cincinnati, Ohio, United States|Cleveland, Ohio, United States|Oklahoma City, Oklahoma, United States|Tulsa, Oklahoma, United States|Bensalem, Pennsylvania, United States|Duncansville, Pennsylvania, United States|Jenkintown, Pennsylvania, United States|Warwick, Rhode Island, United States|Mount Pleasant, South Carolina, United States|Jackson, Tennessee, United States|Jefferson City, Tennessee, United States|Memphis, Tennessee, United States|Cypress, Texas, United States|Dallas, Texas, United States|Lubbock, Texas, United States|Mesquite, Texas, United States|Plano, Texas, United States|Waco, Texas, United States|Salt Lake City, Utah, United States|Sandy, Utah, United States|West Jordan, Utah, United States|Norfolk, Virginia, United States",,"https://ClinicalTrials.gov/show/NCT02447276"
162,"NCT02418754","Study of Intravitreal REGN2176-3 in Participants With Neovascular (""Wet"") Age-Related Macular Degeneration (AMD)","CAPELLA","Terminated","Has Results","Neovascular Age-Related Macular Degeneration","Drug: REGN2176-3|Drug: Intravitreal Aflibercept Injection (IAI)","Change From Baseline in Best Corrected Visual Acuity (BCVA) of the Study Eye at Week 12|Change From Baseline in Central Subfield Retinal Thickness (CST) at Week 12, as Measured by Optical Coherence Tomography (OCT)|Percentage of Participants With Complete Resolution of Intraretinal and Subretinal Fluid From Baseline at Week 12 Measured by Optical Coherence Tomography (OCT)|Change From Baseline in Choroidal Neovascularization (CNV) Area at Week 12 Measured by Fluorescein Angiography (FA)|Change From Baseline in Total Lesion Size at Week 12 Measured by Fluorescein Angiography (FA)|Percentage of Participants Who Gained At Least 15 Letters in BCVA From Baseline at Week 12, Measured by 4-meter Early Treatment Diabetic Retinopathy Scale (ETDRS)|Percent Change From Baseline in Subretinal Hyperreflectivity Material (SHM) at Week 12 Measured by Optical Coherence Tomography (OCT)|Change From Baseline in Central Retinal/Lesion Thickness at Week 12 Measured by Optical Coherence Tomography (OCT)","Regeneron Pharmaceuticals","All","50 Years and older   (Adult, Older Adult)","Phase 2","505","Industry","Interventional","Allocation: Randomized|Intervention Model: Parallel Assignment|Masking: Triple (Participant, Investigator, Outcomes Assessor)|Primary Purpose: Treatment","R2176-3-AMD-1417","May 5, 2015","August 17, 2016","April 3, 2017","April 16, 2015","October 26, 2020","October 26, 2020","Phoenix, Arizona, United States|Tucson, Arizona, United States|Arcadia, California, United States|Beverly Hills, California, United States|Irvine, California, United States|Mountain View, California, United States|Oceanside, California, United States|Sacramento, California, United States|Santa Ana, California, United States|Colorado Springs, Colorado, United States|Fort Lauderdale, Florida, United States|Fort Myers, Florida, United States|Jacksonville, Florida, United States|Melbourne, Florida, United States|Miami, Florida, United States|Plantation, Florida, United States|Tampa, Florida, United States|Winter Haven, Florida, United States|Augusta, Georgia, United States|Marietta, Georgia, United States|Chicago, Illinois, United States|Oak Forest, Illinois, United States|Springfield, Illinois, United States|Urbana, Illinois, United States|Iowa City, Iowa, United States|Shawnee Mission, Kansas, United States|Lexington, Kentucky, United States|Paducah, Kentucky, United States|Baltimore, Maryland, United States|Towson, Maryland, United States|Boston, Massachusetts, United States|Jackson, Michigan, United States|Southfield, Michigan, United States|Minneapolis, Minnesota, United States|Florissant, Missouri, United States|Lincoln, Nebraska, United States|Omaha, Nebraska, United States|Las Vegas, Nevada, United States|Bloomfield, New Jersey, United States|New Brunswick, New Jersey, United States|Albuquerque, New Mexico, United States|Albany, New York, United States|East Setauket, New York, United States|Great Neck, New York, United States|New York, New York, United States|Orchard Park, New York, United States|Rochester, New York, United States|Asheville, North Carolina, United States|Charlotte, North Carolina, United States|Cincinnati, Ohio, United States|Oklahoma City, Oklahoma, United States|Portland, Oregon, United States|Kingston, Pennsylvania, United States|Monroeville, Pennsylvania, United States|Philadelphia, Pennsylvania, United States|Florence, South Carolina, United States|Ladson, South Carolina, United States|West Columbia, South Carolina, United States|Rapid City, South Dakota, United States|Knoxville, Tennessee, United States|Memphis, Tennessee, United States|Nashville, Tennessee, United States|Abilene, Texas, United States|Austin, Texas, United States|Dallas, Texas, United States|Fort Worth, Texas, United States|Houston, Texas, United States|McAllen, Texas, United States|San Antonio, Texas, United States|The Woodlands, Texas, United States|Willow Park, Texas, United States|Salt Lake City, Utah, United States|Burlington, Vermont, United States|Fairfax, Virginia, United States|Bellevue, Washington, United States|Akita, Japan|Asahikawa, Japan|Chiyoda-ku, Japan|Fukushima, Japan|Kawasaki, Japan|Matsumoto, Japan|Nagasaki, Japan|Nagoya, Japan|Osaka, Japan",,"https://ClinicalTrials.gov/show/NCT02418754"
163,"NCT02407756","A Study to Determine the Safety and Tolerability of Dupilumab (REGN668/SAR231893) in Patients Aged ≥6 to <18 Years With Atopic Dermatitis (Eczema)",,"Completed","Has Results","Atopic Dermatitis","Drug: Dupilumab","Pharmacokinetics (PK) of Dupilumab: Maximum Plasma Concentration Observed (Cmax) After Single Administration|PK of Dupilumab: Area Under the Plasma Concentration Versus Time Curve (AUClast) After Single Administration|PK of Dupilumab: Trough Dupilumab Concentration in Serum (Ctrough) Before 3rd and 4th Repeated Dose|Percent Reduction From Baseline in Eczema Area and Severity Index (EASI) at Week 12|Percent Reduction From Baseline in SCORing Atopic Dermatitis (SCORAD) Score at Week 12|Percent Reduction From Baseline in Pruritus Numerical Rating Scale (NRS) at Week 12|Percentage of Subjects With Investigator Global Assessment (IGA) Score of ""0"" or ""1"" (Clear or Almost Clear) at Week 12|Percent Reduction From Baseline in Body Surface Area (BSA) at Week 12","Regeneron Pharmaceuticals|Sanofi","All","6 Years to 17 Years   (Child)","Phase 2","78","Industry","Interventional","Allocation: Non-Randomized|Intervention Model: Single Group Assignment|Masking: None (Open Label)|Primary Purpose: Treatment","R668-AD-1412","March 31, 2015","March 31, 2016","March 31, 2016","April 3, 2015","October 5, 2020","November 27, 2020","Markham, Ontario, Canada|Peterborough, Ontario, Canada|Waterloo, Ontario, Canada|Windsor, Ontario, Canada|Kutna Hora, Czechia|Prague, Czechia|Dresden, Germany|Frankfurt, Germany|Gera, Germany|Hamburg, Germany|Kiel, Germany|Luebeck, Germany|Muenster, Germany|Munich, Germany|Tuebingen, Germany|Kaposvar, Hungary|Miskolc, Hungary|Szeged, Hungary|Szolnok, Hungary|Katowice, Poland|Krakow, Poland|Lodz, Poland|Warszawa, Poland|Wroclaw, Poland|Manchester, United Kingdom|Sheffield, United Kingdom",,"https://ClinicalTrials.gov/show/NCT02407756"
164,"NCT02395133","A Study to Confirm the Efficacy and Safety of Different Dupilumab Dose Regimens in Adults With Atopic Dermatitis (AD)","SOLO-CONTINUE","Completed","Has Results","Atopic Dermatitis","Drug: Dupilumab|Drug: Placebo","Difference Between Current Study Baseline and Week 36 in Percent Change in EASI From Parent Study Baseline (NCT02277743 and NCT02277769)|Percentage of Participants With Eczema Area and Severity Index >= 75% [EASI-75] at Baseline of Current Study Maintaining EASI-75 at Week 36|Percentage of Participants Maintaining Investigator Global Assessment (IGA) Response Within 1 Point of Baseline at Week 36|Percentage of Participants Maintaining Investigator Global Assessment (IGA) Response at 0 or 1 Point at Week 36|Percentage of Participants With Weekly Average of Peak Daily Pruritus Numerical Rating Scale (NRS) Score Increased by 3 or More Points From Baseline to Week 35|Time to First Event of Investigator's Global Assessment (IGA) >= 2 for Participants With IGA 0 or 1 at Baseline|Percentage of Participants With Increased Investigator's Global Assessment (IGA) Score 3 or 4 at Week 36|Percentage of Participants With Eczema Area and Severity Index-50 (EASI-50) (>= 50% Reduction in EASI Score) at Week 36|Absolute Change From Baseline in Eczema Area and Severity Index (EASI) at Week 36|Absolute Change From Baseline in SCORing Atopic Dermatitis (SCORAD) Score at Week 36|Absolute Change From Baseline in Peak Daily Pruritus Numerical Rating Scale (NRS) Score at Week 35|Absolute Change From Baseline in Body Surface Area (BSA) Through Week 36|Absolute Change From Baseline Through in Patient Oriented Eczema Measure (POEM) Through Week 36|Absolute Change From Baseline in Dermatology Life Quality Index (DLQI) Through Week 36|Absolute Change From Baseline in Hospital Anxiety Depression Scale (HADS) Through Week 36|Difference Between Current Study Baseline and Week 36 in Percent Change in SCORAD From Parent Study Baseline|Difference Between Current Study Baseline and Week 35 in Percent Change in Peak Weekly Pruritus NRS From Parent Study Baseline|Annualized Event Rate of Skin Infection Treatment- Emergent Adverse Events (TEAEs)|Annualized Event Rate of Flares|Percentage of Well-Controlled Weeks During the On-treatment Period","Regeneron Pharmaceuticals|Sanofi","All","18 Years and older   (Adult, Older Adult)","Phase 3","422","Industry","Interventional","Allocation: Randomized|Intervention Model: Parallel Assignment|Masking: Triple (Participant, Investigator, Outcomes Assessor)|Primary Purpose: Treatment","R668-AD-1415|2014-003384-38","March 25, 2015","July 2016","October 18, 2016","March 20, 2015","October 17, 2018","March 11, 2020",,,"https://ClinicalTrials.gov/show/NCT02395133"
165,"NCT02383212","Study of REGN2810 (Anti-PD-1) in Patients With Advanced Malignancies",,"Completed","No Results Available","Advanced Cancer|Advanced Malignancies","Drug: Cemiplimab|Radiation: Hypofractionated radiotherapy|Drug: Cyclophosphamide|Drug: Docetaxel|Drug: Carboplatin|Drug: GM-CSF|Drug: Paclitaxel|Drug: Pemetrexed","Incidence of Treatment Emergent Adverse Events (TEAEs)|Incidence of abnormal laboratory findings|Number of participants with dose limiting toxicities (DLTs)|Response Evaluation Criteria in Solid Tumors (RECIST) as measured by Computed Tomography (CT) or Magnetic Resonance Imaging (MRI)|Immune-Related Response Criteria (irRC) applied to RECIST measurements|Incidence of development of anti-cemiplimab antibodies|Antitumor activity measured by progression-free survival (PFS)|Antitumor activity measured by overall survival","Regeneron Pharmaceuticals|Sanofi","All","18 Years and older   (Adult, Older Adult)","Phase 1","398","Industry","Interventional","Allocation: Non-Randomized|Intervention Model: Parallel Assignment|Masking: None (Open Label)|Primary Purpose: Treatment","R2810-ONC-1423|2015-002132-41","February 2, 2015","November 18, 2019","November 18, 2019","March 9, 2015",,"January 27, 2020","Banner MD Anderson Cancer Center, Gilbert, Arizona, United States|Western Regional Medical Center, Goodyear, Arizona, United States|Mayo Clinic, Phoenix, Arizona, United States|University of Arizona Cancer Center, Tucson, Arizona, United States|City of Hope National Medical Center, Duarte, California, United States|The Angeles Clinic and Research Institute, Los Angeles, California, United States|Ronald Reagan UCLA Medical Center, Los Angeles, California, United States|Stanford University, Stanford, California, United States|Sarah Cannon Research Institute at HealthONE, Denver, Colorado, United States|Norwalk Hospital, Norwalk, Connecticut, United States|Georgetown University Medical Center, Washington, District of Columbia, United States|H Lee Moffitt Cancer Center and Research Institute, Tampa, Florida, United States|Winship Cancer Institute, Emory University, Atlanta, Georgia, United States|University of Chicago, Chicago, Illinois, United States|Indiana University, Indianapolis, Indiana, United States|University of Kansas Cancer Center, Fairway, Kansas, United States|Dana Farber Cancer Institute, Boston, Massachusetts, United States|Barbara Ann Karmanos Cancer Center, Detroit, Michigan, United States|Washington University School of Medicine Siteman Cancer Center, Saint Louis, Missouri, United States|Nebraska Methodist Hospital, Omaha, Nebraska, United States|Hackensack University Medical Center, Hackensack, New Jersey, United States|Cancer Institute of New Jersey, New Brunswick, New Jersey, United States|Columbia University Medical Center, New York, New York, United States|Laura & Isaac Perlmutter Cancer Center, New York, New York, United States|Mount Sinai Medical Center, New York, New York, United States|Weill Cornell Medical College, New York, New York, United States|Duke Cancer Institute, Durham, North Carolina, United States|University Hospitals Case Medical Center, Cleveland, Ohio, United States|Stephenson Cancer Center, Oklahoma City, Oklahoma, United States|Providence Portland Medical Center, Portland, Oregon, United States|Penn State Milton S Hershey Medical Center, Hershey, Pennsylvania, United States|University of Pittsburgh Medical Center Shadyside, Pittsburgh, Pennsylvania, United States|Miriam Hospital, Providence, Rhode Island, United States|Sarah Cannon Research Institute, Nashville, Tennessee, United States|Vanderbilt University Medical Center, Nashville, Tennessee, United States|Mary Crowley Cancer Research Center - Medical City, Dallas, Texas, United States|Baylor College of Medicine, Houston, Texas, United States|The University of Texas MD Anderson Cancer Center, Houston, Texas, United States|START South Texas Accelerated Research Therapeutics, San Antonio, Texas, United States|Northwest Medical Specialties, Tacoma, Washington, United States|Peter Maccallum Cancer Centre, Melbourne, Australia|Institut Catala d'Oncologia L'hospitalet, L'Hospitalet de Llobregat, Barcelona, Spain|Hospital Universitario Vall d'Hebron, Barcelona, Spain|Fundacion Jimenez Diaz, Madrid, Spain|Hospital Universitario HM Sanchinarro-CIOCC, Madrid, Spain|Hospital Universitario Ramon y Cajal, Madrid, Spain|MD Anderson Cancer Center, Madrid, Spain",,"https://ClinicalTrials.gov/show/NCT02383212"
166,"NCT02379052","Study of Dupilumab in Adult Participants With Active Eosinophilic Esophagitis (EoE)",,"Completed","Has Results","Eosinophilic Esophagitis","Drug: Dupilumab|Drug: Placebo","Absolute Change From Baseline in Straumann Dysphagia Instrument (SDI) Patient Reported Outcome (PRO) Total Score at Week 10|Percent Change From Baseline in Straumann Dysphagia Instrument (SDI) Patient Reported Outcome (PRO) Total Score at Week 10|Absolute Change From Baseline in Straumann Dysphagia Instrument (SDI) Patient Reported Outcome (PRO) Total Score at Week 12|Percent Change From Baseline in Straumann Dysphagia Instrument (SDI) Patient Reported Outcome (PRO) Total Score at Week 12|Percentage of Participants Achieving a Reduction of ≥ 3 Points in Straumann Dysphagia Instrument (SDI) Patient Reported Outcome (PRO) Total Score From Baseline at Week 10|Percentage of Participants Achieving a Reduction of ≥ 3 Points in Straumann Dysphagia Instrument (SDI) Patient Reported Outcome (PRO) Total Score From Baseline at Week 12|Percent Change From Baseline in Weekly Reported Eosinophilic Esophagitis Activity Index (EEsAI) Patient Reported Outcome (PRO) Score at Week 10|Absolute Change From Baseline in Weekly Reported Eosinophilic Esophagitis Activity Index (EEsAI) Patient Reported Outcome (PRO) Score at Week 10|Percent Change From Baseline in Weekly Reported Eosinophilic Esophagitis Activity Index (EEsAI) Patient Reported Outcome (PRO) Score at Week 12|Absolute Change From Baseline in Weekly Reported Eosinophilic Esophagitis Activity Index (EEsAI) Patient Reported Outcome (PRO) Score at Week 12|Percentage of Participants Achieving ≥ 40% Improvement in Weekly Reported Eosinophilic Esophagitis Activity Index (EEsAI) Patient Reported Outcome (PRO) Score From Baseline at Week 10|Percentage of Participants Achieving ≥ 40% Improvement in Weekly Reported Eosinophilic Esophagitis Activity Index (EEsAI) Patient Reported Outcome (PRO) Score From Baseline at Week 12|Percent Change From Baseline in Peak Esophageal Intraepithelial Eosinophils of 3 Esophageal Regions at Week 12|Absolute Change From Baseline in Eosinophilic Esophagitis-Endoscopic Reference Score (EoE-EREFS) by Feature at Week 12|Change From Baseline in Adult Eosinophilic Esophagitis Quality of Life Questionnaire (EoE-QOL-A) Score at Week 12|Percentage of Participants With Use of Rescue Medication or Procedure (e.g., Esophageal Dilation) Through Week 12|Percent of Participants With Treatment-Emergent Adverse Events (TEAEs) During the Study","Regeneron Pharmaceuticals|Sanofi","All","18 Years to 65 Years   (Adult, Older Adult)","Phase 2","47","Industry","Interventional","Allocation: Randomized|Intervention Model: Parallel Assignment|Masking: Triple (Participant, Investigator, Outcomes Assessor)|Primary Purpose: Treatment","R668-EE-1324","May 12, 2015","February 17, 2017","July 10, 2017","March 4, 2015","February 28, 2020","February 28, 2020","Idaho Falls, Idaho, United States|Chicago, Illinois, United States|Urbana, Illinois, United States|Indianapolis, Indiana, United States|Iowa City, Iowa, United States|Chevy Chase, Maryland, United States|Boston, Massachusetts, United States|New York, New York, United States|Asheville, North Carolina, United States|Chapel Hill, North Carolina, United States|Cincinnati, Ohio, United States|Philadelphia, Pennsylvania, United States|Salt Lake City, Utah, United States|Fairfax, Virginia, United States","""Study Protocol"", https://ClinicalTrials.gov/ProvidedDocs/52/NCT02379052/Prot_000.pdf|""Statistical Analysis Plan"", https://ClinicalTrials.gov/ProvidedDocs/52/NCT02379052/SAP_001.pdf","https://ClinicalTrials.gov/show/NCT02379052"
167,"NCT02326220","Study of Alirocumab (REGN727/SAR236553) in Patients With Heterozygous Familial Hypercholesterolemia (HeFH) Undergoing Low-density Lipoprotein (LDL) Apheresis Therapy","ODYSSEY ESCAPE","Completed","Has Results","Heterozygous Familial Hypercholesterolemia","Drug: Placebo|Drug: Alirocumab","Change in Standardized Rate of Apheresis Treatments From Week 7 to Week 18|Percent Change From Baseline in Calculated LDL-C (Pre-apheresis) at Week 6|Change in Standardized Rate of Apheresis Treatments From Week 15 to Week 18|Percent Change From Baseline in Apolipoprotein B (Apo B) (Pre-apheresis) to Week 6|Percent Change From Baseline in Non-High-Density Lipoprotein Cholesterol (Non-HDL-C) (Pre-apheresis) to Week 6|Percent Change From Baseline in Total Cholesterol (Pre-apheresis) to Week 6|Percent Change From Baseline in Apolipoprotein A (Apo A1) (Pre-apheresis) to Week 6|Percentage of Participants With At Least (>=) 30% Reduction in Calculated LDL-C (Pre-apheresis) at Week 6|Percentage of Participants With At Least (>=) 50% Reduction in Calculated LDL-C (Pre-apheresis) at Week 6|Percent Change From Baseline in Calculated LDL-C (Pre-Apheresis) to Week 18|Percent Change From Baseline in Apolipoprotein B (Apo B) (Pre-apheresis) to Week 18|Percent Change From Baseline in Non-HDL-C (Pre-apheresis) to Week 18|Percent Change From Baseline in Total Cholesterol (Pre-apheresis) to Week 18|Percent Change From Baseline in Apo A1 (Pre-apheresis) to Week 18|Percentage of Participants With At Least (>=) 30% Reduction in Calculated LDL-C (Pre-apheresis) at Week 18|Percentage of Participants With At Least (>=) 50% Reduction in Calculated LDL-C (Pre-apheresis) at Week 18|Change From Baseline in W-BQ22 (Well-being Questionnaire) Index Score at Week 18|Percent Change From Baseline in Lipoprotein (a) (Lp [a]) (Pre-apheresis) to Week 6|Percent Change From Baseline in High-Density Lipoprotein Cholesterol (HDL-C) (Pre-apheresis) to Week 6|Percent Change From Baseline in Triglyceride (TG) Levels (Pre-apheresis) to Week 6|Percent Change From Baseline in Lp (a) (Pre-apheresis) to Week 18|Percent Change From Baseline in HDL-C (Pre-apheresis) to Week 18|Percent Change From Baseline in TG Levels (Pre-apheresis) to Week 18","Regeneron Pharmaceuticals|Sanofi","All","18 Years and older   (Adult, Older Adult)","Phase 3","62","Industry","Interventional","Allocation: Randomized|Intervention Model: Parallel Assignment|Masking: Quadruple (Participant, Care Provider, Investigator, Outcomes Assessor)|Primary Purpose: Treatment","R727-CL-1216","March 31, 2015","January 31, 2016","April 30, 2016","December 29, 2014","May 1, 2020","May 1, 2020","Aurora, Colorado, United States|Hartford, Connecticut, United States|Kansas City, Kansas, United States|Scarborough, Maine, United States|Rochester, Minnesota, United States|Portland, Oregon, United States|Philadelphia, Pennsylvania, United States|Dresden, Sachsen, Germany|Berlin, Germany|Göttingen, Germany|Muenchen (2 locations), Germany|Passau, Germany|Rostock, Germany",,"https://ClinicalTrials.gov/show/NCT02326220"
168,"NCT02290951","Study to Investigate the Safety and Tolerability of Odronextamab in Patients With CD20+ B-Cell Malignancies","ELM-1","Recruiting","No Results Available","Non-Hodgkin Lymphoma|Chronic Lymphocytic Leukemia","Drug: Odronextamab multiple dose levels","Safety/overall frequency of adverse events|Safety/dose limiting toxicities (DLTs)|Antitumor activity as measured by the objective response rate (ORR)|Pharmacokinetics (Concentration of odronextamab)|Immunogenicity (Anti-odronextamab antibodies)|Objective response rate (ORR)|Progression-free survival|Overall Survival|Duration of response (DOR)|Minimal residual disease (MRD) for patients with CLL|Duration of Complete Response (DOCR)","Regeneron Pharmaceuticals","All","18 Years and older   (Adult, Older Adult)","Phase 1","298","Industry","Interventional","Allocation: Non-Randomized|Intervention Model: Parallel Assignment|Masking: None (Open Label)|Primary Purpose: Treatment","R1979-HM-1333|2015-004491-30","January 9, 2015","June 21, 2025","June 21, 2025","November 14, 2014",,"February 23, 2022","University of California, Irvine, Orange, California, United States|Stanford University, Stanford, California, United States|Moffitt Cancer Center, Tampa, Florida, United States|Dana Farber Cancer Institute (Massachusetts General Hospital and Beth Israel), Boston, Massachusetts, United States|Mayo Clinic, Rochester, Minnesota, United States|Rutgers Cancer Institute of New Jersey, New Brunswick, New Jersey, United States|Memorial Sloan Kettering Cancer Center, New York, New York, United States|Weill Cornell Medical College, New York, New York, United States|Centre Hospitalier Lyon-Sud Hospices Civils de Lyon, Pierre, Benite Cedex, France|CHU Hôpital Lyon Sud, Lyon, France|Universitatsklinikum Wurzburg, Wurzburg, Germany",,"https://ClinicalTrials.gov/show/NCT02290951"
169,"NCT02284425","Study of REGN1193 in Patients With Type 2 Diabetes Mellitus",,"Terminated","No Results Available","Diabetes Mellitus, Type 2","Drug: REGN1193|Drug: Placebo","Incidence and severity of treatment emergent adverse events (TEAEs)|Pharmacodynamic profile of REGN1193 as measured by plasma glucose over time|Concentration of REGN1193 in serum over time","Regeneron Pharmaceuticals","All","25 Years to 70 Years   (Adult, Older Adult)","Phase 1","72","Industry","Interventional","Allocation: Randomized|Intervention Model: Single Group Assignment|Masking: Quadruple (Participant, Care Provider, Investigator, Outcomes Assessor)|Primary Purpose: Treatment","R1193-DM-1402","October 2014","December 2015","December 2015","November 6, 2014",,"May 12, 2016","Miami, Florida, United States|Atlanta, Georgia, United States|Knoxville, Tennessee, United States",,"https://ClinicalTrials.gov/show/NCT02284425"
170,"NCT02277769","Study of Dupilumab (REGN668/SAR231893) Monotherapy Administered to Adult Patients With Moderate-to-Severe Atopic Dermatitis","SOLO 2","Completed","Has Results","Dermatitis, Atopic","Drug: Dupilumab|Drug: Placebo (for Dupilumab)","Percentage of Participants With Investigator's Global Assessment (IGA) Score of ""0"" or ""1"" and Reduction From Baseline of ≥2 Points at Week 16|Percentage of Participants With Eczema Area and Severity Index-75 (EASI-75) (≥75% Improvement From Baseline) at Week 16|Percentage of Participants With Improvement (Reduction ≥4 Points) of Weekly Average of Peak Daily Pruritus Numerical Rating Scale (NRS) Score From Baseline to Week 16|Percentage of Participants With Improvement (Reduction ≥3 Points) in Weekly Average of Peak Daily Pruritus Numerical Rating Scale (NRS) Score From Baseline to Week 16|Percent Change From Baseline in Weekly Average of Peak Pruritus Numerical Rating Scale (NRS) Score to Week 16|Percentage of Participants With Improvement (Reduction ≥4 Points) of Pruritus Numerical Rating Scale (NRS) Score From Baseline to Week 4|Percentage of Participants With Improvement (Reduction ≥4 Points) of Pruritus Numerical Rating Scale (NRS) Score From Baseline to Week 2|Change From Baseline in Peak Daily Pruritus Numerical Rating Scale (NRS) Score to Week 16|Percent Change From Baseline in Eczema Area and Severity Index (EASI) Score to Week 16|Percentage of Participants With Eczema Area and Severity Index-50 (EASI-50) (≥50% Improvement From Baseline) at Week 16|Percentage of Participants With Eczema Area and Severity Index-90 (EASI-90) (≥90% Improvement From Baseline) at Week 16|Change From Baseline in Percent Body Surface Area (BSA) to Week 16|Percent Change From Baseline in the SCORing Atopic Dermatitis (SCORAD) Score to Week 16|Change From Baseline in Dermatology Life Quality Index (DLQI) to Week 16|Change From Baseline in Patient Oriented Eczema Measure (POEM) to Week 16|Change From Baseline in Hospital Anxiety Depression Scale (HADS) to Week 16|Percent Change From Baseline in Global Individual Signs Score (GISS) to Week 16|Percent Change From Baseline in Weekly Average of Peak Daily Pruritus NRS Score to Week 2|Percentage of Participants With Skin Infection Treatment Emergent Adverse Events (TEAEs) Requiring Systemic Treatment|Percentage of Participants With Treatment Emergent Serious Adverse Events (TESAEs) From Baseline Through Week 16|Percentage of Participants With Treatment Emergent Adverse Events (TEAEs) Leading to Treatment Discontinuation From Baseline Through Week 16","Regeneron Pharmaceuticals|Sanofi","All","18 Years and older   (Adult, Older Adult)","Phase 3","708","Industry","Interventional","Allocation: Randomized|Intervention Model: Parallel Assignment|Masking: Triple (Participant, Investigator, Outcomes Assessor)|Primary Purpose: Treatment","R668-AD-1416","November 30, 2014","October 31, 2015","January 31, 2016","October 29, 2014","October 16, 2017","June 2, 2020","Anniston, Alabama, United States|Birmingham, Alabama, United States|Phoenix, Arizona, United States|Bakersfield, California, United States|Costa Mesa, California, United States|Fremont, California, United States|Long Beach, California, United States|Los Angeles, California, United States|Orange, California, United States|Roseville, California, United States|Temecula, California, United States|Trumbull, Connecticut, United States|Miami, Florida, United States|Oviedo, Florida, United States|Tampa, Florida, United States|West Palm Beach, Florida, United States|Alpharetta, Georgia, United States|Atlanta, Georgia, United States|Columbus, Georgia, United States|Buffalo Grove, Illinois, United States|Plainfield, Indiana, United States|West Des Moines, Iowa, United States|Overland Park, Kansas, United States|Rockville, Maryland, United States|Washington Park, Maryland, United States|Boston, Massachusetts, United States|Farmington Hills, Michigan, United States|Minneapolis, Minnesota, United States|Plymouth, Minnesota, United States|Saint Joseph, Missouri, United States|Saint Louis, Missouri, United States|Billings, Montana, United States|Bozeman, Montana, United States|Las Vegas, Nevada, United States|Verona, New Jersey, United States|Forest Hills, New York, United States|New York, New York, United States|Smithtown, New York, United States|Chapel Hill, North Carolina, United States|Raleigh, North Carolina, United States|Wilmington, North Carolina, United States|Winston-Salem, North Carolina, United States|Tulsa, Oklahoma, United States|Portland, Oregon, United States|Jenkintown, Pennsylvania, United States|Greer, South Carolina, United States|Arlington, Texas, United States|Austin, Texas, United States|Bellaire, Texas, United States|Houston, Texas, United States|San Antonio, Texas, United States|Richmond, Virginia, United States|Seattle, Washington, United States|Calgary, Alberta, Canada|Edmonton, Alberta, Canada|Surrey, British Columbia, Canada|St. John's, Newfoundland and Labrador, Canada|Ajax, Ontario, Canada|Mississauga, Ontario, Canada|Oakville, Ontario, Canada|Ottawa, Ontario, Canada|Peterborough, Ontario, Canada|Richmond Hill, Ontario, Canada|Montreal, Quebec, Canada|Lille Cedex, France|Marseille, France|Nantes, France|Berlin, Germany|Bochum, Germany|Darmstadt, Germany|Friedrichshafen, Germany|Hamburg, Germany|Kiel, Germany|Hong Kong, Hong Kong|Lucca, Italy|Pisa, Italy|Roma, Italy|Busan, Korea, Republic of|Gyeonggi-do, Korea, Republic of|Incheon, Korea, Republic of|Seoul, Korea, Republic of|Kaunas, Lithuania|Klaipeda, Lithuania|Vilnius, Lithuania|Elblag, Poland|Gdansk, Poland|Katowice, Poland|Poznan, Poland|Torun, Poland|Warsaw, Poland|Stockholm, Sweden|London, United Kingdom|Plymouth, United Kingdom",,"https://ClinicalTrials.gov/show/NCT02277769"
171,"NCT02277743","Study of Dupilumab Monotherapy Administered to Adult Patients With Moderate-to-Severe Atopic Dermatitis","SOLO 1","Completed","Has Results","Dermatitis, Atopic","Drug: Dupilumab|Drug: Placebo (for Dupilumab)","Percentage of Participants With Investigator's Global Assessment (IGA) Score of ""0"" or ""1"" and Reduction From Baseline of ≥2 Points at Week 16|Percentage of Participants With Eczema Area and Severity Index-75 (EASI-75) (≥75% Improvement From Baseline) at Week 16|Percentage of Participants With Improvement (Reduction ≥4 Points) of Pruritus Numerical Rating Scale (NRS) Score From Baseline to Week 16|Percentage of Participants With Improvement (Reduction ≥3 Points) of Pruritus Numerical Rating Scale (NRS) Score From Baseline to Week 16|Percent Change From Baseline in Peak Daily Pruritus Numerical Rating Scale (NRS) Score to Week 16|Percentage of Participants With Improvement (Reduction ≥4 Points) of Pruritus Numerical Rating Scale (NRS) Score From Baseline to Week 4|Percentage of Participants With Improvement (Reduction ≥4 Points) of Pruritus Numerical Rating Scale (NRS) Score From Baseline to Week 2|Change From Baseline in Peak Daily Pruritus Numerical Rating Scale (NRS) Score to Week 16|Percent Change From Baseline in Eczema Area and Severity Index (EASI) Score to Week 16|Percentage of Participants With Eczema Area and Severity Index-50 (EASI-50) (≥50% Improvement From Baseline) at Week 16|Percentage of Participants With Eczema Area and Severity Index-90 (EASI-90) (≥90% Improvement From Baseline) at Week 16|Change From Baseline in Percent Body Surface Area (BSA) to Week 16|Percent Change From Baseline in the SCORing Atopic Dermatitis (SCORAD) Score to Week 16|Change From Baseline in Dermatology Life Quality Index (DLQI) to Week 16|Change From Baseline in Patient Oriented Eczema Measure (POEM) to Week 16|Change From Baseline in Hospital Anxiety Depression Scale (HADS) to Week 16|Percent Change From Baseline in Global Individual Signs Score (GISS) to Week 16|Percent Change From Baseline in Peak Daily Pruritus NRS Score to Week 2|Percentage of Participants With Skin Infection Treatment Emergent Adverse Events (TEAEs) Requiring Systemic Treatment|Percentage of Participants With Treatment Emergent Serious Adverse Events (TESAEs) From Baseline Through Week 16|Percentage of Participants With Treatment Emergent Adverse Events (TEAEs) Leading to Treatment Discontinuation From Baseline Through Week 16","Regeneron Pharmaceuticals|Sanofi","All","18 Years and older   (Adult, Older Adult)","Phase 3","671","Industry","Interventional","Allocation: Randomized|Intervention Model: Parallel Assignment|Masking: Triple (Participant, Investigator, Outcomes Assessor)|Primary Purpose: Treatment","R668-AD-1334","October 2014","November 2015","February 2016","October 29, 2014","November 21, 2017","November 21, 2017","Birmingham, Alabama, United States|Fort Smith, Arkansas, United States|Rogers, Arkansas, United States|Clovis, California, United States|Lomita, California, United States|Los Angeles, California, United States|Oceanside, California, United States|Palmdale, California, United States|Rolling Hills Estates, California, United States|San Diego, California, United States|Santa Monica, California, United States|Stockton, California, United States|Boca Raton, Florida, United States|Clearwater, Florida, United States|Fort Lauderdale, Florida, United States|Miami Lakes, Florida, United States|Miami, Florida, United States|Pensacola, Florida, United States|Tampa, Florida, United States|Newnan, Georgia, United States|Chicago, Illinois, United States|Normal, Illinois, United States|Evansville, Indiana, United States|Indianapolis, Indiana, United States|Louisville, Kentucky, United States|Boston, Massachusetts, United States|Troy, Michigan, United States|Saint Louis, Missouri, United States|Newington, New Hampshire, United States|East Windsor, New Jersey, United States|Buffalo, New York, United States|Corning, New York, United States|New Hyde Park, New York, United States|Rochester, New York, United States|High Point, North Carolina, United States|Bethlehem, Pennsylvania, United States|Upland, Pennsylvania, United States|Chattanooga, Tennessee, United States|Knoxville, Tennessee, United States|San Antonio, Texas, United States|Waco, Texas, United States|Ogden, Utah, United States|Newport News, Virginia, United States|Norfolk, Virginia, United States|Spokane, Washington, United States|Dupnitsa, Bulgaria|Plovdiv, Bulgaria|Sofia, Bulgaria|Winnepeg, Manitoba, Canada|Bathurst, New Brunswick, Canada|Hamilton, Ontario, Canada|Mississauga, Ontario, Canada|Newmarket, Ontario, Canada|Ottawa, Ontario, Canada|Richmond Hill, Ontario, Canada|Toronto, Ontario, Canada|Copenhagen, Denmark|Hellerup, Denmark|Tallinn, Estonia|Tartu, Estonia|Helsinki, Finland|Tampere, Finland|Turku, Finland|Berlin, Germany|Bielefed, Germany|Blaubeuren, Germany|Erlangen, Germany|Halle, Germany|Hamburg, Germany|Hannover, Germany|Muenster, Germany|Munchen, Germany|Osnabruck, Germany|Schwerin, Germany|Stuttgart, Germany|Kurume, Fukuoka, Japan|Fukuyama, Hiroshima, Japan|Inashiki, Ibaraki, Japan|Yokohama, Kanagawa, Japan|Habikino, Osaka, Japan|Neyagawa, Osaka, Japan|Sakai, Osaka, Japan|Takatsuki, Osaka, Japan|Hamamatsu, Shizuoka, Japan|Bunkyo-ku, Tokyo, Japan|Chuo-ku, Tokyo, Japan|Nerima-ku, Tokyo, Japan|Shinagawa, Tokyo, Japan|Shinjuku, Tokyo, Japan|Kofu, Yamanashi, Japan|Gifu, Japan|Hiroshima, Japan|Kyoto, Japan|Osaka, Japan|Singapore, Singapore|Alcaniz, Spain|Alicante, Spain|Barcelona, Spain|Madrid, Spain|Sevilla, Spain|Valencia, Spain",,"https://ClinicalTrials.gov/show/NCT02277743"
172,"NCT02265952","Study of REGN1500 in Participants With Homozygous Familial Hypercholesterolemia (HoFH)",,"Completed","Has Results","Homozygous Familial Hypercholesterolemia","Drug: REGN1500 250 mg SC/15 mg/kg IV/450 mg SC","Percent Change in Low-Density Lipoprotein Cholesterol (LDL-C) From Baseline (Week 0) to Week 4 in the Main Study Period|Absolute Change in Low-Density Lipoprotein Cholesterol (LDL-C) From Baseline (Week 0) to Week 4 in the Main Study Period|Absolute Change in Low-Density Lipoprotein Cholesterol (LDL-C) From Week 2 to Week 4 in the Main Study Period|Percent Change in Low-Density Lipoprotein Cholesterol (LDL-C) From Week 2 to Week 4 in the Main Study Period|Absolute Change in Low-Density Lipoprotein Cholesterol (LDL-C) From Baseline (Week 0) Over Time in the Main Study Period|Percent Change in Low-Density Lipoprotein Cholesterol (LDL-C) From Baseline (Week 0) Over Time in the Main Study Period|Absolute Change in Low-Density Lipoprotein Cholesterol (LDL-C) From Baseline (Week 26) to Week 214 in the Open Label Extension (OLE) Period|Percent Change in Low-Density Lipoprotein Cholesterol (LDL-C) From Baseline (Week 26) to Week 214 in the Open Label Extension (OLE) Period|Absolute Change in Apolipoprotein (Apo B), Non-High-Density Lipoprotein Cholesterol (Non-HDL-C), Total Cholesterol (Total-C), and Lipoprotein(a) (Lp[a]) From Baseline (Week 0) up to Week 26 in the Main Study Period|Percent Change in Apolipoprotein (Apo B), Non-High-Density Lipoprotein Cholesterol (Non-HDL-C), Total Cholesterol (Total-C), and Lipoprotein(a) (Lp[a]) From Baseline (Week 0) up to Week 26 in the Main Study Period|Absolute Change in Apolipoprotein (Apo B), Non-High-Density Lipoprotein Cholesterol (Non-HDL-C), Total Cholesterol (Total-C), and Lipoprotein(a) (Lp[a]) From Baseline (Week 26) to Week 214 in the Open Label Extension (OLE) Period|Percent Change in Apolipoprotein (Apo B), Non-High-Density Lipoprotein Cholesterol (Non-HDL-C), Total Cholesterol (Total-C), and Lipoprotein(a) (Lp[a]) From Baseline (Week 26) to Week 214 in the Open Label Extension (OLE) Period|Percentage of Participants Who Achieved Reduction in Low-Density Lipoprotein Cholesterol (LDL-C) of ≥ 25% From Baseline (Week 0) in the Main Study Period|Percentage of Participants Who Achieved Reduction in Low-Density Lipoprotein Cholesterol (LDL-C) of ≥ 25% From Baseline (Week 26) in the Open Label Extension (OLE) Period|Percentage of Participants Who Achieved Reduction in Low-Density Lipoprotein Cholesterol (LDL-C) of ≥ 50% From Baseline (Week 0) in the Main Study Period|Percentage of Participants Who Achieved Reduction in Low-Density Lipoprotein Cholesterol (LDL-C) of ≥ 50% From Baseline (Week 26) in the Open Label Extension (OLE) Period|Absolute Change in High-Density Lipoprotein Cholesterol (HDL-C), Triglycerides (TG), and Apolipoprotein A-1 (Apo A-1) From Baseline (Week 0) Over Time in the Main Study Period|Percent Change in High-Density Lipoprotein Cholesterol (HDL-C), Triglycerides (TG), and Apolipoprotein A-1 (Apo A-1) From Baseline (Week 0) Over Time in the Main Study Period|Percent Change in High-Density Lipoprotein Cholesterol (HDL-C), Triglycerides (TG), and Apolipoprotein A-1 (Apo A-1) From Baseline (Week 26) to Week 214 in the Open Label Extension (OLE) Period|Absolute Change in High-Density Lipoprotein Cholesterol (HDL-C), Triglycerides (TG), and Apolipoprotein A-1 (Apo A-1) From Baseline (Week 26) to Week 214 in the Open Label Extension (OLE) Period|Absolute Change in Apolipoprotein CIII (Apo CIII) From Baseline (Week 0) Over Time in the Main Study Period|Percent Change in Apolipoprotein CIII (Apo CIII) From Baseline (Week 0) Over Time in the Main Study Period","Regeneron Pharmaceuticals","All","18 Years and older   (Adult, Older Adult)","Phase 2","9","Industry","Interventional","Allocation: N/A|Intervention Model: Single Group Assignment|Masking: None (Open Label)|Primary Purpose: Treatment","R1500-CL-1331|2016-000411-32","February 4, 2015","November 21, 2016","July 23, 2018","October 16, 2014","December 9, 2019","December 9, 2019","Los Angeles, California, United States|Philadelphia, Pennsylvania, United States|Dallas, Texas, United States|Chicoutimi, Quebec, Canada|Amsterdam, Netherlands",,"https://ClinicalTrials.gov/show/NCT02265952"
173,"NCT02260986","Study to Assess the Efficacy and Long-term Safety of Dupilumab (REGN668/SAR231893) in Adult Participants With Moderate-to-Severe Atopic Dermatitis","CHRONOS","Completed","Has Results","Atopic Dermatitis","Drug: Dupilumab|Drug: Placebo (for Dupilumab)|Other: Topical Corticosteroid (TCS)","Percentage of Participants With Investigator's Global Assessment (IGA) Score of ""0"" or ""1"" and Reduction From Baseline of ≥2 Points at Week 16|Percentage of Participants With Eczema Area and Severity Index-75 (EASI-75) (≥75% Improvement From Baseline) at Week 16|Percentage of Participants With Improvement (Reduction ≥4 Points) of Weekly Average of Peak Daily Pruritus Numerical Rating Scale (NRS) Score From Baseline to Week 16|Percentage of Participants With Improvement (Reduction ≥3 Points) of Weekly Average of Peak Daily Pruritus Numerical Rating Scale (NRS) Score From Baseline to Week 16|Percentage of Participants With Investigator's Global Assessment (IGA) Score of ""0"" or ""1"" and Reduction From Baseline of ≥2 Points at Week 52|Percentage of Participants With Eczema Area and Severity Index-75 (EASI-75) (≥75% Improvement From Baseline) at Week 52|Percent Change From Baseline in Weekly Average of Peak Daily Pruritus Numerical Rating Scale (NRS) Score to Week 16|Percentage of Participants With Improvement (Reduction ≥4 Points) of Weekly Average of Peak Daily Pruritus Numerical Rating Scale (NRS) Score From Baseline to Week 52|Percentage of Participants With Improvement (Reduction ≥3 Points) of Weekly Average of Peak Daily Pruritus Numerical Rating Scale (NRS) Score From Baseline to Week 52|Percentage of Participants With Improvement (Reduction ≥4 Points) of Weekly Average of Peak Daily Pruritus Numerical Rating Scale (NRS) Score From Baseline to Week 24|Percentage of Participants With Improvement (Reduction ≥4 Points) of Weekly Average of Peak Daily Pruritus Numerical Rating Scale (NRS) Score From Baseline to Week 4|Percentage of Participants With Improvement (Reduction ≥4 Points) of Weekly Average of Peak Daily Pruritus Numerical Rating Scale (NRS) Score From Baseline to Week 2|Change From Baseline in Weekly Average of Peak Daily Pruritus Numerical Rating Scale (NRS) Score to Week 16|Percent Change From Baseline in Eczema Area and Severity Index (EASI) Score to Week 16|Change From Baseline in Percent Body Surface Area (BSA) Affected by Atopic Dermatitis to Week 16|Percent Change From Baseline in the SCORing Atopic Dermatitis (SCORAD) Score to Week 16|Change From Baseline in Dermatology Life Quality Index (DLQI) to Week 16|Change From Baseline in Patient Oriented Eczema Measure (POEM) to Week 16|Change From Baseline in Hospital Anxiety Depression Scale (HADS) to Week 16|Percent Change From Baseline in Total Global Individual Signs Score (GISS) to Week 16|Proportion of Topical Atopic Dermatitis Medication-Free Days Through Week 52|Percent Change From Baseline in Weekly Average of Peak Daily Pruritus Numerical Rating Scale (NRS) Score to Week 2|Percent Change From Baseline in Eczema Area and Severity Index (EASI) Score to Week 52|Change From Baseline in Percent Body Surface Area (BSA) Affected by Atopic Dermatitis to Week 52|Percent Change From Baseline in the SCORing Atopic Dermatitis (SCORAD) Score to Week 52|Percent Change From Baseline in Global Individual Signs Score (GISS) to Week 52|Change From Baseline in Dermatology Life Quality Index (DLQI) to Week 52|Change From Baseline in Patient Oriented Eczema Measure (POEM) to Week 52|Change From Baseline in Hospital Anxiety Depression Scale (HADS) to Week 52|Number of Flares Through Week 52|Number of Serious Treatment Emergent Adverse Events (TEAEs) Leading to Study Drug Discontinuation Through Week 52|Percentage of Participants With Skin Infection Treatment Emergent Adverse Events (TEAEs) (Excluding Herpetic Infections) From Baseline Through Week 52|Number of Skin Infection TEAEs (Excluding Herpetic Infections) From Baseline Through Week 52|Percentage of Participants With Skin Infection Treatment Emergent Adverse Events (TEAEs) (Excluding Herpetic Infections) Requiring Systemic Treatment From Baseline Through Week 52|Number of Skin Infection Treatment Emergent Adverse Events (TEAEs) (Excluding Herpetic Infections) Requiring Systemic Treatment From Baseline Through Week 52","Regeneron Pharmaceuticals|Sanofi","All","18 Years and older   (Adult, Older Adult)","Phase 3","740","Industry","Interventional","Allocation: Randomized|Intervention Model: Parallel Assignment|Masking: Triple (Participant, Investigator, Outcomes Assessor)|Primary Purpose: Treatment","R668-AD-1224","September 2014","August 2015","October 2016","October 9, 2014","October 17, 2017","October 17, 2017","Phoenix, Arizona, United States|Hot Springs, Arkansas, United States|Little Rock, Arkansas, United States|Encinitas, California, United States|Oceanside, California, United States|Palmdale, California, United States|San Diego, California, United States|New Haven, Connecticut, United States|Trumbull, Connecticut, United States|Edgewater, Florida, United States|Lake Worth, Florida, United States|Miami Lakes, Florida, United States|Orlando, Florida, United States|Tampa, Florida, United States|Alpharetta, Georgia, United States|Columbus, Georgia, United States|Savannah, Georgia, United States|West Dundee, Illinois, United States|Carmel, Indiana, United States|New Albany, Indiana, United States|Rockville, Maryland, United States|Ann Arbor, Michigan, United States|Bay City, Michigan, United States|Edina, Minnesota, United States|Fridley, Minnesota, United States|Saint Louis, Missouri, United States|Omaha, Nebraska, United States|Henderson, Nevada, United States|Verona, New Jersey, United States|Albuquerque, New Mexico, United States|Corning, New York, United States|New York, New York, United States|Smithtown, New York, United States|Stony Brook, New York, United States|Cincinnati, Ohio, United States|Norman, Oklahoma, United States|Oklahoma City, Oklahoma, United States|Lake Oswego, Oregon, United States|Portland, Oregon, United States|Exton, Pennsylvania, United States|Hazleton, Pennsylvania, United States|Philadelphia, Pennsylvania, United States|Austin, Texas, United States|Dallas, Texas, United States|West Jordan, Utah, United States|South Burlington, Vermont, United States|Henrico, Virginia, United States|Norfolk, Virginia, United States|Richmond, Virginia, United States|Spokane, Washington, United States|Phillip, Australian Capital Territory, Australia|Kogarah, New South Wales, Australia|Benowa, Queensland, Australia|Dulwich, Queensland, Australia|Hectorville, South Australia, Australia|Carlton, Victoria, Australia|Surrey, British Columbia, Canada|Vancouver, British Columbia, Canada|Ajax, Ontario, Canada|Barrie, Ontario, Canada|Hamilton, Ontario, Canada|Markham, Ontario, Canada|North Bay, Ontario, Canada|Oakville, Ontario, Canada|Ottawa, Ontario, Canada|Peterborough, Ontario, Canada|Richmond Hill, Ontario, Canada|Toronto, Ontario, Canada|Waterloo, Ontario, Canada|Windsor, Ontario, Canada|Drummondville, Quebec, Canada|Quebec, Canada|Hradec Kralove, Czechia|Nachod, Czechia|Praha 10, Czechia|Praha 5, Czechia|Svitavy, Czechia|Usti nad Labem, Czechia|Oroshaza, Békés, Hungary|Szolnok, Jász-Nagykun-Szolnok, Hungary|Veszprem, Veszprém, Hungary|Budapest, Hungary|Ancona, Italy|Bologna, Italy|Brescia, Italy|Novara, Italy|Pavia, Italy|Perugia, Italy|Roma, Italy|Kitakyushu, Fukuoka, Japan|Amagasaki, Hyôgo, Japan|Yokohama, Kanagawa, Japan|Kamimashiki-gun, Kumamoto, Japan|Saitama-shi, Saitama, Japan|Yaizu, Shizuoka, Japan|Koto-ku, Tokyo, Japan|Setagaya-ku, Tokyo, Japan|Adachi-ku, Tôkyô, Japan|Chiyoda-ku, Tôkyô, Japan|Nakano-ku, Tôkyô, Japan|Nerima-ku, Tôkyô, Japan|Shibuya-ku, Tôkyô, Japan|Shinagawa-ku, Tôkyô, Japan|Shinjuku-ku, Tôkyô, Japan|Suginami-ku, Tôkyô, Japan|Fukuoka, Japan|Bucheon-si, Gyeonggido, Korea, Republic of|Suwon, Gyeonggido, Korea, Republic of|Seoul, Seoul Teugbyeolsi, Korea, Republic of|Seodaemun-gu, Korea, Republic of|Uijeongbu-si, Korea, Republic of|Breda, Noord-Brabant, Netherlands|Amsterdam, Noord-Holland, Netherlands|Rotterdam, Zuid-Holland, Netherlands|Groningen, Netherlands|Utrecht, Netherlands|Dunedin, South Island, New Zealand|Auckland, New Zealand|Wroclaw, Dolnośląskie, Poland|Lublin, Lubelskie, Poland|Warszawa, Mazowieckie, Poland|Krakow, Małopolskie, Poland|Strzelce Opolskie, Opolskie, Poland|Iwonicz Zdroj, Podkarpackie, Poland|Bialystok, Podlaskie, Poland|Gdansk, Pomorskie, Poland|Poznan, Wielkopolskie, Poland|Szczecin, Zachodniopomorskie, Poland|Gdynia, Poland|Łódź, Łódzkie, Poland|Katowice, Śląskie, Poland|Skarzysko-Kamienna, Świętokrzyskie, Poland|Brasov, Braşov, Romania|Bucuresti, Bucureşti, Romania|Cluj-Napoca, Cluj, Romania|Craiova, Dolj, Romania|Targu Mures, Mureş, Romania|Barcelona, Cataluña, Spain|Alicante, Spain|Madrid, Spain|Dundee, Angus, United Kingdom|Edgbaston, Birmingham, United Kingdom|Glasgow, Glasgow City, United Kingdom|Sidcup, Kent, United Kingdom|Northwood, Middlesex, United Kingdom|Liverpool, United Kingdom|Manchester, United Kingdom|Reading, United Kingdom|Salford, United Kingdom",,"https://ClinicalTrials.gov/show/NCT02260986"
174,"NCT02210780","Study of Dupilumab and Immune Responses in Adults With Atopic Dermatitis (AD)",,"Completed","Has Results","Atopic Dermatitis","Drug: Dupilumab|Drug: Placebo","Percentage of Participants With a Positive Response (≥4-Fold Increase) to Tetanus Toxoid (the Adacel [Tdap] Vaccine) at Week 16|Percentage of Participants With a Positive Response (≥2-Fold Increase) to Tetanus Toxoid (the Adacel [Tdap] Vaccine) at Week 16|Percentage of Participants With a Positive Response (SBA Antibody Titer of ≥8 for Serogroup C) to Menomune Vaccine at Week 16|Percentage of Participants Achieving an Investigator's Global Assessment (IGA) Score of ""0"" or ""1"" at Week 16|Percentage of Participants Achieving an Eczema Area and Severity Index-50 (EASI-50) (≥50% Improvement From Baseline) at Week 16|Percentage of Participants Achieving an Eczema Area and Severity Index-75 (EASI-75) (≥75% Improvement From Baseline) at Week 16|Change From Baseline in Peak Weekly Averaged Pruritis Numerical Rating Scale (NRS) Scores at Week 16|Change From Baseline in Body Surface Area (BSA) Affected by AD at Week 16|Change From Baseline in Global Individual Signs Score (GISS) Components (Erythema, Infiltration/Papulation, Excoriations and Lichenification) at Week 16|Changes From Baseline in GISS Cumulative Score to Week 16|Change in Patient Oriented Eczema Measure (POEM) Score From Baseline to Week 16","Regeneron Pharmaceuticals|Sanofi","All","18 Years to 64 Years   (Adult)","Phase 2","194","Industry","Interventional","Allocation: Randomized|Intervention Model: Parallel Assignment|Masking: Triple (Participant, Investigator, Outcomes Assessor)|Primary Purpose: Treatment","R668-AD-1314","August 5, 2014","September 15, 2015","September 15, 2015","August 7, 2014","May 7, 2020","May 7, 2020","Birmingham, Alabama, United States|Fort Smith, Arkansas, United States|Long Beach, California, United States|Los Angeles, California, United States|Mission Viejo, California, United States|Rolling Hills Estates, California, United States|San Diego, California, United States|Santa Monica, California, United States|Denver, Colorado, United States|Jacksonville, Florida, United States|Miami, Florida, United States|Tampa, Florida, United States|Macon, Georgia, United States|Chicago, Illinois, United States|Maywood, Illinois, United States|West Dundee, Illinois, United States|Indianapolis, Indiana, United States|Plainfield, Indiana, United States|Overland Park, Kansas, United States|Boston, Massachusetts, United States|Ann Arbor, Michigan, United States|Troy, Michigan, United States|Saint Louis, Missouri, United States|Hackensack, New Jersey, United States|Albuquerque, New Mexico, United States|Buffalo, New York, United States|Forest Hills, New York, United States|New York, New York, United States|Cleveland, Ohio, United States|Norman, Oklahoma, United States|Tulsa, Oklahoma, United States|Medford, Oregon, United States|Portland, Oregon, United States|Pittsburgh, Pennsylvania, United States|Charleston, South Carolina, United States|Greer, South Carolina, United States|Arlington, Texas, United States|Austin, Texas, United States|Houston, Texas, United States|Webster, Texas, United States|Richmond, Virginia, United States|Seattle, Washington, United States",,"https://ClinicalTrials.gov/show/NCT02210780"
175,"NCT02121080","Study of the Safety and Tolerability of REGN2222(SAR438584) in Healthy Adult Volunteers",,"Completed","No Results Available","Healthy Volunteers","Drug: REGN2222(SAR438584)|Drug: placebo","The incidence and severity of treatment-emergent adverse events (TEAEs) in participants treated with REGN2222 or placebo.|Serum concentration|Presence or absence of antibodies","Regeneron Pharmaceuticals","All","18 Years to 60 Years   (Adult)","Phase 1","132","Industry","Interventional","Allocation: Randomized|Intervention Model: Parallel Assignment|Masking: Quadruple (Participant, Care Provider, Investigator, Outcomes Assessor)|Primary Purpose: Basic Science","R2222-HV-1326","May 2014","February 2015","February 2015","April 23, 2014",,"March 11, 2015","Daytona Beach, Florida, United States|Evansville, Indiana, United States|Dallas, Texas, United States",,"https://ClinicalTrials.gov/show/NCT02121080"
176,"NCT02107872","Study to Assess the Safety and Tolerability of Multiple Ascending Doses of REGN1500",,"Completed","No Results Available","Metabolic Disorders","Drug: REGN1500|Drug: placebo","Safety|Serum concentration","Regeneron Pharmaceuticals","All","18 Years to 65 Years   (Adult, Older Adult)","Phase 1","55","Industry","Interventional","Allocation: Randomized|Intervention Model: Single Group Assignment|Masking: Quadruple (Participant, Care Provider, Investigator, Outcomes Assessor)|Primary Purpose: Treatment","R1500-CL-1321","April 2014","September 2015","September 2015","April 8, 2014",,"September 30, 2015","Daytona Beach, Florida, United States|Evansville, Indiana, United States|Dallas, Texas, United States|San Antonio, Texas, United States",,"https://ClinicalTrials.gov/show/NCT02107872"
177,"NCT02097524","Single-dose Study to Describe the Pharmacodynamics (PD) and Safety of Sarilumab (REGN88/SAR153191) and Tocilizumab in Adults With Rheumatoid Arthritis (RA)",,"Completed","No Results Available","Rheumatoid Arthritis","Drug: Sarilumab|Drug: Tocilizumab","PD parameters|Percentage of TEAEs|PK parameters","Regeneron Pharmaceuticals|Sanofi","All","18 Years and older   (Adult, Older Adult)","Phase 1","105","Industry","Interventional","Allocation: Randomized|Intervention Model: Parallel Assignment|Masking: None (Open Label)|Primary Purpose: Basic Science","6R88-RA-1309","March 2014","April 2015","April 2015","March 27, 2014",,"May 5, 2015","Birmingham, Alabama, United States|Orange, California, United States|Deland, Florida, United States|Edgewater, Florida, United States|Miami Lakes, Florida, United States|Miami, Florida, United States|Granger, Indiana, United States|Grand Blanc, Michigan, United States|Charlotte, North Carolina, United States|Cinicinnati, Ohio, United States|Memphis, Tennessee, United States|Austin, Texas, United States|Carrollton, Texas, United States|Channelview, Texas, United States|Dallas, Texas, United States|Houston, Texas, United States|Mesquite, Texas, United States|Plano, Texas, United States|San Antonio, Texas, United States",,"https://ClinicalTrials.gov/show/NCT02097524"
178,"NCT02061865","Phase 1 Safety Study With Intravitreal (IVT) REGN2176-3 in Patients Aged 50 Years and Older With Wet AMD",,"Completed","No Results Available","Neovascular Wet Age-related Macular Degeneration (AMD)","Drug: REGN2176-3","Safety","Regeneron Pharmaceuticals","All","50 Years and older   (Adult, Older Adult)","Phase 1","12","Industry","Interventional","Allocation: N/A|Intervention Model: Single Group Assignment|Masking: None (Open Label)|Primary Purpose: Treatment","R2176-3-AMD-1303","February 2014","December 2014","December 2014","February 13, 2014",,"February 11, 2015","Beverly Hills, California, United States|Colorado Springs, Colorado, United States|Boston, Massachusetts, United States|Houston, Texas, United States",,"https://ClinicalTrials.gov/show/NCT02061865"
179,"NCT01997164","Study of Intravitreal (IVT) REGN910-3 and IVT REGN910 in Patients With Either Neovascular (""Wet"") Age Related Macular Degeneration (AMD) or Diabetic Macular Edema (DME)",,"Completed","No Results Available","Neovascular Age-Related Macular Degeneration|Diabetic Macular Edema","Drug: REGN910-3|Drug: REGN910|Drug: Intravitreal Aflibercept Injection (IAI)","Incidence of treatment-emergent adverse events (TEAEs)|Pharmacokinetic (PK) profile|Development of Anti-drug antibodies (ADA) after IVT injection of REGN910-3","Regeneron Pharmaceuticals","All","18 Years and older   (Adult, Older Adult)","Phase 1","20","Industry","Interventional","Allocation: Non-Randomized|Intervention Model: Single Group Assignment|Masking: None (Open Label)|Primary Purpose: Basic Science","R910-3-OD-1403","November 2014","October 2015","October 2015","November 27, 2013",,"January 12, 2016","Beverly Hills, California, United States|Winter Haven, Florida, United States|Boston, Massachusetts, United States|West Columbia, South Carolina, United States|Abilene, Texas, United States",,"https://ClinicalTrials.gov/show/NCT01997164"
180,"NCT01979016","Study to Determine the Safety and Effectiveness of Dupilumab for Treatment of Atopic Dermatitis (AD)",,"Completed","Has Results","Atopic Dermatitis (AD)","Drug: Dupilumab|Drug: Placebo|Other: Background treatment","Percent Change From Baseline in the Eczema Area Severity Index Score (EASI) to Week 16|Percentage of Participants With Investigator's Global Assessment (IGA) Score of ""0"" or ""1"" at Week 16|Percentage of Participants Who Achieved IGA Score Reduction From Baseline of ≥2 Points at Week 16|Absolute Change From Baseline in Pruritus Numeric Rating Scale (NRS) at Week 16|Percent Change From Baseline in Pruritus Numeric Rating Scale (NRS) at Week 16|Absolute Change From Baseline in EASI Score to Week 16|Absolute Change From Baseline in SCORing Atopic Dermatitis (SCORAD) Score to Week 16|Percent Change From Baseline in SCORing Atopic Dermatitis (SCORAD) Score to Week 16|Percentage of Participants Who Achieved 50%, 75% and 90% Reduction From Baseline in EASI Score ( EASI-50, EASI-75, and EASI-90 Respectively) at Week 16|Percentage of Participants Who Achieved 50%, 75% and 90% Reduction From Baseline in SCORAD Score (SCORAD-50, SCORAD-75 and SCORAD-90 Respectively) at Week 16|Absolute Change From Baseline in Participant's Oriented Eczema Measure (POEM) Score to Week 16|Percent Change From Baseline in Participant's Oriented Eczema Measure (POEM) Score to Week 16|Change From Baseline in Global Individual Signs Score (GISS) Components (Erythema, Infiltration/Papulation, Excoriations, and Lichenification) to Week 16|Changes From Baseline in GISS Cumulative Score to Week 16","Regeneron Pharmaceuticals|Sanofi","All","18 Years and older   (Adult, Older Adult)","Phase 2","54","Industry","Interventional","Allocation: Randomized|Intervention Model: Parallel Assignment|Masking: Quadruple (Participant, Care Provider, Investigator, Outcomes Assessor)|Primary Purpose: Treatment","R668-AD-1307","December 31, 2013","December 31, 2014","January 31, 2015","November 8, 2013","March 18, 2020","March 18, 2020","Chicago, Illinois, United States|New York, New York, United States|Dallas, Texas, United States|Montreal, Quebec, Canada",,"https://ClinicalTrials.gov/show/NCT01979016"
181,"NCT01963598","Study of the Safety and Efficacy of REGN1033 (SAR391786) in Patients With Sarcopenia",,"Completed","No Results Available","Sarcopenia","Drug: REGN1033 (SAR391786)|Drug: placebo","Percent change in total lean body mass|TEAEs|Change in appendicular lean mass|Change in maximal leg press strength (1-RM)|Change in maximal chest press strength (1-RM)|Change in 4M gait speed|Change in SPPB subscores|Change in distance walked in the 6MWT|Change in regional and total fat mass by DEXA|Change in hand grip strength by handheld dynamometer|Change in unloaded and loaded stair climb power","Regeneron Pharmaceuticals|Sanofi","All","70 Years and older   (Older Adult)","Phase 2","253","Industry","Interventional","Allocation: Randomized|Intervention Model: Parallel Assignment|Masking: Quadruple (Participant, Care Provider, Investigator, Outcomes Assessor)|Primary Purpose: Treatment","R1033-SRC-1239","November 2013","January 2015","February 2015","October 16, 2013",,"March 28, 2016","Anniston, Alabama, United States|Phoenix, Arizona, United States|El Cajon, California, United States|Garden Grove, California, United States|Laguna Hills, California, United States|San Francisco, California, United States|Walnut Creek, California, United States|Aurora, Colorado, United States|Gainesville, Florida, United States|Jacksonville, Florida, United States|Jupiter, Florida, United States|Orlando, Florida, United States|South Miami, Florida, United States|Chicago, Illinois, United States|Baton Rouge, Louisiana, United States|College Park, Maryland, United States|Elkridge, Maryland, United States|Boston, Massachusetts, United States|Edina, Minnesota, United States|Omaha, Nebraska, United States|Albuquerque, New Mexico, United States|High Point, North Carolina, United States|Winston-Salem, North Carolina, United States|Athens, Ohio, United States|Columbus, Ohio, United States|Duncansville, Pennsylvania, United States|Spartanburg, South Carolina, United States|Dallas, Texas, United States|Plano, Texas, United States|San Antonio, Texas, United States|Salt Lake City, Utah, United States|West Jordan, Utah, United States|Richmond, Virginia, United States|Limoges, France|Montpellier Cedex 5, France|Saint-Etienne Cedex 2, France|Toulouse, France|Amsterdam, Netherlands|Leeuwarden, Netherlands|Noord-Brabant, Netherlands|Albacete, Spain|L'Hospitalet de Llobregat, Spain|Madrid, Spain",,"https://ClinicalTrials.gov/show/NCT01963598"
182,"NCT01933763","An Ascending Single-Dose Study of the Safety, Tolerability and Bioeffect of REGN1193",,"Completed","No Results Available","Healthy Volunteers","Drug: REGN1193|Other: Placebo","Number of TEAEs|Serum concentration","Regeneron Pharmaceuticals","All","18 Years to 45 Years   (Adult)","Phase 1","56","Industry","Interventional","Allocation: Randomized|Intervention Model: Single Group Assignment|Masking: Quadruple (Participant, Care Provider, Investigator, Outcomes Assessor)|Primary Purpose: Treatment","R1193-HV-1219","August 2013","January 2015","January 2015","September 2, 2013",,"March 13, 2015","Dallas, Texas, United States",,"https://ClinicalTrials.gov/show/NCT01933763"
183,"NCT01926782","Study to Evaluate the Efficacy and Safety of an Every Four Weeks Treatment Regimen of Alirocumab (REGN727/ SAR236553) in Patients With Primary Hypercholesterolemia (ODYSSEY CHOICE 1)",,"Completed","Has Results","Hypercholesterolemia","Drug: Placebo (for alirocumab)|Drug: Alirocumab|Drug: Statin","Percent Change From Baseline in Calculated LDL-C in Participants Not Receiving Concomitant Statin Therapy - ITT Analysis|Percent Change From Baseline in Calculated LDL-C in Participants Receiving Concomitant Statin Therapy - Intent-to-Treat (ITT Analysis)|Percent Change From Baseline in Calculated LDL-C at Week 24 in Participants Not Receiving Concomitant Statin Therapy - On-Treatment Analysis|Percent Change From Baseline in Calculated LDL-C at Week 24 in Participants Receiving Concomitant Statin Therapy - On-Treatment Analysis|Percent Change From Baseline in Calculated LDL-C at Week 12 in Participants Not Receiving Concomitant Statin Therapy - ITT Analysis|Percent Change From Baseline in Calculated LDL-C at Week 12 in Participants Receiving Concomitant Statin Therapy - ITT Analysis|Percent Change From Baseline in Calculated LDL-C at Week 12 in Participants Not Receiving Concomitant Statin Therapy - On-treatment Analysis|Percent Change From Baseline in Calculated LDL-C at Week 12 in Participants Receiving Concomitant Statin Therapy - On-treatment Analysis|Percent Change From Baseline in Apolipoprotein (Apo) B at Week 24 in Participants Not Receiving Concomitant Statin Therapy - ITT Analysis|Percent Change From Baseline in Apo B at Week 24 in Participants Receiving Concomitant Statin Therapy - ITT Analysis|Percent Change From Baseline in Apo B at Week 24 in Participants Not Receiving Concomitant Statin Therapy - On-Treatment Analysis|Percent Change From Baseline in Apo B at Week 24 in Participants Receiving Concomitant Statin Therapy - On-Treatment Analysis|Percent Change From Baseline in Non-High Density Lipoprotein Cholesterol (Non-HDL-C) at Week 24 in Participants Not Receiving Concomitant Statin Therapy - ITT Analysis|Percent Change From Baseline in Non-HDL-C at Week 24 in Participants Receiving Concomitant Statin Therapy - ITT Analysis|Percent Change From Baseline in Non-HDL-C at Week 24 in Participants Not Receiving Concomitant Statin Therapy - On-Treatment Analysis|Percent Change From Baseline in Non-HDL-C at Week 24 in Participants Receiving Concomitant Statin Therapy - On-Treatment Analysis|Percent Change From Baseline in Total Cholesterol (Total-C) at Week 24 in Participants Not Receiving Concomitant Statin Therapy - ITT Analysis|Percent Change From Baseline in Total-C at Week 24 in Participants Receiving Concomitant Statin Therapy - ITT Analysis|Percent Change From Baseline in Apo B at Week 12 in Participants Not Receiving Concomitant Statin Therapy - ITT Analysis|Percent Change From Baseline in Apo B at Week 12 in Participants Receiving Concomitant Statin Therapy - ITT Analysis|Percent Change From Baseline in Non-HDL-C at Week 12 in Participants Not Receiving Concomitant Statin Therapy - ITT Analysis|Percent Change From Baseline in Non-HDL-C at Week 12 in Participants Receiving Concomitant Statin Therapy - ITT Analysis|Percent Change From Baseline in Total-C at Week 12 in Participants Not Receiving Concomitant Statin Therapy - ITT Analysis|Percent Change From Baseline in Total-C at Week 12 in Participants Receiving Concomitant Statin Therapy - ITT Analysis|Percentage of Very High CV Risk Participants Reaching Calculated LDL-C<70 mg/dL or Moderate or High CV Risk Participants Reaching Calculated LDL-C<100 mg/dL (Without Concomitant Statin Therapy) at Week 24 - ITT Analysis|Percentage of Very High Cardiovascular (CV) Risk Participants Reaching Calculated LDL-C <70 mg/dL or Moderate or High CV Risk Participants Reaching Calculated LDL-C <100 mg/dL (With Concomitant Statin Therapy) at Week 24 - ITT Analysis|Percentage of Very High CV Risk Participants Reaching Calculated LDL-C<70 mg/dL (1.81 mmol/L) or Moderate or High CV Risk Participants Reaching Calculated LDL-C<100 mg/dL(2.59 mmol/L) (Without Concomitant Statin Therapy) at Week 24 - On-Treatment Analysis|Percentage of Very High CV Risk Participants Reaching Calculated LDL-C <70 mg/dL(1.81 mmol/L) or Moderate or High CV Risk Participants Reaching Calculated LDL-C <100 mg/dL(2.59 mmol/L) (With Concomitant Statin Therapy) at Week 24 - On-Treatment Analysis|Percentage of Participants (Without Concomitant Statin Therapy) Reaching Calculated LDL-C <70 mg/dL (1.81 mmol/L) at Week 24 - ITT Analysis|Percentage of Participants (With Concomitant Statin Therapy) Reaching Calculated LDL-C <70 mg/dL (1.81 mmol/L) at Week 24 - ITT Analysis|Percentage of Participants (Without Concomitant Statin Therapy) Reaching Calculated LDL-C <70 mg/dL (1.81 mmol/L) at Week 24 - On-Treatment Analysis|Percentage of Participants (With Concomitant Statin Therapy) Reaching Calculated LDL-C <70 mg/dL (1.81 mmol/L) at Week 24 - On-Treatment Analysis|Percent Change From Baseline in Lipoprotein (a) in Participants Not Receiving Concomitant Statin Therapy at Week 24 - ITT Analysis|Percent Change From Baseline in Lipoprotein (a) in Participants Receiving Concomitant Statin Therapy at Week 24 - ITT Analysis|Percent Change From Baseline in Lipoprotein (a) in Participants Not Receiving Concomitant Statin Therapy at Week 12 - ITT Analysis|Percent Change From Baseline in Lipoprotein (a) in Participants Receiving Concomitant Statin Therapy at Week 12 - ITT Analysis|Percent Change From Baseline in HDL-C in Participants Not Receiving Concomitant Statin Therapy at Week 24 - ITT Analysis|Percent Change From Baseline in HDL-C in Participants Receiving Concomitant Statin Therapy at Week 24 - ITT Analysis|Percent Change From Baseline in HDL-C in Participants Not Receiving Concomitant Statin Therapy at Week 12 - ITT Analysis|Percent Change From Baseline in HDL-C in Participants Receiving Concomitant Statin Therapy at Week 12 - ITT Analysis|Percent Change From Baseline in Fasting Triglycerides in Participants Not Receiving Concomitant Statin Therapy at Week 24 - ITT Analysis|Percent Change From Baseline in Fasting Triglycerides in Participants Receiving Concomitant Statin Therapy at Week 24 - ITT Analysis|Percent Change From Baseline in Fasting Triglycerides in Participants Not Receiving Concomitant Statin Therapy at Week 12 - ITT Analysis|Percent Change From Baseline in Fasting Triglycerides in Participants Receiving Concomitant Statin Therapy at Week 12 - ITT Analysis|Percent Change From Baseline in Apo A1 in Participants Not Receiving Concomitant Statin Therapy at Week 24 - ITT Analysis|Percent Change From Baseline in Apo A1 in Participants Receiving Concomitant Statin Therapy at Week 24 - ITT Analysis|Percent Change From Baseline in Apo A1 in Participants Not Receiving Concomitant Statin Therapy at Week 12 - ITT Analysis|Percent Change From Baseline in Apo A1 in Participants Receiving Concomitant Statin Therapy at Week 12 - ITT Analysis","Regeneron Pharmaceuticals|Sanofi","All","18 Years and older   (Adult, Older Adult)","Phase 3","803","Industry","Interventional","Allocation: Randomized|Intervention Model: Parallel Assignment|Masking: Quadruple (Participant, Care Provider, Investigator, Outcomes Assessor)|Primary Purpose: Treatment","R727-CL-1308","September 2013","September 2014","April 2015","August 21, 2013","March 21, 2017","March 21, 2017","Chandler, Arizona, United States|Goodyear, Arizona, United States|Carmichael, California, United States|Fresno, California, United States|West Hills, California, United States|Wildomar, California, United States|Colorado Springs, Colorado, United States|Golden, Colorado, United States|Boynton Beach, Florida, United States|Jacksonville, Florida, United States|Safety Harbor, Florida, United States|Atlanta, Georgia, United States|Boise, Idaho, United States|Meridian, Idaho, United States|Chicago, Illinois, United States|Gurnee, Illinois, United States|Evansville, Indiana, United States|Indianapolis, Indiana, United States|Iowa City, Iowa, United States|Kansas City, Kansas, United States|Louisville, Kentucky, United States|Monroe, Louisiana, United States|Auburn, Maine, United States|Methuen, Massachusetts, United States|Minneapolis, Minnesota, United States|St. Louis, Missouri, United States|Rochester, New York, United States|Farmville, North Carolina, United States|Greensboro, North Carolina, United States|Greenville, North Carolina, United States|Raleigh, North Carolina, United States|Wilson, North Carolina, United States|Cincinnati, Ohio, United States|Marion, Ohio, United States|Tulsa, Oklahoma, United States|Philadelphia, Pennsylvania, United States|Wyomissing, Pennsylvania, United States|Knoxville, Tennessee, United States|Dallas, Texas, United States|Houston, Texas, United States|San Antonio, Texas, United States|Orem, Utah, United States|Salt Lake City, Utah, United States|South Jordan, Utah, United States|Norfolk, Virginia, United States|Richmond, Virginia, United States|Spokane, Washington, United States|Tacoma, Washington, United States|Kenosha, Wisconsin, United States|Sofia, Bulgaria|Varna, Bulgaria|Victoria, British Columbia, Canada|Oshawa, Ontario, Canada|Toronto, Ontario, Canada|Woodstock, Ontario, Canada|Montreal, Quebec, Canada|Trois-Rivieres, Quebec, Canada|Quebec, Canada|Budapest, Becsi ut, Hungary|Debrecen, HBM, Hungary|Nyiregyhaza, Sz-sz-b_m, Hungary|Ajka, VeszprÃ©m, Hungary|Nagykanizsa, Zala, Hungary|Zalaegerszeg, Zala, Hungary|Tel Hashomer, IL, Israel|Safed, ISR, Israel|Ofakim, South, Israel|Holon, Israel|Tel Hashomer, Israel|Skedsmokorset, Akershus, Norway|Oslo, Norway|Svidnik, Presov, Slovakia|Bratislava, SK, Slovakia|Bratislava, SR, Slovakia|Lucenec, Slovakia|PovaÅ¾skÃ¡ Bystrica, Slovakia|Worton Grange, Reading, Berkshire, United Kingdom|Edgbaston, Birmingham, United Kingdom|Llanishen, Cardiff, United Kingdom|Choley, Lancashire, United Kingdom|Waterloo, Liverpool, United Kingdom|Lloyd Street North, Manchester, United Kingdom|Glasgow, Scotland, United Kingdom",,"https://ClinicalTrials.gov/show/NCT01926782"
184,"NCT01922661","Single Ascending-dose Study of the Safety, Tolerability, and Pharmacokinetics of REGN1908-1909 in Allergic, Adult Subjects",,"Completed","No Results Available","Allergy","Drug: REGN1908-1909|Other: placebo","Safety|Serum concentration","Regeneron Pharmaceuticals","All","18 Years to 55 Years   (Adult)","Phase 1","24","Industry","Interventional","Allocation: Randomized|Intervention Model: Single Group Assignment|Masking: Triple (Participant, Investigator, Outcomes Assessor)|Primary Purpose: Treatment","R1908-HV-1240","August 2013","May 2014","May 2014","August 14, 2013",,"June 10, 2014","Overland Park, Kansas, United States|Baltimore, Maryland, United States",,"https://ClinicalTrials.gov/show/NCT01922661"
185,"NCT01910220","Study to Assess the Safety and Bioeffect of REGN1033 (SAR391786)",,"Completed","No Results Available","Healthy Volunteers","Drug: REGN1033 (SAR391786)|Other: placebo","Percent change in total lean mass|Number of TEAEs|Appendicular lean mass by DXA","Regeneron Pharmaceuticals|Sanofi","All","60 Years and older   (Adult, Older Adult)","Phase 1","125","Industry","Interventional","Allocation: Randomized|Intervention Model: Parallel Assignment|Masking: Triple (Participant, Investigator, Outcomes Assessor)|Primary Purpose: Treatment","R1033-HV-1223","August 2013","June 2014","October 2014","July 29, 2013",,"November 10, 2014","Gainesville, Florida, United States|Orlando, Florida, United States|Boston, Massachusetts, United States|St. Louis, Missouri, United States|Athens, Ohio, United States",,"https://ClinicalTrials.gov/show/NCT01910220"
186,"NCT01893528","Study to Assess the Safety and Tolerability of Ascending Single Doses of REGN2009 in Healthy Volunteers",,"Completed","No Results Available","Healthy Volunteers","Drug: REGN2009|Other: placebo","Number of TEAEs","Regeneron Pharmaceuticals","All","18 Years to 65 Years   (Adult, Older Adult)","Phase 1","49","Industry","Interventional","Allocation: Randomized|Intervention Model: Single Group Assignment|Masking: Triple (Participant, Investigator, Outcomes Assessor)|Primary Purpose: Treatment","R2009-HV-1304","June 2013","September 2014","September 2014","July 9, 2013",,"November 10, 2014","Baltimore, Maryland, United States|Cincinnati, Ohio, United States",,"https://ClinicalTrials.gov/show/NCT01893528"
187,"NCT01859988","Study of Dupilumab Administered to Adult Patients With Moderate-to-Severe Atopic Dermatitis",,"Completed","Has Results","Atopic Dermatitis","Drug: Dupilumab|Drug: Placebo","Percent Change in Eczema Area and Severity Index Score (EASI) From Baseline to Week 16|Percentage of Participants Who Achieved Investigator's Global Assessment (IGA) Response at Week 16|Percentage of Participants Who Achieved IGA Score Reduction of ≥2 at Week 16|Percent Change in Peak Weekly Averaged Pruritus Numerical Rating Scores (NRS) From Baseline to Week 16|Absolute Change in Peak Weekly Averaged Pruritus NRS From Baseline to Week 16|Absolute Change in EASI Score From Baseline to Week 16|Percent Change in SCORing Atopic Dermatitis (SCORAD) Scores From Baseline to Week 16|Absolute Change in SCORAD Scores From Baseline to Week 16|Percentage of Participants Who Achieved 50%, 75% and 90% Reduction From Baseline in EASI Score (EASI-50, EASI-75 and EASI-90 Respectively) at Week 16|Percentage of Participants Who Achieved 50%, 75% and 90% Reduction From Baseline in SCORAD Score (SCORAD-50, SCORAD-75 and SCORAD-90 Respectively) at Week 16|Percent Change in Patient Oriented Eczema Measure (POEM) Scores From Baseline to Week 16|Absolute Change in POEM Scores From Baseline to Week 16|Changes in Global Individual Signs Score (GISS) Components (Erythema, Infiltration/Papulation, Excoriations, and Lichenification) From Baseline to Week 16|Changes in GISS Cumulative Score From Baseline to Week 16","Regeneron Pharmaceuticals|Sanofi","All","18 Years and older   (Adult, Older Adult)","Phase 2","380","Industry","Interventional","Allocation: Randomized|Intervention Model: Parallel Assignment|Masking: Quadruple (Participant, Care Provider, Investigator, Outcomes Assessor)|Primary Purpose: Treatment","R668-AD-1021","May 2013","May 2014","September 2014","May 22, 2013","August 28, 2017","August 28, 2017","Birmingham, Alabama, United States|Mobile, Alabama, United States|Tucson, Arizona, United States|Bakersfield, California, United States|San Diego, California, United States|Santa Monica, California, United States|Jacksonville, Florida, United States|Ormond Beach, Florida, United States|Skokie, Illinois, United States|New Orleans, Louisiana, United States|Andover, Massachusetts, United States|Boston, Massachusetts, United States|Troy, Michigan, United States|Saint Louis, Missouri, United States|New York, New York, United States|Rochester, New York, United States|Winston-Salem, North Carolina, United States|Portland, Oregon, United States|Pittsburgh, Pennsylvania, United States|Johnston, Rhode Island, United States|Greer, South Carolina, United States|Nashville, Tennessee, United States|Houston, Texas, United States|San Antonio, Texas, United States|Seattle, Washington, United States|Vancouver (2 locations), British Columbia, Canada|Winnipeg, Manitoba, Canada|Barrie, Ontario, Canada|Hamilton, Ontario, Canada|Markham, Ontario, Canada|Oakville, Ontario, Canada|Peterborough, Ontario, Canada|Richmond Hill, Ontario, Canada|Waterloo, Ontario, Canada|Windsor, Ontario, Canada|St. Hyacinthe, Quebec, Canada|Quebec, Canada|Kutná Hora, Czechia|Nachod, Czechia|Praha, Czechia|Svitavy, Czechia|Usti nad Labem, Czechia|Augsburg, Germany|Baden, Germany|Berlin, Germany|Bonn, Germany|Dresden, Germany|Dülmen, Germany|Frankfurt/ Main, Germany|Frankfurt/Main, Hessen, Germany|Gera, Germany|Hamburg, Germany|Heidelberg, Germany|Kiel, Germany|Mahlow, Germany|Muenster, Germany|Munich, Germany|Osnabruck, Germany|Tübingen, Germany|Borsod-Abauj-Zemplen, Hungary|Budapest, Hungary|Kaposvár, Hungary|Szeged, Hungary|Szolnok, Hungary|Tolna, Hungary|Fukuoka, Japan|Hokkaido, Japan|Saitama, Japan|Tokyo, Bunkyo-ku, Japan|Tokyo, Chiyoda-ku, Japan|Tokyo, Nakano-ku, Japan|Tokyo, Nerima-ku, Japan|Tokyo, Shibuya-ku, Japan|Tokyo, Shinagawa-ku, Japan|Tokyo, Shinjuku-ku (2 locations), Japan|Tokyo, Suginami-ku (2 locations), Japan|Yokohama, Japan|Gdansk (2 locations), Poland|Katowice, Poland|Lodz, Poland|Lublin, Poland|Poznan, Poland|Warsaw (2 locations), Poland|Wroclaw, Poland",,"https://ClinicalTrials.gov/show/NCT01859988"
188,"NCT01803321","Study to Evaluate the Safety and Tolerability of Two Doses of Rilonacept in Pediatric Subjects With Active Systemic Juvenile Idiopathic Arthritis (SJIA)",,"Completed","No Results Available","Systemic Juvenile Idiopathic Arthritis","Drug: rilonacept (IL-1 Trap)|Other: Placebo","Frequency of treatment emergent adverse events (TEAEs)","Regeneron Pharmaceuticals","All","4 Years to 20 Years   (Child, Adult)","Phase 1","24","Industry","Interventional","Allocation: Randomized|Intervention Model: Single Group Assignment|Masking: Quadruple (Participant, Care Provider, Investigator, Outcomes Assessor)|Primary Purpose: Treatment","IL1T-AI-0504","November 2005","June 2008","June 2008","March 4, 2013",,"March 4, 2013","Los Angeles, California, United States|Wilmington, Delaware, United States|Chicago, Illinois, United States|Hackensack, New Jersey, United States|Long Island, New York, United States|Cincinnati, Ohio, United States|Cleveland, Ohio, United States|Dallas, Texas, United States|Seattle, Washington, United States",,"https://ClinicalTrials.gov/show/NCT01803321"
189,"NCT01749878","Study to Assess the Safety and Tolerability of Single Doses of REGN1500",,"Completed","No Results Available","Hypertriglyceridemia","Drug: REGN1500|Drug: placebo","Safety|Serum concentration of REGN1500","Regeneron Pharmaceuticals","All","18 Years to 65 Years   (Adult, Older Adult)","Phase 1","99","Industry","Interventional","Allocation: Randomized|Intervention Model: Single Group Assignment|Masking: Triple (Participant, Investigator, Outcomes Assessor)|Primary Purpose: Treatment","R1500-HV-1214","December 2012","January 2016","January 2016","December 17, 2012",,"May 12, 2016","Philadelphia, Pennsylvania, United States|Dallas, Texas, United States",,"https://ClinicalTrials.gov/show/NCT01749878"
190,"NCT01730053","Study of Alirocumab (REGN727/SAR236553) added-on to Rosuvastatin Versus Other Lipid Modifying Treatments (LMT) (ODYSSEY OPTIONS II)",,"Completed","Has Results","Hypercholesterolemia","Drug: Alirocumab|Drug: Rosuvastatin|Drug: Ezetimibe|Drug: Placebo","Percent Change From Baseline in Calculated LDL-C at Week 24 - Intent-to-Treat (ITT) Analysis|Percent Change From Baseline in Calculated LDL-C at Week 24 - On-Treatment Analysis|Percent Change From Baseline in Calculated LDL-C at Week 12 - ITT Analysis|Percent Change From Baseline in Calculated LDL-C at Week 12 - On-Treatment Analysis|Percent Change From Baseline in Apolipoprotein (Apo) B at Week 24 - ITT Analysis|Percent Change From Baseline in Apo B at Week 24 - On-Treatment Analysis|Percent Change From Baseline in Non-High-density Lipoprotein Cholesterol (Non-HDL-C) at Week 24 - ITT Analysis|Percent Change From Baseline in Non-HDL-C at Week 24 - On-Treatment Analysis|Percent Change From Baseline in Total Cholesterol (Total-C) at Week 24 - ITT Analysis|Percent Change From Baseline in Apo B at Week 12 - ITT Analysis|Percent Change From Baseline in Non-HDL-C at Week 12 - ITT Analysis|Percent Change From Baseline in Total-C at Week 12 - ITT Analysis|Percentage of Very High CV Risk Participants Reaching Calculated LDL-C <70 mg/dL (1.81 mmol/L) or High CV Risk Participants Reaching Calculated LDL-C <100 mg/dL (2.59 mmol/L) at Week 24 - ITT Analysis|Percentage of Very High CV Risk Participants Reaching Calculated LDL-C <70 mg/dL (1.81 mmol/L) or High CV Risk Participants Reaching Calculated LDL-C <100 mg/dL (2.59 mmol/L) at Week 24 - On-Treatment Analysis|Percentage of Participants Reaching Calculated LDL-C <70 mg/dL (1.81 mmol/L) at Week 24 - ITT Analysis|Percentage of Participants Reaching Calculated LDL-C <70 mg/dL (1.81 mmol/L) at Week 24 - On-Treatment Analysis|Percent Change From Baseline in Lipoprotein(a) at Week 24 - ITT Analysis|Percent Change From Baseline in HDL-C at Week 24 - ITT Analysis|Percent Change From Baseline in Fasting Triglycerides at Week 24 - ITT Analysis|Percent Change From Baseline in Apo A-1 at Week 24 - ITT Analysis|Percent Change From Baseline in Lipoprotein (a) at Week 12 - ITT Analysis|Percent Change From Baseline in HDL-C at Week 12 - ITT Analysis|Percent Change From Baseline in Fasting Triglycerides at Week 12 - ITT Analysis|Percent Change From Baseline in Apo A-1 at Week 12 - ITT Analysis","Regeneron Pharmaceuticals|Sanofi","All","18 Years and older   (Adult, Older Adult)","Phase 3","305","Industry","Interventional","Allocation: Randomized|Intervention Model: Parallel Assignment|Masking: Quadruple (Participant, Care Provider, Investigator, Outcomes Assessor)|Primary Purpose: Treatment","R727-CL-1118","November 30, 2012","April 30, 2014","May 31, 2014","November 21, 2012","October 28, 2015","April 7, 2020","Chandler, Arizona, United States|Tucson, Arizona, United States|Anaheim, California, United States|Beverly Hills, California, United States|Fair Oaks, California, United States|Newport Beach, California, United States|Northridge, California, United States|Sacramento, California, United States|Walnut Creek, California, United States|Milford, Connecticut, United States|Atlantis, Florida, United States|Bradenton, Florida, United States|Clearwater, Florida, United States|Fort Lauderdale, Florida, United States|Jacksonville, Florida, United States|Lakeland, Florida, United States|(2 Locations), Miami, Florida, United States|Oviedo, Florida, United States|Pinellas Park, Florida, United States|Port Orange, Florida, United States|Sarasota, Florida, United States|Tampa, Florida, United States|West Palm Beach, Florida, United States|Winter Park, Florida, United States|Boise, Idaho, United States|Morton, Illinois, United States|Evansville, Indiana, United States|Indianapolis, Indiana, United States|Newton, Kansas, United States|Overland Park, Kansas, United States|Wichita, Kansas, United States|Lexington, Kentucky, United States|Louisville, Kentucky, United States|Auburn, Maine, United States|Bethesda, Maryland, United States|Edina, Minnesota, United States|Rochester, Minnesota, United States|Olive Branch, Mississippi, United States|Port Gibson, Mississippi, United States|Saint Louis, Missouri, United States|Butte, Montana, United States|Williamsville, New York, United States|Cincinnati, Ohio, United States|Marion, Ohio, United States|Portland, Oregon, United States|Warwick, Rhode Island, United States|Greer, South Carolina, United States|Summerville, South Carolina, United States|Kingsport, Tennessee, United States|Dallas, Texas, United States|Fort Worth, Texas, United States|Houston, Texas, United States|Bountiful, Utah, United States|Salt Lake City, Utah, United States|Herston, Australia|New Lambton Heights, Australia|Perth, Australia|Sherwood, Australia|Woolloongabba, Australia|Brampton, Ontario, Canada|Burlington, Ontario, Canada|Etobicoke, Ontario, Canada|London, Ontario, Canada|Newmarket, Ontario, Canada|Thornhill, Ontario, Canada|Toronto, Ontario, Canada|Chicoutimi, Quebec, Canada|Dijon, France|Lille, France|Bad Oeynhausen, Germany|Berlin, Germany|Koeln, Germany|Regensburg, Germany|Ulm, Germany|Chieti, Italy|Genova, Italy|Napoli, Italy|Palermo, Italy|(2 Locations), Roma, Italy|Baja California, Mexico|Distrito Federal, Mexico|(3 Locations), Guadalajara, Mexico|Monterrey, Mexico|Zapopan Jalisco, Mexico|(2 Locations), Barcelona, Spain|Madrid, Spain|Santiago, Spain|Sevilla, Spain|West Bromwich, West Midlands, United Kingdom|Chester, United Kingdom|Peterborough, United Kingdom|Salford, United Kingdom|Stevenage, United Kingdom",,"https://ClinicalTrials.gov/show/NCT01730053"
191,"NCT01730040","Study of the Efficacy and Safety of Alirocumab (REGN727/SAR236553) in Combination With Other Lipid-modifying Treatment (LMT) (ODYSSEY OPTIONS I)",,"Completed","Has Results","Hypercholesterolemia","Drug: Alirocumab|Drug: Atorvastatin|Drug: Ezetimibe|Drug: Rosuvastatin|Drug: Placebo","Percent Change From Baseline in Calculated LDL-C at Week 24 - Intent-to-treat (ITT) Analysis|Percent Change From Baseline in Calculated LDL-C at Week 24 - On-Treatment Analysis|Percent Change From Baseline in Calculated LDL-C at Week 12 - ITT Analysis|Percent Change From Baseline in Calculated LDL-C at Week 12 - On-Treatment Analysis|Percent Change From Baseline in Apolipoprotein (Apo) B at Week 24 - ITT Analysis|Percent Change From Baseline in Apo B at Week 24 - On-Treatment Analysis|Percent Change From Baseline in Non-High-density Lipoprotein Cholesterol (Non-HDL-C) at Week 24 - ITT Analysis|Percent Change From Baseline in Non-HDL-C at Week 24 - On-Treatment Analysis|Percent Change From Baseline in Total Cholesterol (Total-C) at Week 24 - ITT Analysis|Percent Change From Baseline in Apo B at Week 12 - ITT Analysis|Percent Change From Baseline in Non-HDL-C at Week 12 - ITT Analysis|Percent Change From Baseline in Total-C at Week 12 - ITT Analysis|Percentage of Very High CV Risk Participants Reaching Calculated LDL-C <70 mg/dL (1.81 mmol/L) or High CV Risk Participants Reaching Calculated LDL-C <100 mg/dL (2.59 mmol/L) at Week 24 - ITT Analysis|Percentage of Very High CV Risk Participants Reaching Calculated LDL-C <70 mg/dL (1.81 mmol/L) or High CV Risk Participants Reaching Calculated LDL-C <100 mg/dL (2.59 mmol/L) at Week 24 - On-Treatment Analysis|Percentage of Participants Reaching Calculated LDL-C <70 mg/dL (1.81 mmol/L) at Week 24 - ITT Analysis|Percentage of Participants Reaching Calculated LDL-C <70 mg/dL (1.81 mmol/L) at Week 24 - On-Treatment Analysis|Percent Change From Baseline in Lipoprotein(a) at Week 24 - ITT Analysis|Percent Change From Baseline in HDL-C at Week 24 - ITT Analysis|Percent Change From Baseline in Fasting Triglycerides at Week 24 - ITT Analysis|Percent Change From Baseline in Apo A-1 at Week 24 - ITT Analysis|Percent Change From Baseline in Lipoprotein(a) at Week 12 - ITT Analysis|Percent Change From Baseline in HDL-C at Week 12 - ITT Analysis|Percent Change From Baseline in Fasting Triglycerides at Week 12 - ITT Analysis|Percent Change From Baseline in Apo A-1 at Week 12 - ITT Analysis","Regeneron Pharmaceuticals|Sanofi","All","18 Years and older   (Adult, Older Adult)","Phase 3","355","Industry","Interventional","Allocation: Randomized|Intervention Model: Parallel Assignment|Masking: Quadruple (Participant, Care Provider, Investigator, Outcomes Assessor)|Primary Purpose: Treatment","R727-CL-1110","October 2012","April 2014","May 2014","November 21, 2012","August 31, 2015","August 31, 2015","Mobile, Alabama, United States|Chandler, Arizona, United States|Tucson, Arizona, United States|Anaheim, California, United States|Beverly Hills, California, United States|Lakeland, California, United States|Newport Beach, California, United States|Northridge, California, United States|Sacramento, California, United States|Walnut Creek, California, United States|Milford, Connecticut, United States|Atlantis, Florida, United States|Boca Raton, Florida, United States|Clearwater, Florida, United States|Jacksonville, Florida, United States|Miami (2 locations), Florida, United States|Oviedo, Florida, United States|Pinellas Park, Florida, United States|Port Orange, Florida, United States|Sarasota, Florida, United States|Tampa, Florida, United States|West Palm Beach, Florida, United States|Boise, Idaho, United States|Meridian, Idaho, United States|Chicago, Illinois, United States|Morton, Illinois, United States|Indianapolis, Indiana, United States|Newton, Kansas, United States|Overland Park, Kansas, United States|Wichita, Kansas, United States|Lexington, Kentucky, United States|Louisville, Kentucky, United States|Auburn, Maine, United States|Bethesda, Maryland, United States|Edina, Minnesota, United States|Rochester, Minnesota, United States|Olive Branch, Mississippi, United States|Port Gibson, Mississippi, United States|St. Louis, Missouri, United States|Butte, Montana, United States|Las Vegas, Nevada, United States|Williamsville, New York, United States|Winston-Salem, North Carolina, United States|Cleveland, Ohio, United States|Oklahoma City, Oklahoma, United States|Warwick, Rhode Island, United States|Greer, South Carolina, United States|Summerville, South Carolina, United States|Kingsport, Tennessee, United States|Dallas (2 locations), Texas, United States|Fort Worth, Texas, United States|Houston, Texas, United States|Bountiful, Utah, United States|Marion, Utah, United States|Salt Lake City, Utah, United States|Renton, Washington, United States|Herston QLD, Australia|New Lambton Heights, Australia|Perth, Australia|Sherwood, Australia|Woolloongabba, Australia|Brampton, Ontario, Canada|Etobicoke, Ontario, Canada|London, Ontario, Canada|Newmarke, Ontario, Canada|Thornhill, Ontario, Canada|Toronto, Ontario, Canada|Chicoutimi, Quebec, Canada|Dijon, France|Lille, France|Venissieux, France|Bad Oeynhausen, Germany|Berlin, Germany|Koeln, Germany|Munich, Germany|Regensburg, Germany|Ulm, Germany|Chiete, Italy|Genova, Italy|Napoli, Italy|Palermo, Italy|Roma (2 locations), Italy|Distrito Federal, Mexico|Guadalajara, Jalisco, Mexico|Guadalajara, Mexico|Monterrey Nuevo Leon, Mexico|Tijuana Baja California, Mexico|Zapopan Jalisco, Mexico|Barcelona (3 locations), Spain|Madrid, Spain|Sant Joan Despi, Spain|Carmarthen, United Kingdom|Chester, United Kingdom|Peterborough, United Kingdom|Salford, United Kingdom|Stevenage, United Kingdom|West Bromwich, West Midlands, United Kingdom",,"https://ClinicalTrials.gov/show/NCT01730040"
192,"NCT01727869","Study of REGN1400 Alone and in Combination With Erlotinib or Cetuximab in Patients With Certain Types of Cancer",,"Completed","No Results Available","Cancer","Drug: REGN1400|Drug: Erlotinib|Drug: Cetuximab","The primary objective of the study is to characterize the safety profile of REGN1400 alone and in combination with erlotinib or cetuximab|Recommended Phase 2 Dose (RP2D)","Regeneron Pharmaceuticals","All","18 Years and older   (Adult, Older Adult)","Phase 1","56","Industry","Interventional","Allocation: Non-Randomized|Intervention Model: Single Group Assignment|Masking: None (Open Label)|Primary Purpose: Treatment","R1400-ST-1113","October 2012","January 2015","January 2015","November 16, 2012",,"April 6, 2015","Santa Monica, California, United States|Atlanta, Georgia, United States|Detroit, Michigan, United States|Buffalo, New York, United States|New York, New York, United States|San Antonio, Texas, United States",,"https://ClinicalTrials.gov/show/NCT01727869"
193,"NCT01722045","Study to Assess Best Corrected Visual Acuity (BCVA) in Patients With Neovascular Age-Related Macular Degeneration (AMD) Who Are Administered VEGF Trap-Eye (Intravitreal Aflibercept Injection)","RE-VIEW","Completed","Has Results","Age - Related Macular Degeneration (AMD)","Drug: Intravitreal Aflibercept Injection (IAI)","Change in Early Treatment Diabetic Retinopathy Study (ETDRS) Letter Score From Baseline to Week 100 - Last Observation Carried Forward (LOCF)|Percentage of Participants Whose Optical Coherence Tomography (OCT) Status Was ""Dry"" at Week 52 and at Week 100 (LOCF)|Percentage of Participants Who Gained ≥15 ETDRS Letters Compared With Baseline at Week 52 and Week 100 (LOCF)|Change From Baseline in Best Corrected Visual Acuity Score Through Week 52 (LOCF)|Percentage of Participants Who Gained ≥0, ≥5, ≥10, or ≥30 Letters From Baseline in BCVA Through Week 100 (LOCF)|Percentage of Patients Who Lost >0, ≥5, ≥10, or ≥15 Letters From Baseline in BCVA Through Week 100 (LOCF)","Regeneron Pharmaceuticals","All","50 Years and older   (Adult, Older Adult)","Phase 4","154","Industry","Interventional","Allocation: N/A|Intervention Model: Single Group Assignment|Masking: None (Open Label)|Primary Purpose: Treatment","VGFTe-AMD-1124","November 2012","September 2015","September 2015","November 6, 2012","December 22, 2017","December 22, 2017","Phoenix, Arizona, United States|Tucson, Arizona, United States|Beverly Hills, California, United States|Oakland, California, United States|Palm Desert, California, United States|Sacramento, California, United States|Santa Ana, California, United States|Westlake Village, California, United States|Colorado Springs, Colorado, United States|Golden, Colorado, United States|Boynton Beach, Florida, United States|Fort Lauderdale, Florida, United States|Fort Myers, Florida, United States|Pensacola, Florida, United States|Plantation, Florida, United States|Tampa, Florida, United States|Winter Haven, Florida, United States|Augusta, Georgia, United States|Oak Park, Illinois, United States|New Albany, Indiana, United States|Wichita, Kansas, United States|Lexington, Kentucky, United States|Boston, Massachusetts, United States|Worcester, Massachusetts, United States|Jackson, Michigan, United States|Lincoln, Nebraska, United States|Las Vegas, Nevada, United States|Portsmouth, New Hampshire, United States|Bloomfield, New Jersey, United States|Lawrenceville, New Jersey, United States|Northfield, New Jersey, United States|Teaneck, New Jersey, United States|Rochester, New York, United States|Asheville, North Carolina, United States|Oklahoma City, Oklahoma, United States|Portland, Oregon, United States|Salem, Oregon, United States|Kingston, Pennsylvania, United States|Pittsburgh, Pennsylvania, United States|Florence, South Carolina, United States|Ladson, South Carolina, United States|West Columbia, South Carolina, United States|Rapid City, South Dakota, United States|Nashville, Tennessee, United States|Arlington, Texas, United States|Fort Worth, Texas, United States|Houston, Texas, United States|San Antonio, Texas, United States|Seattle, Washington, United States",,"https://ClinicalTrials.gov/show/NCT01722045"
194,"NCT01720576","Study to Assess the Safety and Tolerability of Multiple Ascending Doses of REGN1033 (SAR391786)",,"Completed","No Results Available","Healthy Volunteers","Drug: REGN1033 (SAR391786)|Drug: Placebo","Number of TEAEs|Serum concentration of REGN1033 (SAR391786)|immunogenicity","Regeneron Pharmaceuticals|Sanofi","All","60 Years and older   (Adult, Older Adult)","Phase 1","60","Industry","Interventional","Allocation: Randomized|Intervention Model: Single Group Assignment|Masking: Quadruple (Participant, Care Provider, Investigator, Outcomes Assessor)|Primary Purpose: Treatment","R1033-HV-1204","October 2012","June 2013","June 2013","November 2, 2012",,"September 12, 2013","Daytona Beach, Florida, United States|Evansville, Indiana, United States",,"https://ClinicalTrials.gov/show/NCT01720576"
195,"NCT01709513","Study of Alirocumab (REGN727/SAR236553) in Patients With Primary Hypercholesterolemia and Moderate, High, or Very High Cardiovascular (CV) Risk, Who Are Intolerant to Statins (ODYSSEY ALTERNATIVE)",,"Completed","Has Results","Hypercholesterolemia","Drug: Atorvastatin|Drug: Ezetimibe|Drug: Alirocumab|Drug: Placebo","Percent Change From Baseline in Calculated LDL-C at Week 24 - Intent--To-Treat (ITT) Analysis|Percent Change From Baseline in Calculated LDL-C at Week 24 - On--Treatment Analysis|Percent Change From Baseline in Calculated LDL--C at Week 12 -- ITT Analysis|Percent Change From Baseline in Calculated LDL-C at Week 12 - On--Treatment Analysis|Percent Change From Baseline in Apolipoprotein (Apo) B at Week 24 -- ITT Analysis|Percent Change From Baseline in Apo B at Week 24 -- On--Treatment Analysis|Percent Change From Baseline in Non--High Density Lipoprotein Cholesterol (Non-HDL-C) at Week 24 -- ITT Analysis|Percent Change From Baseline in Non--HDL-C at Week 24 -- On--Treatment Analysis|Percent Change From Baseline in Total Cholesterol (Total--C) at Week 24 - ITT Analysis|Percent Change From Baseline in Apo B at Week 12 -- ITT Analysis|Percent Change From Baseline in Non-HDL-C at Week 12 - ITT Analysis|Percent Change From Baseline in Total-C at Week 12 - ITT Analysis|Percentage of Very High CV Risk Participants Reaching Calculated LDL-C <70 mg/dL (1.81 mmol/L) or Moderate or High CV Risk Participants Reaching Calculated LDL-C <100 mg/dL (2.59 mmol/L) at Week 24 - ITT Analysis|Percentage of Very High CV Risk Participants Reaching Calculated LDL-C <70 mg/dL (1.81 mmol/L) or Moderate or High CV Risk Participants Reaching Calculated LDL-C <100 mg/dL (2.59 mmol/L) at Week 24 - On-Treatment Analysis|Percentage of Participants Reaching Calculated LDL-C <70 mg/dL (1.81 mmol/L) at Week 24 - ITT Analysis|Percentage of Participants Reaching Calculated LDL-C <70 mg/dL (1.81 mmol/L) at Week 24 - On-Treatment Analysis|Percent Change From Baseline in Lipoprotein(a) at Week 24 - ITT Analysis|Percent Change From Baseline in HDL-C at Week 24 - ITT Analysis|Percent Change From Baseline in Fasting Triglycerides at Week 24 - ITT Analysis|Percent Change From Baseline in Apo A-1 at Week 24 - ITT Analysis|Percent Change From Baseline in Lipoprotein(a) at Week 12 -- ITT Analysis|Percent Change in HDL-C From Baseline to Week 12 -- ITT Analysis|Percent Change in Fasting Triglycerides From Baseline to Week 12 -- ITT Analysis|Percent Change From Baseline in Apo A--1 at Week 12 -- ITT Analysis","Regeneron Pharmaceuticals|Sanofi","All","18 Years and older   (Adult, Older Adult)","Phase 3","314","Industry","Interventional","Allocation: Randomized|Intervention Model: Parallel Assignment|Masking: Quadruple (Participant, Care Provider, Investigator, Outcomes Assessor)|Primary Purpose: Treatment","R727-CL-1119","September 30, 2012","May 31, 2014","May 31, 2017","October 18, 2012","August 28, 2015","June 23, 2020","Anaheim, California, United States|Beverly Hills, California, United States|Mission Viejo, California, United States|Newport Beach, California, United States|Northridge, California, United States|Thousand Oaks, California, United States|Hartford, Connecticut, United States|Boynton Beach, Florida, United States|Jacksonville, Florida, United States|Lakeland, Florida, United States|Pembroke Pines, Florida, United States|Sarasota, Florida, United States|Tampa, Florida, United States|Trinity, Florida, United States|Addison, Illinois, United States|Chicago, Illinois, United States|Indianapolis, Indiana, United States|Kansas City, Kansas, United States|Auburn, Maine, United States|Boston, Massachusetts, United States|Minneapolis, Minnesota, United States|Rochester, Minnesota, United States|Saint Louis, Missouri, United States|Clifton, New Jersey, United States|New York, New York, United States|Poughkeepsie, New York, United States|Durham, North Carolina, United States|Cincinnati, Ohio, United States|Marion, Ohio, United States|Danville, Pennsylvania, United States|Philadelphia, Pennsylvania, United States|Port Matilda, Pennsylvania, United States|Scranton, Pennsylvania, United States|Wilkes-Barre, Pennsylvania, United States|Summerville, South Carolina, United States|Kingsport, Tennessee, United States|Nashville, Tennessee, United States|Dallas, Texas, United States|Fort Worth, Texas, United States|Salt Lake City, Utah, United States|Richmond, Virginia, United States|Feldkirch, Austria|Graz, Austria|Innsbruck, Austria|Chicoutimi, Quebec, Canada|Montreal (2 locations), Quebec, Canada|Sainte-Foy, Quebec, Canada|Bron, France|Dijon, France|Lille, France|Paris, France|Saint-Herblain, France|Venissieux, France|Holon, Israel|Jerusalem, Israel|Ofakim, Israel|Safed, Israel|Tel-Hashomer, Israel|Cinisello Balsamo, Italy|Napoli, Italy|Palermo, Italy|Roma, Italy|Oslo (2 Locations), Norway|Burton-on-Trent, United Kingdom|Chesterfield, United Kingdom|Isle Of White, United Kingdom|Londonderry/N. Ireland, United Kingdom|Peterborough, United Kingdom|Salford, United Kingdom|Stevenage, United Kingdom",,"https://ClinicalTrials.gov/show/NCT01709513"
196,"NCT01709500","Study of Alirocumab (REGN727/SAR236553) in Patients With heFH (Heterozygous Familial Hypercholesterolemia) Who Are Not Adequately Controlled With Their LMT (Lipid-Modifying Therapy)","ODYSSEY FH II","Completed","Has Results","Heterozygous Familial Hypercholesterolemia","Drug: LMT (atorvastatin, simvastatin, or rosuvastatin)|Drug: alirocumab|Drug: Placebo","Percent Change From Baseline in Calculated LDL-C at Week 24 - Intent--to--Treat (ITT) Analysis|Percent Change From Baseline in Calculated LDL-C at Week 24 - On-Treatment Analysis|Percent Change From Baseline in Calculated LDL-C at Week 12 - ITT Analysis|Percent Change From Baseline in Calculated LDL-C at Week 12 - On- Treatment Analysis|Percent Change From Baseline in Apolipoprotein (Apo) B at Week 24 - ITT Analysis|Percent Change From Baseline in Apo B at Week 24 - On-Treatment Analysis|Percent Change From Baseline in Non-High -Density Lipoprotein Cholesterol (Non-HDL-C) at Week 24 - ITT Analysis|Percent Change From Baseline in Non-HDL-C at Week 24 - On-Treatment Analysis|Percent Change From Baseline in Total Cholesterol (Total-C) at Week 24 - ITT Analysis|Percent Change From Baseline in Apo B at Week 12 - ITT Analysis|Percent Change From Baseline in Non-HDL-C at Week 12 - ITT Analysis|Percent Change From Baseline in Total-C at Week 12 - ITT Analysis|Percent Change From Baseline in Calculated LDL-C at Week 52 - ITT Analysis|Percentage of Very High CV Risk Participants Reaching Calculated LDL-C <70 mg/dL (1.81 mmol/L) or High CV Risk Participants Reaching Calculated LDL-C <100 mg/dL (2.59 mmol/L) at Week 24 - ITT Analysis|Percentage of Very High CV Risk Participants Reaching Calculated LDL--C <70 mg/dL (1.81 mmol/L) or High CV Risk Participants Reaching Calculated LDL--C <100 mg/dL (2.59 mmol/L) at Week 24 - On-Treatment Analysis|Percentage of Participants Reaching Calculated LDL-C <70 mg/dL (1.81 mmol/L) at Week 24 - ITT Analysis|Percentage of Participants Reaching Calculated LDL--C <70 mg/dL (1.81 mmol/L) at Week 52 - On-Treatment Analysis|Percent Change From Baseline in Lipoprotein (a) at Week 24 - ITT Analysis|Percent Change From Baseline in HDL-C at Week 24 - ITT Analysis|Percent Change From Baseline in Fasting Triglycerides at Week 24 - ITT Analysis|Percent Change From Baseline in Apo A-1 at Week 24 - ITT Analysis|Percent Change From Baseline in Lipoprotein (a) at Week 12 - ITT Analysis|Percent Change From Baseline in HDL-C at Week 12 - ITT Analysis|Percent Change From Baseline in Fasting Triglycerides at Week 12 - ITT Analysis|Percent Change From Baseline in Apo A-1 at Week 12 - ITT Analysis","Regeneron Pharmaceuticals|Sanofi","All","18 Years and older   (Adult, Older Adult)","Phase 3","249","Industry","Interventional","Allocation: Randomized|Intervention Model: Parallel Assignment|Masking: Quadruple (Participant, Care Provider, Investigator, Outcomes Assessor)|Primary Purpose: Treatment","R727-CL-1112","December 2012","May 2014","January 2015","October 18, 2012","October 28, 2015","October 28, 2015","Hradec Kralove, Czech Republic|Praha 2, Czech Republic|Praha 5, Czech Republic|Praha 8, Czech Republic|Trutnov, Czech Republic|Vyskov, Czech Republic|Alkmaar, Netherlands|Amsterdam, Netherlands|Apeldoorn, Netherlands|Enschede, Netherlands|Goes, Netherlands|Groningen, Netherlands|Hoogeveen, Netherlands|Hoorn, Netherlands|Rotterdam, Netherlands|Sittard- Geleen, Netherlands|Utrecht (2 locations), Netherlands|Venlo, Netherlands|Waalwijk, Netherlands|Oslo, Norway|Cardiff, United Kingdom|London, United Kingdom|Manchester, United Kingdom|Middlesex, United Kingdom|Newcastle upon Tyne, United Kingdom|West Bromwich, United Kingdom",,"https://ClinicalTrials.gov/show/NCT01709500"
197,"NCT01688960","Nesvacumab (REGN910/ SAR307746) and Aflibercept (""Ziv-aflibercept"" in the U.S.) in Patients With Advanced Solid Malignancies",,"Completed","No Results Available","Solid Tumors","Drug: nesvacumab (REGN910/ SAR307746)|Drug: aflibercept (ziv-aflibercept)","Maximum Tolerable Dose (MTD) or Recommended Phase 2 Dose (RP2D)|Pharmacokinetics (PK)|Immunogenicity|Antitumor activity|Pharmacodynamics (PD)","Regeneron Pharmaceuticals|Sanofi","All","18 Years and older   (Adult, Older Adult)","Phase 1","48","Industry","Interventional","Allocation: Non-Randomized|Intervention Model: Single Group Assignment|Masking: None (Open Label)|Primary Purpose: Treatment","R910-ST-1114","October 2012","November 2014","November 2014","September 20, 2012",,"March 17, 2015","Indianapolis, Indiana, United States|New York, New York, United States|Oklahoma City, Oklahoma, United States|Philadelphia, Pennsylvania, United States|San Antonio, Texas, United States|Toronto, Canada",,"https://ClinicalTrials.gov/show/NCT01688960"
198,"NCT01639040","Study to Assess the Safety of Dupilumab (REGN668/SAR231893) Administered Concomitantly With Topical Corticosteroids (TCS) in Patients With Moderate-to-severe Atopic Dermatitis (AD)",,"Completed","Has Results","Atopic Dermatitis","Drug: Dupilumab|Drug: Placebo (for Dupilumab)|Other: Topical Corticosteroid (TCS)","Percentage of Participants With Treatment Emergent Adverse Events (TEAEs)","Regeneron Pharmaceuticals|Sanofi","All","18 Years and older   (Adult, Older Adult)","Phase 2","31","Industry","Interventional","Allocation: Randomized|Intervention Model: Parallel Assignment|Masking: Triple (Participant, Investigator, Outcomes Assessor)|Primary Purpose: Treatment","R668-AD-1121","July 2012","December 2012","December 2012","July 12, 2012","October 13, 2017","October 13, 2017","Berlin, Germany|Dresden, Germany|Duelmen, Germany|Frankfurt, Germany|Gera, Germany|Langenau, Germany|Munster, Germany|Szeged-Hungary, Hungary|Szolnok, Hungary|Gdansk, Poland|Lodz, Poland|Lublin, Poland|Warszawa, Poland",,"https://ClinicalTrials.gov/show/NCT01639040"
199,"NCT01605708","Study to Assess the Clinical Activity of a Sequential Dose of REGN846 on Refractory Pruritus in Patients With Atopic Dermatitis",,"Terminated","No Results Available","Pruritus|Atopic Dermatitis","Drug: REGN846","Clinical Activity|Safety and tolerability a single IV dose of REGN846|Pharmacokinetic (PK) profile of a single IV dose of REGN846|Immunogenicity of a single IV dose of REGN846","Regeneron Pharmaceuticals","All","18 Years to 65 Years   (Adult, Older Adult)","Phase 1|Phase 2","19","Industry","Interventional","Allocation: Randomized|Intervention Model: Single Group Assignment|Masking: Triple (Participant, Investigator, Outcomes Assessor)|Primary Purpose: Treatment","R846-AD-1105","June 2012","April 2013","April 2013","May 25, 2012",,"October 28, 2013","Helsinki, Finland|Tampere, Finland|Berlin, Germany|Dresden, Germany|Erfurt, Germany|Frankfurt, Germany|Mahlow, Germany|Mainz, Germany|Osnabrueck, Germany|Tuebingen, Germany|Bydgoszcz, Poland|Poznan, Poland|Warszawa, Poland|Wroclaw, Poland",,"https://ClinicalTrials.gov/show/NCT01605708"
200,"NCT01604824","A Study of Alirocumab in Participants With Autosomal Dominant Hypercholesterolemia (ADH) and Gain-of-Function Mutations (GOFm) of the Proprotein Convertase Subtilisin Kexin 9 (PCSK9) Gene or Loss-of-Function Mutations (LOFm) of the Apolipoprotein (Apo) B Gene",,"Completed","Has Results","Hypercholesterolemia","Drug: Alirocumab|Drug: Placebo","Percent Change in Measured Serum Low-Density Lipoprotein Cholesterol (LDL-C) From Baseline to Day 15|Percent Change in Apolipoprotein (Apo) B100 From Baseline to Day 15|Percent Change in Non High-Density Lipoprotein Cholesterol (Non-HDL-C) From Baseline to Day 15|Percent Change in Total Cholesterol (Total-C) From Baseline to Day 15|Percent Change in Apolipoprotein (Apo) B100/ ApoA-1 Ratio From Baseline to Day 15","Regeneron Pharmaceuticals|Sanofi","All","18 Years to 70 Years   (Adult, Older Adult)","Phase 2","23","Industry","Interventional","Allocation: Randomized|Intervention Model: Parallel Assignment|Masking: Triple (Participant, Investigator, Outcomes Assessor)|Primary Purpose: Treatment","R727-CL-1018","February 22, 2012","June 2, 2014","July 28, 2017","May 24, 2012","June 17, 2020","June 17, 2020","Salt Lake City, Utah, United States|Lille, Cedex, France|Nantes, Cedex, France|Paris, France",,"https://ClinicalTrials.gov/show/NCT01604824"
201,"NCT01576484","Open-Label Extension of Study R727-CL-1003 (NCT01266876) to Evaluate the Long-Term Safety and Efficacy of Alirocumab (REGN727) in Participants With Heterozygous Familial Hypercholesterolemia (HeFH)",,"Completed","Has Results","Hypercholesterolemia|Heterozygous Familial Hypercholesterolemia","Drug: Alirocumab|Drug: Placebo Matched to Alirocumab","Number of Participants Who Experienced Treatment Emergent Adverse Events (TEAEs), Serious TEAEs and TEAEs Leading to Death|Percent Change in Low-density Lipoprotein Cholesterol (LDL-C) From Baseline in the Current Study to Week 24|Percent Change in Low Density Lipoprotein Cholesterol (LDL-C) From Baseline in Current Study to Week 12|Percent Change in Apolipoprotein (Apo) B, Non-High Density Lipoprotein Cholesterol (HDL-C), and Total Cholesterol From Baseline in Current Study to Week 24|Percent Change in Apolipoprotein (Apo) B, Non-High Density Lipoprotein Cholesterol (HDL-C), and Total Cholesterol From Baseline in Current Study to Week 12|Percent Change in Low Density Lipoprotein Cholesterol (LDL-C) From Baseline in Current Study to Week 52|Percentage of Participants With Low Density Lipoprotein Cholesterol (LDL-C) Less Than (<) 70 Milligrams Per Deciliter (mg/dL) for Prior Myocardial Infarction (MI)/Stroke, or <100 mg/dL [2.59 mmol/L] for Participants Without Prior MI/Stroke at Week 24|Percent Change in Lipoprotein a (Lp[a]) at Week 24|Percent Change in High Density Lipoprotein Cholesterol (HDL-C) at Week 24 and Week 12|Percent Change in Lipoprotein a at Week 12|Percent Change in Triglycerides (TG) at Week 24 and Week 12|Percent Change in Apolipoprotein A-1 (Apo A-1) at Week 24 and Week 12|Percent Change in Low Density Lipoprotein Cholesterol (LDL-C) From Baseline in the Current Study to the End of Treatment|Percentage of Participants With Low Density Lipoprotein Cholesterol (LDL-C) Less Than (<) 70 Milligrams Per Deciliter (mg/dL) for Prior MI/Stroke, or <100 mg/dL [2.59 mmol/L] for Participants Without Prior MI/Stroke at Week 12, 52 and End of Treatment|Absolute Change in Low-density Lipoprotein Cholesterol (LDL-C) From Baseline in the Current Study to Weeks 12, 24, 52, and End of Treatment|Percent Change in Apolipoprotein (Apo) B, Non-High Density Lipoprotein Cholesterol (HDL-C), Total Cholesterol, Lipoprotein a (Lp[a]), HDL-C, Triglycerides, and Apolipoprotein A-1 From Baseline in Current Study to Week 52 and End of Treatment|Change in Ratio in Apolipoprotein (Apo) B/Apo A-1 From Baseline in Current Study to Week 12, 24, 52, and End of Treatment.|Percentage of Participants With Apolipoprotein (Apo) B <80 mg/dL at Week 12, 24, 52, and End of Treatment|Percentage of Participants With Non-High Density Lipoprotein Cholesterol (HDL-C) <100 mg/dL (2.59 mmol/L) at Week 12, 24, 52, and End of Treatment|Percentage of Participants With Low Density Lipoprotein Cholesterol (LDL-C) Less Than (<) 70 Milligrams Per Deciliter (mg/dL) and/or ≥ 50% Reduction in LDL-C (if LDL-C >70 mg/dL [1.81 mmol/L]) at Week 12, 24, 52, and End of Treatment","Regeneron Pharmaceuticals|Sanofi","All","18 Years to 75 Years   (Adult, Older Adult)","Phase 2","58","Industry","Interventional","Allocation: Non-Randomized|Intervention Model: Single Group Assignment|Masking: None (Open Label)|Primary Purpose: Treatment","R727-CL-1032","February 28, 2012","December 22, 2016","December 22, 2016","April 12, 2012","August 5, 2020","August 5, 2020","Mission Viejo, California, United States|Newport Beach, California, United States|Thousand Oaks, California, United States|Miami, Florida, United States|Port Orange, Florida, United States|Kansas City, Kansas, United States|Auburn, Maine, United States|Saint Louis, Missouri, United States|Durham, North Carolina, United States|Cincinnati, Ohio, United States|Houston, Texas, United States|Chicoutimi, Quebec, Canada|Montreal, Quebec, Canada|Sainte-Foy, Quebec, Canada",,"https://ClinicalTrials.gov/show/NCT01576484"
202,"NCT01548404","Study of Dupilumab in Adult Patients With Extrinsic Moderate-to-Severe Atopic Dermatitis",,"Completed","Has Results","Atopic Dermatitis","Drug: Placebo|Drug: Dupilumab","Percent Change From Baseline in Eczema Area and Severity Index (EASI) Score at Week 12- Last Observation Carried Forward (LOCF)|Percentage of Participants With Investigator's Global Assessment (IGA) Score of ""0"" or ""1"" at Week 12- LOCF|Percentage of Participants Who Achieved at Least a 50% Reduction From Baseline in the EASI Score (EASI-50) at Week 12- LOCF|Change From Baseline in EASI Score at Week 12- LOCF|Percent Change From Baseline in IGA Score at Week 12- LOCF|Change From Baseline in Percent Body Surface Area (BSA) Affected by Atopic Dermatitis (AD) at Week 12 - LOCF|Change From Baseline in Scoring Atopic Dermatitis (SCORAD) Score at Week 12- LOCF|Change From Baseline in Pruritus Numerical Rating Scale (NRS) to Week 12- LOCF|Change From Baseline in 5-D Pruritus Scale at Week 12","Regeneron Pharmaceuticals|Sanofi","All","18 Years and older   (Adult, Older Adult)","Phase 2","109","Industry","Interventional","Allocation: Randomized|Intervention Model: Parallel Assignment|Masking: Triple (Participant, Investigator, Outcomes Assessor)|Primary Purpose: Treatment","R668-AD-1117","April 2012","March 2013","June 2013","March 8, 2012","August 10, 2018","August 10, 2018","Nachod, Czechia|Svitavy, Czechia|Usti nad Labem, Czechia|Nice, France|Pierre Bénite, France|Toulouse, France|Berlin, Germany|Bonn, Germany|Frankfurt, Germany|Gera, Germany|Heidelberg, Germany|Kiel, Germany|Münster, Germany|Kaposvar, Hungary|Szeged, Hungary|Szekszard, Hungary|Szolnok, Hungary|Gdansk, Poland|Lodz, Poland|Lublin, Poland|Warszawa, Poland",,"https://ClinicalTrials.gov/show/NCT01548404"
203,"NCT01540539","Intravenous/Subcutaneous FIH Study of REGN1154 in Healthy Volunteers",,"Completed","No Results Available","Healthy Volunteers","Drug: REGN1154 or placebo","Total number and severity of TEAEs|Serum concentration|Presence or absence of antibodies","Regeneron Pharmaceuticals","All","18 Years to 65 Years   (Adult, Older Adult)","Phase 1","44","Industry","Interventional","Allocation: Randomized|Intervention Model: Parallel Assignment|Masking: Triple (Participant, Investigator, Outcomes Assessor)","R1154-HV-1116","March 2012","January 2013","January 2013","February 28, 2012",,"January 24, 2014","Melbourne, Australia",,"https://ClinicalTrials.gov/show/NCT01540539"
204,"NCT01521559","Study to Assess the Clinical Efficacy and Safety of Intravitreal Aflibercept Injection (IAI;EYLEA®;BAY86-5321) in Patients With Branch Retinal Vein Occlusion (BRVO)","VIBRANT","Completed","Has Results","Branch Retinal Vein Occlusion","Procedure: Macular Laser Photocoagulation|Drug: Intravitreal Aflibercept Injection (IAI;EYLEA®;BAY86-5321)","Participants Who Gained at Least 15 Letters in Best Corrected Visual Acuity (BCVA) at Week 24 - LOCF|Change From Baseline to Week 24 in BCVA Score - LOCF|Change From Baseline in Central Retinal Thickness (CRT) at Week 24 - LOCF|Change From Baseline in the National Eye Institute Visual Function Questionnaire - 25 (NEI VFQ-25) Questionnaire Total Score at Week 24 - LOCF","Regeneron Pharmaceuticals|Bayer","All","18 Years and older   (Adult, Older Adult)","Phase 3","183","Industry","Interventional","Allocation: Randomized|Intervention Model: Parallel Assignment|Masking: Double (Participant, Outcomes Assessor)|Primary Purpose: Treatment","VGFTe-RVO-1027","April 2012","August 2013","March 2014","January 30, 2012","November 13, 2014","November 13, 2014","Phoenix, Arizona, United States|Tucson, Arizona, United States|Beverly Hills, California, United States|La Jolla, California, United States|Mountain View, California, United States|Palm Desert, California, United States|Sacramento, California, United States|Colorado Springs, Colorado, United States|Fort Myers, Florida, United States|Miami, Florida, United States|Plantation, Florida, United States|Stuart, Florida, United States|Tampa, Florida, United States|Winter Haven, Florida, United States|Augusta, Georgia, United States|Chicago, Illinois, United States|Baltimore (2 locations), Maryland, United States|Hagerstown, Maryland, United States|Boston (2 locations), Massachusetts, United States|Grand Rapids, Michigan, United States|Jackson, Michigan, United States|Southfield, Michigan, United States|Florissant, Missouri, United States|Lincoln, Nebraska, United States|Las Vegas, Nevada, United States|Teaneck, New Jersey, United States|Orchard Park, New York, United States|Syracuse, New York, United States|Charlotte, North Carolina, United States|Oklahoma City, Oklahoma, United States|Portland, Oregon, United States|Kingston, Pennsylvania, United States|West Mifflin, Pennsylvania, United States|Florence, South Carolina, United States|Ladson, South Carolina, United States|West Columbia, South Carolina, United States|Rapid City, South Dakota, United States|Nashville, Tennessee, United States|Abilene, Texas, United States|Ft. Worth, Texas, United States|Harlingen, Texas, United States|Houston, Texas, United States|San Antonio, Texas, United States|Seattle, Washington, United States|Milwaukee, Wisconsin, United States|Vancouver, British Columbia, Canada|Victoria, British Columbia, Canada|Mississauga, Ontario, Canada|Toronto, Ontario, Canada|Urayasu-shi, Chiba, Japan|Amagasaki, Hyogo, Japan|Kagoshima-shi, Kagoshima, Japan|Hamamatsu-shi, Shizuoka, Japan|Fukushima, Japan|Kyoto, Japan|Osaka, Japan",,"https://ClinicalTrials.gov/show/NCT01521559"
205,"NCT01507402","A Study to Assess the Safety and Tolerability of Single Ascending Doses of REGN1033(SAR391786)",,"Completed","No Results Available","Healthy Volunteers","Drug: REGN1033(SAR391786)|Drug: Placebo","Number of TEAEs|Serum concentration|Immunogenicity","Regeneron Pharmaceuticals|Sanofi","All","18 Years to 85 Years   (Adult, Older Adult)","Phase 1","76","Industry","Interventional","Allocation: Randomized|Intervention Model: Parallel Assignment|Masking: Triple (Participant, Investigator, Outcomes Assessor)|Primary Purpose: Treatment","R1033-HV-1107","January 2012","November 2012","November 2012","January 10, 2012",,"November 14, 2012","Honolulu, Hawaii, United States|Evansville, Indiana, United States",,"https://ClinicalTrials.gov/show/NCT01507402"
206,"NCT01484600","Study of the Safety, Tolerability, Pharmacokinetics, and Immunogenicity of REGN668 Administered Subcutaneously to Healthy Volunteers",,"Completed","No Results Available","Healthy","Drug: REGN668: Injection Rate 1|Drug: REGN668: Injection Rate 2","Incidence and severity of treatment-emergent adverse events (TEAEs)|Pharmacokinetic (PK) profile of REGN668|Incidence of anti-REGN668 antibodies","Regeneron Pharmaceuticals|Sanofi","All","18 Years to 55 Years   (Adult)","Phase 1","36","Industry","Interventional","Allocation: Randomized|Intervention Model: Parallel Assignment|Masking: None (Open Label)|Primary Purpose: Treatment","R668-HV-1108","December 2011","February 2012","February 2012","December 2, 2011",,"March 14, 2012","San Antonio, Texas, United States",,"https://ClinicalTrials.gov/show/NCT01484600"
207,"NCT01459796","Study of the Safety and Efficacy of Long-Term Rilonacept Treatment for the Prevention of Gout Flares","UPSURGE","Terminated","Has Results","Gout","Drug: Rilonacept|Drug: Placebo|Drug: Allopurinol","Percentage of Participants With Treatment Emergent Adverse Events (TEAEs)|Percentage of Participants With at Least One Gout Flare From Day 1 to Day 168 (Week 24)|Percentage of Participants With at Least Two Gout Flares From Day 1 to Day 168 (Week 24)|Percentage of Participants With at Least One Gout Flare From Day 1 to Day 364 (Week 52)|Percentage of Participants With at Least Two Gout Flares From Day 1 to Day 364 (Week 52)|Percentage of Participants With Rescue Medication From Day 1 to Day 364 (Week 52)","Regeneron Pharmaceuticals","All","18 Years to 80 Years   (Adult, Older Adult)","Phase 3","220","Industry","Interventional","Allocation: Randomized|Intervention Model: Parallel Assignment|Masking: Triple (Participant, Investigator, Outcomes Assessor)|Primary Purpose: Treatment","IL1T-GA-1101","November 2011","June 2013","June 2013","October 26, 2011","July 18, 2017","July 18, 2017","Birmingham, Alabama, United States|Mesa, Arizona, United States|Phoenix, Arizona, United States|Scottsdale, Arizona, United States|Sierra Vista, Arizona, United States|Tucson, Arizona, United States|Searcy, Arkansas, United States|Concord, California, United States|La Jolla, California, United States|Long Beach, California, United States|Whittier, California, United States|Denver, Colorado, United States|Trumbull, Connecticut, United States|Washington, D.C., District of Columbia, United States|Clearwater, Florida, United States|DeLand, Florida, United States|Delray Beach, Florida, United States|New Port Richey, Florida, United States|Ocala, Florida, United States|Orlando, Florida, United States|Saint Petersburg, Florida, United States|Tampa, Florida, United States|Venice, Florida, United States|Atlanta, Georgia, United States|Boise, Idaho, United States|Coeur d'Alene, Idaho, United States|Meridian, Idaho, United States|Avon, Indiana, United States|Brownsburg, Indiana, United States|Evansville, Indiana, United States|Bowling Green, Kentucky, United States|Elizabethtown, Kentucky, United States|Owensboro, Kentucky, United States|New Orleans, Louisiana, United States|Cumberland, Maryland, United States|Hagerstown, Maryland, United States|Wheaton, Maryland, United States|Fall River, Massachusetts, United States|Edina, Minnesota, United States|Saint Louis, Missouri, United States|Kalispell, Montana, United States|Omaha, Nebraska, United States|Brooklyn, New York, United States|Cary, North Carolina, United States|Charlotte, North Carolina, United States|Greensboro, North Carolina, United States|Greenville, North Carolina, United States|Raleigh, North Carolina, United States|Salisbury, North Carolina, United States|Statesville, North Carolina, United States|Winston-Salem, North Carolina, United States|Akron, Ohio, United States|Carlisle, Ohio, United States|Portland, Oregon, United States|Huntingdon Valley, Pennsylvania, United States|Johnstown, Pennsylvania, United States|Pittsburgh, Pennsylvania, United States|Reading, Pennsylvania, United States|Anderson, South Carolina, United States|Charleston, South Carolina, United States|Columbia, South Carolina, United States|Greenville, South Carolina, United States|Rock Hill, South Carolina, United States|Simpsonville, South Carolina, United States|Dallas, Texas, United States|Fort Worth, Texas, United States|Houston, Texas, United States|Lake Jackson, Texas, United States|North Richland Hills, Texas, United States|San Antonio, Texas, United States|Sugar Land, Texas, United States|Salt Lake City, Utah, United States|Arlington, Virginia, United States|Spokane, Washington, United States",,"https://ClinicalTrials.gov/show/NCT01459796"
208,"NCT01451645","Efficacy and Safety of Colchicine for the Prevention of Gout Flares During the Initiation of Allopurinol",,"Completed","Has Results","Intercritical Gout","Drug: Colchicine (Colcrys®)|Drug: placebo|Drug: allopurinol","Number of Gout Flares Per Participant From Day 1 to Week 16|Percentage of Participants With at Least 1 Gout Flare From Day 1 to Week 16|Percentage of Participants With at Least 2 Gout Flares From Day 1 to Week 16|Mean Number of Gout Flare Days Per Participant Assessed From Day 1 to Week 16","Regeneron Pharmaceuticals","All","18 Years to 70 Years   (Adult, Older Adult)","Phase 4","82","Industry","Interventional","Allocation: Randomized|Intervention Model: Parallel Assignment|Masking: Double (Participant, Investigator)|Primary Purpose: Treatment","IL1T-GA-1103","October 2011","August 2012","September 2012","October 14, 2011","May 12, 2014","May 12, 2014","Alabaster, Alabama, United States|Mesa, Arizona, United States|Upland, California, United States|Trumbull, Connecticut, United States|Debary, Florida, United States|Jacksonville, Florida, United States|Kissimmee, Florida, United States|Canton, Georgia, United States|Boise, Idaho, United States|Lexington, Kentucky, United States|Bethesda, Maryland, United States|Reisterstown, Maryland, United States|Bingham Farms, Michigan, United States|Brooklyn Center, Minnesota, United States|Kansas City, Missouri, United States|Billings, Montana, United States|Elizabeth, New Jersey, United States|Albuquerque, New Mexico, United States|New York, New York, United States|Charlotte, North Carolina, United States|Hickory, North Carolina, United States|Morganton, North Carolina, United States|Winston-Salem, North Carolina, United States|Duncansville, Pennsylvania, United States|Reading, Pennsylvania, United States|West Reading, Pennsylvania, United States|Greer, South Carolina, United States|Mt. Pleasant, South Carolina, United States|Johnson City, Tennessee, United States|Dallas, Texas, United States|Katy, Texas, United States|San Antonio, Texas, United States|Salt Lake City, Utah, United States|West Jordan, Utah, United States|Norfolk, Virginia, United States|Seattle, Washington, United States|Wauwatosa, Wisconsin, United States",,"https://ClinicalTrials.gov/show/NCT01451645"
209,"NCT01385657","Safety and Tolerability of Dupilumab in Participants With Moderate to Severe Atopic Dermatitis",,"Completed","No Results Available","Atopic Dermatitis","Drug: Placebo|Drug: Dupilumab|Other: Background treatment","Percentage of Participants With Treatment Emergent Adverse Events (TEAEs)|Pharmacokinetics of Dupilumab: Peak Plasma Concentration (Cmax)|Pharmacokinetics of Dupilumab: Last Positive (Quantifiable) Concentration (Clast)|Pharmacokinetics of Dupilumab: Time of the Last Positive (Quantifiable) Concentration (Tlast)","Regeneron Pharmaceuticals|Sanofi","All","18 Years and older   (Adult, Older Adult)","Phase 1","37","Industry","Interventional","Allocation: Randomized|Intervention Model: Parallel Assignment|Masking: Triple (Participant, Investigator, Outcomes Assessor)|Primary Purpose: Treatment","R668-AD-1026","July 31, 2011","March 31, 2012","March 31, 2012","June 30, 2011",,"February 26, 2020","Kogarah, New South Wales, Australia|Woolloongabba, Queensland, Australia|Carlton, Victoria, Australia|Nedlands, Western Australia, Australia|Hannover, Niedersachsen, Germany|Bonn, Nordrhein-Westfalen, Germany|Berlin, Germany|Berlin, Germany|Gera, Germany|Munster, Germany|Sydenham, Christchurch, New Zealand|Caversham, Dunedin, New Zealand|Auckland, New Zealand",,"https://ClinicalTrials.gov/show/NCT01385657"
210,"NCT01363440","Study of Intravitreal Aflibercept Injection (IAI; EYLEA®; BAY86-5321) in Patients With Diabetic Macular Edema","VISTA DME","Completed","Has Results","Diabetic Macular Edema","Drug: Intravitreal Aflibercept Injection (IAI; EYLEA®; BAY86-5321)|Procedure: Macular Laser Photocoagulation","Change From Baseline in Best Corrected Visual Acuity (BCVA) as Measured by Early Treatment Diabetic Retinopathy Study (ETDRS) Letter Score at Week 52 - Last Observation Carried Forward (LOCF)|Percentage of Participants Who Gained at Least 10 Letters in BCVA as Measured by ETDRS Letter Score Compared With Baseline at Week 52 - LOCF|Percentage of Participants Who Gained at Least 15 Letters in BCVA as Measured by ETDRS Letter Score Compared With Baseline at Week 52 - LOCF|Percentage of Participants With a ≥2-step Improvement From Baseline in the ETDRS DRSS (Diabetic Retinopathy Severity Score) as Assessed by FP (Fundus Photography) at Week 52 - LOCF|Change From Baseline in Central Retinal Thickness (CRT) at Week 52 as Assessed on Optical Coherence Tomography (OCT) - LOCF|Change From Baseline in National Eye Institute 25-item Visual Function Questionnaire (NEI VFQ-25) Near Activities Subscale at Week 52 - LOCF|Change From Baseline in National Eye Institute 25-item Visual Function Questionnaire (NEI VFQ-25) Distance Activities Subscale at Week 52 - LOCF","Regeneron Pharmaceuticals|Bayer","All","18 Years and older   (Adult, Older Adult)","Phase 3","466","Industry","Interventional","Allocation: Randomized|Intervention Model: Parallel Assignment|Masking: Triple (Participant, Investigator, Outcomes Assessor)|Primary Purpose: Treatment","VGFT-OD-1009","May 2011","January 2013","November 2014","June 1, 2011","April 20, 2015","May 30, 2016","Phoenix, Arizona, United States|Tucson, Arizona, United States|Arcadia, California, United States|Beverly Hills, California, United States|La Jolla, California, United States|Mountain View, California, United States|Oakland, California, United States|Palm Desert, California, United States|Sacramento, California, United States|San Francisco, California, United States|Santa Barbara, California, United States|Torrance, California, United States|Colorado Springs, Colorado, United States|Golden, Colorado, United States|New London, Connecticut, United States|Fort Lauderdale, Florida, United States|Fort Myers, Florida, United States|Miami, Florida, United States|Orlando, Florida, United States|Winter Haven, Florida, United States|Augusta, Georgia, United States|Aiea, Hawaii, United States|Wichita, Kansas, United States|Portland, Maine, United States|Baltimore, Maryland, United States|Boston, Massachusetts, United States|Missoula, Montana, United States|Las Vegas, Nevada, United States|New Brunswick, New Jersey, United States|Northfield, New Jersey, United States|Teaneck, New Jersey, United States|Lynbrook, New York, United States|Orchard Park, New York, United States|Rochester, New York, United States|Asheville, North Carolina, United States|Charlotte, North Carolina, United States|Raleigh, North Carolina, United States|Portland, Oregon, United States|Kingston, Pennsylvania, United States|Pittsburgh, Pennsylvania, United States|Florence, South Carolina, United States|West Columbia, South Carolina, United States|Rapid City, South Dakota, United States|Nashville, Tennessee, United States|Abilene, Texas, United States|Austin, Texas, United States|Harlingen, Texas, United States|Houston, Texas, United States|San Antonio (2 locations), Texas, United States|The Woodlands, Texas, United States|Salt Lake City, Utah, United States",,"https://ClinicalTrials.gov/show/NCT01363440"
211,"NCT01271972","Study of Nesvacumab (REGN910/ SAR307746)",,"Completed","No Results Available","Solid Tumors","Drug: nesvacumab (REGN910/ SAR307746)","Determine the maximum tolerable dose or recommended phase 2 dose of nesvacumab (REGN910/ SAR307746) in patients with advanced solid malignancies|PK/PD profile|Immunogenicity|Anti-tumor activity|Correlative biomarkers","Regeneron Pharmaceuticals|Sanofi","All","18 Years and older   (Adult, Older Adult)","Phase 1","53","Industry","Interventional","Allocation: Non-Randomized|Intervention Model: Single Group Assignment|Masking: None (Open Label)|Primary Purpose: Treatment","R910-ST-1010","January 2011","September 2014","May 2015","January 7, 2011",,"June 16, 2015","San Francisco, California, United States|San Antonio, Texas, United States|Toronto, Ontario, Canada",,"https://ClinicalTrials.gov/show/NCT01271972"
212,"NCT01266876","Study of the Safety and Efficacy of REGN727/SAR236553 in Patients With HeFH Hypercholesterolemia",,"Completed","Has Results","Hypercholesterolemia","Drug: Alirocumab|Drug: Placebo","Percent Change From Baseline in Calculated LDL-C at Week 12 - On-treatment Analysis|Absolute Change From Baseline in Calculated LDL-C at Week 12 - On-treatment Analysis|Percentage of Participants Achieving Calculated LDL-C <100 mg/dL (2.59 mmol/L) at Week 12 - On-treatment Analysis|Percentage of Participants Achieving LDL-C < 70 mg/dL (1.81 mmol/L) at Week 12 - On-treatment Analysis|Percent Change From Baseline in Total Cholesterol at Week 12 - On-treatment Analysis|Absolute Change From Baseline in Total Cholesterol at Week 12 - On-treatment Analysis|Percent Change From Baseline in High Density Lipoprotein Cholesterol (HDL-C) at Week 12 - On-treatment Analysis|Absolute Change From Baseline in HDL-C at Week 12 - On-treatment Analysis|Percent Change From Baseline in Triglycerides at Week 12 - On-treatment Analysis|Absolute Change From Baseline in Triglycerides at Week at 12 - On-treatment Analysis|Percent Change From Baseline in Non-HDL-C at Week 12 - On-treatment Analysis|Absolute Change From Baseline in Non-HDL-C at Week 12 - On-treatment Analysis|Percent Change From Baseline in Apo Lipoprotein B (Apo-B) at Week 12 - On-treatment Analysis|Absolute Change From Baseline in Apo-B at Week 12 - On-treatment Analysis|Percent Change From Baseline in Apolipoprotein - A1 (Apo-A1) at Week 12 - On-treatment Analysis|Absolute Change From Baseline in Apo-A1 at Week 12 - On-treatment Analysis|Absolute Change in the Ratio ApoB/ApoA-1 From Baseline to Week 12 - On-treatment Analysis|Percent Change From Baseline in Lipoprotein(a) at Week 12 - On-treatment Analysis|Absolute Change From Baseline in Lipoprotein(a) at Week 12 - On-treatment Analysis","Regeneron Pharmaceuticals|Sanofi","All","18 Years to 75 Years   (Adult, Older Adult)","Phase 2","77","Industry","Interventional","Allocation: Randomized|Intervention Model: Parallel Assignment|Masking: Triple (Participant, Investigator, Outcomes Assessor)|Primary Purpose: Treatment","R727-CL-1003","January 2011","November 2011","November 2011","December 24, 2010","September 22, 2015","September 22, 2015","Huntsville, Alabama, United States|Mission Viejo, California, United States|Newport Beach, California, United States|Bridgeport, Connecticut, United States|Jacksonville, Florida, United States|Miami, Florida, United States|Port Orange, Florida, United States|Chicago, Illinois, United States|Kansas City, Kansas, United States|Auburn, Maine, United States|Biddeford, Maine, United States|St. Louis, Missouri, United States|Concord, New Hampshire, United States|Durham, North Carolina, United States|Cincinnati, Ohio, United States|Nashville, Tennessee, United States|Houston, Texas, United States|Winnipeg, Manitoba, Canada|London, Ontario, Canada|Chicoutimi, Quebec, Canada|Montreal, Quebec, Canada|St. Foy, Quebec, Canada",,"https://ClinicalTrials.gov/show/NCT01266876"
213,"NCT01259323","Sequential Ascending Dose Study to Assess the Safety and Tolerability of REGN668 (SAR231893) in Patients With Atopic Dermatitis",,"Completed","No Results Available","Dermatitis","Biological: REGN668","The primary endpoint in the study is the incidence of treatment-emergent adverse events (TEAEs) in patients treated with REGN668 or Placebo from baseline through week 12.|The secondary endpoint is to characterize PK profile of study drug REGN668 from baseline through week 12.","Regeneron Pharmaceuticals|Sanofi","All","18 Years and older   (Adult, Older Adult)","Phase 1","30","Industry","Interventional","Allocation: Randomized|Intervention Model: Parallel Assignment|Masking: Double (Participant, Investigator)|Primary Purpose: Treatment","R668-AD-0914","December 2010","July 2012","July 2012","December 14, 2010",,"October 4, 2012","Los Angeles, California, United States|Riverside, California, United States|Miami, Florida, United States|Chicago, Illinois, United States|Troy, Michigan, United States|New York, New York, United States|Rochester, New York, United States|Portland, Oregon, United States|Philadelphia, Pennsylvania, United States|Dallas, Texas, United States",,"https://ClinicalTrials.gov/show/NCT01259323"
214,"NCT01209793","Safety and Tolerability Study of REGN846 (SAR302352) in Healthy Volunteers",,"Completed","No Results Available","Healthy","Biological: REGN846","Incidence and severity of adverse events|PK profile|Immunogenicity","Regeneron Pharmaceuticals|Sanofi","All","18 Years to 65 Years   (Adult, Older Adult)","Phase 1","40","Industry","Interventional","Allocation: Randomized|Intervention Model: Single Group Assignment|Masking: Double (Participant, Investigator)|Primary Purpose: Treatment","R846-HV-1007","November 2010","September 2011","September 2011","September 27, 2010",,"June 1, 2012","Nucleus Network, Melbourne, Australia",,"https://ClinicalTrials.gov/show/NCT01209793"
215,"NCT01197391","Ascending Dose Study of the Safety and Tolerability of REGN728 in Healthy Volunteers",,"Completed","No Results Available","Healthy","Biological: REGN728","The primary endpoint in the study is the percentage of subjects with treatment emergent adverse events, reported from the administration of study drug on day 1 to the completion of the study on day 106.","Regeneron Pharmaceuticals|Sanofi","All","18 Years to 65 Years   (Adult, Older Adult)","Phase 1","48","Industry","Interventional","Allocation: Randomized|Intervention Model: Single Group Assignment|Masking: Double (Participant, Investigator)|Primary Purpose: Treatment","R728-CL-0915","August 2010","March 2012","March 2012","September 9, 2010",,"November 12, 2012","Miramar, Florida, United States|Overland Park, Kansas, United States",,"https://ClinicalTrials.gov/show/NCT01197391"
216,"NCT01187563","A Study of Tocilizumab in Patients With Rheumatoid Arthritis",,"Completed","No Results Available","Rheumatoid Arthritis",,"Safety (clinical and laboratory parameters)|Treatment emergent adverse events","Regeneron Pharmaceuticals","All","18 Years and older   (Adult, Older Adult)",,"16","Industry","Observational","Observational Model: Cohort|Time Perspective: Prospective","0000-RA-1008","August 2010","December 2010","December 2010","August 24, 2010",,"October 13, 2011","Worcester, Massachusetts, United States|Duncansville, Pennsylvania, United States",,"https://ClinicalTrials.gov/show/NCT01187563"
217,"NCT01161082","Ascending Multi-dose Study of REGN727(SAR236553) With and Without Concomitant Atorvastatin",,"Completed","No Results Available","Hypercholesterolemia","Drug: REGN727(SAR236553)","The primary endpoint in the study is to assess the incidence and severity of treatment-emergent adverse events in hyperlipidemic patients treated with REGN727 or placebo receiving stable doses of atorvastatin.|To assess the pharmacodynamic effect of REGN727 added to atorvastatin on lipids|To assess the pharmacodynamic effect of monotherapy REGN727 in hyperlipidemic patients|To assess the pharmacokinetics of REGN727 in hyperlipidemic patients with or without atorvastatin","Regeneron Pharmaceuticals|Sanofi","All","18 Years to 65 Years   (Adult, Older Adult)","Phase 1","72","Industry","Interventional","Allocation: Randomized|Intervention Model: Parallel Assignment|Masking: Double (Participant, Investigator)|Primary Purpose: Treatment","R727-CL-1001","June 2010","May 2011","May 2011","July 13, 2010",,"January 27, 2015","Site 1, Cincinnati, Ohio, United States|Site 2, Knoxville, Tennessee, United States",,"https://ClinicalTrials.gov/show/NCT01161082"
218,"NCT01074372","Ascending Dose Study of the Safety and Tolerability of REGN727 (SAR236553) in Healthy Volunteers",,"Completed","No Results Available","Healthy Volunteers","Drug: REGN727|Drug: Placebo","The incidence of treatment-emergent adverse events in subjects treated with REGN727 or placebo, reported from the administration of study drug on day 1 to the completion of the study on day 106","Regeneron Pharmaceuticals|Sanofi","All","18 Years to 65 Years   (Adult, Older Adult)","Phase 1","32","Industry","Interventional","Allocation: Randomized|Intervention Model: Parallel Assignment|Masking: Double (Participant, Investigator)|Primary Purpose: Treatment","R727-CL-0904","March 2010","November 2010","November 2010","February 24, 2010",,"January 27, 2015","Overland Park, Kansas, United States",,"https://ClinicalTrials.gov/show/NCT01074372"
219,"NCT01055899","Safety Study of a Single Dose of REGN88(SAR153191)in Patients With Rheumatoid Arthritis",,"Completed","No Results Available","Rheumatoid Arthritis","Biological: REGN88","To assess the safety and tolerability of a single dose of subcutaneously administered REGN88 in subjects with rheumatoid arthritis who are receiving concomitant treatment with methotrexate|To assess the PK profile of a single subcutaneous (SC) dose of REGN88, and the immunogenicity of a single SC dose of REGN88","Regeneron Pharmaceuticals|Sanofi","All","18 Years and older   (Adult, Older Adult)","Phase 1","15","Industry","Interventional","Allocation: Randomized|Intervention Model: Single Group Assignment|Masking: Quadruple (Participant, Care Provider, Investigator, Outcomes Assessor)|Primary Purpose: Treatment","6R88-RA-0801","July 2008","March 2009","March 2009","January 26, 2010",,"September 30, 2013","Duncansville, Pennsylvania, United States|Dallas, Texas, United States",,"https://ClinicalTrials.gov/show/NCT01055899"
220,"NCT01026597","Ascending Dose Study of the Safety and Tolerability of REGN727(SAR236553) in Healthy Volunteers",,"Completed","No Results Available","Healthy","Drug: REGN727|Drug: Placebo","The primary endpoint in the study is the incidence of treatment-emergent adverse events in subjects treated with REGN727 or placebo, reported from the administration of study drug on day 1 to the completion of the study on day 106.","Regeneron Pharmaceuticals|Sanofi","All","18 Years to 65 Years   (Adult, Older Adult)","Phase 1","40","Industry","Interventional","Allocation: Randomized|Intervention Model: Parallel Assignment|Masking: Double (Participant, Investigator)|Primary Purpose: Treatment","R727-CL-0902","November 2009","October 2010","October 2010","December 4, 2009",,"January 27, 2015","Overland Park, Kansas, United States",,"https://ClinicalTrials.gov/show/NCT01026597"
221,"NCT01026519","A Safety and Tolerability Study of REGN88(SAR153191) in Subjects With Rheumatoid Arthritis",,"Completed","No Results Available","Rheumatoid Arthritis","Drug: REGN88|Other: Placebo","hs-C reactive protein (hs-CRP)|Subject's Assessment of Pain and Subject's Global Assessment of Disease activity","Regeneron Pharmaceuticals|Sanofi","All","18 Years and older   (Adult, Older Adult)","Phase 1","32","Industry","Interventional","Allocation: Randomized|Intervention Model: Parallel Assignment|Masking: Quadruple (Participant, Care Provider, Investigator, Outcomes Assessor)|Primary Purpose: Treatment","6R88-RA-0803","September 2008","March 2009","May 2009","December 4, 2009",,"September 30, 2013","Institute of Rheumatology under the Russian Academy of Medical Sciences, Moscow, Russian Federation",,"https://ClinicalTrials.gov/show/NCT01026519"
222,"NCT01015027","Ascending Dose Study of the Safety and Tolerability of REGN668(SAR231893) in Normal Healthy Volunteers",,"Completed","No Results Available","Healthy","Biological: REGN668","The primary endpoint in the study is the incidence of treatment-emergent adverse events in subjects treated with REGN668 or placebo, reported from the administration of study drug on day 1 to the completion of the study on day 85/visit 11.|Pharmacokinetics: Serum concentrations of REGN668 over time.","Regeneron Pharmaceuticals|Sanofi","All","18 Years to 65 Years   (Adult, Older Adult)","Phase 1","48","Industry","Interventional","Allocation: Randomized|Intervention Model: Single Group Assignment|Masking: Double (Participant, Investigator)|Primary Purpose: Treatment","R668-AS-0907","October 2009","July 2010","July 2010","November 17, 2009",,"June 17, 2013","Baltimore, Maryland, United States",,"https://ClinicalTrials.gov/show/NCT01015027"
223,"NCT01011959","A Multiple-dose Study of the Safety and Tolerability of REGN88(SAR153191) in Rheumatoid Arthritis Subjects",,"Completed","No Results Available","Rheumatoid Arthritis","Biological: REGN88","Incidence of treatment-emergent adverse events in patients treated with REGN88 and placebo|To evaluate exploratory efficacy endpoints","Regeneron Pharmaceuticals|Sanofi","All","18 Years and older   (Adult, Older Adult)","Phase 1","60","Industry","Interventional","Allocation: Randomized|Intervention Model: Parallel Assignment|Masking: Double (Participant, Investigator)|Primary Purpose: Treatment","6R88-RA-0802","December 2008","August 2009","August 2009","November 11, 2009",,"September 30, 2013","Santa Maria, California, United States|Boca Raton, Florida, United States|Clearwater, Florida, United States|Daytona Beach, Florida, United States|Delray Beach, Florida, United States|Palm Harbor, Florida, United States|Idaho Falls, Idaho, United States|Worcester, Massachusetts, United States|Lansing, Michigan, United States|Flowood, Mississippi, United States|Kalamzaoo, Missouri, United States|St. Louis, Missouri, United States|Reno, Nevada, United States|Charlotte, North Carolina, United States|Cincinnati, Ohio, United States|Toledo, Ohio, United States|Oklahoma City, Oklahoma, United States|Duncansville, Pennsylvania, United States|Greenville, South Carolina, United States|Orangeburg, South Carolina, United States|Hixson, Tennessee, United States|Austin, Texas, United States|Houston, Texas, United States|San Antonio, Texas, United States",,"https://ClinicalTrials.gov/show/NCT01011959"
224,"NCT00964795","Open-label Extension Study of Intravitreal Aflibercept Injection (IAI; EYLEA®; BAY86-5321) in Neovascular (""Wet"") Age-related Macular Degeneration (AMD)",,"Completed","Has Results","Neovascular Age-related Macular Degeneration","Drug: Intravitreal Aflibercept Injection 2mg","Safety and Tolerability of Intravitreal Aflibercept Injection in Participants With Neovascular AMD|Change in BCVA Letter Score (mLOCF)","Regeneron Pharmaceuticals|Bayer","All","50 Years and older   (Adult, Older Adult)","Phase 3","323","Industry","Interventional","Allocation: N/A|Intervention Model: Single Group Assignment|Masking: None (Open Label)|Primary Purpose: Treatment","VGFT-OD-0910","December 2009","August 2013","August 2013","August 25, 2009","March 23, 2015","March 23, 2015","Birmingham (2 locations), Alabama, United States|Phoenix (2 locations), Arizona, United States|Tucson (2 locations), Arizona, United States|Arcadia, California, United States|Beverly Hills, California, United States|Campbell, California, United States|Fresno, California, United States|Fullerton, California, United States|La Jolla, California, United States|Loma Linda, California, United States|Mountain View, California, United States|Oakland, California, United States|Orange, California, United States|Palm Desert, California, United States|Sacramento, California, United States|San Mateo, California, United States|Santa Ana, California, United States|Torrance, California, United States|Westlake Village, California, United States|Yorba Linda, California, United States|Colorado Springs, Colorado, United States|Denver (2 Locations), Colorado, United States|Bridgeport, Connecticut, United States|New Haven, Connecticut, United States|New London, Connecticut, United States|Altamonte Springs, Florida, United States|Boynton Beach, Florida, United States|Fort Myers (2 locations), Florida, United States|Jacksonville, Florida, United States|Miami, Florida, United States|Orlando (2 locations), Florida, United States|Oscala, Florida, United States|Palm Beach Gardens, Florida, United States|Pensacola, Florida, United States|Stuart, Florida, United States|Tampa, Florida, United States|Winter Haven, Florida, United States|Augusta, Georgia, United States|Aiea, Hawaii, United States|Glenview, Illinois, United States|Fort Wayne, Indiana, United States|Indianapolis, Indiana, United States|New Albany, Indiana, United States|Iowa City, Iowa, United States|Wichita, Kansas, United States|Louisville, Kentucky, United States|New Orleans, Louisiana, United States|Bangor, Maine, United States|Portland, Maine, United States|Baltimore (3 Locations), Maryland, United States|Chevy Chase, Maryland, United States|Hagerstown, Maryland, United States|Boston (2 Locations), Massachusetts, United States|Peabody, Massachusetts, United States|Ann Arbor, Michigan, United States|Battle Creek, Michigan, United States|Grand Rapids, Michigan, United States|Jackson, Michigan, United States|Southfield, Michigan, United States|Minneapolis, Minnesota, United States|Rochester, Minnesota, United States|Florissant, Missouri, United States|Kansas City, Missouri, United States|Springfield, Missouri, United States|St. Louis, Missouri, United States|Missoula, Montana, United States|Lincoln, Nebraska, United States|Las Vegas, Nevada, United States|Portsmouth, New Hampshire, United States|Lawrenceville, New Jersey, United States|Northfield, New Jersey, United States|Toms River, New Jersey, United States|Albuquerque, New Mexico, United States|Albany, New York, United States|Brooklyn, New York, United States|Lynbrook, New York, United States|New York (6 locations), New York, United States|Rochester (2 locations), New York, United States|Slingerlands, New York, United States|Syracuse, New York, United States|Asheville, North Carolina, United States|Charlotte, North Carolina, United States|Raleigh, North Carolina, United States|Winston-Salem, North Carolina, United States|Cincinnati, Ohio, United States|Cleveland, Ohio, United States|Oklahoma City, Oklahoma, United States|Ashland, Oregon, United States|Portland (3 Locations), Oregon, United States|Salem, Oregon, United States|Kingston, Pennsylvania, United States|Philadelphia (3 locations), Pennsylvania, United States|Pittsburgh (2 locations), Pennsylvania, United States|West Mifflin, Pennsylvania, United States|Columbia, South Carolina, United States|Greenville, South Carolina, United States|West Columbia, South Carolina, United States|Rapid City, South Dakota, United States|Nashville, Tennessee, United States|Austin (3 Locations), Texas, United States|Dallas, Texas, United States|Fort Worth (2 locations), Texas, United States|Houston, Texas, United States|McAllen, Texas, United States|Odessa, Texas, United States|San Antonio (2 locations), Texas, United States|Tyler, Texas, United States|Salt Lake City (2 locations), Utah, United States|Burlington, Vermont, United States|Charlottesville, Virginia, United States|Fairfax, Virginia, United States|Richmond, Virginia, United States|Seattle, Washington, United States|Madison (2 Locations), Wisconsin, United States|Milwaukee, Wisconsin, United States|Calgary, Alberta, Canada|Vancouver, British Columbia, Canada|Victoria, British Columbia, Canada|Halifax, Nova Scotia, Canada|London, Ontario, Canada|Mississauga, Ontario, Canada|Ottawa, Ontario, Canada|Montreal (2 locations), Quebec, Canada|Regina, Saskatchewan, Canada",,"https://ClinicalTrials.gov/show/NCT00964795"
225,"NCT00958438","PREventative Study Against URate-Lowering Drug-Induced Gout Exacerbations (PRE-SURGE 2)",,"Completed","Has Results","Gout","Drug: Placebo|Drug: Rilonacept","Number of Gout Flares Per Participant Assessed From Day 1 to Day 113 (Week 16)|Number of Modified Gout Flares Per Participant From Day 1 to Day 113 (Week 16)|Percentage of Participants With at Least One Flare From Day 1 to Day 113 (Week 16)|Percentage of Participants With at Least Two Flares From Day 1 to Day 113 (Week 16)|Number of Gout Flare Days Per Participant From Day 1 to Day 113 (Week 16)|Number of Gout Flare Days With Participant's Pain Score of 5 or More (From Daily Diary) Per Participant From Day 1 to Day 113 (Week 16)","Regeneron Pharmaceuticals","All","18 Years to 80 Years   (Adult, Older Adult)","Phase 3","248","Industry","Interventional","Allocation: Randomized|Intervention Model: Parallel Assignment|Masking: Quadruple (Participant, Care Provider, Investigator, Outcomes Assessor)|Primary Purpose: Treatment","IL1T-GA-0816|2008-007762-39","July 2009","December 2010","December 2010","August 13, 2009","April 28, 2017","April 28, 2017","Berlin, Germany|Essen, Germany|Goch, Germany|Hamburg, Germany|Kassel, Germany|Kuenzing, Germany|Lollar, Germany|Magdeburg, Germany|Muenchen, Germany|Rhaunen, Germany|Siegen, Germany|Ahmedabad, India|Bangalore, India|Gandhinagar, India|Hyderabaad, India|Kolkatta, India|Mangalore, India|Pune, India|Secunderabad, India|Vadodara, India|Varanasi, India|Denpasar, Indonesia|Jakarta, Indonesia|Kemerdekaan, Indonesia|Palembang, Indonesia|Semarang, Indonesia|South Sulawesi, Indonesia|West Java, Indonesia|Yogyakarta, Indonesia|Amanzimtoti, South Africa|Benoni, South Africa|Bloemfontein, South Africa|Breyton, South Africa|Cape Town, South Africa|Dundee, South Africa|Durban North, South Africa|Durban, South Africa|Gauteng, South Africa|Johannesburg, South Africa|Kempton Park, South Africa|Krugersdorp, South Africa|KZ-Natal, South Africa|Lenasia, South Africa|Lyttleton, South Africa|Middleburg, South Africa|Port Elizabeth, South Africa|Pretoria, South Africa|Roodepoort, South Africa|Scottburgh, South Africa|Somerset West, South Africa|Soweto, South Africa|Worcester, South Africa|Yungkang City, Tainan, Taiwan|Changhua, Taiwan|Dalin Town, Taiwan|Hualien, Taiwan|Kaohsiung, Taiwan|Kwei-Shan, Taiwan|Taichung, Taiwan|Tainan, Taiwan|Taipei, Taiwan",,"https://ClinicalTrials.gov/show/NCT00958438"
226,"NCT00871559","A Multiple-Ascending-Dose Study of the Safety and Tolerability of REGN421(SAR153192) in Patients With Advanced Solid Malignancies",,"Completed","No Results Available","Advanced Solid Malignancies","Drug: REGN421(SAR153192)","Safety and tolerability|Preliminary evidence of antitumor activity","Regeneron Pharmaceuticals|Sanofi","All","18 Years and older   (Adult, Older Adult)","Phase 1","83","Industry","Interventional","Allocation: Non-Randomized|Intervention Model: Single Group Assignment|Masking: None (Open Label)|Primary Purpose: Treatment","R421-ST-0804","June 2009","February 2014","February 2014","March 30, 2009",,"March 26, 2014","Aurora, Colorado, United States|Indianapolis, Indiana, United States|Boston, Massachusetts, United States|Detroit, Michigan, United States|St. Louis, Missouri, United States|New York, New York, United States|Columbus, Ohio, United States|Oklahoma City, Oklahoma, United States",,"https://ClinicalTrials.gov/show/NCT00871559"
227,"NCT00856310","A Single-Dose Study of the Safety and Tolerability of REGN475(SAR164877) in Healthy Subjects",,"Completed","No Results Available","Healthy","Biological: REGN475 (SAR164877)","Incidence of treatment emergent adverse events in subjects treated with REGN475 or placebo.|Serum concentrations of REGN475.|The presence or absence of antibodies against REGN475.","Regeneron Pharmaceuticals|Sanofi","All","21 Years to 65 Years   (Adult, Older Adult)","Phase 1","56","Industry","Interventional","Allocation: Randomized|Intervention Model: Single Group Assignment|Masking: Triple (Participant, Investigator, Outcomes Assessor)|Primary Purpose: Treatment","R475-PN-0817","February 2009","November 2009","November 2009","March 5, 2009",,"May 10, 2012","Altoona, Pennsylvania, United States",,"https://ClinicalTrials.gov/show/NCT00856310"
228,"NCT00856206","Review of Safety Using Rilonacept in Preventing Gout Exacerbations (RE-SURGE)",,"Completed","Has Results","Gout","Biological: Rilonacept|Other: Placebo","Percentage of Participants With Treatment-Emergent Adverse Events (TEAEs)|Number of Gout Flares Per Participant Assessed From Day 1 to Day 112 (Week 16)|Percentage of Participants With at Least One Flare From Day 1 to Day 112 (Week 16)|Percentage of Participants With at Least Two Flares From Day 1 to Day 112 (Week 16)|Number of Gout Flare Days Per Participant From Day 1 to Day 112 (Week 16)","Regeneron Pharmaceuticals","All","18 Years to 80 Years   (Adult, Older Adult)","Phase 3","1315","Industry","Interventional","Allocation: Randomized|Intervention Model: Parallel Assignment|Masking: Quadruple (Participant, Care Provider, Investigator, Outcomes Assessor)|Primary Purpose: Prevention","IL1T-GA-0815","March 2009","January 2011","January 2011","March 5, 2009","April 28, 2017","April 28, 2017","Alabaster, Alabama, United States|Mesa, Arizona, United States|Burbank, California, United States|Long Beach, California, United States|Los Angeles, California, United States|Upland, California, United States|Brooksville, Florida, United States|Clearwater, Florida, United States|Debary, Florida, United States|Deland, Florida, United States|Jacksonville, Florida, United States|Naples, Florida, United States|Palm Harbor, Florida, United States|St. Petersburg, Florida, United States|Tampa, Florida, United States|Atlanta, Georgia, United States|Canton, Georgia, United States|Decatur, Georgia, United States|Sandy Springs, Georgia, United States|Stockbridge, Georgia, United States|Boise, Idaho, United States|Brownsburg, Indiana, United States|Evansville, Indiana, United States|Greenfield, Indiana, United States|Bowling Green, Kentucky, United States|Elizabethtown, Kentucky, United States|Lexington, Kentucky, United States|New Orleans, Louisiana, United States|Baltimore, Maryland, United States|Springfield, Massachusetts, United States|Worcester, Massachusetts, United States|Bingham Farms, Michigan, United States|Brooklyn Center, Minnesota, United States|Richmond Heights, Missouri, United States|St. Louis, Missouri, United States|Billings, Montana, United States|Kalispell, Montana, United States|Lincoln, Nebraska, United States|Elizabeth, New Jersey, United States|Albuquerque, New Mexico, United States|Brooklyn, New York, United States|Mineola, New York, United States|New York, New York, United States|Roslyn, New York, United States|Durham, North Carolina, United States|Hickory, North Carolina, United States|Mooresville, North Carolina, United States|Morganton, North Carolina, United States|Winston-Salem, North Carolina, United States|Cincinnati, Ohio, United States|Cleveland, Ohio, United States|Middleburg Heights, Ohio, United States|Duncansville, Pennsylvania, United States|Morrisville, Pennsylvania, United States|Ridley Park, Pennsylvania, United States|Willow Grove, Pennsylvania, United States|Anderson, South Carolina, United States|Monck's Corner, South Carolina, United States|Orangeburg, South Carolina, United States|Johnson City, Tennessee, United States|Arlington, Texas, United States|Carrollton, Texas, United States|Corsicana, Texas, United States|Dallas, Texas, United States|Houston, Texas, United States|Lake Jackson, Texas, United States|San Antonio, Texas, United States|Southlake, Texas, United States|Sugarland, Texas, United States|Ogden, Utah, United States|Salt Lake City, Utah, United States|West Jordan, Utah, United States|Norfolk, Virginia, United States|Richmond, Virginia, United States|Seattle, Washington, United States|Oak Creek, Wisconsin, United States|Wauwatosa, Wisconsin, United States|Kuenzing, BY, Germany|Dietzenbach, HE, Germany|Hamburg, HH, Germany|Essen, NW, Germany|Goch, NW, Germany|Siegen, NW, Germany|Rhaunen, RP, Germany|Secundrabad, Andh Prad, India|New Dehli, Delhi, India|Ahmedabad, Gujarat, India|Gandhinagar, Gujarat, India|Bangalore, Karna, India|Mangalore, Karna, India|Mumbai, Mahara, India|Kolkatta, W Bengal, India|Denpasar, Bali, Indonesia|Makassar, South Sulawesi, Indonesia|Padang, West Sumatra, Indonesia|Bandung, Indonesia|Daerah Istimewa Yogyakarta, Indonesia|Malang, Indonesia|South Sumatra, Indonesia|Port Elizabeth, E Cape, South Africa|Bloemfontein, Free State, South Africa|Benoni, Gauteng, South Africa|Centurion, Gauteng, South Africa|Eldoraigne, Gauteng, South Africa|Johannesburg, Gauteng, South Africa|Kempton Park, Gauteng, South Africa|Krugersdorp, Gauteng, South Africa|Lenasia, Gauteng, South Africa|Limpopo, Gauteng, South Africa|Pretoria, Gauteng, South Africa|Rustenburg, Gauteng, South Africa|Soweto, Gauteng, South Africa|Dundee, KZ-Natal, South Africa|Durban North, KZ-Natal, South Africa|Phoenix, KZ-Natal, South Africa|Verulam, KZ-Natal, South Africa|Breyten, Mpumalanga, South Africa|Durban, Mpumalanga, South Africa|Cape Town, W Cape, South Africa|Mpumalanga, South Africa|Changhua, Taiwan|Hualien, Taiwan|Tainan, Taiwan|Taipei, Taiwan",,"https://ClinicalTrials.gov/show/NCT00856206"
229,"NCT00855920","Study Utilizing Rilonacept in Gout Exacerbations","SURGE","Completed","Has Results","Acute Gout Flare","Drug: Rilonacept|Drug: Indomethacin|Other: Placebo (for Indomethacin)|Other: Placebo (for Rilonacept)","Change From Baseline in Patient's Assessment of Pain Using a 5-Point Likert Scale (PAP-LS) in Index Joint to Averaged PAP-LS at 24, 48 and 72 Hours|Change From Baseline in Patient's Assessment of Pain Using a 5-Point Likert Scale (PAP-LS) in Index Joint at 72 Hours|Change From Baseline in Patient's Assessment of Pain Using a 5-Point Likert Scale (PAP-LS) in Index Joint at 48 Hours|Change From Baseline in Patient's Assessment of Pain Using a 5-Point Likert Scale (PAP-LS) in Index Joint at 24 Hours","Regeneron Pharmaceuticals","All","18 Years to 70 Years   (Adult, Older Adult)","Phase 3","225","Industry","Interventional","Allocation: Randomized|Intervention Model: Parallel Assignment|Masking: Quadruple (Participant, Care Provider, Investigator, Outcomes Assessor)|Primary Purpose: Treatment","IL1T-GA-0814","March 2009","February 2010","February 2010","March 5, 2009","April 28, 2017","April 28, 2017","Birmingham, Alabama, United States|Huntsville, Alabama, United States|Mesa, Arizona, United States|Phoenix, Arizona, United States|Sierra Vista, Arizona, United States|Burbank, California, United States|Whittier, California, United States|Clearwater, Florida, United States|Debary, Florida, United States|Deland, Florida, United States|Jupiter, Florida, United States|Orange Park, Florida, United States|Orlando, Florida, United States|Oviedo, Florida, United States|Boise, Idaho, United States|Elizabethtown, Kentucky, United States|Baltimore, Maryland, United States|Wheaton, Maryland, United States|Detroit, Michigan, United States|Stevenville, Michigan, United States|Billings, Montana, United States|Albuquerque, New Mexico, United States|Albany, New York, United States|Burlington, North Carolina, United States|Cary, North Carolina, United States|Raleigh, North Carolina, United States|Raleigh, North Carolina, United States|Wilmington, North Carolina, United States|Willoughby Hills, Ohio, United States|Oklahoma City, Oklahoma, United States|Lake Oswego, Oregon, United States|Portland, Oregon, United States|Johnstown, Pennsylvania, United States|Limerick, Pennsylvania, United States|Norristown, Pennsylvania, United States|Greenville, South Carolina, United States|Bristol, Tennessee, United States|Dallas, Texas, United States|Forth Worth, Texas, United States|Houston, Texas, United States|Irving, Texas, United States|Mesquite, Texas, United States|North Richland Hills, Texas, United States|San Antonio, Texas, United States",,"https://ClinicalTrials.gov/show/NCT00855920"
230,"NCT00794417","A Study of Aflibercept Administered in Combination With Pemetrexed and Cisplatin in Participants With Advanced Carcinoma",,"Terminated","Has Results","Advanced Carcinoma|Non-small Cell Lung Cancer","Drug: Aflibercept|Drug: Pemetrexed|Drug: Cisplatin","Phase 1: Recommended Dose of Aflibercept for Phase 2|Phase 2: Objective Response Rate|Phase 2: Progression-free Survival (PFS)|Phase 1 and 2: Number of Participants With Treatment Emergent Adverse Events (TEAEs)|Phase 1 and 2: Area Under the Plasma Concentration-Time Curve From Time Zero to Infinity (AUC0-inf) of Aflibercept|Phase 1 and 2: Area Under the Plasma Concentration-Time Curve From Time Zero to Infinity (AUC0-inf) of Pemetrexed|Phase 1 and 2: Maximum Observed Plasma Concentration (Cmax) of Aflibercept and Pemetrexed|Phase 1 and 2: Total Body Clearance of Aflibercept|Phase 1 and 2: Total Body Clearance of Pemetrexed|Phase 1 and 2: Terminal Half-Life (t1/2) of Aflibercept|Phase 1 and 2: Terminal Half-Life (t1/2) of Pemetrexed|Phase 1 and 2: Number of Participants With Positive Anti-drug Antibody (ADA) of Aflibercept|Phase 1 and 2: Number of Participants With All Grade Glucose Abnormalities|Phase 1 and 2: Number of Participants With All Grade Hematology Abnormalities","Regeneron Pharmaceuticals|Sanofi","All","18 Years and older   (Adult, Older Adult)","Phase 1|Phase 2","60","Industry","Interventional","Allocation: Non-Randomized|Intervention Model: Single Group Assignment|Masking: None (Open Label)|Primary Purpose: Treatment","VGFT-ST-0708|TCD10767","November 30, 2008","June 30, 2011","June 30, 2011","November 20, 2008","December 10, 2020","December 10, 2020","Arizona Cancer Institute, LLC, Tucson, Arizona, United States|University of Arkansas for Medical Science, Little Rock, Arkansas, United States|Stanford University Medical Center, Stanford, California, United States|Palm Beach Institute of Hematology and Oncology, Boynton Beach, Florida, United States|Edward Hines Jr. VA Medical Center, Hines, Illinois, United States|Kentucky Cancer Clinic, Hazard, Kentucky, United States|Sidney Kimmel Comprehensive Cancer Center, Baltimore, Maryland, United States|Dartmouth-Hitchcock Medical Center, Lebanon, New Hampshire, United States|UNM Cancer Clinic, Albuquerque, New Mexico, United States|Montefiore Medical Center, Bronx, New York, United States|Roswell Park Cancer Institute, Buffalo, New York, United States|Presbyterian Hospital Center for Cancer Research, Charlotte, North Carolina, United States|Erie Regional Cancer Center, Erie, Pennsylvania, United States|Schiffler Cancer Center - Medical Oncology Division, Wheeling, West Virginia, United States|Princess Margaret Hospital, Toronto, Ontario, Canada",,"https://ClinicalTrials.gov/show/NCT00794417"
231,"NCT00789477","DME And VEGF Trap-Eye [Intravitreal Aflibercept Injection (IAI;EYLEA®;BAY86-5321)] INvestigation of Clinical Impact","DA VINCI","Completed","Has Results","Diabetic Macular Edema","Procedure: Laser Photocoagulation|Drug: Intravitreal Aflibercept Injection","Change in BCVA From Baseline to Week 24 - Last Observation Carried Forward (LOCF)|Change in BCVA From Baseline to Week 52 - LOCF|Participants With Gains in ETDRS Letter Score of at Least 15 Letters - LOCF|Change From Baseline in Central Retinal Thickness (CRT) as Assessed by Optical Coherence Tomography (OCT) - LOCF|Number of Focal Laser Treatments","Regeneron Pharmaceuticals|Bayer","All","18 Years and older   (Adult, Older Adult)","Phase 2","221","Industry","Interventional","Allocation: Randomized|Intervention Model: Parallel Assignment|Masking: Quadruple (Participant, Care Provider, Investigator, Outcomes Assessor)|Primary Purpose: Treatment","VGFT-OD-0706","December 2008","December 2009","September 2010","November 11, 2008","September 9, 2014","September 9, 2014","Artesia, California, United States|Beverly Hills, California, United States|Mountain View, California, United States|Pasadena, California, United States|Sacramento, California, United States|Santa Ana, California, United States|Hamden, Connecticut, United States|New London, Connecticut, United States|Boynton Beach, Florida, United States|Fort Lauderdale, Florida, United States|Fort Myers, Florida, United States|Ocala, Florida, United States|Palm Beach Gardens, Florida, United States|Winter Haven, Florida, United States|Augusta, Georgia, United States|Honolulu, Hawaii, United States|Indianapolis, Indiana, United States|Bangor, Maine, United States|Baltimore, Maryland, United States|Boston, Massachusetts, United States|Jackson, Michigan, United States|Kansas City, Missouri, United States|Lincoln, Nebraska, United States|New Brunswick, New Jersey, United States|Northfield, New Jersey, United States|Toms River, New Jersey, United States|Rochester, New York, United States|Charlotte, North Carolina, United States|Raleigh, North Carolina, United States|Cincinnati, Ohio, United States|Pittsburgh, Pennsylvania, United States|Greenville, South Carolina, United States|West Columbia, South Carolina, United States|Nashville, Tennessee, United States|Abilene, Texas, United States|Arlington, Texas, United States|Austin, Texas, United States|Houston, Texas, United States|McAllen, Texas, United States|San Antonio, Texas, United States|San Antonio, Texas, United States|Salt Lake City, Utah, United States|Wien, Austria|Vancouver, British Columbia, Canada|Victoria, British Columbia, Canada|London, Ontario, Canada|Mississauga, Ontario, Canada",,"https://ClinicalTrials.gov/show/NCT00789477"
232,"NCT00610363","Study of the Safety and Effectiveness of Rilonacept for the Prevention of Gout Flares",,"Completed","Has Results","Gout","Biological: Rilonacept|Other: Placebo (for Rilonacept)","Number of Gout Flares Per Participant Assessed From Day 1 to Day 84 (Week 12)|Percentage of Participants With at Least One Gout Flare From Day 1 to Day 84 (Week 12)|Mean Number of Gout Flares Per Month Per Participant From Day 1 to Day 84 (Week 12)|Mean Number of Gout Flare Days Per Participant From Day 1 to Day 84 (Week 12)|Mean Number of Gout Flare Days Per Month Per Participant From Day 1 to Day 84 (Week 12)|Number of Gout Flare Days With Participant's Pain Score of 5 or More (From Daily Diary) Per Participant From Day 1 to Day 84 (Week 12)|Number of Gout Flare Days With Participant's Pain Score of 5 or More (From Daily Diary) Per Month Per Participant From Day 1 to Day 84 (Week 12)","Regeneron Pharmaceuticals","All","18 Years and older   (Adult, Older Adult)","Phase 2","83","Industry","Interventional","Allocation: Randomized|Intervention Model: Parallel Assignment|Masking: Quadruple (Participant, Care Provider, Investigator, Outcomes Assessor)|Primary Purpose: Treatment","IL1T-GA-0619","November 2007","October 2008","October 2008","February 7, 2008","May 2, 2017","May 2, 2017","San Diego, California, United States|Santa Maria, California, United States|Whittier, California, United States|Colorado Srings, Colorado, United States|DeLand, Florida, United States|Ocala, Florida, United States|Orlando, Florida, United States|St. Petersburg, Florida, United States|Tampa, Florida, United States|Tampa, Florida, United States|Dunwoody, Georgia, United States|Honolulu, Hawaii, United States|Boise, Idaho, United States|Indianapolis, Indiana, United States|South Bend, Indiana, United States|Owensboro, Kentucky, United States|Wheaton, Maryland, United States|Billings, Montana, United States|Omaha, Nebraska, United States|Reno, Nevada, United States|Albany, New York, United States|Plainview, New York, United States|Roslyn, New York, United States|Monroe, North Carolina, United States|Raleigh, North Carolina, United States|Cincinnati, Ohio, United States|Mayfield Village, Ohio, United States|Oklahoma City, Oklahoma, United States|Duncansville, Pennsylvania, United States|West Reading, Pennsylvania, United States|Charleston, South Carolina, United States|Grenville, South Carolina, United States|Dallas, Texas, United States|Spokane, Washington, United States",,"https://ClinicalTrials.gov/show/NCT00610363"
233,"NCT00527423","Randomized, Single-Masked, Long-Term, Safety and Tolerability Study of VEGF Trap-Eye in AMD",,"Completed","Has Results","Macular Degeneration","Drug: VEGF Trap Eye","Number of Participants With Adverse Events (AE)|Frequency (Number of Injections)|Mean Change From Baseline of Original Study in Best Corrected Visual Acuity (BCVA) as Measured by Early Treatment Diabetic Retinopathy Study (ETDRS) Letter Score of Study Eye - Observed Values","Regeneron Pharmaceuticals|Bayer","All","50 Years and older   (Adult, Older Adult)","Phase 2","157","Industry","Interventional","Allocation: N/A|Intervention Model: Single Group Assignment|Masking: Single (Participant)|Primary Purpose: Treatment","VGFT-OD-0702","August 2007","October 2011","October 2011","September 10, 2007","June 12, 2013","June 12, 2013","Peoria, Arizona, United States|Phoenix, Arizona, United States|Tucson, Arizona, United States|Beverly Hills, California, United States|Loma Linda, California, United States|Palm Springs, California, United States|Pasadena, California, United States|Poway, California, United States|Westlake Village, California, United States|Ft. Myers, Florida, United States|Stuart, Florida, United States|Winter Haven, Florida, United States|Augusta, Georgia, United States|Glenview, Illinois, United States|Indianapolis, Indiana, United States|Baltimore, Maryland, United States|Hagerstown, Maryland, United States|Boston, Massachusetts, United States|West Springfield, Massachusetts, United States|Toms River, New Jersey, United States|Lynbrook, New York, United States|Charlotte, North Carolina, United States|Oklahoma City, Oklahoma, United States|Portland, Oregon, United States|W. Columbia, South Carolina, United States|Rapid City, South Dakota, United States|Nashville, Tennessee, United States|Austin, Texas, United States|Fort Worth, Texas, United States|Houston, Texas, United States|McAllen, Texas, United States|San Antonio, Texas, United States|Salt Lake City, Utah, United States",,"https://ClinicalTrials.gov/show/NCT00527423"
234,"NCT00509795","Vascular Endothelial Growth Factor VEGF Trap-Eye:Investigation of Efficacy and Safety in Wet Age-Related Macular Degeneration(AMD)","VIEW1","Completed","Has Results","Macular Degeneration","Biological: ranibizumab|Biological: aflibercept injection (VEGF Trap-Eye, BAY86-5321)","Percentage of Patients Who Maintained Vision at Week 52 - Last Observation Carried Forward (LOCF)|Mean Change From Baseline in Best Corrected Visual Acuity (BCVA) as Measured by Early Treatment Diabetic Retinopathy Study (ETDRS) Letter Score at Week 52 - LOCF|Percentage of Patients Who Gained at Least 15 Letters of Vision in the ETDRS Letter Score in the Study Eye at Week 52 - LOCF.|Mean Change From Baseline in National Eye Institute Visual Functioning Questionnaire (NEI VFQ-25) Total Score at Week 52 - LOCF|Mean Change From Baseline in Choroidal Neovascularization (CNV) Area at Week 52 (LOCF)","Regeneron Pharmaceuticals|Bayer","All","50 Years and older   (Adult, Older Adult)","Phase 3","1217","Industry","Interventional","Allocation: Randomized|Intervention Model: Parallel Assignment|Masking: Quadruple (Participant, Care Provider, Investigator, Outcomes Assessor)|Primary Purpose: Treatment","VGFT-OD-0605","August 2007","September 2010","July 2011","August 1, 2007","April 16, 2012","December 28, 2012","Birmingham, Alabama, United States|Birmingham, Alabama, United States|Phoenix, Arizona, United States|Phoenix, Arizona, United States|Tucson, Arizona, United States|Tucson, Arizona, United States|Beverly Hills, California, United States|Campbell, California, United States|Fullerton, California, United States|Glendale, California, United States|Irvine, California, United States|La Jolla, California, United States|Loma Linda, California, United States|Los Angeles, California, United States|Los Angeles, California, United States|Menlo Park, California, United States|Mountain View, California, United States|Oakland, California, United States|Palm Springs, California, United States|Pasadena, California, United States|Poway, California, United States|Sacramento, California, United States|San Diego, California, United States|San Francisco, California, United States|Santa Ana, California, United States|Torrance, California, United States|Ventura, California, United States|Westlake Village, California, United States|Yorba Linda, California, United States|Aurora, Colorado, United States|Denver, Colorado, United States|Denver, Colorado, United States|Bridgeport, Connecticut, United States|Hamden, Connecticut, United States|New Haven, Connecticut, United States|New London, Connecticut, United States|Altamonte Springs, Florida, United States|Boynton Beach, Florida, United States|Fort Myers, Florida, United States|Ft. Lauderdale, Florida, United States|Ft. Myers, Florida, United States|Gainesville, Florida, United States|Jacksonville, Florida, United States|Miami, Florida, United States|Miami, Florida, United States|Mount Dora, Florida, United States|Orlando, Florida, United States|Orlando, Florida, United States|Oscala, Florida, United States|Palm Beach Gardens, Florida, United States|Pensacola, Florida, United States|Sarasota, Florida, United States|Stuart, Florida, United States|Tampa, Florida, United States|Winter Haven, Florida, United States|Augusta, Georgia, United States|Aiea, Hawaii, United States|Honolulu, Hawaii, United States|Oak Brook, Illinois, United States|Fort Wayne, Indiana, United States|Indianapolis, Indiana, United States|Indianapolis, Indiana, United States|Indianapolis, Indiana, United States|New Albany, Indiana, United States|Iowa City, Iowa, United States|Wichita, Kansas, United States|Louisville, Kentucky, United States|Louisville, Kentucky, United States|Paducah, Kentucky, United States|New Orleans, Louisiana, United States|New Orleans, Louisiana, United States|Shreveport, Louisiana, United States|Bangor, Maine, United States|Portland, Maine, United States|Baltimore, Maryland, United States|Baltimore, Maryland, United States|Chevy Chase, Maryland, United States|Hagerstown, Maryland, United States|Towson, Maryland, United States|Boston, Massachusetts, United States|Boston, Massachusetts, United States|Boston, Massachusetts, United States|Boston, Massachusetts, United States|Peabody, Massachusetts, United States|Ann Arbor, Michigan, United States|Battle Creek, Michigan, United States|Detroit, Michigan, United States|Grand Rapids, Michigan, United States|Jackson, Michigan, United States|Royal Oak, Michigan, United States|Southfield, Michigan, United States|West Bloomfield, Michigan, United States|Edina, Minnesota, United States|Minneapolis, Minnesota, United States|Rochester, Minnesota, United States|Florissant, Missouri, United States|Kansas City, Missouri, United States|Kansas City, Missouri, United States|Springfield, Missouri, United States|St. Louis, Missouri, United States|Missoula, Montana, United States|Lincoln, Nebraska, United States|Omaha, Nebraska, United States|Las Vegas, Nevada, United States|Lawrenceville, New Jersey, United States|New Brunswick, New Jersey, United States|Northfield, New Jersey, United States|Teaneck, New Jersey, United States|Toms River, New Jersey, United States|Albuquerque, New Mexico, United States|Albany, New York, United States|Brooklyn, New York, United States|Lynbrook, New York, United States|New York, New York, United States|New York, New York, United States|New York, New York, United States|Poughkeepsie, New York, United States|Rochester, New York, United States|Rochester, New York, United States|Slingerlands, New York, United States|Syracuse, New York, United States|Asheville, North Carolina, United States|Charlotte, North Carolina, United States|Raleigh, North Carolina, United States|Southern Pines, North Carolina, United States|Winston-Salem, North Carolina, United States|Cincinnati, Ohio, United States|Cincinnati, Ohio, United States|Columbus, Ohio, United States|Toledo, Ohio, United States|Oklahoma City, Oklahoma, United States|Ashland, Oregon, United States|Portland, Oregon, United States|Portland, Oregon, United States|Salem, Oregon, United States|Kingston, Pennsylvania, United States|Philadelphia, Pennsylvania, United States|Philadelphia, Pennsylvania, United States|Philadelphia, Pennsylvania, United States|Pittsberg, Pennsylvania, United States|Pittsburgh, Pennsylvania, United States|Pittsburgh, Pennsylvania, United States|West Mifflin, Pennsylvania, United States|Wyomissing, Pennsylvania, United States|Providence, Rhode Island, United States|Charleston, South Carolina, United States|Columbia, South Carolina, United States|Greenville, South Carolina, United States|West Columbia, South Carolina, United States|Rapid City, South Dakota, United States|Memphis, Tennessee, United States|Memphis, Tennessee, United States|Nashville, Tennessee, United States|Abilene, Texas, United States|Austin, Texas, United States|Corpus Cristi, Texas, United States|Dallas, Texas, United States|DeSoto, Texas, United States|Ft. Worth, Texas, United States|Ft. Worth, Texas, United States|Galveston, Texas, United States|Houston, Texas, United States|McAllen, Texas, United States|Odessa, Texas, United States|San Antonio, Texas, United States|Salt Lake City, Utah, United States|Salt Lake City, Utah, United States|Burlington, Vermont, United States|Charlottesville, Virginia, United States|Fairfax, Virginia, United States|Richmond, Virginia, United States|Seattle, Washington, United States|Silverdale, Washington, United States|Madison, Wisconsin, United States|Madison, Wisconsin, United States|Milwaukee, Wisconsin, United States|Calgary, Alberta, Canada|Vancouver, British Columbia, Canada|Victoria, British Columbia, Canada|Halifax, Nova Scotia, Canada|London, Ontario, Canada|Mississauga, Ontario, Canada|Ottawa, Ontario, Canada|Toronto, Ontario, Canada|Toronto, Ontario, Canada|Montreal, Quebec, Canada|Montreal, Quebec, Canada|Regina, Saskatchewan, Canada",,"https://ClinicalTrials.gov/show/NCT00509795"
235,"NCT00320788","Safety and Efficacy of Repeated Intravitreal Administration of Vascular Endothelial Growth Factor (VEGF) Trap in Patients With Wet Age-Related Macular Degeneration (AMD)",,"Completed","Has Results","Macular Degeneration","Biological: aflibercept injection (VEGF Trap-Eye, BAY86-5321)","Mean Change of CR/LT From Baseline at Week 12|Mean Percent Change of CR/LT From Baseline at Week 12|Mean Change in Best Corrected Visual Acuity (BCVA) as Measured by Early Treatment Diabetic Retinopathy Study (ETDRS) From Baseline at Week 12|Percentage of Participants Who Gained at Least 15 Letters of Vision in the ETDRS Letter Score From Baseline at Week 12","Regeneron Pharmaceuticals|Bayer","All","50 Years and older   (Adult, Older Adult)","Phase 2","159","Industry","Interventional","Allocation: Randomized|Intervention Model: Parallel Assignment|Masking: Triple (Participant, Care Provider, Investigator)|Primary Purpose: Treatment","VGFT-OD-0508","April 2006","June 2008","August 2008","May 3, 2006","March 1, 2012","March 1, 2012","Associated Retina Consultants, Phoenix, Arizona, United States|Retina Centers, PC, Tucson, Arizona, United States|Retina Vitreous Associates Medical Group, Beverly Hills, California, United States|Loma Linda University Health Care, Loma Linda, California, United States|Southeast Retina Center, Augusta, Georgia, United States|University of Chicago, Chicago, Illinois, United States|Midwest Eye Institute, Indianapolis, Indiana, United States|Johns Hopkins Hospital School of Medicine, Baltimore, Maryland, United States|Ophthalmic Consultants of Boston, Boston, Massachusetts, United States|New England Retina Consultants PC, West Springfield, Massachusetts, United States|Charlotte Eye, Ear, Nose & Throat Asssociates, Charlotte, North Carolina, United States|Dean A. McGee Eye Institute, Oklahoma City, Oklahoma, United States|Retina Northwest PC, Portland, Oregon, United States|Retina Diagnostic and Treatment Assoc., LLC, Philadelphia, Pennsylvania, United States|Black Hills Regional Eye Institute, Rapid City, South Dakota, United States|Retina-Vitreous Associates, P.C., Nashville, Tennessee, United States|Vitreoretinal Consultants Scurlock Tower Texas Medical Center, Houston, Texas, United States|Medical Center Ophthamology, San Antonio, Texas, United States",,"https://ClinicalTrials.gov/show/NCT00320788"
236,"NCT00320775","Safety and Tolerability Study of Intravitreal VEGF-Trap Administration in Patients With Neovascular AMD",,"Completed","No Results Available","Macular Degeneration","Drug: VEGF Trap","Safety and tolerability, bioeffect|The effect of VEGF Trap administration on excess central retinal/lesion thickness|Best-corrected Early Treatment of Diabetic Retinopathy Study (ETDRS) visual acuity|Extent of CNV leakage|Anti-VEGF Trap antibodies in the systemic circulation|Plasma levels of VEGF Trap","Regeneron Pharmaceuticals|Bayer","All","50 Years and older   (Adult, Older Adult)","Phase 1","51","Industry","Interventional","Allocation: Randomized|Intervention Model: Parallel Assignment|Masking: None (Open Label)|Primary Purpose: Treatment","VGFT-OD-0502","June 2005","June 2008","August 2008","May 3, 2006",,"March 18, 2015","Retina Centers, PC, Tuscon, Arizona, United States|Loma Linda University Health Care, Loma Linda, California, United States|University of Chicago, Chicago, Illinois, United States|Johns Hopkins Hospital School of Medicine, Baltimore, Maryland, United States|Charlotte Eye, Ear, Nose & Throat Asssociates, Charlotte, North Carolina, United States|Dean A. McGee Eye Institute, Oklahoma City, Oklahoma, United States|Retina Diagnostic and Treatment Assoc., LLC, Philadelphia, Pennsylvania, United States|Retina-Vitreous Associates, P.C., Nashville, Tennessee, United States",,"https://ClinicalTrials.gov/show/NCT00320775"
237,"NCT00288704","Rilonacept for Treatment of Cryopyrin-Associated Periodic Syndromes (CAPS)",,"Completed","Has Results","Familial Cold Autoinflammatory Syndrome (FCAS)|Familial Cold Urticaria|Muckle-Wells Syndrome (MWS)|Genetic Diseases, Inborn","Drug: rilonacept 160 mg|Drug: Placebo","Change From Baseline to Week-6 (Part A) Endpoint in Mean Key Symptom Score (KSS)|Mean Change in Key Symptom Score (KSS) From Week 15 to Week 24 (During the Randomized Withdrawal Phase or Part B)","Regeneron Pharmaceuticals","All","7 Years and older   (Child, Adult, Older Adult)","Phase 3","104","Industry","Interventional","Allocation: Randomized|Intervention Model: Parallel Assignment|Masking: Quadruple (Participant, Care Provider, Investigator, Outcomes Assessor)|Primary Purpose: Treatment","IL1T-AI-0505","December 2005","June 2008","August 2008","February 8, 2006","November 13, 2009","December 6, 2011","Little Rock, Arkansas, United States|Palm Desert, California, United States|Upland, California, United States|Jacksonville, Florida, United States|Stuart, Florida, United States|Atlanta, Georgia, United States|Columbus, Georgia, United States|Aurora, Illinois, United States|Louisville, Kentucky, United States|Shreveport, Louisiana, United States|Chesterfield, Michigan, United States|St. Louis, Missouri, United States|New York, New York, United States|Raleigh, North Carolina, United States|Cincinnati, Ohio, United States|Duncansville, Pennsylvania, United States|Columbia, South Carolina, United States|Greer, South Carolina, United States|Chattanooga, Tennessee, United States|Dallas, Texas, United States|Waco, Texas, United States|Cedar City, Utah, United States|Forest, Virginia, United States|Lakewood, Washington, United States",,"https://ClinicalTrials.gov/show/NCT00288704"
238,"NCT01868360","Using Aflibercept Injection to Treat Blood Vessel Growth Over the Cornea",,"Terminated","No Results Available","Corneal Neovascularization","Drug: Subconjunctival aflibercept|Other: Placebo: Standard of care only","Safety defined by incidence and severity of adverse events at week 28|neovascularization regression|Need for immunosuppression|Effect on corneal infections|Change in visual acuity|Mean number of injections|Rescue therapy","Balamurali Ambati|Regeneron Pharmaceuticals|University of Utah","All","18 Years and older   (Adult, Older Adult)","Phase 1","2","Other|Industry","Interventional","Allocation: Randomized|Intervention Model: Parallel Assignment|Masking: None (Open Label)|Primary Purpose: Treatment","AMB65110","June 2013","October 2015","October 2015","June 4, 2013",,"October 7, 2015","John A. Moran Eye Center, Salt Lake City, Utah, United States",,"https://ClinicalTrials.gov/show/NCT01868360"
239,"NCT03085784","Intravitreal Aflibercept Injection for Radiation Retinopathy Trial","ARRT","Active, not recruiting","No Results Available","Radiation Retinopathy","Drug: Aflibercept","Safety of intravitreal Aflibercept for the treatment of radiation retinopathy - Assessed by incidence of adverse events.|Resolution of macular edema (CRT)|Resolution of macular edema (% dry)|Stabilization and improvement in visual acuity|Dosing frequency of intravitreal aflibercept injections|Incidence of neovascularization, vitreous hemorrhage, and need for vitrectomy|Resolution of retinal hemorrhage, retinal exudates, optic disc edema, and capillary non-perfusion","Amy C Schefler, MD|Regeneron Pharmaceuticals|Greater Houston Retina Research","All","18 Years and older   (Adult, Older Adult)","Phase 2","40","Other|Industry","Interventional","Allocation: Randomized|Intervention Model: Parallel Assignment|Masking: None (Open Label)|Primary Purpose: Treatment","ARRT","July 5, 2017","October 2021","October 2021","March 21, 2017",,"December 8, 2020","Retina Consultants of Houston/Texas Medical Center, Houston, Texas, United States|Retina Consultants of Houston, Katy, Texas, United States|Retina Consultants of Houston/The Woodlands, The Woodlands, Texas, United States","""Informed Consent Form"", https://ClinicalTrials.gov/ProvidedDocs/84/NCT03085784/ICF_000.pdf|""Study Protocol and Statistical Analysis Plan"", https://ClinicalTrials.gov/ProvidedDocs/84/NCT03085784/Prot_SAP_001.pdf","https://ClinicalTrials.gov/show/NCT03085784"
240,"NCT03675022","Effect of Dupilumab on Sleep Apnea in Patients With Rhinosinusitis",,"Unknown status","No Results Available","Sleep Apnea|Rhinosinusitis Chronic","Drug: Dupilumab","Percent change in apnea-hypopnea index (AHI) after 16 weeks of dupilumab therapy|Effect of 16 weeks of dupilumab on sleep architecture total sleep time|Effect of 16 weeks of dupilumab on sleep architecture sleep stage percentages|Effect of 16 weeks of dupilumab on sleep architecture arousal index|Effect of 16 weeks of dupilumab on sleep architecture oxygen saturation|Epworth Sleepiness Score (ESS)|Pittsburgh Sleep Quality Index (PSQI)|Functional Outcomes of Sleep Quality (FOSQ)|Subjective sleep quality [visual analog scale(VAS)]|Effect of 16 weeks of dupilumab on nasal resistance with catheter|Effect of 16 weeks of dupilumab on nasal resistance with mask","Brigham and Women's Hospital","All","18 Years to 65 Years   (Adult, Older Adult)","Early Phase 1","22","Other","Interventional","Allocation: N/A|Intervention Model: Single Group Assignment|Masking: None (Open Label)|Primary Purpose: Treatment","2018P001031","August 15, 2018","July 2020","July 2020","September 18, 2018",,"July 11, 2019","Brigham and Women's Hospital, Boston, Massachusetts, United States",,"https://ClinicalTrials.gov/show/NCT03675022"
241,"NCT02457975","Photobiomodulation for the Treatment of Diabetic Macular Edema","PTDME","Completed","No Results Available","Diabetic Retinopathy","Device: 670nm PBM|Drug: intravitreous VEGF-inhibitors","Visual Acuity as assessed by the Early Treatment of Diabetic Retinopathy Study (EDTRS) Classification|Spectral Density-Optical Coherence Tomography (SD-OCT)","Medical College of Wisconsin|University of Wisconsin, Milwaukee","All","18 Years and older   (Adult, Older Adult)","Early Phase 1","16","Other","Interventional","Allocation: Randomized|Intervention Model: Single Group Assignment|Masking: None (Open Label)|Primary Purpose: Treatment","PRO00024065","June 2015","August 30, 2019","August 30, 2019","May 29, 2015",,"September 10, 2019","Medical College of Wisconsin Froedert Hospital, Milwaukee, Wisconsin, United States",,"https://ClinicalTrials.gov/show/NCT02457975"
242,"NCT02045030","Study to Identify Biomarkers of Clinical Response to Aflibercept in Patients With Metastatic Colorectal Cancer",,"Terminated","No Results Available","Metastatic Colorectal Cancer","Drug: aflibercept + FOLFIRI","A biomarker (in blood or tissue) that may be predictive of level of response to aflibercept|Progression free survival (PFS)|Response rate|Disease control rate|Number of participants with adverse events|The quality of life impact of treating with FOLFIRI in combination with Aflibercept","CR-CSSS Champlain-Charles-Le Moyne|Sanofi|Regeneron Pharmaceuticals|Quebec Clinical Research Organization in Cancer","All","18 Years and older   (Adult, Older Adult)","Phase 2","14","Other|Industry","Interventional","Allocation: N/A|Intervention Model: Single Group Assignment|Masking: None (Open Label)|Primary Purpose: Treatment","Q-CROC-04","January 2014","November 2016","November 2016","January 24, 2014",,"November 16, 2016","CSSS Champlain-Charles-Le Moyne, Greenfield Park, Quebec, Canada|Hôpital Maisonneuve-Rosemont, Montreal, Quebec, Canada|Jewish General Hospital, Montreal, Quebec, Canada|Hôpital du Sacré-Coeur de Montréal, Montréal, Quebec, Canada",,"https://ClinicalTrials.gov/show/NCT02045030"
243,"NCT01526070","Study of Bimonthly VEGF Trap-Eye Compared to As-needed Administration or Other Therapy for Exudative Age-Related Macular Degeneration",,"Completed","No Results Available","Exudative Age-related Macular Degeneration","Drug: Intravitreal injection of Aflibercept","Visual Acuity","Stanford University","All","50 Years and older   (Adult, Older Adult)",,"142","Other","Observational","Observational Model: Cohort|Time Perspective: Prospective","SU-02012012-9068","January 2012","July 2014","July 2014","February 3, 2012",,"November 18, 2014","Byers Eye Institute at Stanford, Palo Alto, California, United States",,"https://ClinicalTrials.gov/show/NCT01526070"
244,"NCT04018833","Intravitreal Ranibizumab or Aflibercept After Bevacizumab in Diabetic Macular Edema","SWITCH","Completed","No Results Available","Diabetic Macular Edema|Diabetic Retinopathy","Drug: Ranibizumab 0.5 MG/0.05 ML Intraocular Solution [LUCENTIS]|Drug: Aflibercept 40 MG/ML Intraocular Solution [EYLEA]","Anatomical change|Functional change","Bernardete Pessoa MD|Centro Hospitalar do Porto","All","18 Years to 85 Years   (Adult, Older Adult)",,"40","Other","Observational","Observational Model: Cohort|Time Perspective: Prospective","20190701245703984","January 1, 2012","June 1, 2016","June 30, 2016","July 15, 2019",,"July 23, 2019",,,"https://ClinicalTrials.gov/show/NCT04018833"
245,"NCT03066258","Safety and Tolerability of RGX-314 Gene Therapy for Neovascular AMD Trial",,"Active, not recruiting","No Results Available","Neovascular Age-related Macular Degeneration|Wet Age-related Macular Degeneration","Genetic: RGX-314","Safety (incidence of ocular and non-ocular AEs and SAEs)|Change in best corrected visual acuity|Change in central retinal thickness|Rescue injections (Mean number of rescue injections)|Mean change in area of CNV","Regenxbio Inc.","All","50 Years to 89 Years   (Adult, Older Adult)","Phase 1|Phase 2","42","Industry","Interventional","Allocation: Non-Randomized|Intervention Model: Sequential Assignment|Masking: None (Open Label)|Primary Purpose: Treatment","RGX-314-001","March 31, 2017","November 24, 2019","May 2021","February 28, 2017",,"April 2, 2021","Santa Barbara location, Santa Barbara, California, United States|Baltimore location, Baltimore, Maryland, United States|Boston location, Boston, Massachusetts, United States|Reno location, Reno, Nevada, United States|Philadelphia location 1, Philadelphia, Pennsylvania, United States|Philadelphia location 2, Philadelphia, Pennsylvania, United States|Memphis location, Germantown, Tennessee, United States|Houston location, Houston, Texas, United States",,"https://ClinicalTrials.gov/show/NCT03066258"
246,"NCT04822376","Prophylaxis Vaccine Antibodies Ebola","PROVAE","Not yet recruiting","No Results Available","Ebola Virus Disease","Drug: ansuvimab|Biological: Ervebo","Efficacy|Immunological ancillary study|Tolerance|Lost of follow-up|Humoral immune response|Neutralizing antibodies","ANRS, Emerging Infectious Diseases","All","18 Years and older   (Adult, Older Adult)","Phase 2","250","Other","Interventional","Allocation: Non-Randomized|Intervention Model: Single Group Assignment|Masking: None (Open Label)|Primary Purpose: Prevention","ANRS 0006S","October 17, 2021","April 2022","April 2022","March 30, 2021",,"October 15, 2021","Centre de Traitement Ebola de N'Zerekore, N'Zerekore, Guinea",,"https://ClinicalTrials.gov/show/NCT04822376"
247,"NCT05232110","Compassionate Use of Pozelimab",,"Available","No Results Available","Paroxysmal Nocturnal Hemoglobinuria (PNH)|CD55-deficient Protein-losing Enteropathy (PLE)|CD59 Deficiency","Drug: Pozelimab",,"Regeneron Pharmaceuticals",,"Child, Adult, Older Adult",,,"Industry","Expanded Access:Individual Patients",,"R3918-Pozelimab",,,,"February 9, 2022",,"February 9, 2022",,,"https://ClinicalTrials.gov/show/NCT05232110"
248,"NCT05164250","Compassionate Use (CU) of REGN5458 for Patients With Relapsed or Refractory Multiple Myeloma (MM)",,"Available","No Results Available","Multiple Myeloma","Drug: REGN5458",,"Regeneron Pharmaceuticals",,"Child, Adult, Older Adult",,,"Industry","Expanded Access:Individual Patients",,"R5458-MM",,,,"December 20, 2021",,"December 20, 2021",,,"https://ClinicalTrials.gov/show/NCT05164250"
249,"NCT04776694","Compassionate Use of Dupilumab",,"Available","No Results Available","Bullous Pemphigoid|Eosinophilic Esophagitis (EoE)|Pediatric Asthma|Pediatric and Adolescent Chronic Rhinosinusitis With Nasal Polyps (CRSwNP)|Pediatric Atopic Dermatitis","Drug: Dupilumab",,"Regeneron Pharmaceuticals",,"Child, Adult, Older Adult",,,"Industry","Expanded Access:Individual Patients",,"R668-Dupilumab",,,,"March 2, 2021",,"June 14, 2021",,,"https://ClinicalTrials.gov/show/NCT04776694"
250,"NCT04710056","Expanded Access to REGN4461 for Patients With 1) Generalized Lipodystrophy, 2) Partial Lipodystrophy or 3) Monogenic Obesity Due to LEP or LEPR Loss of Function",,"Available","No Results Available","Generalized Lipodystrophy|Partial Lipodystrophy|Monogenic Obesity Due to LEP or LEPR Loss of Function","Drug: REGN4461",,"Regeneron Pharmaceuticals",,"Child, Adult, Older Adult",,,"Industry","Expanded Access:Individual Patients",,"R4461-LEPR",,,,"January 14, 2021",,"January 14, 2021",,,"https://ClinicalTrials.gov/show/NCT04710056"
251,"NCT04617535","Compassionate Use of REGN-COV2 for the Treatment of COVID-19",,"Available","No Results Available","Covid19","Drug: REGN10933+REGN10987 combination therapy",,"Regeneron Pharmaceuticals",,"Child, Adult, Older Adult",,,"Industry","Expanded Access:Individual Patients",,"R10933-10987-COV",,,,"November 5, 2020",,"November 5, 2020",,,"https://ClinicalTrials.gov/show/NCT04617535"
252,"NCT03379558","Praluent® (Alirocumab) Pregnancy Exposure Registry: An OTIS Pregnancy Surveillance Study",,"Terminated","No Results Available","Hypercholesterolemia","Drug: ALIROCUMAB SAR236553 (REGN727)","Rate of major structural birth defects|Pregnancy outcome: Spontaneous abortion|Pregnancy outcome: Elective abortion|Pregnancy outcome: Still birth|Pregnancy outcome: Preterm delivery|Infant outcome: Pattern of minor structural birth defects|Infant outcome: Small for gestational age|Infant outcome: Postnatal growth deficiency|Infant outcome: serious infections or hospitalizations, adverse reactions to childhood vaccinations|Infant outcome: adequacy of immune response|Infant outcome: adverse neurodevelopment|Breastfeeding/Lactation outcome|Adverse events","Regeneron Pharmaceuticals|Sanofi","Female","Child, Adult, Older Adult",,"37","Industry","Observational","Observational Model: Cohort|Time Perspective: Prospective","OBS14703|U1111-1195-6468","December 19, 2017","September 4, 2020","September 4, 2020","December 20, 2017",,"November 23, 2020","Investigational site UNITED STATES, San Diego, California, United States",,"https://ClinicalTrials.gov/show/NCT03379558"
253,"NCT02127801","Single Ascending-dose Study of the Efficacy, Safety, Tolerability, and Pharmacokinetics of REGN1908-1909 in Allergic, Adult Participants",,"Completed","No Results Available","Allergy","Drug: REGN1908-1909|Drug: placebo","Change in allergic symptom scale score|Incidence rate of treatment-emergent adverse events (TEAEs) through day 85 in participants treated with REGN1908-1909 or placebo|Pharmacokinetic (PK) parameters of REGN1908- REGN1909 administration (i.e. how much REGN1908-1909 is in blood over time and how the body reacts to REGN1908-1909)","Regeneron Pharmaceuticals","All","18 Years to 55 Years   (Adult)","Phase 1","74","Industry","Interventional","Allocation: Randomized|Intervention Model: Single Group Assignment|Masking: Quadruple (Participant, Care Provider, Investigator, Outcomes Assessor)|Primary Purpose: Basic Science","R1908-1909-ALG-1325|U1111-1155-2258|2013-004950-68","October 31, 2014","December 31, 2015","December 31, 2015","May 1, 2014",,"December 16, 2020","Groningen, Netherlands|Auckland, New Zealand|Christchurch, New Zealand|Lund, Sweden|London, United Kingdom",,"https://ClinicalTrials.gov/show/NCT02127801"
254,"NCT00094900","Interleukin-1 Trap to Treat Autoinflammatory Diseases",,"Completed","Has Results","Inflammation|Familial Mediterranean Fever|Still's Disease, Adult-Onset","Drug: IL-1 Trap","Mean Change in Daily Scores|Mean Change in ESR|Mean Change in hsCRP|Mean Change in SAA|Response to Treatment (ACR20) in Patients With Adult Onset Still's Disease|Mean Change in Patient's Global Assessment, by VAS|Mean Change in Physician's Global Assessment, by VAS|Mean Change in Patient's Assessment of Pain, by VAS|Mean Change in Patient's Assessment of Fatigue, by VAS|Mean Change in Tender Joint Count|Mean Change in Tender Joint Count.|Mean Change in Swollen Joint Count|Mean Change in SF-36 Physical Component Score|Mean Change in SF-36 Mental Component Score|Mean Change in WBCs|Mean Change in Ferritin|Mean Change in Serum Amyloid A|Mean Change in C-Reactive Protein|Mean Change in Erythrocyte Sedimentation Rate|Mean Change in Patient's Global Assessment, by VAS in AOSD Subjects|Mean Change in Tender Joint Count in AOSD Subjects|Mean Change in Swollen Joint Count in AOSD Subjects|Mean Change in Prednisone Dose","National Institute of Arthritis and Musculoskeletal and Skin Diseases (NIAMS)|National Institutes of Health Clinical Center (CC)","All","18 Years and older   (Adult, Older Adult)","Phase 2","11","NIH","Interventional","Allocation: N/A|Intervention Model: Single Group Assignment|Masking: None (Open Label)|Primary Purpose: Treatment","050014|05-AR-0014","October 2004","September 2010","December 2010","October 28, 2004","July 10, 2013","March 4, 2014","National Institutes of Health Clinical Center, 9000 Rockville Pike, Bethesda, Maryland, United States",,"https://ClinicalTrials.gov/show/NCT00094900"
255,"NCT01001923","Single Injection of REGN475/SAR164877 in the Treatment of Chronic Pancreatitis Pain",,"Terminated","No Results Available","Abdominal Pain Upper","Drug: REGN475/SAR164877|Drug: Placebo (for REGN475/SAR164877)","Mean change from baseline in pain intensity as assessed by Pain Intensity Numeric Rating Scale (PI-NRS)|Mean change from baseline in pain intensity as assessed by PI-NRS|Percentage of pain-free days (score ""0"" pain on PI-NRS)|Percentage of days with rescue analgesia use|Change from baseline in Short Form-12 Item Quality of Life Questionnaire [SF-12] score|Patient Global Impression of Change [PGIC] score|Percentage of participants with at least 30% and 50% reduction from baseline in pain intensity|Pharmacokinetic: REGN475/SAR164877 serum concentration","Regeneron Pharmaceuticals","All","18 Years to 80 Years   (Adult, Older Adult)","Phase 2","15","Industry","Interventional","Allocation: Randomized|Intervention Model: Parallel Assignment|Masking: Double (Participant, Investigator)|Primary Purpose: Treatment","ACT11286","December 2009","January 2011","January 2011","October 27, 2009",,"May 27, 2013","Sanofi-Aventis Investigational Site Number 840024, Arcadia, California, United States|Sanofi-Aventis Investigational Site Number 840011, Bell Gardens, California, United States|Sanofi-Aventis Investigational Site Number 840003, Monterey, California, United States|Sanofi-Aventis Investigational Site Number 840048, San Diego, California, United States|Sanofi-Aventis Investigational Site Number 840034, Stanford, California, United States|Sanofi-Aventis Investigational Site Number 840031, Miami, Florida, United States|Sanofi-Aventis Investigational Site Number 840029, St. Petersburg, Florida, United States|Sanofi-Aventis Investigational Site Number 840017, Marietta, Georgia, United States|Sanofi-Aventis Investigational Site Number 840013, Worcester, Massachusetts, United States|Sanofi-Aventis Investigational Site Number 840030, Lebanon, New Hampshire, United States|Sanofi-Aventis Investigational Site Number 840023, New York, New York, United States|Sanofi-Aventis Investigational Site Number 840052, Winston Salem, North Carolina, United States|Sanofi-Aventis Investigational Site Number 840005, Cleveland, Ohio, United States|Sanofi-Aventis Investigational Site Number 840043, Dallas, Texas, United States|Sanofi-Aventis Investigational Site Number 840053, Desoto, Texas, United States|Sanofi-Aventis Investigational Site Number 840050, Southlake, Texas, United States|Sanofi-Aventis Investigational Site Number 840040, East Sandy, Utah, United States",,"https://ClinicalTrials.gov/show/NCT01001923"
256,"NCT01001715","Single Injection of REGN475/SAR164877 in Treatment of Vertebral Fracture Pain",,"Terminated","No Results Available","Back Pain","Drug: REGN475/SAR164877|Drug: Placebo (for REGN475/SAR164877)","Mean change from baseline in pain intensity as assessed by Pain Intensity Numeric Rating Scale [PI-NRS]|Mean change from baseline in pain intensity as assessed by PI-NRS|Percentage of pain-free days (score ""0"" pain on PI-NRS)|Percentage of days with rescue analgesia use|Change from baseline in Quality of Life Questionnaire of the European Foundation for Osteoporosis [QUALEFFO] score|Change from baseline in Short Form-12 Item Quality of Life Questionnaire [SF-12] score|Patient Global Impression of Change [PGIC] score|Percentage of participants with at least 30% and 50% reduction from baseline in pain intensity|Pharmacokinetic: REGN475/SAR164877 serum concentration","Regeneron Pharmaceuticals","All","40 Years to 80 Years   (Adult, Older Adult)","Phase 2","41","Industry","Interventional","Allocation: Randomized|Intervention Model: Parallel Assignment|Masking: Double (Participant, Investigator)|Primary Purpose: Treatment","ACT11308","November 2009","January 2011","January 2011","October 27, 2009",,"May 27, 2013","Sanofi-Aventis Investigational Site Number 840005, Beverly Hills, California, United States|Sanofi-Aventis Investigational Site Number 840001, Fresno, California, United States|Sanofi-Aventis Investigational Site Number 840017, Sacramento, California, United States|Sanofi-Aventis Investigational Site Number 840028, San Diego, California, United States|Sanofi-Aventis Investigational Site Number 840008, Stockton, California, United States|Sanofi-Aventis Investigational Site Number 840013, Boynton Beach, Florida, United States|Sanofi-Aventis Investigational Site Number 840047, Clearwater, Florida, United States|Sanofi-Aventis Investigational Site Number 840034, Atlanta, Georgia, United States|Sanofi-Aventis Investigational Site Number 840026, New York, New York, United States|Sanofi-Aventis Investigational Site Number 840044, Fort Worth, Texas, United States|Sanofi-Aventis Investigational Site Number 840023, Southlake, Texas, United States",,"https://ClinicalTrials.gov/show/NCT01001715"
257,"NCT00944892","A Study of the Safety and Efficacy of REGN475(SAR164877) in Patients With Osteoarthritis of the Knee",,"Completed","No Results Available","Osteoarthritis of the Knee","Drug: REGN475|Other: Placebo","The incidence of TEAEs in patients treated with REGN475 or placebo, reported between administration of study drug on Day 1 and the completion of study at the end of week 24 (Day 169).|Change from baseline in The Western Ontario and McMaster Osteoarthritis Index (WOMAC) (total score as well as all 3 subscales: pain, stiffness and function).|Patient assessment of response to treatment over time using the Patient Global Impression of Change.|Change from baseline in patient-rated QOL using the Short-Form 12-Item Questionnaire (SF-12).","Regeneron Pharmaceuticals|Sanofi","All","40 Years to 75 Years   (Adult, Older Adult)","Phase 1|Phase 2","200","Industry","Interventional","Allocation: Randomized|Intervention Model: Parallel Assignment|Masking: Quadruple (Participant, Care Provider, Investigator, Outcomes Assessor)|Primary Purpose: Treatment","R475-PN-0901","August 2009","May 2010","May 2010","July 23, 2009",,"December 8, 2011","Anaheim, California, United States|Tampa, Florida, United States|Salt Lake City, Utah, United States",,"https://ClinicalTrials.gov/show/NCT00944892"
258,"NCT00829829","PREventative Study Against URate-lowering Drug-induced Gout Exacerbations 1","PRE-SURGE1","Completed","Has Results","Intercritical Gout","Other: Placebo|Drug: Rilonacept 80 mg|Drug: Rilonacept 160 mg","Number of Gout Flares Per Participant Assessed From Day 1 to Day 112 (Week 16)|Number of Modified Gout Flares Per Participant From Day 1 to Day 112 (Week 16)|Percentage of Participants With at Least One Gout Flare From Day 1 to Day 112 (Week 16)|Percentage of Participants With at Least Two Gout Flares From Day 1 to Day 112 (Week 16)|Number of Gout Flare Days Per Participant From Day 1 to Day 112 (Week 16)|Number of Gout Flare Days With Participant's Pain Score of 5 or More (From Daily Diary) Per Participant From Day 1 to Day 112 (Week 16)","Regeneron Pharmaceuticals","All","18 Years to 80 Years   (Adult, Older Adult)","Phase 3","241","Industry","Interventional","Allocation: Randomized|Intervention Model: Parallel Assignment|Masking: Quadruple (Participant, Care Provider, Investigator, Outcomes Assessor)|Primary Purpose: Treatment","IL1T-GA-0810","February 2009","May 2010","June 2010","January 27, 2009","April 28, 2017","April 28, 2017","Birmingham, Alabama, United States|Gilbert, Arizona, United States|Peoria, Arizona, United States|Searcy, Arkansas, United States|Concord, California, United States|San Diego, California, United States|Santa Maria, California, United States|Trumball, Connecticut, United States|Washington, District of Columbia, United States|Daytona Beach, Florida, United States|Delray Beach, Florida, United States|Jacksonville, Florida, United States|Jupiter, Florida, United States|Naples, Florida, United States|St. Petersburg, Florida, United States|Gainsville, Georgia, United States|Rome, Georgia, United States|Tucker, Georgia, United States|Woodstock, Georgia, United States|Boise, Idaho, United States|Avon, Indiana, United States|Evansville, Indiana, United States|South Bend, Indiana, United States|Wichita, Kansas, United States|Bowling Green, Kentucky, United States|Owensboro, Kentucky, United States|Baltimore, Maryland, United States|Ellicott City, Maryland, United States|Resistertown, Maryland, United States|Troy, Michigan, United States|Jackson, Mississippi, United States|Florissant, Missouri, United States|Las Vegas, Nevada, United States|Las Vegas, Nevada, United States|Berkeley Heights, New Jersey, United States|Freehold, New Jersey, United States|Brooklyn, New York, United States|Greensboro, North Carolina, United States|Hickory, North Carolina, United States|Morehead City, North Carolina, United States|Raleigh, North Carolina, United States|Raleigh, North Carolina, United States|Salisbury, North Carolina, United States|Akron, Ohio, United States|Cincinnati, Ohio, United States|Middleburg Heights, Ohio, United States|Perrysburg, Ohio, United States|Duncansville, Pennsylvania, United States|Fountain Hill, Pennsylvania, United States|Huntingdon Valley, Pennsylvania, United States|Lancaster, Pennsylvania, United States|Charleston, South Carolina, United States|Columbia, South Carolina, United States|Greer, South Carolina, United States|North Charleston, South Carolina, United States|Rock Hill, South Carolina, United States|Memphis, Tennessee, United States|Dallas, Texas, United States|Dallas, Texas, United States|Houston, Texas, United States|Longview, Texas, United States|Richardson, Texas, United States|San Antonio, Texas, United States|Burke, Virginia, United States|Richmond, Virginia, United States|Spokane, Washington, United States|Tacoma, Washington, United States|Calgary, Alberta, Canada|Burnaby, British Columbia, Canada|Kamloops, British Columbia, Canada|Kelowna, British Columbia, Canada|Quesnel, British Columbia, Canada|Victoria, British Columbia, Canada|Mt. Pearl, Newfoundland and Labrador, Canada|St. John's, Newfoundland and Labrador, Canada|Brampton, Ontario, Canada|Corunna, Ontario, Canada|Fort Erie, Ontario, Canada|Kitchener, Ontario, Canada|Listowel, Ontario, Canada|London, Ontario, Canada|London, Ontario, Canada|Mississauga, Ontario, Canada|Newmarket, Ontario, Canada|Sudbury, Ontario, Canada|Toronto, Ontario, Canada|Windsor, Ontario, Canada|Montreal, Quebec, Canada|Trois-Rivieres, Quebec, Canada|Saskatoon, Saskatchewan, Canada|Quebec, Canada",,"https://ClinicalTrials.gov/show/NCT00829829"
259,"NCT01710332","The Safety & Efficacy of Intravitreal Aflibercept Injection in Patients With Persistent Central Serous Chorioretinopathy","CONTAIN","Completed","Has Results","Central Serous Chorioretinopathy","Drug: Intravitreal Aflibercept Injection","Safety of Intravitreal Aflibercept Injection|Change in Vision Based on Letter Score","Wills Eye|Regeneron Pharmaceuticals","All","18 Years to 60 Years   (Adult)","Phase 2","12","Other|Industry","Interventional","Allocation: Randomized|Intervention Model: Parallel Assignment|Masking: None (Open Label)|Primary Purpose: Treatment","CSRII|20121564","October 2012","June 2013","June 2013","October 19, 2012","April 7, 2017","June 16, 2017","Mid Atlantic Retina- Huntingdon Valley, Huntingdon Valley, Pennsylvania, United States|Mid Atlantic Retna- Wills Eye Institute, Philadelphia, Pennsylvania, United States",,"https://ClinicalTrials.gov/show/NCT01710332"
260,"NCT03207945","Effect of PCSK9 Inhibition on Cardiovascular Risk in Treated HIV Infection (EPIC-HIV Study)","EPIC-HIV","Recruiting","No Results Available","Dyslipidemias|Cardiovascular Diseases|HIV Infections","Drug: Alirocumab|Other: Placebo","FDG PET/CT Endpoint|Flow mediated vasodilation of the brachial artery (FMD) endpoint","University of California, San Francisco|Massachusetts General Hospital","All","40 Years and older   (Adult, Older Adult)","Phase 3","140","Other","Interventional","Allocation: Randomized|Intervention Model: Parallel Assignment|Masking: Quadruple (Participant, Care Provider, Investigator, Outcomes Assessor)|Primary Purpose: Treatment","17-22800","April 30, 2018","November 2021","November 2021","July 5, 2017",,"March 18, 2021","San Francisco General Hospital, San Francisco, California, United States",,"https://ClinicalTrials.gov/show/NCT03207945"
261,"NCT03321513","DRCR.Net Aflibercept vs. Bevacizumab + Deferred Aflibercept for the Treatment of CI-DME","DRCR AC","Completed","No Results Available","Diabetic Macular Edema","Drug: intravitreous aflibercept|Drug: Bevacizumab + Deferred Aflibercept Group","Mean Change in Visual Acuity|Mean change in visual acuity from baseline|Percentages of eyes with a gain (increase) or loss (decrease) of at least 10 or at least 15 letters of visual acuity from baseline|Percentages of eyes with visual acuity 20/20 or greater, 20/40 or greater, and 20/200 or worse|Mean change in optical coherence tomography central subfield thickness from baseline|Percentage of eyes with optical coherence tomography central subfield thickness below the gender-specific spectral domain optical coherence tomography equivalent of 250 µm on Zeiss Stratus OCT|Percentages of eyes with worsening or improvement of diabetic retinopathy on fundus photographs|Percentage of eyes receiving panretinal photocoagulation, vitrectomy, or having vitreous hemorrhage from proliferative diabetic retinopathy|Number of visits|Number of injections|Percentage of eyes that met switch criteria (bevacizumab + deferred aflibercept group only)","Jaeb Center for Health Research","All","18 Years and older   (Adult, Older Adult)","Phase 3","270","Other","Interventional","Allocation: Randomized|Intervention Model: Parallel Assignment|Masking: Double (Participant, Outcomes Assessor)|Primary Purpose: Treatment","DRCR.net Protocol AC","December 7, 2017","December 22, 2021","December 22, 2021","October 25, 2017",,"January 20, 2022","Retinal Diagnostic Center, Campbell, California, United States|Retina Consultants of Orange County, Fullerton, California, United States|Macula & Retina Institute, Glendale, California, United States|Loma Linda University Health Care, Department of Ophthalmology, Loma Linda, California, United States|South Coast Retina Center, Long Beach, California, United States|East Bay Retina Consultants, Inc, Oakland, California, United States|Southern California Desert Retina Consultants, MC, Palm Desert, California, United States|California Eye Specialist Medical Group, Inc., Pasadena, California, United States|California Retina Consultants, Santa Barbara, California, United States|New England Retina Associates, Hamden, Connecticut, United States|National Ophthalmic Research Institute, Fort Myers, Florida, United States|Florida Retina Institute-Jacksonville, Jacksonville, Florida, United States|Florida Retina Consultants, Lakeland, Florida, United States|Retina Macula Specialists of Miami, Miami, Florida, United States|Bascom Palmer Eye Institute Naples, Naples, Florida, United States|Central Florida Retina, Orlando, Florida, United States|Florida Retina Institute, Orlando, Florida, United States|Southeast Eye Institute, P.A. dba Eye Associates of Pinellas, Pinellas Park, Florida, United States|Fort Lauderdale Eye Institute, Plantation, Florida, United States|Orlick Berger Kasper & Patel, PA, Saint Petersburg, Florida, United States|Orlick Berger Kasper & Patel, PA, Saint Petersburg, Florida, United States|Retina Associates of Sarasota, Sarasota, Florida, United States|Sarasota Retina Institute, Sarasota, Florida, United States|Retina Associates of Florida, LLC, Tampa, Florida, United States|Retina Associates of Florida, Tampa, Florida, United States|Retina Specialists of Tampa, Wesley Chapel, Florida, United States|Southeast Retina Center, P.C., Augusta, Georgia, United States|Thomas Eye Group, Sandy Springs, Georgia, United States|Gailey Eye Clinic, Bloomington, Illinois, United States|University of Illinois at Chicago Medical Center, Chicago, Illinois, United States|University Retina and Macula Associates, Oak Forest, Illinois, United States|Illinois Retina Associates, S.C., Oak Park, Illinois, United States|Springfield Clinic, LLP, Springfield, Illinois, United States|Prairie Retina Center, Springfield, Illinois, United States|Indiana University Department of Ophthalmology, Indianapolis, Indiana, United States|Raj K. Maturi, M.D., P.C., Indianapolis, Indiana, United States|John-Kenyon American Eye Institute, New Albany, Indiana, United States|Wolfe Eye Clinic-Cedar Rapids, Hiawatha, Iowa, United States|Mid-America Retina Consultants, P.A., Overland Park, Kansas, United States|Retina Associates, P.A., Shawnee Mission, Kansas, United States|Paducah Retinal Center, Paducah, Kentucky, United States|Eye Associates of Northeast Louisiana dba Haik Humble Eye Center, West Monroe, Louisiana, United States|Mid Atlantic Retina Specialists, Hagerstown, Maryland, United States|The National Retina Institute, Towson, Maryland, United States|Valley Eye Physicians and Surgeons, Ayer, Massachusetts, United States|Joslin Diabetes Center, Boston, Massachusetts, United States|Henry Ford Health System, Dept of Ophthalmology and Eye Care Services, Detroit, Michigan, United States|Retina Specialists of Michigan, Grand Rapids, Michigan, United States|Vitreo-Retinal Associates, Grand Rapids, Michigan, United States|The Retina Institute, Saint Louis, Missouri, United States|Eye Associates of New Mexico, Albuquerque, New Mexico, United States|MaculaCare, New York, New York, United States|Retina Associates of Western New York, Rochester, New York, United States|Western Carolina Clinical Research, LLC, Asheville, North Carolina, United States|Charlotte Eye, Ear, Nose and Throat Assoc., PA, Charlotte, North Carolina, United States|University Hospitals Cleveland Medical Center, Cleveland, Ohio, United States|Cole Eye Institute, Cleveland Clinic, Cleveland, Ohio, United States|Dean A. McGee Eye Institute, Oklahoma City, Oklahoma, United States|Retina Northwest, PC, Portland, Oregon, United States|Cascade Medical Research Institute, LLC, Springfield, Oregon, United States|Retina Vitreous Consultants, Monroeville, Pennsylvania, United States|University of Pennsylvania Scheie Eye Institute, Philadelphia, Pennsylvania, United States|Retinavitreous Associates, dba; Mid Atlantic Retina, Philadelphia, Pennsylvania, United States|Retinavitreous Associates, dba; Mid Atlantic Retina, Philadelphia, Pennsylvania, United States|Southeastern Retina Associates, P.C., Knoxville, Tennessee, United States|Austin Retina Associates, Austin, Texas, United States|Retina Research Center, Austin, Texas, United States|Retina Center of Texas, Grapevine, Texas, United States|Retina and Vitreous of Texas, Houston, Texas, United States|Baylor Eye Physicians and Surgeons, Houston, Texas, United States|Retina Consultants of Houston, PA, Houston, Texas, United States|Texas Retina Associates, Lubbock, Texas, United States|Valley Retina Institute, McAllen, Texas, United States|Retinal Consultants of San Antonio, San Antonio, Texas, United States|Spokane Eye Clinic, Spokane, Washington, United States|Medical College of Wisconsin, Milwaukee, Wisconsin, United States",,"https://ClinicalTrials.gov/show/NCT03321513"
262,"NCT00417417","Rilonacept to Improve Artery Function in Patients With Atherosclerosis",,"Completed","Has Results","Coronary Artery Disease|Atherosclerosis|Inflammation|Endothelial Dysfunction","Drug: Rilonacept|Drug: Placebo","C-Reactive Protein (CRP)","National Heart, Lung, and Blood Institute (NHLBI)|National Institutes of Health Clinical Center (CC)","All","18 Years and older   (Adult, Older Adult)","Phase 2","10","NIH","Interventional","Allocation: Randomized|Intervention Model: Parallel Assignment|Masking: Quadruple (Participant, Care Provider, Investigator, Outcomes Assessor)|Primary Purpose: Treatment","070055|07-H-0055","December 2006","April 2008","April 2008","January 1, 2007","April 13, 2010","April 30, 2012","National Institutes of Health Clinical Center, 9000 Rockville Pike, Bethesda, Maryland, United States",,"https://ClinicalTrials.gov/show/NCT00417417"
263,"NCT05268107","Ethnic Differences in Mechanisms of Action of Dupilumab",,"Not yet recruiting","No Results Available","Atopic Dermatitis","Drug: Dupilumab","Difference in inflammatory response to dupilumab between Caucasian, Asian and African American patients with atopic dermatitis as measured by change in expression of interleukin4 (IL4) from week 0 to 2.|Difference in inflammatory response to dupilumab between Caucasian, Asian and African American patients with atopic dermatitis as measured by change in expression of interleukin13 from week 0 to 2.|Difference in inflammatory response to dupilumab between Caucasian, Asian and African American patients with atopic dermatitis as measured by change in expression of Interferon (IFN) from week 0 to 2.|Difference in inflammatory response to dupilumab between Caucasian, Asian and African American patients with atopic dermatitis as measured by change in expression of interleukin36 from week 0 to 2.|Difference in inflammatory response to dupilumab between Caucasian, Asian and African American patients with atopic dermatitis as measured by change in expression of interleukin4 from week 0 to 16.|Difference in inflammatory response to dupilumab between Caucasian, Asian and African American patients with atopic dermatitis as measured by change in expression of interleukin13 from week 0 to 16.|Difference in inflammatory response to dupilumab between Caucasian, Asian and African American patients with atopic dermatitis as measured by change in expression of IFN from week 0 to 16.|Difference in inflammatory response to dupilumab between Caucasian, Asian and African American patients with atopic dermatitis as measured by change in expression of interleukin36 from week 0 to 16.","University of Michigan|Regeneron Pharmaceuticals","All","18 Years and older   (Adult, Older Adult)","Phase 4","30","Other|Industry","Interventional","Allocation: N/A|Intervention Model: Single Group Assignment|Masking: None (Open Label)|Primary Purpose: Basic Science","HUM00201405/Derm 759","March 2022","December 2023","April 2024","March 7, 2022",,"March 7, 2022","University of Michigan, Ann Arbor, Michigan, United States",,"https://ClinicalTrials.gov/show/NCT05268107"
264,"NCT05265234","Dupilmuab for Atopic Dermatitis Monitored With Noninvasive Imaging.",,"Recruiting","No Results Available","Eczema|Atopic Dermatitis","Drug: Dupilumab|Device: Optical Coherence Tomography|Device: Reflectance confocal microscopy","Eczema Area and Severity Index (EASI)|Validated Investigator Global Assessment scale for Atopic Dermatitis (vIGA-AD)|Noninvasive Imaging (clinical response) with Reflectance Confocal Microscopy (RCM)|Noninvasive Imaging (clinical response) with Optical Coherence Tomography (OCT)","OptiSkin Medical|Regeneron Pharmaceuticals","All","18 Years and older   (Adult, Older Adult)","Phase 4","15","Other|Industry","Interventional","Allocation: N/A|Intervention Model: Single Group Assignment|Masking: None (Open Label)|Primary Purpose: Treatment","OPTI-003","March 1, 2022","March 1, 2023","March 1, 2024","March 3, 2022",,"March 3, 2022","OptiSkin Medical, New York, New York, United States",,"https://ClinicalTrials.gov/show/NCT05265234"
265,"NCT05246267","Dupilumab Treatment Effects in an Ethnically Diverse Population With Chronic Rhinosinusitis With Nasal Polyposis",,"Recruiting","No Results Available","Chronic Rhinosinusitis With Nasal Polyps","Biological: Dupilumab","Change in Sinonasal outcome test (SNOT-22) score, scale 0-110, higher is worse outcome|Change in University of Pennsylvania Smell Identification Test (UPSIT) scores, scale 0-40, lower is worse outcome values|Change in nasal peak flow (NPF) value (L/min)|Change in urinary levels of Leukotriene E4 (uLTE4) levels in ug/L|Change in peripheral blood eosinophil counts in k/uL|Change in Immunoglobulin E (IgE) level in IU/mL","Montefiore Medical Center|Regeneron Pharmaceuticals","All","18 Years to 99 Years   (Adult, Older Adult)",,"60","Other|Industry","Observational","Observational Model: Case-Control|Time Perspective: Prospective","2021-13161","March 1, 2022","June 30, 2026","June 30, 2026","February 18, 2022",,"February 18, 2022","Montefiore Medical Center, Bronx, New York, United States","""Study Protocol and Statistical Analysis Plan"", https://ClinicalTrials.gov/ProvidedDocs/67/NCT05246267/Prot_SAP_000.pdf|""Informed Consent Form"", https://ClinicalTrials.gov/ProvidedDocs/67/NCT05246267/ICF_001.pdf","https://ClinicalTrials.gov/show/NCT05246267"
266,"NCT05128383","Study to Assess Efficacy and Safety of Dupilumab in the Treatment of Keloids",,"Not yet recruiting","No Results Available","Keloid","Drug: Dupilumab","Patient and Observer Scar Assessment Scale (POSAS)|Vancouver Scar Scale (VSS).|Dermatology Life Quality Index (DLQI).|Cutometer|Mexameter|Histology","Beth Israel Deaconess Medical Center|Regeneron Pharmaceuticals","All","18 Years to 65 Years   (Adult, Older Adult)","Phase 2","20","Other|Industry","Interventional","Allocation: N/A|Intervention Model: Single Group Assignment|Masking: None (Open Label)|Primary Purpose: Treatment","2021P000648","December 2021","October 2022","December 2022","November 22, 2021",,"November 22, 2021","Beth Israel Deaconess Medical Center, Boston, Massachusetts, United States",,"https://ClinicalTrials.gov/show/NCT05128383"
267,"NCT05097287","Study Assessing the Long-term Effect of Dupilumab on Prevention of Lung Function Decline in Adult Patients With Uncontrolled Moderate to Severe Asthma",,"Recruiting","No Results Available","Asthma","Drug: Dupilumab|Drug: Placebo","Rate of change from week 8 to week 52 on post-BD FEV1 slope in FeNO population|Rate of change from week 8 to week 52 on post-BD FEV1 slope in the Total population|Rate of change from week 8 to week 104 on post-BD FEV1 slope in the FeNO population|Change from baseline to week 52 in pre-BD FEV1 in FeNO and Total populations|Change from baseline to week 52 in post-BD FEV1 in FeNO and Total populations|Annualized severe exacerbation rate during the 52-week period in FeNO and Total populations|Change from baseline to week 52 in fractional exhaled nitric oxide (FeNO) levels in FeNO and Total populations|Change from baseline to week 52 in Asthma Control Questionnaire 7 items (ACQ-7) in FeNO and Total populations|Change from baseline to week 52 in pre-BD FEV1 % predicted in FeNO and Total populations|Change from baseline to week 52 in Forced Vital Capacity (FVC) in FeNO and Total populations|Rate of change from week 8 to week 104 on post-BD FEV1 slope in Total Population|Change from baseline to week 104 in pre-BD FEV1 in FeNO and Total populations|Change from baseline to week 104 in post-BD FEV1 in FeNO and Total populations|Annualized severe exacerbation rate during the 104-week period in FeNO and Total populations|Change from baseline to week 104 in FeNO levels in FeNO and Total populations|Change from baseline to week 104 in ACQ-7 in FeNO and Total populations|Change from baseline to week 104 in pre-BD FEV1 % predicted in FeNO and Total populations|Change from baseline to week 104 FVC in FeNO and Total populations|Change from baseline to week 52 in Asthma Quality Of Life Questionnaire with Standardized Activities (AQLQ(S)) in FeNO and Total populations|Change from baseline to week 104 in AQLQ(S) in FeNO and Total populations|Rate of change from week 8 to week 156 on post-BD FEV1 slope in FeNO and Total populations|Incidence of treatment-emergent adverse events (TEAEs) and serious adverse events (SAEs)|Incidence of adverse events of special interest (AESIs)","Sanofi|Regeneron Pharmaceuticals","All","18 Years and older   (Adult, Older Adult)","Phase 4","1828","Industry","Interventional","Allocation: Randomized|Intervention Model: Parallel Assignment|Masking: Quadruple (Participant, Care Provider, Investigator, Outcomes Assessor)|Primary Purpose: Treatment","LPS16676|2021-003903-16","December 16, 2021","June 28, 2025","October 15, 2027","October 28, 2021",,"February 18, 2022","Investigational Site Number :8400001, Cullman, Alabama, United States|Investigational Site Number :8400037, Bakersfield, California, United States|Investigational Site Number :8400032, Aventura, Florida, United States|Investigational Site Number :8400079, Miami, Florida, United States|Investigational Site Number :8400007, Owensboro, Kentucky, United States|Investigational Site Number :8400043, Rochester, Michigan, United States|Investigational Site Number :8400055, Bellevue, Nebraska, United States|Investigational Site Number :8400012, Gastonia, North Carolina, United States|Investigational Site Number :8400093, Tulsa, Oklahoma, United States|Investigational Site Number :8400042, Pittsburgh, Pennsylvania, United States|Investigational Site Number :8400026, Greenville, South Carolina, United States|Investigational Site Number :8400006, Rapid City, South Dakota, United States|Investigational Site Number :8400062, Houston, Texas, United States|Investigational Site Number :8400080, Houston, Texas, United States|Investigational Site Number :1240011, Toronto, Ontario, Canada|Investigational Site Number :4100002, Seoul, Seoul-teukbyeolsi, Korea, Republic of|Investigational Site Number :4100005, Seoul, Seoul-teukbyeolsi, Korea, Republic of",,"https://ClinicalTrials.gov/show/NCT05097287"
268,"NCT05094570","Interleukin-4Ra Blockade by Dupilumab Decreases Staphylococcus Colonization and Increases Microbial Diversity in CRSwNP",,"Not yet recruiting","No Results Available","Nasal Polyps|Staphylococcus Aureus","Drug: Dupilumab Prefilled Syringe","To demonstrate that dupilumab reduces staphylococcus aureus|To correlate reduction in Staph aureus with improvements in clinical status|To demonstrate that dupilumab increases microbial diversity","University of Virginia|Regeneron Pharmaceuticals","All","18 Years to 65 Years   (Adult, Older Adult)","Not Applicable","20","Other|Industry","Interventional","Allocation: N/A|Intervention Model: Single Group Assignment|Masking: None (Open Label)|Primary Purpose: Treatment","HSR210309","February 1, 2022","December 31, 2023","December 31, 2024","October 26, 2021",,"December 28, 2021",,,"https://ClinicalTrials.gov/show/NCT05094570"
269,"NCT05064085","Capecitabine In Combination With Cemiplimab In Patient With Metastatic Breast Cancer",,"Recruiting","No Results Available","Hormone Receptor-positive Breast Cancer","Drug: Cemiplimab|Drug: Capecitabine","Recommended Phase 2 Dose (RP2D)|Objective Response Rate (ORR)|Clinical Benefit Rate (CBR)|Progression Free Survival (PFS)","H. Lee Moffitt Cancer Center and Research Institute|Regeneron Pharmaceuticals","All","18 Years and older   (Adult, Older Adult)","Phase 1","12","Other|Industry","Interventional","Allocation: Non-Randomized|Intervention Model: Parallel Assignment|Masking: None (Open Label)|Primary Purpose: Treatment","MCC-20902|R2810-ONC-20109","October 12, 2021","September 2024","September 2024","October 1, 2021",,"March 2, 2022","Moffitt Cancer Center, Tampa, Florida, United States",,"https://ClinicalTrials.gov/show/NCT05064085"
270,"NCT05049122","Dupilumab in Japanese Patients With Chronic Rhinosinusitis With Nasal Polyp (SINUS-M52)",,"Not yet recruiting","No Results Available","Chronic Rhinosinusitis With Nasal Polyps","Drug: Dupilumab SAR231893","Proportion of participants with nasal polyp score (NPS) improvement from baseline ≥1 at Week 24|Change from baseline to Week 24 in bilateral NPS|Change from baseline to Week 24 in in nasal congestion/obstruction (NC) symptom severity score using the CRSwNP nasal symptom diary|Change from baseline to Week 24 in opacification of sinuses assessed by computerized tomography (CT) scan using the Lund Mackay (LMK) score|Change from baseline to Week 24 in total symptom score (TSS)|Change from baseline to Week 24 in loss of smell symptom severity score using the nasal symptom diary|Change from baseline to Week 24 in visual analogue scale (VAS) for rhinosinusitis|Incidence of treatment-emergent adverse events (TEAEs), treatment-emergent serious adverse events (TESAEs), and TEAEs leading to treatment discontinuation","Sanofi|Regeneron Pharmaceuticals","All","18 Years and older   (Adult, Older Adult)","Phase 4","25","Industry","Interventional","Allocation: N/A|Intervention Model: Single Group Assignment|Masking: None (Open Label)|Primary Purpose: Treatment","LPS16872","September 28, 2021","December 28, 2022","June 27, 2023","September 17, 2021",,"September 17, 2021",,,"https://ClinicalTrials.gov/show/NCT05049122"
271,"NCT05036733","Effects of Interleukin (IL)- 4R-alpha Inhibition on Respiratory Microbiome and Immunologic Correlates in Severe Asthma",,"Recruiting","No Results Available","Asthma","Drug: Dupilumab","Changes in alpha-diversity of respiratory microbiota|Change in beta-diversity of respiratory microbiota|Change in relative abundances of microbiota members|Change in respiratory bacterial burden|Changes in alpha-diversity of stool microbiota|Change in beta-diversity of stool microbiota|Forced expiratory volume ( FEV1) / forced vital capacity (FVC) ratio|Forced expiratory volume (FEV1)|Change in Fractional exhaled nitric oxide (FeNO)|Asthma Control Test (ACT)|Mini Asthma Quality of Life Questionnaire Score (mAQLQ)|Sino-nasal outcome test (SNOT-22)|Change in prescribed maintenance corticosteroid use (inhaled or oral), between baseline and 4 months.|Number of asthma exacerbations requiring at least 3 days of oral corticosteroids","University of Michigan|Regeneron Pharmaceuticals","All","18 Years and older   (Adult, Older Adult)","Phase 4","15","Other|Industry","Interventional","Allocation: N/A|Intervention Model: Single Group Assignment|Masking: None (Open Label)|Primary Purpose: Basic Science","HUM00196809","February 22, 2022","July 2023","December 2023","September 8, 2021",,"March 4, 2022","University of Michigan, Ann Arbor, Michigan, United States",,"https://ClinicalTrials.gov/show/NCT05036733"
272,"NCT05013723","Impact of Monoclonal Antibody Treatment on Post-Acute COVID-19 Syndrome","MAbPACs","Not yet recruiting","No Results Available","Post-acute COVID-19 (PACS), or ""Long COVID"" Syndrome","Other: Surveys","Post-acute COVID-19 symptom score (out of 60)|Medically attended visits|Healthcare costs|Diagnostic test costs|Mental health validated psychometric surveys: Depression (PHQ-9),PTSD (PC-PTSD-5)|Post COVID-19 Function Status Scale|Mental health validated psychometric survey: Anxiety (GAD-7)|Quality of life (SF-12)|Primary Care Post-Traumatic Stress Disorder 5","Intermountain Health Care, Inc.|Regeneron Pharmaceuticals","All","18 Years and older   (Adult, Older Adult)",,"260","Other|Industry","Observational","Observational Model: Case-Control|Time Perspective: Retrospective","MAbPACs","August 23, 2021","February 28, 2022","April 1, 2022","August 19, 2021",,"August 19, 2021","Intermountain Medical Center, Murray, Utah, United States",,"https://ClinicalTrials.gov/show/NCT05013723"
273,"NCT04998604","EValuating trEatment RESponses of Dupilumab Versus Omalizumab in Type 2 Patients","EVEREST","Recruiting","No Results Available","Chronic Rhinosinusitis With Nasal Polyps|Asthma","Drug: Dupilumab|Drug: Omalizumab|Drug: Placebo","Change from baseline to Week 24 in Nasal Polyp Score (NPS)|Change from baseline to Week 24 in University of Pennsylvania Smell Identification Test (UPSIT)|Change from baseline to Week 24 in the loss of smell score of the CRSwNP Nasal Symptom Diary|Change from baseline to Week 24 in the nasal congestion (NC) score of the CRSwNP Nasal Symptom Diary|Change from baseline to Week 24 in pre-bronchodilator forced expiratory volume in 1 second (FEV1)|Change from baseline to Week 24 in Total Symptom Score (TSS) derived from the CRSwNP Nasal Symptom Diary|Change from baseline to Week 24 in 22-Item Sino-nasal Outcome Test (SNOT-22) and|Change from baseline to Week 24 in SNOT-22 nasal domain score|Change from baseline to Week 24 in Nasal Peak Inspiratory Flow (NPIF)|Change from baseline to Week 24 in rhinosinusitis visual analogue scale (VAS)|Change from baseline to Week 24 in 7-item Asthma Control Questionnaire (ACQ-7)|Incidence of treatment-emergent adverse events (TEAEs) and serious adverse events (SAEs)|Incidence of adverse events of special interest (AESIs)","Sanofi|Regeneron Pharmaceuticals","All","18 Years and older   (Adult, Older Adult)","Phase 4","422","Industry","Interventional","Allocation: Randomized|Intervention Model: Parallel Assignment|Masking: Triple (Participant, Investigator, Outcomes Assessor)|Primary Purpose: Treatment","LPS16747|2021-000829-27|U1111-1255-4713","September 27, 2021","October 17, 2023","February 7, 2024","August 10, 2021",,"February 21, 2022","Investigational Site Number :8400018, Tucson, Arizona, United States|Investigational Site Number :8400013, Louisville, Kentucky, United States|Investigational Site Number :8400016, Columbia, Missouri, United States|Investigational Site Number :8400015, Rochester, New York, United States|Investigational Site Number :8400014, Columbus, Ohio, United States|Investigational Site Number :8400019, Houston, Texas, United States|Investigational Site Number :8400017, Saint George, Utah, United States|Investigational Site Number :0560003, Bruxelles, Belgium|Investigational Site Number :0560001, Gent, Belgium|Investigational Site Number :0560002, Leuven, Belgium|Investigational Site Number :2030007, Benesov, Czechia|Investigational Site Number :2030001, Hradec Kralove, Czechia|Investigational Site Number :2030003, Ostrava - Poruba, Czechia|Investigational Site Number :2030002, Pardubice, Czechia|Investigational Site Number :2030012, Plzen, Czechia|Investigational Site Number :2030010, Praha 10, Czechia|Investigational Site Number :2030006, Praha 2, Czechia|Investigational Site Number :2030008, Praha 4, Czechia|Investigational Site Number :2030004, Praha 5 - Motol, Czechia|Investigational Site Number :2460001, Helsinki, Finland|Investigational Site Number :2500009, Creteil, France|Investigational Site Number :2500008, Kremlin Bicetre, France|Investigational Site Number :2500006, La Roche sur Yon, France|Investigational Site Number :2500002, Lille, France|Investigational Site Number :2500004, Marseille, France|Investigational Site Number :2500005, Montpellier, France|Investigational Site Number :2500001, Nantes, France|Investigational Site Number :2500007, Toulouse, France|Investigational Site Number :2500003, Vandoeuvre-les-nancy, France|Investigational Site Number :2760001, Münster, Germany|Investigational Site Number :3480007, Budapest, Hungary|Investigational Site Number :3480004, Budapest, Hungary|Investigational Site Number :3480006, Edelény, Hungary|Investigational Site Number :3480002, Pécs, Hungary|Investigational Site Number :3800001, Rozzano, Milano, Italy|Investigational Site Number :6160008, Warszawa, Mazowieckie, Poland|Investigational Site Number :6160005, Katowice, Slaskie, Poland|Investigational Site Number :6160004, Poznan, Wielkopolskie, Poland|Investigational Site Number :6160001, Krakow, Poland|Investigational Site Number :6160006, Sroda Wielkopolska, Poland|Investigational Site Number :6200003, Aveiro, Portugal|Investigational Site Number :7240001, Sevilla, Andalucia, Spain|Investigational Site Number :7240005, Barcelona, Barcelona [Barcelona], Spain|Investigational Site Number :7240003, Jerez de la Frontera, Cádiz, Spain|Investigational Site Number :7240002, Santiago de Compostela, Galicia [Galicia], Spain|Investigational Site Number :7240004, Madrid / Madrid, Madrid, Comunidad De, Spain|Investigational Site Number :7240006, Pamplona, Navarra, Spain|Investigational Site Number :7520003, Göteborg, Sweden|Investigational Site Number :7520002, Lund, Sweden|Investigational Site Number :7520001, Stockholm, Sweden|Investigational Site Number :8260003, Wigan, Lancashire, United Kingdom|Investigational Site Number :8260002, Manchester, United Kingdom|Investigational Site Number :8260001, Newcastle upon Tyne, United Kingdom",,"https://ClinicalTrials.gov/show/NCT04998604"
274,"NCT04988074","Trial of Cemiplimab, or Cemip-Chemo Followed by Biomarker-guided Treatment for Pts w/HPV H&N Ca","MINIMA","Recruiting","No Results Available","HPV-Related Squamous Cell Carcinoma","Drug: Cemiplimab","2-year progression free survival rate|Change in Quality of life as measured by MD Anderson Dysphagia Inventory (MDADI)|Change in quality of life as measured by the Sydney Swallow Questionnaire (SSQ).|Change in swallow function as measured by the Sydney Swallow Questionnaire (SSQ).|Change in swallow function as measured by the MD Anderson Dysphagia Inventory.|To determine 2-year overall survival (OS) for the entire cohort|To determine 2-year rates of locoregional and distant control for the entire cohort|Number of grade 3 toxicities|Number of grade 4 toxicities|Number of grade 3 Immune-related adverse events (irAE)|Number of grade 4 Immune-related adverse events (irAE)","Sidney Kimmel Comprehensive Cancer Center at Johns Hopkins|Regeneron Pharmaceuticals","All","18 Years and older   (Adult, Older Adult)","Phase 2","32","Other|Industry","Interventional","Allocation: Non-Randomized|Intervention Model: Parallel Assignment|Masking: None (Open Label)|Primary Purpose: Treatment","J20118|IRB00259330","December 13, 2021","November 2024","August 2026","August 3, 2021",,"January 12, 2022","Johns Hopkins University, Baltimore, Maryland, United States",,"https://ClinicalTrials.gov/show/NCT04988074"
275,"NCT04831450","Phase 2 Trial of Maintenance Cemiplimab for Head and Neck Squamous Cell Carcinoma (HNSCC)",,"Not yet recruiting","No Results Available","Head and Neck Squamous Cell Carcinoma|HNSCC|Squamous Cell Carcinoma of the Larynx|Squamous Cell Carcinoma of the Oral Cavity|Squamous Cell Carcinoma of Hypopharynx","Drug: Cemiplimab-Rwlc","Progression-Free Survival (PFS)|PFS Rate|Overall Survival (OS)|Incidence of Treatment-Related Toxicity and Adverse Events","University of Miami|Regeneron Pharmaceuticals","All","18 Years and older   (Adult, Older Adult)","Phase 2","44","Other|Industry","Interventional","Allocation: N/A|Intervention Model: Single Group Assignment|Masking: None (Open Label)|Primary Purpose: Treatment","20200543","April 1, 2022","April 1, 2025","April 1, 2025","April 5, 2021",,"January 24, 2022","University of Miami, Miami, Florida, United States",,"https://ClinicalTrials.gov/show/NCT04831450"
276,"NCT04823130","Dupilumab Effect on Pruritus Neuro-mechanisms in Patients With Atopic Dermatitis","DIFFEREN-STAD","Recruiting","No Results Available","Dermatitis Atopic","Drug: Dupilumab SAR231893","Change from baseline in intraepidermal nerve fiber density|Change from baseline in nerve fiber branching|Change from baseline in the outcome of peak pruritus assessed by numeric rating scale (NRS)|Change from baseline in the outcome of eczema and severity index (EASI)|Change from baseline in the outcome of scoring atopic dermatitis (SCORAD)|Change from baseline in the outcome of Patient-Reported Outcomes Measurement Information (PROMIS-itch)|Change from baseline in the outcome of Patient Oriented Eczema Measure (POEM)|Change from baseline in the outcome of Patient Oriented Eczema Measure Dermatology Life Quality Index (DLQI)|Change from baseline in the outcome of Atopic Dermatitis Control Tool (ADCT)|Change from baseline in the outcome of Sleep quality NRS|Change from baseline in the outcome of Skin Pain NRS|Change from baseline in the outcome of Skin Sensitivity NRS|Change from baseline in the outcome of Skin Burning NRS|Proportion of AD participants reaching pruritus NRS ≥4 point improvement from baseline|Incidence of treatment-emergent adverse events","Sanofi|Regeneron Pharmaceuticals","All","18 Years and older   (Adult, Older Adult)","Phase 4","44","Industry","Interventional","Allocation: N/A|Intervention Model: Single Group Assignment|Masking: None (Open Label)|Primary Purpose: Basic Science","LPS16763|2020-003542-36|U1111-1251-5658","April 6, 2021","July 20, 2022","August 17, 2022","March 30, 2021",,"September 24, 2021","Investigational Site Number 8400001, Miami, Florida, United States|Investigational Site Number 8400002, East Windsor, New Jersey, United States|Investigational Site Number 2760001, Münster, Germany",,"https://ClinicalTrials.gov/show/NCT04823130"
277,"NCT04751487","Study to Assess the Efficacy, Safety, and Tolerability of SAR440340/REGN3500/Itepekimab in Chronic Obstructive Pulmonary Disease (COPD) (AERIFY-2)",,"Recruiting","No Results Available","Chronic Obstructive Pulmonary Disease","Drug: Itepekimab SAR440340|Drug: Placebo","Annualized rate of moderate or severe acute exacerbation of COPD (AECOPD) in former smokers|Change from baseline in pre-bronchodilator (BD) forced expiratory volume in 1 second (FEV1) at Week 52 in former smokers|Change from baseline in post-BD FEV1 at Week 52 in former smokers|Change from baseline in pre-BD FEV1 at Week 24 in former smokers|Time to first moderate or severe AECOPD in former smokers|Annualized rate of severe AECOPD in former smokers|Time to first severe AECOPD in former smokers|Annualized rate of corticosteroid-treated AECOPD in former smokers|Change from baseline in Evaluating Respiratory Symptoms in COPD (E-RS:COPD) total score at Week 52 in former smokers|Rate of change in post-BD FEV1 (L) from baseline (post-BD FEV1 slope) in former smokers|Change from baseline in St. George's Respiratory Questionnaire (SGRQ) total score at Week 52 in former smokers|Proportion of participants with a decrease from baseline of at least 4 points in SGRQ total score at Week 52 in former smokers|Incidence of treatment-emergent adverse events (TEAEs), adverse event of special interests (AESIs), serious adverse events (SAEs), and adverse events (AEs) leading to permanent treatment discontinuation in former smokers|Incidence of potentially clinically significant laboratory test, vital signs, and electrocardiogram (ECGs) abnormalities in former smokers|Functional itepekimab concentrations in serum in former smokers|Incidence of treatment-emergent anti-itepekimab antibodies responses in former smokers|Annualized rate of moderate or severe AECOPD in current smokers|Change from baseline in pre-BD FEV1 at Week 52 in current smokers|Incidence of TEAEs, AESIs, SAEs, and AEs leading to permanent treatment discontinuation in current smokers|Incidence of potentially clinically significant laboratory, vital signs, and ECGs abnormalities in current smokers|Functional itepekimab concentrations in serum in current smokers|Incidence of treatment-emergent anti-itepekimab antibodies responses in current smokers","Sanofi|Regeneron Pharmaceuticals","All","40 Years to 85 Years   (Adult, Older Adult)","Phase 3","1170","Industry","Interventional","Allocation: Randomized|Intervention Model: Parallel Assignment|Masking: Quadruple (Participant, Care Provider, Investigator, Outcomes Assessor)|Primary Purpose: Treatment","EFC16819|2020-001819-24|U1111-1250-2843","February 12, 2021","February 2024","July 2024","February 12, 2021",,"February 18, 2022","Investigational Site Number :8400017, Alabaster, Alabama, United States|Investigational Site Number :8400185, San Diego, California, United States|Investigational Site Number :8400011, Greenacres City, Florida, United States|Investigational Site Number :8400018, Loxahatchee Groves, Florida, United States|Investigational Site Number :8400007, Miami, Florida, United States|Investigational Site Number :8400009, Miami, Florida, United States|Investigational Site Number :8400015, Ocala, Florida, United States|Investigational Site Number :8400016, Orlando, Florida, United States|Investigational Site Number :8400008, Tampa, Florida, United States|Investigational Site Number :8400013, Woodstock, Georgia, United States|Investigational Site Number :8400005, Las Vegas, Nevada, United States|Investigational Site Number :8400002, Charlotte, North Carolina, United States|Investigational Site Number :8400004, Columbus, Ohio, United States|Investigational Site Number :8400014, Toledo, Ohio, United States|Investigational Site Number :8400001, Edmond, Oklahoma, United States|Investigational Site Number :8400175, Charleston, South Carolina, United States|Investigational Site Number :8400003, Gaffney, South Carolina, United States|Investigational Site Number :8400020, Rapid City, South Dakota, United States|Investigational Site Number :8400012, Boerne, Texas, United States|Investigational Site Number :0320008, Caba, Buenos Aires, Argentina|Investigational Site Number :0320001, Caba, Buenos Aires, Argentina|Investigational Site Number :0320005, Pergamino, Buenos Aires, Argentina|Investigational Site Number :0320007, Rosario, Santa Fe, Argentina|Investigational Site Number :0320003, Rosario, Santa Fe, Argentina|Investigational Site Number :0320004, Rosario, Santa Fe, Argentina|Investigational Site Number :0320002, Buenos Aires, Argentina|Investigational Site Number :0320006, Caba, Argentina|Investigational Site Number :0760001, Porto Alegre, Rio Grande Do Sul, Brazil|Investigational Site Number :1000008, Blagoevgrad, Bulgaria|Investigational Site Number :1000013, Dupnitsa, Bulgaria|Investigational Site Number :1000004, Gabrovo, Bulgaria|Investigational Site Number :1000009, Haskovo, Bulgaria|Investigational Site Number :1000005, Montana, Bulgaria|Investigational Site Number :1000002, Plovdiv, Bulgaria|Investigational Site Number :1000012, Ruse, Bulgaria|Investigational Site Number :1000003, Ruse, Bulgaria|Investigational Site Number :1000001, Sofia, Bulgaria|Investigational Site Number :1000006, Sofia, Bulgaria|Investigational Site Number :1240006, Sherwood Park, Alberta, Canada|Investigational Site Number :1240014, Kelowna, British Columbia, Canada|Investigational Site Number :1240016, Penticton, British Columbia, Canada|Investigational Site Number :1240012, Moncton, New Brunswick, Canada|Investigational Site Number :1240021, Ajax, Ontario, Canada|Investigational Site Number :1240020, Burlington, Ontario, Canada|Investigational Site Number :1240009, Toronto, Ontario, Canada|Investigational Site Number :1240018, Windsor, Ontario, Canada|Investigational Site Number :1240004, Sherbrooke, Quebec, Canada|Investigational Site Number :1240005, St-charles Borrommee, Quebec, Canada|Investigational Site Number :1240019, Terrebonne, Quebec, Canada|Investigational Site Number :1240001, Trois-Rivieres, Quebec, Canada|Investigational Site Number :1240002, Victoriaville, Quebec, Canada|Investigational Site Number :1240003, Quebec, Canada|Investigational Site Number :2030001, Jindrichuv Hradec III, Czechia|Investigational Site Number :2030009, Mesice, Czechia|Investigational Site Number :2030005, Mlada Boleslav, Czechia|Investigational Site Number :2030008, Olomouc, Czechia|Investigational Site Number :2030004, Ostrava, Czechia|Investigational Site Number :2030002, Praha 4, Czechia|Investigational Site Number :2030006, Teplice, Czechia|Investigational Site Number :2030007, Varnsdorf, Czechia|Investigational Site Number :2080001, Hvidovre, Denmark|Investigational Site Number :2080003, Vejle, Denmark|Investigational Site Number :2500001, Lyon, France|Investigational Site Number :2500002, Montpellier, France|Investigational Site Number :2500003, Pessac, France|Investigational Site Number :2500004, Reims, France|Investigational Site Number :2760004, Berlin, Germany|Investigational Site Number :2760005, Frankfurt am Main, Germany|Investigational Site Number :2760002, Hamburg, Germany|Investigational Site Number :2760006, Koblenz, Germany|Investigational Site Number :2760007, Leipzig, Germany|Investigational Site Number :2760003, Lübeck, Germany|Investigational Site Number :2760001, Mainz, Germany|Investigational Site Number :3480002, Balassagyarmat, Hungary|Investigational Site Number :3480005, Edelény, Hungary|Investigational Site Number :3480004, Hajdunánás, Hungary|Investigational Site Number :3480007, Nyíregyháza, Hungary|Investigational Site Number :3480003, Püspökladány, Hungary|Investigational Site Number :3480001, Százhalombatta, Hungary|Investigational Site Number :3760003, Jerusalem, Israel|Investigational Site Number :3760002, Jerusalem, Israel|Investigational Site Number :3760001, Petah-Tikva, Israel|Investigational Site Number :3760004, Rehovot, Israel|Investigational Site Number :3920023, Nagoya-shi, Aichi, Japan|Investigational Site Number :3920020, Nagoya-shi, Aichi, Japan|Investigational Site Number :3920005, Fukuoka-shi, Fukuoka, Japan|Investigational Site Number :3920027, Fukuoka-shi, Fukuoka, Japan|Investigational Site Number :3920030, Kurume-shi, Fukuoka, Japan|Investigational Site Number :3920032, Yanagawa-shi, Fukuoka, Japan|Investigational Site Number :3920031, Gifu-shi, Gifu, Japan|Investigational Site Number :3920015, Mizunami-shi, Gifu, Japan|Investigational Site Number :3920010, Hiroshima-shi, Hiroshima, Japan|Investigational Site Number :3920021, Kure-shi, Hiroshima, Japan|Investigational Site Number :3920035, Kure-shi, Hiroshima, Japan|Investigational Site Number :3920004, Sapporo-shi, Hokkaido, Japan|Investigational Site Number :3920013, Himeji-shi, Hyogo, Japan|Investigational Site Number :3920009, Sakaide-shi, Kagawa, Japan|Investigational Site Number :3920014, Takamatsu-shi, Kagawa, Japan|Investigational Site Number :3920033, Kawasaki-shi, Kanagawa, Japan|Investigational Site Number :3920011, Konan-ku, Yokohama-shi, Kanagawa, Japan|Investigational Site Number :3920022, Yokohama-Shi, Kanagawa, Japan|Investigational Site Number :3920034, Ikoma-shi, Nara, Japan|Investigational Site Number :3920003, Osaka-shi, Osaka, Japan|Investigational Site Number :3920026, Osaka-shi, Osaka, Japan|Investigational Site Number :3920007, Sakai-shi, Osaka, Japan|Investigational Site Number :3920006, Yao-shi, Osaka, Japan|Investigational Site Number :3920028, Hamamatsu-shi, Shizuoka, Japan|Investigational Site Number :3920002, Hamamatsu-shi, Shizuoka, Japan|Investigational Site Number :3920036, Sano-shi, Tochigi, Japan|Investigational Site Number :3920017, Chuo-ku, Tokyo, Japan|Investigational Site Number :3920024, Chuo-ku, Tokyo, Japan|Investigational Site Number :3920019, Itabashi-ku, Tokyo, Japan|Investigational Site Number :3920029, Kiyose-City, Tokyo, Japan|Investigational Site Number :3920001, Meguro-ku, Tokyo, Japan|Investigational Site Number :3920025, Shibuya-ku, Tokyo, Japan|Investigational Site Number :3920016, Shinagawa-ku, Tokyo, Japan|Investigational Site Number :3920037, Shinagawa-ku, Tokyo, Japan|Investigational Site Number :3920008, Hokkaido, Japan|Investigational Site Number :4100002, Wonju, Gangwon-do, Korea, Republic of|Investigational Site Number :4100003, Incheon, Incheon-gwangyeoksi, Korea, Republic of|Investigational Site Number :4100004, Seoul, Seoul-teukbyeolsi, Korea, Republic of|Investigational Site Number :4100001, Seoul, Korea, Republic of|Investigational Site Number :4840008, Monterrey, Nuevo León, Mexico|Investigational Site Number :4840009, Monterrey, Nuevo León, Mexico|Investigational Site Number :4840002, Monterrey, Nuevo León, Mexico|Investigational Site Number :4840010, Aguascalientes, Mexico|Investigational Site Number :4840003, Chihuahua, Mexico|Investigational Site Number :4840007, Durango, Mexico|Investigational Site Number :4840006, Mexico City, Mexico|Investigational Site Number :4840001, Monterrey, Nuevo León, Mexico|Investigational Site Number :4840004, Veracruz, Mexico|Investigational Site Number :5280005, Arnhem, Netherlands|Investigational Site Number :5280006, Nijmegen, Netherlands|Investigational Site Number :5280008, Zutphen, Netherlands|Investigational Site Number :5280004, Zwolle, Netherlands|Investigational Site Number :5780001, Lørenskog, Norway|Investigational Site Number :6160006, Lublin, Lubelskie, Poland|Investigational Site Number :6160005, Wolomin, Mazowieckie, Poland|Investigational Site Number :6160001, Bialystok, Podlaskie, Poland|Investigational Site Number :6160003, Malbork, Pomorskie, Poland|Investigational Site Number :6160002, Katowice, Slaskie, Poland|Investigational Site Number :6160007, Piekary Slaskie, Slaskie, Poland|Investigational Site Number :6200002, Braga, Portugal|Investigational Site Number :6200011, Guarda, Portugal|Investigational Site Number :6430002, Moscow, Russian Federation|Investigational Site Number :6430001, Moscow, Russian Federation|Investigational Site Number :6430005, Moscow, Russian Federation|Investigational Site Number :6430003, Saint-Petersburg, Russian Federation|Investigational Site Number :6430004, St-Petersburg, Russian Federation|Investigational Site Number :6430006, Ulyanovsk, Russian Federation|Investigational Site Number :7100002, Bellville, South Africa|Investigational Site Number :7100013, Benoni, South Africa|Investigational Site Number :7100001, Cape Town, South Africa|Investigational Site Number :7100005, Durban, South Africa|Investigational Site Number :7100006, Durban, South Africa|Investigational Site Number :7100004, Gatesville, South Africa|Investigational Site Number :7100009, Pretoria, South Africa|Investigational Site Number :7240004, Palma de Mallorca, Balears [Baleares], Spain|Investigational Site Number :7240006, Sant Boi de Llobregat, Barcelona [Barcelona], Spain|Investigational Site Number :7240009, Lleida / Lleida, Catalunya [Cataluña], Spain|Investigational Site Number :7240002, Mérida / Badajoz, Extremadura, Spain|Investigational Site Number :7240007, Madrid / Madrid, Madrid, Comunidad De, Spain|Investigational Site Number :7240008, Pozuelo De Alarcón, Madrid, Spain|Investigational Site Number :7240010, Cáceres, Spain|Investigational Site Number :7240003, Madrid, Spain|Investigational Site Number :7240001, Málaga, Spain|Investigational Site Number :7920005, Balcali Adana, Turkey|Investigational Site Number :7920001, Istanbul, Turkey|Investigational Site Number :7920003, Izmir, Turkey|Investigational Site Number :7920006, Kirikkale, Turkey|Investigational Site Number :7920002, Mersin, Turkey|Investigational Site Number :8260002, Chertsey, Surrey, United Kingdom|Investigational Site Number :8260003, Bradford, United Kingdom|Investigational Site Number :8260005, Liverpool, United Kingdom|Investigational Site Number :8260001, Newcastle upon Tyne, United Kingdom",,"https://ClinicalTrials.gov/show/NCT04751487"
278,"NCT04722523","A Study of Cemiplimab With Chemotherapy and Immunotherapy in People With Head and Neck Cancer",,"Recruiting","No Results Available","Head and Neck Cancer|Head Cancer|Head Cancer Neck|Neck Cancer|Head and Neck Squamous Cell Carcinoma|HNSCC","Drug: Cisplatin|Drug: Carboplatin|Drug: Docetaxel|Drug: Cetuximab|Drug: Cemiplimab|Procedure: Surgical Resection of Primary +/- Neck Dissection|Radiation: Post-operative radiation therapy","Incidence of toxicities graded according to NCI CTCAE","Memorial Sloan Kettering Cancer Center|Regeneron Pharmaceuticals","All","18 Years and older   (Adult, Older Adult)","Phase 1","10","Other|Industry","Interventional","Allocation: N/A|Intervention Model: Sequential Assignment|Masking: None (Open Label)|Primary Purpose: Treatment","20-445","January 20, 2021","June 20, 2023","June 20, 2023","January 25, 2021",,"September 24, 2021","Memoral Sloan Kettering Basking Ridge (Limited Protocol Activities), Basking Ridge, New Jersey, United States|Memoral Sloan Kettering Monmouth (Limited Protocol Activities), Middletown, New Jersey, United States|Memorial Sloan Kettering Bergen (Limited Protocol Activities), Montvale, New Jersey, United States|Memoral Sloan Kettering Westchester (Limited Protocol Activities), Harrison, New York, United States|Memorial Sloan - Kettering Cancer Center, New York, New York, United States",,"https://ClinicalTrials.gov/show/NCT04722523"
279,"NCT04718870","Dupilumab-PEdiatric Skin Barrier Function and LIpidomics STudy in Patients With Atopic Dermatitis","PELISTAD","Recruiting","No Results Available","Dermatitis Atopic","Drug: Dupilumab SAR231893","Percent change from baseline in TEWL after 5 STS assessed on lesional skin in AD patients|Percent change from baseline in TEWL after 20 STS assessed on lesional skin in AD patients|Absolute change from baseline in TEWL after 20 STS assessed on lesional skin in AD patients|Percent change from baseline in TEWL after 20 STS assessed on non-lesional skin in AD patients|Absolute change from baseline in TEWL after 20 STS assessed on non-lesional skin in AD patients|Percent change from baseline in TEWL after 20 STS assessed on normal skin in healthy volunteers|Absolute change from baseline in TEWL after 20 STS assessed on normal skin in healthy volunteers|Percent change from baseline in TEWL after 15 STS assessed on lesional skin in AD patients|Absolute change from baseline in TEWL after 15 STS assessed on lesional skin in AD patients|Percent change from baseline in TEWL after 15 STS assessed on non-lesional skin in AD patients|Absolute change from baseline in TEWL after 15 STS assessed on non-lesional skin in AD patients|Percent change from baseline in TEWL after 15 STS assessed on normal skin in healthy volunteers|Absolute change from baseline in TEWL after 15 STS assessed on normal skin in healthy volunteers|Percent change from baseline in TEWL after 10 STS assessed on lesional skin in AD patients|Absolute change from baseline in TEWL after 10 STS assessed on lesional skin in AD patients|Percent change from baseline in TEWL after 10 STS assessed on non-lesional skin in AD patient|Absolute change from baseline in TEWL after 10 STS assessed on non-lesional skin in AD patient|Percent change from baseline in TEWL after 10 STS assessed on normal skin in healthy volunteer|Absolute change from baseline in TEWL after 10 STS assessed on normal skin in healthy volunteer|Percent change from baseline in TEWL after 5 STS assessed on non-lesional skin in AD patients|Absolute change from baseline in TEWL after 5 STS assessed on non-lesional skin in AD patients|Percent change from baseline in TEWL after 5 STS assessed on normal skin in healthy volunteers|Absolute change from baseline in TEWL after 5 STS assessed on normal skin in healthy volunteers|Percent change in TEWL before STS on lesional skin in AD patients|Absolute change in TEWL before STS on lesional skin in AD patients|Percent change in TEWL before STS on non-lesional skin in AD patients|Absolute change in TEWL before STS on non-lesional skin in AD patients|Percent change in TEWL before STS assessed on normal skin in healthy volunteers|Absolute change in TEWL before STS assessed on normal skin in healthy volunteers|Percent change in TEWL area under the curve for skin barrier function in lesional skin in AD patients|Absolute change in TEWL area under the curve for skin barrier function in lesional skin in AD patients|Percent change in TEWL AUC for skin barrier function in non-lesional skin in AD patients|Absolute change in TEWL AUC for skin barrier function in non-lesional skin in AD patients|Percent change in TEWL AUC for skin barrier function in normal skin in healthy volunteers|Absolute change in TEWL AUC for skin barrier function in normal skin in healthy volunteers|Percent change in TEWL after STS assessed on lesional skin in AD patients|Absolute change in TEWL after STS assessed on lesional skin in AD patients|Percent change in TEWL after STS assessed on non-lesional skin in AD patients|Absolute change in TEWL after STS assessed on non-lesional skin in AD patients|Percent change in TEWL after STS assessed on normal skin in healthy volunteers|Absolute change in TEWL after STS assessed on normal skin in healthy volunteers","Sanofi|Regeneron Pharmaceuticals","All","6 Years to 11 Years   (Child)","Phase 4","48","Industry","Interventional","Allocation: Non-Randomized|Intervention Model: Parallel Assignment|Masking: None (Open Label)|Primary Purpose: Treatment","LPS16764|2020-001518-40|U1111-1255-4378","February 19, 2021","July 21, 2022","October 13, 2022","January 22, 2021",,"March 2, 2022","Investigational Site Number :8400002, Los Angeles, California, United States|Investigational Site Number :8400001, Denver, Colorado, United States|Investigational Site Number :8260001, Sheffield, United Kingdom",,"https://ClinicalTrials.gov/show/NCT04718870"
280,"NCT04706715","LAG3 PET Imaging in Advanced Solid Tumors",,"Recruiting","No Results Available","Metastatic Solid Tumor","Other: 89Zr-DFO-REGN3767|Drug: Cemiplimab","Optimal 89Zr-DFO-REGN3767 dose and PET imaging timepoint|Pharmacokinetics (PK) of 89Zr-DFO-REGN3767|Incidence of adverse events related to 89Zr-DFO-REGN3767 administration as assessed by CTCAE v5.0|Heterogeneity of 89Zr-DFO-REGN3767 antibody tumor uptake|Correlation of tumor tracer uptake with tumor and immune cell LAG3 expression|Correlation of tumor tracer uptake with response to cemiplimab|Assessment of changes in tumor and normal organ uptake","University Medical Center Groningen|Regeneron Pharmaceuticals","All","18 Years and older   (Adult, Older Adult)","Phase 1|Phase 2","38","Other|Industry","Interventional","Allocation: Non-Randomized|Intervention Model: Single Group Assignment|Masking: None (Open Label)|Primary Purpose: Other","202000570","January 18, 2022","September 2024","September 2024","January 13, 2021",,"February 1, 2022","University Medical Center Groninen, Groningen, Netherlands",,"https://ClinicalTrials.gov/show/NCT04706715"
281,"NCT04701983","Study to Assess the Efficacy, Safety, and Tolerability of SAR440340/REGN3500/Itepekimab in Chronic Obstructive Pulmonary Disease (COPD)","AERIFY-1","Recruiting","No Results Available","Chronic Obstructive Pulmonary Disease","Drug: Itepekimab SAR440340|Drug: Placebo","Annualized rate of moderate or severe acute exacerbation of COPD (AECOPD)|Change from baseline in pre-bronchodilator (BD) forced expiratory volume in 1 second (FEV1) at Week 52|Change from baseline in post-BD FEV1 at Week 52|Change from baseline in pre-BD FEV1 at Week 24|Time to first moderate or severe AECOPD|Annualized rate of severe AECOPD|Time to first severe AECOPD|Annualized rate of corticosteroid-treated AECOPD|Change from baseline in Evaluating Respiratory Symptoms in COPD (E-RS:COPD) total score at Week 52|Rate of change in post-BD FEV1 (L) from baseline (post-BD FEV1 slope)|Change from baseline in St. George''s Respiratory Questionnaire (SGRQ) total score at Week 52|Proportion of participants with a decrease from baseline of at least 4 points in SGRQ total score at Week 52|Incidence of treatment-emergent adverse events (TEAEs), adverse event of special interests (AESIs), serious adverse events (SAEs), and adverse events (AEs) leading to permanent treatment discontinuation|Incidence of potentially clinically significant laboratory test, vital signs, and electrocardiogram (ECGs) abnormalities|Functional itepekimab concentrations in serum|Incidence of treatment-emergent anti-itepekimab antibodies responses","Sanofi|Regeneron Pharmaceuticals","All","40 Years to 85 Years   (Adult, Older Adult)","Phase 3","930","Industry","Interventional","Allocation: Randomized|Intervention Model: Parallel Assignment|Masking: Quadruple (Participant, Care Provider, Investigator, Outcomes Assessor)|Primary Purpose: Treatment","EFC16750|2020-001818-38|U1111-1250-2787","December 16, 2020","December 2023","May 2024","January 8, 2021",,"February 18, 2022","Investigational Site Number :8400012, Birmingham, Alabama, United States|Investigational Site Number :8400185, Mobile, Alabama, United States|Investigational Site Number :8400003, Northridge, California, United States|Investigational Site Number :8400180, Boulder, Colorado, United States|Investigational Site Number :8400004, Clearwater, Florida, United States|Investigational Site Number :8400188, Miami Lakes, Florida, United States|Investigational Site Number :8400006, Miami, Florida, United States|Investigational Site Number :8400013, Orlando, Florida, United States|Investigational Site Number :8400183, Atlanta, Georgia, United States|Investigational Site Number :8400007, Lawrenceville, Georgia, United States|Investigational Site Number :8400016, Bangor, Maine, United States|Investigational Site Number :8400177, Bel Air, Maryland, United States|Investigational Site Number :8400002, Saint Charles, Missouri, United States|Investigational Site Number :8400010, Gastonia, North Carolina, United States|Investigational Site Number :8400005, Shelby, North Carolina, United States|Investigational Site Number :8400001, Wilmington, North Carolina, United States|Investigational Site Number :8400011, Winston-Salem, North Carolina, United States|Investigational Site Number :8400014, Cincinnati, Ohio, United States|Investigational Site Number :8400181, Columbia, South Carolina, United States|Investigational Site Number :8400008, Rock Hill, South Carolina, United States|Investigational Site Number :8400015, McKinney, Texas, United States|Investigational Site Number :8400009, Sherman, Texas, United States|Investigational Site Number :8400179, Tomball, Texas, United States|Investigational Site Number :0320001, Caba, Buenos Aires, Argentina|Investigational Site Number :0320002, Caba, Buenos Aires, Argentina|Investigational Site Number :0320003, Rosario, Santa Fe, Argentina|Investigational Site Number :0320004, Mendoza, Argentina|Investigational Site Number :1000005, Dimitrovgrad, Bulgaria|Investigational Site Number :1000001, Sofia, Bulgaria|Investigational Site Number :1000004, Sofia, Bulgaria|Investigational Site Number :1000002, Sofia, Bulgaria|Investigational Site Number :1000003, Stara Zagora, Bulgaria|Investigational Site Number :1520008, Temuco, La Araucanía, Chile|Investigational Site Number :1520007, Curicó, Maule, Chile|Investigational Site Number :1520002, Talca, Maule, Chile|Investigational Site Number :1520009, Santiago, Reg Metropolitana De Santiago, Chile|Investigational Site Number :1520003, Santiago, Reg Metropolitana De Santiago, Chile|Investigational Site Number :1520001, Santiago, Reg Metropolitana De Santiago, Chile|Investigational Site Number :1520006, Santiago, Reg Metropolitana De Santiago, Chile|Investigational Site Number :1520004, Santiago, Reg Metropolitana De Santiago, Chile|Investigational Site Number :1520005, Quillota, Valparaíso, Chile|Investigational Site Number :1560003, Baotou, China|Investigational Site Number :1560004, Beijing, China|Investigational Site Number :1560030, Beijing, China|Investigational Site Number :1560014, Beijing, China|Investigational Site Number :1560002, Changchun, China|Investigational Site Number :1560012, Changsha, China|Investigational Site Number :1560013, Changsha, China|Investigational Site Number :1560047, Changsha, China|Investigational Site Number :1560001, Chengdu, China|Investigational Site Number :1560040, Chengdu, China|Investigational Site Number :1560032, Chongqing, China|Investigational Site Number :1560025, Guangzhou, China|Investigational Site Number :1560006, Guangzhou, China|Investigational Site Number :1560036, Haikou, China|Investigational Site Number :1560022, Hangzhou, China|Investigational Site Number :1560039, Hangzhou, China|Investigational Site Number :1560017, Hefei, China|Investigational Site Number :1560008, Hohhot, China|Investigational Site Number :1560010, Hohhot, China|Investigational Site Number :1560027, Jinan, China|Investigational Site Number :1560031, Nanchang, China|Investigational Site Number :1560038, Nanchang, China|Investigational Site Number :1560035, Nanjing, China|Investigational Site Number :1560023, Nanning, China|Investigational Site Number :1560015, Pingxiang, China|Investigational Site Number :1560043, Shanghai, China|Investigational Site Number :1560034, Shanghai, China|Investigational Site Number :1560009, Shanghai, China|Investigational Site Number :1560005, Shenyang, China|Investigational Site Number :1560020, Shenzhen, China|Investigational Site Number :1560028, Shijiazhuang, China|Investigational Site Number :1560024, Tianjin, China|Investigational Site Number :1560019, Wenzhou, China|Investigational Site Number :1560029, Wuhan, China|Investigational Site Number :1560016, Xi'an, China|Investigational Site Number :1560007, Xuzhou, China|Investigational Site Number :1560026, Yangzhou, China|Investigational Site Number :1560021, Yinchuan, China|Investigational Site Number :1560041, Zhanjiang, China|Investigational Site Number :1560018, Zunyi, China|Investigational Site Number :2030001, Jindrichuv Hradec III, Czechia|Investigational Site Number :2030004, Ostrava, Czechia|Investigational Site Number :2030002, Praha 4, Czechia|Investigational Site Number :2030003, Praha 8, Czechia|Investigational Site Number :3000005, Athens, Greece|Investigational Site Number :3000004, Heraklion, Greece|Investigational Site Number :3000001, Ioannina, Greece|Investigational Site Number :3000002, Thessaloniki, Greece|Investigational Site Number :3480004, Debrecen, Hungary|Investigational Site Number :3480001, Gödöllö, Hungary|Investigational Site Number :3480002, Mosonmagyaróvár, Hungary|Investigational Site Number :3480003, Pécs, Hungary|Investigational Site Number :3760003, Jerusalem, Israel|Investigational Site Number :3760002, Jerusalem, Israel|Investigational Site Number :3760006, Kfar-Saba, Israel|Investigational Site Number :3760001, Petah-Tikva, Israel|Investigational Site Number :3760004, Rehovot, Israel|Investigational Site Number :3760007, Tel Aviv, Israel|Investigational Site Number :3800003, Rozzano, Milano, Italy|Investigational Site Number :3800004, Foggia, Puglia, Italy|Investigational Site Number :3800005, Catania, Italy|Investigational Site Number :3800001, Ferrara, Italy|Investigational Site Number :3800007, Verona, Italy|Investigational Site Number :4840001, Guadalajara, Jalisco, Mexico|Investigational Site Number :4840007, Cuernavaca, Morelos, Mexico|Investigational Site Number :4840002, Cdmx, México, Mexico|Investigational Site Number :4840003, San Juan del Rio, Querétaro, Mexico|Investigational Site Number :4840004, Benito Juarez, Mexico|Investigational Site Number :6160004, Wroclaw, Dolnoslaskie, Poland|Investigational Site Number :6160003, Warszawa, Mazowieckie, Poland|Investigational Site Number :6160001, Bialystok, Podlaskie, Poland|Investigational Site Number :6160002, Ostrowiec Swietokrzyski, Swietokrzyskie, Poland|Investigational Site Number :6420005, Bragadiru, Romania|Investigational Site Number :6420006, Brasov, Romania|Investigational Site Number :6420012, Bucaresti, Romania|Investigational Site Number :6420002, Cluj-Napoca, Romania|Investigational Site Number :6420007, Codlea, Romania|Investigational Site Number :6420010, Deva, Romania|Investigational Site Number :6420001, Iasi, Romania|Investigational Site Number :6420009, Oradea, Romania|Investigational Site Number :6420003, Timisoara, Romania|Investigational Site Number :6430001, Moscow, Russian Federation|Investigational Site Number :6430003, Moscow, Russian Federation|Investigational Site Number :6430002, Moscow, Russian Federation|Investigational Site Number :6430005, Saint-Petersburg, Russian Federation|Investigational Site Number :6430006, St-Petersburg, Russian Federation|Investigational Site Number :7030009, Bardejov, Slovakia|Investigational Site Number :7030007, Humenne, Slovakia|Investigational Site Number :7030003, Levice, Slovakia|Investigational Site Number :7030002, Poprad, Slovakia|Investigational Site Number :7030001, Spisska Nova Ves, Slovakia|Investigational Site Number :1580005, Kaohsiung, Taiwan|Investigational Site Number :1580002, New Taipei City, Taiwan|Investigational Site Number :1580007, Taichung, Taiwan|Investigational Site Number :1580006, Taichung, Taiwan|Investigational Site Number :1580004, Taipei, Taiwan|Investigational Site Number :1580003, Taipei, Taiwan|Investigational Site Number :1580008, Yunlin, Taiwan|Investigational Site Number :8040003, Ivano-Frankivsk, Ukraine|Investigational Site Number :8040007, Ivano-Frankivsk, Ukraine|Investigational Site Number :8040008, Kharkiv, Ukraine|Investigational Site Number :8040006, Kharkiv, Ukraine|Investigational Site Number :8040004, Kyiv, Ukraine|Investigational Site Number :8040001, Kyiv, Ukraine|Investigational Site Number :8040005, Kyiv, Ukraine|Investigational Site Number :8040011, Kyiv, Ukraine",,"https://ClinicalTrials.gov/show/NCT04701983"
282,"NCT04684524","Dupilumab in Allergic Fungal Rhinosinusitis (AFRS) (LIBERTY-AFRS-AI)",,"Recruiting","No Results Available","Allergic Fungal Rhinosinusitis","Drug: Dupilumab SAR231893|Drug: Placebo","Proportion of patients who receive SCS and/or undergo/plan to undergo surgery for AFRS during the planned study treatment period|Change from baseline in sinus opacifications assessed by computerized tomography (CT) scans using the Lund Mackay (LMK) score at Week 52|Change from baseline in sinus opacifications assessed by CT scans using the LMK score at Week 24|Proportion of patients who receive SCS during the planned study treatment period|Proportion of patients who undergo or plan to undergo surgery for AFRS during the planned study treatment period|Total SCS dose during the planned study treatment|Total number of SCS courses during the planned study treatment|Days with SCS treatment during the planned study treatment|Change from baseline in monthly average nasal congestion/obstruction score from the Nasal symptom Diary at Week 24 and Week 52|Change from Baseline in the monthly average anterior/posterior rhinorrhea score from the Nasal Symptom Diary at Week 24 and Week 52|Change from baseline in endoscopic NPS compared to placebo at Week 24 and Week 52|Change from baseline in 22-item sino-nasal outcome test (SNOT-22) total score at Week 24 and Week 52|Change from baseline in monthly average total symptom score (TSS) derived from the Nasal Symptom Diary at Week 24 and Week 52|Change from baseline in visual analog scale (VAS) rhinosinusitis at Week 24 and Week 52|Change from baseline in University of Pennsylvania smell identification test (UPSIT) at Week 24 and Week 52|Change from baseline in the score of decreased/loss of smell using the Nasal Symptom Diary at Week 24 and Week 52|Change from baseline to Week 52 in three Dimensional CT volumetric measurement of the paranasal sinuses|Incidence of treatment-emergent adverse events (TEAEs) or serious adverse events (SAEs) through Week 52|Dupilumab concentration in serum over time|Percent change from baseline in total IgE in serum compared to placebo over the 52 weeks treatment period|Percent change from baseline in fungal-specific IgE in serum compared to placebo over the 52 weeks treatment period|Incidence of treatment-emergent anti-drug antibodies (ADA) to dupilumab over time","Sanofi|Regeneron Pharmaceuticals","All","6 Years and older   (Child, Adult, Older Adult)","Phase 3","120","Industry","Interventional","Allocation: Randomized|Intervention Model: Parallel Assignment|Masking: Quadruple (Participant, Care Provider, Investigator, Outcomes Assessor)|Primary Purpose: Treatment","EFC16724|2020-002999-12|U1111-1246-7549","December 1, 2020","December 30, 2022","November 21, 2023","December 24, 2020",,"February 4, 2022","Investigational Site Number :8400005, Roseville, California, United States|Investigational Site Number :8400001, Tampa, Florida, United States|Investigational Site Number :8400009, Atlanta, Georgia, United States|Investigational Site Number :8400004, Louisville, Kentucky, United States|Investigational Site Number :8400002, Charleston, South Carolina, United States|Investigational Site Number :8400013, Nashville, Tennessee, United States|Investigational Site Number :8400010, Houston, Texas, United States|Investigational Site Number :8400008, Norfolk, Virginia, United States|Investigational Site Number :0320003, Caba, Buenos Aires, Argentina|Investigational Site Number :0320001, Caba, Buenos Aires, Argentina|Investigational Site Number :0320005, Rosario, Santa Fe, Argentina|Investigational Site Number :0320002, Buenos Aires, Argentina|Investigational Site Number :0320004, Mendoza, Argentina|Investigational Site Number :1560005, Beijing, China|Investigational Site Number :1560001, Beijing, China|Investigational Site Number :1560004, Changsha, China|Investigational Site Number :1560003, Chengdu, China|Investigational Site Number :1560013, Fuzhou, China|Investigational Site Number :1560010, Haikou, China|Investigational Site Number :1560006, Hangzhou, China|Investigational Site Number :1560012, Hefei, China|Investigational Site Number :1560002, Nanjing, China|Investigational Site Number :1560011, Qingdao, China|Investigational Site Number :1560009, Shanghai, China|Investigational Site Number :1560008, Taiyuan, China|Investigational Site Number :3760001, Petah-Tikva, Israel|Investigational Site Number :3760002, Rehovot, Israel|Investigational Site Number :3920005, Narita-shi, Chiba, Japan|Investigational Site Number :3920006, Shizuoka-shi, Shizuoka, Japan|Investigational Site Number :3920008, Bunkyo-ku, Tokyo, Japan|Investigational Site Number :3920007, Bunkyo-ku, Tokyo, Japan|Investigational Site Number :3920001, Meguro-ku, Tokyo, Japan|Investigational Site Number :3920004, Ota-ku, Tokyo, Japan|Investigational Site Number :3920003, Shinagawa-ku, Tokyo, Japan|Investigational Site Number :7920004, Adana, Turkey|Investigational Site Number :7920001, Istanbul, Turkey|Investigational Site Number :7920003, Izmir, Turkey|Investigational Site Number :7920005, Malatya, Turkey",,"https://ClinicalTrials.gov/show/NCT04684524"
283,"NCT04681729","Dupilumab for the Treatment of Chronic Inducible Cold Urticaria in Patients Who Remain Symptomatic Despite the Use of H1-antihistamine (LIBERTY-CINDU CUrIADS)",,"Recruiting","No Results Available","Cold Urticaria","Drug: Dupilumab SAR231893|Drug: Placebo|Drug: Non sedating H1-antihistamine","Proportion of participants with negative ice cube provocation test at Week 24 compared with placebo|Change from baseline in urticaria control test at Week 24 compared with placebo|Proportion of well-controlled participants at Week 24 compared with placebo|Proportion of participants with an improvement of ≥3 in UCT-4 item from baseline to Week 24 compared with placebo|Change from baseline in local wheal intensity at the provocation site at Week 12 and 24 using the wheal intensity Likert scale compared with placebo|Change from baseline in local itch severity at the provocation site at Week 12 and 24 using the Peak Pruritus Numerical Rating Scale (NRS) compared with placebo|Change from baseline in local skin burning sensation at the provocation site at Week 12 and Week 24 using the peak burning sensation NRS compared with placebo|Change from baseline in local pain severity at the provocation site at Week 12 and Week 24 using the peak pain sensation NRS compared with placebo|Proportion of participants with negative ice cube provocation test at Week 12 compared with placebo|Proportion of participants with cold exposure triggered urticaria signs and symptoms at Week 12 and Week 24 as measured by ColdUAS compared with placebo|Proportion of days with cold exposure triggered urticaria signs and symptoms at Week 12 and Week 24 as measured by ColdUAS compared with placebo|Proportion of participants with severe cold exposure triggered urticaria signs and symptoms at Week 12 and Week 24 as measured by ColdUAS compared with placebo|Proportion of days with severe cold exposure triggered urticaria signs and symptoms at Week 12 and Week 24 as measured by ColdUAS compared with placebo|Change from baseline in health-related quality-of-life (HRQoL) as measured by Dermatology Life Quality Index (DLQI) at Week 24 compared with placebo|Change from baseline in HRQoL as measured by Children's Dermatology Life Quality Index (CDLQI) at Week 24 compared with placebo|Patient Global Impression of Change (PGIC) of primary acquired chronic inducible ColdU at Week 12 and Week 24 compared with placebo|Change from baseline in Patient Global Impression of Severity (PGIS) of primary acquired chronic inducible ColdU at Week 12 and Week 24 compared with placebo|Change from baseline in Cold Urticaria Quality of Life (ColdU QoL) at Week 24 compared with placebo|Time to first rescue therapy for primary acquired chronic induced ColdU during the planned treatment period compared with placebo|Proportion of participants receiving rescue therapy for primary acquired chronic inducible ColdU during the planned treatment period compared with placebo|Proportion of participants with cold exposure urticaria requiring emergency medical care visit or treatment with epinephrine|Percentages of participants experiencing treatment--emergent adverse events (TEAEs) or serious adverse events (SAEs)|Incidence of treatment-emergent antidrug antibodies (ADA) against dupilumab over time","Sanofi|Regeneron Pharmaceuticals","All","12 Years to 80 Years   (Child, Adult, Older Adult)","Phase 3","78","Industry","Interventional","Allocation: Randomized|Intervention Model: Parallel Assignment|Masking: Quadruple (Participant, Care Provider, Investigator, Outcomes Assessor)|Primary Purpose: Treatment","EFC16720|2020-003756-33|U1111-1246-6913","December 10, 2020","October 14, 2022","January 6, 2023","December 23, 2020",,"February 17, 2022","Investigational Site Number :8400001, San Diego, California, United States|Investigational Site Number :8400007, Boise, Idaho, United States|Investigational Site Number :8400003, Owensboro, Kentucky, United States|Investigational Site Number :8400005, Baltimore, Maryland, United States|Investigational Site Number :8400006, New York, New York, United States|Investigational Site Number :8400004, Cincinnati, Ohio, United States|Investigational Site Number :0320001, Caba, Buenos Aires, Argentina|Investigational Site Number :0320005, Caba, Buenos Aires, Argentina|Investigational Site Number :0320006, Caba, Buenos Aires, Argentina|Investigational Site Number :0320002, Rosario, Santa Fe, Argentina|Investigational Site Number :0320004, San Miguel de Tucuman, Tucumán, Argentina|Investigational Site Number :0320003, Buenos Aires, Argentina|Investigational Site Number :1240008, Edmonton, Alberta, Canada|Investigational Site Number :1240010, Edmonton, Alberta, Canada|Investigational Site Number :1240007, Burlington, Ontario, Canada|Investigational Site Number :1240009, Hamilton, Ontario, Canada|Investigational Site Number :1240001, Toronto, Ontario, Canada|Investigational Site Number :1240005, Saint-Charles-Borromée, Quebec, Canada|Investigational Site Number :1240006, Sherbrooke, Quebec, Canada|Investigational Site Number :1240002, Quebec, Canada|Investigational Site Number :2760002, Berlin, Germany|Investigational Site Number :2760004, Dresden, Germany|Investigational Site Number :2760007, Erlangen, Germany|Investigational Site Number :2760006, Hannover, Germany|Investigational Site Number :2760005, Leipzig, Germany|Investigational Site Number :2760001, Mainz, Germany|Investigational Site Number :3920003, Hiroshima-shi, Hiroshima, Japan|Investigational Site Number :3920005, Sapporo-shi, Hokkaido, Japan|Investigational Site Number :3920008, Kamimashiki Gun, Kumamoto, Japan|Investigational Site Number :3920007, Sakai-shi, Osaka, Japan|Investigational Site Number :3920004, Izumo-shi, Shimane, Japan|Investigational Site Number :3920001, Itabashi-ku, Tokyo, Japan|Investigational Site Number :3920010, Koto-ku, Tokyo, Japan|Investigational Site Number :3920011, Tachikawa-shi, Tokyo, Japan|Investigational Site Number :3920009, Habikino-shi, Japan|Investigational Site Number :3920002, Nagoya-shi, Japan",,"https://ClinicalTrials.gov/show/NCT04681729"
284,"NCT04678882","Dupilumab in Japanese Patients With Atopic Dermatitis",,"Active, not recruiting","No Results Available","Atopic Dermatitis","Drug: Placebo|Drug: Dupilumab SAR231893","Proportion of participants with Eczema Area and Severity Index (EASI)-75 (≥75% improvement from baseline EASI)|Percent change in EASI score|Percent change in weekly average of daily worst itch numerical rating scale (NRS) for participants aged ≥6 years to <12 years old|Proportion of participants with Investigator's Global Assessment (IGA) 0 or 1|Percent change in weekly average of daily worst peak pruritus NRS for participants aged ≥12 years to <18 years old|Percent change in weekly average of daily worst scratch/itch NRS for participants aged ≥6 months to <6 years old|Percent change for intensity of pruritus|Proportion of participants with EASI-50 (≥50% improvement from baseline)|Proportion of participants with EASI-90 (≥90% improvement from baseline)|Change in percent body surface area (BSA) affected by atopic dermatitis (AD)|Change in Children's Dermatology Life Quality Index (CDLQI) (≥4 years)|Change in Infants' Dermatitis Quality of Life Index (IDQOL) (<4 years)|Change in Patient Oriented Eczema Measure (POEM)|Change in weekly average of daily worst peak pruritus NRS for participants aged ≥12 years to <18 years old|Change in weekly average of daily worst itch NRS for participants aged ≥6 years to <12 years old|Change in weekly average of daily worst scratch/itch NRS for participants aged ≥6 months to <6 years old","Sanofi|Regeneron Pharmaceuticals","All","6 Months to 17 Years   (Child)","Phase 3","62","Industry","Interventional","Allocation: Randomized|Intervention Model: Parallel Assignment|Masking: Double (Participant, Investigator)|Primary Purpose: Treatment","EFC16823|2020-002601-26","January 15, 2021","December 14, 2021","September 2023","December 22, 2020",,"February 10, 2022","Investigational Site Number :3920011, Nagoya-shi, Aichi, Japan|Investigational Site Number :3920014, Toyoake-shi, Aichi, Japan|Investigational Site Number :3920015, Fukutsu-shi, Fukuoka, Japan|Investigational Site Number :3920001, Hiroshima-shi, Hiroshima, Japan|Investigational Site Number :3920013, Sapporo-shi, Hokkaido, Japan|Investigational Site Number :3920009, Sapporo-shi, Hokkaido, Japan|Investigational Site Number :3920008, Kobe-shi, Hyogo, Japan|Investigational Site Number :3920007, Kobe-shi, Hyogo, Japan|Investigational Site Number :3920003, Sagamihara-shi, Kanagawa, Japan|Investigational Site Number :3920017, Yokohama-shi, Kanagawa, Japan|Investigational Site Number :3920010, Yokohama-shi, Kanagawa, Japan|Investigational Site Number :3920006, Tsu-shi, Mie, Japan|Investigational Site Number :3920020, Sakai-shi, Osaka, Japan|Investigational Site Number :3920019, Toyonaka-shi, Osaka, Japan|Investigational Site Number :3920016, Kumagaya-shi, Saitama, Japan|Investigational Site Number :3920023, Chuo-ku, Tokyo, Japan|Investigational Site Number :3920002, Itabashi-ku, Tokyo, Japan|Investigational Site Number :3920012, Koto-ku, Tokyo, Japan|Investigational Site Number :3920022, Toshima-ku, Tokyo, Japan|Investigational Site Number :3920021, Habikino-shi, Japan",,"https://ClinicalTrials.gov/show/NCT04678882"
285,"NCT04678856","Dupilumab in CRSsNP (Liberty CRSsNP ORION)",,"Recruiting","No Results Available","Chronicrhinosinusitis Without Nasalpolyps|Sinusitis|Chronic Sinusitis|Sinus Disorder|Respiratory Disorder","Drug: Dupilumab SAR231893|Drug: Placebo","Part A and B: Change from baseline to Week 24 in opacification of sinuses assessed by CT scan using the Lund Mackay (LMK) score|Part A and B: Change from baseline to Week 24 in sTSS|Part A: Change from baseline to Week 52 in opacification of sinuses assessed by CT scan using the LMK score|Part A: Change from baseline to Week 52 in sTSS|Part A and B: Change from baseline in NC symptom severity score|Part A and B: Change from baseline in anterior/posterior rhinorrhea severity score|Part A and B: Change from baseline in facial pain/pressure severity score|Part A and B: Change from baseline in loss of smell symptom severity score|Part A and B: Change from baseline in University of Pennsylvania smell identification test (UPSIT)|Part A and B: Change from baseline in Sino-Nasal Outcome Test-22 item (SNOT-22)|Part A and B: Change from baseline in rhinosinusitis severity visual analog scale (VAS)|Part A and B: Change from baseline in forced expiratory volume (FEV1) in CRSsNP with asthma population|Part A and B: Change from baseline in asthma control questionnaire 6 items (ACQ-6) in CRSsNP with asthma population|Part A and B: Change from baseline in opacification of sinuses assessed by CT scan using the LMK score in CRSsNP with asthma population|Part A and B: Change from baseline in sTSS in CRSsNP with asthma population|Part A and B: Proportion of participants with CRSsNP worsening/acute sinusitis during the planned study treatment period|Part A and B: Annualized rate of SCS course during the planned study treatment period|Part A and B: Normalized Enrichment Score (NES) for the relative change from baseline in the type 2 inflammation transcriptome signature|Part A: Change from baseline to Weeks 24 and 52 in opacification of sinuses assessed by CT scan using LMK score in the screening blood eosinophil count ≥300 cells/mm3 population|Part A: Change from baseline to Weeks 24 and 52 in sTSS in the screening blood eosinophil count ≥300 cells/mm3 population|Part A: Change from baseline in NC symptom severity score in the screening blood eosinophil count ≥300 cells/mm3 population|Part A: Change from baseline in anterior/posterior rhinorrhea severity score in the screening blood eosinophil count ≥300 cells/mm3 population|Part A: Change from baseline in facial pain/pressure severity score in the screening blood eosinophil count ≥300 cells/mm3 population|Part A: Change from baseline in loss of smell symptom severity score in the screening blood eosinophil count ≥300 cells/mm3 population|Part A: Change from baseline in UPSIT in the screening blood eosinophil count ≥300 cells/mm3 population|Part A: Change from baseline in SNOT-22 in the screening blood eosinophil count ≥300 cells/mm3 population|Part A: Change from baseline in rhinosinusitis severity VAS in the screening blood eosinophil count ≥300 cells/mm3 population|Part A: Proportion of participants with CRSsNP worsening/acute sinusitis during the planned study treatment period in the screening blood eosinophil count ≥300 cells/mm3 population|Part A: Annualized rate of SCS course during the planned study treatment period in the screening blood eosinophil count ≥300 cells/mm3 population|Part A: NES for the relative change from baseline in the type 2 inflammation transcriptome signature in the screening blood eosinophil count ≥300 cells/mm3 population|Part A and B: Incidence of treatment-emergent adverse events (TEAEs), of treatment-emergent serious AEs (TESAEs), and TEAEs leading to treatment discontinuation|Part A and B: Dupilumab concentration in serum|Part A and B: Incidence of treatment-emergent anti-drug antibodies (ADA) to dupilumab over time","Sanofi|Regeneron Pharmaceuticals","All","12 Years and older   (Child, Adult, Older Adult)","Phase 3","240","Industry","Interventional","Allocation: Randomized|Intervention Model: Parallel Assignment|Masking: Quadruple (Participant, Care Provider, Investigator, Outcomes Assessor)|Primary Purpose: Treatment","EFC16723|2020-003117-35|U1111-1246-7522","December 2, 2020","July 31, 2023","May 30, 2024","December 22, 2020",,"November 29, 2021","Investigational Site Number :8400010, Roseville, California, United States|Investigational Site Number :8400008, Denver, Colorado, United States|Investigational Site Number :8400003, Denver, Colorado, United States|Investigational Site Number :8400002, Louisville, Kentucky, United States|Investigational Site Number :8400007, Papillion, Nebraska, United States|Investigational Site Number :8400004, Tulsa, Oklahoma, United States|Investigational Site Number :8400006, Dallas, Texas, United States|Investigational Site Number :8400009, Norfolk, Virginia, United States|Investigational Site Number :0560003, Bruxelles, Belgium|Investigational Site Number :0560002, Gent, Belgium|Investigational Site Number :0560001, Leuven, Belgium|Investigational Site Number :1240010, Hamilton, Ontario, Canada|Investigational Site Number :1240001, Montreal, Quebec, Canada|Investigational Site Number :1240012, Montreal, Quebec, Canada|Investigational Site Number :1240002, Trois-Rivieres, Quebec, Canada|Investigational Site Number :1240005, Quebec, Canada|Investigational Site Number :1240003, Quebec, Canada|Investigational Site Number :3480003, Budapest, Hungary|Investigational Site Number :3480004, Budapest, Hungary|Investigational Site Number :3480001, Pécs, Hungary|Investigational Site Number :6200002, Aveiro, Portugal|Investigational Site Number :6200001, Guimarães, Portugal|Investigational Site Number :6200003, Matosinhos, Portugal|Investigational Site Number :6430006, Moscow, Russian Federation|Investigational Site Number :6430005, Moscow, Russian Federation|Investigational Site Number :6430004, St-Petersburg, Russian Federation|Investigational Site Number :6430002, St-Petersburg, Russian Federation|Investigational Site Number :6430003, St-Petersburg, Russian Federation|Investigational Site Number :6430001, Stavropol, Russian Federation|Investigational Site Number :7240002, Sevilla, Andalucia, Spain|Investigational Site Number :7240001, Barcelona, Barcelona [Barcelona], Spain|Investigational Site Number :7240004, Jerez de la Frontera, Cádiz, Spain|Investigational Site Number :7240006, Santiago de Compostela, Galicia [Galicia], Spain|Investigational Site Number :7240005, Madrid / Madrid, Madrid, Comunidad De, Spain|Investigational Site Number :7240009, Madrid, Madrid, Comunidad De, Spain|Investigational Site Number :7240008, Pamplona, Navarra, Spain|Investigational Site Number :8040005, Dnipro, Ukraine|Investigational Site Number :8040001, Ivano-Frankivsk, Ukraine|Investigational Site Number :8040004, Kharkiv, Ukraine|Investigational Site Number :8040008, Kyiv, Ukraine|Investigational Site Number :8040002, Kyiv, Ukraine|Investigational Site Number :8040007, Kyiv, Ukraine",,"https://ClinicalTrials.gov/show/NCT04678856"
286,"NCT04588948","A Pharmacokinetic stuDy of intRavitreal Aflibercept Injection in Vitrectomized and Non-vitrectomized Eyes With Diabetic Macular Edema","DRAW-2","Not yet recruiting","No Results Available","Diabetic Macular Edema","Drug: Intravitreal Aflibercept","Intravitreal Aflibercept Pharmacokinetics|Plasma aflibercept levels|Correlation of drug concentration with ophthalmic outcomes|Safety Outcomes","Stanford University|Regeneron Pharmaceuticals","All","18 Years and older   (Adult, Older Adult)","Phase 2","60","Other|Industry","Interventional","Allocation: Non-Randomized|Intervention Model: Parallel Assignment|Masking: None (Open Label)|Primary Purpose: Treatment","58689|VGFTe-DME-2041","December 2020","June 2021","December 2021","October 19, 2020",,"October 19, 2020","Byers Eye Institute, Palo Alto, California, United States",,"https://ClinicalTrials.gov/show/NCT04588948"
287,"NCT04550962","Description of Characteristics, Such as Age, Previous and Concurrent Treatments, Associated Diseases, of Patients With Asthma Treated With Dupilumab (DUPIXENT)","REVEAL","Recruiting","No Results Available","Asthma","Drug: Dupilumab SAR231893","Baseline Characteristics: Socio-demographics|Baseline Characteristics: Medical history|Baseline Characteristics: Disease characteristics|Baseline Characteristics: Concomitant treatments for asthma|Dupixent and other asthma treatment use patterns|Lung function|Annualized exacerbation rate|Patient reported outcomes|Healthcare Resource Utilization|Number of participants with adverse events (AE) and serious adverse events (SAE)","Sanofi|Regeneron Pharmaceuticals","All","12 Years and older   (Child, Adult, Older Adult)",,"800","Industry","Observational","Observational Model: Cohort|Time Perspective: Prospective","OBS16688","November 2, 2020","May 27, 2026","May 27, 2026","September 16, 2020",,"February 21, 2022","Investigational Site Number :0320001, Ciudad de Buenos Aires, Buenos Aires, Argentina|Investigational Site Number :0320008, Ciudad Autonoma Buenos Aires, Argentina|Investigational Site Number :1520001, Santiago, Reg Metropolitana De Santiago, Chile|Investigational Site Number :1520002, Quillota, Valparaíso, Chile|Investigational Site Number :1700004, Bogota, Colombia|Investigational Site Number :1700003, Bucaramanga, Colombia|Investigational Site Number :3760008, Ashdod, Israel|Investigational Site Number :3760004, Ashkelon, Israel|Investigational Site Number :3760005, Jerusalem, Israel|Investigational Site Number :3760003, Jerusalem, Israel|Investigational Site Number :3760002, Petah-Tikva, Israel|Investigational Site Number :3760006, Rehovot, Israel|Investigational Site Number :3760007, Tel Aviv, Israel|Investigational Site Number :4140001, Kuwait, Kuwait|Investigational Site Number :4220001, Beirut, Lebanon|Investigational Site Number :4840001, Guadalajara, Jalisco, Mexico|Investigational Site Number :4840003, Durango, Mexico|Investigational Site Number :6340001, Doha, Qatar|Investigational Site Number :6430005, Chelyabinsk, Russian Federation|Investigational Site Number :6430007, Moscow, Russian Federation|Investigational Site Number :6430004, Moscow, Russian Federation|Investigational Site Number :6430006, Rostov-on-Don, Russian Federation|Investigational Site Number :6430008, Saratov, Russian Federation|Investigational Site Number :6430002, Stavropol, Russian Federation|Investigational Site Number :6820008, Jeddah, Saudi Arabia|Investigational Site Number :6820005, Jeddah, Saudi Arabia|Investigational Site Number :6820004, Makkah, Saudi Arabia|Investigational Site Number :6820002, Riyadh, Saudi Arabia|Investigational Site Number :7020002, Singapore, Singapore|Investigational Site Number :7020001, Singapore, Singapore|Investigational Site Number :7840001, Dubai, United Arab Emirates|Investigational Site Number :7840004, Sharjah, United Arab Emirates|Investigational Site Number :7840002, Sharjah, United Arab Emirates",,"https://ClinicalTrials.gov/show/NCT04550962"
288,"NCT04526899","Trial With BNT111 and Cemiplimab in Combination or as Single Agents in Patients With Anti-PD-1-refractory/Relapsed, Unresectable Stage III or IV Melanoma",,"Recruiting","No Results Available","Melanoma Stage III|Melanoma Stage IV|Unresectable Melanoma","Biological: BNT111|Biological: Cemiplimab","Objective response rate (ORR) - Arm: BNT111 + cemiplimab|Objective response rate - Arm: BNT111 monotherapy and Arm: Cemiplimab monotherapy|Duration of response (DOR) according to RECIST 1.1|Disease control rate (DCR) according to RECIST 1.1|Time to response (TTR) according to RECIST 1.1|Progression-free survival (PFS) according to RECIST 1.1|ORR according to RECIST 1.1 as assessed by the investigator|DOR according to RECIST 1.1 as assessed by the investigator|DCR according to RECIST 1.1 as assessed by the investigator|TTR according to RECIST 1.1 as assessed by the investigator|PFS according to RECIST 1.1 as assessed by the investigator|Overall survival (OS) - Arm: BNT111 + cemiplimab|Occurrence of treatment-emergent adverse events (TEAE) within a patient including Grade ≥3, serious and/or fatal TEAE by relationship|Occurrence of immune-related adverse events (irAE)|Occurrence of dose reduction and discontinuation of trial treatment within a patient due to TEAE|Occurrence of abnormal laboratory parameters (hematology) within a patient|Changes in laboratory parameters (hematology) compared to baseline|Occurrence of abnormal laboratory parameters (clinical chemistry) within a patient|Changes in laboratory parameters (clinical chemistry) compared to baseline|Occurrence of abnormal laboratory parameters (coagulation factors) within a patient|Changes in laboratory parameters (coagulation factors) compared to baseline|Occurrence of abnormal laboratory parameters (endocrine tests) within a patient|Changes in laboratory parameters (endocrine tests) compared to baseline|Occurrence of abnormal laboratory parameters (serology) within a patient|Changes in laboratory parameters (serology) compared to baseline|Occurrence of abnormal laboratory parameters (urinalysis) within a patient|Changes in laboratory parameters (urinalysis) compared to baseline|Occurrence of abnormal vital signs parameters (body temperature) within a patient|Changes in vital signs parameters (body temperature) compared to baseline|Occurrence of abnormal vital signs parameters (pulse rate) within a patient|Changes in vital signs parameters (pulse rate) compared to baseline|Occurrence of abnormal vital signs parameters (blood pressure) within a patient|Changes in vital signs parameters (blood pressure) compared to baseline|Occurrence of abnormal vital signs parameters (respiratory rate) within a patient|Changes in vital signs parameters (respiratory rate) compared to baseline|Mean changes from baseline in the global health status score of the European Organization for Research and Treatment of Cancer Quality of Life Questionnaire Core 30 items (EORTC QLQ-C30)|Mean changes from baseline in scores of the EORTC QLQ C30 functional and symptoms scales|Time to first clinically meaningful deterioration in global health status score as measured by EORTC QLQ-C30|Time to first clinically meaningful deterioration in symptoms and functioning as measured by EORTC QLQ-C30","BioNTech SE|Regeneron Pharmaceuticals","All","18 Years and older   (Adult, Older Adult)","Phase 2","180","Industry","Interventional","Allocation: Randomized|Intervention Model: Parallel Assignment|Masking: None (Open Label)|Primary Purpose: Treatment","BNT111-01|2020-002195-12","May 19, 2021","May 2022","December 2023","August 26, 2020",,"December 7, 2021","University Of Arizona College Of Medicine, Tucson, Arizona, United States|Saint John's Health Center - John Wayne Cancer Institute (JWCI), Santa Monica, California, United States|Sylvester Comprehensive Cancer Center/ UMHC, Miami, Florida, United States|Lewis Hall Singletary Oncology Center at John D. Archbold Memorial Hospital, Thomasville, Georgia, United States|Rush University Medical Center, Chicago, Illinois, United States|Norton Cancer Institute, Louisville, Kentucky, United States|Oncology Hematology West P.C. dba Nebraska Cancer Specialists, Omaha, Nebraska, United States|Atlantic Health System / Morristown Medical Center, Morristown, New Jersey, United States|Guthrie Medical Group, PC, Sayre, Pennsylvania, United States|Tennessee Oncology Nashville / Sarah Cannon, Nashville, Tennessee, United States|Inova Dwight and Martha Schar Cancer Institute, Fairfax, Virginia, United States|Border Medical Oncology, East Albury, Australia|Helios Klinikum Erfurt, Erfurt, Germany|Universitätsklinikum Schleswig-Holstein (UKSH), Campus Kiel Hautkrebszentrum Kiel, Kiel, Germany|Universitaetsklinikum Leipzig, Leipzig, Germany|Universitaetsmedizin der Johannes Gutenberg Universitat Mainz KoeR, Mainz, Germany|Istituto Di Ricovero E Cura A Carattere Scientifico - Istituto Tumori Giovanni Paolo Ii, Bari, Italy|Azienda ospedaliera universitaria Bologna, Bologna, Italy|Fondazione del Piemonte per l'Oncologia, Istituto di Candiolo (IRCCs), Candiolo, Italy|Istituto Scientifico Romagnolo per lo Studio e la Cura dei Tumpori (IRST), Meldola, Italy|Universita di Siena -Azienda Ospedaliera Universitaria Senese-Policlincio Santa Maria Alle Scotte, Siena, Italy|AOU Citta della Salute e della Scienza di Torino, Turin, Italy|Hospital Clinic de Barcelona, Barcelona, Spain|Institut Català d'Oncologia l'Hospitalet, Barcelona, Spain|Hospital General Universitario Gregorio Maranon, Madrid, Spain|Hospital Universitario Puerta de Hierro - Majadahonda, Madrid, Spain|Hospital Universitario Virgen del Rocio, Sevilla, Spain",,"https://ClinicalTrials.gov/show/NCT04526899"
289,"NCT04520308","An Open-label, Single-arm Longitudinal Study With Dupilumab for Patients With Atopic Dermatitis",,"Not yet recruiting","No Results Available","Atopic Dermatitis|AD|Eczema","Drug: Dupilumab Only Product","Mean change from baseline in nerve length at week 24 in patients with AD|Mean change from baseline in dermal and epidermal nerve branching at week 24 for patients with AD|Mean change from baseline in nerve substance P expression at week 24 for patients with AD|Mean change from baseline in nerve thymic stromal lymphopoietin (TSLP) receptor and IL-31 receptor expression at week 24 for patients with AD|Mean change from baseline in nerve IL-4 receptor alpha (IL-4Rα) expression at week 24 for patients with AD|Mean change from baseline in keratinocyte TSLP expression at week 24 for patients with AD|Mean change from baseline in eosinophil number and proximity to cutaneous nerves at week 24 for patients with AD|Mean change from baseline in extracellular eosinophil peroxidase (EPX) staining at week 24 for patients with AD|Difference between normal control patients and patients with AD at baseline in mean dermal nerve branching|Difference between normal control patients and patients with AD at baseline in mean nerve substance P expression|Difference between normal control patients and patients with AD at baseline in mean nerve TSLP receptor and IL-31 receptor expression|Difference between normal control patients and patients with AD at baseline in mean nerve IL-4Rα expression|Difference between normal control patients and patients with AD at baseline in mean keratinocyte TSLP expression|Difference between normal control patients and patients with AD at baseline in mean eosinophil number and proximity to cutaneous nerves|Difference between normal control patients and patients with AD at baseline in mean extracellular EPX staining|Mean change from baseline scores in pruritus numeric rating scale (NRS) at week 24 for patients with AD|Mean change from baseline in patient global assessment (PGA) at week 24 for patients with AD|Mean change from baseline in investigator's global assessment (IGA) at week 24 for patients with AD|Mean change from baseline in Eczema Area and Severity Index (EASI) at week 24 for patients with AD|Mean change from baseline in Skindex-3 scale ratings at week 24 for patients with AD|Mean change from baseline in Sensitive Scale-10 at week 24 for patients with AD|Mean change from baseline in non-lesional skin sensitivity (stinger assay, measured with skin symptom scale) at week 24 for patients with AD|Mean change from baseline in lesional and non-lesional skin hydration (Trans-Epidermic Water Loss, measured in g/h·m2) at week 24 for patients with AD|Mean change from baseline in lesional and non-lesional skin hydration scores (corneometry, measured in units) at week 24 for patients with AD|Mean change from baseline scores in lesional and non-lesional at-home skin barrier testing (measuring skin hydration by Trans-Epidermic Water Loss and Stratum Corneum Hydration, assessed in units) using a GP device at 24 weeks for patients with AD.","Eric Simpson|Regeneron Pharmaceuticals|Oregon Health and Science University","All","18 Years and older   (Adult, Older Adult)","Phase 4","45","Other|Industry","Interventional","Allocation: N/A|Intervention Model: Single Group Assignment|Masking: None (Open Label)|Primary Purpose: Diagnostic","STUDY00021061","September 1, 2020","February 26, 2021","March 31, 2021","August 20, 2020",,"August 20, 2020",,,"https://ClinicalTrials.gov/show/NCT04520308"
290,"NCT04502862","Dupilumab Asthma Sleep Study","MORPHEO","Recruiting","No Results Available","Asthma","Drug: SAR231893|Drug: Placebo","Change in sleep disturbance score in Asthma Sleep Disturbance Questionnaire|Change in the number of nocturnal awakenings in Sleep Diary|Change in PROMIS sleep-related impairment assessment|Change in sleep quality in Sleep Diary|Change in restorative sleep in Sleep Diary|Change in WASO in Sleep Diary|Change in WASO (actigraphy data)|Change in daytime and nighttime asthma symptoms in Asthma Daytime Symptom Diary (ADSD) and Asthma Nighttime Symptom Diary (ANSD)|Change in pre-bronchodilator (BD) FEV1|Incidence of adverse events","Sanofi|Regeneron Pharmaceuticals","All","18 Years to 65 Years   (Adult, Older Adult)","Phase 4","260","Industry","Interventional","Allocation: Randomized|Intervention Model: Parallel Assignment|Masking: Triple (Participant, Care Provider, Investigator)|Primary Purpose: Treatment","LPS16677|2020-001217-20|U1111-1249-6054","August 10, 2020","June 2022","September 14, 2022","August 6, 2020",,"February 14, 2022","Investigational Site Number :8400003, Bakersfield, California, United States|Investigational Site Number :8400009, Los Angeles, California, United States|Investigational Site Number :8400001, San Jose, California, United States|Investigational Site Number :8400011, Colorado Springs, Colorado, United States|Investigational Site Number :8400012, Sarasota, Florida, United States|Investigational Site Number :8400004, Owensboro, Kentucky, United States|Investigational Site Number :8400010, Bellevue, Nebraska, United States|Investigational Site Number :8400005, Edmond, Oklahoma, United States|Investigational Site Number :8400007, Medford, Oregon, United States|Investigational Site Number :8400008, Charleston, South Carolina, United States|Investigational Site Number :8400006, Boerne, Texas, United States|Investigational Site Number :0320001, Caba, Buenos Aires, Argentina|Investigational Site Number :1240003, Burlington, Ontario, Canada|Investigational Site Number :1240005, Toronto, Ontario, Canada|Investigational Site Number :1240009, Quebec, Canada|Investigational Site Number :1240008, Windsor, Canada|Investigational Site Number :2760002, Berlin, Germany|Investigational Site Number :2760005, Frankfurt am Main, Germany|Investigational Site Number :2760003, Hannover, Germany|Investigational Site Number :2760001, Koblenz, Germany|Investigational Site Number :2760004, Leipzig, Germany|Investigational Site Number :2760006, Lübeck, Germany|Investigational Site Number :3800006, Monserrato, Cagliari, Italy|Investigational Site Number :3800001, Orbassano, Torino, Italy|Investigational Site Number :3800004, Catania, Italy|Investigational Site Number :3800005, Reggio Emilia, Italy|Investigational Site Number :5280005, Arnhem, Netherlands|Investigational Site Number :5280001, Breda, Netherlands|Investigational Site Number :5280002, Leeuwarden, Netherlands|Investigational Site Number :6200001, Aveiro, Portugal|Investigational Site Number :6200008, Coimbra, Portugal|Investigational Site Number :6200007, Guimarães, Portugal|Investigational Site Number :6200006, Lisboa, Portugal|Investigational Site Number :6200003, Matosinhos, Portugal|Investigational Site Number :6200004, Porto, Portugal|Investigational Site Number :6430001, Moscow, Russian Federation|Investigational Site Number :6430002, Moscow, Russian Federation|Investigational Site Number :6430006, Moscow, Russian Federation|Investigational Site Number :6430005, Moscow, Russian Federation|Investigational Site Number :6430007, St-Petersburg, Russian Federation|Investigational Site Number :6430004, St-Petersburg, Russian Federation|Investigational Site Number :7240003, Barcelona, Barcelona [Barcelona], Spain|Investigational Site Number :7240001, Lugo / Lugo, Galicia [Galicia], Spain|Investigational Site Number :7240006, Pozuelo De Alarcón, Madrid, Spain|Investigational Site Number :7240002, Valencia, Valenciana, Comunidad, Spain|Investigational Site Number :7240005, Madrid, Spain|Investigational Site Number :8040002, Ivano-Frankivsk, Ukraine|Investigational Site Number :8040006, Ivano-Frankivsk, Ukraine|Investigational Site Number :8040003, Kharkiv, Ukraine|Investigational Site Number :8040008, Kyiv, Ukraine|Investigational Site Number :8040007, Kyiv, Ukraine|Investigational Site Number :8040005, Vinnytsya, Ukraine|Investigational Site Number :8260001, Cambridge, Cambridgeshire, United Kingdom|Investigational Site Number :8260002, London, London, City Of, United Kingdom",,"https://ClinicalTrials.gov/show/NCT04502862"
291,"NCT04456673","Pivotal Study to Assess the Efficacy, Safety and Tolerability of Dupilumab in Patients With Moderate to Severe COPD With Type 2 Inflammation","NOTUS","Recruiting","No Results Available","Chronic Obstructive Pulmonary Disease","Drug: Dupilumab SAR231893|Drug: Inhaled Corticosteroid|Drug: Inhaled Long-Acting Beta Agonist|Drug: Inhaled Long-Acting Muscarinic Antagonist|Drug: Placebo","Annual rate of acute COPD exacerbation (AECOPD)|Change in pre-bronchodilator FEV1|Change in SGRQ|Improvement in SGRQ|Change in pre-bronchodilator FEV1 from baseline to Week 52|Change in pre-bronchodilator FEV1 from baseline to time points up to Week 44|Change in post-bronchodilator FEV1 lung function|Change in forced expiratory flow (FEF) 25-75%|Annualized rate of severe AECOPD|Time to first AECOPD|Adverse events|Potentially clinically significant abnormality (PCSA) in laboratory tests|Anti-drug antibodies","Sanofi|Regeneron Pharmaceuticals","All","40 Years to 85 Years   (Adult, Older Adult)","Phase 3","924","Industry","Interventional","Allocation: Randomized|Intervention Model: Parallel Assignment|Masking: Quadruple (Participant, Care Provider, Investigator, Outcomes Assessor)|Primary Purpose: Treatment","EFC15805|2018-001954-91|U1111-1211-8837","June 12, 2020","July 1, 2023","October 20, 2023","July 2, 2020",,"February 10, 2022","Investigational Site Number :8400072, Birmingham, Alabama, United States|Investigational Site Number :8400061, Peoria, Arizona, United States|Investigational Site Number :8400065, Tempe, Arizona, United States|Investigational Site Number :8400022, Little Rock, Arkansas, United States|Investigational Site Number :8400031, Bakersfield, California, United States|Investigational Site Number :8400051, Huntington Beach, California, United States|Investigational Site Number :8400032, Newport Beach, California, United States|Investigational Site Number :8400063, Rancho Cucamonga, California, United States|Investigational Site Number :8400015, San Diego, California, United States|Investigational Site Number :8400007, Westminster, California, United States|Investigational Site Number :8400018, Lafayette, Colorado, United States|Investigational Site Number :8400035, Boynton Beach, Florida, United States|Investigational Site Number :8400043, Boynton Beach, Florida, United States|Investigational Site Number :8400092, Cape Coral, Florida, United States|Investigational Site Number :8400020, Clearwater, Florida, United States|Investigational Site Number :8400081, Cutler Bay, Florida, United States|Investigational Site Number :8400021, DeBary, Florida, United States|Investigational Site Number :8400060, DeLand, Florida, United States|Investigational Site Number :8400039, Fort Lauderdale, Florida, United States|Investigational Site Number :8400047, Fort Myers, Florida, United States|Investigational Site Number :8400071, Greenacres City, Florida, United States|Investigational Site Number :8400012, Miami, Florida, United States|Investigational Site Number :8400062, Miami, Florida, United States|Investigational Site Number :8400013, Saint Petersburg, Florida, United States|Investigational Site Number :8400001, Winter Park, Florida, United States|Investigational Site Number :8400048, Adairsville, Georgia, United States|Investigational Site Number :8400045, Blue Ridge, Georgia, United States|Investigational Site Number :8400058, Columbus, Georgia, United States|Investigational Site Number :8400064, Conyers, Georgia, United States|Investigational Site Number :8400052, Lawrenceville, Georgia, United States|Investigational Site Number :8400003, Rincon, Georgia, United States|Investigational Site Number :8400050, Fall River, Massachusetts, United States|Investigational Site Number :8400004, South Dartmouth, Massachusetts, United States|Investigational Site Number :8400053, Detroit, Michigan, United States|Investigational Site Number :8400034, Rochester, Michigan, United States|Investigational Site Number :8400057, Saginaw, Michigan, United States|Investigational Site Number :8400017, Chesterfield, Missouri, United States|Investigational Site Number :8400019, Missoula, Montana, United States|Investigational Site Number :8400016, Lincoln, Nebraska, United States|Investigational Site Number :8400073, Omaha, Nebraska, United States|Investigational Site Number :8400008, Manasquan, New Jersey, United States|Investigational Site Number :8400054, Mineola, New York, United States|Investigational Site Number :8400037, New Windsor, New York, United States|Investigational Site Number :8400044, Westfield, New York, United States|Investigational Site Number :8400042, Charlotte, North Carolina, United States|Investigational Site Number :8400010, Gastonia, North Carolina, United States|Investigational Site Number :8400087, Monroe, North Carolina, United States|Investigational Site Number :8400006, Mooresville, North Carolina, United States|Investigational Site Number :8400025, New Bern, North Carolina, United States|Investigational Site Number :8400068, Winston-Salem, North Carolina, United States|Investigational Site Number :8400024, Toledo, Ohio, United States|Investigational Site Number :8400009, DuBois, Pennsylvania, United States|Investigational Site Number :8400046, Erie, Pennsylvania, United States|Investigational Site Number :8400049, Scottdale, Pennsylvania, United States|Investigational Site Number :8400026, Clinton, South Carolina, United States|Investigational Site Number :8400002, Spartanburg, South Carolina, United States|Investigational Site Number :8400027, Rapid City, South Dakota, United States|Investigational Site Number :8400066, Franklin, Tennessee, United States|Investigational Site Number :8400108, Amarillo, Texas, United States|Investigational Site Number :8400059, Carrollton, Texas, United States|Investigational Site Number :8400011, Cypress, Texas, United States|Investigational Site Number :8400055, Houston, Texas, United States|Investigational Site Number :8400070, Houston, Texas, United States|Investigational Site Number :8400029, Lampasas, Texas, United States|Investigational Site Number :8400028, Longview, Texas, United States|Investigational Site Number :8400069, Plano, Texas, United States|Investigational Site Number :8400038, San Antonio, Texas, United States|Investigational Site Number :8400030, Abingdon, Virginia, United States|Investigational Site Number :8400056, Norfolk, Virginia, United States|Investigational Site Number :8400040, Richmond, Virginia, United States|Investigational Site Number :0320007, Berazategui, Buenos Aires, Argentina|Investigational Site Number :0320006, Caba, Buenos Aires, Argentina|Investigational Site Number :0320004, Caba, Buenos Aires, Argentina|Investigational Site Number :0320001, Caba, Buenos Aires, Argentina|Investigational Site Number :0320003, Caba, Buenos Aires, Argentina|Investigational Site Number :0320010, La Plata, Buenos Aires, Argentina|Investigational Site Number :0320005, Quilmes, Ciudad De Buenos Aires, Argentina|Investigational Site Number :0320011, Cordoba, Córdoba, Argentina|Investigational Site Number :0320008, Rosario, Santa Fe, Argentina|Investigational Site Number :0320009, Rosario, Santa Fe, Argentina|Investigational Site Number :0320002, Buenos Aires, Argentina|Investigational Site Number :0320012, Launs Este, Argentina|Investigational Site Number :0360003, Westmead, New South Wales, Australia|Investigational Site Number :0360006, Box Hill, Victoria, Australia|Investigational Site Number :0360005, Clayton, Victoria, Australia|Investigational Site Number :0360002, Frankston, Victoria, Australia|Investigational Site Number :0360001, Murdoch, Western Australia, Australia|Investigational Site Number :0560002, Edegem, Belgium|Investigational Site Number :0560001, Leuven, Belgium|Investigational Site Number :0560003, Liege, Belgium|Investigational Site Number :0560004, Mechelen, Belgium|Investigational Site Number :0760001, Porto Alegre, Rio Grande Do Sul, Brazil|Investigational Site Number :0760006, Blumenau, Santa Catarina, Brazil|Investigational Site Number :0760007, Santo Andre, São Paulo, Brazil|Investigational Site Number :0760002, Sao Paulo, São Paulo, Brazil|Investigational Site Number :0760003, São Paulo, Brazil|Investigational Site Number :1005021, Dupnitsa, Bulgaria|Investigational Site Number :1005012, Haskovo, Bulgaria|Investigational Site Number :1005011, Montana, Bulgaria|Investigational Site Number :1005008, Plovdiv, Bulgaria|Investigational Site Number :1005015, Ruse, Bulgaria|Investigational Site Number :1005013, Ruse, Bulgaria|Investigational Site Number :1005018, Sofia, Bulgaria|Investigational Site Number :1005003, Sofia, Bulgaria|Investigational Site Number :1005001, Sofia, Bulgaria|Investigational Site Number :1005006, Sofia, Bulgaria|Investigational Site Number :1005002, Sofia, Bulgaria|Investigational Site Number :1005009, Sofia, Bulgaria|Investigational Site Number :1005024, Stara Zagora, Bulgaria|Investigational Site Number :1005004, Stara Zagora, Bulgaria|Investigational Site Number :1005023, Veliko Tyrnovo, Bulgaria|Investigational Site Number :1005019, Vidin, Bulgaria|Investigational Site Number :1005020, Vratsa, Bulgaria|Investigational Site Number :1240010, Ajax, Ontario, Canada|Investigational Site Number :1240008, London, Ontario, Canada|Investigational Site Number :1240009, Sarnia, Ontario, Canada|Investigational Site Number :1240007, Windsor, Ontario, Canada|Investigational Site Number :1240012, QuÃ©bec, Quebec, Canada|Investigational Site Number :1240001, Quebec, Canada|Investigational Site Number :1240005, Quebec, Canada|Investigational Site Number :1520009, Valdivia, Los Ríos, Chile|Investigational Site Number :1520006, Curicó, Maule, Chile|Investigational Site Number :1520001, Talca, Maule, Chile|Investigational Site Number :1520007, Santiago, Reg Metropolitana De Santiago, Chile|Investigational Site Number :1520003, Santiago, Reg Metropolitana De Santiago, Chile|Investigational Site Number :1520002, Santiago, Reg Metropolitana De Santiago, Chile|Investigational Site Number :1520004, Quillota, Valparaíso, Chile|Investigational Site Number :1700002, Bogota, Colombia|Investigational Site Number :1700005, Manizales, Colombia|Investigational Site Number :2030004, Jihlava, Czechia|Investigational Site Number :2030001, Jindrichuv Hradec III, Czechia|Investigational Site Number :2030007, Kralupy nad Vltavou, Czechia|Investigational Site Number :2030003, Miroslav, Czechia|Investigational Site Number :2030002, Strakonice, Czechia|Investigational Site Number :2500009, Bayonne, France|Investigational Site Number :2500010, Besancon, France|Investigational Site Number :2500002, Dijon, France|Investigational Site Number :2500005, Lyon, France|Investigational Site Number :2500004, Marseille, France|Investigational Site Number :2500003, Montpellier, France|Investigational Site Number :2500001, Nantes, France|Investigational Site Number :2500007, Paris, France|Investigational Site Number :2500008, Paris, France|Investigational Site Number :2500006, Pessac, France|Investigational Site Number :2760015, Berlin, Germany|Investigational Site Number :2760017, Darmstadt, Germany|Investigational Site Number :2760009, Frankfurt am Main, Germany|Investigational Site Number :2760002, Hamburg, Germany|Investigational Site Number :2760003, Hannover, Germany|Investigational Site Number :2760007, Koblenz, Germany|Investigational Site Number :2760011, Leipzig, Germany|Investigational Site Number :2760010, Lübeck, Germany|Investigational Site Number :2760012, Mainz, Germany|Investigational Site Number :2760008, Marburg, Germany|Investigational Site Number :2760013, Schwerin, Germany|Investigational Site Number :2760018, Wiesbaden, Germany|Investigational Site Number :3000001, Athens, Greece|Investigational Site Number :3000005, Athens, Greece|Investigational Site Number :3000006, Athens, Greece|Investigational Site Number :3000003, Heraklion, Greece|Investigational Site Number :3000002, Ioannina, Greece|Investigational Site Number :3000007, Palaio Faliro, Athens, Greece|Investigational Site Number :3000004, Thessaloniki, Greece|Investigational Site Number :3480007, Debrecen, Hungary|Investigational Site Number :3480003, Edelény, Hungary|Investigational Site Number :3480004, Gödöllö, Hungary|Investigational Site Number :3480002, Hajdunánás, Hungary|Investigational Site Number :3480005, Szombathely, Hungary|Investigational Site Number :3480001, Százhalombatta, Hungary|Investigational Site Number :4280008, Balvi, Latvia|Investigational Site Number :4280007, Rezekne, Latvia|Investigational Site Number :4280001, Riga, Latvia|Investigational Site Number :4280005, Riga, Latvia|Investigational Site Number :4280006, Riga, Latvia|Investigational Site Number :4280002, Riga, Latvia|Investigational Site Number :4280003, Riga, Latvia|Investigational Site Number :4400001, Kaunas, Lithuania|Investigational Site Number :4400003, Kaunas, Lithuania|Investigational Site Number :4400008, Kaunas, Lithuania|Investigational Site Number :4400007, Klaipeda, Lithuania|Investigational Site Number :4400004, Vilnius, Lithuania|Investigational Site Number :4400005, Vilnius, Lithuania|Investigational Site Number :4840008, Benito Juarez, Ciudad De Mexico, Mexico|Investigational Site Number :4840002, Guadalajara, Jalisco, Mexico|Investigational Site Number :4840011, Zapopan, Jalisco, Mexico|Investigational Site Number :4840004, Monterrey, Nuevo León, Mexico|Investigational Site Number :4840010, Chihuahua, Mexico|Investigational Site Number :4840007, Mexico City, Mexico|Investigational Site Number :4840009, Mexico, Mexico|Investigational Site Number :4840005, Veracruz, Mexico|Investigational Site Number :5280005, Arnhem, Netherlands|Investigational Site Number :5280001, Breda, Netherlands|Investigational Site Number :5280010, Dordrecht, Netherlands|Investigational Site Number :5280009, Harderwijk, Netherlands|Investigational Site Number :5280007, Heerlen, Netherlands|Investigational Site Number :5280002, Leeuwarden, Netherlands|Investigational Site Number :5280006, Nijmegen, Netherlands|Investigational Site Number :5280011, Roermond, Netherlands|Investigational Site Number :5280008, Zutphen, Netherlands|Investigational Site Number :5280004, Zwolle, Netherlands|Investigational Site Number :6040003, Chancay, Peru|Investigational Site Number :6040002, Lima Lima, Peru|Investigational Site Number :6040006, Lima, Peru|Investigational Site Number :6040004, Lima, Peru|Investigational Site Number :6040001, Lima, Peru|Investigational Site Number :6040005, Piura, Peru|Investigational Site Number :6160009, Grudziadz, Kujawsko-pomorskie, Poland|Investigational Site Number :6160007, Krakow, Malopolskie, Poland|Investigational Site Number :6160015, Grodzisk Mazowiecki, Mazowieckie, Poland|Investigational Site Number :6160010, Rzeszow, Podkarpackie, Poland|Investigational Site Number :6160008, Bialystok, Podlaskie, Poland|Investigational Site Number :6160018, Katowice, Slaskie, Poland|Investigational Site Number :6160011, Katowice, Slaskie, Poland|Investigational Site Number :6160014, Elblag, Warminsko-mazurskie, Poland|Investigational Site Number :6160019, Krakow, Poland|Investigational Site Number :6200007, Almada, Portugal|Investigational Site Number :6200006, Aveiro, Portugal|Investigational Site Number :6200008, Coimbra, Portugal|Investigational Site Number :6200011, Covilhã, Portugal|Investigational Site Number :6200002, Guimarães, Portugal|Investigational Site Number :6200005, Leiria, Portugal|Investigational Site Number :6200009, Lisboa, Portugal|Investigational Site Number :6200012, Matosinhos, Portugal|Investigational Site Number :6200003, Porto, Portugal|Investigational Site Number :6200004, Porto, Portugal|Investigational Site Number :6425004, Bacau, Romania|Investigational Site Number :6425003, Cluj-Napoca, Romania|Investigational Site Number :6425005, Constanta, Romania|Investigational Site Number :6425002, Iasi, Romania|Investigational Site Number :6425001, Timisoara, Romania|Investigational Site Number :6430011, Chelyabinsk, Russian Federation|Investigational Site Number :6430001, Moscow, Russian Federation|Investigational Site Number :6430003, Moscow, Russian Federation|Investigational Site Number :6430002, Moscow, Russian Federation|Investigational Site Number :6430009, Nizhny Novgorod, Russian Federation|Investigational Site Number :6430010, Ryazan, Russian Federation|Investigational Site Number :6430013, Saint Petersburg, Russian Federation|Investigational Site Number :6430014, Saint Petersburg, Russian Federation|Investigational Site Number :6430004, St-Petersburg, Russian Federation|Investigational Site Number :6430012, Stavropol, Russian Federation|Investigational Site Number :6430006, Tomsk, Russian Federation|Investigational Site Number :6430008, Ulyanovsk, Russian Federation|Investigational Site Number :6430005, Voronezh, Russian Federation|Investigational Site Number :6880005, Belgrade, Serbia|Investigational Site Number :6880006, Belgrade, Serbia|Investigational Site Number :6880007, Belgrade, Serbia|Investigational Site Number :6880003, Kragujevac, Serbia|Investigational Site Number :6880001, Sremska Kamenica, Serbia|Investigational Site Number :6880002, Valjevo, Serbia|Investigational Site Number :7030007, Banska Bystrica, Slovakia|Investigational Site Number :7030006, Humenne, Slovakia|Investigational Site Number :7030003, Levice, Slovakia|Investigational Site Number :7030001, Poprad, Slovakia|Investigational Site Number :7030002, Spisska Nova Ves, Slovakia|Investigational Site Number :7100004, Cape Town, South Africa|Investigational Site Number :7100014, Chatsworth, South Africa|Investigational Site Number :7100001, Durban, South Africa|Investigational Site Number :7100003, Durban, South Africa|Investigational Site Number :7100002, Gatesville, South Africa|Investigational Site Number :7100009, Johannesburg, South Africa|Investigational Site Number :7100006, Parow, South Africa|Investigational Site Number :7100005, Pretoria, South Africa|Investigational Site Number :7100008, Somerset West, South Africa|Investigational Site Number :7100011, Vereeniging, South Africa|Investigational Site Number :7240007, Oviedo, Asturias, Spain|Investigational Site Number :7240009, Badalona, Barcelona [Barcelona], Spain|Investigational Site Number :7240001, Barcelona, Barcelona [Barcelona], Spain|Investigational Site Number :7240002, Barcelona, Barcelona [Barcelona], Spain|Investigational Site Number :7240006, Madrid, Madrid, Comunidad De, Spain|Investigational Site Number :7240003, Madrid, Madrid, Comunidad De, Spain|Investigational Site Number :7240008, Valencia, Valenciana, Comunidad, Spain|Investigational Site Number :7240010, Málaga, Spain|Investigational Site Number :7240011, Zaragoza, Spain|Investigational Site Number :8040011, Chernivtsi, Ukraine|Investigational Site Number :8040002, Ivano-Frankivsk, Ukraine|Investigational Site Number :8040003, Ivano-Frankivsk, Ukraine|Investigational Site Number :8040001, Kharkiv, Ukraine|Investigational Site Number :8040007, Kyiv, Ukraine|Investigational Site Number :8040004, Kyiv, Ukraine|Investigational Site Number :8040006, Lviv, Ukraine|Investigational Site Number :8040010, Ternopil, Ukraine|Investigational Site Number :8040008, Zaporizhzhia, Ukraine|Investigational Site Number :8040009, Zaporizhzhya, Ukraine|Investigational Site Number :8260003, Cambridge, Cambridgeshire, United Kingdom|Investigational Site Number :8260002, Blackpool, Lancashire, United Kingdom|Investigational Site Number :8260006, Swansea, Neath Port Talbot, United Kingdom|Investigational Site Number :8260007, North Shields, Newcastle Upon Tyne, United Kingdom|Investigational Site Number :8260004, South Shields, Newcastle Upon Tyne, United Kingdom|Investigational Site Number :8260013, Nottingham, Nottinghamshire, United Kingdom|Investigational Site Number :8260012, Aylesbury, United Kingdom|Investigational Site Number :8260001, Bradford, United Kingdom|Investigational Site Number :8260005, Bristol, United Kingdom|Investigational Site Number :8260011, Chippenham, United Kingdom",,"https://ClinicalTrials.gov/show/NCT04456673"
292,"NCT04447417","Dupilumab Skin Barrier Function Study in Atopic Dermatitis","BALISTAD","Completed","No Results Available","Atopic Dermatitis","Drug: Dupilumab SAR231893","Percent change in TEWL after 5 STS on lesional skin in AD patients|Percent change in TEWL after 20 STS on lesional skin in AD patients|Absolute change in TEWL after 20 STS on lesional skin in AD patient|Percent change in TEWL after 20 STS on non-lesional skin in AD patients|Absolute change in TEWL after 20 STS on non-lesional skin in AD patients|Percent change in TEWL after 20 STS on normal skin in healthy volunteers|Absolute change in TEWL after 20 STS on normal skin in healthy volunteers|Percent change in TEWL after 15 STS on lesional skin in AD patients|Absolute change in TEWL after 15 STS on lesional skin in AD patients|Percent change in TEWL after 15 STS on non-lesional skin in AD patients|Absolute change in TEWL after 15 STS on non-lesional skin in AD patients|Percent change in TEWL after 15 STS on normal skin in healthy volunteers|Absolute change in TEWL after 15 STS on normal skin in healthy volunteers|Percent change in TEWL after 10 STS on lesional skin in AD patients|Absolute change in TEWL after 10 STS on lesional skin in AD patients|Percent change in TEWL after 10 STS on non-lesional skin in AD patients|Absolute change in TEWL after 10 STS on non-lesional skin in AD patients|Percent change in TEWL after 10 STS on normal skin in healthy volunteers|Absolute change in TEWL after 10 STS on normal skin in healthy volunteers|Absolute change in TEWL after 5 STS on lesional skin in AD patients|Percent change in TEWL after 5 STS on non-lesional skin in AD patients|Absolute change in TEWL after 5 STS on non-lesional skin in AD patients|Percent change in TEWL after 5 STS on normal skin in healthy volunteers|Absolute change in TEWL after 5 STS on normal skin in healthy volunteers|Percent change in TEWL before STS on lesional skin in AD patients over time|Absolute change in TEWL before STS on lesional skin in AD patients over time|Percent change in TEWL before STS on non-lesional skin in AD patients over time|Absolute change in TEWL before STS on non-lesional skin in AD patients over time|Percent change in TEWL before STS on normal skin in healthy volunteers over time|Absolute change in TEWL before STS on normal skin in healthy volunteers over time|Percent change in TEWL area under the curve (TEWL AUC: a composite measure before and after 5, 10, 15 and 20 STS) for skin barrier function in lesional skin in AD patients|Absolute change in TEWL area under the curve (TEWL AUC: a composite measure before and after 5, 10, 15 and 20 STS) for skin barrier function in lesional skin in AD patients|Percent change in TEWL AUC (a composite measure before and after 5, 10, 15, and 20 STS) for skin barrier function in non-lesional skin in AD patients|Absolute change in TEWL AUC (a composite measure before and after 5, 10, 15, and 20 STS) for skin barrier function in non-lesional skin in AD patients|Percent change in TEWL AUC (a composite measure before and after 5, 10, 15, and 20 STS) for skin barrier function in normal skin in healthy volunteers|Absolute change in TEWL AUC (a composite measure before and after 5, 10, 15, and 20 STS) for skin barrier function in normal skin in healthy volunteers|Percent change from baseline in TEWL after STS assessed on lesional skin in AD patients|Absolute change from baseline in TEWL after STS assessed on lesional skin in AD patients|Percent change from baseline in TEWL after STS assessed on non-lesional skin in AD patients|Absolute change from baseline in TEWL after STS assessed on non-lesional skin in AD patients|Percent change from baseline in TEWL after STS assessed on normal skin in healthy volunteers|Absolute change from baseline in TEWL after STS assessed on normal skin in healthy volunteers","Sanofi|Regeneron Pharmaceuticals","All","12 Years to 65 Years   (Child, Adult, Older Adult)","Phase 4","52","Industry","Interventional","Allocation: Non-Randomized|Intervention Model: Parallel Assignment|Masking: None (Open Label)|Primary Purpose: Treatment","LPS15991|U1111-1244-1409","July 16, 2020","June 17, 2021","June 17, 2021","June 25, 2020",,"July 26, 2021","Investigational Site Number 8400001, Denver, Colorado, United States|Investigational Site Number 1240001, Montreal, Canada",,"https://ClinicalTrials.gov/show/NCT04447417"
293,"NCT04423718","Study to Gather Information on Safety and Use of High Dose Aflibercept Injection Into the Eye in Patients With an Age Related Eye Disorder That Causes Blurred Vision or a Blind Spot Due to Abnormal Blood Vessels That Leak Fluid Into the Light Sensitive Lining Inside the Eye","PULSAR","Active, not recruiting","No Results Available","Neovascular Age-Related Macular Degeneration","Drug: Aflibercept High Dose VEGF Trap-Eye (BAY86-5321)|Drug: Aflibercept VEGF Trap-Eye (Eylea, BAY86-5321)","Change in best corrected visual acuity (BCVA) measured by the Early Treatment Diabetic Retinopathy Study (ETDRS) letter score|Change in BCVA measured by the ETDRS letter score|Proportion of participants with no intraretinal fluid (IRF) and no subretinal fluid (SRF) in central subfield|Proportion of participants gaining at least 15 letters in BCVA|Proportion of participants achieving an ETDRS letter score of at least 69|Change in choroidal neovascularization (CNV) size|Change in total lesion area|Proportion of participants with no IRF and no SRF in the center subfield|Change in central subfield retinal thickness (CST)|Change in National Eye Institute Visual Functioning Questionnaire-25 (NEI-VFQ-25) total score|Treatment-emergent adverse events (AEs) and serious AEs (SAEs)|Systemic exposure to aflibercept as assessed by plasma concentration|Assessment of immunogenicity to aflibercept by measuring the incidence of treatment-emergent anti-drug antibodies (ADA) response","Bayer|Regeneron Pharmaceuticals","All","50 Years and older   (Adult, Older Adult)","Phase 3","1016","Industry","Interventional","Allocation: Randomized|Intervention Model: Parallel Assignment|Masking: Quadruple (Participant, Care Provider, Investigator, Outcomes Assessor)|Primary Purpose: Treatment","20968|2019-003851-12","August 11, 2020","July 18, 2022","May 23, 2023","June 9, 2020",,"February 16, 2022","Arizona Retina and Vitreous Consultants - Research, Phoenix, Arizona, United States|Retina Consultants of Orange County, Fullerton, California, United States|University of California San Diego, La Jolla, California, United States|Jules Stein Eye Institute, UCLA, Los Angeles, California, United States|Northern California Retina-Vitreous Associates, Mountain View, California, United States|California Eye Specialists, Pasadena, California, United States|Retina Consultants of Southern California, Redlands, California, United States|Kaiser Permanente Riverside Medical Center, Riverside, California, United States|Retina Consultants San Diego, San Diego, California, United States|Retina Consultants of Southern Colorado, PC, Colorado Springs, Colorado, United States|New England Retina Associates, New London, Connecticut, United States|Retina Group of Florida, Fort Lauderdale, Florida, United States|Vitreo-Retinal Associates, Gainesville, Florida, United States|Florida Retina Institute, Jacksonville, Florida, United States|Florida Eye Associates, Melbourne, Florida, United States|Retina Macula Specialists of Miami, Miami, Florida, United States|Florida Retina Institute, Orlando, Florida, United States|Retina Specialists, Pensacola, Florida, United States|Retina Vitreous Associates of Florida - Saint Petersburg, Saint Petersburg, Florida, United States|Southern Vitreoretinal Associates, Tallahassee, Florida, United States|Retina Consultants of Hawaii, 'Aiea, Hawaii, United States|Retina Associates IL, Elmhurst, Illinois, United States|University Retina and Macula Associates, Oak Forest, Illinois, United States|Wolfe Eye Clinic, PC, West Des Moines, Iowa, United States|Retina Associates, PA, Shawnee Mission, Kansas, United States|Retina Care Center, Baltimore, Maryland, United States|Ophthalmic Consultants of Boston, Boston, Massachusetts, United States|Vitreo Retinal Surgery PA, Edina, Minnesota, United States|Retina Consultants of Nevada, Las Vegas, Nevada, United States|Retina Center of New Jersey, Bloomfield, New Jersey, United States|NJ Retina, Edison, New Jersey, United States|Eye Associates of New Mexico, Albuquerque, New Mexico, United States|Long Island Vitreoretinal Consultants, Great Neck, New York, United States|Long Island Vitreoretinal Consultants, Hauppauge, New York, United States|Ophthalmic Consultants of Long Island, Lynbrook, New York, United States|Ophthalmic Consultants of the Capital Region, Troy, New York, United States|Wake Forest Baptist Health, Winston-Salem, North Carolina, United States|Midwest Retina - Main Office, Dublin, Ohio, United States|Retina Northwest, PC, Portland, Oregon, United States|Retina Consultants, LLC, Salem, Oregon, United States|Mid Atlantic Retina, Bethlehem, Pennsylvania, United States|Erie Retinal Surgery, Inc., Erie, Pennsylvania, United States|Eye Care Specialists, Kingston, Pennsylvania, United States|Charleston Neuroscience Center, Charleston, South Carolina, United States|Palmetto Retina Center, LLC, West Columbia, South Carolina, United States|Black Hills Regional Eye Institute, Rapid City, South Dakota, United States|Charles Retina Institute, Memphis, Tennessee, United States|Vanderbilt University Medical School, Nashville, Tennessee, United States|Austin Retina Associates, Austin, Texas, United States|Texas Retina Associates, Fort Worth, Texas, United States|Retina Consultants of Houston, Houston, Texas, United States|Valley Retina Institute, McAllen, Texas, United States|Medical Center Ophthalmology Associates, San Antonio, Texas, United States|Retinal Consultants of San Antonio, San Antonio, Texas, United States|Retina Consultants of Houston, The Woodlands, Texas, United States|Fletcher Allen Health Care, Burlington, Vermont, United States|Retina Institute of Virginia, Richmond, Virginia, United States|Spokane Eye Clinical Research, Spokane, Washington, United States|West Virginia University, Morgantown, West Virginia, United States|University of Wisconsin - Madison, Madison, Wisconsin, United States|Organizacion Medica de Investigacion (OMI), Buenos Aires, Ciudad Auton. De Buenos Aires, Argentina|OFTALMOS, Instituto Oftalmologico de Alta Complejidad, Buenos Aires, Ciudad Auton. De Buenos Aires, Argentina|Oftalmólogos especialistas, Rosario, Santa Fe, Argentina|Eyeclinic Albury Wodonga, Albury, New South Wales, Australia|Sydney Retina Clinic, Sydney, New South Wales, Australia|Westmead Hospital, Westmead, New South Wales, Australia|Hobart Eye Surgeons, Hobart, Tasmania, Australia|Marsden Eye Surgery Center, Parramatta, Australia|Klinikum Klagenfurt am Wörthersee, Klagenfurt, Kärnten, Austria|Kepler Universitätsklinikum Campus III, Linz, Oberösterreich, Austria|Konventhospital Barmherzige Brüder Linz, Linz, Oberösterreich, Austria|Medizinische Universität Graz, Graz, Steiermark, Austria|Hanusch-Krankenhaus Wien, Wien, Austria|SOHAT Pentagram, Sofia, Bulgaria|Spec. Hosp. for Active Treatment for Eye Diseases Zrenie, Sofia, Bulgaria|UMHAT Alexandrovska EAD, Sofia, Bulgaria|University Eye Hospital - Akad. Pashev, Sofia, Bulgaria|Multiprofile Hospital for Active Treatment Sveta Sofia, Sofia, Bulgaria|Spec. Hospital For Active Treatment of Eye Diseases Zora, Sofia, Bulgaria|Sveta Petka Eye Hospital, Varna, Bulgaria|Misericordia Health Centre, Winnipeg, Manitoba, Canada|St.Joseph's Health Care-London, London, Ontario, Canada|Toronto Retina Institute, Toronto, Ontario, Canada|Institut de l'Oeil des Laurentides, Boisbriand, Quebec, Canada|The Second Hospital of Anhui medical university, Hefei, Anhui, China|The 1st Affiliated Hospital Fujian Medical University, Fuzhou, Fujian, China|Guangzhou Aier Eye Hospital, Guangzhou, Guangdong, China|Shijiazhuang General Hospital, Shijiazhuang, Hebei, China|Hebei Eye Hospital, Xingtai, Hebei, China|Henan Provincial Ophthalmology Hospital (Henan Eye Institute, Zhengzhou, Henan, China|Union Hospt Tongji Medical Colleg. Huazhong univ. Scien&Tech, Wuhan, Hubei, China|Tongji Hosp. of Tongji Med Coll, Huazhong Uni of Sci & Tech., Wuhan, Hubei, China|The First People's Hospital of Xuzhou, Xuzhou, Jiangsu, China|Jiangxi Provincial People's Hospital, Nanchang, Jiangxi, China|The First Affiliated Hospital of NanChang University, Nanchang, Jiangxi, China|Eye Center of the second Bethune Hospital, jinlin University, Changchun, Jilin, China|Tonghua Central Hospital, Tonghua, Jilin, China|Shenyang He Eye Hospital, Shenyang, Liaoning, China|The People's Hospital of Ningxia Hui Autonomous Region, Yinchuan, Ningxia, China|The First Affiliated Hospital of Xi'an Jiaotong University, Xi'an, Shanxi, China|Aier Eye Hospital (Chengdu), Chengdu, Sichuan, China|The First Affiliated Hospital of Xinjiang Medical University, Urumqi, Xinjiang, China|The 1st Affiliated Hospital of Zhejiang University, Hangzhou, Zhejiang, China|ZheJiang Provincial People's Hospital, Hangzhou, Zhejiang, China|The Affiliated Eye Hospital of Wenzhou Medical College, Wenzhou, Zhejiang, China|Beijing Tongren Hospital, Capital Medical University (East), Beijing, China|Beijing Aier Intech Eye Hospital Co. LTD - Ophthalmology, Beijing, China|Peking University People's Hospital, Beijing, China|Beijing Hospital, Beijing, China|Peking Union Medical College Hospital CAMS, Beijing, China|Chongqing Aier Ophthalmology Hospital, Chongqing, China|Shanghai Tongji Hospital of Tongji University, Shanghai, China|Shanghai General Hospital, Shanghai, China|Tianjin Medical University General Hospital, Tianjin, China|Tianjin Medical University Eye Hospital, Tianjin, China|TianJin eye hospital, Tianjin, China|Fakultni Nemocnice Brno, Brno, Czechia|Fakultni Nemocnice Hradec Kralove, Hradec Kralove, Czechia|Fakultni nemocnice Ostrava, Ostrava, Czechia|Fakultni nemocnice Plzen, Plzen, Czechia|Charles University in Prague, Prague, Czechia|Fakultni nemocnice Kralovske Vinohrady, Praha 10, Czechia|Lexum a.s., Evropska ocni klinika, Praha 4, Czechia|AXON Clinical s.r.o., Praha 5, Czechia|East Tallinn Central Hospital, Tallinn, Estonia|Dr. Kai Noor Silmakabinet OU, Tallinn, Estonia|Tartu University Hospital, Tartu, Estonia|Hopital Avicenne - Bobigny, Bobigny, France|Centre d'Ophtalmologie - Paradis-Monticelli, Marseille, France|Hôpital Lariboisière - Paris, Paris, France|Centre ophtalmologique Saint-Exupéry, Saint-Cyr-Sur-Loire, France|LTD ""Clinic LJ"", Kutaisi, Georgia|JSC ""Evex Hospitals', Tbilisi, Georgia|LTD ""Innova"", Tbilisi, Georgia|LTD Israeli-Georgian Medical Research Clinic ""Helsicore"", Tbilisi, Georgia|LTD ""Chichua Medical Center MZERA"", Tbilisi, Georgia|Aversi Clinic, Tbilisi, Georgia|Budapest Retina Associates, Budapest, Hungary|Szent-Gyorgyi Albert Orvostudomanyi Egyetem, Szeged, Hungary|Barzilai Medical Center, Ashkelon, Israel|Rambam Health Corporation, Haifa, Israel|Bnai Zion Medical Center, Haifa, Israel|Lady Davis Carmel Medical Center, Haifa, Israel|Hadassah Hebrew University Hospital Ein Kerem, Jerusalem, Israel|Meir Medical Center, Kfar Saba, Israel|Chaim Sheba Medical Center, Ramat Gan, Israel|Kaplan Medical Center, Rehovot, Israel|Assuta Medical Centers - HaShalom, Tel Aviv, Israel|Shamir Medical Center (Assaf Harofeh), Zerifin, Israel|A.S.U. Giuliano Isontina, Trieste, Friuli-Venezia Giulia, Italy|Fondazione PTV Policlinico Tor Vergata, Roma, Lazio, Italy|Fondazione Policlinico Universitario Agostino Gemelli IRCCS, Roma, Lazio, Italy|IRCCS Fondazione G.B. Bietti Studio e Ricerca in Otalmologia, Roma, Lazio, Italy|Ospedale San Raffaele s.r.l., Milano, Lombardia, Italy|ASST Fatebenefratelli Sacco, Milano, Lombardia, Italy|A.O.U. di Cagliari, Cagliari, Sardegna, Italy|A.O.U. Policlinico - Vittorio Emanuele, Catania, Sicilia, Italy|A.O. di Perugia, Perugia, Umbria, Italy|A.O.U. di Padova, Padova, Veneto, Italy|Daiyukai Daiichi Hospital, Ichinomiya, Aichi, Japan|Aichi Medical University Hospital, Nagakute, Aichi, Japan|Nagoya University Hospital, Nagoya, Aichi, Japan|Nagoya City University Hospital, Nagoya, Aichi, Japan|Kokura Memorial Hospital, Kitakyushu, Fukuoka, Japan|Kurume University Hospital, Kurume, Fukuoka, Japan|Southern Tohoku Eye Clinic, Koriyama, Fukushima, Japan|Gunma University Hospital, Maebashi, Gunma, Japan|Sapporo City General Hospital, Sapporo, Hokkaido, Japan|KKR Sapporo Medical Center, Sapporo, Hokkaido, Japan|Hyogo Prefectural Amagasaki General Medical Center, Amagasaki, Hyogo, Japan|Kobe University Hospital, Kobe, Hyogo, Japan|Kozawa Eye Hospital and Diabetes Center, Mito, Ibaraki, Japan|Kanazawa Medical University Hospital, Kahoku-gun, Ishikawa, Japan|Kanazawa University Hospital, Kanazawa, Ishikawa, Japan|Kagawa University Hospital, Kita-gun, Kagawa, Japan|Dannoue Eye Clinic, Kawasaki, Kanagawa, Japan|St. Marianna University Hospital, Kawasaki, Kanagawa, Japan|Otakeganka Tsukimino Clinic, Yamato, Kanagawa, Japan|Mie University Hospital, Tsu, Mie, Japan|Shinshu University Hospital, Matsumoto, Nagano, Japan|Nara Medical University Hospital, Kashihara, Nara, Japan|Oita University Hospital, Yufu, Oita, Japan|Kurashiki Medical Clinic, Kurashiki, Okayama, Japan|Kurashiki Medical Center, Kurashiki, Okayama, Japan|University of the Ryukyus Hospital, Nakagami, Okinawa, Japan|Kansai Medical University Hospital, Hirakata, Osaka, Japan|Kansai Medical University Medical Center, Moriguchi, Osaka, Japan|Kindai University Hospital, Osakasayama, Osaka, Japan|The University of Tokyo Hospital, Bunkyo-ku, Tokyo, Japan|St.Luke's International Hospital, Chuoku, Tokyo, Japan|Nishikasai Inouye Eye Hospital, Edogawa-ku, Tokyo, Japan|Tokyo Medical University Hachioji Medical Center, Hachioji, Tokyo, Japan|Tokiwadai Muranaka Eye Clinic, Itabashi-ku, Tokyo, Japan|National Hospital Organization Tokyo Medical Center, Meguro-ku, Tokyo, Japan|Keio University Hospital, Shinjuku-ku, Tokyo, Japan|Tokyo Women's Medical University Hospital, Shinjuku-ku, Tokyo, Japan|Yamaguchi University Hospital, Ube, Yamaguchi, Japan|University of Yamanashi Hospital, Chuo, Yamanashi, Japan|Akita University Hospital, Akita, Japan|Hayashi Eye Hospital, Fukuoka, Japan|Fukushima Medical University Hospital, Fukushima, Japan|Hiroshima University Hospital, Hiroshima, Japan|University of Miyazaki Hospital, Miyazaki, Japan|Japanese Red Cross Nagasaki Genbaku Hospital, Nagasaki, Japan|Okayama University Hospital, Okayama, Japan|Japanese Red Cross Saitama Hospital, Saitama, Japan|Tokushima University Hospital, Tokushima, Japan|Japanese Red Cross Wakayama Medical center, Wakayama, Japan|Yamagata University Hospital, Yamagata, Japan|Seoul National University Bundang Hospital, Seongnam-si, Gyeonggido, Korea, Republic of|Pusan National University Hospital, Busan, Korea, Republic of|Inje University Haeundae Paik Hospital, Busan, Korea, Republic of|Seoul National University Hospital, Seoul, Korea, Republic of|Asan Medical Center, Seoul, Korea, Republic of|Samsung Medical Center, Seoul, Korea, Republic of|Retina Center Nune Eye Hospital, Seoul, Korea, Republic of|Signes Ozolinas Doctor Praxis in Ophthalmology, Jelgava, Latvia|Department of Ophthalmology, Riga, Latvia|Riga East Clinical University Hospital ""Gailezers"", Riga, Latvia|Latvian American Eye Center, Riga, Latvia|Hospital of LT University of Health Sciences Kaunas Clinics, Kaunas, Lithuania|PI Klaipedos University Hospital, Klaipeda, Lithuania|Vilnius University Hospital Santaros Klinikos, Vilnius, Lithuania|Hospital de Vila Franca de Xira, Vila Franca de Xira, Lisboa, Portugal|CHVNGE - Hospital Eduardo Santos Silva, Vila Nova de Gaia, Porto, Portugal|AIBILI, Coimbra, Portugal|Espaco Medico de Coimbra, Coimbra, Portugal|ALM Oftalmolaser - Oftalmologia Medica e Cirurgica, Lisboa, Portugal|CHUP - Hospital Santo Antonio, Porto, Portugal|Irkutsk Branch of FBSI IRTC ""Eye Microsurgery"", Irkutsk, Russian Federation|Scientific Research Institution of Ophthalmic Diseases, Moscow, Russian Federation|FBSI IRTC Eye Microsurgery n.a. acad. S.N. Fyodorov, Moscow, Russian Federation|Regional Ophthalmological Hospital n. a. T.I. Eroshevsky, Samara, Russian Federation|St. Petersburg Medical University n.a. I.P. Pavlov, St. Petersburg, Russian Federation|Clinical Center of Serbia, Belgrade, Serbia|Clinical hospital center Zvezdara, Belgrade, Serbia|Clinical Center Nis, Nis, Serbia|Klinicki centar Vojvodine, Novi Sad, Serbia|National University Hospital, Singapore, Singapore|Singapore National Eye Centre, Singapore, Singapore|Tan Tock Seng Hospital, Singapore, Singapore|Fakultna nemocnica Nitra, Nitra, Slovakia|Nemocnica s Poliklinikou Trebisov, Svet zdravia a.s., Trebisov, Slovakia|Fakultna nemocnica Trencin, Trencin, Slovakia|Fakultna nemocnica s poliklinikou Zilina, Zilina, Slovakia|Instituto Oftalmológico Francisco Gomez Ulla, Santiago de Compostela, A Coruña, Spain|Hospital de l'Esperança, Barcelona, Spain|Hospital Clínic i Provincial de Barcelona, Barcelona, Spain|Hospital de la Santa Creu i de Sant Pau, Barcelona, Spain|Hospital Reina Sofía, Córdoba, Spain|Hospital General Universitario de Valencia, Valencia, Spain|Hospital Universitari i Politècnic La Fe, Valencia, Spain|Hospital Miguel Servet, Zaragoza, Spain|Universitätsspital Basel, Basel, Basel-Stadt, Switzerland|RétinElysée, Lausanne, Vaud, Switzerland|Berner Augenklinik am Lindenhofspital, Bern, Switzerland|Stadtspital Triemli, Zürich, Switzerland|Changhua Christian Hospital, Changhua, Taiwan|Veterans General Hospital, Kaoshiung, Taiwan|Shing-Kong Wu Ho-Su Memorial Hospital, Taipei City, Taiwan|National Taiwan University Hospital, Taipei, Taiwan|Taipei Veterans General Hospital, Taipei, Taiwan|Chang Gung Memorial Hospital at Linkou, Taoyuan, Taiwan|Kharkiv Ophthalmological Clinic #14 named by Hirshman, Kharkiv, Ukraine|Private enterprise private production company "" Acinus"", Kropyvnytskyi, Ukraine|Centralna Polyclinica MVS Ukraiiny, Kyiv, Ukraine|Health Technology Ltd. - Ophthalmic Medical Center, Odesa, Ukraine|Poltava Regional Clinical Hospital n.a. M.V. Skliphosovskyi, Poltava, Ukraine|Ophthalmology Clinic of Professor Sergienko, Vinnitsya, Ukraine",,"https://ClinicalTrials.gov/show/NCT04423718"
294,"NCT04400318","The Effect of Dupilumab on Lung Function and Related Changes in Airway Volumes Detectable by Functional Respiratory Imaging in Patients With Moderate-severe Asthma","VESTIGE","Recruiting","No Results Available","Asthma","Drug: Dupilumab SAR231893|Drug: Placebo","Change from baseline to Week 24 in pre-bronchodilator FEV1|Percent change from baseline to Week 24 in regional airway volumes corrected for lung volume ([s]iVaw) at total lung capacity (TLC)|Percent change from baseline to Week 24 in regional airway volumes corrected for lung volume ([s]iVaw) at functional residual capacity (FRC)|Percent change from baseline to Week 24 in regional airway resistance corrected for lung volume ([s]iRaw) at TLC|Percent change from baseline to Week 24 in regional airway resistance corrected for lung volume ([s]iVaw) at functional residual capacity (FRC)|Change from baseline to Week 24 in lobar volumes (iVlobes) at TLC|Change from baseline to Week 24 in image-based ventilation/perfusion (iV/Q) at TLC|Change from baseline to Week 24 in HRCT-based internal airflow distribution (IAD)|Change from baseline to Week 24 in FeNO|The number of patients with FeNO <25 parts per billion (ppb) at Week 24|Change from baseline to Week 24 in post-bronchodilator FEV1|Change from baseline to Week 24 in ACQ-7|Incidence of treatment emergent adverse events (TEAE) and serious adverse events (SAE) including clinically significant changes in vital signs and laboratory abnormalities|Incidence of adverse events of special interest (AESI )","Sanofi|Regeneron Pharmaceuticals","All","18 Years to 70 Years   (Adult, Older Adult)","Phase 4","153","Industry","Interventional","Allocation: Randomized|Intervention Model: Parallel Assignment|Masking: Triple (Participant, Care Provider, Investigator)|Primary Purpose: Treatment","LPS15834|U1111-1238-4679","June 22, 2020","April 2023","April 2023","May 22, 2020",,"February 14, 2022","Investigational Site Number :8400012, Aurora, Colorado, United States|Investigational Site Number :8400008, Kansas City, Kansas, United States|Investigational Site Number :8400002, Ann Arbor, Michigan, United States|Investigational Site Number :8400010, Chesterfield, Missouri, United States|Investigational Site Number :8400005, Charlotte, North Carolina, United States|Investigational Site Number :8400014, Medford, Oregon, United States|Investigational Site Number :8400007, Anderson, South Carolina, United States|Investigational Site Number :8400009, Charleston, South Carolina, United States|Investigational Site Number :8400013, Greenville, South Carolina, United States|Investigational Site Number :8400004, Spartanburg, South Carolina, United States|Investigational Site Number :8400011, Spartanburg, South Carolina, United States|Investigational Site Number :1000013, Dupnitsa, Bulgaria|Investigational Site Number :1000004, Montana, Bulgaria|Investigational Site Number :1000018, Plovdiv, Bulgaria|Investigational Site Number :1000012, Plovdiv, Bulgaria|Investigational Site Number :1000008, Ruse, Bulgaria|Investigational Site Number :1000015, Sofia, Bulgaria|Investigational Site Number :1000005, Sofia, Bulgaria|Investigational Site Number :1000003, Sofia, Bulgaria|Investigational Site Number :1000006, Sofia, Bulgaria|Investigational Site Number :1000011, Sofia, Bulgaria|Investigational Site Number :1000010, Sofia, Bulgaria|Investigational Site Number :1000002, Sofia, Bulgaria|Investigational Site Number :1000007, Stara Zagora, Bulgaria|Investigational Site Number :2080004, Aalborg, Denmark|Investigational Site Number :2080006, Aarhus N, Denmark|Investigational Site Number :2080003, Copenhagen Nv, Denmark|Investigational Site Number :2080002, Copenhagen, Denmark|Investigational Site Number :2080005, Hellerup, Denmark|Investigational Site Number :2080001, Hvidovre, Denmark|Investigational Site Number :2500002, Lyon, France|Investigational Site Number :2500003, Marseille, France|Investigational Site Number :2500001, Montpellier, France|Investigational Site Number :3800003, Cona, Ferrara, Italy|Investigational Site Number :3800001, Pisa, Italy|Investigational Site Number :6200004, Coimbra, Portugal|Investigational Site Number :6200005, Guimarães, Portugal|Investigational Site Number :6200006, Lisboa, Portugal|Investigational Site Number :6200003, Porto, Portugal|Investigational Site Number :6200001, Porto, Portugal|Investigational Site Number :6420005, Bragadiru, Romania|Investigational Site Number :6420008, Brasov, Romania|Investigational Site Number :6420006, Cluj-Napoca, Romania|Investigational Site Number :6420001, Cluj-Napoca, Romania|Investigational Site Number :6420007, Oradea, Romania|Investigational Site Number :6420003, Timisoara, Romania|Investigational Site Number :6820008, Dammam, Saudi Arabia|Investigational Site Number :6820004, Jeddah, Saudi Arabia|Investigational Site Number :6820006, Riyadh, Saudi Arabia|Investigational Site Number :6820001, Riyadh, Saudi Arabia|Investigational Site Number :6820002, Riyadh, Saudi Arabia|Investigational Site Number :6820010, Riyadh, Saudi Arabia|Investigational Site Number :7240001, Barcelona, Barcelona [Barcelona], Spain|Investigational Site Number :7240002, Santiago de Compostela, Galicia [Galicia], Spain|Investigational Site Number :7240004, Madrid / Madrid, Madrid, Comunidad De, Spain|Investigational Site Number :7240003, Madrid, Madrid, Comunidad De, Spain|Investigational Site Number :7520001, Lund, Sweden|Investigational Site Number :1580004, Kaohsiung, Taiwan|Investigational Site Number :1580002, Taichung, Taiwan|Investigational Site Number :1580003, Tainan, Taiwan|Investigational Site Number :1580001, Taipei, Taiwan|Investigational Site Number :8040003, Chernivtsi, Ukraine|Investigational Site Number :8040001, Ivano-Frankivsk, Ukraine|Investigational Site Number :8040002, Kharkiv, Ukraine|Investigational Site Number :8040004, Kyiv, Ukraine|Investigational Site Number :8040005, Odesa, Ukraine|Investigational Site Number :8040007, Ternopil, Ukraine|Investigational Site Number :8260001, Leicester, Leicestershire, United Kingdom|Investigational Site Number :8260002, Bradford, United Kingdom",,"https://ClinicalTrials.gov/show/NCT04400318"
295,"NCT04398524","A Phase II Study of Cemiplimab and ISA101b in Patients With Recurrent/Metastatic HPV16 Positive OPC",,"Recruiting","No Results Available","Squamous Cell Carcinoma of the Oropharynx","Drug: ISA101B","Objective Response Rate based on radiographic response","ISA Pharmaceuticals|Regeneron Pharmaceuticals","All","18 Years and older   (Adult, Older Adult)","Phase 2","86","Industry","Interventional","Allocation: N/A|Intervention Model: Single Group Assignment|Masking: None (Open Label)|Primary Purpose: Treatment","ISA101b-OPC-03-19","July 1, 2021","December 30, 2022","November 1, 2024","May 21, 2020",,"January 4, 2022","City of Hope National Medical Center, Duarte, California, United States|H. Lee Moffitt Cancer Center & Research Institute, Tampa, Florida, United States|Beth Israel Deaconess Medical Center, Boston, Massachusetts, United States|Washington University, Saint Louis, Missouri, United States|Roswell Park Cancer Institute, Buffalo, New York, United States|Providence Portland Medical Center, Portland, Oregon, United States|The University of Texas M. D. Anderson Cancer Center, Houston, Texas, United States|University Hospital Antwerp, Antwerp, Belgium|University Hospital Ghent, Ghent, Belgium|Centre Hospitalier Universitaire de Liege, Liège, Belgium|Clinic of Oncology, Olomouc, Czechia|Institute of Radiation Oncology, Prague, Czechia|University Hospital Motol, Clinic of Oncology, Prague, Czechia|CHU La Timone - La Timone Children's Hospital, Marseille, France|Georges Pompidou European Hospital, Paris, France|Jean Godinot Institute, Cancer Research Center, Reims, France|Jean Godinot Institute, Reims, France|Paul Strauss Center, Strasbourg, France|Gustave Roussy Institute, Villejuif, France|University Hospital Giessen and Marburg GmbH, Gießen, Germany|Universitätsmedizin Göttingen, Göttingen, Germany|University Hospital Mannheim, Mannheim, Germany|Caritas Klinikum, Saarbruecken, Germany|University Hospital Ulm, Ulm, Germany|Hadassah Medical Center, Jerusalem, Israel|The Tel Aviv Sourasky Medical Cente, Tel Aviv, Israel|Sheba Medical Center, Tel HaShomer, Israel|Fondazione IRCCS Istituto Nazionale dei Tumori, Milan, Italy|Hospital Clinic of Barcelona, Barcelona, Spain|University Hospital Vall d'Hebron, Barcelona, Spain|Royal Marsden Hospital, London, United Kingdom",,"https://ClinicalTrials.gov/show/NCT04398524"
296,"NCT04380038","Viral Infection in Asthma (VIA) Study","VIA","Not yet recruiting","No Results Available","Asthma","Drug: Dupilumab Injectable Product","Change in interleukin-25 transcript expression post-rhinovirus inoculation|Change in transcriptome in nasal brushing samples post-rhinovirus inoculation|Change in the proteome in nasal wash samples post-rhinovirus inoculation|Change in allergen-specific Th2 effector lymphocytes post-rhinovirus inoculation|Change in symptoms post-rhinovirus inoculation","University of Virginia|Regeneron Pharmaceuticals","All","18 Years to 40 Years   (Adult)","Phase 4","60","Other|Industry","Interventional","Allocation: Randomized|Intervention Model: Parallel Assignment|Masking: Quadruple (Participant, Care Provider, Investigator, Outcomes Assessor)|Primary Purpose: Treatment","HSR200039","February 1, 2022","January 31, 2024","January 31, 2024","May 8, 2020",,"October 22, 2021",,,"https://ClinicalTrials.gov/show/NCT04380038"
297,"NCT04339062","Cemiplimab in AlloSCT/SOT Recipients With CSCC","CONTRAC","Recruiting","No Results Available","Cutaneous Squamous Cell Carcinoma|Advanced Cancer","Drug: Cemiplimab|Drug: Everolimus|Drug: Sirolimus|Drug: Prednisone","Rate of Dose Limiting Toxicity|Progression Free Survival Rate|Overall Survival Rate|Overall Response Rate|Therapeutic Response Rate|Secondary Infection Rate","Dana-Farber Cancer Institute|Regeneron Pharmaceuticals","All","18 Years and older   (Adult, Older Adult)","Phase 1","12","Other|Industry","Interventional","Allocation: Non-Randomized|Intervention Model: Parallel Assignment|Masking: None (Open Label)|Primary Purpose: Treatment","19-817","July 15, 2020","July 1, 2022","July 1, 2023","April 8, 2020",,"July 27, 2021","Dana Farber Cancer Institute, Boston, Massachusetts, United States",,"https://ClinicalTrials.gov/show/NCT04339062"
298,"NCT04327388","Sarilumab COVID-19",,"Completed","Has Results","Corona Virus Infection","Drug: Sarilumab SAR153191|Drug: Placebo","Time to Improvement in Clinical Status of Participants (Using 7-point Ordinal Scale Score) by at Least 2 Points|Percentage of Participants Who Were Alive at Day 29|Percentage of Participants With Improvement in Clinical Status (According to 7-point Ordinal Scale Score) by at Least 1 Point From Baseline at Days 4, 7, 15, 21, and 29|Change From Baseline at Days 4, 7, 15, 21, 29 in 7-point Ordinal Scale Score|Time to Resolution of Fever|Time to Resolution of Fever and Improvement in Oxygenation|Number of Days With Fever|Percentage of Participants in Each National Early Warning Score 2 (NEWS2) Clinical Risk Category at Baseline and at Days 4, 7, 15, 21, and 29|Time to National Early Warning Score of Less Than (<) 2 and Maintained for 24 Hours|Change From Baseline at Days 4, 7, 15, 21, and 29 in National Early Warning Score 2|Time-to-improvement in Oxygenation|Percentage of Participants Alive Off Supplemental Oxygen at Day 29|Percentage of Days With Hypoxemia|Percentage of Days With Supplemental Oxygen Use|Percentage of Days With Resting Respiratory Rate > 24 Breaths Per Minute|Time to Oxygen Saturation >= 94% on Room Air|Mean Number of Ventilator Free Days|Percentage of Participants With Initiation of Mechanical Ventilation, Non-invasive Ventilation, or Use of High Flow Nasal Cannula|Percentage of Participants Who Required Rescue Medication|Percentage of Participants Who Needed Intensive Care Unit (ICU) Care During Study|Number of Days of Hospitalization Among Survivors (Alive Participants)|Number of Participants With Treatment-emergent Serious Adverse Events (SAEs)|Number of Participants With Major or Opportunistic Bacterial or Fungal Infections|Number of Participants With Grade 4 Neutropenia and Grade 4 Neutropenia With Concurrent Invasive Infection|Number of Participants With Grade >=2 Infusion Reactions, Grade >=2 Hypersensitivity Reactions and Gastrointestinal Perforation|Number of Participants With Potentially Clinically Significant Laboratory Abnormalities (PCSA): Hematological Parameter - Hemoglobin, Leukocytes and Platelets|Number of Participants With Potentially Clinically Significant Laboratory Abnormalities: Renal Function Parameters|Number of Participants With Potentially Clinically Significant Laboratory Abnormalities: Liver Function Parameters","Sanofi|Regeneron Pharmaceuticals","All","18 Years and older   (Adult, Older Adult)","Phase 3","420","Industry","Interventional","Allocation: Randomized|Intervention Model: Parallel Assignment|Masking: Quadruple (Participant, Care Provider, Investigator, Outcomes Assessor)|Primary Purpose: Treatment","EFC16844|2020-001162-12|U1111-1249-6021","March 28, 2020","July 31, 2020","September 2, 2020","March 31, 2020","May 13, 2021","May 13, 2021","Investigational Site Number 0320001, Caba, Argentina|Investigational Site Number 0320003, Caba, Argentina|Investigational Site Number 0320004, Caba, Argentina|Investigational Site Number 0760003, Porto Alegre, Brazil|Investigational Site Number 0760001, Sao Paulo, Brazil|Investigational Site Number 0760002, Sao Paulo, Brazil|Investigational Site Number 0760004, São José Do Rio Preto, Brazil|Investigational Site Number 0760005, São Paulo, Brazil|Investigational Site Number 1240001, Montreal, Canada|Investigational Site Number 1240005, Montreal, Canada|Investigational Site Number 1240004, Toronto, Canada|Investigational Site Number 1240002, Toronto, Canada|Investigational Site Number 1240003, Vancouver, Canada|Investigational Site Number 1520003, Santiago, Chile|Investigational Site Number 1520002, Santiago, Chile|Investigational Site Number 1520004, Santiago, Chile|Investigational Site Number 1520001, Talca, Chile|Investigational Site Number 2500001, Bordeaux Cedex, France|Investigational Site Number 2500007, Clamart, France|Investigational Site Number 2500006, La Roche Sur Yon Cedex 9, France|Investigational Site Number 2500002, Nantes, France|Investigational Site Number 2500005, Paris Cedex 18, France|Investigational Site Number 2500003, Strasbourg, France|Investigational Site Number 2500004, Suresnes, France|Investigational Site Number 2760002, Essen, Germany|Investigational Site Number 2760004, Köln, Germany|Investigational Site Number 2760001, Münster, Germany|Investigational site number 3760003, Ashdod, Israel|Investigational Site Number 3760002, Jerusalem, Israel|Investigational Site Number 3760001, Ramat Gan, Israel|Investigational Site Number 3800005, Milano, Italy|Investigational Site Number 3800001, Milano, Italy|Investigational Site Number 3800002, Milano, Italy|Investigational Site Number 3800003, Modena, Italy|Investigational Site Number 3800004, Parma, Italy|Investigational Site Number 3800006, Rozzano, Italy|Investigational Site Number 3920002, Fuchu-Shi, Japan|Investigational Site Number 3920003, Iruma-Gun, Japan|Investigational Site Number 3920001, Kamakura-Shi, Japan|Investigational Site Number 6430003, Moscow, Russian Federation|Investigational Site Number 6430002, Moscow, Russian Federation|Investigational Site Number 6430001, Moscow, Russian Federation|Investigational Site Number 7240003, Barcelona, Spain|Investigational Site Number 7240004, Barcelona, Spain|Investigational Site Number 7240002, Madrid, Spain|Investigational Site Number 7240005, Madrid, Spain|Investigational Site Number 7240001, Madrid, Spain","""Study Protocol"", https://ClinicalTrials.gov/ProvidedDocs/88/NCT04327388/Prot_000.pdf|""Statistical Analysis Plan"", https://ClinicalTrials.gov/ProvidedDocs/88/NCT04327388/SAP_001.pdf","https://ClinicalTrials.gov/show/NCT04327388"
299,"NCT04311606","Anti-VEGF Therapy for Acute Thyroid Eye Disease","AcTED","Recruiting","No Results Available","Thyroid Eye Disease","Drug: Sub-tenon injection of saline followed by a sub-tenon injection of aflibercept|Drug: Sub-tenon injection of hyaluronidase (HA) followed by a sub-tenon injection of aflibercept|Drug: Sub-tenon injection of hyaluronidase (HA) alone","Primary Outcome: Safety|Secondary Outcome: Safety|Secondary Outcome: Change in Clinical Activity|Secondary Outcome: Change in Ocular Muscle|Secondary Outcome: Change in Proptosis measured by exophthalmometry|Secondary Outcome: Change in Proptosis by CT scan|Secondary Outcome: Change in Ocular Alignment|Secondary Outcome: Change in Ocular Motility|Secondary Outcome: Change in Vision measured by ETDRS|Secondary Outcome: Change in Vision measured by BCVA|Secondary Outcome: Change in Visual Function|Secondary Outcome: Change in Pain/Discomfort Reported by Subjects|Secondary Outcome: Change in Eyelid Retraction/Position","Massachusetts Eye and Ear Infirmary|Regeneron Pharmaceuticals","All","18 Years and older   (Adult, Older Adult)","Phase 2","24","Other|Industry","Interventional","Allocation: Randomized|Intervention Model: Parallel Assignment|Masking: Double (Participant, Care Provider)|Primary Purpose: Treatment","2019P000939","November 2, 2020","September 30, 2025","January 1, 2027","March 17, 2020",,"February 25, 2022","Mass Eye and Ear, Boston, Massachusetts, United States",,"https://ClinicalTrials.gov/show/NCT04311606"
300,"NCT04291105","Phase 2 Trial of Voyager V1 in Combination With Cemiplimab in Cancer Patients",,"Recruiting","No Results Available","Melanoma|Non Small Cell Lung Cancer","Biological: VV1|Biological: Cemiplimab|Biological: Ipilumumab","Objective response rate (ORR) per imaging assessment|Incidence of Treatment-Emergent Adverse Events assessed by CTCAE v5.0|Serum concentration time|To investigate the pharmacodynamics (PD) of VV1 by measuring serum IFNβ","Vyriad, Inc.|Regeneron Pharmaceuticals","All","18 Years and older   (Adult, Older Adult)","Phase 2","152","Industry","Interventional","Allocation: Non-Randomized|Intervention Model: Sequential Assignment|Masking: None (Open Label)|Primary Purpose: Treatment","VYR-VSV2-203","April 24, 2020","March 2022","March 2023","March 2, 2020",,"January 20, 2022","Mayo Clinical, Phoenix, Arizona, United States|City of Hope Medical Center, Duarte, California, United States|USC Norris Comprehensive Cancer Center, Los Angeles, California, United States|HOAG Memorial Hospital Presbyterian, Newport Beach, California, United States|Saint John's Health Center - John Wayne Cancer Institute (JWCI), Santa Monica, California, United States|Stanford Health Care, Stanford, California, United States|Yale University, New Haven, Connecticut, United States|Georgetown University Medical Center, Washington, District of Columbia, United States|Mayo Clinical, Jacksonville, Florida, United States|University of Miami, Miami, Florida, United States|Ochsner Clinic Foundation, New Orleans, Louisiana, United States|Massachusetts General Hospital Cancer Center, Boston, Massachusetts, United States|Masonic Cancer Center, University of Minnesota, Minneapolis, Minnesota, United States|Mayo Clinic, Rochester, Minnesota, United States|Billings Clinic Montana Cancer Consortium, Billings, Montana, United States|Atlantic Health, Morristown, New Jersey, United States|Rutgers Cancer Institute of New Jersey, New Brunswick, New Jersey, United States|Icahn School of Medicine at Mount Sinai, New York, New York, United States|University of Cincinnati Medical Center, Cincinnati, Ohio, United States|Ohio State University, Columbus, Ohio, United States|UPMC, Pittsburgh, Pennsylvania, United States|Sanford Cancer Center, Sioux Falls, South Dakota, United States|UT Health San Antonio MD Anderson Cancer Center, San Antonio, Texas, United States",,"https://ClinicalTrials.gov/show/NCT04291105"
301,"NCT04256759","Dupilumab for the Treatment of Moderate to Severe Chronic Hepatic Pruritus",,"Recruiting","No Results Available","Pruritus","Drug: Dupilumab 300Mg Solution for Injection","Peak Pruritus Numerical Rating Score (PRNS)|Improvement in weekly average Peak Pruritus Numerical Rating Score (PRNS) ≥3 from baseline.|Improvement in weekly average Peak Pruritus Numerical Rating Score (PRNS) ≥4 from baseline.|Verbal rating scale (VRS)","Mayo Clinic|Regeneron Pharmaceuticals","All","18 Years and older   (Adult, Older Adult)","Phase 2","12","Other|Industry","Interventional","Allocation: N/A|Intervention Model: Single Group Assignment|Masking: None (Open Label)|Primary Purpose: Treatment","19-002757","September 1, 2020","September 2023","December 2023","February 5, 2020",,"November 18, 2021","Mayo Clinic Florida, Jacksonville, Florida, United States",,"https://ClinicalTrials.gov/show/NCT04256759"
302,"NCT04242173","Cemiplimab-rwlc for Unresectable Locally Recurrent and/or Metastatic CSCC",,"Active, not recruiting","No Results Available","Cutaneous Squamous Cell Carcinoma|Cutaneous Squamous Cell Carcinoma of the Head and Neck","Drug: Cemiplimab-Rwlc","Overall Response Rate|Progression Free Survival|Overall Survival","H. Lee Moffitt Cancer Center and Research Institute|Regeneron Pharmaceuticals","All","18 Years and older   (Adult, Older Adult)","Phase 2","3","Other|Industry","Interventional","Allocation: N/A|Intervention Model: Single Group Assignment|Masking: None (Open Label)|Primary Purpose: Treatment","MCC-20114","June 25, 2020","November 19, 2022","January 2023","January 27, 2020",,"February 21, 2022","University of Arizona Cancer Center, Tucson, Arizona, United States|Moffitt Cancer Center, Tampa, Florida, United States",,"https://ClinicalTrials.gov/show/NCT04242173"
303,"NCT04202679","Study of Dupilumab for the Treatment of Patients With Prurigo Nodularis, Inadequately Controlled on Topical Prescription Therapies or When Those Therapies Are Not Advisable (PRIME2)",,"Completed","No Results Available","Neurodermatitis","Drug: Dupilumab SAR231893|Drug: Placebo|Drug: Moisturizers|Drug: Low to medium potent topical corticosteroids|Drug: Topical calcineurin inhibitors","Improvement (reduction) in worst-itch numeric rating scale (WI-NRS) by ≥4|Proportion of participants with Investigator's Global Assessment 0 or 1 score for PN-stage at Week 24|Time to onset of effect on pruritus|Change from baseline in WI-NRS|Percent change from baseline in WI-NRS|Percent change from baseline in WI-NRS over time|Proportion of participants with WI-NRS reduction ≥4 at Week 4|Proportion of participants with WI-NRS reduction ≥4 over time|Onset of action in change from baseline in WI-NRS|Proportion of participants with Investigator's Global Assessment 0 or 1 score for PN-stage|Change from baseline in IGA PN-S score|Proportion of participants with Investigator's Global Assessment 0 or 1 score for PN-Activity|Change from baseline in health-related quality-of-life|Percentage of participants experiencing treatment-emergent adverse events (TEAEs) or serious adverse events (SAEs) from baseline through Week 24|Incidence of treatment-emergent antidrug antibodies (ADA) against dupilumab over time","Sanofi|Regeneron Pharmaceuticals","All","18 Years to 80 Years   (Adult, Older Adult)","Phase 3","160","Industry","Interventional","Allocation: Randomized|Intervention Model: Parallel Assignment|Masking: Quadruple (Participant, Care Provider, Investigator, Outcomes Assessor)|Primary Purpose: Treatment","EFC16460|2019-003801-90|U1111-1241-8174","January 16, 2020","August 30, 2021","November 22, 2021","December 17, 2019",,"December 3, 2021","Investigational Site Number :8400054, Fort Smith, Arkansas, United States|Investigational Site Number :8400008, Sacramento, California, United States|Investigational Site Number :8400005, Pembroke Pines, Florida, United States|Investigational Site Number :8400002, Plainfield, Indiana, United States|Investigational Site Number :8400003, Baltimore, Maryland, United States|Investigational Site Number :8400006, East Windsor, New Jersey, United States|Investigational Site Number :8400001, Sugar Land, Texas, United States|Investigational Site Number :1240002, Calgary, Alberta, Canada|Investigational Site Number :1240006, Surrey, British Columbia, Canada|Investigational Site Number :1240007, Markham, Ontario, Canada|Investigational Site Number :1240008, Newmarket, Ontario, Canada|Investigational Site Number :1240001, Toronto, Ontario, Canada|Investigational Site Number :1240009, Saskatoon, Saskatchewan, Canada|Investigational Site Number :1520005, Valdivia, Los Ríos, Chile|Investigational Site Number :1520006, Osorno, Reg Metropolitana De Santiago, Chile|Investigational Site Number :1520003, Santiago, Reg Metropolitana De Santiago, Chile|Investigational Site Number :1520001, Santiago, Reg Metropolitana De Santiago, Chile|Investigational Site Number :1520004, Santiago, Reg Metropolitana De Santiago, Chile|Investigational Site Number :1520002, Santiago, Chile|Investigational Site Number :2500007, Bordeaux, France|Investigational Site Number :2500001, Brest, France|Investigational Site Number :2500008, Le Mans, France|Investigational Site Number :2500002, Lille, France|Investigational Site Number :2500006, Lyon, France|Investigational Site Number :2500004, Paris, France|Investigational Site Number :2500005, Reims, France|Investigational Site Number :2500003, Toulouse, France|Investigational Site Number :3480004, Debrecen, Hungary|Investigational Site Number :3480002, Orosháza, Hungary|Investigational Site Number :3480005, Pécs, Hungary|Investigational Site Number :3480003, Szeged, Hungary|Investigational Site Number :3800001, Rozzano, Milano, Italy|Investigational Site Number :3800004, Ancona, Italy|Investigational Site Number :3800003, Catanzaro, Italy|Investigational Site Number :3800002, Milano, Italy|Investigational Site Number :4100002, Busan, Busan-gwangyeoksi, Korea, Republic of|Investigational Site Number :4100003, Bucheon-si, Gyeonggi-do, Korea, Republic of|Investigational Site Number :4100007, Incheon, Incheon-gwangyeoksi, Korea, Republic of|Investigational Site Number :4100005, Seoul, Seoul-teukbyeolsi, Korea, Republic of|Investigational Site Number :4100001, Seoul, Seoul-teukbyeolsi, Korea, Republic of|Investigational Site Number :4100006, Seoul, Seoul-teukbyeolsi, Korea, Republic of|Investigational Site Number :6200001, Coimbra, Portugal|Investigational Site Number :6200002, Lisboa, Portugal|Investigational Site Number :6200003, Porto, Portugal|Investigational Site Number :7240008, Santullano, Asturias, Spain|Investigational Site Number :7240009, Badalona, Barcelona [Barcelona], Spain|Investigational Site Number :7240001, Pontevedra, Galicia [Galicia], Spain|Investigational Site Number :7240004, Córdoba, Spain|Investigational Site Number :7240007, Madrid, Spain|Investigational Site Number :7240003, Valencia, Spain|Investigational Site Number :7240002, Zaragoza, Spain|Investigational Site Number :1580005, Hsinchu City, Taiwan|Investigational Site Number :1580006, Kaohsiung, Taiwan|Investigational Site Number :1580008, Taichung, Taiwan|Investigational Site Number :1580001, Taipei, Taiwan|Investigational Site Number :1580002, Taipei, Taiwan|Investigational Site Number :8260001, Redhill, Surrey, United Kingdom",,"https://ClinicalTrials.gov/show/NCT04202679"
304,"NCT04183335","Study of Dupilumab for the Treatment of Patients With Prurigo Nodularis, Inadequately Controlled on Topical Prescription Therapies or When Those Therapies Are Not Advisable (LIBERTY-PN PRIME)",,"Completed","No Results Available","Neurodermatitis","Drug: Dupilumab SAR231893|Drug: Placebo|Drug: Moisturizers|Drug: Low to medium potent topical corticosteroids|Drug: Topical calcineurin inhibitors","Proportion of participants with improvement (reduction) in worst-itch numeric rating scale (WI-NRS) by ≥4 from baseline to Week 24|Time to onset of effect on pruritus as measured by proportion of participants with an improvement (reduction) in WI-NRS by ≥4 from baseline during the 24-week treatment period|Change from baseline in WI-NRS|Percent change from baseline in WI-NRS|Percent change from baseline in WI-NRS over time|Proportion of participants with improvement (reduction) in WI-NRS reduction ≥4|Proportion of participants with WI-NRS reduction ≥ 4 over time until Week 24|Onset of action in change from baseline in WI-NRS|Proportion of participants with Investigator's Global Assessment 0 or 1 score for PN-stage at Week 24|Proportion of participants with IGA PN-S 0 or 1 score at Week 4, 8 and 12|Change from baseline in IGA PN-S score|Proportion of participants with Investigator's Global Assessment 0 or 1 score for PN-Activity (IGA PN-A)|Change from baseline in health-related quality-of-life, (HRQoL), as measured by Dermatology Life Quality Index (DLQI)|Percentage of participants experiencing treatment-emergent adverse events (TEAEs) or serious adverse events (SAEs) from baseline through Week 24|Incidence of treatment-emergent antidrug antibodies (ADA) against dupilumab over time","Sanofi|Regeneron Pharmaceuticals","All","18 Years to 80 Years   (Adult, Older Adult)","Phase 3","151","Industry","Interventional","Allocation: Randomized|Intervention Model: Parallel Assignment|Masking: Quadruple (Participant, Care Provider, Investigator, Outcomes Assessor)|Primary Purpose: Treatment","EFC16459|2019-003774-41|U1111-1241-8153","December 12, 2019","November 12, 2021","February 3, 2022","December 3, 2019",,"February 17, 2022","Investigational Site Number :8400011, Gilbert, Arizona, United States|Investigational Site Number :8400022, Fort Smith, Arkansas, United States|Investigational Site Number :8400026, Sacramento, California, United States|Investigational Site Number :8400014, Miami, Florida, United States|Investigational Site Number :8400004, Columbus, Georgia, United States|Investigational Site Number :8400003, Newnan, Georgia, United States|Investigational Site Number :8400017, Sandy Springs, Georgia, United States|Investigational Site Number :8400016, Indianapolis, Indiana, United States|Investigational Site Number :8400018, Clarkston, Michigan, United States|Investigational Site Number :8400013, Saint Louis, Missouri, United States|Investigational Site Number :8400024, East Windsor, New Jersey, United States|Investigational Site Number :8400009, Athens, Ohio, United States|Investigational Site Number :8400001, Dublin, Ohio, United States|Investigational Site Number :8400007, Tulsa, Oklahoma, United States|Investigational Site Number :8400010, Philadelphia, Pennsylvania, United States|Investigational Site Number :8400015, Charleston, South Carolina, United States|Investigational Site Number :8400006, Bellaire, Texas, United States|Investigational Site Number :8400025, Houston, Texas, United States|Investigational Site Number :8400002, Pflugerville, Texas, United States|Investigational Site Number :8400019, San Antonio, Texas, United States|Investigational Site Number :8400005, Norfolk, Virginia, United States|Investigational Site Number :0320008, Caba, Buenos Aires, Argentina|Investigational Site Number :0320005, Caba, Buenos Aires, Argentina|Investigational Site Number :0320002, Caba, Buenos Aires, Argentina|Investigational Site Number :0320004, Caba, Ciudad De Buenos Aires, Argentina|Investigational Site Number :0320007, Caba, Ciudad De Buenos Aires, Argentina|Investigational Site Number :0320003, San Miguel de Tucuman, Tucumán, Argentina|Investigational Site Number :0320001, Buenos Aires, Argentina|Investigational Site Number :0320006, Caba, Argentina|Investigational Site Number :0320009, Mendoza, Argentina|Investigational Site Number :1560004, Beijing, China|Investigational Site Number :1560001, Chengdu, China|Investigational Site Number :1560002, Hangzhou, China|Investigational Site Number :1560003, Wuxi, China|Investigational Site Number :2500005, Reims, France|Investigational Site Number :3920009, Yokohama-shi, Kanagawa, Japan|Investigational Site Number :3920005, Kyoto-shi, Kyoto, Japan|Investigational Site Number :3920007, Nagasaki-shi, Nagasaki, Japan|Investigational Site Number :3920003, Tokorozawa-shi, Saitama, Japan|Investigational Site Number :3920010, Izumo-shi, Shimane, Japan|Investigational Site Number :3920004, Bunkyo-ku, Tokyo, Japan|Investigational Site Number :3920006, Itabashi-ku, Tokyo, Japan|Investigational Site Number :3920001, Shinagawa-Ku, Tokyo, Japan|Investigational Site Number :3920002, Nagoya-shi, Japan|Investigational Site Number :4100007, Seongnam-si, Gyeonggi-do, Korea, Republic of|Investigational Site Number :4100005, Incheon, Incheon-gwangyeoksi, Korea, Republic of|Investigational Site Number :4100002, Seoul, Seoul-teukbyeolsi, Korea, Republic of|Investigational Site Number :4100003, Seoul, Seoul-teukbyeolsi, Korea, Republic of|Investigational Site Number :4100004, Seoul, Seoul-teukbyeolsi, Korea, Republic of|Investigational Site Number :4100001, Incheon, Korea, Republic of|Investigational Site Number :4840002, Guadalajara, Jalisco, Mexico|Investigational Site Number :4840001, Monterrey, Nuevo León, Mexico|Investigational Site Number :4840005, Monterrey, Nuevo León, Mexico|Investigational Site Number :4840006, Guadalajara, Mexico|Investigational Site Number :4840003, Veracruz, Mexico|Investigational Site Number :6430008, Chelyabinsk, Russian Federation|Investigational Site Number :6430007, Krasnodar, Russian Federation|Investigational Site Number :6430005, Moscow, Russian Federation|Investigational Site Number :6430010, Moscow, Russian Federation|Investigational Site Number :6430006, Moscow, Russian Federation|Investigational Site Number :6430009, Saratov, Russian Federation|Investigational Site Number :6430002, St-Petersburg, Russian Federation|Investigational Site Number :6430001, Stavropol, Russian Federation",,"https://ClinicalTrials.gov/show/NCT04183335"
305,"NCT04180488","Dupilumab for the Treatment of Chronic Spontaneous Urticaria in Patients Who Remain Symptomatic Despite the Use of H1 Antihistamine and Who Are naïve to, Intolerant of, or Incomplete Responders to Omalizumab","CUPID","Active, not recruiting","No Results Available","Chronic Spontaneous Urticaria","Drug: Dupilumab SAR231893|Drug: Placebo|Drug: non sedating H1-antihistamine","Change from baseline in weekly itch severity score (except EU and EU reference countries)|For EU and EU reference countries only: change from baseline in weekly urticaria activity score|Change from baseline in weekly urticaria activity score|Change from baseline in ISS7|Change from baseline in weekly hives severity score|4. Time to ISS7 minimally important (MID) (ISS7 ≥5) response|Proportion of ISS7 MID (≥5 points) responders|Change from baseline in ISS7 at all time points|Proportion of patients with UAS7 ≤6|Proportion of patients with UAS7=0|Change from baseline in angioedema activity score over 7 days (AAS7)|Change from baseline in urticaria control test (UCT)|Proportion of well controlled patients (UCT ≥12)|Change from baseline in health-related quality-of-life - DLQI|Change from baseline in health-related quality-of-life - CDLQI|Patient Global Assessment of Change (PGIC) of CSU|Change from baseline in Patient Global Impression of Severity (PGIS) of CSU|Proportion of patients receiving OCS for CSU during the planned treatment period|Time to event of patients receiving OCS for CSU during the planned treatment period|Percentage of participants experiencing treatment-emergent adverse events (TEAEs) or serious adverse events (SAEs)|Incidence of treatment-emergent ADA against dupilumab over time","Sanofi|Regeneron Pharmaceuticals","All","6 Years to 80 Years   (Child, Adult, Older Adult)","Phase 3","246","Industry","Interventional","Allocation: Randomized|Intervention Model: Parallel Assignment|Masking: Quadruple (Participant, Care Provider, Investigator, Outcomes Assessor)|Primary Purpose: Treatment","EFC16461|2019-003775-19|U1111-1241-8208","December 11, 2019","April 2022","April 17, 2024","November 27, 2019",,"January 11, 2022","Investigational Site Number :8400019, Los Angeles, California, United States|Investigational Site Number :8400017, Sarasota, Florida, United States|Investigational Site Number :8400001, Sweetwater, Florida, United States|Investigational Site Number :8400006, Tampa, Florida, United States|Investigational Site Number :8400018, Savannah, Georgia, United States|Investigational Site Number :8400020, Owensboro, Kentucky, United States|Investigational Site Number :8400016, Baltimore, Maryland, United States|Investigational Site Number :8400009, Saint Louis, Missouri, United States|Investigational Site Number :8400008, Rochester, New York, United States|Investigational Site Number :8400010, Charlotte, North Carolina, United States|Investigational Site Number :8400014, Cincinnati, Ohio, United States|Investigational Site Number :8400015, Tulsa, Oklahoma, United States|Investigational Site Number :8400011, Charleston, South Carolina, United States|Investigational Site Number :8400003, Dallas, Texas, United States|Investigational Site Number :8400007, San Antonio, Texas, United States|Investigational Site Number :0320008, Caba, Buenos Aires, Argentina|Investigational Site Number :0320004, Caba, Buenos Aires, Argentina|Investigational Site Number :0320006, Rosario, Santa Fe, Argentina|Investigational Site Number :0320007, Rosario, Santa Fe, Argentina|Investigational Site Number :0320005, Rosario, Santa Fe, Argentina|Investigational Site Number :0320003, San Miguel de Tucuman, Tucumán, Argentina|Investigational Site Number :0320001, Buenos Aires, Argentina|Investigational Site Number :1240009, Calgary, Alberta, Canada|Investigational Site Number :1240010, Edmonton, Alberta, Canada|Investigational Site Number :1240008, Kingston, Ontario, Canada|Investigational Site Number :1240005, Toronto, Ontario, Canada|Investigational Site Number :1240002, Toronto, Ontario, Canada|Investigational Site Number :1240007, Windsor, Ontario, Canada|Investigational Site Number :1240006, Trois-Rivieres, Quebec, Canada|Investigational Site Number :1240004, Quebec, Canada|Investigational Site Number :1560004, Beijing, China|Investigational Site Number :1560001, Chengdu, China|Investigational Site Number :1560007, Guangzhou, China|Investigational Site Number :1560002, Hangzhou, China|Investigational Site Number :1560008, Hangzhou, China|Investigational Site Number :1560006, Jinan, China|Investigational Site Number :1560003, Shanghai, China|Investigational Site Number :1560005, Wuxi, China|Investigational Site Number :2500001, Brest, France|Investigational Site Number :2500002, Lille, France|Investigational Site Number :2500004, Nantes, France|Investigational Site Number :2500003, Nice, France|Investigational Site Number :2500006, Paris cedex 20, France|Investigational Site Number :2500005, Pierre Benite, France|Investigational Site Number :2760001, Berlin, Germany|Investigational Site Number :2760003, Buxtehude, Germany|Investigational Site Number :2760006, Dresden, Germany|Investigational Site Number :2760007, Kiel, Germany|Investigational Site Number :2760005, Magdeburg, Germany|Investigational Site Number :3480005, Debrecen, Hungary|Investigational Site Number :3480004, Szeged, Hungary|Investigational Site Number :3480003, Szolnok, Hungary|Investigational Site Number :3480002, Szombathely, Hungary|Investigational Site Number :3920005, Hiroshima-shi, Hiroshima, Japan|Investigational Site Number :3920009, Sapporo-shi, Hokkaido, Japan|Investigational Site Number :3920002, Kobe-shi, Hyogo, Japan|Investigational Site Number :3920008, Yokohama-shi, Kanagawa, Japan|Investigational Site Number :3920003, Suita-shi, Osaka, Japan|Investigational Site Number :3920007, Izumo-shi, Shimane, Japan|Investigational Site Number :3920006, Itabashi-ku, Tokyo, Japan|Investigational Site Number :3920001, Shinagawa-Ku, Tokyo, Japan|Investigational Site Number :3920010, Tachikawa-shi, Tokyo, Japan|Investigational Site Number :3920004, Nagoya-shi, Japan|Investigational Site Number :6430008, Chelyabinsk, Russian Federation|Investigational Site Number :6430006, Kazan, Russian Federation|Investigational Site Number :6430007, Krasnodar, Russian Federation|Investigational Site Number :6430005, Moscow, Russian Federation|Investigational Site Number :6430010, Moscow, Russian Federation|Investigational Site Number :6430002, Moscow, Russian Federation|Investigational Site Number :6430009, Saratov, Russian Federation|Investigational Site Number :6430004, Smolensk, Russian Federation|Investigational Site Number :6430003, St-Petersburg, Russian Federation|Investigational Site Number :6430001, Stavropol, Russian Federation|Investigational Site Number :7240003, Barcelona, Barcelona [Barcelona], Spain|Investigational Site Number :7240008, Barcelona, Barcelona [Barcelona], Spain|Investigational Site Number :7240005, Las Palmas de Gran Canaria, Las Palmas, Spain|Investigational Site Number :7240007, Madrid, Madrid, Comunidad De, Spain|Investigational Site Number :7240001, Madrid, Madrid, Comunidad De, Spain|Investigational Site Number :7240002, Pamplona, Navarra, Spain|Investigational Site Number :7240004, Córdoba, Spain|Investigational Site Number :7240006, Madrid Madrid, Spain|Investigational Site Number :7240009, Málaga, Spain|Investigational Site Number :8260002, London, London, City Of, United Kingdom|Investigational Site Number :8260001, Manchester, United Kingdom|Investigational Site Number :8260004, Newcastle upon Tyne, United Kingdom",,"https://ClinicalTrials.gov/show/NCT04180488"
306,"NCT04050436","Study Evaluating Cemiplimab Alone and Combined With RP1 in Treating Advanced Squamous Skin Cancer","CERPASS","Recruiting","No Results Available","Cutaneous Squamous Cell Carcinoma|Advanced Cutaneous Squamous Cell Carcinoma|Metastatic Cutaneous Squamous Cell Carcinoma","Drug: Cemiplimab|Biological: RP1","Objective Response Rate (ORR) according to blinded independent review|Complete Response Rate (CRR) according to blinded independent review|Progression Free Survival (PFS) by blinded independent review.|ORR/CRR by investigator assessment and blinded independent review|ORR/CRR for patients with metastatic or locally advanced disease according to investigator review and blinded independent review|ORR/CRR for patients who have and have not previously received systemic CSCC-directed therapy and blinded independent review|Duration of Response (DOR) per investigator review and blinded independent review|Progression-free Survival (PFS) per investigator review|Overall Survival (OS)|3-year survival|Change in overall scores of patient-reported outcomes in European Organisation for Research and Treatment of Cancer Quality of Life Questionnaire Core 30 (EORTC QLQ-C30)|Evaluation of the safety and tolerability of cemiplimab alone and combined with RP1 as assessed via adverse events (AEs)","Replimune Inc.|Regeneron Pharmaceuticals","All","18 Years and older   (Adult, Older Adult)","Phase 2","180","Industry","Interventional","Allocation: Randomized|Intervention Model: Parallel Assignment|Masking: None (Open Label)|Primary Purpose: Treatment","RPL-002-18","October 8, 2019","October 2022","March 2025","August 8, 2019",,"March 7, 2022","University of California San Diego, La Jolla, California, United States|University of California Los Angeles, Los Angeles, California, United States|UC Irvine, Orange, California, United States|Stanford University, Stanford, California, United States|University of Colorado Cancer Center, Aurora, Colorado, United States|Smilow Cancer Hospital at Yale New Haven, New Haven, Connecticut, United States|University of Miami Health System, Miami, Florida, United States|Orlando Health UF Health Cancer Center, Orlando, Florida, United States|Moffitt McKinley Outpatient Center, Tampa, Florida, United States|Winship Cancer Institute of Emory University, Atlanta, Georgia, United States|Rush University Medical Center, Chicago, Illinois, United States|University of Iowa Hospitals and Clinics, Iowa City, Iowa, United States|Dana-Farber Cancer Institute, Boston, Massachusetts, United States|Perlmutter Cancer Center at NYU Langone Health, New York, New York, United States|Memorial Sloan Kettering Cancer Center, New York, New York, United States|Weill Cornell Medicine, New York, New York, United States|University Of North Carolina at Chapel Hill, Chapel Hill, North Carolina, United States|University of Cincinnati Medical Center, Cincinnati, Ohio, United States|Ohio State University Comprehensive Cancer Center, Columbus, Ohio, United States|Prisma Health Cancer Institute, Greenville, South Carolina, United States|MD Anderson Cancer Center, Houston, Texas, United States|Chris O'Brien Lifehouse, Camperdown, New South Wales, Australia|Southern Medical Day Care Centre, Wollongong, New South Wales, Australia|Tasman Oncology Research Ltd, Southport, Queensland, Australia|Monash Medical Centre, Clayton, Victoria, Australia|Peter MacCallum Cancer Centre, Melbourne, Victoria, Australia|The Alfred Hospital, Melbourne, Victoria, Australia|Sir Charles Gairdner Hospital, Nedlands, Western Australia, Australia|Ottawa Hospital Research Institute, Ottawa, Ontario, Canada|Sunnybrook Health Science Centre, Toronto, Ontario, Canada|Princess Margaret Cancer Centre, Toronto, Ontario, Canada|CHU Besancon - Hopital Jean Minjoz, Besancon, France|CHU Dijon Hopital F. Mitterrand Service de Dermatologie - UMAC, Dijon, France|CHU de Grenoble - Hopital A Michallon, La Tronche, France|CHRU de Lille, Lille, France|Centre Léon Bérard, Lyon, France|Service de Dermatologie et Cancerologie Cutanee Hopital de la Timone, Marseille, France|CHU Nice - Hopital de l'Archet 2, Nice, France|Hospital Saint Louis, Paris, France|Hospices Civils de Lyon, Pierre-Bénite, France|Institut Gustave Roussy, Villejuif, France|Hippocratio General Hospital of Athens, Athens, Greece|Attiko University Hospital, Athens, Greece|Andreas Syggros Hospital, Athens, Greece|Bioclinic of Thessaloniki, Thessaloniki, Greece|Uniwersyteckie Centrum Kliniczne; Centrum Leczenia Czerniaka w Gdańsku, Gdańsk, Poland|Narodowy Instytut Onkologii; Panstwowy Instytut Badawczy Oddzial w Krakowie, Kraków, Poland|Narodowy Instytut Onkologii; Panstwowy Instytut Badawczy, Warsaw, Poland|Hospital Clinic Barcelona, Barcelona, Spain|Hospital Universitario De La Princesa, Madrid, Spain|Hospital Universitario Virgen de la Arrixaca, Murcia, Spain|Clinica Universitaria de Navarra, Pamplona, Spain|Hospital General Universitario De Valencia, Valencia, Spain",,"https://ClinicalTrials.gov/show/NCT04050436"
307,"NCT04046107","Safety and Immunotherapeutic Activity of Cemiplimab in Participants With HBV on Suppressive Antiviral Therapy",,"Recruiting","No Results Available","Hepatitis B Virus","Biological: Cemiplimab","Number of participants who experienced any targeted safety event that is related to study treatment|Number of participants who discontinue treatment and/or study which is related to any adverse event|Number of participants with any AE|Change in quantitative HBsAg from pre-treatment|Number of participants with detectable HBsAg|Number of participants with anti-HBs conversion from negative (at study Week 6) to positive at a subsequent visit|Number of participants with anti-HBe conversion from negative (at study Week 6) to positive at a subsequent visit|Change in quantitative HBeAg from pre-treatment|Detection of hepatitis B core-related antigen (HBcrAg)","National Institute of Allergy and Infectious Diseases (NIAID)|Regeneron Pharmaceuticals","All","18 Years to 70 Years   (Adult, Older Adult)","Phase 1|Phase 2","30","NIH|Industry","Interventional","Allocation: Non-Randomized|Intervention Model: Sequential Assignment|Masking: None (Open Label)|Primary Purpose: Treatment","ACTG A5368|38410","January 17, 2020","April 19, 2023","June 27, 2023","August 6, 2019",,"November 1, 2021","UCLA CARE Center CRS, Los Angeles, California, United States|Ucsf Hiv/Aids Crs, San Francisco, California, United States|The Ponce de Leon Center CRS, Atlanta, Georgia, United States|Johns Hopkins University CRS, Baltimore, Maryland, United States|Massachusetts General Hospital CRS (MGH CRS), Boston, Massachusetts, United States|Columbia P&S CRS, New York, New York, United States|Chapel Hill CRS, Chapel Hill, North Carolina, United States|Cincinnati Clinical Research Site, Cincinnati, Ohio, United States|Puerto Rico AIDS Clinical Trials Unit CRS, San Juan, Puerto Rico",,"https://ClinicalTrials.gov/show/NCT04046107"
308,"NCT04033367","SAR231893-LPS15497- ""Dupilumab Effect on Sleep in AD Patients""",,"Completed","No Results Available","Atopic Dermatitis","Drug: DUPILUMAB|Drug: PLACEBO","Percentage change from baseline to Week 12 in sleep quality numerical rating scale (NRS)|Change from baseline to Week 12 in sleep efficiency based on actigraphy data|Change from baseline to Week 12 in total sleep time based on actigraphy data|Change from baseline to Week 12 in wake after sleep onset based on actigraph data|Change from baseline to Week 12 in sleep latency based on actigraph data|Percent change from baseline to Week 12 in pruritus|Change from baseline to Week 12 in SCORing Atopic Dermatitis (SCORAD) total score|Change from baseline to Week 12 in SCORAD sleep Visual Analog Scale (VAS) subscore|Change from baseline to Week 12 in Patient Oriented Eczema Measure (POEM) total score|EASI50 (50% reduction in Eczema Area and Severity Index score) at Week 12|EASI75 (75% reduction in Eczema Area and Severity Index score) at Week12|Change from baseline to Week 12 in Dermatology Life Quality Index (DLQI) total score|Change from baseline to Week 12 in Patient-Reported Outcomes Measurement Information System (PROMIS) Sleep Related Impairment Short-Form 8a (SF8a) Total Score|Adverse events","Sanofi|Regeneron Pharmaceuticals","All","18 Years and older   (Adult, Older Adult)","Phase 4","186","Industry","Interventional","Allocation: Randomized|Intervention Model: Parallel Assignment|Masking: Quadruple (Participant, Care Provider, Investigator, Outcomes Assessor)|Primary Purpose: Treatment","LPS15497|2018-004705-26|U1111-1223-4147","August 22, 2019","October 6, 2021","October 6, 2021","July 26, 2019",,"October 8, 2021","Investigational Site Number :8400012, North Little Rock, Arkansas, United States|Investigational Site Number :8400002, Redwood City, California, United States|Investigational Site Number :8400001, Rolling Hills Estates, California, United States|Investigational Site Number :8400013, Colorado Springs, Colorado, United States|Investigational Site Number :8400005, Denver, Colorado, United States|Investigational Site Number :8400003, Sarasota, Florida, United States|Investigational Site Number :8400007, Medford, Oregon, United States|Investigational Site Number :8400008, Charleston, South Carolina, United States|Investigational Site Number :0360006, Phillip, Australian Capital Territory, Australia|Investigational Site Number :0360001, Kogarah, New South Wales, Australia|Investigational Site Number :0360007, Woolloongabba, Queensland, Australia|Investigational Site Number :0360003, Carlton, Victoria, Australia|Investigational Site Number :2500001, Brest, France|Investigational Site Number :2500003, Nantes, France|Investigational Site Number :2500002, Paris, France|Investigational Site Number :2500006, Toulouse, France|Investigational Site Number :2760005, Bad Bentheim, Germany|Investigational Site Number :2760002, Frankfurt am Main, Germany|Investigational Site Number :2760006, Friedrichshafen, Germany|Investigational Site Number :2760001, Göttingen, Germany|Investigational Site Number :2760004, Münster, Germany|Investigational Site Number :3760005, Afula, Israel|Investigational Site Number :3760003, Jerusalem, Israel|Investigational Site Number :3800005, Rozzano, Milano, Italy|Investigational Site Number :3800006, Perugia, Italy|Investigational Site Number :3800001, Pisa, Italy|Investigational Site Number :3800004, Reggio Calabria, Italy|Investigational Site Number :3800002, Roma, Italy|Investigational Site Number :3800003, Siena, Italy|Investigational Site Number :7240004, Granada, Andalucia, Spain|Investigational Site Number :7240001, Barcelona / Sabadell, Castilla Y León, Spain|Investigational Site Number :7240003, Manises, Valencia, Spain|Investigational Site Number :7240006, Córdoba, Spain|Investigational Site Number :7240008, Madrid, Spain|Investigational Site Number :7240010, Madrid, Spain|Investigational Site Number :7240005, Sevilla, Spain|Investigational Site Number :7240002, Valencia, Spain|Investigational Site Number :7560001, Bern, Switzerland|Investigational Site Number :7840002, Abu Dhabi, United Arab Emirates|Investigational Site Number :7840001, Dubai, United Arab Emirates|Investigational Site Number :8260002, Dudley, Birmingham, United Kingdom|Investigational Site Number :8260004, Edinburgh, Edinburgh, City Of, United Kingdom",,"https://ClinicalTrials.gov/show/NCT04033367"
309,"NCT04015180","Extension Study to Evaluate the Long-term Outcomes of Subjects in Study 20090","FIREFLEYE next","Active, not recruiting","No Results Available","Retinopathy of Prematurity (ROP)","Drug: Eylea (Aflibercept, BAY86-5321)|Procedure: Laser photocoagulation","Binocular best-corrected visual acuity in Snellen equivalent|Proportion of subjects with ocular AEs and SAEs|Proportion of subjects with systemic AEs and SAEs|Proportion of subjects developing unfavorable ocular structural outcome|Proportion of subjects with absence of active ROP and unfavorable structural outcomes|Best-corrected visual acuity in each eye|Refractive spherical equivalent in each eye|Neurodevelopmental outcomes using BSID-III|Neurodevelopmental outcomes using WPPSI-IV|Neurodevelopmental outcomes using VABS-II|Proportion of subjects with recurrence of ROP|Proportion of subjects requiring treatment for ROP|Proportion of subjects requiring ophthalmological treatment","Bayer|Regeneron Pharmaceuticals","All","up to 13 Months   (Child)","Phase 3","96","Industry","Interventional","Allocation: Non-Randomized|Intervention Model: Parallel Assignment|Masking: None (Open Label)|Primary Purpose: Other","20275|2018-003180-54","March 18, 2020","July 3, 2025","July 3, 2025","July 10, 2019",,"February 9, 2022","Hospital Público Descentralizado ""Dr. Guillermo Rawson"", San Juan, Argentina|AZ St-Jan Brugge Oostende AV, Brugge, Belgium|Hospital das Clínicas de Botucatu - UNESP Botucatu, Botucatu, Sao Paulo, Brazil|Unifesp/Epm, Sao Paulo, Brazil|UMHAT Sveti Georgi, Plovdiv, Bulgaria|Acibadem City Clinic Multiprofile Hospital for Active Treatm, Sofia, Bulgaria|Spec. Hospital of Ophthalm. for Active Treatment Visus, Sofia, Bulgaria|Spec. Hosp. of Ophthalm. Disease for Active Treatment Varna, Varna, Bulgaria|Fakultni nemocnice Ostrava, Ostrava, Czechia|Vseobecna fakultni nemocnice v Praze, Praha 2, Czechia|P & A KYRIAKOU Children's Hospital, Athens, Greece|University General Hospital of Ioannina, Ioannina, Greece|Papageorgiou General Hospital of Thessaloniki, Thessaloniki, Greece|EKBC, Uj Szent Janos Korhaz es Szakrendelo, Budapest, Hungary|Kaplan Medical Center, Rehovot, Israel|IRCCS Ospedale Pediatrico Bambino Gesù, Roma, Lazio, Italy|Fondazione Policlinico Universitario Agostino Gemelli IRCCS, Roma, Lazio, Italy|Fondazione IRCCS Ca' Granda Ospedale Maggiore Policlinico, Milano, Lombardia, Italy|A.O. di Perugia, Perugia, Umbria, Italy|University of Occupational and Environmental Health, Kitakyushu, Fukuoka, Japan|Kurume University Hospital, Kurume, Fukuoka, Japan|Okinawa Prefectural Nanbu Medical Center and Children's MC, Shimajiri-gun, Okinawa, Japan|Kindai University Hospital, Osakasayama, Osaka, Japan|Tokyo Metropolitan Children's Medical Center, Fuchu, Tokyo, Japan|Tokyo Metropolitan Bokutoh Hospital, Sumida-ku, Tokyo, Japan|Tokyo Metropolitan Ohtsuka Hospital, Toshima-ku, Tokyo, Japan|Kyushu University Hospital, Fukuoka, Japan|Fukuoka University Hospital, Fukuoka, Japan|Fukushima Medical University Hospital, Fukushima, Japan|Soon Chun Hyang University Cheonan Hospital, Cheonan-si, Chungcheongnamdo, Korea, Republic of|Asan Medical Center, Seoul, Korea, Republic of|Hospital Kuala Lumpur, Kuala Lumpur, Malaysia|Maxima Medisch Centrum, locatie Veldhoven, Veldhoven, Netherlands|Hospital Prof. Dr. Fernando Fonseca, Amadora, Lisboa, Portugal|CHLO - Hospital Sao Francisco Xavier, Lisboa, Portugal|Clinical Emergency County Hospital, Cluj-Napoca, Cluj, Romania|Spitalul Clinic de Obstretica si Ginecologie ""Cuza Voda"", Iasi, Romania|FSAI NMRC IRTC ""Eye Microsurgery"", Kaluga's Branch, Kaluga, Russian Federation|FGBUZ ""NPC of special children care n.a. Voino-Yaseneckogo"", Moscow, Russian Federation|City Children Hospital ¿1, Saint-Petersburg, Russian Federation|KK Women's and Children's Hospital, Singapore, Singapore|Narodny ustav detskych chorob, Bratislava, Slovakia|Hospital Universitario 12 de Octubre, Madrid, Spain|Hospital Universitario ""La Paz"", Madrid, Spain|Hospital Regional de Málaga, Málaga, Spain|Sahlgrenska Universitetssjukhuset, Göteborg, Sweden|Kaohsiung Medical University Chung-Ho Memorial Hospital, Kaohsiung, Taiwan|Mackay Memorial Hospital, Taipei, Taiwan|S.B.U. Adana Sehir Egitim ve Arastirma Hastanesi, Adana, Turkey|Hacettepe Universitesi Tip Fakultesi, Ankara, Turkey|Gazi Universitesi Tip Fakultesi, Ankara, Turkey|Saglik Bilimleri Universitesi Antalya EA Hastanesi, Antalya, Turkey|Eskisehir Osmangazi Universitesi Tip Fakultesi, Eskisehir, Turkey|The Filatov Institute of Eye Diseases and Tissue Therapy, Odesa, Ukraine|Birmingham Womens Hospital, Birmingham, United Kingdom",,"https://ClinicalTrials.gov/show/NCT04015180"
310,"NCT04004208","Aflibercept for Retinopathy of Prematurity - Intravitreal Injection Versus Laser Therapy","FIREFLEYE","Completed","No Results Available","Retinopathy of Prematurity (ROP)","Drug: Eylea (Aflibercept, BAY86-5321)|Procedure: Laser photocoagulation","Proportion of patients with absence of active ROP and unfavorable structural outcomes|Number of requirement for intervention with a second treatment modality|Recurrence of ROP|To explore new Retinopathy of Prematurity Activity Scale proposed by the International Neonatal Consortium|Number of aflibercept administrations|Number of laser treatments|Proportion of participants with ocular TEAEs and SAEs|Proportion of participants with systemic TEAEs and SAEs|Systemic exposure to free aflibercept (at expected maximum plasma concentration and during elimination period from plasma) determined by sparse sampling|Presence of anti-drug antibodies","Bayer|Regeneron Pharmaceuticals","All","up to 32 Weeks   (Child)","Phase 3","113","Industry","Interventional","Allocation: Randomized|Intervention Model: Parallel Assignment|Masking: None (Open Label)|Primary Purpose: Treatment","20090|2018-002611-99","September 25, 2019","February 12, 2021","February 12, 2021","July 1, 2019",,"August 18, 2021","Many Locations, Multiple Locations, Argentina|Hospital Público Descentralizado ""Dr. Guillermo Rawson"", San Juan, Argentina|Kepler Universitätsklinikum Campus III, Linz, Austria|Many Locations, Multiple Locations, Austria|AZ St-Jan Brugge Oostende AV, Brugge, Belgium|Many Locations, Multiple Locations, Belgium|Hospital das Clínicas de Botucatu - UNESP Botucatu, Botucatu, Sao Paulo, Brazil|Many Locations, Multiple Locations, Brazil|Unifesp/Epm, Sao Paulo, Brazil|Many Locations, Multiple Locations, Bulgaria|UMHAT Sveti Georgi, Plovdiv, Bulgaria|Acibadem City Clinic Multiprofile Hospital for Active Treatm, Sofia, Bulgaria|II SOGHAT Sheinovo, Sofia, Bulgaria|SHOGAT Prof Dimitar Stamatov, Varna, Bulgaria|Many Locations, Multiple Locations, Czechia|Fakultni nemocnice Ostrava, Ostrava, Czechia|Vseobecna fakultni nemocnice v Praze, Praha 2, Czechia|P & A KYRIAKOU Children's Hospital, Athens, Greece|University General Hospital of Ioannina, Ioannina, Greece|Many Locations, Multiple Locations, Greece|Papageorgiou General Hospital of Thessaloniki, Thessaloniki, Greece|Queen Mary Hospital, Hong Kong, Hong Kong|Many Locations, Multiple Locations, Hong Kong|EKBC, Uj Szent Janos Korhaz es Szakrendelo, Budapest, Hungary|Many Locations, Multiple Locations, Hungary|Many Locations, Multiple Locations, Israel|Kaplan Medical Center, Rehovot, Israel|IRCCS Ospedale Pediatrico Bambino Gesù, Roma, Lazio, Italy|Fondazione Policlinico Universitario Agostino Gemelli IRCCS, Roma, Lazio, Italy|Fondazione IRCCS Ca' Granda Ospedale Maggiore Policlinico, Milano, Lombardia, Italy|A.O. di Perugia, Perugia, Umbria, Italy|Many Locations, Multiple Locations, Italy|University of Occupational and Environmental Health, Kitakyushu, Fukuoka, Japan|Kurume University Hospital, Kurume, Fukuoka, Japan|Okinawa Prefectural Nanbu Medical Center and Children's MC, Shimajiri-gun, Okinawa, Japan|Tokyo Metropolitan Children's Medical Center, Fuchu, Tokyo, Japan|Showa University Hospital, Shinagawa, Tokyo, Japan|Tokyo Metropolitan Bokutoh Hospital, Sumida-ku, Tokyo, Japan|Tokyo Metropolitan Ohtsuka Hospital, Toshima-ku, Tokyo, Japan|Kyushu University Hospital, Fukuoka, Japan|Fukuoka University Hospital, Fukuoka, Japan|Fukushima Medical University Hospital, Fukushima, Japan|Many Locations, Multiple Locations, Japan|Saitama Children's Medical Center, Saitama, Japan|Soon Chun Hyang University Cheonan Hospital, Cheonan-si, Chungcheongnamdo, Korea, Republic of|Many Locations, Multiple Locations, Korea, Republic of|Asan Medical Center, Seoul, Korea, Republic of|Samsung Medical Center, Seoul, Korea, Republic of|Hospital Kuala Lumpur, Kuala Lumpur, Malaysia|Many Locations, Multiple Locations, Malaysia|Many Locations, Multiple Locations, Netherlands|Maxima Medisch Centrum, locatie Veldhoven, Veldhoven, Netherlands|Many Locations, Multiple Locations, Poland|Ginekologiczno-Polozniczy SK UM im. K. Marcinkowskiego, Poznan, Poland|Hospital Prof. Dr. Fernando Fonseca, Amadora, Lisboa, Portugal|CHLO - Hospital Sao Francisco Xavier, Lisboa, Portugal|Many Locations, Multiple Locations, Portugal|Clinical Emergency County Hospital, Cluj-Napoca, Cluj, Romania|Spitalul Clinic de Obstretica si Ginecologie ""Cuza Voda"", Iasi, Romania|Many Locations, Multiple Locations, Romania|FSAI NMRC IRTC ""Eye Microsurgery"", Kaluga's Branch, Kaluga, Russian Federation|Russian National Scientific Medical University, Moscow, Russian Federation|FGBUZ ""NPC of special children care n.a. Voino-Yaseneckogo"", Moscow, Russian Federation|Many Locations, Multiple Locations, Russian Federation|Pediatric Medical University, Saint-Petersburg, Russian Federation|City Children Hospital ¿1, Saint-Petersburg, Russian Federation|Many Locations, Multiple Locations, Singapore|KK Women's and Children's Hospital, Singapore, Singapore|Narodny ustav detskych chorob, Bratislava, Slovakia|Many Locations, Multiple Locations, Slovakia|Hospital Universitario 12 de Octubre, Madrid, Spain|Hospital Universitario ""La Paz"", Madrid, Spain|Many Locations, Multiple Locations, Spain|Hospital Regional de Málaga, Málaga, Spain|Sahlgrenska Universitetssjukhuset, Göteborg, Sweden|Many Locations, Multiple Locations, Sweden|Kaohsiung Medical University Chung-Ho Memorial Hospital, Kaohsiung, Taiwan|Many Locations, Multiple Locations, Taiwan|Mackay Memorial Hospital, Taipei, Taiwan|S.B.U. Adana Sehir Egitim ve Arastirma Hastanesi, Adana, Turkey|Hacettepe Universitesi Tip Fakultesi, Ankara, Turkey|Baskent Universitesi Tip Fakultesi Hastanesi, Ankara, Turkey|Gazi Universitesi Tip Fakultesi, Ankara, Turkey|Saglik Bilimleri Universitesi Antalya EA Hastanesi, Antalya, Turkey|Eskisehir Osmangazi Universitesi Tip Fakultesi, Eskisehir, Turkey|Many Locations, Multiple Locations, Turkey|Many Locations, Multiple Locations, Ukraine|MI""Odesa Regional Children's Clinical Hospital"", Odesa, Ukraine|Birmingham Womens Hospital, Birmingham, United Kingdom|Many Locations, Multiple Locations, United Kingdom",,"https://ClinicalTrials.gov/show/NCT04004208"
311,"NCT03992417","Observational Study of Patients Receiving Dupixent® for Atopic Dermatitis (AD)","GLOBOSTAD","Recruiting","No Results Available","Dermatitis Atopic","Drug: Dupilumab SAR231893 (REGN668)","Baseline Characteristics: Medical history|Baseline Characteristics: Socio-demographics|Baseline Characteristics: Disease characteristics|Physician Assessment: Body Surface Area Affected (BSA) by Atopic Dermatitis|Physician Assessment: Eczema Area and Severity Index (EASI)|Physician Assessment: Scoring of Atopic Dermatitis (SCORAD)|Participant Assessment: Patient Oriented Eczema Measure (POEM)|Participant Assessment: Pruritus Numerical Rating Scale (NRS)|Participant Assessment: Skin Pain or Soreness NRS|Participant Assessment: Skin Feeling Hot NRS|Participant Assessment: Skin Sensitivity NRS|Participant Assessment: Sleep Disturbance NRS|Participant Assessment: Dermatology Life Quality Index (DLQI) for adults and Children Dermatology Life Quality Index (CDLQI) for adolescents|Participant Assessment: Juniper Asthma Control Questionnaire (ACQ-5)|Participant Assessment: Allergic Rhinitis-Visual Analog Scale (AR-VAS)|Participant Assessment: Work Productivity and Activity Impairment Questionnaire for AD (WPAI-AD) for adults and Work Productivity and Activity Impairment Questionnaire+Classroom Impairment Questions for AD (WPAI-CIQ-AD) for adolescents|Participant Assessment: Health Care Resource Utilization Questionnaire|Participant Assessment: 9-Item Treatment Satisfaction Questionnaire for Medication (TSQM-9)|Adverse events (AEs)|Participant Assessment: Atopic Dermatitis Control Tool (ADCT) to be collected optionally","Sanofi|Regeneron Pharmaceuticals","All","12 Years and older   (Child, Adult, Older Adult)",,"1000","Industry","Observational","Observational Model: Case-Only|Time Perspective: Prospective","OBS15990","June 11, 2019","April 2026","April 2026","June 20, 2019",,"July 7, 2021","Investigational site Argentina, Argentina, Argentina|Investigational site AUSTRALIA, Australia, Australia|Investigational site AUSTRIA, Austria, Austria|Investigational site Belgium, Belgium, Belgium|Investigational site colombia, Colombia, Colombia|Investigational site Czech Republic, Czech Republic, Czechia|Investigational site Finland, Finland, Finland|Investigational site number 2500011, Antony, France|Investigational site number 2500004, Auxerre, France|Investigational site number 2500003, Bordeaux, France|Investigational site number 2500009, Montpellier, France|Investigational site number 2500006, Pierre-Bénite, France|Investigational site number 2500007, Rennes, France|Investigational site number 2500010, Rouen, France|Investigational site number 2500005, Saint-Mandé, France|Investigational site number 2500002, Toulouse, France|Investigational site number 2500001, Valence, France|Investigational site Greece, Greece, Greece|Investigational site Israel, Israel, Israel|Investigational site Italy, Italy, Italy|Investigational site Japan, Japan, Japan|Investigational site Kuwait, Kuwait, Kuwait|Investigational site Mexico, Mexico, Mexico|Investigational site Netherlands, Netherlands, Netherlands|Investigational site Norway, Norway, Norway|Investigational site Portugal, Portugal, Portugal|Investigational site Russia, Russia, Russian Federation|Investigational site Saudi Arabia, Saudi Arabia, Saudi Arabia|Investigational site Spain, Spain, Spain|Investigational site Taiwan, Taiwan, Taiwan|Investigational site United Arab Emirates, United Arab Emirates, United Arab Emirates",,"https://ClinicalTrials.gov/show/NCT03992417"
312,"NCT03951831","REGN2810 Followed by Chemoimmunotherapy for Newly Metastatic Hormone-sensitive Prostate Cancer",,"Unknown status","No Results Available","Prostate Cancer Metastatic","Drug: REGN2810|Drug: Degarelix|Drug: Leuprolide Acetate|Drug: Docetaxel","Percentage of Subjects Achieving Undetectable PSA at 6 months after Combination Treatment","Mark Stein|Regeneron Pharmaceuticals|Columbia University","Male","18 Years to 99 Years   (Adult, Older Adult)","Phase 2","20","Other|Industry","Interventional","Allocation: N/A|Intervention Model: Single Group Assignment|Masking: None (Open Label)|Primary Purpose: Treatment","AAAS1863","May 2019","September 2020","December 2020","May 15, 2019",,"May 15, 2019","Columbia University Irving Medical Center, New York, New York, United States",,"https://ClinicalTrials.gov/show/NCT03951831"
313,"NCT03935971","The Effects of Dupilumab on Allergic Contact Dermatitis",,"Recruiting","No Results Available","Allergic Contact Dermatitis","Drug: Dupilumab","Change in Investigator's Global Assessment (IGA) score|Change in Body Surface Area (BSA)|Change in Eczema Area and Severity Index (EASI) score|Change in Numerical Rating Scale (NRS) itch|Change in Dermatology Life Quality Index (DLQI)|Change in SLEEPY-Q (Sleep Questionnaire) score|Skin Samples|Blood Samples","Brigham and Women's Hospital|Regeneron Pharmaceuticals","All","18 Years and older   (Adult, Older Adult)","Phase 4","20","Other|Industry","Interventional","Allocation: N/A|Intervention Model: Single Group Assignment|Masking: None (Open Label)|Primary Purpose: Treatment","2018P002882","December 18, 2019","May 2023","May 2023","May 2, 2019",,"October 13, 2021","Brigham and Women's Hospital, Department of Dermatology, Boston, Massachusetts, United States",,"https://ClinicalTrials.gov/show/NCT03935971"
314,"NCT03930732","Pivotal Study to Assess the Efficacy, Safety and Tolerability of Dupilumab in Patients With Moderate-to-severe COPD With Type 2 Inflammation","BOREAS","Active, not recruiting","No Results Available","Chronic Obstructive Pulmonary Disease","Drug: Dupilumab SAR231893|Drug: Inhaled Corticosteroid|Drug: Inhaled Long-Acting Beta Agonist|Drug: Inhaled Long-Acting Muscarinic Antagonist|Drug: Placebo","Annual rate of acute COPD exacerbation (AECOPD)|Change in pre-bronchodilator FEV1|Change in SGRQ|Improvement in SGRQ|Change in pre-bronchodilator FEV1 from baseline to Week 52|Change in pre-bronchodilator FEV1 from baseline to time points up to Week 44|Change in post-bronchodilator FEV1 lung function|Change in forced expiratory flow (FEF) 25-75%|Annualized rate of severe AECOPD|Time to first AECOPD|Adverse events|Potentially clinically significant abnormality (PCSA) in laboratory tests|Anti-drug antibodies","Sanofi|Regeneron Pharmaceuticals","All","40 Years to 80 Years   (Adult, Older Adult)","Phase 3","939","Industry","Interventional","Allocation: Randomized|Intervention Model: Parallel Assignment|Masking: Quadruple (Participant, Care Provider, Investigator, Outcomes Assessor)|Primary Purpose: Treatment","EFC15804|2018-001953-28|U1111-1211-8804","April 15, 2019","February 1, 2023","May 2, 2023","April 29, 2019",,"February 18, 2022","Investigational Site Number :8400030, Andalusia, Alabama, United States|Investigational Site Number :8400041, Birmingham, Alabama, United States|Investigational Site Number :8400013, Birmingham, Alabama, United States|Investigational Site Number :8400059, Dothan, Alabama, United States|Investigational Site Number :8400057, Mobile, Alabama, United States|Investigational Site Number :8400043, Tucson, Arizona, United States|Investigational Site Number :8400034, Colorado Springs, Colorado, United States|Investigational Site Number :8400010, Clearwater, Florida, United States|Investigational Site Number :8400014, Greenacres City, Florida, United States|Investigational Site Number :8400023, Miami, Florida, United States|Investigational Site Number :8400062, Miami, Florida, United States|Investigational Site Number :8400051, Ocala, Florida, United States|Investigational Site Number :8400029, Orlando, Florida, United States|Investigational Site Number :8400032, Panama City, Florida, United States|Investigational Site Number :8400026, Sarasota, Florida, United States|Investigational Site Number :8400055, Dacula, Georgia, United States|Investigational Site Number :8400020, Decatur, Georgia, United States|Investigational Site Number :8400016, Marietta, Georgia, United States|Investigational Site Number :8400025, Woodstock, Georgia, United States|Investigational Site Number :8400012, Baltimore, Maryland, United States|Investigational Site Number :8400038, White Marsh, Maryland, United States|Investigational Site Number :8400050, Ann Arbor, Michigan, United States|Investigational Site Number :8400065, Rochester, Minnesota, United States|Investigational Site Number :8400071, Jackson, Mississippi, United States|Investigational Site Number :8400011, Saint Charles, Missouri, United States|Investigational Site Number :8400004, Saint Louis, Missouri, United States|Investigational Site Number :8400035, Las Vegas, Nevada, United States|Investigational Site Number :8400067, Buffalo, New York, United States|Investigational Site Number :8400070, New York, New York, United States|Investigational Site Number :8400019, Chapel Hill, North Carolina, United States|Investigational Site Number :8400061, Charlotte, North Carolina, United States|Investigational Site Number :8400064, Durham, North Carolina, United States|Investigational Site Number :8400052, Wilmington, North Carolina, United States|Investigational Site Number :8400060, Winston-Salem, North Carolina, United States|Investigational Site Number :8400031, Cleveland, Ohio, United States|Investigational Site Number :8400040, Dayton, Ohio, United States|Investigational Site Number :8400024, Dublin, Ohio, United States|Investigational Site Number :8400005, Edmond, Oklahoma, United States|Investigational Site Number :8400001, Medford, Oregon, United States|Investigational Site Number :8400037, Clairton, Pennsylvania, United States|Investigational Site Number :8400009, Philadelphia, Pennsylvania, United States|Investigational Site Number :8400033, Pittsburgh, Pennsylvania, United States|Investigational Site Number :8400063, Wyomissing, Pennsylvania, United States|Investigational Site Number :8400022, Easley, South Carolina, United States|Investigational Site Number :8400047, Gaffney, South Carolina, United States|Investigational Site Number :8400007, Greenville, South Carolina, United States|Investigational Site Number :8400044, Mount Pleasant, South Carolina, United States|Investigational Site Number :8400046, Rock Hill, South Carolina, United States|Investigational Site Number :8400048, Spartanburg, South Carolina, United States|Investigational Site Number :8400073, Franklin, Tennessee, United States|Investigational Site Number :8400002, Galveston, Texas, United States|Investigational Site Number :8400018, Houston, Texas, United States|Investigational Site Number :8400021, McKinney, Texas, United States|Investigational Site Number :8400027, Sherman, Texas, United States|Investigational Site Number :8400036, Tacoma, Washington, United States|Investigational Site Number :8400008, Greenfield, Wisconsin, United States|Investigational Site Number :0320011, Caba, Buenos Aires, Argentina|Investigational Site Number :0320002, Caba, Buenos Aires, Argentina|Investigational Site Number :0320003, Caba, Buenos Aires, Argentina|Investigational Site Number :0320004, Caba, Buenos Aires, Argentina|Investigational Site Number :0320012, La Plata, Buenos Aires, Argentina|Investigational Site Number :0320007, Quilmes, Ciudad De Buenos Aires, Argentina|Investigational Site Number :0320006, Rosario, Santa Fe, Argentina|Investigational Site Number :0320009, San Miguel de Tucumán, Tucumán, Argentina|Investigational Site Number :0320001, Buenos Aires, Argentina|Investigational Site Number :0320005, Buenos Aires, Argentina|Investigational Site Number :0320008, Mar Del Plata, Argentina|Investigational Site Number :0320010, Mendoza, Argentina|Investigational Site Number :1001004, Haskovo, Bulgaria|Investigational Site Number :1001003, Montana, Bulgaria|Investigational Site Number :1001006, Ruse, Bulgaria|Investigational Site Number :1001009, Sofia, Bulgaria|Investigational Site Number :1001002, Sofia, Bulgaria|Investigational Site Number :1001001, Sofia, Bulgaria|Investigational Site Number :1001005, Stara Zagora, Bulgaria|Investigational Site Number :1001010, Troyan, Bulgaria|Investigational Site Number :1240021, Edmonton, Alberta, Canada|Investigational Site Number :1240015, Edmonton, Alberta, Canada|Investigational Site Number :1240016, Sherwood Park, Alberta, Canada|Investigational Site Number :1240017, Vancouver, British Columbia, Canada|Investigational Site Number :1240007, Vancouver, British Columbia, Canada|Investigational Site Number :1240002, Burlington, Ontario, Canada|Investigational Site Number :1240012, Toronto, Ontario, Canada|Investigational Site Number :1240013, Windsor, Ontario, Canada|Investigational Site Number :1240009, Montreal, Quebec, Canada|Investigational Site Number :1240003, Montreal, Quebec, Canada|Investigational Site Number :1240001, Montreal, Quebec, Canada|Investigational Site Number :1240010, Sherbrooke, Quebec, Canada|Investigational Site Number :1240011, Sherbrooke, Quebec, Canada|Investigational Site Number :1240006, St-charles Borrommee, Quebec, Canada|Investigational Site Number :1240008, Trois-Rivieres, Quebec, Canada|Investigational Site Number :1240020, Victoriaville, Quebec, Canada|Investigational Site Number :1240014, Saskatoon, Saskatchewan, Canada|Investigational Site Number :1240005, Quebec, Canada|Investigational Site Number :1240004, Quebec, Canada|Investigational Site Number :1240019, Quebec, Canada|Investigational Site Number :1240018, Quebec, Canada|Investigational Site Number :1520006, Curicó, Maule, Chile|Investigational Site Number :1520001, Talca, Maule, Chile|Investigational Site Number :1520009, Santiago, Reg Metropolitana De Santiago, Chile|Investigational Site Number :1520003, Santiago, Reg Metropolitana De Santiago, Chile|Investigational Site Number :1520005, Santiago, Reg Metropolitana De Santiago, Chile|Investigational Site Number :1520008, Santiago, Reg Metropolitana De Santiago, Chile|Investigational Site Number :1520002, Santiago, Reg Metropolitana De Santiago, Chile|Investigational Site Number :1520004, Quillota, Valparaíso, Chile|Investigational Site Number :1560037, Baotou, China|Investigational Site Number :1560006, Beijing, China|Investigational Site Number :1560003, Changchun, China|Investigational Site Number :1560022, Changsha, China|Investigational Site Number :1560021, Changsha, China|Investigational Site Number :1560001, Chengdu, China|Investigational Site Number :1560017, Chengdu, China|Investigational Site Number :1560012, Chongqing, China|Investigational Site Number :1560005, Chongqing, China|Investigational Site Number :1560053, Fuzhou, China|Investigational Site Number :1560019, Guangzhou, China|Investigational Site Number :1560036, Guangzhou, China|Investigational Site Number :1560045, Haikou, China|Investigational Site Number :1560018, Haikou, China|Investigational Site Number :1560046, Hangzhou, China|Investigational Site Number :1560009, Hefei, China|Investigational Site Number :1560041, Hefei, China|Investigational Site Number :1560015, Hohhot, China|Investigational Site Number :1560008, Hohhot, China|Investigational Site Number :1560027, Nanchang, China|Investigational Site Number :1560034, Nanjing, China|Investigational Site Number :1560032, Shanghai, China|Investigational Site Number :1560013, Shanghai, China|Investigational Site Number :1560007, Shanghai, China|Investigational Site Number :1560014, Shenyang, China|Investigational Site Number :1560004, Shenyang, China|Investigational Site Number :1560051, Shenzhen, China|Investigational Site Number :1560016, Shijiazhuang, China|Investigational Site Number :1560024, Taiyuan, China|Investigational Site Number :1560010, Tianjin, China|Investigational Site Number :1560028, Urumchi, China|Investigational Site Number :1560052, Wuhan, China|Investigational Site Number :1560020, Xi'An, China|Investigational Site Number :1560054, Xuzhou, China|Investigational Site Number :1560011, Yangzhou, China|Investigational Site Number :1560047, Yinchuan, China|Investigational Site Number :1560031, Zhanjiang, China|Investigational Site Number :1560002, Zhengzhou, China|Investigational Site Number :2030002, Jindrichuv Hradec III, Czechia|Investigational Site Number :2030005, Karlovy Vary, Czechia|Investigational Site Number :2030009, Miroslav, Czechia|Investigational Site Number :2030001, Novy Bor, Czechia|Investigational Site Number :2030003, Praha 4, Czechia|Investigational Site Number :2030008, Praha 6 - Brevnov, Czechia|Investigational Site Number :2030004, Rokycany, Czechia|Investigational Site Number :2030006, Strakonice, Czechia|Investigational Site Number :2080001, Copenhagen Nv, Denmark|Investigational Site Number :2080008, Hellerup, Denmark|Investigational Site Number :2080002, Hvidovre, Denmark|Investigational Site Number :2080006, Naestved, Denmark|Investigational Site Number :2080005, Odense C, Denmark|Investigational Site Number :2080004, Roskilde, Denmark|Investigational Site Number :2080007, Vejle, Denmark|Investigational Site Number :2080003, Ålborg, Denmark|Investigational Site Number :2460003, Pori, Finland|Investigational Site Number :2460002, Tampere, Finland|Investigational Site Number :2460001, Turku, Finland|Investigational Site Number :2760006, Berlin, Germany|Investigational Site Number :2760009, Frankfurt am Main, Germany|Investigational Site Number :2760002, Hamburg, Germany|Investigational Site Number :2760007, Koblenz, Germany|Investigational Site Number :2760011, Leipzig, Germany|Investigational Site Number :2760010, Lübeck, Germany|Investigational Site Number :2760008, Marburg, Germany|Investigational Site Number :3480007, Balassagyarmat, Hungary|Investigational Site Number :3480011, Budapest, Hungary|Investigational Site Number :3480008, Edelény, Hungary|Investigational Site Number :3480001, Gödöllö, Hungary|Investigational Site Number :3480010, Hajdunánás, Hungary|Investigational Site Number :3480002, Komarom, Hungary|Investigational Site Number :3480003, Makó, Hungary|Investigational Site Number :3480006, Mohács, Hungary|Investigational Site Number :3480012, Püspökladány, Hungary|Investigational Site Number :3480005, Szombathely, Hungary|Investigational Site Number :3480004, Százhalombatta, Hungary|Investigational Site Number :3760006, Ashkelon, Israel|Investigational Site Number :3760007, Beer Sheva, Israel|Investigational Site Number :3760003, Haifa, Israel|Investigational Site Number :3760005, Jerusalem, Israel|Investigational Site Number :3760004, Jerusalem, Israel|Investigational Site Number :3760001, Petah-Tikva, Israel|Investigational Site Number :3760002, Rehovot, Israel|Investigational Site Number :3800004, Cona, Ferrara, Italy|Investigational Site Number :3800003, Rozzano, Milano, Italy|Investigational Site Number :3800006, Bologna, Italy|Investigational Site Number :3800002, Catania, Italy|Investigational Site Number :3800007, Pisa, Italy|Investigational Site Number :3800001, Reggio Emilia, Italy|Investigational Site Number :3800005, Roma, Italy|Investigational Site Number :3920013, Kasuga-shi, Fukuoka, Japan|Investigational Site Number :3920011, Himeji-shi, Hyogo, Japan|Investigational Site Number :3920023, Higashiibaraki-gun, Ibaraki, Japan|Investigational Site Number :3920014, Naka-gun, Ibaraki, Japan|Investigational Site Number :3920019, Takamatsu-shi, Kagawa, Japan|Investigational Site Number :3920027, Yokohama-shi, Kanagawa, Japan|Investigational Site Number :3920003, Joyo-shi, Kyoto, Japan|Investigational Site Number :3920017, Kyoto-shi, Kyoto, Japan|Investigational Site Number :3920006, Ueda-shi, Nagano, Japan|Investigational Site Number :3920029, Urasoe-shi, Okinawa, Japan|Investigational Site Number :3920018, Kawachinagano-shi, Osaka, Japan|Investigational Site Number :3920001, Kishiwada-shi, Osaka, Japan|Investigational Site Number :3920028, Osaka-shi, Osaka, Japan|Investigational Site Number :3920012, Sakai-shi, Osaka, Japan|Investigational Site Number :3920021, Hamamatsu-shi, Shizuoka, Japan|Investigational Site Number :3920008, Chuo-ku, Tokyo, Japan|Investigational Site Number :3920030, Chuo-ku, Tokyo, Japan|Investigational Site Number :3920005, Chuo-ku, Tokyo, Japan|Investigational Site Number :3920015, Kokubunji-shi, Tokyo, Japan|Investigational Site Number :3920016, Shinagawa-ku, Tokyo, Japan|Investigational Site Number :3920004, Toshima-ku, Tokyo, Japan|Investigational Site Number :3920026, Toshima-ku, Tokyo, Japan|Investigational Site Number :4100003, Wonju, Gangwon-do, Korea, Republic of|Investigational Site Number :4100004, Seongnam-si, Gyeonggi-do, Korea, Republic of|Investigational Site Number :4100008, Incheon, Incheon-gwangyeoksi, Korea, Republic of|Investigational Site Number :4100001, Seoul, Seoul-teukbyeolsi, Korea, Republic of|Investigational Site Number :4100009, Seoul, Seoul-teukbyeolsi, Korea, Republic of|Investigational Site Number :4100007, Seoul, Seoul-teukbyeolsi, Korea, Republic of|Investigational Site Number :4840002, Guadalajara, Jalisco, Mexico|Investigational Site Number :4840004, Chihuahua, Mexico|Investigational Site Number :4840003, Durango, Mexico|Investigational Site Number :4840006, Mexico Distrito Federal, Mexico|Investigational Site Number :4840001, Monterrey, Mexico|Investigational Site Number :4840007, Oaxaca, Mexico|Investigational Site Number :4840005, Veracruz, Mexico|Investigational Site Number :6160009, Grudziadz, Kujawsko-pomorskie, Poland|Investigational Site Number :6160007, Krakow, Malopolskie, Poland|Investigational Site Number :6160015, Grodzisk Mazowiecki, Mazowieckie, Poland|Investigational Site Number :6160012, Warszawa, Mazowieckie, Poland|Investigational Site Number :6160008, Bialystok, Podlaskie, Poland|Investigational Site Number :6160014, Elblag, Pomorskie, Poland|Investigational Site Number :6160011, Katowice, Slaskie, Poland|Investigational Site Number :6160016, Poznan, Wielkopolskie, Poland|Investigational Site Number :6160006, Poznan, Wielkopolskie, Poland|Investigational Site Number :6420001, Bucharest, Romania|Investigational Site Number :6420009, Bucuresti, Romania|Investigational Site Number :6420008, Bucuresti, Romania|Investigational Site Number :6420003, Cluj-Napoca, Romania|Investigational Site Number :6420004, Cluj-Napoca, Romania|Investigational Site Number :6420007, Constanta, Romania|Investigational Site Number :6420006, Timisoara, Romania|Investigational Site Number :6420010, Timisoara, Romania|Investigational Site Number :6430003, Chelyabinsk, Russian Federation|Investigational Site Number :6430004, Kazan, Russian Federation|Investigational Site Number :6430006, Moscow, Russian Federation|Investigational Site Number :6430001, Moscow, Russian Federation|Investigational Site Number :6430005, Moscow, Russian Federation|Investigational Site Number :6430008, Moscow, Russian Federation|Investigational Site Number :6430002, Moscow, Russian Federation|Investigational Site Number :6430009, Moscow, Russian Federation|Investigational Site Number :6430007, St-Petersburg, Russian Federation|Investigational Site Number :7030007, Banska Bystrica, Slovakia|Investigational Site Number :7030006, Humenne, Slovakia|Investigational Site Number :7030003, Levice, Slovakia|Investigational Site Number :7030001, Poprad, Slovakia|Investigational Site Number :7030002, Spisska Nova Ves, Slovakia|Investigational Site Number :7240096, Santiago de Compostela, A Coruña [La Coruña], Spain|Investigational Site Number :7240002, Barcelona, Barcelona [Barcelona], Spain|Investigational Site Number :7240007, Sant Boi de Llobregat, Barcelona [Barcelona], Spain|Investigational Site Number :7240005, Mérida / Badajoz, Extremadura, Spain|Investigational Site Number :7240006, Pozuelo de Alarcón, Madrid, Spain|Investigational Site Number :7240003, Madrid, Spain|Investigational Site Number :7240001, Málaga, Spain|Investigational Site Number :7240010, Palma de Mallorca, Spain|Investigational Site Number :7240004, Valencia, Spain|Investigational Site Number :7520001, Lund, Sweden|Investigational Site Number :7520002, Stockholm, Sweden|Investigational Site Number :7520003, Örebro, Sweden|Investigational Site Number :7920004, Ankara, Turkey|Investigational Site Number :7920001, Istanbul, Turkey|Investigational Site Number :7920006, Izmir, Turkey|Investigational Site Number :7920007, Izmir, Turkey|Investigational Site Number :7920008, Kirikkale, Turkey|Investigational Site Number :7920005, Manisa, Turkey|Investigational Site Number :7920002, Mersin, Turkey|Investigational Site Number :8040003, Chernivtsi, Ukraine|Investigational Site Number :8040001, Ivano-Frankivsk, Ukraine|Investigational Site Number :8040006, Kharkiv, Ukraine|Investigational Site Number :8040004, Kyiv, Ukraine|Investigational Site Number :8040009, Odesa, Ukraine|Investigational Site Number :8040002, Ternopil, Ukraine|Investigational Site Number :8040005, Vinnytsya, Ukraine|Investigational Site Number :8040007, Zhytomyr, Ukraine",,"https://ClinicalTrials.gov/show/NCT03930732"
315,"NCT03912259","Evaluation of Dupilumab in Chinese Adult Patients With Moderate to Severe Atopic Dermatitis",,"Completed","Has Results","Atopic Dermatitis","Drug: Dupilumab|Drug: Placebo|Drug: Emollient (moisturizer)","Number of Participants With Investigator's Global Assessment (IGA) Score of ""0"" or ""1"" and Reduction From Baseline of Greater Than or Equal to (>=) 2 Points at Week 16|Number of Participants With Eczema Area and Severity Index (EASI) - 75 Response (>= 75% Reduction in Score From Baseline) at Week 16|Number of Participants Who Achieved >=4 Points With Reduction From Baseline in Weekly Average of Peak Daily Pruritus Numerical Rating Scale (NRS) Score at Week 16|Number of Participants Who Achieved >=3 Points With Reduction From Baseline in Weekly Average of Peak Daily Pruritus Numerical Rating Scale Score at Week 16|Percentage Change From Baseline at Week 16 in Weekly Average of Peak Daily Pruritus NRS|Change From Baseline at Week 16 in Weekly Average of Peak Daily Pruritus NRS|Percentage Change From Baseline to Week 16 in EASI Score|Change From Baseline to Week 16 in Percent Body Surface Area (BSA) of AD Involvement|Change From Baseline to Week 16 in Dermatology Life Quality Index (DLQI) Total Score|Change From Baseline to Week 16 in Patient Oriented Eczema Measure (POEM)|Percentage Change From Baseline to Week 2 in Weekly Average of Peak Daily Pruritus NRS|Percentage Change From Baseline to Week 16 in EuroQoL Five Dimensions Questionnaire (EQ-5D) Index Scores|Percentage Change From Baseline to Week 16 in EuroQoL Five Dimensions Questionnaire Visual Analog Scale Scores|Absolute Change From Baseline to Week 16 in EQ-5D Index Scores|Absolute Change From Baseline to Week 16 in EuroQoL Five Dimensions Questionnaire Visual Analog Scale Scores|Number of Participants Who Achieve Reduction of IGA Score by >=2 From Baseline to Week 16|Number of Participants Achieving IGA 0 to 1 and a Reduction of >=2 Points From Baseline Through Week 16|Absolute Change in EASI Score From Baseline at Weeks 2, 4, 8, 12 and 16|Percentage Change in EASI Score From Baseline at Weeks 2, 4, 8, 12 and 16|Number of Participants With EASI-50 (>=50% Improvement From Baseline) at Week 16|Number of Participants With EASI-90 (>=90% Improvement From Baseline) at Week 16|Absolute Change in Weekly Average of Peak Daily Pruritus NRS Score From Baseline Through Week 16|Percentage Change in Weekly Average of Peak Daily Pruritus NRS Score From Baseline Through Week 16|Number of Participants Who Responded ""Absence of Pruritus"" or ""Mild Pruritus"" in the Pruritus Categorical Scale at Week 16|Number of Days of Sick Leave/Missed School Days|Percentage of Participants With at Least One Day Sick Leave/Missed School Days","Sanofi|Regeneron Pharmaceuticals","All","18 Years and older   (Adult, Older Adult)","Phase 3","165","Industry","Interventional","Allocation: Randomized|Intervention Model: Parallel Assignment|Masking: Quadruple (Participant, Care Provider, Investigator, Outcomes Assessor)|Primary Purpose: Treatment","EFC15116|U1111-1190-7728","December 19, 2018","February 14, 2020","February 14, 2020","April 11, 2019","April 5, 2021","April 5, 2021","Investigational Site Number 1560019, Beijing, China|Investigational Site Number 1560001, Beijing, China|Investigational Site Number 1560004, Beijing, China|Investigational Site Number 1560003, Beijing, China|Investigational Site Number 1560010, Beijing, China|Investigational Site Number 1560021, Changchun, China|Investigational Site Number 1560006, Changsha, China|Investigational Site Number 1560017, Chongqing, China|Investigational Site Number 1560026, Hangzhou, China|Investigational Site Number 1560007, Hangzhou, China|Investigational Site Number 1560013, Jinan, China|Investigational Site Number 1560020, Kunming, China|Investigational Site Number 1560030, Lianyungang, China|Investigational Site Number 1560022, Nanjing, China|Investigational Site Number 1560029, Ningbo, China|Investigational Site Number 1560016, Shanghai, China|Investigational Site Number 1560023, Shanghai, China|Investigational Site Number 1560018, Shanghai, China|Investigational Site Number 1560015, Shanghai, China|Investigational Site Number 1560002, Shenyang, China|Investigational Site Number 1560005, Shenyang, China|Investigational Site Number 1560008, Shenyang, China|Investigational Site Number 1560024, Shenzhen, China|Investigational Site Number 1560027, Tianjin, China|Investigational Site Number 1560028, Wuxi, China|Investigational Site Number 1560012, Xi'An, China|Investigational Site Number 1560025, Yancheng, China","""Study Protocol"", https://ClinicalTrials.gov/ProvidedDocs/59/NCT03912259/Prot_000.pdf|""Statistical Analysis Plan"", https://ClinicalTrials.gov/ProvidedDocs/59/NCT03912259/SAP_001.pdf","https://ClinicalTrials.gov/show/NCT03912259"
316,"NCT03886493","Neoadjuvant Dupilumab in Men With Localized High-Risk Prostate Cancer",,"Terminated","Has Results","Prostate Cancer","Drug: Dupilumab","Change in M2-TAM Infiltration From Baseline|Safety as Assessed by Number of Participants Experiencing Adverse Events|Feasibility as Assessed by Number of Participants Who Have an Average Blood Loss in Excess of 2500 mL During Prostatectomy|Feasibility as Assessed by Number of Participants With Average Prostatectomy Operative Time in Excess of 3.5 Hours|Feasibility as Assessed by Number of Participants With Average Hospital Stay in Excess of 4 Days Post-prostatectomy|CD8+ T-cell Infiltration in Post-treatment Prostate Glands|CD4+ T-cell and Treg Infiltration in Post-treatment Prostate Glands|Expression of Apoptosis Marker (Annexin V) in Post-treatment Prostate Tumor Specimen as Measured by Mean Staining Percentage in Tumor Tissue|Expression of Cell Proliferation in Post-treatment Prostate Tumor Specimen as Measured by Mean Staining Percentage of Ki-67 in Tumor Tissue|Proportion of Participants With Pathological Complete Response|Proportion of Participants Who Achieve an Undetectable PSA at 2 Months Post-prostatectomy","Sidney Kimmel Comprehensive Cancer Center at Johns Hopkins|Regeneron Pharmaceuticals","Male","18 Years and older   (Adult, Older Adult)","Phase 2","7","Other|Industry","Interventional","Allocation: N/A|Intervention Model: Single Group Assignment|Masking: None (Open Label)|Primary Purpose: Treatment","J18116|IRB00182718","August 28, 2019","October 6, 2020","October 6, 2020","March 22, 2019","October 15, 2021","October 15, 2021","Johns Hopkins Sidney Kimmel Comprehensive Cancer Center, Baltimore, Maryland, United States","""Study Protocol and Statistical Analysis Plan"", https://ClinicalTrials.gov/ProvidedDocs/93/NCT03886493/Prot_SAP_000.pdf","https://ClinicalTrials.gov/show/NCT03886493"
317,"NCT03787095","Safety and Immunotherapeutic Activity of an Anti-PD-1 Antibody (Cemiplimab) in Participants With HIV-1 on Suppressive cART",,"Terminated","Has Results","HIV Infections","Biological: Cemiplimab|Biological: Placebo","Count of Participants With a Grade >=3 Adverse Event (AE) or Grade >=1 Immune-related AE (irAE) Related to Study Treatment|Count of Participants With a Grade >=1 irAE Related to Study Treatment|Change in HIV-1 Gag-specific CD8+ T Cells by Intracellular Staining for CD107a and Interferon Gamma (IFNg) From Baseline to Post-baseline|Change in HIV-1 Gag-specific CD8+ T Cells by Intracellular Staining for IFNg or CD107a Alone From Baseline to Post-baseline|Change in Polyfunctional Response of HIV-1 Gag-specific CD8+ T Cells by Intracellular Staining for IFNg, CD107a, IL-2, and Tumor Necrosis Factor Alpha (TNFa) From Baseline to Post-baseline|Change in HIV-1 Gag-specific CD8+ T Cells by Intracellular Staining for IFNg and CD107a After Each Infusion","National Institute of Allergy and Infectious Diseases (NIAID)|Regeneron Pharmaceuticals","All","18 Years to 64 Years   (Adult)","Phase 1|Phase 2","5","NIH|Industry","Interventional","Allocation: Randomized|Intervention Model: Sequential Assignment|Masking: Double (Participant, Care Provider)|Primary Purpose: Treatment","ACTG A5370|38399","August 13, 2019","August 18, 2020","August 18, 2020","December 26, 2018","December 9, 2021","March 2, 2022","Alabama CRS, Birmingham, Alabama, United States|UCSD Antiviral Research Center CRS, San Diego, California, United States|Chapel Hill CRS, Chapel Hill, North Carolina, United States","""Study Protocol"", https://ClinicalTrials.gov/ProvidedDocs/95/NCT03787095/Prot_001.pdf|""Statistical Analysis Plan"", https://ClinicalTrials.gov/ProvidedDocs/95/NCT03787095/SAP_002.pdf|""Informed Consent Form"", https://ClinicalTrials.gov/ProvidedDocs/95/NCT03787095/ICF_000.pdf","https://ClinicalTrials.gov/show/NCT03787095"
318,"NCT03782532","Efficacy and Safety Study of Dupilumab in Patients With Persistent Asthma",,"Active, not recruiting","No Results Available","Asthma","Drug: Dupilumab SAR231893|Drug: Placebo|Drug: Asthma Controller Therapies (include prednisone/prednisolone)|Drug: Asthma Reliever Therapies","Change in pre-bronchodilator forced expiratory volume (FEV1)|Annualized rate of severe exacerbation events|Percent change from baseline in pre-bronchodilator FEV1|Annualized rate of loss of asthma control (LOAC) event|Annualized rate of severe exacerbation events resulting in hospitalization or emergency room visit|Time to first severe exacerbation event|Time to first LOAC|Change from baseline in Asthma Control Questionnaire (ACQ)-5 score|Change from baseline in ACQ-7 score|Morning/evening asthma symptom score (e-diary)|Nocturnal awakenings (e-diary)|Use of daily puffs of rescue medication|Change from baseline in Asthma Quality of Life Questionnaire (AQLQ) with Standardized Activities (≥12 years) (AQLQ+12)|Change from baseline in European Quality of Life Working Group Health Status Measure 5 Dimensions, 5 Levels (EQ-5D-5L)|Assessment of adverse events (AEs)","Sanofi|Regeneron Pharmaceuticals","All","12 Years and older   (Child, Adult, Older Adult)","Phase 3","484","Industry","Interventional","Allocation: Randomized|Intervention Model: Parallel Assignment|Masking: Triple (Participant, Care Provider, Investigator)|Primary Purpose: Treatment","EFC13995|U1111-1175-0772","January 25, 2019","May 24, 2022","May 24, 2022","December 20, 2018",,"October 27, 2021","Investigational Site Number :1560013, Baotou, China|Investigational Site Number :1560016, Beijing, China|Investigational Site Number :1560029, Beijing, China|Investigational Site Number :1560015, Beijing, China|Investigational Site Number :1560056, Beijing, China|Investigational Site Number :1560057, Changchun, China|Investigational Site Number :1560010, Changsha, China|Investigational Site Number :1560030, Chengdu, China|Investigational Site Number :1560053, Chengdu, China|Investigational Site Number :1560025, Chongqing, China|Investigational Site Number :1560004, Guangzhou, China|Investigational Site Number :1560001, Guangzhou, China|Investigational Site Number :1560045, Guangzhou, China|Investigational Site Number :1560032, Guiyang, China|Investigational Site Number :1560019, Hangzhou, China|Investigational Site Number :1560007, Hangzhou, China|Investigational Site Number :1560014, Hangzhou, China|Investigational Site Number :1560026, Hangzhou, China|Investigational Site Number :1560043, Hangzhou, China|Investigational Site Number :1560038, Hefei, China|Investigational Site Number :1560044, Hohhot, China|Investigational Site Number :1560008, Hohhot, China|Investigational Site Number :1560022, Lanzhou, China|Investigational Site Number :1560024, Nanchang, China|Investigational Site Number :1560051, Nanjing, China|Investigational Site Number :1560054, Nanjing, China|Investigational Site Number :1560037, Nanjing, China|Investigational Site Number :1560035, Pingxiang, China|Investigational Site Number :1560050, Shanghai, China|Investigational Site Number :1560049, Shanghai, China|Investigational Site Number :1560005, Shanghai, China|Investigational Site Number :1560011, Shanghai, China|Investigational Site Number :1560017, Shanghai, China|Investigational Site Number :1560006, Shanghai, China|Investigational Site Number :1560002, Shanghai, China|Investigational Site Number :1560018, Shenyang, China|Investigational Site Number :1560036, Shenyang, China|Investigational Site Number :1560012, Shenzhen, China|Investigational Site Number :1560042, Shenzhen, China|Investigational Site Number :1560003, Shijiazhuang, China|Investigational Site Number :1560041, Shijiazhuang, China|Investigational Site Number :1560031, Suzhou, China|Investigational Site Number :1560048, Taiyuan, China|Investigational Site Number :1560020, Tianjin, China|Investigational Site Number :1560033, Urumchi, China|Investigational Site Number :1560021, Wenzhou, China|Investigational Site Number :1560052, Wuhan, China|Investigational Site Number :1560028, Wuhan, China|Investigational Site Number :1560040, Xi'an, China|Investigational Site Number :1560046, Xiamen, China|Investigational Site Number :1560027, Xiangtan, China|Investigational Site Number :1560023, Xuzhou, China|Investigational Site Number :1560055, Yangzhou, China|Investigational Site Number :1560047, Zhanjiang, China|Investigational Site Number :3560006, Chandigarh, India|Investigational Site Number :3560002, Coimbatore, India|Investigational Site Number :3560013, Hyderabad, India|Investigational Site Number :3560005, Jaipur, India|Investigational Site Number :3560015, Jaipur, India|Investigational Site Number :3560010, Kolkata, India|Investigational Site Number :3560011, Kozhikode, India|Investigational Site Number :3560012, Mohali, India|Investigational Site Number :3560003, Nagpur, India|Investigational Site Number :3560016, Nagpur, India|Investigational Site Number :3560001, New Delhi, India|Investigational Site Number :3560009, Pune, India|Investigational Site Number :3560007, Vellore, India",,"https://ClinicalTrials.gov/show/NCT03782532"
319,"NCT03712904","Stereotactic Body Radiation Therapy and Aflibercept in Treating Patients With Uveal Melanoma",,"Recruiting","No Results Available","Uveal Melanoma","Radiation: Stereotactic Body Radiation Therapy|Biological: Ziv-Aflibercept","Incidence of grade 3 or higher toxicity according to Common Terminology Criteria for Adverse Events (CTCAE) version 5.0|Radiation maculopathy rate defined as ophthalmoscopic detection of macular edema perivascular sheathing|Radiation papillopathy rate defined as ophthalmoscopic detection of peripapillary encircling nerve fiber layer infarction","Sidney Kimmel Cancer Center at Thomas Jefferson University|Regeneron Pharmaceuticals|Thomas Jefferson University","Female","18 Years and older   (Adult, Older Adult)","Phase 2","36","Other|Industry","Interventional","Allocation: Randomized|Intervention Model: Parallel Assignment|Masking: None (Open Label)|Primary Purpose: Treatment","18P.457","August 9, 2019","October 9, 2023","July 2024","October 19, 2018",,"August 16, 2021","Sidney Kimmel Cancer Center at Thomas Jefferson University, Philadelphia, Pennsylvania, United States",,"https://ClinicalTrials.gov/show/NCT03712904"
320,"NCT03679845","Study to Assess Sarilumab in Halting Progression of Morphea",,"Withdrawn","No Results Available","Morphea, Plaque Form","Drug: Sarilumab","efficacy of sarilumab in plaque type morphea|Physician Global Assessment of Activity (PGA-A)","Massachusetts General Hospital|Regeneron Pharmaceuticals","All","18 Years and older   (Adult, Older Adult)","Phase 1|Phase 2","0","Other|Industry","Interventional","Allocation: N/A|Intervention Model: Single Group Assignment|Masking: None (Open Label)|Primary Purpose: Treatment","2018P002128","September 1, 2019","June 30, 2021","June 30, 2021","September 20, 2018",,"September 8, 2021","CURTIS (Massachusetts General Hospital), Boston, Massachusetts, United States",,"https://ClinicalTrials.gov/show/NCT03679845"
321,"NCT03669718","A Randomized Phase 2 Study of Cemiplimab ± ISA101b in HPV16-Positive OPC",,"Recruiting","No Results Available","Squamous Cell Carcinoma of the Oropharynx|HPV16 Positive","Biological: ISA101b|Drug: Cemiplimab|Other: Placebo","Overall Response Rate|Number of participants with treatment-related adverse events as assessed by NCI CTCAE v5.0 ""Number of participants with treatment-related adverse events as assessed by NCI CTCAE v5.0"".|Duration of response (DOR) by independent review in subjects randomized to receive ISA101b plus cemiplimab compared to placebo plus cemiplimab.","ISA Pharmaceuticals|Regeneron Pharmaceuticals","All","18 Years and older   (Adult, Older Adult)","Phase 2","194","Industry","Interventional","Allocation: Randomized|Intervention Model: Parallel Assignment|Masking: Triple (Participant, Investigator, Outcomes Assessor)|Primary Purpose: Treatment","ISA101b-HN-01-17","November 30, 2018","December 2021","November 2022","September 13, 2018",,"December 13, 2021","City of Hope, Duarte, California, United States|Moores Cancer Center at the UC San Diego Health, San Diego, California, United States|University of California San Francisco, San Francisco, California, United States|Robert H. Lurie Comprehensive Cancer Center, Chicago, Illinois, United States|Revive Research Institute, Inc. - Farmington Hills, Farmington Hills, Michigan, United States|Revive Research Institute, Inc., Sterling Heights, Michigan, United States|Washington University School of Medicine, Saint Louis, Missouri, United States|ICAHN School of Medicine at Mount Sinai, New York, New York, United States|University of Cincinnati Cancer Institute, Cincinnati, Ohio, United States|Providence Portland Medical Center, Portland, Oregon, United States|UPMC Hillman Cancer Center, Pittsburgh, Pennsylvania, United States|M. D. Anderson Cancer Center, Houston, Texas, United States|University of Washington, Seattle, Washington, United States|University Hospital Antwerp, Antwerp, Belgium|Grand Hopital de Chaleroi, Charleroi, Belgium|University Hospital Leuven, Leuven, Belgium|Fakultni nemocnice Olomouc, Olomouc, Czechia|University Hospital Olomouc, Olomouc, Czechia|Nemocnice na Bulovce, Prague, Czechia|Institut Bergonie, Bordeaux, France|Bergonie Institute, Bourdeaux, France|Centre Léon Bérard, Lyon, France|CHU La Timone, Marseille, France|Hopital de la Timone, Marseille, France|Antoine Lacassagne Center, Nice, France|Fondation Hospital Saint Joseph, Paris, France|Gustave Roussy, Paris, France|Hopitaux Universitaires Pitié Salpêtrière Charles Foix, Paris, France|University Hospital, Bonn, Germany|IKrankenhaus Nordwest gGmbH, nstitut für Klinisch-Onkologische Forschung, Frankfurt, Germany|University Hospital Leipzig, Leipzig, Germany|Universitaetsklinikum Ulm, Ulm, Germany|Magyar Honvédség Egészségügyi Központ, Budapest, Hungary|Onkolgiai Klinika, Debrecen, Hungary|Petz Aladar Megyei Oktat Krhz, Gyor, Hungary|Szabolcs Szatmar Bereg Megyei Korhazak Es Egyetemi Oktatokorhaz, Nyiregyhaza, Hungary|University of Pecs Department of Oncotherapy, Pecs, Hungary|Hetenyi Geza Korhaz-Rendelointezet, Szolnok, Hungary|ASST Spedali Civili Brescia, Brescia, Italy|Azienda Ospedaliera San Paolo Polo Universitario, Milan, Italy|Istituto Nazionale dei Tumori, Milan, Italy|National Cancer Institute, Napoli, Italy|UOC Oncologia Medica Ospedale di Sondrio, Sondrio, Italy|Azienda Sanitaria Universitaria Integrata di Udine, Udine, Italy|Antoni van Leeuwenhoek Ziekenhuis, Amsterdam, Netherlands|Leiden University Hospital, Leiden, Netherlands|Radboud University Medical Center, Nijmegen, Netherlands|University Medical Center Utrecht, Utrecht, Netherlands|Hospital Clnic i Provincial de Barcelona, Barcelona, Spain|Hospital Duran i Reynals - Institut Catala dOncologia ICO, Barcelona, Spain|Vall d'Hebron, Barcelona, Spain|Hospital Clinico San Carlos, Madrid, Spain|Hospital Universitario La Paz, Madrid, Spain|The 12 de Octubre University Hospital, Madrid, Spain|Universitario Sanchinarro, Madrid, Spain|Hospital Universitario Virgen de la Victoria, Malaga, Spain|Hospital Universitario de Salamanca, Salamanca, Spain|Hospital Universitario Marqués de Valdecilla Santander, Santander, Spain|Aberdeen Royal Infirmary, Aberdeen, United Kingdom|The Royal Marsden NHS Foundation, Chelsea, United Kingdom|Guy's Hospital, London, United Kingdom|The Royal Marsden NHS Foundation Trust, Sutton, United Kingdom|Beacon Centre Musgrove Park Hospital, Taunton, United Kingdom",,"https://ClinicalTrials.gov/show/NCT03669718"
322,"NCT03667014","The Impact of Dupilumab on Quality of Life in Moderate to Severe Atopic Dermatitis Patients",,"Recruiting","No Results Available","Atopic Dermatitis|Atopic Dermatitis Eczema","Drug: Dupilumab","Psychological General Well-Being scale (PGWB)|Work Productivity and Activity Impairment scale (WPAI:SHP)|Dermatology Life Quality Index (DLQI)|Treatment Satisfaction Questionnaire for Medication (TSQM)|Itch Numerical Rating Scale|Pain Numerical Rating Scale|PSQI","University of California, San Francisco|Regeneron Pharmaceuticals","All","18 Years and older   (Adult, Older Adult)","Phase 4","30","Other|Industry","Interventional","Allocation: N/A|Intervention Model: Single Group Assignment|Masking: None (Open Label)|Primary Purpose: Treatment","Dupilimuab Quality of Life","November 1, 2018","October 2021","December 2021","September 12, 2018",,"November 20, 2020","UCSF Psoriasis and Skin Treatment Center, San Francisco, California, United States",,"https://ClinicalTrials.gov/show/NCT03667014"
323,"NCT03639675","Study to Learn How the Drug Aflibercept Works in in Japanese Patients With Increased Eye Pressure That is Caused by New Blood Vessels Growing in the Eye (Neovascular Glaucoma or NVG). Safety of the Drug and Patients' Tolerability of the Drug Injection is Also Studied","VENERA","Completed","Has Results","Glaucoma, Neovascular","Drug: Aflibercept (EYLEA, BAY86-5321)|Drug: Topical IOP-lowering drugs","Change in Intraocular Pressure (IOP) From Baseline to Week 1|Percentage of Participants Who Had Improved Neovascularization of the Iris (NVI) Grade From Baseline to Week 1","Bayer|Regeneron Pharmaceuticals","All","20 Years and older   (Adult, Older Adult)","Phase 3","16","Industry","Interventional","Allocation: N/A|Intervention Model: Single Group Assignment|Masking: None (Open Label)|Primary Purpose: Treatment","19652","October 3, 2018","February 14, 2019","March 14, 2019","August 21, 2018","February 18, 2020","March 3, 2020","University of Fukui Hospital, Yoshida, Fukui, Japan|Tsukazaki Hospital, Himeji, Hyogo, Japan|Kanazawa University Hospital, Kanazawa, Ishikawa, Japan|St. Marianna University School of Medicine Hospital, Kawasaki, Kanagawa, Japan|Osaka University Hospital, Suita, Osaka, Japan|Takatsuki Red Cross Hospital, Takatsuki, Osaka, Japan|Shimane University Hospital, Izumo, Shimane, Japan","""Study Protocol"", https://ClinicalTrials.gov/ProvidedDocs/75/NCT03639675/Prot_000.pdf|""Statistical Analysis Plan"", https://ClinicalTrials.gov/ProvidedDocs/75/NCT03639675/SAP_001.pdf","https://ClinicalTrials.gov/show/NCT03639675"
324,"NCT03620747","Continuation of TRAVERSE- LTS12551 Evaluating Dupilumab Safety in Patients With Asthma (Long-Term Follow-Up)",,"Active, not recruiting","No Results Available","Asthma","Drug: Dupilumab SAR231893 (REGN668)","Treatment-emergent adverse events (TEAE)|TEAE","Sanofi|Regeneron Pharmaceuticals","All","12 Years and older   (Child, Adult, Older Adult)","Phase 3","750","Industry","Interventional","Allocation: N/A|Intervention Model: Single Group Assignment|Masking: None (Open Label)|Primary Purpose: Treatment","LPS15023|2017-002134-23|U1111-1196-5369","August 30, 2018","February 2022","February 2022","August 8, 2018",,"October 14, 2021","Investigational Site Number :840099, Gilbert, Arizona, United States|Investigational Site Number :840087, Scottsdale, Arizona, United States|Investigational Site Number :840402, Tucson, Arizona, United States|Investigational Site Number :840132, Little Rock, Arkansas, United States|Investigational Site Number :840121, San Jose, California, United States|Investigational Site Number :840403, Denver, Colorado, United States|Investigational Site Number :840130, Denver, Colorado, United States|Investigational Site Number :840115, Ocoee, Florida, United States|Investigational Site Number :840055, Sarasota, Florida, United States|Investigational Site Number :840079, Twin Falls, Idaho, United States|Investigational Site Number :840032, Fort Mitchell, Kentucky, United States|Investigational Site Number :840064, Bangor, Maine, United States|Investigational Site Number :840052, Chevy Chase, Maryland, United States|Investigational Site Number :840073, Gaithersburg, Maryland, United States|Investigational Site Number :840018, Minneapolis, Minnesota, United States|Investigational Site Number :840102, Saint Louis, Missouri, United States|Investigational Site Number :840004, Papillion, Nebraska, United States|Investigational Site Number :840068, West Long Branch, New Jersey, United States|Investigational Site Number :840126, Charlotte, North Carolina, United States|Investigational Site Number :840907, High Point, North Carolina, United States|Investigational Site Number :840942, Toledo, Ohio, United States|Investigational Site Number :840067, Philadelphia, Pennsylvania, United States|Investigational Site Number :840091, Pittsburgh, Pennsylvania, United States|Investigational Site Number :840070, Allen, Texas, United States|Investigational Site Number :840062, Amarillo, Texas, United States|Investigational Site Number :840124, Cypress, Texas, United States|Investigational Site Number :840023, Dallas, Texas, United States|Investigational Site Number :840922, Fort Worth, Texas, United States|Investigational Site Number :840027, Fort Worth, Texas, United States|Investigational Site Number :840008, San Antonio, Texas, United States|Investigational Site Number :840035, Draper, Utah, United States|Investigational Site Number :840077, Murray, Utah, United States|Investigational Site Number :840057, South Burlington, Vermont, United States|Investigational Site Number :840059, Fairfax, Virginia, United States|Investigational Site Number :840951, Bellingham, Washington, United States|Investigational Site Number :032096, Bahia Blanca, Buenos Aires, Argentina|Investigational Site Number :032091, Capital Federal, Buenos Aires, Argentina|Investigational Site Number :032002, La Plata, Buenos Aires, Argentina|Investigational Site Number :032006, Rosario, Santa Fe, Argentina|Investigational Site Number :032005, Rosario, Santa Fe, Argentina|Investigational Site Number :032004, Buenos Aires, Argentina|Investigational Site Number :032003, Ciudad Autonoma Bs As, Argentina|Investigational Site Number :032097, Ciudad Autonoma Buenos Aires, Argentina|Investigational Site Number :032010, Ciudad Autonoma Buenos Aires, Argentina|Investigational Site Number :032001, Ciudad Autonoma Buenos Aires, Argentina|Investigational Site Number :032012, San Miguel de Tucuman, Argentina|Investigational Site Number :032009, San Miguel De TucumÃ¡n, Argentina|Investigational Site Number :056003, Gent, Belgium|Investigational Site Number :124006, Vancouver, British Columbia, Canada|Investigational Site Number :124017, Vancouver, British Columbia, Canada|Investigational Site Number :124016, Hamilton, Ontario, Canada|Investigational Site Number :124013, Ottawa, Ontario, Canada|Investigational Site Number :124002, Toronto, Ontario, Canada|Investigational Site Number :124001, Montreal, Quebec, Canada|Investigational Site Number :124012, Montreal, Quebec, Canada|Investigational Site Number :124010, MontrÃ©al, Quebec, Canada|Investigational Site Number :124014, QuÃ©bec, Quebec, Canada|Investigational Site Number :124007, Trois-Rivieres, Quebec, Canada|Investigational Site Number :124018, Quebec, Canada|Investigational Site Number :250009, Brest cedex 2, France|Investigational Site Number :250010, Lille Cedex, France|Investigational Site Number :250006, Lyon cedex 04, France|Investigational Site Number :250001, Marseille, France|Investigational Site Number :250002, Montpellier cedex 5, France|Investigational Site Number :250005, Nantes cedex, France|Investigational Site Number :250008, Strasbourg, France|Investigational Site Number :276006, Berlin, Germany|Investigational Site Number :276010, Frankfurt am Main, Germany|Investigational Site Number :276011, Grosshansdorf, Germany|Investigational Site Number :276009, Koblenz, Germany|Investigational Site Number :276005, Ruedersdorf, Germany|Investigational Site Number :376001, Kfar- Sava, Israel|Investigational Site Number :376005, Petach-Tikva, Israel|Investigational Site Number :376002, Rechovot, Israel|Investigational Site Number :392106, Mizunami-shi, Gifu, Japan|Investigational Site Number :392043, Ota-shi, Gunma, Japan|Investigational Site Number :392021, Fukuyama-shi, Hiroshima, Japan|Investigational Site Number :392108, Hiroshima-shi, Hiroshima, Japan|Investigational Site Number :392164, Muroran-shi, Hokkaido, Japan|Investigational Site Number :392008, Sapporo-shi, Hokkaido, Japan|Investigational Site Number :392034, Sapporo-shi, Hokkaido, Japan|Investigational Site Number :392006, Tomakomai-shi, Hokkaido, Japan|Investigational Site Number :392162, Kobe-shi, Hyogo, Japan|Investigational Site Number :392020, Naka-gun, Ibaraki, Japan|Investigational Site Number :392011, Sakaide-shi, Kagawa, Japan|Investigational Site Number :392014, Yokohama-shi, Kanagawa, Japan|Investigational Site Number :392153, Kyoto-shi, Kyoto, Japan|Investigational Site Number :392170, Osaki-shi, Miyagi, Japan|Investigational Site Number :392045, Uruma-shi, Okinawa, Japan|Investigational Site Number :392119, Kishiwada-shi, Osaka, Japan|Investigational Site Number :392005, Naruto-shi, Tokushima, Japan|Investigational Site Number :392002, Chuo-ku, Tokyo, Japan|Investigational Site Number :392112, Chuo-ku, Tokyo, Japan|Investigational Site Number :392133, Machida-shi, Tokyo, Japan|Investigational Site Number :392177, Ome-shi, Tokyo, Japan|Investigational Site Number :392038, Setagaya-ku, Tokyo, Japan|Investigational Site Number :392167, Shinagawa-ku, Tokyo, Japan|Investigational Site Number :392173, Tachikawa-shi, Tokyo, Japan|Investigational Site Number :392185, Akashi-shi, Japan|Investigational Site Number :392007, Chuo-Ku, Japan|Investigational Site Number :392012, Edogawa-ku, Japan|Investigational Site Number :392030, Habikino-shi, Japan|Investigational Site Number :392004, Himeji-shi, Japan|Investigational Site Number :392158, Hiroshima-shi, Japan|Investigational Site Number :392013, Iizuka-shi, Japan|Investigational Site Number :392042, Isesaki-shi, Japan|Investigational Site Number :392142, Kasuga-shi, Japan|Investigational Site Number :392040, Kodaira-shi, Japan|Investigational Site Number :392044, Kokubunji-shi, Japan|Investigational Site Number :392010, Kurashiki-shi, Japan|Investigational Site Number :392036, Kyoto-shi, Japan|Investigational Site Number :392144, Minato-ku, Japan|Investigational Site Number :392122, Minato-ku, Japan|Investigational Site Number :392163, Nagoya-shi, Japan|Investigational Site Number :392155, Osakasayama-shi, Japan|Investigational Site Number :392152, Osakasayama-shi, Japan|Investigational Site Number :392127, Ota-ku, Japan|Investigational Site Number :392169, Sagamihara-shi, Japan|Investigational Site Number :392130, Shinjuku-ku, Japan|Investigational Site Number :392165, Sumida-ku, Japan|Investigational Site Number :392146, Tachikawa-shi, Japan|Investigational Site Number :392029, Tsu-shi, Japan|Investigational Site Number :392168, Uozu-shi, Japan|Investigational Site Number :392132, Urasoe-shi, Japan|Investigational Site Number :528001, Arnhem, Netherlands|Investigational Site Number :710009, Brandfort, South Africa|Investigational Site Number :710011, Cape Town, South Africa|Investigational Site Number :710001, Cape Town, South Africa|Investigational Site Number :710091, Cape Town, South Africa|Investigational Site Number :710092, Cape Town, South Africa|Investigational Site Number :710006, Durban, South Africa|Investigational Site Number :710007, Pretoria, South Africa",,"https://ClinicalTrials.gov/show/NCT03620747"
325,"NCT03600818","Evaluation of the Efficacy and Safety of Sarilumab in Patients With Polymyalgia Rheumatica",,"Terminated","No Results Available","Polymyalgia Rheumatica","Drug: Sarilumab SAR153191 (REGN88)|Drug: Sarilumab-matching placebo|Drug: Prednisone|Drug: Prednisone-matching placebo","Proportion of patients with sustained remission|Components of sustained remission (composite measure)|Cumulative corticosteroid dose|Time to first polymyalgia rheumatica (PMR) flare|Change in glucocorticoid toxicity index|Adverse events|Pharmacokinetic","Sanofi|Regeneron Pharmaceuticals","All","50 Years and older   (Adult, Older Adult)","Phase 3","118","Industry","Interventional","Allocation: Randomized|Intervention Model: Parallel Assignment|Masking: Quadruple (Participant, Care Provider, Investigator, Outcomes Assessor)|Primary Purpose: Treatment","EFC15160|2017-002989-42|U1111-1201-0777","October 9, 2018","May 19, 2021","May 19, 2021","July 26, 2018",,"June 21, 2021","Investigational Site Number 8400003, Upland, California, United States|Investigational Site Number 8400005, Denver, Colorado, United States|Investigational Site Number 8400009, Stamford, Connecticut, United States|Investigational Site Number 8400002, Boca Raton, Florida, United States|Investigational Site Number 8400014, Iowa City, Iowa, United States|Investigational Site Number 8400006, Boston, Massachusetts, United States|Investigational Site Number 8400022, New York, New York, United States|Investigational Site Number 8400011, Dallas, Texas, United States|Investigational Site Number 8400025, Lufkin, Texas, United States|Investigational Site Number 8400015, Spokane, Washington, United States|Investigational Site Number 0320001, Buenos Aires, Argentina|Investigational Site Number 0320005, Buenos Aires, Argentina|Investigational Site Number 0320002, Caba, Argentina|Investigational Site Number 0320003, San Miguel de Tucuman, Argentina|Investigational Site Number 0360003, Camberwell, Australia|Investigational Site Number 0360001, Kogarah, Australia|Investigational Site Number 0360002, Maroochydore, Australia|Investigational Site Number 0360004, Woodville South, Australia|Investigational Site Number 0560003, Gent, Belgium|Investigational Site Number 0560001, Leuven, Belgium|Investigational Site Number 1240007, Hamilton, Canada|Investigational Site Number 1240010, Montreal, Canada|Investigational Site Number 1240001, Rimouski, Canada|Investigational Site Number 1240005, Sherbrooke, Canada|Investigational Site Number 1240003, Trois-Rivières, Canada|Investigational Site Number 2330001, Tallinn, Estonia|Investigational Site Number 2500005, Brest Cedex, France|Investigational Site Number 2500011, Caen Cedex 9, France|Investigational Site Number 2500015, Le Kremlin Bicetre, France|Investigational Site Number 2500010, Lille Cedex, France|Investigational Site Number 2500002, Montivilliers, France|Investigational Site Number 2500003, Montpellier, France|Investigational Site Number 2500004, Paris, France|Investigational Site Number 2500016, Pierre Benite Cedex, France|Investigational Site Number 2500014, Toulouse Cedex 09, France|Investigational Site Number 2760008, Bad Abbach, Germany|Investigational Site Number 2760009, Berlin, Germany|Investigational Site Number 2760001, Berlin, Germany|Investigational Site Number 2760002, Dresden, Germany|Investigational Site Number 2760003, Kirchheim Unter Teck, Germany|Investigational Site Number 2760004, München, Germany|Investigational Site Number 2760007, Tübingen, Germany|Investigational Site Number 3480001, Debrecen, Hungary|Investigational Site Number 3760001, Haifa, Israel|Investigational Site Number 3760004, Haifa, Israel|Investigational Site Number 3760003, Kfar Saba, Israel|Investigational Site Number 3760002, Petah-Tikva, Israel|Investigational Site Number 3760005, Tel Hashomer, Israel|Investigational Site Number 3800003, Milano, Italy|Investigational Site Number 3800001, Milano, Italy|Investigational Site Number 3800004, Pisa, Italy|Investigational Site Number 3800002, Reggio Emilia, Italy|Investigational Site Number 3800005, Rozzano, Italy|Investigational Site Number 3800008, Verona, Italy|Investigational Site Number 3920002, Fuchu-Shi, Japan|Investigational Site Number 3920003, Kamakura-Shi, Japan|Investigational Site Number 3920005, Kawachinagano-Shi, Japan|Investigational Site Number 3920001, Takasaki-Shi, Japan|Investigational Site Number 5280003, Alkmaar, Netherlands|Investigational Site Number 5280002, Almelo, Netherlands|Investigational Site Number 5280007, Den Haag, Netherlands|Investigational Site Number 5280005, Leeuwarden, Netherlands|Investigational Site Number 5280004, Nijmegen, Netherlands|Investigational Site Number 5280008, Rotterdam, Netherlands|Investigational Site Number 6430002, Moscow, Russian Federation|Investigational Site Number 6430001, Moscow, Russian Federation|Investigational Site Number 6430003, Moscow, Russian Federation|Investigational Site Number 6430004, Moscow, Russian Federation|Investigational Site Number 6430008, Saint-Petersburg, Russian Federation|Investigational Site Number 7240004, A Coruña / Santiago De Compostela, Spain|Investigational Site Number 7240005, Badalona, Spain|Investigational Site Number 7240001, Getafe, Spain|Investigational Site Number 7240008, Granada, Spain|Investigational Site Number 7240002, Madrid, Spain|Investigational Site Number 7240006, Santander, Spain|Investigational Site Number 7240007, Valencia, Spain|Investigational Site Number 7560001, Bern, Switzerland|Investigational Site Number 7560002, St. Gallen, Switzerland|Investigational Site Number 8260004, Gateshead, United Kingdom|Investigational Site Number 8260003, Leeds, United Kingdom|Investigational Site Number 8260009, Manchester, United Kingdom|Investigational Site Number 8260007, Newport, United Kingdom|Investigational Site Number 8260002, Plymouth, United Kingdom|Investigational Site Number 8260001, Southend, United Kingdom",,"https://ClinicalTrials.gov/show/NCT03600818"
326,"NCT03600805","Evaluation of Efficacy and Safety of Sarilumab in Patients With GCA",,"Terminated","Has Results","Giant Cell Arteritis","Drug: Sarilumab SAR153191|Drug: Sarilumab matching placebo|Drug: Prednisone|Drug: Prednisone matching placebo","Percentage of Participants Who Achieved Sustained Disease Remission at Week 52|Percentage of Participants Who Achieved Sustained Disease Remission at Week 24|Number of Participants With Achievement of Disease Remission up to Week 12: Week 52 Analysis Set|Number of Participants With Achievement of Disease Remission up to Week 12: Intent-to-treat (ITT) Population|Number of Participants With Absence of Disease Flare From Week 12 Through Week 52: Week 52 Analysis Set|Number of Participants With Absence of Disease Flare From Week 12 Through Week 24: ITT Population|Number of Participants With Normalization of C-Reactive Protein From Week 12 Through Week 52: Week 52 Analysis Set|Number of Participants With Normalization of C-Reactive Protein (CRP) From Week 12 Through Week 24: ITT Population|Number of Participants With Successful Adherence to the Prednisone Taper From Week 12 Through Week 52: Week 52 Analysis Set|Number of Participants With Successful Adherence to the Prednisone Taper From Week 12 Through Week 24: ITT Population|Total Cumulative Corticosteroid (Including Prednisone) Dose|Time to First Giant Cell Arteritis Disease Flare|Composite Glucocorticoid Toxicity Index (C-GTI): Cumulative Worsening Score (CWS) and Aggregate Improvement Score (AIS) at Week 24: ITT Population|Composite Glucocorticoid Toxicity Index: Cumulative Worsening Score and Aggregate Improvement Score at Week 52|Number of Participants With Treatment-emergent Adverse Events (TEAEs) and Treatment-emergent Serious Adverse Events (TESAEs)|Pharmacokinetics (PK): Serum Trough Concentration (Ctrough) of Sarilumab|Pharmacokinetics: Serum Drug Concentration of Sarilumab Post-dose at Week 24|Percentage of Participants With Treatment-emergent Antidrug Antibodies (ADA) Response|Pharmacodynamics: Change From Baseline in Erythrocyte Sedimentation Rate (ESR) at Weeks 2, 4, 8, 12, 16, 20, 24, 32, 40, and 52|Pharmacodynamics: Change From Baseline in C-reactive Protein (CRP) Level at Weeks 2, 4, 8, 12, 16, 20, 24, 32, 40, and 52|Pharmacodynamics: Change From Baseline in Interleukin-6 (IL-6) at Weeks 2, 12, 24, and 52|Pharmacodynamics: Change From Baseline in Soluble Interleukin-6 Receptor (sIL-6R) Level at Weeks 2, 12, 24, and 52","Sanofi|Regeneron Pharmaceuticals","All","50 Years and older   (Adult, Older Adult)","Phase 3","83","Industry","Interventional","Allocation: Randomized|Intervention Model: Parallel Assignment|Masking: Quadruple (Participant, Care Provider, Investigator, Outcomes Assessor)|Primary Purpose: Treatment","EFC15068|2017-002988-18|U1111-1200-2184","November 20, 2018","November 24, 2020","November 24, 2020","July 26, 2018","January 14, 2022","January 14, 2022","Investigational Site Number 8400002, Boca Raton, Florida, United States|Investigational Site Number 8400017, Gainesville, Florida, United States|Investigational Site Number 8400014, Iowa City, Iowa, United States|Investigational Site Number 8400018, Portland, Oregon, United States|Investigational Site Number 8400019, Philadelphia, Pennsylvania, United States|Investigational Site Number 8400011, Dallas, Texas, United States|Investigational Site Number 0320001, Buenos Aires, Argentina|Investigational Site Number 0320002, Caba, Argentina|Investigational Site Number 0360003, Camberwell, Australia|Investigational Site Number 0360006, Clayton, Australia|Investigational Site Number 0360001, Kogarah, Australia|Investigational Site Number 0560001, Leuven, Belgium|Investigational Site Number 1240007, Hamilton, Canada|Investigational Site Number 1240010, Montreal, Canada|Investigational Site Number 1240001, Rimouski, Canada|Investigational Site Number 1240005, Sherbrooke, Canada|Investigational Site Number 1240003, Trois-Rivières, Canada|Investigational Site Number 1910001, Zagreb, Croatia|Investigational Site Number 2080002, Aarhus C, Denmark|Investigational Site Number 2080003, Svendborg, Denmark|Investigational Site Number 2330001, Tallinn, Estonia|Investigational Site Number 2500005, Brest Cedex, France|Investigational Site Number 2500002, Montivilliers, France|Investigational Site Number 2500003, Montpellier, France|Investigational Site Number 2500007, Mulhouse, France|Investigational Site Number 2500001, Paris, France|Investigational Site Number 2500006, Pessac, France|Investigational Site Number 2760001, Berlin, Germany|Investigational Site Number 2760002, Dresden, Germany|Investigational Site Number 2760003, Kirchheim Unter Teck, Germany|Investigational Site Number 2760004, München, Germany|Investigational Site Number 2760007, Tübingen, Germany|Investigational Site Number 3480001, Debrecen, Hungary|Investigational Site Number 3760006, Ashkelon, Israel|Investigational Site Number 3760004, Haifa, Israel|Investigational Site Number 3800001, Milano, Italy|Investigational Site Number 3800005, Rozzano, Italy|Investigational Site Number 5280007, Den Haag, Netherlands|Investigational Site Number 5280005, Leeuwarden, Netherlands|Investigational Site Number 5280009, Sittard-Geleen, Netherlands|Investigational Site Number 5280001, Venlo, Netherlands|Investigational Site Number 6200001, Almada, Portugal|Investigational Site Number 6200005, Aveiro, Portugal|Investigational Site Number 6200004, Ponte De Lima, Portugal|Investigational Site Number 6430005, Kemerovo, Russian Federation|Investigational Site Number 6430002, Moscow, Russian Federation|Investigational Site Number 6430003, Moscow, Russian Federation|Investigational Site Number 7050001, Ljubljana, Slovenia|Investigational Site Number 7240010, Bilbao, Spain|Investigational Site Number 7240011, La Coruña, Spain|Investigational Site Number 7240014, Madrid, Spain|Investigational Site Number 7240016, Sabadell, Spain|Investigational Site Number 7240015, Santa Cruz De Tenerife, Spain|Investigational Site Number 7520001, Uppsala, Sweden|Investigational Site Number 7520003, Örebro, Sweden|Investigational Site Number 7560002, St. Gallen, Switzerland|Investigational Site Number 8260006, Aberdeen, United Kingdom|Investigational Site Number 8260004, Gateshead, United Kingdom|Investigational Site Number 8260003, Leeds, United Kingdom|Investigational Site Number 8260005, Manchester, United Kingdom|Investigational Site Number 8260011, Portsmouth, United Kingdom","""Study Protocol"", https://ClinicalTrials.gov/ProvidedDocs/05/NCT03600805/Prot_000.pdf|""Statistical Analysis Plan"", https://ClinicalTrials.gov/ProvidedDocs/05/NCT03600805/SAP_001.pdf","https://ClinicalTrials.gov/show/NCT03600805"
327,"NCT03560466","Assessment of the Safety and Efficacy of Dupilumab in Children With Asthma (Liberty Asthma Excursion)",,"Active, not recruiting","No Results Available","Asthma","Drug: Dupilumab (SAR231893/REGN668)|Drug: Asthma controller therapies (incl. prednisone/prednisolone)|Drug: Asthma reliever therapies","The number of patients experiencing any treatment emergent adverse event (TEAE)|Japan sub-study: Change from baseline in pre-bronchodilator percentage (%) predicted FEV1 at Week 12|Annualized rate of severe asthma exacerbation events during the treatment period|Change from baseline in % predicted FEV1|Change from baseline in absolute FEV1|Change from baseline in FVC|Change from baseline in FEF 25 to 75%|Serum dupilumab concentrations|Incidence of treatment-emergent antidrug antibodies (ADA) against dupilumab|Blood eosinophil counts|Serum total IgE|Japan sub-study: Annualized rate of severe asthma exacerbation events during the treatment period|Japan sub-study: Change from baseline in pre-bronchodilator % predicted FEV1 at Weeks 2, 4, 8, 24, 52, and 64|Japan sub-stud: Change from baseline in absolute FEV1|Japan sub-study: Change from baseline in FVC|Japan sub-study: Change from baseline in FEF 25-75%|Japan sub-study: Change from baseline in ACQ-IA|Japan sub-study: The number of patients experiencing any TEAEs|Japan sub-study: Serum dupilumab concentrations|Japan sub-study: Incidence of treatment-emergent ADA against dupilumab|Japan sub-study: Serum total immunoglobulin E (IgE)|Japan sub-study: Change from Baseline in FeNO","Sanofi|Regeneron Pharmaceuticals","All","6 Years to 11 Years   (Child)","Phase 3","365","Industry","Interventional","Allocation: N/A|Intervention Model: Single Group Assignment|Masking: None (Open Label)|Primary Purpose: Treatment","LTS14424|2017-003317-25|U1111-1200-1757","June 21, 2018","October 30, 2023","October 30, 2023","June 18, 2018",,"February 28, 2022","Investigational Site Number :8400002, Gilbert, Arizona, United States|Investigational Site Number :8400012, Tucson, Arizona, United States|Investigational Site Number :8400001, Rolling Hills Estates, California, United States|Investigational Site Number :8400006, Saint Louis, Missouri, United States|Investigational Site Number :8400022, Lincoln, Nebraska, United States|Investigational Site Number :8400023, Great Neck, New York, United States|Investigational Site Number :8400013, New York, New York, United States|Investigational Site Number :8400007, Rochester, New York, United States|Investigational Site Number :8400004, Charlotte, North Carolina, United States|Investigational Site Number :8400008, Cincinnati, Ohio, United States|Investigational Site Number :8400024, Edmond, Oklahoma, United States|Investigational Site Number :8400003, San Antonio, Texas, United States|Investigational Site Number :0320002, Caba, Buenos Aires, Argentina|Investigational Site Number :0320001, Caba, Buenos Aires, Argentina|Investigational Site Number :0320004, Buenos Aires, Argentina|Investigational Site Number :0320003, Buenos Aires, Argentina|Investigational Site Number :0320006, Mendoza, Argentina|Investigational Site Number :0360005, North Adelaide, South Australia, Australia|Investigational Site Number :0760001, Porto Alegre, Rio Grande Do Sul, Brazil|Investigational Site Number :0760007, Porto Alegre, Rio Grande Do Sul, Brazil|Investigational Site Number :0760002, Sao Paulo, São Paulo, Brazil|Investigational Site Number :0760004, Sao Paulo, São Paulo, Brazil|Investigational Site Number :0760006, Sorocaba, São Paulo, Brazil|Investigational Site Number :1240003, Quebec, Canada|Investigational Site Number :1520001, Valdivia, Los Ríos, Chile|Investigational Site Number :1520005, Santiago, Reg Metropolitana De Santiago, Chile|Investigational Site Number :1520009, Santiago, Reg Metropolitana De Santiago, Chile|Investigational Site Number :1520007, Viña del Mar, Valparaíso, Chile|Investigational Site Number :1520002, Viña del Mar, Valparaíso, Chile|Investigational Site Number :1700004, Antioquia, Colombia|Investigational Site Number :1700002, Cali, Colombia|Investigational Site Number :3480006, Budapest, Hungary|Investigational Site Number :3480002, Gyula, Hungary|Investigational Site Number :3480012, Mezökövesd, Hungary|Investigational Site Number :3480008, Szigetvár, Hungary|Investigational Site Number :3480001, Székesfehérvár, Hungary|Investigational Site Number :3480003, Töröbálint, Hungary|Investigational Site Number :3480007, Zalaegerszeg, Hungary|Investigational Site Number :3800003, Firenze, Italy|Investigational Site Number :3800004, Padova, Italy|Investigational Site Number :3800005, Roma, Italy|Investigational Site Number :3920002, Nagoya-shi, Aichi, Japan|Investigational Site Number :3920005, Yotsukaido-shi, Chiba, Japan|Investigational Site Number :3920008, Shibukawa-shi, Gunma, Japan|Investigational Site Number :3920003, Sapporo-shi, Hokkaido, Japan|Investigational Site Number :3920006, Kamakura-shi, Kanagawa, Japan|Investigational Site Number :3920004, Ritto-shi, Shiga, Japan|Investigational Site Number :3920001, Chuo-ku, Tokyo, Japan|Investigational Site Number :4400005, Siauliai, Lithuania|Investigational Site Number :4400003, Utena, Lithuania|Investigational Site Number :4400001, Vilnius, Lithuania|Investigational Site Number :4400004, Vilnius, Lithuania|Investigational Site Number :4840006, Chihuahua, Mexico|Investigational Site Number :4840004, Chihuahua, Mexico|Investigational Site Number :4840003, Durango, Durango, Mexico|Investigational Site Number :4840001, Monterrey, Nuevo León, Mexico|Investigational Site Number :4840002, Veracruz, Mexico|Investigational Site Number :6160001, Lodz, Lódzkie, Poland|Investigational Site Number :6160002, Poznan, Wielkopolskie, Poland|Investigational Site Number :6430004, Perm, Russian Federation|Investigational Site Number :6430002, Saint Petersburg, Russian Federation|Investigational Site Number :6430001, Saint-Petersburg, Russian Federation|Investigational Site Number :6430005, St Petersburg, Russian Federation|Investigational Site Number :6430003, St. Petersburg, Russian Federation|Investigational Site Number :7100001, Cape Town, South Africa|Investigational Site Number :7240001, Barcelona, Barcelona [Barcelona], Spain|Investigational Site Number :7920005, Adana, Turkey|Investigational Site Number :7920001, Ankara, Turkey|Investigational Site Number :7920003, İstanbul, Turkey|Investigational Site Number :7920004, Istanbul, Turkey|Investigational Site Number :8040007, Chernivtsi, Ukraine|Investigational Site Number :8040004, Dnipro, Ukraine|Investigational Site Number :8040005, Kharkiv, Ukraine|Investigational Site Number :8040008, Kryvyi Rig, Ukraine|Investigational Site Number :8040001, Kyiv, Ukraine|Investigational Site Number :8040002, Zaporizhzhya, Ukraine|Investigational Site Number :8040003, Zaporizhzhya, Ukraine",,"https://ClinicalTrials.gov/show/NCT03560466"
328,"NCT03546907","Proof-of-Concept Study to Assess the Efficacy, Safety and Tolerability of SAR440340 (Anti-IL-33 mAb) in Patients With Moderate-to-severe Chronic Obstructive Pulmonary Disease (COPD)",,"Completed","No Results Available","Chronic Obstructive Pulmonary Disease","Drug: Itepekimab (SAR440340)|Drug: Placebo|Drug: Any Inhaled Corticosteroids as prescribed by treating physician as standard of care|Drug: Any Long Acting Beta Agonist as prescribed by treating physician as standard of care|Drug: Any Long Acting Muscarinic Agonist as prescribed by treating physician as standard of care|Drug: Any short-acting β agonist as prescribed by treating physician as standard of care","Rate of moderate-to-severe acute Exacerbations in chronic obstructive pulmonary disease (AECOPD) patients|Change in pre-bronchodilator forced expiratory volume in 1 second (FEV1)|Time to first COPD Exacerbation|Adverse Events|Change in post-bronchodilator FEV1","Sanofi|Regeneron Pharmaceuticals","All","40 Years to 75 Years   (Adult, Older Adult)","Phase 2","343","Industry","Interventional","Allocation: Randomized|Intervention Model: Parallel Assignment|Masking: Quadruple (Participant, Care Provider, Investigator, Outcomes Assessor)|Primary Purpose: Treatment","ACT15104|2017-003290-34|U1111-1194-2134","July 16, 2018","October 3, 2019","February 19, 2020","June 6, 2018",,"October 12, 2020","Investigational Site Number 8400002, Los Angeles, California, United States|Investigational Site Number 8400003, Riverside, California, United States|Investigational Site Number 8400006, Rolling Hills Estates, California, United States|Investigational Site Number 8400015, Westminster, California, United States|Investigational Site Number 8400013, Jacksonville, Florida, United States|Investigational Site Number 8400012, Columbia, Maryland, United States|Investigational Site Number 8400016, North Dartmouth, Massachusetts, United States|Investigational Site Number 8400020, South Dartmouth, Massachusetts, United States|Investigational Site Number 8400011, Minneapolis, Minnesota, United States|Investigational Site Number 8400005, Jamaica, New York, United States|Investigational Site Number 8400019, Chapel Hill, North Carolina, United States|Investigational Site Number 8400004, Raleigh, North Carolina, United States|Investigational Site Number 8400001, Medford, Oregon, United States|Investigational Site Number 8400009, Philadelphia, Pennsylvania, United States|Investigational Site Number 8400007, Plano, Texas, United States|Investigational Site Number 8400008, Greenfield, Wisconsin, United States|Investigational Site Number 0320001, Buenos Aires, Argentina|Investigational Site Number 0320005, Caba, Argentina|Investigational Site Number 0320002, Caba, Argentina|Investigational Site Number 0320004, Caba, Argentina|Investigational Site Number 0320006, Quilmes, Argentina|Investigational Site Number 0320003, Rosario, Argentina|Investigational Site Number 0360005, Bedford Park, Australia|Investigational Site Number 0360002, Chermside, Australia|Investigational Site Number 0360004, Clayton, Australia|Investigational Site Number 0360003, Frankston, Australia|Investigational Site Number 0360006, Kent Town, Australia|Investigational Site Number 0360001, Murdoch, Australia|Investigational Site Number 1240002, Burlington, Canada|Investigational Site Number 1240009, Hamilton, Canada|Investigational Site Number 1240003, Montreal, Canada|Investigational Site Number 1240001, Montreal, Canada|Investigational Site Number 1240005, Quebec, Canada|Investigational Site Number 1240006, St-Charles Borrommee, Canada|Investigational Site Number 1240008, Trois-Rivieres, Canada|Investigational Site Number 1240007, Vancouver, Canada|Investigational Site Number 1240004, Victoriaville, Canada|Investigational Site Number 1520002, Quillota, Chile|Investigational Site Number 1520001, Santiago, Chile|Investigational Site Number 1520007, Santiago, Chile|Investigational Site Number 1520004, Santiago, Chile|Investigational Site Number 1520003, Talcahuano, Chile|Investigational Site Number 1520005, Talca, Chile|Investigational Site Number 2760006, Berlin, Germany|Investigational Site Number 2760001, Großhansdorf, Germany|Investigational Site Number 2760002, Hamburg, Germany|Investigational Site Number 2760007, Koblenz, Germany|Investigational Site Number 2760004, München, Germany|Investigational Site Number 2760005, Rüdersdorf Bei Berlin, Germany|Investigational Site Number 6160001, Bialystok, Poland|Investigational Site Number 6160008, Bialystok, Poland|Investigational Site Number 6160005, Bydgoszcz, Poland|Investigational Site Number 6160009, Grudziadz, Poland|Investigational Site Number 6160007, Krakow, Poland|Investigational Site Number 6160002, Poznan, Poland|Investigational Site Number 6160006, Poznan, Poland|Investigational Site Number 6160010, Rzeszow, Poland|Investigational Site Number 6160003, Znin, Poland|Investigational Site Number 6430003, Moscow, Russian Federation|Investigational Site Number 6430001, Moscow, Russian Federation|Investigational Site Number 6430005, Moscow, Russian Federation|Investigational Site Number 6430002, Moscow, Russian Federation|Investigational Site Number 6430010, Saint-Petersburg, Russian Federation|Investigational Site Number 6430006, Saint-Petersburg, Russian Federation|Investigational Site Number 6430007, St-Petersburg, Russian Federation|Investigational Site Number 6430009, Stavropol, Russian Federation|Investigational Site Number 6430004, Ulyanovsk, Russian Federation|Investigational Site Number 7920004, Ankara, Turkey|Investigational Site Number 7920001, Istanbul, Turkey|Investigational Site Number 7920006, Izmir, Turkey|Investigational Site Number 7920007, Izmir, Turkey|Investigational Site Number 7920008, Kirikkale, Turkey|Investigational Site Number 7920002, Mersin, Turkey|Investigational Site Number 8040008, Chernivtsi, Ukraine|Investigational Site Number 8040012, Ivano-Frankivsk, Ukraine|Investigational Site Number 8040004, Ivano-Frankivsk, Ukraine|Investigational Site Number 8040002, Kharkiv, Ukraine|Investigational Site Number 8040011, Kharkiv, Ukraine|Investigational Site Number 8040007, Kyiv, Ukraine|Investigational Site Number 8040001, Kyiv, Ukraine|Investigational Site Number 8040006, Odesa, Ukraine|Investigational Site Number 8040003, Ternopil, Ukraine|Investigational Site Number 8040005, Vinnytsya, Ukraine",,"https://ClinicalTrials.gov/show/NCT03546907"
329,"NCT03542110","The Alirocumab for Stopping Atherosclerosis Progression in Saphenous Vein Grafts (ASAP-SVG) Pilot Trial","ASAP-SVG","Terminated","No Results Available","Saphenous Vein Graft Atherosclerosis","Drug: Alirocumab 150 MG/ML subcutaneous injection|Drug: Matching Placebo subcutaneous injection","Nominal change in intermediate SVG lesion percent atheroma volume (PAV) from baseline to 78 weeks post randomization, as assessed by intravascular ultrasonography (IVUS).|Nominal change in TAV and normalized TAV of an intermediate SVG lesion from baseline to 78 weeks|Angiographic failure of target SVG lesion from baseline to 78 weeks.|Incidence of target SVG failure and major adverse cardiac events.","Minneapolis Heart Institute Foundation|Regeneron Pharmaceuticals","All","18 Years and older   (Adult, Older Adult)","Phase 4","46","Other|Industry","Interventional","Allocation: Randomized|Intervention Model: Parallel Assignment|Masking: Quadruple (Participant, Care Provider, Investigator, Outcomes Assessor)|Primary Purpose: Prevention","ASAP-SVG, QR#32711/1","August 4, 2018","June 30, 2020","July 31, 2020","May 31, 2018",,"September 16, 2021","San Francisco VA Medical Center, San Francisco, California, United States|Atlanta VA Medical Center, Atlanta, Georgia, United States|Minneapolis Heart Institute/ Abbott North Western Hospital-Allina Health, Minneapolis, Minnesota, United States|Dallas VA Medical Center, Dallas, Texas, United States",,"https://ClinicalTrials.gov/show/NCT03542110"
330,"NCT03510884","An Efficacy and Safety Study of Alirocumab in Children and Adolescents With Heterozygous Familial Hypercholesterolemia",,"Active, not recruiting","No Results Available","Hypercholesterolaemia","Drug: Alirocumab SAR236553 (REGN727)|Drug: Rosuvastatin|Drug: Atorvastatin|Drug: Simvastatin|Drug: Pravastatin|Drug: Lovastatin|Drug: Fluvastatin|Drug: Ezetimibe|Drug: Cholestyramine|Drug: Nicotinic acid|Drug: Fenofibrate|Drug: Omega-3 fatty acids|Drug: Placebo","Percent change in low-density lipoprotein cholesterol (LDL-C)|Percent change in LDL-C|Percent change in Apo B|Percent change in non-high density lipoprotein cholesterol (non HDL-C)|Percent change in Total-C|Patients with LDL-C level <130 mg/dL (3.37 mmol/L)|Patients with LDL-C level <110 mg/dL (2.84 mmol/L)|Percent change in Lp(a)|Percent change in HDL-C|Percent change in TG|Percent change in Apo A-1|Number of patients with adverse events|Cogstate battery test|Tanner stage","Sanofi|Regeneron Pharmaceuticals","All","8 Years to 17 Years   (Child)","Phase 3","150","Industry","Interventional","Allocation: Randomized|Intervention Model: Parallel Assignment|Masking: Triple (Participant, Care Provider, Investigator)|Primary Purpose: Treatment","EFC14643|2017-001903-60|U1111-1193-0721","May 31, 2018","January 14, 2021","July 2022","April 27, 2018",,"January 13, 2022","Investigational Site Number 8400001, Boca Raton, Florida, United States|Investigational Site Number 8400006, Saint Louis, Missouri, United States|Investigational Site Number 8400002, Charlotte, North Carolina, United States|Investigational Site Number 8400005, Cincinnati, Ohio, United States|Investigational Site Number 8400003, Nashville, Tennessee, United States|Investigational Site Number 0320001, Buenos Aires, Argentina|Investigational Site Number 0400001, Wien, Austria|Investigational Site Number 0760003, Campinas, Brazil|Investigational Site Number 0760004, Porto Alegre, Brazil|Investigational Site Number 0760001, Sao Paulo, Brazil|Investigational Site Number 1000002, Plovdiv, Bulgaria|Investigational Site Number 1240001, Quebec, Canada|Investigational Site Number 2030002, Brno, Czechia|Investigational Site Number 2030001, Praha 5 - Motol, Czechia|Investigational Site Number 2080001, København Ø, Denmark|Investigational Site Number 2460001, Hus, Finland|Investigational Site Number 2500001, Bron Cedex, France|Investigational Site Number 2500002, Nantes Cedex 1, France|Investigational Site Number 3480001, Budapest, Hungary|Investigational Site Number 3800003, Milano, Italy|Investigational Site Number 3800001, Palermo, Italy|Investigational Site Number 3800002, Roma, Italy|Investigational Site Number 4220001, Beirut, Lebanon|Investigational Site Number 4220003, Room Hospital Street, Achrafie, Lebanon|Investigational Site Number 4840008, Guadalajara, Mexico|Investigational Site Number 4840007, Oaxaca, Mexico|Investigational Site Number 5280001, Amsterdam, Netherlands|Investigational Site Number 5780001, Oslo, Norway|Investigational Site Number 6160002, Gdansk, Poland|Investigational Site Number 6160001, Lodz, Poland|Investigational Site Number 6430006, Kazan, Russian Federation|Investigational Site Number 6430001, Kemerovo, Russian Federation|Investigational Site Number 6430004, Moscow, Russian Federation|Investigational Site Number 6430005, Moscow, Russian Federation|Investigational Site Number 6430007, Saint Petersburg, Russian Federation|Investigational Site Number 6430002, Ufa, Russian Federation|Investigational Site Number 7050001, Ljubljana, Slovenia|Investigational Site Number 7100002, Parow, South Africa|Investigational Site Number 7240002, A Coruna, Spain|Investigational Site Number 7240004, Badalona, Spain|Investigational Site Number 7240001, Barcelona / Sabadell, Spain|Investigational Site Number 7240003, Pamplona, Spain|Investigational Site Number 7520001, Stockholm, Sweden|Investigational Site Number 1580001, Taipei, Taiwan|Investigational Site Number 7920002, Ankara, Turkey|Investigational Site Number 7920001, Izmir, Turkey",,"https://ClinicalTrials.gov/show/NCT03510884"
331,"NCT03510715","An Efficacy and Safety Study of Alirocumab in Children and Adolescents With Homozygous Familial Hypercholesterolemia",,"Completed","Has Results","Hypercholesterolemia","Drug: Alirocumab SAR236553 (REGN727)|Drug: Atorvastatin|Drug: Simvastatin|Drug: Fluvastatin|Drug: Pravastatin|Drug: Lovastatin|Drug: Rosuvastatin|Drug: Ezetimibe|Drug: Cholestyramine|Drug: Nicotinic acid|Drug: Fenofibrate|Drug: Omega-3 fatty acids","Percent Change From Baseline in Low-Density Lipoprotein Cholesterol (LDL-C) at Week 12: Intent-to-Treat (ITT) Analysis|Percent Change From Baseline in Low-Density Lipoprotein Cholesterol at Week 12: On-treatment Analysis|Percent Change From Baseline in Low-Density Lipoprotein Cholesterol at Weeks 24 and 48: ITT Analysis/On-treatment Analysis|Percent Change From Baseline in Apolipoprotein (Apo) B at Weeks 12, 24 and 48: ITT Analysis/On-treatment Analysis|Percent Change From Baseline in Non-High Density Lipoprotein Cholesterol (Non-HDL-C) at Weeks 12, 24 and 48 - ITT Analysis/On-treatment Analysis|Percent Change From Baseline in Total Cholesterol (Total-C) at Weeks 12, 24 and 48: ITT Analysis/On-treatment Analysis|Percent Change From Baseline in Lipoprotein a (Lp) (a) at Weeks 12, 24 and 48: ITT Analysis/On-treatment Analysis|Percent Change From Baseline in High Density Lipoprotein Cholesterol (HDL-C) at Weeks 12, 24 and 48: ITT Analysis/On-treatment Analysis|Percent Change From Baseline in Fasting Triglycerides (TG) at Weeks 12, 24 and 48: ITT Analysis/On-treatment Analysis|Percent Change From Baseline in Apolipoprotein A1 (Apo A1) at Weeks 12, 24 and 48: ITT Analysis/On-treatment Analysis|Percentage of Participants Reporting >=15 Percent (%) Reduction in LDL-C Level at Weeks 12, 24 and 48: ITT Analysis/On-treatment Analysis|Absolute Change From Baseline in LDL-C Level at Weeks 12, 24 and 48: ITT Analysis/On-treatment Analysis|Number of Participants With Tanner Staging at Baseline, Weeks 12, 24 and 48","Sanofi|Regeneron Pharmaceuticals","All","8 Years to 17 Years   (Child)","Phase 3","18","Industry","Interventional","Allocation: N/A|Intervention Model: Single Group Assignment|Masking: None (Open Label)|Primary Purpose: Treatment","EFC14660|2017-002297-39|U1111-1200-2046","August 31, 2018","February 17, 2020","February 17, 2020","April 27, 2018","December 29, 2020","December 29, 2020","Investigational Site Number 0760001, Sao Paulo, Brazil|Investigational Site Number 1240001, Quebec, Canada|Investigational Site Number 2080001, Viborg, Denmark|Investigational Site Number 4840006, Oaxaca, Mexico|Investigational Site Number 5280001, Amsterdam, Netherlands|Investigational Site Number 6430002, Kemerovo, Russian Federation|Investigational Site Number 7050001, Ljubljana, Slovenia|Investigational Site Number 7240001, A Coruna, Spain|Investigational Site Number 1580001, Taipei, Taiwan|Investigational Site Number 7920001, Izmir, Turkey","""Study Protocol"", https://ClinicalTrials.gov/ProvidedDocs/15/NCT03510715/Prot_000.pdf|""Statistical Analysis Plan"", https://ClinicalTrials.gov/ProvidedDocs/15/NCT03510715/SAP_001.pdf","https://ClinicalTrials.gov/show/NCT03510715"
332,"NCT03507374","PCSK9 Inhibition in Patients With Symptomatic Intracranial Atherosclerosis","PINNACLE","Terminated","No Results Available","Stroke|Intracranial Atherosclerosis|Intraplaque Hemorrhage","Drug: Alirocumab|Drug: Placebo","Vessel Wall MRI|Post-Contrast Plaque Enhancement","University of Utah|Regeneron Pharmaceuticals","All","18 Years and older   (Adult, Older Adult)","Early Phase 1","20","Other|Industry","Interventional","Allocation: Randomized|Intervention Model: Parallel Assignment|Masking: Quadruple (Participant, Care Provider, Investigator, Outcomes Assessor)|Primary Purpose: Treatment","00104839","October 30, 2018","April 17, 2020","April 17, 2020","April 25, 2018",,"April 21, 2020","University of Utah, Salt Lake City, Utah, United States",,"https://ClinicalTrials.gov/show/NCT03507374"
333,"NCT03480568","Alirocumab in Patients on a Stable Dialysis Regimen",,"Unknown status","No Results Available","Hemodialysis|Peritoneal Dialysis|Hypercholesterolemia|Atherosclerotic Disease","Drug: Alirocumab 150 MG/ML [Praluent]","Change in LDL cholesterol levels|Change in HDL-cholesterol levels|Change in apoprotein B levels","Baylor Research Institute|Regeneron Pharmaceuticals","All","18 Years to 80 Years   (Adult, Older Adult)","Phase 3","20","Other|Industry","Interventional","Allocation: N/A|Intervention Model: Single Group Assignment|Masking: None (Open Label)|Primary Purpose: Treatment","018-038","May 1, 2018","August 31, 2020","December 31, 2020","March 29, 2018",,"February 12, 2020","Baylor Soltero CV Research, Dallas, Texas, United States",,"https://ClinicalTrials.gov/show/NCT03480568"
334,"NCT03468296","Two-week Retreatment Interval Study for Treated Age-related Macular Degeneration Refractory to Monthly Aflibercept","TRISTAR","Unknown status","No Results Available","Neovascular Age-related Macular Degeneration","Drug: Intravitreal Aflibercept Injection 2mg","Adverse Events|Retinal Thickness|Subretinal Fluid Height|Pigment Epithelial Detachment Height|Proportion of Dry Maculas|Best-Corrected Visual Acuity|Change in Best-Corrected Visual Acuity|Proportion gaining >5 letters of Best-Corrected Visual Acuity|Treatment Burden|Ability to Extend Treatment Interval","Tennessee Retina|Regeneron Pharmaceuticals","All","50 Years and older   (Adult, Older Adult)","Phase 4","22","Other|Industry","Interventional","Allocation: Randomized|Intervention Model: Parallel Assignment|Masking: None (Open Label)|Primary Purpose: Treatment","VGFTe-AMD-1819","April 2018","October 2018","July 2019","March 16, 2018",,"April 20, 2018","Tennessee Retina, Nashville, Tennessee, United States",,"https://ClinicalTrials.gov/show/NCT03468296"
335,"NCT03449758","Effect of Sarilumab on Patient-reported Outcomes in Patients With Active Rheumatoid Arthritis","SariPRO","Completed","Has Results","Rheumatoid Arthritis","Drug: SARILUMAB|Drug: Azathioprine|Drug: Chloroquine|Drug: Hydroxychloroquine|Drug: Leflunomide|Drug: Methotrexate|Drug: Sulfasalazine","Change From Baseline in Rheumatoid Arthritis Impact of Disease Total Score at Week 24|Rheumatoid Arthritis Impact of Disease Total Score at Baseline, Weeks 4, 12 and 24|Change From Baseline in Rheumatoid Arthritis Impact of Disease Total Score at Weeks 4 and 12|Hospital Anxiety and Depression Scale (HADS): Anxiety (HADS-A) and Depression (HADS-D) Subscale Scores at Baseline, Weeks 4, 12, and 24|Change From Baseline in Hospital Anxiety and Depression Scale: Anxiety (HADS-A) and Depression (HADS-D) Subscale Scores at Weeks 4, 12 and 24|Multidimensional Assessment of Thymic States (MAThyS) Scale Total Score at Baseline, Weeks 4, 12 and 24|Change From Baseline in Multidimensional Assessment of Thymic States Scale Total Score at Weeks 4, 12 and 24|Functional Assessment of Chronic Illness Therapy - Fatigue (FACIT-F) Total Scores at Baseline, Weeks 4, 12 and 24|Change From Baseline in Functional Assessment of Chronic Illness Therapy - Fatigue Total Scores at Weeks 4, 12 and 24|Stanford Health Assessment Questionnaire Disability Index (HAQ-DI) Total Score at Baseline, Weeks 4, 12 and 24|Change From Baseline in Stanford Health Assessment Questionnaire Disability Index Total Score at Weeks 4, 12 and 24|Duration of Morning Stiffness at Baseline, Weeks 4, 12, and 24|Change From Baseline in Duration of Morning Stiffness at Weeks 4, 12, and 24|International Physical Activity Questionnaire (IPAQ) Total Score at Baseline, Weeks 4, 12 and 24|Change From Baseline in International Physical Activity Questionnaire Total Score at Weeks 4, 12 and 24|Patient Global Assessment (PtGA) of Disease Activity Score by Visual Analog Scale (VAS) at Baseline, Weeks 4, 12 and 24|Change From Baseline in Patient Global Assessment of Disease Activity Score by Visual Analog Scale at Weeks 4, 12, and 24|Erythrocyte Sedimentation Rate (ESR) at Baseline, Weeks 4, 12, and 24|Change From Baseline in Erythrocyte Sedimentation Rate at Weeks 4, 12, and 24|Disease Activity Score-28 for Rheumatoid Arthritis With Erythrocyte Sedimentation Rate (DAS28-ESR) at Baseline, Weeks 4, 12, and 24|Change From Baseline in Disease Activity Score-28 for Rheumatoid Arthritis With Erythrocyte Sedimentation Rate at Weeks 4, 12, and 24|Clinical Disease Activity Index (CDAI) Total Score at Baseline, Weeks 4, 12, and 24|Change From Baseline in Clinical Disease Activity Index Total Score at Weeks 4, 12, and 24|Number of Swollen Joints at Baseline, Weeks 4, 12, and 24|Change From Baseline in Number of Swelling Joints at Weeks 4, 12, and 24|Number of Tender Joints at Baseline, Weeks 4, 12, and 24|Change From Baseline in Number of Tender Joints at Weeks 4, 12, and 24|Number of Participants Achieving Low Disease Activity (DAS28 ESR Score <=3.2) and Remission (DAS28 ESR Score <2.6) at Weeks 12, and 24|Number of Participants Achieving Clinical Disease Activity Index: Low Disease Activity (CDAI Score <=10.0) and Remission (CDAI Score <=2.8) Weeks 12, and 24|Number of Participants With Treatment-emergent Adverse Events (TEAEs) and Serious Adverse Events (SAEs)","Sanofi|Regeneron Pharmaceuticals","All","18 Years and older   (Adult, Older Adult)","Phase 4","84","Industry","Interventional","Allocation: N/A|Intervention Model: Single Group Assignment|Masking: None (Open Label)|Primary Purpose: Treatment","SARILL08755|U1111-1197-7699|2017-002951-27","March 5, 2018","July 31, 2019","July 31, 2019","February 28, 2018","August 10, 2020","August 13, 2020","Investigational Site Number 250007, Argenteuil, France|Investigational Site Number 250006, Besancon, France|Investigational Site Number 250027, Bobigny, France|Investigational Site Number 250016, Bordeaux, France|Investigational Site Number 250014, Caen, France|Investigational Site Number 250032, CAHORS Cedex 9, France|Investigational Site Number 250019, Cannes, France|Investigational Site Number 250013, Cholet, France|Investigational Site Number 250002, Clermont Ferrand, France|Investigational Site Number 250009, Echirolles, France|Investigational Site Number 250005, La Roche Sur Yon, France|Investigational Site Number 250024, Le Mans Cedex 9, France|Investigational Site Number 250004, Lille Cedex, France|Investigational Site Number 250012, Limoges Cedex, France|Investigational Site Number 250021, Lyon, France|Investigational Site Number 250018, Montivilliers, France|Investigational Site Number 250029, MONTPELLIER Cedex 5, France|Investigational Site Number 250025, NANTES Cedex 1, France|Investigational Site Number 250026, Nice cedex 1, France|Investigational Site Number 250020, Paris Cedex 10, France|Investigational Site Number 250011, PARIS Cedex 13, France|Investigational Site Number 250010, Paris, France|Investigational Site Number 250015, Paris, France|Investigational Site Number 250028, Paris, France|Investigational Site Number 250033, Paris, France|Investigational Site Number 250031, Poitiers, France|Investigational Site Number 250023, Pontoise, France|Investigational Site Number 250017, RENNES Cedex, France|Investigational Site Number 250008, Rouen, France|Investigational Site Number 250001, St Etienne, France|Investigational Site Number 250034, Strasbourg Cedex 2, France|Investigational Site Number 250022, Toulouse, France|Investigational Site Number 250003, Tours, France","""Study Protocol"", https://ClinicalTrials.gov/ProvidedDocs/58/NCT03449758/Prot_000.pdf|""Statistical Analysis Plan"", https://ClinicalTrials.gov/ProvidedDocs/58/NCT03449758/SAP_001.pdf","https://ClinicalTrials.gov/show/NCT03449758"
336,"NCT03415178","Usability Study of the Commercial Auto-injector Device and the New Auto-injector Device (SYDNEY) in Patients With High or Very High CV Risk With Hypercholesterolemia Not Adequately Controlled With Their Lipid-Modifying Therapy",,"Completed","Has Results","Hypercholesterolaemia","Drug: Alirocumab SAR236553|Device: Current auto-injector device (AI)|Device: New auto-injector device (SYDNEY)|Drug: Atorvastatin|Drug: Rosuvastatin","Percentage of SYDNEY-Associated Product Technical Complaints (PTCs) (Overall) at the Unsupervised Injections: Single-Arm Period|Percentage of SYDNEY-Associated Product Technical Complaints (PTCs) (by Type) at the Unsupervised Injections: Single-Arm Period|Percentage of Participants With a SYDNEY or Current Auto-Injector (AI)-Associated Product Technical Complaint (PTCs) (Overall and by Type) at the Supervised Injections on Week 0 (Day 1): Parallel-Arm Period|Percentage of Participants With SYDNEY-Associated Product Technical Complaint (PTCs) (Overall and by Type) at the Unsupervised Injections : Single-Arm Period|Injection Experience Questionnaire at Initial Supervised Injection: Overall Ease of Use Scores: Parallel-Arm Period|Patient Perspective Questionnaire After the Last Injection (at Week 12): Single-Arm Period|Injection-Treatment Acceptance Questionnaire (I-TAQ©) After Last Injection (at Week 12) - Overall Acceptance Scores: Single-Arm Period|Maximum Serum Alirocumab Concentration Observed - Cmax : Parallel-Arm Period|Time to Reach Maximum Observed Plasma Concentration (Tmax) of Alirocumab : Parallel-Arm Period|Area Under the Curve-During the Dosing Interval Tau (AUC [0-tau]) : Parallel-Arm Period|Maximum Serum Alirocumab Concentration Observed - Cmax : Single-Arm Period|Time to Reach Maximum Observed Plasma Concentration (Tmax) of Alirocumab: Single-Arm Period|Area Under the Curve-During the Dosing Interval Tau (AUC [0-tau]) : Single-Arm Period|Free Proprotein Convertase Subtilisin Kexin Type 9 (PCSK9) Concentrations : Parallel-Arm Period|Free Proprotein Convertase Subtilisin Kexin Type 9 (PCSK9) Concentrations : Single-Arm Period|Total Proprotein Convertase Subtilisin Kexin Type 9 (PCSK9) Concentrations : Parallel-Arm Period|Total Proprotein Convertase Subtilisin Kexin Type 9 (PCSK9) Concentrations : Single-Arm Period|Number of Participants With Treatment-Emergent Anti-Alirocumab Antibodies (ADA) Positive Response: Parallel-Arm Period|Number of Participants With Treatment-Emergent Anti-Alirocumab Antibodies (ADA) Positive Response According to ADA Status During Parallel-Arm Period: Single Arm Period|Percent Change From Baseline in Low-Density Lipoprotein Cholesterol (LDL-C) at Week 4: Parallel-Arm Period|Percent Change From Baseline in Low-Density Lipoprotein Cholesterol (LDL-C) at Week 8, 12, 16: Single-Arm Period","Sanofi|Regeneron Pharmaceuticals","All","18 Years and older   (Adult, Older Adult)","Phase 3","69","Industry","Interventional","Allocation: Randomized|Intervention Model: Parallel Assignment|Masking: None (Open Label)|Primary Purpose: Treatment","MSC14864|U1111-1186-3466","March 29, 2018","August 9, 2018","August 9, 2018","January 30, 2018","September 9, 2019","September 9, 2019","Investigational Site Number 8400024, Los Angeles, California, United States|Investigational Site Number 8400007, Jacksonville, Florida, United States|Investigational Site Number 8400017, Jacksonville, Florida, United States|Investigational Site Number 8400013, Ponte Vedra, Florida, United States|Investigational Site Number 8400014, Wellington, Florida, United States|Investigational Site Number 8400001, West Des Moines, Iowa, United States|Investigational Site Number 8400019, Topeka, Kansas, United States|Investigational Site Number 8400006, Cincinnati, Ohio, United States|Investigational Site Number 8400010, Cincinnati, Ohio, United States|Investigational Site Number 8400022, Summerville, South Carolina, United States|Investigational Site Number 8400026, Amarillo, Texas, United States|Investigational Site Number 8400005, Richmond, Virginia, United States|Investigational Site Number 8400027, Manitowoc, Wisconsin, United States","""Study Protocol"", https://ClinicalTrials.gov/ProvidedDocs/78/NCT03415178/Prot_000.pdf|""Statistical Analysis Plan"", https://ClinicalTrials.gov/ProvidedDocs/78/NCT03415178/SAP_001.pdf","https://ClinicalTrials.gov/show/NCT03415178"
337,"NCT03411941","Evaluate the Effectiveness of Intravitreal (IVT) Aflibercept Injection in Clinical Practice in naïve Patients With Neovascular Age-related Macular Degeneration (nAMD)","REALE","Completed","No Results Available","Macular Degeneration","Drug: Eylea (Aflibercept, VEGF Trap-Eye, BAY86-5321)","Mean change in VA|Proportion of patients gaining 15 or more letters|Mean change in CRT in µm (measured by OCT)|Presence/absence of SRF (subretinal fluid) by OCT (yes/no)|Presence/absence of IRF (intraretinal fluid) by OCT (yes/no)|Presence/absence of PED (pigment epithelium detachment) (measured by OCT)|Presence/absence of PED Height|Presence/absence of PED type|Correlation of the mean gain in VA with the total number of injections administered|Mean number of IVT aflibercept injections per study eye|Mean number of monitoring visits per study eye|Mean number of combined visits per study eye|Mean number of OCT assessments per study eye","Bayer|Regeneron Pharmaceuticals","All","50 Years and older   (Adult, Older Adult)",,"116","Industry","Observational","Observational Model: Cohort|Time Perspective: Retrospective","18798","February 28, 2018","March 1, 2019","March 1, 2019","January 26, 2018",,"December 5, 2019","Many locations, Multiple Locations, Spain",,"https://ClinicalTrials.gov/show/NCT03411941"
338,"NCT03396861","Treatment of Macular Edema After Cataract Surgery With Subconjunctival Aflibercept","ACME","Terminated","No Results Available","Irvine-Gass Syndrome","Drug: Aflibercept","Adverse Events|Change in visual acuity|Change in central retinal thickness|Proportion of patients needing re-treatment|Proportion of patients needing additional non-study treatment though Month 6|Adverse Events - end of study period","Tufts Medical Center|Regeneron Pharmaceuticals","All","18 Years and older   (Adult, Older Adult)","Phase 1","1","Other|Industry","Interventional","Allocation: N/A|Intervention Model: Single Group Assignment|Masking: None (Open Label)|Primary Purpose: Treatment","12338","February 22, 2019","August 18, 2019","January 2, 2020","January 11, 2018",,"August 21, 2020","Tufts Medical Center, Boston, Massachusetts, United States",,"https://ClinicalTrials.gov/show/NCT03396861"
339,"NCT03387852","Evaluation of SAR440340 and as Combination Therapy With Dupilumab in Moderate-to-Severe Asthma Participants",,"Completed","No Results Available","Asthma","Drug: SAR440340|Drug: Dupilumab|Drug: Fluticasone or Fluticasone/salmeterol combination|Drug: Placebo for SAR440340|Drug: Placebo for dupilumab","Loss of asthma control (LOAC) events|Change in forced expiratory volume in 1 second (FEV1)","Sanofi|Regeneron Pharmaceuticals","All","18 Years to 70 Years   (Adult, Older Adult)","Phase 2","296","Industry","Interventional","Allocation: Randomized|Intervention Model: Parallel Assignment|Masking: Quadruple (Participant, Care Provider, Investigator, Outcomes Assessor)|Primary Purpose: Treatment","ACT15102|2017-003289-29|U1111-1194-2185","March 12, 2018","March 21, 2019","August 7, 2019","January 2, 2018",,"May 18, 2020","Investigational Site Number 8400026, Birmingham, Alabama, United States|Investigational Site Number 8400004, Long Beach, California, United States|Investigational Site Number 8400020, Los Angeles, California, United States|Investigational Site Number 8400001, Rolling Hills Estates, California, United States|Investigational Site Number 8400013, San Jose, California, United States|Investigational Site Number 8400009, Stockton, California, United States|Investigational Site Number 8400016, Colorado Springs, Colorado, United States|Investigational Site Number 8400021, Ann Arbor, Michigan, United States|Investigational Site Number 8400022, Minneapolis, Minnesota, United States|Investigational Site Number 8400007, Papillion, Nebraska, United States|Investigational Site Number 8400025, Edmond, Oklahoma, United States|Investigational Site Number 8400011, Medford, Oregon, United States|Investigational Site Number 8400024, Portland, Oregon, United States|Investigational Site Number 8400010, Dallas, Texas, United States|Investigational Site Number 8400023, Dallas, Texas, United States|Investigational Site Number 8400006, Plano, Texas, United States|Investigational Site Number 8400008, Murray, Utah, United States|Investigational Site Number 8400014, Milwaukee, Wisconsin, United States|Investigational Site Number 0320001, Buenos Aires, Argentina|Investigational Site Number 0320003, Caba, Argentina|Investigational Site Number 0320002, Caba, Argentina|Investigational Site Number 0320004, Caba, Argentina|Investigational Site Number 0320005, Mendoza, Argentina|Investigational Site Number 1520002, Quillota, Chile|Investigational Site Number 1520001, Santiago, Chile|Investigational Site Number 1520009, Santiago, Chile|Investigational Site Number 1520008, Santiago, Chile|Investigational Site Number 1520007, Santiago, Chile|Investigational Site Number 1520004, Santiago, Chile|Investigational Site Number 1520005, Talca, Chile|Investigational Site Number 1520003, Viña Del Mar, Chile|Investigational Site Number 4840005, Chihuahua, Mexico|Investigational Site Number 4840004, Durango, Mexico|Investigational Site Number 4840002, Guadalajara, Mexico|Investigational Site Number 4840006, Monterrey, Mexico|Investigational Site Number 4840001, Monterrey, Mexico|Investigational Site Number 4840003, Veracruz, Mexico|Investigational Site Number 6160001, Bialystok, Poland|Investigational Site Number 6160008, Bialystok, Poland|Investigational Site Number 6160005, Bydgoszcz, Poland|Investigational Site Number 6160007, Krakow, Poland|Investigational Site Number 6160002, Poznan, Poland|Investigational Site Number 6160006, Poznan, Poland|Investigational Site Number 6160003, Znin, Poland|Investigational Site Number 6430003, Moscow, Russian Federation|Investigational Site Number 6430001, Moscow, Russian Federation|Investigational Site Number 6430005, Moscow, Russian Federation|Investigational Site Number 6430008, Ryazan, Russian Federation|Investigational Site Number 6430010, Saint-Petersburg, Russian Federation|Investigational Site Number 6430006, Saint-Petersburg, Russian Federation|Investigational Site Number 6430007, St-Petersburg, Russian Federation|Investigational Site Number 6430009, Stavropol, Russian Federation|Investigational Site Number 6430004, Ulyanovsk, Russian Federation|Investigational Site Number 7920004, Ankara, Turkey|Investigational Site Number 7920003, Bursa, Turkey|Investigational Site Number 7920001, Istanbul, Turkey|Investigational Site Number 7920006, Izmir, Turkey|Investigational Site Number 7920007, Izmir, Turkey|Investigational Site Number 7920008, Kirikkale, Turkey|Investigational Site Number 7920002, Mersin, Turkey|Investigational Site Number 7920009, Rize, Turkey|Investigational Site Number 8040008, Chernivtsi, Ukraine|Investigational Site Number 8040012, Ivano-Frankivsk, Ukraine|Investigational Site Number 8040002, Kharkiv, Ukraine|Investigational Site Number 8040009, Kharkiv, Ukraine|Investigational Site Number 8040011, Kharkiv, Ukraine|Investigational Site Number 8040007, Kyiv, Ukraine|Investigational Site Number 8040001, Kyiv, Ukraine|Investigational Site Number 8040006, Odesa, Ukraine|Investigational Site Number 8040003, Ternopil, Ukraine|Investigational Site Number 8040005, Vinnytsya, Ukraine",,"https://ClinicalTrials.gov/show/NCT03387852"
340,"NCT03382587","Observational Study to Assess Intravitreal Aflibercept Injections Used in a ""Treat and Extend"" Regimen in Treatment-naïve Wet Age-related Macular Degeneration Patients","ASTERIA","Completed","No Results Available","Wet Age-related Macular Degeneration","Drug: Aflibercept (Eylea, BAY86-5321)","Mean change from baseline in best-corrected visual acuity in Early Treatment Diabetic Retinopathy Study letters (ETDRS letters)|Mean change from baseline in best-corrected visual acuity (in Early Treatment Diabetic Retinopathy Study (ETDRS) letters)|Mean change in best-corrected visual acuity in relation to the number of injections administered|Mean interval between injections|Reasons for the interval length|Frequency of disease reactivation|Proportion of eyes gaining or losing ≥ 15 Early Treatment Diabetic Retinopathy Study letters compared to baseline|Mean changes from baseline in central retinal thickness (CRT)|Changes from baseline in retinal fluid|Reasons for termination of therapy (including subsequent therapy at time of discontinuation)|Severity of disease reactivation","Bayer|Regeneron Pharmaceuticals","All","55 Years and older   (Adult, Older Adult)",,"163","Industry","Observational","Observational Model: Cohort|Time Perspective: Other","18574","December 5, 2017","November 9, 2018","November 27, 2018","December 26, 2017",,"August 26, 2019","Many Locations, Multiple Locations, Switzerland",,"https://ClinicalTrials.gov/show/NCT03382587"
341,"NCT03378219","An Observational Study on Sarilumab-exposed Pregnancies",,"Recruiting","No Results Available","Rheumatoid Arthritis -Exposure During Pregnancy","Drug: Sarilumab SAR153191 (REGN88)","Rate of major structural birth defect|Pregnancy Outcomes: Spontaneous abortion|Pregnancy Outcomes: Stillbirth|Pregnancy Outcomes: Premature delivery|Infant Outcomes: pattern of minor structural birth defects|Infant Outcomes: Small for gestational age|Infant Outcomes: Postnatal growth deficiency|Infant Outcomes: Serious or opportunistic infections|Infant Outcomes: Hospitalizations|Infant Outcomes: Malignancies","Sanofi|Regeneron Pharmaceuticals","Female","Child, Adult, Older Adult",,"300","Industry","Observational","Observational Model: Cohort|Time Perspective: Prospective","OBS15155|U1111-1200-1947","May 18, 2018","August 2027","August 2027","December 19, 2017",,"January 13, 2022","United States, New York, New York, United States|CANADA, Canada, Canada",,"https://ClinicalTrials.gov/show/NCT03378219"
342,"NCT03344692","Effect of Alirocumab on Postprandial Hyperlipemia in Patients With Type 2 Diabetes","EUTERPE","Recruiting","No Results Available","Type2 Diabetes","Drug: Alirocumab|Other: Placebo","Total area under the post-prandial triglycerides concentration-time curve from meal-time until 8h (AUC0-8h) after standardized high fat meal.|Effect of treatment with alirocumab versus placebo following a standardized high-fat meal on post-prandial lipid metabolism (plasma lipoproteins, apolipoproteins, ...)|Effect of treatment with alirocumab versus placebo on fasting lipid metabolism following a standardized high fat meal, using the same biomarkers than those used in the post-prandial state, plus indirect markers of cholesterol absorption and synthesis|Effect of treatment with alirocumab versus placebo on fasting and post-prandial and glucose homeostasis following a standardized high-fat meal","Nantes University Hospital|Regeneron Pharmaceuticals","Male","18 Years to 75 Years   (Adult, Older Adult)","Phase 3","16","Other|Industry","Interventional","Allocation: Randomized|Intervention Model: Crossover Assignment|Masking: Quadruple (Participant, Care Provider, Investigator, Outcomes Assessor)|Primary Purpose: Treatment","RC16_0406","February 12, 2019","April 30, 2022","April 30, 2022","November 17, 2017",,"January 13, 2021","University Hospital of Nantes, Nantes, France",,"https://ClinicalTrials.gov/show/NCT03344692"
343,"NCT03294083","A Study of Recombinant Vaccinia Virus in Combination With Cemiplimab for Renal Cell Carcinoma",,"Recruiting","No Results Available","Renal Cell Carcinoma","Biological: Pexastimogene Devacirepvec (Pexa-Vec)|Biological: Cemiplimab","Maximum tolerated dose(MTD) / Maximum feasible dose (MFD)|Severity and frequency of adverse events to determine safety of Pexa-Vec administered by IV infusions or IT injections in combination with IV Cemiplimab|Overall response rate|Progression free survival|Disease control rate|Best radiographic response|Overall survival","SillaJen, Inc.|Regeneron Pharmaceuticals","All","18 Years and older   (Adult, Older Adult)","Phase 1|Phase 2","117","Industry","Interventional","Allocation: Randomized|Intervention Model: Parallel Assignment|Masking: None (Open Label)|Primary Purpose: Treatment","JX594-REN026","June 7, 2018","August 2022","November 2023","September 26, 2017",,"September 2, 2021","Site 2644 University of California, Irvine, Irvine, California, United States|Site 2641 University of Miami, Miami, Florida, United States|Site 2643 Washington University, Saint Louis, Missouri, United States|Site 2642 Billings Clinic, Billings, Montana, United States|Site 2646 The Ohio State University, Columbus, Ohio, United States|Site 2632 Flinders Medical Centre, Bedford Park, Australia|Site 2631, Camperdown, Australia|Site 2612 Kyungpook National University Chilgok Hospital, Daegu, Korea, Republic of|Site 2616 Chungnam National University Hospital, Daejeon, Korea, Republic of|Site 2618 Chonnam National University Hwasun Hospital, Gwangju, Korea, Republic of|Site 2622 Gachon University Gil Medical Center, Incheon, Korea, Republic of|Site 2614 Gyeongsang National University Hospital, Jinju, Korea, Republic of|Site 2613 Dong-A University Hospital, Pusan, Korea, Republic of|Site 2619 Pusan National University Hospital, Pusan, Korea, Republic of|Site 2620 Seoul National University Bundang Hospital, Seongnam-si, Korea, Republic of|Site 2617 CHA University, CHA Bundang Medical Center, Seongnam, Korea, Republic of|Site 2615 Korea University Anam Hospital, Seoul, Korea, Republic of|Site 2610 Severance Hospital, Yonsei University Health System, Seoul, Korea, Republic of|Site 2623 Ajou University Hospital, Suwon, Korea, Republic of|Site 2625 Wonju Severance Christian Hospital, Wŏnju, Korea, Republic of|Site 2624 Pusan National University Yangsan Hospital, Yangsan, Korea, Republic of",,"https://ClinicalTrials.gov/show/NCT03294083"
344,"NCT03278262","The Impact of Baseline Visual Acuity on the Treatment Outcomes in Patients Treated With AflIbercept in Real-life Clinical Setting","INSIGHT","Completed","No Results Available","Wet Macular Degeneration","Drug: Aflibercept (Eylea, BAY86-5321)","Change in Visual Acuity (VA) (Snellen)|Change in Early Treatment Diabetic Retinopathy Study (ETDRS)|Change in Lasbarhetsindex (LIX, Readability Index)|Proportion of patients with Gain of vision 5 to 15 letters; > 15 letters; Loss of vision >5 to <15 letters; >15 letters or Stable -5 to +5 letters at the annual time points|Proportion of patients that recuperate 20/20 vision (driving vision) in all patients and stratified by baseline VA (groups 1-3)|Proportion of patients that recuperate 20/40 vision (driving vision) in all patients and stratified by baseline VA (groups 1-3)|Proportion of patients with no need of Vision Aid support","Bayer|Regeneron Pharmaceuticals","All","Child, Adult, Older Adult",,"2312","Industry","Observational","Observational Model: Cohort|Time Perspective: Retrospective","19473","September 1, 2017","December 31, 2017","December 31, 2017","September 11, 2017",,"October 29, 2018","Many locations, Lund, Sweden",,"https://ClinicalTrials.gov/show/NCT03278262"
345,"NCT03228693","Gene Expression and Biomarker Profiling of Keloid Skin",,"Active, not recruiting","No Results Available","Keloid|Keloid of Ear Lobe|Healthy Adults","Procedure: Biopsy and/or triamcinolone injection|Procedure: Excisional Biopsy","Keloid progression|Gene Expression|Keloid recurrence","Northwestern University|Regeneron Pharmaceuticals","All","18 Years and older   (Adult, Older Adult)","Not Applicable","130","Other|Industry","Interventional","Allocation: Non-Randomized|Intervention Model: Sequential Assignment|Masking: None (Open Label)|Primary Purpose: Other","RVK 09062016","September 11, 2017","February 2022","June 2022","July 25, 2017",,"January 11, 2022","Northwestern University Feinberg School of Medicine Department of Dermatology, Chicago, Illinois, United States",,"https://ClinicalTrials.gov/show/NCT03228693"
346,"NCT03067844","Vascular Effects of Alirocumab in Acute MI-Patients","PACMAN-AMI","Completed","No Results Available","Coronary Vessel|Coronary Circulation|Atheroma; Myocardial","Drug: Alirocumab","Change in percent atheroma volume (PAV)|Change in total lipid-core burden index (LCBItotal)|Change in maximum LCBI in any 4-mm segment (Powered)|Change in minimal fibrous cap thickness (Powered)|Change in mean fibrous cap thickness|Change in average angular extension (AAE) of macrophages|Change in normalized total atheroma volume (NTAV)|Change in LDL-cholesterol|Change in hsCRP|Change in high sensitivity troponin T (hsTnT)|Change in N-terminal prohormone of brain natriuretic peptide (NT-pro-BNP)|Change in further biomarkers|Death|Non-fatal myocardial infarction|Ischemia-driven coronary revascularization|Stroke","University Hospital Inselspital, Berne|Regeneron Pharmaceuticals","All","18 Years and older   (Adult, Older Adult)","Phase 3","294","Other|Industry","Interventional","Allocation: Randomized|Intervention Model: Parallel Assignment|Masking: Quadruple (Participant, Care Provider, Investigator, Outcomes Assessor)|Primary Purpose: Treatment","2016-01382","April 25, 2017","October 13, 2021","October 13, 2021","March 1, 2017",,"February 24, 2022","University Hospital Vienna (AKH), Wien, Austria|Rigshospitalet, Copenhagen, Denmark|Radboud Univerity, Nijmegen Medical Centre, Nijmegen, Gelderland, Netherlands|Erasmus Thoraxcentre, Rotterdam, Netherlands|Basel University Hospital, Basel, Switzerland|Bern University Hospital Inselspital, Bern, Switzerland|Hopitaux Universitaires Geneve, Geneva, Switzerland|Stadtspital Triemli, Zurich, Switzerland|University Hospital Zurich USZ, Zürich, Switzerland",,"https://ClinicalTrials.gov/show/NCT03067844"
347,"NCT03059277","Intravitreal Alfibercept for Center Involved DME Previously Managed With Intravitreal Ranibizumab",,"Withdrawn","No Results Available","Diabetic Macular Edema","Drug: Intravitreal Aflibercept","Change in Central Subfield Thickness (CST)|Mean Change in Visual Acuity|Number of Intravitreal Injections","Southeast Clinical Research Associates, LLC|Regeneron Pharmaceuticals","All","18 Years and older   (Adult, Older Adult)","Phase 4","0","Other|Industry","Interventional","Allocation: N/A|Intervention Model: Single Group Assignment|Masking: None (Open Label)|Primary Purpose: Treatment","VGFTe-DME-1432","June 1, 2018","June 30, 2020","September 30, 2020","February 23, 2017",,"June 14, 2018","Charlotte Eye Ear Nose and Throat Associates, PA, Charlotte, North Carolina, United States|Charlotte Eye Ear Nose and Throat Associates, PA, Statesville, North Carolina, United States",,"https://ClinicalTrials.gov/show/NCT03059277"
348,"NCT03022292","The IAI-OCTA Study; a Study of OCT-Angiography Analysis Efficacy","IAI-OCTA","Completed","Has Results","Wet Macular Degeneration","Drug: Aflibercept Ophthalmic|Device: optovue angiovue","Area of Lesion Measured by Optical Coherence Tomography Angiography (OCTA) Scan.|Best Corrected Visual Acuity (BCVA) -Early Treatment Diabetic Retinopathy Study (ETDRS) Letter Change|Best Corrected Visual Acuity (BCVA) -ETDRS Letter Change|Mean Best Corrected Visual Acuity (BCVA)","University of California, Los Angeles|Regeneron Pharmaceuticals","All","50 Years and older   (Adult, Older Adult)","Phase 4","26","Other|Industry","Interventional","Allocation: N/A|Intervention Model: Single Group Assignment|Masking: None (Open Label)|Primary Purpose: Other","16-000925","March 30, 2017","June 25, 2020","August 31, 2020","January 16, 2017","January 6, 2022","January 6, 2022","Stein Eye Institute of UCLA, Los Angeles, California, United States","""Study Protocol and Statistical Analysis Plan"", https://ClinicalTrials.gov/ProvidedDocs/92/NCT03022292/Prot_SAP_000.pdf","https://ClinicalTrials.gov/show/NCT03022292"
349,"NCT02991469","A Repeated Dose-finding Study of Sarilumab in Children and Adolescents With Systemic Juvenile Idiopathic Arthritis (SKYPS)",,"Recruiting","No Results Available","Juvenile Idiopathic Arthritis","Drug: Sarilumab SAR153191 (REGN88)","Assessment of PK parameter: maximum serum concentration observed (Cmax)|Assessment of PK parameter: Area under the serum concentration versus time curve calculated using the trapezoidal method during a dose interval (AUC0-t)|Assessment of PK parameter: Concentration observed before treatment administration during repeated dosing (Ctrough)|Number of patients with adverse events|Number of patients with local site reactions|Juvenile Idiopathic Arthritis ACR30/50/70/90/100 (in the absence of fever) response rate|Change from baseline in JIA ACR component: Physician's global assessment of disease activity|Change from baseline in JIA ACR Component: Patient / parent assessment of overall well-being|Change from baseline in JIA ACR Component: Childhood Health Assessment Questionnaire (CHAQ) - Disability Index|Change from baseline in JIA ACR Component: Number of joints with active arthritis|Change from baseline in JIA ACR Component: Number of joints with limitation of motion|Change from baseline in JIA ACR Component: High sensitivity C-reactive protein (hs-CRP)|Change from baseline in JIA ACR Component: fever|Change from baseline in Juvenile Arthritis Disease Activity Score-27 (JADAS)|Changes in glucocorticoid use|Changes in IL-6 associated biomarkers: IL6|Changes in IL-6 associated biomarkers: sIL-6R|Proportion of patients receiving glucocorticoids by dose category (glucocorticoid equivalent prednisone dose ≥0.5 mg/kg, ≥0.2 mg/kg and <0.5 mg/kg, <0.2 mg/kg)|Proportion of patients free of glucocorticoids and without JIA flare","Sanofi|Regeneron Pharmaceuticals","All","1 Year to 17 Years   (Child)","Phase 2","72","Industry","Interventional","Allocation: N/A|Intervention Model: Single Group Assignment|Masking: None (Open Label)|Primary Purpose: Treatment","DRI13926|2015-004000-35|U1111-1177-3584","August 9, 2018","January 2023","April 2027","December 13, 2016",,"February 10, 2022","Investigational Site Number :0320004, Tucumán, Argentina|Investigational Site Number :1000001, Plovdiv, Bulgaria|Investigational Site Number :1240110, Calgary, Alberta, Canada|Investigational Site Number :2030042, Praha 5 - Motol, Czechia|Investigational Site Number :2460040, Helsinki, Finland|Investigational Site Number :2500041, Bron, France|Investigational Site Number :2500042, Montpellier, France|Investigational Site Number :2500040, Paris, France|Investigational Site Number :2760064, Berlin, Germany|Investigational Site Number :2760065, Berlin, Germany|Investigational Site Number :2760061, Bremen, Germany|Investigational Site Number :2760062, Hamburg, Germany|Investigational Site Number :2760060, Sankt Augustin, Germany|Investigational Site Number :2760063, Sendenhorst, Germany|Investigational Site Number :3720001, Dublin, Ireland|Investigational Site Number :3800051, Genova, Italy|Investigational Site Number :3800054, Milano, Italy|Investigational Site Number :3800052, Roma, Italy|Investigational Site Number :6430001, Moscow, Russian Federation|Investigational Site Number :6430062, Moscow, Russian Federation|Investigational Site Number :6430063, Moscow, Russian Federation|Investigational Site Number :6430065, Ufa, Russian Federation|Investigational Site Number :7240050, Esplugues de Llobregat, Castilla Y León, Spain|Investigational Site Number :7240052, Madrid, Madrid, Comunidad De, Spain|Investigational Site Number :7240053, Madrid, Spain|Investigational Site Number :7240051, Valencia, Spain|Investigational Site Number :8260031, London, London, City Of, United Kingdom|Investigational Site Number :8260034, Leeds, United Kingdom|Investigational Site Number :8260033, Liverpool, United Kingdom",,"https://ClinicalTrials.gov/show/NCT02991469"
350,"NCT02984982","Evaluation of Effect of Alirocumab on Coronary Atheroma Volume in Japanese Patients Hospitalized for Acute Coronary Syndrome With Hypercholesterolemia","ODYSSEY J-IVUS","Completed","Has Results","Hypercholesterolemia|Acute Coronary Syndrome","Drug: Alirocumab SAR236553|Drug: Atorvastatin|Drug: Rosuvastatin|Drug: Fenofibrate|Drug: Bezafibrate|Drug: Ezetimibe|Drug: Antiplatelets|Drug: Anticoagulants","Percent Change From Baseline in Normalized Total Atheroma Volume (TAV) at Week 36|Absolute Change From Baseline in Percent Atheroma Volume (PAV) at Week 36|Absolute Change From Baseline in Normalized Total Atheroma Volume at Week 36|Absolute Change From Baseline in External Elastic Membrane (EEM) Volume at Week 36|Percent Change From Baseline in External Elastic Membrane Volume at Week 36|Absolute Change From Baseline in Lumen Volume at Week 36|Percent Change From Baseline in Lumen Volume at Week 36|Absolute Change From Baseline in Calculated Low-density Lipoprotein Cholesterol at Week 12 and Week 36|Percent Change From Baseline in Calculated Low-density Lipoprotein Cholesterol at Week 12 and Week 36|Absolute Change From Baseline in Apolipoprotein B (Apo B) at Week 36|Percent Change From Baseline in Apolipoprotein B at Week 36|Absolute Change From Baseline in Non-High-density Lipoprotein Cholesterol (Non-HDL-C) at Week 36|Percent Change From Baseline in Non-High-density Lipoprotein Cholesterol at Week 36|Absolute Change From Baseline in Total Cholesterol (TC) at Week 36|Percent Change From Baseline in Total Cholesterol at Week 36|Absolute Change From Baseline in Lipoprotein (a) (Lp[a]) at Week 36|Percent Change From Baseline in Lipoprotein (a) at Week 36|Absolute Change From Baseline in High-density Lipoprotein Cholesterol at Week 36|Percent Change From Baseline in High-density Lipoprotein Cholesterol at Week 36|Absolute Change From Baseline in Fasting Triglycerides (TGs) at Week 36|Percent Change From Baseline in Fasting Triglycerides at Week 36|Absolute Change From Baseline in Apolipoprotein A-1 (Apo A-1) at Week 36|Percent Change From Baseline in Apolipoprotein A-1 at Week 36|Number of Participants With Cardiovascular (CV) Adverse Events","Sanofi|Regeneron Pharmaceuticals","All","20 Years and older   (Adult, Older Adult)","Phase 4","206","Industry","Interventional","Allocation: Randomized|Intervention Model: Parallel Assignment|Masking: None (Open Label)|Primary Purpose: Treatment","ALIROL08069|U1111-1184-8764","November 15, 2016","July 27, 2018","July 27, 2018","December 7, 2016","September 9, 2019","September 9, 2019","Investigational Site Number 392026, Bunkyō-Ku, Japan|Investigational Site Number 392022, Chiyoda-ku, Japan|Investigational Site Number 392032, Fujisawa-shi, Japan|Investigational Site Number 392004, Fukui-shi, Japan|Investigational Site Number 392007, Fukuoka-shi, Japan|Investigational Site Number 392048, Fukuoka-shi, Japan|Investigational Site Number 392008, Gifu-shi, Japan|Investigational Site Number 392039, Hiroshima-shi, Japan|Investigational Site Number 392028, Isehara-shi, Japan|Investigational Site Number 392036, Itabashi-ku, Japan|Investigational Site Number 392037, Itabashi-ku, Japan|Investigational Site Number 392024, Izumisano-shi, Japan|Investigational Site Number 392013, Izunokuni-shi, Japan|Investigational Site Number 392020, Kawaguchi-shi, Japan|Investigational Site Number 392009, Kitakyushu-shi, Japan|Investigational Site Number 392034, Kitakyushu-shi, Japan|Investigational Site Number 392044, Kochi-shi, Japan|Investigational Site Number 392002, Kumamoto-shi, Japan|Investigational Site Number 392011, Kumamoto-shi, Japan|Investigational Site Number 392003, Kurashiki-shi, Japan|Investigational Site Number 392018, Matsuyama-shi, Japan|Investigational Site Number 392021, Morioka-shi, Japan|Investigational Site Number 392017, Nagakute-shi, Japan|Investigational Site Number 392047, Nagaoka-shi, Japan|Investigational Site Number 392033, Okayama-shi, Japan|Investigational Site Number 392006, Osaka-shi, Japan|Investigational Site Number 392010, Osaka-shi, Japan|Investigational Site Number 392045, Osaka-shi, Japan|Investigational Site Number 392046, Osaka-shi, Japan|Investigational Site Number 392015, Sagamihara-shi, Japan|Investigational Site Number 392019, Sakai-shi, Japan|Investigational Site Number 392035, Sapporo-shi, Japan|Investigational Site Number 392001, Tenri-shi, Japan|Investigational Site Number 392016, Toyoake-shi, Japan|Investigational Site Number 392025, Tsukuba-shi, Japan|Investigational Site Number 392040, Tsukuba-shi, Japan|Investigational Site Number 392005, Wakayama-shi, Japan|Investigational Site Number 392027, Yokohama-shi, Japan|Investigational Site Number 392043, Yokohama-shi, Japan","""Study Protocol"", https://ClinicalTrials.gov/ProvidedDocs/82/NCT02984982/Prot_000.pdf|""Statistical Analysis Plan"", https://ClinicalTrials.gov/ProvidedDocs/82/NCT02984982/SAP_001.pdf","https://ClinicalTrials.gov/show/NCT02984982"
351,"NCT02979015","A Study of Safety, Tolerability, Pharmacokinetics, and Pharmacodynamics of Subcutaneous (SC) Administered Alirocumab in Healthy Chinese Subjects",,"Completed","No Results Available","Hypercholesterolemia","Drug: alirocumab SAR236553 (REGN727)|Drug: placebo","Incidence of adverse events based on standard and systematic assessment including physical examinations, 12 lead ECGs, vital signs and laboratory tests|Incidence of injection site reactions|Change from baseline in LDL-C|Change from baseline in other lipid parameters|Pharmacokinetics: Assessment of serum concentrations of alirocumab|Pharmacokinetics: Assessment of serum concentrations of PCSK9","Sanofi|Regeneron Pharmaceuticals","All","18 Years to 45 Years   (Adult)","Phase 1","35","Industry","Interventional","Allocation: Randomized|Intervention Model: Parallel Assignment|Masking: Double (Participant, Investigator)|Primary Purpose: Treatment","PKD13404|U1111-1133-7871","November 29, 2016","November 27, 2017","November 27, 2017","December 1, 2016",,"December 5, 2017","Investigational Site Number 156001, Beijing, China",,"https://ClinicalTrials.gov/show/NCT02979015"
352,"NCT02948959","Evaluation of Dupilumab in Children With Uncontrolled Asthma","VOYAGE","Completed","Has Results","Asthma","Drug: Dupilumab|Drug: Placebo|Drug: Asthma Controller Therapies|Drug: Asthma Reliever Therapies","Annualized Rate of Severe Exacerbation Events During the 52-Week Treatment Period: Baseline Blood Eosinophils >=300 Cells Per Microliter Population|Annualized Rate of Severe Exacerbation Events During the 52-Week Treatment Period: Type 2 Inflammatory Asthma Phenotype Population|Change From Baseline in Pre-bronchodilator Percent Predicted Forced Expiratory Volume in 1 (FEV1) Second at Week 12: Baseline Blood Eosinophils >=300 Cells Per Microliter Population|Change From Baseline in Pre-bronchodilator Percent Predicted Forced Expiratory Volume in 1 Second (FEV1) at Week 12: Type 2 Inflammatory Asthma Phenotype Population|Change From Baseline in Asthma Control Questionnaire-Interviewer Administered, 7-question Version (ACQ-7-IA) at Week 24: Baseline Blood Eosinophils >=300 Cells Per Microliter Population|Change From Baseline in Asthma Control Questionnaire-Interviewer Administered, 7-question Version at Week 24: Type 2 Inflammatory Asthma Phenotype Population|Change From Baseline in Fractional Exhaled Nitric Oxide Level at Week 12: Baseline Blood Eosinophils >=300 Cells Per Microliter Population|Change From Baseline in Fractional Exhaled Nitric Oxide Level at Week 12: Type 2 Inflammatory Asthma Phenotype Population|Change From Baseline in Pre-bronchodilator Percent Predicted Forced Expiratory Volume in 1 Second at Weeks 2, 4, 8, 24, 36 and 52: Type 2 Inflammatory Asthma Phenotype Population|Change From Baseline in Pre-bronchodilator Percent Predicted Forced Expiratory Volume in 1 Second at Weeks 2, 4, 8, 24, 36 and 52: Baseline Blood Eosinophils >=300 Cells Per Microliter Population|Time to First Severe Exacerbation Event: Kaplan-Meier Estimates During 52-week Treatment Period: Type 2 Inflammatory Asthma Phenotype Population|Time to First Severe Exacerbation Event: Kaplan-Meier Estimates During 52-week Treatment Period: Baseline Blood Eosinophils >=300 Cells Per Microliter Population|Time to First Loss of Asthma Control (LOAC) Event: Kaplan-Meier Estimates During 52-week Treatment Period: Type 2 Inflammatory Asthma Phenotype Population|Time to First Loss of Asthma Control Event: Kaplan-Meier Estimates During 52-week Treatment Period: Baseline Blood Eosinophils >=300 Cells Per Microliter Population|Absolute Change From Baseline in Pre-Bronchodilator FEV1 at Weeks 2, 4, 8, 12, 24, 36, 52: Type 2 Inflammatory Asthma Phenotype Population|Absolute Change From Baseline in Pre-Bronchodilator FEV1 at Weeks 2, 4, 8, 12, 24, 36, 52: Baseline Blood Eosinophils >=300 Cells Per Microliter Population|Percent Change From Baseline in Pre-Bronchodilator Percent Predicted FEV1 at Weeks 2, 4, 8, 12, 24, 36, 52: Type 2 Inflammatory Asthma Phenotype Population|Percent Change From Baseline in Pre-Bronchodilator Percent Predicted FEV1 at Weeks 2, 4, 8, 12, 24, 36, 52: Baseline Blood Eosinophils >=300 Cells Per Microliter Population|Change From Baseline in Morning (AM) Peak Expiratory Flow (PEF) at Weeks 2, 4, 8, 12, 24, 36, and 52: Type 2 Inflammatory Asthma Phenotype Population|Change From Baseline in Evening (PM) Peak Expiratory Flow at Weeks 2, 4, 8, 12, 24, 36, and 52: Type 2 Inflammatory Asthma Phenotype Population|Change From Baseline in Morning (AM) Peak Expiratory Flow at Weeks 2, 4, 8, 12, 24, 36, and 52: Baseline Blood Eosinophils >=300 Cells Per Microliter Population|Change From Baseline in Evening (PM) Peak Expiratory Flow at Weeks 2, 4, 8, 12, 24, 36, and 52: Baseline Blood Eosinophils >=300 Cells Per Microliter Population|Change From Baseline in Forced Vital Capacity (FVC) at Weeks 2, 4, 8, 12, 24, 36, 52: Type 2 Inflammatory Asthma Phenotype Population|Change From Baseline in Forced Vital Capacity at Weeks 2, 4, 8, 12, 24, 36, 52: Baseline Blood Eosinophils >=300 Cells Per Microliter Population|Change From Baseline in Forced Expiratory Flow (FEF) 25-75% at Weeks 2, 4, 8, 12, 24, 36, 52: Type 2 Inflammatory Asthma Phenotype Population|Change From Baseline in Forced Expiratory Flow 25-75% at Weeks 2, 4, 8, 12, 24, 36, 52: Baseline Blood Eosinophils >=300 Cells Per Microliter Population|Change From Baseline in Post-Bronchodilator FEV1 at Weeks 2, 4, 8, 12, 24, 36, and 52: Type 2 Inflammatory Asthma Phenotype Population|Change From Baseline in Post-Bronchodilator FEV1 at Weeks 2, 4, 8, 12, 24, 36, and 52: Baseline Blood Eosinophils >=300 Cells Per Microliter Population|Change From Baseline in Morning Asthma Symptom Score at Weeks 2, 4, 8, 12, 24, 36, and 52: Type 2 Inflammatory Asthma Phenotype Population|Change From Baseline in Evening Asthma Symptom Score at Weeks 2, 4, 8, 12, 24, 36, and 52: Type 2 Inflammatory Asthma Phenotype Population|Change From Baseline in Morning Asthma Symptom Score at Weeks 2, 4, 8, 12, 24, 36, and 52: Baseline Blood Eosinophils >=300 Cells Per Microliter Population|Change From Baseline in Evening Asthma Symptom Score at Weeks 2, 4, 8, 12, 24, 36, and 52: Baseline Blood Eosinophils >=300 Cells Per Microliter Population|Change From Baseline in Asthma Control Questionnaire-Interviewer Administered, 5-question Version (ACQ-5-IA) at Weeks 2, 4, 8, 12, 24, 36, and 52: Type 2 Inflammatory Asthma Phenotype Population|Change From Baseline in Asthma Control Questionnaire-Interviewer Administered, 5-question Version at Weeks 2, 4, 8, 12, 24, 36, and 52: Baseline Blood Eosinophils >=300 Cells Per Microliter Population|Change From Baseline in Asthma Control Questionnaire-Interviewer Administered, 7-question Version at Weeks 2, 4, 8, 12, 36, and 52: Baseline Blood Eosinophils >=300 Cells Per Microliter Population|Change From Baseline in Asthma Control Questionnaire-Interviewer Administered, 7-question Version at Weeks 2, 4, 8, 12, 36, and 52: Type 2 Inflammatory Asthma Phenotype Population|Change From Baseline in Number of Puffs of Reliever Medication Used Per 24 Hours at Weeks 2, 4, 8, 12, 24, 36, and 52: Type 2 Inflammatory Asthma Phenotype Population|Change From Baseline in Number of Puffs of Reliever Medication Used Per 24 Hours at Weeks 2, 4, 8, 12, 24, 36, and 52: Baseline Blood Eosinophils >=300 Cells Per Microliter Population|Change From Baseline in Number of Nocturnal Awakenings Per Night at Weeks 2, 4, 8, 12, 24, 36, and 52: Type 2 Inflammatory Asthma Phenotype Population|Change From Baseline in Number of Nocturnal Awakenings Per Night at Weeks 2, 4, 8, 12, 24, 36, and 52: Baseline Blood Eosinophils >=300 Cells Per Microliter Population|Change From Baseline in Pediatric Asthma Quality of Life (QoL) Questionnaire With Standardized Activities-Interviewer Administered (PAQLQ[S] IA) Scores at Weeks 12, 24, 36, and 52: Type 2 Inflammatory Asthma Phenotype Population|Change From Baseline in Pediatric Asthma Quality of Life Questionnaire With Standardized Activities-Interviewer Administered Scores at Weeks 12, 24, 36, and 52: Baseline Blood Eosinophils >=300 Cells Per Microliter Population|Healthcare Resource Utilization (HCRU): Number of School and Work Days Missed Due to LOAC: Type 2 Inflammatory Asthma Phenotype Population|Healthcare Resource Utilization: Number of School and Work Days Missed Due to LOAC: Baseline Blood Eosinophils >=300 Cells Per Microliter Population|Healthcare Resource Utilization: Percentage of Participants Who Had Missed Greater Than or Equal to 5 School/Work Days Due to LOAC: Type 2 Inflammatory Asthma Phenotype Population|Healthcare Resource Utilization: Percentage of Participants Who Had Missed Greater Than or Equal to 5 School/Work Days Due to LOAC: Baseline Blood Eosinophils >=300 Cells Per Microliter Population|Number of Participants With Treatment-emergent Adverse Events (TEAEs) and Treatment-emergent Serious Adverse Events (TESAEs)|Pharmacokinetics (PK) Assessment: Functional Dupilumab Concentration in Serum|Percentage of Participants With Treatment Emergent Antidrug Antibodies (ADA) Response|Percentage of Participants With Seroconversion","Sanofi|Regeneron Pharmaceuticals","All","6 Years to 11 Years   (Child)","Phase 3","408","Industry","Interventional","Allocation: Randomized|Intervention Model: Parallel Assignment|Masking: Triple (Participant, Care Provider, Investigator)|Primary Purpose: Treatment","EFC14153|2016-001607-23|U1111-1179-4851","April 21, 2017","August 26, 2020","August 26, 2020","October 31, 2016","October 20, 2021","October 20, 2021","Investigational Site Number 840031, Birmingham, Alabama, United States|Investigational Site Number 840002, Gilbert, Arizona, United States|Investigational Site Number 840012, Tucson, Arizona, United States|Investigational Site Number 840001, Rolling Hills Estates, California, United States|Investigational Site Number 840036, Owensboro, Kentucky, United States|Investigational Site Number 840016, Ann Arbor, Michigan, United States|Investigational Site Number 840006, Saint Louis, Missouri, United States|Investigational Site Number 840022, Lincoln, Nebraska, United States|Investigational Site Number 840023, Great Neck, New York, United States|Investigational Site Number 840035, New York, New York, United States|Investigational Site Number 840013, New York, New York, United States|Investigational Site Number 840007, Rochester, New York, United States|Investigational Site Number 840004, Charlotte, North Carolina, United States|Investigational Site Number 840021, Durham, North Carolina, United States|Investigational Site Number 840008, Cincinnati, Ohio, United States|Investigational Site Number 840024, Edmond, Oklahoma, United States|Investigational Site Number 840003, San Antonio, Texas, United States|Investigational Site Number 840018, La Crosse, Wisconsin, United States|Investigational Site Number 032004, Buenos Aires, Argentina|Investigational Site Number 032003, Buenos Aires, Argentina|Investigational Site Number 032002, Caba, Argentina|Investigational Site Number 032001, Caba, Argentina|Investigational Site Number 032006, Mendoza, Argentina|Investigational Site Number 036001, Campbelltown, Australia|Investigational Site Number 036005, North Adelaide, Australia|Investigational Site Number 036003, Parkville/Melbourne, Australia|Investigational Site Number 036002, South Brisbane, Australia|Investigational Site Number 076008, Blumenau, Brazil|Investigational Site Number 076001, Porto Alegre, Brazil|Investigational Site Number 076007, Porto Alegre, Brazil|Investigational Site Number 076003, Sao Paulo, Brazil|Investigational Site Number 076002, Sao Paulo, Brazil|Investigational Site Number 076004, Sao Paulo, Brazil|Investigational Site Number 076006, Sorocaba, Brazil|Investigational Site Number 124004, Edmonton, Canada|Investigational Site Number 124002, Hamilton, Canada|Investigational Site Number 124001, Montreal, Canada|Investigational Site Number 124003, Quebec, Canada|Investigational Site Number 152003, Santiago, Chile|Investigational Site Number 152005, Santiago, Chile|Investigational Site Number 152009, Santiago, Chile|Investigational Site Number 152001, Valdivia, Chile|Investigational Site Number 152007, Viña Del Mar, Chile|Investigational Site Number 152002, Viña Del Mar, Chile|Investigational Site Number 170004, Antioquia, Colombia|Investigational Site Number 170002, Cali, Colombia|Investigational Site Number 348006, Budapest, Hungary|Investigational Site Number 348002, Gyula, Hungary|Investigational Site Number 348012, Mezőkövesd, Hungary|Investigational Site Number 348005, Szeged, Hungary|Investigational Site Number 348008, Szigetvár, Hungary|Investigational Site Number 348001, Székesfehérvár, Hungary|Investigational Site Number 348003, Töröbálint, Hungary|Investigational Site Number 348007, Zalaegerszeg, Hungary|Investigational Site Number 380007, Catania, Italy|Investigational Site Number 380003, Firenze, Italy|Investigational Site Number 380004, Padova, Italy|Investigational Site Number 380005, Roma, Italy|Investigational Site Number 380001, Verona, Italy|Investigational Site Number 440002, Kaunas, Lithuania|Investigational Site Number 440005, Siauliai, Lithuania|Investigational Site Number 440003, Utena, Lithuania|Investigational Site Number 440001, Vilnius, Lithuania|Investigational Site Number 440004, Vilnius, Lithuania|Investigational Site Number 484006, Chihuahua, Mexico|Investigational Site Number 484004, Chihuahua, Mexico|Investigational Site Number 484003, Durango, Mexico|Investigational Site Number 484001, Monterrey, Mexico|Investigational Site Number 484002, Veracruz, Mexico|Investigational Site Number 616001, Lodz, Poland|Investigational Site Number 616002, Poznan, Poland|Investigational Site Number 642001, Bucuresti, Romania|Investigational Site Number 643006, Moscow, Russian Federation|Investigational Site Number 643004, Perm, Russian Federation|Investigational Site Number 643005, Saint Petersburg, Russian Federation|Investigational Site Number 643002, Saint Petersburg, Russian Federation|Investigational Site Number 643001, Saint-Petersburg, Russian Federation|Investigational Site Number 643003, Saint-Petersburg, Russian Federation|Investigational Site Number 710004, Cape Town, South Africa|Investigational Site Number 710001, Cape Town, South Africa|Investigational Site Number 724001, Barcelona, Spain|Investigational Site Number 724006, Esplugues De Llobregat, Spain|Investigational Site Number 724005, Pozuelo De Alarcón, Spain|Investigational Site Number 724002, Santiago De Compostela, Spain|Investigational Site Number 724003, Valencia, Spain|Investigational Site Number 792005, Adana, Turkey|Investigational Site Number 792008, Ankara, Turkey|Investigational Site Number 792001, Ankara, Turkey|Investigational Site Number 792006, Bursa, Turkey|Investigational Site Number 792003, İstanbul, Turkey|Investigational Site Number 792004, Istanbul, Turkey|Investigational Site Number 804007, Chernivtsi, Ukraine|Investigational Site Number 804004, Dnipro, Ukraine|Investigational Site Number 804011, Ivano-Frankivsk, Ukraine|Investigational Site Number 804005, Kharkiv, Ukraine|Investigational Site Number 804008, Kryvyi Rig, Ukraine|Investigational Site Number 804001, Kyiv, Ukraine|Investigational Site Number 804002, Zaporizhzhya, Ukraine|Investigational Site Number 804003, Zaporizhzhya, Ukraine","""Study Protocol"", https://ClinicalTrials.gov/ProvidedDocs/59/NCT02948959/Prot_000.pdf|""Statistical Analysis Plan"", https://ClinicalTrials.gov/ProvidedDocs/59/NCT02948959/SAP_001.pdf","https://ClinicalTrials.gov/show/NCT02948959"
353,"NCT02924311","Routine Clinical Practice for Use of Intravitreal Aflibercept Treatment in Patients With Diabetic Macular Edema","APOLLON","Completed","No Results Available","Diabetic Retinopathy","Drug: Aflibercept (Eylea, VEGF Trap-Eye, BAY86-5321)","Mean change in Best Corrected Visual Acuity from baseline to month 12 in treatment naïve patients and previously treated patients|Mean change in Best Corrected Visual Acuity between baseline and 12-month follow-up for the entire study population|Mean change in Best Corrected Visual Acuity between baseline and 24-month follow-up for all groups|Mean change in Central Retinal Thickness between baseline and 12-month follow-up for all groups|Mean change in Central Retinal Thickness between baseline visit and 24-month follow-up for all groups|Type of the previous treatment(s) in previously treated patients|Duration (months) of the previous treatment in previously treated patients|Date of the last administered treatment in previously treated patients|Reason for starting intravitreal aflibercept|Number of eyes injected|Number of visits with injection|Interval (days) between injections|Type of adjunctive therapy post IVT aflibercept initiation|Proportion of patients with change in fluorescein angiograph outcomes between baseline and 24-month follow-up for all groups|Proportion of patients with change in fundus photography outcomes between baseline and 24-month follow-up for all groups|Proportion of patients with no fluid determined by optical coherence tomography (OCT) between baseline and 24-month follow-up|Mean change in HbA1c level during macular disease monitoring|Mean change in blood pressure during macular disease monitoring|Duration of the disease (DME Monitoring)|Number of visits for monitoring only (DME Monitoring)|Number of visits for injection only (DME Monitoring)|Number of visits combining monitoring and injection (DME Monitoring)|Number of monitoring visits for diabetes (by diabetologists, general practitioners) outside the study center over 12 and 24 months (if known by the ophthalmologist) (DME monitoring)|Number of visits with OCT assessments (DME monitoring)|Number of visits with fundus photography assessments (DME monitoring)|Number of visits with fluorescein angiography assessments (DME monitoring)|Number of visits with visual acuity measurements (DME monitoring)|Number of participants with ocular and non-ocular safety events","Bayer|Regeneron Pharmaceuticals","All","18 Years and older   (Adult, Older Adult)",,"402","Industry","Observational","Observational Model: Cohort|Time Perspective: Prospective","18636","September 21, 2016","August 12, 2019","December 6, 2019","October 5, 2016",,"November 4, 2020","Multiple Locations, France",,"https://ClinicalTrials.gov/show/NCT02924311"
354,"NCT02912468","A Controlled Clinical Study of Dupilumab in Patients With Bilateral Nasal Polyps","SINUS-24","Completed","Has Results","Chronic Rhinosinusitis Phenotype With Nasal Polyps (CRSwNP)","Drug: Dupilumab SAR231893 (REGN668)|Drug: Placebo|Drug: Mometasone furoate 50 micrograms","Change From Baseline at Week 24 in Nasal Congestion/Obstruction Symptom Severity Score|Change From Baseline at Week 24 in Nasal Polyp Score|Change From Baseline at Week 24 in Opacification of Sinuses Measured by Lund-Mackay (LMK) Score|Change From Baseline at Week 24 in Total Symptom Score (TSS)|Change From Baseline at Week 24 in the University of Pennsylvania Smell Identification Test (UPSIT) Score|Change From Baseline at Week 24 in Severity of Decreased/Loss of Smell as Assessed by Participant Daily|Change From Baseline at Week 24 in 22-item Sino-nasal Outcome Test (SNOT-22) Scores|Rescue Treatment Use: Estimate of Percentage of Participants With >=1 Event by Week 24 Obtained Using Kaplan-Meier Method|Change From Baseline at Week 24 in Visual Analogue Scale (VAS) for Rhinosinusitis|Change From Baseline at Week 24 in Nasal Peak Inspiratory Flow (NPIF)|Change From Baseline at Week 24 in Rhinorrhea Daily Symptom Score|Change From Baseline at Week 24 in Forced Expiratory Volume in 1 Second (FEV1) for Participants With Asthma|Change From Baseline at Week 24 in Asthma Control Questionnaire-6 (ACQ-6) Scores for Participants With Asthma|Change From Baseline at Weeks 28, 32, 36, 40, 44 and 48 in Nasal Congestion Symptom Severity Score (Assessments Performed 4-24 Weeks After End of Treatment)|Change From Baseline at Weeks 36 and 48 in Nasal Polyp Score (Assessments Performed 12 and 24 Weeks After End of Treatment)|Change From Baseline at Week 48 in Opacification of Sinuses Measured by Lund-Mackay Score (Assessment Performed 24 Weeks After End of Treatment)|Change From Baseline at Weeks 28, 32, 36, 40, 44 and 48 in Total Symptom Score (Assessments Performed 4-24 Weeks After End of Treatment)|Change From Baseline at Week 48 in University of Pennsylvania Smell Identification Test (Assessment Performed 24 Weeks After End of Treatment)|Change From Baseline at Weeks 28, 32, 36, 40, 44 and 48 in Severity of Decreased/Loss of Smell as Assessed by Participant Daily (Assessments Performed 4-24 Weeks After End of Treatment)|Change From Baseline at Weeks 36 and 48 in 22-item Sino-nasal Outcome Test Scores (Assessments Performed 12 and 24 Weeks After End of Treatment)|Rescue Treatment Use: Estimate of Percentage of Participants With >=1 Event by Week 48 Obtained Using Kaplan-Meier Method|Change From Baseline at Weeks 36 and 48 in Visual Analog Scale for Rhinosinusitis (Assessments Performed 12 and 24 Weeks After End of Treatment)|Change From Baseline at Weeks 28, 32, 36, 40, 44 and 48 in Rhinorrhea Daily Symptom Score (Assessments Performed 4-24 Weeks After End of Treatment)|Change From Baseline at Week 48 in Forced Expiratory Volume in 1 Second for Participants With Asthma (Assessment Performed 24 Weeks After End of Treatment)|Change From Baseline at Week 48 in Asthma Control Questionnaire-6 Scores for Participants With Asthma (Assessment Performed 24 Weeks After End of Treatment)|Number of Participants With Treatment-emergent Adverse Events (TEAEs), Serious Adverse Events (SAEs) and TEAEs Leading to Treatment Discontinuation|Functional Dupilumab Concentration in Serum|Number of Participants With Treatment-Emergent And Treatment-Boosted Anti-drug Antibodies (ADA) Response|Mean Total Systemic Corticosteroids Rescue Dose Prescribed During Treatment Period|Total Systemic Corticosteroids Rescue Intake Duration: Average Duration Per Participant|Change From Baseline at Week 24 in European Quality of Life 5 Dimension (EQ-5D) Visual Analog Scale Score|Change From Baseline at Week 24 in Nasal Congestion Symptom Severity Score: Subgroup of Participants With Asthma|Change From Baseline at Week 24 in Nasal Congestion Symptom Severity Score: Subgroup of Participants With Prior Nasal Polyp Surgery|Change From Baseline at Week 24 in Nasal Polyp Score: Subgroup of Participants With Asthma|Change From Baseline at Week 24 in Nasal Polyp Score: Subgroup of Participants With Prior Nasal Polyp Surgery|Change From Baseline at Week 24 in Opacification of Sinuses Measured by Lund Mackay Score: Subgroup of Participants With Asthma|Change From Baseline at Week 24 in Opacification of Sinuses Measured by Lund Mackay Score: Subgroup of Participants With Prior Nasal Polyp Surgery","Sanofi|Regeneron Pharmaceuticals","All","18 Years and older   (Adult, Older Adult)","Phase 3","276","Industry","Interventional","Allocation: Randomized|Intervention Model: Parallel Assignment|Masking: Double (Participant, Investigator)|Primary Purpose: Treatment","EFC14146|2015-003101-42|U1111-1178-5390","December 5, 2016","July 5, 2018","July 5, 2018","September 23, 2016","July 25, 2019","July 25, 2019","Investigational Site Number 8400009, Long Beach, California, United States|Investigational Site Number 8400004, Orange, California, United States|Investigational Site Number 8400014, San Diego, California, United States|Investigational Site Number 8400002, Stockton, California, United States|Investigational Site Number 8400016, Centennial, Colorado, United States|Investigational Site Number 8400013, Tampa, Florida, United States|Investigational Site Number 8400022, West Des Moines, Iowa, United States|Investigational Site Number 8400007, Boston, Massachusetts, United States|Investigational Site Number 8400005, Rochester, Minnesota, United States|Investigational Site Number 8400021, Saint Louis, Missouri, United States|Investigational Site Number 8400008, Winston-Salem, North Carolina, United States|Investigational Site Number 8400019, Tulsa, Oklahoma, United States|Investigational Site Number 8400020, Medford, Oregon, United States|Investigational Site Number 8400018, Charleston, South Carolina, United States|Investigational Site Number 8400003, Nashville, Tennessee, United States|Investigational Site Number 8400001, Dallas, Texas, United States|Investigational Site Number 8400015, Norfolk, Virginia, United States|Investigational Site Number 8400010, Milwaukee, Wisconsin, United States|Investigational Site Number 1000003, Plovdiv, Bulgaria|Investigational Site Number 1000002, Sofia, Bulgaria|Investigational Site Number 1000001, Sofia, Bulgaria|Investigational Site Number 2030001, Hradec Kralove, Czechia|Investigational Site Number 2030002, Pardubice, Czechia|Investigational Site Number 2030004, Praha 2, Czechia|Investigational Site Number 2500005, La Roche Sur Yon, France|Investigational Site Number 2500007, Lille, France|Investigational Site Number 2500003, Lyon, France|Investigational Site Number 2500001, Montpellier, France|Investigational Site Number 2500006, Nantes, France|Investigational Site Number 2500002, Toulouse, France|Investigational Site Number 2500004, Vandoeuvre-Les-Nancy, France|Investigational Site Number 2760001, Berlin, Germany|Investigational Site Number 2760003, München, Germany|Investigational Site Number 2760002, Münster, Germany|Investigational Site Number 3480006, Budapest, Hungary|Investigational Site Number 3480007, Budapest, Hungary|Investigational Site Number 3480004, Budapest, Hungary|Investigational Site Number 3480003, Budapest, Hungary|Investigational Site Number 3480005, Debrecen, Hungary|Investigational Site Number 3480002, Pécs, Hungary|Investigational Site Number 3480001, Szeged, Hungary|Investigational Site Number 3800007, Bologna, Italy|Investigational Site Number 3800002, Catania, Italy|Investigational Site Number 3800004, Milano, Italy|Investigational Site Number 3800006, Milano, Italy|Investigational Site Number 3800001, Pisa, Italy|Investigational Site Number 3800005, Rozzano, Italy|Investigational Site Number 3800003, Varese, Italy|Investigational Site Number 5280001, Amsterdam, Netherlands|Investigational Site Number 6160002, Katowice, Poland|Investigational Site Number 6160001, Lodz, Poland|Investigational Site Number 6160003, Warszawa, Poland|Investigational Site Number 6420007, Brasov, Romania|Investigational Site Number 6420013, Brasov, Romania|Investigational Site Number 6420003, Bucuresti, Romania|Investigational Site Number 6420009, Cluj-Napoca, Romania|Investigational Site Number 6420008, Craiova, Romania|Investigational Site Number 6420010, Targu-Mures, Romania|Investigational Site Number 6430004, Moscow, Russian Federation|Investigational Site Number 6430003, Moscow, Russian Federation|Investigational Site Number 6430001, Saint-Petersburg, Russian Federation|Investigational Site Number 6430007, Saint-Petersburg, Russian Federation|Investigational Site Number 6430002, St-Petersburg, Russian Federation|Investigational Site Number 6430006, Yaroslavl, Russian Federation|Investigational Site Number 8040002, Ivano-Frankivsk, Ukraine|Investigational Site Number 8040004, Kharkiv, Ukraine|Investigational Site Number 8040005, Kyiv, Ukraine|Investigational Site Number 8040006, Kyiv, Ukraine|Investigational Site Number 8040001, Poltava, Ukraine|Investigational Site Number 8040008, Ternopil, Ukraine|Investigational Site Number 8260001, Bradford, United Kingdom|Investigational Site Number 8260002, Dundee, United Kingdom|Investigational Site Number 8260007, Great Yarmouth, United Kingdom|Investigational Site Number 8260006, London, United Kingdom|Investigational Site Number 8260004, Stockport, United Kingdom|Investigational Site Number 8260005, Wigan, United Kingdom","""Study Protocol"", https://ClinicalTrials.gov/ProvidedDocs/68/NCT02912468/Prot_000.pdf|""Statistical Analysis Plan"", https://ClinicalTrials.gov/ProvidedDocs/68/NCT02912468/SAP_001.pdf","https://ClinicalTrials.gov/show/NCT02912468"
355,"NCT02898454","Controlled Clinical Study of Dupilumab in Patients With Nasal Polyps","SINUS-52","Completed","Has Results","Chronic Rhinosinusitis Phenotype With Nasal Polyps (CRSwNP)","Drug: Dupilumab SAR231893 (REGN668)|Drug: Placebo|Drug: Mometasone furoate nasal spray","Change From Baseline at Week 24 in Nasal Congestion/Obstruction Symptom Severity Score|Change From Baseline at Week 24 in Nasal Polyp Score|Change From Baseline at Week 24 in Opacification of Sinuses Measured by Lund Mackay (LMK) Score|Change From Baseline at Week 24 in Total Symptom Score (TSS)|Change From Baseline at Week 24 in the University of Pennsylvania Smell Identification Test (UPSIT) Score|Change From Baseline at Week 24 in Severity of Decreased/Loss of Smell as Assessed by Participant Daily|Change From Baseline at Week 24 in 22-item Sino-nasal Outcome Test (SNOT-22) Scores|Change From Baseline at Week 52 in Nasal Polyp Score|Change From Baseline at Week 52 in Nasal Congestion/Obstruction Symptom Severity Score|Change From Baseline at Week 52 in 22-item Sino-nasal Outcome Test Scores|Rescue Treatment Use: Estimate of Percentage of Participants With Greater Than or Equal to (>=) 1 Event by Week 52 Obtained Using Kaplan-Meier Method|Change From Baseline at Week 52 in Total Symptom Score|Change From Baseline at Week 52 in the University of Pennsylvania Smell Identification Test Score|Change From Baseline at Week 52 in Severity of Decreased/Loss of Smell|Change From Baseline at Week 52 in Opacification of Sinuses Measured by Lund-Mackay Score|Change From Baseline at Week 24 in Visual Analogue Scale (VAS) for Rhinosinusitis|Change From Baseline at Week 52 in Visual Analogue Scale for Rhinosinusitis|Change From Baseline at Week 24 in Nasal Peak Inspiratory Flow (NPIF)|Change From Baseline at Week 24 in Rhinorrhea Daily Symptom Score|Change From Baseline at Week 52 in Rhinorrhea Daily Symptom Score|Mean Total Systemic Corticosteroids Rescue Dose Prescribed During Treatment Period|Total Systemic Corticosteroids Rescue Intake Duration: Average Duration Per Participant|Changed From Baseline at Week 24 in Forced Expiratory Volume in 1 Second (FEV1) for Participants With Asthma|Change From Baseline at Week 52 in Forced Expiratory Volume in 1 Second for Participants With Asthma|Change From Baseline at Week 24 in Asthma Control Questionnaire-6 (ACQ-6) for Participants With Asthma|Change From Baseline at Week 52 in Asthma Control Questionnaire-6 for Participants With Asthma|Change From Baseline at Week 24 in Nasal Congestion/Obstruction Symptom Severity Score: Subgroup of Participants With Asthma|Change From Baseline at Week 52 in Nasal Congestion/Obstruction Symptom Severity Score: Subgroup of Participants With Asthma|Change From Baseline at Week 24 in Nasal Congestion/Obstruction Symptom Severity Score: Subgroup of Participants With Prior Nasal Polyp Surgery|Change From Baseline at Week 52 in Nasal Congestion/Obstruction Symptom Severity Score: Subgroup of Participants With Prior Nasal Polyp Surgery|Change From Baseline at Week 24 in Nasal Polyp Score: Subgroup of Participants With Asthma|Change From Baseline at Week 52 in Nasal Polyp Score: Subgroup of Participants With Asthma|Change From Baseline at Week 24 in Nasal Polyp Score: Subgroup of Participants With Prior Nasal Polyp Surgery|Change From Baseline at Week 52 in Nasal Polyp Score: Subgroup of Participants With Prior Nasal Polyp Surgery|Change From Baseline at Week 24 in Opacification of Sinuses Measured by Lund Mackay Score: Subgroup of Participants With Asthma|Change From Baseline at Week 52 in Opacification of Sinuses Measured by Lund Mackay Score: Subgroup of Participants With Asthma|Change From Baseline at Week 24 in Opacification of Sinuses Measured by Lund Mackay Score: Subgroup of Participants With Prior Nasal Polyp Surgery|Change From Baseline at Week 52 in Opacification of Sinuses Measured by Lund Mackay Score: Subgroup of Participants With Prior Nasal Polyp Surgery|Number of Participants With Treatment-emergent Adverse Events (TEAEs), Serious Adverse Events (SAEs) and TEAEs Leading to Treatment Discontinuation|Change From Baseline at Week 24 in European Quality of Life 5 Dimension Scale (EQ-5D) Visual Analog Scale Score|Change From Baseline at Week 52 in European Quality of Life 5 Dimension Scale Visual Analog Scale Score|Functional Dupilumab Concentration in Serum|Number of Participants With Treatment-Emergent And Treatment-Boosted Anti-drug Antibodies Response (ADA)","Sanofi|Regeneron Pharmaceuticals","All","18 Years and older   (Adult, Older Adult)","Phase 3","448","Industry","Interventional","Allocation: Randomized|Intervention Model: Parallel Assignment|Masking: Quadruple (Participant, Care Provider, Investigator, Outcomes Assessor)|Primary Purpose: Treatment","EFC14280|2015-001314-10|U1111-1170-7180","November 28, 2016","August 27, 2018","November 16, 2018","September 13, 2016","October 23, 2019","October 23, 2019","Investigational Site Number 8400019, Birmingham, Alabama, United States|Investigational Site Number 8400011, Fresno, California, United States|Investigational Site Number 8400008, Huntington Beach, California, United States|Investigational Site Number 8400004, Rolling Hills Estates, California, United States|Investigational Site Number 8400012, Walnut Creek, California, United States|Investigational Site Number 8400017, Colorado Springs, Colorado, United States|Investigational Site Number 8400006, Denver, Colorado, United States|Investigational Site Number 8400022, New Haven, Connecticut, United States|Investigational Site Number 8400002, Louisville, Kentucky, United States|Investigational Site Number 8400021, Boston, Massachusetts, United States|Investigational Site Number 8400014, Kansas City, Missouri, United States|Investigational Site Number 8400024, Bronx, New York, United States|Investigational Site Number 8400016, North Charleston, North Carolina, United States|Investigational Site Number 8400013, Bethlehem, Pennsylvania, United States|Investigational Site Number 8400005, Philadelphia, Pennsylvania, United States|Investigational Site Number 8400003, Pittsburgh, Pennsylvania, United States|Investigational Site Number 8400009, Salt Lake City, Utah, United States|Investigational Site Number 8400010, Bellevue, Washington, United States|Investigational Site Number 8400007, Milwaukee, Wisconsin, United States|Investigational Site Number 0320006, Buenos Aires, Argentina|Investigational Site Number 0320004, Buenos Aires, Argentina|Investigational Site Number 0320005, Caba, Argentina|Investigational Site Number 0320001, Caba, Argentina|Investigational Site Number 0320007, Caba, Argentina|Investigational Site Number 0320003, Mendoza, Argentina|Investigational Site Number 0320008, Rosario, Argentina|Investigational Site Number 0320002, San Miguel De Tucumán, Argentina|Investigational Site Number 0360002, Clayton, Australia|Investigational Site Number 0360004, Herston, Australia|Investigational Site Number 0360005, Murdoch, Australia|Investigational Site Number 0360001, Parkville, Australia|Investigational Site Number 0360003, Prahran, Australia|Investigational Site Number 0560003, Bruxelles, Belgium|Investigational Site Number 0560001, Gent, Belgium|Investigational Site Number 0560002, Leuven, Belgium|Investigational Site Number 1240007, Kingston, Canada|Investigational Site Number 1240002, Montreal, Canada|Investigational Site Number 1240006, Montreal, Canada|Investigational Site Number 1240005, Ottawa, Canada|Investigational Site Number 1240003, Quebec, Canada|Investigational Site Number 1240004, Quebec, Canada|Investigational Site Number 1240008, Trois-Rivieres, Canada|Investigational Site Number 1240001, Vancouver, Canada|Investigational Site Number 1520009, Quillota, Chile|Investigational Site Number 1520010, San Fernando, Chile|Investigational Site Number 1520005, Santiago, Chile|Investigational Site Number 1520011, Santiago, Chile|Investigational Site Number 1520008, Santiago, Chile|Investigational Site Number 1520006, Santiago, Chile|Investigational Site Number 1520001, Santiago, Chile|Investigational Site Number 1520014, Santiago, Chile|Investigational Site Number 1520003, Talca, Chile|Investigational Site Number 1520007, Viña Del Mar, Chile|Investigational Site Number 3760001, Hadera, Israel|Investigational Site Number 3760003, Nahariya, Israel|Investigational Site Number 3760002, Petah-Tikva, Israel|Investigational Site Number 3760005, Rehovot, Israel|Investigational Site Number 3760004, Tel Hashomer, Israel|Investigational Site Number 3920004, Bunkyo-Ku, Japan|Investigational Site Number 3920009, Bunkyo-Ku, Japan|Investigational Site Number 3920026, Bunkyo-Ku, Japan|Investigational Site Number 3920006, Chiyoda-Ku, Japan|Investigational Site Number 3920024, Fukuoka-Shi, Japan|Investigational Site Number 3920010, Hirakata-Shi, Japan|Investigational Site Number 3920011, Hiroshima-Shi, Japan|Investigational Site Number 3920007, Iida-Shi, Japan|Investigational Site Number 3920015, Inzai-Shi, Japan|Investigational Site Number 3920012, Itabashi-Ku, Japan|Investigational Site Number 3920014, Izumisano-Shi, Japan|Investigational Site Number 3920016, Kawasaki-Shi, Japan|Investigational Site Number 3920020, Kitakyushu-Shi, Japan|Investigational Site Number 3920027, Kitakyushu-Shi, Japan|Investigational Site Number 3920002, Kumamoto-Shi, Japan|Investigational Site Number 3920021, Kumamoto-Shi, Japan|Investigational Site Number 3920003, Kyoto-Shi, Japan|Investigational Site Number 3920023, Meguro-Ku, Japan|Investigational Site Number 3920013, Moriguchi-Shi, Japan|Investigational Site Number 3920025, Okayama-Shi, Japan|Investigational Site Number 3920018, Osaka-Shi, Japan|Investigational Site Number 3920017, Ota-Ku, Japan|Investigational Site Number 3920005, Sendai-Shi, Japan|Investigational Site Number 3920022, Sendai-Shi, Japan|Investigational Site Number 3920001, Shimonoseki-Shi, Japan|Investigational Site Number 3920029, Shinagawa-Ku, Japan|Investigational Site Number 3920030, Shinjyuku-Ku, Japan|Investigational Site Number 3920028, Takatsuki-Shi, Japan|Investigational Site Number 3920019, Yoshida-Gun, Japan|Investigational Site Number 4840001, Chihuahua, Mexico|Investigational Site Number 4840005, Chihuahua, Mexico|Investigational Site Number 4840004, Durango, Mexico|Investigational Site Number 4840002, Guadalajara, Mexico|Investigational Site Number 4840003, Monterrey, Mexico|Investigational Site Number 6200004, Aveiro, Portugal|Investigational Site Number 6200006, Guimarães, Portugal|Investigational Site Number 6200002, Lisboa, Portugal|Investigational Site Number 6200007, Matosinhos, Portugal|Investigational Site Number 6200001, Porto, Portugal|Investigational Site Number 6200005, Viana Do Castelo, Portugal|Investigational Site Number 6430006, Moscow, Russian Federation|Investigational Site Number 6430003, Odintsovo, Russian Federation|Investigational Site Number 6430002, Saint-Petersburg, Russian Federation|Investigational Site Number 6430005, Stavropol, Russian Federation|Investigational Site Number 6430001, Yaroslavl, Russian Federation|Investigational Site Number 7240001, Barcelona, Spain|Investigational Site Number 7240006, Barcelona, Spain|Investigational Site Number 7240003, Jerez De La Frontera, Spain|Investigational Site Number 7240002, Madrid, Spain|Investigational Site Number 7240007, Sevilla, Spain|Investigational Site Number 7240009, Valencia, Spain|Investigational Site Number 7520002, Lund, Sweden|Investigational Site Number 7520001, Stockholm, Sweden|Investigational Site Number 7920004, Ankara, Turkey|Investigational Site Number 7920005, Ankara, Turkey|Investigational Site Number 7920008, Ankara, Turkey|Investigational Site Number 7920013, Bursa, Turkey|Investigational Site Number 7920010, Istanbul, Turkey|Investigational Site Number 7920009, Istanbul, Turkey|Investigational Site Number 7920003, Istanbul, Turkey|Investigational Site Number 7920001, Istanbul, Turkey|Investigational Site Number 7920002, Istanbul, Turkey|Investigational Site Number 7920006, Izmir, Turkey|Investigational Site Number 7920007, Izmir, Turkey|Investigational Site Number 7920011, Rize, Turkey","""Study Protocol"", https://ClinicalTrials.gov/ProvidedDocs/54/NCT02898454/Prot_000.pdf|""Statistical Analysis Plan"", https://ClinicalTrials.gov/ProvidedDocs/54/NCT02898454/SAP_001.pdf","https://ClinicalTrials.gov/show/NCT02898454"
356,"NCT02890992","An 8-Week Dose-Finding Study to Evaluate the Efficacy and Safety of Alirocumab in Children and Adolescents With Heterozygous Familial Hypercholesterolemia","ODYSSEY KIDS","Completed","Has Results","Hypercholesterolaemia","Drug: alirocumab SAR236553 (REGN727)|Drug: statins|Drug: ezetimibe|Drug: cholestyramine|Drug: fenofibrate|Drug: omega-3 fatty acids|Drug: nicotinic acid","Percent Change From Baseline in Calculated Low Density Lipoprotein Cholesterol (LDL-C) at Week 8|Absolute Change From Baseline in Calculated Low Density Lipoprotein Cholesterol (LDL-C) at Week 8|Percentage of Participants Achieving Calculated Low Density Lipoprotein Cholesterol (LDL-C) <130 mg/dL (3.37 mmol/L) at Week 8|Percentage of Participants Achieving Calculated LDL-C <110 mg/dL (2.84 mmol/L) at Week 8|Percent Change From Baseline in Calculated LDL-C at Week 12: Cohort 4|Percent Change From Baseline in Apolipoprotein (Apo) B at Week 8|Percent Change From Baseline in Non-High Density Lipoprotein (HDL-C) at Week 8|Percent Change From Baseline in Total Cholesterol (Total-C) at Week 8|Percent Change From Baseline in Lipoprotein(a) at Week 8|Percent Change From Baseline in Fasting Triglyceride at Week 8|Percent Change From Baseline in High Density Lipoprotein Cholesterol (HDL-C) at Week 8|Percent Change From Baseline in Apolipoprotein A-1 at Week 8|Absolute Change From Baseline in Apolipoprotein B at Week 8|Absolute Change From Baseline in Non-High-Density Lipoprotein (Non-HDL-C) at Week 8|Absolute Change From Baseline in Total Cholesterol (Total-C) at Week 8|Absolute Change From Baseline in Lipoprotein(a) at Week 8|Absolute Change From Baseline in HDL-C at Week 8|Absolute Change From Baseline in Fasting Triglyceride at Week 8|Absolute Change From Baseline in Apolipoprotein A-1 at Week 8|Absolute Change From Baseline in Ratio Apolipoprotein B/Apolipoprotein A-1 at Week 8","Sanofi|Regeneron Pharmaceuticals","All","8 Years to 17 Years   (Child)","Phase 2","42","Industry","Interventional","Allocation: Non-Randomized|Intervention Model: Sequential Assignment|Masking: None (Open Label)|Primary Purpose: Treatment","DFI14223|2015-003766-85|U1111-1178-4764","September 15, 2016","September 13, 2018","February 22, 2019","September 7, 2016","September 6, 2019","September 6, 2019","Investigational Site Number 8400002, Saint Louis, Missouri, United States|Investigational Site Number 8400005, Charlotte, North Carolina, United States|Investigational Site Number 8400001, Cincinnati, Ohio, United States|Investigational Site Number 1240001, Quebec, Canada|Investigational Site Number 2030001, Brno, Czechia|Investigational Site Number 2030003, Praha 5 - Motol, Czechia|Investigational Site Number 2030002, Zlin, Czechia|Investigational Site Number 2500001, Bron Cedex, France|Investigational Site Number 5280001, Amsterdam, Netherlands|Investigational Site Number 5780001, Oslo, Norway|Investigational Site Number 6430001, Kemerovo, Russian Federation|Investigational Site Number 6430004, Saint-Petersburg, Russian Federation|Investigational Site Number 7100001, Parow, South Africa|Investigational Site Number 7240004, A Coruna, Spain|Investigational Site Number 7240001, Madrid, Spain|Investigational Site Number 7520001, Stockholm, Sweden","""Study Protocol"", https://ClinicalTrials.gov/ProvidedDocs/92/NCT02890992/Prot_000.pdf|""Statistical Analysis Plan"", https://ClinicalTrials.gov/ProvidedDocs/92/NCT02890992/SAP_001.pdf","https://ClinicalTrials.gov/show/NCT02890992"
357,"NCT02863354","Intravitreal Aflibercept for Retinal Non-Perfusion in Proliferative Diabetic Retinopathy","RECOVERY","Completed","Has Results","Proliferative Diabetic Retinopathy","Drug: Aflibercept","Number of Participants With Treatment-related Adverse Events as Assessed by CTCAE v4.0|Change in Early Treatment of Diabetic Retinopathy Severity Best Corrected Visual Acuity|Change in Area of Retinal Capillary Non-perfusion Within the Macula|Change in Area of Retinal Capillary Non-perfusion Outside of the Macula|Percentage of Subjects With Neovascularization Regression|Percentage of Subjects With Increased Neovascularization|Percentage of Subjects Who Develop Vitreous Hemorrhage|Percentage of Subjects Treated With Pan-retinal Photocoagulation or Vitrectomy|Percentage of Subjects Who Develop Center-involving Diabetic Macular Edema|Changes in Visual Function Outcomes (Self Reported Visual Function)|Mean Change in Central Subfield Thickness|Change in Area of Total Retinal Capillary Non-perfusion, as Assessed by the Central Reading Center","Charles C Wykoff, PhD, MD|Regeneron Pharmaceuticals|Greater Houston Retina Research","All","18 Years and older   (Adult, Older Adult)","Phase 2","43","Other|Industry","Interventional","Allocation: Randomized|Intervention Model: Parallel Assignment|Masking: None (Open Label)|Primary Purpose: Treatment","RECOVERY","August 2016","May 2019","May 2019","August 11, 2016","April 21, 2021","May 24, 2021","Retina Consultants of Houston/The Medical Center, Houston, Texas, United States|Retina Consultants of Houston/Katy office, Katy, Texas, United States|Retina Consultants of Houston, Kingwood, Texas, United States|Retina Consultants of Houston, The Woodlands, Texas, United States","""Study Protocol"", https://ClinicalTrials.gov/ProvidedDocs/54/NCT02863354/Prot_000.pdf|""Statistical Analysis Plan"", https://ClinicalTrials.gov/ProvidedDocs/54/NCT02863354/SAP_001.pdf","https://ClinicalTrials.gov/show/NCT02863354"
358,"NCT02828033","Rilonacept for Treatment of Autoimmune Neurosensory Hearing Loss",,"Unknown status","No Results Available","Autoimmune Neurosensory Hearing Loss (ANSHL)","Drug: Rilonacept","Improvement in hearing in comparison to baseline values|Pt reported evaluation of auditory acuity|Vertigo evaluation|Tinnitus evaluation|Quality of Life assessment","Stanley Cohen|Regeneron Pharmaceuticals|Metroplex Clinical Research","All","18 Years to 75 Years   (Adult, Older Adult)","Early Phase 1","10","Other|Industry","Interventional","Allocation: N/A|Intervention Model: Single Group Assignment|Masking: None (Open Label)|Primary Purpose: Treatment","Rilonacept IIS 1604","February 1, 2017","March 2018","March 2018","July 11, 2016",,"September 13, 2017","Metroplex Clinical Research Center, Dallas, Texas, United States",,"https://ClinicalTrials.gov/show/NCT02828033"
359,"NCT02811692","Study for Collection of Aflibercept Data in Routine Practice","CODEX","Completed","No Results Available","Eye Diseases","Drug: Aflibercept (Eylea, VEGF Trap-Eye, BAY86-5321)","Change in Best Corrected Visual Acuity (BCVA) using Early Treatment Diabetic Retinopathy Study (ETDRS) or converted to ETDRS.|Change in Central retinal thickness (CRT) as measured by Optical Coherence Tomography (OCT).|Number of injections|Interval (days) between injections per disease|Presence of pigment epithelial detachment (PED) (Y/N)|Proportion of patients with no fluid determined by OCT (absence of fluid includes all types of fluid and location of fluid as determined by the treating ophthalmologist)|Type of adjunctive therapies (ie focal laser, steroids etc.)|Change in score of diabetic retinopathy as determined by treating ophthalmologist","Bayer|Regeneron Pharmaceuticals","All","18 Years and older   (Adult, Older Adult)",,"425","Industry","Observational","Observational Model: Other|Time Perspective: Retrospective","17867|DBOX 2014/00498","September 30, 2016","November 27, 2017","November 27, 2017","June 23, 2016",,"July 2, 2019","Multiple Locations, France",,"https://ClinicalTrials.gov/show/NCT02811692"
360,"NCT02776735","An Open-label, Ascending, Repeated Dose-finding Study of Sarilumab in Children and Adolescents With Polyarticular-course Juvenile Idiopathic Arthritis (pcJIA)","SKYPP","Active, not recruiting","No Results Available","Juvenile Idiopathic Arthritis","Drug: Sarilumab","Assessment of PK parameter: maximum serum concentration observed (Cmax)|Assessment of PK parameter: Area under the serum concentration versus time curve calculated using the trapezoidal method during a dose interval (AUC0-t)|Assessment of PK parameter: Concentration observed before treatment administration during repeated dosing (Ctrough)|Number of patients with adverse events|Number of patients with local site reactions|Juvenile Idiopathic Arthritis (JIA ACR) 30/50/70/90/100 response rate|Change from baseline in JIA ACR Component: Physician's global assessment of disease activity|Change from baseline in JIA ACR Component: Patient / parent assessment of overall well-being|Change from baseline in JIA ACR Component: Childhood Health Assessment Questionnaire (CHAQ) - Disability Index|Change from baseline in JIA ACR Component: Number of joints with active arthritis|Change from baseline in JIA ACR Component: Number of joints with limitation of motion|Change from baseline in JIA ACR Component: High sensitivity C-reactive protein (hs-CRP)|Change from baseline in Juvenile Arthritis Disease Activity Score-27 (JADAS)|Change in IL-6 associated biomarkers: IL6|Change in IL-6 associated biomarkers: sIL-6R","Sanofi|Regeneron Pharmaceuticals","All","2 Years to 17 Years   (Child)","Phase 2","100","Industry","Interventional","Allocation: N/A|Intervention Model: Single Group Assignment|Masking: None (Open Label)|Primary Purpose: Treatment","DRI13925|2015-003999-79|U1111-1177-3487","September 6, 2016","April 9, 2022","December 28, 2023","May 18, 2016",,"January 25, 2022","Investigational Site Number :8400416, Los Angeles, California, United States|Investigational Site Number :8400415, Jacksonville, Florida, United States|Investigational Site Number :8400417, New York, New York, United States|Investigational Site Number :8400418, Cincinnati, Ohio, United States|Investigational Site Number :0320060, Caba, Buenos Aires, Argentina|Investigational Site Number :0320004, Tucumán, Argentina|Investigational Site Number :1240110, Calgary, Alberta, Canada|Investigational Site Number :1240112, Montréal, Quebec, Canada|Investigational Site Number :1520016, Concepcion, Biobío, Chile|Investigational Site Number :2030041, Brno, Czechia|Investigational Site Number :2460040, Helsinki, Finland|Investigational Site Number :2500040, Paris, France|Investigational Site Number :2760064, Berlin, Germany|Investigational Site Number :2760061, Bremen, Germany|Investigational Site Number :2760062, Hamburg, Germany|Investigational Site Number :3800051, Genova, Italy|Investigational Site Number :3800053, Milano, Italy|Investigational Site Number :3800052, Roma, Italy|Investigational Site Number :4840060, Monterrey, Nuevo León, Mexico|Investigational Site Number :4840061, Jalisco, Mexico|Investigational Site Number :5280020, Utrecht, Netherlands|Investigational Site Number :6160074, Bydgoszcz, Kujawsko-pomorskie, Poland|Investigational Site Number :6160070, Lublin, Lubuskie, Poland|Investigational Site Number :6160071, Lodz, Lódzkie, Poland|Investigational Site Number :6160073, Krakow, Malopolskie, Poland|Investigational Site Number :6160072, Sosnowiec, Slaskie, Poland|Investigational Site Number :6430001, Moscow, Russian Federation|Investigational Site Number :6430062, Moscow, Russian Federation|Investigational Site Number :6430063, Moscow, Russian Federation|Investigational Site Number :7240050, Esplugues de Llobregat, Castilla Y León, Spain|Investigational Site Number :7240052, Madrid, Madrid, Comunidad De, Spain|Investigational Site Number :7240053, Madrid, Spain|Investigational Site Number :7240051, Valencia, Spain|Investigational Site Number :8260031, London, London, City Of, United Kingdom|Investigational Site Number :8260033, Liverpool, United Kingdom",,"https://ClinicalTrials.gov/show/NCT02776735"
361,"NCT02715726","Evaluation of Alirocumab Versus Ezetimibe on Top of Statin in Asia in High Cardiovascular Risk Patients With Hypercholesterolemia","ODYSSEY EAST","Completed","Has Results","Hypercholesterolemia","Drug: Alirocumab|Drug: Placebo for alirocumab|Drug: ezetimibe|Drug: placebo for ezetimibe|Drug: atorvastatin|Drug: rosuvastatin|Drug: simvastatin","Percent Change From Baseline in Calculated Low Density Lipoprotein Cholesterol at Week 24: Intent-to-treat (ITT) Analysis|Percent Change From Baseline in Calculated Low Density Lipoprotein Cholesterol at Week 24: On-Treatment Analysis|Percent Change From Baseline in Calculated Low Density Lipoprotein Cholesterol at Week 12: ITT Analysis|Percent Change From Baseline in Calculated Low Density Lipoprotein Cholesterol at Week 12: On-Treatment Analysis|Percent Change From Baseline in Apolipoprotein B (Apo B) at Week 24: ITT Analysis|Percent Change From Baseline in Apolipoprotein B at Week 24: On-Treatment Analysis|Percent Change From Baseline in Non-High Density Lipoprotein Cholesterol (Non-HDL-C) at Week 24: ITT Analysis|Percent Change From Baseline in Non-High Density Lipoprotein Cholesterol at Week 24: On-Treatment Analysis|Percent Change From Baseline in Total Cholesterol (Total-C) at Week 24: ITT Analysis|Percent Change From Baseline in Apolipoprotein B at Week 12: ITT Analysis|Percent Change From Baseline in Non-High Density Lipoprotein Cholesterol at Week 12: ITT Analysis|Percent Change From Baseline in Total Cholesterol at Week 12: ITT Analysis|Percentage of Participants Reaching Calculated Low Density Lipoprotein Cholesterol <70 mg/dL (1.81 mmol/L) at Week 24: ITT Analysis|Percentage of Participants Reaching Calculated Low Density Lipoprotein Cholesterol <70 mg/dL (1.81 mmol/L) at Week 24: On-Treatment Analysis|Percent Change From Baseline in Lipoprotein (a) (Lp[a]) at Week 24: ITT Analysis|Percent Change From Baseline in High Density Lipoprotein Cholesterol at Week 24: ITT Analysis|Percent Change From Baseline in Fasting Triglycerides (TG) at Week 24: ITT Analysis|Percent Change From Baseline in Apolipoprotein A-1 (Apo A-1) at Week 24: ITT Analysis|Percent Change From Baseline in Lipoprotein (a) at Week 12: ITT Analysis|Percent Change From Baseline in High Density Lipoprotein Cholesterol at Week 12: ITT Analysis|Percent Change From Baseline in Fasting Triglycerides at Week 12: ITT Analysis|Percent Change From Baseline in Apolipoprotein A-1 at Week 12 : ITT Analysis","Sanofi|Regeneron Pharmaceuticals","All","18 Years and older   (Adult, Older Adult)","Phase 3","615","Industry","Interventional","Allocation: Randomized|Intervention Model: Parallel Assignment|Masking: Quadruple (Participant, Care Provider, Investigator, Outcomes Assessor)|Primary Purpose: Treatment","EFC13889|U1111-1150-8859","July 27, 2016","August 6, 2018","August 6, 2018","March 22, 2016","September 30, 2019","September 30, 2019","Investigational Site Number 1560027, Beijing, China|Investigational Site Number 1560043, Beijing, China|Investigational Site Number 1560039, Beijing, China|Investigational Site Number 1560012, Beijing, China|Investigational Site Number 1560018, Beijing, China|Investigational Site Number 1560006, Changchun, China|Investigational Site Number 1560020, Changchun, China|Investigational Site Number 1560023, Changsha, China|Investigational Site Number 1560030, Fuzhou, China|Investigational Site Number 1560005, Guangzhou, China|Investigational Site Number 1560040, Guangzhou, China|Investigational Site Number 1560025, Guangzhou, China|Investigational Site Number 1560048, Hangzhou, China|Investigational Site Number 1560037, Hangzhou, China|Investigational Site Number 1560008, Hangzhou, China|Investigational Site Number 1560014, Hohhot, China|Investigational Site Number 1560016, Jinan, China|Investigational Site Number 1560044, Lanzhou, China|Investigational Site Number 1560028, Nanchang, China|Investigational Site Number 1560045, Nanjing, China|Investigational Site Number 1560017, Nanjing, China|Investigational Site Number 1560031, Nanjing, China|Investigational Site Number 1560035, Nanning, China|Investigational Site Number 1560029, Shanghai, China|Investigational Site Number 1560041, Shanghai, China|Investigational Site Number 1560053, Shanghai, China|Investigational Site Number 1560009, Shenyang, China|Investigational Site Number 1560001, Shenyang, China|Investigational Site Number 1560042, Shenyang, China|Investigational Site Number 1560036, Shenzhen, China|Investigational Site Number 1560056, Siping, China|Investigational Site Number 1560021, Taiyuan, China|Investigational Site Number 1560002, Tianjin, China|Investigational Site Number 1560022, Tianjin, China|Investigational Site Number 1560052, Tianjin, China|Investigational Site Number 1560055, Wenzhou, China|Investigational Site Number 1560003, Wuhan, China|Investigational Site Number 1560004, Xi'An, China|Investigational Site Number 1560019, Xuzhou, China|Investigational Site Number 1560054, Yinchuan, China|Investigational Site Number 1560057, Zhanjiang, China|Investigational Site Number 3560017, Belgaum, India|Investigational Site Number 3560001, Gurgaon, India|Investigational Site Number 3560003, Hubli, India|Investigational Site Number 3560010, Kolkata, India|Investigational Site Number 3560019, Kolkata, India|Investigational Site Number 3560020, Mangalore, India|Investigational Site Number 3560006, Mumbai, India|Investigational Site Number 3560007, Nagpur, India|Investigational Site Number 3560004, Nagpur, India|Investigational Site Number 3560008, Nagpur, India|Investigational Site Number 3560016, Nagpur, India|Investigational Site Number 3560014, New Delhi, India|Investigational Site Number 3560005, Pune, India|Investigational Site Number 3560011, Pune, India|Investigational Site Number 3560013, Surat, India|Investigational Site Number 3560015, Vijayawada, India|Investigational Site Number 3560012, Vijaywada, India|Investigational Site Number 7640003, Bangkok-Noi, Thailand|Investigational Site Number 7640004, Bangkok, Thailand|Investigational Site Number 7640001, Muang, Thailand|Investigational Site Number 7640002, Pratumwan, Thailand","""Statistical Analysis Plan"", https://ClinicalTrials.gov/ProvidedDocs/26/NCT02715726/SAP_000.pdf|""Study Protocol"", https://ClinicalTrials.gov/ProvidedDocs/26/NCT02715726/Prot_001.pdf","https://ClinicalTrials.gov/show/NCT02715726"
362,"NCT02689518","EAGLE: Evaluating Genotypes Using Intravitreal Aflibercept Injection","EAGLE","Completed","Has Results","Macular Degeneration|Wet Macular Degeneration","Drug: Intravitreal aflibercept injection","Anatomic Response|Visual/Treatment Response","University of California, San Diego|Regeneron Pharmaceuticals","All","50 Years to 90 Years   (Adult, Older Adult)","Phase 4","50","Other|Industry","Interventional","Allocation: N/A|Intervention Model: Single Group Assignment|Masking: None (Open Label)|Primary Purpose: Treatment","EAGLE","April 2014","November 12, 2019","November 12, 2019","February 24, 2016","March 25, 2021","March 25, 2021","Shiley Eye Center, La Jolla, California, United States","""Study Protocol"", https://ClinicalTrials.gov/ProvidedDocs/18/NCT02689518/Prot_000.pdf","https://ClinicalTrials.gov/show/NCT02689518"
363,"NCT02645747","Retrospective Data Analysis of Patients Treated for Macular Edema Due to Central Retinal Vein Occlusion","RETRO CRVO","Completed","No Results Available","Retinal Vein Occlusion","Drug: Aflibercept (Eylea, BAY86-5321)","Treatment duration|Number of eyes treated (mono-and biocular)|Change in visual acuity (BCVA score)|Number of Eylea injections per treated eye|Estimation of percentage (%) of eyes which need additional treatment after 2 years at the discretion of the treating physician.|Sufficiency of reimbursed number of Eylea injections (max. 9 injections/eye in year 1) for treatment of all patients during the first year of treatment.|Number of patients who discontinued their treatment with Eylea prematurely","Bayer|Regeneron Pharmaceuticals","All","18 Years and older   (Adult, Older Adult)",,"126","Industry","Observational","Observational Model: Other|Time Perspective: Retrospective","18586","January 21, 2016","December 23, 2017","December 23, 2017","January 5, 2016",,"September 6, 2018","Multiple Locations, Belgium",,"https://ClinicalTrials.gov/show/NCT02645747"
364,"NCT02642159","Efficacy and Safety of Alirocumab Versus Usual Care on Top of Maximally Tolerated Statin Therapy in Patients With Type 2 Diabetes and Mixed Dyslipidemia (ODYSSEY DM-Dyslipidemia)",,"Completed","Has Results","Dyslipidemia","Drug: Alirocumab|Drug: Statins|Drug: Ezetimibe|Drug: Fenofibrate|Drug: Nicotinic acid|Drug: Omega-3 fatty acids|Drug: Antihyperglycemic Drug","Percent Change From Baseline in Non-HDL-C at Week 24: Overall Intent-to-treat (ITT) Analysis|Percent Change From Baseline in Non-HDL-C at Week 24: ITT- Intent to Prescribe Fenofibrate Stratum|Percent Change From Baseline in Measured Low-Density Lipoprotein Cholesterol (LDL-C) at Week 24: Overall ITT Analysis|Percent Change From Baseline in Measured LDL-C at Week 24: ITT- Intent to Prescribe Fenofibrate Stratum|Percent Change From Baseline in Non-HDL-C at Week 12: Overall ITT Analysis|Percent Change From Baseline in Non-HDL-C at Week 12: ITT- Intent to Prescribe Fenofibrate Stratum|Percent Change From Baseline in Measured LDL-C at Week 12: Overall ITT Analysis|Percent Change From Baseline in Measured LDL-C at Week 12: ITT- Intent to Prescribe Fenofibrate Stratum|Percent Change From Baseline in Apolipoprotein B (Apo-B) at Week 24: Overall ITT Analysis|Percent Change From Baseline in Apo B at Week 24: ITT- Intent to Prescribe Fenofibrate Stratum|Percent Change From Baseline in Total Cholesterol (Total-C) at Week 24 : Overall ITT Analysis|Percent Change From Baseline in Total-C at Week 24: ITT- Intent to Prescribe Fenofibrate Stratum|Percent Change From Baseline in Lipoprotein(a) at Week 24 : Overall ITT Analysis|Percent Change From Baseline in Lipoprotein(a) at Week 24: ITT- Intent to Prescribe Fenofibrate Stratum|Percent Change From Baseline in Fasting Triglycerides at Week 24: Overall ITT Analysis|Percent Change From Baseline in Fasting Triglycerides at Week 24: ITT- Intent to Prescribe Fenofibrate Stratum|Percent Change From Baseline in HDL-C at Week 24 : Overall ITT Analysis|Percent Change From Baseline in HDL-C at Week 24: ITT- Intent to Prescribe Fenofibrate Stratum|Percent Change From Baseline in LDL-C Particle Number at Week 24: Overall ITT Analysis|Percent Change From Baseline in LDL-C Particle Number at Week 24: ITT- Intent to Prescribe Fenofibrate Stratum|Absolute Change From Baseline in Hemoglobin A1c (HbA1c) at Week 12 and 24 : Overall ITT Analysis|Absolute Change From Baseline in Fasting Plasma Glucose (FPG) at Week 12 and 24 : Overall ITT Analysis|Absolute Change From Baseline in Number of Glucose-Lowering Treatments at Week 12 and 24 : Overall ITT Analysis","Sanofi|Regeneron Pharmaceuticals","All","18 Years and older   (Adult, Older Adult)","Phase 4","413","Industry","Interventional","Allocation: Randomized|Intervention Model: Parallel Assignment|Masking: None (Open Label)|Primary Purpose: Treatment","LPS14354|2015-001934-19|U1111-1172-5262","March 15, 2016","March 22, 2017","May 15, 2017","December 30, 2015","May 1, 2018","May 1, 2018","Investigational Site Number 840-163, Little Rock, Arkansas, United States|Investigational Site Number 840-141, Fresno, California, United States|Investigational Site Number 840-152, Huntington Beach, California, United States|Investigational Site Number 840-115, La Jolla, California, United States|Investigational Site Number 840-118, Los Angeles, California, United States|Investigational Site Number 840-106, Northridge, California, United States|Investigational Site Number 840-176, Port Hueneme, California, United States|Investigational Site Number 840-122, Tarzana, California, United States|Investigational Site Number 840-156, Tustin, California, United States|Investigational Site Number 840-160, Van Nuys, California, United States|Investigational Site Number 840-107, Boca Raton, Florida, United States|Investigational Site Number 840-170, Boynton Beach, Florida, United States|Investigational Site Number 840-114, Bradenton, Florida, United States|Investigational Site Number 840-132, Ocoee, Florida, United States|Investigational Site Number 840-179, Oviedo, Florida, United States|Investigational Site Number 840-123, Tampa, Florida, United States|Investigational Site Number 840-137, Bainbridge, Georgia, United States|Investigational Site Number 840-128, Columbus, Georgia, United States|Investigational Site Number 840-169, Stockbridge, Georgia, United States|Investigational Site Number 840-167, Idaho Falls, Idaho, United States|Investigational Site Number 840-161, Chicago, Illinois, United States|Investigational Site Number 840-184, Crystal Lake, Illinois, United States|Investigational Site Number 840-174, Evanston, Illinois, United States|Investigational Site Number 840-138, Springfield, Illinois, United States|Investigational Site Number 840-108, Louisville, Kentucky, United States|Investigational Site Number 840-183, Paducah, Kentucky, United States|Investigational Site Number 840-190, Metairie, Louisiana, United States|Investigational Site Number 840-151, Rockville, Maryland, United States|Investigational Site Number 840-113, Jefferson City, Missouri, United States|Investigational Site Number 840-120, Saint Louis, Missouri, United States|Investigational Site Number 840-148, Omaha, Nebraska, United States|Investigational Site Number 840-101, Las Vegas, Nevada, United States|Investigational Site Number 840-140, Las Vegas, Nevada, United States|Investigational Site Number 840-178, Albany, New York, United States|Investigational Site Number 840-181, New York, New York, United States|Investigational Site Number 840-157, New York, New York, United States|Investigational Site Number 840-188, Greensboro, North Carolina, United States|Investigational Site Number 840-131, Morehead City, North Carolina, United States|Investigational Site Number 840-158, Morganton, North Carolina, United States|Investigational Site Number 840-129, Fargo, North Dakota, United States|Investigational Site Number 840-104, Columbus, Ohio, United States|Investigational Site Number 840-105, Marion, Ohio, United States|Investigational Site Number 840-175, Maumee, Ohio, United States|Investigational Site Number 840-136, Bend, Oregon, United States|Investigational Site Number 840-187, Murrells Inlet, South Carolina, United States|Investigational Site Number 840-111, Summerville, South Carolina, United States|Investigational Site Number 840-147, Chattanooga, Tennessee, United States|Investigational Site Number 840-159, Knoxville, Tennessee, United States|Investigational Site Number 840-153, Dallas, Texas, United States|Investigational Site Number 840-143, Houston, Texas, United States|Investigational Site Number 840-168, Houston, Texas, United States|Investigational Site Number 840-142, Round Rock, Texas, United States|Investigational Site Number 840-133, Tomball, Texas, United States|Investigational Site Number 840-185, Orem, Utah, United States|Investigational Site Number 840-150, Salt Lake City, Utah, United States|Investigational Site Number 840-126, Chesapeake, Virginia, United States|Investigational Site Number 840-171, Richmond, Virginia, United States|Investigational Site Number 036102, Herston, Australia|Investigational Site Number 036104, Merewether, Australia|Investigational Site Number 036101, St Leonards, Australia|Investigational Site Number 076103, Campinas, Brazil|Investigational Site Number 076104, Fortaleza, Brazil|Investigational Site Number 076101, Sao Paulo, Brazil|Investigational Site Number 076105, São paulo, Brazil|Investigational Site Number 076106, São Paulo, Brazil|Investigational Site Number 076102, SãO Paulo, Brazil|Investigational Site Number 246102, Oulu, Finland|Investigational Site Number 246101, Oulu, Finland|Investigational Site Number 246104, Tampere, Finland|Investigational Site Number 276112, Berlin, Germany|Investigational Site Number 276109, Berlin, Germany|Investigational Site Number 276104, Dippoldiswalde, Germany|Investigational Site Number 276101, Dresden, Germany|Investigational Site Number 276110, Essen, Germany|Investigational Site Number 276108, Essen, Germany|Investigational Site Number 276111, Goch, Germany|Investigational Site Number 276107, Karlsruhe, Germany|Investigational Site Number 276103, Künzing, Germany|Investigational Site Number 276102, Oldenburg in Holstein, Germany|Investigational Site Number 376101, Beer Sheva, Israel|Investigational Site Number 376103, Petach Tikva, Israel|Investigational Site Number 376104, Petach tikva, Israel|Investigational Site Number 376102, Rehovot, Israel|Investigational Site Number 376106, Tel-Aviv, Israel|Investigational Site Number 380104, Bergamo, Italy|Investigational Site Number 380107, Catanzaro, Italy|Investigational Site Number 380103, Napoli, Italy|Investigational Site Number 380108, Padova, Italy|Investigational Site Number 380106, Partinico, Italy|Investigational Site Number 380101, Pisa, Italy|Investigational Site Number 380105, Roma, Italy|Investigational Site Number 380102, Torino, Italy|Investigational Site Number 414101, Kuwait, Kuwait|Investigational Site Number 422101, Beirut, Lebanon|Investigational Site Number 422102, Hazmieh, Lebanon|Investigational Site Number 578101, Oslo, Norway|Investigational Site Number 578102, Oslo, Norway|Investigational Site Number 752102, Göteborg, Sweden|Investigational Site Number 752101, Stockholm, Sweden|Investigational Site Number 756101, Genève, Switzerland|Investigational Site Number 756102, Olten, Switzerland|Investigational Site Number 756103, Reinach, Switzerland|Investigational Site Number 792105, Adana, Turkey|Investigational Site Number 792106, Ankara, Turkey|Investigational Site Number 792102, Ankara, Turkey|Investigational Site Number 792108, Corum, Turkey|Investigational Site Number 792109, Hatay, Turkey|Investigational Site Number 792104, Izmir, Turkey|Investigational Site Number 792101, Izmir, Turkey|Investigational Site Number 792110, Izmir, Turkey|Investigational Site Number 792107, Kayseri, Turkey|Investigational Site Number 792103, Samsun, Turkey|Investigational Site Number 784101, Dubai, United Arab Emirates|Investigational Site Number 826104, Exeter, United Kingdom|Investigational Site Number 826106, Manchester, United Kingdom|Investigational Site Number 826105, Middlesborough, United Kingdom|Investigational Site Number 826103, Stevenage, United Kingdom|Investigational Site Number 826101, Torquay, United Kingdom|Investigational Site Number 826102, West Bromwich, United Kingdom","""Study Protocol"", https://ClinicalTrials.gov/ProvidedDocs/59/NCT02642159/Prot_000.pdf|""Statistical Analysis Plan"", https://ClinicalTrials.gov/ProvidedDocs/59/NCT02642159/SAP_001.pdf","https://ClinicalTrials.gov/show/NCT02642159"
365,"NCT02585778","Efficacy and Safety of Alirocumab Versus Placebo on Top of Maximally Tolerated Lipid Lowering Therapy in Patients With Hypercholesterolemia Who Have Type 1 or Type 2 Diabetes and Are Treated With Insulin (ODYSSEY DM - Insulin)",,"Completed","Has Results","Hypercholesterolaemia","Drug: Alirocumab|Drug: Placebo|Drug: Lipid-Modifying Therapy (LMT)|Drug: Antihyperglycemic Drug","Percent Change From Baseline in Calculated LDL-C at Week 24 - Intent-to-treat (ITT) Analysis|Percentage of Participants Who Experienced Treatment-Emergent Adverse Events (AEs)|Percent Change From Baseline in Calculated LDL-C at Week 24 - On-Treatment Analysis|Percent Change From Baseline in Measured LDL-C at Week 24 - ITT Analysis|Percent Change From Baseline in Calculated LDL-C at Week 12 - ITT Analysis|Percent Change From Baseline in Measured LDL-C at Week 12 - ITT Analysis|Percent Change From Baseline in Non-High Density Lipoprotein Cholesterol (Non-HDL-C) at Week 24 - ITT Analysis|Percent Change From Baseline in Apolipoprotein B (Apo-B) at Week 24 - ITT Analysis|Percent Change From Baseline in Total Cholesterol (Total-C) at Week 24 - ITT Analysis|Percentage of Participants Reaching Calculated LDL-C <70 mg/dL (1.81 mmol/L) at Week 24 - On-Treatment Analysis|Percentage of Participants Reaching Calculated LDL-C <50 mg/dL (1.3 mmol/L) at Week 24 - On-Treatment Analysis|Percentage of Participants Reaching Calculated Non-HDL-C <100 mg/dL at Week 24 - On-Treatment Analysis|Percentage of Participants Reaching Calculated Non-HDL-C <80 mg/dL at Week 24 - On-Treatment Analysis|Percent Change From Baseline in Lipoprotein(a) at Week 24 - ITT Analysis|Percent Change From Baseline in HDL-C at Week 24 - ITT Analysis|Percent Change From Baseline in Fasting Triglycerides at Week 24 - ITT Analysis|Percent Change From Baseline in LDL-C Particle Number at Week 24 - ITT Analysis|Percent Change From Baseline in LDL-C Particle Size at Week 24 - ITT Analysis|Absolute Change From Baseline in Glycosylated Hemoglobin (HbA1c) at Weeks 12 and 24 - ITT Analysis|Absolute Change From Baseline in HbA1c at Weeks 12 and 24 - On-Treatment Analysis|Absolute Change From Baseline in Fasting Plasma Glucose (FPG) at Weeks 12 and 24 - ITT Analysis|Absolute Change From Baseline in FPG at Weeks 12 and 24 - On-Treatment Analysis|Absolute Change From Baseline in Total Daily Insulin Dose at Weeks 12 and 24 - ITT Analysis|Absolute Change From Baseline in Total Daily Insulin Dose at Weeks 12 and 24 - On-Treatment Analysis|Absolute Change From Baseline in Insulin Daily Dose/Kg at Weeks 12 and 24 - ITT Analysis|Absolute Change From Baseline in Insulin Daily Dose/Kg at Weeks 12 and 24 - On-Treatment Analysis|Absolute Change From Baseline in Number of Glucose-Lowering Treatments at Weeks 12 and 24 - ITT Analysis|Absolute Change From Baseline in Number of Glucose-Lowering Treatments at Weeks 12 and 24 - On-Treatment Analysis","Sanofi|Regeneron Pharmaceuticals","All","18 Years and older   (Adult, Older Adult)","Phase 3","517","Industry","Interventional","Allocation: Randomized|Intervention Model: Parallel Assignment|Masking: Double (Participant, Investigator)|Primary Purpose: Treatment","LPS14355|2015-000799-92|U1111-1172-4772","October 23, 2015","April 3, 2017","April 3, 2017","October 23, 2015","May 17, 2018","May 17, 2018","Investigational Site Number 840020, Encino, California, United States|Investigational Site Number 840002, Fresno, California, United States|Investigational Site Number 840029, Oakland, California, United States|Investigational Site Number 840027, Loveland, Colorado, United States|Investigational Site Number 840026, Atlantis, Florida, United States|Investigational Site Number 840006, Bradenton, Florida, United States|Investigational Site Number 840023, Jacksonville, Florida, United States|Investigational Site Number 840028, Palm Harbor, Florida, United States|Investigational Site Number 840022, Ponte Vedra Beach, Florida, United States|Investigational Site Number 840021, Roswell, Georgia, United States|Investigational Site Number 840007, Springfield, Illinois, United States|Investigational Site Number 840011, Indianapolis, Indiana, United States|Investigational Site Number 840015, Valparaiso, Indiana, United States|Investigational Site Number 840010, Des Moines, Iowa, United States|Investigational Site Number 840005, Louisville, Kentucky, United States|Investigational Site Number 840018, Auburn, Maine, United States|Investigational Site Number 840013, Hyattsville, Maryland, United States|Investigational Site Number 840016, Rockville, Maryland, United States|Investigational Site Number 840004, Minneapolis, Minnesota, United States|Investigational Site Number 840012, Jamaica, New York, United States|Investigational Site Number 840014, Maumee, Ohio, United States|Investigational Site Number 840009, Greer, South Carolina, United States|Investigational Site Number 840024, Chattanooga, Tennessee, United States|Investigational Site Number 840001, Austin, Texas, United States|Investigational Site Number 840003, Dallas, Texas, United States|Investigational Site Number 840019, Dallas, Texas, United States|Investigational Site Number 840025, Houston, Texas, United States|Investigational Site Number 840017, Ogden, Utah, United States|Investigational Site Number 840008, Salt Lake City, Utah, United States|Investigational Site Number 040002, Innsbruck, Austria|Investigational Site Number 040005, Linz, Austria|Investigational Site Number 040003, Salzburg, Austria|Investigational Site Number 040004, Salzburg, Austria|Investigational Site Number 040001, Wien, Austria|Investigational Site Number 056002, Edegem, Belgium|Investigational Site Number 056003, Haine-Saint-Paul, Belgium|Investigational Site Number 056001, Leuven, Belgium|Investigational Site Number 250-008, Besancon, France|Investigational Site Number 250-005, Corbeil Essonnes, France|Investigational Site Number 250-004, La Rochelle Cedex 1, France|Investigational Site Number 250-003, Le Creusot, France|Investigational Site Number 250-009, Mulhouse, France|Investigational Site Number 250-002, Nantes cedex 01, France|Investigational Site Number 250-007, Paris, France|Investigational Site Number 250-006, Strasbourg Cedex 2, France|Investigational Site Number 250-001, TOULOUSE Cedex 9, France|Investigational Site Number 276015, Aschaffenburg, Germany|Investigational Site Number 276002, Berlin, Germany|Investigational Site Number 276011, Dortmund, Germany|Investigational Site Number 276019, Dresden, Germany|Investigational Site Number 276014, Dresden, Germany|Investigational Site Number 276009, Dresden, Germany|Investigational Site Number 276021, Hamburg, Germany|Investigational Site Number 276018, Hamburg, Germany|Investigational Site Number 276005, Heidelberg, Germany|Investigational Site Number 276013, Lüneburg, Germany|Investigational Site Number 276022, Magdeburg, Germany|Investigational Site Number 276008, Neumünster, Germany|Investigational Site Number 276017, Neuwied, Germany|Investigational Site Number 276004, Oldenburg, Germany|Investigational Site Number 276003, Pirna, Germany|Investigational Site Number 276006, Riesa, Germany|Investigational Site Number 276010, Saarlouis, Germany|Investigational Site Number 276016, Sulzbach-Rosenberg, Germany|Investigational Site Number 380004, Catania, Italy|Investigational Site Number 380003, Catanzaro, Italy|Investigational Site Number 380011, Como, Italy|Investigational Site Number 380006, Milano, Italy|Investigational Site Number 380007, Milano, Italy|Investigational Site Number 380005, Moncalieri, Italy|Investigational Site Number 380009, Napoli, Italy|Investigational Site Number 380008, Padova, Italy|Investigational Site Number 380002, Palermo, Italy|Investigational Site Number 380001, Pisa, Italy|Investigational Site Number 380010, Roma, Italy|Investigational Site Number 380012, Verona, Italy|Investigational Site Number 528002, Apeldoorn, Netherlands|Investigational Site Number 528005, Groningen, Netherlands|Investigational Site Number 528003, Hoogeveen, Netherlands|Investigational Site Number 528001, Rotterdam, Netherlands|Investigational Site Number 528004, Utrecht, Netherlands|Investigational Site Number 724007, Badalona, Spain|Investigational Site Number 724001, Barcelona, Spain|Investigational Site Number 724006, Ferrol, Spain|Investigational Site Number 724013, Granada, Spain|Investigational Site Number 724005, Madrid, Spain|Investigational Site Number 724004, Madrid, Spain|Investigational Site Number 724011, Majadahonda, Spain|Investigational Site Number 724008, Málaga, Spain|Investigational Site Number 724014, Oviedo, Spain|Investigational Site Number 724009, Palma de Mallorca, Spain|Investigational Site Number 724002, Pamplona, Spain|Investigational Site Number 724010, Sant Joan Despí, Spain|Investigational Site Number 724012, Segovia, Spain|Investigational Site Number 724003, Sevilla, Spain|Investigational Site Number 756001, Olten, Switzerland|Investigational Site Number 756003, St. Gallen, Switzerland|Investigational Site Number 826010, Airdrie, United Kingdom|Investigational Site Number 826011, Bath, United Kingdom|Investigational Site Number 826009, Bournemouth, United Kingdom|Investigational Site Number 826005, Bradford, United Kingdom|Investigational Site Number 826004, Bristol, United Kingdom|Investigational Site Number 826001, Burton On Trent, United Kingdom|Investigational Site Number 826015, Durham, United Kingdom|Investigational Site Number 826012, High Wycombe, United Kingdom|Investigational Site Number 826007, Manchester, United Kingdom|Investigational Site Number 826006, Peterborough, United Kingdom|Investigational Site Number 826003, Southampton, United Kingdom|Investigational Site Number 826008, Truro, United Kingdom|Investigational Site Number 826002, Welwyn Garden City, United Kingdom","""Study Protocol"", https://ClinicalTrials.gov/ProvidedDocs/78/NCT02585778/Prot_000.pdf|""Statistical Analysis Plan"", https://ClinicalTrials.gov/ProvidedDocs/78/NCT02585778/SAP_001.pdf","https://ClinicalTrials.gov/show/NCT02585778"
366,"NCT02585401","Evaluation of Physician Knowledge of Safety and Safe Use Information for Aflibercept in Canada",,"Completed","No Results Available","Age-related Macular Degeneration (AMD)|Central Retinal Vein Occlusion (CRVO)|Diabetic Macular Edema (DME)","Drug: Eylea (Aflibercept, VEGF Trap-Eye, BAY86-5321)","Knowledge and understanding of key information contained in the aflibercept educational materials: the Eylea vial preparation instruction card, the intravitreal injection procedure video, and the product monograph|Investigation whether physicians have received the educational materials","Bayer|Regeneron Pharmaceuticals","All","Child, Adult, Older Adult",,"99","Industry","Observational","Observational Model: Other|Time Perspective: Cross-Sectional","18498","February 18, 2016","March 31, 2016","May 19, 2016","October 23, 2015",,"March 21, 2017","Many Locations, Canada",,"https://ClinicalTrials.gov/show/NCT02585401"
367,"NCT02584504","Efficacy and Safety of Alirocumab in Patients With Hypercholesterolemia Not Adequately Controlled With Non-statin Lipid Modifying Therapy or the Lowest Strength of Statin","ODYSSEY-NIPPON","Completed","Has Results","Hypercholesterolemia","Drug: Alirocumab|Drug: Placebo|Drug: Atorvastatin|Drug: Non-statin Lipid-Modifying Therapy|Other: Diet Alone","Percent Change From Baseline in Calculated LDL-C at Week 12- Intent to Treat (ITT) Analysis|Percent Change From Baseline in Calculated LDL-C at Week 12- On-Treatment Analysis|Percent Change From Baseline in Calculated LDL-C to Averaged Week 10 to 12: ITT Analysis|Percent Change From Baseline in Calculated LDL-C to Averaged Week 10 to 12- On-Treatment Analysis|Percent Change From Baseline in Apolipoprotein B (Apo-B) at Week 12: ITT Analysis|Percent Change From Baseline in Apo-B at Week 12- On-Treatment Analysis|Percent Change From Baseline in Non-High Density Lipoprotein Cholesterol (Non-HDL-C) at Week 12: ITT Analysis|Percent Change From Baseline in Non-HDL-C at Week 12- On-treatment Analysis|Percent Change From Baseline in Total Cholesterol (Total-C) at Week 12- ITT Analysis|Percentage of Participants Reaching Calculated LDL-C Goal at Week 12- ITT Analysis|Percentage of Participants Reaching Calculated LDL-C Goal at Week 12- On-Treatment Analysis|Percent Change From Baseline in Lipoprotein (a) at Week 12: ITT Analysis|Percent Change From Baseline in High Density Lipoprotein Cholesterol (HDL-C) at Week 12- ITT Analysis|Percent Change From Baseline in Fasting Triglycerides (TGs) at Week 12: ITT Analysis|Percent Change From Baseline in Apolipoprotein A-1 (Apo A-1) at Week 12: ITT Analysis","Sanofi|Regeneron Pharmaceuticals","All","20 Years and older   (Adult, Older Adult)","Phase 3","163","Industry","Interventional","Allocation: Randomized|Intervention Model: Parallel Assignment|Masking: Quadruple (Participant, Care Provider, Investigator, Outcomes Assessor)|Primary Purpose: Treatment","EFC14305|U1111-1170-7697","November 30, 2015","April 5, 2017","January 9, 2018","October 22, 2015","May 7, 2018","January 23, 2019","Investigational Site Number 392028, Ageo-Shi, Japan|Investigational Site Number 392007, Chuo-Ku, Japan|Investigational Site Number 392029, Chuo-Ku, Japan|Investigational Site Number 392014, Fukui-Shi, Japan|Investigational Site Number 392023, Hachioji-Shi, Japan|Investigational Site Number 392013, Itoshima-Shi, Japan|Investigational Site Number 392010, Kanazawa-Shi, Japan|Investigational Site Number 392024, Kasuga-Shi, Japan|Investigational Site Number 392004, Kawanishi-Shi, Japan|Investigational Site Number 392015, Kitakyushu-Shi, Japan|Investigational Site Number 392005, Komatsu-Shi, Japan|Investigational Site Number 392032, Matsudo-Shi, Japan|Investigational Site Number 392017, Matsumoto-Shi, Japan|Investigational Site Number 392003, Mito-Shi, Japan|Investigational Site Number 392018, Morioka-Shi, Japan|Investigational Site Number 392009, Moriya-Shi, Japan|Investigational Site Number 392006, Nagoya-Shi, Japan|Investigational Site Number 392011, Nagoya-Shi, Japan|Investigational Site Number 392019, Nagoya-Shi, Japan|Investigational Site Number 392025, Nagoya-Shi, Japan|Investigational Site Number 392027, Osaka-Shi, Japan|Investigational Site Number 392030, Sakura-Shi, Japan|Investigational Site Number 392016, Shinagawa-Ku, Japan|Investigational Site Number 392001, Shinjuku-Ku, Japan|Investigational Site Number 392008, Shinjuku-Ku, Japan|Investigational Site Number 392012, Shizuoka-Shi, Japan|Investigational Site Number 392002, Suita-Shi, Japan|Investigational Site Number 392031, Suita-Shi, Japan|Investigational Site Number 392020, Toyonaka-Shi, Japan|Investigational Site Number 392022, Yao-Shi, Japan","""Study Protocol"", https://ClinicalTrials.gov/ProvidedDocs/04/NCT02584504/Prot_000.pdf|""Statistical Analysis Plan"", https://ClinicalTrials.gov/ProvidedDocs/04/NCT02584504/SAP_001.pdf","https://ClinicalTrials.gov/show/NCT02584504"
368,"NCT02581891","Managing Neovascular (Known as ""Wet"") Age-related Macular Degeneration Over 2 Years Using Different Treatment Schedules of 2 mg Intravitreal Aflibercept Injected in the Eye","ARIES","Completed","Has Results","Macular Degeneration","Drug: Eylea (Intravitreal Aflibercept, VEGF Trap-Eye, BAY86-5321)","Change in BCVA as Measured by the ETDRS Letter Score|Percentage of Participants Maintaining Vision (<3 Lines Loss) at Week 104 Compared With Baseline|Change in BCVA From Baseline to Week 52, Baseline to Week 104, and Week 16 to Week 52|Percentage of Participants Maintaining Vision (<3 Lines Loss) at Week 52 Compared With Baseline|Percentage of Participants Gained 3-line at Week 52 and Week 104 Compared With Baseline|Change in Central Retinal Thickness (CRT)|Number of Study Drug Injections From Baseline to Week 52 and Baseline to Week 104|Duration of Last Treatment Interval|Percentage of Participants Requiring Retreatment at 8 Weeks, 10 Weeks, 12 Weeks, 14 Weeks, and 16 Weeks as the Last Treatment Interval","Bayer|Regeneron Pharmaceuticals","All","50 Years and older   (Adult, Older Adult)","Phase 4","287","Industry","Interventional","Allocation: Randomized|Intervention Model: Parallel Assignment|Masking: None (Open Label)|Primary Purpose: Treatment","17508|2014-003132-39","November 19, 2015","April 26, 2019","April 26, 2019","October 21, 2015","May 21, 2020","May 21, 2020","Strathfield, New South Wales, Australia|Sydney, New South Wales, Australia|Westmead, New South Wales, Australia|East Melbourne, Victoria, Australia|Launceston, Australia|Hamilton, Ontario, Canada|Ottawa, Ontario, Canada|Boisbriand, Quebec, Canada|Creteil Cedex, France|Nice cedex 1, France|Freiburg, Baden-Württemberg, Germany|Tübingen, Baden-Württemberg, Germany|Hannover, Niedersachsen, Germany|Bonn, Nordrhein-Westfalen, Germany|Köln, Nordrhein-Westfalen, Germany|Sulzbach, Saarland, Germany|Chemnitz, Sachsen, Germany|Berlin, Germany|Budapest, Hungary|Budapest, Hungary|Budapest, Hungary|Budapest, Hungary|Budapest, Hungary|Budapest, Hungary|Debrecen, Hungary|Pecs, Hungary|Szombathely, Hungary|Roma, Lazio, Italy|Milano, Lombardia, Italy|Milano, Lombardia, Italy|Padova, Veneto, Italy|Oviedo, Asturias, Spain|Madrid, Spain|Zaragoza, Spain|Canterbury, Kent, United Kingdom|Bristol, United Kingdom|Liverpool, United Kingdom|London, United Kingdom|Oxford, United Kingdom","""Study Protocol"", https://ClinicalTrials.gov/ProvidedDocs/91/NCT02581891/Prot_000.pdf|""Statistical Analysis Plan"", https://ClinicalTrials.gov/ProvidedDocs/91/NCT02581891/SAP_001.pdf","https://ClinicalTrials.gov/show/NCT02581891"
369,"NCT02573233","Evaluation of Dupilumab's Effects on Airway Inflammation in Patients With Asthma","EXPEDITION","Completed","Has Results","Asthma","Drug: Placebo|Drug: Dupilumab SAR231893/REGN668|Drug: fluticasone propionate and salmeterol|Drug: budesonide and formoterol|Drug: mometasone furoate and formoterol","Change From Baseline in Eosinophils Cells Count in the Bronchial Submucosa at Week 12|Change From Baseline in Mucin-Stained Area in the Bronchial Submucosa at Week 12|Change From Baseline in Mast Cells Count (Chymase Positive) in the Bronchial Submucosa at Week 12|Change From Baseline in Mast Cells Count (Tryptase Positive) in the Bronchial Submucosa at Week 12|Change From Baseline in T-Lymphocytes Count in the Bronchial Submucosa at Week 12|Change From Baseline in T-Helper Lymphocytes Count in the Bronchial Submucosa at Week 12|Change From Baseline in Fractional Exhaled Nitric Oxide (FeNO) at Week 12|Average Change in Fractional Exhaled Nitric Oxide (FeNO) From Baseline to Week 6 Through Week 12|Number of Participants With Antidrug Antibodies (ADA)|Pharmacokinetics (PK) Assessment: Serum Functional Dupilumab Concentration|Number of Participants With Treatment Emergent Adverse Events (TEAEs)","Sanofi|Regeneron Pharmaceuticals","All","18 Years to 65 Years   (Adult, Older Adult)","Phase 2","42","Industry","Interventional","Allocation: Randomized|Intervention Model: Parallel Assignment|Masking: Double|Primary Purpose: Treatment","PDY14192|2015-001572-22|U1111-1170-7168","January 27, 2016","January 3, 2018","January 3, 2018","October 9, 2015","January 28, 2019","January 28, 2019","Investigational Site Number 840402, Tucson, Arizona, United States|Investigational Site Number 840403, Denver, Colorado, United States|Investigational Site Number 840401, Boston, Massachusetts, United States|Investigational Site Number 840002, Saint Louis, Missouri, United States|Investigational Site Number 840404, Winston-Salem, North Carolina, United States|Investigational Site Number 840028, Pittsburgh, Pennsylvania, United States|Investigational Site Number 124012, Montreal, Canada|Investigational Site Number 124018, Sainte Foy, Canada|Investigational Site Number 208002, Hvidovre, Denmark|Investigational Site Number 208001, København Nv, Denmark|Investigational Site Number 276013, Frankfurt Am Main, Germany|Investigational Site Number 276011, Großhansdorf, Germany|Investigational Site Number 276012, Hannover, Germany|Investigational Site Number 752001, Lund, Sweden|Investigational Site Number 826010, London, United Kingdom|Investigational Site Number 826009, Oxford, United Kingdom","""Study Protocol"", https://ClinicalTrials.gov/ProvidedDocs/33/NCT02573233/Prot_000.pdf|""Statistical Analysis Plan"", https://ClinicalTrials.gov/ProvidedDocs/33/NCT02573233/SAP_001.pdf","https://ClinicalTrials.gov/show/NCT02573233"
370,"NCT02559180","Treatment of Diabetic Macular Edema With Aflibercept in Subjects Previously Treated With Ranibizumab or Bevacizumab","SwapTwo","Completed","No Results Available","Diabetic Retinopathy|Macular Edema","Drug: aflibercept","Safety and Efficacy|Central Foveal Thickness|Visual Acuity-mean change","Rishi Singh|Regeneron Pharmaceuticals|The Cleveland Clinic","All","18 Years and older   (Adult, Older Adult)","Phase 4","20","Other|Industry","Interventional","Allocation: N/A|Intervention Model: Single Group Assignment|Masking: None (Open Label)|Primary Purpose: Treatment","SwapTwo Study","October 2015","December 2020","December 2020","September 24, 2015",,"January 26, 2021","Cole Eye Institute, Cleveland Clinic, Cleveland, Ohio, United States",,"https://ClinicalTrials.gov/show/NCT02559180"
371,"NCT02541084","Caregiver Burden of Wet Age-related Macular Degeneration (wAMD) in Japan",,"Completed","No Results Available","Wet Macular Degeneration","Drug: Aflibercept (Eylea, VEGF Trap-Eye, BAY86-5321)","Degree of caregiving burden on caregivers (BIC-11)|Relationship between BIC-11 and the number of hospital visits for wAMD treatments|Frequency of hospital visits|Time spent by accompanying caregivers for a clinic visit for wAMD management (minutes)|Estimated costs spent by accompanying caregivers on hospital visits for wAMD management|Level of depression among caregivers (CES-D)|Types of treatments for wAMD|Frequency of treatments|Length of treatment|Dosing schedule|Percentage of patients accompanied by primary caregivers","Bayer|Regeneron Pharmaceuticals","All","Child, Adult, Older Adult",,"72","Industry","Observational","Observational Model: Cohort|Time Perspective: Prospective","17945","August 18, 2015","March 30, 2016","July 30, 2016","September 4, 2015",,"August 22, 2017","Many Locations, Japan",,"https://ClinicalTrials.gov/show/NCT02541084"
372,"NCT02540369","To Describe the Use of Intravitreal Aflibercept and to Describe Follow-up as Well as Treatment Patterns in Patients With Wet Age-related Macular Degeneration (wAMD) or Diabetic Macular Edema (DME) in Routine Clinical Practice in Canada.","PEGASUS","Completed","No Results Available","Wet Macular Degeneration","Drug: Aflibercept (Eylea, VEGF Trap-Eye, BAY86-5321)","Mean change of visual acuity.|Change of visual acuity.|Change of visual acuity by number of Injections.|Change in Retinal thickness.|Treatment patterns used in routine clinical practice setting.|Maximum interval between treatments.|Mean time between injections.|Number of injections at 12 months.|Time to achieve stability of disease.|Number of injections in a year to achieve stability of disease.|In previously treated subpopulation duration of previous treatments|In previously treated subpopulation type of previous treatments.|In previously treated subpopulation reason to switch to Eylea.|Proportion of patients with no fluid determined by Optical coherence tomography (OCT).|Numbers of patients require adjunctive therapies.|Type of adjunctive therapies required by patients|Number of participants with adverse events as a measure of safety and tolerability.|Presence of pigment epithelial detachment (PED) (Y/N)|Diabetic retinopathy severity (mild, moderate, severe).","Bayer|Regeneron Pharmaceuticals","All","18 Years and older   (Adult, Older Adult)",,"2150","Industry","Observational","Observational Model: Cohort|Time Perspective: Prospective","17995","December 14, 2015","September 25, 2017","January 26, 2018","September 3, 2015",,"February 15, 2019","Multiple Locations, Canada",,"https://ClinicalTrials.gov/show/NCT02540369"
373,"NCT02528214","Evaluation of Dupilumab in Patients With Severe Steroid Dependent Asthma","VENTURE","Completed","Has Results","Asthma","Drug: Dupilumab|Drug: Placebo|Drug: Oral corticosteroid therapy (prednisone/prednisolone)|Drug: Inhaled corticosteroid (ICS) therapy|Drug: Albuterol/Salbutamol|Drug: Levalbuterol/Levosalbutamol","Percentage Reduction From Baseline in Oral Corticosteroids (OCS) Dose at Week 24 While Maintaining Asthma Control|Supplementary Presentation of Primary Outcome Measure Data: Median Percentage Reduction From Baseline in Oral Corticosteroids Dose at Week 24 While Maintaining Asthma Control|Percentage of Participants Achieving >= 50% Reduction in Oral Corticosteroids Dose at Week 24 While Maintaining Asthma Control|Percentage of Participants Achieving a Reduction in Oral Corticosteroids Dose to <5 mg/Day at Week 24 While Maintaining Asthma Control|Percentage of Participants Achieving Maximum Possible Reduction in Oral Corticosteroids Dose Per Protocol at Week 24 While Maintaining Asthma Control|Percentage of Participants Who No Longer Required Oral Corticosteroids Dose at Week 24 While Maintaining Asthma Control|Absolute Reduction From Baseline in Oral Corticosteroids Dose at Week 24 While Maintaining Asthma Control","Sanofi|Regeneron Pharmaceuticals","All","12 Years and older   (Child, Adult, Older Adult)","Phase 3","210","Industry","Interventional","Allocation: Randomized|Intervention Model: Parallel Assignment|Masking: Triple (Participant, Care Provider, Investigator)|Primary Purpose: Treatment","EFC13691|2015-001573-40|U1111-1170-7152","October 15, 2015","September 20, 2017","November 13, 2017","August 19, 2015","October 23, 2018","October 1, 2019","Investigational Site Number 840022, Los Angeles, California, United States|Investigational Site Number 840014, Rolling Hills Estates, California, United States|Investigational Site Number 840002, Saint Louis, Missouri, United States|Investigational Site Number 840010, Pittsburgh, Pennsylvania, United States|Investigational Site Number 840062, Amarillo, Texas, United States|Investigational Site Number 840070, McKinney, Texas, United States|Investigational Site Number 840128, McKinney, Texas, United States|Investigational Site Number 840118, Plano, Texas, United States|Investigational Site Number 032003, Buenos Aires, Argentina|Investigational Site Number 032001, Caba, Argentina|Investigational Site Number 032091, Caba, Argentina|Investigational Site Number 056002, Brussels, Belgium|Investigational Site Number 056003, Gent, Belgium|Investigational Site Number 056001, Leuven, Belgium|Investigational Site Number 076011, Sao Paulo, Brazil|Investigational Site Number 076002, Sorocaba, Brazil|Investigational Site Number 076013, São Bernardo Do Campo, Brazil|Investigational Site Number 124009, Calgary, Canada|Investigational Site Number 124016, Hamilton, Canada|Investigational Site Number 124003, Mississauga, Canada|Investigational Site Number 124013, Ottawa, Canada|Investigational Site Number 124002, Toronto, Canada|Investigational Site Number 124017, Vancouver, Canada|Investigational Site Number 152007, Quillota, Chile|Investigational Site Number 152005, Santiago, Chile|Investigational Site Number 152008, Talca, Chile|Investigational Site Number 170001, Bogota, Colombia|Investigational Site Number 170006, Bogota, Colombia|Investigational Site Number 348301, Balassagyarmat, Hungary|Investigational Site Number 348303, Edelény, Hungary|Investigational Site Number 376003, Haifa, Israel|Investigational Site Number 376001, Kfar Saba, Israel|Investigational Site Number 376005, Petah-Tikva, Israel|Investigational Site Number 376002, Rehovot, Israel|Investigational Site Number 376004, Tel Hashomer, Israel|Investigational Site Number 380005, Catania, Italy|Investigational Site Number 380002, Genova, Italy|Investigational Site Number 380008, Napoli, Italy|Investigational Site Number 380009, Palermo, Italy|Investigational Site Number 380001, Pisa, Italy|Investigational Site Number 380003, Reggio Emilia, Italy|Investigational Site Number 484016, Acapulco, Mexico|Investigational Site Number 484013, Chihuahua, Mexico|Investigational Site Number 484001, Guadalajara, Mexico|Investigational Site Number 484002, Mexico, Df, Mexico|Investigational Site Number 484003, Monterrey, Mexico|Investigational Site Number 528001, Arnhem, Netherlands|Investigational Site Number 528002, Dordrecht, Netherlands|Investigational Site Number 616006, Bialystok, Poland|Investigational Site Number 616097, Krakow, Poland|Investigational Site Number 616001, Lodz, Poland|Investigational Site Number 616010, Warszawa, Poland|Investigational Site Number 616011, Znin, Poland|Investigational Site Number 642104, Bucharest, Romania|Investigational Site Number 642103, Bucharest, Romania|Investigational Site Number 642102, Cluj-Napoca, Romania|Investigational Site Number 642107, Cluj-Napoca, Romania|Investigational Site Number 642108, Cluj-Napoca, Romania|Investigational Site Number 642105, Timisoara, Romania|Investigational Site Number 642106, Timisoara, Romania|Investigational Site Number 643006, Moscow, Russian Federation|Investigational Site Number 643007, Moscow, Russian Federation|Investigational Site Number 643011, Saint-Petersburg, Russian Federation|Investigational Site Number 643099, St-Petersburg, Russian Federation|Investigational Site Number 643009, St-Petersburg, Russian Federation|Investigational Site Number 724014, Barcelona, Spain|Investigational Site Number 724002, Barcelona, Spain|Investigational Site Number 724013, Madrid, Spain|Investigational Site Number 724006, Pozuelo De Alarcón, Spain|Investigational Site Number 724007, Sant Boi De Llobregat, Spain|Investigational Site Number 724096, Santiago De Compostela, Spain|Investigational Site Number 804007, Chernivtsi, Ukraine|Investigational Site Number 804004, Ivano-Frankivsk, Ukraine|Investigational Site Number 804009, Ivano-Frankivsk, Ukraine|Investigational Site Number 804001, Kharkiv, Ukraine|Investigational Site Number 804003, Kyiv, Ukraine|Investigational Site Number 804011, Kyiv, Ukraine|Investigational Site Number 804006, Odessa, Ukraine|Investigational Site Number 804002, Poltava, Ukraine|Investigational Site Number 804019, Vinnytsya, Ukraine","""Study Protocol"", https://ClinicalTrials.gov/ProvidedDocs/14/NCT02528214/Prot_000.pdf|""Statistical Analysis Plan"", https://ClinicalTrials.gov/ProvidedDocs/14/NCT02528214/SAP_001.pdf","https://ClinicalTrials.gov/show/NCT02528214"
374,"NCT02503540","Peripheral and Macular Retinal Vascular Perfusion and Leakage in DME and RVO","PERMEATE","Completed","Has Results","Retinal Vein Occlusion|Diabetic Macular Edema|Branch Retinal Vein Occlusion|Central Retinal Vein Occlusion","Drug: Aflibercept","Change in Panretinal Leakage Index at Month 12 From Baseline|Mean Change in Total Leakage Index|Change in Panretinal Ischemic Index|Change in Panretinal Ischemic Index From Baseline at 6 Months|Mean Change From Baseline Central Subfield Thickness|Mean Change From Baseline in Best-corrected Visual Acuity (BCVA) Score Based on ETDRS|Number of Participants Who Gained 15 ETDRS Letters or More of Vision|Number of Patients Who Gained 15 ETDRS Letters or More of Vision|Number of Patients That Showed Visual Acuity 20/40 or Better|Number of Patients That Showed Visual Acuity 20/200 or Worse|Ocular Serious Adverse Events|Number of Participants Who Lost 15 ETDRS Letters or More of Vision|Systemic Serious Adverse Events","Justis Ehlers|Regeneron Pharmaceuticals|The Cleveland Clinic","All","18 Years and older   (Adult, Older Adult)","Phase 4","31","Other|Industry","Interventional","Allocation: N/A|Intervention Model: Single Group Assignment|Masking: None (Open Label)|Primary Purpose: Treatment","15-442","August 18, 2015","February 6, 2018","February 6, 2018","July 21, 2015","February 12, 2020","May 12, 2021","Cole Eye Institute, Cleveland Clinic, Cleveland, Ohio, United States","""Study Protocol and Statistical Analysis Plan"", https://ClinicalTrials.gov/ProvidedDocs/40/NCT02503540/Prot_SAP_000.pdf","https://ClinicalTrials.gov/show/NCT02503540"
375,"NCT02476006","Safety, Tolerability, and Effect of Alirocumab in High Cardiovascular Risk Patients With Severe Hypercholesterolemia Not Adequately Controlled With Conventional Lipid-modifying Therapies (ODYSSEY APPRISE)",,"Completed","Has Results","Hypercholesterolemia","Drug: ALIROCUMAB SAR236553 (REGN727)|Drug: placebo (for injection training only)|Drug: ezetimibe|Drug: atorvastatin|Drug: rosuvastatin|Drug: simvastatin","Percentage of Participants With Treatment Emergent Adverse Events (TEAEs)|Percent Change From Baseline in Calculated Low Density Lipoprotein Cholesterol (LDL-C) at Week 12|Percentage of Participants Reaching Calculated LDL-C <100 mg/dL (2.59 mmol/L) at Week 12|Percentage of Participants Reaching Calculated LDL-C <70 mg/dL (1.81 mmol/L) at Week 12|Percentage of Participants Reaching Calculated LDL-C <70 mg/dL (1.81 mmol/L) and/or >=50% Reduction From Baseline in LDL-C at Week 12|Percent Change From Baseline in Non-High Density Lipoprotein Cholesterol (Non-HDL-C) at Week 12|Percent Change From Baseline in Total Cholesterol (Total-C) at Week 12|Percent Change From Baseline in High Density Lipoprotein Cholesterol at Week 12|Percent Change From Baseline in Triglycerides at Week 12|Assessment of Participant's Acceptability of Self-Injection Using Self Injection Assessment Questionnaire (SIAQ): Feeling About Injections, Self Confidence, Satisfaction With Self-Injections|Assessment of Participant's Acceptability of Self-Injection Using Self Injection Assessment Questionnaire (SIAQ): Self Image, Injection-Site Reactions, Ease of Use","Sanofi|Regeneron Pharmaceuticals","All","18 Years and older   (Adult, Older Adult)","Phase 3","998","Industry","Interventional","Allocation: N/A|Intervention Model: Single Group Assignment|Masking: None (Open Label)|Primary Purpose: Treatment","LPS14245|2015-000620-28|U1111-1163-0984","June 23, 2015","April 12, 2019","April 12, 2019","June 19, 2015","March 30, 2020","March 30, 2020","Investigational Site Number 040001, Graz, Austria|Investigational Site Number 040008, Innsbruck, Austria|Investigational Site Number 040005, Linz, Austria|Investigational Site Number 040006, Linz, Austria|Investigational Site Number 040003, Wien, Austria|Investigational Site Number 040002, Wien, Austria|Investigational Site Number 040004, Wien, Austria|Investigational Site Number 040007, Wien, Austria|Investigational Site Number 040010, Wien, Austria|Investigational Site Number 056005, Aalst, Belgium|Investigational Site Number 056018, Antwerpen, Belgium|Investigational Site Number 056008, Arlon, Belgium|Investigational Site Number 056013, Brugge, Belgium|Investigational Site Number 056010, Brussel, Belgium|Investigational Site Number 056003, Bruxelles, Belgium|Investigational Site Number 056006, Charleroi, Belgium|Investigational Site Number 056007, Edegem, Belgium|Investigational Site Number 056019, Genk, Belgium|Investigational Site Number 056001, Gent, Belgium|Investigational Site Number 056017, Gent, Belgium|Investigational Site Number 056002, Haine St Paul, Belgium|Investigational Site Number 056015, Kortrijk, Belgium|Investigational Site Number 056009, La Louvière, Belgium|Investigational Site Number 056004, Leuven, Belgium|Investigational Site Number 056014, Liège, Belgium|Investigational Site Number 056011, Overpelt, Belgium|Investigational Site Number 056016, Roeselare, Belgium|Investigational Site Number 124018, Calgary, Canada|Investigational Site Number 124015, Cambridge, Canada|Investigational Site Number 124002, Chicoutimi, Canada|Investigational Site Number 124027, Coquitlam, Canada|Investigational Site Number 124025, Edmonton, Canada|Investigational Site Number 124017, Halifax, Canada|Investigational Site Number 124013, Hamilton, Canada|Investigational Site Number 124008, London, Canada|Investigational Site Number 124026, Maple Ridge, Canada|Investigational Site Number 124020, Montreal, Canada|Investigational Site Number 124022, Montreal, Canada|Investigational Site Number 124032, Mount Pearl, Canada|Investigational Site Number 124005, Ottawa, Canada|Investigational Site Number 124024, Peterborough, Canada|Investigational Site Number 124003, Quebec, Canada|Investigational Site Number 124007, Sarnia, Canada|Investigational Site Number 124001, Sherbrooke, Canada|Investigational Site Number 124030, Smiths Falls, Canada|Investigational Site Number 124019, St-Charles Borromee, Canada|Investigational Site Number 124023, Toronto, Canada|Investigational Site Number 124014, Toronto, Canada|Investigational Site Number 124028, Trois-Rivieres, Canada|Investigational Site Number 124011, Vancouver, Canada|Investigational Site Number 124012, Victoria, Canada|Investigational Site Number 124031, Winnipeg, Canada|Investigational Site Number 124009, Woodstock, Canada|Investigational Site Number 203004, Brno, Czechia|Investigational Site Number 203002, Hradec Kralove, Czechia|Investigational Site Number 203001, Praha, Czechia|Investigational Site Number 203005, Uherske Hradiste, Czechia|Investigational Site Number 208001, Esbjerg, Denmark|Investigational Site Number 208002, Roskilde, Denmark|Investigational Site Number 208003, Ålborg, Denmark|Investigational Site Number 246003, Turku, Finland|Investigational Site Number 246001, Varkaus, Finland|Investigational Site Number 250027, Amiens Cedex 1, France|Investigational Site Number 250034, Auxerre, France|Investigational Site Number 250016, Avignon, France|Investigational Site Number 250021, Bayonne, France|Investigational Site Number 250030, Bobigny, France|Investigational Site Number 250045, BORDEAUX Cedex, France|Investigational Site Number 250049, Brest Cedex, France|Investigational Site Number 250054, Bron, France|Investigational Site Number 250015, Caen, France|Investigational Site Number 250047, Clermont Ferrand, France|Investigational Site Number 250013, Corbeil Essonnes, France|Investigational Site Number 250032, Coudray, France|Investigational Site Number 250002, Dijon, France|Investigational Site Number 250040, Dijon, France|Investigational Site Number 250038, GRENOBLE cedex, France|Investigational Site Number 250012, Grenoble, France|Investigational Site Number 250033, Jossigny, France|Investigational Site Number 250035, LE CHESNAY Cedex, France|Investigational Site Number 250036, Lens, France|Investigational Site Number 250042, Lille, France|Investigational Site Number 250004, Lille, France|Investigational Site Number 250037, Limoges Cedex, France|Investigational Site Number 250057, Lyon, France|Investigational Site Number 250048, Marseille Cedex 05, France|Investigational Site Number 250028, Marseille, France|Investigational Site Number 250024, Montpellier, France|Investigational Site Number 250006, Nantes cedex 01, France|Investigational Site Number 250022, Nantes, France|Investigational Site Number 250017, Nice cedex 1, France|Investigational Site Number 250039, NIMES Cedex 9, France|Investigational Site Number 250044, PARIS Cedex 04, France|Investigational Site Number 250001, Paris Cedex 10, France|Investigational Site Number 250014, Paris, France|Investigational Site Number 250041, Paris, France|Investigational Site Number 250026, Paris, France|Investigational Site Number 250051, Pessac, France|Investigational Site Number 250011, POITIERS Cedex, France|Investigational Site Number 250031, Poitiers, France|Investigational Site Number 250010, Reims Cedex, France|Investigational Site Number 250008, Rennes, France|Investigational Site Number 250018, Rouen, France|Investigational Site Number 250023, Saint-Mandé, France|Investigational Site Number 250046, Toulouse Cedex 3, France|Investigational Site Number 250025, TOULOUSE Cedex 9, France|Investigational Site Number 250007, Tours, France|Investigational Site Number 250019, Venissieux, France|Investigational Site Number 250050, VICHY Cedex, France|Investigational Site Number 276001, Berlin, Germany|Investigational Site Number 276003, Magdeburg, Germany|Investigational Site Number 300003, Ampelokipoi, Greece|Investigational Site Number 300002, Ioannina, Greece|Investigational Site Number 300001, Kallithea, Greece|Investigational Site Number 348001, Budapest, Hungary|Investigational Site Number 348002, Debrecen, Hungary|Investigational Site Number 348004, Pécs, Hungary|Investigational Site Number 348003, Szeged, Hungary|Investigational Site Number 616005, Gdansk, Poland|Investigational Site Number 616003, Krakow, Poland|Investigational Site Number 616001, Lodz, Poland|Investigational Site Number 616004, Olsztyn, Poland|Investigational Site Number 616002, Warszawa, Poland|Investigational Site Number 642-003, Bucuresti, Romania|Investigational Site Number 642-002, Iasi, Romania|Investigational Site Number 642-001, Timisoara, Romania|Investigational Site Number 703003, Bratislava, Slovakia|Investigational Site Number 703002, Bratislava, Slovakia|Investigational Site Number 703001, Kosice, Slovakia|Investigational Site Number 705001, Maribor, Slovenia|Investigational Site Number 724009, Alicante, Spain|Investigational Site Number 724011, Alicante, Spain|Investigational Site Number 724003, Córdoba, Spain|Investigational Site Number 724012, Donostia, Spain|Investigational Site Number 724014, Donostia, Spain|Investigational Site Number 724019, Elche, Spain|Investigational Site Number 724017, Galdakao, Spain|Investigational Site Number 724001, Hospitalet de Llobregat, Spain|Investigational Site Number 724020, Inca, Spain|Investigational Site Number 724007, Las Palmas de Gran Canaria, Spain|Investigational Site Number 724004, Madrid, Spain|Investigational Site Number 724008, Madrid, Spain|Investigational Site Number 724010, Madrid, Spain|Investigational Site Number 724005, Málaga, Spain|Investigational Site Number 724002, Santiago de Compostela, Spain|Investigational Site Number 724006, Valencia, Spain|Investigational Site Number 724016, Valencia, Spain|Investigational Site Number 724015, Valladolid, Spain|Investigational Site Number 756005, Baden, Switzerland|Investigational Site Number 756002, Olten, Switzerland|Investigational Site Number 756004, Reinach, Switzerland|Investigational Site Number 756003, St. Gallen, Switzerland|Investigational Site Number 756001, Zürich, Switzerland","""Statistical Analysis Plan"", https://ClinicalTrials.gov/ProvidedDocs/06/NCT02476006/SAP_000.pdf|""Study Protocol"", https://ClinicalTrials.gov/ProvidedDocs/06/NCT02476006/Prot_001.pdf","https://ClinicalTrials.gov/show/NCT02476006"
376,"NCT02462889","IAI Versus Sham as Prophylaxis Against Conversion to Neovascular AMD","PRO-CON","Unknown status","No Results Available","Age-Related Macular Degeneration","Drug: Intravitreal aflibercept injection|Drug: Placebo","Proportion of subjects converting to neovascular AMD at 24 months, characterized by the development of choroidal neovascularization (CNV).|Mean change in visual acuity at 24 months compared to baseline|Percentage of subjects losing less than 15 ETDRS letters at 24 months compared to baseline|Incidence and severity of potential ocular side effects including endophthamitis, retinal detachment, cataract, and intraocular inflammation|Incidence and severity of systemic side effects","Jeffrey S Heier|Regeneron Pharmaceuticals|Ophthalmic Consultants of Boston","All","Child, Adult, Older Adult","Phase 2","128","Other|Industry","Interventional","Allocation: Randomized|Intervention Model: Parallel Assignment|Masking: Single (Participant)|Primary Purpose: Prevention","VGFTe-AMD-1507","June 2015","December 2018","December 2018","June 4, 2015",,"March 31, 2016","Retina-Vitreous Associates Medical Group, Beverly Hills, California, United States|Ophthalmic Consultants of Boston, Boston, Massachusetts, United States|NJ Retina, Edison, New Jersey, United States|Retina Consultants of Houston, Houston, Texas, United States",,"https://ClinicalTrials.gov/show/NCT02462889"
377,"NCT02425501","Special Drug Use Investigation of EYLEA for Diabetic Macular Edema",,"Completed","No Results Available","Choroidal Neovascularization","Drug: Aflibercept (Eylea, BAY86-5321)","Number of participants of Adverse Events|Number of participants of Serious Adverse Events|Mean change in visual acuity from baseline to 12 months|Mean change in retina thickness from baseline to 12 months","Bayer|Regeneron Pharmaceuticals","All","Child, Adult, Older Adult",,"662","Industry","Observational","Observational Model: Cohort|Time Perspective: Prospective","17544|EY1510JP","January 20, 2015","April 26, 2019","August 13, 2019","April 24, 2015",,"September 13, 2019","Multiple Locations, Japan",,"https://ClinicalTrials.gov/show/NCT02425501"
378,"NCT02414854","Evaluation of Dupilumab in Patients With Persistent Asthma (Liberty Asthma Quest)",,"Completed","Has Results","Asthma","Drug: Dupilumab|Drug: Placebo|Drug: Inhaled corticosteroid (ICS) therapy|Drug: Albuterol/Salbutamol|Drug: Levalbuterol/Levosalbutamol","Annualized Rate of Severe Exacerbation Events During The 52-Week Treatment Period: Intent-to-Treat (ITT) Population|Absolute Change From Baseline in Pre-Bronchodilator Forced Expiratory Volume in 1 Second (FEV1) at Week 12: ITT Population|Percent Change From Baseline in Pre-Bronchodilator FEV1 at Week 12: ITT Population|Annualized Rate of Severe Exacerbation Events During The 52-Week Treatment Period: ITT Population With Baseline Eosinophil >=0.15 Giga/L|Absolute Change From Baseline in Pre-Bronchodilator FEV1 at Week 12: ITT Population With Baseline Eosinophil >=0.15 Giga/L|Annualized Rate of Severe Exacerbation Events During The 52-Week Treatment Period: ITT Population With Baseline Eosinophil >=0.3 Giga/L|Absolute Change From Baseline in Pre-Bronchodilator FEV1 at Week 12: ITT Population With Baseline Eosinophil >=0.3 Giga/L|Annualized Rate of Severe Exacerbation Events During The 52-Week Treatment Period: ITT Population With Baseline Eosinophil <0.3 Giga/L|Annualized Rate of Severe Exacerbation Events During The 52-Week Treatment Period: ITT Population With High Dose ICS at Baseline|Absolute Change From Baseline in Pre-Bronchodilator FEV1 at Week 12: ITT Population With High Dose ICS at Baseline|Change From Baseline in Asthma Quality of Life Questionnaire With Standardized Activities (AQLQ [S]) Self-Administered Global Score at Week 24: ITT Population|Change From Baseline in AQLQ (S) Self- Administered Global Score at Week 24: ITT Population With Baseline Eosinophil >=0.3 Giga/L|Change From Baseline in Asthma Control Questionnaire 5-item Version (ACQ-5) Score at Week 24: ITT Population|Annualized Rate of Severe Exacerbation Events Resulting in Hospitalization or Emergency Room Visit During The 52-Week Treatment Period: ITT Population|Absolute Change From Baseline in Pre-Bronchodilator FEV1 at Week 12: ITT Population With Baseline Eosinophil <0.3 Giga/L|Percent Change From Baseline in Pre-Bronchodilator FEV1 at Week 12: ITT Population With Baseline Eosinophil >=0.3 Giga/L|Percent Change From Baseline in Pre-Bronchodilator FEV1 at Week 12: ITT Population With High Dose ICS at Baseline|Percent Change From Baseline in Pre-Bronchodilator FEV1 at Week 12: ITT Population With Baseline Eosinophil >=0.15 Giga/L|Absolute Change From Baseline in Pre-Bronchodilator FEV1 at Weeks 2, 4, 8, 24, 36, and 52: ITT Population|Percent Change From Baseline in Pre-Bronchodilator FEV1 at Weeks 2, 4, 8, 24, 36, and 52: ITT Population|Change From Baseline in Percent Predicted FEV1 at Weeks 2, 4, 8, 12, 24, 36, and 52: ITT Population|Change From Baseline in Morning (AM)/Evening (PM) Peak Expiratory Flow (PEF) at Weeks 2, 4, 8, 12, 24, 36, and 52: ITT Population|Change From Baseline in Forced Vital Capacity (FVC) at Weeks 2, 4, 8, 12, 24, 36, and 52: ITT Population|Change From Baseline in Forced Expiratory Flow (FEF) 25-75% at Weeks 2, 4, 8, 12, 24, 36, and 52: ITT Population|Change From Baseline in Post-Bronchodilator FEV1 at Weeks 2, 4, 8, 12, 24, 36, and 52: ITT Population|Annualized Rate of Loss of Asthma Control (LOAC) Event During The 52-Week Treatment Period: ITT Population|Time to First Severe Exacerbation Event: Kaplan-Meier Estimates During The 52-Week Treatment Period: ITT Population|Time to First LOAC Event: Kaplan-Meier Estimates During The 52-Week Treatment Period: ITT Population|Change From Baseline in ACQ-5 Score at Weeks 2, 4, 8, 12, 36, and 52: ITT Population|Change From Baseline in Asthma Control Questionnaire 7-item Version (ACQ-7) Score at Weeks 2, 4, 8, 12, 24, 36, and 52: ITT Population|Change From Baseline in Morning Asthma Symptom Score at Weeks 2, 4, 8, 12, 24, 36, and 52: ITT Population|Change From Baseline in Evening Asthma Symptom Score at Weeks 2, 4, 8, 12, 24, 36, and 52: ITT Population|Change From Baseline in Number of Nocturnal Awakenings Per Night at Weeks 2, 4, 8, 12, 24, 36, and 52: ITT Population|Change From Baseline in Number of Puffs of Daily Reliever Medication Used Per 24 Hours at Weeks 2, 4, 8, 12, 24, 36, and 52: ITT Population|Change From Baseline in AQLQ (S) Self-Administered Global Score at Weeks 12, 36, and 52: ITT Population|Change From Baseline in European Quality of Life Working Group Health Status Measure 5 Dimensions, 5 Levels (EQ-5D-5L) Scores at Weeks 12, 24, 36, and 52: ITT Population|Change From Baseline in Hospital Anxiety and Depression Scale (HADS) Total Score at Weeks 12, 24, 36, and 52: ITT Population|Change From Baseline in 22-Item Sino Nasal Outcome Test (SNOT-22) Score at Weeks 12, 24, 36, and 52: ITT Population With Bilateral Nasal Polyposis/Chronic Rhinosinusitis|Change From Baseline in Standardized Rhinoconjunctivitis Quality Of Life Questionnaire, Ages 12+ (RQLQ[S]+12) Score at Weeks 12, 24, 36, and 52: ITT Population With Comorbid Allergic Rhinitis","Sanofi|Regeneron Pharmaceuticals","All","12 Years and older   (Child, Adult, Older Adult)","Phase 3","1902","Industry","Interventional","Allocation: Randomized|Intervention Model: Parallel Assignment|Masking: Triple (Participant, Care Provider, Investigator)|Primary Purpose: Treatment","EFC13579|2014-004940-36|U1111-1163-1293","April 27, 2015","July 29, 2017","November 23, 2017","April 13, 2015","October 23, 2018","October 23, 2018","Investigational Site Number 840047, Birmingham, Alabama, United States|Investigational Site Number 840056, Flagstaff, Arizona, United States|Investigational Site Number 840099, Gilbert, Arizona, United States|Investigational Site Number 840087, Scottsdale, Arizona, United States|Investigational Site Number 840132, Little Rock, Arkansas, United States|Investigational Site Number 840109, Bakersfield, California, United States|Investigational Site Number 840052, Costa Mesa, California, United States|Investigational Site Number 840116, Fresno, California, United States|Investigational Site Number 840045, Long Beach, California, United States|Investigational Site Number 840011, Los Angeles, California, United States|Investigational Site Number 840061, Los Angeles, California, United States|Investigational Site Number 840097, Los Angeles, California, United States|Investigational Site Number 840019, Mission Viejo, California, United States|Investigational Site Number 840125, Newport Beach, California, United States|Investigational Site Number 840041, North Hollywood, California, United States|Investigational Site Number 840036, Redwood City, California, United States|Investigational Site Number 840020, Rolling Hills Estates, California, United States|Investigational Site Number 840074, Roseville, California, United States|Investigational Site Number 840021, San Jose, California, United States|Investigational Site Number 840004, Centennial, Colorado, United States|Investigational Site Number 840025, Colorado Springs, Colorado, United States|Investigational Site Number 840034, Denver, Colorado, United States|Investigational Site Number 840130, Denver, Colorado, United States|Investigational Site Number 840102, New Haven, Connecticut, United States|Investigational Site Number 840037, Aventura, Florida, United States|Investigational Site Number 840018, Boynton Beach, Florida, United States|Investigational Site Number 840105, Brandon, Florida, United States|Investigational Site Number 840092, Clearwater, Florida, United States|Investigational Site Number 840122, Hialeah, Florida, United States|Investigational Site Number 840053, Loxahatchee Groves, Florida, United States|Investigational Site Number 840069, Miami, Florida, United States|Investigational Site Number 840123, Ocala, Florida, United States|Investigational Site Number 840071, Ocala, Florida, United States|Investigational Site Number 840115, Ocoee, Florida, United States|Investigational Site Number 840055, Sarasota, Florida, United States|Investigational Site Number 840114, South Miami, Florida, United States|Investigational Site Number 840048, Tampa, Florida, United States|Investigational Site Number 840084, Gainesville, Georgia, United States|Investigational Site Number 840044, Savannah, Georgia, United States|Investigational Site Number 840079, Twin Falls, Idaho, United States|Investigational Site Number 840101, Chicago, Illinois, United States|Investigational Site Number 840015, River Forest, Illinois, United States|Investigational Site Number 840089, Iowa City, Iowa, United States|Investigational Site Number 840032, Fort Mitchell, Kentucky, United States|Investigational Site Number 840009, Owensboro, Kentucky, United States|Investigational Site Number 840064, Bangor, Maine, United States|Investigational Site Number 840080, Baltimore, Maryland, United States|Investigational Site Number 840017, Chevy Chase, Maryland, United States|Investigational Site Number 840073, Gaithersburg, Maryland, United States|Investigational Site Number 840127, White Marsh, Maryland, United States|Investigational Site Number 840014, North Dartmouth, Massachusetts, United States|Investigational Site Number 840005, Minneapolis, Minnesota, United States|Investigational Site Number 840013, Kansas City, Missouri, United States|Investigational Site Number 840002, Saint Louis, Missouri, United States|Investigational Site Number 840093, Saint Louis, Missouri, United States|Investigational Site Number 840026, Missoula, Montana, United States|Investigational Site Number 840078, Omaha, Nebraska, United States|Investigational Site Number 840003, Papillion, Nebraska, United States|Investigational Site Number 840111, Brick, New Jersey, United States|Investigational Site Number 840068, Ocean City, New Jersey, United States|Investigational Site Number 840016, Princeton, New Jersey, United States|Investigational Site Number 840096, Toms River, New Jersey, United States|Investigational Site Number 840031, Bronx, New York, United States|Investigational Site Number 840106, Jamaica, New York, United States|Investigational Site Number 840065, New York, New York, United States|Investigational Site Number 840076, Rochester, New York, United States|Investigational Site Number 840126, Charlotte, North Carolina, United States|Investigational Site Number 840083, Charlotte, North Carolina, United States|Investigational Site Number 840108, Durham, North Carolina, United States|Investigational Site Number 840107, Greensboro, North Carolina, United States|Investigational Site Number 840007, High Point, North Carolina, United States|Investigational Site Number 840046, Cincinnati, Ohio, United States|Investigational Site Number 840049, Middleburg Heights, Ohio, United States|Investigational Site Number 840042, Toledo, Ohio, United States|Investigational Site Number 840112, Edmond, Oklahoma, United States|Investigational Site Number 840121, Oklahoma City, Oklahoma, United States|Investigational Site Number 840104, Tulsa, Oklahoma, United States|Investigational Site Number 840040, Clackamas, Oregon, United States|Investigational Site Number 840039, Medford, Oregon, United States|Investigational Site Number 840001, Portland, Oregon, United States|Investigational Site Number 840085, Hershey, Pennsylvania, United States|Investigational Site Number 840081, Philadelphia, Pennsylvania, United States|Investigational Site Number 840010, Philadelphia, Pennsylvania, United States|Investigational Site Number 840067, Philadelphia, Pennsylvania, United States|Investigational Site Number 840028, Pittsburgh, Pennsylvania, United States|Investigational Site Number 840091, Pittsburgh, Pennsylvania, United States|Investigational Site Number 840029, Lincoln, Rhode Island, United States|Investigational Site Number 840082, Charleston, South Carolina, United States|Investigational Site Number 840117, Greenville, South Carolina, United States|Investigational Site Number 840100, Greer, South Carolina, United States|Investigational Site Number 840054, Spartanburg, South Carolina, United States|Investigational Site Number 840062, Amarillo, Texas, United States|Investigational Site Number 840098, Austin, Texas, United States|Investigational Site Number 840038, Boerne, Texas, United States|Investigational Site Number 840124, Cypress, Texas, United States|Investigational Site Number 840008, Dallas, Texas, United States|Investigational Site Number 840094, Dallas, Texas, United States|Investigational Site Number 840023, El Paso, Texas, United States|Investigational Site Number 840022, Fort Worth, Texas, United States|Investigational Site Number 840027, Fort Worth, Texas, United States|Investigational Site Number 840066, Killeen, Texas, United States|Investigational Site Number 840050, Live Oak, Texas, United States|Investigational Site Number 840070, McKinney, Texas, United States|Investigational Site Number 840128, McKinney, Texas, United States|Investigational Site Number 840118, Plano, Texas, United States|Investigational Site Number 840012, San Antonio, Texas, United States|Investigational Site Number 840129, San Antonio, Texas, United States|Investigational Site Number 840133, Sealy, Texas, United States|Investigational Site Number 840119, Spring, Texas, United States|Investigational Site Number 840035, Draper, Utah, United States|Investigational Site Number 840077, Murray, Utah, United States|Investigational Site Number 840057, South Burlington, Vermont, United States|Investigational Site Number 840059, Fairfax, Virginia, United States|Investigational Site Number 840113, Richmond, Virginia, United States|Investigational Site Number 840051, Bellevue, Washington, United States|Investigational Site Number 840043, Spokane, Washington, United States|Investigational Site Number 032006, Bahia Blanca, Argentina|Investigational Site Number 032002, Buenos Aires, Argentina|Investigational Site Number 032011, Caba, Argentina|Investigational Site Number 032007, Caba, Argentina|Investigational Site Number 032001, Caba, Argentina|Investigational Site Number 032003, Caba, Argentina|Investigational Site Number 032010, Caba, Argentina|Investigational Site Number 032005, Capital Federal, Argentina|Investigational Site Number 032008, La Plata, Argentina|Investigational Site Number 032004, Rosario, Argentina|Investigational Site Number 032012, San Miguel De Tucuman, Argentina|Investigational Site Number 032009, San Miguel De Tucumán, Argentina|Investigational Site Number 036005, Campbelltown, Australia|Investigational Site Number 036001, Clayton, Australia|Investigational Site Number 036002, Frankston, Australia|Investigational Site Number 036006, Glen Osmond, Australia|Investigational Site Number 036003, Murdoch, Australia|Investigational Site Number 036004, Parkville, Australia|Investigational Site Number 076009, Florianópolis, Brazil|Investigational Site Number 076007, Porto Alegre, Brazil|Investigational Site Number 076001, Porto Alegre, Brazil|Investigational Site Number 076003, Salvador, Brazil|Investigational Site Number 076012, Sao Paulo, Brazil|Investigational Site Number 076008, Sao Paulo, Brazil|Investigational Site Number 076006, Sao Paulo, Brazil|Investigational Site Number 076002, Sorocaba, Brazil|Investigational Site Number 076013, São Bernardo Do Campo, Brazil|Investigational Site Number 124019, Burlington, Canada|Investigational Site Number 124009, Calgary, Canada|Investigational Site Number 124003, Mississauga, Canada|Investigational Site Number 124001, Montreal, Canada|Investigational Site Number 124012, Montreal, Canada|Investigational Site Number 124010, Montreal, Canada|Investigational Site Number 124013, Ottawa, Canada|Investigational Site Number 124018, Quebec, Canada|Investigational Site Number 124014, Quebec, Canada|Investigational Site Number 124008, Sherbrooke, Canada|Investigational Site Number 124015, Toronto, Canada|Investigational Site Number 124002, Toronto, Canada|Investigational Site Number 124007, Trois-Rivieres, Canada|Investigational Site Number 124006, Vancouver, Canada|Investigational Site Number 152015, Concepción, Chile|Investigational Site Number 152003, Quillota, Chile|Investigational Site Number 152014, Santiago, Chile|Investigational Site Number 152001, Santiago, Chile|Investigational Site Number 152002, Santiago, Chile|Investigational Site Number 152008, Santiago, Chile|Investigational Site Number 152017, Santiago, Chile|Investigational Site Number 152007, Santiago, Chile|Investigational Site Number 152005, Santiago, Chile|Investigational Site Number 152009, Santiago, Chile|Investigational Site Number 152013, Talcahuano, Chile|Investigational Site Number 152004, Talca, Chile|Investigational Site Number 152016, Temuco, Chile|Investigational Site Number 152010, Valdivia, Chile|Investigational Site Number 152011, Viña Del Mar, Chile|Investigational Site Number 152012, Viña Del Mar, Chile|Investigational Site Number 170006, Bogota, Colombia|Investigational Site Number 170001, Bogota, Colombia|Investigational Site Number 170002, Bogotá, Colombia|Investigational Site Number 170003, Bogotá, Colombia|Investigational Site Number 250002, Brest, France|Investigational Site Number 250011, Lille Cedex, France|Investigational Site Number 250013, Lille, France|Investigational Site Number 250004, Lyon, France|Investigational Site Number 250010, Marseille, France|Investigational Site Number 250005, Montpellier, France|Investigational Site Number 250003, Nantes Cedex 1, France|Investigational Site Number 250012, Paris, France|Investigational Site Number 250001, Paris, France|Investigational Site Number 250008, Strasbourg, France|Investigational Site Number 250014, Vandoeuvre-Les-Nancy, France|Investigational Site Number 276006, Berlin, Germany|Investigational Site Number 276003, Bochum, Germany|Investigational Site Number 276010, Frankfurt Am Main, Germany|Investigational Site Number 276004, Hannover, Germany|Investigational Site Number 276009, Koblenz, Germany|Investigational Site Number 276007, Lübeck, Germany|Investigational Site Number 276001, Mainz, Germany|Investigational Site Number 276005, Rüdersdorf, Germany|Investigational Site Number 348003, Gödöllö, Hungary|Investigational Site Number 380004, Ancona, Italy|Investigational Site Number 380005, Catania, Italy|Investigational Site Number 380003, Ferrara, Italy|Investigational Site Number 380006, Firenze, Italy|Investigational Site Number 380010, Foggia, Italy|Investigational Site Number 380002, Modena, Italy|Investigational Site Number 380009, Palermo, Italy|Investigational Site Number 380001, Pisa, Italy|Investigational Site Number 380014, Reggio Emilia, Italy|Investigational Site Number 380011, Torino, Italy|Investigational Site Number 392185, Akashi-Shi, Japan|Investigational Site Number 392128, Asahikawa-Shi, Japan|Investigational Site Number 392118, Chiyoda-Ku, Japan|Investigational Site Number 392112, Chuo-Ku, Japan|Investigational Site Number 392157, Fukui-Shi, Japan|Investigational Site Number 392137, Fukuoka-Shi, Japan|Investigational Site Number 392117, Fukuyama-Shi, Japan|Investigational Site Number 392121, Habikino-Shi, Japan|Investigational Site Number 392154, Higashiosaka-Shi, Japan|Investigational Site Number 392109, Himeji-Shi, Japan|Investigational Site Number 392108, Hiroshima-Shi, Japan|Investigational Site Number 392158, Hiroshima-Shi, Japan|Investigational Site Number 392107, Iizuka-Shi, Japan|Investigational Site Number 392101, Isesaki-Shi, Japan|Investigational Site Number 392147, Itabashi-Ku, Japan|Investigational Site Number 392150, Kagoshima-Shi, Japan|Investigational Site Number 392178, Kagoshima-Shi, Japan|Investigational Site Number 392110, Kanazawa-Shi, Japan|Investigational Site Number 392136, Kanazawa-Shi, Japan|Investigational Site Number 392142, Kasuga-Shi, Japan|Investigational Site Number 392166, Kawaguchi-Shi, Japan|Investigational Site Number 392119, Kishiwada-Shi, Japan|Investigational Site Number 392162, Kobe-Shi, Japan|Investigational Site Number 392182, Kodaira-Shi, Japan|Investigational Site Number 392174, Kokubunji-Shi, Japan|Investigational Site Number 392131, Koshi-Shi, Japan|Investigational Site Number 392183, Koshigaya-Shi, Japan|Investigational Site Number 392129, Kurashiki-Shi, Japan|Investigational Site Number 392153, Kyoto-Shi, Japan|Investigational Site Number 392176, Kyoto-Shi, Japan|Investigational Site Number 392184, Kyoto-Shi, Japan|Investigational Site Number 392133, Machida-Shi, Japan|Investigational Site Number 392135, Matsuyama-Shi, Japan|Investigational Site Number 392172, Mibu, Japan|Investigational Site Number 392114, Minato-Ku, Japan|Investigational Site Number 392122, Minato-Ku, Japan|Investigational Site Number 392144, Minato-Ku, Japan|Investigational Site Number 392106, Mizunami-Shi, Japan|Investigational Site Number 392164, Muroran-Shi, Japan|Investigational Site Number 392161, Nagakute-Shi, Japan|Investigational Site Number 392163, Nagoya-Shi, Japan|Investigational Site Number 392102, Naka-Gun, Japan|Investigational Site Number 392125, Nakano-Ku, Japan|Investigational Site Number 392115, Naruto-Shi, Japan|Investigational Site Number 392187, Obihiro-Shi, Japan|Investigational Site Number 392177, Ome-Shi, Japan|Investigational Site Number 392152, Osaka Sayama-Shi, Japan|Investigational Site Number 392155, Osaka Sayama-Shi, Japan|Investigational Site Number 392170, Osaki-Shi, Japan|Investigational Site Number 392120, Ota-Ku, Japan|Investigational Site Number 392127, Ota-Ku, Japan|Investigational Site Number 392138, Ota-Shi, Japan|Investigational Site Number 392123, Oura-Gun, Japan|Investigational Site Number 392169, Sagamihara-Shi, Japan|Investigational Site Number 392149, Sapporo-Shi, Japan|Investigational Site Number 392179, Seto-Shi, Japan|Investigational Site Number 392186, Shibuya-Ku, Japan|Investigational Site Number 392139, Shinagawa-Ku, Japan|Investigational Site Number 392167, Shinagawa-Ku, Japan|Investigational Site Number 392130, Shinjuku-Ku, Japan|Investigational Site Number 392165, Sumida-Ku, Japan|Investigational Site Number 392146, Tachikawa-Shi, Japan|Investigational Site Number 392173, Tachikawa-Shi, Japan|Investigational Site Number 392103, Tokyo, Japan|Investigational Site Number 392113, Tomakomai-Shi, Japan|Investigational Site Number 392151, Tsu-Shi, Japan|Investigational Site Number 392168, Uozu-Shi, Japan|Investigational Site Number 392132, Urasoe-Shi, Japan|Investigational Site Number 392134, Uruma-Shi, Japan|Investigational Site Number 392116, Wakayama-Shi, Japan|Investigational Site Number 392140, Yokohama-Shi, Japan|Investigational Site Number 392159, Yonago-Shi, Japan|Investigational Site Number 410002, Bucheon-Si, Korea, Republic of|Investigational Site Number 410015, Busan, Korea, Republic of|Investigational Site Number 410003, Cheongju-Si, Korea, Republic of|Investigational Site Number 410013, Incheon, Korea, Republic of|Investigational Site Number 410008, Seoul, Korea, Republic of|Investigational Site Number 410006, Seoul, Korea, Republic of|Investigational Site Number 410004, Seoul, Korea, Republic of|Investigational Site Number 410012, Seoul, Korea, Republic of|Investigational Site Number 410005, Seoul, Korea, Republic of|Investigational Site Number 410007, Seoul, Korea, Republic of|Investigational Site Number 410009, Seoul, Korea, Republic of|Investigational Site Number 410010, Seoul, Korea, Republic of|Investigational Site Number 410011, Seoul, Korea, Republic of|Investigational Site Number 410001, Suwon, Korea, Republic of|Investigational Site Number 410014, Uijeongbu-Si, Korea, Republic of|Investigational Site Number 484013, Chihuahua, Mexico|Investigational Site Number 484006, Chihuahua, Mexico|Investigational Site Number 484014, Cuautitlan Izcalli, Mexico|Investigational Site Number 484008, Durango, Mexico|Investigational Site Number 484001, Guadalajara, Mexico|Investigational Site Number 484004, Mexico City, Mexico|Investigational Site Number 484003, Monterrey, Mexico|Investigational Site Number 484007, Monterrey, Mexico|Investigational Site Number 484010, México, Mexico|Investigational Site Number 484012, San Juan Del Rio, Mexico|Investigational Site Number 484011, Veracruz, Mexico|Investigational Site Number 484015, Zapopan, Mexico|Investigational Site Number 616006, Bialystok, Poland|Investigational Site Number 616003, Gdansk, Poland|Investigational Site Number 616007, Krakow, Poland|Investigational Site Number 616001, Lodz, Poland|Investigational Site Number 616005, Lodz, Poland|Investigational Site Number 616009, Lodz, Poland|Investigational Site Number 616002, Poznan, Poland|Investigational Site Number 616004, Sopot, Poland|Investigational Site Number 616008, Strzelce Opolskie, Poland|Investigational Site Number 643013, Ekaterinburg, Russian Federation|Investigational Site Number 643006, Moscow, Russian Federation|Investigational Site Number 643003, Moscow, Russian Federation|Investigational Site Number 643005, Moscow, Russian Federation|Investigational Site Number 643002, Moscow, Russian Federation|Investigational Site Number 643004, Moscow, Russian Federation|Investigational Site Number 643001, Moscow, Russian Federation|Investigational Site Number 643011, Ryazan, Russian Federation|Investigational Site Number 643008, Saint-Petersburg, Russian Federation|Investigational Site Number 643009, Saint-Petersburg, Russian Federation|Investigational Site Number 643007, St-Petersburg, Russian Federation|Investigational Site Number 643010, St-Petersburg, Russian Federation|Investigational Site Number 643012, Yaroslavl, Russian Federation|Investigational Site Number 710009, Brandfort, South Africa|Investigational Site Number 710011, Cape Town, South Africa|Investigational Site Number 710004, Cape Town, South Africa|Investigational Site Number 710001, Cape Town, South Africa|Investigational Site Number 710002, Cape Town, South Africa|Investigational Site Number 710010, Cape Town, South Africa|Investigational Site Number 710003, Cape Town, South Africa|Investigational Site Number 710005, Durban, South Africa|Investigational Site Number 710006, Durban, South Africa|Investigational Site Number 710007, Pretoria, South Africa|Investigational Site Number 724002, Barcelona, Spain|Investigational Site Number 724001, Barcelona, Spain|Investigational Site Number 724010, Palma De Mallorca, Spain|Investigational Site Number 724005, Pozuelo De Alarcón, Spain|Investigational Site Number 724004, Sant Boi De Llobregat, Spain|Investigational Site Number 724006, Santiago De Compostela, Spain|Investigational Site Number 724008, Sevilla, Spain|Investigational Site Number 724007, Valencia, Spain|Investigational Site Number 158004, Kaohsiung, Taiwan|Investigational Site Number 158002, Kaohsiung, Taiwan|Investigational Site Number 158008, New Taipei City, Taiwan|Investigational Site Number 158005, Taichung, Taiwan|Investigational Site Number 158007, Taichung, Taiwan|Investigational Site Number 158001, Taipei, Taiwan|Investigational Site Number 158009, Taipei, Taiwan|Investigational Site Number 158006, Taoyuan, Taiwan|Investigational Site Number 792004, Ankara, Turkey|Investigational Site Number 792008, Ankara, Turkey|Investigational Site Number 792003, Bursa, Turkey|Investigational Site Number 792001, Istanbul, Turkey|Investigational Site Number 792007, Istanbul, Turkey|Investigational Site Number 792005, Izmir, Turkey|Investigational Site Number 792010, Izmir, Turkey|Investigational Site Number 792009, Kirikkale, Turkey|Investigational Site Number 792011, Kocaeli, Turkey|Investigational Site Number 792002, Mersin, Turkey|Investigational Site Number 792006, Rize, Turkey|Investigational Site Number 804007, Chernivtsi, Ukraine|Investigational Site Number 804023, Dnipro, Ukraine|Investigational Site Number 804004, Ivano-Frankivsk, Ukraine|Investigational Site Number 804009, Ivano-Frankivsk, Ukraine|Investigational Site Number 804005, Kharkiv, Ukraine|Investigational Site Number 804021, Kharkiv, Ukraine|Investigational Site Number 804001, Kharkiv, Ukraine|Investigational Site Number 804003, Kyiv, Ukraine|Investigational Site Number 804008, Kyiv, Ukraine|Investigational Site Number 804011, Kyiv, Ukraine|Investigational Site Number 804013, Kyiv, Ukraine|Investigational Site Number 804017, Kyiv, Ukraine|Investigational Site Number 804016, Kyiv, Ukraine|Investigational Site Number 804006, Odessa, Ukraine|Investigational Site Number 804002, Poltava, Ukraine|Investigational Site Number 804014, Ternopil, Ukraine|Investigational Site Number 804012, Vinnytsya, Ukraine|Investigational Site Number 804022, Zaporizhia, Ukraine|Investigational Site Number 826001, Bradford, United Kingdom|Investigational Site Number 826002, London, United Kingdom|Investigational Site Number 826005, Newcastle Upon Tyne, United Kingdom|Investigational Site Number 826007, Portsmouth, United Kingdom|Investigational Site Number 826006, South Shields, United Kingdom|Investigational Site Number 826003, Sutton-In-Ashfield, United Kingdom","""Study Protocol"", https://ClinicalTrials.gov/ProvidedDocs/54/NCT02414854/Prot_000.pdf|""Statistical Analysis Plan"", https://ClinicalTrials.gov/ProvidedDocs/54/NCT02414854/SAP_001.pdf","https://ClinicalTrials.gov/show/NCT02414854"
379,"NCT02404558","Single-dose Study to Describe the Safety of Sarilumab and Tocilizumab in Patients With Rheumatoid Arthritis",,"Completed","No Results Available","Rheumatoid Arthritis","Drug: sarilumab SAR153191 (REGN88)|Drug: tocilizumab","Percentage of patients with adverse events|Percentage of patients with potentially clinically significant laboratory abnormalities|Change from baseline in laboratory parameters (hematology and biochemistry)|Weighted average of change from baseline in laboratory parameters (hematology and biochemistry)|Assessment of PK parameter: maximum concentration (Cmax)|Assessment of PK parameter: time to Cmax (tmax)|Assessment of PK parameter: area under the curve from zero time until the last measurable concentration (AUClast)","Sanofi|Regeneron Pharmaceuticals","All","20 Years and older   (Adult, Older Adult)","Phase 1","30","Industry","Interventional","Allocation: Randomized|Intervention Model: Parallel Assignment|Masking: None (Open Label)|Primary Purpose: Treatment","PDY14191|U1111-1163-1359","May 2015","March 2016","March 2016","March 31, 2015",,"March 28, 2016","Investigational Site Number 392001, Sendai-Shi, Japan|Investigational Site Number 392002, Sendai-Shi, Japan|Investigational Site Number 392003, Sendai-Shi, Japan",,"https://ClinicalTrials.gov/show/NCT02404558"
380,"NCT02396316","Japanese Phase 3 Study of Aflibercept in Neovascular Glaucoma Patients","VEGA","Completed","Has Results","Glaucoma, Neovascular","Drug: Aflibercept (Eylea, BAY 86-5321)|Drug: Sham Injection","Change in Intraocular Pressure (IOP) From Baseline to Pre-dose at Week 1|Percentage of Subjects Who Had Improved Neovascularization of the Iris (NVI) Grade From Baseline to Pre-dose at Week 1","Bayer|Regeneron Pharmaceuticals","All","20 Years and older   (Adult, Older Adult)","Phase 3","54","Industry","Interventional","Allocation: Randomized|Intervention Model: Parallel Assignment|Masking: Triple (Participant, Investigator, Outcomes Assessor)|Primary Purpose: Treatment","17584","April 2, 2015","June 16, 2016","September 6, 2016","March 24, 2015","July 21, 2017","September 15, 2017","Yoshida, Fukui, Japan|Amagasaki, Hyogo, Japan|Himeji, Hyogo, Japan|Kobe, Hyogo, Japan|Kanazawa, Ishikawa, Japan|Kawasaki, Kanagawa, Japan|Sendai, Miyagi, Japan|Yufu, Oita, Japan|Hirakata, Osaka, Japan|Suita, Osaka, Japan|Takatsuki, Osaka, Japan|Izumo, Shimane, Japan|Bunkyo-ku, Tokyo, Japan|Mitaka, Tokyo, Japan|Ube, Yamaguchi, Japan|Chuo, Yamanashi, Japan|Gifu, Japan|Kyoto, Japan|Osaka, Japan",,"https://ClinicalTrials.gov/show/NCT02396316"
381,"NCT02392364","Variable Interval Versus Set Interval Aflibercept for DME","EVADE","Completed","No Results Available","Cystoid Macular Edema|Diabetic Macular Edema","Drug: Intravitreal Aflibercept Injection","BCVA Change","California Retina Consultants|Regeneron Pharmaceuticals","All","18 Years and older   (Adult, Older Adult)","Phase 4","50","Other|Industry","Interventional","Allocation: Randomized|Intervention Model: Single Group Assignment|Masking: None (Open Label)|Primary Purpose: Treatment","2014-01-CRC","April 15, 2015","November 15, 2018","November 15, 2018","March 19, 2015",,"January 3, 2019","California Retina Consultants - Bakersfield, Bakersfield, California, United States|California Retina Consultants - Santa Barbara Office, Santa Barbara, California, United States",,"https://ClinicalTrials.gov/show/NCT02392364"
382,"NCT02373202","A Study Assessing the Safety and Efficacy of Sarilumab Added to Non-MTX DMARDs or as Monotherapy in Japanese Patients With Active Rheumatoid Arthritis (SARIL-RA-HARUKA)",,"Completed","Has Results","Rheumatoid Arthritis","Drug: Sarilumab|Drug: Sulfasalazine|Drug: Leflunomide|Drug: Bucillamine|Drug: Tacrolimus|Drug: Mizoribine","Number of Participants With Treatment-Emergent Adverse Events (TEAEs) and Serious Adverse Events (SAEs)|Number of Participants With Potentially Clinically Significant Vital Signs Abnormalities|Number of Participants With Potentially Clinically Significant Electrocardiogram (ECG) Abnormalities|Number of Participants With Potentially Clinically Significant Laboratory Abnormalities: Hematological Parameters|Number of Participants With Potentially Clinically Significant Laboratory Abnormalities: Metabolic Parameters|Number of Participants With Potentially Clinically Significant Laboratory Abnormalities: Electrolytes|Number of Participants With Potentially Clinically Significant Laboratory Abnormalities: Renal Function Parameters|Number of Participants With Potentially Clinically Significant Laboratory Abnormalities: Liver Function Parameters|Percentage of Participants Achieving American College of Rheumatology (ACR) 20, 50 and 70 Responses at Week 52|Change From Baseline at Week 52 in Disease Activity Score for 28 Joints Based on C-Reactive Protein (DAS28-CRP)|Change From Baseline in Health Assessment Questionnaire-Disability Index (HAQ-DI) Score at Week 52","Sanofi|Regeneron Pharmaceuticals","All","20 Years and older   (Adult, Older Adult)","Phase 3","91","Industry","Interventional","Allocation: Randomized|Intervention Model: Parallel Assignment|Masking: Quadruple (Participant, Care Provider, Investigator, Outcomes Assessor)|Primary Purpose: Treatment","LTS13618|U1111-1160-6525","February 2015","November 2016","November 2016","February 26, 2015","January 30, 2018","January 30, 2018","Investigational Site Number 392010, Asahi-Shi, Japan|Investigational Site Number 392001, Asahikawa-Shi, Japan|Investigational Site Number 392070, Beppu-Shi, Japan|Investigational Site Number 392036, Chiba-Shi, Japan|Investigational Site Number 392083, Chuo-Ku, Japan|Investigational Site Number 392004, Fukui-Shi, Japan|Investigational Site Number 392039, Fukuoka-Shi, Japan|Investigational Site Number 392030, Ichinomiya-Shi, Japan|Investigational Site Number 392002, Iizuka-Shi, Japan|Investigational Site Number 392019, Kagoshima-Shi, Japan|Investigational Site Number 392066, Kamakura-Shi, Japan|Investigational Site Number 392050, Kato-Shi, Japan|Investigational Site Number 392037, Kawachi-Nagano-Shi, Japan|Investigational Site Number 392099, Kawasaki-Shi, Japan|Investigational Site Number 392013, Kitakyushu-Shi, Japan|Investigational Site Number 392097, Kochi-Shi, Japan|Investigational Site Number 392065, Kushiro-Shi, Japan|Investigational Site Number 392026, Matsuyama-Shi, Japan|Investigational Site Number 392034, Miyagi-Gun, Japan|Investigational Site Number 392076, Nagoya-Shi, Japan|Investigational Site Number 392080, Nagoya-Shi, Japan|Investigational Site Number 392046, Narashino-Shi, Japan|Investigational Site Number 392059, Oita-Shi, Japan|Investigational Site Number 392062, Okayama-Shi, Japan|Investigational Site Number 392027, Osaki-Shi, Japan|Investigational Site Number 392049, Sagamihara-Shi, Japan|Investigational Site Number 392014, Sapporo-Shi, Japan|Investigational Site Number 392041, Sapporo-Shi, Japan|Investigational Site Number 392073, Sapporo-Shi, Japan|Investigational Site Number 392006, Sasebo-Shi, Japan|Investigational Site Number 392021, Sendai-Shi, Japan|Investigational Site Number 392022, Sendai-Shi, Japan|Investigational Site Number 392033, Sendai-Shi, Japan|Investigational Site Number 392071, Sendai-Shi, Japan|Investigational Site Number 392029, Shizuoka-Shi, Japan|Investigational Site Number 392023, Takaoka-Shi, Japan|Investigational Site Number 392003, Tomakomai-Shi, Japan|Investigational Site Number 392074, Urasoe-Shi, Japan|Investigational Site Number 392079, Urayasu-Shi, Japan|Investigational Site Number 392048, Yokohama-Shi, Japan",,"https://ClinicalTrials.gov/show/NCT02373202"
383,"NCT02332590","Efficacy and Safety of Sarilumab and Adalimumab Monotherapy in Patients With Rheumatoid Arthritis (SARIL-RA-MONARCH)",,"Completed","Has Results","Rheumatoid Arthritis","Drug: Sarilumab|Drug: Adalimumab|Drug: Placebo (for sarilumab)|Drug: Placebo (for adalimumab)","DB Period: Change From Baseline in Disease Activity Score for 28 Joints - Erythrocyte Sedimentation Rate (DAS28-ESR) Score at Week 24|DB Period: Percentage of Participants Achieving Clinical Remission Score (DAS28-ESR <2.6) at Week 24|DB Period: Percentage of Participants Achieving ACR50 Criteria at Week 24|DB Period: Percentage of Participants Achieving ACR70 Criteria at Week 24|DB Period: Percentage of Participants Achieving ACR20 Criteria at Week 24|DB Period: Change From Baseline in HAQ-DI at Week 24|DB Period: Change From Baseline in Short-Form-36 (SF-36) - Physical Component Summary (PCS) Score at Week 24|DB Period: Change From Baseline in Functional Assessment of Chronic Illness Therapy-Fatigue (FACIT-F) Score at Week 24|DB Period: Change From Baseline in SF-36 - Mental Health Component Summary Score at Week 24|DB Period: Change From Baseline in Disease Activity Score for 28 Joints Based on C-Reactive Protein (DAS28-CRP Score) at Week 24|DB Period: Percentage of Participants Achieving Clinical Remission Score (DAS28-CRP <2.6) at Week 24|DB Period: Percentage of Participants Achieving Low Disease Activity (DAS28-ESR < 3.2) at Week 24|DB Period: Percentage of Participants Achieving Clinical Disease Activity Index (CDAI) Remission (CDAI ≤2.8) at Week 24|DB Period: Change From Baseline in CDAI at Week 24|DB Period: Change From Baseline in European Quality of Life-5 Dimension 3 Level (EQ-5D-3L) Scores at Week 24|DB Period: Change From Baseline in Rheumatoid Arthritis Impact of Disease (RAID) at Week 24|DB Period: Change From Baseline in Work Productivity Survey - Rheumatoid Arthritis (WPS-RA) at Week 24: Work Days Missed Due to Arthritis|DB Period: Change From Baseline in WPS-RA at Week 24: Days With Work Productivity Reduced by ≥ 50% Due to Arthritis|DB Period: Change From Baseline in WPS-RA at Week 24: Arthritis Interference With Work Productivity|DB Period: Change From Baseline in WPS-RA at Week 24: House Work Days Missed Due to Arthritis|DB Period: Change From Baseline in WPS-RA at Week 24: Days With Household Work Productivity Reduced by >= 50% Due to Arthritis|DB Period: Change From Baseline in WPS-RA at Week 24: Days With Family/Social/Leisure Activities Missed Due to Arthritis|DB Period: Change From Baseline in WPS-RA at Week 24: Days With Outside Help Hired Due to Arthritis|DB Period: Change From Baseline in WPS-RA at Week 24: RA Interference With Household Work Productivity|DB Period: Change From Baseline in Morning Stiffness VAS at Week 24|DB Period: Change From Baseline in Individual ACR Component - TJC and SJC at Week 24|DB Period: Change From Baseline in Individual ACR Component - Physician Global VAS, Participant Global VAS and Pain VAS at Week 24|DB Period: Change From Baseline in Individual ACR Component - CRP Level at Week 24|DB Period: Change From Baseline in Individual ACR Component- ESR Level at Week 24|DB Period: Number of Participants With Treatment-emergent Adverse Events (TEAEs) and Serious Adverse Events (SAEs)|OLE Period: Number of Participants With Treatment-emergent Adverse Events and Serious Adverse Events|DB Period: Number of Participants With Potentially Clinically Significant Abnormalities (PCSA) - Hematological Parameters|OLE Period: Number of Participants With Potentially Clinically Significant Abnormalities - Hematological Parameters|DB Period: Number of Participants With Potentially Clinically Significant Abnormalities - Liver Function Tests|OLE Period: Number of Participants With Potentially Clinically Significant Abnormalities - Liver Function Tests|DB Period: Number of Participants With Potentially Clinically Significant Abnormalities - Metabolic Parameters|OLE Period: Number of Participants With Potentially Clinically Significant Abnormalities - Metabolic Parameters|DB Period: Number of Participants With Different Post-baseline Categories of High-density Lipoprotein (HDL)|OLE Period: Number of Participants With Different Post-baseline Categories of High-density Lipoprotein|DB Period: Number of Participants With Potentially Clinically Significant Abnormalities - Renal Function|OLE Period: Number of Participants With Potentially Clinically Significant Abnormalities - Renal Function|DB Period: Number of Participants With Potentially Clinically Significant Abnormalities - Urinalysis|OLE Period: Number of Participants With Potentially Clinically Significant Abnormalities - Urinalysis|DB Period: Number of Participants With Potentially Clinically Significant Abnormalities - Electrolytes|OLE Period: Number of Participants With Potentially Clinically Significant Abnormalities - Electrolytes|DB Period: Number of Participants With Potentially Clinically Significant Electrocardiogram (ECG) Abnormalities|OLE Period: Number of Participants With Potentially Clinically Significant Electrocardiogram Abnormalities|DB Period: Number of Participants With Potentially Clinically Significant Vital Signs Abnormalities|OLE Period: Number of Participants With Potentially Clinically Significant Vital Signs Abnormalities|DB Period: Number of Participants With Treatment-emergent and Treatment-boosted Anti-drug Antibody (ADA) Response|Number of Participants With Treatment-emergent and Treatment-boosted Anti-drug Antibody Response During Entire Treatment-emergent Adverse Event Period|DB Period: Pharmacokinetics: Serum Trough (Pre-dose) Concentrations of Functional Sarilumab|OLE Period: Pharmacokinetics: Serum Trough (Pre-dose) Concentrations of Functional Sarilumab","Sanofi|Regeneron Pharmaceuticals","All","18 Years and older   (Adult, Older Adult)","Phase 3","369","Industry","Interventional","Allocation: Randomized|Intervention Model: Parallel Assignment|Masking: Quadruple (Participant, Care Provider, Investigator, Outcomes Assessor)|Primary Purpose: Treatment","EFC14092|2014-002541-22|U1111-1160-6154","January 28, 2015","January 20, 2016","December 29, 2020","January 7, 2015","July 25, 2017","January 21, 2022","Investigational Site Number 840407, Covina, California, United States|Investigational Site Number 840400, Long Beach, California, United States|Investigational Site Number 840141, Whittier, California, United States|Investigational Site Number 840130, Lewes, Delaware, United States|Investigational Site Number 840229, Coral Gables, Florida, United States|Investigational Site Number 840128, Ormond Beach, Florida, United States|Investigational Site Number 840403, Saint Petersburg, Florida, United States|Investigational Site Number 840140, Tampa, Florida, United States|Investigational Site Number 840073, Cumberland, Maryland, United States|Investigational Site Number 840202, Hagerstown, Maryland, United States|Investigational Site Number 840232, Flint, Michigan, United States|Investigational Site Number 840112, Lincoln, Nebraska, United States|Investigational Site Number 840402, Charlotte, North Carolina, United States|Investigational Site Number 840406, Hickory, North Carolina, United States|Investigational Site Number 840404, Middleburg Heights, Ohio, United States|Investigational Site Number 840127, Oklahoma City, Oklahoma, United States|Investigational Site Number 840074, Mesquite, Texas, United States|Investigational Site Number 152005, Osorno, Chile|Investigational Site Number 152001, Puerto Varas, Chile|Investigational Site Number 152002, Santiago, Chile|Investigational Site Number 152050, Santiago, Chile|Investigational Site Number 152014, Talca, Chile|Investigational Site Number 152015, Temuco IX Region, Chile|Investigational Site Number 152007, Viña Del Mar, Chile|Investigational Site Number 203033, Praha 11, Czechia|Investigational Site Number 203001, Praha 2, Czechia|Investigational Site Number 203030, Praha 4, Czechia|Investigational Site Number 203002, Uherske Hradiste, Czechia|Investigational Site Number 276058, Köln, Germany|Investigational Site Number 276021, Osnabrück, Germany|Investigational Site Number 348025, Budapest, Hungary|Investigational Site Number 348020, Budapest, Hungary|Investigational Site Number 348022, Budapest, Hungary|Investigational Site Number 348024, Szombathely, Hungary|Investigational Site Number 348023, Veszprém, Hungary|Investigational Site Number 376032, Ashkelon, Israel|Investigational Site Number 376031, Haifa, Israel|Investigational Site Number 376030, Ramat Gan, Israel|Investigational Site Number 376011, Tel Aviv, Israel|Investigational Site Number 410005, Daegu, Korea, Republic of|Investigational Site Number 410004, Daejeon, Korea, Republic of|Investigational Site Number 410006, Seoul, Korea, Republic of|Investigational Site Number 410001, Seoul, Korea, Republic of|Investigational Site Number 604003, Lima, Peru|Investigational Site Number 604005, Lima, Peru|Investigational Site Number 604022, Lima, Peru|Investigational Site Number 616056, Bytom, Poland|Investigational Site Number 616015, Elblag, Poland|Investigational Site Number 616005, Lublin, Poland|Investigational Site Number 616030, Lublin, Poland|Investigational Site Number 616055, Nadarzyn, Poland|Investigational Site Number 616018, Poznan, Poland|Investigational Site Number 616016, Szczecin, Poland|Investigational Site Number 616004, Warszawa, Poland|Investigational Site Number 616031, Warszawa, Poland|Investigational Site Number 642006, Braila, Romania|Investigational Site Number 642010, Bucharest, Romania|Investigational Site Number 642001, Bucuresti, Romania|Investigational Site Number 642002, Bucuresti, Romania|Investigational Site Number 642005, Galati, Romania|Investigational Site Number 643006, Kemerovo, Russian Federation|Investigational Site Number 643020, Moscow, Russian Federation|Investigational Site Number 643001, Moscow, Russian Federation|Investigational Site Number 643031, Moscow, Russian Federation|Investigational Site Number 643030, Moscow, Russian Federation|Investigational Site Number 643008, Saint-Petersburg, Russian Federation|Investigational Site Number 643011, Saratov, Russian Federation|Investigational Site Number 710011, Cape Town, South Africa|Investigational Site Number 710007, Cape Town, South Africa|Investigational Site Number 710004, Kempton Park, South Africa|Investigational Site Number 724003, Barakaldo, Spain|Investigational Site Number 724011, Barcelona / Sabadell, Spain|Investigational Site Number 724015, Barcelona, Spain|Investigational Site Number 724001, Málaga, Spain|Investigational Site Number 724012, Santiago De Compostela, Spain|Investigational Site Number 724007, Sevilla, Spain|Investigational Site Number 804029, Ivano-Frankivsk, Ukraine|Investigational Site Number 804048, Kharkiv, Ukraine|Investigational Site Number 804014, Kyiv, Ukraine|Investigational Site Number 804047, Kyiv, Ukraine|Investigational Site Number 804037, Lutsk, Ukraine|Investigational Site Number 804046, Lviv, Ukraine|Investigational Site Number 804049, Poltava, Ukraine|Investigational Site Number 804011, Vinnitsya, Ukraine|Investigational Site Number 804043, Vinnitsya, Ukraine|Investigational Site Number 826001, Leytonstone, United Kingdom",,"https://ClinicalTrials.gov/show/NCT02332590"
384,"NCT02321241","Real Life of Aflibercept in France in Patients Refractory to Ranibizumab: Observational Study in Wet AMD","TITAN","Completed","No Results Available","Wet Macular Degeneration","Drug: Aflibercept (EYLEA, BAY-86-5321)","Treatment success rate (defined as a gain of at least 1 letter in BCVA and/or a diminution of CRT (expressed in µm))|Proportion of patients whose BCVA increases by ≥ 0 letter, ≥ 5 letters, ≥ 10 letters, ≥15 letters|Proportion of patients with less than 15 letters loss|Proportion of patients with dry-OCT|Mean duration of treatment with ranibizumab before initiation of aflibercept|Mean change in Central retinal thickness in µm (OCT)","Bayer|Regeneron Pharmaceuticals","All","18 Years and older   (Adult, Older Adult)",,"236","Industry","Observational","Observational Model: Cohort|Time Perspective: Other","17405|EY1413FR","February 1, 2016","January 18, 2017","August 18, 2017","December 22, 2014",,"July 2, 2018","Multiple Locations, France",,"https://ClinicalTrials.gov/show/NCT02321241"
385,"NCT02305238","Japanese Treat and Extend Study of Aflibercept in Neovascular Age-related Macular Degeneration","ALTAIR","Completed","Has Results","Wet Macular Degeneration","Drug: Aflibercept (Eylea, VEGF Trap-Eye, BAY86-5321)","Mean Change From Baseline in BCVA at Week 52|Percentage of Participants Who Maintained Vision at Week 52|Percentage of Participants Who Gained at Least 15 Letters of Vision Compared to Baseline at Week 52|Mean Change in Central Retinal Thickness (CRT) From Baseline at Week 52|Percentage of Participants Without Fluid on Optical Coherence Tomography (OCT) at Week 52","Bayer|Regeneron Pharmaceuticals","All","50 Years and older   (Adult, Older Adult)","Phase 4","288","Industry","Interventional","Allocation: Randomized|Intervention Model: Parallel Assignment|Masking: None (Open Label)|Primary Purpose: Treatment","17668","December 19, 2014","December 22, 2016","December 20, 2017","December 2, 2014","March 12, 2018","January 8, 2019","Ichinomiya, Aichi, Japan|Nagoya, Aichi, Japan|Nagoya, Aichi, Japan|Toyoake, Aichi, Japan|Asahi, Chiba, Japan|Sakura, Chiba, Japan|Koriyama, Fukushima, Japan|Kure, Hiroshima, Japan|Sapporo, Hokkaido, Japan|Sapporo, Hokkaido, Japan|Sapporo, Hokkaido, Japan|Kobe, Hyogo, Japan|Inashiki-gun, Ibaraki, Japan|Mito, Ibaraki, Japan|Morioka, Iwate, Japan|Yokohama, Kanagawa, Japan|Nankoku, Kochi, Japan|Miyakonojo, Miyazaki, Japan|Iida, Nagano, Japan|Matsumoto, Nagano, Japan|Hirakata, Osaka, Japan|Moriguchi, Osaka, Japan|Osakasayama, Osaka, Japan|Takatsuki, Osaka, Japan|Otsu, Shiga, Japan|Chiyoda-ku, Tokyo, Japan|Chuoku, Tokyo, Japan|Hachioji, Tokyo, Japan|Mitaka, Tokyo, Japan|Shinjuku-ku, Tokyo, Japan|Shinjuku-ku, Tokyo, Japan|Taito-ku, Tokyo, Japan|Shimonoseki, Yamaguchi, Japan|Ube, Yamaguchi, Japan|Chuo, Yamanashi, Japan|Fukuoka, Japan|Fukuoka, Japan|Miyazaki, Japan|Okayama, Japan|Osaka, Japan|Osaka, Japan",,"https://ClinicalTrials.gov/show/NCT02305238"
386,"NCT02299336","Long-Term Efficacy & Safety of Aflibercept IVT for the Treatment of DME in Subjects Who Completed the VISTA-DME Trial",,"Completed","Has Results","Diabetic Macular Edema","Drug: Aflibercept|Procedure: Focal Laser","Mean Number of Intravitreal Aflibercept Injections for Subjects Who Were Enrolled and Completed the 3-year VISTA DME (VGFT-OD-1009) Trial|Mean Change in Early Treatment Diabetic Retinopathy Study Best-corrected Visual Acuity From Baseline to Week 52 and Baseline to Week 104|Mean Number of Intravitreal Aflibercept Injections Before and After Receiving First Focal Laser Application.|Percentage of Subjects With Gain or Loss of 0 to 5 Early Treatment Diabetic Retinopathy Study Best-corrected Visual Acuity Letters From Baseline to Week 52 and Baseline to Week 104|Mean Change in Central Retinal Thickness From Baseline to Week 52 and Baseline to Week 104.|Number of Subjects With no Clinically-relevant Diabetic Macular Edema (as Defined in the Protocol) on Spectral Domain Optical Coherence Tomography From Baseline to Week 52 and Baseline to Week 104.|Number of Subjects With Stable, Worsened, or Improved Diabetic Retinopathy|Number of Subjects That Receive Focal Laser Treatment.|Mean Change in Early Treatment Diabetic Retinopathy Study Best-corrected Visual Acuity Before and After Focal Laser Therapy|Mean Change in Central Retinal Thickness Before and After First Focal Laser Treatment|Role of (Ultrawide-field, if Available) Fluorescein Angiography-determined Retinal Ischemia in Predicting Past and Future Anti-VEGF Treatment Burden|Role of (Ultrawide-field, if Available) Fluorescein Angiography-determined Retinal Ischemia in Predicting Visual Outcomes|Role of (Ultrawide-field, if Available) Fluorescein Angiography-determined Retinal Ischemia in Predicting Anatomic Outcomes","Greater Houston Retina Research|Regeneron Pharmaceuticals","All","18 Years and older   (Adult, Older Adult)","Phase 4","60","Other|Industry","Interventional","Allocation: N/A|Intervention Model: Single Group Assignment|Masking: None (Open Label)|Primary Purpose: Treatment","The Endurance 1 Trial","November 24, 2014","January 9, 2017","January 9, 2017","November 24, 2014","June 7, 2018","June 4, 2019","Retina Consultants of Houston/The Medical Center, Houston, Texas, United States|Retina Consultants of Houston/Katy office, Katy, Texas, United States|Retina Consultants of Houston, The Woodlands, Texas, United States",,"https://ClinicalTrials.gov/show/NCT02299336"
387,"NCT02297204","The Endurance 1 Trial","Endurance","Completed","No Results Available","Diabetic Macular Edema","Procedure: Focal Laser Treatment|Drug: aflibercept 2.0 mg","Need for ongoing intravitreal aflibercept injections in the management of DME|Vision change|Vision loss|Change in central retinal thickness|Development of clinically relevant diabetic macular edema|Role of focal laser treatment in management of DME (Proportion of subjects that receive focal laser treatment and mean number of intravitreal aflibercept injections before and after receiving focal laser treatment.)|Evaluation of Diabetic Retinopathy (Proportion of subjects with stable, worsened, or improved diabetic retinopathy as identified by eye examination and imaging.)|Ocular and systemic adverse events","Northern California Retina Vitreous Associates|Regeneron Pharmaceuticals","Female","18 Years and older   (Adult, Older Adult)","Phase 4","9","Other|Industry","Interventional","Allocation: N/A|Intervention Model: Single Group Assignment|Masking: None (Open Label)|Primary Purpose: Prevention","REG-2014-11-006","November 2014","December 13, 2017","March 19, 2018","November 21, 2014",,"February 4, 2019",,,"https://ClinicalTrials.gov/show/NCT02297204"
388,"NCT02293902","A Study Assessing the Efficacy and Safety of Sarilumab Added to MTX in Japanese Patients With Moderately to Severely Active Rheumatoid Arthritis (SARIL-RA-KAKEHASI)",,"Completed","Has Results","Rheumatoid Arthritis","Drug: Sarilumab SAR153191 (REGN88)|Other: Placebo (for sarilumab)|Drug: Methotrexate|Drug: Folic acid","Percentage of Participants Achieving American College of Rheumatology 20 (ACR20) Response at Week 24|Number of Participants With Treatment-Emergent Adverse Events (AEs) and Serious Adverse Events (SAEs)|Number of Participants With Potentially Clinically Significant Vital Signs Abnormalities|Number of Participants With Potentially Clinically Significant Electrocardiogram (ECG) Abnormalities|Number of Participants With Potentially Clinically Significant Laboratory Abnormalities: Hematological Parameters|Number of Participants With Potentially Clinically Significant Laboratory Abnormalities: Metabolic Parameters|Number of Participants With Potentially Clinically Significant Laboratory Abnormalities: Electrolytes|Number of Participants With Potentially Clinically Significant Laboratory Abnormalities: Renal Function Parameters|Number of Participants With Potentially Clinically Significant Laboratory Abnormalities: Liver Function Parameters","Sanofi|Regeneron Pharmaceuticals","All","20 Years to 75 Years   (Adult, Older Adult)","Phase 3","243","Industry","Interventional","Allocation: Randomized|Intervention Model: Parallel Assignment|Masking: Quadruple (Participant, Care Provider, Investigator, Outcomes Assessor)|Primary Purpose: Treatment","EFC14059|U1111-1155-7401","November 2014","October 2016","October 2016","November 19, 2014","January 30, 2018","January 30, 2018","Investigational Site Number 392010, Asahi-Shi, Japan|Investigational Site Number 392001, Asahikawa-Shi, Japan|Investigational Site Number 392035, Asahikawa-Shi, Japan|Investigational Site Number 392070, Beppu-Shi, Japan|Investigational Site Number 392036, Chiba-Shi, Japan|Investigational Site Number 392083, Chuo-Ku, Japan|Investigational Site Number 392047, Fuchu-Shi, Japan|Investigational Site Number 392004, Fukui-Shi, Japan|Investigational Site Number 392007, Fukuoka-Shi, Japan|Investigational Site Number 392038, Fukuoka-Shi, Japan|Investigational Site Number 392039, Fukuoka-Shi, Japan|Investigational Site Number 392078, Fukushima-Shi, Japan|Investigational Site Number 392054, Funabashi-Shi, Japan|Investigational Site Number 392015, Hachioji-Shi, Japan|Investigational Site Number 392085, Hannan-Shi, Japan|Investigational Site Number 392091, Hiroshima-Shi, Japan|Investigational Site Number 392098, Hiroshima-Shi, Japan|Investigational Site Number 392009, Hitachinaka-Shi, Japan|Investigational Site Number 392011, Hitachinaka-Shi, Japan|Investigational Site Number 392030, Ichinomiya-Shi, Japan|Investigational Site Number 392002, Iizuka-Shi, Japan|Investigational Site Number 392019, Kagoshima-Shi, Japan|Investigational Site Number 392066, Kamakura-Shi, Japan|Investigational Site Number 392086, Kamogawa-Shi, Japan|Investigational Site Number 392050, Kato-Shi, Japan|Investigational Site Number 392037, Kawachi-Nagano-Shi, Japan|Investigational Site Number 392093, Kawagoe-Shi, Japan|Investigational Site Number 392099, Kawasaki-Shi, Japan|Investigational Site Number 392016, Kirishima-Shi, Japan|Investigational Site Number 392013, Kitakyushu-Shi, Japan|Investigational Site Number 392024, Kitakyushu-Shi, Japan|Investigational Site Number 392045, Kitakyushu-Shi, Japan|Investigational Site Number 392063, Kiyose-Shi, Japan|Investigational Site Number 392051, Kobe-Shi, Japan|Investigational Site Number 392097, Kochi-Shi, Japan|Investigational Site Number 392040, Koushi-Shi, Japan|Investigational Site Number 392069, Kumamoto-Shi, Japan|Investigational Site Number 392089, Kurashiki-Shi, Japan|Investigational Site Number 392065, Kushiro-Shi, Japan|Investigational Site Number 392026, Matsuyama-Shi, Japan|Investigational Site Number 392081, Matsuyama-Shi, Japan|Investigational Site Number 392094, Matsuyama-Shi, Japan|Investigational Site Number 392042, Meguro-Ku, Japan|Investigational Site Number 392082, Meguro-Ku, Japan|Investigational Site Number 392012, Mito-Shi, Japan|Investigational Site Number 392034, Miyagi-Gun, Japan|Investigational Site Number 392053, Morioka-Shi, Japan|Investigational Site Number 392032, Nagano-Shi, Japan|Investigational Site Number 392064, Nagasaki-Shi, Japan|Investigational Site Number 392043, Nagoya-Shi, Japan|Investigational Site Number 392056, Nagoya-Shi, Japan|Investigational Site Number 392076, Nagoya-Shi, Japan|Investigational Site Number 392080, Nagoya-Shi, Japan|Investigational Site Number 392031, Nakano-Ku, Japan|Investigational Site Number 392046, Narashino-Shi, Japan|Investigational Site Number 392067, Narashino-Shi, Japan|Investigational Site Number 392044, Nishinomiya-Shi, Japan|Investigational Site Number 392059, Oita-Shi, Japan|Investigational Site Number 392062, Okayama-Shi, Japan|Investigational Site Number 392008, Omura-Shi, Japan|Investigational Site Number 392057, Osaka-Shi, Japan|Investigational Site Number 392060, Osaka-Shi, Japan|Investigational Site Number 392061, Osaka-Shi, Japan|Investigational Site Number 392096, Osaka-Shi, Japan|Investigational Site Number 392027, Osaki-Shi, Japan|Investigational Site Number 392049, Sagamihara-Shi, Japan|Investigational Site Number 392072, Saitama-Shi, Japan|Investigational Site Number 392075, Sakai-Shi, Japan|Investigational Site Number 392014, Sapporo-Shi, Japan|Investigational Site Number 392068, Sapporo-Shi, Japan|Investigational Site Number 392073, Sapporo-Shi, Japan|Investigational Site Number 392006, Sasebo-Shi, Japan|Investigational Site Number 392021, Sendai-Shi, Japan|Investigational Site Number 392022, Sendai-Shi, Japan|Investigational Site Number 392033, Sendai-Shi, Japan|Investigational Site Number 392071, Sendai-Shi, Japan|Investigational Site Number 392100, Sendai-Shi, Japan|Investigational Site Number 392029, Shizuoka-Shi, Japan|Investigational Site Number 392025, Sumida-Ku, Japan|Investigational Site Number 392092, Sumida-Ku, Japan|Investigational Site Number 392023, Takaoka-Shi, Japan|Investigational Site Number 392095, Takarazuka-Shi, Japan|Investigational Site Number 392020, Takasaki-Shi, Japan|Investigational Site Number 392088, Takatsuki-Shi, Japan|Investigational Site Number 392018, Tokorozawa-Shi, Japan|Investigational Site Number 392003, Tomakomai-Shi, Japan|Investigational Site Number 392005, Tomakomai-Shi, Japan|Investigational Site Number 392077, Tonami-Shi, Japan|Investigational Site Number 392052, Toshima-Ku, Japan|Investigational Site Number 392058, Toyama-Shi, Japan|Investigational Site Number 392055, Toyonaka-Shi, Japan|Investigational Site Number 392074, Urasoe-Shi, Japan|Investigational Site Number 392079, Urayasu-Shi, Japan|Investigational Site Number 392048, Yokohama-Shi, Japan|Investigational Site Number 392090, Yokohama-Shi, Japan|Investigational Site Number 392101, Yokohama-Shi, Japan",,"https://ClinicalTrials.gov/show/NCT02293902"
389,"NCT02289963","Evaluation of Alirocumab in Addition to Lipid-Modifying Therapy in Patients With High Cardiovascular Risk and Hypercholesterolemia in South Korea and Taiwan",,"Completed","Has Results","Hypercholesterolemia","Drug: Placebo (for Alirocumab)|Drug: Alirocumab|Drug: Lipid-Modifying Therapy (LMT)","Percent Change From Baseline in Calculated LDL-C at Week 24 - Intent-to-Treat (ITT) Analysis|Percent Change From Baseline in Calculated LDL-C at Week 24 - On-Treatment Analysis|Percent Change From Baseline in Calculated LDL-C at Week 12 - ITT Analysis|Percent Change From Baseline in Calculated LDL-C at Week 12 - On-Treatment Analysis|Percent Change From Baseline in Apolipoprotein (Apo) B at Week 24 - ITT Analysis|Percent Change From Baseline in Apo B at Week 24 - On-treatment Analysis|Percent Change From Baseline in Non-High Density Lipoprotein Cholesterol (Non-HDL-C) at Week 24 - ITT Analysis|Percent Change From Baseline in Non-HDL-C at Week 24 - On-treatment Analysis|Percent Change From Baseline in Total Cholesterol (Total-C) at Week 24 - ITT Analysis|Percent Change From Baseline in Apo B at Week 12 - ITT Analysis|Percent Change From Baseline in Non-HDL-C at Week 12 - ITT Analysis|Percent Change From Baseline in Total-C at Week 12 - ITT Analysis|Percentage of Participants Reaching Calculated LDL-C <70 mg/dL (1.81 mmol/L) at Week 24 - ITT Analysis|Percentage of Participants Reaching Calculated LDL-C <70 mg/dL (1.81 mmol/L) at Week 24 - On-treatment Analysis|Percent Change From Baseline in Lipoprotein(a) at Week 24 - ITT Analysis|Percent Change From Baseline in High Density Lipoprotein (HDL-C) at Week 24 - ITT Analysis|Percent Change From Baseline in Fasting Triglycerides at Week 24 - ITT Analysis|Percent Change From Baseline in Apolipoprotein A-1 (Apo A-1) at Week 24 - ITT Analysis|Percent Change From Baseline in Lipoprotein(a) at Week 12- ITT Analysis|Percent Change From Baseline in HDL-C at Week 12 - ITT Analysis|Percent Change From Baseline in Fasting Triglycerides at Week 12 - ITT Analysis|Percent Change From Baseline in Apo A-1 at Week 12 - ITT Analysis","Sanofi|Regeneron Pharmaceuticals","All","18 Years and older   (Adult, Older Adult)","Phase 3","199","Industry","Interventional","Allocation: Randomized|Intervention Model: Parallel Assignment|Masking: Quadruple (Participant, Care Provider, Investigator, Outcomes Assessor)|Primary Purpose: Treatment","EFC14074|U1111-1157-3294","January 2015","April 2016","April 2016","November 13, 2014","June 26, 2017","June 26, 2017","Investigational Site Number 410009, Anyang-Si, Korea, Republic of|Investigational Site Number 410001, Anyang, Korea, Republic of|Investigational Site Number 410017, Busan, Korea, Republic of|Investigational Site Number 410007, Busan, Korea, Republic of|Investigational Site Number 410002, Daegu, Korea, Republic of|Investigational Site Number 410011, Goyang-Si, Korea, Republic of|Investigational Site Number 410003, Gwangju, Korea, Republic of|Investigational Site Number 410012, Incheon, Korea, Republic of|Investigational Site Number 410018, Jeonju-Si, Korea, Republic of|Investigational Site Number 410006, Seoul, Korea, Republic of|Investigational Site Number 410004, Seoul, Korea, Republic of|Investigational Site Number 410015, Seoul, Korea, Republic of|Investigational Site Number 410008, Seoul, Korea, Republic of|Investigational Site Number 410005, Seoul, Korea, Republic of|Investigational Site Number 410010, Seoul, Korea, Republic of|Investigational Site Number 410013, Ulsan, Korea, Republic of|Investigational Site Number 158007, Changhua, Taiwan|Investigational Site Number 158005, Hsinchu, Taiwan|Investigational Site Number 158011, Kaohsiung, Taiwan|Investigational Site Number 158010, Kaohsiung, Taiwan|Investigational Site Number 158006, Taichung, Taiwan|Investigational Site Number 158009, Tainan Hsien, Taiwan|Investigational Site Number 158008, Tainan, Taiwan|Investigational Site Number 158001, Taipei, Taiwan|Investigational Site Number 158003, Taipei, Taiwan|Investigational Site Number 158002, Taipei, Taiwan|Investigational Site Number 158004, Taoyuan Hsien, Taiwan",,"https://ClinicalTrials.gov/show/NCT02289963"
390,"NCT02289924","Aflibercept (Eylea) in roUtine Clinical Practice in patientS With Wet Age-related Macular Degeneration in Italy","PERSEUS-IT","Completed","No Results Available","Wet Macular Degeneration","Drug: Aflibercept (Eylea, VEGF Trap-Eye, BAY86-5321)","Mean change of visual acuity from baseline to 12 months.|Mean change of visual acuity from baseline to 24 months.|Number of clinical visits (visits for injections)|Number of monitoring visits (visits only for diagnostic purposes, but without injections)|Number of combined visits (visits for monitoring and injection)|Number of post-injection monitoring visits (visits only for safety checks after injection)|Number of visits outside the study center after 12 and 24 months|Number of optical coherence tomography (OCT) assessments per patient|Number of visual acuity tests|Number of fundoscopy examinations|Mean time between the injections and visits|Mean time between the first symptoms and diagnosis|Mean time from indication of the Eylea treatment by the treating physician to treatment|Proportion of patients with no fluid|Mean change in retinal thickness from baseline","Bayer|Regeneron Pharmaceuticals","All","Child, Adult, Older Adult",,"912","Industry","Observational","Observational Model: Cohort|Time Perspective: Prospective","17634|EY1415IT","January 9, 2015","March 28, 2019","July 8, 2019","November 13, 2014",,"July 30, 2019","Multiple Locations, Italy",,"https://ClinicalTrials.gov/show/NCT02289924"
391,"NCT02279537","Real Life of Aflibercept In FraNce: oBservatiOnnal Study in Wet AMD","RAINBOW","Completed","No Results Available","Wet Macular Degeneration","Drug: Aflibercept (Eylea, VEGF Trap-Eye, BAY86-5321)","Change in the measurement of best-corrected visual acuity (BCVA) from baseline to 12 months.|Change in Best Corrected Visual Acuity (BCVA) during the second year and until the fourth year of treatment versus the initial visit|Percentage of patients who experienced a gain in BCVA, from initial visit to each follow-up visit (letter score of ≥ 0 letters, ≥ 5 letters, ≥ 10 letters, ≥ 15 letters)|Percentage of patients losing fewer than 15 letters from the initial visit visual acuity at each follow-up visit","Bayer|Regeneron Pharmaceuticals","All","18 Years and older   (Adult, Older Adult)",,"593","Industry","Observational","Observational Model: Cohort|Time Perspective: Other","17374|EY1411FR","January 2, 2014","April 17, 2019","April 17, 2019","October 31, 2014",,"April 16, 2020","Multiple Locations, France",,"https://ClinicalTrials.gov/show/NCT02279537"
392,"NCT02260687","Special Drug Use Investigation of EYLEA for Myopic Choroidal Neovascularization",,"Completed","No Results Available","Choroidal Neovascularization","Drug: Aflibercept (Eylea, VEGF Trap-Eye, BAY86-5321)","Number of episodes of Adverse drug reaction (ADR's)|Number of episodes of Infections|Number of episodes of Serious Adverse Events(SAE's)|Number of episodes of Ocular Adverse events|Mean changes in visual acuity|Mean changes in retina thickness","Bayer|Regeneron Pharmaceuticals","All","Child, Adult, Older Adult",,"353","Industry","Observational","Observational Model: Cohort|Time Perspective: Prospective","17416|EY1414JP","December 5, 2014","April 2, 2018","August 22, 2018","October 9, 2014",,"September 19, 2019","Multiple Locations, Japan",,"https://ClinicalTrials.gov/show/NCT02260687"
393,"NCT02204683","A Pharmacokinetic Study of Intravitreal Aflibercept Injection in Vitrectomized and Non-vitrectomized Eyes With Wet Age-related Macular Degeneration (DRAW).","DRAW","Completed","No Results Available","Neovascular Macular Degeneration","Drug: Aflibercept","Pharmacokinetic (PK) aflibercept aqueous|PK Aflibercept plasma","University of Nebraska|Regeneron Pharmaceuticals","All","50 Years and older   (Adult, Older Adult)","Phase 1","5","Other|Industry","Interventional","Allocation: Non-Randomized|Intervention Model: Single Group Assignment|Masking: None (Open Label)|Primary Purpose: Other","334-14-FB","July 2014","July 2017","July 2017","July 30, 2014",,"July 14, 2017","UNMC Truhlsen Eye Institute, Omaha, Nebraska, United States",,"https://ClinicalTrials.gov/show/NCT02204683"
394,"NCT02171416","Cold Contact Urticaria Treatment With Rilonacept","Cures","Completed","No Results Available","Cold Contact Urticaria","Drug: Rilonacept|Drug: Placebo","To assess the effect of rilonacept on the clinical signs and symptoms of CCU|To assess the safety of rilonacept in subjects with CCU","Charite University, Berlin, Germany|Regeneron Pharmaceuticals","All","18 Years and older   (Adult, Older Adult)","Phase 2","20","Other|Industry","Interventional","Allocation: Randomized|Intervention Model: Parallel Assignment|Masking: Double (Participant, Investigator)|Primary Purpose: Treatment","Cures|2012-005726-30","January 2015","February 28, 2018","May 2018","June 24, 2014",,"July 17, 2018","University Berlin Charité ; Dermatology, Berlin, Germany|Universitätsmedizin, Mainz, Germany",,"https://ClinicalTrials.gov/show/NCT02171416"
395,"NCT02134028","Long-Term Safety Evaluation of Dupilumab in Patients With Asthma (LIBERTY ASTHMA TRAVERSE)",,"Completed","Has Results","Asthma","Drug: Dupilumab","Number of Participants With Treatment-Emergent Adverse Events (TEAEs)|Number of Participants With Potentially Clinically Significant Vital Signs Abnormalities During the TEAE Period|Number of Participants With Potentially Clinically Significant Laboratory Abnormalities: Hematological Parameters (Red Blood Cells [RBCs], Platelets and Coagulation) During the TEAE Period|Number of Severe Exacerbation Events|Annualized Event Rate Per Participant-Years for Severe Exacerbation|Change From Baseline in Forced Expiratory Volume in 1 Second (FEV1) at Weeks 48 and 96|Change From Baseline in Percent Predicted FEV1 at Weeks 48 and 96|Change From Baseline in Forced Vital Capacity (FVC) at Weeks 48 and 96|Change From Baseline in Forced Expiratory Flow (FEF) 25-75% at Weeks 48 and 96|Change From Baseline in Asthma Control Questionnaire 5-Question Version (ACQ-5) Mean Scores at Weeks 24 and 48|Percentage of Participants Achieving ACQ-5 Score Response (ACQ-5 Responders) at Weeks 24 and 48|Change From Baseline in Asthma Quality of Life Questionnaire (AQLQ) Global Scores at Weeks 24 and 48|Percentage of Participants Achieving AQLQ Global Score Response (AQLQ Responders) at Weeks 24 and 48|Serum Concentrations of Dupilumab Over Time Till Week 96|Percentage of Participants With Antidrug Antibodies (ADA) Response|Change From Baseline in Blood Eosinophils Cells Count at Weeks 48 and 96|Change From Baseline in Morning Peak Expiratory Flow (PEF) at Weeks 48 and 96: Participants From Study DRI12544|Change From Baseline in Evening Peak Expiratory Flow (PEF) at Weeks 48 and 96: Participants From Study DRI12544|Change From Baseline in Morning Asthma Symptom Scores at Weeks 48 and 96: Participants From Study DRI12544|Change From Baseline in Evening Asthma Symptom Scores at Weeks 48 and 96: Participants From Study DRI12544|Change From Baseline in Number of Inhalations Per Day of Salbutamol/Albuterol or Levosalbutamol/Levalbuterol for Symptom Relief at Weeks 48 and 96: Participants From Study DRI12544|Change From Baseline in Number of Nocturnal Awakenings at Weeks 48 and 96: Participants From Study DRI12544|Percent Change From Baseline in Oral Corticosteroid (OCS) Dose at Weeks 48, and 96: Participants From Study EFC13691|Percentage of Participants Achieving a Reduction of 50% or Greater (≥ 50% ) in OCS Dose Over Time at Weeks 48 and 96: Participants From Study EFC13691|Percentage of Participants With Background OCS Completely Tapered Off Over Time at Weeks 48 and 96: Participants From Study EFC13691|Change From Baseline in European-Quality of Life-5 Dimension Instrument-3 Levels (EQ-5D-3L) Index Scores at Weeks 48 and 96: Participants From Study DRI12544|Change From Baseline in EQ-5D-3L VAS Scores at Weeks 48 and 96: Participants From Study DRI12544","Sanofi|Regeneron Pharmaceuticals","All","12 Years and older   (Child, Adult, Older Adult)","Phase 3","2282","Industry","Interventional","Allocation: N/A|Intervention Model: Single Group Assignment|Masking: None (Open Label)|Primary Purpose: Treatment","LTS12551|2013-003856-19|U1111-1117-6745","August 5, 2014","October 11, 2019","October 11, 2019","May 8, 2014","November 2, 2020","November 2, 2020","Investigational Site Number 840047, Birmingham, Alabama, United States|Investigational Site Number 840099, Gilbert, Arizona, United States|Investigational Site Number 840087, Scottsdale, Arizona, United States|Investigational Site Number 840402, Tucson, Arizona, United States|Investigational Site Number 840132, Little Rock, Arkansas, United States|Investigational Site Number 840109, Bakersfield, California, United States|Investigational Site Number 840045, Long Beach, California, United States|Investigational Site Number 840019, Los Angeles, California, United States|Investigational Site Number 840029, Los Angeles, California, United States|Investigational Site Number 840022, Los Angeles, California, United States|Investigational Site Number 840044, Newport Beach, California, United States|Investigational Site Number 840041, North Hollywood, California, United States|Investigational Site Number 840014, Rolling Hills Estates, California, United States|Investigational Site Number 840121, San Jose, California, United States|Investigational Site Number 840040, Colorado Springs, Colorado, United States|Investigational Site Number 840403, Denver, Colorado, United States|Investigational Site Number 840006, Denver, Colorado, United States|Investigational Site Number 840024, Denver, Colorado, United States|Investigational Site Number 840130, Denver, Colorado, United States|Investigational Site Number 840902, New Haven, Connecticut, United States|Investigational Site Number 840137, Aventura, Florida, United States|Investigational Site Number 840071, Gainesville, Florida, United States|Investigational Site Number 840115, Ocoee, Florida, United States|Investigational Site Number 840055, Sarasota, Florida, United States|Investigational Site Number 840079, Twin Falls, Idaho, United States|Investigational Site Number 840101, Chicago, Illinois, United States|Investigational Site Number 840032, Fort Mitchell, Kentucky, United States|Investigational Site Number 840017, Louisville, Kentucky, United States|Investigational Site Number 840030, Owensboro, Kentucky, United States|Investigational Site Number 840064, Bangor, Maine, United States|Investigational Site Number 840052, Chevy Chase, Maryland, United States|Investigational Site Number 840073, Gaithersburg, Maryland, United States|Investigational Site Number 840080, Owings Mills, Maryland, United States|Investigational Site Number 840401, Boston, Massachusetts, United States|Investigational Site Number 840018, Minneapolis, Minnesota, United States|Investigational Site Number 840002, Saint Louis, Missouri, United States|Investigational Site Number 840102, Saint Louis, Missouri, United States|Investigational Site Number 840093, Saint Louis, Missouri, United States|Investigational Site Number 840037, Missoula, Montana, United States|Investigational Site Number 840078, Omaha, Nebraska, United States|Investigational Site Number 840004, Papillion, Nebraska, United States|Investigational Site Number 840111, Brick, New Jersey, United States|Investigational Site Number 840068, Ocean City, New Jersey, United States|Investigational Site Number 840011, Princeton, New Jersey, United States|Investigational Site Number 840065, New York, New York, United States|Investigational Site Number 840126, Charlotte, North Carolina, United States|Investigational Site Number 840083, Charlotte, North Carolina, United States|Investigational Site Number 840108, Durham, North Carolina, United States|Investigational Site Number 840107, Greensboro, North Carolina, United States|Investigational Site Number 840907, High Point, North Carolina, United States|Investigational Site Number 840404, Winston-Salem, North Carolina, United States|Investigational Site Number 840015, Cincinnati, Ohio, United States|Investigational Site Number 840146, Cincinnati, Ohio, United States|Investigational Site Number 840049, Middleburg Heights, Ohio, United States|Investigational Site Number 840942, Toledo, Ohio, United States|Investigational Site Number 840112, Edmond, Oklahoma, United States|Investigational Site Number 840104, Tulsa, Oklahoma, United States|Investigational Site Number 840034, Medford, Oregon, United States|Investigational Site Number 840031, Portland, Oregon, United States|Investigational Site Number 840046, Bethlehem, Pennsylvania, United States|Investigational Site Number 840085, Hershey, Pennsylvania, United States|Investigational Site Number 840067, Philadelphia, Pennsylvania, United States|Investigational Site Number 840928, Pittsburgh, Pennsylvania, United States|Investigational Site Number 840091, Pittsburgh, Pennsylvania, United States|Investigational Site Number 840082, Charleston, South Carolina, United States|Investigational Site Number 840117, Greenville, South Carolina, United States|Investigational Site Number 840021, Spartanburg, South Carolina, United States|Investigational Site Number 840062, Amarillo, Texas, United States|Investigational Site Number 840038, Boerne, Texas, United States|Investigational Site Number 840124, Cypress, Texas, United States|Investigational Site Number 840023, Dallas, Texas, United States|Investigational Site Number 840923, El Paso, Texas, United States|Investigational Site Number 840922, Fort Worth, Texas, United States|Investigational Site Number 840027, Fort Worth, Texas, United States|Investigational Site Number 840070, McKinney, Texas, United States|Investigational Site Number 840118, Plano, Texas, United States|Investigational Site Number 840008, San Antonio, Texas, United States|Investigational Site Number 840035, Draper, Utah, United States|Investigational Site Number 840077, Murray, Utah, United States|Investigational Site Number 840057, South Burlington, Vermont, United States|Investigational Site Number 840059, Fairfax, Virginia, United States|Investigational Site Number 840951, Bellingham, Washington, United States|Investigational Site Number 032096, Bahia Blanca, Argentina|Investigational Site Number 032004, Buenos Aires, Argentina|Investigational Site Number 032003, Buenos Aires, Argentina|Investigational Site Number 032011, Caba, Argentina|Investigational Site Number 032097, Caba, Argentina|Investigational Site Number 032001, Caba, Argentina|Investigational Site Number 032010, Caba, Argentina|Investigational Site Number 032091, Caba, Argentina|Investigational Site Number 032095, Capital Federal, Argentina|Investigational Site Number 032002, La Plata, Argentina|Investigational Site Number 032006, Rosario, Argentina|Investigational Site Number 032007, Rosario, Argentina|Investigational Site Number 032005, Rosario, Argentina|Investigational Site Number 032012, San Miguel De Tucuman, Argentina|Investigational Site Number 032009, San Miguel De Tucumán, Argentina|Investigational Site Number 036004, Adelaide, Australia|Investigational Site Number 036005, Campbelltown, Australia|Investigational Site Number 036001, Clayton, Australia|Investigational Site Number 036008, Frankston, Australia|Investigational Site Number 036093, Murdoch, Australia|Investigational Site Number 036003, Nedlands, Australia|Investigational Site Number 036094, Parkville, Australia|Investigational Site Number 036009, Prahran, Australia|Investigational Site Number 036006, Woolloongabba, Australia|Investigational Site Number 056002, Brussels, Belgium|Investigational Site Number 056003, Gent, Belgium|Investigational Site Number 056001, Leuven, Belgium|Investigational Site Number 076009, Florianópolis, Brazil|Investigational Site Number 076007, Porto Alegre, Brazil|Investigational Site Number 076001, Porto Alegre, Brazil|Investigational Site Number 076003, Salvador, Brazil|Investigational Site Number 076012, Sao Paulo, Brazil|Investigational Site Number 076002, Sorocaba, Brazil|Investigational Site Number 076013, São Bernardo Do Campo, Brazil|Investigational Site Number 076006, São Paulo, Brazil|Investigational Site Number 124019, Burlington, Canada|Investigational Site Number 124009, Calgary, Canada|Investigational Site Number 124016, Hamilton, Canada|Investigational Site Number 124003, Mississauga, Canada|Investigational Site Number 124001, Montreal, Canada|Investigational Site Number 124012, Montreal, Canada|Investigational Site Number 124010, Montreal, Canada|Investigational Site Number 124013, Ottawa, Canada|Investigational Site Number 124018, Quebec, Canada|Investigational Site Number 124014, Quebec, Canada|Investigational Site Number 124008, Sherbrooke, Canada|Investigational Site Number 124015, Toronto, Canada|Investigational Site Number 124002, Toronto, Canada|Investigational Site Number 124007, Trois-Rivieres, Canada|Investigational Site Number 124006, Vancouver, Canada|Investigational Site Number 124017, Vancouver, Canada|Investigational Site Number 152007, Quillota, Chile|Investigational Site Number 152024, Santiago, Chile|Investigational Site Number 152005, Santiago, Chile|Investigational Site Number 152014, Santiago, Chile|Investigational Site Number 152011, Santiago, Chile|Investigational Site Number 152018, Santiago, Chile|Investigational Site Number 152002, Santiago, Chile|Investigational Site Number 152013, Santiago, Chile|Investigational Site Number 152023, Talcahuano, Chile|Investigational Site Number 152008, Talca, Chile|Investigational Site Number 152004, Talca, Chile|Investigational Site Number 152010, Valdivia, Chile|Investigational Site Number 152003, Viña Del Mar, Chile|Investigational Site Number 152021, Viña Del Mar, Chile|Investigational Site Number 170001, Bogota, Colombia|Investigational Site Number 170002, Bogotá, Colombia|Investigational Site Number 208002, Hvidovre, Denmark|Investigational Site Number 208001, København Nv, Denmark|Investigational Site Number 250009, Brest, France|Investigational Site Number 250004, La Tronche, France|Investigational Site Number 250010, Lille Cedex, France|Investigational Site Number 250013, Lille Cedex, France|Investigational Site Number 250006, Lyon, France|Investigational Site Number 250001, Marseille, France|Investigational Site Number 250002, Montpellier, France|Investigational Site Number 250005, Nantes, France|Investigational Site Number 250007, Nimes Cedex 9, France|Investigational Site Number 250008, Strasbourg, France|Investigational Site Number 250014, Vandoeuvre-Les-Nancy Cedex, France|Investigational Site Number 276006, Berlin, Germany|Investigational Site Number 276003, Bochum, Germany|Investigational Site Number 276010, Frankfurt Am Main, Germany|Investigational Site Number 276011, Großhansdorf, Germany|Investigational Site Number 276009, Koblenz, Germany|Investigational Site Number 276005, Rüdersdorf Bei Berlin, Germany|Investigational Site Number 348301, Balassagyarmat, Hungary|Investigational Site Number 348303, Edelény, Hungary|Investigational Site Number 348003, Gödöllö, Hungary|Investigational Site Number 376003, Haifa, Israel|Investigational Site Number 376001, Kfar Saba, Israel|Investigational Site Number 376005, Petah-Tikva, Israel|Investigational Site Number 376002, Rehovot, Israel|Investigational Site Number 380010, Ancona, Italy|Investigational Site Number 380009, Catania, Italy|Investigational Site Number 380004, Ferrara, Italy|Investigational Site Number 380008, Foggia, Italy|Investigational Site Number 380002, Genova, Italy|Investigational Site Number 380003, Modena, Italy|Investigational Site Number 380007, Padova, Italy|Investigational Site Number 380099, Palermo, Italy|Investigational Site Number 380001, Pisa, Italy|Investigational Site Number 392185, Akashi-Shi, Japan|Investigational Site Number 392009, Asahi-Shi, Japan|Investigational Site Number 392037, Chiyoda-Ku, Japan|Investigational Site Number 392002, Chuo-Ku, Japan|Investigational Site Number 392007, Chuo-Ku, Japan|Investigational Site Number 392112, Chuo-Ku, Japan|Investigational Site Number 392012, Edogawa-Ku, Japan|Investigational Site Number 392137, Fukuoka-Shi, Japan|Investigational Site Number 392021, Fukuyama-Shi, Japan|Investigational Site Number 392030, Habikino-Shi, Japan|Investigational Site Number 392004, Himeji-Shi, Japan|Investigational Site Number 392032, Hirakata-Shi, Japan|Investigational Site Number 392108, Hiroshima-Shi, Japan|Investigational Site Number 392158, Hiroshima-Shi, Japan|Investigational Site Number 392013, Iizuka-Shi, Japan|Investigational Site Number 392042, Isesaki-Shi, Japan|Investigational Site Number 392023, Kanazawa-Shi, Japan|Investigational Site Number 392142, Kasuga-Shi, Japan|Investigational Site Number 392119, Kishiwada-Shi, Japan|Investigational Site Number 392025, Kobe-Shi, Japan|Investigational Site Number 392162, Kobe-Shi, Japan|Investigational Site Number 392040, Kodaira-Shi, Japan|Investigational Site Number 392044, Kokubunji-Shi, Japan|Investigational Site Number 392131, Koushi-Shi, Japan|Investigational Site Number 392010, Kurashiki-Shi, Japan|Investigational Site Number 392036, Kyoto-Shi, Japan|Investigational Site Number 392153, Kyoto-Shi, Japan|Investigational Site Number 392133, Machida-Shi, Japan|Investigational Site Number 392135, Matsuyama-Shi, Japan|Investigational Site Number 392122, Minato-Ku, Japan|Investigational Site Number 392144, Minato-Ku, Japan|Investigational Site Number 392106, Mizunami-Shi, Japan|Investigational Site Number 392164, Muroran-Shi, Japan|Investigational Site Number 392163, Nagoya-Shi, Japan|Investigational Site Number 392020, Naka-Gun, Japan|Investigational Site Number 392005, Naruto-Shi, Japan|Investigational Site Number 392187, Obihiro-Shi, Japan|Investigational Site Number 392177, Ome-Shi, Japan|Investigational Site Number 392152, Osaka Sayama-Shi, Japan|Investigational Site Number 392155, Osaka Sayama-Shi, Japan|Investigational Site Number 392170, Osaki-Shi, Japan|Investigational Site Number 392127, Ota-Ku, Japan|Investigational Site Number 392043, Ota-Shi, Japan|Investigational Site Number 392169, Sagamihara-Shi, Japan|Investigational Site Number 392024, Sakai-Shi, Japan|Investigational Site Number 392011, Sakaide-Shi, Japan|Investigational Site Number 392008, Sapporo-Shi, Japan|Investigational Site Number 392034, Sapporo-Shi, Japan|Investigational Site Number 392038, Setagaya-Ku, Japan|Investigational Site Number 392179, Seto-Shi, Japan|Investigational Site Number 392186, Shibuya-Ku, Japan|Investigational Site Number 392167, Shinagawa-Ku, Japan|Investigational Site Number 392130, Shinjuku-Ku, Japan|Investigational Site Number 392165, Sumida-Ku, Japan|Investigational Site Number 392146, Tachikawa-Shi, Japan|Investigational Site Number 392173, Tachikawa-Shi, Japan|Investigational Site Number 392006, Tomakomai-Shi, Japan|Investigational Site Number 392029, Tsu-Shi, Japan|Investigational Site Number 392168, Uozu-Shi, Japan|Investigational Site Number 392132, Urasoe-Shi, Japan|Investigational Site Number 392045, Uruma-Shi, Japan|Investigational Site Number 392014, Yokohama-Shi, Japan|Investigational Site Number 410002, Bucheon-Si, Korea, Republic of|Investigational Site Number 410003, Cheongju-Si, Korea, Republic of|Investigational Site Number 410013, Incheon, Korea, Republic of|Investigational Site Number 410006, Seoul, Korea, Republic of|Investigational Site Number 410008, Seoul, Korea, Republic of|Investigational Site Number 410004, Seoul, Korea, Republic of|Investigational Site Number 410012, Seoul, Korea, Republic of|Investigational Site Number 410005, Seoul, Korea, Republic of|Investigational Site Number 410007, Seoul, Korea, Republic of|Investigational Site Number 410010, Seoul, Korea, Republic of|Investigational Site Number 410011, Seoul, Korea, Republic of|Investigational Site Number 410001, Suwon, Korea, Republic of|Investigational Site Number 484013, Chihuahua, Mexico|Investigational Site Number 484006, Chihuahua, Mexico|Investigational Site Number 484014, Cuautitlan Izcalli, Mexico|Investigational Site Number 484005, Distrito Federal, Mexico|Investigational Site Number 484008, Durango, Mexico|Investigational Site Number 484001, Guadalajara, Mexico|Investigational Site Number 484004, Mexico City, Mexico|Investigational Site Number 484003, Monterrey, Mexico|Investigational Site Number 484007, Monterrey, Mexico|Investigational Site Number 484010, México, Mexico|Investigational Site Number 484012, San Juan Del Rio, Mexico|Investigational Site Number 484011, Veracruz, Mexico|Investigational Site Number 528001, Arnhem, Netherlands|Investigational Site Number 528002, Dordrecht, Netherlands|Investigational Site Number 616006, Bialystok, Poland|Investigational Site Number 616004, Gdansk, Poland|Investigational Site Number 616003, Gdansk, Poland|Investigational Site Number 616007, Krakow, Poland|Investigational Site Number 616097, Krakow, Poland|Investigational Site Number 616001, Lodz, Poland|Investigational Site Number 616005, Lodz, Poland|Investigational Site Number 616009, Lodz, Poland|Investigational Site Number 616096, Poznan, Poland|Investigational Site Number 616098, Strzelce Opolskie, Poland|Investigational Site Number 616008, Warszawa, Poland|Investigational Site Number 616010, Warszawa, Poland|Investigational Site Number 616011, Znin, Poland|Investigational Site Number 642104, Bucharest, Romania|Investigational Site Number 642103, Bucharest, Romania|Investigational Site Number 642102, Cluj-Napoca, Romania|Investigational Site Number 642107, Cluj-Napoca, Romania|Investigational Site Number 642105, Timisoara, Romania|Investigational Site Number 642106, Timisoara, Romania|Investigational Site Number 643013, Ekaterinburg, Russian Federation|Investigational Site Number 643096, Moscow, Russian Federation|Investigational Site Number 643002, Moscow, Russian Federation|Investigational Site Number 643005, Moscow, Russian Federation|Investigational Site Number 643007, Moscow, Russian Federation|Investigational Site Number 643012, Moscow, Russian Federation|Investigational Site Number 643001, Moscow, Russian Federation|Investigational Site Number 643006, Novosibirsk, Russian Federation|Investigational Site Number 643091, Ryazan, Russian Federation|Investigational Site Number 643011, Saint-Petersburg, Russian Federation|Investigational Site Number 643010, Saint-Petersburg, Russian Federation|Investigational Site Number 643099, St-Petersburg, Russian Federation|Investigational Site Number 643009, St-Petersburg, Russian Federation|Investigational Site Number 643008, Yaroslavl, Russian Federation|Investigational Site Number 710009, Brandfort, South Africa|Investigational Site Number 710011, Cape Town, South Africa|Investigational Site Number 710001, Cape Town, South Africa|Investigational Site Number 710091, Cape Town, South Africa|Investigational Site Number 710092, Cape Town, South Africa|Investigational Site Number 710002, Cape Town, South Africa|Investigational Site Number 710003, Cape Town, South Africa|Investigational Site Number 710006, Durban, South Africa|Investigational Site Number 710007, Pretoria, South Africa|Investigational Site Number 724014, Barcelona, Spain|Investigational Site Number 724002, Barcelona, Spain|Investigational Site Number 724001, Barcelona, Spain|Investigational Site Number 724010, Palma De Mallorca, Spain|Investigational Site Number 724006, Pozuelo De Alarcón, Spain|Investigational Site Number 724003, Sabadell, Spain|Investigational Site Number 724007, Sant Boi De Llobregat, Spain|Investigational Site Number 724096, Santiago De Compostela, Spain|Investigational Site Number 724008, Sevilla, Spain|Investigational Site Number 724097, Valencia, Spain|Investigational Site Number 158008, New Taipei City, Taiwan|Investigational Site Number 158007, Taichung, Taiwan|Investigational Site Number 158009, Taipei, Taiwan|Investigational Site Number 792002, Ankara, Turkey|Investigational Site Number 792098, Ankara, Turkey|Investigational Site Number 792008, Bursa, Turkey|Investigational Site Number 792007, Istanbul, Turkey|Investigational Site Number 792001, Istanbul, Turkey|Investigational Site Number 792004, Istanbul, Turkey|Investigational Site Number 792003, Istanbul, Turkey|Investigational Site Number 792005, Izmir, Turkey|Investigational Site Number 792090, Izmir, Turkey|Investigational Site Number 792013, Kirikkale, Turkey|Investigational Site Number 792006, Mersin, Turkey|Investigational Site Number 792096, Rize, Turkey|Investigational Site Number 804007, Chernivtsi, Ukraine|Investigational Site Number 804023, Dnipro, Ukraine|Investigational Site Number 804009, Ivano-Frankivsk, Ukraine|Investigational Site Number 804094, Ivano-Frankivsk, Ukraine|Investigational Site Number 804005, Kharkiv, Ukraine|Investigational Site Number 804021, Kharkiv, Ukraine|Investigational Site Number 804001, Kharkiv, Ukraine|Investigational Site Number 804004, Kyiv, Ukraine|Investigational Site Number 804003, Kyiv, Ukraine|Investigational Site Number 804008, Kyiv, Ukraine|Investigational Site Number 804017, Kyiv, Ukraine|Investigational Site Number 804018, Kyiv, Ukraine|Investigational Site Number 804020, Kyiv, Ukraine|Investigational Site Number 804016, Kyiv, Ukraine|Investigational Site Number 804006, Odesa, Ukraine|Investigational Site Number 804002, Poltava, Ukraine|Investigational Site Number 804014, Ternopil, Ukraine|Investigational Site Number 804019, Vinnytsya, Ukraine|Investigational Site Number 804015, Yalta, Ukraine|Investigational Site Number 804022, Zaporizhzhya, Ukraine|Investigational Site Number 804012, Zaporizhzhya, Ukraine|Investigational Site Number 826001, Bradford, United Kingdom|Investigational Site Number 826010, London, United Kingdom|Investigational Site Number 826009, Oxford, United Kingdom|Investigational Site Number 826007, Portsmouth, United Kingdom|Investigational Site Number 826006, South Shields, United Kingdom","""Study Protocol"", https://ClinicalTrials.gov/ProvidedDocs/28/NCT02134028/Prot_000.pdf|""Statistical Analysis Plan"", https://ClinicalTrials.gov/ProvidedDocs/28/NCT02134028/SAP_001.pdf","https://ClinicalTrials.gov/show/NCT02134028"
396,"NCT02121210","To Evaluate the Immunogenicity and Safety of Sarilumab Administered as Monotherapy in Patients With Rheumatoid Arthritis (RA)","SARIL-RA-ONE","Completed","Has Results","Rheumatoid Arthritis","Drug: sarilumab SAR153191 (REGN88)","Percentage of Participants With Incidence of Antidrug Antibodies (ADA)|Serum Sarilumab Concentration","Sanofi|Regeneron Pharmaceuticals","All","18 Years and older   (Adult, Older Adult)","Phase 3","132","Industry","Interventional","Allocation: Randomized|Intervention Model: Parallel Assignment|Masking: None (Open Label)|Primary Purpose: Treatment","EFC13752|2013-002790-22|U1111-1143-4344","June 2014","May 2015","May 2015","April 23, 2014","June 20, 2017","June 20, 2017","Investigational Site Number 840072, Gilbert, Arizona, United States|Investigational Site Number 840049, Upland, California, United States|Investigational Site Number 840220, South Miami, Florida, United States|Investigational Site Number 840230, Elizabethtown, Kentucky, United States|Investigational Site Number 840233, Minot, North Dakota, United States|Investigational Site Number 840127, Oklahoma City, Oklahoma, United States|Investigational Site Number 840011, Tulsa, Oklahoma, United States|Investigational Site Number 840009, Duncansville, Pennsylvania, United States|Investigational Site Number 840025, Jackson, Tennessee, United States|Investigational Site Number 840032, Amarillo, Texas, United States|Investigational Site Number 840074, Mesquite, Texas, United States|Investigational Site Number 840124, Clarksburg, West Virginia, United States|Investigational Site Number 840231, Franklin, Wisconsin, United States|Investigational Site Number 152002, Santiago, Chile|Investigational Site Number 203034, Pardubice, Czechia|Investigational Site Number 203001, Praha 2, Czechia|Investigational Site Number 203002, Uherske Hradiste, Czechia|Investigational Site Number 233010, Tallinn, Estonia|Investigational Site Number 233002, Tallinn, Estonia|Investigational Site Number 348014, Budapest, Hungary|Investigational Site Number 348025, Budapest, Hungary|Investigational Site Number 348021, Esztergom, Hungary|Investigational Site Number 616018, Poznan, Poland|Investigational Site Number 616031, Warszawa, Poland|Investigational Site Number 616012, Wroclaw, Poland|Investigational Site Number 643006, Kemerovo, Russian Federation|Investigational Site Number 643001, Moscow, Russian Federation|Investigational Site Number 643016, Ryazan, Russian Federation",,"https://ClinicalTrials.gov/show/NCT02121210"
397,"NCT02120950","Aflibercept in Polypoidal Choroidal Vasculopathy","PLANET","Completed","Has Results","Neovascular Macular Degeneration","Drug: Aflibercept (Eylea, VEGF Trap-Eye, BAY86-5321)|Other: Visudyne","Mean Change in Best Corrected Visual Acuity (BCVA) as Measured by Early Treatment of Diabetic Retinopathy Study (ETDRS) Letter Scores From Baseline to Week 52 - Last Observation Carried Forward (LOCF)|Percentage of Subjects Who Avoided at Least 15 Letters Loss in ETDRS at Week 52","Bayer|Regeneron Pharmaceuticals","All","50 Years and older   (Adult, Older Adult)","Phase 4","333","Industry","Interventional","Allocation: Randomized|Intervention Model: Parallel Assignment|Masking: Quadruple (Participant, Care Provider, Investigator, Outcomes Assessor)|Primary Purpose: Treatment","16995|2013-004464-54","May 29, 2014","August 12, 2016","July 7, 2017","April 23, 2014","January 15, 2019","December 2, 2020","Liverpool, New South Wales, Australia|Strathfield, New South Wales, Australia|Westmead, New South Wales, Australia|East Melbourne, Victoria, Australia|Parramatta, Australia|München, Germany|Hong Kong, Hong Kong|Kowloon, Hong Kong|Budapest, Hungary|Budapest, Hungary|Budapest, Hungary|Debrecen, Hungary|Nagoya, Aichi, Japan|Urayasu, Chiba, Japan|Ogaki, Gifu, Japan|Maebashi, Gunma, Japan|Asahikawa, Hokkaido, Japan|Sapporo, Hokkaido, Japan|Amagasaki, Hyogo, Japan|Kobe, Hyogo, Japan|Kita, Kagawa, Japan|Tsu, Mie, Japan|Kashihara, Nara, Japan|Hirakata, Osaka, Japan|Suita, Osaka, Japan|Otsu, Shiga, Japan|Hamamatsu, Shizuoka, Japan|Shimotsuke, Tochigi, Japan|Bunkyo-ku, Tokyo, Japan|Chiyoda-ku, Tokyo, Japan|Meguro-ku, Tokyo, Japan|Mitaka, Tokyo, Japan|Shinjuku-ku, Tokyo, Japan|Shinjuku-ku, Tokyo, Japan|Akita, Japan|Aomori, Japan|Chiba, Japan|Fukuoka, Japan|Fukuoka, Japan|Fukushima, Japan|Kumamoto, Japan|Kyoto, Japan|Kyoto, Japan|Nagasaki, Japan|Okayama, Japan|Osaka, Japan|Tokushima, Japan|Wakayama, Japan|Seongnam-si, Gyeonggido, Korea, Republic of|Seoul, Korea, Republic of|Seoul, Korea, Republic of|Seoul, Korea, Republic of|Seoul, Korea, Republic of|Seoul, Korea, Republic of|Singapore, Singapore|Singapore, Singapore|Changhua City, Changhua, Taiwan|Kaohsiung, Taiwan|Taipei City, Taiwan|Taipei, Taiwan|Taipei, Taiwan|Taipei, Taiwan",,"https://ClinicalTrials.gov/show/NCT02120950"
398,"NCT02107898","Efficacy and Safety Evaluation of Alirocumab in Patients With Heterozygous Familial Hypercholesterolemia or High Cardiovascular Risk Patients With Hypercholesterolemia on Lipid Modifying Therapy (ODYSSEY JAPAN)",,"Completed","Has Results","Hypercholesterolemia","Drug: Placebo (for alirocumab)|Drug: Alirocumab|Drug: Lipid-Modifying Therapy (LMT)","Percent Change From Baseline in Calculated LDL-C at Week 24 - Intent-to-Treat (ITT Analysis)|Percent Change From Baseline in Calculated LDL-C at Week 24 - On-Treatment Analysis|Percent Change From Baseline in Calculated LDL-C at Week 12 - ITT Analysis|Percent Change From Baseline in Calculated LDL-C at Week 12 - On-treatment Analysis|Percent Change From Baseline in Apolipoprotein (Apo) B at Week 24 - ITT Analysis|Percent Change From Baseline in Apo B at Week 24 - On-Treatment Analysis|Percent Change From Baseline in Non-High Density Lipoprotein Cholesterol (Non-HDL-C) at Week 24 - ITT Analysis|Percent Change From Baseline in Non-HDL-C at Week 24 - On-Treatment Analysis|Percent Change From Baseline in Total Cholesterol (Total-C) at Week 24 - ITT Analysis|Percent Change From Baseline in Apo B at Week 12 - ITT Analysis|Percent Change From Baseline in Non-HDL-C at Week 12 - ITT Analysis|Percent Change From Baseline in Total-C at Week 12 - ITT Analysis|Percentage of Participants Reaching Calculated LDL-C Goal at Week 24 - ITT Analysis|Percentage of Participants Reaching Calculated LDL-C Goal at Week 24 - On-Treatment Analysis|Percent Change From Baseline in Lipoprotein (a) at Week 24 - ITT Analysis|Percent Change From Baseline in Fasting Triglycerides at Week 24 - ITT Analysis|Percent Change From Baseline in HDL-C at Week 24 - ITT Analysis|Percent Change From Baseline in Apo A1 at Week 24 - ITT Analysis|Percent Change From Baseline in Lipoprotein (a) at Week 12 - ITT Analysis|Percent Change From Baseline in Fasting Triglycerides at Week 12 - ITT Analysis|Percent Change From Baseline in HDL-C at Week 12 - ITT Analysis|Percent Change From Baseline in Apo A1 at Week 12 - ITT Analysis","Sanofi|Regeneron Pharmaceuticals","All","20 Years to 80 Years   (Adult, Older Adult)","Phase 3","216","Industry","Interventional","Allocation: Randomized|Intervention Model: Parallel Assignment|Masking: Quadruple (Participant, Care Provider, Investigator, Outcomes Assessor)|Primary Purpose: Treatment","EFC13672|U1111-1115-7486","March 2014","January 2015","September 2015","April 8, 2014","January 29, 2016","October 4, 2016","Investigational Site Number 392016, Adachi-Ku, Japan|Investigational Site Number 392029, Adachi-Ku, Japan|Investigational Site Number 392024, Aki-Gun, Japan|Investigational Site Number 392012, Chuo-Ku, Japan|Investigational Site Number 392013, Chuo-Ku, Japan|Investigational Site Number 392032, Fukui-Shi, Japan|Investigational Site Number 392004, Hakusan-Shi, Japan|Investigational Site Number 392028, Kaga-Shi, Japan|Investigational Site Number 392002, Kanazawa-Shi, Japan|Investigational Site Number 392005, Kanazawa-Shi, Japan|Investigational Site Number 392023, Kawanishi-Shi, Japan|Investigational Site Number 392009, Kisarazu-Shi, Japan|Investigational Site Number 392026, Kitakyushu-Shi, Japan|Investigational Site Number 392003, Komatsu-Shi, Japan|Investigational Site Number 392011, Kuki-Shi, Japan|Investigational Site Number 392017, Matsumoto-Shi, Japan|Investigational Site Number 392007, Mito-Shi, Japan|Investigational Site Number 392006, Moriya-Shi, Japan|Investigational Site Number 392018, Nagoya-Shi, Japan|Investigational Site Number 392014, Oota-Ku, Japan|Investigational Site Number 392019, Osaka-Shi, Japan|Investigational Site Number 392020, Osaka-Shi, Japan|Investigational Site Number 392022, Osaka-Shi, Japan|Investigational Site Number 392030, Osaka-Shi, Japan|Investigational Site Number 392027, Oyabe-Shi, Japan|Investigational Site Number 392010, Saitama-Shi, Japan|Investigational Site Number 392015, Shinjuku-Ku, Japan|Investigational Site Number 392031, Shizuoka-Shi, Japan|Investigational Site Number 392021, Suita-Shi, Japan|Investigational Site Number 392025, Takamatsu-Shi, Japan|Investigational Site Number 392008, Tsuchiura-Shi, Japan|Investigational Site Number 392001, Yamagata-Shi, Japan",,"https://ClinicalTrials.gov/show/NCT02107898"
399,"NCT02092532","Intravitreal Aflibercept for Neovascular Polypoidal Choroidal Vasculopathy (RIVAL Trial)","RIVAL","Unknown status","No Results Available","Neovascular Polypoidal Choroidal Vasculopathy","Drug: Rescue Intravitreal Aflibercept Injection|Procedure: Rescue Therapy with PDT, Laser or Intravitreal Steroids","Incidence and Severity|Change in Best Corrected Visual Acuity (BCVA)|Photography Assessments","Southeast Retina Center, Georgia|Regeneron Pharmaceuticals","All","18 Years and older   (Adult, Older Adult)","Phase 4","20","Other|Industry","Interventional","Allocation: N/A|Intervention Model: Single Group Assignment|Masking: None (Open Label)|Primary Purpose: Treatment","VGFTe-AMD-1401","March 2014","March 2015","March 2016","March 20, 2014",,"October 15, 2014","Southeast Retina Center, PC, Augusta, Georgia, United States",,"https://ClinicalTrials.gov/show/NCT02092532"
400,"NCT02085005","Capecitabine Plus Aflibercept as Maintenance Therapy Following Capecitabine Plus Oxaliplatin Plus Aflibercept in Patients With Metastatic Colorectal Cancer","Drop and Go","Withdrawn","No Results Available","Colorectal Cancer Metastatic","Drug: Capecitabine|Drug: Aflibercept AVE0005|Drug: Oxaliplatin SR96669","Progression Free Survival rate at 10 months (PFS@10m)|Progression Free Survival (PFS) - Time|Overall Survival (OS) - Time|Assessment of Objective Response Rate (ORR)|Total Score as a measure of Health Related Quality of Life|Number of participants with adverse events","Sanofi|Regeneron Pharmaceuticals","All","18 Years and older   (Adult, Older Adult)","Phase 2","0","Industry","Interventional","Allocation: N/A|Intervention Model: Single Group Assignment|Masking: None (Open Label)|Primary Purpose: Treatment","LPS13787|U1111-1149-0237","March 2014","August 2016","August 2016","March 12, 2014",,"November 18, 2014",,,"https://ClinicalTrials.gov/show/NCT02085005"
401,"NCT02057250","To Evaluate Sarilumab - SAR153191 (REGN88) - Auto-injector Device In Patients With Rheumatoid Arthritis","SARIL-RA-EASY","Completed","Has Results","RA","Drug: Sarilumab|Device: Auto-Injector Device (AID)|Device: Pre-filled Syringe (PFS)|Drug: Methotrexate|Drug: Sulfasalazine|Drug: Leflunomide|Drug: Hydroxychloroquine","Number of Validated AID Associated Product Technical Failures (PTFs)|Area Under the Serum Concentration Versus Time Curve Calculated Using the Trapezoidal Method During a Dose Interval (AUC[0-tau]) for Sarilumab","Sanofi|Regeneron Pharmaceuticals","All","18 Years and older   (Adult, Older Adult)","Phase 3","217","Industry","Interventional","Allocation: Randomized|Intervention Model: Parallel Assignment|Masking: None (Open Label)|Primary Purpose: Treatment","MSC12665|2012-004339-21|U1111-1130-9931","March 2014","February 2015","March 2016","February 7, 2014","June 20, 2017","June 20, 2017","Investigational Site Number 840152, Huntsville, Alabama, United States|Investigational Site Number 840221, Peoria, Arizona, United States|Investigational Site Number 840226, Roseville, California, United States|Investigational Site Number 840223, Boulder, Colorado, United States|Investigational Site Number 840229, Miami, Florida, United States|Investigational Site Number 840236, Orlando, Florida, United States|Investigational Site Number 840155, Palm Harbor, Florida, United States|Investigational Site Number 840220, South Miami, Florida, United States|Investigational Site Number 840202, Hagerstown, Maryland, United States|Investigational Site Number 840232, Flint, Michigan, United States|Investigational Site Number 840233, Kalamazoo, Michigan, United States|Investigational Site Number 840037, Tupelo, Mississippi, United States|Investigational Site Number 840112, Lincoln, Nebraska, United States|Investigational Site Number 840039, Albany, New York, United States|Investigational Site Number 840224, Cincinnati, Ohio, United States|Investigational Site Number 840002, Oklahoma City, Oklahoma, United States|Investigational Site Number 840065, Tulsa, Oklahoma, United States|Investigational Site Number 840009, Duncansville, Pennsylvania, United States|Investigational Site Number 840062, Reading, Pennsylvania, United States|Investigational Site Number 840016, North Charleston, South Carolina, United States|Investigational Site Number 840025, Jackson, Tennessee, United States|Investigational Site Number 840038, Austin, Texas, United States|Investigational Site Number 840230, Carrollton, Texas, United States|Investigational Site Number 840001, Dallas, Texas, United States|Investigational Site Number 840020, Houston, Texas, United States|Investigational Site Number 840239, Houston, Texas, United States|Investigational Site Number 840241, Houston, Texas, United States|Investigational Site Number 840242, Houston, Texas, United States|Investigational Site Number 840069, Lubbock, Texas, United States|Investigational Site Number 840074, Mesquite, Texas, United States|Investigational Site Number 840237, Plano, Texas, United States|Investigational Site Number 152005, Osorno, Chile|Investigational Site Number 152050, Santiago, Chile|Investigational Site Number 152014, Talca, Chile|Investigational Site Number 152007, Viña Del Mar, Chile|Investigational Site Number 484002, Guadalajara, Mexico|Investigational Site Number 484004, Merida, Mexico|Investigational Site Number 484005, Monterrey, Mexico|Investigational Site Number 616002, Bialystok, Poland|Investigational Site Number 616005, Lublin, Poland|Investigational Site Number 616004, Warszawa, Poland|Investigational Site Number 616017, Warszawa, Poland|Investigational Site Number 616012, Wroclaw, Poland|Investigational Site Number 643006, Kemerovo, Russian Federation|Investigational Site Number 643020, Moscow, Russian Federation|Investigational Site Number 643001, Moscow, Russian Federation|Investigational Site Number 643008, Saint-Petersburg, Russian Federation|Investigational Site Number 710050, Bellville, South Africa|Investigational Site Number 710011, Cape Town, South Africa|Investigational Site Number 710007, Cape Town, South Africa|Investigational Site Number 710003, Durban, South Africa|Investigational Site Number 710001, Johannesburg, South Africa|Investigational Site Number 710051, Port Elizabeth, South Africa",,"https://ClinicalTrials.gov/show/NCT02057250"
402,"NCT02040220","Prospective, Non-interventional, Multi-center Post-authorization Safety Study of Eylea for Central Retinal Vein Occlusion (CRVO)","JPMS-CRVO","Completed","No Results Available","Retinal Vein Occlusion","Drug: Aflibercept (Eylea, VEGF Trap-Eye, BAY86-5321)","Number of episodes of adverse drug reactions and adverse events(serious or non-serious, related or not related, ocular or non ocular)|Effectiveness (visual acuity)|Effectiveness (retina thickness)","Bayer|Regeneron Pharmaceuticals","All","Child, Adult, Older Adult",,"385","Industry","Observational","Observational Model: Cohort|Time Perspective: Prospective","16641|EYL-CRVO","January 24, 2014","June 1, 2018","November 9, 2018","January 20, 2014",,"April 10, 2019","Multiple Locations, Japan",,"https://ClinicalTrials.gov/show/NCT02040220"
403,"NCT02023879","Phase III Study To Evaluate Alirocumab in Patients With Hypercholesterolemia Not Treated With a Statin (ODYSSEY CHOICE II)",,"Completed","Has Results","Hypercholesterolemia","Drug: Alirocumab|Drug: Placebo (for Alirocumab)|Drug: Non-statin LMT|Other: Diet Alone","Percent Change From Baseline in Calculated LDL-C at Week 24 - Intent-to-Treat (ITT Analysis)|Percent Change From Baseline in Calculated LDL-C at Week 24 - On-Treatment Analysis|Percent Change From Baseline in Calculated LDL-C at Week 12 - ITT Analysis|Percent Change From Baseline in Calculated LDL-C at Week 12 - On-Treatment Analysis|Percent Change From Baseline in Calculated LDL-C to Averaged Weeks 9 to 12 - ITT- Analysis|Percent Change From Baseline in Calculated LDL-C at Averaged Week 9 to 12 - On-Treatment Analysis|Percent Change From Baseline in Apolipoprotein (Apo) B at Week 24 - ITT Analysis|Percent Change From Baseline in Apo B at Week 24 - On-treatment Analysis|Percent Change From Baseline in Non-HDL-C at Week 24 - ITT Analysis|Percent Change From Baseline in Non-HDL-C at Week 24 - On-treatment Analysis|Percent Change From Baseline in Total-C at Week 24 - ITT Analysis|Percent Change From Baseline in Apo B at Week 12 - ITT Analysis|Percent Change From Baseline in Non-HDL-C at Week 12 - ITT Analysis|Percent Change From Baseline in Total-C at Week 12 - ITT Analysis|Percentage of Very High Cardiovascular (CV) Risk Participants Achieving Calculated LDL-C <70 mg/dL (<1.81 mmol/L) or Moderate or High CV Risk Participants Achieving Calculated LDL-C <100 mg/dL (<2.59 mmol/L) at Week 24 - ITT Analysis|Percentage of Very High CV Risk Participants Achieving Calculated LDL-C< 70 mg/dL (<1.81 mmol/L) or Moderate or High CV Risk Participants Achieving Calculated LDL-C< 100 mg/dL (<2.59 mmol/L) at Week 24 - On-treatment Analysis|Percentage of Participants Achieving Calculated LDL-C< 70 mg/dL (<1.81 mmol/L) at Week 24 - ITT Analysis|Percentage of Participants Achieving Calculated LDL-C <70 mg/dL (<1.81 mmol/L) at Week 24 - On-treatment Analysis|Percent Change From Baseline in Lipoprotein (a) at Week 24 - ITT Analysis|Percent Change From Baseline in Lipoprotein (a) at Week 12 - ITT Analysis|Percent Change From Baseline in HDL-C at Week 24 - ITT Analysis|Percent Change From Baseline in HDL-C at Week 12 - ITT Analysis|Percent Change From Baseline in Fasting Triglycerides at Week 24 - ITT Analysis|Percent Change From Baseline in Fasting Triglycerides at Week 12 - ITT Analysis|Percent Change From Baseline in Apo A-1 at Week 24 - ITT Analysis|Percent Change From Baseline in Apo A-1 at Week 12 - ITT Analysis","Sanofi|Regeneron Pharmaceuticals","All","18 Years and older   (Adult, Older Adult)","Phase 3","233","Industry","Interventional","Allocation: Randomized|Intervention Model: Parallel Assignment|Masking: Triple (Participant, Care Provider, Investigator)|Primary Purpose: Treatment","EFC13786|2013-002659-14|U1111-1146-3517","December 16, 2013","October 27, 2014","June 30, 2017","December 30, 2013","March 15, 2017","July 27, 2018","Investigational Site Number 840703, Beverly Hills, California, United States|Investigational Site Number 840704, Atlantis, Florida, United States|Investigational Site Number 840708, Jacksonville, Florida, United States|Investigational Site Number 840701, Sarasota, Florida, United States|Investigational Site Number 840706, Fall River, Massachusetts, United States|Investigational Site Number 840705, Saint Louis, Missouri, United States|Investigational Site Number 840707, Durham, North Carolina, United States|Investigational Site Number 840702, Summerville, South Carolina, United States|Investigational Site Number 036703, Ashford, Australia|Investigational Site Number 036702, Perth, Australia|Investigational Site Number 036701, Woolloongabba, Australia|Investigational Site Number 056702, Antwerpen, Belgium|Investigational Site Number 056703, Haine-Saint-Paul, Belgium|Investigational Site Number 056701, Leuven, Belgium|Investigational Site Number 124703, Chicoutimi, Canada|Investigational Site Number 124701, Quebec, Canada|Investigational Site Number 124704, Sherbrooke, Canada|Investigational Site Number 124706, Toronto, Canada|Investigational Site Number 124702, Vancouver, Canada|Investigational Site Number 124705, Victoria, Canada|Investigational Site Number 208703, Aarhus, Denmark|Investigational Site Number 208702, Esbjerg, Denmark|Investigational Site Number 208701, Glostrup, Denmark|Investigational Site Number 208704, Hvidovre, Denmark|Investigational Site Number 208705, Køge, Denmark|Investigational Site Number 528701, Amsterdam, Netherlands|Investigational Site Number 528708, Den Helder, Netherlands|Investigational Site Number 528702, Hoogeveen, Netherlands|Investigational Site Number 528703, Hoorn, Netherlands|Investigational Site Number 528706, Rotterdam, Netherlands|Investigational Site Number 528709, Sneek, Netherlands|Investigational Site Number 528704, Utrecht, Netherlands|Investigational Site Number 528707, Venlo, Netherlands|Investigational Site Number 554702, Auckland, New Zealand|Investigational Site Number 554701, Christchurch, New Zealand|Investigational Site Number 724703, A Coruna, Spain|Investigational Site Number 724707, Barcelona, Spain|Investigational Site Number 724710, Barcelona, Spain|Investigational Site Number 724702, Córdoba, Spain|Investigational Site Number 724705, Granada, Spain|Investigational Site Number 724709, Sant Joan Despí, Spain|Investigational Site Number 724706, Santiago De Compostela, Spain|Investigational Site Number 724701, Zaragoza, Spain",,"https://ClinicalTrials.gov/show/NCT02023879"
404,"NCT02017639","Sarilumab Effect on the Pharmacokinetics of Simvastatin",,"Completed","No Results Available","Rheumatoid Arthritis","Drug: sarilumab SAR153191 (REGN88)|Drug: simvastatin","Assessment of PK parameters - area under curve from zero time until the last measurable concentration (AUClast) and AUC for simvastatin|Assessment of additional PK parameters for simvastatin|Assessment of additional PK parameters for simvastatin acid|Safety assessment of sarilumab up to 1 year )","Sanofi|Regeneron Pharmaceuticals","All","18 Years to 75 Years   (Adult, Older Adult)","Phase 1","19","Industry","Interventional","Allocation: Non-Randomized|Intervention Model: Single Group Assignment|Masking: None (Open Label)|Primary Purpose: Health Services Research","INT12684|U1111-1140-5082","January 2014","March 2016","March 2016","December 23, 2013",,"April 7, 2016","Investigational Site Number 840002, Duncansville, Pennsylvania, United States|Investigational Site Number 840003, Jackson, Tennessee, United States|Investigational Site Number 840001, Dallas, Texas, United States|Investigational Site Number 410002, Seoul, Korea, Republic of|Investigational Site Number 498001, Chisinau, Moldova, Republic of",,"https://ClinicalTrials.gov/show/NCT02017639"
405,"NCT01988246","Prevention of Macular Edema In Patients With Diabetic Retinopathy Undergoing Cataract Surgery","PROMISE","Completed","Has Results","Diabetic Retinopathy","Drug: Aflibercept|Drug: Sham","Number of Participants With Ocular and Non-Ocular Adverse Events|Change From Baseline in Best-Corrected Visual Acuity (BCVA) Score","Rishi Singh|Regeneron Pharmaceuticals|The Cleveland Clinic","All","18 Years and older   (Adult, Older Adult)","Phase 1|Phase 2","30","Other|Industry","Interventional","Allocation: Randomized|Intervention Model: Parallel Assignment|Masking: Single (Participant)|Primary Purpose: Prevention","PROMISE Trial","December 2013","April 25, 2018","January 14, 2020","November 20, 2013","May 22, 2020","May 22, 2020","Cole Eye Institute, Cleveland Clinic, Cleveland, Ohio, United States","""Study Protocol and Statistical Analysis Plan"", https://ClinicalTrials.gov/ProvidedDocs/46/NCT01988246/Prot_SAP_000.pdf|""Informed Consent Form"", https://ClinicalTrials.gov/ProvidedDocs/46/NCT01988246/ICF_001.pdf","https://ClinicalTrials.gov/show/NCT01988246"
406,"NCT01959971","Effect of Alirocumab on Lipid Metabolism in Adults With Elevated LDL-Cholesterol",,"Completed","No Results Available","Hypercholesterolemia","Drug: alirocumab|Drug: Placebo","Percent change in Fractional Clearance Rate of apolipoprotein B (apoB) in Low Density Lipoproteins (pools/day) in plasma during alirocumab treatment|Change in lipids turnover parameters measured in isolated Very Low Density Lipoproteins (VLDL), Intermediate Density Lipoproteins (IDL), Low Density Lipoproteins (LDL) and High Density Lipoproteins (HDL)|Change in post-heparin hepatic lipase and lipoprotein lipase activities|Change in lipids and apolipoproteins in plasma lipids panel|Assessment of Lipoprotein particle size profiles|Assessment of serum concentrations of PCSK9|Assessment of safety parameters (clinical laboratory, ECG, vital signs)|Assessment of the serum concentration of alirocumab|Assessment of the serum concentration of anti-alirocumab antibodies","Sanofi|Regeneron Pharmaceuticals","All","18 Years to 65 Years   (Adult, Older Adult)","Phase 1","20","Industry","Interventional","Intervention Model: Crossover Assignment|Masking: Single (Participant)|Primary Purpose: Basic Science","PDY13670|U1111-1141-4567","December 2013","May 2015","May 2015","October 10, 2013",,"May 2, 2017","Investigational Site Number 840001, New York, New York, United States",,"https://ClinicalTrials.gov/show/NCT01959971"
407,"NCT01955629","Study of Aflibercept as Maintenance Therapy Following Induction With Aflibercept in Combination With XELOX, as First-Line Treatment for Metastatic Colorectal Cancer Patient","AMOR","Terminated","Has Results","Colorectal Cancer Metastatic","Drug: Aflibercept AVE0005|Drug: Oxaliplatin|Drug: Capecitabine","Part 1: Number of Participants With Dose Limiting Toxicities (DLTs)|Part 2: Number of Participants With Progression Free Survival (PFS) at 6 Months After the Start of Maintenance Therapy|Part 1: Number of Participants With Tumor Responses (Complete Response [CR], Partial Response [PR], Stable Disease [SD] or Progressive Disease [PD])|Part 2: Progression Free Survival (PFS)|Part 2: Overall Survival (OS)|Part 2: Overall Rate of Resectability of Metastatic Lesions|Part 2: Number of Participants With CR or PR|Part 2: Pharmacodynamic Parameters: Modulation of Circulating Analytes|Part 2: Aflibercept Biomarkers Evaluation","Sanofi|Regeneron Pharmaceuticals","All","18 Years and older   (Adult, Older Adult)","Phase 1|Phase 2","4","Industry","Interventional","Allocation: N/A|Intervention Model: Single Group Assignment|Masking: None (Open Label)|Primary Purpose: Treatment","AFLIBC06561|2013-000858-22|U1111-1143-3015","December 2013","March 2015","March 2015","October 7, 2013","April 18, 2016","April 18, 2016","Investigational Site Number 380-001, Genova, Italy|Investigational Site Number 380-002, Milano, Italy",,"https://ClinicalTrials.gov/show/NCT01955629"
408,"NCT01954394","Open Label Study of Long Term Safety Evaluation of Alirocumab","ODYSSEY OLE","Completed","Has Results","Hypercholesterolemia","Drug: Alirocumab|Drug: Lipid-Modifying Therapy (LMT)","Percentage of Participants Who Experienced Adverse Events (AEs)|Percent Change From Baseline in Calculated LDL-C at Weeks 8, 24, 48, 72, 96, 120, 144 and 168|Absolute Change From Baseline in Calculated LDL-C (mg/dL) at Weeks 8, 24, 48, 72, 96, 120, 144 and 168|Absolute Change From Baseline in Calculated LDL-C (mmol/L) at Weeks 8, 24, 48, 72, 96, 120, 144 and 168|Percentage of Participants Reaching Calculated LDL-C <100 mg/dL (2.59 mmol/L) Over Time|Percentage of Participants Reaching Calculated LDL-C <70 mg/dL (1.81 mmol/L) Over Time|Percentage of Participants With Calculated LDL-C <70 mg/dL (1.81mmol/L) and/or >=50% Reduction in Calculated LDL-C From Baseline (if Calculated LDL-C >=70 mg/dL [1.81mmol/L]) Over Time|Percent Change From Baseline in Non-High Density Lipoprotein Cholesterol (Non-HDL-C) at Weeks 8, 24, 48, 72, 96, 120, 144 and 168|Percent Change From Baseline in Total-cholesterol at Weeks 8, 24, 48, 72, 96, 120, 144 and 168|Percent Change From Baseline in High Density Lipoprotein Cholesterol (HDL-C) at Weeks 8, 24, 48, 72, 96, 120, 144 and 168|Percent Change From Baseline in Fasting Triglycerides (TGs) at Weeks 8, 24, 48, 72, 96, 120, 144 and 168|Percent Change From Baseline in Lipoprotein (a) at Weeks 48, 96, 144 and 168|Percent Change From Baseline in Apolipoprotein-B (Apo-B) at Weeks 48, 96, 144, and 168|Percent Change From Baseline in Apolipoprotein A-1 (Apo A-1) at Weeks 48, 96, 144, and 168|Absolute Change From Baseline in Apo B/Apo A-1 Ratio at Weeks 48, 96, 144, and 168","Sanofi|Regeneron Pharmaceuticals","All","18 Years and older   (Adult, Older Adult)","Phase 3","986","Industry","Interventional","Allocation: N/A|Intervention Model: Single Group Assignment|Masking: None (Open Label)|Primary Purpose: Treatment","LTS13463|2013-002572-40|U1111-1143-3810","December 17, 2013","June 30, 2017","June 30, 2017","October 1, 2013","July 24, 2018","July 24, 2018","Investigational Site Number 840321, Huntsville, Alabama, United States|Investigational Site Number 840341, Tempe, Arizona, United States|Investigational Site Number 840334, Bell Gardens, California, United States|Investigational Site Number 840319, Fountain Valley, California, United States|Investigational Site Number 840336, Los Angeles, California, United States|Investigational Site Number 840339, Mission Viejo, California, United States|Investigational Site Number 840337, Newport Beach, California, United States|Investigational Site Number 840306, Golden, Colorado, United States|Investigational Site Number 840328, Washington, District of Columbia, United States|Investigational Site Number 840344, Atlantis, Florida, United States|Investigational Site Number 840353, Clearwater, Florida, United States|Investigational Site Number 840318, Fort Lauderdale, Florida, United States|Investigational Site Number 840327, Jacksonville, Florida, United States|Investigational Site Number 840309, Miami, Florida, United States|Investigational Site Number 840351, Sarasota, Florida, United States|Investigational Site Number 840315, Evanston, Illinois, United States|Investigational Site Number 840305, Oakbrook Terrace, Illinois, United States|Investigational Site Number 840333, Iowa City, Iowa, United States|Investigational Site Number 840329, Kansas City, Kansas, United States|Investigational Site Number 840345, Auburn, Maine, United States|Investigational Site Number 840338, Biddeford, Maine, United States|Investigational Site Number 840322, Boston, Massachusetts, United States|Investigational Site Number 840346, Framingham, Massachusetts, United States|Investigational Site Number 840317, Saint Louis, Missouri, United States|Investigational Site Number 840349, Saint Louis, Missouri, United States|Investigational Site Number 840314, Morristown, New Jersey, United States|Investigational Site Number 840316, New York, New York, United States|Investigational Site Number 840324, Poughkeepsie, New York, United States|Investigational Site Number 840303, Charlotte, North Carolina, United States|Investigational Site Number 840320, Durham, North Carolina, United States|Investigational Site Number 840348, Raleigh, North Carolina, United States|Investigational Site Number 840340, Cincinnati, Ohio, United States|Investigational Site Number 840302, Marion, Ohio, United States|Investigational Site Number 840330, Portland, Oregon, United States|Investigational Site Number 840352, Beaver, Pennsylvania, United States|Investigational Site Number 840308, Philadelphia, Pennsylvania, United States|Investigational Site Number 840342, Scranton, Pennsylvania, United States|Investigational Site Number 840304, Summerville, South Carolina, United States|Investigational Site Number 840311, Dallas, Texas, United States|Investigational Site Number 840312, Dallas, Texas, United States|Investigational Site Number 840301, Fort Worth, Texas, United States|Investigational Site Number 840343, Bountiful, Utah, United States|Investigational Site Number 840354, Chesapeake, Virginia, United States|Investigational Site Number 840350, Spokane, Washington, United States|Investigational Site Number 032302, Caba, Argentina|Investigational Site Number 032301, Coronel Suarez, Argentina|Investigational Site Number 040302, Graz, Austria|Investigational Site Number 040303, Sankt Stefan, Austria|Investigational Site Number 040301, Wien, Austria|Investigational Site Number 056301, Natoye, Belgium|Investigational Site Number 100302, Sofia, Bulgaria|Investigational Site Number 100301, Sofia, Bulgaria|Investigational Site Number 124303, Chicoutimi, Canada|Investigational Site Number 124302, Montreal, Canada|Investigational Site Number 124301, Quebec, Canada|Investigational Site Number 124306, Sherbrooke, Canada|Investigational Site Number 124305, Toronto, Canada|Investigational Site Number 124304, Victoria, Canada|Investigational Site Number 203307, Hradec Kralove, Czechia|Investigational Site Number 203305, Praha 2, Czechia|Investigational Site Number 203301, Praha 4, Czechia|Investigational Site Number 203306, Praha 5 - Motol, Czechia|Investigational Site Number 203303, Praha 8, Czechia|Investigational Site Number 203309, Trutnov, Czechia|Investigational Site Number 203304, Uherske Hradiste, Czechia|Investigational Site Number 203302, Zlin, Czechia|Investigational Site Number 208301, Aalborg, Denmark|Investigational Site Number 208306, Aarhus, Denmark|Investigational Site Number 208302, Esbjerg, Denmark|Investigational Site Number 208303, Roskilde, Denmark|Investigational Site Number 208304, Svendborg, Denmark|Investigational Site Number 246302, Joensuu, Finland|Investigational Site Number 246301, Kokkola, Finland|Investigational Site Number 246304, Vantaa, Finland|Investigational Site Number 250303, Dijon, France|Investigational Site Number 250304, Lille Cedex, France|Investigational Site Number 250302, Nantes, France|Investigational Site Number 250301, Paris, France|Investigational Site Number 250305, Pessac, France|Investigational Site Number 250306, Rennes, France|Investigational Site Number 276302, Berlin, Germany|Investigational Site Number 276305, Frankfurt A.M., Germany|Investigational Site Number 276306, Leipzig, Germany|Investigational Site Number 276301, Magdeburg, Germany|Investigational Site Number 276307, Witten, Germany|Investigational Site Number 348301, Baja, Hungary|Investigational Site Number 376302, Holon, Israel|Investigational Site Number 376304, Jerusalem, Israel|Investigational Site Number 376303, Safed, Israel|Investigational Site Number 376301, Tel Hashomer, Israel|Investigational Site Number 380302, Chieti, Italy|Investigational Site Number 380304, Milano, Italy|Investigational Site Number 380303, Napoli, Italy|Investigational Site Number 380301, Palermo, Italy|Investigational Site Number 484301, Mexico, Mexico|Investigational Site Number 528317, Alkmaar, Netherlands|Investigational Site Number 528301, Amsterdam-Zuidoost, Netherlands|Investigational Site Number 528320, Apeldoorn, Netherlands|Investigational Site Number 528309, Delfzijl, Netherlands|Investigational Site Number 528313, Eindhoven, Netherlands|Investigational Site Number 528319, Enschede, Netherlands|Investigational Site Number 528322, Goes, Netherlands|Investigational Site Number 528325, Groningen, Netherlands|Investigational Site Number 528302, Groningen, Netherlands|Investigational Site Number 528324, Hoogeveen, Netherlands|Investigational Site Number 528318, Hoorn, Netherlands|Investigational Site Number 528305, Leiden, Netherlands|Investigational Site Number 528311, Maastricht, Netherlands|Investigational Site Number 528312, Nijmegen, Netherlands|Investigational Site Number 528315, Rotterdam, Netherlands|Investigational Site Number 528326, Rotterdam, Netherlands|Investigational Site Number 528303, Utrecht, Netherlands|Investigational Site Number 528323, Utrecht, Netherlands|Investigational Site Number 528321, Venlo, Netherlands|Investigational Site Number 528316, Waalwijk, Netherlands|Investigational Site Number 578301, Bodo, Norway|Investigational Site Number 578305, Oslo, Norway|Investigational Site Number 578304, Oslo, Norway|Investigational Site Number 620302, Funchal, Portugal|Investigational Site Number 620301, Lisboa, Portugal|Investigational Site Number 642302, Timisoara, Romania|Investigational Site Number 643304, Arkhangelsk, Russian Federation|Investigational Site Number 643303, Kazan, Russian Federation|Investigational Site Number 643302, Moscow, Russian Federation|Investigational Site Number 643308, Moscow, Russian Federation|Investigational Site Number 643305, Moscow, Russian Federation|Investigational Site Number 643310, Novosibirsk, Russian Federation|Investigational Site Number 643301, St Petersbourg, Russian Federation|Investigational Site Number 643306, St. Petersburg, Russian Federation|Investigational Site Number 643312, St.Petersburg, Russian Federation|Investigational Site Number 710311, Bellville, South Africa|Investigational Site Number 710307, Bloemfontein, South Africa|Investigational Site Number 710306, Cape Town, South Africa|Investigational Site Number 710302, Cape Town, South Africa|Investigational Site Number 710309, Centurion, South Africa|Investigational Site Number 710312, Parktown, South Africa|Investigational Site Number 710304, Parow, South Africa|Investigational Site Number 710313, Pretoria, South Africa|Investigational Site Number 710303, Pretoria, South Africa|Investigational Site Number 710305, Pretoria, South Africa|Investigational Site Number 710314, Pretoria, South Africa|Investigational Site Number 710315, Roodepoort, South Africa|Investigational Site Number 710310, Somerset West, South Africa|Investigational Site Number 710308, Witbank, South Africa|Investigational Site Number 724303, A Coruna, Spain|Investigational Site Number 724308, Barcelona, Spain|Investigational Site Number 724306, Córdoba, Spain|Investigational Site Number 724312, Granada, Spain|Investigational Site Number 724307, Hospitalet De Llobregat, Spain|Investigational Site Number 724301, Madrid, Spain|Investigational Site Number 724309, Madrid, Spain|Investigational Site Number 724305, Madrid, Spain|Investigational Site Number 724311, Madrid, Spain|Investigational Site Number 724314, Málaga, Spain|Investigational Site Number 724315, Quart De Poblet, Spain|Investigational Site Number 724310, Sabadell, Spain|Investigational Site Number 724313, Sevilla, Spain|Investigational Site Number 724304, Tarragona, Spain|Investigational Site Number 724302, Zaragoza, Spain|Investigational Site Number 752302, Goteborg, Sweden|Investigational Site Number 752301, Stockholm, Sweden|Investigational Site Number 752304, Stockholm, Sweden|Investigational Site Number 826318, Birmingham, United Kingdom|Investigational Site Number 826304, Brighton, United Kingdom|Investigational Site Number 826301, Bristol, United Kingdom|Investigational Site Number 826311, Cambridge, United Kingdom|Investigational Site Number 826310, Cardiff, United Kingdom|Investigational Site Number 826302, Dundee, United Kingdom|Investigational Site Number 826317, Liverpool, United Kingdom|Investigational Site Number 826306, Liverpool, United Kingdom|Investigational Site Number 826312, Manchester, United Kingdom|Investigational Site Number 826303, Manchester, United Kingdom|Investigational Site Number 826305, Middlesex, United Kingdom|Investigational Site Number 826313, Newcastle Upon Tyne, United Kingdom|Investigational Site Number 826309, Reading, United Kingdom|Investigational Site Number 826315, West Bromwich, United Kingdom|Investigational Site Number 826316, West Bromwich, United Kingdom","""Study Protocol"", https://ClinicalTrials.gov/ProvidedDocs/94/NCT01954394/Prot_000.pdf|""Statistical Analysis Plan"", https://ClinicalTrials.gov/ProvidedDocs/94/NCT01954394/SAP_001.pdf","https://ClinicalTrials.gov/show/NCT01954394"
409,"NCT01930552","A Phase I Study of Aflibercept Plus FOLFIRI (Irinotecan, 5-Fluorouracil, and Leucovorin) in Chinese Patients With Advanced Solid Malignancies",,"Completed","No Results Available","Neoplasm Malignant","Drug: Aflibercept AVE0005|Drug: Leucovorin|Drug: Irinotecan|Drug: 5-Fluorouracil","Number of patients with standard safety assessments (adverse events and laboratory tests)|Pharmacokinetics: Assessment of plasma concentrations of aflibercept, CPT-11 (irinotecan) and Fluorouracil (5-FU)|Anti-tumor activity assessment - overall response rate|Anti-tumor activity assessment - duration response|Anti-aflibercept antibody detection","Sanofi|Regeneron Pharmaceuticals","All","18 Years and older   (Adult, Older Adult)","Phase 1","20","Industry","Interventional","Allocation: Non-Randomized|Intervention Model: Single Group Assignment|Masking: None (Open Label)|Primary Purpose: Treatment","TCD11470|U1111-1115-7286","September 2013","December 2014","December 2014","August 29, 2013",,"January 7, 2015","Investigational Site Number 156002, Beijing, China|Investigational Site Number 156001, Guangzhou, China",,"https://ClinicalTrials.gov/show/NCT01930552"
410,"NCT01920893","An Evaluation of Dupilumab in Patients With Nasal Polyposis And Chronic Symptoms Of Sinusitis",,"Completed","Has Results","Nasal Polyps","Drug: Placebo (for dupilumab)|Drug: Dupilumab|Drug: Mometasone furoate nasal spray","Change From Baseline in Bilateral Endoscopic Nasal Polyp Score (NPS) at Week 16|Change From Baseline in Bilateral Endoscopic NPS at Week 16 in Participants With Asthma|Change From Baseline in Participant Reported Symptoms Scores of Sinusitis at Week 16|Change From Baseline in Visual Analogue Scale (VAS) for Rhinosinusitis Symptoms Severity at Week 16|Change From Baseline in Nasal Peak Inspiratory Flow (NPIF) at Week 16|Change From Baseline in Smell Test (University of Pennsylvania Smell Identification Test [UPSIT]) Scores at Week 16|Change From Baseline in Sinus Computed Tomography (CT) Scan Assessments at Week 16: Lund-Mackay Score|Change From Baseline in Sinus Computed Tomography (CT) Scan Assessments at Week 16: Percent Area Occupied by Disease|Time to First Response in NPS: Kaplan-Meier Estimate at Week 16|Change From Baseline in 22-Item Sinonasal Outcome Test (SNOT-22) at Week 16","Sanofi|Regeneron Pharmaceuticals","All","18 Years to 65 Years   (Adult, Older Adult)","Phase 2","60","Industry","Interventional","Allocation: Randomized|Intervention Model: Parallel Assignment|Masking: Triple (Participant, Care Provider, Investigator)|Primary Purpose: Treatment","ACT12340|2013-001803-35|U1111-1130-6475","August 2013","November 2014","November 2014","August 12, 2013","June 2, 2017","June 26, 2017","Investigational Site Number 840014, Rolling Hills Estates, California, United States|Investigational Site Number 840015, Denver, Colorado, United States|Investigational Site Number 840013, Boston, Massachusetts, United States|Investigational Site Number 840002, Lake Oswego, Oregon, United States|Investigational Site Number 840009, Pittsburgh, Pennsylvania, United States|Investigational Site Number 056001, Gent, Belgium|Investigational Site Number 056002, Leuven, Belgium|Investigational Site Number 724001, Barcelona, Spain|Investigational Site Number 724003, Faitanar, Spain|Investigational Site Number 724002, Hospitalet De Llobregat, Spain|Investigational Site Number 724005, Jerez De La Frontera, Spain|Investigational Site Number 724004, Madrid, Spain|Investigational Site Number 752001, Stockholm, Sweden|Investigational Site Number 752002, Stockholm, Sweden",,"https://ClinicalTrials.gov/show/NCT01920893"
411,"NCT01914380","Investigating the Effectiveness of Eylea in Patients With Wet Age-related Macular Degeneration","PERSEUS","Completed","No Results Available","Wet Age-related Macular Degeneration","Drug: Aflibercept (Eylea, VEGF Trap-Eye, BAY86-5321)","Mean change of visual acuity for the total patient population|Mean change of visual acuity for the subgroup of pretreated patients|Mean change of visual acuity for the subgroup of non-pretreated patients|Monitoring of disease activity|Monitoring of treatment patterns|Mean time from indication of Eylea-treatment by the treating physician to start of treatment","Bayer|Regeneron Pharmaceuticals","All","Child, Adult, Older Adult",,"988","Industry","Observational","Observational Model: Cohort|Time Perspective: Prospective","16623|EY1313DE","July 29, 2013","March 31, 2017","March 31, 2017","August 2, 2013",,"March 29, 2018","Multiple Locations, Germany",,"https://ClinicalTrials.gov/show/NCT01914380"
412,"NCT01882868","A Study of Aflibercept in Combination With FOLFIRI in Patients With Second-Line Metastatic Colorectal Cancer in Japan",,"Completed","Has Results","Colorectal Cancer Metastatic","Drug: Aflibercept|Drug: Levofolinate|Drug: Irinotecan|Drug: 5-FU","Percentage of Participants With Overall Response|Progression Free Survival (PFS)|Overall Survival (OS)|Number of Participants With Treatment Emergent Adverse Events (TEAEs)|Aflibercept Immunogenicity Assessment: Number of Participants With Positive Sample(s) in the Anti-drug Antibodies (ADA) Assay and in the Neutralizing Anti-drug Antibodies (NAb) Assay|Maximum Observed Plasma Concentration (Cmax) for Free Aflibercept: ITT Population|Area Under the Concentration Time Curve From Time 0 to 14 Days Post Start of Infusion (AUC0-14 Day) for Free Aflibercept: ITT Population|Area Under the Concentration Time Curve (AUC) for Free Aflibercept: ITT Population|Total Body Clearance (CL) for Free Aflibercept: ITT Population|Volume of Distribution at the Steady State (Vss) for Free Aflibercept: ITT Population|Maximum Observed Plasma Concentration (Cmax) for Free and Vascular Endothelial Growth Factor (VEGF)-Bound Aflibercept: Participants With Additional Blood Sampling for Detailed PK Analysis|Time to Reach Maximum Plasma Concentration Observed (Tmax) for Free and VEGF-Bound Aflibercept in Cycle 1: Participants With Additional Blood Sampling for Detailed PK Analysis|Area Under the Concentration Time Curve From Time 0 to the Time of Last Quantifiable Concentration (AUClast) for Free and VEGF-Bound Aflibercept: Participants With Additional Blood Sampling for Detailed PK Analysis|Area Under the Concentration Time Curve From Time 0 to 14 Days Post Start of Infusion (AUC0-14 Day) for Free and VEGF-Bound Aflibercept: Participants With Additional Blood Sampling for Detailed PK Analysis|Area Under the Concentration Time Curve (AUC) for Free Aflibercept: Participants With Additional Blood Sampling for Detailed PK Analysis|Total Body Clearance (CL) for Free Aflibercept: Participants With Additional Blood Sampling for Detailed PK Analysis|Volume of Distribution at the Steady State (Vss) for Free Aflibercept: Participants With Additional Blood Sampling for Detailed PK Analysis|Terminal Elimination Half-life (t1/2z) for Free Aflibercept: Participants With Additional Blood Sampling for Detailed PK Analysis|Steady State Drug Concentration (Css) for 5-FU: Participants With Additional Blood Sampling for Detailed PK Analysis|Clearance at Steady State (CLss) for 5-FU: Participants With Additional Blood Sampling for Detailed PK Analysis|Maximum Observed Plasma Concentration (Cmax) for Irinotecan and Its Active Metabolite SN-38: Participants With Additional Blood Sampling for Detailed PK Analysis|Area Under the Concentration Time Curve From Time 0 to the Time of Last Quantifiable Concentration (AUClast) for Irinotecan and Its Active Metabolite SN-38: Participants With Additional Blood Sampling for Detailed PK Analysis|Area Under the Concentration Time Curve (AUC) for Irinotecan and Its Active Metabolite SN-38: Participants With Additional Blood Sampling for Detailed PK Analysis|Terminal Elimination Half-life (t1/2z) for Irinotecan and Its Active Metabolite SN-38: Participants With Additional Blood Sampling for Detailed PK Analysis|Active Metabolite SN-38 / Irinotecan Ratio on Area Under the Concentration Time Curve (Rmet): Participants With Additional Blood Sampling for Detailed PK Analysis|Total Body Clearance (CL) for Irinotecan: Participants With Additional Blood Sampling for Detailed PK Analysis|Volume of Distribution at the Steady State (Vss) for Irinotecan: Participants With Additional Blood Sampling for Detailed PK Analysis","Sanofi|Regeneron Pharmaceuticals","All","20 Years and older   (Adult, Older Adult)","Phase 2","62","Industry","Interventional","Allocation: N/A|Intervention Model: Single Group Assignment|Masking: None (Open Label)|Primary Purpose: Treatment","EFC11885|U1111-1120-0173","July 2013","August 2015","August 2015","June 20, 2013","March 14, 2017","March 14, 2017","Investigational Site Number 392011, Chiba-Shi, Japan|Investigational Site Number 392018, Chuo-Ku, Japan|Investigational Site Number 392016, Fukuoka-Shi, Japan|Investigational Site Number 392017, Fukuoka-Shi, Japan|Investigational Site Number 392001, Kashiwa-Shi, Japan|Investigational Site Number 392019, Kawasaki-Shi, Japan|Investigational Site Number 392015, Matsuyama-Shi, Japan|Investigational Site Number 392013, Mitaka-Shi, Japan|Investigational Site Number 392004, Nagoya-Shi, Japan|Investigational Site Number 392006, Osaka-Shi, Japan|Investigational Site Number 392014, Sagamihara-Shi, Japan|Investigational Site Number 392008, Sapporo-Shi, Japan|Investigational Site Number 392003, Sendai-Shi, Japan|Investigational Site Number 392009, Shimotsuke-Shi, Japan|Investigational Site Number 392012, Shinjuku-Ku, Japan|Investigational Site Number 392005, Suita-Shi, Japan|Investigational Site Number 392002, Sunto-Gun, Japan|Investigational Site Number 392010, Tsukuba-Shi, Japan|Investigational Site Number 392007, Yufu-Shi, Japan",,"https://ClinicalTrials.gov/show/NCT01882868"
413,"NCT01871376","Intravitreal Aflibercept Injection for Polypoidal Choroidal Vasculopathy With Hemorrhage or Exudation","EPIC","Completed","No Results Available","Polypoidal Choroidal Vasculopathy","Drug: Intravitreal aflibercept injection 2.0mg","efficacy of intravitreal aflibercept injection of 2.0mg aflibercept|Proportion of Patients with Stable, Improved, Significant Improved, Decreased, Significant Decreased Vision|Proportion of Patients with decrease in Subretinal Hemorrhage and/or Exudates|Proportion of patients with decreased / complete resolution of Polypoidal Polyp.|Proportion of subject with a decrease or complete resolution of branching vascular network from PCV|Determine mean change in Central Foveal Thickness and/or peripapillary edema as measured by SD-OCT|Mean Change in Choroidal Thickness|Proportion of previously treated and treatment naive patients that require additional dosing outside of the protocol determined dosing schedule|Assess changes on Autofluorescence|Incidence and Severity of Ocular and Non-Ocular Adverse Events","Gregg T. Kokame, MD|Regeneron Pharmaceuticals|Hawaii Pacific Health","All","25 Years and older   (Adult, Older Adult)","Phase 4","25","Other|Industry","Interventional","Allocation: Non-Randomized|Intervention Model: Parallel Assignment|Masking: None (Open Label)|Primary Purpose: Treatment","EPIC","May 2013","September 2016","September 2016","June 6, 2013",,"November 23, 2016","Retina Consultants of Hawaii, Aiea, Hawaii, United States",,"https://ClinicalTrials.gov/show/NCT01871376"
414,"NCT01870427","NEWTON: Aflibercept Injection for Previously Treated Macular Edema Associated With Central Retinal Vein Occlusions","NEWTON","Completed","No Results Available","Macular Edema With Central Retinal Vein Occlusions","Drug: Aflibercept (2.0 mg)","Duration of Intravitreal Aflibercept on Treatment Interval|Change in Visual Acuity|Retinal Thickness|Adverse Events|Number of Treatments","Northern California Retina Vitreous Associates|Regeneron Pharmaceuticals","All","18 Years to 100 Years   (Adult, Older Adult)","Phase 4","20","Other|Industry","Interventional","Allocation: N/A|Intervention Model: Single Group Assignment|Masking: None (Open Label)|Primary Purpose: Treatment","NCRVA-2013-Newton-4-01","June 2013","August 2015","August 2016","June 6, 2013",,"December 8, 2016","Northern California Retina Vitreous Associates, Mountain View, California, United States",,"https://ClinicalTrials.gov/show/NCT01870427"
415,"NCT01857544","Study of Intravitreal Aflibercept Injection for Persistent CRVO-associated Macular Edema Despite Prior Anti-VEGF Therapy",,"Unknown status","No Results Available","Retinal Vein Occlusion","Drug: Aflibercept","Complete anatomic resolution of macular edema following central retinal vein occlusion (CRVO) as measured by Optical Coherence Tomography (OCT)|Extent of reduction in macular thickness|Extent of reduction in macular volume|Mean change in best-corrected visual acuity (BCVA)|Proportion of patients with gain or loss of 5, 10, and 15 letters in BCVA|Number and severity of adverse events","Tennessee Retina|Regeneron Pharmaceuticals","All","18 Years and older   (Adult, Older Adult)","Phase 4","10","Other|Industry","Interventional","Allocation: N/A|Intervention Model: Single Group Assignment|Masking: None (Open Label)|Primary Purpose: Treatment","VGFT-OD-1313","June 2013","January 2016","March 2016","May 20, 2013",,"October 29, 2014","Tennessee Retina, PC, Nashville, Tennessee, United States",,"https://ClinicalTrials.gov/show/NCT01857544"
416,"NCT01854047","An Evaluation of Dupilumab in Patients With Moderate to Severe Uncontrolled Asthma",,"Completed","Has Results","Asthma","Drug: Dupilumab|Drug: placebo|Drug: ICS/LABA therapy|Drug: Salbutamol/albuterol|Drug: Levosalbutamol/levalbuterol","Absolute Change From Baseline in Forced Expiratory Volume in 1 Second (FEV1) at Week 12: High Eosinophils -Intent to Treat (HEos-ITT) Population|Absolute Change From Baseline in FEV1 at Week 12: ITT Population|Percent Change From Baseline in FEV1 at Week 12: HEos-ITT Population|Percent Change From Baseline in FEV1 at Week 12: ITT Population|Annualized Event Rate of Severe Exacerbation During The Treatment Period: HEos-ITT Population|Annualized Event Rate of Severe Exacerbation During The Treatment Period: ITT Population|Time to First Severe Exacerbation: Kaplan-Meier Estimates at Week 12 and 24: HEos-ITT Population|Time to First Severe Exacerbation: Kaplan-Meier Estimates at Week 12 and 24: ITT Population|Annualized Event Rate of Loss of Asthma Control (LOAC) During The Treatment Period: HEos-ITT Population|Annualized Event Rate of LOAC During The Treatment Period: ITT Population|Time to First LOAC Event: Kaplan-Meier Estimates at Week 12 and Week 24: HEos-ITT Population|Time to First LOAC Event: Kaplan-Meier Estimates at Week 12 and Week 24: ITT Population|Change From Baseline in Morning Asthma Symptom Score at Week 12: HEos-ITT Population|Change From Baseline in Morning Asthma Symptom Score at Week 12: ITT Population|Change From Baseline in Evening Asthma Symptom Score at Week 12: HEos-ITT Population|Change From Baseline in Evening Asthma Symptom Score at Week 12: ITT Population|Change From Baseline in Asthma Control Questionnaire 5-item Version (ACQ-5) Score at Week 12: HEos-ITT Population|Change From Baseline in ACQ-5 Score at Week 12: ITT Population|Change From Baseline in Asthma Quality of Life Questionnaire (AQLQ) Global Score at Week 12: HEos-ITT Population|Change From Baseline in AQLQ Global Score at Week 12: ITT Population|Change From Baseline in Number of Inhalations Per Day of Salbutamol/Albuterol or Levosalbutamol/Levalbuterol at Week 12: HEos-ITT Population|Change From Baseline in Number of Inhalations Per Day of Salbutamol/Albuterol or Levosalbutamol/Levalbuterol at Week 12: ITT Population","Sanofi|Regeneron Pharmaceuticals","All","18 Years and older   (Adult, Older Adult)","Phase 2","776","Industry","Interventional","Allocation: Randomized|Intervention Model: Parallel Assignment|Masking: Triple (Participant, Care Provider, Investigator)|Primary Purpose: Treatment","DRI12544|2013-000856-16|U1111-1138-3962","June 2013","November 2014","April 2015","May 15, 2013","June 2, 2017","June 26, 2017","Investigational Site Number 840050, Fullerton, California, United States|Investigational Site Number 840041, Huntington Beach, California, United States|Investigational Site Number 840019, Los Angeles, California, United States|Investigational Site Number 840029, Los Angeles, California, United States|Investigational Site Number 840022, Los Angeles, California, United States|Investigational Site Number 840013, Mission Viejo, California, United States|Investigational Site Number 840044, Newport Beach, California, United States|Investigational Site Number 840007, Riverside, California, United States|Investigational Site Number 840014, Rolling Hills Estates, California, United States|Investigational Site Number 840036, San Jose, California, United States|Investigational Site Number 840032, Colorado Springs, Colorado, United States|Investigational Site Number 840040, Colorado Springs, Colorado, United States|Investigational Site Number 840043, Denver, Colorado, United States|Investigational Site Number 840006, Denver, Colorado, United States|Investigational Site Number 840024, Denver, Colorado, United States|Investigational Site Number 840027, Daytona Beach, Florida, United States|Investigational Site Number 840039, Miami, Florida, United States|Investigational Site Number 840048, Albany, Georgia, United States|Investigational Site Number 840026, River Forest, Illinois, United States|Investigational Site Number 840053, Evansville, Indiana, United States|Investigational Site Number 840017, Louisville, Kentucky, United States|Investigational Site Number 840030, Owensboro, Kentucky, United States|Investigational Site Number 840028, Baltimore, Maryland, United States|Investigational Site Number 840052, Wheaton, Maryland, United States|Investigational Site Number 840045, North Dartmouth, Massachusetts, United States|Investigational Site Number 840046, Novi, Michigan, United States|Investigational Site Number 840051, Novi, Michigan, United States|Investigational Site Number 840018, Minneapolis, Minnesota, United States|Investigational Site Number 840002, Saint Louis, Missouri, United States|Investigational Site Number 840003, Saint Louis, Missouri, United States|Investigational Site Number 840037, Missoula, Montana, United States|Investigational Site Number 840004, Papillion, Nebraska, United States|Investigational Site Number 840011, Princeton, New Jersey, United States|Investigational Site Number 840016, Rochester, New York, United States|Investigational Site Number 840025, Cincinnati, Ohio, United States|Investigational Site Number 840015, Cincinnati, Ohio, United States|Investigational Site Number 840020, Cincinnati, Ohio, United States|Investigational Site Number 840001, Oklahoma City, Oklahoma, United States|Investigational Site Number 840031, Lake Oswego, Oregon, United States|Investigational Site Number 840034, Medford, Oregon, United States|Investigational Site Number 840042, Philadelphia, Pennsylvania, United States|Investigational Site Number 840010, Pittsburgh, Pennsylvania, United States|Investigational Site Number 840009, Upland, Pennsylvania, United States|Investigational Site Number 840021, Spartanburg, South Carolina, United States|Investigational Site Number 840023, Dallas, Texas, United States|Investigational Site Number 840005, El Paso, Texas, United States|Investigational Site Number 840008, San Antonio, Texas, United States|Investigational Site Number 840035, Richmond, Virginia, United States|Investigational Site Number 840054, Everett, Washington, United States|Investigational Site Number 840033, Tacoma, Washington, United States|Investigational Site Number 032004, Buenos Aires, Argentina|Investigational Site Number 032003, Buenos Aires, Argentina|Investigational Site Number 032008, Caba, Argentina|Investigational Site Number 032010, Caba, Argentina|Investigational Site Number 032001, Caba, Argentina|Investigational Site Number 032002, La Plata, Argentina|Investigational Site Number 032005, Rosario, Argentina|Investigational Site Number 032006, Rosario, Argentina|Investigational Site Number 032007, Rosario, Argentina|Investigational Site Number 032012, Santa Fe, Argentina|Investigational Site Number 032009, Tucumán, Argentina|Investigational Site Number 036004, Adelaide, Australia|Investigational Site Number 036002, Brisbane, Australia|Investigational Site Number 036005, Campbelltown, Australia|Investigational Site Number 036001, Clayton, Australia|Investigational Site Number 036008, Frankston, Australia|Investigational Site Number 036003, Nedlands, Australia|Investigational Site Number 036009, Prahran, Australia|Investigational Site Number 036006, Woolloongabba, Australia|Investigational Site Number 152007, Quillota, Chile|Investigational Site Number 152011, Santiago, Chile|Investigational Site Number 152001, Santiago, Chile|Investigational Site Number 152002, Santiago, Chile|Investigational Site Number 152014, Santiago, Chile|Investigational Site Number 152003, Santiago, Chile|Investigational Site Number 152005, Santiago, Chile|Investigational Site Number 152012, Santiago, Chile|Investigational Site Number 152013, Santiago, Chile|Investigational Site Number 152008, Talca, Chile|Investigational Site Number 152006, Viña Del Mar, Chile|Investigational Site Number 250009, Brest Cedex, France|Investigational Site Number 250004, Grenoble Cedex 09, France|Investigational Site Number 250010, Lille, France|Investigational Site Number 250006, Lyon, France|Investigational Site Number 250001, Marseille, France|Investigational Site Number 250002, Montpellier, France|Investigational Site Number 250005, Nantes, France|Investigational Site Number 250007, Nimes, France|Investigational Site Number 250003, Pessac, France|Investigational Site Number 250008, Strasbourg, France|Investigational Site Number 250011, Vernon, France|Investigational Site Number 380010, Ancona, Italy|Investigational Site Number 380009, Catania, Italy|Investigational Site Number 380004, Ferrara, Italy|Investigational Site Number 380002, Firenze, Italy|Investigational Site Number 380008, Foggia, Italy|Investigational Site Number 380003, Modena, Italy|Investigational Site Number 380007, Padova, Italy|Investigational Site Number 380001, Pisa, Italy|Investigational Site Number 380005, Torino, Italy|Investigational Site Number 380006, Verona, Italy|Investigational Site Number 392009, Asahi-Shi, Japan|Investigational Site Number 392037, Chiyoda-Ku, Japan|Investigational Site Number 392002, Chuo-Ku, Japan|Investigational Site Number 392007, Chuoh-Ku, Japan|Investigational Site Number 392012, Edogawa-Ku, Japan|Investigational Site Number 392017, Fukuoka-Shi, Japan|Investigational Site Number 392021, Fukuyama-Shi, Japan|Investigational Site Number 392030, Habikino-Shi, Japan|Investigational Site Number 392004, Himeji-Shi, Japan|Investigational Site Number 392032, Hirakata-Shi, Japan|Investigational Site Number 392013, Iizuka-Shi, Japan|Investigational Site Number 392042, Isesaki-Shi, Japan|Investigational Site Number 392026, Itabashi-Ku, Japan|Investigational Site Number 392023, Kanazawa-Shi, Japan|Investigational Site Number 392001, Kitakyushu-Shi, Japan|Investigational Site Number 392022, Kiyose-Shi, Japan|Investigational Site Number 392025, Kobe-Shi, Japan|Investigational Site Number 392040, Kodaira-Shi, Japan|Investigational Site Number 392044, Kokubunji-Shi, Japan|Investigational Site Number 392010, Kurashiki-Shi, Japan|Investigational Site Number 392036, Kyoto-Shi, Japan|Investigational Site Number 392041, Nagaoka-Shi, Japan|Investigational Site Number 392020, Naka-Gun, Japan|Investigational Site Number 392015, Nakano-Ku, Japan|Investigational Site Number 392005, Naruto-Shi, Japan|Investigational Site Number 392043, Ohta-Shi, Japan|Investigational Site Number 392019, Sagamihara-Shi, Japan|Investigational Site Number 392024, Sakai-Shi, Japan|Investigational Site Number 392011, Sakaide-Shi, Japan|Investigational Site Number 392008, Sapporo-Shi, Japan|Investigational Site Number 392034, Sapporo-Shi, Japan|Investigational Site Number 392038, Setagaya-Ku, Japan|Investigational Site Number 392028, Sumida-Ku, Japan|Investigational Site Number 392006, Tomakomai-Shi, Japan|Investigational Site Number 392003, Toride-Shi, Japan|Investigational Site Number 392029, Tsu-Shi, Japan|Investigational Site Number 392018, Tsukubo-Gun, Japan|Investigational Site Number 392045, Uruma-Shi, Japan|Investigational Site Number 392014, Yokohama-Shi, Japan|Investigational Site Number 392035, Yokohama-Shi, Japan|Investigational Site Number 410002, Bucheon, Korea, Republic of|Investigational Site Number 410003, Cheongju, Korea, Republic of|Investigational Site Number 410004, Seoul, Korea, Republic of|Investigational Site Number 410005, Seoul, Korea, Republic of|Investigational Site Number 410001, Suwon, Korea, Republic of|Investigational Site Number 484006, Chihuahua, Mexico|Investigational Site Number 484005, Distrito Federal, Mexico|Investigational Site Number 484001, Guadalajara, Mexico|Investigational Site Number 484004, Mexico City, Mexico|Investigational Site Number 484003, Monterrey, Mexico|Investigational Site Number 554001, Dunedin, New Zealand|Investigational Site Number 554002, Wellington, New Zealand|Investigational Site Number 616006, Bialystok, Poland|Investigational Site Number 616004, Gdansk, Poland|Investigational Site Number 616003, Gdansk, Poland|Investigational Site Number 616007, Krakow, Poland|Investigational Site Number 616001, Lodz, Poland|Investigational Site Number 616005, Lodz, Poland|Investigational Site Number 616008, Warszawa, Poland|Investigational Site Number 643003, Moscow, Russian Federation|Investigational Site Number 643002, Moscow, Russian Federation|Investigational Site Number 643007, Moscow, Russian Federation|Investigational Site Number 643012, Moscow, Russian Federation|Investigational Site Number 643001, Moscow, Russian Federation|Investigational Site Number 643006, Novosibirsk, Russian Federation|Investigational Site Number 643010, Saint-Petersburg, Russian Federation|Investigational Site Number 643011, Saint-Petersburg, Russian Federation|Investigational Site Number 643009, St-Petersburg, Russian Federation|Investigational Site Number 643008, Yaroslavl, Russian Federation|Investigational Site Number 710001, Cape Town, South Africa|Investigational Site Number 710002, Cape Town, South Africa|Investigational Site Number 724005, Barcelona, Spain|Investigational Site Number 724002, Barcelona, Spain|Investigational Site Number 724001, Barcelona, Spain|Investigational Site Number 724004, Cáceres, Spain|Investigational Site Number 724006, Pozuelo De Alarcón, Spain|Investigational Site Number 724003, Sabadell, Spain|Investigational Site Number 724007, Sant Boi De Llobregat, Spain|Investigational Site Number 792011, Amasya, Turkey|Investigational Site Number 792002, Ankara, Turkey|Investigational Site Number 792008, Bursa, Turkey|Investigational Site Number 792007, Istanbul, Turkey|Investigational Site Number 792001, Istanbul, Turkey|Investigational Site Number 792004, Istanbul, Turkey|Investigational Site Number 792003, Istanbul, Turkey|Investigational Site Number 792005, Izmir, Turkey|Investigational Site Number 792013, Kirikkale, Turkey|Investigational Site Number 792006, Mersin, Turkey|Investigational Site Number 804016, Donetsk, Ukraine|Investigational Site Number 804001, Kharkiv, Ukraine|Investigational Site Number 804004, Kyiv, Ukraine|Investigational Site Number 804003, Kyiv, Ukraine|Investigational Site Number 804008, Kyiv, Ukraine|Investigational Site Number 804018, Kyiv, Ukraine|Investigational Site Number 804020, Kyiv, Ukraine|Investigational Site Number 804006, Odessa, Ukraine|Investigational Site Number 804002, Poltava, Ukraine|Investigational Site Number 804019, Vinnytsya, Ukraine|Investigational Site Number 804015, Yalta, Ukraine|Investigational Site Number 804012, Zaporozhye, Ukraine",,"https://ClinicalTrials.gov/show/NCT01854047"
417,"NCT01850680","Single Ascending Dose Study of Safety and Tolerability of Sarilumab and Methotrexate in Japanese Patients With Rheumatoid Arthritis",,"Completed","No Results Available","Rheumatoid Arthritis","Drug: sarilumab SAR153191 (REGN88)|Drug: placebo|Drug: methotrexate|Drug: folic acid","Assessment of safety parameters (adverse events, laboratory data, vital signs, and ECG)|Assessment of the occurrence of anti-sarilumab antibodies|Assessment of the titer of anti-sarilumab antibodies|Assessment of PK parameter - maximum concentration (Cmax)|Assessment of PK parameter - area under curve (AUC)|Assessment of PK parameter - time to maximum concentration (tmax)","Sanofi|Regeneron Pharmaceuticals","All","20 Years to 65 Years   (Adult, Older Adult)","Phase 1","61","Industry","Interventional","Allocation: Randomized|Intervention Model: Parallel Assignment|Masking: Quadruple (Participant, Care Provider, Investigator, Outcomes Assessor)|Primary Purpose: Treatment","TDU13402|U1111-1134-0048","April 2013","December 2013","December 2013","May 9, 2013",,"January 28, 2014","Investigational Site Number 392001, Sendai-Shi, Japan|Investigational Site Number 392002, Sendai-Shi, Japan",,"https://ClinicalTrials.gov/show/NCT01850680"
418,"NCT01813773","Treatment With Intravitreal Aflibercept Injection For Proliferative Diabetic Retinopathy, The A.C.T Study","ACT","Completed","No Results Available","Proliferative Diabetic Retinopathy","Drug: Intravitreal Aflibercept Injection (IAI)","Incidence and severity of adverse events of intravitreal aflibercept injection in the treatment of PDR.|Mean change in the area of fluorescein leakage in mm2 (area of neovascularization) compared to baseline.|Proportion of subjects with complete regression of neovascularization|Mean change in ETDRS BCVA from baseline|Proportion of subjects gaining > 5 letters, > 10 letters and > 15 letters from baseline|Proportion of subjects losing > 5 letters from baseline|Mean change in retinal thickness from baseline as demonstrated by Spectral Domain OCT Imaging|Proportion of subjects without vitreous hemorrhage or pre-retinal hemorrhage|Proportion of subjects with complete avoidance of panretinal laser photocoagulation (PRP)/ additional PRP|Proportion of subjects with avoidance of vitrectomy","Ophthalmic Consultants of Long Island|Regeneron Pharmaceuticals","All","18 Years and older   (Adult, Older Adult)","Phase 2|Phase 3","20","Other|Industry","Interventional","Allocation: Randomized|Intervention Model: Single Group Assignment|Masking: None (Open Label)|Primary Purpose: Treatment","THE A.C.T. STUDY","March 2013","April 2016","April 2016","March 19, 2013",,"June 6, 2016","Ophthalmic Consultants of Long Island, Lynbrook, New York, United States",,"https://ClinicalTrials.gov/show/NCT01813773"
419,"NCT01812707","Efficacy and Safety Evaluation of Alirocumab (SAR236553/REGN727) in Patients With Primary Hypercholesterolemia on Stable Atorvastatin Therapy in Japan",,"Completed","Has Results","Hypercholesterolemia","Drug: Alirocumab|Drug: Placebo (for alirocumab)|Drug: Atorvastatin","Percent Change From Baseline in Calculated LDL-C at Week 12 - On-Treatment Analysis|Absolute Change From Baseline in Calculated LDL-C (mmol/L) at Week 12 - On-Treatment Analysis|Absolute Change From Baseline in Calculated LDL-C (mg/dL) at Week 12 - On-Treatment Analysis|Percentage of Participants Achieving Calculated LDL-C <100 mg/dL (2.59 mmol/L) and < 70 mg/dL (1.81 mmol/L) at Week 12 - On-Treatment Analysis|Percent Change From Baseline in Total Cholesterol, High-Density Lipoprotein Cholesterol (HDL-C), Non-HDL-C, and Apolipoprotein B (Apo-B) at Week 12 - On-Treatment Analysis|Percent Change From Baseline in Fasting Triglycerides and Lipoprotein (a) at Week 12 - On-Treatment Analysis|Absolute Change From Baseline in Apolipoprotein B/Apolipoprotein A-1 (ApoB/ApoA-1) Ratio at Week 12 - On-Treatment Analysis","Sanofi|Regeneron Pharmaceuticals","All","20 Years to 75 Years   (Adult, Older Adult)","Phase 2","100","Industry","Interventional","Allocation: Randomized|Intervention Model: Parallel Assignment|Masking: Double (Participant, Investigator)|Primary Purpose: Treatment","DFI12361|U1111-1134-4749","March 2013","January 2014","January 2014","March 18, 2013","September 24, 2015","October 4, 2016","Investigational Site Number 392002, Koganei-Shi, Japan|Investigational Site Number 392001, Shinjuku-Ku, Japan|Investigational Site Number 392003, Suita-Shi, Japan|Investigational Site Number 392004, Suita-Shi, Japan",,"https://ClinicalTrials.gov/show/NCT01812707"
420,"NCT01785329","Pharmacokinetic of Alirocumab SAR236553 (REGN727) Administered Subcutaneously at 3 Different Injection Sites in Healthy Subjects",,"Completed","No Results Available","Hypercholesterolemia","Drug: alirocumab SAR236553 (REGN727)","Assessment of the serum concentrations of alirocumab SAR236553 (REGN727) after a single subcutaneous administration at 3 different injection sites in healthy subjects as a measure of the pharmacokinetics of this investigational medicinal product.|Assessment of the serum concentrations of low-density lipoprotein cholesterol after a single subcutaneous administration of alirocumab SAR236553 (REGN727) as a measure of the pharmacodynamic effect of this investigational medicinal product.|Assessment of the number of subjects with adverse events after a single subcutaneous administration of alirocumab SAR236553 (REGN727) as a measure of the safety/tolerability of this investigational medicinal product.|Assessment of the serum concentration of anti-drug antibodies after a single subcutaneous dose of alirocumab SAR236553 (REGN727) as a measure of the immunogenicity of this investigational medicinal product.","Sanofi|Regeneron Pharmaceuticals","All","18 Years to 45 Years   (Adult)","Phase 1","60","Industry","Interventional","Allocation: Randomized|Intervention Model: Parallel Assignment|Masking: None (Open Label)|Primary Purpose: Basic Science","BDR13362|2012-005005-40|U1111-1134-2618","February 2013","July 2013","July 2013","February 7, 2013",,"August 19, 2013","Investigational Site Number 826001, London, United Kingdom",,"https://ClinicalTrials.gov/show/NCT01785329"
421,"NCT01783925","Eylea Post Marketing Surveillance(PMS)",,"Completed","No Results Available","Macular Degeneration","Drug: Aflibercept (Eylea, VEGF Trap-Eye, BAY86-5321)","Adverse events (AEs) [including serious adverse events (SAEs) and ocular AEs, especially AEs due to intravitreal injection procedure] and adverse drug reactions (ADRs)|Measurement of BCVA (prior to injection and performing other ocular assessments) by eye chart. [BCVA: Best Corrected Visual Acuity]|Central retinal thickness by OCT with or without.[OCT: Optical Coherence Tomography]|Findings of FAG and/or ICAG. [FAG: Fluorescein Angiography].ICAG: Indocyanine Green Angiography]|IOP(if performed, before/after injection).[IOP: Intra Ocular Pressure]|Measurement of fundus lesion by fundoscopy","Bayer|Regeneron Pharmaceuticals","All","Child, Adult, Older Adult",,"3206","Industry","Observational","Observational Model: Cohort|Time Perspective: Prospective","16469|EY1310KR","April 29, 2014","December 31, 2018","December 31, 2018","February 5, 2013",,"January 8, 2019","Many Locations, Multiple Locations, Korea, Republic of",,"https://ClinicalTrials.gov/show/NCT01783925"
422,"NCT01783886","Efficacy and Safety of VEGF Trap Eye in Diabetic Macular Edema (DME) With Central Involvement","VIVID EAST","Completed","Has Results","Macular Edema","Biological: Aflibercept (Eylea, VEGF Trap-Eye, BAY86-5321)|Procedure: Macular Laser Photocoagulation","Change From Baseline in Best Corrected Visual Acuity (BCVA) as Measured by Early Treatment Diabetic Retinopathy Study (ETDRS) Letter Score at Week 52 - Last Observation Carried Forward (LOCF)|Percentage of Participants Who Gained at Least 10 Letters in BCVA as Measured by ETDRS Letter Score Compared With Baseline at Week 52 - LOCF|Percentage of Participants Who Gained at Least 15 Letters in BCVA as Measured by ETDRS Letter Score Compared With Baseline at Week 52 - LOCF|Percentage of Participants With a Greater Than Equal (>=) Two-step Improvement From Baseline in the ETDRS Diabetic Retinopathy Severity Score (DRSS) as Assessed by Fundus Photography (FP) at Week 52 - LOCF|Change From Baseline in Central Retinal Thickness (CRT) at Week 52 as Assessed on Optical Coherence Tomography (OCT) - LOCF|Change From Baseline in National Eye Institute 25-item Visual Function Questionnaire (NEI VFQ-25) Near Activities Subscale at Week 52 - LOCF|Change From Baseline in National Eye Institute 25-item Visual Function Questionnaire (NEI VFQ-25) Distance Activities Subscale at Week 52 - LOCF","Bayer|Regeneron Pharmaceuticals","All","18 Years and older   (Adult, Older Adult)","Phase 3","381","Industry","Interventional","Allocation: Randomized|Intervention Model: Parallel Assignment|Masking: Triple (Participant, Investigator, Outcomes Assessor)|Primary Purpose: Treatment","15161","February 2013","March 2015","March 2015","February 5, 2013","April 5, 2016","May 12, 2016","Guangzhou, Guangdong, China|Wuhan, Hubei, China|Changsha, Hunan, China|Shenyang, Liaoning, China|Xi'an, Shaanxi, China|Qingdao, Shandong, China|Chengdu, Sichuan, China|Hangzhou, Zhejiang, China|Wenzhou, Zhejiang, China|Beijing, China|Beijing, China|Beijing, China|Beijing, China|Beijing, China|Chongqing, China|Shanghai, China|Tianjin, China|Hong Kong, Hong Kong|Kowloon, Hong Kong|Seoul, Korea, Republic of|Seoul, Korea, Republic of|Moscow, Russian Federation|Moscow, Russian Federation|Novosibirsk, Russian Federation|St. Petersburg, Russian Federation",,"https://ClinicalTrials.gov/show/NCT01783886"
423,"NCT01773954","Repeated Eye Injections of Aflibercept for Treatment of Wet Age Related Macular Degeneration","ATLAS","Completed","Has Results","Age-Related Macular Degeneration|Macular Degeneration","Drug: Intravitreal Aflibercept Injection","Mean Change in Best-corrected Early Treatment Diabetic Retinopathy Study (ETDRS) Letter Score","MidAtlantic Retina|Regeneron Pharmaceuticals|Wills Eye","All","18 Years and older   (Adult, Older Adult)","Not Applicable","40","Other|Industry","Interventional","Allocation: N/A|Intervention Model: Single Group Assignment|Masking: None (Open Label)|Primary Purpose: Treatment","ATLAS|20122054","February 2013","March 2016","March 2016","January 23, 2013","May 2, 2018","May 2, 2018","Mid Atlantic Retina- Cherry Hill, Cherry Hill, New Jersey, United States|Mid Atlantic Retina- Huntingdon Valley, Huntingdon Valley, Pennsylvania, United States|Mid Atlantic Retina- Wills Eye Institute, Philadelphia, Pennsylvania, United States",,"https://ClinicalTrials.gov/show/NCT01773954"
424,"NCT01771081","Evaluation of Changes in Visual Acuity in Patients With Diabetic Macular Edema (DME) Starting Treatment With an Approved Anti-VEGF Therapy","POLARIS","Completed","No Results Available","Ophthalmology|Macular Edema|Macular Degeneration","Drug: Ranibizumab (or other DME treatment)","Changes in visual acuity, assessed by Early Treatment Diabetic Retinopathy Study (ETDRS) or SNELLEN|Demographic and clinical characteristics (Age, sex, race, employment status, severity of DME)|Mean time from diagnosis to first commencement with an approved anti-VEGF therapy|Changes in retinal thickness, measured by Optical Coherence Tomography (OCT)|Presence of clinically significant macular edema, measured as defined by the ETDRS Research Group|Resource utilization in terms of treatment choices, frequency and duration|Mean change in quality of life score (using the NEI VFQ 25), only in countries where used as part of routine practice","Bayer|Regeneron Pharmaceuticals","All","Child, Adult, Older Adult",,"911","Industry","Observational","Observational Model: Cohort","16459|NN1201","April 2013","January 2015","April 2015","January 18, 2013",,"October 28, 2015","Many Locations, France|Many Locations, Germany|Many Locations, Greece|Many Locations, Portugal|Many Locations, Russian Federation|Many Locations, Slovakia|Many Locations, Spain|Many Locations, United Kingdom",,"https://ClinicalTrials.gov/show/NCT01771081"
425,"NCT01768572","To Evaluate The Safety of SAR153191 (REGN88) and Tocilizumab Added to Other RA Drugs in Patients With RA Who Are Not Responding to or Intolerant of Anti-TNF Therapy (SARIL-RA-ASCERTAIN)",,"Completed","Has Results","Rheumatoid Arthritis","Drug: sarilumab SAR153191 (REGN88)|Drug: tocilizumab|Drug: hydroxychloroquine|Drug: methotrexate|Drug: sulfasalazine|Drug: leflunomide|Drug: subcutaneous placebo|Drug: intravenous placebo","Number of Participants With Treatment Emergent Adverse Events (TEAEs)","Sanofi|Regeneron Pharmaceuticals","All","18 Years and older   (Adult, Older Adult)","Phase 3","202","Industry","Interventional","Allocation: Randomized|Intervention Model: Parallel Assignment|Masking: Quadruple (Participant, Care Provider, Investigator, Outcomes Assessor)|Primary Purpose: Treatment","SFY13370|2012-003536-23|U1111-1133-7839","March 2013","October 2014","October 2014","January 15, 2013","June 26, 2017","June 26, 2017","Investigational Site Number 840152, Huntsville, Alabama, United States|Investigational Site Number 840151, Colorado Springs, Colorado, United States|Investigational Site Number 840153, Aventura, Florida, United States|Investigational Site Number 840033, Fort Lauderdale, Florida, United States|Investigational Site Number 840048, Miami, Florida, United States|Investigational Site Number 840155, Palm Harbor, Florida, United States|Investigational Site Number 840013, Wheaton, Maryland, United States|Investigational Site Number 840154, Boston, Massachusetts, United States|Investigational Site Number 840150, Lansing, Michigan, United States|Investigational Site Number 840062, Reading, Pennsylvania, United States|Investigational Site Number 840038, Austin, Texas, United States|Investigational Site Number 840022, Dallas, Texas, United States|Investigational Site Number 840156, Dallas, Texas, United States|Investigational Site Number 840074, Mesquite, Texas, United States|Investigational Site Number 032006, Caba, Argentina|Investigational Site Number 032010, Ramos Mejia, Argentina|Investigational Site Number 032013, Rosario, Argentina|Investigational Site Number 032015, San Fernando, Argentina|Investigational Site Number 032004, San Miguel De Tucuman, Argentina|Investigational Site Number 032005, Tucuman, Argentina|Investigational Site Number 056010, Leuven, Belgium|Investigational Site Number 076001, Curitiba, Brazil|Investigational Site Number 076030, Sao Jose Do Rio Preto, Brazil|Investigational Site Number 203009, Liberec, Czechia|Investigational Site Number 203011, Praha 2, Czechia|Investigational Site Number 203010, Praha 4, Czechia|Investigational Site Number 233010, Tallinn, Estonia|Investigational Site Number 233002, Tallinn, Estonia|Investigational Site Number 246001, Helsinki, Finland|Investigational Site Number 246010, Riihimäki, Finland|Investigational Site Number 348014, Budapest, Hungary|Investigational Site Number 348022, Budapest, Hungary|Investigational Site Number 348021, Esztergom, Hungary|Investigational Site Number 348016, Kistarcsa, Hungary|Investigational Site Number 348009, Szolnok, Hungary|Investigational Site Number 348015, Szombathely, Hungary|Investigational Site Number 376010, Haifa, Israel|Investigational Site Number 376011, Tel Aviv, Israel|Investigational Site Number 380002, Firenze, Italy|Investigational Site Number 380005, Genova, Italy|Investigational Site Number 484008, Durango, Mexico|Investigational Site Number 484035, Leon, Mexico|Investigational Site Number 484009, Merida, Mexico|Investigational Site Number 484001, México, D.F., Mexico|Investigational Site Number 484036, Zapopan, Mexico|Investigational Site Number 528010, Amsterdam, Netherlands|Investigational Site Number 528001, Leiden, Netherlands|Investigational Site Number 578010, Kristiansand, Norway|Investigational Site Number 578006, Tønsberg, Norway|Investigational Site Number 616019, Bydgoszcz, Poland|Investigational Site Number 616054, Bytom, Poland|Investigational Site Number 616030, Lublin, Poland|Investigational Site Number 616031, Warszawa, Poland|Investigational Site Number 616017, Warszawa, Poland|Investigational Site Number 642006, Braila, Romania|Investigational Site Number 642020, Bucharest, Romania|Investigational Site Number 642010, Bucharest, Romania|Investigational Site Number 642021, Bucuresti, Romania|Investigational Site Number 642001, Bucuresti, Romania|Investigational Site Number 642022, Targoviste, Romania|Investigational Site Number 643017, Kemerovo, Russian Federation|Investigational Site Number 643020, Moscow, Russian Federation|Investigational Site Number 643001, Moscow, Russian Federation|Investigational Site Number 643002, Moscow, Russian Federation|Investigational Site Number 643031, Moscow, Russian Federation|Investigational Site Number 643030, Moscow, Russian Federation|Investigational Site Number 643032, St-Petersburg, Russian Federation|Investigational Site Number 724020, Barcelona, Spain|Investigational Site Number 724021, Santander, Spain|Investigational Site Number 724022, Sevilla, Spain|Investigational Site Number 752004, Malmö, Sweden|Investigational Site Number 752002, Uppsala, Sweden|Investigational Site Number 826004, Doncaster, United Kingdom|Investigational Site Number 826006, Edinburgh, United Kingdom|Investigational Site Number 826001, Leeds, United Kingdom|Investigational Site Number 826002, London, United Kingdom|Investigational Site Number 826005, Southampton, United Kingdom|Investigational Site Number 826025, Wigan, United Kingdom",,"https://ClinicalTrials.gov/show/NCT01768572"
426,"NCT01764997","An Evaluation of Sarilumab Plus Methotrexate Compared to Etanercept Plus Methotrexate in RA Patients Not Responding to Adalimumab Plus Methotrexate","RA-COMPARE","Terminated","Has Results","Rheumatoid Arthritis","Drug: Sarilumab|Drug: Etanercept|Drug: Methotrexate|Drug: Placebo (for sarilumab)|Drug: Placebo (for etanercept)|Drug: Adalimumab","Change From Baseline in Disease Activity Score for 28 Joints - C-Reactive Protein (DAS28-CRP) Score at Week 24|Number of Participants With at Least 20% Improvement in American College of Rheumatology (ACR20), at Least 50% Improvement in ACR (ACR50) and at Least 70% Improvement in ACR (ACR70) Efficacy Response Rates at Week 12 and Week 24|Percentage of Participants Achieving Clinical Remission Score (DAS28-CRP) <2.6 at Week 12 and Week 24|Change From Baseline in DAS28-CRP Score at Week 12","Sanofi|Regeneron Pharmaceuticals","All","18 Years and older   (Adult, Older Adult)","Phase 3","776","Industry","Interventional","Allocation: Randomized|Intervention Model: Parallel Assignment|Masking: Quadruple (Participant, Care Provider, Investigator, Outcomes Assessor)|Primary Purpose: Treatment","EFC11574|2012-001984-66|U1111-1131-6653","April 2013","January 2015","January 2015","January 10, 2013","July 27, 2017","July 27, 2017","Investigational Site Number 840004, Birmingham, Alabama, United States|Investigational Site Number 840212, Glendale, California, United States|Investigational Site Number 840211, Thousand Oaks, California, United States|Investigational Site Number 840049, Upland, California, United States|Investigational Site Number 840205, Victorville, California, United States|Investigational Site Number 840201, Denver, Colorado, United States|Investigational Site Number 840209, Danbury, Connecticut, United States|Investigational Site Number 840203, Washington, D.C., District of Columbia, United States|Investigational Site Number 840210, Clearwater, Florida, United States|Investigational Site Number 840128, Ormond Beach, Florida, United States|Investigational Site Number 840063, Palm Harbor, Florida, United States|Investigational Site Number 840060, Sarasota, Florida, United States|Investigational Site Number 840207, Tampa, Florida, United States|Investigational Site Number 840018, Idaho Falls, Idaho, United States|Investigational Site Number 840213, Indianapolis, Indiana, United States|Investigational Site Number 840109, Lake Charles, Louisiana, United States|Investigational Site Number 840073, Cumberland, Maryland, United States|Investigational Site Number 840202, Hagerstown, Maryland, United States|Investigational Site Number 840204, Battle Creek, Michigan, United States|Investigational Site Number 840150, Lansing, Michigan, United States|Investigational Site Number 840200, Jackson, Mississippi, United States|Investigational Site Number 840037, Tupelo, Mississippi, United States|Investigational Site Number 840112, Lincoln, Nebraska, United States|Investigational Site Number 840056, New York, New York, United States|Investigational Site Number 840117, Pittsburgh, Pennsylvania, United States|Investigational Site Number 840016, North Charleston, South Carolina, United States|Investigational Site Number 840025, Jackson, Tennessee, United States|Investigational Site Number 840074, Mesquite, Texas, United States|Investigational Site Number 840061, Tacoma, Washington, United States|Investigational Site Number 840124, Clarksburg, West Virginia, United States|Investigational Site Number 032052, Buenos Aires, Argentina|Investigational Site Number 032050, Buenos Aires, Argentina|Investigational Site Number 032053, La Plata, Argentina|Investigational Site Number 032013, Rosario, Argentina|Investigational Site Number 032051, San Miguel De Tucumán, Argentina|Investigational Site Number 032005, Tucuman, Argentina|Investigational Site Number 032009, Zarate, Argentina|Investigational Site Number 036020, Camperdown, Australia|Investigational Site Number 036004, Heidelberg West, Australia|Investigational Site Number 036014, Victoria Park, Australia|Investigational Site Number 036007, Woodville, Australia|Investigational Site Number 076001, Curitiba, Brazil|Investigational Site Number 076016, Curitiba, Brazil|Investigational Site Number 076006, Goiania, Brazil|Investigational Site Number 076010, Juiz De Fora, Brazil|Investigational Site Number 076005, Rio De Janeiro, Brazil|Investigational Site Number 076013, Vitoria, Brazil|Investigational Site Number 152005, Osorno, Chile|Investigational Site Number 152018, Santiago, Chile|Investigational Site Number 152001, Santiago, Chile|Investigational Site Number 152002, Santiago, Chile|Investigational Site Number 152011, Santiago, Chile|Investigational Site Number 152015, Temuco, Chile|Investigational Site Number 170016, Bogota, Colombia|Investigational Site Number 170001, Bogota, Colombia|Investigational Site Number 170040, Bogotá, Colombia|Investigational Site Number 170007, Bucaramanga, Colombia|Investigational Site Number 170009, Bucaramanga, Colombia|Investigational Site Number 170041, Medellin, Colombia|Investigational Site Number 203004, Ostrava, Czechia|Investigational Site Number 203001, Praha 2, Czechia|Investigational Site Number 203031, Praha 4, Czechia|Investigational Site Number 203033, Praha 4, Czechia|Investigational Site Number 203030, Praha 4, Czechia|Investigational Site Number 203032, Praha, Czechia|Investigational Site Number 203002, Uherske Hradiste, Czechia|Investigational Site Number 203006, Zlin, Czechia|Investigational Site Number 218003, Cuenca, Ecuador|Investigational Site Number 218001, Guayaquil, Ecuador|Investigational Site Number 218002, Quito, Ecuador|Investigational Site Number 246001, Helsinki, Finland|Investigational Site Number 246002, Hyvinkää, Finland|Investigational Site Number 246030, Oulu, Finland|Investigational Site Number 246003, Pori, Finland|Investigational Site Number 246032, Tampere, Finland|Investigational Site Number 250003, Amiens Cedex 1, France|Investigational Site Number 250007, Bobigny, France|Investigational Site Number 250001, La Roche Sur Yon Cedex 9, France|Investigational Site Number 250002, Montpellier, France|Investigational Site Number 250004, Paris Cedex 4, France|Investigational Site Number 250005, Paris, France|Investigational Site Number 250006, Strasbourg, France|Investigational Site Number 250008, Toulouse, France|Investigational Site Number 276007, Berlin, Germany|Investigational Site Number 276057, Berlin, Germany|Investigational Site Number 276056, Dresden, Germany|Investigational Site Number 276055, Dresden, Germany|Investigational Site Number 276051, Erlangen, Germany|Investigational Site Number 276013, Hamburg, Germany|Investigational Site Number 276001, Herne, Germany|Investigational Site Number 276058, Koeln, Germany|Investigational Site Number 276053, Ludwigsfelde, Germany|Investigational Site Number 276050, Rostock, Germany|Investigational Site Number 300010, Athens, Greece|Investigational Site Number 300002, Heraklion, Greece|Investigational Site Number 300014, N. Efkarpia, Greece|Investigational Site Number 300012, Patras, Greece|Investigational Site Number 348001, Budapest, Hungary|Investigational Site Number 348010, Debrecen, Hungary|Investigational Site Number 348021, Esztergom, Hungary|Investigational Site Number 348013, Gy?r, Hungary|Investigational Site Number 348008, Gyula, Hungary|Investigational Site Number 376032, Ashkelon, Israel|Investigational Site Number 376001, Haifa, Israel|Investigational Site Number 376010, Haifa, Israel|Investigational Site Number 376031, Haifa, Israel|Investigational Site Number 376035, Jerusalem, Israel|Investigational Site Number 376030, Ramat Gan, Israel|Investigational Site Number 376011, Tel Aviv, Israel|Investigational Site Number 376034, Tel Hashomer, Israel|Investigational Site Number 380002, Firenze, Italy|Investigational Site Number 380004, Genova, Italy|Investigational Site Number 380005, Genova, Italy|Investigational Site Number 380041, L'Aquila, Italy|Investigational Site Number 380042, Valeggio Sul Mincio, Italy|Investigational Site Number 410020, Busan, Korea, Republic of|Investigational Site Number 410006, Busan, Korea, Republic of|Investigational Site Number 410013, Daegu, Korea, Republic of|Investigational Site Number 410005, Daejeon, Korea, Republic of|Investigational Site Number 410011, Jeonju, Korea, Republic of|Investigational Site Number 410016, Seoul, Korea, Republic of|Investigational Site Number 410015, Seoul, Korea, Republic of|Investigational Site Number 410022, Seoul, Korea, Republic of|Investigational Site Number 410023, Seoul, Korea, Republic of|Investigational Site Number 410021, Seoul, Korea, Republic of|Investigational Site Number 410008, Suwon, Korea, Republic of|Investigational Site Number 428002, Liepaja, Latvia|Investigational Site Number 428001, Riga, Latvia|Investigational Site Number 428003, Ventspils, Latvia|Investigational Site Number 440005, Kaunas, Lithuania|Investigational Site Number 440006, Klaipeda, Lithuania|Investigational Site Number 440010, Panevezys, Lithuania|Investigational Site Number 440011, Vilnius, Lithuania|Investigational Site Number 458012, Batu Caves, Malaysia|Investigational Site Number 458014, Georgetown, Malaysia|Investigational Site Number 458001, Ipoh, Malaysia|Investigational Site Number 458013, Kota Bharu, Malaysia|Investigational Site Number 458002, Kuching, Malaysia|Investigational Site Number 458010, Melaka, Malaysia|Investigational Site Number 458011, Seremban, Malaysia|Investigational Site Number 484027, Cd. Obregon, Mexico|Investigational Site Number 484023, Chihuahua, Mexico|Investigational Site Number 484029, Deleg. Benito Juárez, Mexico|Investigational Site Number 484013, Guadalajara, Mexico|Investigational Site Number 484018, Guadalajara, Mexico|Investigational Site Number 484004, Merida, Mexico|Investigational Site Number 484010, Mexicali, Mexico|Investigational Site Number 484026, Mexicali, Mexico|Investigational Site Number 484052, Mexico City, Mexico|Investigational Site Number 484017, México, Mexico|Investigational Site Number 484025, San Luis, Mexico|Investigational Site Number 484051, Tijuana, Mexico|Investigational Site Number 554007, Auckland, New Zealand|Investigational Site Number 554010, Dunedin, New Zealand|Investigational Site Number 554005, Hamilton, New Zealand|Investigational Site Number 554011, Nelson, New Zealand|Investigational Site Number 604001, Lima, Peru|Investigational Site Number 604010, Lima, Peru|Investigational Site Number 604009, Lima, Peru|Investigational Site Number 604012, Lima, Peru|Investigational Site Number 604007, Lima, Peru|Investigational Site Number 604005, Lima, Peru|Investigational Site Number 604020, Lima, Peru|Investigational Site Number 616019, Bydgoszcz, Poland|Investigational Site Number 616054, Bytom, Poland|Investigational Site Number 616052, Dzialdowo, Poland|Investigational Site Number 616015, Elblag, Poland|Investigational Site Number 616057, Krakow, Poland|Investigational Site Number 616059, Krakow, Poland|Investigational Site Number 616061, Krakow, Poland|Investigational Site Number 616005, Lublin, Poland|Investigational Site Number 616063, Myslenice, Poland|Investigational Site Number 616018, Poznan, Poland|Investigational Site Number 616013, Sosnowiec, Poland|Investigational Site Number 616056, Starachowice, Poland|Investigational Site Number 616016, Szczecin, Poland|Investigational Site Number 616058, Ustron, Poland|Investigational Site Number 616051, Warszawa, Poland|Investigational Site Number 616053, Zyrardow, Poland|Investigational Site Number 642041, Bacau, Romania|Investigational Site Number 642012, Bucharest, Romania|Investigational Site Number 642004, Bucharest, Romania|Investigational Site Number 642023, Bucharest, Romania|Investigational Site Number 642001, Bucuresti, Romania|Investigational Site Number 642040, Bucuresti, Romania|Investigational Site Number 642002, Bucuresti, Romania|Investigational Site Number 642042, Bucuresti, Romania|Investigational Site Number 642005, Galati, Romania|Investigational Site Number 642013, Iasi, Romania|Investigational Site Number 642014, Iasi, Romania|Investigational Site Number 642022, Targoviste, Romania|Investigational Site Number 643006, Kemerovo, Russian Federation|Investigational Site Number 643056, Krasnoyarsk, Russian Federation|Investigational Site Number 643052, Moscow, Russian Federation|Investigational Site Number 643021, Moscow, Russian Federation|Investigational Site Number 643031, Moscow, Russian Federation|Investigational Site Number 643030, Moscow, Russian Federation|Investigational Site Number 643022, Novosibirsk, Russian Federation|Investigational Site Number 643010, Samara, Russian Federation|Investigational Site Number 643011, Saratov, Russian Federation|Investigational Site Number 643059, Smolensk, Russian Federation|Investigational Site Number 643008, St-Petersburg, Russian Federation|Investigational Site Number 643058, St. Peterburg, Russian Federation|Investigational Site Number 643013, Ufa, Russian Federation|Investigational Site Number 643050, Voronezh, Russian Federation|Investigational Site Number 643057, Yaroslavl, Russian Federation|Investigational Site Number 643051, Yaroslavl, Russian Federation|Investigational Site Number 710011, Cape Town, South Africa|Investigational Site Number 710007, Cape Town, South Africa|Investigational Site Number 710008, Pretoria, South Africa|Investigational Site Number 710006, Pretoria, South Africa|Investigational Site Number 710010, Stellenbsoch, South Africa|Investigational Site Number 724043, Córdoba, Spain|Investigational Site Number 724009, La Coruña, Spain|Investigational Site Number 724042, Madrid, Spain|Investigational Site Number 724041, Madrid, Spain|Investigational Site Number 724040, Madrid, Spain|Investigational Site Number 724001, Málaga, Spain|Investigational Site Number 724011, Sabadell, Spain|Investigational Site Number 724012, Santiago De Compostela, Spain|Investigational Site Number 158010, Changhua, Taiwan|Investigational Site Number 158004, Chia-Yi, Taiwan|Investigational Site Number 158012, Kaohsiung, Taiwan|Investigational Site Number 158011, Kaohsiung, Taiwan|Investigational Site Number 158006, Taipei, Taiwan|Investigational Site Number 764003, Bangkok-Noi, Thailand|Investigational Site Number 764002, Bangkok, Thailand|Investigational Site Number 764010, Bangkok, Thailand|Investigational Site Number 764011, Khon Kaen, Thailand|Investigational Site Number 804003, Dnipropetrovsk, Ukraine|Investigational Site Number 804002, Donetsk, Ukraine|Investigational Site Number 804024, Donetsk, Ukraine|Investigational Site Number 804029, Ivano-Frankivsk, Ukraine|Investigational Site Number 804010, Kharkiv, Ukraine|Investigational Site Number 804001, Kharkov, Ukraine|Investigational Site Number 804025, Kiev, Ukraine|Investigational Site Number 804023, Kyiv, Ukraine|Investigational Site Number 804014, Kyiv, Ukraine|Investigational Site Number 804027, Kyiv, Ukraine|Investigational Site Number 804011, Kyiv, Ukraine|Investigational Site Number 804030, Lutsk, Ukraine|Investigational Site Number 804005, Lviv, Ukraine|Investigational Site Number 804033, Lviv, Ukraine|Investigational Site Number 804020, Lviv, Ukraine|Investigational Site Number 804032, Odesa, Ukraine|Investigational Site Number 804022, Odesa, Ukraine|Investigational Site Number 804012, Odessa, Ukraine|Investigational Site Number 804021, Simferopol, Ukraine|Investigational Site Number 804028, Zaporozhye, Ukraine|Investigational Site Number 804031, Zhytomyr, Ukraine|Investigational Site Number 826023, Barnsley, United Kingdom|Investigational Site Number 826022, Birmingham, United Kingdom|Investigational Site Number 826021, Dudley, United Kingdom|Investigational Site Number 826026, Durham, United Kingdom|Investigational Site Number 826027, Durham, United Kingdom|Investigational Site Number 826020, Harlow, United Kingdom|Investigational Site Number 826025, Wigan, United Kingdom",,"https://ClinicalTrials.gov/show/NCT01764997"
427,"NCT01756261","EYLEA [AMD-QOL(Age-Related Macular Degeneration-Quality of Life)] Post-marketing Surveillance in Japan",,"Completed","No Results Available","Macular Degeneration","Drug: Aflibercept (Eylea, VEGF Trap-Eye, BAY86-5321)","Changes in mean NEI-VFQ-25 overall scores of patients after the first intravitreal(ITV) injection of EYLEA|Changes in mean NEI-VFQ-25 subscale scores of patients after the first ITV injection of EYLEA|Changes in mean NEI-VFQ-25 overall scores after the first ITV injection of EYLEA in subpopulations of patient background characteristics and status of EYLEA treatments, ie. Frequency, visual acuity, etc|Changes in mean NEI-VFQ-25 subscale scores after the first ITV injection of EYLEA in subpopulations of patient background characteristics and status of EYLEA treatments, ie. Frequency, visual acuity, etc","Bayer|Regeneron Pharmaceuticals","All","Child, Adult, Older Adult",,"757","Industry","Observational","Observational Model: Cohort|Time Perspective: Prospective","16656|EYL-AMD-QOL","December 26, 2012","July 20, 2016","February 27, 2017","December 25, 2012",,"June 19, 2018","Multiple Locations, Japan",,"https://ClinicalTrials.gov/show/NCT01756261"
428,"NCT01756248","EYLEA Age-Related Macular Degeneration (AMD) Post-marketing Surveillance in Japan",,"Completed","No Results Available","Macular Degeneration","Drug: Aflibercept(Eylea, VEGF Trap-Eye, BAY86-5321)","Number of participants with adverse drug reactions(ADRs) and infections from the first intravitreal(ITV) injection of EYLEA|Number of participants with serious adverse events (SAEs) and ocular adverse events(AEs) (especially AEs due to ITV injection procedure) from the first ITV injection of EYLEA|Number of participants with ADRs, SAEs and ocular AEs ( especially AEs due to ITV injection procedure) in subpopulations of patients background characteristics and status of EYLEA treatments from the first ITV injection of EYLEA|Mean changes in visual acuity|Proportion of patients who maintained visual acuity(corresponding to <15 letters of Early Treatment Diabetic Retinopathy Study(ETDRS) from baseline) and improved visual acuity(corresponding to >0 letter of ETDRS from baseline)|Mean changes in visual acuity in subpopulations of patients background characteristics and status of EYLEA treatments|Number and intervals of ITV injection of EYLEA","Bayer|Regeneron Pharmaceuticals","All","Child, Adult, Older Adult",,"4017","Industry","Observational","Observational Model: Cohort|Time Perspective: Prospective","15895|EYL-AMD","December 26, 2012","December 31, 2018","May 20, 2019","December 25, 2012",,"June 25, 2019","Multiple Locations, Japan",,"https://ClinicalTrials.gov/show/NCT01756248"
429,"NCT01724554","Impact of Intravitreal Aflibercept Injections on Capillary Non-Perfusion","ANDROID","Completed","No Results Available","Central Retinal Vein Occlusion|Proliferative Diabetic Retinopathy","Drug: Intravitreal Aflibercept Injection","Mean Change in Capillary Non-Perfusion","Ophthalmic Consultants of Boston|Regeneron Pharmaceuticals","All","18 Years and older   (Adult, Older Adult)","Phase 1|Phase 2","24","Other|Industry","Interventional","Allocation: Randomized|Intervention Model: Parallel Assignment|Masking: None (Open Label)|Primary Purpose: Treatment","ANDROID","November 2012","October 2014","October 2014","November 9, 2012",,"May 22, 2015","Ophthalmic Consultants of Boston, Boston, Massachusetts, United States",,"https://ClinicalTrials.gov/show/NCT01724554"
430,"NCT01723735","Effect of Alirocumab (SAR236553/REGN727) Administered on Top of Ezetimibe or Fenofibrate on Lipid Profiles in Healthy Subjects",,"Completed","No Results Available","Hypercholesterolemia","Drug: Alirocumab|Drug: Ezetimibe|Drug: Ezetimibe Placebo|Drug: Fenofibrate","Assessment of the effect of alirocumab on LDL-C|Assessment of the pharmacodynamic profile of alirocumab|Pharmacokinetics: Assessment of serum concentrations of alirocumab|Pharmacokinetics: Assessment of serum concentrations of proprotein convertase subtilisin kexin type 9 (PCSK9)","Sanofi|Regeneron Pharmaceuticals","All","18 Years to 65 Years   (Adult, Older Adult)","Phase 1","79","Industry","Interventional","Allocation: Randomized|Intervention Model: Parallel Assignment|Masking: None (Open Label)|Primary Purpose: Basic Science","PKD12910|U1111-1131-3203|2012-003049-13","November 2012","July 2013","July 2013","November 8, 2012",,"September 28, 2016","Investigational Site Number 250001, Rennes, France|Investigational Site Number 250002, Rueil Malmaison, France",,"https://ClinicalTrials.gov/show/NCT01723735"
431,"NCT01722656","Intravitreal Aflibercept Injection for the Treatment of Submacular Vascularized Pigment Epithelial Detachment","EVEN","Completed","No Results Available","Submacular Vascularized Pigment Epithelial Detachments","Drug: Aflibercept","Visual Acuity|Anatomic|Proportion of eyes reaching BCVA greater than or equal to 20/200|Proportion of eyes gaining greater than or equal to 0, 5, and 15 letters on ETDRS chart.|Proportion of eyes losing greater than 5 and 15 letters on ETDRS chart|Mean reduction in central macular thickness from baseline (central 1mm subfield) as measured on an OCT.|Mean changes in choroidal neovascular lesion (CNV) size on fluorescein angiography (FA) and fundus photography (FP) from baseline.|Absence or complete resolution of subretinal fluid and cystoid macular edema.|Mean number of injections|Status of fluorescein staining or leakage (increased or decreased) from baseline.|Ocular safety outcome including ocular complications, i.e. RPE tears, uveitis, endophthalmitis|Systemic safety outcome including cardiovascular events, cerebral vascular events","Southern California Desert Retina Consultants, MC|Regeneron Pharmaceuticals","All","50 Years and older   (Adult, Older Adult)","Phase 4","40","Other|Industry","Interventional","Allocation: N/A|Intervention Model: Single Group Assignment|Masking: None (Open Label)|Primary Purpose: Treatment","EVEN Study","November 2012","September 2015","September 2015","November 7, 2012",,"January 22, 2016","Jules Stein Eye Institute, Los Angeles, California, United States|Southern California Desert Retina Consultants, Palm Desert, California, United States|Black Hills Regional Eye Institute, Rapid City, South Dakota, United States",,"https://ClinicalTrials.gov/show/NCT01722656"
432,"NCT01714115","Use of Eylea for the Treatment of an Optic Nerve Hemangioma",,"No longer available","No Results Available","Retinal Hemangioma","Drug: Aflibercept",,"Vitreous -Retina- Macula Consultants of New York|Regeneron Pharmaceuticals","Male","18 Years and older   (Adult, Older Adult)",,,"Other|Industry","Expanded Access",,"Slakter 1234",,,,"October 25, 2012",,"August 8, 2017","Vitreous Retina Macula Consultants of New York, New York, New York, United States",,"https://ClinicalTrials.gov/show/NCT01714115"
433,"NCT01709578","To Evaluate The Effect Of SAR153191 (REGN88) Added To Other RA Drugs In Patients With RA Who Are Not Responding To Or Intolerant Of Anti-TNF Therapy (SARIL-RA-TARGET)",,"Completed","Has Results","Rheumatoid Arthritis","Drug: Sarilumab|Drug: placebo|Drug: hydroxychloroquine|Drug: methotrexate|Drug: sulfasalazine|Drug: leflunomide","Percentage of Participants Who Achieved at Least 20% Improvement in the American College of Rheumatology (ACR20) Criteria at Week 24|Change From Baseline in the Health Assessment Questionnaire-Disability Index (HAQ-DI) at Week 12|Change From Baseline in Disease Activity Score for 28 Joints -C-Reactive Protein (DAS28--CRP) Score at Week 24|Percentage of Participants Achieving ACR50 Criteria at Week 24|Percentage of Participants Achieving ACR70 Criteria at Week 24|Percentage of Participants Achieving Clinical Remission Score (DAS28-CRP) <2.6 at Week 24|Change From Baseline in Clinical Disease Activity Index (CDAI) at Week 24|Change From Baseline in HAQ-DI at Week 24|Change From Baseline in 36-Item Short-Form Health Survey (SF-36) Physical Component Summary Scores (PCS) at Week 24|Change From Baseline in SF-36 MCS at Week 24|Change From Baseline in the Functional Assessment of Chronic Illness Therapy Fatigue (FACIT-fatigue) Score at Week 24|Change From Baseline in Morning Stiffness VAS at Week 24|Change From Baseline in Work Productivity Survey - Rheumatoid Arthritis (WPS-RA) at Week 24: Work Days Missed Due to RA|Change From Baseline in WPS-RA at Week 24: Days With Work Productivity Reduced by ≥ 50% Due to RA|Change From Baseline in WPS-RA at Week 24: RA Interference With Work Productivity|Change From Baseline in WPS-RA at Week 24: House Work Days Missed Due to RA|Change From Baseline in WPS-RA at Week 24: Days With Household Work Productivity Reduced by ≥ 50% Due to RA|Change From Baseline in WPS-RA at Week 24: Days With Family/Social/Leisure Activities Missed Due to RA|Change From Baseline in WPS-RA at Week 24: Days With Outside Help Hired Due to RA|Change From Baseline in WPS-RA at Week 24: RA Interference With Household Work Productivity|Change From Baseline in Rheumatoid Arthritis Impact of Disease (RAID) Scores at Week 24|Change From Baseline in European Quality of Life-5 Dimension 3 Level (EQ-5D-3L) VAS Scores at Week 24|Percentage of Participants Achieving ACR20, ACR50 and ACR70 Criteria at Week 12|Change From Baseline in DAS28-CRP at Week 12|Percentage of Participants Achieving Clinical Remission Score (DAS28--CRP <2.6) at Week 12|Change From Baseline in SF-36 at Week 12|Change From Baseline in WPS-RA at Week 12: Work Days Missed Due to RA|Change From Baseline in WPS-RA at Week 12: Days With Work Productivity Reduced by ≥ 50% Due to RA|Change From Baseline in WPS-RA at Week 12: RA Interference With Work Productivity|Change From Baseline in WPS-RA at Week 12: House Work Days Missed Due to RA|Change From Baseline in WPS-RA at Week 12: Days With Household Work Productivity Reduced by ≥ 50% Due to RA|Change From Baseline in WPS-RA at Week 12: Days With Family/Social/Leisure Activities Missed Due to RA|Change From Baseline in WPS-RA at Week 12: Days With Outside Help Hired Due to RA|Change From Baseline in WPS-RA at Week 12: RA Interference With Household Work Productivity|Change From Baseline in the FACIT-fatigue at Week 12|Change From Baseline in EQ-5D-3L VAS Scores at Week 12|Change From Baseline in RAID Scores at Week 12|Change From Baseline in Individual ACR Components - TJC and SJC at Week 12 and Week 24|Change From Baseline in Individual ACR Component - Physician Global VAS, Participant Global VAS and Pain VAS at Week 12 and Week 24|Change From Baseline in Individual ACR Component - CRP Level at Week 12 and Week 24|Change From Baseline in Individual ACR Component - HAQ-DI at Week 12 and Week 24","Sanofi|Regeneron Pharmaceuticals","All","18 Years and older   (Adult, Older Adult)","Phase 3","546","Industry","Interventional","Allocation: Randomized|Intervention Model: Parallel Assignment|Masking: Quadruple (Participant, Care Provider, Investigator, Outcomes Assessor)|Primary Purpose: Treatment","EFC10832|U1111-1115-8466|2011-003538-16","October 2012","March 2015","March 2015","October 18, 2012","August 8, 2017","August 8, 2017","Investigational Site Number 840070, Anniston, Alabama, United States|Investigational Site Number 840138, Birmingham, Alabama, United States|Investigational Site Number 840142, Phoenix, Arizona, United States|Investigational Site Number 840134, Fullerton, California, United States|Investigational Site Number 840141, Glendale, California, United States|Investigational Site Number 840111, La Jolla, California, United States|Investigational Site Number 840135, San Diego, California, United States|Investigational Site Number 840021, Santa Maria, California, United States|Investigational Site Number 840100, Stanford, California, United States|Investigational Site Number 840049, Upland, California, United States|Investigational Site Number 840131, Whittier, California, United States|Investigational Site Number 840201, Denver, Colorado, United States|Investigational Site Number 840130, Lewes, Delaware, United States|Investigational Site Number 840125, DeBary, Florida, United States|Investigational Site Number 840048, Miami, Florida, United States|Investigational Site Number 840024, Naples, Florida, United States|Investigational Site Number 840006, Orlando, Florida, United States|Investigational Site Number 840128, Ormond Beach, Florida, United States|Investigational Site Number 840063, Palm Harbor, Florida, United States|Investigational Site Number 840060, Sarasota, Florida, United States|Investigational Site Number 840140, Tampa, Florida, United States|Investigational Site Number 840126, Vero Beach, Florida, United States|Investigational Site Number 840018, Idaho Falls, Idaho, United States|Investigational Site Number 840110, Meridian, Idaho, United States|Investigational Site Number 840052, Kansas City, Kansas, United States|Investigational Site Number 840015, Lexington, Kentucky, United States|Investigational Site Number 840120, Baton Rouge, Louisiana, United States|Investigational Site Number 840109, Lake Charles, Louisiana, United States|Investigational Site Number 840055, Frederick, Maryland, United States|Investigational Site Number 840150, Lansing, Michigan, United States|Investigational Site Number 840137, Saint Clair Shores, Michigan, United States|Investigational Site Number 840037, Tupelo, Mississippi, United States|Investigational Site Number 840112, Lincoln, Nebraska, United States|Investigational Site Number 840106, Orchard Park, New York, United States|Investigational Site Number 840121, Rochester, New York, United States|Investigational Site Number 840115, Roslyn, New York, United States|Investigational Site Number 840118, Smithtown, New York, United States|Investigational Site Number 840139, Syracuse, New York, United States|Investigational Site Number 840123, Charlotte, North Carolina, United States|Investigational Site Number 840116, Wilmington, North Carolina, United States|Investigational Site Number 840127, Oklahoma City, Oklahoma, United States|Investigational Site Number 840011, Tulsa, Oklahoma, United States|Investigational Site Number 840009, Duncansville, Pennsylvania, United States|Investigational Site Number 840117, Pittsburgh, Pennsylvania, United States|Investigational Site Number 840062, Reading, Pennsylvania, United States|Investigational Site Number 840058, Columbia, South Carolina, United States|Investigational Site Number 840025, Jackson, Tennessee, United States|Investigational Site Number 840059, Memphis, Tennessee, United States|Investigational Site Number 840132, Austin, Texas, United States|Investigational Site Number 840022, Dallas, Texas, United States|Investigational Site Number 840114, El Paso, Texas, United States|Investigational Site Number 840133, Houston, Texas, United States|Investigational Site Number 840129, Houston, Texas, United States|Investigational Site Number 840074, Mesquite, Texas, United States|Investigational Site Number 840036, Spokane, Washington, United States|Investigational Site Number 840124, Clarksburg, West Virginia, United States|Investigational Site Number 032015, Buenos Aires, Argentina|Investigational Site Number 032008, Buenos Aires, Argentina|Investigational Site Number 032019, Caba, Argentina|Investigational Site Number 032006, Caba, Argentina|Investigational Site Number 032016, Capital Federal, Argentina|Investigational Site Number 032020, Cordoba, Argentina|Investigational Site Number 032017, La Plata, Argentina|Investigational Site Number 032010, Ramos Mejia, Argentina|Investigational Site Number 032013, Rosario, Argentina|Investigational Site Number 032004, San Miguel De Tucuman, Argentina|Investigational Site Number 032009, Zarate, Argentina|Investigational Site Number 036014, Victoria Park, Australia|Investigational Site Number 040004, Stockerau, Austria|Investigational Site Number 040003, Wien, Austria|Investigational Site Number 076001, Curitiba, Brazil|Investigational Site Number 076016, Curitiba, Brazil|Investigational Site Number 076006, Goiania, Brazil|Investigational Site Number 076010, Juiz De Fora, Brazil|Investigational Site Number 076005, Rio De Janeiro, Brazil|Investigational Site Number 076015, Rio De Janeiro, Brazil|Investigational Site Number 124005, Toronto, Canada|Investigational Site Number 124009, Trois-Rivières, Canada|Investigational Site Number 124104, Victoria, Canada|Investigational Site Number 152015, Temuco, Chile|Investigational Site Number 170001, Bogota, Colombia|Investigational Site Number 170012, Bogota, Colombia|Investigational Site Number 170006, Bogotá, Colombia|Investigational Site Number 170007, Bucaramanga, Colombia|Investigational Site Number 170009, Bucaramanga, Colombia|Investigational Site Number 170014, Chia, Colombia|Investigational Site Number 170019, Medellin, Colombia|Investigational Site Number 203008, Hostivice, Czechia|Investigational Site Number 203004, Ostrava, Czechia|Investigational Site Number 203007, Praha 2, Czechia|Investigational Site Number 203002, Uherske Hradiste, Czechia|Investigational Site Number 203006, Zlin, Czechia|Investigational Site Number 218003, Cuenca, Ecuador|Investigational Site Number 218001, Guayaquil, Ecuador|Investigational Site Number 218002, Quito, Ecuador|Investigational Site Number 276011, Bad Nauheim, Germany|Investigational Site Number 276010, Berlin, Germany|Investigational Site Number 276001, Berlin, Germany|Investigational Site Number 276014, Berlin, Germany|Investigational Site Number 276018, Deggingen, Germany|Investigational Site Number 276004, Erlangen, Germany|Investigational Site Number 276015, Halle/Saale, Germany|Investigational Site Number 276013, Hamburg, Germany|Investigational Site Number 276016, Leipzig, Germany|Investigational Site Number 276017, München, Germany|Investigational Site Number 276021, Osnabrück, Germany|Investigational Site Number 276020, Tübingen, Germany|Investigational Site Number 276019, Zerbst, Germany|Investigational Site Number 300002, Heraklion, Greece|Investigational Site Number 300005, Thessaloniki, Greece|Investigational Site Number 320002, Guatemala City, Guatemala|Investigational Site Number 320003, Guatemala City, Guatemala|Investigational Site Number 320001, Guatemala City, Guatemala|Investigational Site Number 348022, Budapest, Hungary|Investigational Site Number 348003, Debrecen, Hungary|Investigational Site Number 348004, Veszprém, Hungary|Investigational Site Number 348017, Veszprém, Hungary|Investigational Site Number 376001, Haifa, Israel|Investigational Site Number 376003, Petach Tikva, Israel|Investigational Site Number 376002, Tel Hashomer, Israel|Investigational Site Number 380011, Catania, Italy|Investigational Site Number 380002, Firenze, Italy|Investigational Site Number 380005, Genova, Italy|Investigational Site Number 380014, Milano, Italy|Investigational Site Number 380013, Udine, Italy|Investigational Site Number 410017, Daejeon, Korea, Republic of|Investigational Site Number 410016, Seoul, Korea, Republic of|Investigational Site Number 440005, Kaunas, Lithuania|Investigational Site Number 440006, Klaipeda, Lithuania|Investigational Site Number 440007, Vilnius, Lithuania|Investigational Site Number 484023, Chihuahua, Mexico|Investigational Site Number 484018, Guadalajara, Mexico|Investigational Site Number 484002, Guadalajara, Mexico|Investigational Site Number 484024, Guadalajara, Mexico|Investigational Site Number 484010, Mexicali, Mexico|Investigational Site Number 484019, Monterrey, Mexico|Investigational Site Number 484020, Monterrey, Mexico|Investigational Site Number 484005, Monterrey, Mexico|Investigational Site Number 484017, México, Mexico|Investigational Site Number 484021, Queretaro, Mexico|Investigational Site Number 554005, Hamilton, New Zealand|Investigational Site Number 554011, Nelson, New Zealand|Investigational Site Number 554007, Otahuhu, New Zealand|Investigational Site Number 554001, Timaru, New Zealand|Investigational Site Number 554006, Wellington, New Zealand|Investigational Site Number 604010, Lima, Peru|Investigational Site Number 604009, Lima, Peru|Investigational Site Number 604006, Lima, Peru|Investigational Site Number 604012, Lima, Peru|Investigational Site Number 604013, Lima, Peru|Investigational Site Number 604001, Lima, Peru|Investigational Site Number 604008, Lima, Peru|Investigational Site Number 604007, Lima, Peru|Investigational Site Number 604005, Lima, Peru|Investigational Site Number 604014, Lima, Peru|Investigational Site Number 616014, Bialystok, Poland|Investigational Site Number 616019, Bydgoszcz, Poland|Investigational Site Number 616015, Elblag, Poland|Investigational Site Number 616018, Poznan, Poland|Investigational Site Number 616016, Szczecin, Poland|Investigational Site Number 616004, Warszawa, Poland|Investigational Site Number 616017, Warszawa, Poland|Investigational Site Number 616020, Wroclaw, Poland|Investigational Site Number 620002, Lisboa, Portugal|Investigational Site Number 620004, Lisboa, Portugal|Investigational Site Number 620007, Ponte De Lima, Portugal|Investigational Site Number 642001, Bucuresti, Romania|Investigational Site Number 642012, Bucuresti, Romania|Investigational Site Number 642002, Bucuresti, Romania|Investigational Site Number 642014, Iasi, Romania|Investigational Site Number 643001, Moscow, Russian Federation|Investigational Site Number 643021, Moscow, Russian Federation|Investigational Site Number 643022, Novosibirsk, Russian Federation|Investigational Site Number 643008, Saint-Petersburg, Russian Federation|Investigational Site Number 643010, Samara, Russian Federation|Investigational Site Number 703001, Kosice, Slovakia|Investigational Site Number 724016, Barakaldo, Spain|Investigational Site Number 724015, Barcelona, Spain|Investigational Site Number 724014, Cadiz, Spain|Investigational Site Number 724009, La Coruña, Spain|Investigational Site Number 724001, Málaga, Spain|Investigational Site Number 724011, Sabadell, Spain|Investigational Site Number 724017, Santiago De Compostela, Spain|Investigational Site Number 724013, Santiago De Compostela, Spain|Investigational Site Number 724007, Sevilla, Spain|Investigational Site Number 158005, Kaohsiung, Taiwan|Investigational Site Number 158006, Taipei, Taiwan|Investigational Site Number 158002, Taoyuan County, Taiwan|Investigational Site Number 792007, Edirne, Turkey|Investigational Site Number 792008, Gaziantep, Turkey|Investigational Site Number 792009, Samsun, Turkey|Investigational Site Number 804013, Kharkiv, Ukraine|Investigational Site Number 804014, Kyiv, Ukraine|Investigational Site Number 804027, Kyiv, Ukraine|Investigational Site Number 804011, Vinnytsia, Ukraine|Investigational Site Number 804009, Zaporizhzhya, Ukraine",,"https://ClinicalTrials.gov/show/NCT01709578"
434,"NCT01670734","Pharmacokinetic and Tolerability of Alirocumab SAR236553 (REGN727) in Patients With Hepatic Impairment and in Healthy Subjects",,"Completed","No Results Available","Hypercholesterolemia","Drug: alirocumab SAR236553 (REGN727)","Pharmacokinetics: Assessment of serum concentrations of alirocumab SAR236553 (REGN727)|Assessment of PK parameter - terminal elimination half-life (t1/2z) [|Assessment of PK parameter - apparent total body clearance (CL/F)|Assessment of PK parameter - Distribution volume at the steady-state (Vss/F)|Assessment of PK parameter - time to maximum concentration (tmax)|Assessment of PK parameter - Mean Residence Time (MRT [area])|Pharmacodynamics: Change in LDL-C from baseline|Number of participants with Adverse Events","Sanofi|Regeneron Pharmaceuticals","All","18 Years to 75 Years   (Adult, Older Adult)","Phase 1","25","Industry","Interventional","Allocation: Non-Randomized|Intervention Model: Parallel Assignment|Masking: None (Open Label)|Primary Purpose: Basic Science","POP12671|2012-002292-33|U1111-1129-0248","September 2012","May 2013","May 2013","August 22, 2012",,"June 28, 2013","Investigational Site Number 250001, Rennes, France|Investigational Site Number 498001, Chisinau, Moldova, Republic of",,"https://ClinicalTrials.gov/show/NCT01670734"
435,"NCT01670721","Colorectal Cancer Metastatic","AFEQT","Completed","Has Results","Colorectal Cancer Metastatic","Drug: AFLIBERCEPT|Drug: Irinotecan|Drug: Fluorouracil|Drug: Leucovorin","Percentage of Participants With Adverse Events (AEs)|Change From Baseline in Health Related Quality of Life (HRQL) European Organization for Research and Treatment for Cancer Quality of Life Questionnaire Core 30 (EORTC QLQ-C30)|Change From Baseline in HRQL European-Quality of Life-5 Dimension Instrument-3 Levels (EQ-5D-3L) Index Score|Change From Baseline in HRQL EQ-5D-3L VAS Score","Sanofi|Regeneron Pharmaceuticals","All","18 Years and older   (Adult, Older Adult)","Phase 3","175","Industry","Interventional","Allocation: N/A|Intervention Model: Single Group Assignment|Masking: None (Open Label)|Primary Purpose: Treatment","AFLIBL06266|2012-000048-89|U1111-1128-9325","August 2012","June 2015","June 2015","August 22, 2012","November 28, 2016","November 28, 2016","Administrative office, Paris, France",,"https://ClinicalTrials.gov/show/NCT01670721"
436,"NCT01670162","On-label tReatment With Intravitreal Aflibercept injectiOn for Patients With Persistent Pigment epitheliaL Detachments in Neovascular Age Related Macular Degeneration (AMD)","ROLL","Unknown status","No Results Available","Age Related Macular Degeneration|Pigment Epithelial Detachment","Drug: Aflibercept","Proportion of patients with flattening of PED|Mean Change in Best Corrected Visual Acuity (BCVA)|Mean number of injections needed|Mean change in Optical Coherence Tomography (OCT) central retinal thickness|Proportion of patients gaining 5 letters or more letters on Early Treatment Diabetic Retinopathy Study (ETDRS) Chart|Mean change in BCVA|Mean number of injections|Mean change in OCT central retinal thickness|Proportion of patients gaining 5 letters or more","Tennessee Retina|Regeneron Pharmaceuticals","All","50 Years and older   (Adult, Older Adult)","Phase 4","30","Other|Industry","Interventional","Allocation: N/A|Intervention Model: Single Group Assignment|Masking: None (Open Label)|Primary Purpose: Treatment","VGFT-OD-1220","August 2012","November 2015","January 2016","August 21, 2012",,"October 29, 2014","Pacific Eye Associates, San Fransisco, California, United States|Retina Associates of Kentucky, Lexington, Kentucky, United States|Tennessee Retina, P.C., Nashville, Tennessee, United States",,"https://ClinicalTrials.gov/show/NCT01670162"
437,"NCT01663402","ODYSSEY Outcomes: Evaluation of Cardiovascular Outcomes After an Acute Coronary Syndrome During Treatment With Alirocumab",,"Completed","Has Results","Atherosclerotic Cardiovascular Disease","Drug: Alirocumab|Drug: Placebo|Drug: LMT","Time to First Occurrence of Major Adverse Cardiovascular Event (MACE); Percentage of Observed Participants With Outcome Measure Events During the Study|Time to First Occurrence of Any Coronary Heart Disease Event; Percentage of Observed Participants With Outcome Measure Events During the Study|Time to First Occurrence of Any Major Coronary Heart Disease Event; Percentage of Observed Participants With Outcome Measure Events During the Study|Time to First Occurrence of Any Cardiovascular Event; Percentage of Observed Participants With Outcome Measure Events During the Study|Time to First Occurrence of All-Cause Mortality, Non-Fatal Myocardial Infarction, Non-Fatal Ischemic Stroke; Percentage of Observed Participants With Outcome Measure Events During the Study|Time to Coronary Heart Disease Death; Percentage of Observed Participants With Outcome Measure Events During the Study|Time to Cardiovascular Death; Percentage of Observed Participants With Outcome Measure Events During the Study|Time to All-Cause Death; Percentage of Observed Participants With Outcome Measure Events During the Study|Time to First Occurrence of Any Non-Fatal Myocardial Infarction; Percentage of Observed Participants With Outcome Measure Events During the Study|Time to First Occurrence of Fatal or Any Non-Fatal Ischemic Stroke; Percentage of Observed Participants With Outcome Measure Events During the Study|Time to First Occurrence of Any Unstable Angina Requiring Hospitalization; Percentage of Observed Participants With Outcome Measure Events During the Study|Time to First Occurrence of Any Ischemia-Driven Coronary Revascularization Procedure; Percentage of Observed Participants With Outcome Measure Events During the Study|Time to First Occurrence of Any Congestive Heart Failure (CHF) Requiring Hospitalization; Percentage of Observed Participants With Outcome Measure Events During the Study","Sanofi|Regeneron Pharmaceuticals","All","40 Years and older   (Adult, Older Adult)","Phase 3","18924","Industry","Interventional","Allocation: Randomized|Intervention Model: Parallel Assignment|Masking: Double (Participant, Investigator)|Primary Purpose: Prevention","EFC11570|2011-005698-21|U1111-1127-4323","October 2012","January 23, 2018","January 23, 2018","August 13, 2012","March 18, 2019","March 18, 2019","Investigational Site Number 840163, Birmingham, Alabama, United States|Investigational Site Number 840060, Birmingham, Alabama, United States|Investigational Site Number 840117, Huntsville, Alabama, United States|Investigational Site Number 840192, Huntsville, Alabama, United States|Investigational Site Number 840121, Mobile, Alabama, United States|Investigational Site Number 840319, Mobile, Alabama, United States|Investigational Site Number 840332, Atlantis, Arizona, United States|Investigational Site Number 840320, Newport Beach, Arizona, United States|Investigational Site Number 840103, Tucson, Arizona, United States|Investigational Site Number 840084, Tucson, Arizona, United States|Investigational Site Number 840139, Banning, California, United States|Investigational Site Number 840286, Beverly Hills, California, United States|Investigational Site Number 840246, Beverly Hills, California, United States|Investigational Site Number 840353, Beverly Hills, California, United States|Investigational Site Number 840341, Carmichael, California, United States|Investigational Site Number 840299, Chula Vista, California, United States|Investigational Site Number 840164, Fresno, California, United States|Investigational Site Number 840076, Fullerton, California, United States|Investigational Site Number 840073, Huntington Beach, California, United States|Investigational Site Number 840092, La Jolla, California, United States|Investigational Site Number 840208, Long Beach, California, United States|Investigational Site Number 840068, Long Beach, California, United States|Investigational Site Number 840269, Los Alamitos, California, United States|Investigational Site Number 840009, Los Angeles, California, United States|Investigational Site Number 840282, Los Angeles, California, United States|Investigational Site Number 840019, Mission Viejo, California, United States|Investigational Site Number 840336, Moreno Valley, California, United States|Investigational Site Number 840124, Northridge, California, United States|Investigational Site Number 840251, Pasadena, California, United States|Investigational Site Number 840289, Pasadena, California, United States|Investigational Site Number 840312, Port Hueneme, California, United States|Investigational Site Number 840261, San Diego, California, United States|Investigational Site Number 840310, San Diego, California, United States|Investigational Site Number 840024, San Diego, California, United States|Investigational Site Number 840071, Santa Ana, California, United States|Investigational Site Number 840236, Santa Rosa, California, United States|Investigational Site Number 840012, Torrance, California, United States|Investigational Site Number 840096, Aurora, Colorado, United States|Investigational Site Number 840037, Colorado Springs, Colorado, United States|Investigational Site Number 840189, Denver, Colorado, United States|Investigational Site Number 840122, Bridgeport, Connecticut, United States|Investigational Site Number 840219, Guilford, Connecticut, United States|Investigational Site Number 840347, Altamonte Springs, Florida, United States|Investigational Site Number 840066, Clearwater, Florida, United States|Investigational Site Number 840079, Daytona Beach, Florida, United States|Investigational Site Number 840051, Daytona Beach, Florida, United States|Investigational Site Number 840368, Delray Beach, Florida, United States|Investigational Site Number 840242, Fort Lauderdale, Florida, United States|Investigational Site Number 840134, Gainesville, Florida, United States|Investigational Site Number 840327, Hollywood, Florida, United States|Investigational Site Number 840153, Hudson, Florida, United States|Investigational Site Number 840105, Hudson, Florida, United States|Investigational Site Number 840253, Jacksonville, Florida, United States|Investigational Site Number 840141, Jacksonville, Florida, United States|Investigational Site Number 840042, Jacksonville, Florida, United States|Investigational Site Number 840206, Jacksonville, Florida, United States|Investigational Site Number 840063, Jacksonville, Florida, United States|Investigational Site Number 840002, Jupiter, Florida, United States|Investigational Site Number 840119, Largo, Florida, United States|Investigational Site Number 840241, Miami Beach, Florida, United States|Investigational Site Number 840210, Mount Clemens, Florida, United States|Investigational Site Number 840366, New Port Richey, Florida, United States|Investigational Site Number 840311, Palm Beach Gardens, Florida, United States|Investigational Site Number 840280, Palm Harbor, Florida, United States|Investigational Site Number 840054, Panama City, Florida, United States|Investigational Site Number 840239, Pembroke Pines, Florida, United States|Investigational Site Number 840044, Pensacola, Florida, United States|Investigational Site Number 840367, Plantation, Florida, United States|Investigational Site Number 840132, Safety Harbor, Florida, United States|Investigational Site Number 840061, Safety Harbor, Florida, United States|Investigational Site Number 840247, Sarasota, Florida, United States|Investigational Site Number 840264, Tampa, Florida, United States|Investigational Site Number 840082, Tampa, Florida, United States|Investigational Site Number 840213, Trinity, Florida, United States|Investigational Site Number 840165, Wellington, Florida, United States|Investigational Site Number 840323, West Palm Beach, Florida, United States|Investigational Site Number 840075, Atlanta, Georgia, United States|Investigational Site Number 840176, Augusta, Georgia, United States|Investigational Site Number 840048, Covington, Georgia, United States|Investigational Site Number 840065, Cumming, Georgia, United States|Investigational Site Number 840356, Thomasville, Georgia, United States|Investigational Site Number 840114, Tucker, Georgia, United States|Investigational Site Number 840211, Idaho Falls, Idaho, United States|Investigational Site Number 840237, Arlington Heights, Illinois, United States|Investigational Site Number 840292, Chicago, Illinois, United States|Investigational Site Number 840146, Harvey, Illinois, United States|Investigational Site Number 840340, Joliet, Illinois, United States|Investigational Site Number 840196, Peoria, Illinois, United States|Investigational Site Number 840081, Rock Island, Illinois, United States|Investigational Site Number 840090, Rock Island, Illinois, United States|Investigational Site Number 840358, Elkhart, Indiana, United States|Investigational Site Number 840036, Hammond, Indiana, United States|Investigational Site Number 840026, Indianapolis, Indiana, United States|Investigational Site Number 840102, Muncie, Indiana, United States|Investigational Site Number 840145, South Bend, Indiana, United States|Investigational Site Number 840154, Ames, Iowa, United States|Investigational Site Number 840345, Iowa City, Iowa, United States|Investigational Site Number 840283, West Des Moines, Iowa, United States|Investigational Site Number 840335, Kansas City, Kansas, United States|Investigational Site Number 840089, Kansas City, Kansas, United States|Investigational Site Number 840218, Kansas City, Kansas, United States|Investigational Site Number 840140, Overland Park, Kansas, United States|Investigational Site Number 840030, Lexington, Kentucky, United States|Investigational Site Number 840023, Louisville, Kentucky, United States|Investigational Site Number 840007, Louisville, Kentucky, United States|Investigational Site Number 840279, Owensboro, Kentucky, United States|Investigational Site Number 840308, Pikeville, Kentucky, United States|Investigational Site Number 840181, Saint Paul, Kentucky, United States|Investigational Site Number 840254, Alexandria, Louisiana, United States|Investigational Site Number 840344, Lafayette, Louisiana, United States|Investigational Site Number 840187, Lake Charles, Louisiana, United States|Investigational Site Number 840291, Minden, Louisiana, United States|Investigational Site Number 840278, New Orleans, Louisiana, United States|Investigational Site Number 840290, Shreveport, Louisiana, United States|Investigational Site Number 840142, Auburn, Maine, United States|Investigational Site Number 840148, Auburn, Maine, United States|Investigational Site Number 840097, Bangor, Maine, United States|Investigational Site Number 840234, Framingham, Maine, United States|Investigational Site Number 840276, Scarborough, Maine, United States|Investigational Site Number 840351, Annapolis, Maryland, United States|Investigational Site Number 840072, Beltsville, Maryland, United States|Investigational Site Number 840193, Bethesda, Maryland, United States|Investigational Site Number 840200, Columbia, Maryland, United States|Investigational Site Number 840349, Rockville, Maryland, United States|Investigational Site Number 840111, Winfield, Maryland, United States|Investigational Site Number 840056, Boston, Massachusetts, United States|Investigational Site Number 840144, Flint, Michigan, United States|Investigational Site Number 840365, Grandville, Michigan, United States|Investigational Site Number 840093, Kalamazoo, Michigan, United States|Investigational Site Number 840198, Lansing, Michigan, United States|Investigational Site Number 840087, Rochester Hills, Michigan, United States|Investigational Site Number 840004, Springfield, Michigan, United States|Investigational Site Number 840267, Springfield, Michigan, United States|Investigational Site Number 840035, Ypsilanti, Michigan, United States|Investigational Site Number 840199, Duluth, Minnesota, United States|Investigational Site Number 840116, Edina, Minnesota, United States|Investigational Site Number 840281, Minneapolis, Minnesota, United States|Investigational Site Number 840094, Saint Cloud, Minnesota, United States|Investigational Site Number 840324, Saint Paul, Minnesota, United States|Investigational Site Number 840046, Columbia, Missouri, United States|Investigational Site Number 840180, Independence, Missouri, United States|Investigational Site Number 840274, Little Rock, Missouri, United States|Investigational Site Number 840013, Marquette, Missouri, United States|Investigational Site Number 840179, Overland, Missouri, United States|Investigational Site Number 840228, Saint Louis, Missouri, United States|Investigational Site Number 840233, Saint Louis, Missouri, United States|Investigational Site Number 840235, Saint Louis, Missouri, United States|Investigational Site Number 840175, Saint Louis, Missouri, United States|Investigational Site Number 840125, Saint Louis, Missouri, United States|Investigational Site Number 840168, Saint Louis, Missouri, United States|Investigational Site Number 840032, Kalispell, Montana, United States|Investigational Site Number 840033, Grand Island, Nebraska, United States|Investigational Site Number 840015, Omaha, Nebraska, United States|Investigational Site Number 840021, Omaha, Nebraska, United States|Investigational Site Number 840001, Omaha, Nebraska, United States|Investigational Site Number 840221, Las Vegas, Nevada, United States|Investigational Site Number 840062, Nashua, New Hampshire, United States|Investigational Site Number 840077, Bridgewater, New Jersey, United States|Investigational Site Number 840173, Bridgewater, New Jersey, United States|Investigational Site Number 840127, Flemington, New Jersey, United States|Investigational Site Number 840359, Hackensack, New Jersey, United States|Investigational Site Number 840348, Moorestown, New Jersey, United States|Investigational Site Number 840128, New Brunswick, New Jersey, United States|Investigational Site Number 840167, Pomona, New Jersey, United States|Investigational Site Number 840067, Ridgewood, New Jersey, United States|Investigational Site Number 840250, Somerset, New Jersey, United States|Investigational Site Number 840277, Voorhees, New Jersey, United States|Investigational Site Number 840083, Westwood, New Jersey, United States|Investigational Site Number 840222, Bronx, New York, United States|Investigational Site Number 840322, Buffalo, New York, United States|Investigational Site Number 840248, New York, New York, United States|Investigational Site Number 840371, New York, New York, United States|Investigational Site Number 840333, Newburgh, New York, United States|Investigational Site Number 840017, Poughkeepsie, New York, United States|Investigational Site Number 840166, Valhalla, New York, United States|Investigational Site Number 840354, Williamsville, New York, United States|Investigational Site Number 840070, Elizabeth City, North Carolina, United States|Investigational Site Number 840303, Greenville, North Carolina, United States|Investigational Site Number 840182, Greenville, North Carolina, United States|Investigational Site Number 840243, Raleigh, North Carolina, United States|Investigational Site Number 840342, Raleigh, North Carolina, United States|Investigational Site Number 840293, Rocky Mount, North Carolina, United States|Investigational Site Number 840088, Statesville, North Carolina, United States|Investigational Site Number 840052, Wilmington, North Carolina, United States|Investigational Site Number 840306, Baltimore, North Dakota, United States|Investigational Site Number 840214, Fargo, North Dakota, United States|Investigational Site Number 840095, Minot, North Dakota, United States|Investigational Site Number 840257, Mountain Lakes, North Dakota, United States|Investigational Site Number 840364, Akron, Ohio, United States|Investigational Site Number 840131, Cincinnati, Ohio, United States|Investigational Site Number 840045, Columbus, Ohio, United States|Investigational Site Number 840265, Columbus, Ohio, United States|Investigational Site Number 840113, Lorain, Ohio, United States|Investigational Site Number 840115, Lorain, Ohio, United States|Investigational Site Number 840309, Maumee, Ohio, United States|Investigational Site Number 840297, Springfield, Ohio, United States|Investigational Site Number 840172, Toledo, Ohio, United States|Investigational Site Number 840263, Youngstown, Ohio, United States|Investigational Site Number 840334, Oklahoma City, Oklahoma, United States|Investigational Site Number 840337, Oklahoma City, Oklahoma, United States|Investigational Site Number 840018, Tulsa, Oklahoma, United States|Investigational Site Number 840184, Portland, Oregon, United States|Investigational Site Number 840133, Allentown, Pennsylvania, United States|Investigational Site Number 840104, Beaver, Pennsylvania, United States|Investigational Site Number 840170, Camp Hill, Pennsylvania, United States|Investigational Site Number 840020, Doylestown, Pennsylvania, United States|Investigational Site Number 840016, Erie, Pennsylvania, United States|Investigational Site Number 840329, Goodyear, Pennsylvania, United States|Investigational Site Number 840126, Knoxville, Pennsylvania, United States|Investigational Site Number 840249, Lancaster, Pennsylvania, United States|Investigational Site Number 840150, Lancaster, Pennsylvania, United States|Investigational Site Number 840231, Philadelphia, Pennsylvania, United States|Investigational Site Number 840339, Philadelphia, Pennsylvania, United States|Investigational Site Number 840230, Pittsburgh, Pennsylvania, United States|Investigational Site Number 840028, Sayre, Pennsylvania, United States|Investigational Site Number 840069, Scranton, Pennsylvania, United States|Investigational Site Number 840316, Scranton, Pennsylvania, United States|Investigational Site Number 840273, Seven Fields, Pennsylvania, United States|Investigational Site Number 840227, Washington, Pennsylvania, United States|Investigational Site Number 840129, Pawtucket, Rhode Island, United States|Investigational Site Number 840118, Anderson, South Carolina, United States|Investigational Site Number 840190, Greenwood, South Carolina, United States|Investigational Site Number 840360, Lancaster, South Carolina, United States|Investigational Site Number 840314, Myrtle Beach, South Carolina, United States|Investigational Site Number 840008, Rapid City, South Dakota, United States|Investigational Site Number 840285, Chattanooga, Tennessee, United States|Investigational Site Number 840287, Jackson, Tennessee, United States|Investigational Site Number 840040, Johnson City, Tennessee, United States|Investigational Site Number 840238, Knoxville, Tennessee, United States|Investigational Site Number 840195, Oak Ridge, Tennessee, United States|Investigational Site Number 840205, Amarillo, Texas, United States|Investigational Site Number 840352, Amarillo, Texas, United States|Investigational Site Number 840135, Austin, Texas, United States|Investigational Site Number 840301, Dallas, Texas, United States|Investigational Site Number 840152, Dallas, Texas, United States|Investigational Site Number 840157, Dallas, Texas, United States|Investigational Site Number 840229, Fort Worth, Texas, United States|Investigational Site Number 840120, Fort Worth, Texas, United States|Investigational Site Number 840258, Fort Worth, Texas, United States|Investigational Site Number 840136, Kingwood, Texas, United States|Investigational Site Number 840027, Lubbock, Texas, United States|Investigational Site Number 840202, Lufkin, Texas, United States|Investigational Site Number 840270, Odessa, Texas, United States|Investigational Site Number 840162, San Antonio, Texas, United States|Investigational Site Number 840232, San Antonio, Texas, United States|Investigational Site Number 840328, Schertz, Texas, United States|Investigational Site Number 840158, Tyler, Texas, United States|Investigational Site Number 840318, Victoria, Texas, United States|Investigational Site Number 840245, Wichita Falls, Texas, United States|Investigational Site Number 840256, Orem, Utah, United States|Investigational Site Number 840296, Salt Lake City, Utah, United States|Investigational Site Number 840053, Burlington, Vermont, United States|Investigational Site Number 840049, Charlottesville, Virginia, United States|Investigational Site Number 840260, Charlottesville, Virginia, United States|Investigational Site Number 840350, Harrisonburg, Virginia, United States|Investigational Site Number 840215, Leesburg, Virginia, United States|Investigational Site Number 840010, Lynchburg, Virginia, United States|Investigational Site Number 840225, Manassas, Virginia, United States|Investigational Site Number 840022, Richmond, Virginia, United States|Investigational Site Number 840078, Richmond, Virginia, United States|Investigational Site Number 840110, Richmond, Virginia, United States|Investigational Site Number 840149, Roanoke, Virginia, United States|Investigational Site Number 840223, Winchester, Virginia, United States|Investigational Site Number 840025, Bellevue, Washington, United States|Investigational Site Number 840321, Everett, Washington, United States|Investigational Site Number 840326, Spokane, Washington, United States|Investigational Site Number 840086, Tacoma, Washington, United States|Investigational Site Number 840295, Walla Walla, Washington, United States|Investigational Site Number 840262, Burlington, Wisconsin, United States|Investigational Site Number 840298, Green Bay, Wisconsin, United States|Investigational Site Number 840059, Green Bay, Wisconsin, United States|Investigational Site Number 840177, La Crosse, Wisconsin, United States|Investigational Site Number 840300, Manitowoc, Wisconsin, United States|Investigational Site Number 032012, Adrogue, Argentina|Investigational Site Number 032018, Bahia Blanca, Argentina|Investigational Site Number 032050, Caba, Argentina|Investigational Site Number 032048, Caba, Argentina|Investigational Site Number 032023, Caba, Argentina|Investigational Site Number 032020, Caba, Argentina|Investigational Site Number 032041, Caba, Argentina|Investigational Site Number 032011, Caba, Argentina|Investigational Site Number 032045, Caba, Argentina|Investigational Site Number 032010, Ciudad De Buenos Aires, Argentina|Investigational Site Number 032046, Ciudadela, Argentina|Investigational Site Number 032032, Cordoba, Argentina|Investigational Site Number 032019, Cordoba, Argentina|Investigational Site Number 032021, Cordoba, Argentina|Investigational Site Number 032008, Cordoba, Argentina|Investigational Site Number 032042, Cordoba, Argentina|Investigational Site Number 032038, Cordoba, Argentina|Investigational Site Number 032031, Cordoba, Argentina|Investigational Site Number 032017, Coronel Suarez, Argentina|Investigational Site Number 032009, Corrientes, Argentina|Investigational Site Number 032026, Córdoba, Argentina|Investigational Site Number 032049, Córdoba, Argentina|Investigational Site Number 032005, Junin, Argentina|Investigational Site Number 032001, La Plata, Argentina|Investigational Site Number 032040, La Plata, Argentina|Investigational Site Number 032033, Mar Del Plata, Argentina|Investigational Site Number 032014, Mar Del Plata, Argentina|Investigational Site Number 032016, Mendoza, Argentina|Investigational Site Number 032030, Merlo, Argentina|Investigational Site Number 032036, Moron, Argentina|Investigational Site Number 032007, Olivos, Argentina|Investigational Site Number 032044, Olivos, Argentina|Investigational Site Number 032004, Quilmes, Argentina|Investigational Site Number 032025, Rafaela, Argentina|Investigational Site Number 032035, Ramos Mejia, Argentina|Investigational Site Number 032039, Resistencia, Argentina|Investigational Site Number 032028, Rosario, Argentina|Investigational Site Number 032024, Rosario, Argentina|Investigational Site Number 032053, Salta, Argentina|Investigational Site Number 032037, San Isidro, Argentina|Investigational Site Number 032052, San Martin, Argentina|Investigational Site Number 032013, San Martin, Argentina|Investigational Site Number 032002, San Miguel De Tucuman, Argentina|Investigational Site Number 032034, San Miguel De Tucuman, Argentina|Investigational Site Number 032006, San Nicolas, Argentina|Investigational Site Number 032043, Santa Fe, Argentina|Investigational Site Number 032003, Santa Fe, Argentina|Investigational Site Number 032051, Santa Rosa, Argentina|Investigational Site Number 032047, Santiago Del Estero, Argentina|Investigational Site Number 032029, Venado Tuerto, Argentina|Investigational Site Number 032022, Villa Maria, Argentina|Investigational Site Number 032015, Zarate, Argentina|Investigational Site Number 036002, Ashford, Australia|Investigational Site Number 036023, Auchenflower, Australia|Investigational Site Number 036024, Ballarat, Australia|Investigational Site Number 036020, Bedford Park, Australia|Investigational Site Number 036015, Bruce, Australia|Investigational Site Number 036026, Cairns, Australia|Investigational Site Number 036005, Chermside, Australia|Investigational Site Number 036008, Chermside, Australia|Investigational Site Number 036011, Coffs Harbour, Australia|Investigational Site Number 036003, Concord, Australia|Investigational Site Number 036017, Elizabeth Vale, Australia|Investigational Site Number 036006, Fullarton, Australia|Investigational Site Number 036004, Gosford, Australia|Investigational Site Number 036019, Heidelberg West, Australia|Investigational Site Number 036027, Hobart, Australia|Investigational Site Number 036009, Kogarah, Australia|Investigational Site Number 036012, Mildura, Australia|Investigational Site Number 036028, Nambour, Australia|Investigational Site Number 036013, New Lambton, Australia|Investigational Site Number 036010, Perth, Australia|Investigational Site Number 036014, Prahran, Australia|Investigational Site Number 036018, Redcliffe, Australia|Investigational Site Number 036022, Richmond, Australia|Investigational Site Number 036025, Woodville South, Australia|Investigational Site Number 036021, Woolloongabba, Australia|Investigational Site Number 040004, Feldkirch, Austria|Investigational Site Number 040007, Graz, Austria|Investigational Site Number 040001, Salzburg, Austria|Investigational Site Number 040006, Wien, Austria|Investigational Site Number 040003, Wien, Austria|Investigational Site Number 040002, Wien, Austria|Investigational Site Number 056016, Aalst, Belgium|Investigational Site Number 056003, Antwerpen, Belgium|Investigational Site Number 056002, Antwerpen, Belgium|Investigational Site Number 056008, Bonheiden, Belgium|Investigational Site Number 056014, Brasschaat, Belgium|Investigational Site Number 056021, Brussels, Belgium|Investigational Site Number 056005, Bruxelles, Belgium|Investigational Site Number 056004, Bruxelles, Belgium|Investigational Site Number 056017, Edegem, Belgium|Investigational Site Number 056024, Genk, Belgium|Investigational Site Number 056007, Gent, Belgium|Investigational Site Number 056018, Gent, Belgium|Investigational Site Number 056020, La Louviere, Belgium|Investigational Site Number 056009, Leuven, Belgium|Investigational Site Number 056015, Liège, Belgium|Investigational Site Number 056010, Mechelen, Belgium|Investigational Site Number 056013, Mol, Belgium|Investigational Site Number 056001, Ottignies, Belgium|Investigational Site Number 056012, Overpelt, Belgium|Investigational Site Number 056006, Roeselare, Belgium|Investigational Site Number 056019, Tienen, Belgium|Investigational Site Number 070001, Banja Luka, Bosnia and Herzegovina|Investigational Site Number 070002, Banja Luka, Bosnia and Herzegovina|Investigational Site Number 070011, Bihac, Bosnia and Herzegovina|Investigational Site Number 070003, Mostar, Bosnia and Herzegovina|Investigational Site Number 070004, Mostar, Bosnia and Herzegovina|Investigational Site Number 070005, Sarajevo, Bosnia and Herzegovina|Investigational Site Number 070007, Sarajevo, Bosnia and Herzegovina|Investigational Site Number 070010, Sarajevo, Bosnia and Herzegovina|Investigational Site Number 070008, Tuzla, Bosnia and Herzegovina|Investigational Site Number 070009, Tuzla, Bosnia and Herzegovina|Investigational Site Number 070006, Zenica, Bosnia and Herzegovina|Investigational Site Number 076029, Aparecida De Goiania, Brazil|Investigational Site Number 076032, Belem, Brazil|Investigational Site Number 076017, Belo Horizonte, Brazil|Investigational Site Number 076004, Belo Horizonte, Brazil|Investigational Site Number 076022, Belo Horizonte, Brazil|Investigational Site Number 076038, Belo Horizonte, Brazil|Investigational Site Number 076002, Blumenau, Brazil|Investigational Site Number 076011, Brasilia, Brazil|Investigational Site Number 076007, Brasilia, Brazil|Investigational Site Number 076003, Campina Grande Do Sul, Brazil|Investigational Site Number 076006, Campinas, Brazil|Investigational Site Number 076040, Canoas, Brazil|Investigational Site Number 076033, Curitiba, Brazil|Investigational Site Number 076005, Curitiba, Brazil|Investigational Site Number 076009, Fortaleza, Brazil|Investigational Site Number 076008, Fortaleza, Brazil|Investigational Site Number 076012, Goiania, Brazil|Investigational Site Number 076021, Goiania, Brazil|Investigational Site Number 076019, Passo Fundo, Brazil|Investigational Site Number 076018, Pelotas, Brazil|Investigational Site Number 076024, Porto Alegre, Brazil|Investigational Site Number 076026, Porto Alegre, Brazil|Investigational Site Number 076014, Porto Alegre, Brazil|Investigational Site Number 076001, Porto Alegre, Brazil|Investigational Site Number 076027, Porto Alegre, Brazil|Investigational Site Number 076035, Riberao Preto, Brazil|Investigational Site Number 076010, Rio De Janeiro, Brazil|Investigational Site Number 076015, Salvador, Brazil|Investigational Site Number 076041, Salvador, Brazil|Investigational Site Number 076036, Santo Andre, Brazil|Investigational Site Number 076031, Sao Bernardo Do Campo, Brazil|Investigational Site Number 076030, Sao Jose Do Rio Preto, Brazil|Investigational Site Number 076020, Sao Jose Do Rio Preto, Brazil|Investigational Site Number 076025, Sao Paulo, Brazil|Investigational Site Number 076042, Sao Paulo, Brazil|Investigational Site Number 076039, Sao Paulo, Brazil|Investigational Site Number 076013, Sao Paulo, Brazil|Investigational Site Number 076023, Sao Paulo, Brazil|Investigational Site Number 076028, Sao Paulo, Brazil|Investigational Site Number 076016, Tatuí, Brazil|Investigational Site Number 076034, Uberlandia, Brazil|Investigational Site Number 100020, Blagoevgrad, Bulgaria|Investigational Site Number 100012, Burgas, Bulgaria|Investigational Site Number 100011, Pazardzhik, Bulgaria|Investigational Site Number 100013, Pleven, Bulgaria|Investigational Site Number 100018, Pleven, Bulgaria|Investigational Site Number 100005, Plovdiv, Bulgaria|Investigational Site Number 100015, Sandanski, Bulgaria|Investigational Site Number 100023, Smoljan, Bulgaria|Investigational Site Number 100017, Sofia, Bulgaria|Investigational Site Number 100007, Sofia, Bulgaria|Investigational Site Number 100001, Sofia, Bulgaria|Investigational Site Number 100004, Sofia, Bulgaria|Investigational Site Number 100010, Sofia, Bulgaria|Investigational Site Number 100019, Sofia, Bulgaria|Investigational Site Number 100016, Sofia, Bulgaria|Investigational Site Number 100003, Sofia, Bulgaria|Investigational Site Number 100022, Varna, Bulgaria|Investigational Site Number 100014, Veliko Tarnovo, Bulgaria|Investigational Site Number 124033, Calgary, Canada|Investigational Site Number 124017, Cambridge, Canada|Investigational Site Number 124013, Cambridge, Canada|Investigational Site Number 124026, Edmonton, Canada|Investigational Site Number 124019, Edmonton, Canada|Investigational Site Number 124016, Edmonton, Canada|Investigational Site Number 124027, Granby, Canada|Investigational Site Number 124002, Halifax, Canada|Investigational Site Number 124051, Hamilton, Canada|Investigational Site Number 124043, Joliette, Canada|Investigational Site Number 124045, Kitchener, Canada|Investigational Site Number 124053, Levis, Canada|Investigational Site Number 124015, Longueuil, Canada|Investigational Site Number 124004, Moncton, Canada|Investigational Site Number 124040, Montreal, Canada|Investigational Site Number 124032, Montreal, Canada|Investigational Site Number 124036, Montreal, Canada|Investigational Site Number 124042, Montreal, Canada|Investigational Site Number 124028, New Westminster, Canada|Investigational Site Number 124008, Newmarket, Canada|Investigational Site Number 124005, Oshawa, Canada|Investigational Site Number 124007, Ottawa, Canada|Investigational Site Number 124006, Penticton, Canada|Investigational Site Number 124012, Red Deer, Canada|Investigational Site Number 124054, Saint-Jerome, Canada|Investigational Site Number 124024, Sainte-Foy, Canada|Investigational Site Number 124035, Scarborough, Canada|Investigational Site Number 124047, Sherbrooke, Canada|Investigational Site Number 124025, St-Georges, Canada|Investigational Site Number 124044, St. Catherines, Canada|Investigational Site Number 124034, St. John'S, Canada|Investigational Site Number 124021, St. John, Canada|Investigational Site Number 124009, Surrey, Canada|Investigational Site Number 124022, Sydney, Canada|Investigational Site Number 124048, Thetford Mines, Canada|Investigational Site Number 124037, Thunder Bay, Canada|Investigational Site Number 124001, Toronto, Canada|Investigational Site Number 124049, Trois-Rivieres, Canada|Investigational Site Number 124039, Vancouver, Canada|Investigational Site Number 124023, Victoria, Canada|Investigational Site Number 124041, Victoria, Canada|Investigational Site Number 124038, Winnipeg, Canada|Investigational Site Number 152013, Concepcion, Chile|Investigational Site Number 152003, Osorno, Chile|Investigational Site Number 152017, Punta Arenas, Chile|Investigational Site Number 152004, Santiago, Chile|Investigational Site Number 152014, Santiago, Chile|Investigational Site Number 152001, Santiago, Chile|Investigational Site Number 152019, Santiago, Chile|Investigational Site Number 152007, Santiago, Chile|Investigational Site Number 152012, Santiago, Chile|Investigational Site Number 152011, Santiago, Chile|Investigational Site Number 152006, Santiago, Chile|Investigational Site Number 152016, Santiago, Chile|Investigational Site Number 152015, Santiago, Chile|Investigational Site Number 152009, Talca, Chile|Investigational Site Number 152002, Temuco, Chile|Investigational Site Number 152008, Valdivia, Chile|Investigational Site Number 152010, Viña Del Mar, Chile|Investigational Site Number 152018, Viña Del Mar, Chile|Investigational Site Number 156022, Baotou, China|Investigational Site Number 156004, Beijing, China|Investigational Site Number 156005, Beijing, China|Investigational Site Number 156006, Beijing, China|Investigational Site Number 156001, Beijing, China|Investigational Site Number 156082, Beijing, China|Investigational Site Number 156009, Beijing, China|Investigational Site Number 156003, Beijing, China|Investigational Site Number 156002, Beijing, China|Investigational Site Number 156013, Changchun, China|Investigational Site Number 156064, Changchun, China|Investigational Site Number 156052, Changsha, China|Investigational Site Number 156053, Changsha, China|Investigational Site Number 156088, Changsha, China|Investigational Site Number 156057, Chongqing, China|Investigational Site Number 156070, Fuzhou, China|Investigational Site Number 156079, Fuzhou, China|Investigational Site Number 156059, Guangzhou, China|Investigational Site Number 156060, Guangzhou, China|Investigational Site Number 156071, Guangzhou, China|Investigational Site Number 156061, Guangzhou, China|Investigational Site Number 156072, Guiyang, China|Investigational Site Number 156047, Hangzhou, China|Investigational Site Number 156077, Hangzhou, China|Investigational Site Number 156048, Hangzhou, China|Investigational Site Number 156068, Hangzhou, China|Investigational Site Number 156078, Hangzhou, China|Investigational Site Number 156046, Hangzhou, China|Investigational Site Number 156020, Hohhot, China|Investigational Site Number 156032, Jinan, China|Investigational Site Number 156031, Jinan, China|Investigational Site Number 156027, Lanzhou, China|Investigational Site Number 156074, Lanzhou, China|Investigational Site Number 156081, Luzhou, China|Investigational Site Number 156054, Nanchang, China|Investigational Site Number 156055, Nanchang, China|Investigational Site Number 156034, Nanjing, China|Investigational Site Number 156035, Nanjing, China|Investigational Site Number 156039, Shanghai, China|Investigational Site Number 156076, Shanghai, China|Investigational Site Number 156044, Shanghai, China|Investigational Site Number 156043, Shanghai, China|Investigational Site Number 156038, Shanghai, China|Investigational Site Number 156040, Shanghai, China|Investigational Site Number 156016, Shenyang, China|Investigational Site Number 156017, Shenyang, China|Investigational Site Number 156073, Shenzhen, China|Investigational Site Number 156084, Shenzhen, China|Investigational Site Number 156063, Siping, China|Investigational Site Number 156037, Suzhou, China|Investigational Site Number 156066, Tianjin, China|Investigational Site Number 156067, Tianjin, China|Investigational Site Number 156083, Tianjin, China|Investigational Site Number 156025, Tianjin, China|Investigational Site Number 156065, Wenzhou, China|Investigational Site Number 156051, Wuhan, China|Investigational Site Number 156087, Wuhan, China|Investigational Site Number 156029, Xi'An, China|Investigational Site Number 156086, Xi'An, China|Investigational Site Number 156062, Xuzhou, China|Investigational Site Number 156014, Yanji, China|Investigational Site Number 156075, Yueyang, China|Investigational Site Number 156080, Zhanjiang, China|Investigational Site Number 170006, Armenia, Colombia|Investigational Site Number 170003, Barranquilla, Colombia|Investigational Site Number 170011, Barranquilla, Colombia|Investigational Site Number 170013, Barranquilla, Colombia|Investigational Site Number 170022, Bogota D.C., Colombia|Investigational Site Number 170018, Bogota, Colombia|Investigational Site Number 170016, Bogota, Colombia|Investigational Site Number 170010, Cali, Colombia|Investigational Site Number 170001, Cali, Colombia|Investigational Site Number 170017, Cartagena, Colombia|Investigational Site Number 170004, Cartagena, Colombia|Investigational Site Number 170008, Espinal - Tolima, Colombia|Investigational Site Number 170005, Floridablanca, Colombia|Investigational Site Number 170002, Manizales, Colombia|Investigational Site Number 170007, Medellin, Colombia|Investigational Site Number 170009, Medellin, Colombia|Investigational Site Number 170021, Medellin, Colombia|Investigational Site Number 191013, Dubrovnik, Croatia|Investigational Site Number 191017, Krapinske Toplice, Croatia|Investigational Site Number 191009, Opatija, Croatia|Investigational Site Number 191006, Rijeka, Croatia|Investigational Site Number 191012, Slavonski Brod, Croatia|Investigational Site Number 191003, Varazdin, Croatia|Investigational Site Number 191001, Zagreb, Croatia|Investigational Site Number 191002, Zagreb, Croatia|Investigational Site Number 191005, Zagreb, Croatia|Investigational Site Number 191007, Zagreb, Croatia|Investigational Site Number 191008, Zagreb, Croatia|Investigational Site Number 191010, Zagreb, Croatia|Investigational Site Number 191011, Zagreb, Croatia|Investigational Site Number 191015, Zagreb, Croatia|Investigational Site Number 191016, Zagreb, Croatia|Investigational Site Number 191018, Zagreb, Croatia|Investigational Site Number 203003, Brno, Czechia|Investigational Site Number 203020, Ceska Lipa, Czechia|Investigational Site Number 203025, Cesky Krumlov, Czechia|Investigational Site Number 203023, Hodonin, Czechia|Investigational Site Number 203006, Hradec Kralove, Czechia|Investigational Site Number 203019, Kladno, Czechia|Investigational Site Number 203005, Kladno, Czechia|Investigational Site Number 203008, Kromeriz, Czechia|Investigational Site Number 203015, Liberec, Czechia|Investigational Site Number 203024, Marianske Lazne, Czechia|Investigational Site Number 203013, Olomouc, Czechia|Investigational Site Number 203016, Ostrava, Czechia|Investigational Site Number 203014, Pardubice, Czechia|Investigational Site Number 203018, Plzen, Czechia|Investigational Site Number 203011, Praha 10, Czechia|Investigational Site Number 203017, Praha 2, Czechia|Investigational Site Number 203004, Praha 4, Czechia|Investigational Site Number 203021, Praha 4, Czechia|Investigational Site Number 203007, Praha 5 - Motol, Czechia|Investigational Site Number 203012, Praha 5, Czechia|Investigational Site Number 203009, Rakovnik, Czechia|Investigational Site Number 203010, Zlin, Czechia|Investigational Site Number 208016, Aabenraa, Denmark|Investigational Site Number 208012, Aalborg, Denmark|Investigational Site Number 208011, Aarhus N, Denmark|Investigational Site Number 208002, Copenhagen, Denmark|Investigational Site Number 208003, Glostrup, Denmark|Investigational Site Number 208007, Hellerup, Denmark|Investigational Site Number 208006, Herning, Denmark|Investigational Site Number 208018, Hillerød, Denmark|Investigational Site Number 208014, Holbaek, Denmark|Investigational Site Number 208013, Hvidovre, Denmark|Investigational Site Number 208004, Køge, Denmark|Investigational Site Number 208017, Næstved, Denmark|Investigational Site Number 208009, Odense C, Denmark|Investigational Site Number 208015, Silkeborg, Denmark|Investigational Site Number 208008, Slagelse, Denmark|Investigational Site Number 208001, Vejle, Denmark|Investigational Site Number 208010, Viborg, Denmark|Investigational Site Number 233007, Pärnu, Estonia|Investigational Site Number 233004, Tallinn, Estonia|Investigational Site Number 233002, Tallinn, Estonia|Investigational Site Number 233001, Tallinn, Estonia|Investigational Site Number 233005, Tallinn, Estonia|Investigational Site Number 233003, Tartu, Estonia|Investigational Site Number 233006, Viljandimaa, Estonia|Investigational Site Number 246004, Helsinki, Finland|Investigational Site Number 246001, Oulu, Finland|Investigational Site Number 246003, Tampere, Finland|Investigational Site Number 246002, Turku, Finland|Investigational Site Number 250003, Besancon, France|Investigational Site Number 250007, Brest Cedex, France|Investigational Site Number 250010, Cambrai Cedex, France|Investigational Site Number 250018, Clermont-Ferrand Cedex 1, France|Investigational Site Number 250021, Compiegne, France|Investigational Site Number 250002, Dijon, France|Investigational Site Number 250001, Grenoble, France|Investigational Site Number 250009, Limoges Cedex 1, France|Investigational Site Number 250019, Marseille, France|Investigational Site Number 250008, Massy, France|Investigational Site Number 250005, Montfermeil, France|Investigational Site Number 250023, Montpellier Cedex 5, France|Investigational Site Number 250025, Nantes, France|Investigational Site Number 250017, Nice Cedex 01, France|Investigational Site Number 250015, Paris Cedex 12, France|Investigational Site Number 250020, Paris, France|Investigational Site Number 250012, Paris, France|Investigational Site Number 250004, Paris, France|Investigational Site Number 250011, Pau, France|Investigational Site Number 250016, Pessac, France|Investigational Site Number 250026, Rouen, France|Investigational Site Number 250022, Strasbourg Cedex, France|Investigational Site Number 268004, Batumi, Georgia|Investigational Site Number 268001, Kutaisi, Georgia|Investigational Site Number 268005, Tbilisi, Georgia|Investigational Site Number 268002, Tbilisi, Georgia|Investigational Site Number 268003, Tbilisi, Georgia|Investigational Site Number 268008, Tbilisi, Georgia|Investigational Site Number 268009, Tbilisi, Georgia|Investigational Site Number 276013, Aachen, Germany|Investigational Site Number 276019, Bad Krozingen, Germany|Investigational Site Number 276008, Berlin, Germany|Investigational Site Number 276040, Berlin, Germany|Investigational Site Number 276051, Berlin, Germany|Investigational Site Number 276039, Berlin, Germany|Investigational Site Number 276025, Berlin, Germany|Investigational Site Number 276054, Bernau, Germany|Investigational Site Number 276037, Bielefeld, Germany|Investigational Site Number 276016, Bonn, Germany|Investigational Site Number 276009, Bonn, Germany|Investigational Site Number 276001, Dortmund, Germany|Investigational Site Number 276006, Dortmund, Germany|Investigational Site Number 276031, Dortmund, Germany|Investigational Site Number 276050, Dresden, Germany|Investigational Site Number 276024, Eschweiler, Germany|Investigational Site Number 276028, Essen, Germany|Investigational Site Number 276036, Frankfurt Am Main, Germany|Investigational Site Number 276012, Freiburg, Germany|Investigational Site Number 276030, Halle/Saale, Germany|Investigational Site Number 276032, Hamburg, Germany|Investigational Site Number 276017, Hamburg, Germany|Investigational Site Number 276027, Hamburg, Germany|Investigational Site Number 276029, Hamm, Germany|Investigational Site Number 276052, Haßloch, Germany|Investigational Site Number 276014, Heidelberg, Germany|Investigational Site Number 276023, Homburg/Saar, Germany|Investigational Site Number 276035, Kassel, Germany|Investigational Site Number 276046, Leipzig, Germany|Investigational Site Number 276020, Limburg, Germany|Investigational Site Number 276026, Lippstadt, Germany|Investigational Site Number 276044, Lübeck, Germany|Investigational Site Number 276021, Magdeburg, Germany|Investigational Site Number 276015, Mainz, Germany|Investigational Site Number 276010, Marburg, Germany|Investigational Site Number 276018, Münster, Germany|Investigational Site Number 276042, Nürnberg, Germany|Investigational Site Number 276048, Peine, Germany|Investigational Site Number 276053, Rotenburg An Der Fulda, Germany|Investigational Site Number 276045, Rüdersdorf Bei Berlin, Germany|Investigational Site Number 276002, Stuttgart, Germany|Investigational Site Number 276033, Warendorf, Germany|Investigational Site Number 300001, Athens, Greece|Investigational Site Number 300002, Athens, Greece|Investigational Site Number 300007, Athens, Greece|Investigational Site Number 300008, Chios, Greece|Investigational Site Number 300013, Haidari, Greece|Investigational Site Number 300010, Heraklion, Greece|Investigational Site Number 300005, Ioannina, Greece|Investigational Site Number 300003, Marousi, Greece|Investigational Site Number 300006, N. Ionia, Greece|Investigational Site Number 300004, Patra, Greece|Investigational Site Number 300011, Thessaloniki, Greece|Investigational Site Number 300009, Thessaloniki, Greece|Investigational Site Number 320003, Guatemala, Guatemala|Investigational Site Number 320001, Guatemala, Guatemala|Investigational Site Number 320002, Guatemala, Guatemala|Investigational Site Number 320004, Guatemala, Guatemala|Investigational Site Number 344003, Hong Kong, Hong Kong|Investigational Site Number 344001, Shatin, Nt, Hong Kong|Investigational Site Number 348013, Balatonfüred, Hungary|Investigational Site Number 348002, Budapest, Hungary|Investigational Site Number 348012, Budapest, Hungary|Investigational Site Number 348005, Budapest, Hungary|Investigational Site Number 348006, Budapest, Hungary|Investigational Site Number 348008, Debrecen, Hungary|Investigational Site Number 348004, Eger, Hungary|Investigational Site Number 348003, Gyula, Hungary|Investigational Site Number 348010, Pécs, Hungary|Investigational Site Number 348009, Szeged, Hungary|Investigational Site Number 348007, Szekesfehervar, Hungary|Investigational Site Number 348011, Szombathely, Hungary|Investigational Site Number 348001, Zalaegerszeg, Hungary|Investigational Site Number 356060, Ahmedabad, India|Investigational Site Number 356056, Aurangabad, India|Investigational Site Number 356025, Bangalore, India|Investigational Site Number 356028, Bangalore, India|Investigational Site Number 356083, Bangalore, India|Investigational Site Number 356018, Bangalore, India|Investigational Site Number 356026, Bangalore, India|Investigational Site Number 356084, Bangalore, India|Investigational Site Number 356103, Belgaum, India|Investigational Site Number 356019, Bikaner, India|Investigational Site Number 356013, Chennai, India|Investigational Site Number 356012, Chennai, India|Investigational Site Number 356081, Chennai, India|Investigational Site Number 356093, Delhi, India|Investigational Site Number 356038, Delhi, India|Investigational Site Number 356101, Gurgaon, India|Investigational Site Number 356100, Gurgaon, India|Investigational Site Number 356035, Hyderabad, India|Investigational Site Number 356082, Hyderabad, India|Investigational Site Number 356015, Jaipur, India|Investigational Site Number 356053, Karad, India|Investigational Site Number 356102, Karamsad, India|Investigational Site Number 356022, Kochi, India|Investigational Site Number 356106, Kolhapur, India|Investigational Site Number 356067, Kolkata, India|Investigational Site Number 356079, Kolkata, India|Investigational Site Number 356069, Kolkata, India|Investigational Site Number 356089, Ludhiana, India|Investigational Site Number 356095, Mangalore, India|Investigational Site Number 356071, Mumbai, India|Investigational Site Number 356057, Mumbai, India|Investigational Site Number 356007, Mysore, India|Investigational Site Number 356087, Nagpur, India|Investigational Site Number 356098, Nagpur, India|Investigational Site Number 356097, Nagpur, India|Investigational Site Number 356096, Nashik, India|Investigational Site Number 356055, New Delhi, India|Investigational Site Number 356031, New Delhi, India|Investigational Site Number 356041, Panaji, India|Investigational Site Number 356077, Pune, India|Investigational Site Number 356099, Pune, India|Investigational Site Number 356048, Pune, India|Investigational Site Number 356049, Pune, India|Investigational Site Number 356050, Pune, India|Investigational Site Number 356045, Pune, India|Investigational Site Number 356046, Pune, India|Investigational Site Number 356094, Pune, India|Investigational Site Number 356042, Secunderabad, Hyderabad, India|Investigational Site Number 356009, Secunderabad, India|Investigational Site Number 356032, Secunderabad, India|Investigational Site Number 356091, Surat, India|Investigational Site Number 356002, Vijayawada, India|Investigational Site Number 356105, Vijaywada, India|Investigational Site Number 356033, Visakhapatnam, India|Investigational Site Number 356039, Vishkhapattanam, India|Investigational Site Number 356104, Wardha, India|Investigational Site Number 376006, Afula, Israel|Investigational Site Number 376024, Afula, Israel|Investigational Site Number 376009, Ashkelon, Israel|Investigational Site Number 376012, Beer Sheva, Israel|Investigational Site Number 376011, Haifa, Israel|Investigational Site Number 376017, Haifa, Israel|Investigational Site Number 376025, Haifa, Israel|Investigational Site Number 376018, Haifa, Israel|Investigational Site Number 376007, Holon, Israel|Investigational Site Number 376021, Holon, Israel|Investigational Site Number 376016, Jerusalem, Israel|Investigational Site Number 376005, Jerusalem, Israel|Investigational Site Number 376027, Jerusalem, Israel|Investigational Site Number 376002, Kfar Saba, Israel|Investigational Site Number 376013, Kfar Saba, Israel|Investigational Site Number 376004, Nahariya, Israel|Investigational Site Number 376015, Nazareth, Israel|Investigational Site Number 376001, Petah-Tikva, Israel|Investigational Site Number 376019, Petah-Tikva, Israel|Investigational Site Number 376020, Rehovot, Israel|Investigational Site Number 376003, Safed, Israel|Investigational Site Number 376008, Safed, Israel|Investigational Site Number 376010, Tel Aviv, Israel|Investigational Site Number 376014, Tel Aviv, Israel|Investigational Site Number 376022, Tel Hashomer, Israel|Investigational Site Number 376023, Tiberias, Israel|Investigational Site Number 376026, Tzrifin, Israel|Investigational Site Number 380019, Augusta, Italy|Investigational Site Number 380017, Bergamo, Italy|Investigational Site Number 380026, Brescia, Italy|Investigational Site Number 380008, Brescia, Italy|Investigational Site Number 380012, Ferrara, Italy|Investigational Site Number 380027, Forlì, Italy|Investigational Site Number 380015, Livorno, Italy|Investigational Site Number 380033, Massa, Italy|Investigational Site Number 380030, Milano, Italy|Investigational Site Number 380005, Milano, Italy|Investigational Site Number 380003, Milano, Italy|Investigational Site Number 380025, Monza, Italy|Investigational Site Number 380001, Napoli, Italy|Investigational Site Number 380002, Napoli, Italy|Investigational Site Number 380021, Novara, Italy|Investigational Site Number 380009, Osio Sotto, Italy|Investigational Site Number 380007, Palermo, Italy|Investigational Site Number 380013, Perugia, Italy|Investigational Site Number 380031, Rho, Italy|Investigational Site Number 380014, Rimini, Italy|Investigational Site Number 380024, Roma, Italy|Investigational Site Number 380028, Seriate, Italy|Investigational Site Number 380032, Treviso, Italy|Investigational Site Number 380020, Vittorio Veneto, Italy|Investigational Site Number 392013, Amagasaki-Shi, Japan|Investigational Site Number 392041, Amagasaki-Shi, Japan|Investigational Site Number 392029, Fukuoka-Shi, Japan|Investigational Site Number 392019, Hachioji-Shi, Japan|Investigational Site Number 392026, Higashihiroshima-Shi, Japan|Investigational Site Number 392024, Higashiibaraki-Gun, Japan|Investigational Site Number 392003, Hiroshima-Shi, Japan|Investigational Site Number 392002, Itabashi-Ku, Japan|Investigational Site Number 392014, Itabashi-Ku, Japan|Investigational Site Number 392033, Izumisano-Shi, Japan|Investigational Site Number 392020, Kanazawa-Shi, Japan|Investigational Site Number 392015, Kitakyushu-Shi, Japan|Investigational Site Number 392017, Kobe-Shi, Japan|Investigational Site Number 392028, Kobe-Shi, Japan|Investigational Site Number 392037, Kobe-Shi, Japan|Investigational Site Number 392025, Koga-Shi, Japan|Investigational Site Number 392010, Komatsu-Shi, Japan|Investigational Site Number 392035, Komatsushima-Shi, Japan|Investigational Site Number 392023, Kumamoto-Shi, Japan|Investigational Site Number 392031, Kumamoto-Shi, Japan|Investigational Site Number 392039, Kure-Shi, Japan|Investigational Site Number 392012, Kurume-Shi, Japan|Investigational Site Number 392032, Kusatsu-Shi, Japan|Investigational Site Number 392001, Kyoto City, Japan|Investigational Site Number 392027, Minato-Ku, Japan|Investigational Site Number 392016, Morioka-Shi, Japan|Investigational Site Number 392005, Nagoya-Shi, Japan|Investigational Site Number 392022, Nerima-Ku, Japan|Investigational Site Number 392009, Osaka-Shi, Japan|Investigational Site Number 392011, Osaka-Shi, Japan|Investigational Site Number 392040, Osaka-Shi, Japan|Investigational Site Number 392004, Sagamihara-Shi, Japan|Investigational Site Number 392036, Sapporo-Shi, Japan|Investigational Site Number 392034, Shinagawa-Ku, Japan|Investigational Site Number 392018, Suita-Shi, Japan|Investigational Site Number 392030, Tokushima-Shi, Japan|Investigational Site Number 392008, Urasoe-Shi, Japan|Investigational Site Number 392006, Yokohama-Shi, Japan|Investigational Site Number 392021, Yokohama-Shi, Japan|Investigational Site Number 410013, Busan, Korea, Republic of|Investigational Site Number 410003, Busan, Korea, Republic of|Investigational Site Number 410002, Daegu, Korea, Republic of|Investigational Site Number 410012, Goyang-Si, Korea, Republic of|Investigational Site Number 410001, Gwangju, Korea, Republic of|Investigational Site Number 410008, Seongnam, Korea, Republic of|Investigational Site Number 410004, Seoul, Korea, Republic of|Investigational Site Number 410007, Seoul, Korea, Republic of|Investigational Site Number 410010, Seoul, Korea, Republic of|Investigational Site Number 410011, Seoul, Korea, Republic of|Investigational Site Number 410006, Seoul, Korea, Republic of|Investigational Site Number 410009, Suwon, Korea, Republic of|Investigational Site Number 410005, Wonju, Korea, Republic of|Investigational Site Number 428004, Daugavpils, Latvia|Investigational Site Number 428002, Liepaja, Latvia|Investigational Site Number 428006, Riga, Latvia|Investigational Site Number 428001, Riga, Latvia|Investigational Site Number 428005, Riga, Latvia|Investigational Site Number 428003, Ventspils, Latvia|Investigational Site Number 440004, Kaunas, Lithuania|Investigational Site Number 440005, Kaunas, Lithuania|Investigational Site Number 440009, Kaunas, Lithuania|Investigational Site Number 440008, Kaunas, Lithuania|Investigational Site Number 440001, Klaipeda, Lithuania|Investigational Site Number 440006, Klaipeda, Lithuania|Investigational Site Number 440002, Vilnius, Lithuania|Investigational Site Number 440007, Vilnius, Lithuania|Investigational Site Number 440003, Vilnius, Lithuania|Investigational Site Number 807005, Bitola, Macedonia, The Former Yugoslav Republic of|Investigational Site Number 807004, Shtip, Macedonia, The Former Yugoslav Republic of|Investigational Site Number 807002, Skopje, Macedonia, The Former Yugoslav Republic of|Investigational Site Number 807001, Skopje, Macedonia, The Former Yugoslav Republic of|Investigational Site Number 807003, Tetovo, Macedonia, The Former Yugoslav Republic of|Investigational Site Number 458004, Batu Caves, Malaysia|Investigational Site Number 458007, Kota Bharu, Malaysia|Investigational Site Number 458006, Kota Kinabalu, Malaysia|Investigational Site Number 458002, Kuala Lumpur, Malaysia|Investigational Site Number 458005, Kuala Lumpur, Malaysia|Investigational Site Number 458003, Kuching, Malaysia|Investigational Site Number 458001, Sungai Buloh, Malaysia|Investigational Site Number 484005, Aguascalientes, Mexico|Investigational Site Number 484015, Aguascalientes, Mexico|Investigational Site Number 484004, Culiacan, Mexico|Investigational Site Number 484003, Durango, Mexico|Investigational Site Number 484010, Guadalajara, Mexico|Investigational Site Number 484006, Guadalajara, Mexico|Investigational Site Number 484008, Jalapa, Mexico|Investigational Site Number 484019, Mexico D.F., Mexico|Investigational Site Number 484023, Mexico Df, Mexico|Investigational Site Number 484027, Mexico, Mexico|Investigational Site Number 484013, Monterrey, Mexico|Investigational Site Number 484018, Monterrey, Mexico|Investigational Site Number 484011, Monterrey, Mexico|Investigational Site Number 484007, Monterrey, Mexico|Investigational Site Number 484017, Morelia, Mexico|Investigational Site Number 484012, Oaxaca, Mexico|Investigational Site Number 484014, Querétaro, Mexico|Investigational Site Number 484009, San Luis Potosi, Mexico|Investigational Site Number 484002, Tijuana, Mexico|Investigational Site Number 484020, Toluca, Mexico|Investigational Site Number 528006, Alkmaar, Netherlands|Investigational Site Number 528022, Amsterdam, Netherlands|Investigational Site Number 528026, Amsterdam, Netherlands|Investigational Site Number 528021, Apeldoorn, Netherlands|Investigational Site Number 528029, Arnhem, Netherlands|Investigational Site Number 528004, Breda, Netherlands|Investigational Site Number 528002, Delft, Netherlands|Investigational Site Number 528007, Eindhoven, Netherlands|Investigational Site Number 528032, Goes, Netherlands|Investigational Site Number 528012, Gouda, Netherlands|Investigational Site Number 528001, Groningen, Netherlands|Investigational Site Number 528025, Haarlem, Netherlands|Investigational Site Number 528023, Hardenberg, Netherlands|Investigational Site Number 528024, Heerenveen, Netherlands|Investigational Site Number 528016, Hoorn, Netherlands|Investigational Site Number 528019, Leeuwarden, Netherlands|Investigational Site Number 528008, Leiden, Netherlands|Investigational Site Number 528017, Meppel, Netherlands|Investigational Site Number 528030, Nieuwegein, Netherlands|Investigational Site Number 528011, Nijmegen, Netherlands|Investigational Site Number 528015, Purmerend, Netherlands|Investigational Site Number 528018, Roosendaal, Netherlands|Investigational Site Number 528014, Rotterdam, Netherlands|Investigational Site Number 528027, Rotterdam, Netherlands|Investigational Site Number 528005, Sneek, Netherlands|Investigational Site Number 528034, Tiel, Netherlands|Investigational Site Number 528013, Tilburg, Netherlands|Investigational Site Number 528028, Uden, Netherlands|Investigational Site Number 528009, Venlo, Netherlands|Investigational Site Number 528033, Zaandam, Netherlands|Investigational Site Number 528031, Zutphen, Netherlands|Investigational Site Number 528020, Zwolle, Netherlands|Investigational Site Number 554010, Auckland, New Zealand|Investigational Site Number 554001, Christchurch, New Zealand|Investigational Site Number 554006, Dunedin, New Zealand|Investigational Site Number 554004, Hamilton, New Zealand|Investigational Site Number 554011, Lower Hutt, New Zealand|Investigational Site Number 554005, Nelson, New Zealand|Investigational Site Number 554007, New Plymouth, New Zealand|Investigational Site Number 554002, Otahuhu, New Zealand|Investigational Site Number 554008, Palmerston North, New Zealand|Investigational Site Number 554012, Rotorua, New Zealand|Investigational Site Number 554009, Takapuna, New Zealand|Investigational Site Number 554003, Wellington, New Zealand|Investigational Site Number 578004, Arendal, Norway|Investigational Site Number 578013, Bergen, Norway|Investigational Site Number 578009, Hamar, Norway|Investigational Site Number 578006, Kongsvinger, Norway|Investigational Site Number 578003, Oslo, Norway|Investigational Site Number 578005, Oslo, Norway|Investigational Site Number 578012, Stavanger, Norway|Investigational Site Number 578002, Svelvik, Norway|Investigational Site Number 578011, Tynset, Norway|Investigational Site Number 604018, Arequipa, Peru|Investigational Site Number 604004, Callao, Peru|Investigational Site Number 604025, Callao, Peru|Investigational Site Number 604022, Cuzco, Peru|Investigational Site Number 604013, Ica, Peru|Investigational Site Number 604010, Lima, Peru|Investigational Site Number 604008, Lima, Peru|Investigational Site Number 604001, Lima, Peru|Investigational Site Number 604007, Lima, Peru|Investigational Site Number 604005, Lima, Peru|Investigational Site Number 604006, Lima, Peru|Investigational Site Number 604015, Lima, Peru|Investigational Site Number 604016, Lima, Peru|Investigational Site Number 604017, Lima, Peru|Investigational Site Number 604019, Lima, Peru|Investigational Site Number 604003, Lima, Peru|Investigational Site Number 604024, Lima, Peru|Investigational Site Number 604012, Lima, Peru|Investigational Site Number 604020, Piura, Peru|Investigational Site Number 604023, Trujillo, Peru|Investigational Site Number 608012, Cavite, Philippines|Investigational Site Number 608003, Cebu City, Philippines|Investigational Site Number 608013, Cebu City, Philippines|Investigational Site Number 608011, Davao City, Philippines|Investigational Site Number 608010, Davao, Philippines|Investigational Site Number 608006, Iloilo City, Philippines|Investigational Site Number 608002, Makati City, Philippines|Investigational Site Number 608004, Manila, Philippines|Investigational Site Number 608014, Manila, Philippines|Investigational Site Number 608001, Quezon City, Philippines|Investigational Site Number 608009, Quezon City, Philippines|Investigational Site Number 608005, Quezon, Philippines|Investigational Site Number 608008, San Juan, Philippines|Investigational Site Number 616026, Bydgoszcz, Poland|Investigational Site Number 616029, Bydgoszcz, Poland|Investigational Site Number 616010, Chrzanow, Poland|Investigational Site Number 616036, Czeladz, Poland|Investigational Site Number 616034, Gdansk, Poland|Investigational Site Number 616015, Gdansk, Poland|Investigational Site Number 616035, Gdynia, Poland|Investigational Site Number 616005, Gdynia, Poland|Investigational Site Number 616033, Gdynia, Poland|Investigational Site Number 616037, Grodzisk Mazowiecki, Poland|Investigational Site Number 616030, Jelenia Gora, Poland|Investigational Site Number 616031, Krakow, Poland|Investigational Site Number 616002, Krakow, Poland|Investigational Site Number 616012, Leczna, Poland|Investigational Site Number 616017, Legnica, Poland|Investigational Site Number 616019, Lodz, Poland|Investigational Site Number 616016, Lubin, Poland|Investigational Site Number 616021, Olawa, Poland|Investigational Site Number 616039, Olsztyn, Poland|Investigational Site Number 616003, Plock, Poland|Investigational Site Number 616011, Poznan, Poland|Investigational Site Number 616018, Pulawy, Poland|Investigational Site Number 616006, Skierniewice, Poland|Investigational Site Number 616027, Sobotka, Poland|Investigational Site Number 616007, Sokolka, Poland|Investigational Site Number 616022, Swidnik, Poland|Investigational Site Number 616024, Szczecin, Poland|Investigational Site Number 616004, Torun, Poland|Investigational Site Number 616013, Torun, Poland|Investigational Site Number 616025, Torun, Poland|Investigational Site Number 616032, W?Grów, Poland|Investigational Site Number 616040, Warszawa, Poland|Investigational Site Number 616020, Warszawa, Poland|Investigational Site Number 616038, Warszawa, Poland|Investigational Site Number 616008, Warszawa, Poland|Investigational Site Number 616041, Wroclaw, Poland|Investigational Site Number 620004, Almada, Portugal|Investigational Site Number 620005, Aveiro, Portugal|Investigational Site Number 620011, Coimbra, Portugal|Investigational Site Number 620008, Coimbra, Portugal|Investigational Site Number 620001, Leiria, Portugal|Investigational Site Number 620003, Ponta Delgada, Portugal|Investigational Site Number 620002, Setubal, Portugal|Investigational Site Number 620010, Vila Franca De Xira, Portugal|Investigational Site Number 620006, Vila Nova Gaia, Portugal|Investigational Site Number 642001, Braila, Romania|Investigational Site Number 642003, Bucharest, Romania|Investigational Site Number 642012, Bucuresti, Romania|Investigational Site Number 642021, Bucuresti, Romania|Investigational Site Number 642007, Bucuresti, Romania|Investigational Site Number 642008, Bucuresti, Romania|Investigational Site Number 642005, Buzau, Romania|Investigational Site Number 642013, Codlea, Romania|Investigational Site Number 642004, Constanta, Romania|Investigational Site Number 642002, Craiova, Romania|Investigational Site Number 642016, Craiova, Romania|Investigational Site Number 642010, Focsani, Romania|Investigational Site Number 642017, Iasi, Romania|Investigational Site Number 642006, Targoviste, Romania|Investigational Site Number 642019, Targu Mures, Romania|Investigational Site Number 642015, Targu Mures, Romania|Investigational Site Number 642018, Timisoara, Romania|Investigational Site Number 643027, Barnaul, Russian Federation|Investigational Site Number 643037, Kazan, Russian Federation|Investigational Site Number 643013, Kemerovo, Russian Federation|Investigational Site Number 643020, Krasnodar, Russian Federation|Investigational Site Number 643053, Krasnodar, Russian Federation|Investigational Site Number 643033, Moscow, Russian Federation|Investigational Site Number 643002, Moscow, Russian Federation|Investigational Site Number 643011, Moscow, Russian Federation|Investigational Site Number 643029, Moscow, Russian Federation|Investigational Site Number 643028, Moscow, Russian Federation|Investigational Site Number 643004, Moscow, Russian Federation|Investigational Site Number 643016, Moscow, Russian Federation|Investigational Site Number 643023, Moscow, Russian Federation|Investigational Site Number 643044, Moscow, Russian Federation|Investigational Site Number 643022, Moscow, Russian Federation|Investigational Site Number 643031, Moscow, Russian Federation|Investigational Site Number 643043, Nizhny Novgorod, Russian Federation|Investigational Site Number 643034, Novosibirsk, Russian Federation|Investigational Site Number 643052, Novosibirsk, Russian Federation|Investigational Site Number 643050, Novosibirsk, Russian Federation|Investigational Site Number 643035, Omsk, Russian Federation|Investigational Site Number 643039, Perm, Russian Federation|Investigational Site Number 643008, Rostov-Na-Donu, Russian Federation|Investigational Site Number 643017, Ryazan, Russian Federation|Investigational Site Number 643006, Saint - Petersburg, Russian Federation|Investigational Site Number 643015, Saint - Petersburg, Russian Federation|Investigational Site Number 643001, Saint Petersburg, Russian Federation|Investigational Site Number 643007, Saint Petersburg, Russian Federation|Investigational Site Number 643051, Saint-Petersburg, Russian Federation|Investigational Site Number 643042, Saint-Petersburg, Russian Federation|Investigational Site Number 643040, Saint-Petersburg, Russian Federation|Investigational Site Number 643012, Saratov, Russian Federation|Investigational Site Number 643021, Saratov, Russian Federation|Investigational Site Number 643003, Saratov, Russian Federation|Investigational Site Number 643014, Saratov, Russian Federation|Investigational Site Number 643030, St-Petersburg, Russian Federation|Investigational Site Number 643010, St-Petersburg, Russian Federation|Investigational Site Number 643054, St-Petersburg, Russian Federation|Investigational Site Number 643049, Tomsk, Russian Federation|Investigational Site Number 643019, Tyumen, Russian Federation|Investigational Site Number 643025, Tyumen, Russian Federation|Investigational Site Number 643045, Voronezh, Russian Federation|Investigational Site Number 643009, Yaroslavl, Russian Federation|Investigational Site Number 688003, Belgrade, Serbia|Investigational Site Number 688005, Belgrade, Serbia|Investigational Site Number 688006, Belgrade, Serbia|Investigational Site Number 688007, Belgrade, Serbia|Investigational Site Number 688008, Belgrade, Serbia|Investigational Site Number 688010, Belgrade, Serbia|Investigational Site Number 688011, Belgrade, Serbia|Investigational Site Number 688013, Belgrade, Serbia|Investigational Site Number 688015, Belgrade, Serbia|Investigational Site Number 688002, Belgrade, Serbia|Investigational Site Number 688012, Kragujevac, Serbia|Investigational Site Number 688016, Leskovac, Serbia|Investigational Site Number 688001, Niska Banja, Serbia|Investigational Site Number 688004, Nis, Serbia|Investigational Site Number 688018, Pancevo, Serbia|Investigational Site Number 688009, Sremska Kamenica, Serbia|Investigational Site Number 688017, Sremska Mitrovica, Serbia|Investigational Site Number 688014, Valjevo, Serbia|Investigational Site Number 702002, Singapore, Singapore|Investigational Site Number 702003, Singapore, Singapore|Investigational Site Number 702001, Singapore, Singapore|Investigational Site Number 703001, Bardejov, Slovakia|Investigational Site Number 703008, Bratislava, Slovakia|Investigational Site Number 703020, Bratislava, Slovakia|Investigational Site Number 703014, Bratislava, Slovakia|Investigational Site Number 703013, Bratislava, Slovakia|Investigational Site Number 703023, Dolny Kubin, Slovakia|Investigational Site Number 703002, Kosice, Slovakia|Investigational Site Number 703009, Kosice, Slovakia|Investigational Site Number 703016, Kosice, Slovakia|Investigational Site Number 703019, Kosice, Slovakia|Investigational Site Number 703007, Kosice, Slovakia|Investigational Site Number 703012, Kralovsky Chlmec, Slovakia|Investigational Site Number 703006, Lucenec, Slovakia|Investigational Site Number 703010, Lucenec, Slovakia|Investigational Site Number 703003, Nitra, Slovakia|Investigational Site Number 703004, Presov, Slovakia|Investigational Site Number 703018, Svidnik, Slovakia|Investigational Site Number 703022, Trebisov, Slovakia|Investigational Site Number 703005, Zilina, Slovakia|Investigational Site Number 705001, Celje, Slovenia|Investigational Site Number 705004, Izola, Slovenia|Investigational Site Number 705002, Jesenice, Slovenia|Investigational Site Number 705005, Ljubljana, Slovenia|Investigational Site Number 705006, Ljubljana, Slovenia|Investigational Site Number 710017, Alberton, South Africa|Investigational Site Number 710007, Bellville, South Africa|Investigational Site Number 710015, Bloemfontein, South Africa|Investigational Site Number 710009, Cape Town, South Africa|Investigational Site Number 710010, Cape Town, South Africa|Investigational Site Number 710005, Chatsworth, South Africa|Investigational Site Number 710006, Durban, South Africa|Investigational Site Number 710004, Durban, South Africa|Investigational Site Number 710002, Durban, South Africa|Investigational Site Number 710012, Johannesburg, South Africa|Investigational Site Number 710014, Johannesburg, South Africa|Investigational Site Number 710019, Kempton Park, South Africa|Investigational Site Number 710011, Kimberley, South Africa|Investigational Site Number 710021, Kuils River, South Africa|Investigational Site Number 710018, Parow, South Africa|Investigational Site Number 710008, Pretoria, South Africa|Investigational Site Number 710016, Pretoria, South Africa|Investigational Site Number 710020, Stellenbosch, South Africa|Investigational Site Number 710013, Tongaat, South Africa|Investigational Site Number 710022, Western Cape, South Africa|Investigational Site Number 710003, Worcester, South Africa|Investigational Site Number 724010, Alcalá De Henares, Spain|Investigational Site Number 724007, Almería, Spain|Investigational Site Number 724037, Barcelona, Spain|Investigational Site Number 724041, Barcelona, Spain|Investigational Site Number 724038, Barcelona, Spain|Investigational Site Number 724008, Barcelona, Spain|Investigational Site Number 724039, Cáceres, Spain|Investigational Site Number 724042, Córdoba, Spain|Investigational Site Number 724027, Fuenlabrada, Spain|Investigational Site Number 724002, Girona, Spain|Investigational Site Number 724013, Granada, Spain|Investigational Site Number 724032, Guadalajara, Spain|Investigational Site Number 724025, Hospitalet De Llobregat, Spain|Investigational Site Number 724003, Huelva, Spain|Investigational Site Number 724021, León, Spain|Investigational Site Number 724026, Lleida, Spain|Investigational Site Number 724006, Lugo, Spain|Investigational Site Number 724030, Madrid, Spain|Investigational Site Number 724020, Madrid, Spain|Investigational Site Number 724015, Madrid, Spain|Investigational Site Number 724031, Madrid, Spain|Investigational Site Number 724033, Madrid, Spain|Investigational Site Number 724017, Madrid, Spain|Investigational Site Number 724035, Majadahonda, Spain|Investigational Site Number 724036, Murcia, Spain|Investigational Site Number 724016, Málaga, Spain|Investigational Site Number 724043, Málaga, Spain|Investigational Site Number 724001, Oviedo, Spain|Investigational Site Number 724022, Sabadell, Spain|Investigational Site Number 724029, San Sebastian De Los Reyes, Spain|Investigational Site Number 724028, Santander, Spain|Investigational Site Number 724034, Santiago De Compostela, Spain|Investigational Site Number 724014, Sevilla, Spain|Investigational Site Number 724024, Tarragona, Spain|Investigational Site Number 724019, Valencia, Spain|Investigational Site Number 724009, Valencia, Spain|Investigational Site Number 724011, Valencia, Spain|Investigational Site Number 724023, Valladolid, Spain|Investigational Site Number 724005, Vigo, Spain|Investigational Site Number 724040, Zaragoza, Spain|Investigational Site Number 144002, Colombo 7, Sri Lanka|Investigational Site Number 144004, Colombo 8, Sri Lanka|Investigational Site Number 144003, Colombo, Sri Lanka|Investigational Site Number 144010, Colombo, Sri Lanka|Investigational Site Number 144005, Colombo, Sri Lanka|Investigational Site Number 144006, Colombo, Sri Lanka|Investigational Site Number 144001, Colombo, Sri Lanka|Investigational Site Number 144008, Kandy, Sri Lanka|Investigational Site Number 144009, Kurunegala, Sri Lanka|Investigational Site Number 144007, Ragama, Sri Lanka|Investigational Site Number 752001, Falun, Sweden|Investigational Site Number 752016, Göteborg, Sweden|Investigational Site Number 752011, Halmstad, Sweden|Investigational Site Number 752006, Karlshamn, Sweden|Investigational Site Number 752008, Karlskrona, Sweden|Investigational Site Number 752004, Kristianstad, Sweden|Investigational Site Number 752013, Köping, Sweden|Investigational Site Number 752015, Malmö, Sweden|Investigational Site Number 752012, Mölndal, Sweden|Investigational Site Number 752009, Stockholm, Sweden|Investigational Site Number 752002, Stockholm, Sweden|Investigational Site Number 752014, Sundsvall, Sweden|Investigational Site Number 752007, Uppsala, Sweden|Investigational Site Number 756005, Basel, Switzerland|Investigational Site Number 756003, Geneve, Switzerland|Investigational Site Number 756004, Lugano, Switzerland|Investigational Site Number 756002, Zürich, Switzerland|Investigational Site Number 158003, Changhua, Taiwan|Investigational Site Number 158008, Division Of Cardiology, Taiwan|Investigational Site Number 158014, Hsinchu, Taiwan|Investigational Site Number 158013, Kaohsiung, Taiwan|Investigational Site Number 158004, Taichung, Taiwan|Investigational Site Number 158009, Tainan, Taiwan|Investigational Site Number 158011, Tainan, Taiwan|Investigational Site Number 158005, Taipei, Taiwan|Investigational Site Number 158001, Taipei, Taiwan|Investigational Site Number 158010, Taipei, Taiwan|Investigational Site Number 158007, Taipei, Taiwan|Investigational Site Number 158012, Taoyuan Hsien, Taiwan|Investigational Site Number 158002, Yunlin, Taiwan|Investigational Site Number 764009, Bangkok-Noi, Thailand|Investigational Site Number 764001, Bangkok, Thailand|Investigational Site Number 764011, Bangkok, Thailand|Investigational Site Number 764007, Bangkok, Thailand|Investigational Site Number 764012, Bangkok, Thailand|Investigational Site Number 764005, Hat Yai, Thailand|Investigational Site Number 764008, Klong Luang, Thailand|Investigational Site Number 764002, Moung, Thailand|Investigational Site Number 764003, Muang, Thailand|Investigational Site Number 764010, Nonthaburi, Thailand|Investigational Site Number 764006, Pratumwan, Thailand|Investigational Site Number 792007, Adana, Turkey|Investigational Site Number 792009, Ankara, Turkey|Investigational Site Number 792006, Bursa, Turkey|Investigational Site Number 792016, Eskisehir, Turkey|Investigational Site Number 792014, Istanbul, Turkey|Investigational Site Number 792005, Istanbul, Turkey|Investigational Site Number 792011, Istanbul, Turkey|Investigational Site Number 792013, Istanbul, Turkey|Investigational Site Number 792004, Izmir, Turkey|Investigational Site Number 792003, Izmir, Turkey|Investigational Site Number 792015, Kocaeli, Turkey|Investigational Site Number 792010, Mersin, Turkey|Investigational Site Number 804015, Chernivtsi, Ukraine|Investigational Site Number 804018, Dnipropetrovsk, Ukraine|Investigational Site Number 804027, Donetsk, Ukraine|Investigational Site Number 804012, Donetsk, Ukraine|Investigational Site Number 804010, Ivano-Frankivsk, Ukraine|Investigational Site Number 804006, Kharkiv, Ukraine|Investigational Site Number 804003, Kharkiv, Ukraine|Investigational Site Number 804009, Kharkiv, Ukraine|Investigational Site Number 804020, Khmelnytskyi, Ukraine|Investigational Site Number 804001, Kiev, Ukraine|Investigational Site Number 804002, Kiev, Ukraine|Investigational Site Number 804011, Kyiv, Ukraine|Investigational Site Number 804014, Kyiv, Ukraine|Investigational Site Number 804025, Kyiv, Ukraine|Investigational Site Number 804034, Kyiv, Ukraine|Investigational Site Number 804036, Kyiv, Ukraine|Investigational Site Number 804016, Kyiv, Ukraine|Investigational Site Number 804030, Kyiv, Ukraine|Investigational Site Number 804028, Lutsk, Ukraine|Investigational Site Number 804033, Lviv, Ukraine|Investigational Site Number 804031, Lviv, Ukraine|Investigational Site Number 804029, Mykolaiv, Ukraine|Investigational Site Number 804013, Odesa, Ukraine|Investigational Site Number 804004, Odessa, Ukraine|Investigational Site Number 804017, Simferopol, Ukraine|Investigational Site Number 804035, Sumy, Ukraine|Investigational Site Number 804007, Uzhgorod, Ukraine|Investigational Site Number 804005, Vinnitsya, Ukraine|Investigational Site Number 804008, Vinnytsia, Ukraine|Investigational Site Number 804026, Zaporizhia, Ukraine|Investigational Site Number 804024, Zhytomyr, Ukraine|Investigational Site Number 804032, Zhytomyr, Ukraine|Investigational Site Number 826018, Basildon, United Kingdom|Investigational Site Number 826015, Birmingham, United Kingdom|Investigational Site Number 826030, Birmingham, United Kingdom|Investigational Site Number 826038, Bournemouth, United Kingdom|Investigational Site Number 826025, Bradford, United Kingdom|Investigational Site Number 826027, Burton On Trent, United Kingdom|Investigational Site Number 826017, Cardiff, United Kingdom|Investigational Site Number 826010, Chertsey, United Kingdom|Investigational Site Number 826012, Chesterfield, United Kingdom|Investigational Site Number 826039, Chichester, United Kingdom|Investigational Site Number 826024, Cumbria, United Kingdom|Investigational Site Number 826041, Dudley, United Kingdom|Investigational Site Number 826021, Harrow, United Kingdom|Investigational Site Number 826026, High Wycombe, United Kingdom|Investigational Site Number 826028, Hull, United Kingdom|Investigational Site Number 826034, London, United Kingdom|Investigational Site Number 826004, Manchester, United Kingdom|Investigational Site Number 826011, Newcastle Upon Tyne, United Kingdom|Investigational Site Number 826036, Northampton, United Kingdom|Investigational Site Number 826019, Peterborough, United Kingdom|Investigational Site Number 826020, Plymouth, United Kingdom|Investigational Site Number 826040, Portadown, United Kingdom|Investigational Site Number 826016, Portsmouth, United Kingdom|Investigational Site Number 826014, Redhill, United Kingdom|Investigational Site Number 826007, Rhyl, United Kingdom|Investigational Site Number 826001, Romford, United Kingdom|Investigational Site Number 826009, Rotherham, United Kingdom|Investigational Site Number 826002, Sheffield, United Kingdom|Investigational Site Number 826032, South Shields, United Kingdom|Investigational Site Number 826013, St Leonards, United Kingdom|Investigational Site Number 826005, Stoke-On-Trent, United Kingdom|Investigational Site Number 826031, Sunderland, United Kingdom|Investigational Site Number 826022, Truro, United Kingdom|Investigational Site Number 826035, Wigan, United Kingdom|Investigational Site Number 826003, Worcester, United Kingdom","""Study Protocol"", https://ClinicalTrials.gov/ProvidedDocs/02/NCT01663402/Prot_000.pdf|""Statistical Analysis Plan"", https://ClinicalTrials.gov/ProvidedDocs/02/NCT01663402/SAP_001.pdf","https://ClinicalTrials.gov/show/NCT01663402"
438,"NCT01661270","A Study of Aflibercept Versus Placebo With FOLFIRI in Patients With Metastatic Colorectal Cancer Previously Treated With an Oxaliplatin Chemotherapy","AFLAME","Completed","Has Results","Colorectal Cancer Metastatic","Drug: Aflibercept|Drug: Placebo","Progression-free Survival (PFS)|Overall Survival (OS)|Percentage of Participants With Objective Response","Sanofi|Regeneron Pharmaceuticals","All","18 Years and older   (Adult, Older Adult)","Phase 3","332","Industry","Interventional","Allocation: Randomized|Intervention Model: Parallel Assignment|Masking: Double (Participant, Investigator)|Primary Purpose: Treatment","EFC11338|U1111-1115-7227","July 2012","October 2014","July 2015","August 9, 2012","November 26, 2015","October 18, 2016","Investigational Site Number 156003, Beijing, China|Investigational Site Number 156001, Beijing, China|Investigational Site Number 156002, Beijing, China|Investigational Site Number 156004, Beijing, China|Investigational Site Number 156016, Chengdu, China|Investigational Site Number 156020, Chongqing, China|Investigational Site Number 156021, Fuzhou, China|Investigational Site Number 156008, Guangzhou, China|Investigational Site Number 156010, Hangzhou, China|Investigational Site Number 156011, Hangzhou, China|Investigational Site Number 156009, Hangzhou, China|Investigational Site Number 156015, Harbin, China|Investigational Site Number 156012, Nanjing, China|Investigational Site Number 156013, Nanjing, China|Investigational Site Number 156006, Shanghai, China|Investigational Site Number 156007, Shanghai, China|Investigational Site Number 156014, Shenyang, China|Investigational Site Number 156005, Tianjin, China|Investigational Site Number 156019, Wuhan, China|Investigational Site Number 156018, Wuhan, China|Investigational Site Number 156017, Xi'An, China|Investigational Site Number 344002, Hong Kong, Hong Kong|Investigational Site Number 344001, Shatin, Nt, Hong Kong|Investigational Site Number 392006, Amagasaki-Shi, Japan|Investigational Site Number 392003, Bunkyo-Ku, Japan|Investigational Site Number 392004, Bunkyo-Ku, Japan|Investigational Site Number 392009, Gifu-Shi, Japan|Investigational Site Number 392002, Kitaadachi-Gun, Japan|Investigational Site Number 392001, Kobe-Shi, Japan|Investigational Site Number 392005, Kochi-Shi, Japan|Investigational Site Number 392007, Kumamoto-Shi, Japan|Investigational Site Number 392008, Nagakute-Shi, Japan|Investigational Site Number 392010, Takatsuki-Shi, Japan|Investigational Site Number 702002, Singapore, Singapore|Investigational Site Number 702001, Singapore, Singapore|Investigational Site Number 158003, Taipai, Taiwan|Investigational Site Number 158002, Taipei, Taiwan",,"https://ClinicalTrials.gov/show/NCT01661270"
439,"NCT01644474","Efficacy and Safety of Alirocumab (SAR236553/REGN727) Versus Ezetimibe in Patients With Hypercholesterolemia","ODYSSEY MONO","Completed","Has Results","Hypercholesterolemia","Drug: Alirocumab|Drug: Ezetimibe|Drug: Placebo (for Alirocumab)|Drug: Placebo (for Ezetimibe)","Percent Change From Baseline in Calculated LDL-C at Week 24 - Intent-to-Treat (ITT) Analysis|Percent Change From Baseline in Calculated LDL-C at Week 12 - ITT Analysis|Percent Change From Baseline in Apolipoprotein B (Apo B) at Week 24 - ITT Analysis|Percent Change From Baseline in Non-High Density Lipoprotein Cholesterol (Non-HDL-C) at Week 24 - ITT Analysis|Percent Change From Baseline in Total Cholesterol (Total-C) at Week 24 - ITT Analysis|Percent Change From Baseline in Apo B at Week 12 - ITT Analysis|Percent Change From Baseline in Non-HDL-C at Week 12 - ITT Analysis|Percent Change From Baseline in Total-C at Week 12 - ITT Analysis|Percentage of Participants Achieving Calculated LDL-C <100 mg/dL (2.59 mmol/L) at Week 24 - ITT Analysis|Percentage of Participants Achieving Calculated LDL-C <70 mg/dL (1.81 mmol/L) at Week 24 - ITT Analysis|Percent Change From Baseline in Lipoprotein (a) at Week 24 - ITT Analysis|Percent Change From Baseline in HDL-C at Week 24 - ITT Analysis|Percent Change From Baseline in HDL-C at Week 12 - ITT Analysis|Percent Change From Baseline in Lipoprotein (a) at Week 12 - ITT Analysis|Percent Change From Baseline in Fasting Triglycerides at Week 24 - ITT Analysis|Percent Change From Baseline in Fasting Triglycerides at Week 12 - ITT Analysis|Percent Change From Baseline in Apolipoprotein A-1 (Apo A-1) at Week 24 - ITT Analysis|Percent Change From Baseline in Apo A-1 at Week 12 - ITT Analysis","Sanofi|Regeneron Pharmaceuticals","All","18 Years and older   (Adult, Older Adult)","Phase 3","103","Industry","Interventional","Allocation: Randomized|Intervention Model: Parallel Assignment|Masking: Quadruple (Participant, Care Provider, Investigator, Outcomes Assessor)|Primary Purpose: Treatment","EFC11716|U1111-1124-1167|2011-001424-38","July 2012","July 2013","July 2013","July 19, 2012","November 6, 2015","November 6, 2015","Investigational Site Number 840603, Overland Park, Kansas, United States|Investigational Site Number 840601, Cincinnati, Ohio, United States|Investigational Site Number 840602, Richmond, Virginia, United States|Investigational Site Number 056601, Antwerpen, Belgium|Investigational Site Number 246601, Helsinki, Finland|Investigational Site Number 528602, Groningen, Netherlands|Investigational Site Number 528601, Rotterdam, Netherlands|Investigational Site Number 528603, Velp, Netherlands",,"https://ClinicalTrials.gov/show/NCT01644474"
440,"NCT01644188","Efficacy and Safety of Alirocumab (SAR236553/REGN727) Versus Ezetimibe on Top of Statin in High Cardiovascular Risk Patients With Hypercholesterolemia (ODYSSEY COMBO II)",,"Completed","Has Results","Hypercholesterolemia","Drug: Alirocumab|Drug: Placebo (for alirocumab)|Drug: Ezetimibe|Drug: Placebo (for ezetimibe)|Drug: Lipid Modifying Therapy (LMT)","Percent Change From Baseline in Calculated LDL-C at Week 24 - Intent-to-treat (ITT) Analysis|Percent Change From Baseline in Calculated LDL--C at Week 24 - On--Treatment Analysis|Percent Change From Baseline in Calculated LDL-C at Week 12 - ITT Analysis|Percent Change From Baseline in Calculated LDL-C at Week 12 - On-Treatment Analysis|Percent Change From Baseline in Apolipoprotein B (Apo-B) at Week 24 - ITT Analysis|Percent Change From Baseline in Apo B at Week 24 - On-Treatment Analysis|Percent Change From Baseline in Non-High Density Lipoprotein Cholesterol (Non-HDL-C) at Week 24 - ITT Analysis|Percent Change From Baseline in Non-HDL-C at Week 24 - On-Treatment Analysis|Percent Change From Baseline in Total Cholesterol (Total-C) at Week 24 - ITT Analysis|Percent Change From Baseline in Apo-B at Week 12 - ITT Analysis|Percent Change From Baseline in Non-HDL-C at Week 12 - ITT Analysis|Percent Change From Baseline in Total-C at Week 12 - ITT Analysis|Percent Change From Baseline in Calculated LDL-C at Week 52 - ITT Analysis|Percentage of Participants Achieving Calculated LDL-C <70 mg/dL (1.81 mmol/L) at Week 24 - ITT Analysis|Percentage of Participants Achieving Calculated LDL-C <70 mg/dL (1.81 mmol/L) at Week 24 - On-Treatment Analysis|Percent Change From Baseline in Lipoprotein(a) at Week 24 - ITT Analysis|Percent Change From Baseline in HDL-C at Week 24 - ITT Analysis|Percent Change From Baseline in Fasting Triglycerides at Week 24 - ITT Analysis|Percent Change From Baseline in Apolipoprotein A-1 (Apo A-1) at Week 24 - ITT Analysis|Percent Change From Baseline in Lipoprotein(a) at Week 12 - ITT Analysis|Percent Change From Baseline in HDL-C at Week 12 - ITT Analysis|Percent Change From Baseline in Fasting Triglycerides at Week 12 - ITT Analysis|Percent Change From Baseline in Apo A-1 at Week 12 - ITT Analysis","Sanofi|Regeneron Pharmaceuticals","All","18 Years and older   (Adult, Older Adult)","Phase 3","720","Industry","Interventional","Allocation: Randomized|Intervention Model: Parallel Assignment|Masking: Quadruple (Participant, Care Provider, Investigator, Outcomes Assessor)|Primary Purpose: Treatment","EFC11569|U1111-1121-4315|2011-004130-34","August 2012","May 2014","July 2015","July 18, 2012","November 6, 2015","August 4, 2016","Investigational Site Number 840980, Birmingham, Alabama, United States|Investigational Site Number 840918, Phoenix, Arizona, United States|Investigational Site Number 840925, Tucson, Arizona, United States|Investigational Site Number 840959, Anaheim, California, United States|Investigational Site Number 840301, Beverly Hills, California, United States|Investigational Site Number 840933, Chino, California, United States|Investigational Site Number 840991, Lincoln, California, United States|Investigational Site Number 840979, Los Angeles, California, United States|Investigational Site Number 840952, Palm Springs, California, United States|Investigational Site Number 840930, Thousand Oaks, California, United States|Investigational Site Number 840921, Vista, California, United States|Investigational Site Number 840962, Boynton Beach, Florida, United States|Investigational Site Number 840987, Bradenton, Florida, United States|Investigational Site Number 840302, Clearwater, Florida, United States|Investigational Site Number 840935, Jacksonville, Florida, United States|Investigational Site Number 840903, Miami, Florida, United States|Investigational Site Number 840920, Miami, Florida, United States|Investigational Site Number 840943, Ocala, Florida, United States|Investigational Site Number 840981, Oveido, Florida, United States|Investigational Site Number 840961, Port Orange, Florida, United States|Investigational Site Number 840303, Sarasota, Florida, United States|Investigational Site Number 840986, St. Petersburg, Florida, United States|Investigational Site Number 840988, St. Petersburg, Florida, United States|Investigational Site Number 840995, Meridian, Idaho, United States|Investigational Site Number 840902, Evansville, Indiana, United States|Investigational Site Number 840960, Topeka, Kansas, United States|Investigational Site Number 840940, Oxon Hill, Maryland, United States|Investigational Site Number 840966, Fall River, Massachusetts, United States|Investigational Site Number 840917, Kansas City, Missouri, United States|Investigational Site Number 840998, St. Louis, Missouri, United States|Investigational Site Number 840946, Butte, Montana, United States|Investigational Site Number 840914, Lincoln, Nebraska, United States|Investigational Site Number 840949, Albuquerque, New Mexico, United States|Investigational Site Number 840974, New Windsor, New York, United States|Investigational Site Number 840955, Greenville, North Carolina, United States|Investigational Site Number 840938, Lexington, North Carolina, United States|Investigational Site Number 840976, Smithfield, North Carolina, United States|Investigational Site Number 840985, Winston-Salem, North Carolina, United States|Investigational Site Number 840963, Cincinnati, Ohio, United States|Investigational Site Number 840970, Lyndhust, Ohio, United States|Investigational Site Number 840906, Marion, Ohio, United States|Investigational Site Number 840997, Marion, Ohio, United States|Investigational Site Number 840964, Perrysburg, Ohio, United States|Investigational Site Number 840913, Charleston, South Carolina, United States|Investigational Site Number 840912, Greer, South Carolina, United States|Investigational Site Number 840992, Summerville, South Carolina, United States|Investigational Site Number 840932, Bristol, Tennessee, United States|Investigational Site Number 840944, Nashville, Tennessee, United States|Investigational Site Number 840994, Fort Worth, Texas, United States|Investigational Site Number 840973, Houston, Texas, United States|Investigational Site Number 840939, Houston, Texas, United States|Investigational Site Number 840945, Sugar Land, Texas, United States|Investigational Site Number 840971, Tomball, Texas, United States|Investigational Site Number 840982, Orem, Utah, United States|Investigational Site Number 840931, Norfolk, Virginia, United States|Investigational Site Number 840984, Richmond, Virginia, United States|Investigational Site Number 840928, Renton, Washington, United States|Investigational Site Number 840990, Spokane, Washington, United States|Investigational Site Number 124902, Brampton, Canada|Investigational Site Number 124914, Mirabel, Canada|Investigational Site Number 124903, Montreal, Canada|Investigational Site Number 124918, Toronto, Canada|Investigational Site Number 208913, Esbjerg, Denmark|Investigational Site Number 208914, Glostrup, Denmark|Investigational Site Number 208905, Hellerup, Denmark|Investigational Site Number 208911, Herlev, Denmark|Investigational Site Number 208907, Hvidovre, Denmark|Investigational Site Number 208901, København S, Denmark|Investigational Site Number 208906, Køge, Denmark|Investigational Site Number 208908, Roskilde, Denmark|Investigational Site Number 208903, Silkeborg, Denmark|Investigational Site Number 250906, Dijon, France|Investigational Site Number 250907, Montpellier Cedex 5, France|Investigational Site Number 250903, Nantes, France|Investigational Site Number 250905, Nimes, France|Investigational Site Number 348908, Budapest, Hungary|Investigational Site Number 348901, Budapest, Hungary|Investigational Site Number 348903, Budapest, Hungary|Investigational Site Number 348905, Debrecen, Hungary|Investigational Site Number 348906, Szekesfehervar, Hungary|Investigational Site Number 376908, Holon, Israel|Investigational Site Number 376903, Kfar Saba, Israel|Investigational Site Number 376906, Ofakim, Israel|Investigational Site Number 376902, Petach Tikva, Israel|Investigational Site Number 376904, Rehovot, Israel|Investigational Site Number 376907, Safed, Israel|Investigational Site Number 376901, Tel Aviv, Israel|Investigational Site Number 410908, Anyang-Si, Korea, Republic of|Investigational Site Number 410920, Busan, Korea, Republic of|Investigational Site Number 410926, Daegu, Korea, Republic of|Investigational Site Number 410923, Gwangju, Korea, Republic of|Investigational Site Number 410909, Seoul, Korea, Republic of|Investigational Site Number 410922, Seoul, Korea, Republic of|Investigational Site Number 410921, Seoul, Korea, Republic of|Investigational Site Number 410905, Seoul, Korea, Republic of|Investigational Site Number 410901, Seoul, Korea, Republic of|Investigational Site Number 410914, Seoul, Korea, Republic of|Investigational Site Number 410924, Seoul, Korea, Republic of|Investigational Site Number 410915, Suwon, Korea, Republic of|Investigational Site Number 410913, Uijeongbu, Korea, Republic of|Investigational Site Number 410927, Wonju, Korea, Republic of|Investigational Site Number 643906, Barnaul, Russian Federation|Investigational Site Number 643903, Kemerovo, Russian Federation|Investigational Site Number 643927, Moscow, Russian Federation|Investigational Site Number 643928, Moscow, Russian Federation|Investigational Site Number 643931, Moscow, Russian Federation|Investigational Site Number 643924, Moscow, Russian Federation|Investigational Site Number 643932, Moscow, Russian Federation|Investigational Site Number 643908, Moscow, Russian Federation|Investigational Site Number 643904, Moscow, Russian Federation|Investigational Site Number 643911, Orenburg, Russian Federation|Investigational Site Number 643921, Ryazan, Russian Federation|Investigational Site Number 643925, Saint-Petersburg, Russian Federation|Investigational Site Number 643922, Saint-Petersburg, Russian Federation|Investigational Site Number 643929, Saratov, Russian Federation|Investigational Site Number 643914, St-Petersburg, Russian Federation|Investigational Site Number 710917, Alberton, South Africa|Investigational Site Number 710909, Bloemfontein, South Africa|Investigational Site Number 710914, Bloemfontein, South Africa|Investigational Site Number 710905, Cape Town, South Africa|Investigational Site Number 710904, Cape Town, South Africa|Investigational Site Number 710918, Middelburg, South Africa|Investigational Site Number 710913, Pretoria, South Africa|Investigational Site Number 710915, Somerset West, South Africa|Investigational Site Number 804905, Kiev, Ukraine|Investigational Site Number 804902, Uzhhorod, Ukraine",,"https://ClinicalTrials.gov/show/NCT01644188"
441,"NCT01644175","Efficacy and Safety of Alirocumab (SAR236553/REGN727) Versus Placebo on Top of Lipid-Modifying Therapy in Patients With High Cardiovascular Risk and Hypercholesterolemia (ODYSSEY COMBO I)",,"Completed","Has Results","Hypercholesterolemia","Drug: Placebo (for alirocumab)|Drug: Alirocumab|Drug: Lipid-Modifying Therapy (LMT)","Percent Change From Baseline in Calculated LDL-C at Week 24 - Intent-to-Treat (ITT) Analysis|Percent Change From Baseline in Calculated LDL-C at Week 24 - On-Treatment Analysis|Percent Change From Baseline in Calculated LDL-C at Week 12 - ITT Analysis|Percent Change From Baseline in Calculated LDL-C at Week 12 - On-Treatment Analysis|Percent Change From Baseline in Apolipoprotein (Apo) B at Week 24 - ITT Analysis|Percent Change From Baseline in Apo B at Week 24 - On-treatment Analysis|Percent Change From Baseline in Non-High Density Lipoprotein Cholesterol (Non-HDL-C) at Week 24 - ITT Analysis|Percent Change From Baseline in Non-HDL-C at Week 24 - On-treatment Analysis|Percent Change From Baseline in Total Cholesterol (Total-C) at Week 24 - ITT Analysis|Percent Change From Baseline in Apo B at Week 12 - ITT Analysis|Percent Change From Baseline in Non-HDL-C at Week 12 - ITT Analysis|Percent Change From Baseline in Total-C at Week 12 - ITT Analysis|Percent Change From Baseline in Calculated LDL-C at Week 52 - ITT Analysis|Percentage of Participants Reaching Calculated LDL-C <70 mg/dL (1.81 mmol/L) at Week 24 - ITT Analysis|Percentage of Participants Reaching Calculated LDL-C <70 mg/dL (1.81 mmol/L) at Week 24 - On-treatment Analysis|Percent Change From Baseline in Lipoprotein(a) at Week 24 - ITT Analysis|Percent Change From Baseline in HDL-C at Week 24 - ITT Analysis|Percent Change From Baseline in Fasting Triglycerides at Week 24 - ITT Analysis|Percent Change From Baseline in Apolipoprotein A-1 at Week 24 - ITT Analysis|Percent Change From Baseline in Lipoprotein(a) at Week 12- ITT Analysis|Percent Change From Baseline in HDL-C at Week 12 - ITT Analysis|Percent Change From Baseline in Fasting Triglycerides at Week 12 - ITT Analysis|Percent Change From Baseline in Apo A-1 at Week 12 - ITT Analysis","Sanofi|Regeneron Pharmaceuticals","All","18 Years and older   (Adult, Older Adult)","Phase 3","316","Industry","Interventional","Allocation: Randomized|Intervention Model: Parallel Assignment|Masking: Quadruple (Participant, Care Provider, Investigator, Outcomes Assessor)|Primary Purpose: Treatment","EFC11568|U1111-1121-4356","July 2012","April 2014","April 2014","July 18, 2012","November 6, 2015","November 6, 2015","Investigational Site Number 840857, Birmingham, Alabama, United States|Investigational Site Number 840891, Mobile, Alabama, United States|Investigational Site Number 840876, Montgomery, Alabama, United States|Investigational Site Number 840865, Glendale, Arizona, United States|Investigational Site Number 840826, Jonesboro, Arkansas, United States|Investigational Site Number 840870, Burbank, California, United States|Investigational Site Number 840851, Los Angeles, California, United States|Investigational Site Number 840845, Los Gatos, California, United States|Investigational Site Number 840844, Sacramento, California, United States|Investigational Site Number 840801, San Jose, California, United States|Investigational Site Number 840886, Tarzana, California, United States|Investigational Site Number 840862, Torrance, California, United States|Investigational Site Number 840893, Vista, California, United States|Investigational Site Number 840867, Boca Raton, Florida, United States|Investigational Site Number 840884, Boynton Beach, Florida, United States|Investigational Site Number 840836, Clearwater, Florida, United States|Investigational Site Number 840866, Coral Gables, Florida, United States|Investigational Site Number 840895, Ft. Lauderdale, Florida, United States|Investigational Site Number 840820, Hialeah, Florida, United States|Investigational Site Number 840805, Miami, Florida, United States|Investigational Site Number 840811, Oviedo, Florida, United States|Investigational Site Number 840881, Port Orange, Florida, United States|Investigational Site Number 840816, West Palm Beach, Florida, United States|Investigational Site Number 840850, Columbus, Georgia, United States|Investigational Site Number 840840, Eagle, Idaho, United States|Investigational Site Number 840842, Chicago, Illinois, United States|Investigational Site Number 840898, Evanston, Illinois, United States|Investigational Site Number 840847, Morton, Illinois, United States|Investigational Site Number 840896, Indianapolis, Indiana, United States|Investigational Site Number 840894, Michigan City, Indiana, United States|Investigational Site Number 840838, Mishawaka, Indiana, United States|Investigational Site Number 840823, Paducah, Kentucky, United States|Investigational Site Number 840858, Eunice, Louisiana, United States|Investigational Site Number 840802, New Orleans, Louisiana, United States|Investigational Site Number 840855, Salisbury, Massachusetts, United States|Investigational Site Number 840890, Battle Creek, Michigan, United States|Investigational Site Number 840832, Southfield, Michigan, United States|Investigational Site Number 840839, Edina, Minnesota, United States|Investigational Site Number 840888, Minneapolis, Minnesota, United States|Investigational Site Number 840837, Port Gibson, Mississippi, United States|Investigational Site Number 840814, Jefferson City, Missouri, United States|Investigational Site Number 840833, Sparks, Nevada, United States|Investigational Site Number 840817, Newington, New Hampshire, United States|Investigational Site Number 840853, New Windsor, New York, United States|Investigational Site Number 840822, Rochester, New York, United States|Investigational Site Number 840824, Cary, North Carolina, United States|Investigational Site Number 840880, Smithfield, North Carolina, United States|Investigational Site Number 840502, Winston-Salem, North Carolina, United States|Investigational Site Number 840852, Winston-Salem, North Carolina, United States|Investigational Site Number 840846, Cincinnati, Ohio, United States|Investigational Site Number 840899, Cincinnati, Ohio, United States|Investigational Site Number 840831, Columbus, Ohio, United States|Investigational Site Number 840860, Kettering, Ohio, United States|Investigational Site Number 840809, Willoughby Hills, Ohio, United States|Investigational Site Number 840818, Norman, Oklahoma, United States|Investigational Site Number 840812, Eugene, Oregon, United States|Investigational Site Number 840803, Downington, Pennsylvania, United States|Investigational Site Number 840869, Philadelphia, Pennsylvania, United States|Investigational Site Number 840825, Pittsburgh, Pennsylvania, United States|Investigational Site Number 840872, Anderson, South Carolina, United States|Investigational Site Number 840885, Charleston, South Carolina, United States|Investigational Site Number 840813, Greer, South Carolina, United States|Investigational Site Number 840827, Mt. Pleasant, South Carolina, United States|Investigational Site Number 840868, Corpus Christi, Texas, United States|Investigational Site Number 840877, Houston, Texas, United States|Investigational Site Number 840841, Houston, Texas, United States|Investigational Site Number 840830, San Antonio, Texas, United States|Investigational Site Number 840854, San Antonio, Texas, United States|Investigational Site Number 840883, San Antonio, Texas, United States|Investigational Site Number 840889, Tomball, Texas, United States|Investigational Site Number 840878, Bountiful, Utah, United States|Investigational Site Number 840819, Orem, Utah, United States|Investigational Site Number 840863, Salt Lake City, Utah, United States|Investigational Site Number 840804, Manassas, Virginia, United States|Investigational Site Number 840882, Norfolk, Virginia, United States|Investigational Site Number 840810, Weber City, Virginia, United States",,"https://ClinicalTrials.gov/show/NCT01644175"
442,"NCT01623115","Efficacy and Safety of Alirocumab (SAR236553/REGN727) Versus Placebo on Top of Lipid-Modifying Therapy in Patients With Heterozygous Familial Hypercholesterolemia Not Adequately Controlled With Their Lipid-Modifying Therapy","ODYSSEY FH I","Completed","Has Results","Hypercholesterolemia","Drug: Alirocumab|Drug: Placebo (for alirocumab)|Drug: Lipid Modifying Therapy (LMT)","Percent Change From Baseline in Calculated LDL-C at Week 24 - Intent-to-Treat (ITT) Analysis|Percent Change From Baseline in Calculated LDL-C at Week 24 - On-Treatment Analysis|Percent Change From Baseline in Calculated LDL-C at Week 12 - ITT Analysis|Percent Change From Baseline in Calculated LDL-C at Week 12 - On-Treatment Analysis|Percent Change From Baseline in Apolipoprotein B (Apo B) at Week 24 - ITT Analysis|Percent Change From Baseline in Apo B at Week 24 - On-Treatment Analysis|Percent Change From Baseline in Non-High Density Lipoprotein Cholesterol (Non-HDL-C) at Week 24 - ITT Analysis|Percent Change From Baseline in Non-HDL-C at Week 24 - On-Treatment Analysis|Percent Change From Baseline in Total Cholesterol (Total-C) at Week 24 - ITT Analysis|Percent Change From Baseline in Apo B at Week 12 - ITT Analysis|Percent Change From Baseline in Non-HDL-C at Week 12 - ITT Analysis|Percent Change From Baseline in Total-C at Week 12 - ITT Analysis|Percent Change From Baseline in Calculated LDL-C at Week 52 - ITT Analysis|Percentage of Very High Cardiovascular (CV) Risk Participants Achieving Calculated LDL-C < 70 mg/dL (<1.81 mmol/L) or High CV Risk Participants Achieving Calculated LDL-C < 100 mg/dL (<2.59 mmol/L) at Week 24 - ITT Analysis|Percentage of Very High CV Risk Participants Achieving Calculated LDL-C < 70 mg/dL (<1.81 mmol/L) or High CV Risk Participants Achieving Calculated LDL-C < 100 mg/dL (<2.59 mmol/L) at Week 24 - On- Treatment Analysis|Percentage of Participants Achieving Calculated LDL-C <70 mg/dL (1.81 mmol/L) at Week 24 - ITT Analysis|Percentage of Participants Achieving Calculated LDL-C <70 mg/dL (1.81 mmol/L) at Week 24 - On-Treatment Analysis|Percent Change From Baseline in Lipoprotein (a) at Week 24 - ITT Analysis|Percent Change From Baseline in HDL-C at Week 24 - ITT Analysis|Percent Change From Baseline in Fasting Triglycerides at Week 24 - ITT Analysis|Percent Change From Baseline in Apolipoprotein A-1 (Apo A-1) at Week 24 - ITT Analysis|Percent Change From Baseline in Lipoprotein (a) at Week 12 - ITT Analysis|Percent Change From Baseline in HDL-C at Week 12 - ITT Analysis|Percent Change From Baseline in Fasting Triglycerides at Week 12 - ITT Analysis|Percent Change From Baseline in Apo A-1 at Week 12 - ITT Analysis","Sanofi|Regeneron Pharmaceuticals","All","18 Years and older   (Adult, Older Adult)","Phase 3","486","Industry","Interventional","Allocation: Randomized|Intervention Model: Parallel Assignment|Masking: Quadruple (Participant, Care Provider, Investigator, Outcomes Assessor)|Primary Purpose: Treatment","EFC12492|U1111-1121-4275|2011-005109-56","July 2012","April 2014","December 2014","June 19, 2012","November 4, 2015","February 8, 2016","Investigational Site Number 840417, Bell Gardens, California, United States|Investigational Site Number 840429, Long Beach, California, United States|Investigational Site Number 840419, Los Angeles, California, United States|Investigational Site Number 840421, Mission Viejo, California, United States|Investigational Site Number 840412, Newport Beach, California, United States|Investigational Site Number 840428, Newport Beach, California, United States|Investigational Site Number 840461, Northridge, California, United States|Investigational Site Number 840452, Washington, District of Columbia, United States|Investigational Site Number 840456, Miami, Florida, United States|Investigational Site Number 840418, Ponte Vedra, Florida, United States|Investigational Site Number 840455, Evanston, Illinois, United States|Investigational Site Number 840415, Kansas City, Kansas, United States|Investigational Site Number 840425, Auburn, Maine, United States|Investigational Site Number 840411, Boston, Massachusetts, United States|Investigational Site Number 840409, St Louis, Missouri, United States|Investigational Site Number 840407, Morristown, New Jersey, United States|Investigational Site Number 840408, New York, New York, United States|Investigational Site Number 840401, Charlotte, North Carolina, United States|Investigational Site Number 840410, Durham, North Carolina, United States|Investigational Site Number 840430, Cincinnati, Ohio, United States|Investigational Site Number 840424, Portland, Oregon, United States|Investigational Site Number 840404, Philadelphia, Pennsylvania, United States|Investigational Site Number 840426, Philadelphia, Pennsylvania, United States|Investigational Site Number 840406, Nashville, Tennessee, United States|Investigational Site Number 840460, Dallas, Texas, United States|Investigational Site Number 840422, Bountiful, Utah, United States|Investigational Site Number 040403, Graz, Austria|Investigational Site Number 040402, Wien, Austria|Investigational Site Number 040405, Wien, Austria|Investigational Site Number 124404, Chicoutimi, Canada|Investigational Site Number 124401, Montreal, Canada|Investigational Site Number 124403, Quebec, Canada|Investigational Site Number 124406, Sherbrooke, Canada|Investigational Site Number 124407, Toronto, Canada|Investigational Site Number 203401, Praha, Czech Republic|Investigational Site Number 203403, Praha, Czech Republic|Investigational Site Number 203405, Uherske Hradiste, Czech Republic|Investigational Site Number 203402, Zlin, Czech Republic|Investigational Site Number 208401, Copenhagen, Denmark|Investigational Site Number 208403, Esbjerg, Denmark|Investigational Site Number 250403, Dijon, France|Investigational Site Number 250401, Paris Cedex 13, France|Investigational Site Number 250402, Saint Herblain, France|Investigational Site Number 376402, Holon, Israel|Investigational Site Number 376405, Jerusalem, Israel|Investigational Site Number 376404, Safed, Israel|Investigational Site Number 376401, Tel Hashomer, Israel|Investigational Site Number 528406, Amsterdam, Netherlands|Investigational Site Number 528410, Amsterdam, Netherlands|Investigational Site Number 528408, Den Helder, Netherlands|Investigational Site Number 528402, Groningen, Netherlands|Investigational Site Number 528411, Leiden, Netherlands|Investigational Site Number 528416, Maastricht, Netherlands|Investigational Site Number 528409, Nieuwegein, Netherlands|Investigational Site Number 528412, Sliedrecht, Netherlands|Investigational Site Number 578401, Bodø, Norway|Investigational Site Number 643402, Arkhangelsk, Russian Federation|Investigational Site Number 643407, Kazan, Russian Federation|Investigational Site Number 643409, Moscow, Russian Federation|Investigational Site Number 643413, Moscow, Russian Federation|Investigational Site Number 643401, Moscow, Russian Federation|Investigational Site Number 643412, Novisibirsk, Russian Federation|Investigational Site Number 643408, St-Petersburg, Russian Federation|Investigational Site Number 643406, St-Petersburg, Russian Federation|Investigational Site Number 643404, St-Petersburg, Russian Federation|Investigational Site Number 643410, Yaroslavl, Russian Federation|Investigational Site Number 710401, Bloemfontein, South Africa|Investigational Site Number 710405, Bloemfontein, South Africa|Investigational Site Number 710406, Cap Town, South Africa|Investigational Site Number 710402, Cape Town, South Africa|Investigational Site Number 710407, Parktown, South Africa|Investigational Site Number 710403, Parow, South Africa|Investigational Site Number 710408, Pretoria, South Africa|Investigational Site Number 710404, Rondebosch, South Africa|Investigational Site Number 710409, Somerset West, South Africa|Investigational Site Number 724403, A Coruna, Spain|Investigational Site Number 724408, Barcelona, Spain|Investigational Site Number 724406, Córdoba, Spain|Investigational Site Number 724407, Hospitalet De Llobregat, Spain|Investigational Site Number 724409, Madrid, Spain|Investigational Site Number 724401, Madrid, Spain|Investigational Site Number 724405, Madrid, Spain|Investigational Site Number 724404, Reus, Spain|Investigational Site Number 724402, Zaragoza, Spain|Investigational Site Number 752404, Goteborg, Sweden|Investigational Site Number 752401, Stockholm, Sweden|Investigational Site Number 826402, London, United Kingdom|Investigational Site Number 826403, London, United Kingdom|Investigational Site Number 826408, London, United Kingdom|Investigational Site Number 826409, London, United Kingdom|Investigational Site Number 826405, Manchester, United Kingdom",,"https://ClinicalTrials.gov/show/NCT01623115"
443,"NCT01617655","Efficacy and Safety of Alirocumab (SAR236553/REGN727) Versus Placebo on Top of Lipid-Modifying Therapy in Patients With Heterozygous Familial Hypercholesterolemia (ODYSSEY HIGH FH)",,"Completed","Has Results","Hypercholesterolaemia","Drug: Alirocumab|Drug: Placebo (for alirocumab)|Drug: Lipid Modifying Therapy (LMT)","Percent Change From Baseline in Calculated LDL-C at Week 24 - ITT Analysis|Percent Change From Baseline in Calculated LDL-C at Week 24 - On-Treatment Analysis|Percent Change From Baseline in Calculated LDL-C at Week 12 - ITT Analysis|Percent Change From Baseline in Calculated LDL-C at Week 12 - On-Treatment Analysis|Percent Change From Baseline in Apolipoprotein B (Apo B) at Week 24 - ITT Analysis|Percent Change From Baseline in Apo B at Week 24 - On-Treatment Analysis|Percent Change From Baseline in Non-High Density Lipoprotein Cholesterol (Non-HDL-C) at Week 24 - ITT Analysis|Percent Change From Baseline in Non-HDL-C at Week 24 - On-Treatment Analysis|Percent Change From Baseline in Total Cholesterol (Total-C) at Week 24 - ITT Analysis|Percent Change From Baseline in Apo B at Week 12 - ITT Analysis|Percent Change From Baseline in Non-HDL-C at Week 12 - ITT Analysis|Percent Change From Baseline in Total-C at Week 12 - ITT Analysis|Percent Change From Baseline in Calculated LDL-C at Week 52 - ITT Analysis|Percentage of Very High Cardiovascular (CV) Risk Participants Achieving Calculated LDL-C < 70 mg/dL (<1.81 mmol/L) or High CV Risk Participants Achieving Calculated LDL-C < 100 mg/dL (<2.59 mmol/L) at Week 24 - ITT Analysis|Percentage of Very High CV Risk Participants Achieving Calculated LDL-C < 70 mg/dL (<1.81 mmol/L) or High CV Risk Participants Achieving Calculated LDL-C < 100 mg/dL (<2.59 mmol/L) at Week 24 - On-Treatment Analysis|Percent Change From Baseline in Lipoprotein (a) at Week 24 - ITT Analysis|Percent Change From Baseline in HDL-C at Week 24 - ITT Analysis|Percent Change From Baseline in Fasting Triglycerides at Week 24 - ITT Analysis|Percent Change From Baseline in Apolipoprotein A-1 (Apo A-1) at Week 24 - ITT Analysis|Percent Change From Baseline in Lipoprotein (a) at Week 12 - ITT Analysis|Percent Change From Baseline in HDL-C at Week 12 - ITT Analysis|Percent Change From Baseline in Fasting Triglycerides at Week 12 - ITT Analysis|Percent Change From Baseline in Apo A-1 at Week 12 - ITT Analysis|Percentage of Participants Achieving Calculated LDL-C <70 mg/dL (1.81 mmol/L) at Week 24 - ITT Analysis|Percentage of Participants Achieving Calculated LDL-C <70 mg/dL (1.81 mmol/L) at Week 24 - On-Treatment Analysis","Sanofi|Regeneron Pharmaceuticals","All","18 Years and older   (Adult, Older Adult)","Phase 3","107","Industry","Interventional","Allocation: Randomized|Intervention Model: Parallel Assignment|Masking: Quadruple (Participant, Care Provider, Investigator, Outcomes Assessor)|Primary Purpose: Treatment","EFC12732|U1111-1128-5459|2012-001096-37","June 2012","May 2014","January 2015","June 12, 2012","November 6, 2015","October 4, 2016","Investigational Site Number 840742, Bell Gardens, California, United States|Investigational Site Number 840703, Newport Beach, California, United States|Investigational Site Number 840712, Newport Beach, California, United States|Investigational Site Number 840743, Northridge, California, United States|Investigational Site Number 840734, Washington, District of Columbia, United States|Investigational Site Number 840738, Miami, Florida, United States|Investigational Site Number 840710, Ponte Vedra, Florida, United States|Investigational Site Number 840701, New York, New York, United States|Investigational Site Number 840702, Durham, North Carolina, United States|Investigational Site Number 840714, Cincinnati, Ohio, United States|Investigational Site Number 840705, Philadelphia, Pennsylvania, United States|Investigational Site Number 840709, Philadelphia, Pennsylvania, United States|Investigational Site Number 840713, Philadelphia, Pennsylvania, United States|Investigational Site Number 840736, Dallas, Texas, United States|Investigational Site Number 124704, Quebec, Canada|Investigational Site Number 124703, Sherbrooke, Canada|Investigational Site Number 528713, Amsterdam, Netherlands|Investigational Site Number 528701, Amsterdam, Netherlands|Investigational Site Number 528704, Groningen, Netherlands|Investigational Site Number 528716, Leiden, Netherlands|Investigational Site Number 528709, Utrecht, Netherlands|Investigational Site Number 643706, Arkhangelsk, Russian Federation|Investigational Site Number 643705, Kazan, Russian Federation|Investigational Site Number 643703, Moscow, Russian Federation|Investigational Site Number 643711, Moscow, Russian Federation|Investigational Site Number 643708, Moscow, Russian Federation|Investigational Site Number 643702, Saint Petersburg, Russian Federation|Investigational Site Number 643710, St-Petersburg, Russian Federation|Investigational Site Number 643709, St-Petersburg, Russian Federation|Investigational Site Number 643707, Yaroslavl, Russian Federation|Investigational Site Number 710701, Bloemfontein, South Africa|Investigational Site Number 710704, Bloemfontein, South Africa|Investigational Site Number 710706, Cap Town, South Africa|Investigational Site Number 710702, Parktown, South Africa|Investigational Site Number 710703, Somerset West, South Africa",,"https://ClinicalTrials.gov/show/NCT01617655"
444,"NCT01617148","Wet Macular Degeneration Study to Compare Ranibizumab or Bevacizumab to Aflibercept",,"Completed","Has Results","Exudative Macular Degeneration","Drug: Aflibercept","Change in Central Subfield Thickness From Baseline at 12 Months|Change in Best-corrected Visual Acuity From Baseline at 12 Months|Change in Macular Volume From Baseline at 12 Months.|Change in Cube Average Thickness From Baseline at 12 Months|Percentage of Patients Who Gained Greater Than 15 Letters of Vision From Baseline at 12 Months.|Percentage of Patients Who Lost Greater Than 15 Letters of Vision From Baseline at 12 Months|Percentage of Subjects Who Were 20/40 or Better at Month 12.|Percentage of Subjects Who Were 20/200 or Worse at Month 12.","Rishi Singh|Regeneron Pharmaceuticals|The Cleveland Clinic","All","50 Years and older   (Adult, Older Adult)","Phase 4","26","Other|Industry","Interventional","Allocation: N/A|Intervention Model: Single Group Assignment|Masking: None (Open Label)|Primary Purpose: Treatment","VGFTe-AMD-1211","June 2012","December 2013","December 2015","June 12, 2012","July 26, 2018","July 26, 2018","Cole Eye Institute, Cleveland Clinic, Cleveland, Ohio, United States",,"https://ClinicalTrials.gov/show/NCT01617148"
445,"NCT01579760","Intravitreal Aflibercept Injection for Radiation Retinopathy",,"Completed","No Results Available","Radiation Retinopathy|Macular Edema","Drug: Aflibercept every 2 months|Drug: Aflibercept monthly","Incidence of adverse events|Severity of adverse events|Mean change in best corrected visual acuity from baseline|Mean change in central foveal thickness by optical coherence tomography (OCT) from baseline|Mean visual acuity|Mean central foveal thickness|Proportion of patients gaining 3 lines of vision|Mean change in lesion characteristics (lesion size, leakage)|Proportion of patients with no fluid on OCT|Mean change in macular volume","Washington University School of Medicine|Regeneron Pharmaceuticals","All","18 Years and older   (Adult, Older Adult)","Phase 1","9","Other|Industry","Interventional","Allocation: Randomized|Intervention Model: Parallel Assignment|Masking: Single (Participant)|Primary Purpose: Treatment","aflibercept2012","November 2012","January 2019","March 27, 2019","April 18, 2012",,"April 25, 2019","Washington University School of Medicine, Saint Louis, Missouri, United States|Retina Consultants of Houston, Houston, Texas, United States",,"https://ClinicalTrials.gov/show/NCT01579760"
446,"NCT01571284","Safety and Quality of Life Study of Aflibercept in Patients With Metastatic Colorectal Cancer Previously Treated With an Oxaliplatin-Based Regimen",,"Completed","Has Results","Colorectal Cancer Metastatic","Drug: AFLIBERCEPT AVE0005|Drug: FOLFIRI","Number of Participants With Treatment-Emergent Adverse Events (TEAEs)|Number of Participants With Abnormal Hematological Parameters|Number of Participants With International Normalized Ratio (INR)|Number of Participants With Abnormal Electrolytes Parameters|Number of Participants With Abnormal Renal and Liver Function Parameters|Creatinine Clearance of Aflibercept Plus FOLFIRI|Number of Participants With Other Abnormal Biochemistry Parameters|Number of Participants With Abnormal Non-Gradable Biochemistry Parameters|Number of Participants With Proteinuria Events|Number of Participants With Proteinuria Grade >=2|Number of Participants With Urinary Protein-Creatinine Ratio (UPCR)|Number of Participants With Proteinuria (Grade>=2) Concomitant With Hematuria and /or Hypertension|Number of Participants With Cycle Delay and/or Dose Modification|Mean Change From Baseline in Health Related Quality of Life (HRQL) European Organization for Research and Treatment for Cancer Quality of Life Questionnaire Core 30 (EORTC QLQ-C30 Score): Global Health Status|Mean Change From Baseline in HRQL EORTC QLQ-C30 Score: Functional Scales|Change From Baseline in HRQL EORTC QLQ-C30 Score: Symptom Scales|Change From Baseline in HRQL EQ-5D-3L Quality of Life: Single Index Utility Score|Change From Baseline in HRQL EQ-5D-3L VAS Score","Sanofi|Regeneron Pharmaceuticals","All","18 Years and older   (Adult, Older Adult)","Phase 3","781","Industry","Interventional","Allocation: N/A|Intervention Model: Single Group Assignment|Masking: None (Open Label)|Primary Purpose: Treatment","AFLIBC06097|2011-005724-17|U1111-1125-8949","May 30, 2012","January 31, 2017","January 31, 2017","April 5, 2012","February 27, 2018","April 17, 2018","Investigational Site Number 840-002, Muscle Shoals, Alabama, United States|Investigational Site Number 840-008, Corona, California, United States|Investigational Site Number 840-007, Fountain Valley, California, United States|Investigational Site Number 840-004, Riverside, California, United States|Investigational Site Number 840-006, Indianapolis, Indiana, United States|Investigational Site Number 840-011, Metairie, Louisiana, United States|Investigational Site Number 840-001, Rockville, Maryland, United States|Investigational Site Number 840-010, Howell, New Jersey, United States|Investigational Site Number 840-012, Albuquerque, New Mexico, United States|Investigational Site Number 840-009, Farmington, New Mexico, United States|Investigational Site Number 840-003, Lake Success, New York, United States|Investigational Site Number 840-005, Middletown, Ohio, United States|Investigational Site Number 056010, Aalst, Belgium|Investigational Site Number 056015, Arlon, Belgium|Investigational Site Number 056004, Bonheiden, Belgium|Investigational Site Number 056001, Edegem, Belgium|Investigational Site Number 056012, Gent, Belgium|Investigational Site Number 056009, Haine-Saint-Paul, Belgium|Investigational Site Number 056003, Liège, Belgium|Investigational Site Number 056007, Liège, Belgium|Investigational Site Number 056014, Loverval, Belgium|Investigational Site Number 056013, Turnhout, Belgium|Investigational Site Number 056002, Verviers, Belgium|Investigational Site Number 056011, Yvoir, Belgium|Investigational Site Number 008, Brasília, Brazil|Investigational Site Number 009, Curitiba, Brazil|Investigational Site Number 012, Fortaleza, Brazil|Investigational Site Number 006, Passo Fundo, Brazil|Investigational Site Number 003, Porto Alegre, Brazil|Investigational Site Number 002, Rio de Janeiro, Brazil|Investigational Site Number 011, Salvador, Brazil|Investigational Site Number 013, Sao Jose do Rio Preto, Brazil|Investigational Site Number 001, São Paulo, Brazil|Investigational Site Number 004, São Paulo, Brazil|Investigational Site Number 005, São Paulo, Brazil|Investigational Site Number 124002, Calgary, Canada|Investigational Site Number 124003, Montreal, Canada|Investigational Site Number 124005, Montreal, Canada|Investigational Site Number 124004, Ottawa, Canada|Investigational Site Number 124006, Québec, Canada|Investigational Site Number 124001, Toronto, Canada|Investigational Site Number 152001, Santiago, Chile|Investigational Site Number 152003, Santiago, Chile|Investigational Site Number 203005, Brno, Czechia|Investigational Site Number 203003, Olomouc, Czechia|Investigational Site Number 203001, Ostrava, Czechia|Investigational Site Number 203002, Praha 2, Czechia|Investigational Site Number 203004, Praha 5, Czechia|Investigational Site Number 203006, Zlin, Czechia|Investigational Site Number 208001, Cph Ø, Denmark|Investigational Site Number 208003, Hillerød, Denmark|Investigational Site Number 208002, Odense C, Denmark|Investigational Site Number 246001, Oulu, Finland|Investigational Site Number 246002, Turku, Finland|Investigational Site Number 276-016, Aschaffenburg, Germany|Investigational Site Number 276-010, Augsburg, Germany|Investigational Site Number 276-011, Berlin, Germany|Investigational Site Number 276-012, Erlangen, Germany|Investigational Site Number 276-009, Frankfurt am Main, Germany|Investigational Site Number 276-013, Frankfurt am Main, Germany|Investigational Site Number 276-004, Halle, Germany|Investigational Site Number 276-007, Krefeld, Germany|Investigational Site Number 276-003, Lebach, Germany|Investigational Site Number 276-019, Leipzig, Germany|Investigational Site Number 276-008, Ludwigsburg, Germany|Investigational Site Number 276-018, Magdeburg, Germany|Investigational Site Number 276-014, Magdeburg, Germany|Investigational Site Number 276-006, Moers, Germany|Investigational Site Number 276-001, München, Germany|Investigational Site Number 276-002, München, Germany|Investigational Site Number 276-015, Northeim, Germany|Investigational Site Number 276-017, Velbert, Germany|Investigational Site Number 276-005, Weiden/Oberpfalz, Germany|Investigational Site Number 276-020, Wolfsburg, Germany|Investigational Site Number 372002, Dublin 24, Ireland|Investigational Site Number 372004, Galway, Ireland|Investigational Site Number 372001, Wilton, Ireland|Investigational Site Number 376002, Haifa, Israel|Investigational Site Number 376001, Jerusalem, Israel|Investigational Site Number 376005, Petach Tikva, Israel|Investigational Site Number 376003, Tel Aviv, Israel|Investigational Site Number 376004, Tel Hashomer, Israel|Investigational Site Number 380-005, Ancona, Italy|Investigational Site Number 380-029, Bergamo, Italy|Investigational Site Number 380-021, Bologna, Italy|Investigational Site Number 380-004, Brescia, Italy|Investigational Site Number 380-007, Candiolo, Italy|Investigational Site Number 380-012, Catania, Italy|Investigational Site Number 380-019, Catanzaro, Italy|Investigational Site Number 380-023, Firenze, Italy|Investigational Site Number 380-001, Genova, Italy|Investigational Site Number 380-014, Meldola, Italy|Investigational Site Number 380-016, Messina, Italy|Investigational Site Number 380-013, Milano, Italy|Investigational Site Number 380-015, Milano, Italy|Investigational Site Number 380-025, Milano, Italy|Investigational Site Number 380-022, Napoli, Italy|Investigational Site Number 380-028, Novara, Italy|Investigational Site Number 380-017, Padova, Italy|Investigational Site Number 380-002, Pisa, Italy|Investigational Site Number 380-008, Reggio Emilia, Italy|Investigational Site Number 380-024, Roma, Italy|Investigational Site Number 380-010, Roma, Italy|Investigational Site Number 380-011, Roma, Italy|Investigational Site Number 380-006, San Giovanni Rotondo, Italy|Investigational Site Number 380-026, Sassari, Italy|Investigational Site Number 380-020, Terni, Italy|Investigational Site Number 380-009, Torino, Italy|Investigational Site Number 380-003, Udine, Italy|Investigational Site Number 380-018, Verona, Italy|Investigational Site Number 1, Beirut, Lebanon|Investigational Site Number 484002, Mexico DF, Mexico|Investigational Site Number 484009, Mexico DF, Mexico|Investigational Site Number 484001, Monterrey, Mexico|Investigational Site Number 484010, México, D.F., Mexico|Investigational Site Number 528001, Hoofddorp, Netherlands|Investigational Site Number 528002, Zwolle, Netherlands|Investigational Site Number 578002, Bergen, Norway|Investigational Site Number 578001, Oslo, Norway|Investigational Site Number 630-001, Rio Peidras, Puerto Rico|Investigational Site Number 643003, Kazan, Russian Federation|Investigational Site Number 643001, Moscow, Russian Federation|Investigational Site Number 643004, Moscow, Russian Federation|Investigational Site Number 643005, Moscow, Russian Federation|Investigational Site Number 643002, Moscow, Russian Federation|Investigational Site Number 643006, Moscow, Russian Federation|Investigational Site Number 643009, Saint-Petersburg, Russian Federation|Investigational Site Number 724016, Alicante, Spain|Investigational Site Number 724008, Barakaldo, Spain|Investigational Site Number 724012, Cáceres, Spain|Investigational Site Number 724002, Córdoba, Spain|Investigational Site Number 724013, Donostia, Spain|Investigational Site Number 724014, L'Hospitalet de Llobregat, Spain|Investigational Site Number 724003, Madrid, Spain|Investigational Site Number 724015, Madrid, Spain|Investigational Site Number 724005, Madrid, Spain|Investigational Site Number 724004, Málaga, Spain|Investigational Site Number 724010, Sabadell, Spain|Investigational Site Number 724011, Santander, Spain|Investigational Site Number 724006, Santiago de Compostela, Spain|Investigational Site Number 724001, Valencia, Spain|Investigational Site Number 724009, Valencia, Spain|Investigational Site Number 724007, Zaragoza, Spain|Investigational Site Number 752_002, Jönköping, Sweden|Investigational Site Number 752_001, Växjö, Sweden|Investigational Site Number 764005, Bangkok,TH, Thailand|Investigational Site Number 764002, Bangkok, Thailand|Investigational Site Number 764003, Bangkok, Thailand|Investigational Site Number 764008, Bangkok, Thailand|Investigational Site Number 764001, Bangkok, Thailand|Investigational Site Number 764006, Bangkok, Thailand|Investigational Site Number 764009, Chiang Mai, Thailand|Investigational Site Number 764004, Khon Kaen, Thailand|Investigational Site Number 764010, Laksi, Thailand|Investigational Site Number 764007, Lopburi, Thailand|Investigational Site Number 792-06, Adana, Turkey|Investigational Site Number 792-01, Ankara, Turkey|Investigational Site Number 792-09, Ankara, Turkey|Investigational Site Number 792-08, Ankara, Turkey|Investigational Site Number 792-02, Capa, Turkey|Investigational Site Number 792010, Edirne, Turkey|Investigational Site Number 792-05, Gaziantep, Turkey|Investigational Site Number 792012, Istanbul, Turkey|Investigational Site Number 792-03, Istanbul, Turkey|Investigational Site Number 792-04, Istanbul, Turkey|Investigational Site Number 792-007, Izmir, Turkey|Investigational Site Number 792011, Izmir, Turkey|Investigational Site Number 826005, Dudley, United Kingdom|Investigational Site Number 826011, Hull, United Kingdom|Investigational Site Number 826008, Leicester, United Kingdom|Investigational Site Number 826007, London, United Kingdom|Investigational Site Number 826012, London, United Kingdom|Investigational Site Number 826003, Maidstone,, United Kingdom|Investigational Site Number 826009, Manchester, United Kingdom|Investigational Site Number 826004, Newcastle upon tyne, United Kingdom|Investigational Site Number 826006, Northwood, United Kingdom|Investigational Site Number 826002, Southampton, United Kingdom|Investigational Site Number 826001, Sutton, United Kingdom|Investigational Site Number 826010, Taunton, United Kingdom","""Study Protocol"", https://ClinicalTrials.gov/ProvidedDocs/84/NCT01571284/Prot_000.pdf|""Statistical Analysis Plan"", https://ClinicalTrials.gov/ProvidedDocs/84/NCT01571284/SAP_001.pdf","https://ClinicalTrials.gov/show/NCT01571284"
447,"NCT01543568","Study for Recalcitrant Age Related Macular Degeneration","TURF","Completed","Has Results","Age Related Macular Degeneration","Drug: aflibercept 2.0 mg","The Number of Patients With no Fluid on OCT|Mean Change in OCT Central Foveal Thickness|Average Time to Resolution of Intraretinal Cysts and Sub Retinal Fluid on OCT|The Percentage of Patients Who Lose > 15 Letters Visual Acuity|Mean Change in Visual Acuity (BCVA)|Quantitative Change in Area (μ) From Baseline in Choroidal Neovascular Lesion Characteristics/Size as Measured by FA/Fundus Photos|Mean Number of 0.2 mg Aflibercept Injections Administered","David M. Brown, M.D.|Regeneron Pharmaceuticals|Greater Houston Retina Research","All","50 Years and older   (Adult, Older Adult)","Phase 4","46","Other|Industry","Interventional","Allocation: N/A|Intervention Model: Single Group Assignment|Masking: None (Open Label)|Primary Purpose: Treatment","TURF-01","February 2012","October 2014","October 2014","March 5, 2012","January 2, 2017","January 2, 2017","Retina Consultants of Houston, Houston, Texas, United States",,"https://ClinicalTrials.gov/show/NCT01543568"
448,"NCT01538719","IL1-TRAP, Rilonacept, in Systemic Sclerosis",,"Completed","Has Results","Scleroderma|Systemic Sclerosis|Diffuse Scleroderma|Diffuse Systemic Sclerosis","Drug: Rilonacept|Other: Placebo","Change in 2- Gene Biomarker|Change in Modified Rodnan Skin Score","Boston University|Regeneron Pharmaceuticals","All","18 Years and older   (Adult, Older Adult)","Phase 1|Phase 2","24","Other|Industry","Interventional","Allocation: Randomized|Intervention Model: Parallel Assignment|Masking: Quadruple (Participant, Care Provider, Investigator, Outcomes Assessor)|Primary Purpose: Treatment","H31332","December 2011","January 2017","August 11, 2017","February 24, 2012","May 1, 2018","May 1, 2018","Boston University Medical Center, Boston, Massachusetts, United States",,"https://ClinicalTrials.gov/show/NCT01538719"
449,"NCT01537653","Safety, Tolerability and Pharmacokinetics of SAR231893 (REGN668) in Healthy Japanese Adult Male Subjects",,"Completed","No Results Available","Healthy","Drug: SAR231893 (REGN668)|Drug: placebo","Number of subjects with standard safety assessments (adverse events, physical examinations, 12 lead ECGs, vital signs and laboratory tests)|Pharmacokinetics: Serum concentrations of SAR231893 (REGN668) over time|Pharmacodynamics: Serum total Immunoglobulin E (IgE) and Thymus and activation regulated chemokine (TARC) over time","Sanofi|Regeneron Pharmaceuticals","Male","20 Years to 45 Years   (Adult)","Phase 1","32","Industry","Interventional","Allocation: Randomized|Intervention Model: Parallel Assignment|Masking: Double (Participant, Investigator)|Primary Purpose: Treatment","TDU12265|U1111-1127-2719","March 2012","October 2012","October 2012","February 23, 2012",,"December 6, 2013","Investigational Site Number 392001, Toshima-Ku, Japan",,"https://ClinicalTrials.gov/show/NCT01537653"
450,"NCT01537640","Comparison of the Pharmacokinetics and Safety of Two SAR231893 (REGN668) Drug Products in Healthy Subjects",,"Completed","No Results Available","Healthy","Biological: SAR231893 (REGN668) DP1|Biological: SAR231893 (REGN668) DP2","Assessment of serum concentrations of SAR231893 (REGN668)|Pain evaluation at injection site using Visual Analog Scale (VAS)|Erythema at injection site by measuring diameter|Edema at injection site by measuring diameter|Number of participants experiencing adverse events","Sanofi|Regeneron Pharmaceuticals","All","18 Years to 45 Years   (Adult)","Phase 1","30","Industry","Interventional","Allocation: Randomized|Intervention Model: Parallel Assignment|Masking: Double (Participant, Investigator)|Primary Purpose: Treatment","PKM12350|U1111-1119-3152","February 2012","July 2012","July 2012","February 23, 2012",,"December 6, 2013","Investigational Site Number 840001, Daytona Beach, Florida, United States",,"https://ClinicalTrials.gov/show/NCT01537640"
451,"NCT01512966","Japanese Safety Study of VEGF Trap-Eye in DME (Diabetic Macular Edema)","VIVID-Japan","Completed","No Results Available","Macular Edema","Biological: VEGF Trap-Eye (BAY86-5321)","Adverse Event collection|Change from baseline in BCVA (best corrected visual acuity) letter score","Bayer|Regeneron Pharmaceuticals","All","18 Years and older   (Adult, Older Adult)","Phase 3","73","Industry","Interventional","Allocation: N/A|Intervention Model: Single Group Assignment|Masking: None (Open Label)|Primary Purpose: Treatment","15657","January 2012","September 2013","September 2013","January 20, 2012",,"October 9, 2014","Matsuyama, Ehime, Japan|Maebashi, Gunma, Japan|Kobe, Hyogo, Japan|Mito, Ibaraki, Japan|Kita, Kagawa, Japan|Kawasaki, Kanagawa, Japan|Sendai, Miyagi, Japan|Kashihara, Nara, Japan|Suita, Osaka, Japan|Otsu, Shiga, Japan|Shimotsuke, Tochigi, Japan|Kagoshima, Japan|Kyoto, Japan|Okayama, Japan|Osaka, Japan|Osaka, Japan|Saga, Japan|Wakayama, Japan",,"https://ClinicalTrials.gov/show/NCT01512966"
452,"NCT01507831","Long-term Safety and Tolerability of Alirocumab (SAR236553/REGN727) Versus Placebo on Top of Lipid-Modifying Therapy in High Cardiovascular Risk Patients With Hypercholesterolemia (ODYSSEY Long Term)",,"Completed","Has Results","Hypercholesterolemia","Drug: Placebo (for alirocumab)|Drug: Alirocumab|Drug: Lipid-Modifying Therapy (LMT)","Percentage of Participants Who Experienced Adverse Events (AEs)|Percent Change From Baseline in Calculated LDL-C at Week 24 - Intent-to-Treat (ITT) Analysis|Percent Change From Baseline in Calculated LDL-C at Week 24 - On-Treatment Analysis|Percent Change From Baseline in Calculated LDL-C at Week 12 - ITT Analysis|Percent Change From Baseline in Calculated LDL-C at Week 12 - On-treatment Analysis|Percent Change From Baseline in Measured LDL-C at Week 24 - ITT Analysis|Percent Change From Baseline in Apolipoprotein (Apo) B at Week 24 - ITT Analysis|Percent Change From Baseline in Apo B at Week 24 - On-Treatment Analysis|Percent Change From Baseline in Non-High Density Lipoprotein Cholesterol (Non-HDL-C) at Week 24 - ITT Analysis|Percent Change From Baseline in Non-HDL-C at Week 24 - On-Treatment Analysis|Percent Change From Baseline in Total Cholesterol (Total-C) at Week 24 - ITT Analysis|Percent Change From Baseline in Apo B at Week 12 - ITT Analysis|Percent Change From Baseline in Non-HDL-C at Week 12 - ITT Analysis|Percent Change From Baseline in Total-C at Week 12 - ITT Analysis|Percentage of Very High Cardiovascular (CV) Risk Participants Reaching Calculated LDL-C <70 mg/dL (1.81 mmol/L) or High CV Risk Participants Reaching Calculated LDL-C <100 mg/dL (2.59 mmol/L) at Week 24 - ITT Analysis|Percentage of Very High CV Risk Participants Reaching Calculated LDL-C <70 mg/dL (1.81 mmol/L) or High CV Risk Participants Reaching Calculated LDL-C <100 mg/dL (2.59 mmol/L) at Week 24 - On-Treatment Analysis|Percentage of Participants Reaching Calculated LDL-C <70 mg/dL (1.81 mmol/L) at Week 24 - ITT Analysis|Percentage of Participants Reaching Calculated LDL-C <70 mg/dL (1.81 mmol/L) at Week 24 - On-Treatment Analysis|Percent Change From Baseline in Lipoprotein (a) at Week 24 - ITT Analysis|Percent Change From Baseline in HDL-C at Week 24 - ITT Analysis|Percent Change From Baseline in Fasting Triglycerides at Week 24 - ITT Analysis|Percent Change From Baseline in Apo A1 at Week 24 - ITT Analysis|Percent Change From Baseline in Lipoprotein (a) at Week 12 - ITT Analysis|Percent Change From Baseline in HDL-C at Week 12 - ITT Analysis|Percent Change From Baseline in Fasting Triglycerides at Week 12 - ITT Analysis|Percent Change From Baseline in Apo A1 at Week 12 - ITT Analysis","Sanofi|Regeneron Pharmaceuticals","All","18 Years and older   (Adult, Older Adult)","Phase 3","2341","Industry","Interventional","Allocation: Randomized|Intervention Model: Parallel Assignment|Masking: Quadruple (Participant, Care Provider, Investigator, Outcomes Assessor)|Primary Purpose: Treatment","LTS11717|2011-002806-59|U1111-1121-3928","January 2012","November 2014","November 2014","January 11, 2012","December 22, 2015","December 22, 2015","Investigational Site Number 840159, Huntsville, Alabama, United States|Investigational Site Number 840028, Gilbert, Arizona, United States|Investigational Site Number 840035, Sierra Vista, Arizona, United States|Investigational Site Number 840052, Tempe, Arizona, United States|Investigational Site Number 840065, Tempe, Arizona, United States|Investigational Site Number 840079, Tempe, Arizona, United States|Investigational Site Number 840094, Tempe, Arizona, United States|Investigational Site Number 840103, Tucson, Arizona, United States|Investigational Site Number 840209, Beverly Hills, California, United States|Investigational Site Number 840194, Beverly Hills, California, United States|Investigational Site Number 840207, Fresno, California, United States|Investigational Site Number 840101, Lincoln, California, United States|Investigational Site Number 840076, Long Beach, California, United States|Investigational Site Number 840214, Pasadena, California, United States|Investigational Site Number 840045, Sacramento, California, United States|Investigational Site Number 840163, Santa Rosa, California, United States|Investigational Site Number 840086, Colorado Springs, Colorado, United States|Investigational Site Number 840077, Golden, Colorado, United States|Investigational Site Number 840224, Bridgeport, Connecticut, United States|Investigational Site Number 840134, Guilford, Connecticut, United States|Investigational Site Number 840246, Hartford, Connecticut, United States|Investigational Site Number 840055, Stamford, Connecticut, United States|Investigational Site Number 840091, Stamford, Connecticut, United States|Investigational Site Number 840150, Atlantis, Florida, United States|Investigational Site Number 840020, Bradenton, Florida, United States|Investigational Site Number 840041, Brandon, Florida, United States|Investigational Site Number 840184, Clearwater, Florida, United States|Investigational Site Number 840242, Clearwater, Florida, United States|Investigational Site Number 840039, Clearwater, Florida, United States|Investigational Site Number 840182, Crystal River, Florida, United States|Investigational Site Number 840002, Daytona Beach, Florida, United States|Investigational Site Number 840166, Daytona Beach, Florida, United States|Investigational Site Number 840167, Fleming Island, Florida, United States|Investigational Site Number 840018, Fort Lauderdale, Florida, United States|Investigational Site Number 840090, Ft. Lauderdale, Florida, United States|Investigational Site Number 840153, Jacksonville, Florida, United States|Investigational Site Number 840181, Jacksonville, Florida, United States|Investigational Site Number 840152, Jacksonville, Florida, United States|Investigational Site Number 840154, Lake Mary, Florida, United States|Investigational Site Number 840059, Largo, Florida, United States|Investigational Site Number 840221, Miami, Florida, United States|Investigational Site Number 840021, New Port Richey, Florida, United States|Investigational Site Number 840122, New Smyrna Beach, Florida, United States|Investigational Site Number 840151, Ocala, Florida, United States|Investigational Site Number 840108, Ormond Beach, Florida, United States|Investigational Site Number 840067, Palm Harbor, Florida, United States|Investigational Site Number 840006, Pembroke Pines, Florida, United States|Investigational Site Number 840168, Ponte Vedra, Florida, United States|Investigational Site Number 840164, Sarasota, Florida, United States|Investigational Site Number 840175, Sarasota, Florida, United States|Investigational Site Number 840001, St. Petersburg, Florida, United States|Investigational Site Number 840003, St. Petersburg, Florida, United States|Investigational Site Number 840036, West Palm Beach, Florida, United States|Investigational Site Number 840117, Cumming, Georgia, United States|Investigational Site Number 840110, Roswell, Georgia, United States|Investigational Site Number 840026, Savannah, Georgia, United States|Investigational Site Number 840075, Meridian, Idaho, United States|Investigational Site Number 840027, Evansville, Indiana, United States|Investigational Site Number 840093, Indianapolis, Indiana, United States|Investigational Site Number 840222, Iowa City, Iowa, United States|Investigational Site Number 840165, West Des Moines, Iowa, United States|Investigational Site Number 840200, Kansas City, Kansas, United States|Investigational Site Number 840040, Wichita, Kansas, United States|Investigational Site Number 840061, Wichita, Kansas, United States|Investigational Site Number 840032, Wichita, Kansas, United States|Investigational Site Number 840084, Wichita, Kansas, United States|Investigational Site Number 840244, Biddeford, Maine, United States|Investigational Site Number 840158, Framingham, Maine, United States|Investigational Site Number 840193, Novi, Michigan, United States|Investigational Site Number 840162, Saginaw, Michigan, United States|Investigational Site Number 840033, Saint Louis, Missouri, United States|Investigational Site Number 840113, St. Louis, Missouri, United States|Investigational Site Number 840095, Henderson, Nevada, United States|Investigational Site Number 840096, Henderson, Nevada, United States|Investigational Site Number 840022, Edison, New Jersey, United States|Investigational Site Number 840011, Hillsborough, New Jersey, United States|Investigational Site Number 840049, Trenton, New Jersey, United States|Investigational Site Number 840097, Bronxville, New York, United States|Investigational Site Number 840129, Brooklyn, New York, United States|Investigational Site Number 840160, Poughkeepsie, New York, United States|Investigational Site Number 840217, Asheville, North Carolina, United States|Investigational Site Number 840023, Charlotte, North Carolina, United States|Investigational Site Number 840083, Greensboro, North Carolina, United States|Investigational Site Number 840104, Raleigh, North Carolina, United States|Investigational Site Number 840068, Cincinnati, Ohio, United States|Investigational Site Number 840007, Dayton, Ohio, United States|Investigational Site Number 840013, Marion, Ohio, United States|Investigational Site Number 840161, Mentor, Ohio, United States|Investigational Site Number 840005, Tulsa, Oklahoma, United States|Investigational Site Number 840170, Beaver, Pennsylvania, United States|Investigational Site Number 840180, Camp Hill, Pennsylvania, United States|Investigational Site Number 840004, Duncansville, Pennsylvania, United States|Investigational Site Number 840046, Jersey Shore, Pennsylvania, United States|Investigational Site Number 840155, Phoenixville, Pennsylvania, United States|Investigational Site Number 840177, Scranton, Pennsylvania, United States|Investigational Site Number 840202, Wyomissing, Pennsylvania, United States|Investigational Site Number 840073, Charleston, South Carolina, United States|Investigational Site Number 840087, Greenville, South Carolina, United States|Investigational Site Number 840074, Simpsonville, South Carolina, United States|Investigational Site Number 840105, Varnville, South Carolina, United States|Investigational Site Number 840190, Knoxville, Tennessee, United States|Investigational Site Number 840092, Dallas, Texas, United States|Investigational Site Number 840212, Dallas, Texas, United States|Investigational Site Number 840058, Fort Worth, Texas, United States|Investigational Site Number 840149, Fort Worth, Texas, United States|Investigational Site Number 840070, Fort Worth, Texas, United States|Investigational Site Number 840038, Houston, Texas, United States|Investigational Site Number 840047, Houston, Texas, United States|Investigational Site Number 840053, Plano, Texas, United States|Investigational Site Number 840072, Sugar Land, Texas, United States|Investigational Site Number 840241, Tyler, Texas, United States|Investigational Site Number 840031, Salt Lake City, Utah, United States|Investigational Site Number 840204, Chesapeake, Virginia, United States|Investigational Site Number 840120, Spokane, Washington, United States|Investigational Site Number 840111, Milwaukee, Wisconsin, United States|Investigational Site Number 032006, Buenos Aires, Argentina|Investigational Site Number 032010, Caba, Argentina|Investigational Site Number 032008, Capital Federal, Argentina|Investigational Site Number 032001, Coronel Suarez, Argentina|Investigational Site Number 032004, Resistencia, Argentina|Investigational Site Number 032007, Zarate, Argentina|Investigational Site Number 056005, Antwerpen, Belgium|Investigational Site Number 056004, Genk, Belgium|Investigational Site Number 056001, Natoye, Belgium|Investigational Site Number 056002, Wetteren, Belgium|Investigational Site Number 100008, Pleven, Bulgaria|Investigational Site Number 100014, Plovdiv, Bulgaria|Investigational Site Number 100005, Sofia, Bulgaria|Investigational Site Number 100012, Sofia, Bulgaria|Investigational Site Number 100015, Sofia, Bulgaria|Investigational Site Number 100009, Sofia, Bulgaria|Investigational Site Number 100001, Sofia, Bulgaria|Investigational Site Number 100013, Stara Zagora, Bulgaria|Investigational Site Number 100007, Varna, Bulgaria|Investigational Site Number 124013, Cambridge, Canada|Investigational Site Number 124027, Coquitlam, Canada|Investigational Site Number 124001, Hawkesbury, Canada|Investigational Site Number 124002, London, Canada|Investigational Site Number 124009, Mirabel, Canada|Investigational Site Number 124018, Montreal, Canada|Investigational Site Number 124007, Ottawa, Canada|Investigational Site Number 124011, Quebec, Canada|Investigational Site Number 124005, Saint John'S, Canada|Investigational Site Number 124008, Sarnia, Canada|Investigational Site Number 124022, Terrebonne, Canada|Investigational Site Number 124003, Vancouver, Canada|Investigational Site Number 124006, Victoria, Canada|Investigational Site Number 124015, Woodstock, Canada|Investigational Site Number 152007, Osorno, Chile|Investigational Site Number 152008, Santiago, Chile|Investigational Site Number 152006, Santiago, Chile|Investigational Site Number 152004, Temuco, Chile|Investigational Site Number 170004, Barranquilla, Colombia|Investigational Site Number 170005, Barranquilla, Colombia|Investigational Site Number 170008, Barranquilla, Colombia|Investigational Site Number 170001, Manizales, Colombia|Investigational Site Number 170003, Medellin, Colombia|Investigational Site Number 203004, Praha 2, Czech Republic|Investigational Site Number 203007, Praha 5, Czech Republic|Investigational Site Number 203006, Praha 5, Czech Republic|Investigational Site Number 208005, Aarhus, Denmark|Investigational Site Number 208004, Hellerup, Denmark|Investigational Site Number 208003, Slagelse, Denmark|Investigational Site Number 208001, Svendborg, Denmark|Investigational Site Number 208002, Viborg, Denmark|Investigational Site Number 246002, Joensuu, Finland|Investigational Site Number 246001, Kokkola, Finland|Investigational Site Number 246003, Kuopio, Finland|Investigational Site Number 246004, Vantaa, Finland|Investigational Site Number 250007, Bandol, France|Investigational Site Number 250003, Broglie, France|Investigational Site Number 250014, Bron Cedex, France|Investigational Site Number 250004, Dijon, France|Investigational Site Number 250006, Lille Cedex, France|Investigational Site Number 250009, Nantes, France|Investigational Site Number 250001, Nantes, France|Investigational Site Number 250002, Paris Cedex 13, France|Investigational Site Number 250010, Pessac, France|Investigational Site Number 250012, Rennes, France|Investigational Site Number 250005, Vieux Conde, France|Investigational Site Number 250008, Vihiers, France|Investigational Site Number 276001, Bad Wörishofen, Germany|Investigational Site Number 276007, Berlin, Germany|Investigational Site Number 276005, Berlin, Germany|Investigational Site Number 276014, Berlin, Germany|Investigational Site Number 276008, Bochum, Germany|Investigational Site Number 276009, Dresden, Germany|Investigational Site Number 276004, Essen, Germany|Investigational Site Number 276010, Frankfurt A.M., Germany|Investigational Site Number 276011, Görlitz, Germany|Investigational Site Number 276019, Hannover, Germany|Investigational Site Number 276013, Leipzig, Germany|Investigational Site Number 276012, Magdeburg, Germany|Investigational Site Number 276003, Magdeburg, Germany|Investigational Site Number 276006, Schwerin, Germany|Investigational Site Number 276015, Witten, Germany|Investigational Site Number 348003, Baja, Hungary|Investigational Site Number 348007, Budapest, Hungary|Investigational Site Number 348009, Budapest, Hungary|Investigational Site Number 348008, Budapest, Hungary|Investigational Site Number 348013, Budapest, Hungary|Investigational Site Number 348004, Debrecen, Hungary|Investigational Site Number 348002, Nagykanizsa, Hungary|Investigational Site Number 348006, Nyiregyhaza, Hungary|Investigational Site Number 348001, Sopron, Hungary|Investigational Site Number 348011, Urhida, Hungary|Investigational Site Number 376002, Afula, Israel|Investigational Site Number 376003, Holon, Israel|Investigational Site Number 376005, Holon, Israel|Investigational Site Number 376004, Nazareth, Israel|Investigational Site Number 380006, Chieti, Italy|Investigational Site Number 380002, Cinisello Balsamo, Italy|Investigational Site Number 380009, Milano, Italy|Investigational Site Number 380007, Napoli, Italy|Investigational Site Number 380001, Palermo, Italy|Investigational Site Number 380005, Pozzilli, Italy|Investigational Site Number 380008, Vittorio Veneto, Italy|Investigational Site Number 380010, Zingonia-Osio Sotto, Italy|Investigational Site Number 484010, Df, Mexico|Investigational Site Number 484004, Mexico, Mexico|Investigational Site Number 484008, Not Provided, Mexico|Investigational Site Number 484001, San Luis Potosi, Mexico|Investigational Site Number 484002, Tijuana, Mexico|Investigational Site Number 484009, Torreon, Mexico|Investigational Site Number 484003, Xalapa, Mexico|Investigational Site Number 528013, Amsterdam, Netherlands|Investigational Site Number 528001, Amsterdam, Netherlands|Investigational Site Number 528004, Breda, Netherlands|Investigational Site Number 528005, Eindhoven, Netherlands|Investigational Site Number 528007, Groningen, Netherlands|Investigational Site Number 528011, Hoogeveen, Netherlands|Investigational Site Number 528002, Hoorn, Netherlands|Investigational Site Number 528008, Leiderdorp, Netherlands|Investigational Site Number 528009, Rotterdam, Netherlands|Investigational Site Number 528006, Velp, Netherlands|Investigational Site Number 528012, Venlo, Netherlands|Investigational Site Number 528010, Zoetermeer, Netherlands|Investigational Site Number 578005, Elverum, Norway|Investigational Site Number 578001, Hamar, Norway|Investigational Site Number 578002, Oslo, Norway|Investigational Site Number 578004, Skedsmokorset, Norway|Investigational Site Number 578003, Stavanger, Norway|Investigational Site Number 616008, Gdynia, Poland|Investigational Site Number 616003, Gdynia, Poland|Investigational Site Number 616001, Gniewkowo, Poland|Investigational Site Number 616010, Katowice, Poland|Investigational Site Number 616018, Krakow, Poland|Investigational Site Number 616004, Piotrkow Trybunalski, Poland|Investigational Site Number 616013, Pulawy, Poland|Investigational Site Number 616009, Warszawa, Poland|Investigational Site Number 616007, Wroclaw, Poland|Investigational Site Number 620006, Funchal / Madeira, Portugal|Investigational Site Number 620002, Lisboa, Portugal|Investigational Site Number 620001, Lisboa, Portugal|Investigational Site Number 620005, Porto, Portugal|Investigational Site Number 642005, Baia Mare, Romania|Investigational Site Number 642002, Brasov, Romania|Investigational Site Number 642004, Targu Mures, Romania|Investigational Site Number 642001, Timisoara, Romania|Investigational Site Number 643005, Barnaul, Russian Federation|Investigational Site Number 643012, Moscow, Russian Federation|Investigational Site Number 643008, Moscow, Russian Federation|Investigational Site Number 643014, Perm, Russian Federation|Investigational Site Number 643006, St Petersburg, Russian Federation|Investigational Site Number 643009, St.Petersburg, Russian Federation|Investigational Site Number 643004, Yaroslavl, Russian Federation|Investigational Site Number 710010, Centurion, South Africa|Investigational Site Number 710008, Meyerspark, South Africa|Investigational Site Number 710011, Middelburg, South Africa|Investigational Site Number 710006, Parktown, South Africa|Investigational Site Number 710004, Pretoria, South Africa|Investigational Site Number 710001, Pretoria, South Africa|Investigational Site Number 710002, Pretoria, South Africa|Investigational Site Number 710009, Roodepoort, South Africa|Investigational Site Number 710003, Somerset West, South Africa|Investigational Site Number 710005, Witbank, South Africa|Investigational Site Number 710007, Worcester, South Africa|Investigational Site Number 724006, Córdoba, Spain|Investigational Site Number 724003, Granada, Spain|Investigational Site Number 724002, Madrid, Spain|Investigational Site Number 724007, Málaga, Spain|Investigational Site Number 724008, Quart De Poblet, Spain|Investigational Site Number 724005, Reus, Spain|Investigational Site Number 724001, Sabadell, Spain|Investigational Site Number 724004, Sevilla, Spain|Investigational Site Number 752002, Rättvik, Sweden|Investigational Site Number 752006, Stockholm, Sweden|Investigational Site Number 752003, Stockholm, Sweden|Investigational Site Number 752004, Stockholm, Sweden|Investigational Site Number 752001, Örebro, Sweden|Investigational Site Number 804012, Chernivtsi, Ukraine|Investigational Site Number 804003, Dnipropetrovsk, Ukraine|Investigational Site Number 804002, Donetsk, Ukraine|Investigational Site Number 804014, Kharkiv, Ukraine|Investigational Site Number 804016, Kiev, Ukraine|Investigational Site Number 804011, Kyiv, Ukraine|Investigational Site Number 804010, Kyiv, Ukraine|Investigational Site Number 804001, Kyiv, Ukraine|Investigational Site Number 804008, Kyiv, Ukraine|Investigational Site Number 804013, Kyiv, Ukraine|Investigational Site Number 804005, Zhytomyr, Ukraine|Investigational Site Number 826004, Addlestone, United Kingdom|Investigational Site Number 826009, Birmingham, United Kingdom|Investigational Site Number 826016, Birmingham, United Kingdom|Investigational Site Number 826021, Blackpool, United Kingdom|Investigational Site Number 826023, Cambridge, United Kingdom|Investigational Site Number 826012, Cardiff, United Kingdom|Investigational Site Number 826024, Chichester, United Kingdom|Investigational Site Number 826006, Chorley, United Kingdom|Investigational Site Number 826010, Glasgow, United Kingdom|Investigational Site Number 826003, Irvine, United Kingdom|Investigational Site Number 826008, Liverpool, United Kingdom|Investigational Site Number 826005, Liverpool, United Kingdom|Investigational Site Number 826025, Manchester, United Kingdom|Investigational Site Number 826007, Manchester, United Kingdom|Investigational Site Number 826001, Middlesex, United Kingdom|Investigational Site Number 826019, Penzance, United Kingdom|Investigational Site Number 826011, Reading, United Kingdom|Investigational Site Number 826013, Romford, United Kingdom|Investigational Site Number 826014, Soham, United Kingdom",,"https://ClinicalTrials.gov/show/NCT01507831"
453,"NCT01495208","Open Label to Study to Evaluate Effect of Alfilbercept on Patients With (FVPED) Fibrovascular Pigment Epithelial Detachment",,"Withdrawn","No Results Available","Fibrovascular Pigment Epithelial Detachment","Drug: Aflibercept","Change in retinal anatomy (size of FVPED, sub-retinal fluid and retinal volume) from baseline; measured using Spectralis OCT (Heidelberg Engineering, Germany)|Mean change in best corrected visual acuity (BCVA) from baseline; measured by ETDRS visual refraction at 4 meters.|Mean change in best corrected visual acuity (BCVA) from baseline; measured by ETDRS","Vitreous -Retina- Macula Consultants of New York|Regeneron Pharmaceuticals","All","50 Years and older   (Adult, Older Adult)","Phase 4","0","Other|Industry","Interventional","Allocation: N/A|Intervention Model: Single Group Assignment|Masking: None (Open Label)|Primary Purpose: Treatment","EVER STUDY","December 2011","October 2012","October 2012","December 19, 2011",,"July 16, 2018","Vitreous Retina Macula Consultants of New York, New York, New York, United States",,"https://ClinicalTrials.gov/show/NCT01495208"
454,"NCT01482910","VEGF Trap-Eye: Investigation of Efficacy and Safety in Chinese Subjects With Wet AMD (Age-Related Macular Degeneration)",,"Completed","Has Results","Macular Degeneration","Biological: Aflibercept (Eylea, VEGF Trap-Eye, BAY86-5321)|Drug: Visudyne","Change From Baseline in Best Corrected Visual Acuity (BCVA) as Measured by ETDRS Letter Score at Week 28 - Last Observation Carried Forward (LOCF)|Percentage of Participants Who Lost Fewer Than 15 Letters at Week 28 - LOCF","Bayer|Regeneron Pharmaceuticals","All","50 Years and older   (Adult, Older Adult)","Phase 3","304","Industry","Interventional","Allocation: Randomized|Intervention Model: Parallel Assignment|Masking: Triple (Participant, Investigator, Outcomes Assessor)|Primary Purpose: Treatment","13406","December 2011","March 2014","August 2014","December 1, 2011","March 13, 2015","November 4, 2016","Guangzhou, Guangdong, China|Changsha, Hunan, China|Xi'an, Shaanxi, China|Qingdao, Shandong, China|Chengdu, Sichuan, China|Hangzhou, Zhejiang, China|Hangzhou, Zhejiang, China|Wenzhou, Zhejiang, China|Beijing, China|Beijing, China|Beijing, China|Beijing, China|Shanghai, China|Tianjin, China",,"https://ClinicalTrials.gov/show/NCT01482910"
455,"NCT01448317","Ascending Dose Study of the Safety and Tolerability of Alirocumab (SAR236553/REGN727) in Japanese Healthy Volunteers",,"Completed","No Results Available","Hypercholesterolemia","Drug: Alirocumab (Solution)|Drug: Alirocumab (Lyophilized formulation)|Drug: Placebo (Solution)|Drug: Placebo (Lyophilized formulation)","Number of participants with Adverse Events|Change in serum Low-Density Lipoprotein Cholesterol (LDL-C) from baseline to each visit.|Change in ApolipoproteinB, ApolipoproteinA1 and Lipoprotein(a) from baseline to each visit.|Change in Total Cholesterol (T-C), High-Density Lipoprotein Cholesterol (HDL-C), Very Low-Density Lipoprotein Cholesterol (VLDL-C) and Triglycerides (TG) from baseline to each visit.","Sanofi|Regeneron Pharmaceuticals","Male","20 Years to 65 Years   (Adult, Older Adult)","Phase 1","32","Industry","Interventional","Allocation: Randomized|Intervention Model: Parallel Assignment|Masking: Double (Participant, Investigator)|Primary Purpose: Treatment","TDU12190|U1111-1118-1213","May 2011","January 2012","January 2012","October 7, 2011",,"September 28, 2016","Sanofi-Aventis Administrative Office, Tokyo, Japan",,"https://ClinicalTrials.gov/show/NCT01448317"
456,"NCT01448304","Study of the Tolerability, Safety, Pharmacokinetics and Pharmacodynamics of Alirocumab SAR236553 (REGN727)",,"Completed","No Results Available","Hypercholesterolemia","Drug: alirocumab SAR236553 (REGN727)","Pain using present pain intensity (PPI) verbal questionnaire|Erythema at injection site by measuring diameter and qualitative assessment|Edema at injection site by measuring diameter and qualitative assessment|Assessment of PK parameter - time to maximum concentration (tmax)|Assessment of PK parameter - maximum concentration (Cmax)|Assessment of PK parameter - area under curve (AUC)|Assessment of PK parameter - cluster of differentiation (CD) biomarker (CD29)|Assessment of PK parameter - terminal elimination half-life (t1/2z)|Pharmacodynamics: Change in LDL-C from baseline|Number of participants with Adverse Events","Sanofi|Regeneron Pharmaceuticals","All","18 Years to 65 Years   (Adult, Older Adult)","Phase 1","24","Industry","Interventional","Allocation: Randomized|Intervention Model: Parallel Assignment|Masking: Double (Participant, Investigator)|Primary Purpose: Treatment","PKD12011|U1111-1119-3056","June 2011","September 2011","September 2011","October 7, 2011",,"June 28, 2013","Sanofi-Aventis Administrative Office, Bridgewater, New Jersey, United States",,"https://ClinicalTrials.gov/show/NCT01448304"
457,"NCT01448239","Injection Site Tolerability, Safety, Pharmacokinetics and Pharmacodynamics Study After a Single Dose Subcutaneous Treatment of Alirocumab SAR236553 (REGN727)",,"Completed","No Results Available","Hypercholesterolemia","Drug: alirocumab SAR236553 (REGN727)","Pain using present pain intensity (PPI) verbal questionnaire|Erythema at injection site by measuring diameter and qualitative assessment|Edema at injection site by measuring diameter and qualitative assessment|Assessment of PK parameter - time to maximum concentration (tmax)|Assessment of PK parameter - maximum concentration (Cmax)|Assessment of PK parameter - area under curve (AUC)|Assessment of PK parameter - cluster of differentiation (CD) biomarker (CD29)|Assessment of PK parameter - terminal elimination half-life (t1/2z)|Pharmacodynamics: Change in LDL-C from baseline|Number of participants with Adverse Events","Sanofi|Regeneron Pharmaceuticals","All","18 Years to 65 Years   (Adult, Older Adult)","Phase 1","24","Industry","Interventional","Allocation: Randomized|Intervention Model: Parallel Assignment|Masking: Double (Participant, Investigator)|Primary Purpose: Treatment","PKD12010|U1111-1118-2935","February 2011","May 2011","May 2011","October 7, 2011",,"June 28, 2013","Sanofi-Aventis Administrative Office, Bridgewater, New Jersey, United States",,"https://ClinicalTrials.gov/show/NCT01448239"
458,"NCT01443650","Injection Site Tolerability, Safety, Pharmacokinetics, Pharmacodynamics in Different Single-Dose Treatments of Alirocumab SAR236553 (REGN727) in Healthy Subjects",,"Completed","No Results Available","Hypercholesterolemia","Drug: alirocumab SAR236553 (REGN727)","Pain using Present Pain Intensity (PPI) verbal questionnaire and Visual Analog Scale (VAS)|Erythema at injection site by measuring diameter and qualitative assessment|Edema at injection site by measuring diameter and qualitative assessment|Assessment of PK parameter - time to maximum concentration (tmax)|Pharmacodynamics: Change in LDL-C from baseline|Number of participants with Adverse Events|Assessment of PK parameter - maximum concentration (Cmax)|Assessment of PK parameter - area under curve (AUC)|Assessment of PK parameter - area under curve versus time curve (AUC0-D29)|Assessment of PK parameter - plasma concentration on Day 29 (C D29)|Assessment of PK parameter - terminal elimination half-life (t1/2z)","Sanofi|Regeneron Pharmaceuticals","All","18 Years to 65 Years   (Adult, Older Adult)","Phase 1","36","Industry","Interventional","Allocation: Randomized|Intervention Model: Parallel Assignment|Masking: Double (Participant, Investigator)|Primary Purpose: Treatment","PKD12275|U1111-1120-0670","July 2011","November 2011","November 2011","September 30, 2011",,"June 28, 2013","Sanofi-Aventis Administrative Office, Bridgewater, New Jersey, United States",,"https://ClinicalTrials.gov/show/NCT01443650"
459,"NCT01331681","Intravitreal Aflibercept Injection in Vision Impairment Due to DME","VIVID-DME","Completed","Has Results","Diabetes Mellitus|Macular Edema","Biological: VEGF Trap-Eye (BAY86-5321)|Procedure: Macular Laser Photocoagulation (Control)","Change From Baseline in BCVA (Best Corrected Visual Acuity) as Measured by Early Treatment Diabetic Retinopathy Study (ETDRS) Letter Score at Week 52 - Last Observation Carried Forward (LOCF)|Percentage of Participants Who Gained at Least 10 Letters in BCVA as Measured by ETDRS Letter Score Compared With Baseline at Week 52 - LOCF|Percentage of Participants Who Gained at Least 15 Letters in BCVA as Measured by ETDRS Letter Score Compared With Baseline at Week 52 - LOCF|Percentage of Participants With a ≥2-step Improvement From Baseline in the ETDRS DRSS (Diabetic Retinopathy Severity Score) as Assessed by FP (Fundus Photography) at Week 52 - LOCF|Change From Baseline in Central Retinal Thickness (CRT) at Week 52 as Assessed on Optical Coherence Tomography (OCT) - LOCF|Change From Baseline in National Eye Institute 25-item Visual Function Questionnaire (NEI VFQ-25) Near Activities Subscale at Week 52 - LOCF|Change From Baseline in National Eye Institute 25-item Visual Function Questionnaire (NEI VFQ-25) Distance Activities Subscale at Week 52 - LOCF","Bayer|Regeneron Pharmaceuticals","All","18 Years and older   (Adult, Older Adult)","Phase 3","406","Industry","Interventional","Allocation: Randomized|Intervention Model: Parallel Assignment|Masking: Triple (Participant, Investigator, Outcomes Assessor)|Primary Purpose: Treatment","91745|2010-022364-12","May 2011","June 2013","March 2015","April 8, 2011","September 9, 2014","April 19, 2016","Chatswood, New South Wales, Australia|Sydney, New South Wales, Australia|Westmead, New South Wales, Australia|East Melbourne, Victoria, Australia|Prahran, Victoria, Australia|Nedlands, Western Australia, Australia|Parramatta, Australia|Linz, Oberösterreich, Austria|Linz, Austria|Wien, Austria|Hradec Kralove, Czech Republic|Olomouc, Czech Republic|Ostrava, Czech Republic|Praha 10, Czech Republic|Zlin, Czech Republic|Glostrup, Denmark|Odense C, Denmark|Århus C, Denmark|Bordeaux, France|Creteil Cedex, France|Lyon, France|Marseille, France|Nantes Cedex, France|Paris, France|Paris, France|Paris, France|Freiburg, Baden-Württemberg, Germany|Heidelberg, Baden-Württemberg, Germany|Mannheim, Baden-Württemberg, Germany|Tübingen, Baden-Württemberg, Germany|München, Bayern, Germany|Darmstadt, Hessen, Germany|Göttingen, Niedersachsen, Germany|Aachen, Nordrhein-Westfalen, Germany|Bochum, Nordrhein-Westfalen, Germany|Bonn, Nordrhein-Westfalen, Germany|Köln, Nordrhein-Westfalen, Germany|Münster, Nordrhein-Westfalen, Germany|Ludwigshafen, Rheinland-Pfalz, Germany|Mainz, Rheinland-Pfalz, Germany|Chemnitz, Sachsen, Germany|Dresden, Sachsen, Germany|Leipzig, Sachsen, Germany|Kiel, Schleswig-Holstein, Germany|Berlin, Germany|Budapest, Hungary|Budapest, Hungary|Budapest, Hungary|Debrecen, Hungary|Veszprem, Hungary|Zalaegerszeg, Hungary|Ancona, Italy|Milano, Italy|Milano, Italy|Padova, Italy|Roma, Italy|Roma, Italy|Nagoya, Aichi, Japan|Nagoya, Aichi, Japan|Asahikwa, Hokkaido, Japan|Sapporo, Hokkaido, Japan|Kawasaki, Kanagawa, Japan|Sendai, Miyagi, Japan|Matsumoto, Nagano, Japan|Yufu, Oita, Japan|Hirakata, Osaka, Japan|Chiyoda-ku, Tokyo, Japan|Itabashi-ku, Tokyo, Japan|Mitaka, Tokyo, Japan|Shinjuku-ku, Tokyo, Japan|Akita, Japan|Chiba, Japan|Fukuoka, Japan|Nagasaki, Japan|Osaka, Japan|Wakayama, Japan|Bialystok, Poland|Bytom, Poland|Wroclaw, Poland|Wroclaw, Poland|Santiago de Compostela, A Coruña, Spain|Oviedo, Asturias, Spain|San Cugat del Vallès, Barcelona, Spain|Alicante, Spain|Barcelona, Spain|Pamplona, Spain|Valencia, Spain|Changhua City, Changhua, Taiwan|Kaohsiung, Taiwan|Taipei, Taiwan",,"https://ClinicalTrials.gov/show/NCT01331681"
460,"NCT01328522","Comparison of the Safety and Pharmacokinetics of Two SAR153191 (REGN88) Drug Products in Rheumatoid Arthritis Patients",,"Completed","No Results Available","Rheumatoid Arthritis","Drug: SAR153191 (REGN88)","Occurrence of potentially clinically significant abnormalities in clinical laboratory test results|Occurrence of Adverse Events|Pain evaluation using the Present Pain Intensity (PPI) verbal questionnaire|Pain evaluation using Visual Analog Scale (VAS)|Diameter of the erythema at injection site|Diameter of the edema at injection site|Serum concentration of SAR153191: Maximum plasma concentration (Cmax), first time to reach Cmax (tmax), area under the plasma concentration (AUClast and AUC)","Sanofi|Regeneron Pharmaceuticals","All","18 Years to 75 Years   (Adult, Older Adult)","Phase 1","32","Industry","Interventional","Allocation: Randomized|Intervention Model: Parallel Assignment|Masking: Single (Participant)|Primary Purpose: Treatment","PKM12058|U1111-1119-2883","May 2011","September 2011","September 2011","April 4, 2011",,"October 24, 2011","Investigational Site Number 840003, Beverly Hills, California, United States|Investigational Site Number 840001, Ocala, Florida, United States|Investigational Site Number 840004, Duncansville, Pennsylvania, United States|Investigational Site Number 840002, Dallas, Texas, United States",,"https://ClinicalTrials.gov/show/NCT01328522"
461,"NCT01312961","Efficacy, Safety, and Tolerability of Dupilumab in Patients With Persistent Moderate to Severe Eosinophilic Asthma",,"Completed","Has Results","Asthma","Drug: Dupilumab|Drug: Placebo (for Dupilumab)|Drug: Fluticasone/Salmeterol combination therapy|Drug: Fluticasone monotherapy|Drug: Albuterol|Drug: Levalbuterol","Percentage of Participants With Asthma Exacerbation|Time to First Asthma Exacerbation: Kaplan-Meier Estimates at Week 4, Week 8 and Week 12|Percentage of Participants With Composite Asthma Events|Change From Baseline in Forced Expiratory Flow in One Second (FEV1) to Week 12|Change From Baseline in Peak Expiratory Flow (PEF) to Week 12|Change From Baseline in Asthma Control Questionnaire (5-question Version [ACQ-5]) to Week 12|Change From Baseline in 22-item Sinonasal Outcome Test (SNOT-22) Score to Week 12|Change From Baseline in Morning Asthma Symptom Scores to Week 12|Change From Baseline in Evening Asthma Symptom Scores to Week 12|Change From Baseline in Number of Nocturnal Awakenings Per Day to Week 12|Change From Baseline in Number of Inhalations Per Day of Albuterol or Levalbuterol to Week 12","Sanofi|Regeneron Pharmaceuticals","All","18 Years to 65 Years   (Adult, Older Adult)","Phase 2","104","Industry","Interventional","Allocation: Randomized|Intervention Model: Parallel Assignment|Masking: Triple (Participant, Care Provider, Investigator)|Primary Purpose: Treatment","ACT11457|U1111-1117-7826","March 2011","October 2012","October 2012","March 11, 2011","June 8, 2017","June 8, 2017","Investigational Site Number 840047, Anaheim, California, United States|Investigational Site Number 840046, Long Beach, California, United States|Investigational Site Number 840032, Los Angeles, California, United States|Investigational Site Number 840036, Los Angeles, California, United States|Investigational Site Number 840005, Mission Viejo, California, United States|Investigational Site Number 840007, Orange, California, United States|Investigational Site Number 840048, Riverside, California, United States|Investigational Site Number 840035, Rolling Hills Estates, California, United States|Investigational Site Number 840041, San Francisco, California, United States|Investigational Site Number 840042, San Francisco, California, United States|Investigational Site Number 840039, San Jose, California, United States|Investigational Site Number 840024, Santa Rosa, California, United States|Investigational Site Number 840002, Stockton, California, United States|Investigational Site Number 840031, Colorado Springs, Colorado, United States|Investigational Site Number 840011, Denver, Colorado, United States|Investigational Site Number 840017, Denver, Colorado, United States|Investigational Site Number 840026, New Haven, Connecticut, United States|Investigational Site Number 840044, Tallahassee, Florida, United States|Investigational Site Number 840029, Tampa, Florida, United States|Investigational Site Number 840028, Indianapolis, Indiana, United States|Investigational Site Number 840038, Iowa City, Iowa, United States|Investigational Site Number 840021, Overland Park, Kansas, United States|Investigational Site Number 840053, Owensboro, Kentucky, United States|Investigational Site Number 840014, Baltimore, Maryland, United States|Investigational Site Number 840015, North Dartmouth, Massachusetts, United States|Investigational Site Number 840003, Minneapolis, Minnesota, United States|Investigational Site Number 840010, Minneapolis, Minnesota, United States|Investigational Site Number 840006, Saint Louis, Missouri, United States|Investigational Site Number 840013, Saint Louis, Missouri, United States|Investigational Site Number 840022, Bozeman, Montana, United States|Investigational Site Number 840025, Omaha, Nebraska, United States|Investigational Site Number 840008, Papillion, Nebraska, United States|Investigational Site Number 840018, Princeton, New Jersey, United States|Investigational Site Number 840004, Winston-Salem, North Carolina, United States|Investigational Site Number 840023, Sylvania, Ohio, United States|Investigational Site Number 840045, Oklahoma City, Oklahoma, United States|Investigational Site Number 840001, Lake Oswego, Oregon, United States|Investigational Site Number 840012, Medford, Oregon, United States|Investigational Site Number 840016, Portland, Oregon, United States|Investigational Site Number 840040, Hershey, Pennsylvania, United States|Investigational Site Number 840037, Pittsburgh, Pennsylvania, United States|Investigational Site Number 840009, Upland, Pennsylvania, United States|Investigational Site Number 840027, Charleston, South Carolina, United States|Investigational Site Number 840030, El Paso, Texas, United States|Investigational Site Number 840050, San Antonio, Texas, United States|Investigational Site Number 840052, South Burlington, Vermont, United States|Investigational Site Number 840049, Richmond, Virginia, United States|Investigational Site Number 840020, Seattle, Washington, United States|Investigational Site Number 840019, Tacoma, Washington, United States|Investigational Site Number 840034, Madison, Wisconsin, United States",,"https://ClinicalTrials.gov/show/NCT01312961"
462,"NCT01288469","Efficacy and Safety Evaluation of Alirocumab (SAR236553/REGN727) When Co-administered With High Dose of Atorvastatin in Patients With Primary Hypercholesterolemia",,"Completed","Has Results","Hypercholesterolemia","Drug: Alirocumab|Drug: Placebo (for alirocumab)|Drug: Atorvastatin|Drug: Placebo (for atorvastatin)","Percent Change From Baseline in Calculated LDL-C at Week 8 - On-treatment Analysis|Absolute Change From Baseline in Calculated LDL-C (mmol/L) at Week 8 - On-treatment Analysis|Absolute Change From Baseline in Calculated LDL-C (mg/dL) at Week 8 - On-treatment Analysis|Percentage of Participants Achieving Calculated LDL-C <100 mg/dL (2.59 mmol/L) and < 70 mg/dL (1.81 mmol/L) at Week 8 - On-treatment Analysis|Percent Change From Baseline in Total Cholesterol, Fasting Triglycerides, Non-high-Density Lipoprotein Cholesterol (Non-HDL-C), Apolipoprotein B (Apo-B) and Lipoprotein(a) at Week 8 - On-treatment Analysis|Percent Change From Baseline in High-Density Lipoprotein Cholesterol (HDL-C) at Week 8 - On-treatment Analysis|Absolute Change in the Ratio Apolipoprotein B/Apolipoprotein A-1 (ApoB/ApoA-1) From Baseline to Week 8 - On-treatment Analysis","Sanofi|Regeneron Pharmaceuticals","All","18 Years to 75 Years   (Adult, Older Adult)","Phase 2","92","Industry","Interventional","Allocation: Randomized|Intervention Model: Parallel Assignment|Masking: Quadruple (Participant, Care Provider, Investigator, Outcomes Assessor)|Primary Purpose: Treatment","DFI11566|U1111-1117-9994","January 2011","September 2011","September 2011","February 2, 2011","September 24, 2015","September 24, 2015","Investigational Site Number 840616, Mesa, Arizona, United States|Investigational Site Number 840601, Tucson, Arizona, United States|Investigational Site Number 840610, Los Angeles, California, United States|Investigational Site Number 840608, Newport Beach, California, United States|Investigational Site Number 840603, Doral, Florida, United States|Investigational Site Number 840611, Jacksonville, Florida, United States|Investigational Site Number 840618, Jupiter, Florida, United States|Investigational Site Number 840612, Miami, Florida, United States|Investigational Site Number 840614, Miami, Florida, United States|Investigational Site Number 840607, St. Petersburg, Florida, United States|Investigational Site Number 840605, Chicago, Illinois, United States|Investigational Site Number 840619, Chicago, Illinois, United States|Investigational Site Number 840604, Edison, New Jersey, United States|Investigational Site Number 840606, Rochester, New York, United States|Investigational Site Number 840615, Cincinnati, Ohio, United States|Investigational Site Number 840617, Cincinnati, Ohio, United States|Investigational Site Number 840602, Eugene, Oregon, United States|Investigational Site Number 840621, Richmond, Virginia, United States|Investigational Site Number 840609, Olympia, Washington, United States|Investigational Site Number 840613, Oregon, Wisconsin, United States",,"https://ClinicalTrials.gov/show/NCT01288469"
463,"NCT01288443","Efficacy and Safety Evaluation of Alirocumab (SAR236553/REGN727) in Patients With Primary Hypercholesterolemia on Stable Atorvastatin Therapy",,"Completed","Has Results","Hypercholesterolemia","Drug: Alirocumab|Drug: Placebo (for alirocumab)|Drug: Atorvastatin","Percent Change From Baseline in Calculated LDL-C at Week 12 - On-Treatment Analysis|Absolute Change From Baseline in Calculated LDL-C (mmol/L) at Week 12 - On-Treatment Analysis|Absolute Change From Baseline in Calculated LDL-C (mg/dL) at Week 12 - On-Treatment Analysis|Percentage of Participants Achieving Calculated LDL-C <100 mg/dL (2.59 mmol/L) and <70 mg/dL (1.81 mmol/L) at Week 12 - On-Treatment Analysis|Percent Change From Baseline in Total Cholesterol, High-density Lipoprotein Cholesterol (HDL-C), Non-HDL-C and Apolipoprotein B (Apo-B) at Week 12 - On-Treatment Analysis|Percent Change From Baseline in Fasting Triglycerides and Lipoprotein(a) at Week 12 - On-Treatment Analysis|Absolute Change in the Ratio Apolipoprotein B/Apolipoprotein A-1 (ApoB/ApoA-1) From Baseline to Week 12 - On-Treatment Analysis","Sanofi|Regeneron Pharmaceuticals","All","18 Years to 75 Years   (Adult, Older Adult)","Phase 2","183","Industry","Interventional","Allocation: Randomized|Intervention Model: Parallel Assignment|Masking: Quadruple (Participant, Care Provider, Investigator, Outcomes Assessor)|Primary Purpose: Treatment","DFI11565|U1111-1116-5252","January 2011","December 2011","December 2011","February 2, 2011","September 24, 2015","September 24, 2015","Investigational Site Number 840525, Tempe, Arizona, United States|Investigational Site Number 840516, Los Angeles, California, United States|Investigational Site Number 840528, Mission Viejo, California, United States|Investigational Site Number 840509, Newport Beach, California, United States|Investigational Site Number 840523, Palm Springs, California, United States|Investigational Site Number 840534, Westlake Village, California, United States|Investigational Site Number 840530, Colorado Springs, Colorado, United States|Investigational Site Number 840504, Aventura, Florida, United States|Investigational Site Number 840519, Aventura, Florida, United States|Investigational Site Number 840514, Jacksonville, Florida, United States|Investigational Site Number 840539, Jupiter, Florida, United States|Investigational Site Number 840502, Miami, Florida, United States|Investigational Site Number 840520, Pembroke Pines, Florida, United States|Investigational Site Number 840524, Ponte Vedra, Florida, United States|Investigational Site Number 840536, Port Orange, Florida, United States|Investigational Site Number 840507, St. Petersburg, Florida, United States|Investigational Site Number 840527, Chicago, Illinois, United States|Investigational Site Number 840506, Evansville, Indiana, United States|Investigational Site Number 840529, Indianapolis, Indiana, United States|Investigational Site Number 840515, Wichita, Kansas, United States|Investigational Site Number 840532, Madisonville, Kentucky, United States|Investigational Site Number 840535, Auburn, Maine, United States|Investigational Site Number 840503, Brockton, Massachusetts, United States|Investigational Site Number 840512, Las Vegas, Nevada, United States|Investigational Site Number 840505, Edison, New Jersey, United States|Investigational Site Number 840538, Rochester, New York, United States|Investigational Site Number 840508, Raleigh, North Carolina, United States|Investigational Site Number 840522, Statesville, North Carolina, United States|Investigational Site Number 840511, Cincinnati, Ohio, United States|Investigational Site Number 840526, Cincinnati, Ohio, United States|Investigational Site Number 840510, Lyndhurst, Ohio, United States|Investigational Site Number 840533, Tulsa, Oklahoma, United States|Investigational Site Number 840537, Eugene, Oregon, United States|Investigational Site Number 840521, Bristol, Tennessee, United States|Investigational Site Number 840531, Bountiful, Utah, United States|Investigational Site Number 840517, Norfolk, Virginia, United States|Investigational Site Number 840518, Richmond, Virginia, United States|Investigational Site Number 840513, Olympia, Washington, United States",,"https://ClinicalTrials.gov/show/NCT01288443"
464,"NCT01249664","VEGF Trap-Eye in Choroidal Neovascularization Secondary to Pathologic Myopia (mCNV)","Myrror","Completed","Has Results","Myopia, Pathological","Biological: VEGF Trap-Eye (BAY86-5321)|Procedure: No Drug","Mean Change in Best Corrected Visual Acuity (BCVA) as Measured by Early Treatment Diabetic Retinopathy Study (ETDRS) From Baseline to Week 24 - Last Observation Carried Forward (LOCF)|Percentage of Participants Who Gained at Least 15 Letters in BCVA as Measured by ETDRS at Week 24 Using the LOCF Approach|Mean Change in Best Corrected Visual Acuity (BCVA) as Measured by ETDRS From Baseline to Week 24 - Observed Cases|Percentage of Participants Who Gained at Least 10 Letters in BCVA at Week 24 - LOCF|Percentage of Participants Who Gained at Least 5 Letters in BCVA at Week 24 - LOCF|Percentage of Participants Who Gained at Least 15 Letters in BCVA at Week 48 - LOCF|Percentage of Participants Who Gained at Least 10 Letters in BCVA at Week 48 - LOCF|Percentage of Participants Who Gained at Least 5 Letters in BCVA at Week 48 - LOCF|Percentage of Participants Who Lost at Least 15 Letters in BCVA at Week 24 - LOCF|Percentage of Participants Who Lost at Least 10 Letters in BCVA at Week 24 - LOCF|Percentage of Participants Who Lost at Least 5 Letters in BCVA at Week 24 - LOCF|Percentage of Participants Who Lost at Least 15 Letters in BCVA at Week 48 - LOCF|Percentage of Participants Who Lost at Least 10 Letters in BCVA at Week 48 - LOCF|Percentage of Participants Who Lost at Least 5 Letters in BCVA at Week 48 - LOCF|Mean Change in Central Retinal Thickness (CRT) as Assessed by Optical Coherence Tomography (OCT) From Baseline to Week 24 - LOCF|Mean Change in Central Retinal Thickness (CRT) as Assessed by Optical Coherence Tomography (OCT) From Baseline to Week 48 - LOCF|Mean Change in Choroidal Neovascularization (CNV) Lesion Size as Assessed by Fluorescein Angiography (FA) From Baseline to Week 24 - LOCF|Mean Change in Choroidal Neovascularization (CNV) Lesion Size as Assessed by Fluorescein Angiography (FA) From Baseline to Week 48 - LOCF|Mean Change in European Five-dimensional Health Scale (EQ-5D) Score From Baseline to Week 24 - LOCF|Mean Change in National Eye Institute 25-item Visual Function Questionnaire (NEI VFQ-25) Total Score From Baseline to Week 24 - LOCF|Percentage of Participants Who Were Withdrawn From Study Drug During the First 24 Weeks|Mean Change in Area of Leakage From Baseline at Week 24 - LOCF","Bayer|Regeneron Pharmaceuticals","All","18 Years and older   (Adult, Older Adult)","Phase 3","122","Industry","Interventional","Allocation: Randomized|Intervention Model: Parallel Assignment|Masking: Quadruple (Participant, Care Provider, Investigator, Outcomes Assessor)|Primary Purpose: Treatment","15170","December 2010","February 2013","August 2013","November 30, 2010","April 1, 2014","May 5, 2014","Kowloon, Hong Kong|Nagoya, Aichi, Japan|Nagoya, Aichi, Japan|Urayasu, Chiba, Japan|Matsuyama, Ehime, Japan|Sendai, Miyagi, Japan|Suita, Osaka, Japan|Otsu, Shiga, Japan|Bunkyo-ku, Tokyo, Japan|Chiyoda-ku, Tokyo, Japan|Shinjuku-ku, Tokyo, Japan|Fukuoka, Japan|Fukushima, Japan|Kyoto, Japan|Osaka, Japan|Osaka, Japan|Seoul, Korea, Republic of|Singapore, Singapore|Taipei, Taiwan|Taoyuan, Taiwan",,"https://ClinicalTrials.gov/show/NCT01249664"
465,"NCT01217814","Effect of SAR153191 (REGN88) With Methotrexate in Patients With Active Rheumatoid Arthritis Who Failed TNF-α Blockers",,"Terminated","Has Results","Rheumatoid Arthritis","Drug: Sarilumab|Drug: Placebo|Drug: Golimumab|Drug: methotrexate (MTX)|Drug: Folic/folinic acid","Percentage of Participants Who Achieved at Least 20% Improvement in American College of Rheumatology (ACR20) Core Set Disease Activity Index at Week 12|Percentage of Participants Who Achieved at Least 50% Improvement in American College of Rheumatology (ACR50) Core Set Disease Activity Index at Week 12|Percentage of Participants Who Achieved at Least 70% Improvement in American College of Rheumatology Core (ACR70) Set Disease Activity Index at Week 12|Disease Activity Score for 28 Joints (DAS28) at Week 12|European League Against Rheumatism (EULAR) Response at Week 12|Percentage of Participants Achieving DAS28 Remission Score < 2.6 at Week 12|Pharmacokinetic (PK) Parameter: Serum Concentration of Functional and Bound Sarilumab","Sanofi|Regeneron Pharmaceuticals","All","18 Years to 75 Years   (Adult, Older Adult)","Phase 2","16","Industry","Interventional","Allocation: Randomized|Intervention Model: Parallel Assignment|Masking: Triple (Participant, Care Provider, Investigator)|Primary Purpose: Treatment","ACT11575|2010-021020-94|U1111-1115-3763","November 2010","September 2011","September 2011","October 8, 2010","September 1, 2017","September 1, 2017","Investigational Site Number 840026, Freehold, New Jersey, United States|Investigational Site Number 840043, New York, New York, United States|Investigational Site Number 840025, Jackson, Tennessee, United States|Investigational Site Number 840038, Austin, Texas, United States|Investigational Site Number 170004, Barranquilla, Colombia|Investigational Site Number 170005, Barranquilla, Colombia|Investigational Site Number 170007, Bucaramanga, Colombia|Investigational Site Number 203002, Uherske Hradiste, Czechia|Investigational Site Number 380002, Firenze, Italy|Investigational Site Number 380005, Genova, Italy|Investigational Site Number 484008, Durango, Mexico|Investigational Site Number 484002, Guadalajara, Mexico|Investigational Site Number 724004, Oviedo, Spain|Investigational Site Number 724002, Valencia, Spain",,"https://ClinicalTrials.gov/show/NCT01217814"
466,"NCT01148615","A Study of Intravenous Aflibercept With Docetaxel in Chinese Patients With Solid Tumors",,"Completed","No Results Available","Neoplasm Malignant","Drug: Aflibercept (AVE0005)|Drug: Docetaxel (XRP6976)","Dose-Limiting Toxicity (DLT)|Global safety profile based on treatment emergent adverse events, serious adverse events, and laboratory abnormalities|Pharmacokinetic parameters of aflibercept|Pharmacokinetic parameters of docetaxel|Tumor response rate as calculated by the Response Evaluation Criteria in Solid Tumors (RECIST v1.1)|Immunogenicity of Aflibercept|Endogenous free VEGF","Sanofi|Regeneron Pharmaceuticals","All","18 Years and older   (Adult, Older Adult)","Phase 1","20","Industry","Interventional","Allocation: N/A|Intervention Model: Single Group Assignment|Masking: None (Open Label)|Primary Purpose: Treatment","TCD11382|U1111-1116-5774","July 2010","September 2011","December 2011","June 22, 2010",,"January 13, 2012","Sanofi-Aventis Investigational Site Number 156001, Guangzhou, China",,"https://ClinicalTrials.gov/show/NCT01148615"
467,"NCT01146652","Long Term Evaluation of Sarilumab in Rheumatoid Arthritis Patients (SARIL-RA-EXTEND)",,"Completed","Has Results","Rheumatoid Arthritis","Drug: SAR153191 (REGN88)","Number of Participants With Treatment-Emergent Adverse Events (TEAEs) and Serious Adverse Events (SAEs)|Sub-study: Number of Participants Reported Product Technical Complaints (PTC), Product Technical Failures (PTF) and/or Failed Drug Deliveries (FDD) With Pre-filled Syringe With Safety System|Sub-study: Number of Product Technical Complaints - Product Technical Failures With Pre-filled Syringe With Safety System|Sub-study: Number of Failed Drug Deliveries Associated With Pre-filled Syringe With Safety System|Sub-study: Number of Product Technical Complaints With Pre-filled Syringe With Safety System|Percentage of Participants Achieving American College of Rheumatology 20 (ACR20) Response|Percentage of Participants Achieving American College of Rheumatology 50 (ACR50) Response|Percentage of Participants Achieving American College of Rheumatology 70 (ACR70) Response|Percentage of Participants With Disease Activity Score for 28 Joints (DAS28) Remission|Percentage of Participants Achieving Good Response, Moderate Response or Non-response Using the European League Against Rheumatism (EULAR) Response Criteria|Change From Baseline in DAS28-CRP Score at Weeks 0, 4, 8, 12, 24, 36, 48, 60, 72, 84, 96, 120, 144, 168, 192, 216, 240, 264, 288, 312, 336, 360, 384, 408, 432, 456, 480, 504 and 516 of LTS11210|Change From Baseline in Health Assessment Questionnaire-Disability Index (HAQ-DI) Scores at Week 0, 4, 8, 12, 24, 36, 48, 60, 72, 84, 96, 120, 144, 168, 192, 216, 240 and 264 of LTS11210|Change From Baseline in Van Der Heijde Modified Total Sharp Score (mTSS) at Week 0 and Week 48 of LTS11210: Campaign 1 X-ray Data - Participants From EFC11072 Part B|Change From Baseline in Van Der Heijde Modified Total Sharp Score (mTSS) at Week 48 and Week 96 of LTS11210: Campaign 2 X-ray Data - Participants From EFC11072 Part B|Change From Baseline in Van Der Heijde Modified Total Sharp Score (mTSS) at Week 96, Week 144 and Week 192 of LTS11210: Campaign 3 X-ray Data - Participants From EFC11072 Part B|Percentage of Participants With no Radiographic Progression of the Van Der Heijde Modified Total Sharp Score at Week 0 and 48 of LTS11210: Campaign 1 X-ray Data - Participants From EFC11072 Part B|Percentage of Participants With no Radiographic Progression of the Van Der Heijde Modified Total Sharp Score at Week 48 and Week 96 of LTS11210: Campaign 2 X-ray Data - Participants From EFC11072 Part B|Percentage of Participants With no Radiographic Progression of the Van Der Heijde Modified Total Sharp Score at Week 96, 144 and 192 of LTS11210: Campaign 3 X-ray Data - Participants From EFC11072 Part B|Change From Baseline in Tender Joint Count (TJC) at Week 0, 4, 8, 12, 24, 36, 48, 60, 72, 84, 96, 120, 144, 168, 192, 216, 240, 264, 288, 312, 336, 360, 384, 408, 432, 456, 480, 504 and 516 of LTS11210|Change From Baseline in Swollen Joint Count (SJC) at Week 0, 4, 8, 12, 24, 36, 48, 60, 72, 84, 96, 120, 144, 168, 192, 216, 240, 264, 288, 312, 336, 360, 384, 408, 432, 456, 480, 504 and 516 of LTS11210|Change From Baseline in Physician's Global Assessments of Disease Activity Visual Analogue Scale (VAS) Score at Week 0, 4, 8, 12, 24, 36, 48, 60, 72, 84, 96, 120, 144, 168, 192, 216, 240, and 264 of LTS11210|Change From Baseline in Participant Global Assessment of Disease Activity Visual Analogue Scale Score at Week 0, 4, 8, 12, 24, 36, 48, 60, 72, 84, 96, 120, 144, 168, 192, 216, 240, 264, 288, 312, 336, 360, 384, 408, 432, 456, 480, 504 and 516 of LTS11210|Change From Baseline in Participant's Assessment of Pain Visual Analogue Scale Score at Week 0, 4, 8, 12, 24, 36, 48, 60, 72, 84, 96, 120, 144, 168, 192, 216, 240, and 264 of LTS11210|Change From Baseline in Short Form 36 (SF-36; Version 2) Physical Component Summary (PCS) Score at Week 0, 12, 24, 36, 48, 60, 72, 84, 96, 120, 144, 168, 192, 216, 240 and 264 of LTS11210 - Participants From EFC11072, ACT11575 and EFC10832 Only|Change From Baseline in Short Form 36 (SF-36; Version 2) Mental Component Summary Score at Week 0, 12, 24, 36, 48, 60, 72, 84, 96, 120, 144, 168, 192, 216, 240 and 264 of LTS11210 - Participants From EFC11072, ACT11575 and EFC10832 Only|Change From Baseline in Functional Assessment of Chronic Illness Therapy Fatigue (FACIT-fatigue) Total Score at Week 0, 12, 24, 36, 48, 60, 72, 84, 96, 120, 144, 168, 192, 216, 240 and 264 of LTS11210-Participants From EFC11072, ACT11575 and EFC10832 Only|Change From Baseline in Sleep Visual Analogue Scale Score at Week 0, 12, 24, 36, 48, 60, 72, 84, 96, 120, 144, 168, 192, 216, 240 and 264 of LTS11210 - Participants From EFC11072, and ACT11575 Only|Change From Baseline in Work Productivity and Activity Impairment (WPAI): Percent Work Time Missed Due to RA at Week 0, 12, 24, 36, 48, 60, 72, 84, 96, 120, 144, 168, 192, 216, 240 and 264 of LTS11210 - Participants From EFC11072 and ACT11575 Only|Change From Baseline in Work Productivity and Activity Impairment: Percent Impairment While Working Due to RA at Weeks 0, 12, 24, 36, 48, 60, 72, 84, 96, 120, 144, 168, 192, 216, 240 and 264 of LTS11210 - Participants From EFC11072, and ACT11575 Only|Change From Baseline in Work Productivity and Activity Impairment: Percent Overall Work Impairment Due to RA at Weeks 0, 12, 24, 36, 48, 60, 72, 84, 96, 120, 144, 168, 192, 216, 240 and 264 of LTS11210 - Participants From EFC11072, and ACT11575 Only|Change From Baseline in Work Productivity and Activity Impairment: Percent Activity Impairment Due to RA at Weeks 0, 12, 24, 36, 48, 60, 72, 84, 96, 120, 144, 168, 192, 216, 240 and 264 of LTS11210 - Participants From EFC11072, and ACT11575 Only|Change From Baseline in Work Productivity Survey - Rheumatoid Arthritis (WPS-RA) at Weeks 0, 12, 24, 36, 48, 60, 72, 84, 96, 120, 144, 168, 192, 216, 240 and 264 of LTS11210: Work Days Missed Due to Arthritis - Participants From EFC10832 Only|Change From Baseline in WPS-RA at Weeks 0, 12, 24, 36, 48, 60, 72, 84, 96, 120, 144, 168, 192, 216, 240 and 264 of LTS11210: Days With Work Productivity Reduced by >=50% Due to Arthritis - Participants From EFC10832 Only|Change From Baseline in WPS-RA at Weeks 0, 12, 24, 36, 48, 60, 72, 84, 96, 120, 144, 168, 192, 216, 240 and 264 of LTS11210: Arthritis Interference With Work Productivity - Participants From EFC10832 Only|Change From Baseline in WPS-RA at Weeks 0, 12, 24, 36, 48, 60, 72, 84, 96, 120, 144, 168, 192, 216, 240 and 264 of LTS11210: House Work Days Missed Due to Arthritis - Participants From EFC10832 Only|Change From Baseline in WPS-RA at Weeks 0, 12, 24, 36, 48, 60, 72, 84, 96, 120, 144, 168, 192, 216, 240 and 264 of LTS11210: Days With Household Work Productivity Reduced by >=50% Due to Arthritis - Participants From EFC10832 Only|Change From Baseline in WPS-RA at Weeks 0, 12, 24, 36, 48, 60, 72, 84, 96, 120, 144, 168, 192, 216, 240 and 264 of LTS11210: Days With Family/Social/Leisure Activities Missed Due to Arthritis - Participants From EFC10832 Only|Change From Baseline in WPS-RA at Weeks 0, 12, 24, 36, 48, 60, 72, 84, 96, 120, 144, 168, 192, 216, 240 and 264 of LTS11210: Days With Outside Help Hired Due to Arthritis- Participants From EFC10832 Only|Change From Baseline in WPS-RA at Weeks 0, 12, 24, 36, 48, 60, 72, 84, 96, 120, 144, 168, 192, 216, 240 and 264 of LTS11210: Arthritis Interference With Household Work Productivity - Participants From EFC10832 Only|Sub-study: Number of Participants Who Reported Adverse Events Related to Pre-filled Syringe With Safety System","Sanofi|Regeneron Pharmaceuticals","All","18 Years and older   (Adult, Older Adult)","Phase 3","2023","Industry","Interventional","Allocation: Non-Randomized|Intervention Model: Parallel Assignment|Masking: None (Open Label)|Primary Purpose: Treatment","LTS11210|2010-019262-86","June 21, 2010","December 31, 2020","December 31, 2020","June 17, 2010","January 24, 2022","January 24, 2022","Investigational Site Number 840070, Anniston, Alabama, United States|Investigational Site Number 840138, Birmingham, Alabama, United States|Investigational Site Number 840152, Huntsville, Alabama, United States|Investigational Site Number 840072, Gilbert, Arizona, United States|Investigational Site Number 840141, Glendale, Arizona, United States|Investigational Site Number 840134, Fullerton, California, United States|Investigational Site Number 840008, La Jolla, California, United States|Investigational Site Number 840135, San Diego, California, United States|Investigational Site Number 840021, Santa Maria, California, United States|Investigational Site Number 840100, Stanford, California, United States|Investigational Site Number 840049, Upland, California, United States|Investigational Site Number 840151, Colorado Springs, Colorado, United States|Investigational Site Number 840130, Lewes, Delaware, United States|Investigational Site Number 840153, Aventura, Florida, United States|Investigational Site Number 840050, Clearwater, Florida, United States|Investigational Site Number 840033, Fort Lauderdale, Florida, United States|Investigational Site Number 840041, Gainesville, Florida, United States|Investigational Site Number 840067, Jupiter, Florida, United States|Investigational Site Number 840048, Miami, Florida, United States|Investigational Site Number 840024, Naples, Florida, United States|Investigational Site Number 840006, Orlando, Florida, United States|Investigational Site Number 840128, Ormond Beach, Florida, United States|Investigational Site Number 840063, Palm Harbor, Florida, United States|Investigational Site Number 840155, Palm Harbor, Florida, United States|Investigational Site Number 840060, Sarasota, Florida, United States|Investigational Site Number 840140, Tampa, Florida, United States|Investigational Site Number 840126, Vero Beach, Florida, United States|Investigational Site Number 840003, Atlanta, Georgia, United States|Investigational Site Number 840028, Decatur, Georgia, United States|Investigational Site Number 840027, Marietta, Georgia, United States|Investigational Site Number 840018, Idaho Falls, Idaho, United States|Investigational Site Number 840046, Chicago, Illinois, United States|Investigational Site Number 840052, Kansas City, Kansas, United States|Investigational Site Number 840230, Elizabethtown, Kentucky, United States|Investigational Site Number 840015, Lexington, Kentucky, United States|Investigational Site Number 840120, Baton Rouge, Louisiana, United States|Investigational Site Number 840109, Lake Charles, Louisiana, United States|Investigational Site Number 840055, Frederick, Maryland, United States|Investigational Site Number 840013, Wheaton, Maryland, United States|Investigational Site Number 840154, Boston, Massachusetts, United States|Investigational Site Number 840150, Lansing, Michigan, United States|Investigational Site Number 840137, Saint Clair Shores, Michigan, United States|Investigational Site Number 840112, Lincoln, Nebraska, United States|Investigational Site Number 840026, Freehold, New Jersey, United States|Investigational Site Number 840115, Lake Success, New York, United States|Investigational Site Number 840056, New York, New York, United States|Investigational Site Number 840043, New York, New York, United States|Investigational Site Number 840106, Orchard Park, New York, United States|Investigational Site Number 840118, Smithtown, New York, United States|Investigational Site Number 840116, Wilmington, North Carolina, United States|Investigational Site Number 840233, Minot, North Dakota, United States|Investigational Site Number 840002, Oklahoma City, Oklahoma, United States|Investigational Site Number 840127, Oklahoma City, Oklahoma, United States|Investigational Site Number 840011, Tulsa, Oklahoma, United States|Investigational Site Number 840065, Tulsa, Oklahoma, United States|Investigational Site Number 840010, Bethlehem, Pennsylvania, United States|Investigational Site Number 840009, Duncansville, Pennsylvania, United States|Investigational Site Number 840062, Reading, Pennsylvania, United States|Investigational Site Number 840058, Columbia, South Carolina, United States|Investigational Site Number 840016, North Charleston, South Carolina, United States|Investigational Site Number 840025, Jackson, Tennessee, United States|Investigational Site Number 840059, Memphis, Tennessee, United States|Investigational Site Number 840032, Amarillo, Texas, United States|Investigational Site Number 840038, Austin, Texas, United States|Investigational Site Number 840001, Dallas, Texas, United States|Investigational Site Number 840022, Dallas, Texas, United States|Investigational Site Number 840012, Dallas, Texas, United States|Investigational Site Number 840129, Houston, Texas, United States|Investigational Site Number 840069, Lubbock, Texas, United States|Investigational Site Number 840074, Mesquite, Texas, United States|Investigational Site Number 840020, Nassau Bay, Texas, United States|Investigational Site Number 840103, San Antonio, Texas, United States|Investigational Site Number 840036, Spokane, Washington, United States|Investigational Site Number 840061, Tacoma, Washington, United States|Investigational Site Number 840124, Clarksburg, West Virginia, United States|Investigational Site Number 032006, Caba, Argentina|Investigational Site Number 032007, Caba, Argentina|Investigational Site Number 032008, Caba, Argentina|Investigational Site Number 032019, Capital Federal, Argentina|Investigational Site Number 032016, Capital Federal, Argentina|Investigational Site Number 032002, Cordoba, Argentina|Investigational Site Number 032020, Cordoba, Argentina|Investigational Site Number 032003, Córdoba, Argentina|Investigational Site Number 032017, La Plata, Argentina|Investigational Site Number 032012, Mar Del Plata, Argentina|Investigational Site Number 032011, Quilmes, Argentina|Investigational Site Number 032010, Ramos Mejia, Argentina|Investigational Site Number 032001, Rosario, Argentina|Investigational Site Number 032013, Rosario, Argentina|Investigational Site Number 032015, San Fernando, Argentina|Investigational Site Number 032005, San Miguel De Tucuman, Argentina|Investigational Site Number 032004, San Miguel De Tucuman, Argentina|Investigational Site Number 032009, Zarate, Argentina|Investigational Site Number 036003, Camperdown, Australia|Investigational Site Number 036012, Fitzroy, Australia|Investigational Site Number 036010, Garran, Australia|Investigational Site Number 036004, Heidelberg West, Australia|Investigational Site Number 036001, Maroochydore, Australia|Investigational Site Number 036014, Victoria Park, Australia|Investigational Site Number 036007, Woodville, Australia|Investigational Site Number 040001, Graz, Austria|Investigational Site Number 112002, Minsk, Belarus|Investigational Site Number 112001, Minsk, Belarus|Investigational Site Number 056010, Leuven, Belgium|Investigational Site Number 076001, Curitiba, Brazil|Investigational Site Number 076006, Goiania, Brazil|Investigational Site Number 076010, Juiz De Fora, Brazil|Investigational Site Number 076004, Porto Alegre, Brazil|Investigational Site Number 076005, Rio De Janeiro, Brazil|Investigational Site Number 076015, Rio De Janeiro, Brazil|Investigational Site Number 076011, Salvador, Brazil|Investigational Site Number 076002, Sao Paulo, Brazil|Investigational Site Number 076003, Sao Paulo, Brazil|Investigational Site Number 076013, Vitoria, Brazil|Investigational Site Number 124003, Mississauga, Canada|Investigational Site Number 124002, St. Catharines, Canada|Investigational Site Number 124005, Toronto, Canada|Investigational Site Number 124009, Trois-Rivières, Canada|Investigational Site Number 124104, Victoria, Canada|Investigational Site Number 124012, Winnipeg, Canada|Investigational Site Number 152005, Osorno, Chile|Investigational Site Number 152012, Santiago, Chile|Investigational Site Number 152002, Santiago, Chile|Investigational Site Number 152011, Santiago, Chile|Investigational Site Number 152009, Santiago, Chile|Investigational Site Number 152001, Santiago, Chile|Investigational Site Number 152013, Santiago, Chile|Investigational Site Number 152008, Santiago, Chile|Investigational Site Number 152014, Talca, Chile|Investigational Site Number 152015, Temuco IX Region, Chile|Investigational Site Number 152004, Valdivia, Chile|Investigational Site Number 152006, Vina Del Mar, Chile|Investigational Site Number 152007, Viña Del Mar, Chile|Investigational Site Number 170005, Barranquilla, Colombia|Investigational Site Number 170004, Barranquilla, Colombia|Investigational Site Number 170001, Bogota, Colombia|Investigational Site Number 170008, Bogota, Colombia|Investigational Site Number 170006, Bogotá, Colombia|Investigational Site Number 170003, Bogotá, Colombia|Investigational Site Number 170007, Bucaramanga, Colombia|Investigational Site Number 170009, Bucaramanga, Colombia|Investigational Site Number 203009, Liberec, Czechia|Investigational Site Number 203004, Ostrava, Czechia|Investigational Site Number 203034, Pardubice, Czechia|Investigational Site Number 203001, Praha 2, Czechia|Investigational Site Number 203007, Praha 2, Czechia|Investigational Site Number 203011, Praha 2, Czechia|Investigational Site Number 203010, Praha 4, Czechia|Investigational Site Number 203002, Uherske Hradiste, Czechia|Investigational Site Number 203006, Zlin, Czechia|Investigational Site Number 218003, Cuenca, Ecuador|Investigational Site Number 218001, Guayaquil, Ecuador|Investigational Site Number 218002, Quito, Ecuador|Investigational Site Number 233001, Tallinn, Estonia|Investigational Site Number 233010, Tallinn, Estonia|Investigational Site Number 233002, Tallinn, Estonia|Investigational Site Number 246001, Helsinki, Finland|Investigational Site Number 246002, Hyvinkää, Finland|Investigational Site Number 246003, Pori, Finland|Investigational Site Number 246010, Riihimäki, Finland|Investigational Site Number 276011, Bad Nauheim, Germany|Investigational Site Number 276010, Berlin, Germany|Investigational Site Number 276007, Berlin, Germany|Investigational Site Number 276008, Berlin, Germany|Investigational Site Number 276014, Berlin, Germany|Investigational Site Number 276018, Deggingen, Germany|Investigational Site Number 276015, Halle/Saale, Germany|Investigational Site Number 276005, Hamburg, Germany|Investigational Site Number 276013, Hamburg, Germany|Investigational Site Number 276001, Herne, Germany|Investigational Site Number 276016, Leipzig, Germany|Investigational Site Number 276017, München, Germany|Investigational Site Number 276021, Osnabrück, Germany|Investigational Site Number 276020, Tübingen, Germany|Investigational Site Number 276019, Zerbst, Germany|Investigational Site Number 300002, Heraklion, Greece|Investigational Site Number 300003, Thessaloniki, Greece|Investigational Site Number 300005, Thessaloniki, Greece|Investigational Site Number 320002, Guatemala City, Guatemala|Investigational Site Number 320003, Guatemala City, Guatemala|Investigational Site Number 320001, Guatemala, Guatemala|Investigational Site Number 348006, Budapest, Hungary|Investigational Site Number 348014, Budapest, Hungary|Investigational Site Number 348025, Budapest, Hungary|Investigational Site Number 348022, Budapest, Hungary|Investigational Site Number 348010, Debrecen, Hungary|Investigational Site Number 348003, Debrecen, Hungary|Investigational Site Number 348021, Esztergom, Hungary|Investigational Site Number 348013, Györ, Hungary|Investigational Site Number 348009, Szolnok, Hungary|Investigational Site Number 348015, Szombathely, Hungary|Investigational Site Number 348004, Székesfehérvár, Hungary|Investigational Site Number 348005, Sátoraljaújhely, Hungary|Investigational Site Number 376001, Haifa, Israel|Investigational Site Number 376010, Haifa, Israel|Investigational Site Number 376011, Tel Aviv, Israel|Investigational Site Number 376002, Tel Hashomer, Israel|Investigational Site Number 380005, Genova, Italy|Investigational Site Number 410014, Anyang-Si, Korea, Republic of|Investigational Site Number 410006, Busan, Korea, Republic of|Investigational Site Number 410004, Daegu, Korea, Republic of|Investigational Site Number 410017, Daejeon, Korea, Republic of|Investigational Site Number 410005, Daejeon, Korea, Republic of|Investigational Site Number 410010, Gwangju, Korea, Republic of|Investigational Site Number 410001, Incheon, Korea, Republic of|Investigational Site Number 410009, Incheon, Korea, Republic of|Investigational Site Number 410011, Jeonju, Korea, Republic of|Investigational Site Number 410007, Seoul, Korea, Republic of|Investigational Site Number 410012, Seoul, Korea, Republic of|Investigational Site Number 410016, Seoul, Korea, Republic of|Investigational Site Number 410003, Seoul, Korea, Republic of|Investigational Site Number 410008, Suwon, Korea, Republic of|Investigational Site Number 440001, Kaunas, Lithuania|Investigational Site Number 440006, Klaipeda, Lithuania|Investigational Site Number 440002, Vilnius, Lithuania|Investigational Site Number 440007, Vilnius, Lithuania|Investigational Site Number 458001, Ipoh, Malaysia|Investigational Site Number 458002, Kuching, Malaysia|Investigational Site Number 484023, Chihuahua, Mexico|Investigational Site Number 484008, Durango, Mexico|Investigational Site Number 484018, Guadalajara, Mexico|Investigational Site Number 484002, Guadalajara, Mexico|Investigational Site Number 484035, Leon, Mexico|Investigational Site Number 484009, Merida, Mexico|Investigational Site Number 484007, Metepec, Mexico|Investigational Site Number 484010, Mexicali, Mexico|Investigational Site Number 484003, Mexico City, Mexico|Investigational Site Number 484019, Monterrey, Mexico|Investigational Site Number 484020, Monterrey, Mexico|Investigational Site Number 484005, Monterrey, Mexico|Investigational Site Number 484004, Mérida, Mexico|Investigational Site Number 484001, México, D.F., Mexico|Investigational Site Number 484017, México, Mexico|Investigational Site Number 484021, Queretaro, Mexico|Investigational Site Number 528010, Amsterdam, Netherlands|Investigational Site Number 554004, Christchurch, New Zealand|Investigational Site Number 554011, Nelson, New Zealand|Investigational Site Number 554007, Otahuhu, New Zealand|Investigational Site Number 554002, Rotorua, New Zealand|Investigational Site Number 554001, Timaru, New Zealand|Investigational Site Number 604001, Lima, Peru|Investigational Site Number 604010, Lima, Peru|Investigational Site Number 604008, Lima, Peru|Investigational Site Number 604009, Lima, Peru|Investigational Site Number 604006, Lima, Peru|Investigational Site Number 604012, Lima, Peru|Investigational Site Number 604013, Lima, Peru|Investigational Site Number 604007, Lima, Peru|Investigational Site Number 604005, Lima, Peru|Investigational Site Number 608003, Cebu City, Philippines|Investigational Site Number 608001, Manila, Philippines|Investigational Site Number 616014, Bialystok, Poland|Investigational Site Number 616002, Bialystok, Poland|Investigational Site Number 616003, Bialystok, Poland|Investigational Site Number 616019, Bydgoszcz, Poland|Investigational Site Number 616054, Bytom, Poland|Investigational Site Number 616015, Elblag, Poland|Investigational Site Number 616001, Krakow, Poland|Investigational Site Number 616005, Lublin, Poland|Investigational Site Number 616030, Lublin, Poland|Investigational Site Number 616018, Poznan, Poland|Investigational Site Number 616016, Szczecin, Poland|Investigational Site Number 616006, Torun, Poland|Investigational Site Number 616031, Warszawa, Poland|Investigational Site Number 616004, Warszawa, Poland|Investigational Site Number 616017, Warszawa, Poland|Investigational Site Number 616020, Wroclaw, Poland|Investigational Site Number 616012, Wroclaw, Poland|Investigational Site Number 620002, Lisboa, Portugal|Investigational Site Number 642006, Braila, Romania|Investigational Site Number 642010, Bucharest, Romania|Investigational Site Number 642021, Bucuresti, Romania|Investigational Site Number 642001, Bucuresti, Romania|Investigational Site Number 642020, Bucuresti, Romania|Investigational Site Number 642002, Bucuresti, Romania|Investigational Site Number 642005, Galati, Romania|Investigational Site Number 643006, Kemerovo, Russian Federation|Investigational Site Number 643017, Kemerovo, Russian Federation|Investigational Site Number 643020, Moscow, Russian Federation|Investigational Site Number 643001, Moscow, Russian Federation|Investigational Site Number 643002, Moscow, Russian Federation|Investigational Site Number 643021, Moscow, Russian Federation|Investigational Site Number 643004, Moscow, Russian Federation|Investigational Site Number 643012, Moscow, Russian Federation|Investigational Site Number 643031, Moscow, Russian Federation|Investigational Site Number 643030, Moscow, Russian Federation|Investigational Site Number 643009, Novosibirsk, Russian Federation|Investigational Site Number 643016, Ryazan, Russian Federation|Investigational Site Number 643008, Saint-Petersburg, Russian Federation|Investigational Site Number 643010, Samara, Russian Federation|Investigational Site Number 643011, Saratov, Russian Federation|Investigational Site Number 643007, St-Petersburg, Russian Federation|Investigational Site Number 643032, St-Petersburg, Russian Federation|Investigational Site Number 643014, St-Petersburg, Russian Federation|Investigational Site Number 643013, Ufa, Russian Federation|Investigational Site Number 710011, Cape Town, South Africa|Investigational Site Number 710007, Cape Town, South Africa|Investigational Site Number 710009, Cape Town, South Africa|Investigational Site Number 710003, Durban, South Africa|Investigational Site Number 710002, Durban, South Africa|Investigational Site Number 710001, Johannesburg, South Africa|Investigational Site Number 710004, Kempton Park, South Africa|Investigational Site Number 710005, Pretoria, South Africa|Investigational Site Number 710006, Pretoria, South Africa|Investigational Site Number 710010, Stellenbosch, South Africa|Investigational Site Number 724016, Barakaldo, Spain|Investigational Site Number 724015, Barcelona, Spain|Investigational Site Number 724014, Cádiz, Spain|Investigational Site Number 724009, La Coruña, Spain|Investigational Site Number 724001, Málaga, Spain|Investigational Site Number 724011, Sabadell, Spain|Investigational Site Number 724012, Santiago De Compostela, Spain|Investigational Site Number 724013, Santiago De Compostela, Spain|Investigational Site Number 724022, Sevilla, Spain|Investigational Site Number 724007, Sevilla, Spain|Investigational Site Number 752002, Uppsala, Sweden|Investigational Site Number 158006, Taichung, Taiwan|Investigational Site Number 158002, Taoyuan County, Taiwan|Investigational Site Number 764001, Bangkok, Thailand|Investigational Site Number 764003, Bangkok, Thailand|Investigational Site Number 792008, Gaziantep, Turkey|Investigational Site Number 804003, Dnipro, Ukraine|Investigational Site Number 804010, Kharkiv, Ukraine|Investigational Site Number 804013, Kharkiv, Ukraine|Investigational Site Number 804014, Kyiv, Ukraine|Investigational Site Number 804004, Kyiv, Ukraine|Investigational Site Number 804027, Kyiv, Ukraine|Investigational Site Number 804005, Lviv, Ukraine|Investigational Site Number 804006, Simferopol, Ukraine|Investigational Site Number 804011, Vinnytsya, Ukraine|Investigational Site Number 804009, Zaporizhzhya, Ukraine|Investigational Site Number 826004, Doncaster, United Kingdom|Investigational Site Number 826006, Edinburgh, United Kingdom|Investigational Site Number 826002, Leytonstone, United Kingdom|Investigational Site Number 826005, Southampton, United Kingdom","""Study Protocol"", https://ClinicalTrials.gov/ProvidedDocs/52/NCT01146652/Prot_000.pdf|""Statistical Analysis Plan"", https://ClinicalTrials.gov/ProvidedDocs/52/NCT01146652/SAP_001.pdf","https://ClinicalTrials.gov/show/NCT01146652"
468,"NCT01118728","Extension Study for Long Term Evaluation of SAR153191 (REGN88) in Patients With Ankylosing Spondylitis","SUSTAIN","Terminated","Has Results","Ankylosing Spondylitis","Drug: Sarilumab","Percentage of Participants Experiencing Any Treatment-emergent Adverse Event (TEAE), Serious Adverse Event (SAE) and Treatment Discontinuation|Percentage of Participants Who Achieved 20% Response in Ankylosing Spondylitis (AS) Working Group Criteria for Response (ASAS20)","Sanofi|Regeneron Pharmaceuticals","All","18 Years and older   (Adult, Older Adult)","Phase 2","223","Industry","Interventional","Allocation: N/A|Intervention Model: Single Group Assignment|Masking: None (Open Label)|Primary Purpose: Treatment","LTS11298|2010-019263-11","June 2010","December 2011","December 2011","May 7, 2010","June 21, 2017","June 21, 2017","Sanofi-Aventis Administrative Office, Bridgewater, New Jersey, United States|Sanofi-Aventis Administrative Office, Macquarie Park, New South Wales, Australia|Sanofi-Aventis Administrative Office, Wien, Austria|Sanofi-Aventis Administrative Office, Diegem, Belgium|Sanofi-Aventis Administrative Office, Laval, Canada|Sanofi-Aventis Administrative Office, Praha, Czechia|Sanofi-Aventis Administrative Office, Paris, France|Sanofi-Aventis Administrative Office, Budapest, Hungary|Sanofi-Aventis Administrative Office, Vilnius, Lithuania|Sanofi-Aventis Administrative Office, Gouda, Netherlands|Sanofi-Aventis Administrative Office, Warszawa, Poland|Sanofi-Aventis Administrative Office, Barcelona, Spain",,"https://ClinicalTrials.gov/show/NCT01118728"
469,"NCT01061736","Evaluation of Sarilumab (SAR153191/REGN88) on Top of Methotrexate in Rheumatoid Arthritis Patients","RA-MOBILITY","Completed","Has Results","Rheumatoid Arthritis","Drug: Sarilumab|Drug: Placebo (for sarilumab)|Drug: Methotrexate|Drug: Folic Acid","Part A: Percentage of Participants Achieving American College of Rheumatology 20% (ACR20) Response at Week 12|Part B: Percentage of Participants Achieving ACR20 Response at Week 24|Part B: Change From Baseline in Health Assessment Question Disability Index (HAQ-DI) at Week 16|Part B: Change From Baseline in Van Der Heijde Modified Total Sharp Score (mTSS) at Week 52|Part B: Percentage of Participants Achieving a Major Clinical Response at Week 52","Sanofi|Regeneron Pharmaceuticals","All","18 Years to 75 Years   (Adult, Older Adult)","Phase 2|Phase 3","1675","Industry","Interventional","Allocation: Randomized|Intervention Model: Parallel Assignment|Masking: Triple (Participant, Investigator, Outcomes Assessor)|Primary Purpose: Treatment","EFC11072|2009-016266-90","March 2010","October 2013","October 2013","February 3, 2010","June 28, 2017","June 28, 2017","Investigational Site Number 840070, Anniston, Alabama, United States|Investigational Site Number 840004, Birmingham, Alabama, United States|Investigational Site Number 840072, Gilbert, Arizona, United States|Investigational Site Number 840029, Beverly Hills, California, United States|Investigational Site Number 840007, Palm Desert, California, United States|Investigational Site Number 840008, San Francisco, California, United States|Investigational Site Number 840021, Santa Maria, California, United States|Investigational Site Number 840049, Upland, California, United States|Investigational Site Number 840050, Dunedin, Florida, United States|Investigational Site Number 840041, Jacksonville, Florida, United States|Investigational Site Number 840067, Jupiter, Florida, United States|Investigational Site Number 840048, Miami, Florida, United States|Investigational Site Number 840006, Orlando, Florida, United States|Investigational Site Number 840063, Palm Harbor, Florida, United States|Investigational Site Number 840060, Sarasota, Florida, United States|Investigational Site Number 840003, Atlanta, Georgia, United States|Investigational Site Number 840028, Decatur, Georgia, United States|Investigational Site Number 840027, Marietta, Georgia, United States|Investigational Site Number 840018, Idaho Falls, Idaho, United States|Investigational Site Number 840046, Chicago, Illinois, United States|Investigational Site Number 840015, Lexington, Kentucky, United States|Investigational Site Number 840073, Cumberland, Maryland, United States|Investigational Site Number 840055, Frederick, Maryland, United States|Investigational Site Number 840013, Wheaton, Maryland, United States|Investigational Site Number 840066, Saint Louis, Missouri, United States|Investigational Site Number 840071, Omaha, Nebraska, United States|Investigational Site Number 840056, New York, New York, United States|Investigational Site Number 840068, Hickory, North Carolina, United States|Investigational Site Number 840044, Toledo, Ohio, United States|Investigational Site Number 840002, Oklahoma City, Oklahoma, United States|Investigational Site Number 840011, Tulsa, Oklahoma, United States|Investigational Site Number 840065, Tulsa, Oklahoma, United States|Investigational Site Number 840010, Bethlehem, Pennsylvania, United States|Investigational Site Number 840009, Duncansville, Pennsylvania, United States|Investigational Site Number 840062, Reading, Pennsylvania, United States|Investigational Site Number 840058, Columbia, South Carolina, United States|Investigational Site Number 840016, North Charleston, South Carolina, United States|Investigational Site Number 840025, Jackson, Tennessee, United States|Investigational Site Number 840001, Dallas, Texas, United States|Investigational Site Number 840022, Dallas, Texas, United States|Investigational Site Number 840012, Dallas, Texas, United States|Investigational Site Number 840020, Houston, Texas, United States|Investigational Site Number 840069, Lubbock, Texas, United States|Investigational Site Number 840074, Mesquite, Texas, United States|Investigational Site Number 840061, Tacoma, Washington, United States|Investigational Site Number 032005, Buenos Aires, Argentina|Investigational Site Number 032007, Buenos Aires, Argentina|Investigational Site Number 032008, Buenos Aires, Argentina|Investigational Site Number 032006, Caba, Argentina|Investigational Site Number 032002, Cordoba, Argentina|Investigational Site Number 032003, Córdoba, Argentina|Investigational Site Number 032012, Mar Del Plata, Argentina|Investigational Site Number 032011, Quilmes, Argentina|Investigational Site Number 032010, Ramos Mejia, Argentina|Investigational Site Number 032001, Rosario, Argentina|Investigational Site Number 032004, Tucuman, Argentina|Investigational Site Number 032009, Zarate, Argentina|Investigational Site Number 036003, Camperdown, Australia|Investigational Site Number 036005, Clayton, Australia|Investigational Site Number 036002, East Malvern, Australia|Investigational Site Number 036012, Fitzroy, Australia|Investigational Site Number 036010, Garran, Australia|Investigational Site Number 036004, Heidelberg West, Australia|Investigational Site Number 036009, Herston, Australia|Investigational Site Number 036001, Maroochydore, Australia|Investigational Site Number 036006, St Leonards, Australia|Investigational Site Number 036011, Sydney, Australia|Investigational Site Number 036014, Victoria Park, Australia|Investigational Site Number 036007, Woodville, Australia|Investigational Site Number 040001, Graz, Austria|Investigational Site Number 040002, Wien, Austria|Investigational Site Number 112002, Minsk, Belarus|Investigational Site Number 112001, Minsk, Belarus|Investigational Site Number 056003, Genk, Belgium|Investigational Site Number 056001, Liège, Belgium|Investigational Site Number 076008, Campinas, Brazil|Investigational Site Number 076012, Campinas, Brazil|Investigational Site Number 076001, Curitiba, Brazil|Investigational Site Number 076006, Goiania, Brazil|Investigational Site Number 076010, Juiz De Fora, Brazil|Investigational Site Number 076004, Porto Alegre, Brazil|Investigational Site Number 076005, Rio De Janeiro, Brazil|Investigational Site Number 076011, Salvador, Brazil|Investigational Site Number 076002, Sao Paulo, Brazil|Investigational Site Number 076003, Sao Paulo, Brazil|Investigational Site Number 076013, Vitoria, Brazil|Investigational Site Number 124004, Burlington, Canada|Investigational Site Number 124003, Mississauga, Canada|Investigational Site Number 124008, Newmarket, Canada|Investigational Site Number 124002, St. Catharines, Canada|Investigational Site Number 124005, Toronto, Canada|Investigational Site Number 124001, Toronto, Canada|Investigational Site Number 124012, Winnipeg, Canada|Investigational Site Number 152005, Osorno, Chile|Investigational Site Number 152010, Puerto Montt, Chile|Investigational Site Number 152012, Santiago, Chile|Investigational Site Number 152001, Santiago, Chile|Investigational Site Number 152002, Santiago, Chile|Investigational Site Number 152008, Santiago, Chile|Investigational Site Number 152009, Santiago, Chile|Investigational Site Number 152011, Santiago, Chile|Investigational Site Number 152013, Santiago, Chile|Investigational Site Number 152014, Talca, Chile|Investigational Site Number 152004, Valdivia, Chile|Investigational Site Number 152006, Vina Del Mar, Chile|Investigational Site Number 152007, Viña Del Mar, Chile|Investigational Site Number 170004, Barranquilla, Colombia|Investigational Site Number 170001, Bogota, Colombia|Investigational Site Number 170008, Bogota, Colombia|Investigational Site Number 170003, Bogotá, Colombia|Investigational Site Number 170006, Bogotá, Colombia|Investigational Site Number 170007, Bucaramanga, Colombia|Investigational Site Number 170009, Bucaramanga, Colombia|Investigational Site Number 170002, Medellin, Colombia|Investigational Site Number 203005, Brno, Czechia|Investigational Site Number 203004, Hlucin, Czechia|Investigational Site Number 203001, Praha 2, Czechia|Investigational Site Number 203002, Uherske Hradiste, Czechia|Investigational Site Number 818001, Cairo, Egypt|Investigational Site Number 818002, Cairo, Egypt|Investigational Site Number 233001, Tallinn, Estonia|Investigational Site Number 233002, Tallinn, Estonia|Investigational Site Number 246001, Helsinki, Finland|Investigational Site Number 246002, Hyvinkää, Finland|Investigational Site Number 246003, Pori, Finland|Investigational Site Number 276007, Berlin, Germany|Investigational Site Number 276008, Berlin, Germany|Investigational Site Number 276004, Erlangen, Germany|Investigational Site Number 276003, Frankfurt Am Main, Germany|Investigational Site Number 276015, Halle/Saale, Germany|Investigational Site Number 276005, Hamburg, Germany|Investigational Site Number 276013, Hamburg, Germany|Investigational Site Number 276012, Heidelberg, Germany|Investigational Site Number 276001, Herne, Germany|Investigational Site Number 276006, Hildesheim, Germany|Investigational Site Number 300001, Athens, Greece|Investigational Site Number 300002, Heraklion, Greece|Investigational Site Number 300003, Thessaloniki, Greece|Investigational Site Number 348006, Budapest, Hungary|Investigational Site Number 348014, Budapest, Hungary|Investigational Site Number 348003, Debrecen, Hungary|Investigational Site Number 348010, Debrecen, Hungary|Investigational Site Number 348011, Eger, Hungary|Investigational Site Number 348013, Gy?r, Hungary|Investigational Site Number 348015, Szombathely, Hungary|Investigational Site Number 348005, Sátoraljaújhely, Hungary|Investigational Site Number 348004, Veszprém, Hungary|Investigational Site Number 356015, Ahmedabad, India|Investigational Site Number 356007, Bangalore, India|Investigational Site Number 356003, Chennai, India|Investigational Site Number 356012, Hyderabad, India|Investigational Site Number 356005, Hyderabad, India|Investigational Site Number 356011, Lucknow, India|Investigational Site Number 356013, Lucknow, India|Investigational Site Number 356001, Maharashtra, India|Investigational Site Number 356010, Mumbai, India|Investigational Site Number 356004, Mumbai, India|Investigational Site Number 356002, New Delhi, India|Investigational Site Number 356008, New Delhi, India|Investigational Site Number 410014, Anyang, Korea, Republic of|Investigational Site Number 410006, Busan, Korea, Republic of|Investigational Site Number 410004, Daegu, Korea, Republic of|Investigational Site Number 410013, Daegu, Korea, Republic of|Investigational Site Number 410005, Daejeon, Korea, Republic of|Investigational Site Number 410010, Gwangju, Korea, Republic of|Investigational Site Number 410009, Incheon, Korea, Republic of|Investigational Site Number 410001, Incheon, Korea, Republic of|Investigational Site Number 410011, Jeonju, Korea, Republic of|Investigational Site Number 410007, Seoul, Korea, Republic of|Investigational Site Number 410012, Seoul, Korea, Republic of|Investigational Site Number 410003, Seoul, Korea, Republic of|Investigational Site Number 410002, Seoul, Korea, Republic of|Investigational Site Number 410008, Suwon, Korea, Republic of|Investigational Site Number 440001, Kaunas, Lithuania|Investigational Site Number 440002, Vilnius, Lithuania|Investigational Site Number 458001, Ipoh, Malaysia|Investigational Site Number 458002, Kuching, Malaysia|Investigational Site Number 458003, Putrajaya, Malaysia|Investigational Site Number 484008, Durango, Mexico|Investigational Site Number 484002, Guadalajara, Mexico|Investigational Site Number 484004, Merida, Mexico|Investigational Site Number 484009, Merida, Mexico|Investigational Site Number 484007, Metepec, Mexico|Investigational Site Number 484003, Mexico City, Mexico|Investigational Site Number 484001, Mexico, D.F., Mexico|Investigational Site Number 484005, Monterrey, Mexico|Investigational Site Number 528002, Heerlen, Netherlands|Investigational Site Number 554004, Christchurch, New Zealand|Investigational Site Number 554002, Rotorua, New Zealand|Investigational Site Number 554003, Tauranga, New Zealand|Investigational Site Number 554001, Timaru, New Zealand|Investigational Site Number 578004, Kristiansand, Norway|Investigational Site Number 578006, Tønsberg, Norway|Investigational Site Number 608003, Cebu City, Philippines|Investigational Site Number 608001, Manila, Philippines|Investigational Site Number 608002, Manila, Philippines|Investigational Site Number 616002, Bialystok, Poland|Investigational Site Number 616003, Bialystok, Poland|Investigational Site Number 616001, Krakow, Poland|Investigational Site Number 616005, Lublin, Poland|Investigational Site Number 616006, Torun, Poland|Investigational Site Number 616004, Warszawa, Poland|Investigational Site Number 616012, Wroclaw, Poland|Investigational Site Number 620003, Aveiro, Portugal|Investigational Site Number 620001, Lisboa, Portugal|Investigational Site Number 620002, Lisboa, Portugal|Investigational Site Number 642006, Braila, Romania|Investigational Site Number 642004, Bucharest, Romania|Investigational Site Number 642010, Bucharest, Romania|Investigational Site Number 642001, Bucuresti, Romania|Investigational Site Number 642002, Bucuresti, Romania|Investigational Site Number 642003, Bucuresti, Romania|Investigational Site Number 642005, Galati, Romania|Investigational Site Number 642008, Ploiesti, Romania|Investigational Site Number 643017, Kemerovo, Russian Federation|Investigational Site Number 643006, Kemerovo, Russian Federation|Investigational Site Number 643004, Moscow, Russian Federation|Investigational Site Number 643020, Moscow, Russian Federation|Investigational Site Number 643001, Moscow, Russian Federation|Investigational Site Number 643002, Moscow, Russian Federation|Investigational Site Number 643012, Moscow, Russian Federation|Investigational Site Number 643009, Novosibirsk, Russian Federation|Investigational Site Number 643016, Ryazan, Russian Federation|Investigational Site Number 643014, Saint-Petersburg, Russian Federation|Investigational Site Number 643010, Samara, Russian Federation|Investigational Site Number 643011, Saratov, Russian Federation|Investigational Site Number 643007, St-Petersburg, Russian Federation|Investigational Site Number 643008, St-Petersburg, Russian Federation|Investigational Site Number 643013, Ufa, Russian Federation|Investigational Site Number 710011, Cape Town, South Africa|Investigational Site Number 710007, Cape Town, South Africa|Investigational Site Number 710009, Cape Town, South Africa|Investigational Site Number 710003, Durban, South Africa|Investigational Site Number 710002, Durban, South Africa|Investigational Site Number 710001, Johannesburg, South Africa|Investigational Site Number 710004, Kempton Park, South Africa|Investigational Site Number 710005, Pretoria, South Africa|Investigational Site Number 710006, Pretoria, South Africa|Investigational Site Number 710008, Pretoria, South Africa|Investigational Site Number 710010, Stellenbosch, South Africa|Investigational Site Number 724010, Barcelona, Spain|Investigational Site Number 724009, La Coruña, Spain|Investigational Site Number 724011, Sabadell, Spain|Investigational Site Number 724012, Santiago De Compostela, Spain|Investigational Site Number 724007, Sevilla, Spain|Investigational Site Number 158002, Linkou, Taiwan|Investigational Site Number 158001, Taipei, Taiwan|Investigational Site Number 764001, Bangkok, Thailand|Investigational Site Number 764003, Bangkok, Thailand|Investigational Site Number 792003, Adana, Turkey|Investigational Site Number 792002, Ankara, Turkey|Investigational Site Number 792005, Ankara, Turkey|Investigational Site Number 792004, Antalya, Turkey|Investigational Site Number 792001, Izmir, Turkey|Investigational Site Number 804003, Dnipropetrovsk, Ukraine|Investigational Site Number 804002, Donetsk, Ukraine|Investigational Site Number 804010, Kharkov, Ukraine|Investigational Site Number 804008, Kyiv, Ukraine|Investigational Site Number 804004, Kyiv, Ukraine|Investigational Site Number 804005, Lviv, Ukraine|Investigational Site Number 804006, Simferopol, Ukraine|Investigational Site Number 804009, Zaporizhzhia, Ukraine",,"https://ClinicalTrials.gov/show/NCT01061736"
470,"NCT01061723","Dose Ranging Study to Evaluate the Efficacy and Safety of SAR153191 (REGN88) in Patients With Ankylosing Spondylitis","ALIGN","Completed","Has Results","Ankylosing Spondylitis","Drug: Sarilumab|Drug: Placebo","Percentage of Participants Who Achieved 20% Response According to the Assessment in Ankylosing Spondylitis (AS) Working Group Criteria for Response (ASAS20) at Week 12|Percentage of Participants Who Achieved 40% Response According to the Assessment in AS Working Group Criteria for Response (ASAS40) at Week 12|Percentage of Participants Who Achieved Partial Remission According to the Assessment in AS Working Group Criteria for Response (ASAS) at Week 12|Change From Baseline in Ankylosing Spondylitis Disease Activity Score (ASDAS) at Week 12|Change From Baseline in BASDAI Score at Week 12|Change From Baseline in Range of Motion Assessed by the Bath AS Metrology Index (BASMI) at Week 12|Change From Baseline in Magnetic Resonance Imaging (MRI) Score of the Spine Assessed by the Berlin Modification of the AS Spine MRI-active (ASspiMRI-a) Score at Week 12|Percentage of Participants Who Achieved ASAS 5/6 Improvement Criteria at Week 12|Change From Baseline in Chest Expansion at Week 12|Change From Baseline in Swollen Joint Index at Week 12|Change From Baseline in Hs-CRP at Week 12|Change From Baseline in ASAS Individual Components at Week 12","Sanofi|Regeneron Pharmaceuticals","All","18 Years to 75 Years   (Adult, Older Adult)","Phase 2","301","Industry","Interventional","Allocation: Randomized|Intervention Model: Parallel Assignment|Masking: Triple (Participant, Investigator, Outcomes Assessor)|Primary Purpose: Treatment","DRI11073|2009-016068-35","February 2010","June 2011","June 2011","February 3, 2010","August 8, 2017","August 8, 2017","Investigational Site Number 840006, Birmingham, Alabama, United States|Investigational Site Number 840033, Anaheim, California, United States|Investigational Site Number 840027, Los Angeles, California, United States|Investigational Site Number 840007, San Diego, California, United States|Investigational Site Number 840013, San Francisco, California, United States|Investigational Site Number 840017, Upland, California, United States|Investigational Site Number 840009, Boca Raton, Florida, United States|Investigational Site Number 840001, Naples, Florida, United States|Investigational Site Number 840032, Orlando, Florida, United States|Investigational Site Number 840015, Boise, Idaho, United States|Investigational Site Number 840021, Rock Island, Illinois, United States|Investigational Site Number 840018, Kansas City, Kansas, United States|Investigational Site Number 840003, Wheaton, Maryland, United States|Investigational Site Number 840029, Worcester, Massachusetts, United States|Investigational Site Number 840008, Lansing, Michigan, United States|Investigational Site Number 840002, Saint Louis, Missouri, United States|Investigational Site Number 840028, Freehold, New Jersey, United States|Investigational Site Number 840016, Albany, New York, United States|Investigational Site Number 840036, Syracuse, New York, United States|Investigational Site Number 840010, Toledo, Ohio, United States|Investigational Site Number 840005, Oklahoma City, Oklahoma, United States|Investigational Site Number 840023, Bethlehem, Pennsylvania, United States|Investigational Site Number 840014, Duncansville, Pennsylvania, United States|Investigational Site Number 840004, Dallas, Texas, United States|Investigational Site Number 840030, Houston, Texas, United States|Investigational Site Number 840034, Chesapeake, Virginia, United States|Investigational Site Number 036001, East Malvern, Australia|Investigational Site Number 036003, Hobart, Australia|Investigational Site Number 036004, Shenton Park, Australia|Investigational Site Number 036002, Woolloongabba, Australia|Investigational Site Number 040001, Graz, Austria|Investigational Site Number 040002, Wien, Austria|Investigational Site Number 056003, Brussels, Belgium|Investigational Site Number 056005, Genk, Belgium|Investigational Site Number 056001, Gent, Belgium|Investigational Site Number 056002, Leuven, Belgium|Investigational Site Number 056004, Liège, Belgium|Investigational Site Number 124007, London, Canada|Investigational Site Number 124004, Montreal, Canada|Investigational Site Number 124008, Newmarket, Canada|Investigational Site Number 124003, Pointe-Claire, Canada|Investigational Site Number 124001, Quebec, Canada|Investigational Site Number 124006, Saskatoon, Canada|Investigational Site Number 124005, Toronto, Canada|Investigational Site Number 124009, Trois-Rivières, Canada|Investigational Site Number 124002, Vancouver, Canada|Investigational Site Number 124010, Vancouver, Canada|Investigational Site Number 203003, Brno, Czechia|Investigational Site Number 203005, Hlucin, Czechia|Investigational Site Number 203002, Hradec Kralove, Czechia|Investigational Site Number 203001, Praha 2, Czechia|Investigational Site Number 203004, Uherske Hradiste, Czechia|Investigational Site Number 250001, Besancon, France|Investigational Site Number 250005, Bordeaux, France|Investigational Site Number 250002, Creteil Cedex, France|Investigational Site Number 250003, Paris, France|Investigational Site Number 276002, Berlin, Germany|Investigational Site Number 276004, Erlangen, Germany|Investigational Site Number 276003, Frankfurt Am Main, Germany|Investigational Site Number 276005, Hamburg, Germany|Investigational Site Number 276001, Herne, Germany|Investigational Site Number 348001, Budapest, Hungary|Investigational Site Number 348003, Debrecen, Hungary|Investigational Site Number 348005, Sátoraljaújhely, Hungary|Investigational Site Number 348004, Veszprém, Hungary|Investigational Site Number 440001, Kaunas, Lithuania|Investigational Site Number 440002, Vilnius, Lithuania|Investigational Site Number 528001, Amsterdam, Netherlands|Investigational Site Number 528002, Nijmegen, Netherlands|Investigational Site Number 616002, Bialystok, Poland|Investigational Site Number 616001, Krakow, Poland|Investigational Site Number 616004, Lublin, Poland|Investigational Site Number 616005, Torun, Poland|Investigational Site Number 616003, Warszawa, Poland|Investigational Site Number 724005, Barcelona, Spain|Investigational Site Number 724004, La Coruña, Spain|Investigational Site Number 724002, Madrid, Spain|Investigational Site Number 724001, Sevilla, Spain|Investigational Site Number 792002, Ankara, Turkey|Investigational Site Number 792001, Izmir, Turkey",,"https://ClinicalTrials.gov/show/NCT01061723"
471,"NCT01012973","Vascular Endothelial Growth Factor (VEGF) Trap-Eye: Investigation of Efficacy and Safety in Central Retinal Vein Occlusion (CRVO)","GALILEO","Completed","Has Results","Retinal Vein Occlusion","Biological: Aflibercept Injection (EYLEA, VEGF Trap-Eye, BAY86-5321)|Other: Sham treatment","Percentage of Participants Who Gained at Least 15 Letters in BCVA as Measured by ETDRS Letter Score Compared With Baseline at Week 24 With Discontinued Participants Before Week 24 Evaluated as Failures|Change From Baseline in BCVA as Measured by Early Treatment Diabetic Retinopathy Study (ETDRS) Letter Score at Week 24 - Last Observation Carried Forward (LOCF)|Change From Baseline in Central Retinal Thickness (CRT) at Week 24 - LOCF|Percentage of Participants Who Developed Neovascularization During the First 24 Weeks|Change From Baseline in National Eye Institute 25-item Visual Function Questionnaire (NEI VFQ-25) Total Score at Week 24 - LOCF|Change From Baseline in European Five-dimensional Health Scale (EQ-5D) Score at Week 24 - LOCF","Bayer|Regeneron Pharmaceuticals","All","18 Years and older   (Adult, Older Adult)","Phase 3","177","Industry","Interventional","Allocation: Randomized|Intervention Model: Parallel Assignment|Masking: Triple (Participant, Investigator, Outcomes Assessor)|Primary Purpose: Treatment","14130|2009-010973-19","October 2009","February 2011","February 2012","November 13, 2009","November 22, 2012","November 2, 2014","Chatswood, New South Wales, Australia|Parramatta, New South Wales, Australia|Sydney, New South Wales, Australia|Westmead, New South Wales, Australia|East Melbourne, Victoria, Australia|Nedlands, Western Australia, Australia|Innsbruck, Austria|Linz, Austria|Wien, Austria|Paris, Cedex 12, France|Nantes, Cedex 1, France|Bordeaux, France|Dijon, France|Marseille, France|Paris, France|Freiburg, Baden-Württemberg, Germany|Heidelberg, Baden-Württemberg, Germany|Tübingen, Baden-Württemberg, Germany|München, Bayern, Germany|Regensburg, Bayern, Germany|Darmstadt, Hessen, Germany|Frankfurt, Hessen, Germany|Marburg, Hessen, Germany|Göttingen, Niedersachsen, Germany|Aachen, Nordrhein-Westfalen, Germany|Bonn, Nordrhein-Westfalen, Germany|Essen, Nordrhein-Westfalen, Germany|Köln, Nordrhein-Westfalen, Germany|Münster, Nordrhein-Westfalen, Germany|Ludwigshafen, Rheinland-Pfalz, Germany|Mainz, Rheinland-Pfalz, Germany|Homburg, Saarland, Germany|Chemnitz, Sachsen, Germany|Dresden, Sachsen, Germany|Dresden, Sachsen, Germany|Leipzig, Sachsen, Germany|Kiel, Schleswig-Holstein, Germany|Lübeck, Schleswig-Holstein, Germany|Berlin, Germany|Hamburg, Germany|Budapest, Hungary|Budapest, Hungary|Budapest, Hungary|Debrecen, Hungary|Veszprem, Hungary|Zalaegerszeg, Hungary|Ancona, Italy|Bari, Italy|Catania, Italy|Firenze, Italy|Milano, Italy|Milano, Italy|Milano, Italy|Padova, Italy|Roma, Italy|Roma, Italy|Torino, Italy|Nagoya, Aichi, Japan|Nagoya, Aichi, Japan|Urayasu, Chiba, Japan|Suita, Osaka, Japan|Chiyoda-ku, Tokyo, Japan|Kyoto, Japan|Seongnam-si, Gyeonggido, Korea, Republic of|Incheon, Korea, Republic of|Seoul, Korea, Republic of|Seoul, Korea, Republic of|Seoul, Korea, Republic of|Seoul, Korea, Republic of|Riga, Latvia|Riga, Latvia|Singapore, Singapore|Singapore, Singapore",,"https://ClinicalTrials.gov/show/NCT01012973"
472,"NCT00921661","Study of Intravenous Aflibercept in Combination With FOLFIRI in Japanese Patients With Metastatic Colorectal Cancer",,"Completed","No Results Available","Colorectal Neoplasms|Neoplasm Metastasis","Drug: AVE0005 (aflibercept)","Dose-limiting toxicity (DLT) combination with FOLFIRI|physical examination, laboratory safety tests, adverse events|Pharmacokinetics|Tumor burden, endogenous free VEGF|Immunogenicity","Sanofi|Regeneron Pharmaceuticals","All","20 Years and older   (Adult, Older Adult)","Phase 1","16","Industry","Interventional","Allocation: Non-Randomized|Intervention Model: Single Group Assignment|Masking: None (Open Label)|Primary Purpose: Treatment","TCD10794","June 2009","June 2012","June 2012","June 16, 2009",,"November 9, 2012","Sanofi-Aventis Administrative Office, Tokyo, Japan",,"https://ClinicalTrials.gov/show/NCT00921661"
473,"NCT00876044","A Study to Evaluate the Effects of Aflibercept on QTc Interval in Cancer Patients","QUTIE","Completed","No Results Available","Cancer","Drug: aflibercept (AVE0005)|Drug: placebo","ECG parameters (QTcF interval)|Other ECG parameters|Clinical safety (adverse events, serious adverse events)|Pharmacokinetic parameters","Sanofi|Regeneron Pharmaceuticals","All","18 Years and older   (Adult, Older Adult)","Phase 1","88","Industry","Interventional","Allocation: Randomized|Intervention Model: Parallel Assignment|Masking: Quadruple (Participant, Care Provider, Investigator, Outcomes Assessor)|Primary Purpose: Treatment","TES10897|EudraCT:2008-006796-80","April 2009","February 2010","November 2010","April 6, 2009",,"May 5, 2016","Sanofi-Aventis Administrative Office, Bridgewater, New Jersey, United States|Sanofi-Aventis Administrative Office, Diegem, Belgium|Sanofi-Aventis Administrative Office, Horsholm, Denmark|Sanofi-Aventis Administrative Office, Berlin, Germany|Sanofi-Aventis Administrative Office, Milano, Italy|Sanofi-Aventis Administrative Office, Bucuresti, Romania|Sanofi-Aventis Administrative Office, Istanbul, Turkey",,"https://ClinicalTrials.gov/show/NCT00876044"
474,"NCT00644124","Aflibercept and Standard Chemotherapy (R-CHOP) in First Line of Non Hodgkin B-cell Lymphoma",,"Completed","No Results Available","Lymphoma, Non-Hodgkin","Drug: aflibercept","selected dose of aflibercept based on Dose Limiting Toxicities observed|Adverse events|Response rate|Progression free survival|Biomarkers","Sanofi|Regeneron Pharmaceuticals","All","18 Years and older   (Adult, Older Adult)","Phase 1","25","Industry","Interventional","Allocation: Non-Randomized|Intervention Model: Parallel Assignment|Masking: None (Open Label)|Primary Purpose: Treatment","TCD10173|EudraCT 2007-003737-16","March 2008","October 2011","October 2011","March 26, 2008",,"May 6, 2016","Sanofi-Aventis Administrative Office, Paris, France",,"https://ClinicalTrials.gov/show/NCT00644124"
475,"NCT00637377","Vascular Endothelial Growth Factor (VEGF) Trap-Eye: Investigation of Efficacy and Safety in Wet Age-Related Macular Degeneration (AMD)","VIEW 2","Completed","Has Results","Macular Degeneration","Drug: Ranibizumab|Biological: Aflibercept Injection (EYLEA, VEGF Trap-Eye, BAY86-5321)","Percentage of Participants Who Maintained Vision at Week 52 - Last Observation Carried Forward (LOCF)|Mean Change From Baseline in Best Corrected Visual Acuity (BCVA) as Measured by ETDRS Letter Score at Week 52 - LOCF|Percentage of Participants Who Gained at Least 15 Letters of Vision in the ETDRS Letter Score in the Study Eye at Week 52 - LOCF|Mean Change From Baseline in National Eye Institute 25-item Visual Function Questionnaire (NEI VFQ-25) Total Score at Week 52 - LOCF|Mean Change From Baseline in Choroidal Neovascularization (CNV) Area at Week 52 - LOCF","Bayer|Regeneron Pharmaceuticals","All","50 Years and older   (Adult, Older Adult)","Phase 3","1240","Industry","Interventional","Allocation: Randomized|Intervention Model: Parallel Assignment|Masking: Quadruple (Participant, Care Provider, Investigator, Outcomes Assessor)|Primary Purpose: Treatment","91689|2007-000583-25","April 2008","September 2010","August 2011","March 18, 2008","January 23, 2012","December 12, 2014","Buenos Aires, Ciudad Auton. de Buenos Aires, Argentina|Buenos Aires, Ciudad Auton. de Buenos Aires, Argentina|Buenos Aires, Ciudad Auton. de Buenos Aires, Argentina|Buenos Aires, Ciudad Auton. de Buenos Aires, Argentina|Rosario, Santa Fe, Argentina|Córdoba, Argentina|Chatswood, New South Wales, Australia|Sydney, New South Wales, Australia|Westmead, New South Wales, Australia|East Melbourne, Victoria, Australia|Parkville, Victoria, Australia|Nedlands, Western Australia, Australia|Parramatta, Australia|Innsbruck, Austria|Linz, Austria|Wien, Austria|Liege, Belgium|Ribeirão Preto, Sao Paulo, Brazil|São Paulo, Sao Paulo, Brazil|Minas Gerais, Brazil|Sao Paulo, Brazil|Medellín, Antioquia, Colombia|Cali, Cauca, Colombia|Bogota, Distrito Capital de Bogotá, Colombia|Brno, Czech Republic|Olomouc, Czech Republic|Praha 10, Czech Republic|Praha 4, Czech Republic|Usti nad Labem, Czech Republic|Paris, Cedex 12, France|Nantes, Cedex 1, France|Besancon, France|Bordeaux, France|Dijon, France|Lyon, France|Lyon, France|Marseille, France|Paris, France|Paris, France|Freiburg, Baden-Württemberg, Germany|Heidelberg, Baden-Württemberg, Germany|Tübingen, Baden-Württemberg, Germany|München, Bayern, Germany|Regensburg, Bayern, Germany|Darmstadt, Hessen, Germany|Aachen, Nordrhein-Westfalen, Germany|Bonn, Nordrhein-Westfalen, Germany|Essen, Nordrhein-Westfalen, Germany|Köln, Nordrhein-Westfalen, Germany|Münster, Nordrhein-Westfalen, Germany|Ludwigshafen, Rheinland-Pfalz, Germany|Mainz, Rheinland-Pfalz, Germany|Homburg, Saarland, Germany|Dresden, Sachsen, Germany|Dresden, Sachsen, Germany|Leipzig, Sachsen, Germany|Kiel, Schleswig-Holstein, Germany|Lübeck, Schleswig-Holstein, Germany|Berlin, Germany|Hamburg, Germany|Budapest, Hungary|Budapest, Hungary|Budapest, Hungary|Veszprem, Hungary|Ahemedabad - 4, Gujrat, India|Wadala, Mumbai, Maharashtra, India|Chennai, Tamil Nadu, India|Coimbatore, Tamil Nadu, India|Madurai, Tamil Nadu, India|Pondicherry, Tamil Nadu, India|Bangalore, India|Chandigarh, India|Hyderabad, India|Kerala, India|Kolkata, India|Mumbai, India|New Delhi, India|New Delhi, India|Orissa, India|Afula, Israel|Beer Sheva, Israel|Haifa, Israel|Jerusalem, Israel|Kfar Saba, Israel|Petach Tikva, Israel|Rehovot, Israel|Tel Aviv, Israel|Tel Hashomer, Israel|Zrifin, Israel|Ancona, Italy|Bari, Italy|Catania, Italy|Genova, Italy|Milano, Italy|Milano, Italy|Milano, Italy|Padova, Italy|Roma, Italy|Roma, Italy|Roma, Italy|Torino, Italy|Udine, Italy|Varese, Italy|Verona, Italy|Nagoya, Aichi, Japan|Nagoya, Aichi, Japan|Urayasu, Chiba, Japan|Maebashi, Gunma, Japan|Sapporo, Hokkaido, Japan|Kita, Kagawa, Japan|Hirakata, Osaka, Japan|Suita, Osaka, Japan|Otsu, Shiga, Japan|Chiyoda-ku, Tokyo, Japan|Shinjuku-ku, Tokyo, Japan|Fukuoka, Japan|Fukushima, Japan|Kagoshima, Japan|Kyoto, Japan|Seongnam, Gyeonggido, Korea, Republic of|Incheon, Korea, Republic of|Seoul, Korea, Republic of|Seoul, Korea, Republic of|Seoul, Korea, Republic of|Seoul, Korea, Republic of|Riga, Latvia|Riga, Latvia|Riga, Latvia|Mexico City, Distrito Federal, Mexico|Zapopan, Jalisco, Mexico|Metepec, México, Mexico|Monterrey, Nuevo Leon, Mexico|Monterrey, Nuevo Leon, Mexico|Chihuahua, Mexico|Mexico City, Mexico|México D.F., Mexico|Leiden, ZA, Netherlands|Amsterdam, Netherlands|Groningen, Netherlands|Nijmegen, Netherlands|Rotterdam, Netherlands|Bydgoszcz, Poland|Gdansk, Poland|Katowice, Poland|Poznan, Poland|Warszaa, Poland|Warszawa, Poland|Wroclaw, Poland|Coimbra, Portugal|Porto, Portugal|Singapore, Singapore|Singapore, Singapore|Singapore, Singapore|Singapore, Singapore|Banska Bystrica, Slovakia|Bratislava, Slovakia|Santiago de Compostela, A Coruña, Spain|Oviedo, Asturias, Spain|Pamplona, Navarra, Spain|Alicante, Spain|Barcelona, Spain|Barcelona, Spain|Barcelona, Spain|Barcelona, Spain|Madrid, Spain|Madrid, Spain|Malaga, Spain|Sevilla, Spain|Sevilla, Spain|Valencia, Spain|Valencia, Spain|Valladolid, Spain|Linköping, Sweden|Stockholm, Sweden|Örebro, Sweden|Basel, Switzerland|Bern, Switzerland|Genève, Switzerland|Zürich, Switzerland|Southampton, Hampshire, United Kingdom|Camberley, Surrey, United Kingdom|Aberdeen, United Kingdom|Belfast, United Kingdom|Birmingham, United Kingdom|Liverpool, United Kingdom|London, United Kingdom|London, United Kingdom|Plymouth, United Kingdom|Torquay, United Kingdom",,"https://ClinicalTrials.gov/show/NCT00637377"
476,"NCT00574275","Aflibercept Compared to Placebo in Term of Efficacy in Patients Treated With Gemcitabine for Metastatic Pancreatic Cancer","VANILLA","Terminated","Has Results","Pancreatic Neoplasm","Drug: Aflibercept (ziv-aflibercept, AVE0005, VEGF trap, ZALTRAP®)|Drug: Placebo|Drug: Gemcitabine","Overall Survival (OS)|Progression Free Survival (PFS) Based on Response Evaluation Criteria in Solid Tumors [RECIST] Criteria|Objective Response Rate (ORR) Assessed by the Investigators According to RECIST Criteria|Clinical Benefit|Safety-Number of Participants With Adverse Events (AE)|Number of Participants With Anti-drug Antibodies","Sanofi|Regeneron Pharmaceuticals","All","18 Years and older   (Adult, Older Adult)","Phase 3","546","Industry","Interventional","Allocation: Randomized|Intervention Model: Parallel Assignment|Masking: Triple (Participant, Care Provider, Investigator)|Primary Purpose: Treatment","EFC10547|EudraCT 2007-003476-19","December 2007","October 2009","November 2010","December 17, 2007","September 25, 2012","June 7, 2016","Sanofi-Aventis Administrative Office, Bridgewater, New Jersey, United States|Sanofi-Aventis Administrative Office, Buenos Aires, Argentina|Sanofi-Aventis Administrative Office, Wien, Austria|Sanofi-Aventis Administrative Office, Diegem, Belgium|Sanofi-Aventis Administrative Office, Sofia, Bulgaria|Sanofi-Aventis Administrative Office, Laval, Canada|Sanofi-Aventis Administrative Office, Santiago, Chile|Sanofi-Aventis Administrative Office, Santafe de Bogota, Colombia|Sanofi-Aventis Administrative Office, Nikosia, Cyprus|Sanofi-Aventis Administrative Office, Praha, Czech Republic|Sanofi-Aventis Administrative Office, Paris, France|Sanofi-Aventis Administrative Office, Berlin, Germany|Sanofi-Aventis Administrative Office, Athens, Greece|Sanofi-Aventis Administrative Office, Budapest, Hungary|Sanofi-Aventis Administrative Office, Mumbai, India|Sanofi-Aventis Administrative Office, Milano, Italy|Sanofi-Aventis Administrative Office, Mexico, Mexico|Sanofi-Aventis Administrative Office, Warszawa, Poland|Sanofi-Aventis Administrative Office, Puerto Rico, Puerto Rico|Sanofi-Aventis Administrative Office, Bucuresti, Romania|Sanofi-Aventis Administrative Office, Moscow, Russian Federation|Sanofi-Aventis Administrative Office, Brastislava, Slovakia|Sanofi-Aventis Administrative Office, Barcelona, Spain|Sanofi-Aventis Administrative Office, Geneva, Switzerland",,"https://ClinicalTrials.gov/show/NCT00574275"
477,"NCT00545246","A Phase I Study of Intravenous Aflibercept in Combination With Docetaxel in Japanese Cancer Patients",,"Completed","No Results Available","Neoplasms","Drug: aflibercept (AVE0005)|Drug: docetaxel","Dose-limiting toxicity (DLT) defined as grade 3 or higher National Cancer Institute - Common Terminology Criteria (NCI-CTC) toxicities|safety: physical examination, laboratory safety tests, adverse events|pharmacokinetic values|objective response rate","Sanofi|Regeneron Pharmaceuticals","All","20 Years and older   (Adult, Older Adult)","Phase 1","12","Industry","Interventional","Allocation: Non-Randomized|Intervention Model: Single Group Assignment|Masking: None (Open Label)|Primary Purpose: Treatment","TCD10091","October 2007","July 2012","July 2012","October 17, 2007",,"October 16, 2013","Sanofi-Aventis Investigational Site Number 392002, Iruma-gun, Japan|Sanofi-Aventis Investigational Site Number 392001, Sunto-Gun, Japan",,"https://ClinicalTrials.gov/show/NCT00545246"
478,"NCT00532155","A Study of Aflibercept Versus Placebo in Patients With Second-Line Docetaxel for Locally Advanced or Metastatic Non-Small-Cell Lung Cancer","VITAL","Completed","Has Results","Carcinoma|Non Small Cell Lung","Drug: Aflibercept (ziv-aflibercept, AVE0005, VEGF trap, ZALTRAP®)|Drug: Placebo|Drug: Docetaxel (Taxotere®)|Drug: Dexamethasone (pre- and post-medication for docetaxel)","Overall Survival (OS)|Progression Free Survival (PFS)|Overall Response (OR) Rate as Per Response Evaluation Criteria in Solid Tumours (RECIST) Criteria|Health Related Quality of Life (HRQL) Assessed by the Lung Cancer Symptom Scale (LCSS)|Health Related Quality of Life (HRQL) Assessed by the Average Symptom Burden Index (ASBI)","Sanofi|Regeneron Pharmaceuticals","All","18 Years and older   (Adult, Older Adult)","Phase 3","913","Industry","Interventional","Allocation: Randomized|Intervention Model: Parallel Assignment|Masking: Triple (Participant, Care Provider, Investigator)|Primary Purpose: Treatment","EFC10261|EudraCT 2007-000819-29","September 2007","January 2011","October 2011","September 20, 2007","January 1, 2013","June 7, 2016","Sanofi-Aventis Administrative Office, Bridgewater, New Jersey, United States|Sanofi-Aventis Administrative Office, Buenos Aires, Argentina|sanofi-aventis Australia & New Zealand administrative office, Macquarie Park, New South Wales, Australia|Sanofi-Aventis Administrative Office, Wien, Austria|Sanofi-Aventis Administrative Office, Sao Paulo, Brazil|Sanofi-Aventis Administrative Office, Sofia, Bulgaria|Sanofi-Aventis Administrative Office, Laval, Canada|Sanofi-Aventis Administrative Office, Santiago, Chile|Sanofi-Aventis Administrative Office, Shangai, China|Sanofi-Aventis Administrative Office, Praha, Czech Republic|Sanofi-Aventis Administrative Office, Tallinn, Estonia|Sanofi-Aventis Administrative Office, Helsinki, Finland|Sanofi-Aventis Administrative Office, Paris, France|Sanofi-Aventis Administrative Office, Berlin, Germany|Sanofi-Aventis Administrative Office, Athens, Greece|Sanofi-Aventis Administrative Office, Causeway Bay, Hong Kong|Sanofi-Aventis Administrative Office, Budapest, Hungary|Sanofi-Aventis Administrative Office, Mumbai, India|Sanofi-Aventis Administrative Office, Milano, Italy|Sanofi-Aventis Administrative Office, Seoul, Korea, Republic of|Sanofi-Aventis Administrative Office, Kuala Lumpur, Malaysia|Sanofi-Aventis Administrative Office, Gouda, Netherlands|Sanofi-Aventis Administrative Office, Warszawa, Poland|Sanofi-Aventis Administrative Office, Porto Salvo, Portugal|Sanofi-Aventis Administrative Office, Bucuresti, Romania|Sanofi-Aventis Administrative Office, Moscow, Russian Federation|Sanofi-Aventis Administrative Office, Singapore, Singapore|Sanofi-Aventis Administrative Office, Barcelona, Spain|Sanofi-Aventis Administrative Office, Bromma, Sweden|Sanofi-Aventis Administrative Office, Taipei, Taiwan|Sanofi-Aventis Administraive Office, Istanbul, Turkey|Sanofi-Aventis Admnistrative Office, Guildford Surrey, United Kingdom",,"https://ClinicalTrials.gov/show/NCT00532155"
479,"NCT00519285","Aflibercept in Combination With Docetaxel in Metastatic Androgen Independent Prostate Cancer","VENICE","Completed","Has Results","Prostatic Neoplasms|Neoplasm Metastasis","Drug: Aflibercept|Drug: Placebo (for aflibercept)|Drug: Docetaxel|Drug: Prednisone or Prednisolone","Overall Survival Time|Prostate Specific Antigen Response Rate|Time to Skeletal Related Events|Progression Free Survival Time|Tumor Response Rate in Participants With Measurable Disease|Prostate Specific Antigen Progression-free Survival Time|Pain Progression-free Survival Time|Pain Response Rate|Change From Baseline in Functional Assessment of Cancer Therapy-Prostate Total Score as a Measure of Health Related Quality of Life|Number of Participants With Adverse Events as a Measure of Safety|Number of Participants With Positive Anti-aflibercept Antibody Levels as a Measure of Immunogenicity of Aflibercept","Sanofi|Regeneron Pharmaceuticals","Male","18 Years and older   (Adult, Older Adult)","Phase 3","1224","Industry","Interventional","Allocation: Randomized|Intervention Model: Parallel Assignment|Masking: Triple (Participant, Care Provider, Investigator)|Primary Purpose: Treatment","EFC6546|2006-004756-20","August 2007","April 2012","April 2012","August 22, 2007","October 10, 2013","July 22, 2016","Sanofi-Aventis Administrative Office, Bridgewater, New Jersey, United States|Sanofi-Aventis Administrative Office, Buenos Aires, Argentina|Sanofi-Aventis Administrative Office, Macquarie Park, Australia|Sanofi-Aventis Administrative Office, Diegem, Belgium|Sanofi-Aventis Administrative Office, Sao Paulo, Brazil|Sanofi-Aventis Administrative Office, Laval, Canada|Sanofi-Aventis Administrative Office, Providencia Santiago, Chile|Sanofi-Aventis Administrative Office, City of Zagreb, Croatia|Sanofi-Aventis Administrative Office, Praha, Czech Republic|Sanofi-Aventis Administrative Office, Horsholm, Denmark|Sanofi-Aventis Administrative Office, Tallinn, Estonia|Sanofi-Aventis Administrative Office, Paris, France|Sanofi-Aventis Administrative Office, Frankfurt, Germany|Sanofi-Aventis Administrative Office, Hong Kong, Hong Kong|Sanofi-Aventis Administrative Office, Budapest, Hungary|Sanofi-Aventis Administrative Office, Natanya, Israel|Sanofi-Aventis Administrative Office, Milan, Italy|Sanofi-Aventis Administrative Office, Seoul, Korea, Republic of|Sanofi-Aventis Administrative Office, Gouda, Netherlands|Sanofi-Aventis Administrative Office, Warsaw, Poland|Sanofi-Aventis Administrative Office, Porto Salvo, Portugal|Sanofi-Aventis Administrative Office, Moscow, Russian Federation|Sanofi-Aventis Administrative Office, Singapore, Singapore|Sanofi-Aventis Administrative Office, Gauteng, South Africa|Sanofi-Aventis Administrative Office, Barcelona, Spain|Sanofi-Aventis Administrative Office, Bromma, Sweden|Sanofi-Aventis Administrative Office, Geneva, Switzerland|Sanofi-Aventis Administrative Office, Taipei, Taiwan|Sanofi-Aventis Administrative Office, Istanbul, Turkey|Sanofi-Aventis Administrative Office, Kiev, Ukraine|Sanofi-Aventis Administrative Office, Guildford Surrey, United Kingdom",,"https://ClinicalTrials.gov/show/NCT00519285"
480,"NCT00479076","A Phase I Study of Intravenous Aflibercept in Combination With S-1 in Japanese Cancer Patients",,"Completed","No Results Available","Neoplasms","Drug: aflibercept (AVE0005)|Drug: S-1","Dose-limiting toxicity (DLT) defined as grade 3 or higher National Cancer Institute - Common Terminology Criteria (NCI-CTC) toxicities|safety: physical examination, laboratory safety tests, adverse events|pharmacokinetic values|objective response rate","Sanofi|Regeneron Pharmaceuticals","All","20 Years and older   (Adult, Older Adult)","Phase 1","22","Industry","Interventional","Allocation: Randomized|Intervention Model: Parallel Assignment|Masking: None (Open Label)|Primary Purpose: Treatment","TED10089","March 2007","January 2011","January 2011","May 25, 2007",,"January 26, 2011","Sanofi-Aventis Administrative Office, Tokyo, Japan",,"https://ClinicalTrials.gov/show/NCT00479076"
481,"NCT00396591","AVE0005 (VEGF Trap) in Patients With Recurrent Symptomatic Malignant Ascites",,"Completed","Has Results","Ovarian Neoplasms","Drug: Aflibercept (ziv-aflibercept, AVE0005, VEGF trap, ZALTRAP®)","Percentage of Participants With a Repeat Paracentesis Response (RPR)|Time to Repeat Paracentesis (TRP)|60-day Frequency of Paracentesis (FOP)|Progression-free Survival (PFS) Time|Overall Survival (OS) Time|Number of Participants With a Positive Anti-drug Antibody Response|Safety - Number of Participants With Adverse Events (AE)","Sanofi|Regeneron Pharmaceuticals","Female","18 Years and older   (Adult, Older Adult)","Phase 2","16","Industry","Interventional","Allocation: Non-Randomized|Intervention Model: Single Group Assignment|Masking: None (Open Label)|Primary Purpose: Treatment","ARD6772|EUDRACT: 2006-000604-16","October 2006","November 2008","November 2008","November 7, 2006","January 10, 2013","January 10, 2013","Sanofi-Aventis Administrative Office, Bridgewater, New Jersey, United States|Sanofi-Aventis Administrative Office, Milano, Italy|Sanofi-Aventis Administrative Office, Bromma, Sweden",,"https://ClinicalTrials.gov/show/NCT00396591"
482,"NCT00327444","Study of the Effect of Intravenous AVE0005 (VEGF Trap) in Advanced Ovarian Cancer Patients With Recurrent Symptomatic Malignant Ascites",,"Completed","Has Results","Ovarian Neoplasms|Ascites","Drug: aflibercept (ziv-aflibercept, AVE0005, VEGF trap, ZALTRAP®)|Drug: Placebo","Time to Repeat Paracentesis (TRP)|Area Under the Curve (AUC) for Participant Assessed Ascites Impact Measure (AIM)|60-Day Frequency of Paracentesis (FOP)|Plasma Levels of Free and VEGF-bound Aflibercept","Sanofi|Regeneron Pharmaceuticals","Female","18 Years and older   (Adult, Older Adult)","Phase 2|Phase 3","58","Industry","Interventional","Allocation: Randomized|Intervention Model: Parallel Assignment|Masking: Double (Participant, Investigator)|Primary Purpose: Treatment","EFC6125|EudraCT : 2005-005026-31|AVE0005A /3001","July 2006","October 2009","October 2009","May 18, 2006","January 1, 2013","January 1, 2013","Sanofi-Aventis Administrative Office, Bridgewater, New Jersey, United States|Sanofi-Aventis Administrative Office, Vienna, Austria|Sanofi-Aventis Administrative Office, Diegem, Belgium|Sanofi-Aventis Administrative Office, Laval, Canada|Sanofi-Aventis Administrative Office, Budapest, Hungary|Sanofi-Aventis Administrative Office, Mumbai, India|Sanofi-Aventis Administrative Office, Natanya, Israel|Sanofi-Aventis Administrative Office, Barcelona, Spain|Sanofi-Aventis Administrative Office, Guildford Surrey, United Kingdom",,"https://ClinicalTrials.gov/show/NCT00327444"
483,"NCT00327171","Study of AVE0005 (VEGF Trap) in Patients With Chemoresistant Advanced Ovarian Cancer",,"Completed","Has Results","Neoplasms|Cancer of the Ovary","Drug: Aflibercept (ziv-aflibercept, AVE0005, VEGF trap, ZALTRAP®)","Number of Participants With Confirmed Objective Response (OR) as Per Response Evaluation Criteria in Solid Tumors (RECIST) Based on the Analysis by an Independent Review Committee (IRC) - Simon's Cohort|Number of Participants With Confirmed Objective Response (OR) as Per Response Evaluation Criteria in Solid Tumors (RECIST) Based on the Analysis by the IRC - Efficacy Evaluable Population|Number of Participants With a Clinical Benefit Response (CBR) as Per RECIST Based on the Analysis by the IRC|Duration of Response (DR) Based on the Analysis by an Independent Review Committee (IRC)|Tumor Marker Response Rate (TMRR) Based on the Gynecologic Cancer Intergroup (GCIG) Definition|Time to Tumor Progression (TTP) as Per RECIST Based on the Analysis by the IRC|Time to Tumor Marker (CA-125) Progression (TTMP)|Number of Participants With Disease Progression Events for Progression-free Survival (PFS) Analysis by the IRC.|Progression-free Survival (PFS) Time Based on Analysis by the IRC|Overall Survival (OS) Time|Overall Safety - Number of Participants With Adverse Events (AE)|Participant's Assessment of Health Related Quality of Life (HRQL) Using a by Using the Functional Assessment of Cancer Therapy-Ovarian (FACT-O) Questionnaire","Sanofi|Regeneron Pharmaceuticals","Female","18 Years and older   (Adult, Older Adult)","Phase 2","218","Industry","Interventional","Allocation: Randomized|Intervention Model: Parallel Assignment|Masking: Double (Participant, Investigator)|Primary Purpose: Treatment","ARD6122|AVE0005","May 2006","April 2008","March 2010","May 18, 2006","October 18, 2012","June 7, 2016","Sanofi-Aventis Administrative Office, Bridgewater, New Jersey, United States|Sanofi-Aventis Administrative Office, Macquarie Park, Australia|Sanofi-Aventis Administrative Office, Laval, Canada|Sanofi-Aventis Administrative Office, Paris, France|Sanofi-Aventis Administrative Office, Berlin, Germany|Sanofi-Aventis Administrative Office, Milano, Italy|Sanofi-Aventis Administrative Office, Gouda, Netherlands|Sanofi-Aventis Administrative Office, Porto Salvo, Portugal|Sanofi-Aventis Administrative Office, Barcelona, Spain|Sanofi-Aventis Administrative Office, Bromma, Sweden|Sanofi-Aventis Administrative Office, Geneva, Switzerland",,"https://ClinicalTrials.gov/show/NCT00327171"
484,"NCT00284141","Study of AVE0005 (VEGF Trap) in Locally Advanced or Metastatic Platinum- and Erlotinib- Resistant Non-small-cell-lung Adenocarcinoma",,"Completed","Has Results","Pulmonary Diseases|Neoplasms, Lung","Drug: Aflibercept (ziv-aflibercept, AVE0005, VEGF trap, ZALTRAP®)","Confirmed Objective Response (OR) Based Upon Modified Response Evaluation Criteria in Solid Tumors (RECIST) Assessed by the Independent Review Committee (IRC).|Confirmed Objective Response Based Upon Modified Response Evaluation Criteria in Solid Tumors (RECIST) Assessed by the Investigator.|Duration of Response (DR)|Progression-free Survival (PFS) Time Assessed by the Independent Review Committee (IRC)|Progression-free Survival (PFS) Time Assessed by the Investigator|Overall Survival (OS)|Heath-related Quality of Life (QOL) Measured Via the Lung Cancer Subscale|Overall Safety - Number of Participants With Adverse Events|Number of Participants With Laboratory Abnormalities|Peak of Free Aflibercept (VEGF Trap)|Free and VEGF-bound Trough Aflibercept Concentrations (VEGF Trap)|Number of Participants With Anti-drug Antibodies","Sanofi|Regeneron Pharmaceuticals","All","18 Years and older   (Adult, Older Adult)","Phase 2","98","Industry","Interventional","Allocation: Non-Randomized|Intervention Model: Single Group Assignment|Masking: None (Open Label)|Primary Purpose: Treatment","ARD6123|AVE0005B/2001","January 2006","July 2008","July 2008","January 31, 2006","December 10, 2012","December 10, 2012","Sanofi-Aventis Administrative Office, Bridgewater, New Jersey, United States|Sanofi-Aventis Administrative Office, Laval, Canada|Sanofi-Aventis Administrative Office, Paris, France",,"https://ClinicalTrials.gov/show/NCT00284141"
485,"NCT05247866","Efficacy of Dupilumab on Facilitated Food Introduction in Eosinophilic Esophagitis",,"Not yet recruiting","No Results Available","Eosinophilic Esophagitis","Dietary Supplement: EoE food introduction-1st|Dietary Supplement: E0E food introduction-2nd|Dietary Supplement: EoE Food introduction-3rd dose|Drug: Dupilumab","Esophageal Eosinophilia (number of eosinophils in the esophagus)|Pediatric Eosinophilic Esophagitis Symptom Score (total score based on pediatric symptom score)","Children's Hospital of Philadelphia|Regeneron Pharmaceuticals|Genzyme, a Sanofi Company","All","6 Years to 25 Years   (Child, Adult)","Phase 4","30","Other|Industry","Interventional","Allocation: N/A|Intervention Model: Single Group Assignment|Masking: None (Open Label)|Primary Purpose: Treatment","21-019416","March 2022","September 2025","September 2025","February 21, 2022",,"February 21, 2022","Children's Hospital of Philadelphia, Philadelphia, Pennsylvania, United States",,"https://ClinicalTrials.gov/show/NCT05247866"
486,"NCT04988022","Dupilumab in the Treatment of Keloids",,"Recruiting","No Results Available","Keloid","Drug: Dupilumab|Drug: Placebo","Change from baseline in dimensions of keloid lesions at 24 weeks|Change from baseline in dimensions of keloid lesions at weeks 4, 16, 24, 48, and 52 of treatment with dupilumab","Icahn School of Medicine at Mount Sinai|Regeneron Pharmaceuticals|Sanofi","All","18 Years and older   (Adult, Older Adult)","Phase 4","44","Other|Industry","Interventional","Allocation: Randomized|Intervention Model: Crossover Assignment|Masking: Quadruple (Participant, Care Provider, Investigator, Outcomes Assessor)|Primary Purpose: Treatment","GCO 20-3159","May 11, 2021","December 31, 2023","December 31, 2023","August 3, 2021",,"August 3, 2021","Icahn School of Medicine at Mount Sinai, New York, New York, United States",,"https://ClinicalTrials.gov/show/NCT04988022"
487,"NCT04975152","Neoadjuvant Cemiplimab in Stage I-II Merkel Cell Carcinoma: Safety and Biomarker Analysis",,"Recruiting","No Results Available","Merkel Cell Carcinoma","Drug: Cemiplimab-Rwlc","Number of Participants With Adverse Events Related to Study Treatment|Relapse Free Survival|Overall Survival","H. Lee Moffitt Cancer Center and Research Institute|Regeneron Pharmaceuticals|Sanofi-Synthelabo","All","18 Years and older   (Adult, Older Adult)","Phase 1","30","Other|Industry","Interventional","Allocation: N/A|Intervention Model: Single Group Assignment|Masking: None (Open Label)|Primary Purpose: Treatment","MCC-20794","July 20, 2021","July 2023","July 2026","July 23, 2021",,"December 27, 2021","Moffitt Cancer Center, Tampa, Florida, United States",,"https://ClinicalTrials.gov/show/NCT04975152"
488,"NCT04708145","Long-Term Efficacy and Safety of Intravitreal Aflibercept Injections for the Treatment of Diabetic Retinopathy for Subjects Who Completed the 2-Year PANORAMA Trial","VOYAGE","Recruiting","No Results Available","Diabetic Retinopathy","Drug: Aflibercept Injection","DRSS Level Achievement in the VOYAGE study|DRSS Level Achievement in the PANORAMA study|DRSS Level Improvement|Injection Frequency|Subjects without Treatment|PDR Events|Center-Involved Diabetic Macular Edema Development|Change in Visual Acuity|Change in Central Retinal Thickness|Change in Area of Nonperfusion|Changes in Visual Function (HVF)|Changes in Visual Function|Incidence of Adverse Events","Greater Houston Retina Research|Regeneron Pharmaceuticals|Clinical Trials Resource Group, LLC","All","18 Years and older   (Adult, Older Adult)","Phase 4","150","Other|Industry","Interventional","Allocation: Randomized|Intervention Model: Parallel Assignment|Masking: None (Open Label)|Primary Purpose: Treatment","VOYAGE","June 1, 2021","June 2023","June 2023","January 13, 2021",,"January 24, 2022","Retina Vitreous Associates Medical Group, Beverly Hills, California, United States|Central Florida Retina Center, Orlando, Florida, United States|Center for Retina and Macular Disease, Winter Haven, Florida, United States|Marietta Eye Clinic, Marietta, Georgia, United States|John Kenyon American Eye Institute, New Albany, Indiana, United States|Cumberland Valley Retina Consultants, P.C., Hagerstown, Maryland, United States|Dean McGee Eye Institute, Oklahoma City, Oklahoma, United States|Palmetto Retina Center, LLC - Florence, Florence, South Carolina, United States|Palmetto Retina Center, West Columbia, South Carolina, United States|Charles Retina Institute, Germantown, Tennessee, United States|Retina Consultants of Texas, Bellaire, Texas, United States|Valley Retina Institute, Harlingen, Texas, United States|Strategic Clinical Research Group, LLC, Willow Park, Texas, United States|Emanuelli Research and Development Center, LLC, Arecibo, Puerto Rico",,"https://ClinicalTrials.gov/show/NCT04708145"
489,"NCT04543071","Chemo4METPANC Combination Chemokine Inhibitor, Immunotherapy, and Chemotherapy in Pancreatic Adenocarcinoma",,"Recruiting","No Results Available","Pancreatic Cancer|Adenocarcinoma of the Pancreas|Adenocarcinoma","Drug: Motixafortide|Drug: Cemiplimab|Drug: Gemcitabine|Drug: Nab paclitaxel","Overall Response Rate (Complete Response (CR) + Partial Response (PR))|Incidence of Treatment Related Toxicities|Median Overall Survival|Median Progression Free Survival|Duration of Clinical Benefit|Disease Control Rate","Gulam Manji|Regeneron Pharmaceuticals|BioLine Rx|Columbia University","All","18 Years and older   (Adult, Older Adult)","Phase 2","10","Other|Industry","Interventional","Allocation: N/A|Intervention Model: Single Group Assignment|Masking: None (Open Label)|Primary Purpose: Treatment","AAAS9513","December 2021","July 1, 2025","August 1, 2025","September 9, 2020",,"November 23, 2021","Columbia University Irving Medical Center, New York, New York, United States|Brown University, Providence, Rhode Island, United States",,"https://ClinicalTrials.gov/show/NCT04543071"
490,"NCT03750760","Early Alirocumab to Reduce LDL-C in Myocardial Infarction","EARLY","Withdrawn","No Results Available","Myocardial Infarction|Dyslipidemias","Drug: Alirocumab|Drug: Atorvastatin 80mg|Drug: Ezetimibe 10mg","Percentage change in LDL-C in enhanced care group verses standard of care group at 2 weeks after randomisation|Percentage change in LDL-C at 7 weeks in enhanced care verses standard of care.|Proportion of patients who achieve a LDL < 50mg/dL (1.29mmol/L) at week 2, 4 and 7 in enhanced care verses standard of care|Proportion of patients in standard of care who need ezetimibe 10 mg to be added in the standard of care pathway at week 4|Proportion of patients with reported adverse events (AEs)|Proportion of patients with reported serious adverse events (SAEs)|Proportion of patients with reported adverse events of special interest (AESIs)","Imperial College London|Regeneron Pharmaceuticals|Baim Institute for Clinical Research","All","18 Years and older   (Adult, Older Adult)","Phase 4","0","Other|Industry","Interventional","Allocation: Randomized|Intervention Model: Parallel Assignment|Masking: None (Open Label)|Primary Purpose: Treatment","18HH4627|2018-002429-49","January 2020","December 2020","December 2021","November 23, 2018",,"June 13, 2019","Royal Devon & Exeter Hospital, Exeter, Devon, United Kingdom|The Royal Bournemouth General Hospital, Bournemouth, Dorset, United Kingdom|East Sussex Healthcare NHS Trust, Saint Leonards-on-Sea, East Sussex, United Kingdom|Basildon Hospital, Basildon, Essex, United Kingdom|St Mary's Hospital, London, Greater London, United Kingdom|Queen Alexandra Hospital, Portsmouth, Hampshire, United Kingdom|Southampton General Hospital, Southampton, Hampshire, United Kingdom|Northwick Park Hospital, Harrow, Middlesex, United Kingdom|Hull Royal Infirmary, Hull, North Humberside, United Kingdom|Queens Medical Centre, Nottingham, Nottinghamshire, United Kingdom|St Peters Hospital, Chertsey, Surrey, United Kingdom|East Surrey Hospital, Redhill, Surrey, United Kingdom|Freeman Hospital, Newcastle Upon Tyne, Tyne And Wear, United Kingdom|Queen Elizabeth Medical Centre, Birmingham, West Midlands, United Kingdom|City Hospital, Birmingham, West Midlands, United Kingdom|Worchestershire Royal Hospital, Worcester, Worcestershire, United Kingdom|Northern General Hospital, Sheffield, Yorkshire, United Kingdom",,"https://ClinicalTrials.gov/show/NCT03750760"
491,"NCT03678545","Dupilumab in Eosinophilic Gastritis",,"Recruiting","No Results Available","Eosinophilic Gastritis|Eosinophilic Gastroenteritis","Drug: Dupilumab (blinded)|Drug: Placebo (blinded)|Drug: Dupilumab (open-label)","Relative change of peak eosinophil counts in the stomach|Induction of disease remission|Change in histologic score of gastric mucosa|Changes in endoscopic score before and after treatment with dupilumab|Changes in clinical symptoms as measured by the Severity of Dyspepsia Assessment tool.|Change in blood eosinophil counts|Assessment of the value of baseline blood and esophageal biomarkers in predicting responsiveness to dupilumab.","Children's Hospital Medical Center, Cincinnati|Regeneron Pharmaceuticals|National Institutes of Health (NIH)","All","12 Years to 70 Years   (Child, Adult, Older Adult)","Phase 2","40","Other|Industry|NIH","Interventional","Allocation: Randomized|Intervention Model: Parallel Assignment|Masking: Triple (Participant, Care Provider, Investigator)|Primary Purpose: Treatment","IRB 2020-0798","May 14, 2021","January 2023","July 2023","September 19, 2018",,"February 23, 2022","Children's Hospital Colorado, Aurora, Colorado, United States|Northwestern Medicine Digestive Health Center, Chicago, Illinois, United States|Riley Children's Hospital, Indianapolis, Indiana, United States|Tufts Medical Center, Boston, Massachusetts, United States|University of North Carolina School of Medicine, Chapel Hill, North Carolina, United States|Cincinnati Children's Hospital Medical Center, Cincinnati, Ohio, United States|The Children's Hospital of Philadelphia, Philadelphia, Pennsylvania, United States|University of Pennsylvania, Philadelphia, Pennsylvania, United States|Texas Children's Hospital, Houston, Texas, United States",,"https://ClinicalTrials.gov/show/NCT03678545"
492,"NCT03531294","Intravitreal Aflibercept as Indicated by Real-Time Objective Imaging to Achieve Diabetic Retinopathy Improvement",,"Completed","No Results Available","Diabetic Retinopathy","Drug: Aflibercept Injection","Incidence of Adverse Events for diabetic retinopathy subjects who receive intravitreal Aflibercept|Correlation of DRSS and leakage index|Correlation between Reading Center DRSS Level and Physician determined DR severity|Number of IAI|Mean number of IAI (NPDR VS PDR)|ETDRS-BCVA change|Changes in Visual Function|DRSS Change|Change in Non-Perfusion|Change in Vascular Leakage|Change in microaneurysms|Change in CST|DME development|PDR Development|Cytokine Levels","Greater Houston Retina Research|Regeneron Pharmaceuticals|The Cleveland Clinic","All","18 Years and older   (Adult, Older Adult)","Phase 2","40","Other|Industry","Interventional","Allocation: Randomized|Intervention Model: Parallel Assignment|Masking: None (Open Label)|Primary Purpose: Treatment","PRIME","May 23, 2018","April 9, 2021","April 9, 2021","May 21, 2018",,"May 21, 2021","Retina Consultants of Houston/The Medical Center, Houston, Texas, United States|Retina Consultants of Houston, The Woodlands, Texas, United States",,"https://ClinicalTrials.gov/show/NCT03531294"
493,"NCT03293030","Immunogenetic Profiling of Dupilumab for the Treatment of Atopic Dermatitis",,"Recruiting","No Results Available","Atopic Dermatitis|Atopic Dermatitis Eczema|Eczema|Atopic Dermatitis and Related Conditions","Drug: Dupilumab","CD4+ T effector cells expressing IL-4|Number of differentially expressed genes and pathways|Microbiome","University of California, San Francisco|Regeneron Pharmaceuticals|Sanofi","All","18 Years and older   (Adult, Older Adult)","Phase 4","15","Other|Industry","Interventional","Allocation: N/A|Intervention Model: Single Group Assignment|Masking: None (Open Label)|Primary Purpose: Treatment","Dupilumab Immunogenetics","October 22, 2018","December 31, 2022","June 30, 2023","September 26, 2017",,"August 11, 2021","UCSF Psoriasis and Skin Treatment Center, San Francisco, California, United States",,"https://ClinicalTrials.gov/show/NCT03293030"
494,"NCT03004001","Effect of PCSK9-Antibody (Alirocumab) on Dyslipidemia Secondary to Nephrotic Syndrome",,"Terminated","No Results Available","Nephrotic Syndrome","Drug: Alirocumab|Drug: Alirocumab placebo|Drug: Atorvastatin","Levels of plasma lipoproteins|Levels of PCSK9|Triglyceride-rich lipoproteins (Remnants)|Lipidomics","Gloria Vega|Regeneron Pharmaceuticals|Aventis Pharmaceuticals|Dallas VA Medical Center","All","18 Years to 75 Years   (Adult, Older Adult)","Not Applicable","3","U.S. Fed|Industry","Interventional","Allocation: Randomized|Intervention Model: Crossover Assignment|Masking: Double (Participant, Investigator)|Primary Purpose: Treatment","VA16-029","January 2017","December 2019","December 2019","December 28, 2016",,"October 6, 2020","DallasVAMC, Dallas, Texas, United States",,"https://ClinicalTrials.gov/show/NCT03004001"
495,"NCT02938949","Alirocumab in Patients With Acute Myocardial Infarction",,"Completed","Has Results","Myocardial Infarction|Hypercholesterolemia","Drug: alirocumab|Drug: placebo","Changes in Low-density Lipoprotein (LDL) Cholesterol|Change in Inflammatory Markers (hsCRP)","Virginia Commonwealth University|Regeneron Pharmaceuticals|Sanofi","All","21 Years and older   (Adult, Older Adult)","Phase 4","20","Other|Industry","Interventional","Allocation: Randomized|Intervention Model: Parallel Assignment|Masking: Triple (Participant, Care Provider, Investigator)|Primary Purpose: Treatment","HM20008008","January 2017","August 2018","August 16, 2018","October 19, 2016","September 6, 2019","September 6, 2019","Virginia Commonwealth University, Richmond, Virginia, United States","""Study Protocol and Statistical Analysis Plan"", https://ClinicalTrials.gov/ProvidedDocs/49/NCT02938949/Prot_SAP_000.pdf","https://ClinicalTrials.gov/show/NCT02938949"
496,"NCT05031455","Mechanisms of Dupilumab in AERD",,"Not yet recruiting","No Results Available","Aspirin-exacerbated Respiratory Disease","Biological: Dupilumab|Drug: Placebo","Rate of positive challenges to aspirin challenge","Scripps Clinic|University of California, San Diego|Regeneron Pharmaceuticals","All","18 Years and older   (Adult, Older Adult)","Phase 2","16","Other|Industry","Interventional","Allocation: Randomized|Intervention Model: Parallel Assignment|Masking: Triple (Participant, Care Provider, Investigator)|Primary Purpose: Treatment","SHUCSD06242020","January 1, 2022","December 31, 2024","February 28, 2025","September 2, 2021",,"September 2, 2021",,,"https://ClinicalTrials.gov/show/NCT05031455"
497,"NCT02341664","Patient and Provider Assessment of Lipid Management Registry","PALM","Completed","No Results Available","Hyperlipidemia|Hypercholesterolemia|Cardiovascular Disease|Diabetes|Chronic Kidney Disease (CKD)|Hypertension|Smoking|Myocardial Infarction (MI)|Unstable Angina|Angina|Coronary Artery Disease (CAD)|Stroke|Transient Ischemic Attack (TIA)|Carotid Stenosis|Peripheral Arterial Disease|Atherosclerosis|Claudication",,"Lipid-lowering therapy use among a contemporary, nationally representative, community-based sample of adult patients receiving primary and subspecialty care in the US.","Duke University|Regeneron Pharmaceuticals|Sanofi","All","18 Years and older   (Adult, Older Adult)",,"7658","Other|Industry","Observational","Observational Model: Cohort|Time Perspective: Cross-Sectional","Pro00058405","May 2015","February 2016","February 2016","January 19, 2015",,"March 2, 2020","Cardiology and Medicine Clinic, Little Rock, Arkansas, United States|COR Healthcare, San Pedro, California, United States|Ventura Cardiology Consultants Medical Group, Inc, Ventura, California, United States|Wellness Clinical Research, LLC, Hialeah Gardens, Florida, United States|Maya Research Center, Inc, Hialeah, Florida, United States|Infinity Clinical Research, Plantation, Florida, United States|Midwest Heart and Vascular Specialists, LLC, Overland Park, Kansas, United States|Krishnan Challappa, MD, PSC, Elizabethtown, Kentucky, United States|HealthEast Clinical Trials Office, Saint Paul, Minnesota, United States|Long Island Heart Associates, Mineola, New York, United States|Gotham Cardiovascular Research, New York, New York, United States|New Bern Internal Medicine, New Bern, North Carolina, United States|Detweiler Family Medicine Associates, PC, Lansdale, Pennsylvania, United States|Charleston Internal Medicine, Inc., Charleston, West Virginia, United States",,"https://ClinicalTrials.gov/show/NCT02341664"
498,"NCT04296864","Evaluation of Dupilumab in Patients With Atopic Keratoconjunctivitis (AKC)",,"Recruiting","No Results Available","Atopic Keratoconjunctivitis","Drug: Dupilumab","Percentage of treatment responders","Andover Eye Associates|Statistics & Data Corporation|Regeneron Pharmaceuticals","All","18 Years and older   (Adult, Older Adult)","Phase 2","42","Industry|Other","Interventional","Allocation: Randomized|Intervention Model: Parallel Assignment|Masking: Double (Participant, Investigator)|Primary Purpose: Treatment","18-290-0002","February 10, 2020","August 2022","December 2022","March 5, 2020",,"November 26, 2021","Premiere Practice Management, LLC, Los Angeles, California, United States|Colorado Eye Consultants/Corneal Consultants of Colorado, Littleton, Colorado, United States|Encore Medical Research, LLC, Hollywood, Florida, United States|Andover Eye Associates, Andover, Massachusetts, United States|University of Michigan- Kellogg Eye Center, Ann Arbor, Michigan, United States|Silverstein Eye Centers, Kansas City, Missouri, United States|Mercy Clinic Eye Specialists, Springfield, Missouri, United States|Northwell Health Physician Partners Ophthalmology at Great Neck, Great Neck, New York, United States|Gerald W. Zaidman, MD, Hawthorne, New York, United States|Vita Eye Clinic, Shelby, North Carolina, United States|Vantage EyeCare, LLC., Bala-Cynwyd, Pennsylvania, United States|Advancing Vision Research, LLC, Smyrna, Tennessee, United States|Eye Associates of Central Texas, Round Rock, Texas, United States",,"https://ClinicalTrials.gov/show/NCT04296864"
499,"NCT04148352","Dupilumab and Milk OIT for the Treatment of Cow's Milk Allergy",,"Recruiting","No Results Available","Allergies Food Milk","Drug: Dupilumab|Other: Placebo","Proportion of subjects treated with dupilumab plus milk protein OIT vs placebo plus milk protein OIT who tolerate at least 2040 mg (cumulative) cow's milk protein during DBPCFC to milk at week 18|Proportion of participants who tolerate at least 1040 mg cumulative milk protein at week 18 DBPCFC|Proportion of participants who tolerate 4040 mg cumulative milk protein at week 18 DBPCFC|Proportion of participants who tolerate at least 1040 mg cumulative milk protein at week 24 DBPCFC|Proportion of participants who tolerate at least 2040 mg cumulative milk protein at week 24 DBPCFC|Proportion of participants who tolerate 4040 mg cumulative milk protein at week 24 DBPCFC|Change in the cumulative tolerated dose (CTD) of milk protein during DBPCFC from baseline to week 18 across cohorts as pairwise comparisons of all treatment groups|Change in the cumulative tolerated dose (CTD) of milk protein during DBPCFC from baseline to week 24 across cohorts as pairwise comparisons of all treatment groups","Andrew J Long, PharmD|Robert Levin Charitable Fund|Regeneron Pharmaceuticals|Stanford University","All","4 Years to 50 Years   (Child, Adult)","Phase 2","116","Other|Industry","Interventional","Allocation: Randomized|Intervention Model: Parallel Assignment|Masking: Triple (Participant, Care Provider, Investigator)|Primary Purpose: Treatment","IRB-52976","October 18, 2021","October 2022","November 2022","November 1, 2019",,"November 2, 2021","Phoenix Children's Hospital, Phoenix, Arizona, United States|Mayo Clinic, Scottsdale, Arizona, United States|Sean N. Parker Center for Allergy & Asthma Research at Stanford University, Mountain View, California, United States",,"https://ClinicalTrials.gov/show/NCT04148352"
500,"NCT03477864","Stereotactic Body Radiation Therapy With REGN2810 and/or Ipilimumab Before Surgery in Treating Participants With Progressive Advanced or Oligometastatic Prostate Cancer",,"Withdrawn","No Results Available","Stage III Prostate Cancer|Stage IIIA Prostate Cancer|Stage IIIB Prostate Cancer|Stage IIIC Prostate Cancer|Stage IV Prostate Cancer|Stage IVA Prostate Cancer|Stage IVB Prostate Cancer","Biological: Ipilimumab|Radiation: Stereotactic Body Radiation Therapy (SBRT)|Procedure: Radical Prostatectomy|Biological: Anti-PD-1 Monoclonal Antibody REGN2810","Incidence of adverse events as defined by National Cancer Institute (NCI) Common Terminology Criteria for Adverse Events (CTCAE) version 4.03 criteria|Overall pathologic response rate|Prostate specific antigen (PSA) progression free survival|Radiographic progression free survival","Sidney Kimmel Cancer Center at Thomas Jefferson University|Prostate Cancer Foundation|Regeneron Pharmaceuticals|Thomas Jefferson University","Male","18 Years and older   (Adult, Older Adult)","Phase 1","0","Other|Industry","Interventional","Allocation: Randomized|Intervention Model: Sequential Assignment|Masking: None (Open Label)|Primary Purpose: Treatment","17G.508","December 24, 2018","November 4, 2019","November 4, 2019","March 26, 2018",,"November 12, 2019",,,"https://ClinicalTrials.gov/show/NCT03477864"
501,"NCT02992301","Assessment of Atherosclerotic Plaque Characteristics Change by DCE-MRI With Alirocumab",,"Unknown status","No Results Available","Atherosclerosis|Hyperlipidemia","Drug: Alirocumab","Changes in carotid atherosclerotic plaque characteristics as evidenced by effect on the volume transfer constant( Ktrans) and lipid-rich necrotic core (LRNC) size.|Associations between reductions in atherogenic lipids and changes in atherosclerotic plaque characteristics","Westside Medical Associates of Los Angeles|University of Washington|Regeneron Pharmaceuticals","All","18 Years and older   (Adult, Older Adult)","Phase 4","35","Other|Industry","Interventional","Allocation: N/A|Intervention Model: Single Group Assignment|Masking: None (Open Label)|Primary Purpose: Treatment","WMALA-99-032","November 2016","November 2019","November 2019","December 14, 2016",,"April 26, 2019","Westside Medical Associates of Los Angeles, Beverly Hills, California, United States",,"https://ClinicalTrials.gov/show/NCT02992301"
502,"NCT00561470","Aflibercept Versus Placebo in Combination With Irinotecan and 5-FU in the Treatment of Patients With Metastatic Colorectal Cancer After Failure of an Oxaliplatin Based Regimen","VELOUR","Completed","Has Results","Colorectal Neoplasms|Neoplasm Metastasis","Drug: Placebo|Drug: Aflibercept (ziv-aflibercept, AVE0005, VEGF trap, ZALTRAP®)|Drug: FOLFIRI (Irinotecan, 5-Fluorouracil, and Leucovorin)","Overall Survival (OS)|Progression-free Survival (PFS) Assessed by Independent Review Committee (IRC)|Overall Objective Response Rate (ORR) Based on the Tumor Assessment by the Independent Review Committee (IRC) as Per Response Evaluation Criteria in Solid Tumours (RECIST) Criteria|Number of Participants With Adverse Events (AE)|Immunogenicity Assessment: Number of Participants With Positive Sample(s) in the Anti-drug Antibodies (ADA) Assay and in the Neutralizing Anti-drug Antibodies (NAb) Assay","Sanofi|Regeneron Pharmaceuticals|NSABP Foundation Inc","All","18 Years and older   (Adult, Older Adult)","Phase 3","1226","Industry|Other","Interventional","Allocation: Randomized|Intervention Model: Parallel Assignment|Masking: Triple (Participant, Care Provider, Investigator)|Primary Purpose: Treatment","EFC10262|EudraCT 2007-000820-42","November 2007","February 2011","June 2012","November 21, 2007","September 28, 2012","September 28, 2012","Sanofi-Aventis Investigational Site Number 840119, Birmingham, Alabama, United States|Sanofi-Aventis Investigational Site Number 840074, Muscle Shoals, Alabama, United States|Sanofi-Aventis Investigational Site Number 840093, Hot Springs, Arizona, United States|Sanofi-Aventis Investigational Site Number 840080, Anaheim, California, United States|Sanofi-Aventis Investigational Site Number 840076, Fountain Valley, California, United States|Sanofi-Aventis Investigational Site Number 840120, Fountain Valley, California, United States|Sanofi-Aventis Investigational Site Number 840073, Greenbrae, California, United States|Sanofi-Aventis Investigational Site Number 840101, Hayward, California, United States|Sanofi-Aventis Investigational Site Number 840046, La Jolla, California, United States|Sanofi-Aventis Investigational Site Number 840116, Loma Linda, California, United States|Sanofi-Aventis Investigational Site Number 840048, Long Beach, California, United States|Sanofi-Aventis Investigational Site Number 840201, Oakland, California, United States|Sanofi-Aventis Investigational Site Number 840901, Roseville, California, United States|Sanofi-Aventis Investigational Site Number 840042, Sacramento, California, United States|Sanofi-Aventis Investigational Site Number 840301, Sacramento, California, United States|Sanofi-Aventis Investigational Site Number 840112, Salinas, California, United States|Sanofi-Aventis Investigational Site Number 840006, San Diego, California, United States|Sanofi-Aventis Investigational Site Number 840106, San Diego, California, United States|Sanofi-Aventis Investigational Site Number 840206, San Diego, California, United States|Sanofi-Aventis Investigational Site Number 840306, San Diego, California, United States|Sanofi-Aventis Investigational Site Number 840406, San Diego, California, United States|Sanofi-Aventis Investigational Site Number 840506, San Diego, California, United States|Sanofi-Aventis Investigational Site Number 840606, San Diego, California, United States|Sanofi-Aventis Investigational Site Number 840706, San Diego, California, United States|Sanofi-Aventis Investigational Site Number 840806, San Diego, California, United States|Sanofi-Aventis Investigational Site Number 840906, San Diego, California, United States|Sanofi-Aventis Investigational Site Number 840401, San Francisco, California, United States|Sanofi-Aventis Investigational Site Number 840601, San Jose, California, United States|Sanofi-Aventis Investigational Site Number 840501, Santa Clara, California, United States|Sanofi-Aventis Investigational Site Number 840801, South San Francisco, California, United States|Sanofi-Aventis Investigational Site Number 840001, Vallejo, California, United States|Sanofi-Aventis Investigational Site Number 840701, Walnut Creek, California, United States|Sanofi-Aventis Investigational Site Number 840071, Stamford, Connecticut, United States|Sanofi-Aventis Investigational Site Number 840014, Newark, Delaware, United States|Sanofi-Aventis Investigational Site Number 840089, Boynton Beach, Florida, United States|Sanofi-Aventis Investigational Site Number 840041, Gainesville, Florida, United States|Sanofi-Aventis Investigational Site Number 840031, Gainesville, Florida, United States|Sanofi-Aventis Investigational Site Number 840122, Miami, Florida, United States|Sanofi-Aventis Investigational Site Number 840079, The Villages, Florida, United States|Sanofi-Aventis Investigational Site Number 840087, Chicago, Illinois, United States|Sanofi-Aventis Investigational Site Number 840019, Decatur, Illinois, United States|Sanofi-Aventis Investigational Site Number 840115, Elk Grove Village, Illinois, United States|Sanofi-Aventis Investigational Site Number 840010, Naperville, Illinois, United States|Sanofi-Aventis Investigational Site Number 840113, Quincy, Illinois, United States|Sanofi-Aventis Investigational Site Number 840072, Indianapolis, Indiana, United States|Sanofi-Aventis Investigational Site Number 840047, Indianapolis, Indiana, United States|Sanofi-Aventis Investigational Site Number 840034, Munster, Indiana, United States|Sanofi-Aventis Investigational Site Number 840088, Louisville, Kentucky, United States|Sanofi-Aventis Investigational Site Number 840096, Paducah, Kentucky, United States|Sanofi-Aventis Investigational Site Number 840043, Baton Rouge, Louisiana, United States|Sanofi-Aventis Investigational Site Number 840084, Metairie, Louisiana, United States|Sanofi-Aventis Investigational Site Number 840015, New Orleans, Louisiana, United States|Sanofi-Aventis Investigational Site Number 840070, Rockville, Maryland, United States|Sanofi-Aventis Investigational Site Number 840029, Salisbury, Maryland, United States|Sanofi-Aventis Investigational Site Number 840053, Pontiac, Michigan, United States|Sanofi-Aventis Investigational Site Number 840021, St Louis Park, Minnesota, United States|Sanofi-Aventis Investigational Site Number 840081, Kansas City, Missouri, United States|Sanofi-Aventis Investigational Site Number 840052, St Louis, Missouri, United States|Sanofi-Aventis Investigational Site Number 840114, St. Louis, Missouri, United States|Sanofi-Aventis Investigational Site Number 840049, Las Vegas, Nevada, United States|Sanofi-Aventis Investigational Site Number 840044, Albuquerque, New Mexico, United States|Sanofi-Aventis Investigational Site Number 840036, Albany, New York, United States|Sanofi-Aventis Investigational Site Number 840094, Lake Success, New York, United States|Sanofi-Aventis Investigational Site Number 840017, Syracuse, New York, United States|Sanofi-Aventis Investigational Site Number 840097, Syracuse, New York, United States|Sanofi-Aventis Investigational Site Number 840035, Burlington, North Carolina, United States|Sanofi-Aventis Investigational Site Number 840024, Charlotte, North Carolina, United States|Sanofi-Aventis Investigational Site Number 840026, Charlotte, North Carolina, United States|Sanofi-Aventis Investigational Site Number 840005, Goldsboro, North Carolina, United States|Sanofi-Aventis Investigational Site Number 840004, Hendersonville, North Carolina, United States|Sanofi-Aventis Investigational Site Number 840075, Winston-Salem, North Carolina, United States|Sanofi-Aventis Investigational Site Number 840098, Cincinnati, Ohio, United States|Sanofi-Aventis Investigational Site Number 840011, Kettering, Ohio, United States|Sanofi-Aventis Investigational Site Number 840086, Middletown, Ohio, United States|Sanofi-Aventis Investigational Site Number 840008, Toledo, Ohio, United States|Sanofi-Aventis Investigational Site Number 840039, Portland, Oregon, United States|Sanofi-Aventis Investigational Site Number 840118, Bethlehem, Pennsylvania, United States|Sanofi-Aventis Investigational Site Number 840033, Philadelphia, Pennsylvania, United States|Sanofi-Aventis Investigational Site Number 840012, Pittsburgh, Pennsylvania, United States|Sanofi-Aventis Investigational Site Number 840082, Pawtucket, Rhode Island, United States|Sanofi-Aventis Investigational Site Number 840095, Woonsocket, Rhode Island, United States|Sanofi-Aventis Investigational Site Number 840085, Charleston, South Carolina, United States|Sanofi-Aventis Investigational Site Number 840037, Spartanburg, South Carolina, United States|Sanofi-Aventis Investigational Site Number 840078, Corpus Christi, Texas, United States|Sanofi-Aventis Investigational Site Number 840117, Temple, Texas, United States|Sanofi-Aventis Investigational Site Number 840099, Seattle, Washington, United States|Sanofi-Aventis Investigational Site Number 840002, Marshfield, Wisconsin, United States|Sanofi-Aventis Investigational Site Number 032003, Bahia Blanca, Argentina|Sanofi-Aventis Investigational Site Number 032006, Buenos Aires, Argentina|Sanofi-Aventis Investigational Site Number 032005, Ciudad De Buenos Aires, Argentina|Sanofi-Aventis Investigational Site Number 032007, Salta, Argentina|Sanofi-Aventis Investigational Site Number 036004, Hornsby, Australia|Sanofi-Aventis Investigational Site Number 036001, Kingswood, Australia|Sanofi-Aventis Investigational Site Number 036002, Kurralta Park, Australia|Sanofi-Aventis Investigational Site Number 036005, Melbourne, Australia|Sanofi-Aventis Investigational Site Number 036003, Melbourne, Australia|Sanofi-Aventis Investigational Site Number 036007, Nedlands, Australia|Sanofi-Aventis Investigational Site Number 036006, Subiaco, Australia|Sanofi-Aventis Investigational Site Number 040001, Wien, Austria|Sanofi-Aventis Investigational Site Number 056006, Bonheiden, Belgium|Sanofi-Aventis Investigational Site Number 056007, Bruxelles, Belgium|Sanofi-Aventis Investigational Site Number 056002, Bruxelles, Belgium|Sanofi-Aventis Investigational Site Number 056004, Bruxelles, Belgium|Sanofi-Aventis Investigational Site Number 056001, Gent, Belgium|Sanofi-Aventis Investigational Site Number 056005, Haine-Saint-Paul, Belgium|Sanofi-Aventis Investigational Site Number 056003, Leuven, Belgium|Sanofi-Aventis Investigational Site Number 076004, Porto Alegre, Brazil|Sanofi-Aventis Investigational Site Number 076005, Porto Alegre, Brazil|Sanofi-Aventis Investigational Site Number 076002, Porto Alegre, Brazil|Sanofi-Aventis Investigational Site Number 076008, Rio De Janeiro, Brazil|Sanofi-Aventis Investigational Site Number 076003, Rio De Janeiro, Brazil|Sanofi-Aventis Investigational Site Number 076001, Santo Andre, Brazil|Sanofi-Aventis Investigational Site Number 076007, Sao Paulo, Brazil|Sanofi-Aventis Investigational Site Number 076006, Sao Paulo, Brazil|Sanofi-Aventis Investigational Site Number 152002, Santiago, Chile|Sanofi-Aventis Investigational Site Number 152003, Santiago, Chile|Sanofi-Aventis Investigational Site Number 152001, Santiago, Chile|Sanofi-Aventis Investigational Site Number 152005, Santiago, Chile|Sanofi-Aventis Investigational Site Number 152004, Viña Del Mar, Chile|Sanofi-Aventis Investigational Site Number 203002, Brno, Czech Republic|Sanofi-Aventis Investigational Site Number 203001, Brno, Czech Republic|Sanofi-Aventis Investigational Site Number 203004, Praha 5, Czech Republic|Sanofi-Aventis Investigational Site Number 208001, Odense C, Denmark|Sanofi-Aventis Investigational Site Number 208003, Ålborg, Denmark|Sanofi-Aventis Investigational Site Number 233002, Tallinn, Estonia|Sanofi-Aventis Investigational Site Number 233001, Tartu, Estonia|Sanofi-Aventis Investigational Site Number 250002, Brest, France|Sanofi-Aventis Investigational Site Number 250004, Clichy Cx, France|Sanofi-Aventis Investigational Site Number 250005, La Roche Sur Yon, France|Sanofi-Aventis Investigational Site Number 250001, Lyon Cedex 03, France|Sanofi-Aventis Investigational Site Number 250003, Paris, France|Sanofi-Aventis Investigational Site Number 276003, Aschaffenburg, Germany|Sanofi-Aventis Investigational Site Number 276002, Essen, Germany|Sanofi-Aventis Investigational Site Number 276001, Halle / Saale, Germany|Sanofi-Aventis Investigational Site Number 276005, Magdeburg, Germany|Sanofi-Aventis Investigational Site Number 276004, Magdeburg, Germany|Sanofi-Aventis Investigational Site Number 276006, München, Germany|Sanofi-Aventis Investigational Site Number 300005, Athens, Greece|Sanofi-Aventis Investigational Site Number 300004, Athens, Greece|Sanofi-Aventis Investigational Site Number 300001, Heraklion, Greece|Sanofi-Aventis Investigational Site Number 300002, Ilion, Athens, Greece|Sanofi-Aventis Investigational Site Number 300003, Patras, Greece|Sanofi-Aventis Investigational Site Number 380007, Ancona, Italy|Sanofi-Aventis Investigational Site Number 380005, Aviano, Italy|Sanofi-Aventis Investigational Site Number 380004, Candiolo, Italy|Sanofi-Aventis Investigational Site Number 380003, Genova, Italy|Sanofi-Aventis Investigational Site Number 380001, Milano, Italy|Sanofi-Aventis Investigational Site Number 380002, Milano, Italy|Sanofi-Aventis Investigational Site Number 380008, Rozzano, Italy|Sanofi-Aventis Investigational Site Number 380006, San Giovanni Rotondo, Italy|Sanofi-Aventis Investigational Site Number 410001, Goyang, Korea, Republic of|Sanofi-Aventis Investigational Site Number 410003, Seoul, Korea, Republic of|Sanofi-Aventis Investigational Site Number 410005, Seoul, Korea, Republic of|Sanofi-Aventis Investigational Site Number 410002, Seoul, Korea, Republic of|Sanofi-Aventis Investigational Site Number 410004, Seoul, Korea, Republic of|Sanofi-Aventis Investigational Site Number 528004, Amsterdam, Netherlands|Sanofi-Aventis Investigational Site Number 528001, Blaricum, Netherlands|Sanofi-Aventis Investigational Site Number 528005, Breda, Netherlands|Sanofi-Aventis Investigational Site Number 528002, Rotterdam, Netherlands|Sanofi-Aventis Investigational Site Number 528003, Sittard-Geleen, Netherlands|Sanofi-Aventis Investigational Site Number 554009, Auckland, New Zealand|Sanofi-Aventis Investigational Site Number 554010, Christchurch, New Zealand|Sanofi-Aventis Investigational Site Number 578002, Bergen, Norway|Sanofi-Aventis Investigational Site Number 578001, Oslo, Norway|Sanofi-Aventis Investigational Site Number 578003, Stavanger, Norway|Sanofi-Aventis Investigational Site Number 616005, Czestochowa, Poland|Sanofi-Aventis Investigational Site Number 616004, Elblag, Poland|Sanofi-Aventis Investigational Site Number 616007, Krakow, Poland|Sanofi-Aventis Investigational Site Number 616003, Lodz, Poland|Sanofi-Aventis Investigational Site Number 616002, Poznan, Poland|Sanofi-Aventis Investigational Site Number 616006, Rybnik, Poland|Sanofi-Aventis Investigational Site Number 616001, Wroclaw, Poland|Sanofi-Aventis Investigational Site Number 630001, San Juan, Puerto Rico|Sanofi-Aventis Investigational Site Number 642004, Alba Iulia, Romania|Sanofi-Aventis Investigational Site Number 642007, Bucharest, Romania|Sanofi-Aventis Investigational Site Number 642001, Bucuresti, Romania|Sanofi-Aventis Investigational Site Number 642002, Bucuresti, Romania|Sanofi-Aventis Investigational Site Number 642003, Cluj Napoca, Romania|Sanofi-Aventis Investigational Site Number 642006, Iasi, Romania|Sanofi-Aventis Investigational Site Number 642005, Suceava, Romania|Sanofi-Aventis Investigational Site Number 643001, Moscow, Russian Federation|Sanofi-Aventis Investigational Site Number 643006, Moscow, Russian Federation|Sanofi-Aventis Investigational Site Number 643002, Moscow, Russian Federation|Sanofi-Aventis Investigational Site Number 643003, Saint-Petersburg, Russian Federation|Sanofi-Aventis Investigational Site Number 643004, St-Petersburg, Russian Federation|Sanofi-Aventis Investigational Site Number 643007, St-Petersburg, Russian Federation|Sanofi-Aventis Investigational Site Number 710004, Cape Town, South Africa|Sanofi-Aventis Investigational Site Number 710005, Durban, South Africa|Sanofi-Aventis Investigational Site Number 710008, Durban, South Africa|Sanofi-Aventis Investigational Site Number 710001, Parktown, South Africa|Sanofi-Aventis Investigational Site Number 710006, Port Elizabeth, South Africa|Sanofi-Aventis Investigational Site Number 710007, Pretoria, South Africa|Sanofi-Aventis Investigational Site Number 710003, Pretoria, South Africa|Sanofi-Aventis Investigational Site Number 724002, Barakaldo, Spain|Sanofi-Aventis Investigational Site Number 724005, Barcelona, Spain|Sanofi-Aventis Investigational Site Number 724001, Barcelona, Spain|Sanofi-Aventis Investigational Site Number 724006, Madrid, Spain|Sanofi-Aventis Investigational Site Number 724003, Madrid, Spain|Sanofi-Aventis Investigational Site Number 724007, Reus, Spain|Sanofi-Aventis Investigational Site Number 752002, Stockholm, Sweden|Sanofi-Aventis Investigational Site Number 752003, Sundsvall, Sweden|Sanofi-Aventis Investigational Site Number 752001, Uppsala, Sweden|Sanofi-Aventis Investigational Site Number 792005, Adana, Turkey|Sanofi-Aventis Investigational Site Number 792004, Ankara, Turkey|Sanofi-Aventis Investigational Site Number 792001, Ankara, Turkey|Sanofi-Aventis Investigational Site Number 792002, Izmir, Turkey|Sanofi-Aventis Investigational Site Number 792003, Kayseri, Turkey|Sanofi-Aventis Investigational Site Number 804005, Dnipropetrovsk, Ukraine|Sanofi-Aventis Investigational Site Number 804004, Donetsk, Ukraine|Sanofi-Aventis Investigational Site Number 804006, Kharkiv, Ukraine|Sanofi-Aventis Investigational Site Number 804002, Kharkov, Ukraine|Sanofi-Aventis Investigational Site Number 826001, Aberdeen, United Kingdom|Sanofi-Aventis Investigational Site Number 826010, Bournemouth, United Kingdom|Sanofi-Aventis Investigational Site Number 826009, Dudley, United Kingdom|Sanofi-Aventis Investigational Site Number 826008, London, United Kingdom|Sanofi-Aventis Investigational Site Number 826004, London, United Kingdom|Sanofi-Aventis Investigational Site Number 826007, London, United Kingdom|Sanofi-Aventis Investigational Site Number 826011, London, United Kingdom|Sanofi-Aventis Investigational Site Number 826002, Manchester, United Kingdom|Sanofi-Aventis Investigational Site Number 826003, Northwood, United Kingdom|Sanofi-Aventis Investigational Site Number 826005, Sutton, United Kingdom",,"https://ClinicalTrials.gov/show/NCT00561470"
503,"NCT04826393","ASP8374 + Cemiplimab in Recurrent Glioma",,"Recruiting","No Results Available","Glioblastoma|Recurrent Glioblastoma","Drug: ASP8374|Drug: cemiplimab|Drug: 89Zr-Df-IAB22M2C","Maxium Tolerated Dose-MTD/ Phase 2 Recommend Dose-RP2D - Cohort 1|CD8+ TIL Tumor Density-Cohort 2|Rate of Adverse Events|progression-free survival (PFS)|overall survival (OS).","Dana-Farber Cancer Institute|Regeneron Pharmaceuticals|Astellas Pharma Inc|ImaginAb, Inc.","All","18 Years and older   (Adult, Older Adult)","Phase 1","24","Other|Industry","Interventional","Allocation: Randomized|Intervention Model: Single Group Assignment|Masking: None (Open Label)|Primary Purpose: Treatment","21-054","February 2022","June 1, 2022","December 30, 2022","April 1, 2021",,"February 7, 2022","Brigham and Women's Hospital, Boston, Massachusetts, United States|University of Cincinnati Medical Center, Cincinnati, Ohio, United States",,"https://ClinicalTrials.gov/show/NCT04826393"
504,"NCT01909791","Treatment for CI-DME in Eyes With Very Good VA Study","Protocol V","Completed","Has Results","Diabetic Macular Edema","Procedure: Prompt Laser|Drug: Prompt aflibercept|Procedure: Deferred laser|Drug: Deferred aflibercept","Number of Eyes With at Least 5-letter Decrease in E-ETDRS Visual Acuity Letter Score From Baseline|Number of Eyes With at Least 5-letter Increase or at Least 5-, 10-, or 15-letter Decrease in E-ETDRS Visual Acuity Letter Score From Baseline|Change in E-ETDRS Visual Acuity Letter Score From Baseline|Change in E-ETDRS Visual Acuity Letter Score From Baseline Over 2 Years (Area Under the Curve)|Change in OCT Central Subfield Thickness From Baseline|Number of Eyes With at Least 1 or 2 Logarithmic-step Central Subfield Thickness Improvement and Worsening|Number of Eyes With no Center-involved Diabetic Macular Edema and at Least 10% Central Subfield Thickness Decrease|Cumulative Number of Intraocular Injections of 2.0-mg Aflibercept Received Per Participant|Number of Eyes With ≥ 2-step Worsening of Diabetic Retinopathy|For Eyes Randomized to Initial Laser Photocoagulation and Initial Observation Groups, the Percentage Receiving Aflibercept Treatment|Number of Eyes With at Least 5-, 10-, or 15-letter Decrease in E-ETDRS Visual Acuity Letter Score From Baseline|Cumulative Number of Focal/Grid Photocoagulation Sessions Performed Per Participant|Number of Eyes With ≥ 2-step Improvement of Diabetic Retinopathy","Jaeb Center for Health Research|Regeneron Pharmaceuticals|National Eye Institute (NEI)|National Institutes of Health (NIH)","All","18 Years and older   (Adult, Older Adult)","Phase 3","702","Other|Industry|NIH","Interventional","Allocation: Randomized|Intervention Model: Parallel Assignment|Masking: Single (Outcomes Assessor)|Primary Purpose: Treatment","DRCR.net Protocol V|EY14231|EY23207|EY18817","October 2013","September 11, 2018","September 11, 2018","July 29, 2013","January 3, 2020","July 31, 2020","Arizona Retina and Vitreous Consultants, Phoenix, Arizona, United States|University of Arizona Medical Center/Department of Ophthalmology, Tucson, Arizona, United States|Jones Eye Institute/University of Arkansas for Medical Sciences, Little Rock, Arkansas, United States|Retinal Diagnostic Center, Campbell, California, United States|Loma Linda University Health Care, Dept. of Ophthalmology, Loma Linda, California, United States|South Coast Retina Center, Long Beach, California, United States|Southern California Desert Retina Consultants, MC, Palm Desert, California, United States|Retina Consultants of Southern California, Redlands, California, United States|Retinal Consultants Medical Group, Inc., Sacramento, California, United States|California Retina Consultants, Santa Barbara, California, United States|Bay Area Retina Associates, Walnut Creek, California, United States|Retinal Consultants of Southern California Medical Group, Inc., Westlake Village, California, United States|Retina Group of New England, New London, Connecticut, United States|New England Retina Associates, Norwich, Connecticut, United States|National Ophthalmic Research Institute, Fort Myers, Florida, United States|University of Florida College of Med., Department of Ophthalmology, Jacksonville, Florida, United States|Florida Retina Consultants, Lakeland, Florida, United States|Retina Macula Specialists of Miami, Miami, Florida, United States|Bascom Palmer Eye Institute, Miami, Florida, United States|Ocala Eye Retina Consultants, Ocala, Florida, United States|Magruder Eye Institute, Orlando, Florida, United States|Fort Lauderdale Eye Institute, Plantation, Florida, United States|Center for Sight, Sarasota, Florida, United States|Sarasota Retina Institute, Sarasota, Florida, United States|Retina Associates of Florida, P.A., Tampa, Florida, United States|Emory Eye Center, Atlanta, Georgia, United States|Southeast Retina Center, P.C., Augusta, Georgia, United States|Marietta Eye Clinic, Marietta, Georgia, United States|Thomas Eye Group, Sandy Springs, Georgia, United States|Northwestern Medical Faculty Foundation, Chicago, Illinois, United States|University of Illinois at Chicago Medical Center, Chicago, Illinois, United States|NorthShore University HealthSystem, Glenview, Illinois, United States|Illinois Retina Associates, Joliet, Illinois, United States|University Retina and Macula Associates, Oak Forest, Illinois, United States|Carle Foundation Hospital, Urbana, Illinois, United States|Raj Maturi, Indianapolis, Indiana, United States|John-Kenyon American Eye Institute, New Albany, Indiana, United States|Medical Associates Clinic, P.C., Dubuque, Iowa, United States|Wolfe Eye Clinic, West Des Moines, Iowa, United States|University of Kansas Medical Center, Dept. of Ophthalmology, Prairie Village, Kansas, United States|Retina Associates, P.A., Shawnee Mission, Kansas, United States|Retina and Vitreous Associates of Kentucky, Lexington, Kentucky, United States|Paducah Retinal Center, Paducah, Kentucky, United States|Elman Retina Group, P.A., Baltimore, Maryland, United States|Wilmer Eye Institute at Johns Hopkins, Baltimore, Maryland, United States|Joslin Diabetes Center, Boston, Massachusetts, United States|Vitreo-Retinal Associates, PC, Worcester, Massachusetts, United States|Kellogg Eye Center, University of Michigan, Ann Arbor, Michigan, United States|Henry Ford Health System, Dept of Ophthalmology and Eye Care Services, Detroit, Michigan, United States|Retina Vitreous Center, Grand Blanc, Michigan, United States|Retina Specialists of Michigan, Grand Rapids, Michigan, United States|Vitreo-Retinal Associates, Grand Rapids, Michigan, United States|Andersen Eye Associates, Saginaw, Michigan, United States|Retina Center, PA, Minneapolis, Minnesota, United States|University of Minnesota, Minneapolis, Minnesota, United States|Mayo Clinic Department of Ophthalmology, Rochester, Minnesota, United States|Mid-America Retina Consultants, P.A., Kansas City, Missouri, United States|The Retina Institute, Saint Louis, Missouri, United States|Eyesight Ophthalmic Services, PA, Portsmouth, New Hampshire, United States|The Institute of Ophthalmology and Visual Science (IOVS), Newark, New Jersey, United States|Retinal and Ophthalmic Consultants, PC, Northfield, New Jersey, United States|Eye Associates of New Mexico, Albuquerque, New Mexico, United States|Ross Eye Institute, SUNY Buffalo, Buffalo, New York, United States|The New York Eye and Ear Infirmary/Faculty Eye Practice, New York, New York, United States|MaculaCare, New York, New York, United States|Retina Associates of Western New York, Rochester, New York, United States|University of Rochester, Rochester, New York, United States|Retina-Vitreous Surgeons of Central New York, PC, Syracuse, New York, United States|Western Carolina Retinal Associates, PA, Asheville, North Carolina, United States|University of North Carolina, Chapel Hill, North Carolina, United States|Charlotte Eye, Ear, Nose and Throat Assoc., PA, Charlotte, North Carolina, United States|Retina Associates of Cleveland, Inc., Beachwood, Ohio, United States|Case Western Reserve University, Cleveland, Ohio, United States|Retina Vitreous Center, Edmond, Oklahoma, United States|Oregon Retina, LLP, Eugene, Oregon, United States|Retina Northwest, PC, Portland, Oregon, United States|Casey Eye Institute, Portland, Oregon, United States|Family Eye Group, Lancaster, Pennsylvania, United States|Retina Vitreous Consultants, Monroeville, Pennsylvania, United States|University of Pennsylvania Scheie Eye Institute, Philadelphia, Pennsylvania, United States|Carolina Retina Center, Columbia, South Carolina, United States|Palmetto Retina Center, West Columbia, South Carolina, United States|Southeastern Retina Associates, Chattanooga, Tennessee, United States|Southeastern Retina Associates, PC, Kingsport, Tennessee, United States|Southeastern Retina Associates, P.C., Knoxville, Tennessee, United States|Southwest Retina Specialists, Amarillo, Texas, United States|Austin Retina Associates, Austin, Texas, United States|Retina Research Center, Austin, Texas, United States|Retina and Vitreous of Texas, Houston, Texas, United States|Baylor Eye Physicians and Surgeons, Houston, Texas, United States|Retina Consultants of Houston, PA, Houston, Texas, United States|Texas Retina Associates, Lubbock, Texas, United States|Valley Retina Institute, McAllen, Texas, United States|Retinal Consultants of San Antonio, San Antonio, Texas, United States|Retina Associates of Utah, P.C., Salt Lake City, Utah, United States|Retina Institute of Virginia, Richmond, Virginia, United States|Virginia Commonwealth University, Dept. of Ophthalmology, Richmond, Virginia, United States|University of Washington Medical Center, Seattle, Washington, United States|Spokane Eye Clinic, Spokane, Washington, United States|University of Wisconsin-Madison, Dept of Ophthalmology/Retina Service, Madison, Wisconsin, United States|Alberta Retina Consultants, Edmonton, Alberta, Canada|University Health Network - Toronto Western Hospital, Toronto, Ontario, Canada|UBC/VCHA Eye Care Centre, Vancouver, Canada","""Study Protocol"", https://ClinicalTrials.gov/ProvidedDocs/91/NCT01909791/Prot_000.pdf|""Statistical Analysis Plan"", https://ClinicalTrials.gov/ProvidedDocs/91/NCT01909791/SAP_001.pdf","https://ClinicalTrials.gov/show/NCT01909791"
505,"NCT03544866","The Impact of Pediatric Skin Disorders: The ""Big"" Study",,"Active, not recruiting","No Results Available","Chronic Pediatric Skin Conditions",,"Measure the stigma experienced by children as a function of the child's perceived skin lesion visibility using the altered Neuro-QoL stigma tool","Northwestern University|Pediatric Dermatology Research Alliancce|Regeneron Pharmaceuticals|Immunex Corporation","All","8 Years to 17 Years   (Child)",,"1666","Other|Industry","Observational","Observational Model: Cohort|Time Perspective: Prospective","ASP02172016","November 16, 2018","May 31, 2021","January 31, 2022","June 4, 2018",,"December 7, 2021","Department of Dermatology, Northwestern University Feinberg School of Medicine and Lurie Children's Hospital, Chicago, Illinois, United States",,"https://ClinicalTrials.gov/show/NCT03544866"
506,"NCT03359356","Treatment of Alopecia Areata (AA) With Dupilumab in Patients With and Without Atopic Dermatitis (AD)",,"Completed","Has Results","Alopecia Areata","Drug: Dupilumab|Drug: Placebo","Change From Baseline in the Severity of Alopecia Tool (SALT) Score at Week 24|Change From Week 24 in the SALT Score at Week 48|Change From Baseline in the SALT Score at Week 48|Number of Patients Achieving at Least 50% Improvement in Severity of Alopecia Tool (SALT) Score (SALT-50) at Weeks 24 and 48 Compared to Baseline|Number of Patients Achieving at Least 75% Improvement in SALT-75 at Weeks 24 and 48|Number of Patients Achieving at Least 90% Improvement in Severity of Alopecia Tool (SALT) Score (SALT-90) at Weeks 24 and 48|Change in Alopecia Areata Symptom Impact Scale (AASIS)|Change in Alopecia Areata Quality of Life Questionnaire|Eyelash/Eyebrow Assessment Score Weeks 12, 24, 36, and 48 Compared to Baseline|Change in EASI Scores From Baseline at Week 24 and 48|Number of Adverse Events","Icahn School of Medicine at Mount Sinai|Rockefeller University|Regeneron Pharmaceuticals|Sanofi","All","18 Years and older   (Adult, Older Adult)","Phase 2","60","Other|Industry","Interventional","Allocation: Randomized|Intervention Model: Parallel Assignment|Masking: Triple (Participant, Investigator, Outcomes Assessor)|Primary Purpose: Treatment","GCO 17-1084","January 9, 2018","January 14, 2020","December 17, 2020","December 2, 2017","February 14, 2022","February 14, 2022","Icahn School of Medicine at Mount Sinai, New York, New York, United States|The Rockefeller University Laboratory for Investigative Dermatology, New York, New York, United States","""Study Protocol and Statistical Analysis Plan"", https://ClinicalTrials.gov/ProvidedDocs/56/NCT03359356/Prot_SAP_000.pdf","https://ClinicalTrials.gov/show/NCT03359356"
507,"NCT02858076","Anti-VEGF vs. Prompt Vitrectomy for VH From PDR","AB","Completed","Has Results","Proliferative Diabetic Retinopathy|Vitreous Hemorrhage","Drug: 2-mg Intravitreous Aflibercept Injection|Procedure: Prompt Vitrectomy Plus Panretinal Photocoagulation","E-ETDRS Visual Acuity Letter Score (Area Under the Curve From Baseline)|E-ETDRS Visual Acuity Letter Score|Snellen Equivalent Range (Visual Acuity Score)|Recurrent Vitreous Hemorrhage|Retinal Neovascularization on Clinical Exam","Jaeb Center for Health Research|National Institutes of Health (NIH)|Regeneron Pharmaceuticals|National Eye Institute (NEI)","All","18 Years and older   (Adult, Older Adult)","Phase 2|Phase 3","205","Other|NIH|Industry","Interventional","Allocation: Randomized|Intervention Model: Parallel Assignment|Masking: Single (Outcomes Assessor)|Primary Purpose: Treatment","DRCR.net Protocol AB|EY14231|EY23207|EY18817","November 2016","January 2020","January 2020","August 8, 2016","January 19, 2021","April 20, 2021","Retinal Diagnostic Center, Campbell, California, United States|Macula & Retina Institute, Glendale, California, United States|Atlantis Eye Care, Huntington Beach, California, United States|Loma Linda University Health Care, Department of Ophthalmology, Loma Linda, California, United States|Shashi D Ganti, MD PC, Porterville, California, United States|Florida Retina Consultants, Lakeland, Florida, United States|Southeast Eye Institute, P.A. dba Eye Associates of Pinellas, Pinellas Park, Florida, United States|Retina Associates of Sarasota, Sarasota, Florida, United States|Retina Associates of Florida, P.A., Tampa, Florida, United States|Emory Eye Center, Atlanta, Georgia, United States|Southeast Retina Center, P.C., Augusta, Georgia, United States|Marietta Eye Clinic, Marietta, Georgia, United States|Thomas Eye Group, Sandy Springs, Georgia, United States|Gailey Eye Clinic, Bloomington, Illinois, United States|Northwestern Medical Faculty Foundation, Chicago, Illinois, United States|University of Illinois at Chicago Medical Center, Chicago, Illinois, United States|Carle Foundation Hospital, Urbana, Illinois, United States|Raj K. Maturi, MD, PC, Indianapolis, Indiana, United States|John-Kenyon American Eye Institute, New Albany, Indiana, United States|Retina Associates, P.A., Shawnee Mission, Kansas, United States|Paducah Retinal Center, Paducah, Kentucky, United States|Eye Associates of Northeast Louisiana dba Haik Humble Eye Center, West Monroe, Louisiana, United States|Elman Retina Group, P.A., Baltimore, Maryland, United States|Wilmer Eye Institute at Johns Hopkins, Baltimore, Maryland, United States|Valley Eye Physicians and Surgeons, Ayer, Massachusetts, United States|Joslin Diabetes Center, Boston, Massachusetts, United States|Kellogg Eye Center, University of Michigan, Ann Arbor, Michigan, United States|Henry Ford Health System, Dept of Ophthalmology and Eye Care Services, Detroit, Michigan, United States|Retina Specialists of Michigan, Grand Rapids, Michigan, United States|Retina Center, PA, Minneapolis, Minnesota, United States|Mayo Clinic Department of Ophthalmology, Rochester, Minnesota, United States|Mid-America Retina Consultants, P.A., Kansas City, Missouri, United States|The Retina Institute, Saint Louis, Missouri, United States|The New York Eye and Ear Infirmary/Faculty Eye Practice, New York, New York, United States|MaculaCare, New York, New York, United States|Weill Cornell Medical College, New York, New York, United States|Retina-Vitreous Surgeons of Central New York, PC, Syracuse, New York, United States|Kittner Eye Center, Chapel Hill, North Carolina, United States|Charlotte Eye, Ear, Nose and Throat Assoc., PA, Charlotte, North Carolina, United States|Retina Associates of Cleveland, Inc., Beachwood, Ohio, United States|University Hospitals Cleveland Medical Center, Cleveland, Ohio, United States|Retina Vitreous Center, Edmond, Oklahoma, United States|Dean A. McGee Eye Institute, Oklahoma City, Oklahoma, United States|Oregon Retina, LLP, Eugene, Oregon, United States|Retina Northwest, PC, Portland, Oregon, United States|Casey Eye Institute, Portland, Oregon, United States|Retina Vitreous Consultants, Monroeville, Pennsylvania, United States|Palmetto Retina Center, West Columbia, South Carolina, United States|Southeastern Retina Associates, Chattanooga, Tennessee, United States|Southeastern Retina Associates, P.C., Knoxville, Tennessee, United States|Southwest Retina Specialists, Amarillo, Texas, United States|Retina Research Center, Austin, Texas, United States|Retina and Vitreous of Texas, Houston, Texas, United States|Baylor Eye Physicians and Surgeons, Houston, Texas, United States|Texas Retina Associates, Lubbock, Texas, United States|Valley Retina Institute, McAllen, Texas, United States|Medical Center Ophthalmology Associates, San Antonio, Texas, United States|Retinal Consultants of San Antonio, San Antonio, Texas, United States|Spokane Eye Clinic, Spokane, Washington, United States|Medical College of Wisconsin, Milwaukee, Wisconsin, United States|UBC/VCHA Eye Care Centre, Vancouver, British Columbia, Canada|University Health Network - Toronto Western Hospital, Toronto, Ontario, Canada","""Study Protocol"", https://ClinicalTrials.gov/ProvidedDocs/76/NCT02858076/Prot_000.pdf|""Statistical Analysis Plan"", https://ClinicalTrials.gov/ProvidedDocs/76/NCT02858076/SAP_001.pdf|""Informed Consent Form"", https://ClinicalTrials.gov/ProvidedDocs/76/NCT02858076/ICF_002.pdf","https://ClinicalTrials.gov/show/NCT02858076"
508,"NCT01627249","Comparative Effectiveness Study of Intravitreal Aflibercept, Bevacizumab, and Ranibizumab for Diabetic Macular Edema","Protocol T","Completed","Has Results","Diabetic Macular Edema","Drug: 2.0 mg intravitreal aflibercept|Drug: 1.25 mg intravitreal bevacizumab|Drug: 0.3 mg intravitreal ranibizumab","Overall Change in Electronic Early Treatment Diabetic Retinopathy Study Visual Acuity Letter Score From Baseline to 1-year|Change in Electronic Early Treatment Diabetic Retinopathy Study Visual Acuity Letter Score From Baseline to 1-year: Baseline Visual Acuity Letter Score <69|Change in Electronic Early Treatment Diabetic Retinopathy Study Visual Acuity Letter Score From Baseline to 1-year: Baseline Visual Acuity Letter Score 78-69|Overall Change in Optical Coherence Tomography Central Subfield Thickness|Change in Optical Coherence Tomography Central Subfield Thickness: Baseline Visual Acuity Letter Score <69|Change in Optical Coherence Tomography Central Subfield Thickness: Baseline Visual Acuity Letter Score 78-69|Overall Change in Retinal Volume|Total Number of Injections Prior to 1 Year|Total Number of Laser Treatments|Eyes Receiving 1 or More Alternative Treatments for DME Other Than Laser","Jaeb Center for Health Research|National Eye Institute (NEI)|Genentech, Inc.|Regeneron Pharmaceuticals","All","18 Years and older   (Adult, Older Adult)","Phase 3","660","Other|NIH|Industry","Interventional","Allocation: Randomized|Intervention Model: Parallel Assignment|Masking: Single (Participant)|Primary Purpose: Treatment","DRCR.net Protocol T|EY14231|EY23207|EY18817","August 2012","October 2014","April 18, 2019","June 25, 2012","December 16, 2015","August 10, 2020","Retina Associates, Tucson, Arizona, United States|Retina-Vitreous Associates Medical Group, Beverly Hills, California, United States|Loma Linda University Health Care, Dept. of Ophthalmology, Loma Linda, California, United States|Southern California Desert Retina Consultants, MC, Palm Desert, California, United States|California Retina Consultants, Santa Barbara, California, United States|Bay Area Retina Associates, Walnut Creek, California, United States|Retinal Consultants of Southern California Medical Group, Inc., Westlake Village, California, United States|New England Retina Associates, Norwich, Connecticut, United States|Gulf Coast Retina Center, Clearwater, Florida, United States|Retina Group of Florida, Fort Lauderdale, Florida, United States|National Ophthalmic Research Institute, Fort Myers, Florida, United States|Central Florida Retina Institute, Lakeland, Florida, United States|Ocala Eye Retina Consultants, Ocala, Florida, United States|Magruder Eye Institute, Orlando, Florida, United States|Fort Lauderdale Eye Institute, Plantation, Florida, United States|Sarasota Retina Institute, Sarasota, Florida, United States|Retina Associates of Florida, P.A., Tampa, Florida, United States|Emory Eye Center, Atlanta, Georgia, United States|Georgia Retina, P.C., Atlanta, Georgia, United States|Thomas Eye Group, Atlanta, Georgia, United States|Southeast Retina Center, P.C., Augusta, Georgia, United States|Retina Consultants of Hawaii, Inc., Honolulu, Hawaii, United States|Northwestern Medical Faculty Foundation, Chicago, Illinois, United States|University of Illinois at Chicago Medical Center, Chicago, Illinois, United States|NorthShore University HealthSystem, Glenview, Illinois, United States|Raj K. Maturi, M.D., P.C., Indianapolis, Indiana, United States|John-Kenyon American Eye Institute, New Albany, Indiana, United States|Medical Associates Clinic, P.C., Dubuque, Iowa, United States|Wolfe Eye Clinic, West Des Moines, Iowa, United States|Retina Associates, P.A., Shawnee Mission, Kansas, United States|Retina and Vitreous Associates of Kentucky, Lexington, Kentucky, United States|Paducah Retinal Center, Paducah, Kentucky, United States|Elman Retina Group, P.A., Baltimore, Maryland, United States|Wilmer Eye Institute at Johns Hopkins, Baltimore, Maryland, United States|Ophthalmic Consultants of Boston, Boston, Massachusetts, United States|Joslin Diabetes Center, Boston, Massachusetts, United States|Vitreo-Retinal Associates, PC, Worcester, Massachusetts, United States|Henry Ford Health System, Dept of Ophthalmology and Eye Care Services, Detroit, Michigan, United States|Retina Vitrous Center, Grand Blanc, Michigan, United States|Retina Specialists of Michigan, Grand Rapids, Michigan, United States|Vitreo-Retinal Associates, Grand Rapids, Michigan, United States|Retina Center, PA, Minneapolis, Minnesota, United States|Mayo Clinic Department of Ophthalmology, Rochester, Minnesota, United States|Barnes Retina Institute, Saint Louis, Missouri, United States|Eyesight Ophthalmic Services, PA, Portsmouth, New Hampshire, United States|The Institute of Ophthalmology and Visual Science (IOVS), Newark, New Jersey, United States|Eye Associates of New Mexico, Albuquerque, New Mexico, United States|University of New Mexico Health Sciences Center, Albuquerque, New Mexico, United States|Montefiore Medical Center, Bronx, New York, United States|The New York Eye and Ear Infirmary/Faculty Eye Practice, New York, New York, United States|MaculaCare, New York, New York, United States|Mount Sinai School of Medicine, Dept. of Ophthalmology, New York, New York, United States|Retina Associates of Western New York, Rochester, New York, United States|University of Rochester, Rochester, New York, United States|Retina-Vitreous Surgeons of Central New York, PC, Syracuse, New York, United States|Western Carolina Retinal Associates, PA, Asheville, North Carolina, United States|University of North Carolina, Chapel Hill, North Carolina, United States|Charlotte Eye, Ear, Nose and Throat Assoc., PA, Charlotte, North Carolina, United States|Wake Forest University Eye Center, Winston-Salem, North Carolina, United States|Retina Associates of Cleveland, Inc., Beachwood, Ohio, United States|Case Western Reserve University, Cleveland, Ohio, United States|OSU Eye Physicians and Surgeons, LLC., Columbus, Ohio, United States|Retina Vitreous Center, Edmond, Oklahoma, United States|Dean A. McGee Eye Institute, Oklahoma City, Oklahoma, United States|Retina Northwest, PC, Portland, Oregon, United States|Casey Eye Institute, Portland, Oregon, United States|Family Eye Group, Lancaster, Pennsylvania, United States|University of Pennsylvania Scheie Eye Institute, Philadelphia, Pennsylvania, United States|Retina Vitrous Consultants, Pittsburgh, Pennsylvania, United States|Storm Eye Institute, Medical University of South Carolina, Charleston, South Carolina, United States|Palmetto Retina Center, Columbia, South Carolina, United States|Carolina Retina Center, Columbia, South Carolina, United States|Southeastern Retina Associates, PC, Kingsport, Tennessee, United States|Southeastern Retina Associates, P.C., Knoxville, Tennessee, United States|Southwest Retina Specialists, Amarillo, Texas, United States|Austin Retina Associates, Austin, Texas, United States|Retina Research Center, Austin, Texas, United States|Retina and Vitreous of Texas, Houston, Texas, United States|Baylor Eye Physicians and Surgeons, Houston, Texas, United States|Retina Consultants of Houston, PA, Houston, Texas, United States|Texas Retina Associates, Lubbock, Texas, United States|Valley Retina Institute, McAllen, Texas, United States|Retinal Consultants of San Antonio, San Antonio, Texas, United States|Retina Associates of Utah, P.C., Salt Lake City, Utah, United States|Virginia Retina Center, Leesburg, Virginia, United States|Retina Institute of Virginia, Richmond, Virginia, United States|University of Washington Medical Center, Seattle, Washington, United States|Spokane Eye Clinic, Spokane, Washington, United States|University of Wisconsin-Madison, Dept of Ophthalmology/Retina Service, Madison, Wisconsin, United States|Medical College of Wiconsin, Milwaukee, Wisconsin, United States",,"https://ClinicalTrials.gov/show/NCT01627249"
509,"NCT03389893","Effect of Dupilumab (Anti-IL4Rα) on the Host-Microbe Interface in Atopic Dermatitis",,"Terminated","Has Results","Atopic Dermatitis (AD)","Drug: Dupilumab|Drug: Placebo","Staphylococcus Aureus Abundance on Lesional Skin, Dupilumab+Open Label Extension and Follow-Up Versus Placebo+Open Label Extension and Follow-Up|Staphylococcus Aureus Abundance on Non-lesional Skin, Dupilumab+Open Label Extension and Follow-Up Versus Placebo+Open Label Extension and Follow-Up|Transepidermal Water Loss (TEWL) of Non-lesional and Lesional Skin, Dupilumab+Open Label Extension and Follow-Up Versus Placebo+Open Label Extension and Follow-Up|Transepidermal Water Loss (TEWL) Area Under the Curve (AUC) on Non-Lesional Skin, Dupilumab+Open Label Extension and Follow-Up Versus Placebo+Open Label Extension and Follow-Up|Transepidermal Water Loss (TEWL) Slope on Non-Lesional Skin, Dupilumab+Open Label Extension and Follow-Up Versus Placebo+Open Label Extension and Follow-Up|Eczema Area and Severity Index (EASI) Score Within Each Treatment Group, Dupilumab+Open Label Extension and Follow-Up Versus Placebo+Open Label Extension and Follow-Up|Investigator Global Assessment (IGA) Score Within Each Treatment Group, Dupilumab+Open Label Extension and Follow-Up Versus Placebo+Open Label Extension and Follow-Up|SCORing Atopic Dermatitis (SCORAD) Score Within Each Treatment Group, Dupilumab+Open Label Extension and Follow-Up Versus Placebo+Open Label Extension and Follow-Up|Pruritus Numerical Rating Scale (Pruritus NRS) Score Within Each Treatment Group, Dupilumab+Open Label Extension and Follow-Up Versus Placebo+Open Label Extension and Follow-Up","National Institute of Allergy and Infectious Diseases (NIAID)|Regeneron Pharmaceuticals|Sanofi|Atopic Dermatitis Research Network|Rho Federal Systems Division, Inc.","All","18 Years to 75 Years   (Adult, Older Adult)","Phase 4","72","NIH|Industry|Other","Interventional","Allocation: Randomized|Intervention Model: Parallel Assignment|Masking: Triple (Participant, Care Provider, Investigator)|Primary Purpose: Treatment","DAIT ADRN-09|U19AI117673|NIAID DAIT CRMS ID#: 38439","July 25, 2018","April 3, 2020","September 9, 2020","January 4, 2018","June 14, 2021","October 4, 2021","University of California San Diego, La Jolla, California, United States|Children's Hospital Los Angeles, Los Angeles, California, United States|Stanford University, Stanford, California, United States|National Jewish Health, Denver, Colorado, United States|University of Florida, Gainesville, Florida, United States|University of Rochester Medical Center, Rochester, New York, United States|Duke University, Durham, North Carolina, United States|Oregon Health Sciences University, Portland, Oregon, United States|University of Pennsylvania, Philadelphia, Pennsylvania, United States","""Study Protocol"", https://ClinicalTrials.gov/ProvidedDocs/93/NCT03389893/Prot_001.pdf|""Statistical Analysis Plan"", https://ClinicalTrials.gov/ProvidedDocs/93/NCT03389893/SAP_002.pdf|""Informed Consent Form"", https://ClinicalTrials.gov/ProvidedDocs/93/NCT03389893/ICF_003.pdf","https://ClinicalTrials.gov/show/NCT03389893"
510,"NCT02634333","Anti-VEGF Treatment for Prevention of PDR/DME",,"Active, not recruiting","Has Results","Diabetic Retinopathy|Diabetic Macular Edema","Procedure: Prompt Sham|Drug: Prompt aflibercept|Procedure: Deferred laser|Drug: Deferred aflibercept","Development of PDR and/or DME (Whichever Came First)|Change in Visual Acuity From Baseline","Jaeb Center for Health Research|Regeneron Pharmaceuticals|Juvenile Diabetes Research Foundation|National Eye Institute (NEI)|National Institutes of Health (NIH)","All","18 Years and older   (Adult, Older Adult)","Phase 3","399","Other|Industry|NIH","Interventional","Allocation: Randomized|Intervention Model: Parallel Assignment|Masking: Double (Participant, Outcomes Assessor)|Primary Purpose: Prevention","DRCR.net Protocol W|EY14231|EY23207|EY18817","January 2016","May 2020","May 2022","December 18, 2015","November 24, 2021","November 24, 2021","Arizona Retina and Vitreous Consultants, Phoenix, Arizona, United States|University of Arizona Medical Center/Department of Ophthalmology, Tucson, Arizona, United States|Atlantis Eye Care, Huntington Beach, California, United States|Loma Linda University Health Care, Department of Ophthalmology, Loma Linda, California, United States|East Bay Retina Consultants, Inc., Oakland, California, United States|Southern California Desert Retina Consultants, MC, Palm Desert, California, United States|Shashi D Ganti, MD PC, Porterville, California, United States|Retina Consultants of Southern California, Redlands, California, United States|U.C. Davis Eye Center, Sacramento, California, United States|California Retina Consultants, Santa Barbara, California, United States|Retinal Consultants of Southern California Medical Group, Inc., Westlake Village, California, United States|New England Retina Associates, Hamden, Connecticut, United States|Retina Group of Florida, Fort Lauderdale, Florida, United States|National Ophthalmic Research Institute, Fort Myers, Florida, United States|University of Florida College of Med., Department of Ophthalmology, Jacksonville Health Science Cent, Jacksonville, Florida, United States|Florida Retina Institute-Jacksonville, Jacksonville, Florida, United States|Florida Retina Consultants, Lakeland, Florida, United States|Bascom Palmer Eye Institute, Miami, Florida, United States|Magruder Eye Institute, Orlando, Florida, United States|Florida Retina Institute, Orlando, Florida, United States|Southeast Eye Institute, P.A. dba Eye Associates of Pinellas, Pinellas Park, Florida, United States|Fort Lauderdale Eye Institute, Plantation, Florida, United States|Sarasota Retina Institute, Sarasota, Florida, United States|Retina Associates of Florida, P.A., Tampa, Florida, United States|Emory Eye Center, Atlanta, Georgia, United States|Southeast Retina Center, P.C., Augusta, Georgia, United States|Marietta Eye Clinic, Marietta, Georgia, United States|Thomas Eye Group, Sandy Springs, Georgia, United States|Gailey Eye Clinic, Bloomington, Illinois, United States|Northwestern Medical Faculty Foundation, Chicago, Illinois, United States|University of Illinois at Chicago Medical Center, Chicago, Illinois, United States|Springfield Clinic, LLP, Springfield, Illinois, United States|Raj K. Maturi, M.D., P.C., Indianapolis, Indiana, United States|Medical Associates Clinic, P.C., Dubuque, Iowa, United States|Wolfe Eye Clinic, West Des Moines, Iowa, United States|Retina Associates, P.A., Shawnee Mission, Kansas, United States|Paducah Retinal Center, Paducah, Kentucky, United States|Eye Associates of Northeast Louisiana dba Haik Humble Eye Center, West Monroe, Louisiana, United States|Elman Retina Group, P.A., Baltimore, Maryland, United States|Wilmer Eye Institute at Johns Hopkins, Baltimore, Maryland, United States|Mid Atlantic Retina Specialists, Hagerstown, Maryland, United States|Valley Eye Physicians and Surgeons, Ayer, Massachusetts, United States|Joslin Diabetes Center, Boston, Massachusetts, United States|Henry Ford Health System, Dept of Ophthalmology and Eye Care Services, Detroit, Michigan, United States|Vitreo-Retinal Associates, Grand Rapids, Michigan, United States|Retina Center, PA, Minneapolis, Minnesota, United States|Mid-America Retina Consultants, P.A., Kansas City, Missouri, United States|Retinal and Ophthalmic Consultants, PC, Northfield, New Jersey, United States|Eye Associates of New Mexico, Albuquerque, New Mexico, United States|The New York Eye and Ear Infirmary/Faculty Eye Practice, New York, New York, United States|MaculaCare, New York, New York, United States|University of Rochester, Rochester, New York, United States|Retina-Vitreous Surgeons of Central New York, PC, Syracuse, New York, United States|Western Carolina Clinical Research, LLC, Asheville, North Carolina, United States|Kittner Eye Center, Chapel Hill, North Carolina, United States|Charlotte Eye, Ear, Nose and Throat Assoc., PA, Charlotte, North Carolina, United States|Retina Associates of Cleveland, Inc., Beachwood, Ohio, United States|University Hospitals Cleveland Medical Center, Cleveland, Ohio, United States|Oregon Retina, LLP, Eugene, Oregon, United States|Retina Northwest, PC, Portland, Oregon, United States|Casey Eye Institute, Portland, Oregon, United States|Retina Vitreous Consultants, Monroeville, Pennsylvania, United States|University of Pennsylvania Scheie Eye Institute, Philadelphia, Pennsylvania, United States|Carolina Retina Center, Columbia, South Carolina, United States|Palmetto Retina Center, West Columbia, South Carolina, United States|Southeastern Retina Associates, Chattanooga, Tennessee, United States|Southeastern Retina Associates, P.C., Knoxville, Tennessee, United States|Southwest Retina Specialists, Amarillo, Texas, United States|Austin Retina Associates, Austin, Texas, United States|Retina Research Center, Austin, Texas, United States|Robert E. Torti, MD, PA dba Retina Specialists, DeSoto, Texas, United States|Retina Center of Texas, Grapevine, Texas, United States|Retina and Vitreous of Texas, Houston, Texas, United States|Baylor Eye Physicians and Surgeons, Houston, Texas, United States|Retina Consultants of Houston, PA, Houston, Texas, United States|Texas Retina Associates, Lubbock, Texas, United States|Valley Retina Institute, McAllen, Texas, United States|Retinal Consultants of San Antonio, San Antonio, Texas, United States|Retina Institute of Virginia, Richmond, Virginia, United States|Virginia Commonwealth University, Dept. of Ophthalmology, Richmond, Virginia, United States|University of Wisconsin-Madison, Dept of Ophthalmology/Retina Service, Madison, Wisconsin, United States|UBC/VCHA Eye Care Centre, Vancouver, British Columbia, Canada|Nova Scotia District Health Authority, Halifax, Nova Scotia, Canada|Toronto Retina Institute (TRI), North York, Ontario, Canada|University Health Network - Toronto Western Hospital, Toronto, Ontario, Canada","""Study Protocol"", https://ClinicalTrials.gov/ProvidedDocs/33/NCT02634333/Prot_000.pdf|""Statistical Analysis Plan"", https://ClinicalTrials.gov/ProvidedDocs/33/NCT02634333/SAP_001.pdf","https://ClinicalTrials.gov/show/NCT02634333"
511,"NCT01418781","CLinical Prediction Rule Score in Veterans",,"Withdrawn","No Results Available","Gout",,"Health care costs|Health utility index, SF-6D|Health care utilization|Activity limitation on Katz 6 ADL|Mortality","jasvinder singh|VA Office of Research and Development|Takeda|Novartis|Regeneron Pharmaceuticals|Minneapolis Veterans Affairs Medical Center","All","Child, Adult, Older Adult",,"0","U.S. Fed|Industry","Observational","Observational Model: Cohort|Time Perspective: Prospective","MVAMC-3669A","January 2008","March 2010","March 2010","August 17, 2011",,"March 16, 2016","Minneapolis VA Medical Center, Minneapolis, Minnesota, United States",,"https://ClinicalTrials.gov/show/NCT01418781"
512,"NCT04502966","Grass Pollen Immunotherapy Plus Dupilumab for Tolerance Induction","GRADUATE","Recruiting","No Results Available","Allergic Rhinoconjunctivitis|Grass Pollen Allergy","Biological: Dupixent®|Biological: Grazax®|Drug: Dupixent® Placebo|Drug: Grazax® Placebo","TNSS Area Under Curve (AUC) Post Nasal Allergen Challenge (NAC) Over the First Hour After the Challenge (0-1 Hour (hr): A Comparison between the Grazax® +Dupixent® and the Grazax® Placebo +Dupixent® Placebo Treatment Arms|TNSS Area Under Curve (AUC) Post Nasal Allergen Challenge (NAC) Over the First Hour After the Challenge (0-1 Hour (hr): A Comparison between the Grazax® +Dupixent® and Grazax® + Dupixent® Placebo Treatment Arms|Peak Nasal Inspiratory Flow (PNIF) (Delta PNIF Area Under the Curve [AUC] 0-1 hr): A Comparison Between Treatment Arms|Peak Nasal Inspiratory Flow (PNIF) (Delta PNIF Area Under the Curve [AUC] 0-1 hr): A Comparison between the Grazax® +Dupixent® and the Grazax® Placebo +Dupixent® Placebo Treatment Arms|Frequency, Severity, and Relatedness of Adverse Events (AEs) byTreatment Arm|Weekly Seasonal Symptoms Score (Visual analogue scale [VAS] 0-10 cms): A Comparison Between the Grazax® +Dupixent® and Grazax® Placebo +Dupixent® Placebo Treatment Arms|Weekly Rhinitis Quality of Life Scores Using the Juniper Mini-Rhinoconjunctivitis Quality of Life Questionnaire: A Comparison Between the Grazax® +Dupixent® and Grazax® Placebo +Dupixent® Placebo Treatment Arms|Global Rhinitis Evaluation Scores: A Comparison Between the Grazax® +Dupixent® and Grazax® Placebo +Dupixent® Placebo Treatment Arms","National Institute of Allergy and Infectious Diseases (NIAID)|Immune Tolerance Network (ITN)|ALK-Abelló A/S|Regeneron Pharmaceuticals|PPD|Rho Federal Systems Division, Inc.","All","18 Years to 65 Years   (Adult, Older Adult)","Phase 2","120","NIH|Other|Industry","Interventional","Allocation: Randomized|Intervention Model: Parallel Assignment|Masking: Triple (Participant, Care Provider, Investigator)|Primary Purpose: Treatment","DAIT ITN084AD|NIAID CRMS ID#: 38629|2018-003456-20","November 9, 2020","January 2025","January 2025","August 6, 2020",,"June 8, 2021","Royal Brompton Hospital, London, United Kingdom",,"https://ClinicalTrials.gov/show/NCT04502966"
513,"NCT02986984","Transformative Research in Diabetic Nephropathy","TRIDENT","Recruiting","No Results Available","Diabetic Nephropathies|Diabetic Glomerulosclerosis","Other: There is no intervention","Rapid progression of kidney function loss|Serious Adverse Events","University of Pennsylvania|Columbia University|MOUNT SINAI HOSPITAL|University of Michigan|University of Miami|University of North Carolina|Northwestern University|Metro Health, Michigan|University of New Mexico|Stanford University|The University of Texas Health Science Center at San Antonio|Baylor Research Institute|Ohio State University|Yale University|Albert Einstein College of Medicine|Oregon Health and Science University|University of Arizona|Lehigh Valley Health Network|University of Arkansas|University of Southern California|University of Virginia|Georgia Nephrology Research Institute|Regeneron Pharmaceuticals|Boehringer Ingelheim|GlaxoSmithKline|Gilead Sciences|Juvenile Diabetes Research Foundation|Novo Nordisk A/S","All","18 Years to 100 Years   (Adult, Older Adult)",,"400","Other|Industry","Observational","Observational Model: Cohort|Time Perspective: Prospective","824503","December 2016","December 2022","December 2022","December 8, 2016",,"February 25, 2021","University of Arizona, Tucson, Arizona, United States|University of Arkansas for Medical Sciences, Little Rock, Arkansas, United States|University of Southern California, Los Angeles, California, United States|Stanford University, Palo Alto, California, United States|Yale University, New Haven, Connecticut, United States|University of Miami, Miami, Florida, United States|Georgia Nephrology, Lawrenceville, Georgia, United States|Northwestern University, Chicago, Illinois, United States|University of Michigan, Ann Arbor, Michigan, United States|University of New Mexico, Albuquerque, New Mexico, United States|Albert Einstein College of Medicine, Bronx, New York, United States|Mount Sinai Hospital, New York, New York, United States|Columbia University, New York, New York, United States|University of North Carolina, Chapel Hill, North Carolina, United States|MetroHealth, Cleveland, Ohio, United States|Ohio State University, Columbus, Ohio, United States|Oregon Health & Science University, Portland, Oregon, United States|Lehigh Valley Health Network, Allentown, Pennsylvania, United States|University of Pennsylvania, Philadelphia, Pennsylvania, United States|Vanderbilt University, Nashville, Tennessee, United States|Baylor Research Institute, Dallas, Texas, United States|University of Texas Health Science Center at San Antonio, San Antonio, Texas, United States|University of Virginia, Charlottesville, Virginia, United States",,"https://ClinicalTrials.gov/show/NCT02986984"
